PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Yu-Rice, Y; Jin, Y; Han, B; Qu, Y; Johnson, J; Watanabe, T; Cheng, L; Deng, N; Tanaka, H; Gao, B; Liu, Z; Sun, Z; Bose, S; Giuliano, A; Cui, X				Yu-Rice, Y.; Jin, Y.; Han, B.; Qu, Y.; Johnson, J.; Watanabe, T.; Cheng, L.; Deng, N.; Tanaka, H.; Gao, B.; Liu, Z.; Sun, Z.; Bose, S.; Giuliano, A. E.; Cui, X.			FOXC1 is involved in ERa silencing by counteracting GATA3 binding and is implicated in endocrine resistance	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; GENE-EXPRESSION PATTERNS; BREAST-CANCER CELLS; TRANSCRIPTIONAL REGULATION; FORKHEAD DOMAIN; POOR-PROGNOSIS; TAMOXIFEN; PROTEIN; FOXA1; OVEREXPRESSION	Estrogen receptor-alpha (ER alpha) mediates the essential biological function of estrogen in breast development and tumorigenesis. Multiple mechanisms, including pioneer factors, coregulators and epigenetic modifications have been identified as regulators of ER alpha signaling in breast cancer. However, previous studies of ER alpha regulation have focused on luminal and HER2-positive subtypes rather than basal-like breast cancer (BLBC), in which ER alpha is underexpressed. In addition, mechanisms that account for the decrease or loss of ER expression in recurrent tumors after endocrine therapy remain elusive. Here, we demonstrate a novel FOXC1-driven mechanism that suppresses ERa expression in breast cancer. We find that FOXC1 competes with GATA-binding protein 3 (GATA3) for the same binding regions in the cis-regulatory elements upstream of the ER alpha gene and thereby downregulates ER alpha expression and consequently its transcriptional activity. The forkhead domain of FOXC1 is essential for the competition with GATA3 for DNA binding. Counteracting the action of GATA3 at the ER alpha promoter region, overexpression of FOXC1 hinders recruitment of RNA polymerase II and increases histone H3K9 trimethylation at ER alpha promoters. Importantly, ectopic FOXC1 expression in luminal breast cancer cells reduces sensitivity to estrogen and tamoxifen. Furthermore, in breast cancer patients with ER-positive primary tumors who received adjuvant tamoxifen treatment, FOXC1 expression is associated with decreased or undetectable ER expression in recurrent tumors. Our findings highlight a clinically relevant mechanism that contributes to the low or absent ER alpha expression in BLBC. This study suggests a new paradigm to study ER alpha regulation during breast cancer progression and indicates a role of FOXC1 in the modulation of cellular response to endocrine treatment.	[Yu-Rice, Y.; Jin, Y.; Han, B.; Qu, Y.; Johnson, J.; Watanabe, T.; Tanaka, H.; Gao, B.; Giuliano, A. E.; Cui, X.] Cedars Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA; [Cheng, L.; Sun, Z.] Chongqing Med Univ, Affiliated Hosp 2, Dept Breast & Thyroid Surg, Chongqing, Peoples R China; [Deng, N.; Liu, Z.] Cedars Sinai Med Ctr, Dept Surg, Biostat & Bioinformat Res Ctr, Los Angeles, CA 90048 USA; [Bose, S.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Pathol, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; Chongqing Medical University; Cedars Sinai Medical Center; Cedars Sinai Medical Center	Cui, X (corresponding author), Cedars Sinai Med Ctr, 8700 Beverly Blvd,Davis Bldg 2065, Los Angeles, CA 90048 USA.	Xiaojiang.Cui@cshs.org		Johnson, Jeffrey/0000-0003-2912-443X; Tanaka, Hisashi/0000-0001-9223-4186	National Institutes of Health [CA151610]; Avon Foundation for Women [02-2014-063]; David Salomon Translational Breast Cancer Research Fund; Eleanor and Glenn Padnick Discovery Fund in Cellular Therapy; Margie and Robert E. Petersen Foundation; Linda and Jim Lippman Research Fund; Fashion Footwear Charitable Foundation of New York, Inc.; NATIONAL CANCER INSTITUTE [R01CA151610] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Avon Foundation for Women; David Salomon Translational Breast Cancer Research Fund; Eleanor and Glenn Padnick Discovery Fund in Cellular Therapy; Margie and Robert E. Petersen Foundation; Linda and Jim Lippman Research Fund; Fashion Footwear Charitable Foundation of New York, Inc.; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Julia Gee for discussion about antiestrogen experiments. This work was supported by the National Institutes of Health (CA151610), the Avon Foundation for Women (02-2014-063) and David Salomon Translational Breast Cancer Research Fund, and Eleanor and Glenn Padnick Discovery Fund in Cellular Therapy to Xiaojiang Cui, the Fashion Footwear Charitable Foundation of New York, Inc., associates for Breast and Prostate Cancer Studies, the Margie and Robert E. Petersen Foundation, and the Linda and Jim Lippman Research Fund to Armando Giuliano.	Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Augereau P, 2006, MOL PHARMACOL, V69, P1338, DOI 10.1124/mol.105.017376; Badve S, 2011, MODERN PATHOL, V24, P157, DOI 10.1038/modpathol.2010.200; Bartkuhn M, 2008, BBA-MOL CELL RES, V1783, P2161, DOI 10.1016/j.bbamcr.2008.07.011; Becker M, 2005, MOL CANCER THER, V4, P151; Bernardo GM, 2010, DEVELOPMENT, V137, P2045, DOI 10.1242/dev.043299; Berry FB, 2002, J BIOL CHEM, V277, P10292, DOI 10.1074/jbc.M110266200; Berry FB, 2008, HUM MOL GENET, V17, P490, DOI 10.1093/hmg/ddm326; Bulger M, 2010, DEV BIOL, V339, P250, DOI 10.1016/j.ydbio.2009.11.035; Caizzi L, 2014, P NATL ACAD SCI USA, V111, P4892, DOI 10.1073/pnas.1315445111; Cimino-Mathews A, 2013, HUM PATHOL, V44, P1341, DOI 10.1016/j.humpath.2012.11.003; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Gaughan L, 2013, NUCLEIC ACIDS RES, V41, P6892, DOI 10.1093/nar/gkt469; Guo SQ, 2004, MOL CELL BIOL, V24, P8681, DOI 10.1128/MCB.24.19.8681-8690.2004; Han BC, 2015, CELL REP, V13, P1046, DOI 10.1016/j.celrep.2015.09.063; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Jensen TW, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv148; Kos M, 2001, MOL ENDOCRINOL, V15, P2057, DOI 10.1210/me.15.12.2057; Kume T, 1998, CELL, V93, P985, DOI 10.1016/S0092-8674(00)81204-0; Kuukasjarvi T, 1996, J CLIN ONCOL, V14, P2584, DOI 10.1200/JCO.1996.14.9.2584; Ma YX, 2010, MOL ENDOCRINOL, V24, P76, DOI 10.1210/me.2009-0218; Madureira PA, 2006, J BIOL CHEM, V281, P25167, DOI 10.1074/jbc.M603906200; Magnani L, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002368; Manavathi B, 2014, FRONT CELL DEV BIOL, V2, DOI 10.3389/fcell.2014.00034; Marconett CN, 2010, MOL BIOL CELL, V21, P1166, DOI 10.1091/mbc.E09-08-0689; Mohammed H, 2013, CELL REP, V3, P342, DOI 10.1016/j.celrep.2013.01.010; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Obrero M, 2002, J BIOL CHEM, V277, P45695, DOI 10.1074/jbc.M208092200; Osborne CK, 1998, BREAST CANCER RES TR, V51, P227, DOI 10.1023/A:1006132427948; Oyama M, 2011, J BIOL CHEM, V286, P818, DOI 10.1074/jbc.M110.156877; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Prest SJ, 2002, FASEB J, V16, P592, DOI 10.1096/fj.01-0498fje; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Ray PS, 2010, CANCER RES, V70, P3870, DOI 10.1158/0008-5472.CAN-09-4120; Ross-Innes CS, 2010, GENE DEV, V24, P171, DOI 10.1101/gad.552910; Saleem RA, 2004, NUCLEIC ACIDS RES, V32, P4182, DOI 10.1093/nar/gkh742; Saleem RA, 2003, HUM MOL GENET, V12, P2993, DOI 10.1093/hmg/ddg324; Schultz JR, 2003, MOL CELL ENDOCRINOL, V201, P165, DOI 10.1016/S0303-7207(02)00415-X; Sengupta S, 2010, HORM MOL BIOL CLIN I, V2, P235, DOI 10.1515/HMBCI.2010.025; Shenker NS, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1335-5; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sparano JA, 2010, SURG ONCOL CLIN N AM, V19, P581, DOI 10.1016/j.soc.2010.03.008; Theodorou V, 2013, GENOME RES, V23, P12, DOI 10.1101/gr.139469.112; Wei LX, 2013, TUMOR BIOL, V34, P941, DOI 10.1007/s13277-012-0629-3; Xia LM, 2013, HEPATOLOGY, V57, P610, DOI 10.1002/hep.26029; Xu Y, 2014, HISTOPATHOLOGY, V64, P963, DOI 10.1111/his.12347; Ye Q, 2015, AM J CANCER RES, V5, P1519; Yoshida T, 2000, CARCINOGENESIS, V21, P2193, DOI 10.1093/carcin/21.12.2193	49	21	25	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2016	35	41					5400	5411		10.1038/onc.2016.78	http://dx.doi.org/10.1038/onc.2016.78			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA5QU	27041579	Green Accepted			2022-12-17	WOS:000386677800006
J	O'Connor, C; Lohan, F; Campos, J; Ohlsson, E; Salome, M; Forde, C; Artschwager, R; Liskamp, RM; Cahill, MR; Kiely, PA; Porse, B; Keeshan, K				O'Connor, C.; Lohan, F.; Campos, J.; Ohlsson, E.; Salome, Mara; Forde, C.; Artschwager, R.; Liskamp, R. M.; Cahill, M. R.; Kiely, P. A.; Porse, B.; Keeshan, K.			The presence of C/EBP alpha and its degradation are both required for TRIB2-mediated leukaemia	ONCOGENE			English	Article							BINDING-PROTEIN-ALPHA; CEBPA; MUTATIONS; TRIB2; EXPRESSION; C/EBP-ALPHA-P-30; PROTEASOME; COOPERATE; ABSENCE; COP1	C/EBP alpha (p42 and p30 isoforms) is commonly dysregulated in cancer via the action of oncogenes, and specifically in acute myeloid leukaemia (AML) by mutation. Elevated TRIB2 leads to the degradation of C/EBP alpha p42, leaving p30 intact in AML. Whether this relationship is a cooperative event in AML transformation is not known and the molecular mechanism involved remains elusive. Using mouse genetics, our data reveal that in the complete absence of C/EBP alpha, TRIB2 was unable to induce AML. Only in the presence of C/EBP alpha p42 and p30, were TRIB2 and p30 able to cooperate to decrease the latency of disease. We demonstrate that the molecular mechanism involved in the degradation of C/EBP alpha p42 requires site-specific direct interaction between TRIB2 and C/EBP alpha p42 for the K48-specific ubiquitin-dependent proteasomal degradation of C/EBP alpha p42. This interaction and ubiquitination is dependent on a critical C terminal lysine residue on C/EBP alpha. We show effective targeting of this pathway pharmacologically using proteasome inhibitors in TRIB2-positive AML cells. Together, our data show that excess p30 cooperated with TRIB2 only in the presence of p42 to accelerate AML, and the direct interaction and degradation of C/EBP alpha p42 is required for TRIB2-mediated AML.	[O'Connor, C.; Lohan, F.; Campos, J.; Salome, Mara; Keeshan, K.] Univ Glasgow, Inst Canc Sci, Paul OGorman Leukaemia Res Ctr, 21 Shelley Rd, Glasgow G12 0XB, Lanark, Scotland; [Ohlsson, E.; Porse, B.] Univ Copenhagen, Fac Hlth Sci, Rigshosp, Finsen Lab, Copenhagen, Denmark; [Ohlsson, E.; Porse, B.] Univ Copenhagen, BRIC, Copenhagen, Denmark; [Ohlsson, E.; Porse, B.] Univ Copenhagen, Fac Hlth Sci, Danish Stem Cell Ctr DanStem, Copenhagen, Denmark; [Forde, C.] Univ Coll Cork, Cork, Ireland; [Artschwager, R.; Liskamp, R. M.] Univ Glasgow, Sch Chem, Glasgow, Lanark, Scotland; [Cahill, M. R.] Cork Univ Hosp, Dept Haematol, Cork, Ireland; [Kiely, P. A.] Univ Limerick, Dept Life Sci, Mat & Surface Sci Inst, Limerick, Ireland; [Kiely, P. A.] Univ Limerick, Stokes Inst, Limerick, Ireland	University of Glasgow; Rigshospitalet; University of Copenhagen; University of Copenhagen; University of Copenhagen; University College Cork; University of Glasgow; University College Cork; University of Limerick; University of Limerick	Keeshan, K (corresponding author), Univ Glasgow, Inst Canc Sci, Paul OGorman Leukaemia Res Ctr, 21 Shelley Rd, Glasgow G12 0XB, Lanark, Scotland.	Karen.keeshan@glasgow.ac.uk	Salomé, Mara/I-9423-2018; Keeshan, Karen/L-5615-2013; Liskamp, Rob M/I-5889-2012	Salomé, Mara/0000-0003-3267-650X; Keeshan, Karen/0000-0001-7266-0890; Liskamp, Rob M/0000-0001-8897-8975; O'Connor, Caitriona/0000-0002-7638-9804; Cahill, Mary R/0000-0002-1655-3078; Porse, Bo/0000-0001-6043-0844	Kay Kendall foundation [KKL501]; Howat foundation; Cancer UK; Childrens Leukaemia Research Project grant; Science Foundation Ireland Infrastructure award; Mid-Western Cancer Foundation; centre grant from the NovoNordisk Foundation (The Novo Nordisk Foundation Section for Stem Cell Biology in Human Disease); Novo Nordisk Foundation Section for Basic Stem Cell Biology [Porse group] Funding Source: researchfish	Kay Kendall foundation; Howat foundation; Cancer UK; Childrens Leukaemia Research Project grant; Science Foundation Ireland Infrastructure award(Science Foundation Ireland); Mid-Western Cancer Foundation; centre grant from the NovoNordisk Foundation (The Novo Nordisk Foundation Section for Stem Cell Biology in Human Disease); Novo Nordisk Foundation Section for Basic Stem Cell Biology	We thank all the technical staff at the Paul O'Gorman Leukaemia Research Centre. We thank the Cancer Research UK Glasgow Centre (C596/A18076) and the Biological Service Unit facilities at the Cancer Research UK Beatson Institute (C596/A17196) and the Biological Services at the University of Glasgow. We thank Ruaidhri Carmody for reagents and critical review of the work. We thank the Kay Kendall foundation (KKL501) and the Howat foundation for Flow cytometry facility funding. Work in the Keeshan lab was supported by the Howat Foundation and Children with Cancer UK. CO'C was supported by Childrens Leukaemia Research Project grant. PK was supported by Science Foundation Ireland Infrastructure award and the Mid-Western Cancer Foundation. Work in the Porse lab was supported by a centre grant from the NovoNordisk Foundation (The Novo Nordisk Foundation Section for Stem Cell Biology in Human Disease).	Andreu-Vieyra C, 2014, EXPERT OPIN BIOL TH, V14, P1685, DOI 10.1517/14712598.2014.953050; Annamaneni S, 2014, HEMATOLOGY, V19, P42, DOI 10.1179/1607845413Y.0000000081; Bennett KL, 2007, CANCER RES, V67, P4657, DOI 10.1158/0008-5472.CAN-06-4793; Bereshchenko O, 2009, CANCER CELL, V16, P390, DOI 10.1016/j.ccr.2009.09.036; Brouwer AJ, 2012, J MED CHEM, V55, P10995, DOI 10.1021/jm301443r; Carnicer MJ, 2008, ANN HEMATOL, V87, P819, DOI 10.1007/s00277-008-0528-2; Colleran A, 2013, P NATL ACAD SCI USA, V110, P618, DOI 10.1073/pnas.1208446110; Collins C, 2014, P NATL ACAD SCI USA, V111, P9899, DOI 10.1073/pnas.1402238111; Fasan A, 2014, LEUKEMIA, V28, P794, DOI 10.1038/leu.2013.273; Fasan A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054365; Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0; Friedman AD, 2015, INT J HEMATOL, V101, P330, DOI 10.1007/s12185-015-1764-6; Geletu M, 2007, BLOOD, V110, P3301, DOI 10.1182/blood-2007-01-071035; Grandinetti KB, 2011, ONCOGENE, V14, P1; Hasemann MS, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004079; Hattori T, 2003, ONCOGENE, V22, P1273, DOI 10.1038/sj.onc.1206204; Jin GA, 2007, BLOOD, V109, P3998, DOI 10.1182/blood-2006-08-041202; Keeshan K, 2008, BLOOD CELL MOL DIS, V40, P119, DOI 10.1016/j.bcmd.2007.06.005; Keeshan K, 2006, CANCER CELL, V10, P401, DOI 10.1016/j.ccr.2006.09.012; Keeshan K, 2010, BLOOD, V116, P4948, DOI 10.1182/blood-2009-10-247361; Kirstetter P, 2008, CANCER CELL, V13, P299, DOI 10.1016/j.ccr.2008.02.008; Leroy H, 2005, LEUKEMIA, V19, P329, DOI 10.1038/sj.leu.2403614; Mancini E, 2011, EMBO J, V8, P1; Ohlsson E, 2014, J EXP MED, V211, P5, DOI 10.1084/jem.20130932; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2008, J CLIN ONCOL, V26, P5088, DOI 10.1200/JCO.2008.16.5563; Paz-Priel Ido, 2011, Critical Reviews in Oncogenesis, V16, P93; Pulikkan JA, 2010, LEUKEMIA, V24, P914, DOI 10.1038/leu.2010.37; Quintana-Bustamante O, 2012, LEUKEMIA, V26, P1537, DOI 10.1038/leu.2012.38; Rishi L, 2014, BLOOD, V123, P2389, DOI 10.1182/blood-2013-07-511683; Taskesen E, 2011, BLOOD, V117, P2469, DOI 10.1182/blood-2010-09-307280; Trivedi AK, 2007, ONCOGENE, V26, P1789, DOI 10.1038/sj.onc.1209964; Wagner K, 2006, P NATL ACAD SCI USA, V103, P6338, DOI 10.1073/pnas.0508143103; Wouters BJ, 2007, BLOOD, V110, P3706, DOI 10.1182/blood-2007-02-073486; Xu SS, 2014, FEBS LETT, V588, P4334, DOI 10.1016/j.febslet.2014.09.042; Ye M, 2013, NAT CELL BIOL, V15, P385, DOI 10.1038/ncb2698; Yokoyama T, 2012, BLOOD, V119, P2608, DOI 10.1182/blood-2010-12-324806; Zhang P, 2004, IMMUNITY, V21, P853, DOI 10.1016/j.immuni.2004.11.006	38	21	21	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2016	35	40					5272	5281		10.1038/onc.2016.66	http://dx.doi.org/10.1038/onc.2016.66			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DZ7NO	26996668	Green Submitted, Green Accepted			2022-12-17	WOS:000386053000006
J	Jin, H; Lee, K; Kim, YH; Oh, HK; Maeng, YI; Kim, TH; Suh, DS; Bae, J				Jin, H.; Lee, K.; Kim, Y-H; Oh, H. K.; Maeng, Y-I; Kim, T-H; Suh, D-S; Bae, J.			Scaffold protein FHL2 facilitates MDM2-mediated degradation of IER3 to regulate proliferation of cervical cancer cells	ONCOGENE			English	Article							HUMAN-PAPILLOMAVIRUS TYPE-16; UBIQUITIN-PROTEASOME SYSTEM; LIM-ONLY PROTEIN; GENE IEX-1; TRIGGERS APOPTOSIS; IN-VIVO; P53; EXPRESSION; TARGET; IDENTIFICATION	The expression of immediate early response 3 (IER3), a protein with a short half-life, is rapidly induced by various cellular stimuli. We recently reported that IER3 induces the apoptosis of cervical cancer cells and that its expression is downregulated in patients with cervical cancer. However, the molecular mechanism involved in the rapid degradation of IER3 remains unknown. Here, we demonstrate that MDM2 is an E3 ligase that interacts with IER3 and promotes its ubiquitination, followed by proteasomal degradation. Polyubiquitination of the conserved lysine 60 of IER3 is essential for its degradation. In addition, four and a half LIM domains protein 2 (FHL2) binds to both IER3 and MDM2, allowing for efficient MDM2-mediated IER3 degradation by facilitating an association between MDM2 and IER3. Moreover, IER3 induces cell cycle arrest in cervical cancer cells and its activity is further enhanced in cells in which FHL2 or MDM2 was silenced, thereby preventing IER3 degradation. The E6 and E7 oncoproteins of human papilloma virus 18 regulated IER3 expression. FHL2 expression was significantly higher in the squamous epithelium of cervical carcinoma tissues than in non-cancerous cervical tissues, whereas cervical carcinoma expression of IER3 was downregulated in this region. Thus, we determined the molecular mechanism responsible for IER3 degradation, involving a ternary complex of IER3, MDM2 and FHL2, which may contribute to cervical tumor growth. Furthermore, we demonstrated that FHL2 serves as a scaffold for E3 ligase and its substrate during the ubiquitination reaction, a function that has not been previously reported for this protein.	[Jin, H.; Bae, J.] Chung Ang Univ, Sch Pharm, 84 Heukseok Ro, Seoul 156756, South Korea; [Lee, K.] Chung Ang Univ, Dept Life Sci, Seoul, South Korea; [Kim, Y-H] Catholic Univ Daegu, Sch Med, Dept Microbiol, Daegu, South Korea; [Oh, H. K.; Maeng, Y-I] Catholic Univ Daegu, Sch Med, Dept Pathol, Daegu, South Korea; [Kim, T-H] Chosun Univ, Sch Med, Dept Biochem, Gwangju, South Korea; [Suh, D-S] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea	Chung Ang University; Chung Ang University; Catholic University of Daegu; Catholic University of Daegu; Chosun University; University of Ulsan; Asan Medical Center	Bae, J (corresponding author), Chung Ang Univ, Sch Pharm, 84 Heukseok Ro, Seoul 156756, South Korea.	jeehyeon@cau.ac.kr	Park, Sang-Youel/D-5966-2012	Park, Sang-Youel/0000-0003-0575-6045; Jin, Hanyong/0000-0002-5850-0791	National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning [2014R1A2A2A01006839, NRF-2015R1A5A1008958, NRF-2015R1A2A1A15054332]; Next-Generation BioGreen 21 Program, the Rural Development Administration of the Republic of Korea [PJ01117703]	National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning; Next-Generation BioGreen 21 Program, the Rural Development Administration of the Republic of Korea	This research was supported by the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (2014R1A2A2A01006839; NRF-2015R1A5A1008958; NRF-2015R1A2A1A15054332) and by the Next-Generation BioGreen 21 Program (PJ01117703), the Rural Development Administration of the Republic of Korea.	Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; Arlt A, 2001, ONCOGENE, V20, P69, DOI 10.1038/sj.onc.1204061; Arlt A, 2011, EUR J CELL BIOL, V90, P545, DOI 10.1016/j.ejcb.2010.10.002; Bae JY, 2003, J BIOL CHEM, V278, P5195, DOI 10.1074/jbc.M201988200; Balsas P, 2012, LEUKEMIA RES, V36, P212, DOI 10.1016/j.leukres.2011.09.011; Bernard HU, 2010, VIROLOGY, V401, P70, DOI 10.1016/j.virol.2010.02.002; Campo-Fernandez B, 2007, J VIROL, V81, P1027, DOI 10.1128/JVI.01699-06; Chan KK, 1998, GENE, V210, P345, DOI 10.1016/S0378-1119(97)00644-6; Chen JZ, 2015, REV MED VIROL, V25, P24, DOI 10.1002/rmv.1823; Ciechanover A, 2005, CELL DEATH DIFFER, V12, P1178, DOI 10.1038/sj.cdd.4401692; Ding LH, 2009, J CLIN INVEST, V119, P349, DOI 10.1172/JCI35930; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Genini M, 1997, DNA CELL BIOL, V16, P433, DOI 10.1089/dna.1997.16.433; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hayashi H, 2009, ARTERIOSCL THROM VAS, V29, P909, DOI 10.1161/ATVBAHA.108.178541; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; Hwang SG, 2002, J BIOL CHEM, V277, P2923, DOI 10.1074/jbc.M109113200; Im HJ, 2002, J BIOL CHEM, V277, P14612, DOI 10.1074/jbc.M109414200; Jin H, 2015, SCI REP-UK, V5, DOI 10.1038/srep08367; Johannessen M, 2006, CELL MOL LIFE SCI, V63, P268, DOI 10.1007/s00018-005-5438-z; Jung CR, 2010, J CLIN INVEST, V120, P4493, DOI 10.1172/JCI42674; Kadrmas JL, 2004, NAT REV MOL CELL BIO, V5, P920, DOI 10.1038/nrm1499; Kim JH, 2014, J REPROD DEVELOP, V60, P14, DOI 10.1262/jrd.2013-090; Kim JH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms3936; Kirkin V, 2011, CURR OPIN GENET DEV, V21, P21, DOI 10.1016/j.gde.2010.10.004; Kleiber K, 2007, ANTICANCER RES, V27, P55; Komander D, 2012, ANNU REV BIOCHEM, V81, P203, DOI 10.1146/annurev-biochem-060310-170328; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lee MJ, 2013, PROG NEUROBIOL, V105, P49, DOI 10.1016/j.pneurobio.2013.03.001; Li HY, 2001, CELL MOTIL CYTOSKEL, V48, P11, DOI 10.1002/1097-0169(200101)48:1<11::AID-CM2>3.0.CO;2-I; Lipkowitz S, 2011, NAT REV CANCER, V11, P629, DOI 10.1038/nrc3120; Manzo-Merino J, 2015, VIROLOGY, V476, P100, DOI 10.1016/j.virol.2014.11.025; Mille F, 2009, NAT CELL BIOL, V11, P739, DOI 10.1038/ncb1880; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Muerkoster SS, 2008, ONCOGENE, V27, P1122, DOI 10.1038/sj.onc.1210728; Munoz N, 2006, VACCINE, V24, P1, DOI 10.1016/j.vaccine.2006.05.115; Ng CF, 2011, CANCER LETT, V304, P97, DOI 10.1016/j.canlet.2011.02.001; Pawlikowska P, 2010, CELL DEATH DIFFER, V17, P1739, DOI 10.1038/cdd.2010.56; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Qian Z, 2009, LEUKEMIA, V23, P1650, DOI 10.1038/leu.2009.78; Ryou SM, 2014, J CONTROL RELEASE, V196, P287, DOI 10.1016/j.jconrel.2014.10.021; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schilling D, 2001, ONCOGENE, V20, P7992, DOI 10.1038/sj.onc.1204965; Suh DS, 2015, J PROTEOME RES, V14, P2446, DOI 10.1021/pr501230b; Sun Y, 2006, NEOPLASIA, V8, P645, DOI 10.1593/neo.06376; Wu MX, 2013, EXPERT OPIN THER TAR, V17, P593, DOI 10.1517/14728222.2013.768234; Wu MX, 2003, APOPTOSIS, V8, P11, DOI 10.1023/A:1021688600370; Yoon S, 2009, BIOCHEM BIOPH RES CO, V382, P400, DOI 10.1016/j.bbrc.2009.03.037; Zienert E, 2015, CANCER LETT, V364, P17, DOI 10.1016/j.canlet.2015.04.019	50	21	22	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2016	35	39					5106	5118		10.1038/onc.2016.54	http://dx.doi.org/10.1038/onc.2016.54			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX5PI	26973248	Green Published, hybrid			2022-12-17	WOS:000384433000003
J	Ahronian, LG; Zhu, LJ; Chen, YW; Chu, HC; Klimstra, DS; Lewis, BC				Ahronian, L. G.; Zhu, L. J.; Chen, Y-W; Chu, H-C; Klimstra, D. S.; Lewis, B. C.			A novel KLF6-Rho GTPase axis regulates hepatocellular carcinoma cell migration and dissemination	ONCOGENE			English	Article							PROSTATE-CANCER PROGRESSION; NUCLEOTIDE EXCHANGE FACTOR; TUMOR-SUPPRESSOR GENE; RECURRENT MUTATIONS; DOWN-REGULATION; MOUSE MODEL; METASTASIS; EXPRESSION; RECEPTOR; P53	The presence of invasion into the extra-hepatic portion of the portal vein or the development of distant metastases renders hepatocellular carcinoma (HCC) patients ineligible for the only potential curative options for this malignancy-tumor resection or organ transplantation. Gene expression profiling of murine HCC cell lines identified KLF6 as a potential regulator of HCC cell migration. KLF6 knockdown increases cell migration, consistent with the correlation between decreased KLF6 mRNA levels and the presence of vascular invasion in human HCC. Concordantly, single-copy deletion of Klf6 in a HCC mouse model results in increased tumor formation, increased metastasis to the lungs and decreased survival, indicating that KLF6 suppresses both HCC development and metastasis. By combining gene expression profiling and chromatin immunoprecipitation coupled to deep sequencing, we identified novel transcriptional targets of KLF6 in HCC cells including VAV3, a known activator of the RAC1 small GTPase. Indeed, RAC1 activity is increased in KLF6-knockdown cells in a VAV3-dependent manner, and knockdown of either RAC1 or VAV3 impairs HCC cell migration. Together, our data demonstrate a novel function for KLF6 in constraining HCC dissemination through the regulation of a VAV3-RAC1 signaling axis.	[Ahronian, L. G.; Zhu, L. J.; Lewis, B. C.] Univ Massachusetts, Dept Mol Cell & Canc Biol, Sch Med, 364 Plantat St,LRB 521, Worcester, MA 01605 USA; [Zhu, L. J.; Lewis, B. C.] Univ Massachusetts, Program Mol Med, Sch Med, Worcester, MA 01605 USA; [Zhu, L. J.] Univ Massachusetts, Program Bioinformat & Integrat Biol, Sch Med, Worcester, MA 01605 USA; [Chen, Y-W; Chu, H-C] Natl Hlth Res Inst, Natl Inst Canc Res, Maioli, Taiwan; [Klimstra, D. S.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Lewis, B. C.] Univ Massachusetts, Canc Ctr, Sch Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; National Health Research Institutes - Taiwan; Memorial Sloan Kettering Cancer Center; University of Massachusetts System; University of Massachusetts Worcester	Lewis, BC (corresponding author), Univ Massachusetts, Dept Mol Cell & Canc Biol, Sch Med, 364 Plantat St,LRB 521, Worcester, MA 01605 USA.	Brian.Lewis@umassmed.edu		Zhu, Lihua/0000-0001-7416-0590	NIH grant [R01 CA121171]; NATIONAL CANCER INSTITUTE [P30CA008748, R01CA121171] Funding Source: NIH RePORTER	NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Genentech for sharing Klf6<SUP>flox</SUP> mice; Scott Friedman for providing the Klf6<SUP>flox</SUP> mice and sharing data before publication. We thank JiuFeng Cai and Victor Adelanwa for technical assistance; Dr Kerry Burnstein for providing the VAV3 expression constructs; Karl Simin, Leslie Shaw, Scot Wolfe and members of the Lewis lab for helpful discussions and critical review of the manuscript. The assistance of the Memorial Sloan-Kettering Cancer Center Genomics Core and the University of Massachusetts Medical School Genomics and Deep Sequencing core facilities is gratefully acknowledged. This study was supported by NIH grant R01 CA121171 to BCL. The funders played no role in the design, execution or interpretation of the study.	BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Budhu A, 2006, CANCER CELL, V10, P99, DOI 10.1016/j.ccr.2006.06.016; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Chen LL, 2010, J CLIN INVEST, V120, P1178, DOI 10.1172/JCI40665; Chen YW, 2007, CANCER RES, V67, P7589, DOI 10.1158/0008-5472.CAN-07-0381; Chen YW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069389; Chen YW, 2009, NEOPLASIA, V11, P835, DOI 10.1593/neo.09476; Das A, 2006, J BIOL CHEM, V281, P39105, DOI 10.1074/jbc.M607720200; Difeo A, 2006, ONCOGENE, V25, P6026, DOI 10.1038/sj.onc.1209611; Ding J, 2010, NAT CELL BIOL, V12, P390, DOI 10.1038/ncb2039; Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027; Fujimoto A, 2012, NAT GENET, V44, P760, DOI 10.1038/ng.2291; Gehrau RC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008929; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hatami R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004688; Hayat MJ, 2007, ONCOLOGIST, V12, P20, DOI 10.1634/theoncologist.12-1-20; Hirsch DS, 2001, J BIOL CHEM, V276, P875, DOI 10.1074/jbc.M007039200; Iizuka N, 2004, ANTICANCER RES, V24, P4085; Ito G, 2004, CANCER RES, V64, P3838, DOI 10.1158/0008-5472.CAN-04-0185; IZUMI R, 1992, J SURG ONCOL, V49, P151, DOI 10.1002/jso.2930490305; Joberty G, 1999, MOL CELL BIOL, V19, P6585; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kan ZY, 2013, GENOME RES, V23, P1422, DOI 10.1101/gr.154492.113; Kaposi-Novak P, 2006, J CLIN INVEST, V116, P1582, DOI 10.1172/JCI27236; Katyal S, 2000, RADIOLOGY, V216, P698, DOI 10.1148/radiology.216.3.r00se24698; Kremer-Tal S, 2004, HEPATOLOGY, V40, P1047, DOI 10.1002/hep.20460; Kremer-Tal S, 2007, J HEPATOL, V46, P645, DOI 10.1016/j.jhep.2006.10.012; Lee JS, 2004, GASTROENTEROLOGY, V127, pS51, DOI 10.1053/j.gastro.2004.09.015; Leow CC, 2009, J BIOL CHEM, V284, P21057, DOI 10.1074/jbc.M109.001776; Lewis BC, 2005, MOL CELL BIOL, V25, P1228, DOI 10.1128/MCB.25.4.1228-1237.2005; Lewis BC, 1997, MOL CELL BIOL, V17, P4967, DOI 10.1128/MCB.17.9.4967; Lin KT, 2012, CANCER RES, V72, P3000, DOI 10.1158/0008-5472.CAN-11-2502; Lu X, 2010, CLIN CANCER RES, V16, P5928, DOI 10.1158/1078-0432.CCR-10-1360; Lyons LS, 2006, MOL ENDOCRINOL, V20, P1061, DOI 10.1210/me.2005-0346; Narla G, 2005, CANCER RES, V65, P1213, DOI 10.1158/0008-5472.CAN-04-4249; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Narla G, 2008, J CLIN INVEST, V118, P2711, DOI 10.1172/JCI34780; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Tan BB, 2014, TUMOR BIOL, V35, P1481, DOI 10.1007/s13277-013-1204-2; Tarocchi M, 2011, HEPATOLOGY, V54, P522, DOI 10.1002/hep.24413; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Vetter D, 2012, HEPATOLOGY, V56, P1361, DOI 10.1002/hep.25810; Villanueva A, 2011, J HEPATOL, V55, P724, DOI 10.1016/j.jhep.2011.03.018; Wurmbach E, 2007, HEPATOLOGY, V45, P938, DOI 10.1002/hep.21622; Xue W, 2008, GENE DEV, V22, P1439, DOI 10.1101/gad.1672608; Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212-9224.2000; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zheng Q, 2008, NUCLEIC ACIDS RES, V36, pW358, DOI 10.1093/nar/gkn276; Zhou X, 2008, INT J ONCOL, V32, P1285; Zhu LJ, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-237	52	21	21	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2016	35	35					4653	4662		10.1038/onc.2016.2	http://dx.doi.org/10.1038/onc.2016.2			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU6PE	26876204	Green Accepted			2022-12-17	WOS:000382336300011
J	Kim, JE; Roh, E; Lee, MH; Yu, DH; Kim, DJ; Lim, TG; Jung, SK; Peng, C; Cho, YY; Dickinson, S; Alberts, D; Bowden, GT; Einspahr, J; Stratton, SP; Curiel-Lewandrowski, C; Bode, AM; Lee, KW; Dong, Z				Kim, J-E; Roh, E.; Lee, M. H.; Yu, D. H.; Kim, D. J.; Lim, T-G; Jung, S. K.; Peng, C.; Cho, Y-Y; Dickinson, S.; Alberts, D.; Bowden, G. T.; Einspahr, J.; Stratton, S. P.; Curiel-Lewandrowski, C.; Bode, A. M.; Lee, K. W.; Dong, Z.			Fyn is a redox sensor involved in solar ultraviolet light-induced signal transduction in skin carcinogenesis	ONCOGENE			English	Article							SRC-FAMILY KINASES; TYROSINE PHOSPHORYLATION; PKC-DELTA; C-DELTA; APOPTOSIS; CANCER; ACTIVATION; RADIATION; STRESS; TARGET	Solar ultraviolet (UV) light is a major etiological factor in skin carcinogenesis, with solar UV-stimulated signal transduction inducing pathological changes and skin damage. The primary sensor of solar UV-induced cellular signaling has not been identified. We use an experimental system of solar simulated light (SSL) to mimic solar UV and we demonstrate that Fyn is a primary redox sensor involved in SSL-induced signal transduction. Reactive oxygen species (ROS) generated by SSL exposure directly oxidize Cys488 of Fyn, resulting in increased Fyn kinase activity. Fyn oxidation was increased in mouse skin after SSL exposure and Fyn-knockout mice formed larger and more tumors compared with Fyn wild-type mice when exposed to SSL for an extended period of time. Murine embryonic fibroblasts (MEFs) lacking Fyn and cells in which Fyn expression was knocked down were resistant to SSL-induced apoptosis. Furthermore, cells expressing mutant Fyn (C448A) were resistant to SSL-induced apoptosis. These findings suggest that Fyn acts as a regulatory nexus between solar UV, ROS and signal transduction during skin carcinogenesis.	[Kim, J-E; Roh, E.; Lee, M. H.; Yu, D. H.; Kim, D. J.; Lim, T-G; Jung, S. K.; Peng, C.; Cho, Y-Y; Bode, A. M.; Dong, Z.] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA; [Kim, J-E; Lim, T-G; Jung, S. K.; Lee, K. W.] Seoul Natl Univ, Dept Agr Biotechnol, Seoul 151921, South Korea; [Kim, J-E; Lim, T-G; Lee, K. W.] Seoul Natl Univ, Adv Inst Convergence Technol, Suwon, Gyeonggi Do, South Korea; [Lee, M. H.] China US Hormel Canc Inst, Zhenzhou, Henan, Peoples R China; [Lim, T-G; Jung, S. K.] Korea Food Res Inst, Div Strateg Food Res, Songnam, Gyeonggi Do, South Korea; [Cho, Y-Y] Catholic Univ Korea, Coll Pharm, Bucheon Si, Gyeonggi Do, South Korea; [Dickinson, S.; Alberts, D.; Bowden, G. T.; Einspahr, J.; Stratton, S. P.; Curiel-Lewandrowski, C.] Univ Arizona, Ctr Canc, Tucson, AZ USA	University of Minnesota System; Seoul National University (SNU); Seoul National University (SNU); Korea Food Research Institute (KFRI); Catholic University of Korea; University of Arizona	Dong, Z (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.; Lee, KW (corresponding author), Seoul Natl Univ, Dept Agr Biotechnol, Seoul 151921, South Korea.	kiwon@snu.ac.kr; zgdong@hi.umn.edu	Lee, Ki Won/M-4114-2018; kim, jong-eun/B-3550-2017; Lim, Tae-Gyu/AAO-8475-2020; Cho, Yong-Yeon/AAD-4263-2020	kim, jong-eun/0000-0002-5030-6126; Lim, Tae-Gyu/0000-0001-6930-9565; Cho, Yong-Yeon/0000-0003-1107-2651	National Institutes of Health [CA077646, CA027502, CA166011, CA172457, R37CA081064]; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [F00044]; Leap Research Program through the National Research Foundation, Ministry of Science, ICT and Future Planning, Republic of Korea [2015R1A2A1A10053567]; Hormel Foundation; NATIONAL CANCER INSTITUTE [P01CA027502, R37CA081064, R01CA077646, R21CA172457, R01CA166011] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology; Leap Research Program through the National Research Foundation, Ministry of Science, ICT and Future Planning, Republic of Korea; Hormel Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by The Hormel Foundation and National Institutes of Health grants to ZD (CA077646, CA027502, CA166011, CA172457 and R37CA081064), the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (F00044) and the Leap Research Program through the National Research Foundation, Ministry of Science, ICT and Future Planning, Republic of Korea (2015R1A2A1A10053567).	Abdel-Malek ZA, 2010, PIGM CELL MELANOMA R, V23, P171, DOI 10.1111/j.1755-148X.2010.00679.x; Aleshin A, 2010, NEOPLASIA, V12, P599, DOI 10.1593/neo.10328; Basu A, 2010, THESCIENTIFICWORLDJO, V10, P2272, DOI 10.1100/tsw.2010.214; Benes C, 2001, AM J PHYSIOL-CELL PH, V280, pC1498, DOI 10.1152/ajpcell.2001.280.6.C1498; Bickers DR, 2006, J INVEST DERMATOL, V126, P2565, DOI 10.1038/sj.jid.5700340; Breitkreutz D, 2007, J CANCER RES CLIN, V133, P793, DOI 10.1007/s00432-007-0280-3; Byun S, 2013, CARCINOGENESIS, V34, P397, DOI 10.1093/carcin/bgs358; Byun S, 2010, CANCER RES, V70, P2415, DOI 10.1158/0008-5472.CAN-09-4093; Chan CB, 2010, DIABETES, V59, P883, DOI 10.2337/db09-1404; Chen ZY, 2011, CARCINOGENESIS, V32, P1419, DOI 10.1093/carcin/bgr088; Fukunaga M, 2001, BIOCHEM BIOPH RES CO, V289, P573, DOI 10.1006/bbrc.2001.6025; Giannoni E, 2005, MOL CELL BIOL, V25, P6391, DOI 10.1128/MCB.25.15.6391-6403.2005; Giannoni E, 2010, FREE RADICAL BIO MED, V49, P516, DOI 10.1016/j.freeradbiomed.2010.04.025; Hanson KM, 2002, PHOTOCHEM PHOTOBIOL, V76, P57, DOI 10.1562/0031-8655(2002)076<0057:OAQOUI>2.0.CO;2; Humphries MJ, 2008, ONCOGENE, V27, P3045, DOI 10.1038/sj.onc.1210967; Joseloff E, 2002, J BIOL CHEM, V277, P12318, DOI 10.1074/jbc.M111618200; Jung SK, 2008, CANCER RES, V68, P6021, DOI 10.1158/0008-5472.CAN-08-0899; Krutmann J, 2010, TXB AGING SKIN, P101; Kulms D, 2002, J INVEST DERM SYMP P, V7, P46, DOI 10.1046/j.1523-1747.2002.19638.x; Lee KM, 2010, BIOCHEM PHARMACOL, V80, P2042, DOI 10.1016/j.bcp.2010.06.042; Lee KM, 2010, CANCER PREV RES, V3, P454, DOI 10.1158/1940-6207.CAPR-09-0137; Li JX, 2012, CANCER RES, V72, P260, DOI 10.1158/0008-5472.CAN-11-2596; Li WJ, 2007, J BIOL CHEM, V282, P1161, DOI 10.1074/jbc.M606583200; Lippens S, 2009, APOPTOSIS, V14, P549, DOI 10.1007/s10495-009-0324-z; Liu KD, 2013, CANCER RES, V73, P2181, DOI 10.1158/0008-5472.CAN-12-3408; Loesch M, 2008, FRONT BIOSCI-LANDMRK, V13, P3581, DOI 10.2741/2951; Madan V, 2010, LANCET, V375, P673, DOI 10.1016/S0140-6736(09)61196-X; Narayanan DL, 2010, INT J DERMATOL, V49, P978, DOI 10.1111/j.1365-4632.2010.04474.x; Oi N, 2012, CANCER PREV RES, V5, P1103, DOI 10.1158/1940-6207.CAPR-11-0397; Parkin DM, 2011, BRIT J CANCER, V105, pS66, DOI 10.1038/bjc.2011.486; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Raj D, 2006, J INVEST DERMATOL, V126, P243, DOI 10.1038/sj.jid.5700008; Saito YD, 2010, CANCER-AM CANCER SOC, V116, P1629, DOI 10.1002/cncr.24879; Shim JH, 2010, CANCER PREV RES, V3, P670, DOI 10.1158/1940-6207.CAPR-09-0185; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019; Tang X, 2007, CELL DEATH DIFFER, V14, P368, DOI 10.1038/sj.cdd.4402011; Vasant C, 2003, FREE RADICAL BIO MED, V35, P1082, DOI 10.1016/S0891-5849(03)00471-4; Wagener FADTG, 2013, INT J MOL SCI, V14, P9126, DOI 10.3390/ijms14059126; Xu YR, 2005, J DERMATOL SCI, pS1, DOI 10.1016/j.descs.2005.06.002; Yoo SK, 2011, NATURE, V480, P109, DOI 10.1038/nature10632; Zhao L, 2009, CANCER RES, V69, P9439, DOI 10.1158/0008-5472.CAN-09-2976	42	21	21	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 4	2016	35	31					4091	4101		10.1038/onc.2015.471	http://dx.doi.org/10.1038/onc.2015.471			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8GG	26686094	Green Accepted			2022-12-17	WOS:000381020900007
J	Peixoto, P; Blomme, A; Costanza, B; Ronca, R; Rezzola, S; Palacios, AP; Schoysman, L; Boutry, S; Goffart, N; Peulen, O; Maris, P; Di Valentin, E; Hennequiere, V; Bianchi, E; Henry, A; Meunier, P; Rogister, B; Muller, RN; Delvenne, P; Bellahcene, A; Castronovo, V; Turtoi, A				Peixoto, P.; Blomme, A.; Costanza, B.; Ronca, R.; Rezzola, S.; Palacios, A. P.; Schoysman, L.; Boutry, S.; Goffart, N.; Peulen, O.; Maris, P.; Di Valentin, E.; Hennequiere, V.; Bianchi, E.; Henry, A.; Meunier, P.; Rogister, B.; Muller, R. N.; Delvenne, P.; Bellahcene, A.; Castronovo, V.; Turtoi, A.			HDAC7 inhibition resets STAT3 tumorigenic activity in human glioblastoma independently of EGFR and PTEN: new opportunities for selected targeted therapies	ONCOGENE			English	Article							HISTONE DEACETYLASE INHIBITORS; EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASE GENES; NF-KAPPA-B; INTRATUMORAL HETEROGENEITY; TUMOR; CANCER; BRAIN; AMPLIFICATION; ANGIOGENESIS	To date, the mutational status of EGFR and PTEN has been shown as relevant for favoring pro-or anti-tumor functions of STAT3 in human glioblastoma multiforme (GBM). We have screened genomic data from 154 patients and have identified a strong positive correlation between STAT3 and HDAC7 expression. In the current work we show the existence of a subpopulation of patients overexpressing HDAC7 and STAT3 that has particularly poor clinical outcome. Surprisingly, the somatic mutation rate of both STAT3 and HDAC7 was insignificant in GBM comparing with EGFR, PTEN or TP53. Depletion of HDAC7 in a range of GBM cells induced the expression of tyrosine kinase JAK1 and the tumor suppressor AKAP12. Both proteins synergistically sustained the activity of STAT3 by inducing its phosphorylation (JAK1) and protein expression (AKAP12). In absence of HDAC7, activated STAT3 was responsible for significant imbalance of secreted pro-/anti-angiogenic factors. This inhibited the migration and sprouting of endothelial cells in paracrine fashion in vitro as well as angiogenesis in vivo. In a murine model of GBM, induced HDAC7-silencing decreased the tumor burden by threefold. The current data show for the first time that silencing HDAC7 can reset the tumor suppressor activity of STAT3, independently of the EGFR/PTEN/TP53 background of the GBM. This effect could be exploited to overcome tumor heterogeneity and provide a new rationale behind the development of specific HDAC7 inhibitors for clinical use.	[Peixoto, P.; Blomme, A.; Costanza, B.; Palacios, A. P.; Peulen, O.; Maris, P.; Hennequiere, V.; Henry, A.; Bellahcene, A.; Castronovo, V.; Turtoi, A.] Univ Liege, GIGA Canc, Metastasis Res Lab, Ave Hop 3,Tour Patho 4, B-4000 Liege, Belgium; [Ronca, R.; Rezzola, S.] Univ Brescia, Dept Mol & Translat Med, Brescia, Italy; [Schoysman, L.; Meunier, P.] Univ Hosp Liege, Dept Radiol, Liege, Belgium; [Boutry, S.; Muller, R. N.] Univ Mons, Dept Gen Organ & Biomed Chem, NMR & Mol Imaging Lab, Mons, Belgium; [Boutry, S.; Muller, R. N.] Ctr Microscopy & Mol Imaging, Charleroi, Belgium; [Goffart, N.; Rogister, B.] Univ Liege, GIGA Neurosci, Liege, Belgium; [Di Valentin, E.] Univ Liege, GIGA Viral Vectors Platform, Liege, Belgium; [Bianchi, E.; Delvenne, P.] Univ Hosp Liege, Dept Pathol, Liege, Belgium	University of Liege; University of Brescia; University of Liege; University of Mons; University of Liege; University of Liege; University of Liege	Turtoi, A (corresponding author), Univ Liege, GIGA Canc, Metastasis Res Lab, Ave Hop 3,Tour Patho 4, B-4000 Liege, Belgium.	a.turtoi@ulg.ac.be	Rezzola, Sara/AAA-2745-2019; Blomme, Arnaud/AAM-1440-2020; Rezzola, Sara/AAE-8980-2020; Blomme, Arnaud/AGO-7915-2022; Ronca, Roberto/AAC-6470-2022; Peulen, Olivier/C-1250-2018; Rogister, Bernard/AAJ-9591-2020; Maris, Pamela/ABG-2488-2021; Turtoi, Andrei/ABD-1271-2021	Rezzola, Sara/0000-0003-1193-8929; Blomme, Arnaud/0000-0003-4183-8726; Ronca, Roberto/0000-0001-8979-7068; Peulen, Olivier/0000-0002-6933-0134; Turtoi, Andrei/0000-0003-3813-6635; Peixoto, Paul/0000-0001-6302-7823; Di Valentin, Emmanuel/0000-0002-5287-7950; Costanza, Brunella/0000-0001-8279-805X; Maris, Pamela/0000-0002-4471-9717	University of Liege (Concerted Research Action Program (IDEA project)); National Fund for Scientific Research (FNRS/TELEVIE); European Regional Development Fund and Wallonia	University of Liege (Concerted Research Action Program (IDEA project)); National Fund for Scientific Research (FNRS/TELEVIE)(Fonds de la Recherche Scientifique - FNRS); European Regional Development Fund and Wallonia	The authors acknowledge the experimental support of Dr Chantal Humblet and Ms Alice Marquet (GIGA-histology platform, ULg), Dr Sandra Ormenese (GIGA-imaging platform, ULg) as well as of Evgenia Turtoi (Metastasis Research Laboratory) for the immunohistochemistry analysis and of Naima Maloujahmoum (Metastasis Research Laboratory) for the cell culture. The authors are also thankful to Dr Stephanie Gofflot from the institutional Biobank of the University Hospital Liege for providing GBM fresh tissues and to Dr Gilles Doumont (group of Prof Serge Goldman, Universite libre de Bruxelles) for help with animal experiments. The authors are grateful to Ms. Ana Turtoi for proofreading the manuscript. The results shown in this work are in part based on data generated by the TCGA Research Network: http://cancergenome.nih.gov/. This work was supported with grants from the University of Liege (Concerted Research Action Program (IDEA project)) and from the National Fund for Scientific Research (FNRS/TELEVIE). Andrei Turtoi is a post-doctoral research fellow (FNRS/TELEVIE) and Akeila Bellahcene is a senior research associate (FNRS). Arnaud Blomme is a post-doctoral research fellow (FNRS/TELEVIE). The Center for Microscopy and Molecular Imaging (CMMI) is supported by the European Regional Development Fund and Wallonia. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Atkinson GP, 2010, EXPERT REV NEUROTHER, V10, P575, DOI 10.1586/ERN.10.21; Bezecny P, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0985-5; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chang SR, 2006, CELL, V126, P321, DOI 10.1016/j.cell.2006.05.040; Dauer DJ, 2005, ONCOGENE, V24, P3397, DOI 10.1038/sj.onc.1208469; de la Iglesia N, 2008, J NEUROSCI, V28, P5870, DOI 10.1523/JNEUROSCI.5385-07.2008; de la Iglesia N, 2008, GENE DEV, V22, P449, DOI 10.1101/gad.1606508; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x; EMI N, 1991, J VIROL, V65, P1202, DOI 10.1128/JVI.65.3.1202-1207.1991; Fan QW, 2013, CANCER CELL, V24, P438, DOI 10.1016/j.ccr.2013.09.004; Frattini V, 2013, NAT GENET, V45, P1141, DOI 10.1038/ng.2734; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gelman IH, 2012, CANCER METAST REV, V31, P493, DOI 10.1007/s10555-012-9360-1; Goeppert B, 2013, J NEUROPATH EXP NEUR, V72, P933, DOI 10.1097/NEN.0b013e3182a59a88; Hamer PCDW, 2010, NEURO-ONCOLOGY, V12, P304, DOI 10.1093/neuonc/nop068; Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037; Inda MD, 2014, CANCERS, V6, P226, DOI 10.3390/cancers6010226; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Lee SW, 2003, NAT MED, V9, P900, DOI 10.1038/nm889; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liang Y, 2005, P NATL ACAD SCI USA, V102, P5814, DOI 10.1073/pnas.0402870102; Little SE, 2012, CANCER RES, V72, P1614, DOI 10.1158/0008-5472.CAN-11-4069; Lokker NA, 2002, CANCER RES, V62, P3729; LUNDJOHANSEN M, 1990, CANCER RES, V50, P6039; Monk M, 2001, ONCOGENE, V20, P8085, DOI 10.1038/sj.onc.1205088; Mottet D, 2007, CIRC RES, V101, P1237, DOI 10.1161/CIRCRESAHA.107.149377; Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5; Schneller D, 2011, HEPATOLOGY, V54, P164, DOI 10.1002/hep.24329; Snuderl M, 2011, CANCER CELL, V20, P810, DOI 10.1016/j.ccr.2011.11.005; Su B, 2013, ONCOGENE, V32, P2016, DOI 10.1038/onc.2012.218; Suresh Kp, 2011, J Hum Reprod Sci, V4, P8, DOI 10.4103/0974-1208.82352; Szerlip NJ, 2012, P NATL ACAD SCI USA, V109, P3041, DOI 10.1073/pnas.1114033109; Talasila KM, 2013, ACTA NEUROPATHOL, V125, P683, DOI 10.1007/s00401-013-1101-1; Turtoi Andrei, 2015, Critical Reviews in Oncogenesis, V20, P119; Turtoi A, 2015, B CANCER, V102, P17, DOI 10.1016/j.bulcan.2014.12.006; Turtoi A, 2012, ANGIOGENESIS, V15, P543, DOI 10.1007/s10456-012-9279-8; West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738; Wheeler SE, 2010, ONCOGENE, V29, P5135, DOI 10.1038/onc.2009.279; Xiao H, 2003, J BIOL CHEM, V278, P11197, DOI 10.1074/jbc.M210816200; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166	47	21	22	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	34					4481	4494		10.1038/onc.2015.506	http://dx.doi.org/10.1038/onc.2015.506			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU4AC	26853466				2022-12-17	WOS:000382153100006
J	Tesio, M; Trinquand, A; Macintyre, E; Asnafi, V				Tesio, M.; Trinquand, A.; Macintyre, E.; Asnafi, V.			Oncogenic PTEN functions and models in T-cell malignancies	ONCOGENE			English	Review							ACUTE LYMPHOBLASTIC-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; TUMOR-SUPPRESSOR PTEN; DEFICIENT MICE; CANCER SUSCEPTIBILITY; PHOSPHATASE-ACTIVITY; INITIATING CELLS; PROSTATE-CANCER; MESSENGER-RNAS; PTEN(+/-) MICE	PTEN is a protein phosphatase that is crucial to prevent the malignant transformation of T-cells. Although a numerous mechanisms regulate its expression and function, they are often altered in T-cell acute lymphoblastic leukaemias and T-cell lymphomas. As such, PTEN inactivation frequently occurs in these malignancies, where it can be associated with chemotherapy resistance and poor prognosis. Different Pten knockout models recapitulated the development of T-cell leukaemia/lymphoma, demonstrating that PTEN loss is at the center of a complex oncogenic network that sustains and drives tumorigenesis via the activation of multiple signalling pathways. These aspects and their therapeutic implications are discussed in this review.	Univ Paris Descartes Sorbonne Cite, INEM, INSERM U1151, Paris, France; Hop Necker Enfants Malad, AP HP, Lab Oncohematol, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Asnafi, V (corresponding author), Univ Paris 5 Descartes, Hop Necker Enfants Malad, Hematol Lab, INEM INSERM U1151, 149 Rue Sevres, F-75015 Paris, France.	vahid.asnafi@nck.aphp.fr	Trinquand, Amélie/AAV-7203-2021	Macintyre-Davi, Elizabeth Anne/0000-0003-0520-0493; TESIO, Melania/0000-0001-9291-0797	'Fondation de France' Fellowship; INCa (Institut National du Cancer: 'Soutien a la Recherche Translationnelle')	'Fondation de France' Fellowship; INCa (Institut National du Cancer: 'Soutien a la Recherche Translationnelle')	This work has been supported by a 'Fondation de France' Fellowship to MT and a grant from INCa (Institut National du Cancer: 'Soutien a la Recherche Translationnelle 2012') to AT.	Aifantis I, 2008, NAT REV IMMUNOL, V8, P380, DOI 10.1038/nri2304; Alimonti A, 2010, NAT GENET, V42, P454, DOI 10.1038/ng.556; Bandapalli OR, 2013, HAEMATOLOGICA, V98, P928, DOI 10.3324/haematol.2012.073585; Bayascas JR, 2005, CURR BIOL, V15, P1839, DOI 10.1016/j.cub.2005.08.066; Blackburn JS, 2014, CANCER CELL, V25, P366, DOI 10.1016/j.ccr.2014.01.032; Bonnet M, 2011, BLOOD, V117, P6650, DOI 10.1182/blood-2011-02-336842; Campbell RB, 2003, J BIOL CHEM, V278, P33617, DOI 10.1074/jbc.C300296200; Chiarini F, 2008, LEUKEMIA, V22, P1106, DOI 10.1038/leu.2008.79; Chung JH, 2005, CANCER RES, V65, P4108, DOI 10.1158/0008-5472.CAN-05-0124; Clappier E, 2011, J EXP MED, V208, P653, DOI 10.1084/jem.20110105; Cristofoletti C, 2013, BLOOD, V122, P3511, DOI 10.1182/blood-2013-06-510578; Denning G, 2007, ONCOGENE, V26, P3930, DOI 10.1038/sj.onc.1210175; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dose M, 2014, P NATL ACAD SCI USA, V111, P391, DOI 10.1073/pnas.1315752111; Fala F, 2008, MOL PHARMACOL, V74, P884, DOI 10.1124/mol.108.047639; Finlay DK, 2009, J EXP MED, V206, P2441, DOI 10.1084/jem.20090219; Freeman D, 2006, CANCER RES, V66, P6492, DOI 10.1158/0008-5472.CAN-05-4143; Gazzola A, 2009, HAEMATOL-HEMATOL J, V94, P1036, DOI 10.3324/haematol.2009.006718; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Georgescu MM, 2000, CANCER RES, V60, P7033; Gothert JR, 2005, BLOOD, V105, P2724, DOI 10.1182/blood-2004-08-3037; Grimaldi C, 2012, LEUKEMIA, V26, P91, DOI 10.1038/leu.2011.269; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Guo W, 2008, NATURE, V453, P529, DOI 10.1038/nature06933; Guo W, 2011, P NATL ACAD SCI USA, V108, P1409, DOI 10.1073/pnas.1006937108; Gutierrez A, 2009, BLOOD, V114, P647, DOI 10.1182/blood-2009-02-206722; Hagenbeek TJ, 2008, LEUKEMIA, V22, P608, DOI 10.1038/sj.leu.2405056; Hagenbeek TJ, 2004, J EXP MED, V200, P883, DOI 10.1084/jem.20040495; Hopkins BD, 2013, SCIENCE, V341, P399, DOI 10.1126/science.1234907; Hsieh AC, 2010, CANCER CELL, V17, P249, DOI 10.1016/j.ccr.2010.01.021; Jenkinson S, 2016, LEUKEMIA, V30, P39, DOI 10.1038/leu.2015.206; Johnsson P, 2013, NAT STRUCT MOL BIOL, V20, P440, DOI 10.1038/nsmb.2516; Jotta PY, 2010, LEUKEMIA, V24, P239, DOI 10.1038/leu.2009.209; Kalaitzidis D, 2012, CELL STEM CELL, V11, P429, DOI 10.1016/j.stem.2012.06.009; Kharas MG, 2010, BLOOD, V115, P1406, DOI 10.1182/blood-2009-06-229443; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; La Starza R, 2014, BLOOD, V124, P3577, DOI 10.1182/blood-2014-06-578856; Lee JY, 2010, CELL STEM CELL, V7, P593, DOI 10.1016/j.stem.2010.09.015; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liang H, 2014, CELL METAB, V19, P836, DOI 10.1016/j.cmet.2014.03.023; Liu XH, 2010, J CLIN INVEST, V120, P2497, DOI 10.1172/JCI42382; Locke FL, 2013, J IMMUNOL, V191, P1677, DOI 10.4049/jimmunol.1202018; Magee JA, 2012, CELL STEM CELL, V11, P415, DOI 10.1016/j.stem.2012.05.026; Malstrom S, 2001, P NATL ACAD SCI USA, V98, P14967, DOI 10.1073/pnas.231467698; Maser RS, 2007, NATURE, V447, P966, DOI 10.1038/nature05886; Mavrakis KJ, 2010, NAT CELL BIOL, V12, P372, DOI 10.1038/ncb2037; Medyouf H, 2010, BLOOD, V115, P1175, DOI 10.1182/blood-2009-04-214718; Mendes RD, 2014, BLOOD, V124, P567, DOI 10.1182/blood-2014-03-562751; Miething C, 2014, NATURE, V510, P402, DOI 10.1038/nature13239; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Naguib A, 2015, MOL CELL, V58, P255, DOI 10.1016/j.molcel.2015.03.011; Nakahata S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4393; Newton RH, 2015, BLOOD, V125, P852, DOI 10.1182/blood-2014-04-571372; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Papadavid E, 2014, EXP DERMATOL, V23, P931, DOI 10.1111/exd.12547; Piovan E, 2013, CANCER CELL, V24, P766, DOI 10.1016/j.ccr.2013.10.022; Planchon SM, 2008, J CELL SCI, V121, P249, DOI 10.1242/jcs.022459; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Remke M, 2009, BLOOD, V114, P1053, DOI 10.1182/blood-2008-10-186536; Scarisbrick JJ, 2000, BLOOD, V95, P2937, DOI 10.1182/blood.V95.9.2937.009k15_2937_2942; Schubbert S, 2014, CANCER RES, V74, P7048, DOI 10.1158/0008-5472.CAN-14-1470; Signer RAJ, 2014, NATURE, V509, P49, DOI 10.1038/nature13035; Silva A, 2008, J CLIN INVEST, V118, P3762, DOI 10.1172/JCI34616; Silva A, 2010, HAEMATOL-HEMATOL J, V95, P674, DOI 10.3324/haematol.2009.011999; Soond DR, 2012, J IMMUNOL, V188, P5935, DOI 10.4049/jimmunol.1102116; Stambolic V, 2000, CANCER RES, V60, P3605; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Subramaniam PS, 2012, CANCER CELL, V21, P459, DOI 10.1016/j.ccr.2012.02.029; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Svensson RU, 2011, AM J PATHOL, V179, P502, DOI 10.1016/j.ajpath.2011.03.014; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tan YF, 2008, CANCER RES, V68, P1296, DOI 10.1158/0008-5472.CAN-07-3218; Tandon P, 2011, P NATL ACAD SCI USA, V108, P2361, DOI 10.1073/pnas.1013629108; Tay Y, 2011, CELL, V147, P344, DOI 10.1016/j.cell.2011.09.029; Tesio M, 2013, J EXP MED, V210, P2337, DOI 10.1084/jem.20122768; Trinquand A, 2013, J CLIN ONCOL, V31, P4333, DOI 10.1200/JCO.2012.48.5292; Uner AH, 2005, LEUKEMIA LYMPHOMA, V46, P1463, DOI 10.1080/10428190500144813; Van Vlierberghe P, 2012, J CLIN INVEST, V122, P3398, DOI 10.1172/JCI61269; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Walker SM, 2004, BIOCHEM J, V379, P301, DOI 10.1042/BJ20031839; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wilson A, 2004, GENE DEV, V18, P2747, DOI 10.1101/gad.313104; Xue L, 2008, P NATL ACAD SCI USA, V105, P2022, DOI 10.1073/pnas.0712059105; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; You DW, 2015, CELL REP, V10, P2055, DOI 10.1016/j.celrep.2015.02.056; Zhang J, 2011, LEUKEMIA, V25, P1857, DOI 10.1038/leu.2011.220; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747; Zuurbier L, 2012, HAEMATOL-HEMATOL J, V97, P1405, DOI 10.3324/haematol.2011.059030	94	21	21	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					3887	3896		10.1038/onc.2015.462	http://dx.doi.org/10.1038/onc.2015.462			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	26616857				2022-12-17	WOS:000381013100001
J	Workenhe, ST; Ketela, T; Moffat, J; Cuddington, BP; Mossman, KL				Workenhe, S. T.; Ketela, T.; Moffat, J.; Cuddington, B. P.; Mossman, K. L.			Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells	ONCOGENE			English	Article							HERPES-SIMPLEX-VIRUS; ANTITUMOR EFFICACY; THERAPEUTIC-EFFICACY; TOPOISOMERASE-I; SR PROTEINS; PHOSPHORYLATION; SPLICEOSOME; APOPTOSIS; GENES; HSV-1	Oncolytic human herpes simplex virus type 1 (HSV-1) shows promising treatment efficacy in late-stage clinical trials. The anticancer activity of oncolytic viruses relies on deregulated pathways in cancer cells, which make them permissive to oncolysis. To identify pathways that restrict HSV-1 KM100-mediated oncolysis, this study used a pooled genome-wide short hairpin RNA library and found that depletion of the splicing factor arginine-rich splicing factor 2 (SRSF2) leads to enhanced cytotoxicity of breast cancer cells by KM100. Serine/arginine-rich (SR) proteins are a family of RNA-binding phosphoproteins that control both constitutive and alternative pre-mRNA splicing. Further characterization showed that KM100 infection of HS578T cells under conditions of low SRSF2 leads to pronounced apoptosis without a corresponding increase in virus replication. As DNA topoisomerase I inhibitors can limit the phosphorylation of SRSF2, we combined a topoisomerase I inhibitor chemotherapeutic with KM100 and observed synergistic anticancer effect in vitro and prolonged survival of tumor-bearing mice in vivo.	[Workenhe, S. T.; Cuddington, B. P.; Mossman, K. L.] McMaster Univ, Inst Infect Dis Res, McMaster Immunol Res Ctr, Dept Pathol & Mol Med, 1280 Main St West,MDCL 5026, Hamilton, ON L8S 4K1, Canada; [Ketela, T.; Moffat, J.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada	McMaster University; University of Toronto	Workenhe, ST; Mossman, KL (corresponding author), McMaster Univ, Inst Infect Dis Res, McMaster Immunol Res Ctr, Dept Pathol & Mol Med, 1280 Main St West,MDCL 5026, Hamilton, ON L8S 4K1, Canada.	samuelworkenhe@gmail.com; mossk@mcmaster.ca	Moffat, Jason/AAC-1110-2020	Moffat, Jason/0000-0002-5663-8586	Cancer Research Society; Canadian Cancer Society Research Institute	Cancer Research Society; Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS))	These studies were supported by operating grants to KLM from the Cancer Research Society and the Canadian Cancer Society Research Institute.	Anczukow O, 2012, NAT STRUCT MOL BIOL, V19, P220, DOI 10.1038/nsmb.2207; Bolyard C, 2014, CLIN CANCER RES, V20, P6479, DOI 10.1158/1078-0432.CCR-14-0463; Bonnal S, 2012, NAT REV DRUG DISCOV, V11, P847, DOI 10.1038/nrd3823; Cheema TA, 2011, CLIN CANCER RES, V17, P7383, DOI 10.1158/1078-0432.CCR-11-1762; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Ciomei M, 2006, CLIN CANCER RES, V12, P2856, DOI 10.1158/1078-0432.CCR-05-1859; Diallo JS, 2010, MOL THER, V18, P1123, DOI 10.1038/mt.2010.67; Edmond V, 2013, CELL CYCLE, V12, P1267, DOI 10.4161/cc.24363; Edmond V, 2011, EMBO J, V30, P510, DOI 10.1038/emboj.2010.333; Hummel JL, 2005, MOL THER, V12, P1101, DOI 10.1016/j.ymthe.2005.07.533; Ilkow CS, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003836; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Ketela T, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-213; Kumler I, 2013, BREAST CANCER RES TR, V138, P347, DOI 10.1007/s10549-013-2476-3; Mahoney DJ, 2010, CYTOKINE GROWTH F R, V21, P161, DOI 10.1016/j.cytogfr.2010.02.013; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Moorman NJ, 2010, J VIROL, V84, P5260, DOI 10.1128/JVI.02733-09; Mossman KL, 1999, J VIROL, V73, P9726, DOI 10.1128/JVI.73.12.9726-9733.1999; Pilch B, 2001, CANCER RES, V61, P6876; Quidville V, 2013, CANCER RES, V73, P2247, DOI 10.1158/0008-5472.CAN-12-2501; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; Rovero S, 2000, J IMMUNOL, V165, P5133, DOI 10.4049/jimmunol.165.9.5133; Russell SJ, 2012, NAT BIOTECHNOL, V30, P658, DOI 10.1038/nbt.2287; Sobol PT, 2011, MOL THER, V19, P335, DOI 10.1038/mt.2010.264; Solier S, 2010, CANCER RES, V70, P8055, DOI 10.1158/0008-5472.CAN-10-2491; Soret J, 2003, CANCER RES, V63, P8203; Stickeler E, 1999, ONCOGENE, V18, P3574, DOI 10.1038/sj.onc.1202671; Tahara M, 2013, BIOCHEM BIOPH RES CO, V434, P753, DOI 10.1016/j.bbrc.2013.03.128; Twyffels L, 2011, FEBS J, V278, P3246, DOI 10.1111/j.1742-4658.2011.08274.x; Ueno M, 2002, EUR UROL, V42, P390, DOI 10.1016/S0302-2838(02)00321-4; Vanderbeeken MC, 2013, CURR BREAST CANCER R, V5, P31, DOI 10.1007/s12609-012-0098-0; Walsh D, 2004, GENE DEV, V18, P660, DOI 10.1101/gad.1185304; Walsh D, 2011, NAT REV MICROBIOL, V9, P860, DOI 10.1038/nrmicro2655; Workenhe ST, 2013, CANCER IMMUNOL RES, V1, P309, DOI 10.1158/2326-6066.CIR-13-0059-T; Workenhe ST, 2014, MOL THER, V22, P123, DOI 10.1038/mt.2013.238; Workenhe ST, 2009, MOL IMMUNOL, V46, P2955, DOI 10.1016/j.molimm.2009.06.015; Zhang J, 2013, CANCER DISCOV, V3, P1228, DOI 10.1158/2159-8290.CD-13-0253	38	21	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2016	35	19					2465	2474		10.1038/onc.2015.303	http://dx.doi.org/10.1038/onc.2015.303			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GQ	26257065				2022-12-17	WOS:000376165500005
J	Liu, J; You, P; Chen, G; Fu, X; Zeng, X; Wang, C; Huang, Y; An, L; Wan, X; Navone, N; Wu, CL; McKeehan, WL; Zhang, Z; Zhong, W; Wang, F				Liu, J.; You, P.; Chen, G.; Fu, X.; Zeng, X.; Wang, C.; Huang, Y.; An, L.; Wan, X.; Navone, N.; Wu, C-L; McKeehan, W. L.; Zhang, Z.; Zhong, W.; Wang, F.			Hyperactivated FRS2 alpha-mediated signaling in prostate cancer cells promotes tumor angiogenesis and predicts poor clinical outcome of patients	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; EXPRESSION; FGFR1; PROGRESSION; ACTIVATION; INDUCTION; MOUSE; GENE; ADENOCARCINOMA; AMPLIFICATION	Metastasis of tumors requires angiogenesis, which is comprised of multiple biological processes that are regulated by angiogenic factors. The fibroblast growth factor (FGF) is a potent angiogenic factor and aberrant FGF signaling is a common property of tumors. Yet, how the aberration in cancer cells contributes to angiogenesis in the tumor is not well understood. Most studies of its angiogenic signaling mechanisms have been in endothelial cells. FGF receptor substrate 2 alpha (FRS2 alpha) is an FGF receptor-associated protein required for activation of downstream signaling molecules that include those in the mitogen-activated protein and AKT kinase pathways. Herein, we demonstrated that overactivation and hyperactivity of FRS2 alpha, as well as overexpression of cJUN and HIF1 alpha, were positively correlated with vessel density and progression of human prostate cancer (PCa) toward malignancy. We also demonstrate that FGF upregulated the production of vascular endothelial growth factor A mainly by increasing expression of cJUN and HIF1 alpha. This then promoted recruitment of endothelial cells and vessel formation for the tumor. Tumor angiogenesis in mouse PCa tissues was compromised by tissue-specific ablation of Frs2 alpha in prostate epithelial cells. Depletion of Frs2 alpha expression in human PCa cells and in a preclinical xenograft model, MDA PCa 118b, also significantly suppressed tumor angiogenesis accompanied with decreased tumor growth in the bone. The results underscore the angiogenic role of FRS2 alpha-mediated signaling in tumor epithelial cells in angiogenesis. They provide a rationale for treating PCa with inhibitors of FGF signaling. They also demonstrate the potential of overexpressed FRS2 alpha as a biomarker for PCa diagnosis, prognosis and response to therapies.	[Liu, J.; You, P.; Chen, G.; Fu, X.; Zeng, X.; Wang, C.; Huang, Y.; An, L.; McKeehan, W. L.; Wang, F.] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Ctr Canc & Stem Cell Biol, Houston, TX USA; [Liu, J.; You, P.; Chen, G.; Fu, X.; Zeng, X.; Wang, C.; Huang, Y.; An, L.; McKeehan, W. L.; Wang, F.] Texas A&M Hlth Sci Ctr, Coll Med, Houston, TX USA; [You, P.; Zhang, Z.] Xiamen Univ, Affiliated Zhongshan Hosp, Xiamen, Peoples R China; [Chen, G.; Fu, X.; Zhong, W.] Guangzhou Med Univ, Guangzhou Peoples Hosp 1, Guangdong Key Lab Clin Mol Med & Diagnost, Dept Urol, Guangzhou, Guangdong, Peoples R China; [Zeng, X.] Jinan Univ, Inst Tissue Transplantat & Immunol, Guangzhou, Guangdong, Peoples R China; [Wang, C.] Wenzhou Med Univ, Coll Pharm, Wenzhou, Peoples R China; [Wan, X.; Navone, N.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Wu, C-L] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Wu, C-L] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA; [Wu, C-L] Harvard Univ, Sch Med, Boston, MA USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Xiamen University; Guangzhou Medical University; Jinan University; Wenzhou Medical University; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Zhang, Z; Zhong, W; Wang, F (corresponding author), Texas A&M Univ, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	zzy11603@163.com; wdezhong@21cn.com; fwang@ibt.tamhsc.edu		Liu, Junchen/0000-0003-2765-9780	National Institutes of Health [CA96824, DE023106, CA140388]; Cancer Prevention and Research Institution of Texas [CPRIT110555]; National Natural Science Foundation of China [81170699, 81272813, 81101712, 81270761, 510180, 81072016]; NATIONAL CANCER INSTITUTE [R01CA096824, P50CA140388, P50CA083639, R56CA096824] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R56DE023106] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institution of Texas; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Dr Stefan Siwko and Samantha Del Castillo for critical reading of the manuscript. This work was supported in part by the National Institutes of Health CA96824 and DE023106 to FW, CA140388 to NN, WLM and FW, and The Cancer Prevention and Research Institution of Texas CPRIT110555 to FW and WLM, and the National Natural Science Foundation of China 81170699, 81272813 to CW, 81101712, 81270761 to XL, 510180 to WZ and 81072016 to ZYZ.	Acevedo VD, 2007, CANCER CELL, V12, P559, DOI 10.1016/j.ccr.2007.11.004; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; Devilard E, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-272; Francescone RA, 2011, JOVE-J VIS EXP, DOI 10.3791/3040; Giri D, 1999, J CELL PHYSIOL, V180, P53, DOI 10.1002/(SICI)1097-4652(199907)180:1<53::AID-JCP6>3.0.CO;2-P; Giri D, 1999, CLIN CANCER RES, V5, P1063; Gotoh N, 2004, P NATL ACAD SCI USA, V101, P17144, DOI 10.1073/pnas.0407577101; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Harris AL, 1996, BREAST CANCER RES TR, V38, P97, DOI 10.1007/BF01803788; Huang XQ, 2006, CANCER RES, V66, P1481, DOI 10.1158/0008-5472.CAN-05-2412; Huang YQ, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0820-4; Jin CL, 2003, CANCER RES, V63, P8784; Jin CL, 2003, PROSTATE, V57, P160, DOI 10.1002/pros.10283; Li ZG, 2008, J CLIN INVEST, V118, P2697, DOI 10.1172/JCI33093; Lin YS, 2007, GENESIS, V45, P554, DOI 10.1002/dvg.20327; McDougall SR, 2006, J THEOR BIOL, V241, P564, DOI 10.1016/j.jtbi.2005.12.022; McKeehan W. L., 2009, HDB CELL SIGNALING; Memarzadeh S, 2007, CANCER CELL, V12, P572, DOI 10.1016/j.ccr.2007.11.002; Ozen M, 2001, J NATL CANCER I, V93, P1783, DOI 10.1093/jnci/93.23.1783; Pages G, 2005, CARDIOVASC RES, V65, P564, DOI 10.1016/j.cardiores.2004.09.032; Polnaszek N, 2003, CANCER RES, V63, P5754; Song ZG, 2000, CANCER RES, V60, P6730; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Teishima J, 2014, ANTICANCER RES, V34, P695; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Valencia T, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-484; Valta MP, 2008, INT J CANCER, V123, P22, DOI 10.1002/ijc.23422; Wan XH, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009332; Wang F, 2004, PROSTATE, V58, P1, DOI 10.1002/pros.10311; Wang JH, 2004, CLIN CANCER RES, V10, P6169, DOI 10.1158/1078-0432.CCR-04-0408; Wang XK, 2011, GENE CHROMOSOME CANC, V50, P849, DOI 10.1002/gcc.20906; WEIDNER N, 1993, AM J PATHOL, V143, P401; Winter SF, 2007, ONCOGENE, V26, P4897, DOI 10.1038/sj.onc.1210288; Yang F, 2013, CANCER RES, V73, P3716, DOI 10.1158/0008-5472.CAN-12-3274; Yu EM, 2010, DISCOV MED, V10, P521; Zhang KQ, 2013, CANCER RES, V73, P1298, DOI 10.1158/0008-5472.CAN-12-2086; Zhang YY, 2008, DEVELOPMENT, V135, P775, DOI 10.1242/dev.009910; Zhong WD, 2012, INT J CANCER, V130, P300, DOI 10.1002/ijc.25982	41	21	21	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2016	35	14					1750	1759		10.1038/onc.2015.239	http://dx.doi.org/10.1038/onc.2015.239			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DI6LM	26096936	Green Accepted			2022-12-17	WOS:000373610400002
J	Alfano, L; Costa, C; Caporaso, A; Altieri, A; Indovina, P; Macaluso, M; Giordano, A; Pentimalli, F				Alfano, L.; Costa, C.; Caporaso, A.; Altieri, A.; Indovina, P.; Macaluso, M.; Giordano, A.; Pentimalli, F.			NONO regulates the intra-S-phase checkpoint in response to UV radiation	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; STRAND BREAK REPAIR; SPLICING-FACTOR; MESSENGER-RNA; CHK1 ACTIVATION; ATR ACTIVATION; RPA-SSDNA; PROTEIN; PHOSPHORYLATION; REPLICATION	The main risk factor for skin cancer is ultraviolet (UV) exposure, which causes DNA damage. Cells respond to UV-induced DNA damage by activating the intra-S-phase checkpoint, which prevents replication fork collapse, late origin firing and stabilizes fragile sites. Recently, the 54-kDa multifunctional protein NONO was found to be involved in the non-homologous end-joining DNA repair process and in poly ADP-ribose polymerase 1 activation. Interestingly, NONO is mutated in several tumour types and emerged as a crucial factor underlying both melanoma development and progression. Therefore, we set out to evaluate whether NONO could be involved in the DNA-damage response to UV radiations. We generated NONO-silenced HeLa cell clones and found that lack of NONO decreased cell growth rate. Then, we challenged NONO-silenced cells with exposure to UV radiations and found that NONO-silenced cells, compared with control cells, continued to synthesize DNA, failed to block new origin firing and impaired CHK1S345 phosphorylation showing a defective checkpoint activation. Consistently, NONO is present at the sites of UV-induced DNA damage where it localizes to RAD9 foci. To position NONO in the DNA-damage response cascade, we analysed the loading onto chromatin of various intra-S-phase checkpoint mediators and found that NONO favours the loading of topoisomerase II-binding protein 1 acting upstream of the ATM and Rad3-related kinase activity. Strikingly, re-expression of NONO, through an sh-resistant mRNA, rescued CHK1S345 phosphorylation in NONO-silenced cells. Interestingly, NONO silencing affected cell response to UV radiations also in a melanoma cell line. Overall, our data uncover a new role for NONO in mediating the cellular response to UV-induced DNA damage.	[Alfano, L.; Costa, C.; Altieri, A.; Pentimalli, F.] IRCCS, Ist Nazl Tumori Fdn G Pascale, CROM, Naples, Italy; [Caporaso, A.; Indovina, P.; Giordano, A.] Univ Siena, Dept Med Surg & Neurosci, Via Laterina 8, I-53100 Siena, Italy; [Caporaso, A.; Indovina, P.; Giordano, A.] ITT, Siena, Italy; [Indovina, P.; Macaluso, M.; Giordano, A.] Temple Univ, Sbarro Inst Canc Res & Mol Med, Coll Sci & Technol, BioLife Sci Bldg,Suite 333,1900N 12th St, Philadelphia, PA 19122 USA; [Indovina, P.; Macaluso, M.; Giordano, A.] Temple Univ, Coll Sci & Technol, Ctr Biotechnol, BioLife Sci Bldg,Suite 333,1900N 12th St, Philadelphia, PA 19122 USA	IRCCS Fondazione Pascale; University of Siena; ISPRO Istituto per lo studio, la prevenzione e la rete oncologica; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Giordano, A (corresponding author), Temple Univ, Sbarro Inst Canc Res & Mol Med, Coll Sci & Technol, BioLife Sci Bldg,Suite 333,1900N 12th St, Philadelphia, PA 19122 USA.; Giordano, A (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Biotechnol, BioLife Sci Bldg,Suite 333,1900N 12th St, Philadelphia, PA 19122 USA.; Pentimalli, F (corresponding author), IRCCS, Ist Nazl Per Lo Studio E La Cura Dei Tumori Fdn G, Oncol Res Ctr Mercogliano CROM, Via Ammiraglio Bianco, I-83013 Avellino, Italy.	giordano@temple.edu; f.pentimalli@istitutotumori.na.it	Costa, Caterina/N-1742-2019; Pentimalli, Francesca/K-4936-2014; Alfano, Luigi/B-8330-2015; Giordano, Antonio/F-1927-2010; Costa, Caterina/ABE-2452-2020; Giordano, Antonio/AAU-1201-2020	Costa, Caterina/0000-0003-0909-7366; Pentimalli, Francesca/0000-0003-4740-6801; Alfano, Luigi/0000-0002-4516-9956; Giordano, Antonio/0000-0002-5959-016X; Giordano, Antonio/0000-0002-5959-016X; Indovina, Paola/0000-0001-8416-435X	Sbarro Health Research Organization; Human Health Foundation; Commonwealth of Pennsylvania; Associazione Italiana per la Ricerca sul Cancro [AIRC IG 15690]	Sbarro Health Research Organization; Human Health Foundation; Commonwealth of Pennsylvania; Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	We are thankful to the Sbarro Health Research Organization (http://www.shro.org), the Human Health Foundation (http://www.hhfonlus.org), the Commonwealth of Pennsylvania and the Associazione Italiana per la Ricerca sul Cancro (AIRC IG 15690) for their support. We are grateful to Pasquale Barba and Laura Pisapia (Consiglio Nazionale delle Ricerche-Institute of Genetics and Biophysics, Naples, Italy) for the FACS analyses. We also thank Larry M Karnitz, Division of Oncology Research, Mayo Clinic, Rochester, MN, USA for his help in sharing reagents and Marco G Paggi, Regina Elena National Cancer Institute, Rome, Italy for the M14 cell line. Prof Giordano is the director of research line 3 at CROM, Istituto Nazionale Tumori 'Fondazione G. Pascale'-IRCCS, Naples, Italy.	Adamson B, 2012, NAT CELL BIOL, V14, P318, DOI 10.1038/ncb2426; Banck MS, 2013, J CLIN INVEST, V123, P2502, DOI 10.1172/JCI67963; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bladen CL, 2005, J BIOL CHEM, V280, P5205, DOI 10.1074/jbc.M412758200; Branzei D, 2009, DNA REPAIR, V8, P1038, DOI 10.1016/j.dnarep.2009.04.014; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; Delacroix S, 2007, GENE DEV, V21, P1472, DOI 10.1101/gad.1547007; DONG BH, 1993, NUCLEIC ACIDS RES, V21, P4085, DOI 10.1093/nar/21.17.4085; Duursma AM, 2013, MOL CELL, V50, P116, DOI 10.1016/j.molcel.2013.03.006; Ellison V, 2003, PLOS BIOL, V1, P231, DOI 10.1371/journal.pbio.0000033; Flynn RL, 2011, TRENDS BIOCHEM SCI, V36, P133, DOI 10.1016/j.tibs.2010.09.005; Furuya K, 2004, GENE DEV, V18, P1154, DOI 10.1101/gad.291104; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Ishiguro H, 2003, INT J CANCER, V105, P26, DOI 10.1002/ijc.11021; Ishii T, 2010, J BIOL CHEM, V285, P41993, DOI 10.1074/jbc.M110.161661; Kaufmann WK, 2010, CARCINOGENESIS, V31, P751, DOI 10.1093/carcin/bgp230; Kowalska E, 2013, P NATL ACAD SCI USA, V110, P1592, DOI 10.1073/pnas.1213317110; Krietsch J, 2012, NUCLEIC ACIDS RES, V40, P10287, DOI 10.1093/nar/gks798; Kuhnert A, 2012, J CELL BIOCHEM, V113, P1744, DOI 10.1002/jcb.24045; Kumagai A, 2006, CELL, V124, P943, DOI 10.1016/j.cell.2005.12.041; Lee J, 2010, MOL BIOL CELL, V21, P926, DOI 10.1091/mbc.E09-11-0958; Li SY, 2014, NUCLEIC ACIDS RES, V42, P9771, DOI 10.1093/nar/gku650; Li SY, 2009, NUCLEIC ACIDS RES, V37, P6746, DOI 10.1093/nar/gkp741; Liu QH, 2000, GENE DEV, V14, P1448; Liu SQ, 2012, NUCLEIC ACIDS RES, V40, P10780, DOI 10.1093/nar/gks849; Liu S, 2006, MOL CELL BIOL, V26, P6056, DOI 10.1128/MCB.00492-06; Liu SZ, 2011, MOL CELL, V43, P192, DOI 10.1016/j.molcel.2011.06.019; Ma HT, 2011, METHODS MOL BIOL, V761, P151, DOI 10.1007/978-1-61779-182-6_10; Marechal A, 2014, MOL CELL, V53, P235, DOI 10.1016/j.molcel.2013.11.002; Martinez-Ramos I, 2005, J CELL BIOCHEM, V96, P79, DOI 10.1002/jcb.20428; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Medhurst AL, 2008, J CELL SCI, V121, P3933, DOI 10.1242/jcs.033688; Mordes DA, 2008, GENE DEV, V22, P1478, DOI 10.1101/gad.1666208; Nelson LD, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-38; Oakley GG, 2010, FRONT BIOSCI-LANDMRK, V15, P883, DOI 10.2741/3652; Parrilla-Castellar ER, 2004, DNA REPAIR, V3, P1009, DOI 10.1016/j.dnarep.2004.03.032; Paulsen RD, 2009, MOL CELL, V35, P228, DOI 10.1016/j.molcel.2009.06.021; Pavao M, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-15; Rajesh C, 2011, NUCLEIC ACIDS RES, V39, P132, DOI 10.1093/nar/gkq738; Rappas M, 2011, NUCLEIC ACIDS RES, V39, P313, DOI 10.1093/nar/gkq743; Rosonina E, 2005, MOL CELL BIOL, V25, P6734, DOI 10.1128/MCB.25.15.6734-6746.2005; Salton M, 2010, CELL CYCLE, V9, P1568, DOI 10.4161/cc.9.8.11298; Schiffnery S, 2011, CARCINOGENESIS, V32, P1176, DOI 10.1093/carcin/bgr103; Shav-Tal Y, 2002, FEBS LETT, V531, P109, DOI 10.1016/S0014-5793(02)03447-6; Sievers C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012735; Skalsky YM, 2001, ONCOGENE, V20, P178, DOI 10.1038/sj.onc.1204056; Stracker TH, 2011, NAT REV MOL CELL BIO, V12, P90, DOI 10.1038/nrm3047; Straub T, 2000, BIOCHEMISTRY-US, V39, P7552, DOI 10.1021/bi992898e; Swift LH, 2014, INT J MOL SCI, V15, P3403, DOI 10.3390/ijms15033403; Talman V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020053; Wang X, 2006, MOL CELL, V23, P331, DOI 10.1016/j.molcel.2006.06.022; Willis N, 2009, CELL DIV, V4, DOI 10.1186/1747-1028-4-13; Zhang Z, 2001, CELL, V106, P465, DOI 10.1016/S0092-8674(01)00466-4; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, P NATL ACAD SCI USA, V100, P13827, DOI 10.1073/pnas.2336100100; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	59	21	21	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					567	576		10.1038/onc.2015.107	http://dx.doi.org/10.1038/onc.2015.107			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	25893301				2022-12-17	WOS:000369548800004
J	Rodriguez-Perales, S; Torres-Ruiz, R; Suela, J; Acquadro, F; Martin, MC; Yebra, E; Ramirez, JC; Alvarez, S; Cigudosa, JC				Rodriguez-Perales, S.; Torres-Ruiz, R.; Suela, J.; Acquadro, F.; Martin, M. C.; Yebra, E.; Ramirez, J. C.; Alvarez, S.; Cigudosa, J. C.			Truncated RUNX1 protein generated by a novel t(1;21)(p32;q22) chromosomal translocation impairs the proliferation and differentiation of human hematopoietic progenitors	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; INCREASED FLT3 EXPRESSION; POINT MUTATIONS; MYELODYSPLASTIC SYNDROME; STEM-CELLS; TRANSCRIPTIONAL ACTIVATION; AML1/PEBP2-ALPHA-B GENE; ACQUIRED TRISOMY-21	We have identified a new t(1;21)(p32;q22) chromosomal translocation in a MDS/AML patient that results in expression of an aberrant C-terminally truncated RUNX1 protein lacking several regulatory domains. As similar truncated RUNX1 proteins are generated by genetic aberrations including chromosomal translocations and point mutations, we used the t(1;21)(p32;q22) chromosomal translocation as a model to explore whether C-terminally truncated RUNX1 proteins trigger effects similar to those induced by well-characterized leukemogenic RUNX1 fusion genes. In vitro analysis of transduced human hematopoietic/progenitor stem cells showed that truncated RUNX1 proteins increase proliferation and self-renewal and disrupt the differentiation program by interfering with RUNX1b. These effects are similar to but milder than those induced by the RUNX1/ETO fusion protein. GSEA analysis confirmed similar altered gene expression patterns in the truncated RUNX1 and RUNX1/ETO models, with both models showing alterations in genes involved in self-renewal and leukemogenesis, including homeobox genes, primitive erythroid genes and leukemogenic transcription factors. We propose that C-terminally truncated RUNX1 proteins can contribute to leukemogenesis in a similar way to RUNX1 fusion genes but through a milder phenotype.	[Rodriguez-Perales, S.; Suela, J.; Acquadro, F.; Martin, M. C.; Alvarez, S.; Cigudosa, J. C.] Spanish Natl Canc Res Ctr CNIO, Human Canc Genet Program, Mol Cytogenet Grp, Madrid 28029, Spain; [Torres-Ruiz, R.; Ramirez, J. C.] Fdn Ctr Nacl Invest Cardiovasc CNIC, Viral Vector Tech Unit, Madrid, Spain; [Yebra, E.] Hosp Severo Ochoa, Hematol Serv, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Cardiovasculares (CNIC); Severo Ochoa University Hospital	Rodriguez-Perales, S (corresponding author), Spanish Natl Canc Res Ctr CNIO, Human Canc Genet Program, Mol Cytogenet Grp, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	srodriguezp@cnio.es; jccigudosa@cnio.es	Rodriguez-Perales, Sandra/T-7667-2017; Cigudosa, Juan C/E-4105-2016; Ruiz, Raul Torres/J-1649-2018; SUELA, JAVIER/K-3968-2016	Rodriguez-Perales, Sandra/0000-0001-7221-3636; Ruiz, Raul Torres/0000-0001-9606-0398; 	INTRASALUD project [PI 12-00425]	INTRASALUD project	This work was supported by an INTRASALUD project PI 12-00425 to JCC. We thank all the coworkers in our laboratory for their excellent technical assistance.	Afonja O, 2000, LEUKEMIA RES, V24, P849, DOI 10.1016/S0145-2126(00)00059-X; Agerstam H, 2007, GENE CHROMOSOME CANC, V46, P635, DOI 10.1002/gcc.20442; Alvarez S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012197; Aoki T, 2008, INT J HEMATOL, V88, P571, DOI 10.1007/s12185-008-0198-9; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Chen CY, 2007, BRIT J HAEMATOL, V139, P405, DOI 10.1111/j.1365-2141.2007.06811.x; Cherry AM, 2001, CANCER GENET CYTOGEN, V129, P155, DOI 10.1016/S0165-4608(01)00439-3; Chinen Y, 2008, ONCOGENE, V27, P2249, DOI 10.1038/sj.onc.1210857; Christiansen DH, 2004, BLOOD, V104, P1474, DOI 10.1182/blood-2004-02-0754; De Braekeleer E, 2011, FUTURE ONCOL, V7, P77, DOI 10.2217/FON.10.158; Dicker F, 2007, BLOOD, V110, P1308, DOI 10.1182/blood-2007-02-072595; Drabkin H, 2002, LEUKEMIA, V16, P186, DOI 10.1038/sj.leu.2402354; Figueroa ME, 2010, CANCER CELL, V17, P13, DOI 10.1016/j.ccr.2009.11.020; Frank R, 1995, ONCOGENE, V11, P2667; Friedman AD, 2009, J CELL PHYSIOL, V219, P520, DOI 10.1002/jcp.21738; Gilliland D Gary, 2004, Hematology Am Soc Hematol Educ Program, P80; HAGEMEIJER A, 1984, Cancer Genetics and Cytogenetics, V11, P284; Harada H, 2004, BLOOD, V103, P2316, DOI 10.1182/blood-2003-09-3074; Hayashi K, 2000, J IMMUNOL, V165, P6816, DOI 10.4049/jimmunol.165.12.6816; Hromas R, 2001, BLOOD, V97, P2168, DOI 10.1182/blood.V97.7.2168; Kawagoe H, 1999, LEUKEMIA, V13, P687, DOI 10.1038/sj.leu.2401410; Kurokawa M, 2003, CANCER SCI, V94, P841, DOI 10.1111/j.1349-7006.2003.tb01364.x; Lawrence HJ, 2005, BLOOD, V106, P3988, DOI 10.1182/blood-2005-05-2003; Lawrence HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/sj.leu.2401578; Li Z, 2007, J BIOL CHEM, V282, P3428, DOI 10.1074/jbc.C600277200; Liu X, 2009, LEUKEMIA, V23, P739, DOI 10.1038/leu.2008.350; Maiques-Diaz A, 2012, LEUKEMIA, V26, P1329, DOI 10.1038/leu.2011.376; Maki K, 2012, INT J HEMATOL, V96, P268, DOI 10.1007/s12185-012-1112-z; Matsuura S, 2012, BLOOD, V120, P4028, DOI 10.1182/blood-2012-01-404533; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Mikhail FM, 2004, GENE CHROMOSOME CANC, V39, P110, DOI 10.1002/gcc.10302; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Miyoshi OSMHIYSO, 1995, NUCLEIC ACIDS RES, V23, P1; Mulloy JC, 2003, BLOOD, V102, P4369, DOI 10.1182/blood-2003-05-1762; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; Nguyen TDT, 2006, GENE CHROMOSOME CANC, V45, P918, DOI 10.1002/gcc.20355; Niebuhr BB, 2008, BLOOD CELL MOL DIS, V40, P8; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; OFFIT K, 1991, GENE CHROMOSOME CANC, V3, P189, DOI 10.1002/gcc.2870030304; Osato M, 2004, ONCOGENE, V23, P4284, DOI 10.1038/sj.onc.1207779; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Osato M, 2001, INT J HEMATOL, V74, P245, DOI 10.1007/BF02982056; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; Proudfoot NJ, 2011, GENE DEV, V25, P1770, DOI 10.1101/gad.17268411; Ramsey H, 2003, LEUKEMIA, V17, P1665, DOI 10.1038/sj.leu.2403048; Rhoades KL, 2000, BLOOD, V96, P2108; Roumier C, 2003, BLOOD, V101, P1277, DOI 10.1182/blood-2002-05-1474; Schnittger S, 2011, BLOOD, V117, P2348, DOI 10.1182/blood-2009-11-255976; Silva FPG, 2007, HAEMATOLOGICA, V92, P1123, DOI 10.3324/haematol.11296; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Stevens-Kroef MJPL, 2006, LEUKEMIA, V20, P1187, DOI 10.1038/sj.leu.2404210; Taketani T, 2003, GENE CHROMOSOME CANC, V38, P1, DOI 10.1002/gcc.10246; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Tang JL, 2009, BLOOD, V114, P5352, DOI 10.1182/blood-2009-05-223784; Torres R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4964; Torres R, 2014, GENE THER, V21, P343, DOI 10.1038/gt.2014.1; Tsuzuki S, 2007, PLOS MED, V4, P880, DOI 10.1371/journal.pmed.0040172; Uchida H, 1997, J IMMUNOL, V158, P2251; Wei H, 2008, FEBS LETT, V582, P2167, DOI 10.1016/j.febslet.2008.05.030; Yamagata T, 2005, INT J HEMATOL, V82, P1, DOI 10.1532/IJH97.05075; Yeh JRJ, 2008, DEVELOPMENT, V135, P401, DOI 10.1242/dev.008904; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	63	21	22	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2016	35	1					125	134		10.1038/onc.2015.70	http://dx.doi.org/10.1038/onc.2015.70			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DA4ZT	25798834				2022-12-17	WOS:000367812400012
J	Malin, D; Strekalova, E; Petrovic, V; Rajanala, H; Sharma, B; Ugolkov, A; Gradishar, WJ; Cryns, VL				Malin, D.; Strekalova, E.; Petrovic, V.; Rajanala, H.; Sharma, B.; Ugolkov, A.; Gradishar, W. J.; Cryns, V. L.			ERK-regulated alpha B-crystallin induction by matrix detachment inhibits anoikis and promotes lung metastasis in vivo	ONCOGENE			English	Article							CIRCULATING TUMOR-CELLS; BREAST-CANCER; INDUCED APOPTOSIS; ACTIVATION; RESISTANCE; CARCINOMA; MARKER; EXPRESSION; CASPASE-3; MORPHOGENESIS	Evasion of extracellular matrix detachment-induced apoptosis ('anoikis') is a defining characteristic of metastatic tumor cells. The ability of metastatic carcinoma cells to survive matrix detachment and escape anoikis enables them to disseminate as viable circulating tumor cells and seed distant organs. Here we report that alpha B-crystallin, an antiapoptotic molecular chaperone implicated in the pathogenesis of diverse poor-prognosis solid tumors, is induced by matrix detachment and confers anoikis resistance. Specifically, we demonstrate that matrix detachment downregulates extracellular signal-regulated kinase (ERK) activity and increases alpha B-crystallin protein and messenger RNA (mRNA) levels. Moreover, we show that ERK inhibition in adherent cancer cells mimics matrix detachment by increasing alpha B-crystallin protein and mRNA levels, whereas constitutive ERK activation suppresses alpha B-crystallin induction during matrix detachment. These findings indicate that ERK inhibition is both necessary and sufficient for alpha B-crystallin induction by matrix detachment. To examine the functional consequences of alpha B-crystallin induction in anoikis, we stably silenced alpha B-crystallin in two different metastatic carcinoma cell lines. Strikingly, silencing alpha B-crystallin increased matrix detachment-induced caspase activation and apoptosis but did not affect cell viability of adherent cancer cells. In addition, silencing alpha B-crystallin in metastatic carcinoma cells reduced the number of viable circulating tumor cells and inhibited lung metastasis in two orthotopic models, but had little or no effect on primary tumor growth. Taken together, our findings point to alpha B-crystallin as a novel regulator of anoikis resistance that is induced by matrix detachment-mediated suppression of ERK signaling and promotes lung metastasis. Our results also suggest that alpha B-crystallin represents a promising molecular target for antimetastatic therapies.	[Malin, D.; Strekalova, E.; Petrovic, V.; Rajanala, H.; Sharma, B.; Cryns, V. L.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Carbone Canc Ctr, Madison, WI 53705 USA; [Ugolkov, A.] Northwestern Univ, Ctr Dev Therapeut, Evanston, IL USA; [Gradishar, W. J.] Northwestern Univ, Dept Med, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL USA	University of Wisconsin System; University of Wisconsin Madison; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Cryns, VL (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Carbone Canc Ctr, MFCB 4144,1685 Highland Ave, Madison, WI 53705 USA.	vlcryns@medicine.wisc.edu	Ugolkov, Andrey/T-3012-2019	SHARMA, BHAWNA/0000-0002-4570-2335; Rajanala, Sai Harisha/0000-0002-7096-3756	Susan G. Komen; NATIONAL CANCER INSTITUTE [P30CA014520] Funding Source: NIH RePORTER	Susan G. Komen(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are indebted to Dr Janet Price for providing the MDA-MB-435-LvBr1 cell line. We also thank Dr Caroline Alexander and members of the Cryns lab for their critical reading of the manuscript. Breast Cancer Research Foundation (VLC and WJG), Susan G. Komen for the Cure Postdoctoral Fellowship Award (DM and VP) and P30CA014520 University of Wisconsin Comprehensive Cancer Center core facility support.	Arrigo AP, 2014, CANCERS, V6, P333, DOI 10.3390/cancers6010333; Avivar-Valderas A, 2013, ONCOGENE, V32, P4932, DOI 10.1038/onc.2012.512; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Boisvert-Adamo K, 2009, MOL CANCER RES, V7, P549, DOI 10.1158/1541-7786.MCR-08-0358; Brunquell C, 2012, MOL CANCER RES, V10, P1482, DOI 10.1158/1541-7786.MCR-12-0144; Chelouche-Lev D, 2004, CANCER-AM CANCER SOC, V100, P2543, DOI 10.1002/cncr.20304; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Dimberg A, 2008, BLOOD, V111, P2015, DOI 10.1182/blood-2007-04-087841; Frankel A, 2001, CANCER RES, V61, P4837; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gorges TM, 2013, CANCER IMMUNOL IMMUN, V62, P931, DOI 10.1007/s00262-012-1387-1; Guadamillas MC, 2011, J CELL SCI, V124, P3189, DOI 10.1242/jcs.072165; Haenssen KK, 2010, J CELL SCI, V123, P1373, DOI 10.1242/jcs.050906; Hou JM, 2012, J CLIN ONCOL, V30, P525, DOI 10.1200/JCO.2010.33.3716; Huang XY, 2013, HEPATOLOGY, V57, P2235, DOI 10.1002/hep.26255; Ivanov O, 2008, BREAST CANCER RES TR, V111, P411, DOI 10.1007/s10549-007-9796-0; Kamradt MC, 2005, J BIOL CHEM, V280, P11059, DOI 10.1074/jbc.M413382200; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; Kase S, 2010, BLOOD, V115, P3398, DOI 10.1182/blood-2009-01-197095; Kim HS, 2011, J BREAST CANCER, V14, P14, DOI 10.4048/jbc.2011.14.1.14; Laguinge LM, 2008, CANCER RES, V68, P909, DOI 10.1158/0008-5472.CAN-06-1806; Malin D, 2014, CLIN CANCER RES, V20, DOI 10.1158/1078-0432.CCR-13-1255; Malin D, 2011, CLIN CANCER RES, V17, P5005, DOI 10.1158/1078-0432.CCR-11-0099; Mao Y, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-101; Mao YW, 2004, CELL DEATH DIFFER, V11, P512, DOI 10.1038/sj.cdd.4401384; Marconi A, 2004, J CELL SCI, V117, P5815, DOI 10.1242/jcs.01490; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Moyano JV, 2006, J CLIN INVEST, V116, P261, DOI 10.1172/JCI25888; Nam DH, 2008, CLIN CANCER RES, V14, P4059, DOI 10.1158/1078-0432.CCR-07-4039; PINDER SE, 1994, J PATHOL, V174, P209, DOI 10.1002/path.1711740310; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Schmelzle T, 2007, P NATL ACAD SCI USA, V104, P3787, DOI 10.1073/pnas.0700115104; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Sitterding SM, 2008, ANN DIAGN PATHOL, V12, P33, DOI 10.1016/j.anndiagpath.2007.02.004; Stegh AH, 2008, P NATL ACAD SCI USA, V105, P10703, DOI 10.1073/pnas.0712034105; Valentijn AJ, 2003, J CELL BIOL, V162, P599, DOI 10.1083/jcb.200302154; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989	40	21	22	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	2015	34	45					5626	5634		10.1038/onc.2015.12	http://dx.doi.org/10.1038/onc.2015.12			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GA	25684139	Green Accepted			2022-12-17	WOS:000364594300004
J	Wang, N; Ding, H; Liu, C; Li, X; Wei, L; Yu, J; Liu, M; Ying, M; Gao, W; Jiang, H; Wang, Y				Wang, N.; Ding, H.; Liu, C.; Li, X.; Wei, L.; Yu, J.; Liu, M.; Ying, M.; Gao, W.; Jiang, H.; Wang, Y.			A novel recurrent CHEK2 Y390C mutation identified in high-risk Chinese breast cancer patients impairs its activity and is associated with increased breast cancer risk	ONCOGENE			English	Article							DNA-DAMAGE CHECKPOINT; OVARIAN-CANCER; HEREDITARY BREAST; CHK2 KINASE; P53; SUSCEPTIBILITY; GENES; FAMILIES; VARIANT; BRCA1	Certain predisposition factors such as BRCA1/2 and CHEK2 mutations cause familial breast cancers that occur early. In China, breast cancers are diagnosed at relatively younger age, and higher percentage of patients are diagnosed before 40 years, than that in Caucasians. However, the prevalence for BRCA1/2 mutations and reported CHEK2 germline mutations is much lower or absent in Chinese population, arguing for the need to study other novel risk alleles among Chinese breast cancer patients. In this study, we searched for CHEK2 mutations in young, high-risk breast cancer patients in China and detected a missense variant Y390C (1169A4G) in 12 of 150 patients (8.0%) and 2 in 250 healthy controls (0.8%, P = 0.0002). Four of the Y390C carriers have family history of breast and/or ovarian cancer. In patients without family history, Y390C carriers tend to develop breast cancer early, before 35 years of age. The codon change at Y390, a highly conserved residue located in CHEK2's kinase domain, appeared to significantly impair CHEK2 activity. Functional analysis suggested that the CHEK2 Y390C mutation is deleterious as judged by the mutant protein's inability to inactivate CDC25A or to activate p53 after DNA damage. Cells expressing the CHEK2 Y390C variant showed impaired p21 and Puma expression after DNA damage, and the deregulated cell cycle checkpoint and apoptotic response may help conserve mutations and therefore contribute to tumorigeneisis. Taken together, our results not only identified a novel CHEK2 allele that is associated with cancer families and confers increased breast cancer risk, but also showed that this allele significantly impairs CHEK2 function during DNA damage response. Our results provide further insight on how the function of such an important cancer gene may be impaired by existing mutations to facilitate tumorigenesis. It also offers a new subject for breast cancer monitoring, prevention and management.	[Wang, N.; Liu, C.; Wei, L.; Ying, M.; Gao, W.; Wang, Y.] Second Mil Med Univ, Dept Oncol, Changhai Hosp, Shanghai, Peoples R China; [Ding, H.; Liu, C.; Li, X.; Yu, J.; Liu, M.; Jiang, H.] Chinese Acad Sci, State Key Lab Cell Biol, Inst Biochem & Cell Biol, Key Lab Syst Biol,Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China; [Wei, L.] PLA, Hosp 401, Dept Oncol, Qingdao, Peoples R China; [Wang, Y.] Shanghai Jiao Tong Univ, Xinhua Canc Ctr, Sch Med, Xinhua Hosp, Shanghai 200030, Peoples R China	Naval Medical University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University	Jiang, H (corresponding author), Chinese Acad Sci, State Key Lab Cell Biol, Inst Biochem & Cell Biol, Key Lab Syst Biol,Shanghai Inst Biol Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	hai@sibcb.ac.cn; yajiewao459@163.com		jiang, hai/0000-0002-2508-5413; Ding, Hongyu/0000-0002-7531-4771	major scientific research project [2013CB910404]; Natural Science Foundation of the People's Republic of China [81372854, 31371418, 81202096, 81102010]; Shanghai Science and Technology Committee [114119a7500, 06DZ19505, 13NM1401504]	major scientific research project; Natural Science Foundation of the People's Republic of China(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Committee(Shanghai Science & Technology Committee)	This study was supported by the major scientific research project (2013CB910404), Natural Science Foundation of the People's Republic of China (No. 81372854; 31371418; 81202096; 81102010), and Shanghai Science and Technology Committee (No. 114119a7500, No. 06DZ19505 and No. 13NM1401504). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. We thank Dr Qingpeng Kong of the Kunming Institute of Zoology, Chinese Academy of Sciences for his help in analysis of the 1000 human genome project.	Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033; Antoni L, 2007, NAT REV CANCER, V7, P925, DOI 10.1038/nrc2251; Apostolou P, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/747318; Baloch AH, 2014, MOL BIOL REP, V41, P1103, DOI 10.1007/s11033-013-2956-x; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Baysal BE, 2004, GYNECOL ONCOL, V95, P62, DOI 10.1016/j.ygyno.2004.07.015; Brinkman H, 2006, CLIN GENET, V70, P526, DOI 10.1111/j.1399-0004.2006.00711.x; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Cai Z, 2009, MOL CELL, V35, P818, DOI 10.1016/j.molcel.2009.09.007; Cao AY, 2010, BREAST CANCER RES TR, V120, P271, DOI 10.1007/s10549-009-0598-4; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Cybulski C, 2011, J CLIN ONCOL, V29, P3747, DOI 10.1200/JCO.2010.34.0778; de Miranda NFCC, 2013, J EXP MED, V210, P1729, DOI 10.1084/jem.20122842; Easton D, 2004, AM J HUM GENET, V74, P1175, DOI 10.1086/421251; Gonzalez-Hormazabal P, 2008, BREAST CANCER RES TR, V110, P543, DOI 10.1007/s10549-007-9743-0; Gutierrez-Enriquez S, 2014, INT J CANCER, V134, P2088, DOI 10.1002/ijc.28540; Jiang H, 2011, NAT CHEM BIOL, V7, P92, DOI 10.1038/NCHEMBIO.503; Jiang H, 2009, GENE DEV, V23, P1895, DOI 10.1101/gad.1815309; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Kwong A, 2008, WORLD J SURG, V32, P2554, DOI 10.1007/s00268-008-9589-6; Lacroix M, 2005, BREAST CANCER RES TR, V89, P297, DOI 10.1007/s10549-004-2172-4; Liede A, 2002, HUM MUTAT, V20, P413, DOI 10.1002/humu.10154; Liu C, 2012, ASIAN PAC J CANCER P, V13, P1355, DOI 10.7314/APJCP.2012.13.4.1355; Meindl A, 2010, NAT GENET, V42, P410, DOI 10.1038/ng.569; Novak DJ, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-239; O'Driscoll M, 2006, NAT REV GENET, V7, P45, DOI 10.1038/nrg1746; Osorio A, 2012, HUM MOL GENET, V21, P2889, DOI 10.1093/hmg/dds115; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Shieh SY, 2000, GENE DEV, V14, P289; Sodha N, 2002, HUM MUTAT, V19, P173, DOI 10.1002/humu.10031; Song QK, 2014, ASIAN PAC J CANCER P, V15, P10021, DOI 10.7314/APJCP.2014.15.22.10021; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Stracker TH, 2009, DNA REPAIR, V8, P1047, DOI 10.1016/j.dnarep.2009.04.012; Takacova S, 2012, CANCER CELL, V21, P517, DOI 10.1016/j.ccr.2012.01.021; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; Vahteristo P, 2001, CANCER RES, V61, P5718; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walsh T, 2007, CANCER CELL, V11, P103, DOI 10.1016/j.ccr.2007.01.010; Wang C, 2008, ADV THER, V25, P496, DOI 10.1007/s12325-008-0057-3; Weischer M, 2008, J CLIN ONCOL, V26, P542, DOI 10.1200/JCO.2007.12.5922; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200	44	21	22	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2015	34	40					5198	5205		10.1038/onc.2014.443	http://dx.doi.org/10.1038/onc.2014.443			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CS6ZP	25619829				2022-12-17	WOS:000362233400009
J	Sales, KU; Friis, S; Abusleme, L; Moutsopoulos, NM; Bugge, TH				Sales, K. U.; Friis, S.; Abusleme, L.; Moutsopoulos, N. M.; Bugge, T. H.			Matriptase promotes inflammatory cell accumulation and progression of established epidermal tumors	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; TRANSMEMBRANE SERINE-PROTEASE; FACTOR ACTIVATOR INHIBITOR-2; GENE-EXPRESSION; PROSTATE; CANCER; RAS; POTENT; OVEREXPRESSION; PROGNOSIS	Deregulation of matriptase is a consistent feature of human epithelial cancers and correlates with poor disease outcome. We have previously shown that matriptase promotes multi-stage squamous cell carcinogenesis in transgenic mice through dual activation of pro-hepatocyte growth factor-cMet-Akt-mTor proliferation/survival signaling and PAR-2-Gai-NF kappa B inflammatory signaling. Matriptase was congenitally and constitutively deregulated in our prior studies, and therefore it was unclear if aberrant matriptase signaling supports only initiation of tumor formation or if it is also critical for the progression of established tumors. To determine this, we here have generated triple-transgenic mice with constitutive deregulation of matriptase and simultaneous inducible expression of the cognate matriptase inhibitor, hepatocyte growth factor inhibitor (HAI)-2. As expected, constitutive expression of HAI-2 suppressed the formation of matriptase-dependent tumors in 7,12-Dimethylbenz(a)anthracene-treated mouse skin. Interestingly, however, the induction of HAI-2 expression in already established tumors markedly impaired malignant progression and caused regression of individual tumors. Tumor regression correlated with reduced accumulation of tumor-associated inflammatory cells, likely caused by diminished expression of pro-tumorigenic inflammatory cytokines. The data suggest that matriptase-dependent signaling may be a therapeutic target for both squamous cell carcinoma chemoprevention and for the treatment of established tumors.	[Sales, K. U.; Friis, S.; Abusleme, L.; Moutsopoulos, N. M.; Bugge, T. H.] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; [Sales, K. U.] Natl Inst Dent & Craniofacial Res, Clin Res Core, NIH, Bethesda, MD 20892 USA; [Sales, K. U.] Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Cell & Mol Biol, BR-14049 Ribeirao Preto, Brazil; [Friis, S.] Univ Copenhagen, Fac Hlth & Med Sci, Dept Cellular & Mol Med, Copenhagen, Denmark	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Universidade de Sao Paulo; University of Copenhagen	Bugge, TH (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Room 211,30 Convent Dr, Bethesda, MD 20892 USA.	thomas.bugge@nih.gov	Moutsopoulos, Niki/A-9538-2019; sales, katiuchia u/J-4880-2012	sales, katiuchia/0000-0002-3768-5790; Abusleme, Loreto/0000-0002-7210-1236	NIDCR Intramural Research Program; Sao Paulo Research Foundation [2014/14311-0]; Harboe Foundation; Lundbeck Foundation;  [17.12.1981]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000699] Funding Source: NIH RePORTER	NIDCR Intramural Research Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Sao Paulo Research Foundation(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Harboe Foundation; Lundbeck Foundation(Lundbeckfonden); ; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Dr Mary Jo Danton and Dr J Silvio Gutkind for critically reviewing this manuscript. We also thank Andrew Cho and Dr Ashok Kulkarni, NIDCR Gene Targeting Facility, for generation of transgenic mice. Histology was performed by Histoserv, Inc., Germantown, MD, USA. The study was supported by the NIDCR Intramural Research Program (THB), Sao Paulo Research Foundation 2014/14311-0 (KUS), The Harboe Foundation, The Foundation of 17.12.1981 and the Lundbeck Foundation (SF).	Baba T, 2012, J PATHOL, V228, P181, DOI 10.1002/path.3993; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BALMAIN A, 1985, BRIT J CANCER, V51, P1, DOI 10.1038/bjc.1985.1; Bergum C, 2010, PROSTATE, V70, P1422, DOI 10.1002/pros.21177; Bhatt AS, 2007, P NATL ACAD SCI USA, V104, P5771, DOI 10.1073/pnas.0606514104; Bhatt AS, 2005, ONCOGENE, V24, P5333, DOI 10.1038/sj.onc.1208582; Bocheva G, 2009, J INVEST DERMATOL, V129, P1816, DOI 10.1038/jid.2008.449; Cheng HX, 2009, CANCER RES, V69, P1828, DOI 10.1158/0008-5472.CAN-08-3728; Cheng MF, 2014, HISTOPATHOLOGY, V65, P24, DOI 10.1111/his.12361; Chou FP, 2013, AM J PATHOL, V183, P1306, DOI 10.1016/j.ajpath.2013.06.024; Desilets A, 2006, FEBS LETT, V580, P2227, DOI 10.1016/j.febslet.2006.03.030; Enyedy IJ, 2001, J MED CHEM, V44, P1349, DOI 10.1021/jm000395x; Forbs D, 2005, INT J ONCOL, V27, P1061; Galkin AV, 2004, PROSTATE, V61, P228, DOI 10.1002/pros.20094; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gray K, 2014, THROMB HAEMOSTASIS, V112, P402, DOI 10.1160/TH13-11-0895; Ha SY, 2014, VIRCHOWS ARCH, V464, P19, DOI 10.1007/s00428-013-1504-3; Hoang CD, 2004, CHEST, V125, P1843, DOI 10.1378/chest.125.5.1843; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; Jin JS, 2007, HISTOL HISTOPATHOL, V22, P305, DOI 10.14670/HH-22.305; Jin JS, 2006, MODERN PATHOL, V19, P447, DOI 10.1038/modpathol.3800495; Kang JY, 2003, CANCER RES; Kilpatrick LM, 2006, BLOOD, V108, P2616, DOI 10.1182/blood-2006-02-001073; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Long YQ, 2001, BIOORG MED CHEM LETT, V11, P2515, DOI 10.1016/S0960-894X(01)00493-0; Lopez-Otin C, 2008, J BIOL CHEM, V283, P30433, DOI 10.1074/jbc.R800035200; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; Nakamura K, 2009, ANN ONCOL, V20, P63, DOI 10.1093/annonc/mdn556; Oberst MD, 2002, CLIN CANCER RES, V8, P1101; Quimbar P, 2013, J BIOL CHEM, V288, P13885, DOI 10.1074/jbc.M113.460030; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Saleem M, 2006, CANCER EPIDEM BIOMAR, V15, P217, DOI 10.1158/1055-9965.EPI-05-0737; Sales KU, 2015, ONCOGENE, V34, P288, DOI 10.1038/onc.2013.563; Santin AD, 2003, CANCER, V98, P1898, DOI 10.1002/cncr.11753; Sun J, 2003, BIOCHEMISTRY-US, V42, P892, DOI 10.1021/bi026878f; Szabo R, 2011, ONCOGENE, V30, P2003, DOI 10.1038/onc.2010.586; Szabo R, 2008, J BIOL CHEM, V283, P29495, DOI 10.1074/jbc.M801970200; Szabo R, 2009, DEVELOPMENT, V136, P2653, DOI 10.1242/dev.038430; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Tanimoto H, 2005, BRIT J CANCER, V92, P278, DOI 10.1038/sj.bjc.6602320; Tsai CH, 2014, ONCOGENE, V33, P4643, DOI 10.1038/onc.2013.412; Ustach CV, 2010, CANCER RES, V70, P9631, DOI 10.1158/0008-5472.CAN-10-0511; Vitale-Cross L, 2004, CANCER RES, V64, P8804, DOI 10.1158/0008-5472.CAN-04-2623; Vogel LK, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-176; Wu SR, 2010, AM J PATHOL, V177, P3145, DOI 10.2353/ajpath.2010.100228; Ye JJ, 2014, CANCER SCI, V105, P44, DOI 10.1111/cas.12306; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6	47	21	21	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2015	34	35					4664	4672		10.1038/onc.2014.391	http://dx.doi.org/10.1038/onc.2014.391			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BS	25486433	Green Accepted			2022-12-17	WOS:000360189300012
J	Roy, BC; Subramaniam, D; Ahmed, I; Jala, VR; Hester, CM; Greiner, KA; Haribabu, B; Anant, S; Umar, S				Roy, B. C.; Subramaniam, D.; Ahmed, I.; Jala, V. R.; Hester, C. M.; Greiner, K. A.; Haribabu, B.; Anant, S.; Umar, S.			Role of bacterial infection in the epigenetic regulation of Wnt antagonist WIF1 by PRC2 protein EZH2	ONCOGENE			English	Article							HISTONE METHYLTRANSFERASE; BREAST-CANCER; E-CADHERIN; IN-VIVO; CATENIN; PROLIFERATION; REPRESSION; PATHWAY; OVEREXPRESSION; TUMORIGENESIS	The enhancer of zeste homolog-2 (EZH2) represses gene transcription through histone H3 lysine-27-trimethylation (H3K27me3). Citrobacter rodentium (CR) promotes crypt hyperplasia and tumorigenesis by aberrantly regulating Wnt/beta-catenin signaling. We aimed at investigating EZH2's role in epigenetically regulating Wnt/beta-catenin signaling following bacterial infection. NIH: Swiss outbred and Apc(Min/+) mice were infected with CR (10(8) CFU); BLT1(-/)-Apc(Min/+) mice, azoxymethane (AOM)/dextran sodium sulfate (DSS)-treated mice and de-identified human adenocarcinoma samples were the models of colon cancer. Following infection with wild-type but not mutant CR, elevated EZH2 levels in the crypt at days 6 and 12 (peak hyperplasia) coincided with increases in H3K27me3 and beta-catenin levels, respectively. Chromatin immunoprecipitation revealed EZH2 and H3K27me3's occupancy on WIF1 (Wnt inhibitory factor 1) promoter resulting in reduced WIF1 mRNA and protein expression. Following EZH2 knockdown via small interfering RNA or EZH2-inhibitor deazaneplanocin A (Dznep) either alone or in combination with histone deacetylase inhibitor suberoylanilide hydroxamic acid, WIF1 promoter activity increased significantly while the overexpression of EZH2 attenuated WIF1 reporter activity. Ectopic overexpression of SET domain mutant (F681Y) almost completely rescued WIF1 reporter activity and partially rescued WIF1 protein levels, whereas H3K27me3 levels were significantly attenuated suggesting that an intact methyltransferases activity is required for EZH2-dependent effects. Interestingly, although beta-catenin levels were lower in EZH2-knocked down cells, F681Y mutants exhibited only partial reduction in beta-catenin levels. Besides EZH2, increases in miR-203 expression in the crypts at days 6 and 12 post infection correlated with reduced levels of its target WIF1; overexpression of miR-203 in primary colonocytes decreased WIF1 mRNA and protein levels. Elevated levels of EZH2 and beta-catenin with concomitant decrease in WIF1 expression in the polyps of CR-infected Apc(Min/+) mice paralleled changes recorded in BLT1(-/-) Apc(Min/+), AOM/DSS and human adenocarcinomas. Thus, EZH2-induced downregulation of WIF1 expression may partially regulate Wnt/beta-catenin-dependent crypt hyperplasia in response to CR infection.	[Roy, B. C.; Subramaniam, D.; Ahmed, I.; Hester, C. M.; Greiner, K. A.; Anant, S.; Umar, S.] Univ Kansas, Med Ctr, Dept Mol Physiol, Kansas City, KS 66160 USA; [Roy, B. C.; Subramaniam, D.; Ahmed, I.; Hester, C. M.; Greiner, K. A.; Anant, S.; Umar, S.] Univ Kansas, Med Ctr, Dept Integrat Physiol, Kansas City, KS 66160 USA; [Roy, B. C.; Subramaniam, D.; Ahmed, I.; Hester, C. M.; Greiner, K. A.; Anant, S.; Umar, S.] Univ Kansas, Med Ctr, Family Med Res Div, Kansas City, KS 66160 USA; [Jala, V. R.; Haribabu, B.] Univ Kansas, James Graham Brown Canc Ctr, Kansas City, KS 66160 USA; [Jala, V. R.; Haribabu, B.] Univ Kansas, Dept Microbiol & Immunol, Kansas City, KS 66160 USA; [Anant, S.; Umar, S.] Univ Kansas, Ctr Canc, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas; University of Kansas	Umar, S (corresponding author), Univ Kansas, Med Ctr, Ctr Canc, 3901 Rainbow Blvd,4028 Wahl Hall East, Kansas City, KS 66160 USA.	sumar@kumc.edu	Bodduluri, Haribabu/A-2584-2010; Anant, Shrikant/AAF-8020-2020; Jala, Venkatakrishna R/K-7255-2018	Bodduluri, Haribabu/0000-0002-8261-3294; Jala, Venkatakrishna R/0000-0002-4206-7305	National Institutes of Health [R01 CA131413]; University of Kansas Medical Center, Kansas City, KS, USA; NATIONAL CANCER INSTITUTE [R01CA131413] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Kansas Medical Center, Kansas City, KS, USA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Philip R Hardwidge (Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS, USA) for Citrobacter rodentium mutants. This work was partially supported by the National Institutes of Health Grant R01 CA131413 and start-up funds from the University of Kansas Medical Center, Kansas City, KS, USA.	Ahmed I, 2013, AM J PHYSIOL-GASTR L, V304, pG356, DOI 10.1152/ajpgi.00372.2012; Ahmed I, 2012, INFECT IMMUN, V80, P3107, DOI 10.1128/IAI.00236-12; Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; BOFFA LC, 1978, J BIOL CHEM, V253, P3364; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Cao Q, 2011, CANCER CELL, V20, P187, DOI 10.1016/j.ccr.2011.06.016; Chan DW, 2006, GASTROENTEROLOGY, V131, P1218, DOI 10.1053/j.gastro.2006.07.020; Chandrakesan P, 2014, ONCOGENE, V33, P2639, DOI 10.1038/onc.2013.210; Chandrakesan P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079432; Chandrakesan P, 2010, J BIOL CHEM, V285, P33485, DOI 10.1074/jbc.M110.129353; Cheng ASL, 2011, CANCER RES, V71, P4028, DOI 10.1158/0008-5472.CAN-10-3342; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Deng WY, 2004, P NATL ACAD SCI USA, V101, P3597, DOI 10.1073/pnas.0400326101; Hamon MA, 2008, CELL HOST MICROBE, V4, P100, DOI 10.1016/j.chom.2008.07.009; Hayashi Y, 2013, GUT, V62, P1536, DOI 10.1136/gutjnl-2011-301625; Ihara A, 2007, J PHARMACOL SCI, V103, P24, DOI 10.1254/jphs.FP0060651; Joshi P, 2008, J BIOL CHEM, V283, P27757, DOI 10.1074/jbc.M804442200; Jung HY, 2013, MOL CELL, V52, P193, DOI 10.1016/j.molcel.2013.08.028; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159; Li X, 2009, AM J PATHOL, V175, P1246, DOI 10.2353/ajpath.2009.090042; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; Lu JA, 2011, CANCER RES, V71, P225, DOI 10.1158/0008-5472.CAN-10-1850; Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013; Newman JV, 2001, J INFECT DIS, V184, P227, DOI 10.1086/321998; Sasaki M, 2008, LAB INVEST, V88, P873, DOI 10.1038/labinvest.2008.52; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Sellin JH, 2001, CANCER RES, V61, P2899; Sellin JH, 2009, EXP CELL RES, V315, P97, DOI 10.1016/j.yexcr.2008.10.019; Shen L, 2013, ONCOTARGETS THER, V6, P321, DOI 10.2147/OTT.S42453; Taniguchi H, 2012, ONCOGENE, V31, P1988, DOI 10.1038/onc.2011.387; Umar S, 2005, ONCOGENE, V24, P6709, DOI 10.1038/sj.onc.1208820; Umar S, 2003, CELL PROLIFERAT, V36, P361, DOI 10.1046/j.1365-2184.2003.00291.x; Umar S, 2007, AM J PHYSIOL-GASTR L, V292, pG599, DOI 10.1152/ajpgi.00343.2006; Umar S, 2012, CURR COLORECT CANC R, V8, P298, DOI 10.1007/s11888-012-0143-4; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449; Zhang XW, 2012, CANCER CELL, V22, P506, DOI 10.1016/j.ccr.2012.09.003	38	21	22	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2015	34	34					4519	4530		10.1038/onc.2014.386	http://dx.doi.org/10.1038/onc.2014.386			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BR	25486432	Green Accepted			2022-12-17	WOS:000360189200011
J	Radulovich, N; Leung, L; Ibrahimov, E; Navab, R; Sakashita, S; Zhu, CQ; Kaufman, E; Lockwood, WW; Thu, KL; Fedyshyn, Y; Moffat, J; Lam, WL; Tsao, MS				Radulovich, N.; Leung, L.; Ibrahimov, E.; Navab, R.; Sakashita, S.; Zhu, C-Q; Kaufman, E.; Lockwood, W. W.; Thu, K. L.; Fedyshyn, Y.; Moffat, J.; Lam, W. L.; Tsao, M-S			Coiled-coil domain containing 68 (CCDC68) demonstrates a tumor-suppressive role in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article							DNA COPY NUMBER; HOMOZYGOUS DELETIONS; EXPRESSION; CANCER; GENE; ASSOCIATION; INSTABILITY; METASTASIS; PHENOTYPE	Using integrative genomics and functional screening, we identified coiled-coil domain containing 68 (CCDC68) as a novel putative tumor suppressor gene (TSG) in pancreatic ductal adenocarcinoma (PDAC). CCDC68 allelic losses were documented in 48% of primary PDAC patient tumors, 50% of PDAC cell lines and 30% of primary patient derived xenografts. We also discovered a single nucleotide polymorphism (SNP) variant (SNP rs1344011) that leads to exon skipping and generation of an unstable protein isoform CCDC68 Delta(69-114) in 31% of PDAC patients. Overexpression of full length CCDC68 (CCDC68(wt)) in PANC-1 and Hs.766T PDAC cell lines lacking CDCC68 expression decreased proliferation and tumorigenicity in scid mice. In contrast, the downregulation of endogenous CCDC68 in MIAPaca-2 cells increased tumor growth rate. These effects were not observed with the deletion-containing isoform, CCDC68 Delta(69-114).	[Radulovich, N.; Leung, L.; Ibrahimov, E.; Navab, R.; Sakashita, S.; Zhu, C-Q; Kaufman, E.; Tsao, M-S] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON M5G 2M9, Canada; [Radulovich, N.; Tsao, M-S] Univ Toronto, Dept Lab Med, Toronto, ON, Canada; [Radulovich, N.; Tsao, M-S] Univ Toronto, Dept Pathobiol, Toronto, ON, Canada; [Leung, L.; Tsao, M-S] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Lockwood, W. W.; Thu, K. L.; Lam, W. L.] Univ British Columbia, British Columbia Canc Res Ctr, Vancouver, BC V5Z 1M9, Canada; [Lockwood, W. W.; Thu, K. L.; Lam, W. L.] Univ British Columbia, Dept Pathol, Vancouver, BC, Canada; [Fedyshyn, Y.; Moffat, J.] Univ Toronto, Banting & Best Dept Med Res, Dept Mol Genet, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University of Toronto; British Columbia Cancer Agency; University of British Columbia; University of British Columbia; University of Toronto	Tsao, MS (corresponding author), Univ Hlth Network, Princess Margaret Canc Ctr, 200 Elizabeth St,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	ming.tsao@uhn.on.ca	Tsao, Ming-Sound/M-3503-2017; Navab, Roya/AGD-7380-2022; Tsao, Ming Sound/AFQ-7332-2022; Moffat, Jason/AAC-1110-2020	Tsao, Ming Sound/0000-0002-9160-5405; Moffat, Jason/0000-0002-5663-8586; Thu, Kelsie/0000-0001-9262-7238; Zhu, ChangQi/0000-0002-9992-0258	Canadian Cancer Society Research Institute [700809]; Canadian Institutes of Health Research [MOP-49585]; Ontario Ministry of Health and Long Term Care; Terry Fox Foundation STIHR Program in Molecular Pathology of Cancer at CIHR [STP 53912]	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Ontario Ministry of Health and Long Term Care(Ministry of Health and Long-Term Care, Ontario); Terry Fox Foundation STIHR Program in Molecular Pathology of Cancer at CIHR(Canadian Institutes of Health Research (CIHR))	Olga Ludkovksy (FISH), Ni Liu (PCR) and Dennis Wang (support in ICGC analysis). This study was supported by the Canadian Cancer Society Research Institute grant#700809, Canadian Institutes of Health Research grant MOP-49585 and the Ontario Ministry of Health and Long Term Care. N. Radulovich and K. Thu are Vanier Canada Graduate Scholars. Dr S. Sakashita is supported by the Terry Fox Foundation STIHR Program in Molecular Pathology of Cancer at CIHR (STP 53912). Dr Tsao is the M. Qasim Choksi Chair in Lung Cancer Translational Research.	Bashyam MD, 2005, NEOPLASIA, V7, P556, DOI 10.1593/neo.04586; Calhoun ES, 2006, CANCER RES, V66, P7920, DOI 10.1158/0008-5472.CAN-06-0721; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Devitt G, 2006, INT J CANCER, V118, P2210, DOI 10.1002/ijc.21626; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Eichmuller S, 2001, P NATL ACAD SCI USA, V98, P629, DOI 10.1073/pnas.021386498; Furukawa T, 1996, AM J PATHOL, V148, P1763; Gerhardt A, 2004, CANCER LETT, V208, P197, DOI 10.1016/j.canlet.2003.11.021; Harada T, 2008, ONCOGENE, V27, P1951, DOI 10.1038/sj.onc.1210832; Harada T, 2009, PANCREATOLOGY, V9, P13, DOI 10.1159/000178871; Hassan NZA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092553; Hirsch FR, 2003, J CLIN ONCOL, V21, P3798, DOI 10.1200/JCO.2003.11.069; Hofstetter G, 2010, ONCOGENE, V29, P1997, DOI 10.1038/onc.2009.482; Hong OY, 2000, AM J PATHOL, V157, P1623, DOI 10.1016/S0002-9440(10)64800-6; Hruban RH, 2008, INT J CLIN EXP PATHO, V1, P306; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kimmelman AC, 2008, P NATL ACAD SCI USA, V105, P19372, DOI 10.1073/pnas.0809966105; Lefter LP, 2002, GENE CHROMOSOME CANC, V34, P234, DOI 10.1002/gcc.10060; Leung L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084366; Lockwood WW, 2006, EUR J HUM GENET, V14, P139, DOI 10.1038/sj.ejhg.5201531; Mak AB, 2010, MOL CELL PROTEOMICS, V9, P811, DOI 10.1074/mcp.M000002-MCP201; Myhre S, 2013, MOL ONCOL, V7, P704, DOI 10.1016/j.molonc.2013.02.018; Navab R, 2009, NEOPLASIA, V11, P1292, DOI 10.1593/neo.09622; Nowak NJ, 2005, CANCER GENET CYTOGEN, V161, P36, DOI 10.1016/j.cancergencyto.2005.01.009; Qian JY, 2005, CANCER RES, V65, P5045, DOI 10.1158/0008-5472.CAN-04-3208; Radulovich N, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-24; Radulovich N, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-24; Sharrard RM, 2000, BBA-GENE STRUCT EXPR, V1494, P282, DOI 10.1016/S0167-4781(00)00210-4; Sheffer M, 2009, P NATL ACAD SCI USA, V106, P7131, DOI 10.1073/pnas.0902232106; Tammaro C, 2012, BIOCHEM SOC T, V40, P768, DOI 10.1042/BST20120140; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Thu KL, 2014, ONCOGENE, V33, P279, DOI 10.1038/onc.2012.595; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515	34	21	23	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4238	4247		10.1038/onc.2014.357	http://dx.doi.org/10.1038/onc.2014.357			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25381825	Green Accepted, Bronze			2022-12-17	WOS:000359199800010
J	Cetinbas, N; Daugaard, M; Mullen, AR; Hajee, S; Rotblat, B; Lopez, A; Li, A; DeBerardinis, RJ; Sorensen, PH				Cetinbas, N.; Daugaard, M.; Mullen, A. R.; Hajee, S.; Rotblat, B.; Lopez, A.; Li, A.; DeBerardinis, R. J.; Sorensen, P. H.			Loss of the tumor suppressor Hace1 leads to ROS-dependent glutamine addiction	ONCOGENE			English	Article							LIGASE HACE1; CANCER; METABOLISM; GROWTH; GENERATION; METHYLATION; EXPRESSION; BIOLOGY; PROTEIN; RAC1	Cellular transformation is associated with altered glutamine (Gln) metabolism. Tumor cells utilize Gln in the tricarboxylic acid (TCA) cycle to maintain sufficient pools of biosynthetic precursors to support rapid growth and proliferation. However, Gln metabolism also generates NADPH, and Gln-derived glutamate is used for synthesis of glutathione (GSH). As both NADPH and GSH are antioxidants, Gln may also contribute to redox balance in transformed cells. The Hace1 E3 ligase is a tumor suppressor inactivated in diverse human cancers. Hace1 targets the Rac1 GTPase for degradation at Rac1-dependent NADPH oxidase complexes, blocking superoxide generation by the latter. Consequently, loss of Hace1 increases reactive oxygen species (ROS) levels in vitro and in vivo. Given the link between Hace1 loss and increased ROS, we investigated whether genetic inactivation of Hace1 alters Gln metabolism. We demonstrate that mouse embryonic fibroblasts (MEFs) derived from Hace1(-/-) mice are highly sensitive to Gln withdrawal, leading to enhanced cell death compared with wild-type (wt) MEFs, and Gln depletion or chemical inhibition of Gln uptake blocks soft agar colony formation by Hace1(-/-) MEFs. Hace1(-/-) MEFs exhibit increased Gln uptake and ammonia secretion, and metabolic labeling using C-13-Gln revealed that Hace1 loss increases incorporation of Gln carbons into the TCA cycle intermediates. Gln starvation markedly increases ROS levels in Hace1(-/-) but not in wt MEFs, and treatment with the antioxidant N-acetyl cysteine or the TCA cycle intermediate oxaloacetate efficiently rescues Gln starvation-induced ROS elevation and cell death in Hace1(-/-) MEFs. Finally, Gln starvation increases superoxide levels in Hace1(-/-) MEFs, and NADPH oxidase inhibitors block the induction of superoxide and cell death by Gln starvation. Together, these results suggest that increased ROS production due to Hace1 loss leads to Gln addiction as a mechanism to cope with increased ROS-induced oxidative stress.	[Cetinbas, N.; Daugaard, M.; Hajee, S.; Rotblat, B.; Lopez, A.; Li, A.; Sorensen, P. H.] BC Canc Res Ctr, Dept Mol Oncol, Vancouver, BC V5Z 1L3, Canada; [Cetinbas, N.; Daugaard, M.; Rotblat, B.; Sorensen, P. H.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; [Mullen, A. R.; DeBerardinis, R. J.] Texas So Univ, Med Ctr, Dept Pediat, Dallas, TX USA; [Mullen, A. R.; DeBerardinis, R. J.] Texas So Univ, Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX USA	British Columbia Cancer Agency; University of British Columbia; Texas Southern University; Texas Southern University	Sorensen, PH (corresponding author), BC Canc Res Ctr, Dept Mol Oncol, 675 W10th Ave,Room 4112, Vancouver, BC V5Z 1L3, Canada.	psor@mail.ubc.ca	damiani, chiara/R-4256-2016; Rotblat, Barak/H-5970-2019; Daugaard, Mads/Y-6483-2018	Rotblat, Barak/0000-0003-2985-7115; Daugaard, Mads/0000-0001-8383-055X	Canadian Institute of Health Research [MOP-123416]; British Columbia Cancer Foundation [R01 CA157996]; Damon-Runyon Cancer Research Foundation; Canadian Institutes of Health Research; Frederick Banting; Charles Best Canada; NATIONAL CANCER INSTITUTE [R01CA157996] Funding Source: NIH RePORTER	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); British Columbia Cancer Foundation; Damon-Runyon Cancer Research Foundation; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Frederick Banting; Charles Best Canada; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by funds from the Canadian Institute of Health Research (MOP-123416) and British Columbia Cancer Foundation through generous donations from Team Finn and Ride to Conquer Cancer (to PHS), and from the National Institutes of Health (R01 CA157996) and Damon-Runyon Cancer Research Foundation (to RJD). NC was funded by the Canadian Institutes of Health Research, Frederick Banting and Charles Best Canada Graduate Scholarship Doctoral Award.	Anglesio MS, 2004, HUM MOL GENET, V13, P2061, DOI 10.1093/hmg/ddh215; Cantor JR, 2012, CANCER DISCOV, V2, P881, DOI 10.1158/2159-8290.CD-12-0345; Castillo-Lluva S, 2013, ONCOGENE, V32, P1735, DOI 10.1038/onc.2012.189; Cheng G, 2006, J BIOL CHEM, V281, P17718, DOI 10.1074/jbc.M512751200; Cheng TL, 2011, P NATL ACAD SCI USA, V108, P8674, DOI 10.1073/pnas.1016627108; Daugaard M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3180; DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; DeBerardinis RJ, 2008, GENET MED, V10, P267, DOI 10.1097/GIM.0b013e31818b0d9b; Diskin SJ, 2012, NAT GENET, V44, P1126, DOI 10.1038/ng.2387; Fan J, 2014, NATURE, V510, P298, DOI 10.1038/nature13236; Fernandez CA, 1996, J MASS SPECTROM, V31, P255, DOI 10.1002/(SICI)1096-9888(199603)31:3<255::AID-JMS290>3.0.CO;2-3; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gianni D, 2010, ACS CHEM BIOL, V5, P981, DOI 10.1021/cb100219n; Hibi K, 2008, ANTICANCER RES, V28, P1581; Huang YL, 2010, BLOOD, V115, P1226, DOI 10.1182/blood-2009-05-221275; Klimberg VS, 1996, AM J SURG, V172, P418; Li XN, 2004, CLIN CANCER RES, V10, P1150, DOI 10.1158/1078-0432.CCR-0747-3; MOLDAVE K, 1957, J BIOL CHEM, V229, P463; Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044; Nicolay BN, 2013, GENE DEV, V27, P182, DOI 10.1101/gad.206227.112; Rajagopalan KN, 2011, J NUCL MED, V52, P1005, DOI 10.2967/jnumed.110.084244; Reynolds MR, 2014, ONCOGENE, V33, P556, DOI 10.1038/onc.2012.635; Rotblat B, 2014, P NATL ACAD SCI USA, V111, P3032, DOI 10.1073/pnas.1314421111; Sakata M, 2009, ANTICANCER RES, V29, P2231; Shanware NP, 2011, J MOL MED, V89, P229, DOI 10.1007/s00109-011-0731-9; Slade I, 2010, J MED GENET, V47, P342, DOI 10.1136/jmg.2009.072983; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Thelander EF, 2008, LEUKEMIA LYMPHOMA, V49, P477, DOI 10.1080/10428190701817282; Tong XM, 2009, CURR OPIN GENET DEV, V19, P32, DOI 10.1016/j.gde.2009.01.002; Torrino S, 2011, DEV CELL, V21, P959, DOI 10.1016/j.devcel.2011.08.015; Ueyama T, 2006, MOL CELL BIOL, V26, P2160, DOI 10.1128/MCB.26.6.2160-2174.2006; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Wellen KE, 2010, GENE DEV, V24, P2784, DOI 10.1101/gad.1985910; Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Zhang L, 2007, NAT MED, V13, P1060, DOI 10.1038/nm1621	39	21	25	3	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					4005	4010		10.1038/onc.2014.316	http://dx.doi.org/10.1038/onc.2014.316			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25284589	Green Accepted			2022-12-17	WOS:000358544200013
J	Redmond, AM; Byrne, C; Bane, FT; Brown, GD; Tibbitts, P; O'Brien, K; Hill, ADK; Carroll, JS; Young, LS				Redmond, A. M.; Byrne, C.; Bane, F. T.; Brown, G. D.; Tibbitts, P.; O'Brien, K.; Hill, A. D. K.; Carroll, J. S.; Young, L. S.			Genomic interaction between ER and HMGB2 identifies DDX18 as a novel driver of endocrine resistance in breast cancer cells	ONCOGENE			English	Article							RECEPTOR COACTIVATOR SRC-1; ESTROGEN-RECEPTOR; DNA-BINDING; TAMOXIFEN RESISTANCE; HORMONE-RECEPTORS; FOXA1 EXPRESSION; IN-VITRO; PROTEINS; TRANSCRIPTION; PROGRESSION	Breast cancer resistance to endocrine therapies such as tamoxifen and aromatase inhibitors is a significant clinical problem. Steroid receptor coactivator-1 (SRC-1), a coregulatory protein of the oestrogen receptor (ER), has previously been shown to have a significant role in the progression of breast cancer. The chromatin protein high mobility group box 2 (HMGB2) was identified as an SRC-1 interacting protein in the endocrine-resistant setting. We investigated the expression of HMGB2 in a cohort of 1068 breast cancer patients and found an association with increased disease-free survival time in patients treated with endocrine therapy. However, it was also verified that HMGB2 expression could be switched on in endocrine-resistant tumours from breast cancer patients. To explore the function of this poorly characterized protein, we performed HMGB2 ChIPseq and found distinct binding patterns between the two contexts. In the resistant setting, the HMGB2, SRC-1 and ER complex are enriched at promoter regions of target genes, with bioinformatic analysis indicating a switch in binding partners between the sensitive and resistant phenotypes. Integration of binding and gene expression data reveals a concise set of target genes of this complex including the RNA helicase DDX18. Modulation of DDX18 directly affects growth of tamoxifen-resistant cells, suggesting that it may be a critical downstream effector of the HMGB2:ER complex. This study defines HMGB2 interactions with the ER complex at specific target genes in the tamoxifen-resistant setting.	[Redmond, A. M.; Byrne, C.; Bane, F. T.; Tibbitts, P.; O'Brien, K.; Hill, A. D. K.; Young, L. S.] Royal Coll Surgeons Ireland, Endocrine Oncol Res Grp, Dept Surg, Dublin 2, Ireland; [Redmond, A. M.; Brown, G. D.; Carroll, J. S.] Univ Cambridge, Cambridge Inst, Canc Res UK, Cambridge CB2 0RE, England	Royal College of Surgeons - Ireland; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Carroll, JS (corresponding author), Univ Cambridge, Li Ka Shing Ctr, Cambridge Inst, Canc Res UK, Robinson Way, Cambridge CB2 0RE, England.	jason.carroll@cruk.cam.ac.uk; lyoung@rcsi.ie	Byrne, Christopher/D-2824-2016	Carroll, Jason/0000-0003-3643-0080; Young, Leonie/0000-0002-4904-0367	Irish Research Council for Science Engineering and Technology; Marie Curie Actions under FP7; Breast Cancer Ireland; Health Research Board; University of Cambridge; Cancer Research UK; Hutchison Whampoa Limited; European Molecular Biology Organisation; Cancer Research UK [20411] Funding Source: researchfish	Irish Research Council for Science Engineering and Technology(Irish Research Council for Science, Engineering and TechnologyCGIAR); Marie Curie Actions under FP7; Breast Cancer Ireland; Health Research Board; University of Cambridge(University of Cambridge); Cancer Research UK(Cancer Research UK); Hutchison Whampoa Limited; European Molecular Biology Organisation; Cancer Research UK(Cancer Research UK)	We would like to acknowledge the support of Irish Research Council for Science Engineering and Technology co-funded by Marie Curie Actions under FP7, Breast Cancer Ireland, Health Research Board, The University of Cambridge, Cancer Research UK, Hutchison Whampoa Limited and European Molecular Biology Organisation. We thank the members of the genomics core facility and Stuart MacArthur, former member of the bioinformatics core facility at Cancer Research UK.	Al-Azawi D, 2008, ONCOGENE, V27, P3021, DOI 10.1038/sj.onc.1210964; Badve S, 2007, CLIN CANCER RES, V13, P4415, DOI 10.1158/1078-0432.CCR-07-0122; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Cairns JM, 2008, BIOINFORMATICS, V24, P2921, DOI 10.1093/bioinformatics/btn557; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Davies C, 2011, LANCET, V378, P771, DOI 10.1016/S0140-6736(11)60993-8; de Leeuw R, 2013, ONCOGENE, V32, P3543, DOI 10.1038/onc.2012.361; Dillon MF, 2008, ENDOCR-RELAT CANCER, V15, P745, DOI 10.1677/ERC-08-0009; Dunning MJ, 2007, BIOINFORMATICS, V23, P2183, DOI 10.1093/bioinformatics/btm311; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hisamatsu Y, 2012, ANN SURG ONCOL, V19, P1145, DOI 10.1245/s10434-011-2094-4; Jolma A, 2013, CELL, V152, P327, DOI 10.1016/j.cell.2012.12.009; Kharchenko PV, 2008, NAT BIOTECHNOL, V26, P1351, DOI 10.1038/nbt.1508; Laurent B, 2010, BLOOD, V115, P687, DOI 10.1182/blood-2009-06-230094; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li Q, ANN APPL STAT, V5, P1752; Limer JL, 2006, INT J CANCER, V119, P515, DOI 10.1002/ijc.21863; Liu T, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r83; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; McBryan J, 2012, CANCER RES, V72, P548, DOI 10.1158/0008-5472.CAN-11-2073; McCartan D, 2012, CANCER RES, V72, P220, DOI 10.1158/0008-5472.CAN-11-1976; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; Melvin VS, 2004, J BIOL CHEM, V279, P14763, DOI 10.1074/jbc.M313335200; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; ONATE SA, 1995, SCIENCE, V270, P1354; Payne EM, 2011, BLOOD, V118, P903, DOI 10.1182/blood-2010-11-318022; Qin L, 2009, CANCER RES, V69, P3819, DOI 10.1158/0008-5472.CAN-08-4389; Redmond AM, 2009, CLIN CANCER RES, V15, P2098, DOI 10.1158/1078-0432.CCR-08-1649; Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730; Schmidt D, 2009, METHODS, V48, P240, DOI 10.1016/j.ymeth.2009.03.001; Shiota M, 2008, CANCER SCI, V99, P1950, DOI 10.1111/j.1349-7006.2008.00912.x; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Stros M, 2010, BBA-GENE REGUL MECH, V1799, P101, DOI 10.1016/j.bbagrm.2009.09.008; TREMETHICK DJ, 1986, J BIOL CHEM, V261, P6986; Walsh CA, 2014, CANCER RES, V74, P2533, DOI 10.1158/0008-5472.CAN-13-2133; Wang W, 2013, ONCOL LETT, V5, P884, DOI 10.3892/ol.2012.1091; Wortham NC, 2009, ONCOGENE, V28, P4053, DOI 10.1038/onc.2009.261; Zappavigna V, 1996, EMBO J, V15, P4981, DOI 10.1002/j.1460-2075.1996.tb00878.x; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhang ZH, 2011, NUCLEIC ACIDS RES, V39, pW391, DOI 10.1093/nar/gkr387	44	21	21	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	29					3871	3880		10.1038/onc.2014.323	http://dx.doi.org/10.1038/onc.2014.323			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM9BV	25284587				2022-12-17	WOS:000358001600012
J	Wei, F; Ojo, D; Lin, X; Wong, N; He, L; Yan, J; Xu, S; Major, P; Tang, D				Wei, F.; Ojo, D.; Lin, X.; Wong, N.; He, L.; Yan, J.; Xu, S.; Major, P.; Tang, D.			BMI1 attenuates etoposide-induced G2/M checkpoints via reducing ATM activation	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; STRAND BREAK REPAIR; CELL SELF-RENEWAL; POLYCOMB GROUP PROTEINS; MYC TRANSGENIC MICE; GROUP GENE BMI1; GENOMIC INSTABILITY; MOLECULAR MARKER; PROSTATE-CANCER; HISTONE H2AX	The BMI1 protein contributes to stem cell pluripotency and oncogenesis via multiple functions, including its newly identified role in DNA damage response (DDR). Although evidence clearly demonstrates that BMI1 facilitates the repair of double-stranded breaks via homologous recombination (HR), it remains unclear how BMI1 regulates checkpoint activation during DDR. We report here that BMI1 has a role in G2/M checkpoint activation in response to etoposide (ETOP) treatment. Ectopic expression of BMI1 in MCF7 breast cancer and DU145 prostate cancer cells significantly reduced ETOP-induced G2/M arrest. Conversely, knockdown of BMI1 in both lines enhanced the arrest. Consistent with ETOP-induced activation of the G2/M checkpoints via the ATM pathway, overexpression and knockdown of BMI1, respectively, reduced and enhanced ETOP-induced phosphorylation of ATM at serine 1981 (ATM pS1981). Furthermore, the phosphorylation of ATM targets, including gamma H2AX, threonine 68 (T68) on CHK2 (CHK2 pT68) and serine 15 (S15) on p53 were decreased in overexpression and increased in knockdown BMI1 cells in response to ETOP. In line with the requirement of NBS1 in ATM activation, we were able to show that BMI1 associates with NBS1 and that this interaction altered the binding of NBS1 with ATM. BMI1 consists of a ring finger (RF), helix-turn-helix-turn-helix-turn (HT), proline/serine (PS) domain and two nuclear localization signals (NLS). Although deletion of either RF or HT did not affect the association of BMI1 with NBS1, the individual deletions of PS and one NLS (KRMK) robustly reduced the interaction. Stable expression of these BMI1 mutants decreased ETOP-induced ATM pS1981 and CHK2 pT68, but not ETOP-elicited gamma H2AX in MCF7 cells. Furthermore, ectopic expression of BMI1 in non-transformed breast epithelial MCF10A cells also compromised ETOP-initiated ATM pS1981 and gamma H2AX. Taken together, we provide compelling evidence that BMI1 decreases ETOP-induced G2/M checkpoint activation via reducing NBS1-mediated ATM activation.	[Wei, F.; Ojo, D.; Lin, X.; Wong, N.; He, L.; Yan, J.; Xu, S.; Tang, D.] McMaster Univ, Dept Med, Div Nephrol, Hamilton, ON, Canada; [Wei, F.; Ojo, D.; Lin, X.; Wong, N.; He, L.; Yan, J.; Xu, S.; Tang, D.] Father Sean OSullivan Res Inst, Hamilton, ON, Canada; [Wei, F.; Ojo, D.; Lin, X.; Wong, N.; He, L.; Yan, J.; Xu, S.; Tang, D.] St Josephs Hosp, Hamilton Ctr Kidney Res, Hamilton, ON L8N 4A6, Canada; [Wei, F.] Inst Women & Childrens Hlth, Genet Lab, Shenzhen, Guangdong, Peoples R China; [He, L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA; [Major, P.] McMaster Univ, Dept Oncol, Hamilton, ON, Canada	McMaster University; McGill University; McMaster University; Harvard University; Harvard Medical School; Massachusetts General Hospital; McMaster University	Tang, D (corresponding author), St Josephs Hosp, Father Sean OSullivan Res Inst, T3310,50 Charlton Ave East, Hamilton, ON L8N 4A6, Canada.	damut@mcmaster.ca	Tang, Damu/AAQ-1786-2021	Tang, Damu/0000-0002-3282-9521	CIHR grant [MOP-84381]	CIHR grant(Canadian Institutes of Health Research (CIHR))	This work was supported by a CIHR grant (MOP-84381) to D Tang.	Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Akala OO, 2008, NATURE, V453, P228, DOI 10.1038/nature06869; Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bea S, 2001, CANCER RES, V61, P2409; Bruggeman SWM, 2005, GENE DEV, V19, P1438, DOI 10.1101/gad.1299305; Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chagraoui J, 2006, GENE DEV, V20, P2110, DOI 10.1101/gad.1453406; Chagraoui J, 2011, P NATL ACAD SCI USA, V108, P5284, DOI 10.1073/pnas.1014263108; Cohen KJ, 1996, MOL CELL BIOL, V16, P5527; Crea F, 2011, INT J CANCER, V128, P1946, DOI 10.1002/ijc.25522; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; de Napoles M, 2004, DEV CELL, V7, P663, DOI 10.1016/j.devcel.2004.10.005; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; Dong QH, 2011, J INVEST DERMATOL, V131, P1216, DOI 10.1038/jid.2011.11; Facchino S, 2010, J NEUROSCI, V30, P10096, DOI 10.1523/JNEUROSCI.1634-10.2010; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gieni RS, 2011, CELL CYCLE, V10, P883, DOI 10.4161/cc.10.6.14907; Ginjala V, 2011, MOL CELL BIOL, V31, P1972, DOI 10.1128/MCB.00981-10; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; HAUPT Y, 1993, ONCOGENE, V8, P3161; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Hemenway CS, 1998, ONCOGENE, V16, P2541, DOI 10.1038/sj.onc.1202042; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Ismail IH, 2010, J CELL BIOL, V191, P45, DOI 10.1083/jcb.201003034; Kim JH, 2004, BREAST, V13, P383, DOI 10.1016/j.breast.2004.02.010; Kim JH, 2004, CANCER LETT, V203, P217, DOI 10.1016/j.canlet.2003.07.009; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Levine SS, 2004, TRENDS BIOCHEM SCI, V29, P478, DOI 10.1016/j.tibs.2004.07.007; Li ZZ, 2006, J BIOL CHEM, V281, P20643, DOI 10.1074/jbc.M602461200; Liu ZG, 2012, ONCOL REP, V27, P1116, DOI 10.3892/or.2011.1615; Mihara K, 2006, BLOOD, V107, P305, DOI 10.1182/blood-2005-06-2393; Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Nacerddine K, 2012, J CLIN INVEST, V122, P1920, DOI 10.1172/JCI57477; O'Driscoll M, 2006, NAT REV GENET, V7, P45, DOI 10.1038/nrg1746; Pan MR, 2011, J BIOL CHEM, V286, P28599, DOI 10.1074/jbc.M111.256297; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Prigent C, 2003, J CELL SCI, V116, P3677, DOI 10.1242/jcs.00735; QUELLE DE, 1995, CELL, V83, P993; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Siddique HR, 2012, STEM CELLS, V30, P372, DOI 10.1002/stem.1035; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Song LB, 2006, CANCER RES, V66, P6225, DOI 10.1158/0008-5472.CAN-06-0094; Tang D, 2001, J BIOL CHEM, V276, P30461, DOI 10.1074/jbc.M102045200; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; van Galen JC, 2007, J CLIN PATHOL, V60, P167, DOI 10.1136/jcp.2006.038752; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Vonlanthen S, 2001, BRIT J CANCER, V84, P1372, DOI 10.1054/bjoc.2001.1791; Wang EF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017918; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wei FX, 2010, CELL SIGNAL, V22, P1783, DOI 10.1016/j.cellsig.2010.07.007; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	64	21	23	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	2015	34	23					3063	3075		10.1038/onc.2014.235	http://dx.doi.org/10.1038/onc.2014.235			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3EX	25088203				2022-12-17	WOS:000356100500011
J	Girardot, M; Pecquet, C; Chachoua, I; Van Hees, J; Guibert, S; Ferrant, A; Knoops, L; Baxter, EJ; Beer, PA; Giraudier, S; Moriggl, R; Vainchenker, W; Green, AR; Constantinescu, SN				Girardot, M.; Pecquet, C.; Chachoua, I.; Van Hees, J.; Guibert, S.; Ferrant, A.; Knoops, L.; Baxter, E. J.; Beer, P. A.; Giraudier, S.; Moriggl, R.; Vainchenker, W.; Green, A. R.; Constantinescu, S. N.			Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation	ONCOGENE			English	Article							TYROSINE KINASE JAK2; MYELOPROLIFERATIVE NEOPLASMS; FUNCTION-MUTATION; TRANSCRIPTION; REQUIREMENT; TARGETS; CDNA	STAT (Signal Transducer and Activator of Transcription) transcription factors are constitutively activated in most hematopoietic cancers. We previously identified a target gene, LPP/miR-28 (LIM domain containing preferred translocation partner in lipoma), induced by constitutive activation of STAT5, but not by transient cytokine-activated STAT5. miR-28 exerts negative effects on thrombopoietin receptor signaling and platelet formation. Here, we demonstrate that, in transformed hematopoietic cells, STAT5 and p53 must be synergistically bound to chromatin for induction of LPP/miR-28 transcription. Genome-wide association studies show that both STAT5 and p53 are co-localized on the chromatin at 463 genomic positions in proximal promoters. Chromatin binding of p53 is dependent on persistent STAT5 activation at these proximal promoters. The transcriptional activity of selected promoters bound by STAT5 and p53 was significantly changed upon STAT5 or p53 inhibition. Abnormal expression of several STAT5-p53 target genes (LEP, ATP5J, GTF2A2, VEGFC, NPY1R and NPY5R) is frequently detected in platelets of myeloproliferative neoplasm (MPN) patients, but not in platelets from healthy controls. In conclusion, persistently active STAT5 can recruit normal p53, like in the case of MPN cells, but also p53 mutants, such as p53 M133K in human erythroleukemia cells, leading to pathologic gene expression that differs from canonical STAT5 or p53 transcriptional programs.	[Girardot, M.; Pecquet, C.; Chachoua, I.; Van Hees, J.; Knoops, L.; Constantinescu, S. N.] Ludwig Inst Canc Res, Brussels, Belgium; [Girardot, M.; Pecquet, C.; Chachoua, I.; Van Hees, J.; Knoops, L.; Constantinescu, S. N.] Catholic Univ Louvain, Duve Inst, Brussels, Belgium; [Girardot, M.] Univ Montpellier, CNRS, Inst Mol Genet, UMR5535, F-34059 Montpellier, France; [Guibert, S.] Univ Strasbourg, CNRS, Biotechnol & Cell Signalling, ESBS,UMR 7242, Illkirch Graffenstaden, France; [Ferrant, A.; Knoops, L.] Clin Univ St Luc, Dept Hematol, B-1200 Brussels, Belgium; [Baxter, E. J.; Beer, P. A.; Green, A. R.] Univ Cambridge, Cambridge Inst Med Res, Cambridge, England; [Giraudier, S.; Vainchenker, W.] Inst Gustave Roussy, INSERM, U1009, F-94805 Villejuif, France; [Giraudier, S.] Univ Paris 12, Hop Henri Mondor, AP HP, PRB Cellulotheque Hematol,Lab Hematol, F-94010 Creteil, France; [Moriggl, R.] Ludwig Boltzmann Inst Canc Res, Vienna, Austria	Ludwig Institute for Cancer Research; Universite Catholique Louvain; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; University of Cambridge; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Ludwig Boltzmann Institute	Constantinescu, SN (corresponding author), Univ Louvain Brussels, Signal Transduct Unit, Ludwig Inst Canc Res, B-1200 Brussels, Belgium.	michael.girardot@igmm.cnrs.fr; stefan.constantinescu@bru.licr.org	Moriggl, Richard/H-8118-2019; Chachoua, Ilyas/AAB-3326-2019	Moriggl, Richard/0000-0003-0918-9463; Chachoua, Ilyas/0000-0002-5112-5394; Green, Anthony/0000-0002-9795-0218; Vainchenker, William/0000-0003-4705-202X; Christian, Pecquet/0000-0002-8623-3483; Baxter, Elizabeth Joanna/0000-0002-5946-5238; Constantinescu, Stefan N./0000-0002-8599-2699	FRS-FNRS, Belgium (Mandat d'Impulsion); FRS-FNRS, Belgium (FRSM); Salus Sanguinis Foundation; Action de Recherche Concertee projects of the University catholique de Louvain, Brussels [MEXP31C1, ARC10/15-027]; Fondation contre le Cancer, Brussels; PAI Programs [BCHM61B5]; Belgian Medical Genetics Initiative (BeMG), Belgium; Atlantic Philanthropies, New York; Austrian Science Fund (FWF) [SFB-F2807/SFB-F4707]; Austrian Science Fund (FWF) [F 2807] Funding Source: researchfish; Cancer Research UK [12765] Funding Source: researchfish	FRS-FNRS, Belgium (Mandat d'Impulsion); FRS-FNRS, Belgium (FRSM)(Fonds de la Recherche Scientifique - FNRS); Salus Sanguinis Foundation; Action de Recherche Concertee projects of the University catholique de Louvain, Brussels; Fondation contre le Cancer, Brussels; PAI Programs; Belgian Medical Genetics Initiative (BeMG), Belgium; Atlantic Philanthropies, New York; Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Cancer Research UK(Cancer Research UK)	We thank Guido Bommer for invaluable p53 reagents and extremely useful criticisms and suggestions. We are grateful for generous support to SNC from the FRS-FNRS, Belgium (Mandat d'Impulsion and FRSM), the Salus Sanguinis Foundation, the Action de Recherche Concertee projects MEXP31C1 and ARC10/15-027 of the University catholique de Louvain, Brussels, the Fondation contre le Cancer, Brussels, the PAI Programs BCHM61B5 and Belgian Medical Genetics Initiative (BeMG), Belgium and the Atlantic Philanthropies, New York (for SNC). RM was supported by SFB-F2807/SFB-F4707 from the Austrian Science Fund (FWF).	BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Borgel J, 2010, NAT GENET, V42, P1093, DOI 10.1038/ng.708; Casetti L, 2013, CANCER RES, V73, P2052, DOI 10.1158/0008-5472.CAN-12-3955; Chipoy C, 2007, ONCOGENE, V26, P6653, DOI 10.1038/sj.onc.1210492; Constantinescu SN, 2008, TRENDS BIOCHEM SCI, V33, P122, DOI 10.1016/j.tibs.2007.12.002; Dawson MR, 2009, NATURE, V461, pE4, DOI 10.1038/nature08254; DEJONG J, 1995, P NATL ACAD SCI USA, V92, P3313, DOI 10.1073/pnas.92.8.3313; Fritsche M, 1998, MOL CELL ENDOCRINOL, V143, P143, DOI 10.1016/S0303-7207(98)00140-3; Girardot M, 2010, BLOOD, V116, P437, DOI 10.1182/blood-2008-06-165985; HIGUTI T, 1991, BIOCHEM BIOPH RES CO, V178, P793, DOI 10.1016/0006-291X(91)90178-A; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Klampfl T, 2013, NEW ENGL J MED, V369, P2379, DOI 10.1056/NEJMoa1311347; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Kramer Oliver H, 2012, JAKSTAT, V1, P203, DOI 10.4161/jkst.21232; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Lin YP, 2002, BLOOD, V100, P3990, DOI 10.1182/blood-2002-02-0504; Liu F, 2011, CANCER CELL, V19, P283, DOI 10.1016/j.ccr.2010.12.020; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Moucadel V, 2005, J BIOL CHEM, V280, P13364, DOI 10.1074/jbc.M407326200; Mouzaki A, 2009, CYTOKINE, V48, P203, DOI 10.1016/j.cyto.2009.07.006; Nakatake M, 2012, ONCOGENE, V31, P1323, DOI 10.1038/onc.2011.313; Nangalia J, 2013, NEW ENGL J MED, V369, P2391, DOI 10.1056/NEJMoa1312542; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pecquet C, 2012, BLOOD, V119, P4625, DOI 10.1182/blood-2011-08-372524; Rajala HLM, 2013, BLOOD, V121, P4541, DOI 10.1182/blood-2012-12-474577; Shi S, 2006, NAT GENET, V38, P1071, DOI 10.1038/ng1860; Stark GR, 2012, IMMUNITY, V36, P503, DOI 10.1016/j.immuni.2012.03.013; Townsend PA, 2004, J BIOL CHEM, V279, P5811, DOI 10.1074/jbc.M302637200; Walz C, 2012, BLOOD, V119, P3550, DOI 10.1182/blood-2011-12-397554; Wood TJJ, 1997, MOL CELL ENDOCRINOL, V130, P69, DOI 10.1016/S0303-7207(97)00075-0; Yan DQ, 2012, BLOOD, V119, P3539, DOI 10.1182/blood-2011-03-345215; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	36	21	21	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2015	34	10					1323	1332		10.1038/onc.2014.60	http://dx.doi.org/10.1038/onc.2014.60			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC9JX	24681953	Green Accepted			2022-12-17	WOS:000350687100012
J	Lung, HL; Man, OY; Yeung, MC; Ko, JMY; Cheung, AKL; Law, EWL; Yu, Z; Shuen, WH; Tung, E; Chan, SHK; Bangarusamy, DK; Cheng, Y; Yang, X; Kan, R; Phoon, Y; Chan, KC; Chua, D; Kwong, DL; Lee, AWM; Ji, MF; Lung, ML				Lung, H. L.; Man, O. Y.; Yeung, M. C.; Ko, J. M. Y.; Cheung, A. K. L.; Law, E. W. L.; Yu, Z.; Shuen, W. H.; Tung, E.; Chan, S. H. K.; Bangarusamy, D. K.; Cheng, Y.; Yang, X.; Kan, R.; Phoon, Y.; Chan, K. C.; Chua, D.; Kwong, D. L.; Lee, A. W. M.; Ji, M. F.; Lung, M. L.			SAA1 polymorphisms are associated with variation in antiangiogenic and tumor-suppressive activities in nasopharyngeal carcinoma	ONCOGENE			English	Article							SERUM AMYLOID-A; AORTIC SMOOTH-MUSCLE; EPSTEIN-BARR-VIRUS; ARG-GLY-ASP; ACUTE-PHASE; MONOCHROMOSOME TRANSFER; EXTRACELLULAR-MATRIX; EPITHELIAL-CELLS; EXPRESSION; PROTEIN	Nasopharyngeal carcinoma (NPC) is a cancer that occurs in high frequency in Southern China. A previous functional complementation approach and the subsequent cDNA microarray analysis have identified that serum amyloid A1 (SAA1) is an NPC candidate tumor suppressor gene. SAA1 belongs to a family of acute-phase proteins that are encoded by five polymorphic coding alleles. The SAA1 genotyping results showed that only three SAA1 isoforms (SAA1.1, 1.3 and 1.5) were observed in both Hong Kong NPC patients and healthy individuals. This study aims to determine the functional role of SAA1 polymorphisms in tumor progression and to investigate the relationship between SAA1 polymorphisms and NPC risk. Indeed, we have shown that restoration of SAA1.1 and 1.3 in the SAA1-deficient NPC cell lines could suppress tumor formation and angiogenesis in vitro and in vivo. The secreted SAA1.1 and SAA1.3 proteins can block cell adhesion and induce apoptosis in the vascular endothelial cells. In contrast, the SAA1.5 cannot induce apoptosis or inhibit angiogenesis because of its weaker binding affinity to alpha V beta 3 integrin. This can explain why SAA1.5 has no tumor-suppressive effects. Furthermore, the NPC tumors with this particular SAA1.5/1.5 genotype showed higher levels of SAA1 gene expression, and SAA1.1 and 1.3 alleles were preferentially inactivated in tumor tissues that were examined. These findings further strengthen the conclusion for the defective function of SAA1.5 in suppression of tumor formation and angiogenesis. Interestingly, the frequency of the SAA1.5/1.5 genotype in NPC patients was similar to 2-fold higher than in the healthy individuals (P = 0.00128, odds ratio = 2.28), which indicates that this SAA1 genotype is significantly associated with a higher NPC risk. Collectively, this homozygous SAA1.5/1.5 genotype appears to be a recessive susceptibility gene, which has lost the antiangiogenic function, whereas SAA1.1 and SAA1.3 are the dominant alleles of the tumor suppressor phenotype.	[Lung, H. L.; Man, O. Y.; Yeung, M. C.; Ko, J. M. Y.; Cheung, A. K. L.; Law, E. W. L.; Yu, Z.; Shuen, W. H.; Tung, E.; Chan, S. H. K.; Cheng, Y.; Yang, X.; Kan, R.; Phoon, Y.; Chan, K. C.; Chua, D.; Kwong, D. L.; Lung, M. L.] Univ Hong Kong, Dept Clin Oncol, Pokfulam, Hong Kong, Peoples R China; [Lung, H. L.; Man, O. Y.; Yeung, M. C.; Ko, J. M. Y.; Cheung, A. K. L.; Law, E. W. L.; Yu, Z.; Shuen, W. H.; Tung, E.; Chan, S. H. K.; Cheng, Y.; Yang, X.; Kan, R.; Phoon, Y.; Chan, K. C.; Chua, D.; Kwong, D. L.; Lung, M. L.] Univ Hong Kong, Ctr Canc Res, Pokfulam, Hong Kong, Peoples R China; [Tung, E.; Chua, D.; Kwong, D. L.; Lee, A. W. M.; Lung, M. L.] Univ Hong Kong, Ctr Nasopharyngeal Carcinoma Res, Hong Kong, Hong Kong, Peoples R China; [Bangarusamy, D. K.] Inst Biomed Sci, Genome Inst Singapore, Singapore, Singapore; [Chua, D.] Hong Kong Sanat & Hosp, Comprehens Oncol Ctr, Hong Kong, Hong Kong, Peoples R China; [Lee, A. W. M.] Pamela Youde Nethersole Eastern Hosp, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; [Lee, A. W. M.] Univ Hong Kong, Shenzhen Hosp, Dept Clin Oncol, Shenzhen, Peoples R China; [Ji, M. F.] Zhongshan City Hosp, Ctr Canc, Zhongshan, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Pamela Youde Nethersole Eastern Hospital; University of Hong Kong	Lung, HL (corresponding author), Univ Hong Kong, Dept Clin Oncol, L6-02,Fac Med Bldg,21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	hllung2@hku.hk; mlilung@hku.hk	Cheng, Yue/Z-4456-2019; Ko, Josephine/U-2972-2019; Lung, Maria Li/C-4495-2009	Ko, Josephine/0000-0002-7997-331X; Ji, Mingfang/0000-0003-4727-2858; Lung, Maria Li/0000-0003-2559-3626	Research Grants Council of the Hong Kong Special Administrative Region [HKU772309]	Research Grants Council of the Hong Kong Special Administrative Region(Hong Kong Research Grants Council)	We acknowledge the AoE NPC Tissue Bank for providing the NPC specimens and the NPC TMA. We thank the Hong Kong Red Cross for providing us the blood from healthy individuals. We also thank Dr Edison Tak-Bun Liu for their microarray support in the Genome Institute of Singapore (GIS); Dr Sai Wah Tsao for providing us the immortalized cell lines; Dr John M Nicholls for the TMA analysis and Dr Pui Man Chiu for her help in constructing the NPC TMA and SAA immunohistochemistry staining; Dr Didier Trono for the supply of the lentiviral vectors, pWPI, pMD2. G and psPAX2. We thank Dr David Root for the supply of the lentihair pLKO. 1-TRC cloning vector and Dr David Sabatini for the pLKO. 1-scramble shRNA construct. This work was supported by the General Research Fund (HKU772309 to HLL) of the Research Grants Council of the Hong Kong Special Administrative Region.	Adham M, 2012, CHIN J CANCER, V31, P185, DOI 10.5732/cjc.011.10328; Amal Chandra Kataki, 2011, Chinese Journal of Cancer, V30, P106; Avraamides CJ, 2008, NAT REV CANCER, V8, P604, DOI 10.1038/nrc2353; BADOLATO R, 1994, J EXP MED, V180, P203, DOI 10.1084/jem.180.1.203; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; CABANA VG, 1989, J LIPID RES, V30, P39; Chan KC, 2011, INT J CANCER, V129, P1826, DOI 10.1002/ijc.25855; Cheng Y, 2000, GENE CHROMOSOME CANC, V28, P82, DOI 10.1002/(SICI)1098-2264(200005)28:1<82::AID-GCC10>3.0.CO;2-8; Cheung ST, 1999, INT J CANCER, V83, P121, DOI 10.1002/(SICI)1097-0215(19990924)83:1<121::AID-IJC21>3.0.CO;2-F; CHIANG HS, 1995, BRIT J CANCER, V71, P265, DOI 10.1038/bjc.1995.54; Cho WCS, 2004, CLIN CANCER RES, V10, P43, DOI 10.1158/1078-0432.CCR-0413-3; Deng W, 2004, ONCOGENE, V23, P9090, DOI 10.1038/sj.onc.1208119; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524; HOFFMAN JS, 1982, J BIOL CHEM, V257, P518; HUANG DP, 1980, INT J CANCER, V26, P127, DOI 10.1002/ijc.2910260202; Huang Z, 2012, ONCOGENE, V31, P3709, DOI 10.1038/onc.2011.529; Iwamoto Y, 1996, BRIT J CANCER, V73, P589, DOI 10.1038/bjc.1996.102; Ko JMY, 2008, MOL CANCER RES, V6, P592, DOI 10.1158/1541-7786.MCR-07-0154; Kumon Y, 2002, SCAND J IMMUNOL, V56, P504, DOI 10.1046/j.1365-3083.2002.01169.x; Li HM, 2006, INT J CANCER, V119, P1567, DOI 10.1002/ijc.22032; LIANG JS, 1995, J LIPID RES, V36, P37; Liang JS, 1996, J LIPID RES, V37, P2109; Liao QL, 2008, CLIN EXP METASTAS, V25, P465, DOI 10.1007/s10585-008-9152-8; Lindhorst E, 1997, BBA-PROTEIN STRUCT M, V1339, P143, DOI 10.1016/S0167-4838(96)00227-0; Liu CB, 2012, PATHOL ONCOL RES, V18, P117, DOI 10.1007/s12253-011-9459-7; Liu Q, 2013, CHIN J CANCER, V32, P325, DOI 10.5732/cjc.012.10189; Lo PHY, 2010, CANCER RES, V70, P5567, DOI 10.1158/0008-5472.CAN-09-4510; Lung HL, 2005, ONCOGENE, V24, P6525, DOI 10.1038/sj.onc.1208812; Lung HL, 2008, INT J CANCER, V123, P401, DOI 10.1002/ijc.23528; Lung HL, 2006, CANCER RES, V66, P9385, DOI 10.1158/0008-5472.CAN-06-0590; Malle E, 2009, CELL MOL LIFE SCI, V66, P9, DOI 10.1007/s00018-008-8321-x; MITCHELL TI, 1991, J CLIN INVEST, V87, P1177, DOI 10.1172/JCI115116; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Mould AP, 2011, CURR PROTOC CELL BIO; NICOSIA RF, 1991, AM J PATHOL, V138, P829; Perron-Sierra F, 2002, BIOORG MED CHEM LETT, V12, P3291, DOI 10.1016/S0960-894X(02)00696-0; PRECIADOPATT L, 1994, EUR J BIOCHEM, V223, P35, DOI 10.1111/j.1432-1033.1994.tb18963.x; PreciadoPatt L, 1996, J IMMUNOL, V156, P1189; Protopopov AI, 2002, J GENE MED, V4, P397, DOI 10.1002/jgm.283; Robertson G P, 1999, Mol Cell Biol Res Commun, V2, P1, DOI 10.1006/mcbr.1999.0141; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Strissel KJ, 1997, EXP CELL RES, V237, P275, DOI 10.1006/excr.1997.3783; Sung HJ, 2011, J PROTEOME RES, V10, P1383, DOI 10.1021/pr101154j; Thorn CF, 2002, J IMMUNOL, V169, P399, DOI 10.4049/jimmunol.169.1.399; Treuting P.M., 2012, COMP ANATOMY HISTOLO; Tsang CM, 2010, INT J CANCER, V127, P1570, DOI 10.1002/ijc.25173; Uhlar CM, 1999, EUR J BIOCHEM, V265, P501, DOI 10.1046/j.1432-1327.1999.00657.x; Urieli-Shoval S, 1998, J HISTOCHEM CYTOCHEM, V46, P1377, DOI 10.1177/002215549804601206; Venetsanakos E, 2002, EXP CELL RES, V273, P21, DOI 10.1006/excr.2001.5424; Wei WI, 2005, LANCET, V365, P2041, DOI 10.1016/S0140-6736(05)66698-6; Wong VCL, 2012, INT J CANCER, V130, P83, DOI 10.1002/ijc.25970; XU LL, 1995, J IMMUNOL, V155, P1184; YAMADA T, 1994, BBA-MOL BASIS DIS, V1226, P323, DOI 10.1016/0925-4439(94)90044-2; Yamada T, 1999, CLIN CHEM LAB MED, V37, P381, DOI 10.1515/CCLM.1999.063; Zhang H, 2006, CANCER GENET CYTOGEN, V165, P25, DOI 10.1016/j.cancergencyto.2005.07.016	56	21	21	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2015	34	7					878	889		10.1038/onc.2014.12	http://dx.doi.org/10.1038/onc.2014.12			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB2QF	24608426				2022-12-17	WOS:000349472000008
J	Tago, K; Funakoshi-Tago, M; Itoh, H; Furukawa, Y; Kikuchi, J; Kato, T; Suzuki, K; Yanagisawa, K				Tago, K.; Funakoshi-Tago, M.; Itoh, H.; Furukawa, Y.; Kikuchi, J.; Kato, T.; Suzuki, K.; Yanagisawa, K.			Arf tumor suppressor disrupts the oncogenic positive feedback loop including c-Myc and DDX5	ONCOGENE			English	Article						Arf; c-Myc; DDX5	RNA HELICASE P68; DEAD-BOX; RIBOSOME BIOGENESIS; TRANSCRIPTIONAL ACTIVITY; CELL-PROLIFERATION; PROTEIN; P53; P19(ARF); PATHWAYS; PROMOTES	Tumor suppressor protein p19(ARF) (Arf; p14(ARF) in humans) functions in both p53-dependent and -independent modes to counteract hyper-proliferative signals caused by proto-oncogene activation, but its p53-independent activities remain poorly understood. Using the tandem affinity purification-tag technique, we purified Arf-containing protein complexes and identified p68 DEAD-box protein (DDX5) as a novel interacting protein of Arf. In this study, we found that DDX5 interacts with c-Myc, and harbors essential roles for c-Myc-mediated transcription and its transforming activity. Furthermore, when c-Myc was forcibly expressed, the expression level of DDX5 protein was drastically increased through the acceleration of protein synthesis of DDX5, suggesting the presence of an oncogenic positive feedback loop including c-Myc and DDX5. Strikingly, Arf blocked the physical interaction between DDX5 and c-Myc, and drove away DDX5 from the promoter of c-Myc target genes. These observations most likely indicate the mechanism by which Arf causes p53-independent tumor-suppressive activity.	[Tago, K.; Yanagisawa, K.] Jichi Med Univ, Sch Med, Dept Biochem, Div Struct Biochem, Shimotsuke, Tochigi 3290498, Japan; [Funakoshi-Tago, M.] Keio Univ, Dept Biochem, Fac Pharm, Minato Ku, Tokyo 108, Japan; [Itoh, H.] Nara Inst Sci & Technol, Grad Sch Biol Sci, Dept Cell Biol, Lab Signal Transduct, Ikoma, Japan; [Furukawa, Y.; Kikuchi, J.] Jichi Med Univ, Ctr Mol Med, Div Stem Cell Regulat, Shimotsuke, Tochigi 3290498, Japan; [Kato, T.; Suzuki, K.] Jichi Med Univ, Saitama Med Ctr, Dept Surg, Omiya Ku, Shimotsuke, Tochigi 3290498, Japan	Jichi Medical University; Keio University; Nara Institute of Science & Technology; Jichi Medical University; Jichi Medical University	Tago, K (corresponding author), Jichi Med Univ, Sch Med, Dept Biochem, Div Struct Biochem, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.	ktago@jichi.ac.jp	Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418	MEXT [20770103]; Takeda Science Foundation; Grants-in-Aid for Scientific Research [25118721] Funding Source: KAKEN	MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Charles Sherr and Martine Roussel for critical advice and reagents, and Michael Washburn of Stowers Institute for Medical Research Proteomics Center for performing MudPIT analysis. This work was supported by a grant-in-aid for scientific research from the MEXT (20770103), MEXT-supported program for the strategic research foundation at private universities (2013-2017) and the Takeda Science Foundation.	Bates GJ, 2005, EMBO J, V24, P543, DOI 10.1038/sj.emboj.7600550; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Causevic M, 2001, ONCOGENE, V20, P7734, DOI 10.1038/sj.onc.1204976; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Chen LH, 2003, ONCOGENE, V22, P5348, DOI 10.1038/sj.onc.1206851; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Datta A, 2004, J BIOL CHEM, V279, P36698, DOI 10.1074/jbc.M312305200; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Dubey P, 1997, J EXP MED, V185, P695, DOI 10.1084/jem.185.4.695; Duran RV, 2012, MOL CELL, V47, P349, DOI 10.1016/j.molcel.2012.05.043; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Heinlein UAO, 1998, J PATHOL, V184, P345, DOI 10.1002/(SICI)1096-9896(199804)184:4<345::AID-PATH1243>3.0.CO;2-6; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Jacobs AMF, 2007, ONCOGENE, V26, P5866, DOI 10.1038/sj.onc.1210387; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kelly-Spratt KS, 2004, PLOS BIOL, V2, P1138, DOI 10.1371/journal.pbio.0020242; Kuo ML, 2008, CELL CYCLE, V7, P3378, DOI 10.4161/cc.7.21.6930; LANE DP, 1980, NATURE, V288, P167, DOI 10.1038/288167a0; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Martin DE, 2006, CELL METAB, V4, P259, DOI 10.1016/j.cmet.2006.09.002; Packham G, 1997, ONCOGENE, V15, P1219, DOI 10.1038/sj.onc.1201273; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; QUELLE DE, 1995, CELL, V83, P993; Reinhardt HC, 2009, CURR OPIN CELL BIOL, V21, P245, DOI 10.1016/j.ceb.2009.01.018; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Saporita AJ, 2011, CANCER RES, V71, P6708, DOI 10.1158/0008-5472.CAN-11-1472; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Tago K, 2005, P NATL ACAD SCI USA, V102, P7689, DOI 10.1073/pnas.0502978102; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Xirodimas DP, 2002, FEBS LETT, V528, P207, DOI 10.1016/S0014-5793(02)03310-0; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036; Yang LQ, 2005, MOL CANCER RES, V3, P355, DOI 10.1158/1541-7786.MCR-05-0022; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	48	21	22	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2015	34	3					310	318		10.1038/onc.2013.561	http://dx.doi.org/10.1038/onc.2013.561			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ3RY	24469041				2022-12-17	WOS:000348145500005
J	Glenn, ST; Jones, CA; Sexton, S; Levea, CM; Caraker, SM; Hajduczok, G; Gross, KW				Glenn, S. T.; Jones, C. A.; Sexton, S.; Levea, C. M.; Caraker, S. M.; Hajduczok, G.; Gross, K. W.			Conditional deletion of p53 and Rb in the renin-expressing compartment of the pancreas leads to a highly penetrant metastatic pancreatic neuroendocrine carcinoma	ONCOGENE			English	Article						glucagonoma; renin; pancreas; PanNET	MULTIPLE ENDOCRINE NEOPLASIA; ANGIOTENSIN SYSTEM; TRANSGENIC MICE; MOUSE MODEL; MUTANT MICE; ALPHA-CELLS; TUMORS; TYPE-1; INHIBITORS; MEN1	Efforts to model human pancreatic neuroendocrine tumors (PanNETs) in animals have been moderately successful, with minimal evidence for glucagonomas or metastatic spread. The renin gene, although classically associated with expression in the kidney, is also expressed in many other extrarenal tissues including the pancreas. To induce tumorigenesis within renin-specific tissues, floxed alleles of p53 and Rb were selectively abrogated using Cre-recombinase driven by the renin promoter. The primary neoplasm generated is a highly metastatic islet cell carcinoma of the pancreas. Lineage tracing identifies descendants of renin-expressing cells as pancreatic alpha cells despite a lack of active renin expression in the mature pancreas. Both primary and metastatic tumors express high levels of glucagon; furthermore, an increased level of glucagon is found in the serum, identifying the pancreatic cancer as a functional glucagonoma. This new model is highly penetrant and exhibits robust frequency of metastases to the lymph nodes and the liver, mimicking human disease, and provides a useful platform for better understanding pancreatic endocrine differentiation and development, as well as islet cell carcinogenesis. The use of fluorescent reporters for lineage tracing of the cells contributing to disease initiation and progression provides an unique opportunity to dissect the timeline of disease, examining mechanisms of the metastatic process, as well as recovering primary and metastatic cells for identifying cooperating mutations that are necessary for progression of disease.	[Glenn, S. T.; Jones, C. A.; Gross, K. W.] Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; [Sexton, S.] Roswell Pk Canc Inst, Dept Lab Anim Resources, Buffalo, NY 14263 USA; [Levea, C. M.] Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA; [Caraker, S. M.] IDEXX RADIL, Columbia, MO USA; [Hajduczok, G.] SUNY Buffalo, Dept Physiol & Biophys, Buffalo, NY 14260 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute; Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Gross, KW (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Elm & Carlton Str, Buffalo, NY 14263 USA.	Kenneth.Gross@roswellpark.org			NIH [5R01HL048459, R21CA164795, R21CA169717]; CCSG [CA016056]; Genomics Shared Resource (GSR); National Science Foundation Major Research Instrumentation [DBI 0923133]; NATIONAL CANCER INSTITUTE [P30CA016056, R21CA164795, R21CA169717] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048459] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CCSG; Genomics Shared Resource (GSR); National Science Foundation Major Research Instrumentation(National Science Foundation (NSF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was funded by the NIH grants 5R01HL048459, R21CA164795 and R21CA169717. We would like to thank the CCSG funded (CA016056) Roswell Park Gene Targeting and Transgenic Resource and the Genomics Shared Resource (GSR). Confocal Microscopy was performed at the University at Buffalo North Campus Imaging Facility using a Zeiss LSM 710 purchased through National Science Foundation Major Research Instrumentation grant DBI 0923133. We would also like to thank MK Ellsworth and Caretta Reese for maintenance of the mouse colonies, as well as Dominic Smiraglia and Elizabeth Repasky for critical reading and discussion of work. A special thank you to Dr George Deeb for his insightful observations on anatomy.	Benson C, 2005, BRIT J CANCER, V92, P7, DOI 10.1038/sj.bjc.6602229; Bertolino P, 2003, MOL ENDOCRINOL, V17, P1880, DOI 10.1210/me.2003-0154; Bertolino P, 2003, CANCER RES, V63, P4836; Carlsson P O, 2001, JOP, V2, P26; Crabtree JS, 2003, MOL CELL BIOL, V23, P6075, DOI 10.1128/MCB.23.17.6075-6085.2003; Crabtree JS, 2001, P NATL ACAD SCI USA, V98, P1118, DOI 10.1073/pnas.98.3.1118; Desgraz R, 2009, DEVELOPMENT, V136, P3567, DOI 10.1242/dev.039214; Ehehalt F, 2009, ONCOLOGIST, V14, P456, DOI 10.1634/theoncologist.2008-0259; Flesken-Nikitin A, 2003, CANCER RES, V63, P3459; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Glenn ST, 2008, PHYSIOL GENOMICS, V35, P243, DOI 10.1152/physiolgenomics.00017.2008; Gomez RA, 1998, KIDNEY INT, V54, pS12, DOI 10.1046/j.1523-1755.1998.06703.x; Gromada J, 2007, ENDOCR REV, V28, P84, DOI 10.1210/er.2006-0007; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HARVEY M, 1995, CANCER RES, V55, P1146; Haumaitre C, 2008, MOL CELL BIOL, V28, P6373, DOI 10.1128/MCB.00413-08; Hu Wenwei, 2010, Genes Cancer, V1, P360; Johansson KA, 2007, DEV CELL, V12, P457, DOI 10.1016/j.devcel.2007.02.010; Jones CA, 2000, PHYSIOL GENOMICS, V4, P75, DOI 10.1152/physiolgenomics.2000.4.1.75; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Lam K Y, 2001, JOP, V2, P40; Lam KY, 2002, EUR J ENDOCRINOL, V146, P567, DOI 10.1530/eje.0.1460567; Lammert E, 2003, MECH DEVELOP, V120, P59, DOI 10.1016/S0925-4773(02)00332-5; Lau T, 2004, DIABETOLOGIA, V47, P240, DOI 10.1007/s00125-003-1295-1; Leung KK, 2012, STEM CELLS, V30, P525, DOI 10.1002/stem.1008; Leung PS, 2007, J PHYSIOL-LONDON, V580, P31, DOI 10.1113/jphysiol.2006.126193; Leung PS, 2005, PANCREAS, V30, P293, DOI 10.1097/01.mpa.0000158028.76666.76; Leung PS, 2003, INT J BIOCHEM CELL B, V35, P838, DOI 10.1016/S1357-2725(02)00179-6; Leung PS, 2001, J MOL ENDOCRINOL, V26, P155, DOI 10.1677/jme.0.0260155; Liu LX, 2005, MODERN PATHOL, V18, P1632, DOI 10.1038/modpathol.3800490; Loffler KA, 2007, INT J CANCER, V120, P259, DOI 10.1002/ijc.22288; Lopez MLSS, 2004, DEV CELL, V6, P719; Lu JL, 2010, GASTROENTEROLOGY, V138, P1954, DOI 10.1053/j.gastro.2010.01.046; Marino S, 2000, GENE DEV, V14, P994; Nishimura H, 1999, INTERNAL MED, V38, P315, DOI 10.2169/internalmedicine.38.315; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; RINDI G, 1991, VIRCHOWS ARCH A, V419, P115, DOI 10.1007/BF01600225; RUTTMAN E, 1980, VIRCHOWS ARCH A, V388, P51, DOI 10.1007/BF00430676; Schwitzgebel VM, 2000, DEVELOPMENT, V127, P3533; Shen HCJ, 2010, ENDOCRINOLOGY, V151, P4024, DOI 10.1210/en.2009-1251; Shen HCJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004897; Shen HCJ, 2009, CANCER RES, V69, P1858, DOI 10.1158/0008-5472.CAN-08-3662; SIGMUND CD, 1990, J BIOL CHEM, V265, P19916; Snippert HJ, 2010, CELL, V143, P134, DOI 10.1016/j.cell.2010.09.016; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Sparwasser T, 2004, GENESIS, V38, P39, DOI 10.1002/gene.10249; Tahmasebi M, 1999, J ENDOCRINOL, V161, P317, DOI 10.1677/joe.0.1610317; Tang LH, 2012, CLIN CANCER RES, V18, P4612, DOI 10.1158/1078-0432.CCR-11-3264; Tikellis C, 2006, INT J BIOCHEM CELL B, V38, P737, DOI 10.1016/j.biocel.2005.08.007; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480	51	21	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2014	33	50					5706	5715		10.1038/onc.2013.514	http://dx.doi.org/10.1038/onc.2013.514			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW2AB	24292676	Green Accepted			2022-12-17	WOS:000346089300006
J	Avivar-Valderas, A; Wen, HC; Aguirre-Ghiso, JA				Avivar-Valderas, A.; Wen, H. C.; Aguirre-Ghiso, J. A.			Stress signaling and the shaping of the mammary tissue in development and cancer	ONCOGENE			English	Review						stress; anoikis; mammary gland; ECM; breast cancer; autophagy	UNFOLDED PROTEIN RESPONSE; EXTRACELLULAR-MATRIX DETACHMENT; ANCHORAGE-DEPENDENT FIBROBLASTS; HEAT-SHOCK PROTEINS; P38 MAP KINASE; EPITHELIAL-CELLS; BREAST-CANCER; ER STRESS; LUMEN FORMATION; TUMOR-GROWTH	The postnatal mammary gland develops extensively through cycles of proliferation, branching, involution and remodeling. We review recent advances made in the field of stress signaling pathways and its roles in mammary gland organogenesis, how they contribute to normal organ specification and homeostasis and how its subversion by oncogenes leads to cancer. We analyze stress signaling in mammary gland biology taking into account the interrelationship with the extracellular matrix and adhesion signaling during morphogenesis. By integrating the information gathered from in vivo and three dimensional in vitro organogenesis studies, we review the novel contribution of p38(SAPK), c-Jun NH2-terminal kinase and PKR-like endoplasmic reticulum kinase ( PERK) signaling pathways to the timely activation of cell death, correct establishment of polarity and growth arrest and autophagy, respectively. We also review the evidence supporting that the activation of the aforementioned stress kinases maintain breast acinar structures as part of a tumor suppressive program and that its deregulation is commonplace during breast cancer initiation.	[Avivar-Valderas, A.; Aguirre-Ghiso, J. A.] Mt Sinai Sch Med, Dept Med, Div Hematol & Oncol, New York, NY 10029 USA; [Avivar-Valderas, A.; Aguirre-Ghiso, J. A.] Mt Sinai Sch Med, Dept Otolaryngol, New York, NY 10029 USA; [Avivar-Valderas, A.; Wen, H. C.; Aguirre-Ghiso, J. A.] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY 10029 USA; [Wen, H. C.] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA; [Aguirre-Ghiso, J. A.] Mt Sinai Sch Med, Black Family Stem Cell Inst, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Avivar-Valderas, A (corresponding author), Mt Sinai Sch Med, Dept Med, One Gustave L Levy Pl, New York, NY 10029 USA.	alvaro.avivar-valderas@mssm.edu; huei-chi.wen@mssm.edu; julio.aguirre-ghiso@mssm.edu	Wen, Huei-Chi/ABD-7417-2021	Aguirre-Ghiso, Julio/0000-0002-6694-6507	Samuel Waxman Cancer Research Foundation Tumor Dormancy Program; NIH/National Cancer Institute [CA109182, CA163131]; NIEHS [ES017146]; NYSTEM; NATIONAL CANCER INSTITUTE [U54CA163131, R01CA109182] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES017146] Funding Source: NIH RePORTER	Samuel Waxman Cancer Research Foundation Tumor Dormancy Program; NIH/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NYSTEM; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This study was supported by the grant from Samuel Waxman Cancer Research Foundation Tumor Dormancy Program, NIH/National Cancer Institute (CA109182, CA163131), NIEHS (ES017146) and NYSTEM to JAA-G.	Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Akaogi K, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-65; Almholt K, 2007, J MAMMARY GLAND BIOL, V12, P83, DOI 10.1007/s10911-007-9040-x; Avivar-Valderas A, 2013, ONCOGENE, V32, P4932, DOI 10.1038/onc.2012.512; Avivar-Valderas A, 2011, MOL CELL BIOL, V31, P3616, DOI 10.1128/MCB.05164-11; Barrantes ID, 2012, BIOCHEM SOC T, V40, P79, DOI 10.1042/BST20110676; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bateman JF, 2009, NAT REV GENET, V10, P173, DOI 10.1038/nrg2520; BENECKE BJ, 1978, CELL, V14, P931, DOI 10.1016/0092-8674(78)90347-1; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Blais JD, 2006, MOL CELL BIOL, V26, P9517, DOI 10.1128/MCB.01145-06; Bobrovnikova-Marjon E, 2010, ONCOGENE, V29, P3881, DOI 10.1038/onc.2010.153; Bobrovnikova-Marjon E, 2008, P NATL ACAD SCI USA, V105, P16314, DOI 10.1073/pnas.0808517105; Bragado P, 2013, NAT CELL BIOL, V15, P1351, DOI 10.1038/ncb2861; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; Bruno RD, 2012, SEMIN CELL DEV BIOL, V23, P591, DOI 10.1016/j.semcdb.2012.03.007; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Cao JX, 2009, EMBO J, V28, P1505, DOI 10.1038/emboj.2009.101; Cellurale C, 2012, CANCER RES, V72, P472, DOI 10.1158/0008-5472.CAN-11-1628; Cellurale C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012469; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Danes CG, 2008, CANCER RES, V68, P1760, DOI 10.1158/0008-5472.CAN-07-3177; Das M, 2011, GENE DEV, V25, P634, DOI 10.1101/gad.1989311; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Debnath J, 2008, AUTOPHAGY, V4, P351, DOI 10.4161/auto.5523; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Dong J, 2011, DEVELOPMENT, V138, P5247, DOI 10.1242/dev.069203; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Ellis R. John, 1999, Current Opinion in Structural Biology, V9, P102, DOI 10.1016/S0959-440X(99)80013-X; Espina V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010240; FARMER SR, 1978, CELL, V15, P627, DOI 10.1016/0092-8674(78)90031-4; Feder ME, 1999, ANNU REV PHYSIOL, V61, P243, DOI 10.1146/annurev.physiol.61.1.243; Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092; Gorrini C, 2005, P NATL ACAD SCI USA, V102, P9200, DOI 10.1073/pnas.0409513102; Gupta S, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.74; HALL HG, 1982, P NATL ACAD SCI-BIOL, V79, P4672, DOI 10.1073/pnas.79.15.4672; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Hart LS, 2012, J CLIN INVEST, V122, P4621, DOI 10.1172/JCI62973; Horak P, 2010, P NATL ACAD SCI USA, V107, P4675, DOI 10.1073/pnas.0907705107; Humphreys RC, 1996, DEVELOPMENT, V122, P4013; Jechlinger M, 2009, GENE DEV, V23, P1677, DOI 10.1101/gad.1801809; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Kim MS, 2003, CANCER RES, V63, P5454; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Kultz D, 2003, J EXP BIOL, V206, P3119, DOI 10.1242/jeb.00549; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Lambros MB, 2010, MODERN PATHOL, V23, P1334, DOI 10.1038/modpathol.2010.121; LI S, 1994, MOL ENDOCRINOL, V8, P1328, DOI 10.1210/me.8.10.1328; Li XY, 2001, FEBS LETT, V492, P210, DOI 10.1016/S0014-5793(01)02254-2; Liang GQ, 2008, HUM MOL GENET, V17, P3254, DOI 10.1093/hmg/ddn221; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liu CL, 2012, J GERIATR CARDIOL, V9, P258, DOI 10.3724/SP.J.1263.2012.02292; Lockshin RA, 2007, J CELL MOL MED, V11, P1214, DOI 10.1111/j.1582-4934.2007.00150.x; Lyons TR, 2011, NAT MED, V17, P1109, DOI 10.1038/nm.2416; Maekawa T, 2007, MOL CELL BIOL, V27, P1730, DOI 10.1128/MCB.01579-06; Mailleux AA, 2007, DEV CELL, V12, P221, DOI 10.1016/j.devcel.2006.12.003; Mandriota SJ, 2010, J BIOL CHEM, V285, P13092, DOI 10.1074/jbc.M109.078360; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Mao LL, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2794; Martin-Belmonte F, 2008, CURR BIOL, V18, P507, DOI 10.1016/j.cub.2008.02.076; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Merksamer PI, 2010, J CELL SCI, V123, P1003, DOI 10.1242/jcs.035832; Mikhailov A, 2007, CURR BIOL, V17, P2162, DOI 10.1016/j.cub.2007.11.028; Milani M, 2009, CANCER RES, V69, P4415, DOI 10.1158/0008-5472.CAN-08-2839; Miller AL, 2007, CANCER CELL INT, V7, DOI 10.1186/1475-2867-7-3; Miller AL, 2005, MOL ENDOCRINOL, V19, P1569, DOI 10.1210/me.2004-0528; Murtagh J, 2004, J CELL BIOL, V166, P133, DOI 10.1083/jcb.200403020; O'Sullivan AW, 2009, WORLD J SURG ONCOL, V7, DOI 10.1186/1477-7819-7-89; OSSOWSKI L, 1979, CELL, V16, P929, DOI 10.1016/0092-8674(79)90108-9; Park MA, 2008, CANCER BIOL THER, V7, P1648, DOI 10.4161/cbt.7.10.6623; Park MA, 2008, AUTOPHAGY, V4, P513, DOI 10.4161/auto.5725; Provenzano PP, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-11; Puri PL, 2000, GENE DEV, V14, P574; Qi AQ, 2005, J NEUROSCI RES, V80, P510, DOI 10.1002/jnr.20491; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Ravid D, 2005, ONCOGENE, V24, P1338, DOI 10.1038/sj.onc.1208337; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Rodier F, 2007, NUCLEIC ACIDS RES, V35, P7475, DOI 10.1093/nar/gkm744; Rosen JM, 1998, BIOCHEM SOC SYMP, P101; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Ruark E, 2013, NATURE, V493, P406, DOI 10.1038/nature11725; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Schedin P., 2010, COLD SPRING HARB PER, V3; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Sequeira SJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000615; Sequeira SJ, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-64; Sivaraman L, 2001, P NATL ACAD SCI USA, V98, P12379, DOI 10.1073/pnas.221459098; Smith ML, 1996, MUTAT RES-REV GENET, V340, P109, DOI 10.1016/S0165-1110(96)90043-3; Sun PQ, 2007, CELL, V128, P295, DOI 10.1016/j.cell.2006.11.050; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Talukder AH, 2002, ONCOGENE, V21, P4289, DOI 10.1038/sj.onc.1205529; Timofeev O, 2005, CELL CYCLE, V4, P118, DOI 10.4161/cc.4.1.1342; Verfaillie T, 2012, CELL DEATH DIFFER, V19, P1880, DOI 10.1038/cdd.2012.74; Waetzig V, 2003, J BIOL CHEM, V278, P567, DOI 10.1074/jbc.M207391200; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Wei JW, 2008, J CELL PHYSIOL, V217, P693, DOI 10.1002/jcp.21543; Wen HC, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001684; Yazinski SA, 2009, P NATL ACAD SCI USA, V106, P21282, DOI 10.1073/pnas.0904965106; ZETTL KS, 1992, P NATL ACAD SCI USA, V89, P9069, DOI 10.1073/pnas.89.19.9069	112	21	22	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2014	33	48					5483	5490		10.1038/onc.2013.554	http://dx.doi.org/10.1038/onc.2013.554			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZO	24413078	Green Accepted			2022-12-17	WOS:000346087900001
J	Wilson, CH; Gamper, I; Perfetto, A; Auw, J; Littlewood, TD; Evan, GI				Wilson, C. H.; Gamper, I.; Perfetto, A.; Auw, J.; Littlewood, T. D.; Evan, G. I.			The kinetics of ER fusion protein activation in vivo	ONCOGENE			English	Article							RECOMBINATION; TAMOXIFEN; MOUSE; TISSUES; VITRO; CELLS; MICE; CRE; MYC	Reversibly switchable proteins are powerful tools with which to explore protein function in vitro and in vivo. For example, the activity of many proteins fused to the hormone-binding domain of the modified oestrogen receptor (ERTAM) can be regulated by provision or removal of 4-hydroxytamoxifen (4-OHT). Despite the widespread use of ERTAM fusions in vivo, inadequate data are available as to the most efficacious routes for systemic tamoxifen delivery. In this study, we have used two well-characterized ERTAM fusion proteins, both reversibly activated by 4-OHT, to compare the effectiveness and kinetics of 4-OHT delivery in mice in vivo by either tamoxifen in food or by intraperitoneal injection. Our data indicate that dietary tamoxifen offers an effective, facile and ethically preferable means for long-term activation of ERTAM fusion proteins in vivo.	[Wilson, C. H.; Gamper, I.; Perfetto, A.; Auw, J.; Littlewood, T. D.; Evan, G. I.] Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	University of Cambridge	Evan, GI (corresponding author), Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.	gie20@cam.ac.uk		Wilson, Catherine/0000-0002-5333-0295	CRUK [A12077]; ERC [294851]; Cancer Research UK [12077, 13061] Funding Source: researchfish	CRUK(Cancer Research UK); ERC(European Research Council (ERC)European Commission); Cancer Research UK(Cancer Research UK)	We thank Debbie Burkhart for her advice with experimental procedures and the support staff within the biomedical facility of the Gurdon Institute. We thank Cyprotex Discovery Limited for LC/MS analysis. This work is supported by CRUK (Programme Grant A12077) and the ERC (Advanced Investigator Award 294851).	Christophorou MA, 2005, NAT GENET, V37, P718, DOI 10.1038/ng1572; Desta Z, 2004, J PHARMACOL EXP THER, V310, P1062, DOI 10.1124/jpet.104.065607; Ellisor D, 2010, MOL CELL NEUROSCI, V45, P132, DOI 10.1016/j.mcn.2010.06.004; Feil R, 1996, P NATL ACAD SCI USA, V93, P10887, DOI 10.1073/pnas.93.20.10887; Hameyer D, 2007, PHYSIOL GENOMICS, V31, P32, DOI 10.1152/physiolgenomics.00019.2007; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; ROBINSON SP, 1991, DRUG METAB DISPOS, V19, P36; Zhang Y, 1996, NUCLEIC ACIDS RES, V24, P543, DOI 10.1093/nar/24.4.543	11	21	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2014	33	40					4877	4880		10.1038/onc.2014.78	http://dx.doi.org/10.1038/onc.2014.78			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0EH	24662815	hybrid, Green Accepted, Green Published			2022-12-17	WOS:000343240100009
J	Zhao, L; Ye, P; Gonda, TJ				Zhao, L.; Ye, P.; Gonda, T. J.			The MYB proto-oncogene suppresses monocytic differentiation of acute myeloid leukemia cells via transcriptional activation of its target gene GFI1	ONCOGENE			English	Article						U937; MYB; GFI1; monocytic differentiation; target gene	HUMAN HEMATOPOIETIC-CELLS; FINGER PROTEIN GFI-1; C-MYB; INSERTIONAL MUTAGENESIS; CONSTITUTIVE EXPRESSION; LYMPHOBLASTIC-LEUKEMIA; HUMAN NEUTROPENIA; REPRESSOR GFI-1; STEM-CELLS; T-ALL	The MYB gene is a master regulator of hematopoiesis and contributes to leukemogenesis in several species including humans. Although it is clear that MYB can promote proliferation, suppress apoptosis and block differentiation, the identities of the MYB target genes that mediate these effects have only been partially elucidated. Several studies, including our own, have collectively identified substantial numbers of MYB target genes, including candidates for each of these activities; however, functional validation, particularly in the case of differentiation suppression, has lagged well behind. Here we show that GFI1, which encodes an important regulator of hematopoietic stem cell (HSC) function and granulocytic differentiation, is a direct target of MYB in myeloid leukemia cells. Chromatin immunoprecipitation and reporter studies identified a functional MYB-binding site in the promoter region of GFI, whereas ectopic expression and small hairpin RNA-mediated knockdown of MYB resulted in concomitant increases and decreases, respectively, in GFI1 expression. We also demonstrate that GFI1, like MYB, can block the induced monocytic differentiation of a human acute myeloid leukemia cell line, and most importantly, that GFI1 is essential for MYB's ability to block monocytic differentiation. Thus, we have identified a target of MYB that is a likely mediator of its myeloid differentiation-blocking activity, and which may also be involved in MYB's activities in regulating normal HSC function and myeloid differentiation.	[Zhao, L.; Ye, P.; Gonda, T. J.] Univ Queensland, Diamantina Inst, Brisbane, Qld, Australia; [Ye, P.; Gonda, T. J.] Univ Queensland, Sch Pharm, Pharm Australia Ctr Excellence, Brisbane, Qld, Australia	University of Queensland; University of Queensland	Gonda, TJ (corresponding author), Univ Queensland, Pharm Australia Ctr Excellence, Sch Pharm, Level 4,20 Cornwall St, Woolloongabba, Qld 4102, Australia.	t.gonda@uq.edu.au	Zhao, Liang/K-1484-2014	Zhao, Liang/0000-0002-3489-7421; Gonda, Thomas/0000-0002-8792-3021	National Health and Medical Research Council of Australia; University of Queensland Postdoctoral Fellowship	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); University of Queensland Postdoctoral Fellowship(University of Queensland)	This work was supported in part by a grant from the National Health and Medical Research Council of Australia (to TJG) and a University of Queensland Postdoctoral Fellowship (to PY).	Adati Naoki, 2009, BMC Res Notes, V2, P153, DOI 10.1186/1756-0500-2-153; Barry SC, 2001, HUM GENE THER, V12, P1103, DOI 10.1089/104303401750214311; Belloni E, 2011, LEUKEMIA, V25, P733, DOI 10.1038/leu.2010.317; Bert AG, 2000, PLASMID, V44, P173, DOI 10.1006/plas.2000.1474; Bonadies N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016330; Brown CY, 2010, HUM GENE THER, V21, P1005, DOI 10.1089/hum.2009.107; CASTANEDA VL, 1991, LEUKEMIA, V5, P142; Clappier E, 2007, BLOOD, V110, P1251, DOI 10.1182/blood-2006-12-064683; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; Dahl R, 2007, J BIOL CHEM, V282, P6473, DOI 10.1074/jbc.M607613200; Drabsch Y, 2007, P NATL ACAD SCI USA; Dreyling MH, 1996, P NATL ACAD SCI USA, V93, P4804, DOI 10.1073/pnas.93.10.4804; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Fu SL, 1997, CELL GROWTH DIFFER, V8, P35; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Hock H, 2004, NATURE, V431, P1002, DOI 10.1038/nature02994; Hock H, 2003, IMMUNITY, V18, P109, DOI 10.1016/S1074-7613(02)00501-0; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; Horman SR, 2009, BLOOD, V113, P5466, DOI 10.1182/blood-2008-09-179747; Huang M, 2010, ACTA HAEMATOL-BASEL, V123, P1, DOI 10.1159/000253856; Karsunky H, 2002, NAT GENET, V30, P295, DOI 10.1038/ng831; Khandanpour C, 2013, CANCER CELL, V23, P200, DOI 10.1016/j.ccr.2013.01.011; Knopfova L, 2008, NEOPLASMA, V55, P286; Lahortiga I, 2007, NAT GENET, V39, P593, DOI 10.1038/ng2025; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Lidonnici MR, 2010, CANCER RES, V70, P7949, DOI 10.1158/0008-5472.CAN-10-1667; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; Murati A, 2009, LEUKEMIA, V23, P85, DOI 10.1038/leu.2008.257; Nakata Y, 2007, MOL CELL BIOL, V27, P2048, DOI 10.1128/MCB.01100-06; O'Neil J, 2007, J EXP MED, V204, P3059, DOI 10.1084/jem.20071637; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Pattabiraman DR, 2013, LEUKEMIA, V27, P269, DOI 10.1038/leu.2012.225; Person RE, 2003, NAT GENET, V34, P308, DOI 10.1038/ng1170; Phelan J, 2010, NARRATIVE, V18, P1; Quelen C, 2011, BLOOD, V117, P5719, DOI 10.1182/blood-2011-01-333013; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; Ramsay RG, 2005, INT J BIOCHEM CELL B, V37, P1254, DOI 10.1016/j.biocel.2004.12.011; Ramsay RG, 2008, NAT REV CANCER, V8, P523, DOI 10.1038/nrc2439; Schmidt T, 1998, ONCOGENE, V17, P2661, DOI 10.1038/sj.onc.1202191; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; Skalamera D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020057; Suzuki H, 2009, NAT GENET, V41, P553, DOI 10.1038/ng.375; van der Meer LT, 2010, LEUKEMIA, V24, P1834, DOI 10.1038/leu.2010.195; Vassen L, 2012, AM J BLOOD RES, V2, P228; Wang Tian-Tian, 2010, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V18, P834; Wei W, 2008, CELL RES, V18, P677, DOI 10.1038/cr.2008.60; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; Wolff L, 1996, CURR TOP MICROBIOL, V211, P191; Wolff L, 2001, BLOOD CELL MOL DIS, V27, P483, DOI 10.1006/bcmd.2001.0409; Ye P, 2013, LEUKEMIA RES, V37, P595, DOI 10.1016/j.leukres.2013.01.012; Zarebski A, 2008, IMMUNITY, V28, P370, DOI 10.1016/j.immuni.2007.12.020; Zeng H, 2004, EMBO J, V23, P4116, DOI 10.1038/sj.emboj.7600419; Zhan Rong, 2010, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V18, P849; Zhao L, 2011, NUCLEIC ACIDS RES, V39, P4664, DOI 10.1093/nar/gkr024; Zornig M, 1996, ONCOGENE, V12, P1789	57	21	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2014	33	35					4442	4449		10.1038/onc.2013.419	http://dx.doi.org/10.1038/onc.2013.419			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MR	24121275				2022-12-17	WOS:000341157800009
J	Barbetti, V; Morandi, A; Tusa, I; Digiacomo, G; Riverso, M; Marzi, I; Cipolleschi, MG; Bessi, S; Giannini, A; Di Leo, A; Dello Sbarba, P; Rovida, E				Barbetti, V.; Morandi, A.; Tusa, I.; Digiacomo, G.; Riverso, M.; Marzi, I.; Cipolleschi, M. G.; Bessi, S.; Giannini, A.; Di Leo, A.; Dello Sbarba, P.; Rovida, E.			Chromatin-associated CSF-1R binds to the promoter of proliferation-related genes in breast cancer cells	ONCOGENE			English	Article						CSF-1; nuclear proteins; breast cancer; Fms; nuclear receptor tyrosine kinase	COLONY-STIMULATING FACTOR; FIBROBLAST-GROWTH-FACTOR; FACTOR-I; NUCLEAR TRANSLOCATION; FACTOR-RECEPTOR; C-FMS; MACROPHAGE PRODUCTION; SIGNAL-TRANSDUCTION; TYROSINE KINASE; CERVICAL-CANCER	The colony-stimulating factor-1 (CSF-1) and its receptor CSF-1R physiologically regulate the monocyte/macrophage system, trophoblast implantation and breast development. An abnormal CSF-1R expression has been documented in several human epithelial tumors, including breast carcinomas. We recently demonstrated that CSF-1/CSF-1R signaling drives proliferation of breast cancer cells via 'classical' receptor tyrosine kinase signaling, including activation of the extracellular signal-regulated kinase 1/2. In this paper, we show that CSF-1R can also localize within the nucleus of breast cancer cells, either cell lines or tissue specimens, irrespectively of their intrinsic molecular subtype. We found that the majority of nuclear CSF-1R is located in the chromatin-bound subcellular compartment. Chromatin immunoprecipitation revealed that CSF-1R, once in the nucleus, binds to the promoters of the proliferation-related genes CCND1, c-JUN and c-MYC. CSF-1R also binds the promoter of its ligand CSF-1 and positively regulates CSF-1 expression. The existence of such a receptor/ligand regulatory loop is a novel aspect of CSF-1R signaling. Moreover, our results provided the first evidence of a novel localization site of CSF-1R in breast cancer cells, suggesting that CSF-1R could act as a transcriptional regulator on proliferation-related genes.	[Barbetti, V.; Morandi, A.; Tusa, I.; Digiacomo, G.; Riverso, M.; Marzi, I.; Cipolleschi, M. G.; Dello Sbarba, P.; Rovida, E.] Univ Florence, Sez Patol, Dipartimento Sci Biomed Sperimentali & Clin, Ist Toscano Tumori, I-50134 Florence, Italy; [Bessi, S.; Giannini, A.] Osped Prato, Prato, Italy; [Di Leo, A.] Hosp Prato, Ist Toscano Tumori, Dept Oncol, Sandro Pitigliani Med Oncol Unit, Prato, Italy	ISPRO Istituto per lo studio, la prevenzione e la rete oncologica; University of Florence; Prato Hospital; ISPRO Istituto per lo studio, la prevenzione e la rete oncologica; Prato Hospital	Rovida, E (corresponding author), Univ Florence, Sez Patol, Dipartimento Sci Biomed Sperimentali & Clin, Viale GB Morgagni 50, I-50134 Florence, Italy.	erovida@unifi.it	Morandi, Andrea/AAC-1901-2022; Rovida, Elisabetta/F-3565-2015; Dello Sbarba, Persio/AAX-9887-2020	Morandi, Andrea/0000-0002-9222-5332; Rovida, Elisabetta/0000-0002-5949-3239; Tusa, Ignazia/0000-0002-9198-2630	Istituto Toscano Tumori, Associazione Italiana per la Ricerca sul Cancro, Ministero della Salute (Ricerca Finalizzata) [RF-TOS-2008-1163728]; Regione Toscana (Programma per la Ricerca in Materia di Salute); Associazione Italiana per la Lotta contro le Leucemie e i Linfomi (sezione di Prato); Fondazione Cassa di Risparmio di Volterra; Fondazione Oretta Bartolomei-Corsi	Istituto Toscano Tumori, Associazione Italiana per la Ricerca sul Cancro, Ministero della Salute (Ricerca Finalizzata)(Fondazione AIRC per la ricerca sul cancro); Regione Toscana (Programma per la Ricerca in Materia di Salute)(Regione Toscana); Associazione Italiana per la Lotta contro le Leucemie e i Linfomi (sezione di Prato)(Fondazione AIRC per la ricerca sul cancro); Fondazione Cassa di Risparmio di Volterra; Fondazione Oretta Bartolomei-Corsi(Fondazione CarifeFondazione Caritro)	This work was supported by Istituto Toscano Tumori, Associazione Italiana per la Ricerca sul Cancro, Ministero della Salute (Ricerca Finalizzata, Grant number RF-TOS-2008-1163728), Regione Toscana (Programma per la Ricerca in Materia di Salute), Associazione Italiana per la Lotta contro le Leucemie e i Linfomi (sezione di Prato), Fondazione Cassa di Risparmio di Volterra, Fondazione Oretta Bartolomei-Corsi. We thank Professor Clare M Isacke (Breakthrough Breast Cancer Research Centre, London, UK) for revising the manuscript.	Barbetti V, 2008, ONCOGENE, V27, P1767, DOI 10.1038/sj.onc.1210820; Barbetti V, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.49; Barbetti V, 2013, EPIGENETICS-US, V8, P210, DOI 10.4161/epi.23538; Brameier M, 2007, BIOINFORMATICS, V23, P1159, DOI 10.1093/bioinformatics/btm066; Bryant DM, 2005, TRAFFIC, V6, P947, DOI 10.1111/j.1600-0854.2005.00332.x; Chioni AM, 2012, J CELL BIOL, V197, P801, DOI 10.1083/jcb.201108077; D'Angelo MA, 2008, TRENDS CELL BIOL, V18, P456, DOI 10.1016/j.tcb.2008.07.009; Dittmann K, 2010, STRAHLENTHER ONKOL, V186, P1, DOI 10.1007/s00066-009-2026-4; Feng YY, 1999, BIOCHEM BIOPH RES CO, V256, P192, DOI 10.1006/bbrc.1998.9790; GUILBERT LJ, 1986, J BIOL CHEM, V261, P4024; Hamilton JA, 1997, J LEUKOCYTE BIOL, V62, P145, DOI 10.1002/jlb.62.2.145; Hammes LS, 2008, GYNECOL ONCOL, V110, P445, DOI 10.1016/j.ygyno.2008.04.038; Ide H, 2002, P NATL ACAD SCI USA, V99, P14404, DOI 10.1073/pnas.222537099; Johnston CL, 1995, J BIOL CHEM, V270, P30643, DOI 10.1074/jbc.270.51.30643; KACINSKI BM, 1991, ONCOGENE, V6, P941; Kacinski BM, 1997, MOL REPROD DEV, V46, P71, DOI 10.1002/(SICI)1098-2795(199701)46:1<71::AID-MRD11>3.0.CO;2-6; Kirma N, 2007, CANCER RES, V67, P1918, DOI 10.1158/0008-5472.CAN-06-1991; Kluger HM, 2004, CLIN CANCER RES, V10, P173, DOI 10.1158/1078-0432.CCR-0699-3; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Lin HS, 2008, SCIENCE, V320, P807, DOI 10.1126/science.1154370; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Maher MG, 1998, CLIN CANCER RES, V4, P1851; Mancini A, 2004, ONCOGENE, V23, P6581, DOI 10.1038/sj.onc.1207841; Mayo LD, 2001, J BIOL CHEM, V276, P25184, DOI 10.1074/jbc.M102932200; Morandi A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027450; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Offterdinger M, 2004, J BIOL CHEM, V279, P36972, DOI 10.1074/jbc.M405830200; Offterdinger M, 2002, J CELL BIOL, V157, P929, DOI 10.1083/jcb.200109033; Peng H, 2001, MOL BIOL CELL, V12, P449, DOI 10.1091/mbc.12.2.449; Pixley FJ, 2004, TRENDS CELL BIOL, V14, P628, DOI 10.1016/j.tcb.2004.09.016; Reilly JF, 2001, J CELL BIOL, V152, P1307, DOI 10.1083/jcb.152.6.1307; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; ROUSSEL MF, 1994, J CELL SCI, P105; Rovida E, 2005, BIOL CHEM, V386, P919, DOI 10.1515/BC.2005.107; Rovida E, 2002, ONCOGENE, V21, P3670, DOI 10.1038/sj.onc.1205409; Rovida E, 2008, J IMMUNOL, V180, P4166, DOI 10.4049/jimmunol.180.6.4166; SCHOLL SM, 1994, JNCI-J NATL CANCER I, V86, P120, DOI 10.1093/jnci/86.2.120; Sehat B, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000628; Seol KC, 2003, BIOCHEM BIOPH RES CO, V306, P898, DOI 10.1016/S0006-291X(03)01046-5; SHADLE PJ, 1989, J CELL BIOCHEM, V40, P91, DOI 10.1002/jcb.240400110; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; Stachowiak MK, 1996, MOL BRAIN RES, V38, P161, DOI 10.1016/0169-328X(96)00010-1; STANLEY ER, 1978, NATURE, V274, P168, DOI 10.1038/274168a0; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; Toy EP, 2009, NEOPLASIA, V11, P136, DOI 10.1593/neo.81150; Wang SC, 2004, CANCER CELL, V6, P251, DOI 10.1016/j.ccr.2004.07.012; Wang YN, 2010, ONCOGENE, V29, P3997, DOI 10.1038/onc.2010.157; Yee LD, 2000, ANTICANCER RES, V20, P4379; Yeung YG, 1998, J BIOL CHEM, V273, P17128, DOI 10.1074/jbc.273.27.17128; Zwaenepoel O, 2012, FASEB J, V26, P691, DOI 10.1096/fj.11-189753	51	21	24	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2014	33	34					4359	4364		10.1038/onc.2013.542	http://dx.doi.org/10.1038/onc.2013.542			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MK	24362524	hybrid, Green Published			2022-12-17	WOS:000341156900009
J	Galli, GG; Multhaupt, HA; Carrara, M; de Lichtenberg, KH; Christensen, IBJ; Linnemann, D; Santoni-Rugiu, E; Calogero, RA; Lund, AH				Galli, G. G.; Multhaupt, H. A.; Carrara, M.; de Lichtenberg, K. H.; Christensen, I. B. J.; Linnemann, D.; Santoni-Rugiu, E.; Calogero, R. A.; Lund, A. H.			Prdm5 suppresses Apc(Min)-driven intestinal adenomas and regulates monoacylglycerol lipase expression	ONCOGENE			English	Article						PRDM5; APC; adenoma; intestinal cancer	ATP CITRATE LYASE; DNA METHYLATION; CELL-GROWTH; CANCER; DIFFERENTIATION; IDENTIFICATION; BIOCONDUCTOR; BIOLOGY; PROTEIN; TOPHAT	PRDM proteins are tissue-specific transcription factors often deregulated in diseases, particularly in cancer where different members have been found to act as oncogenes or tumor suppressors. PRDM5 is a poorly characterized member of the PRDM family for which several studies have reported a high frequency of promoter hypermethylation in cancer types of gastrointestinal origin. We report here the characterization of Prdm5 knockout mice in the context of intestinal carcinogenesis. We demonstrate that loss of Prdm5 increases the number of adenomas throughout the murine small intestine on an Apc(Min) background. By using the genome-wide ChIP-seq (chromatin immunoprecipitation (ChIP) followed by DNA sequencing) and transcriptome analyses we identify loci encoding proteins involved in metabolic processes as prominent PRDM5 targets and characterize monoacylglycerol lipase (Mgll) as a direct PRDM5 target in human colon cancer cells and in Prdm5 mutant mouse intestines. Moreover, we report the downregulation of PRDM5 protein expression in human colon neoplastic lesions. In summary, our data provide the first causal link between Prdm5 loss and intestinal carcinogenesis, and uncover an extensive and novel PRDM5 target repertoire likely facilitating the tumor-suppressive functions of PRDM5.	[Galli, G. G.; de Lichtenberg, K. H.; Lund, A. H.] Univ Copenhagen, Ctr Epigenet, BRIC, DK-2200 Copenhagen, Denmark; [Multhaupt, H. A.] Univ Copenhagen, Dept Biomed Sci, DK-2200 Copenhagen, Denmark; [Carrara, M.; Calogero, R. A.] Univ Turin, Ctr Mol Biotechnol, Dept Clin & Biol Sci, Turin, Italy; [Christensen, I. B. J.] Univ Copenhagen, Rigshosp, Fac Hlth Sci, Finsen Lab, DK-2200 Copenhagen, Denmark; [Linnemann, D.] Herlev Hosp, Dept Pathol, DK-2730 Herlev, Denmark; [Santoni-Rugiu, E.] Rigshosp, Ctr Diagnost, Dept Pathol, DK-2100 Copenhagen, Denmark	University of Copenhagen; University of Copenhagen; University of Turin; Rigshospitalet; University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital; Rigshospitalet; University of Copenhagen	Lund, AH (corresponding author), Univ Copenhagen, Ctr Epigenet, BRIC, Ole Maaloes Vej 5, DK-2200 Copenhagen, Denmark.	anders.lund@bric.ku.dk	Calogero, Raffaele/K-9428-2019; Carrara, Matteo/J-8692-2016; Santoni-Rugiu, Eric/H-4913-2019; Lund, Anders H./F-4786-2014; Santoni-Rugiu, Eric/AAH-3368-2020	Calogero, Raffaele/0000-0002-2848-628X; Carrara, Matteo/0000-0002-8559-8296; Lund, Anders H./0000-0002-7407-3398; Santoni-Rugiu, Eric/0000-0002-2283-3535; Galli, Giorgio/0000-0002-9401-060X; Honnens de Lichtenberg, Kristian/0000-0002-3905-9574	Danish National Research Foundation; Danish National Advanced Technology Foundation; Novo Nordisk Foundation; EC FP7 programs (ONCOMIRS) [201102]; Lundbeck Foundation; Danish Cancer Society	Danish National Research Foundation(Danmarks Grundforskningsfond); Danish National Advanced Technology Foundation; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); EC FP7 programs (ONCOMIRS); Lundbeck Foundation(Lundbeckfonden); Danish Cancer Society(Danish Cancer Society)	We would like to acknowledge Julia Sidenius Johansen for her advice on TMA stainings, Bettina Mentz for excellent technical assistance and Fengqin Jia for mouse genotyping. This work was supported by the Danish National Research Foundation, the Danish National Advanced Technology Foundation, the Novo Nordisk Foundation, the EC FP7 programs (ONCOMIRS, grant agreement number 201102), the Lundbeck Foundation and the Danish Cancer Society.	Bauer DE, 2005, ONCOGENE, V24, P6314, DOI 10.1038/sj.onc.1208773; Cheng HY, 2010, J CANCER RES CLIN, V136, P1821, DOI 10.1007/s00432-010-0840-9; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Deng QD, 2004, ONCOGENE, V23, P4903, DOI 10.1038/sj.onc.1207615; Duan Z, 2007, MOL CELL BIOL, V27, P6889, DOI 10.1128/MCB.00762-07; Fog CK, 2012, BIOESSAYS, V34, P50, DOI 10.1002/bies.201100107; Galli GG, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002711; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008; HIDALGO IJ, 1989, GASTROENTEROLOGY, V96, P736; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Kim D, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r72; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Meani N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004273; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Nathke IS, 2004, ANNU REV CELL DEV BI, V20, P337, DOI 10.1146/annurev.cellbio.20.012103.094541; Nomura DK, 2011, CHEM BIOL, V18, P846, DOI 10.1016/j.chembiol.2011.05.009; Nomura DK, 2010, CELL, V140, P49, DOI 10.1016/j.cell.2009.11.027; PURDIE CA, 1994, ONCOGENE, V9, P603; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Roberts A, 2011, BIOINFORMATICS, V27, P2325, DOI 10.1093/bioinformatics/btr355; Sanges R, 2007, BIOINFORMATICS, V23, P3406, DOI 10.1093/bioinformatics/btm469; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Shu XS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027346; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Watanabe Y, 2007, CLIN CANCER RES, V13, P4786, DOI 10.1158/1078-0432.CCR-07-0305; Watanabe Y, 2009, GASTROENTEROLOGY, V136, P2149, DOI 10.1053/j.gastro.2009.02.085; Wright EMMB, 2011, AM J HUM GENET, V88, P767, DOI 10.1016/j.ajhg.2011.05.007; Ye L, 2011, CANCER LETT, V307, P6, DOI 10.1016/j.canlet.2011.03.007	36	21	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3342	3350		10.1038/onc.2013.283	http://dx.doi.org/10.1038/onc.2013.283			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23873026	Green Submitted			2022-12-17	WOS:000338443400014
J	Borgdorff, V; Rix, U; Winter, GE; Gridling, M; Muller, AC; Breitwieser, FP; Wagner, C; Colinge, J; Bennett, KL; Superti-Furga, G; Wagner, SN				Borgdorff, V.; Rix, U.; Winter, G. E.; Gridling, M.; Mueller, A. C.; Breitwieser, F. P.; Wagner, C.; Colinge, J.; Bennett, K. L.; Superti-Furga, G.; Wagner, S. N.			A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF	ONCOGENE			English	Article						MITF; melanoma; AMPK; compound C; midostaurin; sunitinib	ACTIVATED PROTEIN-KINASE; TRANSCRIPTION FACTOR; GLUCOSE DEPRIVATION; SIGNALING PATHWAYS; LINEAGE SURVIVAL; ENERGY SENSOR; CELL-GROWTH; MICROPHTHALMIA; CANCER; PROLIFERATION	The microphthalmia-associated transcription factor (MITF) is indispensable for the viability of melanocytic cells, is an oncogene in melanoma and has a cell type-specific expression pattern. As the modulation of MITF activity by direct chemical targeting remains a challenge, we assessed a panel of drugs for their ability to downregulate MITF expression or activity by targeting its upstream modulators. We found that the multi-kinase inhibitors midostaurin and sunitinib downregulate MITF protein levels. To identify the target molecules shared by both the drugs in melanocytic cells, a chemical proteomic approach was applied and AMP-activated kinase (AMPK) was identified as the relevant target for the observed phenotype. RNA interference and chemical inhibition of AMPK led to a decrease in MITF protein levels. Reduction of MITF protein levels was the result of proteasomal degradation, which was preceded by enhanced phosphorylation of MITF mediated by ERK. As expected, downregulation of MITF protein levels by AMPK inhibition was associated with decreased viability. Together, these results identify AMPK as an important regulator for the maintenance of MITF protein levels in melanocytic cells.	[Borgdorff, V.; Wagner, C.; Wagner, S. N.] Med Univ Vienna, Dept Dermatol, Div Immunol Allergy & Infect Dis, A-1090 Vienna, Austria; [Borgdorff, V.; Rix, U.; Winter, G. E.; Gridling, M.; Mueller, A. C.; Breitwieser, F. P.; Colinge, J.; Bennett, K. L.; Superti-Furga, G.; Wagner, S. N.] Austrian Acad Sci, CeMM Res Ctr Mol Med, A-1010 Vienna, Austria	Medical University of Vienna; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences	Wagner, SN (corresponding author), Med Univ Vienna, Dept Dermatol, Div Immunol Allergy & Infect Dis, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	vborgdorff@gmail.com; stephan.wagner@meduniwien.ac.at	Superti-Furga, Giulio/F-4755-2015; Superti-Furga, Giulio/AAE-5681-2019; Colinge, Jacques/Z-2613-2019; Colinge, Jacques/D-1578-2017	Superti-Furga, Giulio/0000-0002-0570-1768; Colinge, Jacques/0000-0003-2466-4824; Colinge, Jacques/0000-0003-2466-4824; Winter, Georg/0000-0001-6606-1437; Wagner, Stephan/0000-0003-4941-7029; Mueller, Andre/0000-0002-0608-8176; Bennett, Keiryn L./0000-0001-9356-7708; Breitwieser, Florian P/0000-0001-6192-0853	FWF-Austrian Science Fund [L590-B12]; Austrian Academy of Sciences; GEN-AU initiative of the Austrian Federal Ministry for Science and Research (PLACEBO GZ) [BMWF-70.081/0018-II/1a/2008, APP-III 820965]; Austrian Science Fund (FWF) [P 24321, L 590] Funding Source: researchfish	FWF-Austrian Science Fund(Austrian Science Fund (FWF)); Austrian Academy of Sciences; GEN-AU initiative of the Austrian Federal Ministry for Science and Research (PLACEBO GZ); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	We thank Hans Widlund (Harvard Skin Disease Research Center, Brigham and Women's Hospital, Boston, MA, USA) for providing us with human immortalised melanocytes with and without ectopic expression of BRAF<SUP>V600E</SUP> and HA-MITF as described in Garraway et al.<SUP>1</SUP> We thank Gaurav Pathria for helpful discussions and critical reading of the manuscript. This study was funded by FWF-Austrian Science Fund (L590-B12) to SNW. The team at CeMM is supported by the Austrian Academy of Sciences, and the GEN-AU initiative of the Austrian Federal Ministry for Science and Research (PLACEBO GZ BMWF-70.081/0018-II/1a/2008 and APP-III 820965).	Bennett KL, 2011, J PROTEOMICS, V74, P151, DOI 10.1016/j.jprot.2010.10.002; Bertolotto C, 2011, NATURE, V480, P94, DOI 10.1038/nature10539; Bodmer M, 2010, DIABETES CARE, V33, P1304, DOI 10.2337/dc09-1791; Breitwieser FP, 2011, J PROTEOME RES, V10, P2758, DOI 10.1021/pr1012784; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Cheli Y, 2011, ONCOGENE, V30, P2307, DOI 10.1038/onc.2010.598; Colinge J, 2003, PROTEOMICS, V3, P1454, DOI 10.1002/pmic.200300485; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Du JH, 2008, BIOCHEM BIOPH RES CO, V368, P402, DOI 10.1016/j.bbrc.2008.01.099; Esteve-Puig R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004771; Fay JR, 2009, CANCER PREV RES, V2, P301, DOI 10.1158/1940-6207.CAPR-08-0166; Fernbach NV, 2009, J PROTEOME RES, V8, P4753, DOI 10.1021/pr900455x; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Gilar M, 2005, J SEP SCI, V28, P1694, DOI 10.1002/jssc.200500116; Giuliano S, 2010, CANCER RES, V70, P3813, DOI 10.1158/0008-5472.CAN-09-2913; Goding CR, 2011, ONCOGENE, V30, P2304, DOI 10.1038/onc.2010.641; HA J, 1994, J BIOL CHEM, V269, P22162; Hagelkruys Astrid, 2011, Handb Exp Pharmacol, V206, P13, DOI 10.1007/978-3-642-21631-2_2; Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; Horike N, 2010, PIGM CELL MELANOMA R, V23, P809, DOI 10.1111/j.1755-148X.2010.00760.x; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Janjetovic K, 2011, EUR J PHARMACOL, V668, P373, DOI 10.1016/j.ejphar.2011.07.004; Junttila MR, 2008, FASEB J, V22, P954, DOI 10.1096/fj.06-7859rev; Karaman MW, 2008, NAT BIOTECHNOL, V26, P127, DOI 10.1038/nbt1358; Kim KY, 2009, CANCER RES, V69, P4018, DOI 10.1158/0008-5472.CAN-08-2641; Kim MJ, 2010, J BIOL CHEM, V285, P14617, DOI 10.1074/jbc.M109.085456; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Laderoute KR, 2010, CANCER BIOL THER, V10, P68, DOI 10.4161/cbt.10.1.12162; Lee KH, 2011, J BIOL CHEM, V286, P39247, DOI 10.1074/jbc.M111.264598; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Miller AJ, 2005, J BIOL CHEM, V280, P146, DOI 10.1074/jbc.M411757200; Murakami H, 2005, PIGM CELL RES, V18, P265, DOI 10.1111/j.1600-0749.2005.00234.x; Park HU, 2009, MOL CANCER THER, V8, P733, DOI 10.1158/1535-7163.MCT-08-0631; Rappsilber J, 2003, ANAL CHEM, V75, P663, DOI 10.1021/ac026117i; Rix U, 2007, BLOOD, V110, P4055, DOI 10.1182/blood-2007-07-102061; Ross PL, 2004, MOL CELL PROTEOMICS, V3, P1154, DOI 10.1074/mcp.M400129-MCP200; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; Strub T, 2011, ONCOGENE, V30, P2319, DOI 10.1038/onc.2010.612; Takeda K, 2000, HUM MOL GENET, V9, P125, DOI 10.1093/hmg/9.1.125; Tomic T, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.86; Vaahtomeri K, 2011, FEBS LETT, V585, P944, DOI 10.1016/j.febslet.2010.12.034; Wellbrock C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002734; Widlund HR, 2003, ONCOGENE, V22, P3035, DOI 10.1038/sj.onc.1206443; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Wu M, 2000, GENE DEV, V14, P301; Yokoyama S, 2008, PIGM CELL MELANOMA R, V21, P457, DOI 10.1111/j.1755-148X.2008.00480.x; Yokoyama S, 2011, NATURE, V480, P99, DOI 10.1038/nature10630; Zarrinkar PP, 2009, BLOOD, V114, P2984, DOI 10.1182/blood-2009-05-222034; Zheng B, 2009, MOL CELL, V33, P237, DOI 10.1016/j.molcel.2008.12.026; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	55	21	22	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2531	2539		10.1038/onc.2013.185	http://dx.doi.org/10.1038/onc.2013.185			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23728343				2022-12-17	WOS:000336033600013
J	Marino-Enriiquez, A; Ou, WB; Cowley, G; Luo, B; Jonker, AH; Mayeda, M; Okamoto, M; Eilers, G; Czaplinski, JT; Sicinska, E; Wang, Y; Taguchi, T; Demetri, GD; Root, DE; Fletcher, JA				Marino-Enriquez, A.; Ou, W-B; Cowley, G.; Luo, B.; Jonker, A. H.; Mayeda, M.; Okamoto, M.; Eilers, G.; Czaplinski, J. T.; Sicinska, E.; Wang, Y.; Taguchi, T.; Demetri, G. D.; Root, D. E.; Fletcher, J. A.			Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors	ONCOGENE			English	Article						CDC37; HSP90; GIST; targeted therapy; functional genomics; shRNA library	IMATINIB MESYLATE; RESISTANCE; INHIBITOR; MUTATIONS; ACTIVATION; CANCER; TRIAL	Most gastrointestinal stromal tumors (GISTs) contain KIT or PDGFRA kinase gain-of-function mutations, and therefore respond clinically to imatinib and other tyrosine kinase inhibitor (TKI) therapies. However, clinical progression subsequently results from selection of TKI-resistant clones, typically containing secondary mutations in the KIT kinase domain, which can be heterogeneous between and within GIST metastases in a given patient. TKI-resistant KIT oncoproteins require HSP90 chaperoning and are potently inactivated by HSP90 inhibitors, but clinical applications in GIST patients are constrained by the toxicity resulting from concomitant inactivation of various other HSP90 client proteins, beyond KIT and PDGFRA. To identify novel targets responsible for KIT oncoprotein function, we performed parallel genome-scale short hairpin RNA (shRNA)-mediated gene knockdowns in KIT-mutant GIST-T1 and GIST882. GIST cells were infected with a lentiviral shRNA pooled library targeting 11 194 human genes, and allowed to proliferate for 5-7 weeks, at which point assessment of relative hairpin abundance identified the HSP90 cofactor, CDC37, as one of the top six GIST-specific essential genes. Validations in treatment-naive (GIST-T1, GIST882) vs imatinib-resistant GISTs (GIST48, GIST430) demonstrated that: (1) CDC37 interacts with oncogenic KIT; (2) CDC37 regulates expression and activation of KIT and downstream signaling intermediates in GIST; and (3) unlike direct HSP90 inhibition, CDC37 knockdown accomplishes prolonged KIT inhibition (420 days) in GIST. These studies highlight CDC37 as a key biologic vulnerability in both imatinib-sensitive and imatinib-resistant GIST. CDC37 targeting is expected to be selective for KIT/PDGFRA and a subset of other HSP90 clients, and thereby represents a promising strategy for inactivating the myriad KIT/PDGFRA oncoproteins in TKI-resistant GIST patients.	[Marino-Enriquez, A.; Ou, W-B; Jonker, A. H.; Mayeda, M.; Eilers, G.; Wang, Y.; Fletcher, J. A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Marino-Enriquez, A.] Univ Autonoma Madrid, Hosp Univ La Paz, Fdn Invest Biomed FIBHULP, IdiPAZ,Dept Anat Patol, Madrid, Spain; [Ou, W-B] Tsinghua Univ, Yangtze Delta Reg Inst, Zhejiang Prov Key Lab Appl Enzymol, Jiaxing, Zhejiang, Peoples R China; [Cowley, G.; Luo, B.; Okamoto, M.; Root, D. E.] Harvard & MIT, Broad Inst, RNAi Platform, Cambridge, MA USA; [Czaplinski, J. T.; Sicinska, E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Mol Oncol Pathol Med Oncol, Boston, MA 02115 USA; [Taguchi, T.] Kochi Univ, Grad Sch Kuroshio Sci, Dept Human Hlth & Med Sci, Nankoku, Kochi, Japan; [Demetri, G. D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Sarcoma & Bone Oncol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Autonomous University of Madrid; Hospital Universitario La Paz; Tsinghua University; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Kochi University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Marino-Enriiquez, A (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	admarino@partners.org; jfletcher@partners.org	Jonker, Anneliene/AAW-4326-2020; Ou, Wen-Bin/J-1142-2019	, Wenbin/0000-0002-6311-9442; Marino-Enriquez, Adrian/0000-0002-7680-9901	GI SPORE [1P50CA12703-05]; Virginia and Daniel K Ludwig Trust for Cancer Research; Paul's Posse and Team Cesarini of the Pan Mass Challenge; LifeRaft Group; GIST Cancer Research Fund; Sarcoma Alliance for Research Through Collaboration (SARC) Career Development Award; Qianjiang Talents Project of Zhejiang [2012R10079]; Science and Technology Bureau of Jiaxing, Zhejiang [2012AY1039]; Major Science and Technology Special Project of Zhejiang Province [2012C03007-4]; RNAI Consortium (TRC); NATIONAL CANCER INSTITUTE [P50CA127003] Funding Source: NIH RePORTER	GI SPORE; Virginia and Daniel K Ludwig Trust for Cancer Research; Paul's Posse and Team Cesarini of the Pan Mass Challenge; LifeRaft Group; GIST Cancer Research Fund; Sarcoma Alliance for Research Through Collaboration (SARC) Career Development Award; Qianjiang Talents Project of Zhejiang; Science and Technology Bureau of Jiaxing, Zhejiang; Major Science and Technology Special Project of Zhejiang Province; RNAI Consortium (TRC); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Adrian Marino-Enriquez, Wen-Bin Ou, Yuexiang Wang, Jonathan A Fletcher and George D Demetri, are supported by the GI SPORE 1P50CA12703-05, Virginia and Daniel K Ludwig Trust for Cancer Research, Paul's Posse and Team Cesarini of the Pan Mass Challenge, LifeRaft Group and the GIST Cancer Research Fund. Adrian Marino-Enriquez is also supported by a Sarcoma Alliance for Research Through Collaboration (SARC) Career Development Award. Wen-Bin Ou is also supported by Qianjiang Talents Project of Zhejiang (2012R10079), a grant from the Science and Technology Bureau of Jiaxing, Zhejiang (2012AY1039) and the Major Science and Technology Special Project of Zhejiang Province (2012C03007-4). The RNAI Consortium (TRC) supported the development of pooled screening methods used for these screens.	Agaram NP, 2008, GENE CHROMOSOME CANC, V47, P853, DOI 10.1002/gcc.20589; Antonescu CR, 2005, CLIN CANCER RES, V11, P4182, DOI 10.1158/1078-0432.CCR-04-2245; Antonescu CR, 2011, J PATHOL, V223, P251, DOI 10.1002/path.2798; Bauer S, 2006, CANCER RES, V66, P9153, DOI 10.1158/0008-5472.CAN-06-0165; Chandarlapaty S, 2008, CLIN CANCER RES, V14, P240, DOI 10.1158/1078-0432.CCR-07-1667; Cheung HW, 2011, P NATL ACAD SCI USA, V108, P12372, DOI 10.1073/pnas.1109363108; DeMatteo RP, 2009, LANCET, V373, P1097, DOI 10.1016/S0140-6736(09)60500-6; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Demetri GD, 2010, P GASTR CANC S; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Heinrich MC, 2006, J CLIN ONCOL, V24, P4764, DOI 10.1200/JCO.2006.06.2265; Heinrich MC, 2008, J CLIN ONCOL, V26, P5352, DOI 10.1200/JCO.2007.15.7461; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Lee CH, 2012, P NATL ACAD SCI USA, V109, P929, DOI 10.1073/pnas.1115528109; Liegl B, 2008, J PATHOL, V216, P64, DOI 10.1002/path.2382; Luo B, 2008, P NATL ACAD SCI USA, V105, P20380, DOI 10.1073/pnas.0810485105; Rubin BP, 2001, CANCER RES, V61, P8118; Smith JR, 2009, CELL CYCLE, V8, P362, DOI 10.4161/cc.8.3.7531; Smyth T, 2012, MOL CANCER THER, V11, P1799, DOI 10.1158/1535-7163.MCT-11-1046; Vaughan CK, 2008, MOL CELL, V31, P886, DOI 10.1016/j.molcel.2008.07.021; Verweij J, 2004, LANCET, V364, P1127, DOI 10.1016/S0140-6736(04)17098-0; Xu WP, 2012, MOL CELL, V47, P434, DOI 10.1016/j.molcel.2012.05.015; Zhang T, 2009, J BIOL CHEM, V284, P35381, DOI 10.1074/jbc.M109.051532	23	21	22	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2014	33	14					1872	1876		10.1038/onc.2013.127	http://dx.doi.org/10.1038/onc.2013.127			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RE	23584476	Green Accepted			2022-12-17	WOS:000334345500013
J	Tang, J; Li, Y; Lyon, K; Camps, J; Dalton, S; Ried, T; Zhao, S				Tang, J.; Li, Y.; Lyon, K.; Camps, J.; Dalton, S.; Ried, T.; Zhao, S.			Cancer driver-passenger distinction via sporadic human and dog cancer comparison: a proof-of-principle study with colorectal cancer	ONCOGENE			English	Article						CRC driver-passenger distinction; sporadic canine CRCs; human-dog comparison; epithelial cell apicobasal polarity; genomic amplifications/deletions	CELL POLARITY; TUMOR-SUPPRESSOR; DOMESTIC DOG; GENOME; SEQUENCE; PROTEIN; COLON; TRANSITION; NETWORK; BREAST	Herein we report a proof-of-principle study illustrating a novel dog-human comparison strategy that addresses a central aim of cancer research, namely cancer driver-passenger distinction. We previously demonstrated that sporadic canine colorectal cancers (CRCs) share similar molecular pathogenesis mechanisms as their human counterparts. In this study, we compared the genome-wide copy number abnormalities between 29 human and 10 canine sporadic CRCs. This led to the identification of 73 driver candidate genes (DCGs), altered in both species, and with 27 from the whole genome and 46 from dog-human genomic rearrangement breakpoint (GRB) regions, as well as 38 passenger candidate genes (PCGs), altered in humans only and located in GRB regions. We noted that DCGs significantly differ from PCGs in every analysis conducted to assess their cancer relevance and biological functions. Importantly, although PCGs are not enriched in any specific functions, DCGs possess significantly enhanced functionality closely associated with cell proliferation and death regulation, as well as with epithelial cell apicobasal polarity establishment/maintenance. These observations support the notion that, in sporadic CRCs of both species, cell polarity genes not only contribute in preventing cancer cell invasion and spreading, but also likely serve as tumor suppressors by modulating cell growth. This pilot study validates our novel strategy and has uncovered four new potential cell polarity and colorectal tumor suppressor genes (RASA3, NUPL1, DENND5A and AVL9). Expansion of this study would make more driver-passenger distinctions for cancers with large genomic amplifications or deletions, and address key questions regarding the relationship between cancer pathogenesis and epithelial cell polarity control in mammals.	[Tang, J.; Li, Y.; Lyon, K.; Dalton, S.; Zhao, S.] Univ Georgia, Inst Bioinformat, Dept Biochem & Mol Biol, Athens, GA 30602 USA; [Camps, J.; Ried, T.] NCI, Genet Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	University System of Georgia; University of Georgia; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zhao, S (corresponding author), Univ Georgia, Inst Bioinformat, Dept Biochem & Mol Biol, B304B Life Sci Bldg,120 Green St, Athens, GA 30602 USA.	szhao@bmb.uga.edu	Tang, Jie/D-3764-2015; Camps, Jordi/AAG-3080-2020	Tang, Jie/0000-0002-3991-2539; Camps, Jordi/0000-0002-3165-3640; Dalton, Stephen/0000-0002-3450-1263	American Cancer Society; Georgia Cancer Coalition; NCI [P50 CA128613]; NATIONAL CANCER INSTITUTE [ZIABC010833, P50CA128613, ZIABC010835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM085354] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); Georgia Cancer Coalition; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Ms Huan Xiong for her work; Dr Bert Vogelstein for providing various CRC lines and Dr Timothy A Chan of Memorial Sloan-Kettering Cancer Center for providing the IHA cells; and Drs Dong M Shin, J David Puett, Claiborne Glover, Georgia Chen, and Lisa J Stubb for their help and advice on this study. This work was funded by the American Cancer Society and the Georgia Cancer Coalition (principal investigator (PI): S Zhao), as well as NCI P50 CA128613 (PI: Dr Dong M Shin) and GM085354 (PI: Dr Stephen Dalton).	Amann T, 2009, EXPERT OPIN THER TAR, V13, P1411, DOI 10.1517/14728220903307509; Bachmann O, 2011, ACTA PHYSIOL, V201, P33, DOI 10.1111/j.1748-1716.2010.02153.x; Barrios A, 2003, CURR BIOL, V13, P1571, DOI 10.1016/j.cub.2003.08.030; Beck CR, 2010, CELL, V141, P1159, DOI 10.1016/j.cell.2010.05.021; Belleannee C, 2010, AM J PHYSIOL-CELL PH, V298, pC817, DOI 10.1152/ajpcell.00460.2009; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; Bouanene H, 2010, DIS MARKERS, V28, P385, DOI [10.3233/DMA-2010-0719, 10.1155/2010/918457]; Boyko AR, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-2-216; Bryant DM, 2008, NAT REV MOL CELL BIO, V9, P887, DOI 10.1038/nrm2523; Camps J, 2008, CANCER RES, V68, P1284, DOI 10.1158/0008-5472.CAN-07-2864; Dehal P, 2001, SCIENCE, V293, P104, DOI 10.1126/science.1060310; Farabaugh SM, ONCOGENE, V31, P552; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Haber DA, 2007, NATURE, V446, P145, DOI 10.1038/446145a; Harsay E, 2007, MOL BIOL CELL, V18, P1203, DOI 10.1091/mbc.E06-11-1035; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987; Iden S, 2008, NAT REV MOL CELL BIO, V9, P846, DOI 10.1038/nrm2521; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Jacobson Kenneth A, 2009, Handb Exp Pharmacol, P123, DOI 10.1007/978-3-540-89615-9_5; Ji XL, 2008, GENOMICS, V91, P249, DOI 10.1016/j.ygeno.2007.10.014; Ji XL, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-426; Jin BL, 2009, CANCER RES, V69, P7412, DOI 10.1158/0008-5472.CAN-09-0116; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Krais AM, 2011, CARCINOGENESIS, V32, P1388, DOI 10.1093/carcin/bgr090; Lee MH, 2008, J CELL SCI, V121, P1141, DOI 10.1242/jcs.016634; Levy F, 2005, MOL BIOL CELL, V16, P1777, DOI 10.1091/mbc.E04-09-0803; Li R, 2008, NAT REV MOL CELL BIO, V9, P860, DOI 10.1038/nrm2522; Lin J, 2007, GENOME RES, V17, P1304, DOI 10.1101/gr.6431107; Lindblad-Toh K, 2005, NATURE, V438, P803, DOI 10.1038/nature04338; Llovera L, 2012, CANCER LETT, V326, P114, DOI 10.1016/j.canlet.2012.08.001; Lott ST, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000068; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nafisi H, 2008, J BIOL CHEM, V283, P35908, DOI 10.1074/jbc.M803622200; Neff MW, 2006, CELL, V124, P229, DOI 10.1016/j.cell.2006.01.008; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Pontius JU, 2007, GENOME RES, V17, P1675, DOI 10.1101/gr.6380007; Reinhardt HC, 2010, MOL CELL, V40, P34, DOI 10.1016/j.molcel.2010.09.018; Rowell JL, 2011, TRENDS MOL MED, V17, P380, DOI 10.1016/j.molmed.2011.02.004; Royer C, 2011, CELL DEATH DIFFER, V18, P1470, DOI 10.1038/cdd.2011.60; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Skaletsky H, 2003, NATURE, V423, P825, DOI 10.1038/nature01722; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Tang J, 2010, GENOME RES, V20, P341, DOI 10.1101/gr.092726.109; Veeriah S, 2009, P NATL ACAD SCI USA, V106, P9435, DOI 10.1073/pnas.0900571106; Youmans L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050813	50	21	23	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					814	822		10.1038/onc.2013.17	http://dx.doi.org/10.1038/onc.2013.17			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23416983	Green Accepted			2022-12-17	WOS:000331626900002
J	Choi, HH; Choi, HK; Jung, SY; Hyle, J; Kim, BJ; Yoon, K; Cho, EJ; Youn, HD; Lahti, JM; Qin, J; Kim, ST				Choi, H-H; Choi, H-K; Jung, S. Y.; Hyle, J.; Kim, B-J; Yoon, K.; Cho, E-J; Youn, H-D; Lahti, J. M.; Qin, J.; Kim, S-T			CHK2 kinase promotes pre-mRNA splicing via phosphorylating CDK11p110	ONCOGENE			English	Article						CHK2; pre-mRNA splicing; CDK11; DNA damage response pathway	DNA-DAMAGE CHECKPOINT; ACTIVATION; CANCER; P53; SUSCEPTIBILITY; COMPLEXES; BRCA1; CELLS; CHEK2; ATM	Checkpoint kinase 2 (CHK2) kinase is a key mediator in many cellular responses to genotoxic stresses, including ionizing radiation (IR) and topoisomerase inhibitors. Upon IR, CHK2 is activated by ataxia telangiectasia mutated kinase and regulates the S-phase and G1-S checkpoints, apoptosis and DNA repair by phosphorylating downstream target proteins, such as p53 and Brca1. In addition, CHK2 is thought to be a multi-organ cancer susceptibility gene. In this study, we used a tandem affinity purification strategy to identify proteins that interact with CHK2 kinase. Cyclin-dependent kinase 11 (CDK11)(p110) kinase, implicated in pre-mRNA splicing and transcription, was identified as a CHK2-interacting protein. CHK2 kinase phosphorylated CDK11(p110) on serine 737 in vitro. Unexpectedly, CHK2 kinase constitutively phosphorylated CDK11(p110) in a DNA damage-independent manner. At a molecular level, CDK11(p110) phosphorylation was required for homodimerization without affecting its kinase activity. Overexpression of CHK2 promoted pre-mRNA splicing. Conversely, CHK2 depletion decreased endogenous splicing activity. Mutation of the phosphorylation site in CDK11(p110) to alanine abrogated its splicing-activating activity. These results provide the first evidence that CHK2 kinase promotes pre-mRNA splicing via phosphorylating CDK11(p110).	[Choi, H-H; Choi, H-K; Kim, S-T] Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Dept Mol Cell Biol, 300 Chunchung Dong, Suwon 440746, South Korea; [Jung, S. Y.; Kim, B-J; Qin, J.] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Ctr Mol Discovery, Houston, TX 77030 USA; [Hyle, J.; Lahti, J. M.] St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA; [Yoon, K.] Sungkyunkwan Univ, Sch Life Sci & Biotechnol, Suwon 440746, South Korea; [Cho, E-J] Sungkyunkwan Univ, Sch Pharm, Suwon 440746, South Korea; [Youn, H-D] Seoul Natl Univ, Coll Med, Canc Res Inst, Natl Res Lab Metab Checkpoint,Dept Biomed Sci, Seoul, South Korea; [Youn, H-D] Seoul Natl Univ, Coll Med, Canc Res Inst, Natl Res Lab Metab Checkpoint,Dept Biochem & Mol, Seoul, South Korea	Sungkyunkwan University (SKKU); Baylor College of Medicine; St Jude Children's Research Hospital; Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Seoul National University (SNU); Seoul National University (SNU)	Kim, ST (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Dept Mol Cell Biol, 300 Chunchung Dong, Suwon 440746, South Korea.	stkim@skku.edu	Lahti, Jari/P-7987-2018; Cho, Eun-Jung/AAR-1785-2020	Lahti, Jari/0000-0002-4310-5297; Cho, Eun-Jung/0000-0002-6610-5329; Jung, Sung Yun/0000-0003-1521-7977; Yoon, Keejung/0000-0002-2361-9039	NRF [20110008174]; Ministry of Science and Technology, Republic of Korea.; NATIONAL CANCER INSTITUTE [R01CA067938, P30CA021765] Funding Source: NIH RePORTER	NRF; Ministry of Science and Technology, Republic of Korea.(Ministry of Science & Technology (MOST), Republic of Korea); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Richard R Vaillancourt for providing HA-CDK11<SUP>p110</SUP> expression vector; Dr Anglus I Lamond for pBSAL4 plasmid; Dr Gideon Dreyfuss for pCMV-Luc 2CP/ARE and pCMV-Luc 2CP/Intron/ARE plasmids; Dr Eperon for the pTN24 plasmids; Dr Jin-Hyun Ahn for pDEST-SG5-HA, pDEST-SG5-flag destination vectors and early passage human diploid fibroblast cell lines. This work was supported by NRF Grants 20110008174, funded by the Ministry of Science and Technology, Republic of Korea.	Ahn J, 2002, J BIOL CHEM, V277, P48418, DOI 10.1074/jbc.M208321200; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Blencowe BJ, 2003, CURR BIOL, V13, pR149, DOI 10.1016/S0960-9822(03)00079-4; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Chi YY, 2011, J BIOL CHEM, V286, P1748, DOI 10.1074/jbc.M110.107367; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Cybulski C, 2004, AM J HUM GENET, V75, P1131, DOI 10.1086/426403; Darbon JM, 2000, J BIOL CHEM, V275, P15363, DOI 10.1074/jbc.275.20.15363; Dong XY, 2003, AM J HUM GENET, V72, P270, DOI 10.1086/346094; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Franck N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014600; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hu DL, 2003, J BIOL CHEM, V278, P8623, DOI 10.1074/jbc.M210057200; Hu DL, 2007, J CELL SCI, V120, P2424, DOI 10.1242/jcs.007963; LAMOND AI, 1987, GENE DEV, V1, P532, DOI 10.1101/gad.1.6.532; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lee SB, 2001, CANCER RES, V61, P8062; Loyer P, 2008, J BIOL CHEM, V283, P7721, DOI 10.1074/jbc.M708188200; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Nasim MT, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf108; Nybakken K, 2005, NAT GENET, V37, P1323, DOI 10.1038/ng1682; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; Pabla N, 2008, J BIOL CHEM, V283, P6572, DOI 10.1074/jbc.M707568200; Petretti C, 2006, EMBO REP, V7, P418, DOI 10.1038/sj.embor.7400639; Pommier Y, 2006, CLIN CANCER RES, V12, P2657, DOI 10.1158/1078-0432.CCR-06-0743; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Sachs NA, 2003, BBA-GEN SUBJECTS, V1624, P98, DOI 10.1016/j.bbagen.2003.10.001; Seo GJ, 2003, BIOCHEM BIOPH RES CO, V304, P339, DOI 10.1016/S0006-291X(03)00589-8; Shieh SY, 2000, GENE DEV, V14, P289; Solier S, 2009, MOL CELL BIOL, V29, P68, DOI 10.1128/MCB.00581-08; Stolz A, 2010, NAT CELL BIOL, V12, P492, DOI 10.1038/ncb2051; Trembley JH, 2002, J BIOL CHEM, V277, P2589, DOI 10.1074/jbc.M109755200; Valente ST, 2009, MOL CELL, V36, P279, DOI 10.1016/j.molcel.2009.10.004; Ward AJ, 2010, J PATHOL, V220, P152, DOI 10.1002/path.2649; Wilker EW, 2007, NATURE, V446, P329, DOI 10.1038/nature05584; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Younis I, 2010, MOL CELL BIOL, V30, P1718, DOI 10.1128/MCB.01301-09; Zong HL, 2007, MOL CELL BIOL, V27, P7125, DOI 10.1128/MCB.01753-06	41	21	29	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					108	115		10.1038/onc.2012.535	http://dx.doi.org/10.1038/onc.2012.535			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23178491	Green Accepted			2022-12-17	WOS:000329212000012
J	Okudaira, N; Okamura, T; Tamura, M; Iijma, K; Goto, M; Matsunaga, A; Ochiai, M; Nakagama, H; Kano, S; Fujii-Kuriyama, Y; Ishizaka, Y				Okudaira, N.; Okamura, T.; Tamura, M.; Iijma, K.; Goto, M.; Matsunaga, A.; Ochiai, M.; Nakagama, H.; Kano, S.; Fujii-Kuriyama, Y.; Ishizaka, Y.			Long interspersed element-1 is differentially regulated by food-borne carcinogens via the aryl hydrocarbon receptor	ONCOGENE			English	Article						PhIP; MeIQx; aryl hydrocarbon receptor; breast carcinomas; ER alpha	HUMAN L1 RETROTRANSPOSITION; NON-LTR RETROTRANSPOSONS; HUMAN LINE-1 PROTEIN; SOMATIC RETROTRANSPOSITION; NUCLEOTIDE ELEMENT-1; HETEROCYCLIC AMINES; DIOXIN RECEPTOR; MICE LACKING; COOKED FOOD; EXPRESSION	A single human cell contains more than 5.0 x 10(5) copies of long interspersed element-1 (L1), 80-100 of which are competent for retrotransposition (L1-RTP). Recent observations have revealed the presence of de novo L1 insertions in various tumors, but little is known about its mechanism. Here, we found that 2-amino-1-methyl-6-phenylimidazo[ 4,5-b] pyridine (PhIP) and 2-amino-3, 8-dimethyl-imidazo[ 4,5-f] quinoxaline (MeIQx), food-borne carcinogens that are present in broiled meats, induced L1-RTP. This induction was dependent on a cellular cascade comprising the aryl hydrocarbon receptor (AhR), a mitogen-activated protein kinase, and CCAAT/ enhancer-binding protein b. Notably, these compounds exhibited differential induction of L1-RTP. MeIQx-induced L1-RTP was dependent on AhR nuclear translocator 1 (ARNT1), a counterpart of AhR required for gene expression in response to environmental pollutants. By contrast, PhIP-induced L1-RTP did not require ARNT1 but was dependent on estrogen receptor a (ERa) and AhR repressor. In vivo studies using transgenic mice harboring the human L1 gene indicated that PhIP-induced L1-RTP was reproducibly detected in the mammary gland, which is a target organ of PhIP-induced carcinoma. Moreover, picomolar levels of each compound induced L1-RTP, which is comparable to the PhIP concentration detected in human breast milk. Data suggest that somatic cells possess machineries that induce L1-RTP in response to the carcinogenic compounds. Together with data showing that micromolar levels of heterocyclic amines (HCAs) were non-genotoxic, our observations indicate that L1-RTP by environmental compounds is a novel type of genomic instability, further suggesting that analysis of L1-RTP by HCAs is a novel approach to clarification of modes of carcinogenesis.	[Okudaira, N.; Tamura, M.; Iijma, K.; Matsunaga, A.; Ishizaka, Y.] Natl Ctr Global Hlth & Med NCGM, Dept Intractable Dis, Shinjuku Ku, Tokyo 1628655, Japan; [Okudaira, N.; Kano, S.] Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki, Japan; [Okamura, T.; Goto, M.] Natl Ctr Global Hlth & Med NCGM, Dept Lab Anim Med, Shinjuku Ku, Tokyo 1628655, Japan; [Ochiai, M.; Nakagama, H.] Natl Canc Ctr, Div Canc Dev Syst, Chuo Ku, Tokyo, Japan; [Kano, S.] Natl Ctr Global Hlth & Med NCGM, Dept Trop Med & Malaria, Shinjuku Ku, Tokyo 1628655, Japan; [Fujii-Kuriyama, Y.] Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo, Japan; [Okamura, T.] Dept Infect Dis, Sect Anim Model, Tokyo, Japan	University of Tsukuba; National Cancer Center - Japan; University of Tokyo	Ishizaka, Y (corresponding author), Natl Ctr Global Hlth & Med NCGM, Dept Intractable Dis, Shinjuku Ku, 1-21-1 Toyama, Tokyo 1628655, Japan.	zakay@ri.ncgm.go.jp		yuan ren, hou teng/0000-0001-6288-4583	Ministry of Health, Labor and Welfare of Japan [09156296]; Log-range Research Initiative (LRI) from Japan; Chemical Industry Association (JCIA); Tokyo Biochemical Research Foundation; JointUse Research facility, Hyogo College of Medicine	Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Log-range Research Initiative (LRI) from Japan; Chemical Industry Association (JCIA); Tokyo Biochemical Research Foundation; JointUse Research facility, Hyogo College of Medicine	We are grateful to Drs Elena. T Luning Prak (University of Pennsylvania Medical Center), Gilbert Nicolas (University of Michigan Medical School) and Gabriele Vielhaber (Symrise, Germany) for providing pEF06R, pCEP4/L1mneoI/ColE1 and MNF, respectively. An antibody to AhRR was a kind gift from Dr Mark E Hahn (Woods Hole Oceanographic Institution). This work was supported in parts by a Grant-in-Aid for Research from the Ministry of Health, Labor and Welfare of Japan (09156296), and a research grant for the Log-range Research Initiative (LRI) from Japan Chemical Industry Association (JCIA). NO was an applicant supported by Grant-in-Aid from the Tokyo Biochemical Research Foundation. This work was supported in part by a JointUse Research facility, Hyogo College of Medicine.	Babushok DV, 2007, HUM MUTAT, V28, P527, DOI 10.1002/humu.20486; Baillie JK, 2011, NATURE, V479, P534, DOI 10.1038/nature10531; Bannert N, 2004, P NATL ACAD SCI USA, V101, P14572, DOI 10.1073/pnas.0404838101; Beischlag TV, 2008, CRIT REV EUKAR GENE, V18, P207, DOI 10.1615/CritRevEukarGeneExpr.v18.i3.20; Belancio VP, 2008, GENOME RES, V18, P343, DOI 10.1101/gr.5558208; Belancio VP, 2010, SEMIN CANCER BIOL, V20, P200, DOI 10.1016/j.semcancer.2010.06.001; Beraldi R, 2006, MOL REPROD DEV, V73, P279, DOI 10.1002/mrd.20423; Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100; Coufal NG, 2011, P NATL ACAD SCI USA, V108, P20382, DOI 10.1073/pnas.1100273108; Coufal NG, 2009, NATURE, V460, P1127, DOI 10.1038/nature08248; Dewannieux M, 2003, NAT GENET, V35, P41, DOI 10.1038/ng1223; Eguchi H, 1997, J BIOL CHEM, V272, P17640, DOI 10.1074/jbc.272.28.17640; Ema M, 1996, MOL CELL BIOL, V16, P5865; Farkash EA, 2006, NUCLEIC ACIDS RES, V34, P1196, DOI 10.1093/nar/gkj522; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; Fritsche E, 2007, P NATL ACAD SCI USA, V104, P8851, DOI 10.1073/pnas.0701764104; Gasior SL, 2006, J MOL BIOL, V357, P1383, DOI 10.1016/j.jmb.2006.01.089; Georgiou I, 2009, HUM MOL GENET, V18, P1221, DOI 10.1093/hmg/ddp022; Gilbert N, 2005, MOL CELL BIOL, V25, P7780, DOI 10.1128/MCB.25.17.7780-7795.2005; Gilbert N, 2002, CELL, V110, P315, DOI 10.1016/S0092-8674(02)00828-0; Goodier JL, 2008, CELL, V135, P23, DOI 10.1016/j.cell.2008.09.022; Goodier JL, 2007, MOL CELL BIOL, V27, P6469, DOI 10.1128/MCB.00332-07; Hahn ME, 2009, BIOCHEM PHARMACOL, V77, P485, DOI 10.1016/j.bcp.2008.09.016; Hahn ME, 2002, CHEM-BIOL INTERACT, V141, P131, DOI 10.1016/S0009-2797(02)00070-4; Hancks DC, 2012, CURR OPIN GENET DEV, V22, P191, DOI 10.1016/j.gde.2012.02.006; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Hohjoh H, 1996, EMBO J, V15, P630, DOI 10.1002/j.1460-2075.1996.tb00395.x; Ishizaka Y, PROTEIN KINASES, P187; Iskow RC, 2010, CELL, V141, P1253, DOI 10.1016/j.cell.2010.05.020; ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503; Jurka J, 1997, P NATL ACAD SCI USA, V94, P1872, DOI 10.1073/pnas.94.5.1872; Kale Shubha P, 2005, Int J Environ Res Public Health, V2, P14, DOI 10.3390/ijerph2005010014; Kano H, 2009, GENE DEV, V23, P1303, DOI 10.1101/gad.1803909; Karchner SI, 2009, MOL CELL BIOL, V29, P3465, DOI 10.1128/MCB.00206-09; Kazazian HH, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-62; KLEMAN MI, 1992, CARCINOGENESIS, V13, P1619, DOI 10.1093/carcin/13.9.1619; Konkel MK, 2010, SEMIN CANCER BIOL, V20, P211, DOI 10.1016/j.semcancer.2010.03.001; Lauber SN, 2007, CANCER RES, V67, P9597, DOI 10.1158/0008-5472.CAN-07-1661; Lauber SN, 2004, CARCINOGENESIS, V25, P2509, DOI 10.1093/carcin/bgh268; LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39; Lee E, 2012, SCIENCE, V337, P967, DOI 10.1126/science.1222077; Macia A, 2011, MOL CELL BIOL, V31, P300, DOI 10.1128/MCB.00561-10; Martin SL, 2005, J MOL BIOL, V348, P549, DOI 10.1016/j.jmb.2005.03.003; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; McIntosh BE, 2010, ANNU REV PHYSIOL, V72, P625, DOI 10.1146/annurev-physiol-021909-135922; MIKI Y, 1992, CANCER RES, V52, P643; Mimura J, 1997, GENES CELLS, V2, P645, DOI 10.1046/j.1365-2443.1997.1490345.x; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; Muotri AR, 2010, NATURE, V468, P443, DOI 10.1038/nature09544; Nakai Y, 2007, CANCER RES, V67, P1378, DOI 10.1158/0008-5472.CAN-06-1336; Nishikawa A, 2005, TOXICOL SCI, V84, P243, DOI 10.1093/toxsci/kfi079; OHGAKI H, 1987, CARCINOGENESIS, V8, P665, DOI 10.1093/carcin/8.5.665; Okudaira N, 2011, CANCER SCI, V102, P2000, DOI 10.1111/j.1349-7006.2011.02060.x; Okudaira N, 2010, P NATL ACAD SCI USA, V107, P18487, DOI 10.1073/pnas.1001252107; Oricchio E, 2007, ONCOGENE, V26, P4226, DOI 10.1038/sj.onc.1210214; Osborne CK, 2004, BRIT J CANCER, V90, pS2, DOI 10.1038/sj.bjc.6601629; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Quintana FJ, 2008, NATURE, V453, P65, DOI 10.1038/nature06880; Raiz J, 2012, NUCLEIC ACIDS RES, V40, P1666, DOI 10.1093/nar/gkr863; Schut HAJ, 1999, CARCINOGENESIS, V20, P353, DOI 10.1093/carcin/20.3.353; Scott KA, 2007, CHEM RES TOXICOL, V20, P88, DOI 10.1021/tx0601861; Shimizu Y, 2000, P NATL ACAD SCI USA, V97, P779, DOI 10.1073/pnas.97.2.779; Shirai T, 1997, CANCER RES, V57, P195; Stribinskis V, 2006, CANCER RES, V66, P2616, DOI 10.1158/0008-5472.CAN-05-3478; Sugimura T, 2004, CANCER SCI, V95, P290, DOI 10.1111/j.1349-7006.2004.tb03205.x; Symer DE, 2002, CELL, V110, P327, DOI 10.1016/S0092-8674(02)00839-5; Ting DT, 2011, SCIENCE, V331, P593, DOI 10.1126/science.1200801; Veldhoen M, 2008, NATURE, V453, P106, DOI 10.1038/nature06881; Vitullo P, 2012, MOL REPROD DEV, V79, P118, DOI 10.1002/mrd.22003; Wallace N, 2008, GENE, V419, P1, DOI 10.1016/j.gene.2008.04.007; Wei W, 2000, ANAL BIOCHEM, V284, P435, DOI 10.1006/abio.2000.4675; Wei W, 2001, MOL CELL BIOL, V21, P1429, DOI 10.1128/MCB.21.4.1429-1439.2001; Weiss C, 2005, ONCOGENE, V24, P4975, DOI 10.1038/sj.onc.1208679; Wincent E, 2012, P NATL ACAD SCI USA, V109, P4479, DOI 10.1073/pnas.1118467109; Wiseman M, 2008, P NUTR SOC, V67, P253, DOI 10.1017/S002966510800712X; Woodcock DM, 1997, J BIOL CHEM, V272, P7810, DOI 10.1074/jbc.272.12.7810	77	21	21	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4903	4912		10.1038/onc.2012.516	http://dx.doi.org/10.1038/onc.2012.516			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23208499	hybrid, Green Published			2022-12-17	WOS:000325717800006
J	Malatesta, M; Peschiaroli, A; Memmi, EM; Zhang, J; Antonov, A; Green, DR; Barlev, NA; Garabadgiu, AV; Zhou, P; Melino, G; Bernassola, F				Malatesta, M.; Peschiaroli, A.; Memmi, E. M.; Zhang, J.; Antonov, A.; Green, D. R.; Barlev, N. A.; Garabadgiu, A. V.; Zhou, P.; Melino, G.; Bernassola, F.			The Cul4A-DDB1 E3 ubiquitin ligase complex represses p73 transcriptional activity	ONCOGENE			English	Article						apoptosis; p73; protein ubiquitylation	TUMOR-SUPPRESSOR FUNCTIONS; DNA-DAMAGE; PROTEIN; CELLS; DDB1; STABILITY; MDM2; P53; DEGRADATION; INSTABILITY	The Cullin4A (cul4A)-dependent ligase (CDL4A) E3 has been implicated in a variety of biological processes, including cell cycle progression and DNA damage response. Remarkably, CDL4A exerts its function through both proteolytic and non-proteolytic events. Here, we show that the p53 family member p73 is able to interact with the CDL4A complex through its direct binding to the receptor subunit DNA-binding protein 1 (DDB1). As a result, the CDL4A complex is able to monoubiquitylate p73. Modification of p73 by CDL4A-mediated ubiquitylation does not affect p73 protein stability, but negatively regulates p73-dependent transcriptional activity. Indeed, genetic or RNA interference-mediated depletion of DDB1 induces the expression of several p73 target genes in a p53-independent manner. In addition, by exploiting a bioinformatic approach, we found that elevated expression of Cul4A in human breast carcinomas is associated with repression of p73 target genes. In conclusion, our findings add a novel insight into the regulation of p73 by the CDL4A complex, through the inhibition of its transcriptional function.	[Malatesta, M.; Memmi, E. M.; Melino, G.; Bernassola, F.] Univ Roma Tor Vergata, Dept Expt Med & Surg, I-00133 Rome, Italy; [Peschiaroli, A.; Melino, G.] Univ Roma Tor Vergata, IDI IRCCS, Biochem Lab, Dept Expt Med & Surg, I-00133 Rome, Italy; [Peschiaroli, A.] CNR, Inst Cellular Biol & Neurobiol, Dept Biomed, Rome, Italy; [Zhang, J.; Zhou, P.] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY USA; [Zhang, J.; Zhou, P.] Weill Cornell Grad Sch Med Sci, New York, NY USA; [Antonov, A.; Melino, G.] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England; [Green, D. R.] St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; [Barlev, N. A.; Garabadgiu, A. V.; Melino, G.] St Petersburg State Inst Technol, St Petersburg, Russia; [Barlev, N. A.] Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; [Bernassola, F.] European Inst Oncol, Dept Expt Oncol, Milan, Italy	University of Rome Tor Vergata; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Cornell University; Cornell University; Qatar Foundation (QF); Weill Cornell Medical College Qatar; University of Leicester; St Jude Children's Research Hospital; Saint Petersburg State Institute of Technology; University of Leicester; IRCCS European Institute of Oncology (IEO)	Melino, G (corresponding author), Univ Roma Tor Vergata, IDI IRCCS, Biochem Lab, Dept Expt Med & Surg, Via Montpellier 1, I-00133 Rome, Italy.	gerry.melino@uniroma2.it; bernasso@uniroma2.it	Green, Douglas R/N-8083-2018; Barlev, Nikolai A/K-5268-2017	Green, Douglas R/0000-0002-7332-1417; Barlev, Nikolai A/0000-0001-7111-2446; PESCHIAROLI, ANGELO/0000-0001-6311-2382; Garabadjiu, Alexander/0000-0001-9972-8517	MIUR/PRIN [20078P7T3K_001, (20078P7T3K_001)/FIRB, RBIP06LCA9_0023, RBIP06LCA9_0C, 2008MRLSNZ_004]; AIRC [9202, 2008-2010_33-08, 5471]; Medical Research Council, UK; Odysseus, Belgium; VIB, Belgium; Alleanza contro il Cancro [ACC12]; AIRC 5xmille [9979]; Ric Finalizzata [08-GIOV_RIC]; NIH [2R01CA098210, 5R01CA 118085]; RFBS [10-04-01234]; MCB RAS; Russian Federal grants [16.740.11.036, 11.G34.31.0069]; US NIH; Medical Research Council [MC_U132670600] Funding Source: researchfish; MRC [MC_U132670600] Funding Source: UKRI; NATIONAL CANCER INSTITUTE [R01CA118085, R01CA098210] Funding Source: NIH RePORTER	MIUR/PRIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); AIRC(Fondazione AIRC per la ricerca sul cancro); Medical Research Council, UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Odysseus, Belgium; VIB, Belgium; Alleanza contro il Cancro; AIRC 5xmille(Fondazione AIRC per la ricerca sul cancro); Ric Finalizzata; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); RFBS; MCB RAS; Russian Federal grants; US NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Michele Pagano for fruitful discussions on the topics covered in this article, and to Emre Sayan for providing the His-p73 alpha recombinant protein. This work has been supported by the MIUR/PRIN grant 20078P7T3K_001 and AIRC grant 9202 awarded to FB, the Medical Research Council, UK; Odysseus and VIB, Belgium; grants from 'Alleanza contro il Cancro' (ACC12), MIUR/PRIN (20078P7T3K_001)/FIRB (RBIP06LCA9_0023, RBIP06LCA9_0C), AIRC (2008-2010_33-08) (grant number 5471), AIRC 5xmille (grant number 9979), MIUR/PRIN 2008MRLSNZ_004 to GM, the Ric Finalizzata 08-GIOV_RIC awarded to AP, the NIH grants 2R01CA098210, 5R01CA 118085 and Irma T Hirschl Career Scientist Award to PZ. This work was supported by funding from RFBS (10-04-01234), MCB RAS, Russian Federal grants 16.740.11.036 (to NB) and 11.G34.31.0069 (to GM). DRG was supported by grants from the US NIH.	Angers S, 2006, NATURE, V443, P590, DOI 10.1038/nature05175; Banks D, 2006, CELL CYCLE, V5, P1719, DOI 10.4161/cc.5.15.3150; Busuttil V, 2010, P NATL ACAD SCI USA, V107, P18061, DOI 10.1073/pnas.1006163107; Cang Y, 2007, P NATL ACAD SCI USA, V104, P2733, DOI 10.1073/pnas.0611311104; Cang Y, 2006, CELL, V127, P929, DOI 10.1016/j.cell.2006.09.045; Chen LC, 1998, CANCER RES, V58, P3677; Chen XA, 2001, J BIOL CHEM, V276, P48175, DOI 10.1074/jbc.M106808200; Choi SH, 2010, GENE DEV, V24, P1236, DOI 10.1101/gad.1920310; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Greer SF, 2003, NAT IMMUNOL, V4, P1074, DOI 10.1038/ni985; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Hannah J, 2009, DNA REPAIR, V8, P536, DOI 10.1016/j.dnarep.2009.01.011; HERSHKOVITZROKA.O, 2010, PLOS ONE, V5; Higa LA, 2006, NAT CELL BIOL, V8, P1277, DOI 10.1038/ncb1490; Hu J, 2004, NAT CELL BIOL, V6, P1003, DOI 10.1038/ncb1172; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kopanja D, 2009, ONCOGENE, V28, P2456, DOI 10.1038/onc.2009.86; Lee J, 2007, MOL CELL, V26, P775, DOI 10.1016/j.molcel.2007.06.001; Leung-Pineda V, 2009, CANCER RES, V69, P2630, DOI 10.1158/0008-5472.CAN-08-3382; Li T, 2006, CELL, V124, P105, DOI 10.1016/j.cell.2005.10.033; Liu LR, 2009, MOL CELL, V34, P451, DOI 10.1016/j.molcel.2009.04.020; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; Nag A, 2004, CANCER RES, V64, P8152, DOI 10.1158/0008-5472.CAN-04-2598; Nishitani H, 2008, J BIOL CHEM, V283, P29045, DOI 10.1074/jbc.M806045200; Peschiaroli A, 2009, ONCOGENE, V28, P3157, DOI 10.1038/onc.2009.177; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Sayan AE, 2005, BIOCHEM BIOPH RES CO, V330, P186, DOI 10.1016/j.bbrc.2005.02.145; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; van der Horst A, 2006, NAT CELL BIOL, V8, P1064, DOI 10.1038/ncb1469	30	21	21	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2013	32	39					4721	4726		10.1038/onc.2012.463	http://dx.doi.org/10.1038/onc.2012.463			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23085759				2022-12-17	WOS:000325072200014
J	Sedgwick, GG; Townsend, K; Martin, A; Shimwell, NJ; Grand, RJA; Stewart, GS; Nilsson, J; Turnell, AS				Sedgwick, G. G.; Townsend, K.; Martin, A.; Shimwell, N. J.; Grand, R. J. A.; Stewart, G. S.; Nilsson, J.; Turnell, A. S.			Transcriptional intermediary factor 1 gamma binds to the anaphase-promoting complex/cyclosome and promotes mitosis	ONCOGENE			English	Article						TIF1 gamma; APC/C; mitosis, spindle assembly checkpoint	SPINDLE-ASSEMBLY CHECKPOINT; CYCLIN-A; SIGNALING PATHWAY; UBIQUITIN LIGASE; APC/C; DEGRADATION; CDC20; DESTRUCTION; COMPLEX; KINASE	The anaphase-promoting complex/cyclosome (APC/C) is an ubiquitin ligase that functions during mitosis. Here we identify the transcriptional regulator, transcriptional intermediary factor 1 gamma, TIF1 gamma, as an APC/C-interacting protein that regulates APC/C function. TIF1 gamma is not a substrate for APC/C-dependent ubiquitylation but instead, associates specifically with the APC/C holoenzyme and Cdc20 to affect APC/C activity and progression through mitosis. RNA interference studies indicate that TIF1 gamma knockdown results in a specific reduction in APC/C ubiquitin ligase activity, the stabilization of APC/C substrates, and an increase in the time taken for cells to progress through mitosis from nuclear envelope breakdown to anaphase. TIF1 gamma knockdown cells are also characterized by the inappropriate presence of cyclin A at metaphase, and an increase in the number of cells that fail to undergo metaphase-to-anaphase transition. Expression of a small interfering RNA-resistant TIF1 gamma species relieves the mitotic phenotype imposed by TIF1 gamma knockdown and allows for mitotic progression. Binding studies indicate that TIF1 gamma is also a component of the APC/C-mitotic checkpoint complex (MCC), but is not required for MCC dissociation from the APC/C once the spindle assembly checkpoint (SAC) is satisfied. TIF1 gamma inactivation also results in chromosome misalignment at metaphase and SAC activation; inactivation of the SAC relieves the mitotic block imposed by TIF1 gamma knockdown. Together these data define novel functions for TIF1 gamma during mitosis and suggest that a reduction in APC/C ubiquitin ligase activity promotes SAC activation.	[Sedgwick, G. G.; Townsend, K.; Martin, A.; Shimwell, N. J.; Grand, R. J. A.; Stewart, G. S.; Turnell, A. S.] Univ Birmingham, Sch Canc Sci, Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England; [Sedgwick, G. G.; Nilsson, J.] Univ Copenhagen, NNF Ctr Prot Res, Copenhagen N, Denmark	University of Birmingham; University of Copenhagen	Turnell, AS (corresponding author), Univ Birmingham, Sch Canc Sci, Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England.	a.s.turnell@bham.ac.uk		Nilsson, Jakob/0000-0003-4100-1125; Stewart, Grant/0000-0002-0960-3241	CR-UK [C10000/A7542]; University of Birmingham, College of Medical and Dental Sciences Research Development Fund; Danish Cancer Society; Lundbeck Foundation; Cancer Research UK [13030] Funding Source: researchfish	CR-UK(Cancer Research UK); University of Birmingham, College of Medical and Dental Sciences Research Development Fund; Danish Cancer Society(Danish Cancer Society); Lundbeck Foundation(Lundbeckfonden); Cancer Research UK(Cancer Research UK)	We thank Francis Barr, Andrew Fry, Stefano Piccolo, Frank Rauscher III, Hughes de The and Hiroyuki Yamano for reagents. This work was funded by CR-UK (C10000/A7542) and The University of Birmingham, College of Medical and Dental Sciences Research Development Fund. JN is supported by The Danish Cancer Society and the Lundbeck Foundation.	Blackford AN, 2010, P NATL ACAD SCI USA, V107, P12251, DOI 10.1073/pnas.0914605107; Chaudhry MA, 2002, ONCOGENE, V21, P1934, DOI 10.1038/sj.onc.1205264; Choi E, 2009, EMBO J, V28, P2077, DOI 10.1038/emboj.2009.123; Chung EN, 2003, NAT CELL BIOL, V5, P748, DOI 10.1038/ncb1022; D'Angiolella V, 2003, GENE DEV, V17, P2520, DOI 10.1101/gad.267603; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Di Fiore B, 2010, J CELL BIOL, V190, P501, DOI 10.1083/jcb.201001083; Dupont S, 2005, CELL, V121, P87, DOI 10.1016/j.cell.2005.01.033; Dupont S, 2009, CELL, V136, P123, DOI 10.1016/j.cell.2008.10.051; Ge S, 2009, CELL CYCLE, V8, P167, DOI 10.4161/cc.8.1.7606; Hayes MJ, 2006, NAT CELL BIOL, V8, P607, DOI 10.1038/ncb1410; He W, 2006, CELL, V125, P929, DOI 10.1016/j.cell.2006.03.045; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; Izawa D, 2011, NAT CELL BIOL, V13, P223, DOI 10.1038/ncb2165; Klugbauer S, 1999, ONCOGENE, V18, P4388, DOI 10.1038/sj.onc.1202824; Mansfeld J, 2011, NAT CELL BIOL, V13, P1234, DOI 10.1038/ncb2347; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Matyskiela ME, 2009, MOL CELL, V34, P68, DOI 10.1016/j.molcel.2009.02.027; Miller JJ, 2006, GENE DEV, V20, P2410, DOI 10.1101/gad.1454006; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Nilsson J, 2008, NAT CELL BIOL, V10, P1411, DOI 10.1038/ncb1799; Peng HZ, 2002, J MOL BIOL, V320, P629, DOI 10.1016/S0022-2836(02)00477-1; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Qi W, 2007, J BIOL CHEM, V282, P3672, DOI 10.1074/jbc.M609376200; Ransom DG, 2004, PLOS BIOL, V2, P1188, DOI 10.1371/journal.pbio.0020237; Rasti M, 2006, EMBO J, V25, P2710, DOI 10.1038/sj.emboj.7601169; Reddy SK, 2007, NATURE, V446, P921, DOI 10.1038/nature05734; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Ricke RM, 2011, J CELL BIOL, V193, P1049, DOI 10.1083/jcb.201012035; Shimwell NJ, 2009, ONCOGENE, V28, P686, DOI 10.1038/onc.2008.417; Stegmeier F, 2007, NATURE, V446, P876, DOI 10.1038/nature05694; Townsend K, 2009, J BIOL CHEM, V284, P33939, DOI 10.1074/jbc.M109.009191; Turnell AS, 2006, BRIT J CANCER, V95, P555, DOI 10.1038/sj.bjc.6603304; Turnell AS, 2005, NATURE, V438, P690, DOI 10.1038/nature04151; Venturini L, 1999, ONCOGENE, V18, P1209, DOI 10.1038/sj.onc.1202655; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wolthuis R, 2008, MOL CELL, V30, P290, DOI 10.1016/j.molcel.2008.02.027; Xu YX, 2007, CELL CYCLE, V6, P2896, DOI 10.4161/cc.6.23.4977; Yang Y, 2009, SCIENCE, V326, P575, DOI 10.1126/science.1177087; Yu H, 2007, MOL CELL, V27, P3, DOI 10.1016/j.molcel.2007.06.009; Zeng X, 2010, CANCER CELL, V18, P382, DOI 10.1016/j.ccr.2010.08.010; Zhang LY, 2011, J BIOL CHEM, V286, P10041, DOI 10.1074/jbc.M110.205518	42	21	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2013	32	39					4622	4633		10.1038/onc.2012.501	http://dx.doi.org/10.1038/onc.2012.501			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23160376	Green Accepted			2022-12-17	WOS:000325072200004
J	Maglic, D; Zhu, S; Fry, EA; Taneja, P; Kai, F; Kendig, RD; Sugiyama, T; Miller, LD; Willingham, MC; Inoue, K				Maglic, D.; Zhu, S.; Fry, E. A.; Taneja, P.; Kai, F.; Kendig, R. D.; Sugiyama, T.; Miller, L. D.; Willingham, M. C.; Inoue, K.			Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer	ONCOGENE			English	Article						Dmp1 (Dmtf1); breast cancer; loss of heterozygosity; relapse-free survival; Ki67; prognostic marker	TRANSCRIPTION FACTOR DMP1; MDM2 PROTEIN EXPRESSION; CELL-CYCLE ARREST; GENE-EXPRESSION; ARF; P53; HETEROZYGOSITY; LOCALIZATION; MUTATIONS; ACTIVATOR	Our recent study showed critical roles of Dmp1 as a sensor of oncogenic Ras, HER2/neu signaling and activation of the Arf-p53 pathway. To elucidate the role of human DMP1 (hDMP1) in breast cancer, one hundred and ten pairs of human breast cancer specimen were studied for the alterations of the hDMP1-ARF-Hdm2-p53 pathway with follow up of clinical outcomes. Loss of heterozygosity (LOH) of the hDMP1 locus was found in 42% of human breast carcinomas, while that of INK4a/ARF and p53 were found in 20 and 34%, respectively. Hdm2 amplification was found in 13% of the same sample, which was found independently of LOH for hDMP1. Conversely, LOH for hDMP1 was found in mutually exclusive fashion with that of INK4a/ARF and p53, and was associated with low Ki67 index and diploid karyotype. Consistently, LOH for hDMP1 was associated with luminal A category and longer relapse-free survival, while that of p53 was associated with non-luminal A and shorter survival. Thus, loss of hDMP1 could define a new disease category associated with prognosis of breast cancer patients. Human breast epithelial cells/cancer cells with wild-type p53 were sensitive to growth inhibition by activated Dmp1: ER while those that delete p14(ARF) or p53, and/or Hdm2 amplification showed partial or nearly complete resistance, indicating that p53 is a critical target for hDMP1 to exhibit its biological activity.	[Maglic, D.; Zhu, S.; Fry, E. A.; Taneja, P.; Kai, F.; Kendig, R. D.; Sugiyama, T.; Willingham, M. C.; Inoue, K.] Wake Forest Univ Hlth Sci, Dept Pathol, Winston Salem, NC 27157 USA; [Maglic, D.; Fry, E. A.; Taneja, P.; Kai, F.; Kendig, R. D.; Sugiyama, T.; Miller, L. D.; Inoue, K.] Wake Forest Univ Hlth Sci, Dept Canc Biol, Winston Salem, NC 27157 USA; [Maglic, D.; Zhu, S.; Inoue, K.] Wake Forest Univ Hlth Sci, Dept Grad Program Mol Med, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University School of Medicine; Wake Forest University; Wake Forest University School of Medicine; Wake Forest University; Wake Forest University School of Medicine	Inoue, K (corresponding author), Wake Forest Univ Hlth Sci, Dept Pathol, Med Ctr Blvd,2102 Gray Bldg, Winston Salem, NC 27157 USA.	kinoue@triad.rr.com		Miller, Lance/0000-0003-3799-2528	ACS [RSG-07-207-01-MGO]; NIH/NCI [5R01CA106314]; WFUHS [20595]; Susan G Komen Foundation [KG080179]; DOD [BC100907]; NATIONAL CANCER INSTITUTE [R01CA106314] Funding Source: NIH RePORTER	ACS(American Cancer Society); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); WFUHS; Susan G Komen Foundation(Susan G. Komen Breast Cancer Foundation); DOD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to R Weinberg for HMEC cells; C Sherr, and M Roussel for plasmid DNAs. We thank G Hawkins and Abdoulaye Diallo for LOH analyses of breast cancer samples. We also thank G Kucera for providing information on human breast cancer patients' samples, Guangchao Sui, Tim Kute for helpful discussions, Guorui Deng, and Jordan Chapman for technical assistance. K Inoue is supported by ACS RSG-07-207-01-MGO, NIH/NCI 5R01CA106314, and by Director's Challenge Award #20595 from WFUHS. P Taneja was supported by the Susan G Komen Foundation postdoctoral fellowship KG080179. D Maglic has been supported by DOD pre-doctoral fellowship BC100907.	BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; Bodner SM, 1999, GENE, V229, P223, DOI 10.1016/S0378-1119(98)00591-5; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Frazier DP, 2012, CANCER RES, V72, P1740, DOI 10.1158/0008-5472.CAN-11-2410; Gasco M, 2003, HUM MUTAT, V21, P301, DOI 10.1002/humu.10173; Hirai H, 1996, MOL CELL BIOL, V16, P6457; Hortobagyi GN, 1998, NEW ENGL J MED, V339, P974, DOI 10.1056/NEJM199810013391407; Inoue K, 2007, ONCOGENE, V26, P4329, DOI 10.1038/sj.onc.1210226; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Inoue K, 2001, GENE DEV, V15, P2934, DOI 10.1101/gad.929901; Inoue K, 2000, GENE DEV, V14, P1797; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Inoue K, 2008, CANCER RES, V68, P4487, DOI 10.1158/0008-5472.CAN-07-6791; Kristjansson AK, 1997, ANTICANCER RES, V17, P93; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Mallakin A, 2006, ONCOGENE, V25, P7703, DOI 10.1038/sj.onc.1209750; Mallakin A, 2007, CANCER CELL, V12, P381, DOI 10.1016/j.ccr.2007.08.034; Mallakin A, 2010, INT J CANCER, V126, P1403, DOI 10.1002/ijc.24938; Manfredi JJ, 2010, GENE DEV, V24, P1580, DOI 10.1101/gad.1941710; MARCHETTI A, 1995, J PATHOL, V175, P31, DOI 10.1002/path.1711750106; Masood S, 2005, CLIN LAB MED, V25, P809, DOI 10.1016/j.cll.2005.08.012; Ross JS, 2003, AM J CLIN PATHOL, V120, P822, DOI 10.1309/6CQ7AXQ6WHHBXUWH; Ross JS, 2005, MOL ONCOLOGY BREAST; Shetty A, 2005, BRIT J CANCER, V93, P1295, DOI 10.1038/sj.bjc.6602829; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Smeets SJ, 2011, CLIN CANCER RES, V17, P4959, DOI 10.1158/1078-0432.CCR-11-0462; Sreeramaneni R, 2005, MOL CELL BIOL, V25, P220, DOI 10.1128/MCB.25.1.220-232.2005; Sugiyama T, 2008, EXPERT REV MOL DIAGN, V8, P435, DOI 10.1586/14737159.8.4.435; Taneja P, 2010, CLIN MED INSIGHTS-ON, V4, P15; Taneja P, 2010, CANCER RES, V70, P9084, DOI 10.1158/0008-5472.CAN-10-0159; Tschan MP, 2003, J BIOL CHEM, V278, P42750, DOI 10.1074/jbc.M307067200; Turbin DA, 2006, MODERN PATHOL, V19, P69, DOI 10.1038/modpathol.3800484; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Wasielewski M, 2006, BREAST CANCER RES TR, V99, P97, DOI 10.1007/s10549-006-9186-z; Wiesner FG, 2009, BREAST, V18, P135, DOI 10.1016/j.breast.2009.02.009	37	21	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2013	32	35					4120	4129		10.1038/onc.2012.423	http://dx.doi.org/10.1038/onc.2012.423			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IG	23045280	Green Accepted			2022-12-17	WOS:000323748500007
J	Zhu, Y; Zhao, T; Itasaka, S; Zeng, L; Yeom, CJ; Hirota, K; Suzuki, K; Morinibu, A; Shinomiya, K; Ou, G; Yoshimura, M; Hiraoka, M; Harada, H				Zhu, Y.; Zhao, T.; Itasaka, S.; Zeng, L.; Yeom, C. J.; Hirota, K.; Suzuki, K.; Morinibu, A.; Shinomiya, K.; Ou, G.; Yoshimura, M.; Hiraoka, M.; Harada, H.			Involvement of decreased hypoxia-inducible factor 1 activity and resultant G(1)-S cell cycle transition in radioresistance of perinecrotic tumor cells	ONCOGENE			English	Article						radiation therapy; radioresistance; tumor microenvironments; hypoxia; hypoxia-inducible factor 1 (HIF-1)	DOUBLE-STRAND BREAKS; SOLID TUMORS; DNA-DAMAGE; FACTOR-I; IONIZING-RADIATION; MAMMALIAN-CELLS; STRESS-RESPONSE; CANCER-THERAPY; HISTONE H2AX; EXPRESSION	Cancer patients often suffer from local tumor recurrence after radiation therapy. Some intracellular and extracellular factors, such as activity of hypoxia-inducible factor 1 (HIF-1), cell cycle status and oxygen availability, have been suggested to affect DNA damage responses and eventual radioresistant characteristics of cancer cells. But when, where, and how these factors affect one another and induce cellular radioresistance is largely unknown. Here, we analyzed mechanistic and spatio-temporal relationships among them in highly heterogeneous tumor microenvironments. Experiments in vitro demonstrated that a decrease in the glucose concentration reduced the transcriptional activity of HIF-1 and expression of a downstream gene for the cell cycle regulator p27(Kip1) even under hypoxic conditions. Then, the proportion of cells in the radioresistant S phase increased, whereas that radiosensitive G(1) phase decreased, significantly. Immunohistochemical analyses showed that cancer cells in perinecrotic hypoxic regions, which should be under low-glucose conditions, expressed little HIF-1 alpha, and therefore, were mainly in S phase and less damaged by radiation treatment. Continuous administration of glucagon, which increases the blood glucose concentration and so improves glucose availability in perinecrotic hypoxic regions, induced HIF-1 alpha expression and increased radiation-induced DNA damage. Taken all together, these results indicate that cancer cells in perinecrotic regions, which would be under low-glucose and hypoxic conditions, obtain radioresistance by decreasing the level of both HIF-1 activity and p27(Kip1) expression, and adjusting their cell cycle to the radioresistant S phase. Oncogene (2013) 32, 2058-2068; doi:10.1038/onc.2012.223; published online 18 June 2012	[Zhu, Y.; Zhao, T.; Zeng, L.; Yeom, C. J.; Morinibu, A.; Shinomiya, K.; Harada, H.] Kyoto Univ, Grp Radiat & Tumor Biol, Career Path Promot Unit Young Life Scientists, Kyoto, Japan; [Zhu, Y.; Zhao, T.; Itasaka, S.; Zeng, L.; Ou, G.; Yoshimura, M.; Hiraoka, M.] Kyoto Univ, Dept Radiat Oncol & Image Appl Therapy, Grad Sch Med, Kyoto, Japan; [Zhu, Y.] Chongqing Med Univ, Affiliated Hosp 1, Dept Oncol, Chongqing, Peoples R China; [Zhao, T.; Itasaka, S.] Fourth Mil Med Univ, Dept Radiat Med, Xian, Shaanxi, Peoples R China; [Hirota, K.] Kyoto Univ, Kyoto Univ Hosp, Dept Anesthesia, Kyoto, Japan; [Suzuki, K.] Nagasaki Univ, Grad Sch Biomed Sci, Div Radiat Biol, Dept Radiol & Radiat Biol, Nagasaki 852, Japan	Kyoto University; Kyoto University; Chongqing Medical University; Air Force Military Medical University; Kyoto University; Nagasaki University	Harada, H (corresponding author), Kyoto Univ, Grp Radiat & Tumor Biol, Career Path Promot Unit Young Life Scientists, Sakyo Ku, Yoshida Konoe Cho, Kyoto, Japan.	hharada@kuhp.kyoto-u.ac.jp	; Hirota, Kiichi/E-9181-2010	Yuxi, Zhu/0000-0001-7563-505X; Hirota, Kiichi/0000-0003-1110-0827	Funding Program for NEXT Generation World-Leading Researchers (NEXT Program) from the Japan Society for the Promotion of Science (JSPS), Japan [LS071]; Program for Promotion of Fundamental Studies in Health Science from the National Institute of Biomedical Innovation (NIBIO), Japan [09-25]; Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan [21791184, 22791190]; Sagawa Foundation for the Promotion of Cancer Research; International Science and Technology Cooperation Project of China and Japan [2010DFA31900]; Grants-in-Aid for Scientific Research [24659695] Funding Source: KAKEN	Funding Program for NEXT Generation World-Leading Researchers (NEXT Program) from the Japan Society for the Promotion of Science (JSPS), Japan; Program for Promotion of Fundamental Studies in Health Science from the National Institute of Biomedical Innovation (NIBIO), Japan; Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Sagawa Foundation for the Promotion of Cancer Research; International Science and Technology Cooperation Project of China and Japan; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr Masahiro Inoue for discussions and Dr GL Semenza for the plasmid pcDNA3-HIF-1 alpha-CA, which expresses the constitutively active mutant form of HIF-1 alpha (HIF-1 alpha-CA). This study was supported by the Funding Program for NEXT Generation World-Leading Researchers (NEXT Program) from the Japan Society for the Promotion of Science (JSPS), Japan to HH (No. LS071), by the Program for Promotion of Fundamental Studies in Health Science from the National Institute of Biomedical Innovation (NIBIO), Japan to HH (No. 09-25), by Grants-in-aid for Young Scientists (B) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan to HH (No. 21791184). and SI (No. 22791190), by the Sagawa Foundation for the Promotion of Cancer Research to HH, and by the International Science and Technology Cooperation Project of China and Japan to ZL and HH (No. 2010DFA31900).	Aebersold DM, 2001, CANCER RES, V61, P2911; Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Berra E, 2001, EMBO REP, V2, P615, DOI 10.1093/embo-reports/kve130; Box AH, 2004, CARCINOGENESIS, V25, P2325, DOI 10.1093/carcin/bgh274; BROWN JM, 1993, BRIT J CANCER, V67, P1163, DOI 10.1038/bjc.1993.220; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Brown JM, 1998, CANCER RES, V58, P1408; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Chan DA, 2007, CANCER METAST REV, V26, P333, DOI 10.1007/s10555-007-9063-1; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DESCHNER EE, 1959, RADIAT RES, V11, P115, DOI 10.2307/3570739; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Gardner LB, 2001, J BIOL CHEM, V276, P7919, DOI 10.1074/jbc.M010189200; Gorski DH, 1999, CANCER RES, V59, P3374; GRAY LH, 1953, BRIT J RADIOL, V26, P638, DOI 10.1259/0007-1285-26-312-638; Harada H, 2009, BRIT J CANCER, V100, P747, DOI 10.1038/sj.bjc.6604939; Harada H, 2007, BIOCHEM BIOPH RES CO, V360, P791, DOI 10.1016/j.bbrc.2007.06.149; Harada H, 2005, MOL IMAGING, V4, P182; Harada H, 2006, FEBS LETT, V580, P5718, DOI 10.1016/j.febslet.2006.09.025; Harada H, 2009, J BIOL CHEM, V284, P5332, DOI 10.1074/jbc.M806653200; Irie Nobuyuki, 2004, Brain Tumor Pathol, V21, P1, DOI 10.1007/BF02482169; Ishikawa H, 2004, INT J RADIAT ONCOL, V60, P513, DOI 10.1016/j.ijrobp.2004.03.025; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kizaka-Kondoh S, 2003, CANCER SCI, V94, P1021, DOI 10.1111/j.1349-7006.2003.tb01395.x; Kizaka-Kondoh S, 2009, CANCER SCI, V100, P1366, DOI 10.1111/j.1349-7006.2009.01195.x; Kizaka-Kondoh S, 2009, ADV DRUG DELIVER REV, V61, P623, DOI 10.1016/j.addr.2009.01.006; Li XC, 2008, CLIN SCI, V114, P591, DOI 10.1042/CS20070257; Liao D, 2007, CANCER METAST REV, V26, P281, DOI 10.1007/s10555-007-9066-y; Moeller BJ, 2004, CELL CYCLE, V3, P1107; Moeller BJ, 2004, CANCER CELL, V5, P429, DOI 10.1016/S1535-6108(04)00115-1; PALCIC B, 1984, RADIAT RES, V100, P328, DOI 10.2307/3576354; Pryde F, 2005, J CELL SCI, V118, P2043, DOI 10.1242/jcs.02336; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 2011, AM J PHYSIOL-CELL PH, V301, pC550, DOI 10.1152/ajpcell.00176.2011; Semenza GL, 2009, SEMIN CANCER BIOL, V19, P12, DOI 10.1016/j.semcancer.2008.11.009; SINCLAIR WK, 1968, RADIAT RES, V33, P620, DOI 10.2307/3572419; Sobhanifar S, 2005, CANCER RES, V65, P7259, DOI 10.1158/0008-5472.CAN-04-4480; Sullivan R, 2007, CANCER METAST REV, V26, P319, DOI 10.1007/s10555-007-9062-2; TERASIMA T, 1963, BIOPHYS J, V3, P11, DOI 10.1016/S0006-3495(63)86801-0; THOMLINSON RH, 1955, BRIT J CANCER, V9, P539, DOI 10.1038/bjc.1955.55; Tomida A, 1999, ANTI-CANCER DRUG DES, V14, P169; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VAUPEL P, 1989, CANCER RES, V49, P6449; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Webb GC, 2002, DIABETES, V51, P398, DOI 10.2337/diabetes.51.2.398; Zeng LH, 2008, CANCER SCI, V99, P2327, DOI 10.1111/j.1349-7006.2008.00943.x	51	21	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 18	2013	32	16					2058	2068		10.1038/onc.2012.223	http://dx.doi.org/10.1038/onc.2012.223			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130LY	22710721	hybrid, Green Published, Green Submitted			2022-12-17	WOS:000317919900007
J	Ishikawa, Y; Hosogane, M; Okuyama, R; Aoyama, S; Onoyama, I; Nakayama, KI; Nakayama, K				Ishikawa, Y.; Hosogane, M.; Okuyama, R.; Aoyama, S.; Onoyama, I.; Nakayama, K. I.; Nakayama, K.			Opposing functions of Fbxw7 in keratinocyte growth, differentiation and skin tumorigenesis mediated through negative regulation of c-Myc and Notch	ONCOGENE			English	Article						ubiquitin ligase; Fbxw7; Notch; c-Myc; keratinocyte	F-BOX PROTEIN; TUMOR-SUPPRESSOR; STEM-CELLS; CYCLIN-E; GENE; DEGRADATION; CANCER; SEL-10; DETERMINANT; PROTEOLYSIS	The tumor suppressor Fbxw7 (also known as Sel-10, hCdc4, hAgo, or Fbw7) is an F-box protein that functions as the substrate-recognition subunit of an SCF ubiquitin ligase complex and targets a group of oncoproteins for degradation. We now show that Fbxw7 regulates the proliferation and differentiation of keratinocytes by mediating the degradation of c-Myc and Notch proteins. Fbxw7-deficient keratinocytes showed an increased proliferative capacity that was dependent on the accumulation of c-Myc but not on that of Notch. Fbxw7 deficiency also resulted in the premature differentiation of keratinocytes in a manner dependent on both c-Myc and Notch. Although Fbxw7-deficient keratinocytes proliferated excessively in vitro, loss of Fbxw7 did not predispose keratinocytes to the formation of squamous cell carcinoma in vivo induced by the expression of oncogenic Ras, possibly because the stem cell population of keratinocytes becomes exhausted as a result of enhanced Notch activity. Indeed, suppression of Notch signaling by additional ablation of RBP-J in Fbxw7-deficient keratinocytes conferred a more aggressive tumorigenic capacity. Collectively, these results indicate that Fbxw7 controls the proliferation and differentiation of keratinocytes, and that it exerts both inhibitory and stimulatory actions in skin carcinogenesis by counteracting the proliferation-promoting effect of c-Myc and the tumor-suppressive effect of Notch, respectively. Oncogene (2013) 32, 1921-1932; doi:10.1038/onc.2012.213; published online 4 June 2012	[Ishikawa, Y.; Hosogane, M.; Aoyama, S.; Nakayama, K.] Tohoku Univ, Grad Sch Med, United Ctr Adv Res & Translat Med, Dept Cell Proliferat, Sendai, Miyagi 9808575, Japan; [Ishikawa, Y.; Hosogane, M.; Aoyama, S.; Onoyama, I.; Nakayama, K. I.; Nakayama, K.] Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama, Japan; [Okuyama, R.] Shinshu Univ, Grad Sch Med, Dept Dermatol, Matsumoto, Nagano 390, Japan; [Onoyama, I.; Nakayama, K. I.] Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 812, Japan	Tohoku University; Japan Science & Technology Agency (JST); Shinshu University; Kyushu University	Nakayama, K (corresponding author), Tohoku Univ, Grad Sch Med, United Ctr Adv Res & Translat Med, Dept Cell Proliferat,Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	nakayak2@med.tohoku.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology of Japan; Global Center of Excellence Program of Japan; Grants-in-Aid for Scientific Research [23591615] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Global Center of Excellence Program of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank T Honjo for Rbpj<SUP>F/F</SUP> mice; IM de Alboran for c-Myc<SUP>F/F</SUP> mice; R Tsunematsu for the NICD1 plasmid; T Kitamura for pMX-puro and Plat-E cells; Y Gotoh for pMX-Cre-SV40-GFP; S Ikawa for the cDNA-encoding H-Ras<SUP>G12V</SUP>; E Ogawa and E Nishimura for technical advice; Y Ono, T Senga and N Yanagihara for technical assistance; and other laboratory members for discussion. This study was supported in part by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and by the Global Center of Excellence Program of Japan.	Akhoondi S, 2007, CANCER RES, V67, P9006, DOI 10.1158/0008-5472.CAN-07-1320; Ang XLL, 2005, ONCOGENE, V24, P2860, DOI 10.1038/sj.onc.1208614; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Babaei-Jadidi R, 2011, J EXP MED, V208, P295, DOI 10.1084/jem.20100830; BARRANDON Y, 1985, P NATL ACAD SCI USA, V82, P5390, DOI 10.1073/pnas.82.16.5390; Benitah SA, 2005, SCIENCE, V309, P933, DOI 10.1126/science.1113579; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; Dotto GP, 2005, SCIENCE, V309, P890, DOI 10.1126/science.1117192; Fuchs E, 2008, J CELL BIOL, V180, P273, DOI 10.1083/jcb.200708185; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Ishikawa Y, 2008, ONCOGENE; Jin JP, 2004, GENE DEV, V18, P2573, DOI 10.1101/gad.1255304; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Koch U, 2007, CELL MOL LIFE SCI, V64, P2746, DOI 10.1007/s00018-007-7164-1; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lefort K, 2007, GENE DEV, V21, P562, DOI 10.1101/gad.1484707; Mandinova A, 2008, EMBO J, V27, P1243, DOI 10.1038/emboj.2008.45; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Masuda K, 2010, ONCOGENE, V29, P1798, DOI 10.1038/onc.2009.469; Matsumoto A, 2011, J BIOL CHEM, V286, P13754, DOI 10.1074/jbc.M110.194936; Matsuoka S, 2008, GENE DEV, V22, P986, DOI 10.1101/gad.1621808; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; MORRIS RJ, 1988, CANCER RES, V48, P6285; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Okuyama R, 2007, ONCOGENE, V26, P4478, DOI 10.1038/sj.onc.1210235; Onoyama I, 2007, J EXP MED, V204, P2875, DOI 10.1084/jem.20062299; Owens DM, 2003, NAT REV CANCER, V3, P444, DOI 10.1038/nrc1096; Perez-Losada J, 2005, CANCER RES, V65, P6488, DOI 10.1158/0008-5472.CAN-05-1294; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Rounbehler RJ, 2001, ONCOGENE, V20, P5341, DOI 10.1038/sj.onc.1204691; Senoo M, 2007, CELL, V129, P523, DOI 10.1016/j.cell.2007.02.045; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Tan Y, 2008, CANC LETT; Tanigakik K, 2002, NAT IMMUNOL, V3, P443, DOI 10.1038/ni793; Tetzlaff MT, 2004, P NATL ACAD SCI USA, V101, P3338, DOI 10.1073/pnas.0307875101; Thompson BJ, 2008, J EXP MED, V205, P1395, DOI 10.1084/jem.20080277; Thompson BJ, 2007, J EXP MED, V204, P1825, DOI 10.1084/jem.20070872; Tsunematsu R, 2004, J BIOL CHEM, V279, P9417, DOI 10.1074/jbc.M312337200; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yu L, 2009, J ONCOL, V2009, DOI 10.1155/2009/780874	49	21	22	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2013	32	15					1921	1932		10.1038/onc.2012.213	http://dx.doi.org/10.1038/onc.2012.213			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126GB	22665065				2022-12-17	WOS:000317599900006
J	Sakamoto, K; Hikiba, Y; Nakagawa, H; Hirata, Y; Hayakawa, Y; Kinoshita, H; Nakata, W; Sakitani, K; Takahashi, R; Akanuma, M; Kamata, H; Maeda, S				Sakamoto, K.; Hikiba, Y.; Nakagawa, H.; Hirata, Y.; Hayakawa, Y.; Kinoshita, H.; Nakata, W.; Sakitani, K.; Takahashi, R.; Akanuma, M.; Kamata, H.; Maeda, S.			Promotion of DNA repair by nuclear IKK beta phosphorylation of ATM in response to genotoxic stimuli	ONCOGENE			English	Article						IKK beta; ATM; NF-kappa B; DNA damage	NF-KAPPA-B; ACTIVATION IN-VIVO; DAMAGE RESPONSE; KINASE IKK; AUTOPHOSPHORYLATION SITES; ATAXIA-TELANGIECTASIA; MASS-SPECTROMETRY; STRAND BREAKS; STRESS; CANCER	Ataxia-telangiectasia mutated (ATM) is one of the key molecules involved in the cellular response to DNA damage. A portion of activated ATM is exported from the nucleus into the cytoplasm, where it activates the I kappa B kinase/nuclear factor kappa B (IKK/NF-kappa B) signaling pathway. It has been thought that activated IKK beta, which is a critical kinase for NF-kappa B activation, generally resides in the cytoplasm and phosphorylates cytoplasmic downstream molecules, such as IkB alpha. Here, we identified a new role for IKK beta during the response to DNA damage. ATM phosphorylation in response to alkylating agents consisted of two phases: the early phase (up to 3 h) and late phase (after 6 h). A portion of the activated IKK beta generated during the DNA damage response was found to translocate into the nucleus and directly phosphorylate ATM in the late phase. Furthermore, the phosphorylation of ATM by nuclear IKK beta was suggested to promote DNA repair. In parallel, activated IKK beta induced classical NF-kappa B activation and was involved in anti-apoptosis. Our findings define the function of IKK beta during the response to DNA damage, which promotes cell survival and DNA repair, and maintains cellular homeostasis. Oncogene (2013) 32, 1854-1862; doi: 10.1038/onc.2012.192; published online 21 May 2012	[Sakamoto, K.; Hikiba, Y.; Akanuma, M.] Asahi Life Fdn, Inst Adult Dis, Div Gastroenterol, Tokyo, Japan; [Nakagawa, H.; Hirata, Y.; Hayakawa, Y.; Kinoshita, H.; Nakata, W.; Sakitani, K.; Takahashi, R.] Univ Tokyo, Dept Gastroenterol, Tokyo, Japan; [Kamata, H.] Hiroshima Univ, Grad Sch Biomed Sci, Lab Biomed Chem, Dept Mol Med Sci, Hiroshima, Japan; [Maeda, S.] Yokohama City Univ, Dept Gastroenterol, Yokohama, Kanagawa 2360004, Japan	Asahi Life Foundation; University of Tokyo; Hiroshima University; Yokohama City University	Maeda, S (corresponding author), Yokohama City Univ, Dept Gastroenterol, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.	shinmaeda2-gi@umin.ac.jp	Kamata, Hideaki/N-3907-2017; Hayakawa, Yoku/AAI-8581-2020; Nakagawa, Hayato/I-2837-2012	Hayakawa, Yoku/0000-0002-3988-2499; Nakagawa, Hayato/0000-0002-6973-5094; Sakitani, Kosuke/0000-0002-4537-6023	Ministry of Education, Culture, Sports, Science and Technology of Japan [22300317]; Naito Foundation; Grants-in-Aid for Scientific Research [22300317] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Naito Foundation(Naito Memorial Foundation); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We are grateful to Dr Yosef Shiloh for providing us with the ATM-encoding plasmid. SM was supported by grants-in-aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan (22300317) and Naito Foundation.	Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Biton S, 2011, CELL, V145, P92, DOI 10.1016/j.cell.2011.02.023; CHAN JYH, 1983, CARCINOGENESIS, V4, P1097, DOI 10.1093/carcin/4.9.1097; Chou WC, 2008, EMBO J, V27, P3140, DOI 10.1038/emboj.2008.229; Daniel JA, 2008, J CELL BIOL, V183, P777, DOI 10.1083/jcb.200805154; Debiak M, 2004, DNA REPAIR, V3, P359, DOI 10.1016/j.dnarep.2003.11.013; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Golding SE, 2009, MOL CANCER THER, V8, P2894, DOI 10.1158/1535-7163.MCT-09-0519; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Guo Z, 2010, SCIENCE, V330, P517, DOI 10.1126/science.1192912; Hayakawa Y, 2009, J GASTROENTEROL, V44, P935, DOI 10.1007/s00535-009-0098-7; Hegde ML, 2008, CELL RES, V18, P27, DOI 10.1038/cr.2008.8; Hinz M, 2010, MOL CELL, V40, P63, DOI 10.1016/j.molcel.2010.09.008; Hirata Y, 2006, INFECT IMMUN, V74, P1452, DOI 10.1128/IAI.74.3.1452-1461.2006; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kenneth NS, 2010, EMBO J, V29, P2966, DOI 10.1038/emboj.2010.171; Kim YC, 2009, NAT CELL BIOL, V11, P92, DOI 10.1038/ncb1817; Kozlov SV, 2006, EMBO J, V25, P3504, DOI 10.1038/sj.emboj.7601231; Kurz EU, 2004, J BIOL CHEM, V279, P53272, DOI 10.1074/jbc.M406879200; Landvik NE, 2010, MUTAT RES-FUND MOL M, V684, P11, DOI 10.1016/j.mrfmmm.2009.11.004; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Maeda S, 2008, CANCER SCI, V99, P836, DOI 10.1111/j.1349-7006.2008.00763.x; Maeda S, 2009, HEPATOLOGY, V50, P1851, DOI 10.1002/hep.23199; Masutani M, 2000, MUTAT RES-REV MUTAT, V462, P159, DOI 10.1016/S1383-5742(00)00033-8; MEYN MS, 1995, CANCER RES, V55, P5991; Miyamoto S, 2011, CELL RES, V21, P116, DOI 10.1038/cr.2010.179; Palmieri D, 2011, ONCOGENE, V30, P3024, DOI 10.1038/onc.2011.21; Pellegrini M, 2006, NATURE, V443, P222, DOI 10.1038/nature05112; Pusapati RV, 2006, P NATL ACAD SCI USA, V103, P1446, DOI 10.1073/pnas.0507367103; Roberts KP, 2006, CHEM RES TOXICOL, V19, P300, DOI 10.1021/tx0502589; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Sakamoto K, 2010, GASTROENTEROLOGY, V139, P226, DOI 10.1053/j.gastro.2010.03.047; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; So SR, 2009, J CELL BIOL, V187, P977, DOI 10.1083/jcb.200906064; Stern N, 2002, J BIOL CHEM, V277, P602, DOI 10.1074/jbc.M106798200; Stilmann M, 2009, MOL CELL, V36, P365, DOI 10.1016/j.molcel.2009.09.032; Taricani L, 2009, CELL CYCLE, V8, P482, DOI 10.4161/cc.8.3.7661; Tice RR, 2000, ENVIRON MOL MUTAGEN, V35, P206, DOI 10.1002/(SICI)1098-2280(2000)35:3<206::AID-EM8>3.0.CO;2-J; Tsuchiya Y, 2010, MOL CELL, V39, P570, DOI 10.1016/j.molcel.2010.07.030; Wong YH, 2007, NUCLEIC ACIDS RES, V35, pW588, DOI 10.1093/nar/gkm322; Wu LX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018447; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Wu ZH, 2010, MOL CELL, V40, P75, DOI 10.1016/j.molcel.2010.09.010; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou XF, 2005, ANAL BIOCHEM, V343, P84, DOI 10.1016/j.ab.2005.05.007	51	21	22	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2013	32	14					1854	1862		10.1038/onc.2012.192	http://dx.doi.org/10.1038/onc.2012.192			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	118RQ	22614018				2022-12-17	WOS:000317043900011
J	Angus, SP; Nevins, JR				Angus, S. P.; Nevins, J. R.			A role for Mediator complex subunit MED13L in Rb/E2F-induced growth arrest	ONCOGENE			English	Article						tumor suppressor; cell cycle; senescence	RETINOBLASTOMA TUMOR-SUPPRESSOR; CELL-CYCLE ARREST; ONCOGENE-INDUCED SENESCENCE; IN-VIVO; S-PHASE; TRANSCRIPTIONAL REGULATION; TARGET GENES; C/EBP-BETA; ZNF217; PROTEIN	The Rb/E2F pathway is deregulated in virtually all human tumors. It is clear that, in addition to Rb itself, essential cofactors required for transcriptional repression and silencing of E2F target genes are mutated or lost in cancer. To identify novel cofactors required for Rb/E2F-mediated inhibition of cell proliferation, we performed a genome-wide short hairpin RNA screen. In addition to several known Rb cofactors, the screen identified components of the Mediator complex, a large multiprotein coactivator required for RNA polymerase II transcription. We show that the Mediator complex subunit MED13L is required for Rb/E2F control of cell growth, the complete repression of cell cycle target genes, and cell cycle inhibition.	[Angus, S. P.; Nevins, J. R.] Duke Univ, Med Ctr, Duke Inst Genome Sci & Policy, Durham, NC 27710 USA	Duke University	Nevins, JR (corresponding author), Duke Univ, Med Ctr, Duke Inst Genome Sci & Policy, Durham, NC 27710 USA.	j.nevins@duke.edu		Angus, Steven/0000-0002-7655-657X	National Cancer Institute Integrative Cancer Biology Program via grant National Institutes of Health [5-U54-CA112952]; NIH [F32CA113177]; NATIONAL CANCER INSTITUTE [U54CA112952, R01CA104663, F32CA113177] Funding Source: NIH RePORTER	National Cancer Institute Integrative Cancer Biology Program via grant National Institutes of Health; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	All aspects of the research were supported under the National Cancer Institute Integrative Cancer Biology Program via grant National Institutes of Health 5-U54-CA112952. SPA was supported by NIH F32CA113177. We thank Lazlo Jakoi for technical assistance and all the members of the Nevins lab for their critical feedback and suggestions. We are grateful to Bernard Mathey-Prevot and Jeffrey Chang for comments on the manuscript. We thank Kaye Culler for assistance in submitting the manuscript. We are grateful to T Kitamura for providing Plat-E and Plat-A retroviral packaging cells, J DeCaprio for providing the T98G-EcoR cells, and E Knudsen for providing the -608Cyclin A-Luc and PSM-Rb plasmids.	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Alexander K, 2001, MOL CELL BIOL, V21, P3616, DOI 10.1128/MCB.21.11.3616-3631.2001; Angus SP, 2004, MOL CELL BIOL, V24, P5404, DOI 10.1128/MCB.24.12.5404-5420.2004; Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Banck MS, 2009, EPIGENETICS-US, V4, P100, DOI 10.4161/epi.4.2.7953; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Conaway RC, 2005, TRENDS BIOCHEM SCI, V30, P250, DOI 10.1016/j.tibs.2005.03.002; Cowger JJM, 2007, ONCOGENE, V26, P3378, DOI 10.1038/sj.onc.1210126; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ding N, 2008, MOL CELL, V31, P347, DOI 10.1016/j.molcel.2008.05.023; Donner AJ, 2007, MOL CELL, V27, P121, DOI 10.1016/j.molcel.2007.05.026; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Firestein R, 2008, NATURE, V455, P547, DOI 10.1038/nature07179; Greider Carol W., 2004, Cell, VS116, pS83, DOI 10.1016/S0092-8674(04)00053-4; Ha L, 2007, P NATL ACAD SCI USA, V104, P10968, DOI 10.1073/pnas.0611638104; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Huang GQ, 2005, HUM MOL GENET, V14, P3219, DOI 10.1093/hmg/ddi352; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; Knuesel MT, 2009, GENE DEV, V23, P439, DOI 10.1101/gad.1767009; Kornberg RD, 2005, TRENDS BIOCHEM SCI, V30, P235, DOI 10.1016/j.tibs.2005.03.011; Krig SR, 2007, J BIOL CHEM, V282, P9703, DOI 10.1074/jbc.M611752200; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Malik S, 2010, NAT REV GENET, V11, P761, DOI 10.1038/nrg2901; Medina PP, 2008, EPIGENETICS-US, V3, P64, DOI 10.4161/epi.3.2.6153; Meloni AR, 2005, MOL CANCER RES, V3, P575, DOI 10.1158/1541-7786.MCR-05-0088; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Mo XM, 2004, MOL CELL, V13, P241, DOI 10.1016/S1097-2765(03)00521-5; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Morris EJ, 2008, NATURE, V455, P552, DOI 10.1038/nature07310; Muncke N, 2003, CIRCULATION, V108, P2843, DOI 10.1161/01.CIR.0000103684.77636.CD; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nonet GH, 2001, CANCER RES, V61, P1250; Prieur A, 2008, CURR OPIN CELL BIOL, V20, P150, DOI 10.1016/j.ceb.2008.01.007; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Quinlan KGR, 2007, BBA-REV CANCER, V1775, P333, DOI 10.1016/j.bbcan.2007.05.001; Quinlan KGR, 2006, MOL CELL BIOL, V26, P8159, DOI 10.1128/MCB.00680-06; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Sato S, 2004, MOL CELL, V14, P685, DOI 10.1016/j.molcel.2004.05.006; Sebastian T, 2005, EMBO J, V24, P3301, DOI 10.1038/sj.emboj.7600789; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Sever-Chroneos Z, 2001, MOL CELL BIOL, V21, P4032, DOI 10.1128/MCB.21.12.4032-4045.2001; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Sun G, 2008, INT J ONCOL, V32, P1065; Wang L, 2008, GENETICS, V180, P269, DOI 10.1534/genetics.108.092478; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weissman B, 2009, CANCER RES, V69, P8223, DOI 10.1158/0008-5472.CAN-09-2166; Wolyniec K, 2009, ONCOGENE, V28, P2502, DOI 10.1038/onc.2009.101; Yang H, 2002, MOL CELL BIOL, V22, P3103, DOI 10.1128/MCB.22.9.3103-3110.2002; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	62	21	21	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	44					4709	4717		10.1038/onc.2011.622	http://dx.doi.org/10.1038/onc.2011.622			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032MW	22249253	Green Accepted			2022-12-17	WOS:000310724400006
J	Bock, FJ; Peintner, L; Tanzer, M; Manzl, C; Villunger, A				Bock, F. J.; Peintner, L.; Tanzer, M.; Manzl, C.; Villunger, A.			P53-induced protein with a death domain (PIDD): master of puppets?	ONCOGENE			English	Review						PIDD; Caspase-2; RAIDD; p53; NF kappa B	NF-KAPPA-B; DNA-DAMAGE RESPONSE; GENOTOXIC STRESS; CASPASE-2 ACTIVATION; TUMOR SUPPRESSION; INDUCED APOPTOSIS; FEEDBACK LOOP; P53; CANCER; ATM	P53-induced protein with a death domain (PIDD) has been described as primary p53 target gene, induced upon DNA damage. More than 10 years after its discovery, its physiological role in the DNA damage response remains enigmatic, as it seems to be able to execute life-death decisions in vitro, yet genetic ablation in mice failed to reveal an obvious phenotype. Nonetheless, evidence is accumulating that it contributes to the fine-tuning of the DNA-damage response by orchestrating critical processes such as caspase activation or nuclear factor kappa B translocation and can also exert additional nuclear functions, for example, the modulation of translesion synthesis. In this review, we aim to integrate these observations and propose possible unexplored functions of PIDD.	[Bock, F. J.; Peintner, L.; Tanzer, M.; Manzl, C.; Villunger, A.] Innsbruck Med Univ, Bioctr, Div Dev Immunol, A-6020 Innsbruck, Austria	Medical University of Innsbruck	Villunger, A (corresponding author), Innsbruck Med Univ, Bioctr, Div Dev Immunol, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	Andreas.Villunger@i-med.ac.at		Peintner, Lukas/0000-0002-0445-1445; Bock, Florian/0000-0002-1133-1767	Austrian Science Fund (FWF) [Y212-B12, SFB021]; EU-FP6 RTN 'Apoptrain'; Tyrolean Science Fund (TWF); 'Krebshilfe-Tirol'	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); EU-FP6 RTN 'Apoptrain'; Tyrolean Science Fund (TWF); 'Krebshilfe-Tirol'	This review is dedicated to the late Jurg Tschopp, who spearheaded research on PIDD, a great scientist, colleague and mentor. Research on PIDD in our laboratory is supported by grants from the Austrian Science Fund (FWF; Y212-B12 and SFB021), EU-FP6 RTN 'Apoptrain', the Tyrolean Science Fund (TWF) and the 'Krebshilfe-Tirol'.	Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Berube C, 2005, P NATL ACAD SCI USA, V102, P14314, DOI 10.1073/pnas.0506475102; Bradley G, 2007, BRIT J CANCER, V96, P1425, DOI 10.1038/sj.bjc.6603745; Cuenin S, 2008, ONCOGENE, V27, P387, DOI 10.1038/sj.onc.1210635; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Grosjean-Raillard J, 2009, ONCOGENE, V28, P1099, DOI 10.1038/onc.2008.457; Hasegawa H, 2011, LEUKEMIA, V25, P575, DOI 10.1038/leu.2010.315; Hayden MS, 2006, ONCOGENE, V25, P6758, DOI 10.1038/sj.onc.1209943; Heinen CD, 2002, CANCER BIOL THER, V1, P477, DOI 10.4161/cbt.1.5.160; Heinz LX, 2012, CELL DEATH DIFFER, V19, P722, DOI 10.1038/cdd.2011.147; Hinz M, 2010, MOL CELL, V40, P63, DOI 10.1016/j.molcel.2010.09.008; Ho LH, 2008, ONCOGENE, V27, P3393, DOI 10.1038/sj.onc.1211005; Ho LH, 2009, P NATL ACAD SCI USA, V106, P5336, DOI 10.1073/pnas.0811928106; Huang L, 2011, BIOCHEM BIOPH RES CO, V407, P86, DOI 10.1016/j.bbrc.2011.02.114; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Janssens S, 2006, CELL DEATH DIFFER, V13, P773, DOI 10.1038/sj.cdd.4401843; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Jin HS, 2009, CANCER RES, V69, P1782, DOI 10.1158/0008-5472.CAN-08-2256; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kerley-Hamilton JS, 2005, ONCOGENE, V24, P6090, DOI 10.1038/sj.onc.1208755; Kim IR, 2009, APOPTOSIS, V14, P1039, DOI 10.1007/s10495-009-0375-1; Krumschnabel G, 2009, CELL DEATH DIFFER, V16, P195, DOI 10.1038/cdd.2008.170; Lee MH, 2011, MOL CELL, V43, P180, DOI 10.1016/j.molcel.2011.06.017; Li J, 2008, ONCOGENE, V27, P6194, DOI 10.1038/onc.2008.297; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Logette E, 2011, CELL DEATH DIFFER, V18, P1036, DOI 10.1038/cdd.2011.19; Mabb AM, 2006, NAT CELL BIOL, V8, P986, DOI 10.1038/ncb1458; Manzl C, 2009, J CELL BIOL, V185, P291, DOI 10.1083/jcb.200811105; Meek DW, 2009, NAT REV CANCER, V9, P714, DOI 10.1038/nrc2716; Miyamoto S, 2011, CELL RES, V21, P116, DOI 10.1038/cr.2010.179; Niizuma K, 2008, P NATL ACAD SCI USA, V105, P16368, DOI 10.1073/pnas.0806222105; Oliver TG, 2011, MOL CELL, V43, P57, DOI 10.1016/j.molcel.2011.06.012; Oliver TG, 2010, GENE DEV, V24, P837, DOI 10.1101/gad.1897010; Olsson A, 2007, CELL DEATH DIFFER, V14, P1561, DOI 10.1038/sj.cdd.4402196; Olsson M, 2009, ONCOGENE, V28, P1949, DOI 10.1038/onc.2009.36; Pick R, 2006, BIOCHEM BIOPH RES CO, V349, P1329, DOI 10.1016/j.bbrc.2006.08.176; Pop C, 2009, J BIOL CHEM, V284, P21777, DOI 10.1074/jbc.R800084200; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Rosenblum JS, 1999, P NATL ACAD SCI USA, V96, P11370, DOI 10.1073/pnas.96.20.11370; Sidi S, 2008, CELL, V133, P864, DOI 10.1016/j.cell.2008.03.037; Sohn D, 2011, CELL DEATH DIFFER, V18, P1664, DOI 10.1038/cdd.2011.34; Stilmann M, 2009, MOL CELL, V36, P365, DOI 10.1016/j.molcel.2009.09.032; Telliez JB, 2000, BBA-PROTEIN STRUCT M, V1478, P280, DOI 10.1016/S0167-4838(00)00029-7; Tinel A, 2011, CELL DEATH DIFFER, V18, P506, DOI 10.1038/cdd.2010.124; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tinel A, 2007, EMBO J, V26, P197, DOI 10.1038/sj.emboj.7601473; Vakifahmetoglu H, 2006, ONCOGENE, V25, P5683, DOI 10.1038/sj.onc.1209569; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Wu ZH, 2010, MOL CELL, V40, P75, DOI 10.1016/j.molcel.2010.09.010; Yang YB, 2011, MOL CELL BIOL, V31, P2774, DOI 10.1128/MCB.01139-10	53	21	21	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	45					4733	4739		10.1038/onc.2011.639	http://dx.doi.org/10.1038/onc.2011.639			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036NF	22266869	Green Accepted			2022-12-17	WOS:000311033000001
J	Zheng, ZY; Cheng, CM; Fu, XR; Chen, LY; Xu, L; Terrillon, S; Wong, ST; Bar-Sagi, D; Songyang, Z; Chang, EC				Zheng, Z-Y; Cheng, C-M; Fu, X-R; Chen, L-Y; Xu, L.; Terrillon, S.; Wong, S. T.; Bar-Sagi, D.; Songyang, Z.; Chang, E. C.			CHMP6 and VPS4A mediate the recycling of Ras to the plasma membrane to promote growth factor signaling	ONCOGENE			English	Article						signal transduction; tumorigenesis; trafficking; ESCRT-III	ENDOPLASMIC-RETICULUM; RECEPTOR ENDOCYTOSIS; LIVING CELLS; H-RAS; PROTEINS; TRAFFICKING; BINDING; RIN1; UBIQUITINATION; SEGREGATION	While Ras is well-known to function on the plasma membrane (PM) to mediate growth factor signaling, increasing evidence suggests that Ras has complex roles in the cytoplasm. To uncover these roles, we screened a cDNA library and isolated H-Ras-binding proteins that also influence Ras functions. Many isolated proteins regulate trafficking involving endosomes; CHMP6/VPS20 and VPS4A, which interact with ESCRT-III (Endosomal Sorting Complex Required for Transport-III), were chosen for further study. We showed that the binding is direct and occurs in endosomes. Furthermore, the binding is most efficient when H-Ras has a functional effector-binding loop, and is GTP-bound and ubiquitylated. CHMP6 and VPS4A also bound to N-Ras but not K-Ras. Repressing CHMP6 and VPS4A blocked Ras-induced transformation, which correlated with inefficient Ras localization to the PM as measured by cell fractionation and photobleaching. Moreover, silencing CHMP6 and VPS4A also blocked epidermal growth factor receptor (EGFR) recycling. These data suggest that Ras interacts with key ESCRT-III components to promote recycling of itself and EGFR back to the PM to create a positive feedback loop to enhance growth factor signaling.	[Cheng, C-M; Chang, E. C.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Chen, L-Y; Songyang, Z.] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Xu, L.; Terrillon, S.; Bar-Sagi, D.] NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; [Wong, S. T.] Methodist Hosp, Res Inst, Dept Syst Med & Bioengn, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; New York University; The Methodist Hospital System; The Methodist Hospital - Houston	Chang, EC (corresponding author), Baylor Coll Med, Lester & Sue Smith Breast Ctr, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	echang1@bcm.tmc.edu	Chen, Liuh-Yow/AAA-3963-2021	Chen, Liuh-Yow/0000-0002-9857-068X; Bar-Sagi, Dafna/0000-0003-2597-8948	Susan G Komen for the Cure Foundation [PDF0707860]; Human Frontier Science Program [LT00147/2005]; NIH [U54CA149169, CA133249, GM081627, CA90464, CA107187, GM81627, P50-CA58183]; NATIONAL CANCER INSTITUTE [P50CA058183, R01CA090464, K99CA149169, R01CA133249, R01CA055360, R01CA107187, R00CA149169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM095599, P01GM081627] Funding Source: NIH RePORTER	Susan G Komen for the Cure Foundation(Susan G. Komen Breast Cancer Foundation); Human Frontier Science Program(Human Frontier Science Program); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Gary Chamness and Evelin Young for thoughtfully reading the manuscript. We are particularly grateful for the generosity of Wesley Sundquist, Mark Philips and Juan Bonifacino for providing many reagents and for sharing unpublished results that are critical for this study. Z-Y Z is supported by a postdoctoral fellowship from the Susan G Komen for the Cure Foundation (PDF0707860). ST was supported by a fellowship from Human Frontier Science Program (LT00147/2005). STW is supported by a grant from NIH (U54CA149169). ZS is a Leukemia and Lymphoma Society Scholar and is supported by grants from NIH (CA133249 and GM081627). ECC is supported by grants from NIH (CA90464, CA107187, GM81627 and P50-CA58183).	Balbis A, 2007, ENDOCRINOLOGY, V148, P2944, DOI 10.1210/en.2006-1674; Baldys A, 2009, BIOCHEMISTRY-US, V48, P9321, DOI 10.1021/bi900865u; Barbieri MA, 2003, J BIOL CHEM, V278, P32027, DOI 10.1074/jbc.M304324200; Belgareh-Touze N, 2002, MOL BIOL CELL, V13, P1694, DOI 10.1091/mbc.01-12-0597; Castle A, 2005, J CELL SCI, V118, P3769, DOI 10.1242/jcs.02503; Chang EC, 2006, CELL CYCLE, V5, P1936, DOI 10.4161/cc.5.17.3187; Chen LY, 2007, MOL CELL BIOL, V27, P5898, DOI 10.1128/MCB.00603-07; Cheng CM, 2011, CELL CYCLE, V10, P1180, DOI 10.4161/cc.10.8.15259; Cheng CM, 2011, MOL CELL BIOL, V31, P983, DOI 10.1128/MCB.00137-10; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; Fehrenbacher N, 2009, MOL ONCOL, V3, P297, DOI 10.1016/j.molonc.2009.06.004; Gurskaya NG, 2006, NAT BIOTECHNOL, V24, P461, DOI 10.1038/nbt1191; Han LM, 1997, P NATL ACAD SCI USA, V94, P4954, DOI 10.1073/pnas.94.10.4954; Howard TL, 2001, J CELL SCI, V114, P2395; Huang JR, 2007, J MOL BIOL, V370, P356, DOI 10.1016/j.jmb.2007.04.039; Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552; Jura N, 2006, MOL CELL, V21, P679, DOI 10.1016/j.molcel.2006.02.011; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kerppola TK, 2008, METHOD CELL BIOL, V85, P431, DOI 10.1016/S0091-679X(08)85019-4; Lamesch P, 2007, GENOMICS, V89, P307, DOI 10.1016/j.ygeno.2006.11.012; Leifer CA, 2004, J IMMUNOL, V173, P1179, DOI 10.4049/jimmunol.173.2.1179; Lu A, 2009, J CELL BIOL, V184, P863, DOI 10.1083/jcb.200807186; Morita E, 2010, P NATL ACAD SCI USA, V107, P12889, DOI 10.1073/pnas.1005938107; Nebl G, 2004, CELL SIGNAL, V16, P235, DOI 10.1016/S0898-6568(03)00133-5; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Raiborg C, 2008, EXP CELL RES, V314, P801, DOI 10.1016/j.yexcr.2007.10.014; Raiborg C, 2009, NATURE, V458, P445, DOI 10.1038/nature07961; Roy S, 2002, MOL CELL BIOL, V22, P5128, DOI 10.1128/MCB.22.14.5128-5140.2002; Rual JF, 2004, GENOME RES, V14, P2128, DOI 10.1101/gr.2973604; Sasaki AT, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001518; Su Y, 2007, CANCER BIOL THER, V6, P202, DOI 10.4161/cbt.6.2.3628; Tall GG, 2001, DEV CELL, V1, P73, DOI 10.1016/S1534-5807(01)00008-9; Wakana Y, 2005, BIOCHEM BIOPH RES CO, V334, P1198, DOI 10.1016/j.bbrc.2005.07.012; Wouters FS, 2001, TRENDS CELL BIOL, V11, P203, DOI 10.1016/S0962-8924(01)01982-1; Xu LZ, 2010, CURR BIOL, V20, P1372, DOI 10.1016/j.cub.2010.06.051; Yan H, 2010, CURR BIOL, V20, P1378, DOI 10.1016/j.cub.2010.06.058	37	21	21	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2012	31	43					4630	4638		10.1038/onc.2011.607	http://dx.doi.org/10.1038/onc.2011.607			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029WP	22231449	Green Accepted			2022-12-17	WOS:000310528200006
J	Sugihara, E; Shimizu, T; Kojima, K; Onishi, N; Kai, K; Ishizawa, J; Nagata, K; Hashimoto, N; Honda, H; Kanno, M; Miwa, M; Okada, S; Andreeff, M; Saya, H				Sugihara, E.; Shimizu, T.; Kojima, K.; Onishi, N.; Kai, K.; Ishizawa, J.; Nagata, K.; Hashimoto, N.; Honda, H.; Kanno, M.; Miwa, M.; Okada, S.; Andreeff, M.; Saya, H.			Ink4a and Arf are crucial factors in the determination of the cell of origin and the therapeutic sensitivity of Myc-induced mouse lymphoid tumor	ONCOGENE			English	Article						Myc; cell of origin; Ink4a; Arf; pre-B ALL/LBL; Mdm2 inhibitor	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; C-MYC; STEM-CELL; SELF-RENEWAL; APOPTOSIS; P53; OVEREXPRESSION; SUPPRESSION; MDM2	The cell of origin of tumors and the factors determining the cell of origin remain unclear. In this study, a mouse model of precursor B acute lymphoblastic leukemia/lymphoma (pre-B ALL/LBL) was established by retroviral transduction of Myc genes (N-Myc or c-Myc) into mouse bone marrow cells. Hematopoietic stem cells (HSCs) exhibited the highest susceptibility to N-Myc-induced pre-B ALL/LBL versus lymphoid progenitors, myeloid progenitors and committed progenitor B cells. N-Myc was able to induce pre-B ALL/LBL directly from progenitor B cells in the absence of Ink4a and Arf. Arf was expressed higher in progenitor B cells than Ink4a. In addition, N-Myc induced pre-B ALL/LBL from Arf(-/-) progenitor B cells suggesting that Arf has a predominant role in determining the cell of origin of pre-B ALL/LBL. Tumor cells derived from Ink4a/Arf(-/-) progenitor B cells exhibited a higher rate of proliferation and were more chemoresistant than those derived from wild-type HSCs. Furthermore, the Mdm2 inhibitor Nutlin-3 restored p53 and induced massive apoptosis in mouse pre-B ALL/LBL cells derived from Ink4a/Arf(-/-) cells and human B-ALL cell lines lacking Ink4a and Arf expression, suggesting that Mdm2 inhibition may be a novel therapeutic approach to the treatment of Ink4a/Arf(-/-) B-ALL/LBL, such as is frequently found in Ph+ ALL and relapsed ALL. Collectively, these findings indicate that Ink4a and Arf are critical determining factors of the cell of origin and the therapeutic sensitivity of Myc-induced lymphoid tumors. Oncogene (2012) 31, 2849-2861; doi:10.1038/onc.2011.462; published online 10 October 2011	[Saya, H.] Keio Univ, Div Gene Regulat, Inst Adv Med Res, Sch Med,Shinjuku Ku, Tokyo 1608582, Japan; [Sugihara, E.; Shimizu, T.; Saya, H.] CREST, Japan Sci & Technol Agcy, Tokyo, Japan; [Kojima, K.; Andreeff, M.] Univ Texas Houston, MD Anderson Canc Ctr, Sect Mol Hematol & Therapy, Dept Leukemia, Houston, TX 77030 USA; [Nagata, K.] Kyowa Hakko Kirin Co Ltd, Drug Discovery Res Labs, Shizuoka, Japan; [Honda, H.] Hiroshima Univ, Dept Dis Model, Res Inst Radiat Biol & Med, Hiroshima, Japan; [Kanno, M.] Hiroshima Univ, Dept Immunol, Grad Sch Biosci, Hiroshima, Japan; [Miwa, M.] Nagahama Inst Bio Sci & Technol, Shiga, Japan; [Okada, S.] Kumamoto Univ, Div Hemopoiesis, Ctr AIDS Res, Kumamoto, Japan	Keio University; Japan Science & Technology Agency (JST); University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; Kyowa Kirin Ltd; Hiroshima University; Hiroshima University; Kumamoto University	Saya, H (corresponding author), Keio Univ, Div Gene Regulat, Inst Adv Med Res, Sch Med,Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.	hsaya@a5.keio.jp	Okada, Seiji/F-5785-2013; Hashimoto, Norisato/J-5922-2013; Sugihara, Eiji/J-8058-2013; ONISHI, Nobuyuki/L-6296-2013; Saya, Hideyuki/J-4325-2013	Sugihara, Eiji/0000-0002-3233-1045; Saya, Hideyuki/0000-0001-6610-1902; Kanno, masamoto/0000-0001-9169-3444	NIH; Hoffmann-La Roche, Nutley, NJ; Ministry of Education, Culture, Sports, Science and Technology of Japan; US National Institutes of Health [CA55164, CA136411, CA100632]; NATIONAL CANCER INSTITUTE [P50CA136411, P30CA016672, P01CA055164, P50CA100632] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [23616003] Funding Source: KAKEN	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Hoffmann-La Roche, Nutley, NJ; Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Dr Andreeff's work is supported by grants from the NIH and by Hoffmann-La Roche, Nutley, NJ.; We thank I Ishimatsu, Y Hata and S Suzuki for technical assistance, K Arai for help in the preparation of the manuscript, CJ Sherr (St Jude Children's Research Hospital) for providing Arf<SUP>-/-</SUP> mice, Dr A Kenny (Memorial Sloan-Kettering Cancer Center) for providing the N-Myc cDNA, Dr T Kitamura (The University of Tokyo) for providing the retroviral vector pMXs-IG and Plat-E cells and Dr A Iwama (Chiba University) for providing the Bmi1 cDNA. This work was supported by grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (HS) and the US National Institutes of Health CA55164, CA136411 and CA100632 (MA).	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Ausserlechner MJ, 2001, J BIOL CHEM, V276, P10984, DOI 10.1074/jbc.M008188200; Calabretta B, 2004, BLOOD, V103, P4010, DOI 10.1182/blood-2003-12-4111; Cano F, 2008, MOL CANCER THER, V7, P730, DOI 10.1158/1535-7163.MCT-07-2032; Cardone M, 2005, MOL CELL BIOL, V25, P2395, DOI 10.1128/MCB.25.6.2395-2405.2005; Castor A, 2005, NAT MED, V11, P630, DOI 10.1038/nm1253; Cobaleda C, 2000, BLOOD, V95, P1007, DOI 10.1182/blood.V95.3.1007.003k35_1007_1013; Cobaleda C, 2009, BIOESSAYS, V31, P600, DOI 10.1002/bies.200800234; Cox CV, 2004, BLOOD, V104, P2919, DOI 10.1182/blood-2004-03-0901; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Gu L, 2008, LEUKEMIA, V22, P730, DOI 10.1038/leu.2008.11; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Hong DL, 2008, SCIENCE, V319, P336, DOI 10.1126/science.1150648; Hotfilder M, 2005, CANCER RES, V65, P1442, DOI 10.1158/0008-5472.CAN-04-1356; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Iwama A, 2004, IMMUNITY, V21, P843, DOI 10.1016/j.immuni.2004.11.004; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kawagoe H, 2007, CANCER RES, V67, P10677, DOI 10.1158/0008-5472.CAN-07-1118; Kojima K, 2005, BLOOD, V106, P3150, DOI 10.1182/blood-2005-02-0553; Kojima K, 2006, BLOOD, V108, P993, DOI 10.1182/blood-2005-12-5148; le Viseur C, 2008, CANCER CELL, V14, P47, DOI 10.1016/j.ccr.2008.05.015; Luo H, 2005, BLOOD, V106, P2452, DOI 10.1182/blood-2005-02-0734; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Morse HC, 2002, BLOOD, V100, P246, DOI 10.1182/blood.V100.1.246; Mullighan CG, 2008, SCIENCE, V322, P1377, DOI 10.1126/science.1164266; Mullighan CG, 2008, GENE DEV, V22, P1411, DOI 10.1101/gad.1673908; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Shimizu T, 2010, ONCOGENE, V29, P5687, DOI 10.1038/onc.2010.312; Sugihara E, 2006, CANCER RES, V66, P4020, DOI 10.1158/0008-5472.CAN-05-3250; Tsuji K, 2002, BIOCHEM BIOPH RES CO, V295, P621, DOI 10.1016/S0006-291X(02)00723-4; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; Wang PY, 2008, BLOOD, V112, P4184, DOI 10.1182/blood-2008-02-142190; Wilson A, 2004, GENE DEV, V18, P2747, DOI 10.1101/gad.313104; Yasuda T, 2008, IMMUNITY, V28, P499, DOI 10.1016/j.immuni.2008.02.015	40	21	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	23					2849	2861		10.1038/onc.2011.462	http://dx.doi.org/10.1038/onc.2011.462			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958YW	21986948	Bronze, Green Accepted			2022-12-17	WOS:000305277900005
J	Kim, DS; Choi, YB; Han, BG; Park, SY; Jeon, Y; Kim, DH; Ahn, ER; Shin, JE; Lee, BI; Lee, H; Hong, KM; Kim, SY				Kim, D-S; Choi, Y-B; Han, B-G; Park, S-Y; Jeon, Y.; Kim, D-H; Ahn, E-R; Shin, J-E; Lee, B. I.; Lee, H.; Hong, K-M; Kim, S-Y			Cancer cells promote survival through depletion of the von Hippel-Lindau tumor suppressor by protein crosslinking	ONCOGENE			English	Article						transglutaminase 2; NF-kappa B; von Hippel-Lindau; IGF-1R; HIF-1 alpha; EPO	KAPPA-B ACTIVATION; GROWTH-FACTOR RECEPTOR; BREAST-CANCER; TISSUE TRANSGLUTAMINASE; NECROSIS-FACTOR; DRUG-RESISTANT; FACTOR-I; PATHWAY; EXPRESSION; CARCINOMA	Nuclear factor-kappa B (NF-kappa B) and insulin-like growth factor-1 (IGF-1)-mediated signaling is associated with different tumors including renal cell carcinoma. NF-kappa B- and IGF-1-mediated signaling is found to be inhibited in the presence of wild-type von Hippel-Lindau (VHL) tumor suppresser gene. Therefore, negative regulator of VHL may be a good target for regulating NF-kappa B and IGF-1R. In this study, we found that VHL, a tumor suppressor protein that downregulates the NF-kappa B activity and the stability of IGF-1R was depleted by TGase 2 through polymerization via crosslinking and proteasomal degradation in kidney, breast and ovary cancer cell lines. We also found that TGase 2 knockdown promotes hypoxia-inducible factor 1 alpha (HIF-1 alpha) degradation, and thereby decrease HIF-1 alpha transcriptional activity. Importantly, VHL expression was decreased in vivo in TGase-2-transgenic mice, and this was associated with increased NF-kappa B activity and the levels of expression of IGF-1R, HIF-1 alpha and erythropoietin in kidney tissue. These results suggest a novel mechanism of regulation of the VHL tumor suppressor by TGase 2 that appears to be independent of the known cancer regulatory mechanisms. Oncogene (2011) 30, 4780-4790; doi: 10.1038/onc.2011.183; published online 30 May 2011	[Kim, D-S; Choi, Y-B; Han, B-G; Park, S-Y; Kim, D-H; Ahn, E-R; Shin, J-E; Lee, B. I.; Hong, K-M; Kim, S-Y] Natl Canc Ctr, Canc Cell & Mol Biol Branch, Div Canc Biol, Res Inst, Goyang 410769, Kyunggi Do, South Korea; [Jeon, Y.; Lee, H.] Res Inst, Div Canc Biol, Canc Resources Branch, Goyang, South Korea	National Cancer Center - Korea (NCC)	Kim, SY (corresponding author), Natl Canc Ctr, Canc Cell & Mol Biol Branch, Div Canc Biol, Res Inst, 323 Ilsan Ro, Goyang 410769, Kyunggi Do, South Korea.	kimsooyoul@gmail.com			National Cancer Center in Korea [NCC0810180-1, NCC1110011-1]; National Research Foundation of Korea; Ministry of Education, Science and Technology [20090086078]	National Cancer Center in Korea; National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by a research grant (NCC0810180-1 and NCC1110011-1) from the National Cancer Center in Korea and by Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (no. 20090086078).	Carroll VA, 2006, CANCER RES, V66, P6264, DOI 10.1158/0008-5472.CAN-05-2519; Casa AJ, 2008, FRONT BIOSCI-LANDMRK, V13, P3273, DOI 10.2741/2925; Cowey CL, 2009, CURR ONCOL REP, V11, P94, DOI 10.1007/s11912-009-0015-5; Curtis CD, 2005, METH MOLEC MED, V103, P123; Gangadharan C, 2009, J CELL BIOCHEM, V107, P203, DOI 10.1002/jcb.22115; Herman JF, 2006, ONCOGENE, V25, P3049, DOI 10.1038/sj.onc.1209324; Iismaa SE, 2009, PHYSIOL REV, V89, P991, DOI 10.1152/physrev.00044.2008; Jang GY, 2010, ONCOGENE, V29, P356, DOI 10.1038/onc.2009.342; Jung YJ, 2003, BIOCHEM J, V370, P1011, DOI 10.1042/BJ20021279; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kim DS, 2006, CANCER RES, V66, P10936, DOI 10.1158/0008-5472.CAN-06-1521; Kim DS, 2010, BIOCHEM BIOPH RES CO, V399, P300, DOI 10.1016/j.bbrc.2010.07.078; Kim DS, 2009, FRONT BIOSCI-LANDMRK, V14, P2514, DOI 10.2741/3394; Kim JM, 2008, J MOL BIOL, V384, P756, DOI 10.1016/j.jmb.2008.10.010; Lee JM, 2004, J BIOL CHEM, V279, P53725, DOI 10.1074/jbc.M407627200; Maiuri L, 2008, J IMMUNOL, V180, P7697, DOI 10.4049/jimmunol.180.11.7697; Mehta K, 2004, CLIN CANCER RES, V10, P8068, DOI 10.1158/1078-0432.CCR-04-1107; Otrock ZK, 2009, CRIT REV ONCOL HEMAT, V70, P93, DOI 10.1016/j.critrevonc.2009.01.001; Park KS, 2009, FRONT BIOSCI-LANDMRK, V14, P1945, DOI 10.2741/3354; Park SS, 2006, J BIOL CHEM, V281, P34965, DOI 10.1074/jbc.M604150200; Qi H, 2003, CANCER RES, V63, P7076; Seo JS, 2010, J ETHNOPHARMACOL, V130, P578, DOI 10.1016/j.jep.2010.05.055; Shao MH, 2009, CANCER RES, V69, P9192, DOI 10.1158/0008-5472.CAN-09-1257; Tischoff I, 2008, Z GASTROENTEROL, V46, P1202, DOI 10.1055/s-2008-1027406; Verma A, 2007, DRUG RESIST UPDATE, V10, P144, DOI 10.1016/j.drup.2007.06.002; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; Yuen JSP, 2007, ONCOGENE, V26, P6499, DOI 10.1038/sj.onc.1210474; Yuen JSP, 2009, MOL CANCER THER, V8, P1448, DOI 10.1158/1535-7163.MCT-09-0101	28	21	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2011	30	48					4780	4790		10.1038/onc.2011.183	http://dx.doi.org/10.1038/onc.2011.183			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863AH	21625219				2022-12-17	WOS:000298134700002
J	Uzawa, K; Ishigami, T; Fushimi, K; Kawata, T; Shinozuka, K; Kasamatsu, A; Sakamoto, Y; Ogawara, K; Shiiba, M; Bukawa, H; Ito, H; Tanzawa, H				Uzawa, K.; Ishigami, T.; Fushimi, K.; Kawata, T.; Shinozuka, K.; Kasamatsu, A.; Sakamoto, Y.; Ogawara, K.; Shiiba, M.; Bukawa, H.; Ito, H.; Tanzawa, H.			Targeting fibroblast growth factor receptor 3 enhances radiosensitivity in human squamous cancer cells	ONCOGENE			English	Article						fibroblast growth factor receptor 3 gene; FGFR3; radiosensitivity; squamous cell carcinoma	DIFFERENTIATION; INHIBITION; EXPRESSION	Conventional therapies including radiation therapy cannot cure squamous cell carcinoma (SCC), and new treatments are clearly required. Our recent studies have shown that SCC cell lines exhibiting radioresistance show significant upregulation of the fibroblast growth factor receptor 3 (FGFR3) gene. We hypothesized that inhibiting FGFR3 would suppress tumor cell radioresistance and provide a new treatment approach for human SCCs. In the present study, we found that RNA interference-mediated FGFR3 depletion in HSC-2 cells, a radioresistant cell line, induced radiosensitivity and inhibited tumor growth. Use of an FGFR3 inhibitor (PD173074) obtained similar results with suppression of the autophosphorylation extracellular signal-regulated kinase pathway in HSC-2 cells and lung cancer cell lines. Moreover, the antitumor growth effect of the combination of PD173074 and radiation in vivo was also greater than that with either drug alone or radiation alone. Our results provided novel information on which to base further mechanistic study of radiosensitization by inhibiting FGFR3 in human SCC cells and for developing strategies to improve outcomes with concurrent radiotherapy. Oncogene (2011) 30, 4447-4452; doi:10.1038/onc.2011.159; published online 16 May 2011	[Uzawa, K.] Chiba Univ, Dept Clin Mol Biol, Grad Sch Med, Chuo Ku, Chiba 2608670, Japan; [Uzawa, K.; Kasamatsu, A.; Sakamoto, Y.; Ogawara, K.; Shiiba, M.; Tanzawa, H.] Chiba Univ Hosp, Div Dent Oral & Maxillofacial Surg, Chiba, Japan; [Kawata, T.; Ito, H.] Chiba Univ, Dept Radiol, Grad Sch Med, Chiba 2608670, Japan; [Shinozuka, K.; Bukawa, H.] Univ Tsukuba, Dept Oral & Maxillofacial Surg, Inst Clin Med, Grad Sch Comprehens Human Sci, Ibaraki, Japan	Chiba University; Chiba University; Chiba University; University of Tsukuba	Uzawa, K (corresponding author), Chiba Univ, Dept Clin Mol Biol, Grad Sch Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	uzawak@faculty.chiba-u.jp		Uzawa, Katsuhiro/0000-0002-7036-0859	Ministry of Education, Science, Sports and Culture of Japan [22659364]; Japan Society for Promotion of Science [1952163]; 21st Century Center of Excellence Programs grant;  [19659520]	Ministry of Education, Science, Sports and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); 21st Century Center of Excellence Programs grant; 	We thank Lynda C Charters for proofreading this manuscript. This work was supported by a grant-in-aid from the Ministry of Education, Science, Sports and Culture of Japan (no. 22659364), a grant-in-aid from the Japan Society for Promotion of Science Fellows (1952163), a grant-in-aid for Exploratory Research (19659520) and the 21st Century Center of Excellence Programs grant.	BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; FOWLER JF, 1974, INT J RADIAT BIOL, V25, P213, DOI 10.1080/09553007414550271; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; Henson B J, 2010, Cytogenet Genome Res, V128, P192, DOI 10.1159/000308303; Ishigami T, 2007, INT J CANCER, V120, P2262, DOI 10.1002/ijc.22561; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Knowles MA, 2008, FUTURE ONCOL, V4, P71, DOI 10.2217/14796694.4.1.71; Koziczak M, 2004, ONCOGENE, V23, P3501, DOI 10.1038/sj.onc.1207331; Masih-Khan E, 2006, BLOOD, V108, P3465, DOI 10.1182/blood-2006-04-017087; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; Pardo OE, 2009, CANCER RES, V69, P8645, DOI 10.1158/0008-5472.CAN-09-1576; Rosty C, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-15; Shintani S, 2003, INT J CANCER, V107, P1030, DOI 10.1002/ijc.11437; Studer G, 2007, RADIAT ONCOL, V2, DOI 10.1186/1748-717X-2-16; Toulany M, 2006, CLIN CANCER RES, V12, P4119, DOI 10.1158/1078-0432.CCR-05-2454; Trudel S, 2004, BLOOD, V103, P3521, DOI 10.1182/blood-2003-10-3650	18	21	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2011	30	43					4447	4452		10.1038/onc.2011.159	http://dx.doi.org/10.1038/onc.2011.159			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HQ	21577207				2022-12-17	WOS:000296356500007
J	Zhai, Y; Iura, A; Yeasmin, S; Wiese, AB; Wu, R; Feng, Y; Fearon, ER; Cho, KR				Zhai, Y.; Iura, A.; Yeasmin, S.; Wiese, A. B.; Wu, R.; Feng, Y.; Fearon, E. R.; Cho, K. R.			MSX2 is an oncogenic downstream target of activated WNT signaling in ovarian endometrioid adenocarcinoma	ONCOGENE			English	Article						MSX2; ovarian cancer; endometrioid; WNT signaling; beta-catenin	BETA-CATENIN GENE; CELL FACTOR; NEOPLASTIC TRANSFORMATION; EXPRESSION ANALYSIS; WNT/BETA-CATENIN; HOMEOBOX GENE; UP-REGULATION; CLEAR-CELL; HOX GENES; CARCINOMAS	Ovarian endometrioid adenocarcinomas (OEAs) frequently exhibit constitutive activation of canonical WNT signaling, usually as a result of oncogenic mutations that stabilize and dysregulate the beta-catenin protein. In previous work, we used microarray-based methods to compare gene expression in OEAs with and without dysregulated beta-catenin as a strategy for identifying novel beta-catenin/TCF target genes with important roles in ovarian cancer pathogenesis. Among the genes highlighted by the microarray studies was MSX2, which encodes a homeobox transcription factor. We found MSX2 expression was markedly increased in primary human and murine OEAs with dysregulated beta-catenin compared with OEAs with intact beta-catenin regulation. WNT pathway activation by WNT3a ligand or GSK3b inhibitor treatment potently induced MSX2 and ectopic expression of a dominant negative form of TCF4 inhibited MSX2 expression in ovarian cancer cells. Chromatin immunoprecipitation studies demonstrated that beta-catenin/TCF directly regulates MSX2 expression via binding to TCF binding elements in multiple regions of the MSX2 gene. Notably, ectopic MSX2 expression was found to promote neoplastic transformation of the rodent RK3E model epithelial cell line and to enhance the invasiveness of immortalized human ovarian epithelial cells in vitro and ovarian carcinoma cells in vivo. Inhibition of endogenous MSX2 expression in ovarian endometrioid cancer cells carrying a beta-catenin mutation using shRNA approaches inhibited neoplastic properties of the cells in vitro and in vivo. Expression of MSX2 in selected ovarian carcinoma cells induced changes suggestive of epithelial-mesenchymal transition (EMT), but based on analysis of ovarian cell lines and primary tumor tissues, effects of MSX2 on EMT appear to be complex and context-dependent. Our findings indicate MSX2 is a direct downstream transcriptional target of beta-catenin/TCF and has a key contributing role in the cancer phenotype of OEAs carrying WNT/beta-catenin pathway defects. Oncogene (2011) 30, 4152-4162; doi:10.1038/onc.2011.123; published online 18 April 2011	[Zhai, Y.; Iura, A.; Yeasmin, S.; Wiese, A. B.; Wu, R.; Fearon, E. R.; Cho, K. R.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; [Feng, Y.; Fearon, E. R.; Cho, K. R.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; [Fearon, E. R.] Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; [Fearon, E. R.; Cho, K. R.] Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Cho, KR (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1506 BSRB,109 Zina Pitcher, Ann Arbor, MI 48109 USA.	kathcho@umich.edu		Cho, Kathleen/0000-0003-0500-9998; Saito, Ayaka/0000-0002-9916-0463	National Cancer Institute [RO1 CA94172, RO1 CA85463]; NATIONAL CANCER INSTITUTE [R01CA094172, R01CA085463] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We wish to thank Rork Kuick for assistance in analyzing the microarray data from human and mouse tissue samples. This work was supported by grants from the National Cancer Institute (RO1 CA94172 and RO1 CA85463).	Bendall AJ, 2000, GENE, V247, P17, DOI 10.1016/S0378-1119(00)00081-0; Bommer GT, 2010, J BIOL CHEM, V285, P1928, DOI 10.1074/jbc.M109.060319; Catasus L, 2004, HUM PATHOL, V35, P1360, DOI 10.1016/j.humpath.2004.07.019; Chamorro MN, 2005, EMBO J, V24, P73, DOI 10.1038/sj.emboj.7600460; Cheng WJ, 2005, NAT MED, V11, P531, DOI 10.1038/nm1230; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Di Bari MG, 2009, J CELL PHYSIOL, V219, P659, DOI 10.1002/jcp.21712; Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173; Dodig M, 1999, DEV BIOL, V209, P298, DOI 10.1006/dbio.1999.9258; Gamallo C, 1999, AM J PATHOL, V155, P527, DOI 10.1016/S0002-9440(10)65148-6; Hendrix ND, 2006, CANCER RES, V66, P1354, DOI 10.1158/0008-5472.CAN-05-3694; Hussein SM, 2003, J BIOL CHEM, V278, P48805, DOI 10.1074/jbc.M305472200; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Jiang TX, 1999, J INVEST DERMATOL, V113, P230, DOI 10.1046/j.1523-1747.1999.00680.x; Kolligs FT, 2002, CANCER CELL, V1, P145, DOI 10.1016/S1535-6108(02)00035-1; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Kuo KT, 2009, AM J PATHOL, V174, P1597, DOI 10.2353/ajpath.2009.081000; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Parker DS, 2008, MOL CELL BIOL, V28, P1815, DOI 10.1128/MCB.01230-07; Ramos C, 2005, TRENDS GENET, V21, P624, DOI 10.1016/j.tig.2005.09.001; Sagae S, 1999, JPN J CANCER RES, V90, P510, DOI 10.1111/j.1349-7006.1999.tb00777.x; Satoh K, 2004, J MAMMARY GLAND BIOL, V9, P195, DOI 10.1023/B:JOMG.0000037162.84758.b5; Satoh K, 2008, AM J PATHOL, V172, P926, DOI 10.2353/ajpath.2008.070346; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; Schwartz DR, 2003, CANCER RES, V63, P2913; Schwartz DR, 2002, CANCER RES, V62, P4722; Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826; Shao JS, 2005, J CLIN INVEST, V115, P1210, DOI 10.1172/JCI200524140; Song LY, 2009, DEVELOPMENT, V136, P3161, DOI 10.1242/dev.037440; SUZUKI M, 1993, BIOCHEM BIOPH RES CO, V194, P187, DOI 10.1006/bbrc.1993.1802; Takahashi C, 1996, ONCOGENE, V12, P2137; Whyte DB, 2006, BIOCHEM BIOPH RES CO, V340, P469, DOI 10.1016/j.bbrc.2005.12.025; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8; Wright K, 1999, INT J CANCER, V82, P625, DOI 10.1002/(SICI)1097-0215(19990827)82:5<625::AID-IJC1>3.0.CO;2-2; Wu R, 2001, CANCER RES, V61, P8247; Wu R, 2007, CANCER CELL, V11, P321, DOI 10.1016/j.ccr.2007.02.016; Zhai Y, 2002, AM J PATHOL, V160, P1229, DOI 10.1016/S0002-9440(10)62550-3; Zhai Y, 2007, CANCER RES, V67, P10163, DOI 10.1158/0008-5472.CAN-07-2056	38	21	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	40					4152	4162		10.1038/onc.2011.123	http://dx.doi.org/10.1038/onc.2011.123			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	833ZK	21499300	Green Accepted, Bronze			2022-12-17	WOS:000295924600002
J	Wasylishen, AR; Stojanova, A; Oliveri, S; Rust, AC; Schimmer, AD; Penn, LZ				Wasylishen, A. R.; Stojanova, A.; Oliveri, S.; Rust, A. C.; Schimmer, A. D.; Penn, L. Z.			New model systems provide insights into Myc-induced transformation	ONCOGENE			English	Article						Myc; structure-function; cellular transformation; simian virus 40; hTERT	C-MYC; TRANSGENIC MICE; TRANSACTIVATION DOMAIN; CELL-TRANSFORMATION; ESSENTIAL COFACTOR; BURKITTS-LYMPHOMA; INDUCED APOPTOSIS; N-MYC; FIBROBLASTS; MUTATIONS	The ability of Myc to promote cellular transformation is well established; however, a better understanding of the mechanisms through which Myc mediates tumorigenesis is essential for the development of therapeutic approaches to target this potent oncoprotein. Structure-function studies in rodent fibroblast cells have provided the basis for much of our current understanding of these mechanisms. To build on these approaches, we have characterized three novel human cell line models of Myc-dependent transformation: MCF10A, SH-EP Tet21/N-Myc, and LF1/TERT/LT/ST cells. We have also evaluated Myc family proteins (c-Myc and L-Myc), a naturally occurring isoform of Myc (MycS), and a set of N-terminal domain mutants (DMBII, W135E, T58A) for their ability to promote anchorage-independent growth in these models. Taken together, these results provide the field with three new human cell-based models to study Myc activity, highlight the importance of cellular context, and challenge the paradigm that the ability of Myc to promote tumorigenesis is exclusively MBII-dependent. Oncogene (2011) 30, 3727-3734; doi:10.1038/onc.2011.88; published online 28 March 2011	[Wasylishen, A. R.; Stojanova, A.; Oliveri, S.; Rust, A. C.; Schimmer, A. D.; Penn, L. Z.] Princess Margaret Hosp, Ontario Canc Inst, Campbell Family Inst Canc Res, Toronto, ON M5G 2M9, Canada; [Wasylishen, A. R.; Stojanova, A.; Oliveri, S.; Rust, A. C.; Schimmer, A. D.; Penn, L. Z.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Penn, LZ (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, Campbell Family Inst Canc Res, 9-628,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	lpenn@uhnres.utoronto.ca		Penn, Linda/0000-0001-8133-5459; Schimmer, Aaron/0000-0003-4023-3899; Wasylishen, Amanda/0000-0002-1940-5169	Canadian Cancer Society Research Institute; Ontario Graduate Scholarship; Canadian Breast Cancer Foundation; Ontario Ministry of Health and Long Term Care	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Ontario Graduate Scholarship(Ontario Graduate Scholarship); Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); Ontario Ministry of Health and Long Term Care(Ministry of Health and Long-Term Care, Ontario)	We would like to acknowledge technical assistance from Ms Caitlin Latimer. We thank the members of the Penn Lab for helpful discussions and critical review of this manuscript. This research was funded by a grant from the Canadian Cancer Society Research Institute (LZP), an Ontario Graduate Scholarship (AS), and a Canadian Breast Cancer Foundation Ontario Region Doctoral Fellowship (ARW). Additional support was provided by the Ontario Ministry of Health and Long Term Care. The views expressed do not necessarily reflect those of the OMOHLTC.	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BREIT S, 1989, J NEUROSCI RES, V24, P21, DOI 10.1002/jnr.490240105; Callus BA, 2008, CELL DEATH DIFFER, V15, P213, DOI 10.1038/sj.cdd.4402245; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; Chen W, 2003, HISTOL HISTOPATHOL, V18, P541, DOI 10.14670/HH-18.541; Cleveland J L, 1988, Oncogene Res, V3, P357; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; Cowling VH, 2007, MOL CELL BIOL, V27, P5135, DOI 10.1128/MCB.02282-06; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Drayton S, 2002, CURR OPIN GENET DEV, V12, P98, DOI 10.1016/S0959-437X(01)00271-4; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; Gustafson WC, 2010, ONCOGENE, V29, P1249, DOI 10.1038/onc.2009.512; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Herbst A, 2005, EMBO REP, V6, P177, DOI 10.1038/sj.embor.7400333; Kim SS, 2007, CANCER RES, V67, P9616, DOI 10.1158/0008-5472.CAN-07-0644; Kuttler F, 2001, ONCOGENE, V20, P6084, DOI 10.1038/sj.onc.1204827; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Landay M, 2000, CELL DEATH DIFFER, V7, P697, DOI 10.1038/sj.cdd.4400701; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; Lutz W, 1996, ONCOGENE, V13, P803; Malynn BA, 2000, GENE DEV, V14, P1390; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Schwab M, 2004, CANCER LETT, V204, P179, DOI 10.1016/S0304-3835(03)00454-3; SOULE HD, 1990, CANCER RES, V50, P6075; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Vervoorts J, 2006, J BIOL CHEM, V281, P34725, DOI 10.1074/jbc.R600017200; Wei WY, 2003, MOL CELL BIOL, V23, P2859, DOI 10.1128/MCB.23.8.2859-2870.2003; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; Wu JH, 2004, CANCER RES, V64, P6461, DOI 10.1158/0008-5472.CAN-04-0866	38	21	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	34					3727	3734		10.1038/onc.2011.88	http://dx.doi.org/10.1038/onc.2011.88			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	21441954	Green Accepted			2022-12-17	WOS:000294244500008
J	Fiaschetti, G; Castelletti, D; Zoller, S; Schramm, A; Schroeder, C; Nagaishi, M; Stearns, D; Mittelbronn, M; Eggert, A; Westermann, F; Ohgaki, H; Shalaby, T; Pruschy, M; Arcaro, A; Grotzer, MA				Fiaschetti, G.; Castelletti, D.; Zoller, S.; Schramm, A.; Schroeder, C.; Nagaishi, M.; Stearns, D.; Mittelbronn, M.; Eggert, A.; Westermann, F.; Ohgaki, H.; Shalaby, T.; Pruschy, M.; Arcaro, A.; Grotzer, M. A.			Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma	ONCOGENE			English	Article						BMP7; MYC; medulloblastoma; brain tumor; pediatric cancer	C-MYC; BREAST-CANCER; CHOROID-PLEXUS; HUMAN PROSTATE; TUMOR-GROWTH; IN-VIVO; BMP; EXPRESSION; METASTASIS; RECEPTORS	Medulloblastoma (MB) is the most common malignant brain tumor in children. It is known that overexpression and/or amplification of the MYC oncogene is associated with poor clinical outcome, but the molecular mechanisms and the MYC downstream effectors in MB remain still elusive. Besides contributing to elucidate how progression of MB takes place, most importantly, the identification of novel MYC-target genes will suggest novel candidates for targeted therapy in MB. A group of 209 MYC-responsive genes was obtained from a complementary DNA microarray analysis of a MB-derived cell line, following MYC overexpression and silencing. Among the MYC-responsive genes, we identified the members of the bone morphogenetic protein (BMP) signaling pathway, which have a crucial role during the development of the cerebellum. In particular, the gene BMP7 was identified as a direct target of MYC. A positive correlation between MYC and BMP7 expression was documented by analyzing two distinct sets of primary MB samples. Functional studies in vitro using a small-molecule inhibitor of the BMP/SMAD signaling pathway reproduced the effect of the small interfering RNA-mediated silencing of BMP7. Both approaches led to a block of proliferation in a panel of MB cells and to inhibition of SMAD phosphorylation. Altogether, our findings indicate that high MYC levels drive BMP7 overexpression, promoting cell survival in MB cells. This observation suggests the potential relevance of targeting the BMP/SMAD pathway as a novel therapeutic approach for the treatment of childhood MB. Oncogene (2011) 30, 2823-2835; doi: 10.1038/onc.2011.10; published online 14 February 2011	[Fiaschetti, G.; Castelletti, D.; Shalaby, T.; Grotzer, M. A.] Univ Childrens Hosp, Dept Oncol, CH-8032 Zurich, Switzerland; [Zoller, S.] UZH ETH, Funct Genom Ctr Zurich, Zurich, Switzerland; [Schramm, A.; Eggert, A.] Univ Childrens Hosp Essen, Div Hematol Oncol, Essen, Germany; [Schroeder, C.; Westermann, F.] German Canc Res Ctr, Dept Tumor Genet, Heidelberg, Germany; [Nagaishi, M.; Ohgaki, H.] World Hlth Org, Int Agcy Res Canc, Sect Mol Pathol, Lyon, France; [Stearns, D.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA; [Mittelbronn, M.] Goethe Univ Frankfurt, Inst Neurol, Edinger Inst, Frankfurt, Germany; [Pruschy, M.] Univ Zurich Hosp, Dept Radiat Oncol, CH-8091 Zurich, Switzerland; [Arcaro, A.] Univ Bern, Div Pediat Hematol Oncol, Dept Clin Res, Bern, Switzerland	University Children's Hospital Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); World Health Organization; International Agency for Research on Cancer (IARC); Johns Hopkins University; Goethe University Frankfurt; University of Zurich; University Zurich Hospital; University of Bern	Grotzer, MA (corresponding author), Univ Childrens Hosp, Dept Oncol, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	Michael.Grotzer@kispi.uzh.ch	Arcaro, Alexandre/G-1711-2010; Schramm, Alexander/G-5688-2010; Eggert, Angelika/AAE-6907-2022; Westermann, Frank/F-7509-2013	Arcaro, Alexandre/0000-0001-9107-2947; Schramm, Alexander/0000-0001-7670-7529; Eggert, Angelika/0000-0003-3476-8184; Mittelbronn, Michel/0000-0002-2998-052X; Grotzer, Michael/0000-0002-1154-2732; Pruschy, Martin/0000-0002-3124-9015	European Community [037260]	European Community(European Commission)	Giulio Fiaschetti and Deborah Castelletti were supported by the European Community FP6, project STREP (EET-pipeline, number: 037260).	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Alder J, 1999, NAT NEUROSCI, V2, P535, DOI 10.1038/9189; Aldosari N, 2002, ARCH PATHOL LAB MED, V126, P540; Anderson GJ, 2008, NAT CHEM BIOL, V4, P15, DOI 10.1038/nchembio0108-15; Arihiro K, 2001, PATHOL INT, V51, P100, DOI 10.1046/j.1440-1827.2001.01164.x; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Behesti H, 2009, INT J BIOCHEM CELL B, V41, P435, DOI 10.1016/j.biocel.2008.06.017; Calvo MB, 2009, CLIN TRANSL ONCOL, V11, P126, DOI 10.1007/S12094-009-0328-8; Buijs JT, 2007, CANCER RES, V67, P8742, DOI 10.1158/0008-5472.CAN-06-2490; Buijs JT, 2007, AM J PATHOL, V171, P1047, DOI 10.2353/ajpath.2007.070168; Buijs JT, 2010, CURR PHARM DESIGN, V16, P1291; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chizhikov VV, 2006, DEVELOPMENT, V133, P2793, DOI 10.1242/dev.02441; Crawford JR, 2007, LANCET NEUROL, V6, P1073, DOI 10.1016/S1474-4422(07)70289-2; Dai JL, 2008, CANCER RES, V68, P5785, DOI 10.1158/0008-5472.CAN-07-6541; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Dziegielewska KM, 2001, MICROSC RES TECHNIQ, V52, P5, DOI 10.1002/1097-0029(20010101)52:1<5::AID-JEMT3>3.3.CO;2-A; Eberhart CG, 2002, CANCER-AM CANCER SOC, V94, P552, DOI 10.1002/cncr.10189; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Engelhard HH, 2005, CANC TREAT, V125, P71; Feeley BT, 2005, J BONE MINER RES, V20, P2189, DOI 10.1359/JBMR.050802; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Filmus J, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-5-224; Gilbertson RJ, 2008, ANNU REV PATHOL-MECH, V3, P341, DOI 10.1146/annurev.pathmechdis.3.121806.151518; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Grimmer MR, 2008, GENE DEV, V22, P693, DOI 10.1101/gad.1657808; Grisaru S, 2001, DEV BIOL, V231, P31, DOI 10.1006/dbio.2000.0127; Grotzer MA, 2009, CURR CANCER DRUG TAR, V9, P176, DOI 10.2174/156800909787580962; Guessous F, 2008, J CELL PHYSIOL, V217, P577, DOI 10.1002/jcp.21542; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Guo X, 2009, CELL RES, V19, P71, DOI 10.1038/cr.2008.302; Gurney JG, 2001, CURR OPIN ONCOL, V13, P160, DOI 10.1097/00001622-200105000-00005; Herms J, 2000, INT J CANCER, V89, P395; Iantosca MR, 1999, J NEUROSCI RES, V56, P248; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Krizhanovsky V, 2006, MECH DEVELOP, V123, P67, DOI 10.1016/j.mod.2005.09.005; Kunz F, 2006, NEUROPATHOLOGY, V26, P393, DOI 10.1111/j.1440-1789.2006.00694.x; Lamont JM, 2004, CLIN CANCER RES, V10, P5482, DOI 10.1158/1078-0432.CCR-03-0721; Langenfeld EM, 2003, CARCINOGENESIS, V24, P1445, DOI 10.1093/carcin/bgg100; Littlewood T D, 1990, Adv Dent Res, V4, P69; Luo JY, 2007, LAB INVEST, V87, P97, DOI 10.1038/labinvest.3700509; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Marino S, 2005, TRENDS MOL MED, V11, P17, DOI 10.1016/j.molmed.2004.11.008; Miyazaki H, 2004, ONCOGENE, V23, P9326, DOI 10.1038/sj.onc.1208127; Miyazono K, 1999, BONE, V25, P91, DOI 10.1016/S8756-3282(99)00113-1; Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009; Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148; Mulhern RK, 2005, J CLIN ONCOL, V23, P5511, DOI 10.1200/JCO.2005.00.703; Neben K, 2004, CANCER RES, V64, P3103, DOI 10.1158/0008-5472.CAN-03-3968; Piccirillo SGM, 2007, ERNST SCHERING FOUND, V5, P59, DOI 10.1007/2789_2007_044; Polkinghorn WR, 2007, NAT CLIN PRACT ONCOL, V4, P295, DOI 10.1038/ncponc0794; Raida M, 2005, INT J ONCOL, V26, P1465; Redzic ZB, 2004, ADV DRUG DELIVER REV, V56, P1695, DOI 10.1016/j.addr.2004.07.005; Romer J, 2005, CANCER RES, V65, P4975, DOI 10.1158/0008-5472.CAN-05-0481; Rossi A, 2008, CLIN CANCER RES, V14, P971, DOI 10.1158/1078-0432.CCR-07-2072; Sieber C, 2009, CYTOKINE GROWTH F R, V20, P343, DOI 10.1016/j.cytogfr.2009.10.007; Stearns D, 2006, CANCER RES, V66, P673, DOI 10.1158/0008-5472.CAN-05-1580; Sutter R, 2010, ONCOGENE, V29, P1845, DOI 10.1038/onc.2009.472; Thawani JP, 2010, NEUROSURGERY, V66, P233, DOI 10.1227/01.NEU.0000363722.42097.C2; Thompson MC, 2006, J CLIN ONCOL, V24, P1924, DOI 10.1200/JCO.2005.04.4974; Vita M, 2006, SEMIN CANCER BIOL, V16, P318, DOI 10.1016/j.semcancer.2006.07.015; von Bueren AO, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-19; Walsh DW, 2010, TRENDS CELL BIOL, V20, P244, DOI 10.1016/j.tcb.2010.01.008; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Yabe T, 2002, J NEUROSCI RES, V68, P161, DOI 10.1002/jnr.10210; Yan WS, 2007, CANCER RES, V67, P9117, DOI 10.1158/0008-5472.CAN-07-0996; Yanagita M, 2005, CYTOKINE GROWTH F R, V16, P309, DOI 10.1016/j.cytogfr.2005.02.007; Yanagita M, 2009, BIOFACTORS, V35, P113, DOI 10.1002/biof.15; Ye L, 2007, INT J ONCOL, V30, P521; Ye L, 2009, INT J MOL MED, V24, P591, DOI 10.3892/ijmm_00000269; Yui PB, 2008, NAT CHEM BIOL, V4, P33, DOI 10.1038/nchembio.2007.54; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103; Zhao H, 2008, GENE DEV, V22, P722, DOI 10.1101/gad.1636408	73	21	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	25					2823	2835		10.1038/onc.2011.10	http://dx.doi.org/10.1038/onc.2011.10			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	781ZV	21317922				2022-12-17	WOS:000291977800003
J	Mohammad, HP; Zhang, W; Prevas, HS; Leadem, BR; Zhang, M; Herman, JG; Hooker, CM; Watkins, DN; Karim, B; Huso, DL; Baylin, SB				Mohammad, H. P.; Zhang, W.; Prevas, H. S.; Leadem, B. R.; Zhang, M.; Herman, J. G.; Hooker, C. M.; Watkins, D. N.; Karim, B.; Huso, D. L.; Baylin, S. B.			Loss of a single Hic1 allele accelerates polyp formation in Apc(Delta 716) mice	ONCOGENE			English	Article						Hic1; Min; Polyp; DNA hypermethylation; colon cancer	TUMOR-SUPPRESSOR GENE; MULTIPLE INTESTINAL NEOPLASIA; STEM-CELLS; SOX9; EXPRESSION; CANCER; SIRT1; COLON; IDENTIFICATION; TUMORIGENESIS	Adenomatous polyposis coli (APC) gene mutations have been implicated in familial and sporadic gastrointestinal (GI) cancers. APC mutations are associated with autosomal dominant inheritance of disease in humans. Similarly, mice that contain a single mutant APC gene encoding a protein truncated at residue 716 (Apc(Delta 716)) develop multiple polyps throughout the GI tract as early as 4 weeks after birth. Inactivation of another tumor suppressor gene, Hypermethylated in Cancer 1 (HIC1), often occurs in human colon cancers, among others, via CpG island hypermethylation. Homozygous deletion of Hic1 in mice results in major developmental defects and embryonic lethality. Hic1 heterozygotes have previously been shown to develop tumors of a variety of tissue types. We now report that loss of a single Hic1 allele can promote crypt hyperplasia and neoplasia of the GI tract, and Hic1(+/-), Apc(+/Delta 716) double heterozygotes (DH) develop increased numbers of polyps throughout the GI tract at 60 days. Hic1 expression is absent in polyps from DH mice, with concomitant increased expression of two transcriptional repression targets of Hic1, Sirt1 and Sox9. Together, our data suggest that loss of a gene frequently silenced via epigenetic mechanisms, Hic1, can cooperate with loss of a gene mutated in GI cancer, Apc, to promote tumorigenesis in an in vivo model of multiple intestinal neoplasia. Oncogene (2011) 30, 2659-2669; doi:10.1038/onc.2010.633; published online 7 February 2011	[Baylin, S. B.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Inst Johns Hopkins, Baltimore, MD 21231 USA; [Watkins, D. N.] Monash Univ, Ctr Canc Res, Monash Inst Med Res, Clayton, Vic, Australia; [Karim, B.; Huso, D. L.] Johns Hopkins Univ, Dept Mol & Comparat Pathobiol, Baltimore, MD 21231 USA	Johns Hopkins University; Monash University; Johns Hopkins University	Baylin, SB (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Inst Johns Hopkins, 1650 Orleans St,CRB I 541, Baltimore, MD 21231 USA.	sbaylin@jhmi.edu	zhang, wei/A-7015-2011; Watkins, David N/I-6113-2013		National Cancer Institute [CA043318]; National Institutes of Environmental Health Sciences [ES015226, ES011858]; American Cancer Society; NATIONAL CANCER INSTITUTE [R01CA043318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011858, R01ES015226] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Guosheng Liu for technical assistance with dissection, Kimberly Briggs for primers, Robert Beatty for assistance with Hic1<SUP>+/-</SUP> breeding and Kathy Bender for manuscript submission. This work was supported by grants from the National Cancer Institute CA043318 (SBB), National Institutes of Environmental Health Sciences ES015226 and ES011858 (SBB). Additional support was provided by the American Cancer Society (HM and WZ).	Barker N, 2008, GENE DEV, V22, P1856, DOI 10.1101/gad.1674008; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; BARNARD NJ, 1987, J PATHOL, V152, P287, DOI 10.1002/path.1711520407; Bastide P, 2007, J CELL BIOL, V178, P635, DOI 10.1083/jcb.200704152; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; Boily G, 2009, ONCOGENE, V28, P2882, DOI 10.1038/onc.2009.147; Boivin GP, 2003, GASTROENTEROLOGY, V124, P762, DOI 10.1053/gast.2003.50094; Briggs KJ, 2008, GENE DEV, V22, P770, DOI 10.1101/gad.1640908; Carter MG, 2000, HUM MOL GENET, V9, P413, DOI 10.1093/hmg/9.3.413; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077; Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Deltour S, 2002, MOL CELL BIOL, V22, P4890, DOI 10.1128/MCB.22.13.4890-4901.2002; Deltour S, 1998, BBA-GENE STRUCT EXPR, V1443, P230, DOI 10.1016/S0167-4781(98)00219-X; Dong SM, 2001, CLIN CANCER RES, V7, P1982; Dupasquier S, 2009, J CELL SCI, V122, P2191, DOI 10.1242/jcs.036483; Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; Guerardel C, 2001, J BIOL CHEM, V276, P3078, DOI 10.1074/jbc.M008690200; Hao LY, 2005, CELL, V123, P1121, DOI 10.1016/j.cell.2005.11.020; Holloway KR, 2010, P NATL ACAD SCI USA, V107, P9216, DOI 10.1073/pnas.0911325107; Lu BJ, 2008, AM J CLIN PATHOL, V130, P897, DOI 10.1309/AJCPW1W8GJBQGCNI; Maekawa M, 2001, CLIN CHEM LAB MED, V39, P121, DOI 10.1515/CCLM.2001.021; McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Nosho K, 2009, GASTROENTEROLOGY, V137, P1609, DOI 10.1053/j.gastro.2009.08.002; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Oster H, 2006, CANCER RES, V66, P6955, DOI 10.1158/0008-5472.CAN-06-0268; Pinte S, 2004, J BIOL CHEM, V279, P38313, DOI 10.1074/jbc.M401610200; Polakis P, 2000, GENE DEV, V14, P1837; PONDER BAJ, 1985, NATURE, V313, P689, DOI 10.1038/313689a0; Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Stuber E, 1998, GASTROENTEROLOGY, V115, P1205, DOI 10.1016/S0016-5085(98)70092-7; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Valenta T, 2006, EMBO J, V25, P2326, DOI 10.1038/sj.emboj.7601147; Van Rechem C, 2009, J BIOL CHEM, V284, P20927, DOI 10.1074/jbc.M109.022350; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wu SG, 2009, NAT MED, V15, P1016, DOI 10.1038/nm.2015; Zhang W, 2010, ONCOGENE, V29, P2467, DOI 10.1038/onc.2010.12	44	21	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	23					2659	2669		10.1038/onc.2010.633	http://dx.doi.org/10.1038/onc.2010.633			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778CV	21297660	Green Published, hybrid			2022-12-17	WOS:000291677800006
J	Perier, A; Fregni, G; Wittnebel, S; Gad, S; Allard, M; Gervois, N; Escudier, B; Azzarone, B; Caignard, A				Perier, A.; Fregni, G.; Wittnebel, S.; Gad, S.; Allard, M.; Gervois, N.; Escudier, B.; Azzarone, B.; Caignard, A.			Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma	ONCOGENE			English	Article						von Hippel-Lindau mutation; NK cells; renal cell carcinoma; immunotherapy	TUMOR-SUPPRESSOR GENE; NK CELLS; IFN-GAMMA; HLA-G; DOWN-REGULATION; POOR SURVIVAL; EXPRESSION; CANCER; RECEPTORS; HYPOXIA	The tumor suppressor gene von Hippel-Lindau (VHL) is involved in the development of sporadic clear-cell renal cell carcinoma (RCC). VHL interferes with angiogenesis and also controls cell adhesion and invasion. Therapies that target VHL-controlled genes are currently being evaluated in RCC patients. RCC is a immunogenic tumor and treatment with interleukin-2 (IL2) or interferon (IFN)-alpha results in regression in some patients. We used two renal tumor cell lines (RCC6 and RCC4) carrying VHL loss-of-function mutations to investigate the role of mutant VHL in susceptibility to natural killer (NK) cell-mediated lysis. The RCC6 and RCC4 cell lines were transfected with the wild-type gene to restore the function of VHL. The presence of the gene in RCC cells downregulated hypoxia-inducible factor (HIF)-1 alpha and subsequently decreased vascular endothelial growth factor (VEGF) production. Relative to control transfectants and parental cells, pVHL-transfected cell lines activated resting and IL2-activated NK cells less strongly, as assessed by IFN gamma secretion, NK degranulation and cell lysis. NKG2A, a human leukocyte antigen (HLA)-I-specific inhibitory NK receptor, controls the lysis of tumor targets. We show that HLA-I expression in RCC-pVHL cells is stronger than that in parental and controls cells, although the expression of activating receptor NK ligands remains unchanged. Blocking NKG2A/HLA-I interactions substantially increased lysis of RCC-pVHL, but had little effect on the lysis of VHL-mutated RCC cell lines. In addition, in response to IFN alpha, the exponential growth of RCC-pVHL was inhibited more than that of RCC-pE cells, indicating that VHL mutations may be involved in IFN alpha resistance. These results indicate that a decreased expression of HLA-I molecules in mutated VHL renal tumor cells sensitizes them to NK-mediated lysis. These results suggest that combined immunotherapy with anti-angiogenic drugs may be beneficial for patients with mutated VHL. Oncogene (2011) 30, 2622-2632; doi:10.1038/onc.2010.638; published online 24 January 2011	[Perier, A.; Fregni, G.; Caignard, A.] Univ Paris 05, CNRS, INSERM, Inst Cochin,UMR 8104,U1016, F-75014 Paris, France; [Fregni, G.] Inst Gustave Roussy, INSERM, U753, F-94805 Villejuif, France; [Gad, S.] Inst Gustave Roussy, INSERM, U753, Lab Genet Oncol EPHE, F-94805 Villejuif, France; [Allard, M.; Gervois, N.] INSERM, U892, Nantes, France; [Escudier, B.] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France; [Azzarone, B.] Univ Paris 11, Hop Paul Brousse, INSERM, UMR 542, Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Caignard, A (corresponding author), Univ Paris 05, CNRS, INSERM, Inst Cochin,UMR 8104,U1016, Batiment Gustave Roussy,27 Rue Faubourg St Jacque, F-75014 Paris, France.	anne.caignard@inserm.fr	Gervois, Nadine/K-6658-2015; Azzarone, Bruno/AAH-9251-2019; allard, mathilde/C-9577-2018; Caignard, Anne/F-8159-2013	Gervois, Nadine/0000-0002-0092-3919; Azzarone, Bruno/0000-0002-5962-3849; allard, mathilde/0000-0002-2217-1295; Caignard, Anne/0000-0001-9923-6045; GAD (LAPITEAU), Sophie/0000-0002-3158-6791	INSERM; INCa; la Fondation pour la Recherche Medicale (FRM); la Ligue Nationale contre le Cancer	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); INCa(Institut National du Cancer (INCA) France); la Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); la Ligue Nationale contre le Cancer(Ligue nationale contre le cancer)	This work was supported by grants from INSERM, INCa, la Fondation pour la Recherche Medicale (FRM) and la Ligue Nationale contre le Cancer. AP had a grant from FRM. We thank Dr Nadege Bercovici for helpful discussion and reading of manuscript.	Aggelis V, 2009, PROTEOMICS, V9, P2118, DOI 10.1002/pmic.200800756; Alberti L, 2004, INT J CANCER, V111, P653, DOI 10.1002/ijc.20287; Atkins D, 2004, J UROLOGY, V171, P885, DOI 10.1097/01.ju.0000094807.95420.fe; Atkins MB, 2009, CANCER-AM CANCER SOC, V115, P2327, DOI 10.1002/cncr.24231; Banks RE, 2006, CANCER RES, V66, P2000, DOI 10.1158/0008-5472.CAN-05-3074; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Chuang SS, 2001, J IMMUNOL, V167, P6210, DOI 10.4049/jimmunol.167.11.6210; Cozar J, 2005, CANCER IMMUNOL IMMUN, V54, P858, DOI 10.1007/s00262-004-0646-1; Donskov F, 2002, BRIT J CANCER, V87, P194, DOI 10.1038/sj.bjc.6600437; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; Gad S, 2007, BRIT J CANCER, V96, P336, DOI 10.1038/sj.bjc.6603492; Gati A, 2004, INT J CANCER, V109, P393, DOI 10.1002/ijc.11730; Gilfillan S, 2008, J EXP MED, V205, P2965, DOI 10.1084/jem.20081752; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gobin SJP, 2000, HUM IMMUNOL, V61, P1102, DOI 10.1016/S0198-8859(00)00198-1; Grabmaier K, 2004, ONCOGENE, V23, P5624, DOI 10.1038/sj.onc.1207764; Ibrahim EC, 2001, CANCER RES, V61, P6838; Ivanov SV, 2007, ONCOGENE, V26, P802, DOI 10.1038/sj.onc.1209842; Ivanova AV, 2001, J BIOL CHEM, V276, P15306, DOI 10.1074/jbc.M010516200; Kilburn BA, 2000, BIOL REPROD, V62, P739, DOI 10.1095/biolreprod62.3.739; Kopper L, 2006, PATHOL ONCOL RES, V12, P5, DOI 10.1007/BF02893425; Lahn M, 1999, EUR UROL, V35, P70, DOI 10.1159/000019821; Lanier LL, 2000, J EXP MED, V191, P1259, DOI 10.1084/jem.191.8.1259; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Linehan WM, 2009, CANCER-AM CANCER SOC, V115, P2252, DOI 10.1002/cncr.24230; Martin-Fontecha A, 2004, NAT IMMUNOL, V5, P1260, DOI 10.1038/ni1138; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Moretta A, 2001, ANNU REV IMMUNOL, V19, P197, DOI 10.1146/annurev.immunol.19.1.197; Moretta L, 2004, EMBO J, V23, P255, DOI 10.1038/sj.emboj.7600019; Mouillot G, 2007, HUM IMMUNOL, V68, P277, DOI 10.1016/j.humimm.2006.10.016; Negrier S, 1998, NEW ENGL J MED, V338, P1272, DOI 10.1056/NEJM199804303381805; Osborne A, 1997, NUCLEIC ACIDS RES, V25, P5095, DOI 10.1093/nar/25.24.5095; Parker AS, 2005, UROLOGY, V65, P1090, DOI 10.1016/j.urology.2004.12.040; Patard JJ, 2009, BRIT J CANCER, V101, P1417, DOI 10.1038/sj.bjc.6605298; Patard JJ, 2008, INT J CANCER, V123, P395, DOI 10.1002/ijc.23496; Rajagopalan S, 2001, J IMMUNOL, V167, P1877, DOI 10.4049/jimmunol.167.4.1877; Reefman E, 2010, J IMMUNOL, V184, P4852, DOI 10.4049/jimmunol.0803954; Rini BI, 2009, LANCET, V373, P1119, DOI 10.1016/S0140-6736(09)60229-4; Schleypen JS, 2006, CLIN CANCER RES, V12, P718, DOI 10.1158/1078-0432.CCR-05-0857; Schleypen JS, 2003, INT J CANCER, V106, P905, DOI 10.1002/ijc.11321; Segerer S, 2006, KIDNEY INT, V69, P1765, DOI 10.1038/sj.ki.5000337; Seliger B, 2000, IMMUNOL TODAY, V21, P455, DOI 10.1016/S0167-5699(00)01692-3; Smits KM, 2008, CLIN CANCER RES, V14, P782, DOI 10.1158/1078-0432.CCR-07-1753; Urcan E, 2010, DENT MATER, V26, P51, DOI 10.1016/j.dental.2009.08.007; Viey E, 2005, J IMMUNOL, V174, P1338, DOI 10.4049/jimmunol.174.3.1338; WHALEY JM, 1994, AM J HUM GENET, V55, P1092; Wittnebel S, 2007, CANCER RES, V67, P5594, DOI 10.1158/0008-5472.CAN-06-4406; Wysocki PJ, 2010, CANCER GENE THER, V17, P465, DOI 10.1038/cgt.2010.2; Yang JC, 2003, J CLIN ONCOL, V21, P3127, DOI 10.1200/JCO.2003.02.122; Yao M, 2002, JNCI-J NATL CANCER I, V94, P1569; Zagzag D, 2005, LAB INVEST, V85, P328, DOI 10.1038/labinvest.3700233; Zhu J, 2006, J IMMUNOL METHODS, V309, P25, DOI 10.1016/j.jim.2005.10.018	54	21	21	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	23					2622	2632		10.1038/onc.2010.638	http://dx.doi.org/10.1038/onc.2010.638			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778CV	21258414				2022-12-17	WOS:000291677800003
J	Xu, H; Zheng, L; Dai, H; Zhou, M; Hua, Y; Shen, B				Xu, H.; Zheng, L.; Dai, H.; Zhou, M.; Hua, Y.; Shen, B.			Chemical-induced cancer incidence and underlying mechanisms in Fen1 mutant mice	ONCOGENE			English	Article						FEN1; long-patch base excision repair; methylnitrosourea; tetraploidy; aneuploidy; cancer	BASE EXCISION-REPAIR; DNA-POLYMERASE-BETA; FLAP ENDONUCLEASE-1; LUNG-CANCER; HUMAN-CELLS; DAMAGE; INSTABILITY; GLYCOSYLASES; REPLICATION; STIMULATION	A critical observation in sporadic cancers is that not all individuals are equally prone to developing cancer following exposure to a given environmental carcinogen. Epidemiological studies have suggested that the difference in the timing of cancer onset in response to exogenous DNA damage is likely attributable to genetic variations, such as those associated with base excision repair (BER) genes. To test this long-standing hypothesis and elucidate how a genetic variation in the BER gene flap endonuclease 1 (FEN1) results in susceptibility to environment insults and causes cancer, we established a mutant mouse model carrying a point mutation (E160D) in Fen1. We demonstrate that the E160D mutation impairs the ability of FEN1 to process DNA intermediate structures in long-patch BER using nuclear extracts or reconstituted purified BER proteins. E160D cells were more sensitive to the base-damaging agents methylnitrosourea and hydrogen peroxide, leading to DNA strand breaks, chromosomal breakage and chromosome instabilities in response these DNA insults. We further show that E160D mice are significantly more susceptible to exposure to methylnitrosourea and develop lung adenocarcinoma. Thus, our current study demonstrates that a subtle genetic variation (E160D) in BER genes (FEN1) may cause a functional deficiency in repairing base damage, such that individuals carrying the mutation or similar mutations are predisposed to chemical-induced cancer development. Oncogene (2011) 30, 1072-1081; doi:10.1038/onc.2010.482; published online 25 October 2010	[Xu, H.; Hua, Y.; Shen, B.] Zhejiang Univ, Inst Nucl Agr Sci, Chinese Minist Agr Nucl Agr Sci, Key Lab, Hangzhou 310029, Zhejiang, Peoples R China; [Xu, H.; Zheng, L.; Dai, H.; Zhou, M.; Shen, B.] City Hope Natl Med Ctr, Dept Canc Biol, Duarte, CA 91010 USA; [Xu, H.; Zheng, L.; Dai, H.; Zhou, M.; Shen, B.] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA	Zhejiang University; City of Hope; City of Hope; Beckman Research Institute of City of Hope	Shen, B (corresponding author), City Hope Natl Med Ctr, Dept Canc Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.	yjhua@zju.edu.cn; bshen@coh.org		Shen, Binghui/0000-0002-4408-407X	NIH [R01 CA073764]; China Scholarship Council (CSC); NATIONAL CANCER INSTITUTE [R01CA073764] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); China Scholarship Council (CSC)(China Scholarship Council); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the microscopy core facility of City of Hope for technical assistance with immunofluorescence staining of MEF cells. We thank D Finger for technical advice on purification of FEN1 proteins. We thank SR da Costa and K Walker for editorial assistance. All protocols involving animal use were approved by the research animal care committee of City of Hope National Medical Center and Beckman Research Institute in compliance with the Public Health Service Policy on Use of Laboratory Animals. This work was supported by an NIH grant R01 CA073764 to BHS and a scholarship from China Scholarship Council (CSC) to HX.	Asagoshi K, 2010, DNA REPAIR, V9, P109, DOI 10.1016/j.dnarep.2009.11.002; Balakrishnan L, 2009, J BIOL CHEM, V284, P15158, DOI 10.1074/jbc.M109.000505; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Chang JS, 2009, CARCINOGENESIS, V30, P78, DOI 10.1093/carcin/bgn261; Cistulli C, 2004, DNA REPAIR, V3, P581, DOI 10.1016/j.dnarep.2003.09.012; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Donny W, 2004, J BIOL CHEM, V279, P25268, DOI 10.1074/jbc.M400804200; Figueroa JD, 2007, HUM GENET, V121, P233, DOI 10.1007/s00439-006-0294-y; Frank G, 2001, J BIOL CHEM, V276, P36295, DOI 10.1074/jbc.M103397200; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Guo ZG, 2009, NUCLEIC ACIDS RES, V37, P3431, DOI 10.1093/nar/gkp201; Jackson DA, 1998, J CELL BIOL, V140, P1285, DOI 10.1083/jcb.140.6.1285; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Krokan HE, 1997, BIOCHEM J, V325, P1; Landi S, 2005, EXP LUNG RES, V31, P223, DOI 10.1080/01902140490495624; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Liu P, 2008, MOL CELL BIOL, V28, P4975, DOI 10.1128/MCB.00457-08; Liu Y, 2005, J BIOL CHEM, V280, P3665, DOI 10.1074/jbc.M412922200; Liu Y, 2004, ANNU REV BIOCHEM, V73, P589, DOI 10.1146/annurev.biochem.73.012803.092453; Merrick CJ, 2004, J BIOL CHEM, V279, P20067, DOI 10.1074/jbc.M400022200; MING Y, 2009, HUM MUTAT, V30, P1320; Nakamura J, 1998, CANCER RES, V58, P222; Pascucci B, 2005, NUCLEIC ACIDS RES, V33, P280, DOI 10.1093/nar/gki168; Prasad R, 2005, DNA REPAIR, V4, P1347, DOI 10.1016/j.dnarep.2005.08.009; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Ranalli TA, 2002, J BIOL CHEM, V277, P41715, DOI 10.1074/jbc.M207207200; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Shen BH, 2005, BIOESSAYS, V27, P717, DOI 10.1002/bies.20255; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; VAINIO H, 1994, SCAND J WORK ENV HEA, V20, P235, DOI 10.5271/sjweh.1402; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Wang YX, 2005, NAT GENET, V37, P750, DOI 10.1038/ng1587; Zheng L, 2008, MOL CELL, V32, P325, DOI 10.1016/j.molcel.2008.09.024; Zheng L, 2007, NAT MED, V13, P812, DOI 10.1038/nm1599	40	21	21	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	9					1072	1081		10.1038/onc.2010.482	http://dx.doi.org/10.1038/onc.2010.482			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729PX	20972458	Green Accepted			2022-12-17	WOS:000287964100006
J	Zhan, Y; Modi, N; Stewart, AM; Hieronimus, RI; Liu, J; Gutmann, DH; Chadee, DN				Zhan, Y.; Modi, N.; Stewart, A. M.; Hieronimus, R. I.; Liu, J.; Gutmann, D. H.; Chadee, D. N.			Regulation of mixed lineage kinase 3 is required for Neurofibromatosis-2-mediated growth suppression in human cancer	ONCOGENE			English	Article						MLK3; NF2; MAPK; B-Raf; Cdc42	NF2 TUMOR-SUPPRESSOR; MEDIATES CONTACT INHIBITION; TYPE-2 GENE-PRODUCT; N-TERMINAL KINASE; CELL-PROLIFERATION; B-RAF; ACTIVATION LOOP; NIH 3T3-CELLS; SCHWANN-CELLS; MERLIN	The Neurofibromatosis-2 (NF2) tumor suppressor merlin negatively regulates cell proliferation in numerous cell types. We have previously shown that the NF2 protein (merlin/schwannomin) associates with mixed lineage kinase 3 (MLK3), a mitogen-activated protein kinase (MAPK) kinase kinase that is required for the proliferation of normal and neoplastic cells. In this study, we show that merlin inhibits MLK3 activity, as well as the activation of its downstream effectors, B-Raf, extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK). The ability of merlin to regulate MLK3 activity requires a direct association between MLK3 and residues in the C-terminal region of merlin. Merlin integrates Rho GTPase family signaling with MAPK activity by inhibiting the binding between MLK3 and its upstream activator, Cdc42. Furthermore, we demonstrate that MLK3 is required for merlin-mediated suppression of cell proliferation and invasion. Collectively, these results establish merlin as a potent inhibitor of MLK3, ERK and JNK activation in cancer, and provide a mechanistic link between deregulated MAPK and Rho GTPase signaling in NF2 growth control. Oncogene (2011) 30, 781-789; doi:10.1038/onc.2010.453; published online 4 October 2010	[Zhan, Y.; Modi, N.; Stewart, A. M.; Hieronimus, R. I.; Chadee, D. N.] Univ Toledo, Dept Biol Sci, Toledo, OH 43606 USA; [Liu, J.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Gutmann, D. H.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	University System of Ohio; University of Toledo; University of Texas System; UTMD Anderson Cancer Center; Washington University (WUSTL)	Chadee, DN (corresponding author), Univ Toledo, Dept Biol Sci, 2801 W Bancroft St, Toledo, OH 43606 USA.	deborah.chadee@utoledo.edu	ZHAN, YU/P-4025-2014	Gutmann, David/0000-0002-3127-5045	National Institutes of Health [1 R15 CA132006-01]; American Cancer Society (Ohio Division); NATIONAL CANCER INSTITUTE [R15CA132006] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society (Ohio Division)(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr J Kyriakis for the FLAG-Cdc42 constructs and Dr D Lim for HEI193 cells. This work was supported by National Institutes of Health Grant 1 R15 CA132006-01 and by an American Cancer Society (Ohio Division) grant (to D.N.C.).	Chadee DN, 2006, P NATL ACAD SCI USA, V103, P4463, DOI 10.1073/pnas.0510651103; Chadee DN, 2004, CELL CYCLE, V3, P1227, DOI 10.4161/cc.3.10.1187; Chadee DN, 2004, NAT CELL BIOL, V6, P770, DOI 10.1038/ncb1152; Chadee DN, 2002, MOL CELL BIOL, V22, P737, DOI 10.1128/MCB.22.3.737-749.2002; Cho YY, 2004, CANCER RES, V64, P3855, DOI 10.1158/0008-5472.CAN-04-0201; Du Y, 2005, J BIOL CHEM, V280, P42984, DOI 10.1074/jbc.M502671200; Fernandez-Valle C, 2002, NAT GENET, V31, P354, DOI 10.1038/ng930; Fraenzer JT, 2003, INT J ONCOL, V23, P1493; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Gollob JA, 2006, SEMIN ONCOL, V33, P392, DOI 10.1053/j.seminoncol.2006.04.002; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; Goutebroze L, 2000, MOL CELL BIOL, V20, P1699, DOI 10.1128/MCB.20.5.1699-1712.2000; Gutmann DH, 2001, HUM MOL GENET, V10, P825, DOI 10.1093/hmg/10.8.825; Hartkamp J, 1999, CANCER RES, V59, P2195; Hung G, 2002, INT J ONCOL, V20, P475; Ikeda K, 1999, J NEUROSURG, V91, P85, DOI 10.3171/jns.1999.91.1.0085; Jannatipour M, 2001, J BIOL CHEM, V276, P33093, DOI 10.1074/jbc.M105792200; Jin HC, 2006, NATURE, V442, P576, DOI 10.1038/nature04856; Khatlani TS, 2007, ONCOGENE, V26, P2658, DOI 10.1038/sj.onc.1210050; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lee JY, 2006, ONCOGENE, V25, P1143, DOI 10.1038/sj.onc.1209150; Leung IWL, 2001, J BIOL CHEM, V276, P1961, DOI 10.1074/jbc.M004092200; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; LUTCHMAN M, 1995, CANCER RES, V55, P2270; McClatchey AI, 1997, GENE DEV, V11, P1253, DOI 10.1101/gad.11.10.1253; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Morrison H, 2007, CANCER RES, V67, P520, DOI 10.1158/0008-5472.CAN-06-1608; Obremski VJ, 1998, J NEUROBIOL, V37, P487, DOI 10.1002/(SICI)1097-4695(199812)37:4<487::AID-NEU1>3.3.CO;2-2; Okada T, 2005, J CELL BIOL, V171, P361, DOI 10.1083/jcb.200503165; Poulikakos PI, 2006, ONCOGENE, V25, P5960, DOI 10.1038/sj.onc.1209587; Ramesh V, 2004, NAT REV NEUROSCI, V5, P462, DOI 10.1038/nrn1407; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Reed N, 2001, TRENDS MOL MED, V7, P157, DOI 10.1016/S1471-4914(01)01955-4; Rennefahrt U, 2004, CANCER LETT, V215, P113, DOI 10.1016/j.canlet.2004.05.015; Rennefahrt UEE, 2002, J BIOL CHEM, V277, P29510, DOI 10.1074/jbc.M203010200; Rong R, 2004, ONCOGENE, V23, P8447, DOI 10.1038/sj.onc.1207794; Scoles DR, 2000, HUM MOL GENET, V9, P1567, DOI 10.1093/hmg/9.11.1567; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Sun CX, 2002, J CELL SCI, V115, P3991, DOI 10.1242/jcs.00094; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Vacratsis PO, 2000, J BIOL CHEM, V275, P27893; Velho S, 2010, HUM MOL GENET, V19, P697, DOI 10.1093/hmg/ddp536; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Zhang H, 2001, J BIOL CHEM, V276, P45598, DOI 10.1074/jbc.M107176200	46	21	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	7					781	789		10.1038/onc.2010.453	http://dx.doi.org/10.1038/onc.2010.453			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722OT	20890305	Green Accepted			2022-12-17	WOS:000287444600003
J	Hebbard, L; Cecena, G; Golas, J; Sawada, J; Ellies, LG; Charbono, A; Williams, R; Jimenez, RE; Wankell, M; Arndt, KT; DeJoy, SQ; Rollins, RA; Diesl, V; Follettie, M; Chen, L; Rosfjord, E; Cardiff, RD; Komatsu, M; Boschelli, F; Oshima, RG				Hebbard, L.; Cecena, G.; Golas, J.; Sawada, J.; Ellies, L. G.; Charbono, A.; Williams, R.; Jimenez, R. E.; Wankell, M.; Arndt, K. T.; DeJoy, S. Q.; Rollins, R. A.; Diesl, V.; Follettie, M.; Chen, L.; Rosfjord, E.; Cardiff, R. D.; Komatsu, M.; Boschelli, F.; Oshima, R. G.			Control of mammary tumor differentiation by SKI-606 (bosutinib)	ONCOGENE			English	Article						Src; SKI-606; mouse; breast cancer; Ezh2	SRC TYROSINE KINASE; C-SRC; BREAST-CANCER; GENE-EXPRESSION; EZH2; ACTIVATION; INHIBITOR; INDUCTION; GROWTH; MODEL	C-Src is infrequently mutated in human cancers but it mediates oncogenic signals of many activated growth factor receptors and thus remains a key target for cancer therapy. However, the broad function of Src in many cell types and processes requires evaluation of Src-targeted therapeutics within a normal developmental and immune-competent environment. In an effort to understand the appropriate clinical use of Src inhibitors, we tested an Src inhibitor, SKI-606 (bosutinib), in the MMTV-PyVmT transgenic mouse model of breast cancer. Tumor formation in this model is dependent on the presence of Src, but the necessity of Src kinase activity for tumor formation has not been determined. Furthermore, Src inhibitors have not been examined in an autochthonous tumor model that permits assessment of effects on different stages of tumor progression. Here we show that oral administration of SKI-606 inhibited the phosphorylation of Src in mammary tumors and caused a rapid decrease in the Ezh2 Polycomb group histone H3K27 methyltransferase and an increase in epithelial organization. SKI-606 prevented the appearance of palpable tumors in over 50% of the animals and stopped tumor growth in older animals with pre-existing tumors. These antitumor effects were accompanied by decreased cellular proliferation, altered tumor blood vessel organization and dramatically increased differentiation to lactational and epidermal cell fates. SKI-606 controls the development of mammary tumors by inducing differentiation. Oncogene (2011) 30, 301-312; doi:10.1038/onc.2010.412; published online 6 September 2010	[Hebbard, L.; Cecena, G.; Charbono, A.; Williams, R.; Wankell, M.; Oshima, R. G.] Sanford Burnham Med Res Inst, Canc Res Ctr, La Jolla, CA 92037 USA; [Golas, J.; Arndt, K. T.; DeJoy, S. Q.; Rollins, R. A.; Diesl, V.; Follettie, M.; Chen, L.; Rosfjord, E.; Boschelli, F.] Pfizer Res, Ctr Integrat Biol & Biotherapeut, Pearl River, NY USA; [Sawada, J.; Komatsu, M.] Sanford Burnham Med Res Inst, Lake Nona, FL USA; [Ellies, L. G.] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA; [Jimenez, R. E.] Univ Calif San Diego, Program Biomed Sci, La Jolla, CA 92093 USA; [Cardiff, R. D.] Univ Calif Davis, Ctr Genom Pathol, Davis, CA 95616 USA	Sanford Burnham Prebys Medical Discovery Institute; Pfizer; Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California Davis	Oshima, RG (corresponding author), Sanford Burnham Med Res Inst, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rgoshima@burnham.org	Hebbard, Lionel/O-1489-2017; Sawada, Junko/C-9199-2012; Hebbard, Lionel w/F-7272-2014; Komatsu, Masanobu/AAV-3013-2020; Hebbard, Lionel/W-4057-2019; Rollins, Robert/R-2978-2019	Hebbard, Lionel/0000-0002-7094-9065; Rosfjord, Edward/0000-0002-3449-7444; Komatsu, Masanobu/0000-0001-7548-137X; Williams, Roy/0000-0002-5442-9166	Pfizer Research; NCI Cancer Center [2 P30 CA030199, R01 CA125255]; NATIONAL CANCER INSTITUTE [P30CA030199, R01CA125255] Funding Source: NIH RePORTER	Pfizer Research(Pfizer); NCI Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Mina Bissell, Lawrence Berkley National Laboratory for the gift of casein antibody, and Robert Abraham, Pfizer Research for his interest and support of the project. This work was supported by a collaborative research grant from Pfizer Research, and shared resource support from the NCI Cancer Center Support Grant 2 P30 CA030199 and R01 CA125255 (MK).	Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Boschelli DH, 2001, J MED CHEM, V44, P3965, DOI 10.1021/jm0102250; Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Cheung ATW, 1997, INT J ONCOL, V11, P69; Coluccia AML, 2006, CANCER RES, V66, P2279, DOI 10.1158/0008-5472.CAN-05-2057; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; Criscuoli ML, 2005, BLOOD, V105, P1508, DOI 10.1182/blood-2004-06-2246; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Ezhkova E, 2009, CELL, V136, P1122, DOI 10.1016/j.cell.2008.12.043; Finn RS, 2008, ANN ONCOL, V19, P1379, DOI 10.1093/annonc/mdn291; Galang CK, 2004, J BIOL CHEM, V279, P11281, DOI 10.1074/jbc.M311887200; Golas JM, 2005, CANCER RES, V65, P5358, DOI 10.1158/0008-5472.CAN-04-2484; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Ishizawar RC, 2007, ONCOGENE, V26, P3503, DOI 10.1038/sj.onc.1210138; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Jallal H, 2007, CANCER RES, V67, P1580, DOI 10.1158/0008-5472.CAN-06-2027; Kim H, 2005, ONCOGENE, V24, P7599, DOI 10.1038/sj.onc.1208898; Kim H, 2005, ONCOGENE, V24, P5629, DOI 10.1038/sj.onc.1208718; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Klein A, 2005, J MOL MED, V83, P362, DOI 10.1007/s00109-004-0625-1; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Li X, 2009, AM J PATHOL, V175, P1246, DOI 10.2353/ajpath.2009.090042; Li Z, 2007, CANCER CELL, V12, P542, DOI 10.1016/j.ccr.2007.11.012; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Liu M, 2005, CANCER RES, V65, P5325, DOI 10.1158/0008-5472.CAN-04-4589; Maglione JE, 2001, CANCER RES, V61, P8298; Man AK, 2003, MOL CELL BIOL, V23, P8614, DOI 10.1128/MCB.23.23.8614-8625.2003; Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; Neznanov N, 1999, CANCER RES, V59, P4242; Oshima RG, 2004, CANCER RES, V64, P169, DOI 10.1158/0008-5472.CAN-03-1944; Rix LLR, 2009, LEUKEMIA, V23, P477, DOI 10.1038/leu.2008.334; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Rudolph MC, 2007, PHYSIOL GENOMICS, V28, P323, DOI 10.1152/physiolgenomics.00020.2006; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; Silva CM, 2007, MOL ENDOCRINOL, V21, P1499, DOI 10.1210/me.2007-0109; SPECTOR DH, 1978, P NATL ACAD SCI USA, V75, P4102, DOI 10.1073/pnas.75.9.4102; Summy JM, 2006, CLIN CANCER RES, V12, P1398, DOI 10.1158/1078-0432.CCR-05-2692; Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395; Vultur A, 2008, MOL CANCER THER, V7, P1185, DOI 10.1158/1535-7163.MCT-08-0126; Watkin H, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-6; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130	51	21	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	3					301	312		10.1038/onc.2010.412	http://dx.doi.org/10.1038/onc.2010.412			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709DY	20818417	Green Accepted, Green Submitted			2022-12-17	WOS:000286418800005
J	Madison, DL; Lundblad, JR				Madison, D. L.; Lundblad, J. R.			C-terminal binding protein and poly(ADP)ribose polymerase 1 contribute to repression of the p21(waf1/cip1) promoter	ONCOGENE			English	Article						Poly(ADP)ribose Polymerase; p21; CtBP; PARP inhibitor	ADENOVIRUS E1A; POLY(ADP-RIBOSE) POLYMERASE-1; CELLULAR PHOSPHOPROTEIN; COREPRESSOR FUNCTION; NEGATIVE MODULATION; CANCER-CELLS; TRANSCRIPTION; PARP-1; CTBP; ACTIVATION	Transcriptional repression by the C-terminal binding protein (CtBP) is proposed to require nicotinamide adenine dinucleotide dehydrogenase (NAD(H). Previous studies have implicated CtBP in transcriptional repression of the p21(waf1/cip1) gene. Similarly, the NAD-dependent poly(adenosine diphosphate) ribose polymerase 1 (PARP1) may affect p21 expression via its NAD-dependent enzymatic activity; we therefore asked if PARP1 and CtBP were functionally linked in regulating p21 transcription. We found that restraint of basal p21 transcription requires both CtBP and PARP1. PARP inhibition attenuated activation of p21 transcription by both p53-independent and p53-dependent processes, in a CtBP-dependent manner. CtBP1 + 2 or PARP1 + 2 knockdown partially activated p21 gene expression, suggesting relief of a corepressor function dependent on both proteins. We localized CtBP-responsive repression elements to the proximal promoter region, and found ZBRK1 overexpression could also overcome DNA damage-dependent, but not p53-dependent activation through this region. By chromatin immunoprecipitation we find dismissal of CtBP from the proximal promoter following DNA-damage, and that PARP1 associates with a CtBP corepressor complex in nuclear extracts. We propose a model in which both CtBP and PARP functionally interact in a corepressor complex as components of a molecular switch necessary for p21 repression, and following DNA damage signals activation of p21 transcription by corepressor dismissal and coactivator recruitment. Oncogene (2010) 29, 6027-6039; doi:10.1038/onc.2010.338; published online 16 August 2010	[Madison, D. L.; Lundblad, J. R.] Oregon Hlth & Sci Univ, Div Endocrinol, Dept Med, Portland, OR 97239 USA; [Madison, D. L.] Portland VA Med Ctr, Endocrine Sect, Dept Hosp & Specialty Med, Portland, OR USA	Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center	Madison, DL (corresponding author), Oregon Hlth & Sci Univ, Div Endocrinol, Dept Med, L-604,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	Madisond@ohsu.edu			 [NIDDK R01DK060133];  [NCI K08CA109158]; NATIONAL CANCER INSTITUTE [K08CA109158] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060133] Funding Source: NIH RePORTER	; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work as supported by Grants (NIDDK R01DK060133) to JRL and DLM (NCI K08CA109158). We thank J Hildebrand (University of Pittsburgh) for the CtBP MEFs, R Klein (OHSU) for access to and assistance with real time PCR, R Kwok (University of Michigan) for the p53 expression construct and Madeleine Pham and Loren Brown for technical assistance.	Altmeyer M, 2009, NUCLEIC ACIDS RES, V37, P3723, DOI 10.1093/nar/gkp229; Ambrose HE, 2007, ONCOGENE, V26, P6244, DOI 10.1038/sj.onc.1210434; Amiri KI, 2006, ONCOGENE, V25, P7714, DOI 10.1038/sj.onc.1209751; Balasubramanian P, 2003, FEBS LETT, V537, P157, DOI 10.1016/S0014-5793(03)00119-4; Bergman LM, 2006, APOPTOSIS, V11, P879, DOI 10.1007/s10495-006-6651-4; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chinnadurai G, 2007, INT J BIOCHEM CELL B, V39, P1593, DOI 10.1016/j.biocel.2007.01.025; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; Furuta S, 2006, CANCER CELL, V10, P13, DOI 10.1016/j.ccr.2006.05.022; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Grooteclaes M, 2003, P NATL ACAD SCI USA, V100, P4568, DOI 10.1073/pnas.0830998100; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Haapajarvi T, 1999, EXP CELL RES, V248, P272, DOI 10.1006/excr.1999.4403; Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002; Ju BG, 2004, CELL, V119, P815, DOI 10.1016/j.cell.2004.11.017; Kameoka M, 2004, J VIROL, V78, P8931, DOI 10.1128/JVI.78.16.8931-8934.2004; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002; Kolthur-Seetharam U, 2006, CELL CYCLE, V5, P873, DOI 10.4161/cc.5.8.2690; Kraus WL, 2008, CURR OPIN CELL BIOL, V20, P294, DOI 10.1016/j.ceb.2008.03.006; Krishnakumar R, 2008, SCIENCE, V319, P819, DOI 10.1126/science.1149250; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; Lee YK, 2007, J BIOL CHEM, V282, P1595, DOI 10.1074/jbc.M606306200; Li M, 2004, BIOCHEM J, V382, P323, DOI 10.1042/BJ20040593; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Mottet D, 2009, ONCOGENE, V28, P243, DOI 10.1038/onc.2008.371; MOYED HS, 1983, J BACTERIOL, V155, P557, DOI 10.1128/JB.155.2.557-564.1983; Nardini M, 2003, EMBO J, V22, P3122, DOI 10.1093/emboj/cdg283; Nibu Y, 1998, EMBO J, V17, P7009, DOI 10.1093/emboj/17.23.7009; Ocker M, 2007, INT J BIOCHEM CELL B, V39, P1367, DOI 10.1016/j.biocel.2007.03.001; Ogino H, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-41; Pavri R, 2005, MOL CELL, V18, P83, DOI 10.1016/j.molcel.2005.02.034; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Quinlan KGR, 2006, MOL CELL BIOL, V26, P8159, DOI 10.1128/MCB.00680-06; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; Takasawa R, 2005, APOPTOSIS, V10, P1121, DOI 10.1007/s10495-005-0901-8; Tan W, 2004, J BIOL CHEM, V279, P6576, DOI 10.1074/jbc.M312270200; Tao ZH, 2009, J AM CHEM SOC, V131, P14258, DOI 10.1021/ja906135d; Verger A, 2006, MOL CELL BIOL, V26, P4882, DOI 10.1128/MCB.02402-05; Wieler S, 2003, J BIOL CHEM, V278, P18914, DOI 10.1074/jbc.M211641200; Wilson AJ, 2008, MOL BIOL CELL, V19, P4062, DOI 10.1091/mbc.E08-02-0139; Zhang QH, 2005, P NATL ACAD SCI USA, V102, P2802, DOI 10.1073/pnas.0409373102; Zhang QH, 2002, SCIENCE, V295, P1895; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7	52	21	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	45					6027	6039		10.1038/onc.2010.338	http://dx.doi.org/10.1038/onc.2010.338			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	678VA	20711239	Green Accepted			2022-12-17	WOS:000284108700005
J	Yamaguchi, H; Chen, CT; Chou, CK; Pal, A; Bornmann, W; Hortobagyi, GN; Hung, MC				Yamaguchi, H.; Chen, C-T; Chou, C-K; Pal, A.; Bornmann, W.; Hortobagyi, G. N.; Hung, M-C			Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation	ONCOGENE			English	Article						HDAC inhibitors; E1A; apoptosis; Bim; gene therapy	OVARIAN-CANCER CELLS; HUMAN BREAST-CANCER; GENE-THERAPY; CLINICAL-TRIAL; HER-2/NEU-OVEREXPRESSING BREAST; E1A-LIPOSOME COMPLEX; TUMOR-CELLS; IN-VIVO; EXPRESSION; DELIVERY	Histone deacetylase inhibitors (HDACi) are potent anticancer agents for variety of cancer types. Suberoylanilide hydroxamic acid (SAHA) has been approved as a drug to treat cutaneous T cell lymphoma, and the combination of HDACi and other agents have been actively tested in many clinical trials. Adenovirus 5 early region 1A (E1A) has been shown to exhibit high tumor suppressor activity, and gene therapy using E1A has been tested in clinical trials. Here, we showed that proapoptotic activity of HDACi was robustly enhanced by E1A in multiple cancer cells, but not in normal cells. Moreover, we showed that combination of E1A gene therapy and SAHA showed high therapeutic efficacy with low toxicity in vivo ovarian and breast xenograft models. SAHA downregulated Bcl-XL and upregulated proapoptotic BH3-only protein Bim, whose expression was further enhanced by E1A in cancer cells. These alterations of Bcl-2 family proteins were critical for apoptosis induced by the combination in cancer cells. SAHA enhanced acetylation of histone H3 in Bim promoter region, while E1A upregulated Egr-1, which was directly involved in Bim transactivation. Together, our results provide not only a novel insight into the mechanisms underlying anti-tumor activity of E1A, but also a rationale for the combined HDACi and E1A gene therapy in future clinical trials. Oncogene (2010) 29, 5619-5629; doi:10.1038/onc.2010.295; published online 2 August 2010	[Yamaguchi, H.; Chen, C-T; Chou, C-K; Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Chen, C-T; Hung, M-C] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA; [Pal, A.] Univ Texas MD Anderson Canc Ctr, Dept Expt Diagnost Imaging, Houston, TX 77030 USA; [Bornmann, W.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Hortobagyi, G. N.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; [Hung, M-C] China Med Univ & Hosp, Ctr Mol Med, Taichung, Taiwan; [Hung, M-C] China Med Univ & Hosp, Grad Inst Canc Biol, Taichung, Taiwan; [Hung, M-C] Asia Univ, Taichung, Taiwan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Asia University Taiwan	Hung, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Unit 079, Houston, TX 77030 USA.	mhung@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; CHOU, CHAO-KAI/0000-0001-5231-5264	SPORE Grant in ovarian cancer and breast cancer [P50 CA83639, PO50 CA116199]; National Breast Cancer Foundation; MDACC China Medical University and Hospital Sister Institution; Cancer Center [CA16672]; Cancer Research Center of Excellence [DOH99-TD-C-111-005]; Taiwan Department of Health; MARCUS Foundation; NATIONAL CANCER INSTITUTE [P01CA099031, R01CA109311, P50CA083639, P50CA116199, P30CA016672] Funding Source: NIH RePORTER	SPORE Grant in ovarian cancer and breast cancer; National Breast Cancer Foundation; MDACC China Medical University and Hospital Sister Institution; Cancer Center; Cancer Research Center of Excellence; Taiwan Department of Health; MARCUS Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Jingwen Liu (Palo Alto Health Care System) and Thomas E Eling (National Institute of Health) for Egr-1 dominant negative expression plasmid and Egr-1 luciferase plasmid, respectively. We thank Dr Yongkun Wei for help in carrying out statistical analysis of xenograft experiments. We thank Drs Jennifer L. Hsu and Stephanie Miller for help in preparation of this paper. This work was supported by a SPORE Grant in ovarian cancer and breast cancer (P50 CA83639 and PO50 CA116199), the National Breast Cancer Foundation, MDACC China Medical University and Hospital Sister Institution Fund, Cancer Center Support Grant CA16672, DOH99-TD-C-111-005 Cancer Research Center of Excellence, Taiwan Department of Health, and the MARCUS Foundation. In memoriam, Mrs Serena Lin-Guo for her courageous fight against breast cancer.	Baek SJ, 2003, J BIOL CHEM, V278, P5845, DOI 10.1074/jbc.M208394200; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Brader KR, 1997, CLIN CANCER RES, V3, P2017; Burgess A, 2004, ONCOGENE, V23, P6693, DOI 10.1038/sj.onc.1207893; BYRD PJ, 1988, ONCOGENE, V2, P477; Chang JY, 1997, ONCOGENE, V14, P561, DOI 10.1038/sj.onc.1200861; Chou CK, 2009, MOL CARCINOGEN, V48, P1048, DOI 10.1002/mc.20557; Cook JL, 2005, FRONT BIOSCI-LANDMRK, V10, P1396, DOI 10.2741/1628; Day CP, 2006, CANCER GENE THER, V13, P706, DOI 10.1038/sj.cgt.7700945; Deng J, 1998, ONCOGENE, V17, P2167, DOI 10.1038/sj.onc.1202148; FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; Frisch SM, 2004, CLIN CANCER RES, V10, P2905, DOI 10.1158/1078-0432.CCR-04-0644; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Hortobagyi GN, 2001, J CLIN ONCOL, V19, P3422, DOI 10.1200/JCO.2001.19.14.3422; Hubberstey AV, 2002, CANCER GENE THER, V9, P321, DOI 10.1038/sj.cgt.7700436; Hung MC, 2000, ADV EXP MED BIOL, V465, P171; Lane AA, 2009, J CLIN ONCOL, V27, P5459, DOI 10.1200/JCO.2009.22.1291; Liao Y, 2004, CANCER GENE THER, V11, P594, DOI 10.1038/sj.cgt.7700743; Liao Y, 2007, ADV EXP MED BIOL, V608, P144; Liu JW, 2005, ONCOGENE, V24, P2020, DOI 10.1038/sj.onc.1208385; Lo HW, 2005, ADV GENET, V54, P235, DOI 10.1016/S0065-2660(05)54010-0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lubieniecka JM, 2008, CANCER RES, V68, P4303, DOI 10.1158/0008-5472.CAN-08-0092; Madhusudan S, 2004, CLIN CANCER RES, V10, P2986, DOI 10.1158/1078-0432.CCR-03-0291; Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Pan LN, 2007, CANCER, V109, P1676, DOI 10.1002/cncr.22585; Pirollo KF, 2008, CANCER RES, V68, P1247, DOI 10.1158/0008-5472.CAN-07-5810; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; Stoff-Khalili MA, 2006, CANCER GENE THER, V13, P633, DOI 10.1038/sj.cgt.7700929; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Ueno NT, 2002, CANCER RES, V62, P6712; Ueno NT, 2000, CLIN CANCER RES, V6, P250; Ueno NT, 1997, ONCOGENE, V15, P953, DOI 10.1038/sj.onc.1201250; Ungerstedt JS, 2005, P NATL ACAD SCI USA, V102, P673, DOI 10.1073/pnas.0408732102; Uren RT, 2005, J BIOL CHEM, V280, P2266, DOI 10.1074/jbc.M411106200; Villaret D, 2002, HEAD NECK-J SCI SPEC, V24, P661, DOI 10.1002/hed.10107; Wang YN, 2006, MOL PHARMACOL, V69, P85, DOI 10.1124/mol.105.016220; Xie XM, 2007, CANCER CELL, V12, P52, DOI 10.1016/j.ccr.2007.05.009; Xie XM, 2009, MOL CANCER THER, V8, P2375, DOI 10.1158/1535-7163.MCT-09-0056; Xing X, 1997, GENE THER, V4, P238, DOI 10.1038/sj.gt.3300376; Xing X, 1998, GENE THER, V5, P1538, DOI 10.1038/sj.gt.3300771; Xu WS, 2006, P NATL ACAD SCI USA, V103, P15540, DOI 10.1073/pnas.0607518103; Yamaguchi H, 2003, CANCER RES, V63, P1483; YAN DH, 1991, ONCOGENE, V6, P343; Yang XJ, 2008, NAT REV MOL CELL BIO, V9, P206, DOI 10.1038/nrm2346; Yoo GH, 2001, CLIN CANCER RES, V7, P1237; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1995, ONCOGENE, V11, P1383; Zhang F, 2003, J BIOL CHEM, V278, P44246, DOI 10.1074/jbc.M305564200	58	21	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2010	29	41					5619	5629		10.1038/onc.2010.295	http://dx.doi.org/10.1038/onc.2010.295			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FX	20676141	Green Accepted			2022-12-17	WOS:000282946900008
J	Oh, W; Lee, EW; Lee, D; Yang, MR; Ko, A; Yoon, CH; Lee, HW; Bae, YS; Choi, CY; Song, J				Oh, W.; Lee, E-W; Lee, D.; Yang, M-R; Ko, A.; Yoon, C-H; Lee, H-W; Bae, Y-S; Choi, C. Y.; Song, J.			Hdm2 negatively regulates telomerase activity by functioning as an E3 ligase of hTERT	ONCOGENE			English	Article						Hdm2; telomerase; hTERT; p53; ubiquitination	HUMAN TUMOR-CELLS; DOWN-REGULATION; LIFE-SPAN; P53; CANCER; APOPTOSIS; EXPRESSION; DEGRADATION; GROWTH; MDM2	In this study, we identified posttranslational regulation of human telomerase reverse-transcriptase (hTERT) by the E3 ligase Hdm2. The telomerase activity generated by exogenous hTERT in U2OS cells was reduced on adriamycin treatment. The overexpressed levels of hTERT were also decreased under the same conditions. These processes were reversed by treatment with a proteasome inhibitor or depletion of Hdm2. Furthermore, intrinsic telomerase activity was increased in HCT116 cells with ablation of Hdm2. Immunoprecipitation analyses showed that hTERT and Hdm2 bound to each other in multiple domains. Ubiquitination analyses showed that Hdm2 could polyubiquitinate hTERT principally at the N-terminus, which was further degraded in a proteasome-dependent manner. An hTERT mutant with all five lysine residues at the N-terminus of hTERT that mutated to arginine became resistant to Hdm2-mediated ubiquitination and degradation. In U2OS cells, depletion of Hdm2 or addition of the Hdm2-resistant hTERT mutant strengthened the cellular protective effects against apoptosis. Similar results were obtained with the Hdm2-stable H1299 cell line. These observations indicate that Hdm2 is an E3 ligase of hTERT. Oncogene (2010) 29, 4101-4112; doi:10.1038/onc.2010.160; published online 10 May 2010	[Oh, W.; Lee, E-W; Yang, M-R; Ko, A.; Song, J.] Sungkyunkwan Univ, Dept Biotechnol & Bioengn, Suwon 440746, South Korea; [Lee, D.; Yoon, C-H; Bae, Y-S; Choi, C. Y.] Sungkyunkwan Univ, Dept Biol Sci, Suwon 440746, South Korea; [Lee, H-W] Yonsei Univ, Dept Biochem, Seoul 120749, South Korea	Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Yonsei University	Song, J (corresponding author), Sungkyunkwan Univ, Dept Biotechnol & Bioengn, Suwon 440746, South Korea.	jso678@skku.edu	Lee, Eun-Woo/AAP-9603-2020	Song, Jaewhan/0000-0001-8152-9210; Ko, Aram/0000-0003-4997-3092; Lee, Eun-Woo/0000-0002-5156-0003	Ministry of Health and Welfare, Republic of Korea [0820110, A080333]	Ministry of Health and Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea)	This work was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (0820110) and by a grant of the Korea Healthcare technology R&D Project, Ministry of Health and Welfare, Republic of Korea (A080333).	Akiyama M, 2002, CANCER RES, V62, P3876; Blackburn EH, 2000, NAT STRUCT BIOL, V7, P847, DOI 10.1038/79594; Blasco MA, 2003, CURR OPIN GENET DEV, V13, P70, DOI 10.1016/S0959-437X(02)00011-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bouska A, 2009, TRENDS BIOCHEM SCI, V34, P279, DOI 10.1016/j.tibs.2009.02.006; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Cairney CJ, 2008, BIOCHIMIE, V90, P13, DOI 10.1016/j.biochi.2007.07.025; Camus S, 2007, ONCOGENE, V26, P4059, DOI 10.1038/sj.onc.1210188; Cao Y, 2002, ONCOGENE, V21, P3130, DOI 10.1038/sj.onc.1205419; Carroll VA, 2008, CANCER RES, V68, P545, DOI 10.1158/0008-5472.CAN-06-4738; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; Cong YS, 2008, CELL RES, V18, P725, DOI 10.1038/cr.2008.74; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; Dairkee SH, 2007, ONCOGENE, V26, P6269, DOI 10.1038/sj.onc.1210452; Dalla Torre CA, 2002, BRAZ J MED BIOL RES, V35, P65, DOI 10.1590/S0100-879X2002000100009; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Dimri GP, 2002, CANCER RES, V62, P4736; Enge M, 2009, CANCER CELL, V15, P171, DOI 10.1016/j.ccr.2009.01.019; Froment P, 2008, CELL CYCLE, V7, P3098, DOI 10.4161/cc.7.19.6807; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Harley CB, 2008, NAT REV CANCER, V8, P167, DOI 10.1038/nrc2275; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; Kim JH, 2005, GENE DEV, V19, P776, DOI 10.1101/gad.1289405; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Kusumoto M, 1999, CLIN CANCER RES, V5, P2140; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Luiten RM, 2003, BLOOD, V101, P4512, DOI 10.1182/blood-2002-07-2018; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Oh W, 2006, J BIOL CHEM, V281, P17457, DOI 10.1074/jbc.M601857200; Oh W, 2009, J CELL SCI, V122, P2613, DOI 10.1242/jcs.048066; Rahman R, 2005, ONCOGENE, V24, P1320, DOI 10.1038/sj.onc.1208232; Roth A, 2003, BLOOD, V102, P849, DOI 10.1182/blood-2002-07-2015; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; Shats I, 2004, J BIOL CHEM, V279, P50976, DOI 10.1074/jbc.M402502200; Teng LS, 2003, J CLIN ENDOCR METAB, V88, P1362, DOI 10.1210/jc.2002-021222; Urquidi V, 2000, ANNU REV MED, V51, P65, DOI 10.1146/annurev.med.51.1.65; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Wu YL, 2006, J CELL SCI, V119, P2797, DOI 10.1242/jcs.03001; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhang Z, 2005, CURR CANCER DRUG TAR, V5, P9, DOI 10.2174/1568009053332618	44	21	22	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	2010	29	28					4101	4112		10.1038/onc.2010.160	http://dx.doi.org/10.1038/onc.2010.160			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	625JW	20453884				2022-12-17	WOS:000279892400010
J	Singh, J; Aaronson, SA; Mlodzik, M				Singh, J.; Aaronson, S. A.; Mlodzik, M.			Drosophila Abelson kinase mediates cell invasion and proliferation through two distinct MAPK pathways	ONCOGENE			English	Article						Drosophila; Abl; Src; kinase; cell invasive behavior	ABL TYROSINE KINASE; BREAST-CANCER CELLS; BINDING PROTEIN RAC; C-ABL; SIGNALING PATHWAY; FAMILY KINASES; DISC EVERSION; BCR-ABL; SRC; JNK	The Abelson (Abl) family of non-receptor tyrosine kinases has an important role in cell morphogenesis, motility, and proliferation. Although the function of Abl has been extensively studied in leukemia, its role in epithelial cell invasion remains obscure. Using the Drosophila wing epithelium as an in vivo model system, we show that overexpression (activation) of Drosophila Abl (dAbl) causes loss of epithelial apical/basal cell polarity and secretion of matrix metalloproteinases, resulting in a cellular invasion and apoptosis. Our in vivo data indicate that dAbl acts downstream of the Src kinases, which are known regulators of cell adhesion and invasion. Downstream of dAbl, Rac GTPases activate two distinct MAPK pathways: c-Jun N-terminal kinase signaling (required for cell invasion and apoptosis) and ERK signaling (inducing cell proliferation). Activated Abl also increases the activity of Src members through a positive feedback loop leading to signal amplification. Thus, targeting Src-Abl, using available dual inhibitors, could be of therapeutic importance in tumor cell metastasis. Oncogene (2010) 29, 4033-4045; doi:10.1038/onc.2010.155; published online 10 May 2010	[Singh, J.; Mlodzik, M.] Mt Sinai Sch Med, Dept Dev & Regenerat Biol, New York, NY 10029 USA; [Aaronson, S. A.] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Mlodzik, M (corresponding author), Mt Sinai Sch Med, Dept Dev & Regenerat Biol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	marek.mlodzik@mssm.edu			NIH/NCI; NIH/National Eye Institute [R01 EY14597]; NATIONAL EYE INSTITUTE [R01EY014597, R01EY013256] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	We thank the Bloomington Stock Center, DSHB, Ed Giniger, and Ross Cagan for fly stocks and antibodies. We are grateful to members of the Mlodzik lab for helpful suggestions, discussions, and criticism, Ross Cagan and members of the Cagan lab for discussion and reagents, in particular Tirtha Das. We also thank William Gault for critical reading of the manuscript, Nadinath Nillegoda, and Maneesha Chhikara for helpful comments and suggestions, and Joyce Lau, Sophy Okello, and Andrea Blitzer for technical help. Confocal laser microscopy was performed at the MSSM Microscopy SRF, supported by an NIH/NCI shared instrumentation grant. This research was supported by NIH/National Eye Institute Grant R01 EY14597 to MM.	Araujo J, 2010, CANCER TREAT REV, V36, P492, DOI 10.1016/j.ctrv.2010.02.015; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Boureux A, 2005, J CELL SCI, V118, P3717, DOI 10.1242/jcs.02491; BRAND AH, 1993, DEVELOPMENT, V118, P401; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Das J, 2006, J MED CHEM, V49, P6819, DOI 10.1021/jm060727j; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Golas JM, 2003, CANCER RES, V63, P375; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARDEN N, 1995, DEVELOPMENT, V121, P903; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Huh JR, 2004, CURR BIOL, V14, P1262, DOI 10.1016/j.cub.2004.06.015; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; Lanier LM, 2000, CURR OPIN NEUROBIOL, V10, P80, DOI 10.1016/S0959-4388(99)00058-6; Lin J, 2008, ONCOGENE, V27, P4385, DOI 10.1038/onc.2008.86; Luster AD, 2005, NAT IMMUNOL, V6, P1182, DOI 10.1038/ni1275; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; Pastor-Pareja JC, 2004, DEV CELL, V7, P387, DOI 10.1016/j.devcel.2004.07.022; Pedraza LG, 2004, ONCOGENE, V23, P4754, DOI 10.1038/sj.onc.1207635; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Ryoo HD, 2004, DEV CELL, V7, P491, DOI 10.1016/j.devcel.2004.08.019; Salhia B, 2008, AM J PATHOL, V173, P1828, DOI 10.2353/ajpath.2008.080043; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Shindo M, 2008, DEVELOPMENT, V135, P1355, DOI 10.1242/dev.015982; Sirvent A, 2007, ONCOGENE, V26, P7313, DOI 10.1038/sj.onc.1210543; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Srivastava A, 2007, P NATL ACAD SCI USA, V104, P2721, DOI 10.1073/pnas.0611666104; Stevens TL, 2008, MOL BIOL CELL, V19, P378, DOI 10.1091/mbc.E07-01-0008; Sugimura M, 2000, JPN J CANCER RES, V91, P395, DOI 10.1111/j.1349-7006.2000.tb00958.x; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; Vidal M, 2006, DEV CELL, V10, P33, DOI 10.1016/j.devcel.2005.11.007; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; Yang JH, 2008, BIOCHEM BIOPH RES CO, V374, P512, DOI 10.1016/j.bbrc.2008.07.057	48	21	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	2010	29	28					4033	4045		10.1038/onc.2010.155	http://dx.doi.org/10.1038/onc.2010.155			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	625JW	20453880	Green Accepted			2022-12-17	WOS:000279892400004
J	Walter, K; Cockerill, PN; Barlow, R; Clarke, D; Hoogenkamp, M; Follows, GA; Richards, SJ; Cullen, MJ; Bonifer, C; Tagoh, H				Walter, K.; Cockerill, P. N.; Barlow, R.; Clarke, D.; Hoogenkamp, M.; Follows, G. A.; Richards, S. J.; Cullen, M. J.; Bonifer, C.; Tagoh, H.			Aberrant expression of CD19 in AML with t(8;21) involves a poised chromatin structure and PAX5	ONCOGENE			English	Article						t(8;21); mixed lineage phenotype; PAX5; CD19; chromatin structure; epigenetic regulation	ACUTE MYELOID-LEUKEMIA; B-LYMPHOPOIESIS; GENE-EXPRESSION; FUSION PROTEIN; AML1-ETO; TRANSCRIPTION; TARGET; CELLS; METHYLATION; TRANSLOCATION	Correct hematopoietic differentiation requires the tightly regulated execution of lineage-specific and stage-restricted gene expression programs. This process is disturbed in hematological malignancies that typically show incomplete differentiation but often also display a mixed lineage phenotype. Co-expression of lymphoid and myeloid molecules is a well-known feature of acute myeloblastic leukemia (AML) with t(8;21). These cells consistently express the B-cell-specific transcription factor PAX5, and the B-cell-specific cell surface protein CD19. However, the functional consequences of PAX5 expression are unknown. To address this question, we studied the chromatin features of CD19, which is a direct target of PAX5 in cells with and without the t( 8; 21) chromosomal translocation. We show that CD19 chromatin exists in a poised configuration in myeloid progenitors and that this poised chromatin structure facilitates PAX5-dependent CD19 activation. Our results also show a positive correlation between PAX5 and CD19 expression in t(8;21)-positive AML cells and demonstrate that PAX5 binds to the promoter and enhancer of CD19 gene and remodels chromatin structure at the promoter. This study shows that expression of PAX5 in leukemic cells has functional consequences and points to an important role of a progenitor-specific chromatin configuration in myeloid leukemia. Oncogene (2010) 29, 2927-2937; doi:10.1038/onc.2010.56; published online 8 March 2010	[Walter, K.; Cockerill, P. N.; Barlow, R.; Clarke, D.; Hoogenkamp, M.; Follows, G. A.; Bonifer, C.; Tagoh, H.] Univ Leeds, St Jamess Univ Hosp, Leeds Inst Mol Med, Sect Expt Haematol, Leeds, W Yorkshire, England; [Richards, S. J.; Cullen, M. J.] St Jamess Inst Oncol, Haematol Malignancy Diagnost Serv, Leeds, W Yorkshire, England	Saint James's University Hospital; University of Leeds; Saint James's University Hospital	Tagoh, H (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	hiromi.tagoh@imp.ac.at	Tagoh, Hiromi/B-2954-2009	Tagoh, Hiromi/0000-0001-9905-6992; Richards, Stephen/0000-0002-8421-5353; Bonifer, Constanze/0000-0002-4267-0825; Cockerill, Peter/0000-0002-4410-8174; Hoogenkamp, Maarten/0000-0003-2429-1271	Leukaemia & Lymphoma Research; Kay Kendall Leukaemia Fund; Research Council UK	Leukaemia & Lymphoma Research; Kay Kendall Leukaemia Fund; Research Council UK(UK Research & Innovation (UKRI))	We thank M Busslinger for providing reagents including antibodies and plasmids and S Valeaux and A Ebert for technical assistance. This work was supported by Leukaemia & Lymphoma Research and by the Kay Kendall Leukaemia Fund. HT holds a Research Council UK academic fellowship.	Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Attema JL, 2007, P NATL ACAD SCI USA, V104, P12371, DOI 10.1073/pnas.0704468104; Berg T, 2008, HAEMATOL-HEMATOL J, V93, P1728, DOI 10.3324/haematol.13044; Bonifer C, 2005, CELL CYCLE, V4, P211; Cobaleda C, 2007, NAT IMMUNOL, V8, P463, DOI 10.1038/ni1454; Decker T, 2009, IMMUNITY, V30, P508, DOI 10.1016/j.immuni.2009.01.012; DREXLER HG, 1991, LEUKEMIA, V5, P637; DREXLER HG, 1993, LEUKEMIA, V7, P489; Elagib KE, 2007, CANCER LETT, V251, P179, DOI 10.1016/j.canlet.2006.10.010; Follows GA, 2003, EMBO J, V22, P2798, DOI 10.1093/emboj/cdg250; Gibson SE, 2006, AM J CLIN PATHOL, V126, P916, DOI 10.1309/UJUL60UPUP3YJE93; Graf T, 2002, BLOOD, V99, P3089, DOI 10.1182/blood.V99.9.3089; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KITA K, 1992, BLOOD, V80, P470; Kohler C, 2008, TRENDS CELL BIOL, V18, P236, DOI 10.1016/j.tcb.2008.02.005; Kondo M, 2000, NATURE, V407, P383, DOI 10.1038/35030112; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; Kwon K, 2008, IMMUNITY, V28, P751, DOI 10.1016/j.immuni.2008.04.014; Lefevre P, 2005, J BIOL CHEM, V280, P27552, DOI 10.1074/jbc.M502422200; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; MATOZAKI S, 1995, BRIT J HAEMATOL, V89, P805; Mikhail FM, 2002, CANCER GENET CYTOGEN, V135, P96, DOI 10.1016/S0165-4608(01)00633-1; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; Miyamoto T, 1996, BLOOD, V87, P4789, DOI 10.1182/blood.V87.11.4789.bloodjournal87114789; Moreau T, 2004, MOL THER, V10, P45, DOI 10.1016/j.ymthe.2004.04.005; Mulloy JC, 2005, P NATL ACAD SCI USA, V102, P4016, DOI 10.1073/pnas.0404701102; Nishida S, 2006, BLOOD, V107, P3303, DOI 10.1182/blood-2005-04-1656; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Ooi SKT, 2007, NATURE, V448, P714, DOI 10.1038/nature05987; Orford K, 2008, DEV CELL, V14, P798, DOI 10.1016/j.devcel.2008.04.002; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Peterson LF, 2007, LEUKEMIA, V21, P2010, DOI 10.1038/sj.leu.2404849; Peterson LF, 2007, BLOOD, V110, P799, DOI 10.1182/blood-2006-11-019265; READING CL, 1993, BLOOD, V81, P3083; Roessler S, 2007, MOL CELL BIOL, V27, P579, DOI 10.1128/MCB.01192-06; Schessl C, 2005, J CLIN INVEST, V115, P2159, DOI 10.1172/JCI24225; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Seet CS, 2004, J EXP MED, V199, P1689, DOI 10.1084/jem.20032202; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Tagoh H, 2006, EMBO J, V25, P1070, DOI 10.1038/sj.emboj.7600997; Tagoh H, 2004, EMBO J, V23, P4275, DOI 10.1038/sj.emboj.7600421; Tiacci E, 2004, CANCER RES, V64, P7399, DOI 10.1158/0008-5472.CAN-04-1865; Tonks A, 2007, LEUKEMIA, V21, P2495, DOI 10.1038/sj.leu.2404961; Valbuena JR, 2006, AM J CLIN PATHOL, V126, P235, DOI 10.1309/LG0Q0VXYBETJ4VHE; Walter K, 2008, BLOOD, V112, P1673, DOI 10.1182/blood-2008-02-142786; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Xie HF, 2004, CELL, V117, P663, DOI 10.1016/S0092-8674(04)00419-2	49	21	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	20					2927	2937		10.1038/onc.2010.56	http://dx.doi.org/10.1038/onc.2010.56			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599DM	20208555				2022-12-17	WOS:000277890400004
J	Gabai, VL; Sherman, MY; Yaglom, JA				Gabai, V. L.; Sherman, M. Y.; Yaglom, J. A.			HSP72 depletion suppresses gamma H2AX activation by genotoxic stresses via p53/p21 signaling	ONCOGENE			English	Article						Hsp72; senescence; radiation; doxorubicine; nutlin-3	HEAT-SHOCK PROTEINS; DNA-DAMAGE; CELLS; CANCER; SENESCENCE; REPAIR; INSTABILITY; KINASES	Knockout of heat shock protein Hsp72 was shown to promote chromosomal instability and increase radiation sensitivity of mouse fibroblasts. Here, we report that downregulation of Hsp72 in human tumor cells leads to suppression of a specific branch of the DNA damage response (DDR) that facilitates DNA repair following genotoxic insults, that is, reduced accumulation of the phosphorylated form of histone H2AX (gamma H2AX). This inhibition was due to decreased expression of H2AX as well as higher rate of gamma H2AX dephosphorylation. Formation of gamma H2AX and MDC1 radiation-induced foci was impaired in Hsp72-depleted cells, which in turn enhanced DNA damage, resulting in sensitization of cells to gamma-radiation and doxorubicin. These effects of Hsp72 knockdown were dependent on activation of the p53/p21-signaling pathway. Overall, permanent activation of the p53/p21 signaling in Hsp72-depleted cells specifically impaired the gamma H2AX pathway of the DDR, enhanced DNA damage following genotoxic insults, and led to further stimulation of the p53/p21 pathway, thus creating a positive feedback loop. The resulting strong induction of p21 precipitated senescence following exposure to DNA-damaging agents, thus accounting for higher sensitivity of cells to genotoxic stresses. Oncogene (2010) 29, 1952-1962; doi:10.1038/onc.2009.480; published online 11 January 2010	[Gabai, V. L.; Sherman, M. Y.; Yaglom, J. A.] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Gabai, VL (corresponding author), Boston Univ, Sch Med, Dept Biochem, 15 Stoughton St, Boston, MA 02118 USA.	gabai@bu.edu; yaglom@bu.edu	Gabai, Vladimir L/I-1650-2013; qiao, zhixin/I-3408-2012	Gabai, Vladimir L/0000-0003-4505-4718; Yaglom, Julia/0000-0002-8723-3506	American Cancer Society Institutional; NIH; Grunnen-baum Award	American Cancer Society Institutional(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Grunnen-baum Award	This work was supported by American Cancer Society Institutional Grant (VLG); NIH grant (MYS) and Grunnen-baum Award (JAY).	Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Cao C, 2006, MOL CANCER THER, V5, P411, DOI 10.1158/1535-7163.MCT-05-0356; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Efeyan A, 2007, CANCER RES, V67, P7350, DOI 10.1158/0008-5472.CAN-07-0200; Gabai VL, 2008, CANCER RES, V68, P1834, DOI 10.1158/0008-5472.CAN-07-5656; Gorbunova V, 2007, NUCLEIC ACIDS RES, V35, P7466, DOI 10.1093/nar/gkm756; Hunt CR, 2004, MOL CELL BIOL, V24, P899, DOI 10.1128/MCB.24.2.899-911.2004; Kabakov AE, 2006, RADIAT RES, V165, P410, DOI 10.1667/RR3514.1; Li L, 2005, J CELL BIOCHEM, V94, P298, DOI 10.1002/jcb.20355; Lou ZK, 2006, MOL CELL, V21, P187, DOI 10.1016/j.molcel.2005.11.025; Niida H, 2006, MUTAGENESIS, V21, P3, DOI 10.1093/mutage/gei063; O'Callaghan-Sunol C, 2007, CANCER RES, V67, P11779, DOI 10.1158/0008-5472.CAN-07-2441; O'Callaghan-Sunol Cornelia, 2007, V2, P169; Park JH, 2006, EMBO J, V25, P3986, DOI 10.1038/sj.emboj.7601291; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sedelnikova OA, 2004, NAT CELL BIOL, V6, P168, DOI 10.1038/ncb1095; Sedelnikova OA, 2008, AGING CELL, V7, P89, DOI 10.1111/j.1474-9726.2007.00354.x; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Vassilev LT, 2007, TRENDS MOL MED, V13, P23, DOI 10.1016/j.molmed.2006.11.002; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Yaglom J, 2003, MOL CELL BIOL, V23, P3813, DOI 10.1128/MCB.23.11.3813-3824.2003; Yaglom JA, 2007, CANCER RES, V67, P2373, DOI 10.1158/0008-5472.CAN-06-3796	24	21	24	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	13					1952	1962		10.1038/onc.2009.480	http://dx.doi.org/10.1038/onc.2009.480			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	577CV	20062073				2022-12-17	WOS:000276199600008
J	Madeo, A; Vinciguerra, M; Lappano, R; Galgani, M; Gasperi-Campani, A; Maggiolini, M; Musti, AM				Madeo, A.; Vinciguerra, M.; Lappano, R.; Galgani, M.; Gasperi-Campani, A.; Maggiolini, M.; Musti, A. M.			c-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells	ONCOGENE			English	Article						c-Jun; c-Fos; AP-1; JNK; apoptosis; 4-hydroxytamoxifen	COUPLED RECEPTOR GPR30; TRANSCRIPTION FACTOR; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; ESTROGEN-RECEPTOR; INDUCED APOPTOSIS; OXIDATIVE STRESS; MAP KINASES; C/EBP-BETA; IN-VIVO	The c-Jun N-terminal kinase (JNK) has been shown to mediate tamoxifen-induced apoptosis in breast cancer cells. However, the downstream mediators of the JNK pathway linking tamoxifen to effectors of apoptosis have yet to be identified. In this study, we analysed whether c-Jun, the major nuclear target of JNK, has a role in tamoxifen-induced apoptosis of SkBr3 breast cancer cells. We show that before DNA fragmentation and caspase 3/7 activation, cytotoxic concentrations of 4-hydroxytamoxifen (OHT) induced JNK-dependent phosphorylation of c-Jun at JNK sites earlier shown to regulate c-Jun-mediated apoptosis. In addition, OHT induced ERK-dependent expression of c-Fos and transactivation of an AP-1-responsive promoter. In particular, the ectopic expression of dominant-negative constructs blocking either AP-1 activity or c-Jun N-terminal phosphorylation prevented DNA fragmentation after OHT treatment. Furthermore, both c-Fos expression and c-Jun N-terminal phosphorylation preceded OHT-dependent activation of caspase 3-7 in different types of tamoxifen-sensitive cancer cells, but not in OHT-resistant LNCaP prostate cancer cells. Taken together, our results indicate that the c-Jun/c-Fos AP-1 complex has a pro-apoptotic role in OHT-treated cancer cells and suggest that pharmacological boosts of c-Jun activation may be useful in a combination therapy setting to sensitize cancer cells to tamoxifen-mediated cell death. Oncogene (2010) 29, 978-991; doi:10.1038/onc.2009.400; published online 23 November 2009	[Madeo, A.; Lappano, R.; Maggiolini, M.; Musti, A. M.] Univ Calabria, Dept Pharmacobiol, I-87036 Cosenza, Italy; [Vinciguerra, M.; Galgani, M.] Univ Naples Federico 2, Dept Cellular & Mol Biol & Pathol, Naples, Italy; [Gasperi-Campani, A.] Univ Bologna, Dept Expt Pathol, I-40126 Bologna, Italy; [Gasperi-Campani, A.] Univ Bologna, Interdepartmental Ctr Res Canc, I-40126 Bologna, Italy	University of Calabria; University of Naples Federico II; University of Bologna; University of Bologna	Maggiolini, M (corresponding author), Univ Calabria, Dept Pharmacobiol, Via P Bucci, I-87036 Cosenza, Italy.	marcellomaggiolini@yahoo.it; ammusti@yahoo.it	Galgani, Mario/AAC-3298-2022; Lappano, Rosamaria/Z-4857-2019; Musti, Anna Maria/M-2520-2019; Maggiolini, Marcello/Z-4729-2019	Maggiolini, Marcello/0000-0002-7485-854X; Galgani, Mario/0000-0001-8414-1676; Lappano, Rosamaria/0000-0002-9374-9701; MUSTI, Anna Maria/0000-0003-1443-2739	Associazione Italiana Ricerca sul Cancro (AIRC); Ministero dell'Universita' e Ricerca; Regione Calabria	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero dell'Universita' e Ricerca(Ministry of Education, Universities and Research (MIUR)); Regione Calabria(Regione Calabria)	We thank Dr Lidia Albanito for continuous helpful experimental assistance. We thank Dr Anna Grazia Recchia for the English revision of the paper. We are grateful to C Vinson, K Nose and H van Dam for gifts of reagents. Funding for this project was provided by the Associazione Italiana Ricerca sul Cancro (AIRC), Ministero dell'Universita' e Ricerca, Regione Calabria.	Albanito L, 2008, ENDOCRINOLOGY, V149, P3799, DOI 10.1210/en.2008-0117; Albanito L, 2007, CANCER RES, V67, P1859, DOI 10.1158/0008-5472.CAN-06-2909; Ballatori N, 2009, BIOL CHEM, V390, P191, DOI 10.1515/BC.2009.033; Bannister AJ, 1995, ONCOGENE, V11, P2509; Basu S, 2004, GLYCOCONJUGATE J, V20, P563; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dunn C, 2002, CELL SIGNAL, V14, P585, DOI 10.1016/S0898-6568(01)00275-3; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Friesen C, 2004, CELL DEATH DIFFER, V11, pS73, DOI 10.1038/sj.cdd.4401431; Ham J, 2005, CELL DEATH DIFFER, V12, P1015, DOI 10.1038/sj.cdd.4401689; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Kallio A, 2005, APOPTOSIS, V10, P1395, DOI 10.1007/s10495-005-2137-z; Lagadec C, 2008, ONCOGENE, V27, P1472, DOI 10.1038/sj.onc.1210749; Lee YS, 2000, CELL DEATH DIFFER, V7, P925, DOI 10.1038/sj.cdd.4400717; Liu HT, 2000, J IMMUNOL, V164, P4277, DOI 10.4049/jimmunol.164.8.4277; LOVE RR, 1989, J CLIN ONCOL, V7, P803, DOI 10.1200/JCO.1989.7.6.803; Mabuchi S, 2004, ENDOCRINOLOGY, V145, P1302, DOI 10.1210/en.2003-0709; Maggiolini M, 2004, J BIOL CHEM, V279, P27008, DOI 10.1074/jbc.M403588200; Mandlekar S, 2000, CANCER RES, V60, P5995; Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881; Morton S, 2003, EMBO J, V22, P3876, DOI 10.1093/emboj/cdg388; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; NEPHEW KP, 1993, ENDOCRINOLOGY, V133, P419, DOI 10.1210/en.133.1.419; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; Pope R, 2000, CYTOKINE, V12, P1171, DOI 10.1006/cyto.2000.0691; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Prossnitz ER, 2009, MOL CELL ENDOCRINOL, V308, P32, DOI 10.1016/j.mce.2009.03.026; Raivich G, 2008, J NEUROCHEM, V107, P898, DOI 10.1111/j.1471-4159.2008.05684.x; Raivich G, 2006, PROG NEUROBIOL, V78, P347, DOI 10.1016/j.pneurobio.2006.03.006; Recktenwald CV, 2008, CANCER RES, V68, P10086, DOI 10.1158/0008-5472.CAN-08-0360; Schiff R, 2000, J NATL CANCER I, V92, P1926, DOI 10.1093/jnci/92.23.1926; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shen HM, 1996, FREE RADICAL BIO MED, V21, P139, DOI 10.1016/0891-5849(96)00019-6; Smith WL, 1997, ACAD RADIOL, V4, P657, DOI 10.1016/S1076-6332(05)80273-9; STROBER W, 2001, CURR PROTOC IMMUNO S, V21; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Vinciguerr M, 2008, INT J BIOCHEM CELL B, V40, P307, DOI 10.1016/j.biocel.2007.08.001; Vivacqua A, 2006, MOL ENDOCRINOL, V20, P631, DOI 10.1210/me.2005-0280; Vivacqua A, 2006, MOL PHARMACOL, V70, P1414, DOI 10.1124/mol.106.026344; Wada T, 2004, NAT CELL BIOL, V6, P215, DOI 10.1038/ncb1098; Watson A, 1998, J NEUROSCI, V18, P751; Weiss C, 2003, EMBO J, V22, P3686, DOI 10.1093/emboj/cdg364; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Young TW, 2004, CANCER RES, V64, P4577, DOI 10.1158/0008-5472.CAN-04-0222	49	21	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					978	991		10.1038/onc.2009.400	http://dx.doi.org/10.1038/onc.2009.400			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19935718				2022-12-17	WOS:000274604400005
J	Villaronga, MA; Lavery, DN; Bevan, CL; Llanos, S; Belandia, B				Villaronga, M. A.; Lavery, D. N.; Bevan, C. L.; Llanos, S.; Belandia, B.			HEY1 Leu94Met gene polymorphism dramatically modifies its biological functions	ONCOGENE			English	Article						HEY1; androgen receptor; p53; Notch; single-nucleotide polymorphism	MESENCHYMAL TRANSITION; SIGNALING PATHWAYS; PROSTATE-CANCER; NOTCH PATHWAY; TARGET GENES; P53; CELLS; GROWTH; HERP; DIFFERENTIATION	The hairy/enhancer-of-split related with YRPW motif 1 (HEY1) is a member of the basic-helix-loop-helix-Orange (bHLH-O) family of transcriptional repressors that mediate Notch signaling. Several cancer-related pathways also regulate HEY1 expression, and HEY1 itself acts as an indirect positive regulator of the p53 tumor suppressor protein and a negative regulator of androgen receptor activity. In this study we show how a naturally occurring non-synonymous polymorphism at codon 94 of HEY1, which results in a substitution of leucine by methionine (Leu94Met), converts HEY1 from an androgen receptor corepressor to an androgen receptor co-activator without affecting its intrinsic transcriptional repressive domains. The polymorphism Leu94Met also abolishes HEY1-mediated activation of p53 and suppresses the ability of HEY1 to induce p53-dependent cell-cycle arrest and aberrant cell differentiation in human osteosarcoma U2OS cells. Moreover, expression of HEY1, but not of the variant Leu94Met, confers sensitivity to p53-activating chemotherapeutic drugs on U2OS cells. In addition, we have identified motifs in HEY1 that are critical for the regulation of its subcellular localization and analysed how mutations in those motifs affect both HEY1 and HEY1-Leu94Met functions. These findings suggest that the polymorphism Leu94Met in HEY1 radically alters its biological activities and may affect oncogenic processes. Oncogene (2010) 29, 411-420; doi:10.1038/onc.2009.309; published online 5 October 2009	[Villaronga, M. A.; Belandia, B.] Univ Autonoma Madrid, CSIC, Dept Canc Biol, Inst Invest Biomed, Madrid 28029, Spain; [Lavery, D. N.; Bevan, C. L.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Oncol, Androgen Signalling Lab, London, England; [Llanos, S.] Spanish Natl Canc Res Ctr CNIO, Tumor Suppress Grp, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Imperial College London; Centro Nacional de Investigaciones Oncologicas (CNIO)	Belandia, B (corresponding author), Univ Autonoma Madrid, CSIC, Dept Canc Biol, Inst Invest Biomed, Arturo Duperier 4, Madrid 28029, Spain.	sllanos@cnio.es; bbelandia@iib.uam.es	Bevan, Charlotte L/K-2276-2012; Belandia, Borja/H-1509-2015; Lavery, Derek/C-6706-2011; , Susana/AAA-9282-2019; Bevan, Charlotte/T-7769-2019	Bevan, Charlotte L/0000-0002-7533-0552; Belandia, Borja/0000-0003-2448-206X; Llanos, Susana/0000-0002-8555-9326	MICINN [SAF2007-62642, SAF2006-07785]; Fundacion de Investigacion Medica Mutua Madrilena; FIS [RD06/0020/0036]; CRESCENDO [FP-018652]; Cancer Research UK [C11509/A8570]	MICINN(Ministry of Science and Innovation, Spain (MICINN)Spanish GovernmentEuropean Commission); Fundacion de Investigacion Medica Mutua Madrilena; FIS(Instituto de Salud Carlos III); CRESCENDO(European Commission); Cancer Research UK(Cancer Research UK)	We thank Ana Aranda for her continuous support and Linn Markert for technical assistance. This study was supported by the MICINN (SAF2007-62642, SAF2006-07785), the Fundacion de Investigacion Medica Mutua Madrilena, the FIS (RD06/0020/0036), the CRESCENDO (FP-018652) and Cancer Research UK (C11509/A8570).	Ban J, 2008, CANCER RES, V68, P7100, DOI 10.1158/0008-5472.CAN-07-6145; Belandia B, 2005, MOL CELL BIOL, V25, P1425, DOI 10.1128/MCB.25.4.1425-1436.2005; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Davis RL, 2001, ONCOGENE, V20, P8342, DOI 10.1038/sj.onc.1205094; Espinosa JM, 2008, ONCOGENE, V27, P4013, DOI 10.1038/onc.2008.37; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Fuke S, 2005, J BIOCHEM, V137, P205, DOI 10.1093/jb/mvi020; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Giovannini C, 2009, J HEPATOL, V50, P969, DOI 10.1016/j.jhep.2008.12.032; Huang QH, 2004, P NATL ACAD SCI USA, V101, P3456, DOI 10.1073/pnas.0308562100; Hulleman E, 2009, J CELL MOL MED, V13, P136, DOI 10.1111/j.1582-4934.2008.00307.x; Hunter KW, 2006, CANCER RES, V66, P1251, DOI 10.1158/0008-5472.CAN-05-3705; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Iso T, 2001, MOL CELL BIOL, V21, P6080, DOI 10.1128/MCB.21.17.6080-6089.2001; Iso T, 2001, MOL CELL BIOL, V21, P6071, DOI 10.1128/MCB.21.17.6071-6079.2001; Itoh F, 2004, EMBO J, V23, P541, DOI 10.1038/sj.emboj.7600065; Karsenty G, 2008, ANNU REV GENOM HUM G, V9, P183, DOI 10.1146/annurev.genom.9.081307.164437; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Lengner CJ, 2006, J CELL BIOL, V172, P909, DOI 10.1083/jcb.200508130; Leong KG, 2008, DIFFERENTIATION, V76, P699, DOI 10.1111/j.1432-0436.2008.00288.x; Lu C, 2009, APOPTOSIS, V14, P597, DOI 10.1007/s10495-009-0330-1; Maier MM, 2000, BIOCHEM BIOPH RES CO, V275, P652, DOI 10.1006/bbrc.2000.3354; Nakagawa O, 2000, P NATL ACAD SCI USA, V97, P13655, DOI 10.1073/pnas.250485597; Pietsch EC, 2006, ONCOGENE, V25, P1602, DOI 10.1038/sj.onc.1209367; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Sakamoto M, 2003, J BIOL CHEM, V278, P44808, DOI 10.1074/jbc.M300448200; Satow T, 2001, J NEUROSCI, V21, P1265; Sivertsen EA, 2007, EUR J IMMUNOL, V37, P2937, DOI 10.1002/eji.200636759; Tanaka M, 2009, BRIT J CANCER, V100, P1957, DOI 10.1038/sj.bjc.6605060; Undevia SD, 2005, NAT REV CANCER, V5, P447, DOI 10.1038/nrc1629; Villaronga MA, 2008, CURR CANCER DRUG TAR, V8, P566, DOI 10.2174/156800908786241096; Whibley C, 2009, NAT REV CANCER, V9, P95, DOI 10.1038/nrc2584; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Zamurovic N, 2004, J BIOL CHEM, V279, P37704, DOI 10.1074/jbc.M403813200; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069; Zhang YX, 2006, INT J CANCER, V119, P2071, DOI 10.1002/ijc.22077	36	21	21	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					411	420		10.1038/onc.2009.309	http://dx.doi.org/10.1038/onc.2009.309			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19802006	Green Accepted, Green Published			2022-12-17	WOS:000273793200010
J	Singh, P; Marikkannu, R; Bitomsky, N; Klempnauer, KH				Singh, P.; Marikkannu, R.; Bitomsky, N.; Klempnauer, K-H			Disruption of the Pdcd4 tumor suppressor gene in chicken DT40 cells reveals its role in the DNA-damage response	ONCOGENE			English	Article						Pdcd4; DT40; DNA damage; UV; tumor suppressor	PROTEIN PDCD4; TRANSLATION INITIATION; EUKARYOTIC TRANSLATION; STRUCTURAL BASIS; EXPRESSION; TRANSFORMATION; BINDING; MA-3; TRANSCRIPTION; INHIBITION	The programmed cell death gene 4 (Pdcd4) gene has been implicated as a new tumor suppressor gene in the development of several types of human cancer. Pdcd4 interacts with the translation initiation factor, eIF4A, and is thought to act as a translation inhibitor. Here, we have used the chicken B-cell line DT40 to disrupt the Pdcd4 gene by homologous recombination. Our study shows that cells lacking a functional Pdcd4 gene are viable and have no obvious defects when cultivated under normal growth conditions. However, Pdcd4 knockout cells show an increased sensitivity to agents that cause DNA damage, such as UV light, etoposide or ethyl-methanesulfonate. In summary, our findings show that Pdcd4 has an important function in the cellular response to DNA damage. Low Pdcd4 expression, which is frequently observed in tumor cells, might therefore contribute to tumorigenesis by disturbing the cellular DNA-damage response. Oncogene (2009) 28, 3758-3764; doi: 10.1038/onc.2009.239; published online 17 August 2009	[Singh, P.; Marikkannu, R.; Bitomsky, N.; Klempnauer, K-H] Univ Munster, Inst Biochem, D-48149 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.	klempna@uni-muenster.de	Singh, Priyanka/GRF-6098-2022; Singh, Priyanka/N-1372-2018	Singh, Priyanka/0000-0003-0841-1544; Singh, Priyanka/0000-0002-5928-6280	Deutsche Krebshilfe [10-1716]; Graduate School of Chemistry (GSC-MS) at the University of Munster	Deutsche Krebshilfe(Deutsche Krebshilfe); Graduate School of Chemistry (GSC-MS) at the University of Munster	We thank B Berkenfeld for excellent technical assistance. This study was supported by grants from the Deutsche Krebshilfe (10-1716) and the Wilhelm-Sander-Stiftung (2004.088.1). PS and RM were supported by fellowships from the Graduate School of Chemistry (GSC-MS) at the University of Munster.	Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Bitomsky N, 2008, ONCOGENE, V27, P4820, DOI 10.1038/onc.2008.115; Bitomsky N, 2004, ONCOGENE, V23, P7484, DOI 10.1038/sj.onc.1208064; Bohm M, 2003, ONCOGENE, V22, P4905, DOI 10.1038/sj.onc.1206710; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; Chang JH, 2009, P NATL ACAD SCI USA, V106, P3148, DOI 10.1073/pnas.0808275106; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Goke A, 2002, BIOCHEM BIOPH RES CO, V297, P78, DOI 10.1016/S0006-291X(02)02129-0; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; LaRonde-LeBlanc N, 2007, MOL CELL BIOL, V27, P147, DOI 10.1128/MCB.00867-06; Leupold JH, 2007, ONCOGENE, V26, P4550, DOI 10.1038/sj.onc.1210234; Loh PG, 2009, EMBO J, V28, P274, DOI 10.1038/emboj.2008.278; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Mudduluru G, 2007, CANCER-AM CANCER SOC, V110, P1697, DOI 10.1002/cncr.22983; Palamarchuk A, 2005, CANCER RES, V65, P11282, DOI 10.1158/0008-5472.CAN-05-3469; Schlichter U, 2001, BBA-GENE STRUCT EXPR, V1520, P99, DOI 10.1016/S0167-4781(01)00252-4; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Suzuki C, 2008, P NATL ACAD SCI USA, V105, P3274, DOI 10.1073/pnas.0712235105; Takao N, 1999, ONCOGENE, V18, P7002, DOI 10.1038/sj.onc.1203172; Wang Q, 2008, ONCOGENE, V27, P1527, DOI 10.1038/sj.onc.1210793; Waters LC, 2007, ONCOGENE, V26, P4941, DOI 10.1038/sj.onc.1210305; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2006, MOL CELL BIOL, V26, P1297, DOI 10.1128/MCB.26.4.1297-1306.2006; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Zhang H, 2006, ONCOGENE, V25, P6101, DOI 10.1038/sj.onc.1209634	32	21	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2009	28	42					3758	3764		10.1038/onc.2009.239	http://dx.doi.org/10.1038/onc.2009.239			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	509MY	19684621				2022-12-17	WOS:000271023200008
J	Komatsu, S; Takenobu, H; Ozaki, T; Ando, K; Koida, N; Suenaga, Y; Ichikawa, T; Hishiki, T; Chiba, T; Iwama, A; Yoshida, H; Ohnuma, N; Nakagawara, A; Kamijo, T				Komatsu, S.; Takenobu, H.; Ozaki, T.; Ando, K.; Koida, N.; Suenaga, Y.; Ichikawa, T.; Hishiki, T.; Chiba, T.; Iwama, A.; Yoshida, H.; Ohnuma, N.; Nakagawara, A.; Kamijo, T.			Plk1 regulates liver tumor cell death by phosphorylation of TAp63	ONCOGENE			English	Article						p63; phosphorylation; Plk1; apoptosis	POLO-LIKE KINASE-1; DNA-DAMAGE; HEPATOCELLULAR-CARCINOMA; P73-DEPENDENT APOPTOSIS; EPIDERMAL DEVELOPMENT; PHYSICAL INTERACTION; P63 EXPRESSION; P53 HOMOLOG; CANCER; GENE	We previously found that Plk1 inhibited the p53/p73 activity through its direct phosphorylation. In this study, we investigated the functional role of Plk1 in modulating the p53 family member TAp63, resulting in the control of apoptotic cell death in liver tumor cells. Immunoprecipitation and in vitro pull-down assay showed that p63 binds to the kinase domain of Plk1 through its DNA-binding region. in vitro kinase assay indicated that p63 is phosphorylated by Plk1 at Ser-52 of the transactivating (TA) domain. Plk1 decreased the protein stability of TAp63 by its phosphorylation and suppressed TAp63-induced cell death. Furthermore, Plk1 knockdown in p53-mutated liver tumor cells transactivated p53 family downstream effectors, PUMA, p21(Cip1/WAF1) and 14-3-3 sigma, and induced apoptotic cell death. Double knockdown of Plk1/p63 attenuated Plk1 knockdown-induced apoptotic cell death and transactivation. Intriguingly, both Plk1 and p63 are highly expressed in the side population (SP) fraction of liver tumor cells compared to non-SP fraction cells, suggesting the significance of Plk1/TAp63 in the control of cell death in tumor-initiating SP fraction cells. Thus, Plk1 controls TAp63 by its phosphorylation and regulates apoptotic cell death in liver tumor cells. Plk1/TAp63 may be a suitable candidate as a molecular target of liver tumor treatments. Oncogene (2009) 28, 3631-3641; doi: 10.1038/onc.2009.216; published online 10 August 2009	[Kamijo, T.] Chiba Canc Ctr, Res Inst, Div Biochem, Chuo Ku, Chiba 2608717, Japan; [Komatsu, S.; Hishiki, T.; Yoshida, H.; Ohnuma, N.] Chiba Univ, Grad Sch Med, Dept Pediat Surg, Chiba, Japan; [Chiba, T.; Iwama, A.] Chiba Univ, Grad Sch Med, Dept Cellular & Mol Med, Chiba, Japan	Chiba Cancer Center; Chiba University; Chiba University	Kamijo, T (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem, Chuo Ku, 666-2 Nitona, Chiba 2608717, Japan.	tkamijo@chiba-cc.jp		Suenaga, Yusuke/0000-0001-6902-5386; Takenobu, Hisanori/0000-0001-7355-1565	Ministry of Health, Labor, and Welfare; Ministry of Health, Labor, and Welfare of Japan [20-13]; Ministry of Education, Culture, Sports, Science and Technology, Japan; Grants-in-Aid for Scientific Research [21390317] Funding Source: KAKEN	Ministry of Health, Labor, and Welfare(Ministry of Health, Labour and Welfare, Japan); Ministry of Health, Labor, and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank K Sakurai for technical assistance and Daniel Mrozek, Medical English Service, for editorial assistance. This work was supported, in part, by a grant-in-aid from the Ministry of Health, Labor, and Welfare for Third Term Comprehensive Control Research for Cancer; a grant-in-aid for Cancer Research (20-13) from the Ministry of Health, Labor, and Welfare of Japan; and a grant-in-aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan.	Ando K, 2004, J BIOL CHEM, V279, P25549, DOI 10.1074/jbc.M314182200; Blandino G, 2004, CELL CYCLE, V3, P886; Bruix J, 2002, HEPATOLOGY, V35, P519, DOI 10.1053/jhep.2002.32089; Candi E, 2007, CELL CYCLE, V6, P274, DOI 10.4161/cc.6.3.3797; Candi E, 2006, J CELL SCI, V119, P4617, DOI 10.1242/jcs.03265; Chiba T, 2006, HEPATOLOGY, V44, P240, DOI 10.1002/hep.21227; Eckerdt F, 2006, CANCER RES, V66, P6895, DOI 10.1158/0008-5472.CAN-06-0358; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Ghioni P, 2005, CELL CYCLE, V4, P183, DOI 10.4161/cc.4.1.1359; Gressner O, 2005, EMBO J, V24, P2458, DOI 10.1038/sj.emboj.7600708; Huang YP, 2004, CELL CYCLE, V3, P1587, DOI 10.4161/cc.3.12.1290; Ichikawa T, 2008, ONCOGENE, V27, P409, DOI 10.1038/sj.onc.1210658; Kato S, 1999, CANCER RES, V59, P5908; Koga F, 2003, CLIN CANCER RES, V9, P5501; Koida N, 2008, J BIOL CHEM, V283, P8555, DOI 10.1074/jbc.M710608200; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lu LY, 2008, MOL CELL BIOL, V28, P6870, DOI 10.1128/MCB.00392-08; MacPartlin M, 2008, J BIOL CHEM, V283, P15754, DOI 10.1074/jbc.M801394200; Massion PP, 2003, CANCER RES, V63, P7113; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Moll UM, 2004, MOL CANCER RES, V2, P371; Montesano R, 1997, JNCI-J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Petitjean A, 2005, ONCOGENE, V24, P512, DOI 10.1038/sj.onc.1208215; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; Shen HM, 1996, MUTAT RES-REV GENET, V366, P23, DOI 10.1016/S0165-1110(96)90005-6; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Suh EK, 2006, NATURE, V444, P624, DOI 10.1038/nature05337; Urist MJ, 2002, AM J PATHOL, V161, P1199, DOI 10.1016/S0002-9440(10)64396-9; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Westfall MD, 2005, CELL CYCLE, V4, P710, DOI 10.4161/cc.4.5.1685; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Winkles JA, 2005, ONCOGENE, V24, P260, DOI 10.1038/sj.onc.1208219; Yamada S, 2004, ONCOGENE, V23, P5901, DOI 10.1038/sj.onc.1207782; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhou JB, 2008, CELL CYCLE, V7, P1360, DOI 10.4161/cc.7.10.5953	44	21	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2009	28	41					3631	3641		10.1038/onc.2009.216	http://dx.doi.org/10.1038/onc.2009.216			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KJ	19668228				2022-12-17	WOS:000270851800004
J	Chan, CB; Liu, X; Jang, SW; Hsu, SIH; Williams, I; Kang, S; Chen, J; Ye, K				Chan, C. B.; Liu, X.; Jang, S-W; Hsu, S. I-H; Williams, I.; Kang, S.; Chen, J.; Ye, K.			NGF inhibits human leukemia proliferation by downregulating cyclin A1 expression through promoting acinus/CtBP2 association	ONCOGENE			English	Article						acinus; CtBP2; cyclin A1; gambogic amide; leukemia; NGF	NERVE GROWTH-FACTOR; TERMINAL BINDING-PROTEIN; ACUTE MYELOID-LEUKEMIA; CANCER CELL-LINES; CHROMATIN CONDENSATION; HEMATOPOIETIC-CELLS; COREPRESSOR CTBP; RETINOIC ACID; TRKA RECEPTOR; CO-REPRESSOR	Cyclin A1 is essential for leukemia progression, and its expression is tightly regulated by acinus, a nuclear speckle protein. However, the molecular mechanism of how acinus mediates cyclin A1 expression remains elusive. Here we show that transcription corepressor CtBP2 directly binds acinus, which is regulated by nerve growth factor (NGF), inhibiting its stimulatory effect on cyclin A1, but not cyclin A2, expression in leukemia. NGF, a cognate ligand for the neurotrophic receptor TrkA, promotes the interaction between CtBP2 and acinus through triggering acinus phosphorylation by Akt. Overexpression of CtBP2 diminishes cyclin A1 transcription, whereas depletion of CtBP2 abolishes NGF's suppressive effect on cyclin A1 expression. Strikingly, gambogic amide, a newly identified TrkA agonist, potently represses cyclin A1 expression, thus blocking K562 cell proliferation. Moreover, gambogic amide ameliorates the leukemia progression in K562 cells inoculated nude mice. Hence, NGF downregulates cyclin A1 expression through escalating CtBP2/acinus complex formation, and gambogic amide might be useful for human leukemia treatment. Oncogene (2009) 28, 3825-3836; doi:10.1038/onc.2009.236; published online 10 August 2009	[Chan, C. B.; Liu, X.; Jang, S-W; Williams, I.; Ye, K.] Emory Univ, Dept Pathol & Lab Med, Sch Med, Atlanta, GA 30322 USA; [Hsu, S. I-H] Natl Univ Singapore, Dept Med, Fac Med, Singapore 117548, Singapore; [Kang, S.; Chen, J.] Emory Univ, Winship Canc Inst, Sch Med, Atlanta, GA 30322 USA	Emory University; National University of Singapore; Emory University	Ye, K (corresponding author), Emory Univ, Dept Pathol & Lab Med, Sch Med, Room 145,Whitehead Bldg,615 Michael St, Atlanta, GA 30322 USA.	kye@emory.edu			NIH [RO1 NS060680]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS060680] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work is supported by a grant from NIH (RO1 NS060680) to K Ye. We thank Dr G Chinnadurai (Saint Louis University Health Sciences Center) for GST-CtBP1 plasmid.	BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Chan CB, 2007, CELL DEATH DIFFER, V14, P1688, DOI 10.1038/sj.cdd.4402179; Chen J, 2008, LIFE SCI, V83, P103, DOI 10.1016/j.lfs.2008.05.003; CHEVALIER S, 1994, BLOOD, V83, P1479; DEWECK Z, 1987, BIOCHEMISTRY-US, V26, P4769, DOI 10.1021/bi00389a026; Fjeld CC, 2003, P NATL ACAD SCI USA, V100, P9202, DOI 10.1073/pnas.1633591100; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; Garriga-Canut M, 2006, NAT NEUROSCI, V9, P1382, DOI 10.1038/nn1791; Guo QL, 2004, ACTA PHARMACOL SIN, V25, P769; Hong EG, 2007, AM J PHYSIOL-ENDOC M, V293, pE1687, DOI 10.1152/ajpendo.00256.2007; Hu YX, 2005, EMBO J, V24, P3543, DOI 10.1038/sj.emboj.7600823; JACKSON GR, 1992, BRAIN RES, V592, P239, DOI 10.1016/0006-8993(92)91681-4; Jang SW, 2008, CANCER RES, V68, P4559, DOI 10.1158/0008-5472.CAN-08-0021; Jang SW, 2007, P NATL ACAD SCI USA, V104, P16329, DOI 10.1073/pnas.0706662104; Ji P, 2005, ONCOGENE, V24, P2739, DOI 10.1038/sj.onc.1208356; Kaebisch A, 1996, BRIT J HAEMATOL, V95, P102, DOI 10.1046/j.1365-2141.1996.d01-1874.x; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; Kato T, 2005, J CLIN INVEST, V115, P2716, DOI 10.1172/JCI24280; Katsanis N, 1998, GENOMICS, V47, P294, DOI 10.1006/geno.1997.5115; Kramer A, 1998, LEUKEMIA, V12, P893, DOI 10.1038/sj.leu.2401051; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; Li ZX, 2009, BLOOD, V113, P2028, DOI 10.1182/blood-2008-05-155200; Liao C, 2001, P NATL ACAD SCI USA, V98, P6853, DOI 10.1073/pnas.121540098; Liu W, 2005, WORLD J GASTROENTERO, V11, P3655, DOI 10.3748/wjg.v11.i24.3655; Liu X, 2007, ONCOGENE, V26, P4918, DOI 10.1038/sj.onc.1210290; McLure KG, 2004, MOL CELL BIOL, V24, P9958, DOI 10.1128/MCB.24.22.9958-9967.2004; Meyer J, 2007, LEUKEMIA, V21, P2171, DOI 10.1038/sj.leu.2404882; Miller JP, 2007, CELL CYCLE, V6, P2932, DOI 10.4161/cc.6.23.5042; MISSALE C, 1993, P NATL ACAD SCI USA, V90, P7961, DOI 10.1073/pnas.90.17.7961; Missale C, 1998, P NATL ACAD SCI USA, V95, P5366, DOI 10.1073/pnas.95.9.5366; Nardini M, 2006, PROTEIN SCI, V15, P1042, DOI 10.1110/ps.062115406; Pereda MP, 2000, MOL CELL ENDOCRINOL, V167, P99, DOI 10.1016/S0303-7207(00)00286-0; Qiang L, 2008, BIOCHEM PHARMACOL, V75, P1083, DOI 10.1016/j.bcp.2007.10.033; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Schwerk C, 2003, MOL CELL BIOL, V23, P2981, DOI 10.1128/MCB.23.8.2981-2990.2003; Shankar DB, 2005, CANCER CELL, V7, P351, DOI 10.1016/j.ccr.2005.02.018; Shu WX, 2008, BASIC CLIN PHARMACOL, V103, P530, DOI 10.1111/j.1742-7843.2008.00292.x; Sigala S, 1999, CLIN CANCER RES, V5, P1211; Skaper SD, 2008, CNS NEUROL DISORD-DR, V7, P46, DOI 10.2174/187152708783885174; Tange TO, 2005, RNA, V11, P1869, DOI 10.1261/rna.2155905; Tao ZJ, 2007, CANCER BIOL THER, V6, P691, DOI 10.4161/cbt.6.5.3960; Thio SSC, 2004, NUCLEIC ACIDS RES, V32, P1836, DOI 10.1093/nar/gkh344; TRIA MA, 1994, EXP NEUROL, V127, P178, DOI 10.1006/exnr.1994.1093; TSUDA T, 1991, BLOOD, V77, P971; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Vucetic Z, 2008, MOL CELL BIOL, V28, P2549, DOI 10.1128/MCB.01199-07; Wolgemuth DJ, 2004, INT J ANDROL, V27, P192, DOI 10.1111/j.1365-2605.2004.00480.x; Xie P, 2000, LEUKEMIA RES, V24, P751, DOI 10.1016/S0145-2126(00)00044-8; Xie P, 1997, NEUROREPORT, V8, P1067, DOI 10.1097/00001756-199703240-00001; Xu XY, 2009, INT J DERMATOL, V48, P186, DOI 10.1111/j.1365-4632.2009.03946.x; Yang R, 1997, CANCER RES, V57, P913; Yang R, 1999, BLOOD, V93, P2067; Ye KQ, 1999, J NEUROSCI, V19, P10747, DOI 10.1523/JNEUROSCI.19-24-10747.1999; Ying WH, 2005, J NEUROSCI RES, V79, P216, DOI 10.1002/jnr.20289; Zhang QH, 2002, SCIENCE, V295, P1895	55	21	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	43					3825	3836		10.1038/onc.2009.236	http://dx.doi.org/10.1038/onc.2009.236			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512KT	19668232	Green Accepted			2022-12-17	WOS:000271248400006
J	Uhlmann-Schiffler, H; Kiermayer, S; Stahl, H				Uhlmann-Schiffler, H.; Kiermayer, S.; Stahl, H.			The DEAD box protein Ddx42p modulates the function of ASPP2, a stimulator of apoptosis	ONCOGENE			English	Article						apoptosis; ASPP2; Ddx42p; p53; ubiquitination	MESSENGER-RNA; KAPPA-B; TUMOR-SUPPRESSOR; P53; HELICASE; 53BP2; EXPRESSION; P68; PROLIFERATION; INHIBITION	Ddx42p is a recently characterized mammalian DEAD box protein with unknown cellular function. We found that in human cells Ddx42p physically interacts with ASPP2, a major apoptosis inducer known to enhance p53 transactivation of proapoptotic genes. The proteins interact via a domain within the carboxy-terminal part of Ddx42p and a mid-amino-terminal sequence as well as the ankyrin-SH3 region of ASPP2. Overexpression of Ddx42p interferes with apoptosis induction by ASPP2, whereas Ddx42p knockdown reduces the survival rate of cultured human cells. In addition, ASPP2 is found in cytoplasm and nucleus at low Ddx42p level, and predominantly in cytoplasm at high concentration of Ddx42p, respectively. Our results show that Ddx42p is capable of modulating ASPP2 function. Oncogene (2009) 28, 2065-2073; doi:10.1038/onc.2009.75; published online 20 April 2009	[Uhlmann-Schiffler, H.; Kiermayer, S.; Stahl, H.] Univ Saarland, Dept Med Biochem & Mol Biol, D-6642 Homburg, Germany	Saarland University	Uhlmann-Schiffler, H (corresponding author), Univ Saarland, Dept Med Biochem & Mol Biol, Kirrberger St Geb 45, D-6642 Homburg, Germany.	heike.uhlmann.schiffler@uniklinikum-saarland.de			Saarland Ministry of Education, Culture and Science	Saarland Ministry of Education, Culture and Science	We thank Anna-Maria Bohrer for technical assistance and Martina Sester for support in flow cytometry experiments. This work was supported by a grant of the Saarland Ministry of Education, Culture and Science to HU-S.	Bagnasco L, 2007, FASEB J, V21, P1256, DOI 10.1096/fj.06-7082com; Bates GJ, 2005, EMBO J, V24, P543, DOI 10.1038/sj.emboj.7600550; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Chao CH, 2006, CANCER RES, V66, P6579, DOI 10.1158/0008-5472.CAN-05-2415; Chen YZ, 2003, J NEUROCHEM, V85, P801, DOI 10.1046/j.1471-4159.2003.01727.x; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; Fuller-Pace FV, 2006, NUCLEIC ACIDS RES, V34, P4206, DOI 10.1093/nar/gkl460; Goh PY, 2004, J VIROL, V78, P5288, DOI 10.1128/JVI.78.10.5288-5298.2004; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Gutti RK, 2008, J BIOL CHEM, V283, P17055, DOI 10.1074/jbc.M708449200; Hock J, 2007, EMBO REP, V8, P1052, DOI 10.1038/sj.embor.7401088; Ishizuka A, 2002, GENE DEV, V16, P2497, DOI 10.1101/gad.1022002; Jalal C, 2007, NUCLEIC ACIDS RES, V35, P3590, DOI 10.1093/nar/gkm058; Katz C, 2008, P NATL ACAD SCI USA, V105, P12277, DOI 10.1073/pnas.0711269105; Kobayashi S, 2005, GENES CELLS, V10, P253, DOI 10.1111/j.1365-2443.2005.00835.x; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lin CW, 2008, VIRUS RES, V137, P49, DOI 10.1016/j.virusres.2008.05.015; Lin F, 2008, CANCER BIOL THER, V7, P1669, DOI 10.4161/cbt.7.10.6660; Linder P, 2006, NUCLEIC ACIDS RES, V34, P4168, DOI 10.1093/nar/gkl468; Liu ZJ, 2005, FEBS LETT, V579, P1587, DOI 10.1016/j.febslet.2005.01.069; Lopez CD, 2000, MOL CELL BIOL, V20, P8018, DOI 10.1128/MCB.20.21.8018-8025.2000; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Rotem S, 2008, J BIOL CHEM, V283, P18990, DOI 10.1074/jbc.M708717200; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859; Takahashi N, 2005, GENES CELLS, V10, P803, DOI 10.1111/j.1365-2443.2005.00878.x; Tidow H, 2007, J MOL BIOL, V371, P948, DOI 10.1016/j.jmb.2007.05.024; Trigiante G, 2006, NAT REV CANCER, V6, P217, DOI 10.1038/nrc1818; Uhlmann-Schiffler H, 2006, NUCLEIC ACIDS RES, V34, P10, DOI 10.1093/nar/gkj403; Uhlmann-Schiffler H, 2002, J BIOL CHEM, V277, P1066, DOI 10.1074/jbc.M107535200; Vives V, 2006, GENE DEV, V20, P1262, DOI 10.1101/gad.374006; Will CL, 2002, EMBO J, V21, P4978, DOI 10.1093/emboj/cdf480; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Zhu ZY, 2005, J BIOL CHEM, V280, P34473, DOI 10.1074/jbc.M503736200	35	21	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2009	28	20					2065	2073		10.1038/onc.2009.75	http://dx.doi.org/10.1038/onc.2009.75			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	448BI	19377511				2022-12-17	WOS:000266235800001
J	Garrison, JB; Samuel, T; Reed, JC				Garrison, J. B.; Samuel, T.; Reed, J. C.			TRAF2-binding BIR1 domain of c-IAP2/MALT1 fusion protein is essential for activation of NF-kappa B	ONCOGENE			English	Article						TRAF2; c-IAP2/MALT1; NF-kappa B; TRAF6; BIR1; B-cell lymphoma	MALT LYMPHOMA; CELL LYMPHOMA; INHIBITOR; APOPTOSIS; GENE; T(11/18)(Q21,Q21); BCL10; UBIQUITINATION; TRANSLOCATION; TRAF2	Marginal zone mucosa-associated lymphoid tissue (MALT) B-cell lymphoma is the most common extranodal non-Hodgkin lymphoma. The t(11;18)(q21;q21) translocation occurs frequently in MALT lymphomas and creates a chimeric NF-kappa B-activating protein containing the baculoviral IAP repeat (BIR) domains of c-IAP2 (inhibitor of apoptosis protein 2) fused with portions of the MALT1 protein. The BIR1 domain of c-IAP2 interacts directly with TRAF2 (TNF alpha-receptor-associated factor-2), but its role in NF-kappa B activation is still unclear. Here, we investigated the role of TRAF2 in c-IAP2/MALT1-induced NF-kappa B activation. We show the BIR1 domain of c-IAP2 is essential for NF-kappa B activation, whereas BIR2 and BIR3 domains are not. Studies of c-IAP2/MALT1 BIR1 mutant (E47A/R48A) that fails to activate NF-kappa B showed loss of TRAF2 binding, but retention of TRAF6 binding, suggesting that interaction of c-IAP2/MALT1 with TRAF6 is insufficient forNF-kappa B induction. In addition, a dominant-negative TRAF2 mutant or down-regulation of TRAF2 achieved by small interfering RNA inhibited NF-kappa B activation by c-IAP2/MALT1 showing that TRAF2 is indispensable. Comparisons of the bioactivity of intact c-IAP2/MALT1 oncoprotein and BIR1 E47A/R48A c-IAP2/MALT1 mutant that cannot bind TRAF2 in a lymphoid cell line provided evidence that TRAF2 interaction is critical for c-IAP2/MALT1mediated increases in the NF-kappa B activity, increased expression of endogenous NF-kappa B target genes (c-FLIP, TRAF1), and resistance to apoptosis.	[Garrison, J. B.; Samuel, T.; Reed, J. C.] Burnham Inst Med Res, Ctr Canc, Program Apoptosis & Cell Death Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst Med Res, Ctr Canc, Program Apoptosis & Cell Death Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	reedoffice@burnham.org						Akagi T, 1999, ONCOGENE, V18, P5785, DOI 10.1038/sj.onc.1203018; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Habelhah H, 2004, EMBO J, V23, P322, DOI 10.1038/sj.emboj.7600044; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Lucas PC, 2007, ONCOGENE, V26, P5643, DOI 10.1038/sj.onc.1210342; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Morgan JA, 1999, CANCER RES, V59, P6205; Noels H, 2007, J BIOL CHEM, V282, P10180, DOI 10.1074/jbc.M611038200; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Samuel T, 2006, J BIOL CHEM, V281, P1080, DOI 10.1074/jbc.M509381200; Schimmer AD, 2006, CELL DEATH DIFFER, V13, P179, DOI 10.1038/sj.cdd.4401826; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Streubel B, 2003, BLOOD, V101, P2335, DOI 10.1182/blood-2002-09-2963; Thome M, 2004, NAT REV IMMUNOL, V4, P348, DOI 10.1038/nri1352; Varfolomeev E, 2006, J BIOL CHEM, V281, P29022, DOI 10.1074/jbc.M605116200; Vega F, 2001, ADV ANAT PATHOL, V8, P313, DOI 10.1097/00125480-200111000-00001; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767; Zhou HL, 2005, CANCER CELL, V7, P425, DOI 10.1016/j.ccr.2005.04.012; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273; Zucca E, 2000, BLOOD, V96, P410	27	21	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2009	28	13					1584	1593		10.1038/onc.2009.17	http://dx.doi.org/10.1038/onc.2009.17			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427LJ	19234489				2022-12-17	WOS:000264780500003
J	Gustafson, TL; Wellberg, E; Laffin, B; Schilling, L; Metz, RP; Zahnow, CA; Porter, WW				Gustafson, T. L.; Wellberg, E.; Laffin, B.; Schilling, L.; Metz, R. P.; Zahnow, C. A.; Porter, W. W.			Ha-Ras transformation of MCF10A cells leads to repression of Singleminded-2s through NOTCH and C/EBP beta	ONCOGENE			English	Article						Singleminded-2s; NOTCH; C/EBP-beta; mammary gland	ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; SINGLE-MINDED GENE; HUMAN-BREAST; TRANSCRIPTION FACTOR; TRANSGENIC MICE; ONCOGENIC RAS; SELF-RENEWAL; MAMMARY; EXPRESSION	We have previously shown that Singleminded-2s (SIM2s), a member of the basic helix-loop-helix Per-Arnt-Sim (bHLH/PAS) family of transcription factors, is downregulated in breast cancer samples and has tumor suppressor activity. However, the mechanism by which SIM2s is repressed in breast cancer cells has not been determined. In this study, we show that transformation of MCF10A cells by Harvey-Ras (Ha-Ras) induces CCAAT/enhance binding protein beta (C/EBP beta) and activates the NOTCH signaling pathway to block SIM2s gene expression. NOTCH-mediated repression acts through a C-repeat binding factor 1 (CBF1)-independent mechanism, as introduction of CBF1 had no effect on SIM2s expression. Consistent with C/ebp beta-dependent inhibition of SIM2s, C/ebp beta(-/-) mouse mammary glands express high levels of SIM2s and reestablishment of C/ebp beta isoforms decreased SIM2s mRNA levels in C/ebp beta immortalized mammary epithelial cell lines. These studies illustrate a novel pathway of tumor suppressor gene silencing in Ha-Ras-transformed breast epithelial cells and identify SIM2s as a target of C/EBP beta and NOTCH signaling.	[Gustafson, T. L.; Wellberg, E.; Laffin, B.; Schilling, L.; Metz, R. P.; Porter, W. W.] Texas A&M Univ, Dept Integrat Biosci, Coll Vet Med, College Stn, TX 77843 USA; [Zahnow, C. A.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Dept Oncol, Baltimore, MD USA	Texas A&M University System; Texas A&M University College Station; Johns Hopkins University; Johns Hopkins Medicine	Porter, WW (corresponding author), Texas A&M Univ, Dept Integrat Biosci, Coll Vet Med, College Stn, TX 77843 USA.	wporter@cvm.tamu.edu	Wellberg, Elizabeth/AFQ-6450-2022	Metz, Richard/0000-0002-9876-3385	National Cancer Institute [RO1CA111551, R01CA113795]; Howard Hughes Medical Institute Predoctoral Fellowship; NATIONAL CANCER INSTITUTE [R01CA113795, R01CA111551] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Howard Hughes Medical Institute Predoctoral Fellowship(Howard Hughes Medical Institute); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Bryan and Alana Welm (Huntsman Cancer Institute, Salt Lake City, UT, USA) for the Ha-Ras parent construct, Jeff Rosen (Baylor College of Medicine, Houston, TX, USA) for providing the C/ebpb<SUP>-/-</SUP> mammary glands and Michael Lewis (Baylor College of Medicine, Houston, TX, USA) for critical reading of the paper. We also thank Keelan Anderson for technical assistance. This work was supported by awards from the National Cancer Institute RO1CA111551 (WWP), R01CA113795 (CAZ) and Howard Hughes Medical Institute Predoctoral Fellowship (TG).	Aleman MJ, 2005, P NATL ACAD SCI USA, V102, P12765, DOI 10.1073/pnas.0505484102; Arias AM, 2002, CURR OPIN GENET DEV, V12, P524, DOI 10.1016/S0959-437X(02)00336-2; Baldwin BR, 2004, MOL CELL BIOL, V24, P3682, DOI 10.1128/MCB.24.9.3682-3691.2004; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; CREWS S, 1992, J EXP ZOOL, V261, P234, DOI 10.1002/jez.1402610303; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Deyoung MP, 2002, ANTICANCER RES, V22, P3149; Dunn KL, 2005, BIOCHEM CELL BIOL, V83, P1, DOI 10.1139/O04-121; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Grimm SL, 2003, J MAMMARY GLAND BIOL, V8, P191, DOI 10.1023/A:1025900908026; Halvorsen OJ, 2007, CLIN CANCER RES, V13, P892, DOI 10.1158/1078-0432.CCR-06-1207; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Kewley RJ, 2004, INT J BIOCHEM CELL B, V36, P189, DOI 10.1016/S1357-2725(03)00211-5; Khleif SN, 1999, J IMMUNOTHER, V22, P155, DOI 10.1097/00002371-199903000-00007; Kiaris H, 2004, AM J PATHOL, V165, P695, DOI 10.1016/S0002-9440(10)63333-0; Kwak HI, 2007, CARCINOGENESIS, V28, P259, DOI 10.1093/carcin/bgl122; Laffin B, 2008, MOL CELL BIOL, V28, P1936, DOI 10.1128/MCB.01701-07; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Liu SL, 2005, BREAST CANCER RES, V7, P86, DOI 10.1186/bcr1021; Martinez-Lacaci I, 2000, INT J CANCER, V88, P44, DOI 10.1002/1097-0215(20001001)88:1<44::AID-IJC7>3.0.CO;2-8; Metz RP, 2006, J BIOL CHEM, V281, P10839, DOI 10.1074/jbc.M508858200; Milde-Langosch K, 2003, BREAST CANCER RES TR, V79, P175, DOI 10.1023/A:1023929504884; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NIELSEN LL, 1991, CANCER RES, V51, P3762; Sansone P, 2007, STEM CELLS, V25, P807, DOI 10.1634/stemcells.2006-0442; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Shim M, 2005, CANCER RES, V65, P861; Shuman JD, 2004, MOL CELL BIOL, V24, P7380, DOI 10.1128/MCB.24.17.7380-7391.2004; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Sundaram MV, 2005, GENE DEV, V19, P1825, DOI 10.1101/gad.1330605; von Lintig FC, 2000, BREAST CANCER RES TR, V62, P51, DOI 10.1023/A:1006491619920; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zahnow CA, 2002, BREAST CANCER RES, V4, P109, DOI 10.1186/bcr428; Zahnow CA, 1997, J NATL CANCER I, V89, P1887, DOI 10.1093/jnci/89.24.1887; Zahnow CA, 2001, CANCER RES, V61, P261; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299	39	21	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	12					1561	1568		10.1038/onc.2008.497	http://dx.doi.org/10.1038/onc.2008.497			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	424AH	19169276	Green Accepted			2022-12-17	WOS:000264537400008
J	Xu, K; Chang, CM; Gao, H; Shu, HK				Xu, K.; Chang, C-M; Gao, H.; Shu, H-KG			Epidermal growth factor-dependent cyclooxygenase-2 induction in gliomas requires protein kinase C-delta	ONCOGENE			English	Article						epidermal growth factor receptor; cyclooxygenase-2; protein kinase C-delta; Sp1 transcription factor; glioma	VASCULAR SMOOTH-MUSCLE; MAPK SIGNAL PATHWAYS; FACTOR RECEPTOR; MESSENGER-RNA; SP1 PHOSPHORYLATION; COX-2 INHIBITOR; CELL-LINES; IN-VITRO; GLIOBLASTOMA-MULTIFORME; MALIGNANT GLIOMAS	Earlier, we showed that epidermal growth factor receptor (EGFR) signaling in human glioma cells increased cyclooxygenase-2 (COX-2) expression through p38-mitogen-activated protein kinase (MAPK)-dependent activation of the Sp family of transcription factors. Further mechanistic details of EGFR-dependent induction of COX-2 expression in glioma cells remained elusive. Protein kinase Cs (PKCs) comprise a family of serine-threonine kinases that are major mediators of signaling from receptor tyrosine kinases. Here, we report that PKC-delta, a novel PKC isoform, plays a role in EGF-dependent COX-2 induction in human glioma cells. Pharmacological inhibition and genetic silencing (through siRNA or dominant-negative expression) of PKC-delta confirm a role for this PKC isoform in EGF-dependent COX-2 induction. Overexpression of a functional PKC-delta enhanced COX-2 expression indicating that PKC-delta is not only necessary but also sufficient to regulate COX-2 levels. Inhibition of p38-MAPK pharmacologically or with siRNA further shows that p38-MAPK is required for activation of PKC-delta by EGF while inhibition of PKC-delta had no discernible effects on p38-MAPK activation. Finally, EGF stimulation promotes physical interactions between PKC-delta and Sp1 resulting in phosphorylation and nuclear localization of this transcription factor. These data provide the first evidence that PKC-delta is a critical link between p38-MAPK and Sp1-dependent COX-2 expression in human glioma cells.	[Xu, K.; Chang, C-M; Gao, H.; Shu, H-KG] Emory Univ, Dept Radiat Oncol, Atlanta, GA 30332 USA	Emory University	Shu, HK (corresponding author), Emory Univ, Dept Radiat Oncol, 1365 Clifton Rd,NE,Bldg C,Room C-3082, Atlanta, GA 30332 USA.	hui-kuo@radonc.emory.org			Childhood Brain Tumor Foundation	Childhood Brain Tumor Foundation	This study was supported, in part, by a grant to H-K Shu from the Childhood Brain Tumor Foundation. We thank Dr Jiahuai Han for providing mammalian expression plasmids-containing MKK3 and MKK6 and Dr Jae-Won Soh for providing mammalian expression plasmids-containing PKC-delta variants.	Abbott KL, 2000, MOL PHARMACOL, V58, P946, DOI 10.1124/mol.58.5.946; Awasthi V, 2000, AM J PHYSIOL-LUNG C, V279, pL942, DOI 10.1152/ajplung.2000.279.5.L942; Baltuch GH, 1996, BRAIN RES, V710, P143, DOI 10.1016/0006-8993(95)01395-4; Bijnsdorp IV, 2007, J NEURO-ONCOL, V85, P25, DOI 10.1007/s11060-007-9385-4; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Bredel M, 1997, ACTA NEUROCHIR, V139, P1000, DOI 10.1007/BF01411552; Buccoliero AM, 2006, CLIN NEUROPATHOL, V25, P59; Chupreta S, 2000, AM J PHYSIOL-CELL PH, V278, pC697, DOI 10.1152/ajpcell.2000.278.4.C697; COULDWELL WT, 1991, NEUROSURGERY, V29, P880, DOI 10.1227/00006123-199112000-00013; COULDWELL WT, 1990, J NEUROSURG, V73, P594, DOI 10.3171/jns.1990.73.4.0594; D'Addario M, 2002, J BIOL CHEM, V277, P47541, DOI 10.1074/jbc.M207681200; D'Addario M, 2006, GENE, V379, P51, DOI 10.1016/j.gene.2006.04.012; Doller A, 2007, MOL BIOL CELL, V18, P2137, DOI 10.1091/mbc.E06-09-0850; Guan ZH, 1998, J BIOL CHEM, V273, P28670, DOI 10.1074/jbc.273.44.28670; Hofmann J, 2004, CURR CANCER DRUG TAR, V4, P125, DOI 10.2174/1568009043481579; Hsieh HL, 2007, CELL SIGNAL, V19, P330, DOI 10.1016/j.cellsig.2006.07.006; HUMPHREY PA, 1991, BIOCHEM BIOPH RES CO, V178, P1413, DOI 10.1016/0006-291X(91)91051-D; Iwabu A, 2004, J BIOL CHEM, V279, P14551, DOI 10.1074/jbc.M311981200; Joki T, 2000, CANCER RES, V60, P4926; Kang KB, 2007, INT J RADIAT ONCOL, V67, P888, DOI 10.1016/j.ijrobp.2006.09.055; Karim A, 2005, ANTICANCER RES, V25, P675; Kuwahara J, 2000, Nucleic Acids Symp Ser, P265; Lee J, 2006, FASEB J, V20, P2375, DOI 10.1096/fj.06-5957fje; Lee MY, 2006, AM J PHYSIOL-GASTR L, V291, pG744, DOI 10.1152/ajpgi.00551.2005; Li B, 2004, ONCOGENE, V23, P4594, DOI 10.1038/sj.onc.1207602; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Machide M, 1998, J NEUROCHEM, V71, P592; Martelli AM, 2003, HISTOL HISTOPATHOL, V18, P1301, DOI 10.14670/HH-18.1301; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Mimura Y, 2004, J INVEST DERMATOL, V122, P1390, DOI 10.1111/j.0022-202X.2004.22618.x; MORIYA M, 1994, NEUROREPORT, V5, P929, DOI 10.1097/00001756-199404000-00019; Murphy TJ, 2002, METHOD ENZYMOL, V345, P539; Musashi M, 2000, INT J HEMATOL, V72, P12; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Pang LH, 2002, FASEB J, V16, P1435, DOI 10.1096/fj.02-0169fje; Park YS, 2007, ARTERIOSCL THROM VAS, V27, P1319, DOI 10.1161/ATVBAHA.106.132837; POLLACK IF, 1990, J NEUROSURG, V73, P98, DOI 10.3171/jns.1990.73.1.0098; Prayson Richard A, 2002, Ann Diagn Pathol, V6, P148, DOI 10.1053/adpa.2002.33900; Rafty LA, 2001, NUCLEIC ACIDS RES, V29, P1027, DOI 10.1093/nar/29.5.1027; Reisinger K, 2003, J CELL SCI, V116, P225, DOI 10.1242/jcs.00237; Rojo AI, 2006, FREE RADICAL BIO MED, V41, P247, DOI 10.1016/j.freeradbiomed.2006.04.002; Rosell R, 2006, CLIN CANCER RES, V12, P7222, DOI 10.1158/1078-0432.CCR-06-0627; Shono T, 2001, CANCER RES, V61, P4375; Sminia P, 2005, J CANCER RES CLIN, V131, P653, DOI 10.1007/s00432-005-0020-5; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Subbaramaiah K, 1998, J BIOL CHEM, V273, P32943, DOI 10.1074/jbc.273.49.32943; Wang HQ, 2001, MOL PHARMACOL, V59, P860, DOI 10.1124/mol.59.4.860; Xu KM, 2007, CANCER RES, V67, P6121, DOI 10.1158/0008-5472.CAN-07-0141; Xu KM, 2000, J BIOL CHEM, V275, P7604, DOI 10.1074/jbc.275.11.7604; Xu Q, 2000, J BIOL CHEM, V275, P24583, DOI 10.1074/jbc.M003894200; Yu WS, 2003, J BIOL CHEM, V278, P11167, DOI 10.1074/jbc.M211424200; Zheng XL, 2001, J BIOL CHEM, V276, P13822, DOI 10.1074/jbc.M011031200	54	21	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	11					1410	1420		10.1038/onc.2008.500	http://dx.doi.org/10.1038/onc.2008.500			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421JE	19169273				2022-12-17	WOS:000264354400002
J	Hutcheson, J; Perlman, H				Hutcheson, J.; Perlman, H.			BH3-only proteins in rheumatoid arthritis: potential targets for therapeutic intervention	ONCOGENE			English	Review						rheumatoid arthritis; Bim; Bid; BH3-only; BH3 mimetic; apoptosis	BCL-2 FAMILY-MEMBER; CYTOCHROME-C RELEASE; BH3 MIMETIC ABT-737; SYNOVIAL FIBROBLASTS; B-CELLS; INDUCED APOPTOSIS; IN-VIVO; BIM; EXPRESSION; DEATH	Rheumatoid arthritis (RA) is a debilitating disease, resulting in the destruction of bone and cartilage, and in the permanent disfigurement of joints. Although the precise cause of RA is currently unresolved, it has become clear that the damaging effects are a result of the toxic milieu caused by an influx of inflammatory cells and the resulting heightened proinflammatory state within the joint. As the amount of literature suggesting that this preponderance of cells is a result of decreased local apoptosis in the joint continues to increase, in this review, we describe how Bcl-2 family pro-apoptotic BH3-only proteins, particularly Bim and Bid, could act to protect against the development of the disease. We also suggest a role for BH3-mimetic drugs as potential therapeutics in the treatment of RA. Oncogene (2009) 27, S168-S175; doi: 10.1038/onc.2009.54	[Hutcheson, J.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Rheumat Dis, Simmons Arthrit Res Ctr, Dallas, TX 75390 USA; [Perlman, H.] St Louis Univ, Dept Mol Microbiol Immunol, St Louis, MO 63103 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; Saint Louis University	Perlman, H (corresponding author), Northwestern Univ, Div Rheumatol, Dept Med, Feinberg Sch Med, 240 E Huron St,McGaw M300, Chicago, IL 60611 USA.	perlmanh@slu.edu		Hutcheson, Jack/0000-0002-6317-2788	National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI067590] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR002147, R01AR054796, R01AR050250] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	J Hutcheson has declared no conflict of interest. H Perlman is currently receiving grant support from the National Institutes of Health (NIH, Bethesda, MD, USA) and was in receipt of a grant from Reata Pharmaceuticals (Irving, TX, USA) from July 2007 to August 2008.	Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635; Alfredsson J, 2005, CELL DEATH DIFFER, V12, P136, DOI 10.1038/sj.cdd.4401537; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Brennan F, 2007, CURR OPIN RHEUMATOL, V19, P296, DOI 10.1097/BOR.0b013e32805e87f1; Bugatti S, 2007, AUTOIMMUN REV, V7, P137, DOI 10.1016/j.autrev.2007.02.017; Busteed S, 2006, CLIN RHEUMATOL, V25, P789, DOI 10.1007/s10067-005-0191-0; Cha HS, 2006, ARTHRITIS RHEUM-US, V54, P587, DOI 10.1002/art.21631; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Davey GM, 2002, J EXP MED, V196, P947, DOI 10.1084/jem.20020827; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534; Enders A, 2003, J EXP MED, V198, P1119, DOI 10.1084/jem.20030411; Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661; FIRESTEIN GS, 1995, J CLIN INVEST, V96, P1631, DOI 10.1172/JCI118202; Fischer SF, 2007, BLOOD, V110, P3978, DOI 10.1182/blood-2007-05-091306; Fujisawa K, 1996, J CLIN INVEST, V98, P271, DOI 10.1172/JCI118789; Harjacek M, 2001, J RHEUMATOL, V28, P1914; Haupt S, 2003, J CELL SCI, V116, P4077, DOI 10.1242/jcs.00739; Hilbers I, 2003, RHEUMATOL INT, V23, P75, DOI 10.1007/s00296-002-0255-2; Hildeman DA, 2002, IMMUNITY, V16, P759, DOI 10.1016/S1074-7613(02)00322-9; Hsu YH, 2006, ARTHRITIS RHEUM-US, V54, P2722, DOI 10.1002/art.22039; Hughes P, 2006, CURR DIRECT AUTOIMMU, V9, P74; Hutcheson J, 2005, J EXP MED, V201, P1949, DOI 10.1084/jem.20041484; Hutcheson J, 2008, IMMUNITY, V28, P206, DOI 10.1016/j.immuni.2007.12.015; Hutcheson J, 2007, IMMUNOBIOLOGY, V212, P629, DOI 10.1016/j.imbio.2007.05.003; Ikeuchi H, 2005, ARTHRITIS RHEUM-US, V52, P1037, DOI 10.1002/art.20965; Kashiwagi H, 2007, ANN SURG ONCOL, V14, P1763, DOI 10.1245/s10434-006-9298-z; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Labi V, 2008, CELL DEATH DIFFER, V15, P977, DOI 10.1038/cdd.2008.37; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu HT, 2006, ARTHRITIS RHEUM-US, V54, P3174, DOI 10.1002/art.22132; Liu HT, 2005, J IMMUNOL, V175, P8337, DOI 10.4049/jimmunol.175.12.8337; Liu HT, 2004, RHEUM DIS CLIN N AM, V30, P603, DOI 10.1016/j.rdc.2004.04.010; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Matsumoto S, 1996, J RHEUMATOL, V23, P1345; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859; Mott JL, 2008, MOL CANCER THER, V7, P2339, DOI 10.1158/1535-7163.MCT-08-0285; Murphy CA, 2003, J EXP MED, V198, P1951, DOI 10.1084/jem.20030896; NAKAJIMA T, 1995, ARTHRITIS RHEUM, V38, P485, DOI 10.1002/art.1780380405; Nguyen M, 2007, P NATL ACAD SCI USA, V104, P19512, DOI 10.1073/pnas.0709443104; O'Brien SM, 2009, BLOOD, V113, P299, DOI 10.1182/blood-2008-02-137943; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; Oliver PM, 2006, J EXP MED, V203, P731, DOI 10.1084/jem.20051407; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Pellegrini M, 2003, P NATL ACAD SCI USA, V100, P14175, DOI 10.1073/pnas.2336198100; Perez-Galan P, 2007, BLOOD, V109, P4441, DOI 10.1182/blood-2006-07-034173; Perlman H, 2000, J IMMUNOL, V164, P5227, DOI 10.4049/jimmunol.164.10.5227; Perlman H, 2001, ARTHRITIS RHEUM, V44, P21, DOI 10.1002/1529-0131(200101)44:1<21::AID-ANR4>3.0.CO;2-8; Pope RM, 2002, NAT REV IMMUNOL, V2, P527, DOI 10.1038/nri846; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Salmon M, 1997, J CLIN INVEST, V99, P439, DOI 10.1172/JCI119178; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Scatizzi JC, 2006, ARTHRITIS RHEUM, V54, P3182, DOI 10.1002/art.22133; Scatizzi JC, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2204; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Sugiyama M, 1996, ANN RHEUM DIS, V55, P442, DOI 10.1136/ard.55.7.442; Sutton VR, 2000, J EXP MED, V192, P1403, DOI 10.1084/jem.192.10.1403; Szekanecz Z, 2007, CURR OPIN RHEUMATOL, V19, P289, DOI 10.1097/BOR.0b013e32805e87ae; Trudel S, 2007, BLOOD, V109, P5430, DOI 10.1182/blood-2006-10-047951; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Villunger A, 2004, P NATL ACAD SCI USA, V101, P7052, DOI 10.1073/pnas.0305757101; Wakeyama H, 2007, J BONE MINER RES, V22, P1631, DOI 10.1359/JBMR.070619; Walczak H, 2001, TRENDS BIOCHEM SCI, V26, P452, DOI 10.1016/S0968-0004(01)01895-3; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Waterhouse NJ, 2005, J BIOL CHEM, V280, P4476, DOI 10.1074/jbc.M410985200; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zhang HD, 1997, J CLIN INVEST, V100, P1951, DOI 10.1172/JCI119726; Zinkel SS, 2003, GENE DEV, V17, P229, DOI 10.1101/gad.1045603	77	21	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S168	S175		10.1038/onc.2009.54	http://dx.doi.org/10.1038/onc.2009.54			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641502	Green Accepted			2022-12-17	WOS:000268566800015
J	Tong, Y; Ben-Shlomo, A; Zhou, C; Wawrowsky, K; Melmed, S				Tong, Y.; Ben-Shlomo, A.; Zhou, C.; Wawrowsky, K.; Melmed, S.			Pituitary tumor transforming gene 1 regulates Aurora kinase A activity	ONCOGENE			English	Article						PTTG1; Aurora kinase A; drug response	HUMAN-CELLS; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; OVARIAN-CANCER; HUMAN SECURIN; HISTONE H3; A KINASE; PTTG; CHECKPOINT; EXPRESSION	Pituitary tumor transforming gene 1 (PTTG1), a transforming gene highly expressed in several cancers, is a mammalian securin protein regulating both G1/S and G2/M phases. Using protein array screening, we showed PTTG1 interacting with Aurora kinase A (Aurora-A), and confirmed the interaction using co-immunoprecipitation, His-tagged pull-down assays and intracellular immunofluorescence colocalization. PTTG1 transfection into HCT116 cells prevented Aurora-A T288 autophosphorylation, inhibited phosphorylation of the histone H3 Aurora-A substrate and resulted in abnormally condensed chromatin. PTTG1-null cell proliferation was more sensitive to Aurora-A knock down and to Aurora kinase Inhibitor III treatment. The results indicate that PTTG1 and Aurora-A interact to regulate cellular responses to anti-neoplastic drugs. PTTG1 knockdown is therefore a potential approach to improve the efficacy of tumor Aurora kinase inhibitors.	[Tong, Y.; Ben-Shlomo, A.; Zhou, C.; Wawrowsky, K.; Melmed, S.] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Dept Med, David Geffen Sch Med,Cedars Sinai Res Inst, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Melmed, S (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Dept Med, David Geffen Sch Med,Cedars Sinai Res Inst, 8700 Beverly Blvd,Acad Affairs,Room 2015, Los Angeles, CA 90048 USA.	melmed@csmc.edu	Zhou, Cuiqi/B-1568-2010; Ben-Shlomo, Anat/AAH-6009-2021		NIH [CA 75979, T32 DK007770]; The Doris Factor Molecular Endocrinology Laboratory; NATIONAL CANCER INSTITUTE [R01CA075979] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007770] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); The Doris Factor Molecular Endocrinology Laboratory; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	PTTG1 WT and KO HCT116 cells were kindly provided by Dr Bert Vogelstein, Johns Hopkins University. PTTG1-GFP and PTTG1-PCDNA3.1 plasmids were kindly provided by Dr Run Yu. Supported by NIH Grant CA 75979 (SM), T32 DK007770, and The Doris Factor Molecular Endocrinology Laboratory.	Akino K, 2005, J SURG RES, V129, P142, DOI 10.1016/j.jss.2005.04.019; Bernal JA, 2008, CELL DEATH DIFFER, V15, P202, DOI 10.1038/sj.cdd.4402254; Bernal JA, 2002, NAT GENET, V32, P306, DOI 10.1038/ng997; Bernal JA, 2007, J BIOCHEM, V141, P737, DOI 10.1093/jb/mvm076; Boelaert K, 2003, FASEB J, V17, P1631, DOI 10.1096/fj.02-0948com; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; Chen SS, 2002, EMBO J, V21, P4491, DOI 10.1093/emboj/cdf409; Chien WW, 2000, J BIOL CHEM, V275, P19422, DOI 10.1074/jbc.M910105199; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; Donangelo I, 2006, ENDOCRINOLOGY, V147, P4781, DOI 10.1210/en.2006-0544; El-Naggar SM, 2007, INT J ONCOL, V31, P137; Eyers PA, 2003, CURR BIOL, V13, P691, DOI 10.1016/S0960-9822(03)00166-0; Gadea BB, 2005, MOL BIOL CELL, V16, P1305, DOI 10.1091/mbc.E04-10-0891; Gil-Bernabe AM, 2006, MOL CELL BIOL, V26, P4017, DOI 10.1128/MCB.01904-05; Heaney AP, 1999, NAT MED, V5, P1317, DOI 10.1038/15275; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Horn V, 2007, MOL BIOL CELL, V18, P1233, DOI 10.1091/mbc.E06-12-1152; Hornig NCD, 2002, CURR BIOL, V12, P973, DOI 10.1016/S0960-9822(02)00847-3; Hutterer A, 2006, DEV CELL, V11, P147, DOI 10.1016/j.devcel.2006.06.002; Ikezoe T, 2007, MOL CANCER THER, V6, P1851, DOI 10.1158/1535-7163.MCT-07-0067; Kakar SS, 2006, INT J ONCOL, V29, P387; Kim D, 2006, CLIN OTOLARYNGOL, V31, P246; Kim DS, 2007, CARCINOGENESIS, V28, P749, DOI 10.1093/carcin/bgl202; Krystyniak A, 2006, ONCOGENE, V25, P338, DOI 10.1038/sj.onc.1209056; Lai YQ, 2007, J BIOCHEM MOL BIOL, V40, P966; Li JJ, 2006, PHARMACOL THERAPEUT, V111, P974, DOI 10.1016/j.pharmthera.2006.02.006; Li M, 2007, MOL CELL BIOL, V27, P3481, DOI 10.1128/MCB.02088-06; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; McCabe CJ, 2003, CLIN ENDOCRINOL, V58, P141, DOI 10.1046/j.1365-2265.2003.01598.x; Mountzios G, 2008, CANCER TREAT REV, V34, P175, DOI 10.1016/j.ctrv.2007.09.005; Ohashi S, 2006, ONCOGENE, V25, P7691, DOI 10.1038/sj.onc.1209754; Pascreau Gaetan, 2003, Prog Cell Cycle Res, V5, P369; Pei L, 1999, J BIOL CHEM, V274, P3151, DOI 10.1074/jbc.274.5.3151; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Pei L, 2001, J BIOL CHEM, V276, P8484, DOI 10.1074/jbc.M009654200; Pei L, 2000, J BIOL CHEM, V275, P31191, DOI 10.1074/jbc.M002451200; Pereira G, 2003, SCIENCE, V302, P2120, DOI 10.1126/science.1091936; Prigent C, 2003, J CELL SCI, V116, P3677, DOI 10.1242/jcs.00735; Saez C, 1999, ONCOGENE, V18, P5473, DOI 10.1038/sj.onc.1202914; Sheleg SV, 2007, J VIROL, V81, P7894, DOI 10.1128/JVI.00555-07; Solbach C, 2004, BREAST, V13, P80, DOI 10.1016/j.breast.2003.09.008; Sun CB, 2007, BIOCHEM BIOPH RES CO, V352, P220, DOI 10.1016/j.bbrc.2006.11.004; Tarabykin V, 2000, MECH DEVELOP, V92, P301, DOI 10.1016/S0925-4773(00)00243-4; Tong Y, 2007, ONCOGENE, V26, P5596, DOI 10.1038/sj.onc.1210339; Vlotides G, 2007, ENDOCR REV, V28, P165, DOI 10.1210/er.2006-0042; Vogel C, 2005, J BIOL CHEM, V280, P4025, DOI 10.1074/jbc.C400545200; Vogel C, 2007, CANCER RES, V67, P339, DOI 10.1158/0008-5472.CAN-06-2548; Waizenegger IC, 2002, CURR BIOL, V12, P1368, DOI 10.1016/S0960-9822(02)01073-4; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Wang H, 2001, GENE DEV, V15, P1361, DOI 10.1101/gad.893201; Wang ZY, 2000, J BIOL CHEM, V275, P7459, DOI 10.1074/jbc.275.11.7459; Wang ZY, 2003, P NATL ACAD SCI USA, V100, P3428, DOI 10.1073/pnas.0638052100; Wang ZY, 2001, MOL ENDOCRINOL, V15, P1870, DOI 10.1210/me.15.11.1870; XUE Y, 2008, MOL CELL PROTEOMICS; Yang H, 2006, INT J CANCER, V119, P2304, DOI 10.1002/ijc.22154; Yu R, 2003, ENDOCRINOLOGY, V144, P4991, DOI 10.1210/en.2003-0305; ZHANG D, 2008, ONCOGENE; Zhang DW, 2004, ONCOGENE, V23, P8720, DOI 10.1038/sj.onc.1208153; Zhang Y, 2007, BIOCHEM BIOPH RES CO, V357, P347, DOI 10.1016/j.bbrc.2007.03.129; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	63	21	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	49					6385	6395		10.1038/onc.2008.234	http://dx.doi.org/10.1038/onc.2008.234			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363JK	18663361				2022-12-17	WOS:000260263400008
J	Lin, SH; Cheng, CJ; Lee, YC; Ye, X; Tsai, WW; Kim, J; Pasqualini, R; Arap, W; Navone, NM; Tu, SM; Hu, M; Yu-Lee, LY; Logothetis, CJ				Lin, S-H; Cheng, C-J; Lee, Y-C; Ye, X.; Tsai, W-W; Kim, J.; Pasqualini, R.; Arap, W.; Navone, N. M.; Tu, S-M; Hu, M.; Yu-Lee, L-Y; Logothetis, C. J.			A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation	ONCOGENE			English	Article						prostate cancer; bone metastasis; osteoblast; p45-sErbB3	EXPRESSION; OSTEOBLASTS; CARCINOMAS; METASTASIS; MDA-BF-1; ISOFORM; PROTEIN; GROWTH; TUMORS; MICE	ErbB3 is a transmembrane growth factor receptor that has been implicated in the pathogenesis of human cancer. After finding that a truncated form of ErbB3 was present and upregulated in metastatic prostate cancer cells in lymph nodes and bone, we explored the pathophysiological functions of this unusual form of ErbB3 in the context of mouse calvaria as well as osteoblasts in vitro and the femur microenvironment in vivo. Here we demonstrate that prostate cancer cells expressed an alternatively spliced transcript that encodes a 45-kDa glycosylated protein (p45-sErbB3). The recombinant p45-sErbB3 purified from conditioned medium stimulated calvarial bone formation and induced osteoblast differentiation. Overexpression of p45-sErbB3 in the osteolytic prostate cancer cell line PC-3 converted its phenotype from bone lysing to bone forming upon injection into the femurs of immunodeficient mice. Further, we detected sErbB3 in plasma samples from patients with castration-resistant prostate cancer with bone metastasis. These observations establish that p45- sErbB3 is a structurally and functionally unique gene product of ErbB3 and suggest that p45- sErbB3 is likely one ofthe factors involved in the osteoblastic bone metastases of prostate cancer.	[Lin, S-H; Lee, Y-C; Ye, X.; Tsai, W-W] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; [Lin, S-H; Kim, J.; Pasqualini, R.; Arap, W.; Navone, N. M.; Tu, S-M; Logothetis, C. J.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Cheng, C-J] Taipei Med Univ, Dept Pathol, Taipei, Taiwan; [Hu, M.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Yu-Lee, L-Y] Baylor Coll Med, Dept Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Taipei Medical University; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Lin, SH (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	slin@mdanderson.org			National Institutes of Health [CA111479, P50-CA90270, DK53176]; Charlotte Geyer Foundation; Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE [R01CA111479, P50CA090270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053176] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Charlotte Geyer Foundation; Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Karen Earley, Weiping Luo, Matthew Gal. one for technical assistance, Dr Jian Kuang for critical reading of the manuscript and Christine Wogan for editing the manuscript. This work was supported by National Institutes of Health grants CA111479, P50-CA90270 and DK53176; the Charlotte Geyer Foundation and the Prostate Cancer Foundation.	ALIMANDI M, 1995, ONCOGENE, V10, P1813; Berruti A, 2000, J UROLOGY, V164, P1248, DOI 10.1016/S0022-5347(05)67149-2; BHARGAVA U, 1988, BONE, V9, P155, DOI 10.1016/8756-3282(88)90005-1; Chen NY, 2007, CANCER RES, V67, P6544, DOI 10.1158/0008-5472.CAN-07-1330; Choueiri MB, 2006, CANCER METAST REV, V25, P601, DOI 10.1007/s10555-006-9034-y; Corey E, 2002, PROSTATE, V52, P20, DOI 10.1002/pros.10091; Hellyer NJ, 2001, J BIOL CHEM, V276, P42153, DOI 10.1074/jbc.M102079200; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Liang AK, 2005, PROTEIN EXPRES PURIF, V44, P58, DOI 10.1016/j.pep.2005.03.025; LIN SH, 2008, CLIN CANC R IN PRESS; Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528; LOW SH, 1991, J BIOL CHEM, V266, P13391; Naidu R, 1998, BRIT J CANCER, V78, P1385, DOI 10.1038/bjc.1998.689; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Soos G, 1996, INT J CANCER, V66, P280, DOI 10.1002/(SICI)1097-0215(19960410)66:2<280::AID-IJC24>3.0.CO;2-F; Vakar-Lopez F, 2004, J PATHOL, V203, P688, DOI 10.1002/path.1568; Wu TT, 1998, INT J CANCER, V77, P887, DOI 10.1002/(SICI)1097-0215(19980911)77:6<887::AID-IJC15>3.0.CO;2-Z; Yang J, 2001, CANCER RES, V61, P5652; Yi ES, 1997, MODERN PATHOL, V10, P142	19	21	24	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	39					5195	5203		10.1038/onc.2008.156	http://dx.doi.org/10.1038/onc.2008.156			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GO	18490922	Green Accepted			2022-12-17	WOS:000258915100003
J	Vincent, T; Kukalev, A; Andang, M; Pettersson, R; Percipalle, P				Vincent, T.; Kukalev, A.; Andang, M.; Pettersson, R.; Percipalle, P.			The glycogen synthase kinase (GSK) 3 beta represses RNA polymerase I transcription	ONCOGENE			English	Article						GSK3 beta; PTEN; rDNA; Pol I transcription; cell proliferation; tumour suppressors	TUMOR SUPPRESSION; PTEN; GLYCOGEN-SYNTHASE-KINASE-3-BETA; PHOSPHORYLATION; KINASE-3-BETA; INHIBITOR; PATHWAYS; HOMOLOG; COMPLEX; PROTEIN	Several oncogenic proteins and tumour suppressors target the RNA polymerase I and interfere with rRNA synthesis. Here, we show that the glycogen synthase kinase (GSK) 3 beta, which phosphorylates the tumour suppressor PTEN (phosphatase and tensin homologue deleted on chromosome 10), is selectively enriched in nucleoli of RAS-transformed cells. Immunoprecipitation and chromatin immunoprecipitation assays performed on epithelial and endothelial cells transformed with oncogenic RAS show that GSK3 beta and PTEN are part of the same complex and associate with promoter and coding region of the rDNA. An active GSK3 beta mutant abolished nucleolar BrUTP incorporation and associated with the member of the selectivity factor 1 complex TAF(I)110. Finally, GSK3 beta inhibition upregulated 45S, 18S and 28S rRNA synthesis in RAS-transformed epithelial cells as revealed by semiquantitative real-time PCR and promoted cellular proliferation. Our results underscore a repressive function for GSK3 beta in rRNA biogenesis supporting its role as a tumour supressor.	[Kukalev, A.; Percipalle, P.] Karolinska Inst, Dept Cell & Mol Biol, Med Nobel Inst, S-17177 Stockholm, Sweden; [Vincent, T.; Pettersson, R.] Karolinska Inst, Stockholm Branch, Ludwig Inst Canc Res, S-17177 Stockholm, Sweden; [Andang, M.] Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Ludwig Institute for Cancer Research; Karolinska Institutet	Percipalle, P (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Med Nobel Inst, Box 285,Nobels Vag 3, S-17177 Stockholm, Sweden.	piergiorgio.percipalle@ki.se	Andäng, Michael/GRE-9898-2022; VIncent, Theresa/HDN-9575-2022	Vincent, Theresa/0000-0002-7248-066X; Andang, Michael/0000-0002-2886-7891	Swedish Research Council (Vetenskapsra det); Cancerfonden; Lars Hiertas Minne Foundation; Jeansson Foundation	Swedish Research Council (Vetenskapsra det)(Swedish Research Council); Cancerfonden(Swedish Cancer Society); Lars Hiertas Minne Foundation; Jeansson Foundation	We thank J Arbiser (Emory University, USA) and H Beug ( Institute of Molecular Pathology, Vienna) for providing EpRAS and SVR cells. This work was supported by grants from the Swedish Research Council (Vetenskapsra det), Cancerfonden, the Lars Hiertas Minne Foundation and the Jeansson Foundation to PP.	Al-Khouri AM, 2005, J BIOL CHEM, V280, P35195, DOI 10.1074/jbc.M503045200; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Baker SJ, 2007, CELL, V128, P25, DOI 10.1016/j.cell.2006.12.023; Bijur GN, 2003, NEUROREPORT, V14, P2415, DOI 10.1097/00001756-200312190-00025; Chu EC, 2004, MED SCI MONITOR, V10, pRA235; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Leslie NR, 2004, BIOCHEM J, V382, P1, DOI 10.1042/BJ20040825; Ma C, 2007, CANCER RES, V67, P7756, DOI 10.1158/0008-5472.CAN-06-4665; Mayer C, 2005, CELL CYCLE, V4, P1036, DOI 10.4161/cc.4.8.1925; Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010; Morisco C, 2000, J BIOL CHEM, V275, P14466, DOI 10.1074/jbc.275.19.14466; Percipalle P, 2006, EMBO REP, V7, P525, DOI 10.1038/sj.embor.7400657; Salas TR, 2003, J BIOL CHEM, V278, P41338, DOI 10.1074/jbc.M302972200; Savino TM, 1999, J CELL SCI, V112, P1889; Seither P, 1996, GENOMICS, V37, P135, DOI 10.1006/geno.1996.0531; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Tseng AS, 2006, CHEM BIOL, V13, P957, DOI 10.1016/j.chembiol.2006.08.004; Wang YM, 2006, J INFRARED MILLIM W, V25, P50; White RJ, 2005, NAT REV MOL CELL BIO, V6, P69, DOI 10.1038/nrm1551; Zhang C, 2005, MOL CELL BIOL, V25, P6899, DOI 10.1128/MCB.25.16.6899-6911.2005	25	21	21	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	39					5254	5259		10.1038/onc.2008.152	http://dx.doi.org/10.1038/onc.2008.152			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GO	18490923				2022-12-17	WOS:000258915100009
J	Sanchez, A; Setien, F; Martinez, N; Oliva, JL; Herranz, M; Fraga, MF; Alaminos, M; Esteller, M; Rojas, JM				Sanchez, A.; Setien, F.; Martinez, N.; Oliva, J. L.; Herranz, M.; Fraga, M-F; Alaminos, M.; Esteller, M.; Rojas, J. M.			Epigenetic inactivation of the ERK inhibitor Spry2 in B-cell diffuse lymphomas	ONCOGENE			English	Article						hSpry2; epigenetic; lymphomas; B cells; suppressor gene	SPROUTY PROTEINS; PROSTATE-CANCER; DNA METHYLATION; CPG ISLANDS; SUPPRESSOR	Spry2 has been characterized as a negative regulator of the extracellular-regulated kinase (ERK) pathway. In this study we analysed whether epigenetic alterations of hSpry2 promoter occur in human lymphoid/hematopoietic malignancies. Our results revealed that hSpry2 promoter was hypermethylated in the HT cell line derived from a B-cell diffuse lymphoma, which correlated with decreased hSpry2 expression. We detected deregulation of the ERK pathway in these cells, but not in other blood cell lines expressing hSpry2. In addition, the ectopic overexpression of hSpry2 in HT cells drastically reduced the activation of ERK upon phorbol 12-myristate-13-acetate stimulation. Nude mice inoculated with HT mock cells developed tumors seven times larger than those from HT-hSpry2-transfected cells. We found hypermethylation of hSpry2 promoter in 37% ( 26 cases out of 71) of primary tumors from patients with B-cell diffuse lymphoma but none in normal B lymphocytes from 37 healthy individuals. Finally, we detected that hSpry2 promoter hypermethylation was associated with a significant decrease in the 5-year survival rate. These data suggest that hSpry2 could be important in lymphoid malignancies.	[Sanchez, A.; Martinez, N.; Oliva, J. L.; Rojas, J. M.] Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Biologi Celular, Madrid 28220, Spain; [Setien, F.; Herranz, M.; Fraga, M-F; Alaminos, M.; Esteller, M.] Spanish Natl Canc Ctr, Canc Epigenet Lab, Mol Pathol Programme, Madrid, Spain	Instituto de Salud Carlos III; Centro Nacional de Microbiologa (CNM); Centro Nacional de Investigaciones Oncologicas (CNIO)	Rojas, JM (corresponding author), Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Biologi Celular, Carretera Majadahonda Pozuelo,Km 2, Madrid 28220, Spain.	jmrojas@isciii.es	Rojas, José M/D-3718-2018; Fraga, Mario F/H-7824-2017; ALAMINOS, MIGUEL/N-9960-2016; Esteller, Manel/L-5956-2014; Rojas, José M./AAA-3354-2021; Herranz, Michel/L-2561-2016	Rojas, José M/0000-0002-5383-3482; Fraga, Mario F/0000-0001-8450-2603; ALAMINOS, MIGUEL/0000-0003-4876-2672; Esteller, Manel/0000-0003-4490-6093; Rojas, José M./0000-0002-7547-2825; 	Ministerio de Educacion y Ciencia, Spain [SAF2006-04247]; Fundacion Mutua Madrilena Automovilista [FMMA-2005]; Fundacio la Caixa [BM04/179-02]; Comunidad de Madrid, Spain [GR/SAL/0291/2004]; Instituto de Salud Carlos III; Spanish Association Against Cancer (AECC) [FIS01-04)]	Ministerio de Educacion y Ciencia, Spain(Spanish Government); Fundacion Mutua Madrilena Automovilista; Fundacio la Caixa(La Caixa FoundationEuropean Commission); Comunidad de Madrid, Spain(Comunidad de Madrid); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Spanish Association Against Cancer (AECC)	We thank Dr A Torano and Dr M Dominguez for the comments and help to recruit the healthy volunteers. AS was recipient of a fellowship from the Instituto de Salud Carlos III. This work was supported by grants SAF2006-04247 from the Ministerio de Educacion y Ciencia, Spain; FMMA-2005 from the Fundacion Mutua Madrilena Automovilista; BM04/179-02 from the Fundacio la Caixa'; GR/SAL/0291/2004 from the Comunidad de Madrid, Spain and RETICS from the Instituto de Salud Carlos III (Red Tematica de Investigacion Cooperativa en Cancer) to JMR; and the Health (FIS, FIS01-04) and Science (I+D+I) departments of the Spanish Government to ME and the Spanish Association Against Cancer (AECC) to JMR and ME.	Bundschu K, 2007, BIOESSAYS, V29, P897, DOI 10.1002/bies.20632; Cabrita MA, 2008, ANGIOGENESIS, V11, P53, DOI 10.1007/s10456-008-9089-1; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Esteller M, 2002, J NATL CANCER I, V94, P26; Fraga MF, 2004, CANCER RES, V64, P5527, DOI 10.1158/0008-5472.CAN-03-4061; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Lo TL, 2006, CANCER LETT, V242, P141, DOI 10.1016/j.canlet.2005.12.032; Lopez-Serra L, 2006, CANCER RES, V66, P8342, DOI 10.1158/0008-5472.CAN-06-1932; Martinez N, 2007, CELL SIGNAL, V19, P2277, DOI 10.1016/j.cellsig.2007.07.008; Mason JM, 2006, TRENDS CELL BIOL, V16, P45, DOI 10.1016/j.tcb.2005.11.004; McKie AB, 2005, ONCOGENE, V24, P2166, DOI 10.1038/sj.onc.1208371; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Wang JH, 2006, PROSTATE, V66, P613, DOI 10.1002/pros.20353	14	21	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2008	27	36					4969	4972		10.1038/onc.2008.129	http://dx.doi.org/10.1038/onc.2008.129			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18427547				2022-12-17	WOS:000258596900011
J	Fleury, L; Gerus, M; Lavigne, AC; Richard-Foy, H; Bystricky, K				Fleury, L.; Gerus, M.; Lavigne, A. C.; Richard-Foy, H.; Bystricky, K.			Eliminating epigenetic barriers induces transient hormone-regulated gene expression in estrogen receptor negative breast cancer cells	ONCOGENE			English	Article						breast cancer; chromatin; ER alpha; PR; methylation	BONE MORPHOGENETIC PROTEIN-6; HISTONE DEACETYLASE INHIBITION; DNA METHYLATION; PROGESTERONE-RECEPTOR; PROSTATE-CANCER; COPY NUMBER; ALPHA; BINDING; PROGRESSION; PROMOTER	In breast cancer, approximately one-third of tumors express neither the estrogen receptor ( ER alpha) nor estrogen-regulated genes such as the progesterone receptor gene ( PR). Our study provides new insights into the mechanism allowing hormone-activated expression of ER alpha target genes silenced in ER alpha-negative mammary tumor cells. In cell lines derived from ER alpha-negative MDA-MB231 cells, stable expression of different levels of ER alpha from a transgene did not result in transcription of PR. A quantitative comparative analysis demonstrates that inhibiting DNA methyltransferases using 5-aza-2 '-deoxycytidine or specific disruption of DNMT1 by small interfering RNAs and treatment with the histone-deacetylase inhibitor trichostatin A enabled ER alpha-mediated hormone-dependent expression of endogenous PR. We show that demethylation of a CpG island located in the first exon of PR was a prerequisite for ER alpha binding to these regulatorysequences. Although not a general requirement, DNA demethylation is also necessary for derepression of a subset of ER alpha target genes involved in tumorigenesis. PR transcription did not subsist 4 days after removal of the DNA methyltransferase blocking agents, suggesting that hormone-induced expression of ER alpha target genes in ER alpha-negative tumor cells is transient. Our observations support a model where an epigenetic mark confers stable silencing by precluding ER alpha access to promoters.	[Fleury, L.; Gerus, M.; Lavigne, A. C.; Richard-Foy, H.; Bystricky, K.] Univ Toulouse, Lab Biol Mol Eucaryote, IBCG, F-31062 Toulouse, Midi Pyrenees, France; [Fleury, L.; Gerus, M.; Lavigne, A. C.; Richard-Foy, H.; Bystricky, K.] CNRS, UMR 5099, Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Bystricky, K (corresponding author), Univ Toulouse, Lab Biol Mol Eucaryote, IBCG, 118 Route Narbonne, F-31062 Toulouse, Midi Pyrenees, France.	kerstin@ibcg.biotoul.fr	Bystricky, Kerstin/AAA-3003-2020; Lavigne, Anne-Claire/O-8805-2015; BYSTRICKY, Kerstin/B-8670-2009	Bystricky, Kerstin/0000-0001-6717-3721; BYSTRICKY, Kerstin/0000-0001-6717-3721				Ahram M, 2002, MOL CARCINOGEN, V33, P9, DOI 10.1002/mc.10019; Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Balleine RL, 2000, GENE CHROMOSOME CANC, V29, P48, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1005>3.0.CO;2-O; Baron S, 2007, J BIOL CHEM, V282, P11732, DOI 10.1074/jbc.M610079200; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Giamarchi C, 1999, ONCOGENE, V18, P533, DOI 10.1038/sj.onc.1202317; GOODFELLOW PJ, 1995, J NATL CANCER I, V87, P1515, DOI 10.1093/jnci/87.20.1515; Hamdy FC, 1997, CANCER RES, V57, P4427; Heikinheimo AK, 1999, CANCER RES, V59, P5815; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kininis M, 2007, MOL CELL BIOL, V27, P5090, DOI 10.1128/MCB.00083-07; Kwon YS, 2007, P NATL ACAD SCI USA, V104, P4852, DOI 10.1073/pnas.0700715104; Lacroix M, 2004, ENDOCR-RELAT CANCER, V11, P497, DOI 10.1677/erc.1.00758; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Lande-Diner L, 2007, J BIOL CHEM, V282, P12194, DOI 10.1074/jbc.M607838200; Lazennec G, 1999, MOL ENDOCRINOL, V13, P969, DOI 10.1210/me.13.6.969; Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045; Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087; Lin CY, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r66; Lopez-Serra L, 2006, CANCER RES, V66, P8342, DOI 10.1158/0008-5472.CAN-06-1932; Metivier R, 2004, EMBO J, V23, P3653, DOI 10.1038/sj.emboj.7600377; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; Nagaraja GM, 2006, ONCOGENE, V25, P2328, DOI 10.1038/sj.onc.1209265; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Petz LN, 2004, J STEROID BIOCHEM, V88, P113, DOI 10.1016/j.jsbmb.2003.11.008; Platet N, 2004, CRIT REV ONCOL HEMAT, V51, P55, DOI 10.1016/j.critrevonc.2004.02.001; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Rae JM, 2005, BREAST CANCER RES TR, V92, P141, DOI 10.1007/s10549-005-1483-4; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; ROODI N, 1995, JNCI-J NATL CANCER I, V87, P446, DOI 10.1093/jnci/87.6.446; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Rubin MA, 2004, CANCER RES, V64, P3814, DOI 10.1158/0008-5472.CAN-03-3881; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046; Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906; TOUITOU I, 1991, J STEROID BIOCHEM, V40, P231, DOI 10.1016/0960-0760(91)90187-A; Tyteca S, 2006, EMBO J, V25, P1680, DOI 10.1038/sj.emboj.7601066; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Yang XW, 2001, CANCER RES, V61, P7025; Zhang M, 2007, J STEROID BIOCHEM, V105, P91, DOI 10.1016/j.jsbmb.2007.01.002	46	21	22	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2008	27	29					4075	4085		10.1038/onc.2008.41	http://dx.doi.org/10.1038/onc.2008.41			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18317449				2022-12-17	WOS:000257325100007
J	D'Assoro, AB; Busby, R; Acu, ID; Quatraro, C; Reinholz, MM; Farrugia, DJ; Schroeder, MA; Allen, C; Stivala, F; Galanis, E; Salisbury, JL				D'Assoro, A. B.; Busby, R.; Acu, I. D.; Quatraro, C.; Reinholz, M. M.; Farrugia, D. J.; Schroeder, M. A.; Allen, C.; Stivala, F.; Galanis, E.; Salisbury, J. L.			Impaired p53 function leads to centrosome amplification, acquired ER alpha phenotypic heterogeneity and distant metastases in breast cancer MCF-7 xenografts	ONCOGENE			English	Article						cell cycle; estrogen independence; mitosis; tumor progression	CELL-CYCLE PROGRESSION; CHROMOSOME INSTABILITY; DIFFERENTIAL REGULATION; GENOMIC INSTABILITY; ENDOCRINE THERAPY; ESTROGEN; RECEPTOR; EXPRESSION; MDM2; OVEREXPRESSION	In this study, we establish an MCF-7 xenograft model that mimics the progression of human breast carcinomas typified by loss of p53 integrity, development of centrosome amplification, acquired estrogen receptor (ER alpha) heterogeneity, overexpression of Mdm2 and metastatic spread from the primary tumor to distant organs. MCF-7 cells with abrogated p53 function (vMCF-7D(np53)) maintained nuclear ERa expression and normal centrosome characteristics in vitro. However, following mitogen stimulation, they developed centrosome amplification and a higher frequency of aberrant mitotic spindles. Centrosome amplification was dependent on cdk2/cyclin activity since treatment with the small molecule inhibitor SU9516 suppressed centriole reduplication. In contrast to the parental MCF-7 cells, when introduced into nude mice as xenografts, tumors derived from the vMCF-7(DNp53) cell line developed a strikingly altered phenotype characterized by increased tumor growth, higher tumor histopathology grade, centrosome amplification, loss of nuclear ERa expression, increased expression of Mdm-2 oncoprotein and resistance to the antiestrogen tamoxifen. Importantly, while MCF-7 xenografts did not develop distant metastases, primary tumors derived from vMCF-7(DNp53) cells gave rise to lung metastases. Taken together, these observations indicate that abrogation of p53 function and consequent deregulation of the G1/S cell cycle transition leads to centrosome amplification responsible for breast cancer progression.	[D'Assoro, A. B.; Busby, R.; Acu, I. D.; Quatraro, C.; Farrugia, D. J.; Salisbury, J. L.] Mayo Clin, Coll Med, Tumor Biol Program, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; [Allen, C.; Galanis, E.] Mayo Clin, Coll Med, Dept Mol Med, Rochester, MN 55905 USA; [Reinholz, M. M.] Mayo Clin, Coll Med, Dept Lab Med & Expt Pathol, Rochester, MN 55905 USA; [D'Assoro, A. B.] Univ Catania, Dept Biomed Sci, Catania, Italy	Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Catania	Salisbury, JL (corresponding author), Mayo Clin, Coll Med, Tumor Biol Program, Dept Biochem & Mol Biol, Guggenheim 14,200 1st St SW, Rochester, MN 55905 USA.	Salisbury@mayo.edu	Farrugia, Daniel/E-4752-2015	Salisbury, Jeffrey/0000-0001-9257-4578	NCI NIH HHS [R01 CA072836-09, CA72836, R01 CA072836, BC022276] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072836] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akli S, 2004, CANCER RES, V64, P3198, DOI 10.1158/0008-5472.CAN-03-3672; Angeloni SV, 2004, J ENDOCRINOL, V180, P497, DOI 10.1677/joe.0.1800497; Bennett RA, 2004, ONCOGENE, V23, P6823, DOI 10.1038/sj.onc.1207561; Bindels EMJ, 2002, ONCOGENE, V21, P8158, DOI 10.1038/sj.onc.1206012; Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C; Calaf GM, 2006, INT J ONCOL, V28, P285; Caldon CE, 2006, J CELL BIOCHEM, V97, P261, DOI 10.1002/jcb.20690; Cicatiello L, 2004, MOL CELL BIOL, V24, P7260, DOI 10.1128/MCB.24.16.7260-7274.2004; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; D'Assoro AB, 2004, ONCOGENE, V23, P4068, DOI 10.1038/sj.onc.1207568; D'Assoro AB, 2001, MARC MALPIG SYMP SER, V7, P103; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; Duensing A, 2007, ONCOGENE, V26, P6280, DOI 10.1038/sj.onc.1210456; Duensing A, 2006, ONCOGENE, V25, P2943, DOI 10.1038/sj.onc.1209310; Duensing A, 2006, CELL CYCLE, V5, P2899, DOI 10.4161/cc.5.24.3567; Duong V, 2007, CANCER RES, V67, P5513, DOI 10.1158/0008-5472.CAN-07-0967; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249; Giacinti L, 2006, ONCOLOGIST, V11, P1, DOI 10.1634/theoncologist.11-1-1; Glass AG, 2007, JNCI-J NATL CANCER I, V99, P1152, DOI 10.1093/jnci/djm059; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Hasegawa K, 2006, CLIN CANCER RES, V12, P1868, DOI 10.1158/1078-0432.CCR-05-1803; Helguero LA, 2005, ONCOGENE, V24, P6605, DOI 10.1038/sj.onc.1208807; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Hwang HC, 2005, ONCOGENE, V24, P2776, DOI 10.1038/sj.onc.1208613; Ingle JN, 2004, CLIN CANCER RES, V10, p362S, DOI 10.1158/1078-0432.CCR-031200; Joe AK, 2005, ANTICANCER RES, V25, P273; Kawamura K, 2004, CANCER RES, V64, P4800, DOI 10.1158/0008-5472.CAN-03-3908; Kinyamu HK, 2003, MOL CELL BIOL, V23, P5867, DOI 10.1128/MCB.23.16.5867-5881.2003; Knippschild U, 1996, ONCOGENE, V12, P1755; Kurokawa H, 2000, CANCER RES, V60, P5887; Kurokawa H, 2003, CLIN CANCER RES, V9, p511S; Kurokawa L, 2001, CLIN CANCER RES, V7, p4436S; Lee S, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1367; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lewis JS, 2005, ONCOL RES, V15, P113, DOI 10.3727/096504005776367924; Li JJ, 2004, P NATL ACAD SCI USA, V101, P18123, DOI 10.1073/pnas.0408273101; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; Mawson A, 2005, MOL CELL ENDOCRINOL, V229, P161, DOI 10.1016/j.mce.2004.08.002; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; Medina D, 2003, CANCER RES, V63, P1067; Sluder G, 2000, CURR TOP DEV BIOL, V49, P267; Span PN, 2003, ONCOGENE, V22, P4898, DOI 10.1038/sj.onc.1206818; Suizu F, 2006, MOL CELL BIOL, V26, P1463, DOI 10.1128/MCB.26.4.1463-1479.2006; Torres EM, 2007, SCIENCE, V317, P916, DOI 10.1126/science.1142210; Turbin DA, 2006, MODERN PATHOL, V19, P69, DOI 10.1038/modpathol.3800484	49	21	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	28					3901	3911		10.1038/onc.2008.18	http://dx.doi.org/10.1038/onc.2008.18			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18264135	Green Accepted			2022-12-17	WOS:000257089000002
J	Tschan, MP; Reddy, VA; Ress, A; Arvidsson, G; Fey, MF; Torbett, BE				Tschan, M. P.; Reddy, V. A.; Ress, A.; Arvidsson, G.; Fey, M. F.; Torbett, B. E.			PU.1 binding to the p53 family of tumor suppressors impairs their transcriptional activity	ONCOGENE			English	Article						PU.1; p53; p73; transcriptional repression	HEMATOPOIETIC STEM-CELLS; SELF-RENEWAL; FRIEND; GENE; EXPRESSION; ROLES; P73; PROGRESSION	The transcription factor PU.1 is essential for terminal myeloid differentiation, B- and T-cell development, erythropoiesis and hematopoietic stem cell maintenance. PU.1 functions as oncogene in Friend virus-induced erythroleukemia and as tumor suppressor in acute myeloid leukemias. Moreover, Friend virus-induced erythroleukemia requires maintenance of PU.1 expression and the disruption of p53 function greatly accelerates disease progression. It has been hypothesized that p53-mediated expression of the p21(Cip1) cell cycle inhibitor during differentiation of pre-erythroleukemia cells promotes selection against p53 function. In addition to the blockage of erythroblast differentiation provided by increased levels of PU.1, we propose that PU.1 alters p53 function. We demonstrate that PU.1 reduces the transcriptional activity of the p53 tumor suppressor family and thus inhibits activation of genes important for cell cycle regulation and apoptosis. Inhibition is mediated through binding of PU.1 to the DNA-binding and/or oligomerization domains of p53/p73 proteins. Lastly, knocking down endogenous PU.1 in p53 wild-type REH B-cell precursor leukemia cells leads to increased expression of the p53 target p21Cip1.	[Reddy, V. A.; Torbett, B. E.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; [Tschan, M. P.; Ress, A.; Arvidsson, G.; Fey, M. F.] Univ Bern, Dept Clin Res, Bern, Switzerland; [Fey, M. F.] Univ Hosp Bern, Dept Med Oncol, CH-3010 Bern, Switzerland	Scripps Research Institute; University of Bern; University of Bern; University Hospital of Bern	Torbett, BE (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	betorbet@scripps.edu		Arvidsson, Gustav/0000-0001-7396-1820; Tschan, Mario P./0000-0001-5897-3647	NIAID NIH HHS [AI49165] Funding Source: Medline; NIDDK NIH HHS [DK49886] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049886] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Back J, 2004, BLOOD, V103, P3615, DOI 10.1182/blood-2003-11-4089; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Benard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172; Britschgi C, 2006, ONCOGENE, V25, P2030, DOI 10.1038/sj.onc.1209240; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Goldschneider D, 2005, J CELL SCI, V118, P1245, DOI 10.1242/jcs.01704; Houston IB, 2007, EXP HEMATOL, V35, P374, DOI 10.1016/j.exphem.2006.11.003; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Iwasaki H, 2005, BLOOD, V106, P1590, DOI 10.1182/blood-2005-03-0860; Jundt F, 2002, BLOOD, V99, P3060, DOI 10.1182/blood.V99.8.3060; Kelley LL, 1998, ONCOGENE, V17, P1119, DOI 10.1038/sj.onc.1202037; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Miyake N, 2006, STEM CELLS, V24, P653, DOI 10.1634/stemcells.2005-0328; Moll UM, 2004, MOL CANCER RES, V2, P371; Moreau-Gachelin F, 2006, HAEMATOLOGICA, V91, P1644; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; Nutt SL, 2005, J EXP MED, V201, P221, DOI 10.1084/jem.20041535; Pluta A, 2006, LEUKEMIA, V20, P757, DOI 10.1038/sj.leu.2404166; Prasher JM, 2001, ONCOGENE, V20, P2946, DOI 10.1038/sj.onc.1204395; Rimmele P, 2007, BLOOD, V109, P3007, DOI 10.1182/blood-2006-03-006718; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6	25	21	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	24					3489	3493		10.1038/sj.onc.1211004	http://dx.doi.org/10.1038/sj.onc.1211004			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193090				2022-12-17	WOS:000256309900014
J	Ohmori, K; Endo, Y; Yoshida, Y; Ohata, H; Taya, Y; Enari, M				Ohmori, K.; Endo, Y.; Yoshida, Y.; Ohata, H.; Taya, Y.; Enari, M.			Monomeric but not trimeric clathrin heavy chain regulates p53-mediated transcription	ONCOGENE			English	Article						clathrin heavy chain; gene transcription; monomer; p53; tumor suppressor	UBIQUITIN LIGASE; TUMOR-SUPPRESSOR; MITOTIC SPINDLE; P53; PROTEIN; MDM2; IDENTIFICATION; DEGRADATION; EXPRESSION; SUPERHELIX	Tumor suppressor p53 protein is the transcription factor responsible for various genes including DNA repair, growth arrest, apoptosis and antiangiogenesis. Recently, we showed that clathrin heavy chain (CHC), which was originally identified as a cytosolic protein regulating endocytosis, is present in nuclei and functions as a coactivator for p53. Here, we determined the detailed p53-binding site of CHC and a CHC deletion mutant containing this region (CHC833-1406) behaved as a monomer in cells. Monomeric CHC833-1406 still had a higher ability to transactivate p53 than wild-type CHC although this CHC mutant no longer had endocytic function. Moreover, similar to wild-type CHC, monomeric CHC enhances p53-mediated transcription through the recruitment of histone acetyltransferase p300. Immunofluorescent microscopic analysis exhibited that CHC833-1406 is predominantly localized in nuclei, suggesting that there may be a certain regulatory domain for nuclear export in the C-terminus of CHC. Thus, the trimerization domain of CHC is not necessary for the transactivation of p53 target genes and these data provide further evidence that nuclear CHC plays a role distinct from clathrin-mediated endocytosis.	[Ohmori, K.; Endo, Y.; Yoshida, Y.; Ohata, H.; Taya, Y.; Enari, M.] Japan Sci & Technol Agcy, SORST, Chuo Ku, Tokyo 1040045, Japan; [Ohmori, K.; Endo, Y.; Yoshida, Y.; Ohata, H.; Taya, Y.; Enari, M.] Natl Canc Ctr, Res Inst, Div Radiol, Chuo Ku, Tokyo 1040045, Japan; [Ohmori, K.] Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Chiba, Japan	Japan Science & Technology Agency (JST); National Cancer Center - Japan; University of Tokyo	Enari, M (corresponding author), Natl Canc Ctr, Res Inst, Div Radiol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	ytaya@gan2.res.ncc.go.jp; menari@gan2.res.ncc.go.jp	Enari, Masato/E-5507-2014	Enari, Masato/0000-0003-4293-3848				Barth M, 2004, J CELL SCI, V117, P2051, DOI 10.1242/jcs.01062; Bourdon JC, 2003, CELL DEATH DIFFER, V10, P397, DOI 10.1038/sj.cdd.4401243; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen CY, 2002, EMBO J, V21, P6072, DOI 10.1093/emboj/cdf594; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Dell'Angelica EC, 2001, TRENDS CELL BIOL, V11, P315, DOI 10.1016/S0962-8924(01)02043-8; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; ENARI M, 1953, GENE DEV, V20, P1087; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Kang JH, 2005, CELL, V123, P833, DOI 10.1016/j.cell.2005.09.011; Kim HL, 2000, EXP MOL MED, V32, P222, DOI 10.1038/emm.2000.36; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; KIRCHHAUSEN T, 1981, CELL, V23, P755, DOI 10.1016/0092-8674(81)90439-6; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kumar S, 2006, MOL CELL ENDOCRINOL, V246, P147, DOI 10.1016/j.mce.2005.11.028; Kutay U, 2005, TRENDS CELL BIOL, V15, P121, DOI 10.1016/j.tcb.2005.01.005; Lafer EM, 2002, TRAFFIC, V3, P513, DOI 10.1034/j.1600-0854.2002.30801.x; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 2003, CANCER RES, V63, P2596; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; McPherson PS, 2001, TRAFFIC, V2, P375, DOI 10.1034/j.1600-0854.2001.002006375.x; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Nakamura Y, 2006, CANCER SCI, V97, P633, DOI 10.1111/j.1349-7006.2006.00214.x; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Prives C, 1999, J PATHOL, V187, P112; Royle SJ, 2005, NATURE, V434, P1152, DOI 10.1038/nature03502; Royle SJ, 2006, J CELL SCI, V119, P4071, DOI 10.1242/jcs.03192; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Seo YR, 2002, ONCOGENE, V21, P731, DOI 10.1038/sj.onc.1205129; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Vecchi M, 2001, J CELL BIOL, V153, P1511, DOI 10.1083/jcb.153.7.1511; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wakeham DE, 2003, EMBO J, V22, P4980, DOI 10.1093/emboj/cdg511; Ybe JA, 1999, NATURE, V399, P371, DOI 10.1038/20708; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Ziegler E. C., 2005, SCI STKE, pre6, DOI DOI 10.1126/STKE.2842005RE6	42	21	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2008	27	15					2215	2227		10.1038/sj.onc.1210854	http://dx.doi.org/10.1038/sj.onc.1210854			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17952123				2022-12-17	WOS:000254621300012
J	Guirouilh-Barbat, J; Huck, S; Lopez, BS				Guirouilh-Barbat, J.; Huck, S.; Lopez, B. S.			S-phase progression stimulates both the mutagenic KU-independent pathway and mutagenic processing of KU-dependent intermediates, for nonhomologous end joining	ONCOGENE			English	Article						double strand break repair; nonhomologous end joining; S phase; genetic instability; cell cycle; mammalian cells	DOUBLE-STRAND BREAKS; MAMMALIAN-CELL CYCLE; HOMOLOGOUS RECOMBINATION; V(D)J RECOMBINATION; DNA-REPAIR; NHEJ; TRANSLOCATIONS; REARRANGEMENTS; INVOLVEMENT; STABILITY	We used intrachromosomal substrates to directly monitor the effect of the cell cycle on the efficiency and the accuracy of nonhomologous end joining (NHEJ) in mammalian cells. We show that both KU and KU-independent (KU-alt) pathways are efficient when maintaining cells in G(1)/S, in G(2)/M or during dynamic progression through S phase. In addition, the accuracy of NHEJ is barely altered when the cells are blocked in G(1)/S or in G(2)/M. However, progression through S phase increases the frequency of deletions, which is a hallmark of the KU-alt pathway. Moreover, we show that the intermediates that are generated by the KU-dependent end joining of non-fully complementary ends, and which contain mismatches, nicks or gap intermediates, are less accurately processed when the cells progress through S phase. In conclusion, both KU and KU-alt processes are active throughout the cell cycle, but the repair is more error prone during S phase, both by increasing the mutagenic KU-alt pathway and decreasing the accuracy of the repair of the intermediates generated by the KU-dependent pathway.	[Guirouilh-Barbat, J.; Huck, S.; Lopez, B. S.] Inst Radiobiol Cellulaire & Mol, DSV, UMR CEA,UMR 217, CNRS, F-92265 Fontenay Aux Roses, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Lopez, BS (corresponding author), Inst Radiobiol Cellulaire & Mol, DSV, UMR CEA,UMR 217, CNRS, 18 Route Panorama,BAT 05, F-92265 Fontenay Aux Roses, France.	bernard.lopez@cea.fr	guirouilh-barbat, josée/AAX-7140-2020; Lopez, Bernard S/O-7308-2017; guirouilh-barbat, josee/O-7286-2017	Lopez, Bernard S/0000-0001-5088-0155; guirouilh-barbat, josee/0000-0002-8845-7333				Audebert M, 2004, J BIOL CHEM, V279, P55117, DOI 10.1074/jbc.M404524200; Ausubel F., 1999, CURRENT PROTOCOLS MO; Capp JP, 2007, NUCLEIC ACIDS RES, V35, P3551, DOI 10.1093/nar/gkm243; Capp JP, 2006, NUCLEIC ACIDS RES, V34, P2998, DOI 10.1093/nar/gkl380; Cohen PE, 2001, BIOESSAYS, V23, P996, DOI 10.1002/bies.1145; Couedel C, 2004, GENE DEV, V18, P1293, DOI 10.1101/gad.1209204; Feldmann E, 2000, NUCLEIC ACIDS RES, V28, P2585, DOI 10.1093/nar/28.13.2585; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; GILBERT DM, 1995, J BIOL CHEM, V270, P9597, DOI 10.1074/jbc.270.16.9597; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; Guirouilh-Barbat J, 2004, MOL CELL, V14, P611, DOI 10.1016/j.molcel.2004.05.008; Honma M, 2003, ENVIRON MOL MUTAGEN, V42, P288, DOI 10.1002/em.10201; Honma M, 2007, DNA REPAIR, V6, P781, DOI 10.1016/j.dnarep.2007.01.004; JEGGO PA, 1990, MUTAT RES, V239, P1, DOI 10.1016/0165-1110(90)90028-A; Jung D, 2004, CELL, V116, P299, DOI 10.1016/S0092-8674(04)00039-X; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; LEVENSON V, 1993, NUCLEIC ACIDS RES, V21, P3997, DOI 10.1093/nar/21.17.3997; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Mills KD, 2004, GENE DEV, V18, P1283, DOI 10.1101/gad.1204304; Rodrigue A, 2006, EMBO J, V25, P222, DOI 10.1038/sj.emboj.7600914; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Saintigny Y, 2007, ONCOGENE, V26, P2769, DOI 10.1038/sj.onc.1210075; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; STAMATO TD, 1988, RADIAT RES, V115, P325, DOI 10.2307/3577168; Wang HC, 2003, NUCLEIC ACIDS RES, V31, P5377, DOI 10.1093/nar/gkg728; Weinstock DM, 2006, BLOOD, V107, P777, DOI 10.1182/blood-2005-06-2437; Zucman-Rossi J, 1998, P NATL ACAD SCI USA, V95, P11786, DOI 10.1073/pnas.95.20.11786	29	21	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2008	27	12					1726	1736		10.1038/sj.onc.1210807	http://dx.doi.org/10.1038/sj.onc.1210807			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17891177				2022-12-17	WOS:000253962100008
J	Grochova, D; Vankova, J; Damborsky, J; Ravcukova, B; Smarda, J; Vojtesek, B; Smardova, J				Grochova, D.; Vankova, J.; Damborsky, J.; Ravcukova, B.; Smarda, J.; Vojtesek, B.; Smardova, J.			Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast	ONCOGENE			English	Article						p53; FASAY; transactivation; conformation; temperature-dependent mutants; discriminating mutants	CYTOPROTECTIVE AMINOTHIOL WR1065; WILD-TYPE P53; TUMOR-SUPPRESSOR; FUNCTIONAL ASSAY; TRANSCRIPTION FACTOR; MONOCLONAL-ANTIBODY; MUTATION ANALYSIS; SENSITIVE MUTANT; HUMAN CANCERS; DNA-BINDING	The p53 gene is often mutated during cancer development. Frequency and functional consequences of these mutations vary in different tumor types. We analysed conformation and temperature dependency of 23 partially inactivating temperature-dependent (td) p53 mutants derived from various human tumors in yeast. We found considerable differences in transactivation capabilities and discriminative character of various p53 mutants. No correlations in transactivation rates and conformations of the td p53 proteins were detected. Amifostine-induced p53 reactivation occurred only in 13 of 23 td mutants, and this effect was temperature dependent and responsive element specific. The most of the p53 mutations (10/13) reactivated by amifostine were located in the part of the p53 gene coding for hydrophobic b-sandwich structure of the DNA-binding domain.	[Grochova, D.; Vankova, J.; Ravcukova, B.; Smardova, J.] Univ Hosp, Dept Pathol, Brno 62500, Czech Republic; [Grochova, D.; Vankova, J.; Damborsky, J.; Smardova, J.] Masaryk Univ, Fac Sci, CS-61137 Brno, Czech Republic; [Vojtesek, B.] Masaryk Memory Canc Inst, Dept Expt Oncol, Brno, Czech Republic	University Hospital Brno; Masaryk University Brno; Masaryk Memorial Cancer Institute	Smardova, J (corresponding author), Univ Hosp, Dept Pathol, Jihlavska 20, Brno 62500, Czech Republic.	janasmarda@seznam.cz	Damborsky, Jiri/H-3799-2012	Damborsky, Jiri/0000-0002-7848-8216				Acosta JC, 2003, MOL CANCER THER, V2, P893; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Dearth LR, 2007, CARCINOGENESIS, V28, P289, DOI 10.1093/carcin/bgl132; Di Como CJ, 1998, ONCOGENE, V16, P2527; DiGiammarino EL, 2002, NAT STRUCT BIOL, V9, P12, DOI 10.1038/nsb730; Flaman JM, 1998, ONCOGENE, V16, P1369, DOI 10.1038/sj.onc.1201889; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Gaitonde SV, 2000, ONCOGENE, V19, P4042, DOI 10.1038/sj.onc.1203756; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Hansen S, 1996, J BIOL CHEM, V271, P3917; Inga A, 2002, MOL CELL BIOL, V22, P8612, DOI 10.1128/MCB.22.24.8612-8625.2002; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Jia LQ, 1997, MOL CARCINOGEN, V19, P243, DOI 10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Lane DR, 2003, DRUG DISCOV TODAY, V8, P347, DOI 10.1016/S1359-6446(03)02669-2; Levine AJ, 2006, CELL DEATH DIFFER, V13, P1027, DOI 10.1038/sj.cdd.4401910; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Maurici D, 2001, ONCOGENE, V20, P3533, DOI 10.1038/sj.onc.1204428; McLure KG, 1999, EMBO J, V18, P763, DOI 10.1093/emboj/18.3.763; MILNER J, 1987, ONCOGENE, V1, P453; Nenutil R, 2005, J PATHOL, V207, P251, DOI 10.1002/path.1838; North S, 2000, ONCOGENE, V19, P1206, DOI 10.1038/sj.onc.1203413; North S, 2002, MOL CARCINOGEN, V33, P181, DOI 10.1002/mc.10038; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Pataer A, 2006, CANCER GENE THER, V13, P806, DOI 10.1038/sj.cgt.7700960; Pavlova S, 2003, INT J ONCOL, V23, P121; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; SCHATZBERG AF, 1992, J CLIN PSYCHIAT, V53, P20; Selivanova G, 2007, ONCOGENE, V26, P2243, DOI 10.1038/sj.onc.1210295; Shiraishi K, 2004, J BIOL CHEM, V279, P348, DOI 10.1074/jbc.M310815200; Smardova J, 2005, DIFFERENTIATION, V73, P261, DOI 10.1111/j.1432-0436.2005.00028.x; Smardova J, 2004, ONCOL REP, V11, P923; Smardova J, 2001, TUMOR BIOL, V22, P59; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; Xirodimas DP, 1999, J BIOL CHEM, V274, P28042, DOI 10.1074/jbc.274.39.28042; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	40	21	21	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2008	27	9					1243	1252		10.1038/sj.onc.1210748	http://dx.doi.org/10.1038/sj.onc.1210748			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17724467				2022-12-17	WOS:000253407000006
J	Yuan, TC; Lin, FF; Veeramani, S; Chen, SJ; Earp, HS; Lin, MF				Yuan, T-C; Lin, F-F; Veeramani, S.; Chen, S-J; Earp, H. S., III; Lin, M-F			ErbB-2 via PYK2 upregulates the adhesive ability of androgen receptor-positive human prostate cancer cells	ONCOGENE			English	Article						prostate cancer; cell adhesion; PYK2; ErbB-2	PROTEIN-TYROSINE-PHOSPHATASE; ACID-PHOSPHATASE; KINASE; PROLIFERATION; EXPRESSION; PHOSPHORYLATION; ASSOCIATION; ACTIVATION; PAXILLIN; INVASION	Aberrant regulation in the adhesive ability of cancer cells is closely associated with their metastatic activity. In this study, we examine the role of ErbB-2 in regulating the adhesive ability of androgen receptor (AR)-positive human prostate cancer (PCa) cells, the major cell population of PCa. Utilizing different LNCaP and MDA PCa2b cells as model systems, we found that ErbB-2 activity was correlated with PYK2 activity and adhesive ability in those cells. Increased ErbB-2 expression or activity in LNCaP C-33 cells enhanced PYK2 activation and cell adhesion, while the high PYK2 activity and the rapid adhesion of LNCaP C-81 cells were decreased by diminishing ErbB-2 expression or activity. Knockdown studies revealed the predominant role of ErbB-2 in regulating LNCaP C-81 cell adhesion. Coimmunoprecipitation showed that C-81 cells had increased interaction between ErbB-2 and PYK2. Elevated ErbB-2 activity in LNCaP cells correlated with increased ERK/MAPK activity and enhanced adhesive ability, which were abolished by the expression of K457A-PYK2 mutant or the treatment of PD98059, a MEK inhibitor. In summary, our data suggested that ErbB-2, via PYK2-ERK/MAPK, upregulates the adhesive ability of AR-positive human PCa cells.	Univ Nebraska Med Ctr, Coll Med, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pathol & Lab Med, Chapel Hill, NC 27515 USA; Univ Nebraska Med Ctr, Eppley Inst Res Canc, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of North Carolina; University of North Carolina Chapel Hill; University of Nebraska System; University of Nebraska Medical Center	Lin, MF (corresponding author), Univ Nebraska Med Ctr, Coll Med, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	mlin@unmc.edu	Veeramani, Suresh/P-7838-2019	Veeramani, Suresh/0000-0001-9217-0872	NATIONAL CANCER INSTITUTE [R01CA088184] Funding Source: NIH RePORTER; NCI NIH HHS [CA88184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Chen SJ, 2007, PROSTATE, V67, P557, DOI 10.1002/pros.20551; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Haier J, 2001, APMIS, V109, P241, DOI 10.1034/j.1600-0463.2001.d01-118.x; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; Knudsen BS, 2006, J CELL BIOCHEM, V99, P345, DOI 10.1002/jcb.20934; Lakkakorpi PT, 2003, J BIOL CHEM, V278, P11502, DOI 10.1074/jbc.M206579200; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; Lipinski CA, 2005, NEOPLASIA, V7, P435, DOI 10.1593/neo.04712; Meng TC, 2000, ONCOGENE, V19, P2664, DOI 10.1038/sj.onc.1203576; Meng TC, 1998, J BIOL CHEM, V273, P22096, DOI 10.1074/jbc.273.34.22096; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Park SY, 2007, CELL SIGNAL, V19, P289, DOI 10.1016/j.cellsig.2006.07.005; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; Signoretti S, 2000, JNCI-J NATL CANCER I, V92, P1918, DOI 10.1093/jnci/92.23.1918; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Tremblay L, 1996, INT J CANCER, V68, P164, DOI 10.1002/(SICI)1097-0215(19961009)68:2<169::AID-IJC4>3.0.CO;2-W; Vafa A, 1998, INT J ONCOL, V13, P1191; van der Horst EH, 2005, INT J CANCER, V113, P689, DOI 10.1002/ijc.20643; Veeramani S, 2005, ENDOCR-RELAT CANCER, V12, P805, DOI 10.1677/erc.1.00950; Wang X, 2002, J BIOL CHEM, V277, P15426, DOI 10.1074/jbc.M111218200; Zrihan-Licht S, 2000, ONCOGENE, V19, P1318, DOI 10.1038/sj.onc.1203422	29	21	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7552	7559		10.1038/sj.onc.1210570	http://dx.doi.org/10.1038/sj.onc.1210570			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17563746				2022-12-17	WOS:000251282100007
J	Mizutani, K; Ito, H; Iwamoto, I; Morishita, R; Deguchi, T; Nozawa, Y; Asano, T; Nagata, KI				Mizutani, K.; Ito, H.; Iwamoto, I.; Morishita, R.; Deguchi, T.; Nozawa, Y.; Asano, T.; Nagata, K-I			Essential roles of ERK-mediated phosphorylation of vinexin in cell spreading, migration and anchorage-independent growth	ONCOGENE			English	Article						ERK; vinexin; adaptor protein; cytokeleton; phosphorylation	ADHESION PROTEIN VINEXIN; SIGNAL-REGULATED KINASE; CYTOSKELETAL ORGANIZATION; ADAPTER PROTEIN; ACTIVATION; EXPRESSION; INTERACTS; VINCULIN; COMPLEX; GAMMA	Vinexin is an adaptor protein supposed to play pivotal roles in various cellular events such as cell adhesion, cytoskeletal organization, signa ling and gene expression. Despite the possible importance, physiological functions and regulatory mechanisms of vinexin are largely unknown. In addition, although vinexin was reported to be phosphorylated by extracellular signal-regulated kinase ( ERK), physiological significance of the phosphorylation remains to be elucidated. Here we carried out characterization of endogenous vinexin and found that it was enriched at the leading edge of migrating cells and focal adhesions of spread cells. In the analyses using ERK-phosphorylated vinexin-specific antibody, the phosphorylation signal was also detected at the leading edges of migrating cells and at cell periphery of spreading cells, whereas only faint signal was observed at focal adhesions of well-spread cells. We then established LNCaP cell lines stably expressing GFP-fused vinexin beta or two mutants at Ser189 that mimic the ERK-phosphorylated or -unphosphorylated vinexinb. Based on the analyses using the lines, the phosphorylation was likely to inhibit the cell spreading and migration. On the other hand, anchorage-independent cell growth was inhibited by unphosphorylated vinexin beta. Taken together, ERK-mediated phosphorylation of vinexinb is strongly suggested to occur in a spatio-temporally regulated manner and play important roles in cell spreading, migration and anchorage-independent growth.	Aichi Human Serv Ctr, Inst Dev Res, Dept Mol Neurobiol, Kasugai, Aichi 4800392, Japan; Gifu Univ, Sch Med, Dept Urol, Gifu 500, Japan; Gifu Int Inst Biotechnol, Gifu, Japan	Gifu University	Nagata, KI (corresponding author), Aichi Human Serv Ctr, Inst Dev Res, Dept Mol Neurobiol, 713-8 Kamiya, Kasugai, Aichi 4800392, Japan.	knagata@inst-hsc.jp		Ito, Hidenori/0000-0002-6527-477X				Akamatsu M, 1999, J BIOL CHEM, V274, P35933, DOI 10.1074/jbc.274.50.35933; Bour G, 2005, J BIOL CHEM, V280, P17027, DOI 10.1074/jbc.M501344200; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Ito H, 2007, J NEUROCHEM, V100, P545, DOI 10.1111/j.1471-4159.2006.04222.x; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; Kioka N, 2002, CELL STRUCT FUNCT, V27, P1, DOI 10.1247/csf.27.1; Matsuyama M, 2005, GENES CELLS, V10, P421, DOI 10.1111/j.1365-2443.2005.00844.x; Mitsushima M, 2006, GENES CELLS, V11, P281, DOI 10.1111/j.1365-2443.2006.00932.x; Mitsushima M, 2004, J BIOL CHEM, V279, P34570, DOI 10.1074/jbc.M402304200; Nagata K, 2004, J BIOL CHEM, V279, P55895, DOI 10.1074/jbc.M406153200; Suwa A, 2002, J BIOL CHEM, V277, P13053, DOI 10.1074/jbc.M108644200; Takahashi H, 2005, BIOCHEM BIOPH RES CO, V336, P239, DOI 10.1016/j.bbrc.2005.08.064; Tujague M, 2004, J BIOL CHEM, V279, P9255, DOI 10.1074/jbc.M312160200	13	21	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2007	26	50					7122	7131		10.1038/sj.onc.1210512	http://dx.doi.org/10.1038/sj.onc.1210512			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17486060				2022-12-17	WOS:000250715000006
J	Shal, A; Nguyen, ML; Wagstaff, J; Jiang, YH; Lambert, PF				Shal, A.; Nguyen, M. L.; Wagstaff, J.; Jiang, Y-h; Lambert, P. F.			HPV16 E6 confers p53-dependent and p53-independent phenotypes in the epidermis of mice deficient for E6AP	ONCOGENE			English	Article						E6; E6AP; p53	HUMAN-PAPILLOMAVIRUS TYPE-16; UBIQUITIN-PROTEIN LIGASE; CELL-CYCLE REGULATION; EPITHELIAL HYPERPLASIA; MEDIATED DEGRADATION; P53 PROTEIN; HPV-16 E6; ONCOPROTEIN; E6-AP; GENE	High-risk human papillomaviruses are the causative agents of cervical and other anogenital cancers. In these cancers, two viral oncogenes, E6 and E7, are expressed. E6 is best known for its ability to inactivate the tumor suppressor p53, which is thought to arise through ubiquitin-mediated degradation of p53 and involve a ternary complex between E6, p53 and the E3 ligase, E6AP. In mice transgenic for wild-type HPV16 E6, its expression leads to epithelial hyperplasia and an abrogation of normal cellular responses to DNA damage. Whereas only the latter phenotype is dependent upon E6's inactivation of p53, both are reduced in transgenic mice expressing an E6 mutant severely reduced in its binding to E6AP and other cellular proteins that bind E6 through a shared alpha-helix motif. Here, we investigated whether E6AP is required for the induction of the above phenotypes through the use of both E6AP-mutant and E6AP-null mice. E6, in the absence of E6AP retains an ability to induce epithelial hyperplasia, abrogate DNA damage responses and inhibit the induction (of p53 protein following exposure to ionizing radiation. We conclude that E6 is able to induce both p53-dependent and p53-independent phenotypes through E6AP-independent pathways in the mouse.	Univ Wisconsin, Sch Med & Publ Hlth, McArdle Lab Canc Res, Dept Canc Biol, Madison, WI 53706 USA; Caroinas Med Ctr, Dept Pediat, Charlotte, NC USA; Baylor Univ, Baylor Coll Med, Dept Mol & Human Genet, Houston, TX USA	University of Wisconsin System; University of Wisconsin Madison; Baylor College of Medicine; Baylor University	Lambert, PF (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, McArdle Lab Canc Res, Dept Canc Biol, 1400 Univ Ave, Madison, WI 53706 USA.	plambert@wisc.edu	Lambert, Paul F/F-3747-2012		NCI NIH HHS [R01 CA098428, T32 CA009135, P01 CA022443, P01 CA022443-300006, CA022443, P30 CA014520, R01 CA098428-04S1, R01 CA098428-04, P01 CA022443-290006, CA009135, R01 CA098428-05, P01 CA022443-310006, CA098428, CA014520] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098428, P01CA022443, P30CA014520, T32CA009135] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arbeit JM, 1996, P NATL ACAD SCI USA, V93, P2930, DOI 10.1073/pnas.93.7.2930; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Cooper B, 2003, VIROLOGY, V306, P87, DOI 10.1016/S0042-6822(02)00012-0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Gao QS, 2002, CANCER RES, V62, P3315; Gewin L, 2001, J VIROL, V75, P7198, DOI 10.1128/JVI.75.15.7198-7201.2001; Gillison ML, 2001, CURR OPIN ONCOL, V13, P183, DOI 10.1097/00001622-200105000-00009; Grm HS, 2004, J GEN VIROL, V85, P2815, DOI 10.1099/vir.0.80035-0; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; Hengstermann A, 2001, P NATL ACAD SCI USA, V98, P1218, DOI 10.1073/pnas.031470698; Hengstermann A, 2005, J VIROL, V79, P9296, DOI 10.1128/JVI.79.14.9296-9300.2005; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P5249, DOI 10.1073/pnas.92.11.5249-a; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Jiang YH, 1998, NEURON, V21, P799, DOI 10.1016/S0896-6273(00)80596-6; Kelley ML, 2005, J VIROL, V79, P3737, DOI 10.1128/JVI.79.6.3737-3747.2005; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Kumar A, 2002, MOL CELL BIOL, V22, P5801, DOI 10.1128/MCB.22.16.5801-5812.2002; Lee DC, 2004, J COMMUN NETW-S KOR, V6, P78, DOI 10.1109/JCN.2004.6596990; Liu XF, 2005, J BIOL CHEM, V280, P10807, DOI 10.1074/jbc.M410343200; Massimi P, 2004, ONCOGENE, V23, P8033, DOI 10.1038/sj.onc.1207977; Matsumoto Y, 2006, J MED VIROL, V78, P501, DOI 10.1002/jmv.20568; Matsuura T, 1997, NAT GENET, V15, P74, DOI 10.1038/ng0197-74; Miura K, 2002, NEUROBIOL DIS, V9, P149, DOI 10.1006/nbdi.2001.0463; MUNGER K, 1989, J VIROL, V63, P4417; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; NAKAO M, 1994, HUM MOL GENET, V3, P309, DOI 10.1093/hmg/3.2.309; Nguyen M, 2002, J VIROL, V76, P13039, DOI 10.1128/JVI.76.24.13039-13048.2002; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Nguyen MM, 2003, MOL CELL BIOL, V23, P8970, DOI 10.1128/MCB.23.24.8970-8981.2003; Nomine Y, 2006, MOL CELL, V21, P665, DOI 10.1016/j.molcel.2006.01.024; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; Riley RR, 2003, CANCER RES, V63, P4862; Salvat C, 2004, J BIOL CHEM, V279, P18935, DOI 10.1074/jbc.M312201200; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Simonson SJS, 2005, CANCER RES, V65, P8266, DOI 10.1158/0008-5472.CAN-05-1651; Song S, 2000, VIROLOGY, V267, P141, DOI 10.1006/viro.1999.0106; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; Song SY, 1998, P NATL ACAD SCI USA, V95, P2290, DOI 10.1073/pnas.95.5.2290; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; Thomas MC, 2005, MOL CELL, V17, P251, DOI 10.1016/j.molcel.2004.12.016; Traidej M, 2000, ANTISENSE NUCLEIC A, V10, P17, DOI 10.1089/oli.1.2000.10.17; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	55	21	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2007	26	23					3321	3328		10.1038/sj.onc.1210130	http://dx.doi.org/10.1038/sj.onc.1210130			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17130828	Green Accepted			2022-12-17	WOS:000246579600002
J	Stinchcombe, TE; Socinski, MA				Stinchcombe, T. E.; Socinski, M. A.			Bevacizumab in the treatment of non-small-cell lung cancer	ONCOGENE			English	Review						monoclonal antibody; targeted therapy; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; MONOCLONAL-ANTIBODY; BIOLOGIC MARKERS; PLUS CARBOPLATIN; CLINICAL-TRIAL; PHASE-II; CHEMOTHERAPY; COMBINATION; ANGIOGENESIS	Lung cancer is the leading cause of cancer death in the United States. The majority of patients present with advanced disease, and treatment with standard cytotoxic chemotherapy improves survival and quality of life in patients with a preserved functional status. However, the prognosis is poor with the majority of patients dying in less than a year. Treatment with standard cytotoxic chemotherapy has reached a therapeutic plateau, and new therapeutic approaches have investigated therapies that target the specific molecular pathways involved in carcinogenesis and angiogenesis. The most promising strategy for inhibiting angiogenesis involves agents that either target the proangiogenesis growth factor, vascular endothelial growth factor A (VEGF) by preventing binding to the receptor or inhibiting the downstream signaling of the vascular endothelial growth factor receptor. The only therapeutic agent approved for the treatment of lung cancer is bevacizumab, a monoclonal antibody that binds to VEGF. A recent phase III trial revealed a statistically significant improvement in response rate, progression free and overall survival with combination of bevacizumab with chemotherapy over chemotherapy alone. Attempts to identify surrogate markers of antiangiogenesis activity are currently ongoing, and may assist in the selection of patients for antiangiogenesis therapy and the development of this class of agents.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Multidisciplinary Thorac Oncol Program, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Socinski, MA (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Multidisciplinary Thorac Oncol Program, 3009 Old Clin Bldg,CB 7305, Chapel Hill, NC 27599 USA.	Socinski@med.unc.edu						Adjei AA, 2006, J CLIN ONCOL, V24, P4054, DOI 10.1200/JCO.2006.07.4658; Bates DO, 2001, J PHYSIOL-LONDON, V533, P263, DOI 10.1111/j.1469-7793.2001.0263b.x; Brahmer JR, 2006, J CLIN ONCOL, V24, p373S; Brewer GJ, 2000, CLIN CANCER RES, V6, P1; BULZEBRUCK H, 1992, CANCER-AM CANCER SOC, V70, P1102, DOI 10.1002/1097-0142(19920901)70:5<1102::AID-CNCR2820700514>3.0.CO;2-5; CALVERT AH, 1989, J CLIN ONCOL, V7, P1748, DOI 10.1200/JCO.1989.7.11.1748; D'Amico TA, 1999, J THORAC CARDIOV SUR, V117, P736, DOI 10.1016/S0022-5223(99)70294-1; Davis DW, 2003, BRIT J CANCER, V89, P8, DOI 10.1038/sj.bjc.6601035; Delbaldo C, 2004, JAMA-J AM MED ASSOC, V292, P470, DOI 10.1001/jama.292.4.470; Douillard JY, 2005, J CLIN ONCOL, V23, p624S; Dowlati A, 2006, J CLIN ONCOL, V24, p370S; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Dy GK, 2006, CLIN LUNG CANCER, V7, pS145, DOI 10.3816/CLC.2006.s.006; Fehrenbacher L, 2006, J CLIN ONCOL, V24, p379S; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FOLKMAN J, 1990, CANCER METAST REV, V9, P171, DOI 10.1007/BF00046358; Folkman J, 1992, Semin Cancer Biol, V3, P65; FONTANINI G, 1995, J PATHOL, V177, P57, DOI 10.1002/path.1711770110; Gordon MS, 2001, J CLIN ONCOL, V19, P843, DOI 10.1200/JCO.2001.19.3.843; Govindan R, 2006, J CLIN ONCOL, V24, P4539, DOI 10.1200/JCO.2005.04.4859; Herbst RS, 2005, J CLIN ONCOL, V23, P3243, DOI 10.1200/JCO.2005.18.853; Herbst RS, 2005, J CLIN ONCOL, V23, P2544, DOI 10.1200/JCO.2005.02.477; Herbst RS, 2002, J CLIN ONCOL, V20, P3804, DOI 10.1200/JCO.2002.05.102; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Johnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022; Le Chevalier T, 2004, NEW ENGL J MED, V350, P351, DOI 10.1056/nejmoa031644; Lucchi M, 1997, EUR J CARDIO-THORAC, V12, P535, DOI 10.1016/S1010-7940(97)00218-2; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Margolin K, 2001, J CLIN ONCOL, V19, P851, DOI 10.1200/JCO.2001.19.3.851; Morgan B, 2003, J CLIN ONCOL, V21, P3955, DOI 10.1200/JCO.2003.08.092; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pfister DG, 2004, J CLIN ONCOL, V22, P330, DOI 10.1200/JCO.2004.09.053; Robinson CJ, 2001, J CELL SCI, V114, P853; SANDLER A, 2006, J CLIN ONCOLOGY 2006, V24; SANDLER A, 2006, 4I ANN M AM SOC CLIN; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Schellinger PD, 1999, J NEURO-ONCOL, V44, P275, DOI 10.1023/A:1006308808769; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Treat J, 2005, J CLIN ONCOL, V23, p627S; Ushijima C, 2001, LUNG CANCER-J IASLC, V34, P233, DOI 10.1016/S0169-5002(01)00246-X; Wakelee HA, 2006, CANCER-AM CANCER SOC, V106, P2208, DOI 10.1002/cncr.21869; Wakelee HA, 2006, CLIN LUNG CANCER, V8, P18, DOI 10.3816/CLC.2006.n.028; Winton T, 2005, NEW ENGL J MED, V352, P2589, DOI 10.1056/NEJMoa043623; Yanagawa H, 1999, CANCER IMMUNOL IMMUN, V48, P396, DOI 10.1007/s002620050592; Yano S, 2000, AM J PATHOL, V157, P1893, DOI 10.1016/S0002-9440(10)64828-6; Yano T, 2000, EUR J CANCER, V36, P601, DOI 10.1016/S0959-8049(99)00327-5	50	21	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3691	3698		10.1038/sj.onc.1210366	http://dx.doi.org/10.1038/sj.onc.1210366			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530022				2022-12-17	WOS:000246816100011
J	Kuang, SQ; Ling, X; Sanchez-Gonzalez, B; Yang, H; Andreeff, M; Garcia-Manero, G				Kuang, S-Q; Ling, X.; Sanchez-Gonzalez, B.; Yang, H.; Andreeff, M.; Garcia-Manero, G.			Differential tumor suppressor properties and transforming growth factor-beta responsiveness of p57KIP2 in leukemia cells with aberrant p57KIP2 promoter DNA methylation	ONCOGENE			English	Article						p57KIP2; DNA methylation; leukemia; cell cycle; transforming growth factor-beta	ACUTE LYMPHOCYTIC-LEUKEMIA; BECKWITH-WIEDEMANN-SYNDROME; DEPENDENT KINASE INHIBITOR; CYCLE REGULATORY PATHWAY; ACUTE MYELOID-LEUKEMIA; CDK INHIBITOR; MULTIPLE GENES; P57(KIP2) GENE; VALPROIC ACID; HYPERMETHYLATION	To investigate if the tumor suppressor properties of p57KIP2 are dependent on its DNA methylation status, we studied the impact of several stress stimuli in leukemic cell lines with different p57KIP2 promoter DNA methylation levels. p57KIP2 reactivation was observed after stimulation with transforming growth factor-beta, other cytokines, high-density culture or serum withdrawal in p57KIP2 promoter unmethylated cells but not in methylated cells. In these cells, p57KIP2 reactivation required the use of a hypomethylating agent or a histone deacetylase inhibitor. Overexpression of p57KIP2 in p57KIP2 promoter methylated leukemic cell lines resulted in cell growth arrest and the induction of apoptosis. In contrast, overexpression of p57KIP2 in partially methylated cells only resulted in a moderate inhibition of cell growth and had no impact on apoptosis. Transduction of unmethylated cells expressing high levels of p57KIP2 with p57KIP2 short hairpin RNA resulted in increased cell proliferation. These results suggest that the tumor suppressive properties of p57KIP2 in leukemia may depend on the intrinsic promoter DNA methylation status of the gene.	Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Garcia-Manero, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Box 428,1515 Holcombe Blvd, Houston, TX 77030 USA.	ggarciam@mdanderson.org			NATIONAL CANCER INSTITUTE [R21CA105771, R21CA100067] Funding Source: NIH RePORTER; NCI NIH HHS [CA100067, CA105771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bonilla F, 1998, INT J ONCOL, V12, P583; Bueso-Ramos C, 2005, J CLIN ONCOL, V23, P3932, DOI 10.1200/JCO.2005.02.998; Canalli AA, 2005, LEUKEMIA RES, V29, P881, DOI 10.1016/j.leukres.2004.11.023; Garcia-Manero G, 2004, BLOOD, V104, p78A; Garcia-Manero G, 2003, CANCER, V97, P695, DOI 10.1002/cncr.11090; Garcia-Manero G, 2002, CLIN CANCER RES, V8, P2217; Gutierrez MI, 2003, LEUKEMIA, V17, P1845, DOI 10.1038/sj.leu.2403060; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; Kikuchi T, 2002, ONCOGENE, V21, P2741, DOI 10.1038/sj.onc.1205376; Kondo M, 1996, ONCOGENE, V12, P1365; Kuang SQ, 2002, J BIOL CHEM, V277, P45356, DOI 10.1074/jbc.C200509200; Lam WWK, 1999, J MED GENET, V36, P518; Li JQ, 2003, INT J ONCOL, V23, P1537; Ling XY, 2005, CANCER RES, V65, P2532, DOI 10.1158/0008-5472.CAN-04-2425; Ling XY, 2003, CANCER RES, V63, P298; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; Melki JR, 1999, CANCER RES, V59, P3730; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; Orlow I, 1996, CANCER RES, V56, P1219; Roman-Gomez J, 2004, BLOOD, V104, P2492, DOI 10.1182/blood-2004-03-0954; Scandura JM, 2004, P NATL ACAD SCI USA, V101, P15231, DOI 10.1073/pnas.0406771101; Shen LL, 2003, BLOOD, V101, P4131, DOI 10.1182/blood-2002-08-2466; Sherr CJ, 2000, CANCER RES, V60, P3689; Sui L, 2002, ANTICANCER RES, V22, P3191; Takahashi K, 2000, J BIOCHEM-TOKYO, V127, P73, DOI 10.1093/oxfordjournals.jbchem.a022586; Taniguchi T, 1997, ONCOGENE, V14, P1201, DOI 10.1038/sj.onc.1200934; Tokino T, 1996, HUM GENET, V97, P625, DOI 10.1007/s004390050106; Toyota M, 2001, BLOOD, V97, P2823, DOI 10.1182/blood.V97.9.2823; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Yang H, 2005, LEUKEMIA RES, V29, P739, DOI 10.1016/j.leukres.2004.11.022	33	21	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1439	1448		10.1038/sj.onc.1209907	http://dx.doi.org/10.1038/sj.onc.1209907			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16936778				2022-12-17	WOS:000244558800008
J	Depeille, PE; Ding, Y; Bromberg-White, JL; Duesbery, NS				Depeille, P. E.; Ding, Y.; Bromberg-White, J. L.; Duesbery, N. S.			MKK signaling and vascularization	ONCOGENE			English	Review						kinase; cancer; angiogenesis	ACTIVATED PROTEIN-KINASE; ENDOTHELIAL GROWTH-FACTOR; MAP-KINASE; EMBRYONIC DEATH; NOONAN-SYNDROME; TUMOR-GROWTH; PERMEABILITY FACTOR; GERMLINE MUTATIONS; TARGETED DELETION; CELLS SECRETE	In 1998, George Vande Woude's lab discovered that anthrax lethal factor (LF), the principal virulence component of anthrax toxin, was a zinc-metalloprotease that cleaved and inactivated mitogen-activated protein kinase kinases (MKK). It was perhaps not surprising, given the known roles of MKK1 and 2 in cell proliferation, that LF was subsequently found to dramatically inhibit tumor growth in vivo. What was not anticipated, however, was that the tumors treated with LF would have a substantially reduced vascular content. This intriguing result was one of the first indications that MKK signaling plays an important role in promoting tumor vascularization in vivo. In the following short review, we will compare in vitro and in vivo evidence that supports the hypothesis that MKK signaling pathways are essential for vascularization.	Van Andel Res Inst, Lab Canc & Dev Cell Biol, Grand Rapids, MI 49503 USA	Van Andel Institute	Duesbery, NS (corresponding author), Van Andel Res Inst, Lab Canc & Dev Cell Biol, 333 Bostwick Ave,NE, Grand Rapids, MI 49503 USA.	duesbery@vai.org		DUESBERY, NICK/0000-0002-4258-5655; Duesbery, Nicholas/0000-0002-5708-4984	NATIONAL CANCER INSTITUTE [R21CA108438, R01CA109308] Funding Source: NIH RePORTER; NCI NIH HHS [CA 109308, CA 108438] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams RH, 2000, MOL CELL, V6, P109, DOI 10.1016/S1097-2765(00)00012-5; Aoki Y, 2005, NAT GENET, V37, P1038, DOI 10.1038/ng1641; Araki T, 2004, NAT MED, V10, P849, DOI 10.1038/nm1084; Beardmore VA, 2005, MOL CELL BIOL, V25, P10454, DOI 10.1128/MCB.25.23.10454-10464.2005; Belanger LF, 2003, MOL CELL BIOL, V23, P4778, DOI 10.1128/MCB.23.14.4778-4787.2003; Bonnesen B, 2005, BLOOD, V106, P3396, DOI 10.1182/blood-2005-04-1739; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Chi HB, 2005, P NATL ACAD SCI USA, V102, P3846, DOI 10.1073/pnas.0500026102; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Duesbery NS, 2001, P NATL ACAD SCI USA, V98, P4089, DOI 10.1073/pnas.061031898; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Ennis BW, 2005, J PHARMACOL EXP THER, V313, P325, DOI 10.1124/jpet.104.078873; Ergun S, 2001, ANGIOGENESIS, V4, P193, DOI DOI 10.1023/A:1014027218980; Estep AL, 2006, AM J MED GENET A, V140A, P8, DOI 10.1002/ajmg.a.31078; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fong GH, 1999, DEVELOPMENT, V126, P3015; Fragale A, 2004, HUM MUTAT, V23, P267, DOI 10.1002/humu.20005; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Giroux S, 1999, CURR BIOL, V9, P369, DOI 10.1016/S0960-9822(99)80164-X; Gripp KW, 2005, AM J MED GENET C, V137C, P72, DOI 10.1002/ajmg.c.30065; Hatano N, 2003, GENES CELLS, V8, P847, DOI 10.1046/j.1365-2443.2003.00680.x; Hayashi M, 2005, CANCER RES, V65, P7699, DOI 10.1158/0008-5472.CAN-04-4540; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Hood JD, 2003, J CELL BIOL, V162, P933, DOI 10.1083/jcb.200304105; Hood JD, 2002, SCIENCE, V296, P2404, DOI 10.1126/science.1070200; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Keren B, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.021451; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kontaridis MI, 2006, J BIOL CHEM, V281, P6785, DOI 10.1074/jbc.M513068200; Kowanetz M, 2006, CLIN CANCER RES, V12, P5018, DOI 10.1158/1078-0432.CCR-06-1520; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; Matsumoto T, 2002, J CELL BIOL, V156, P149, DOI 10.1083/jcb.200103096; Merks JHM, 2005, AM J MED GENET A, V134A, P132, DOI 10.1002/ajmg.a.30603; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Mudgett JS, 2000, P NATL ACAD SCI USA, V97, P10454, DOI 10.1073/pnas.180316397; Niihori T, 2006, NAT GENET, V38, P294, DOI 10.1038/ng1749; Nishina H, 1999, DEVELOPMENT, V126, P505; Pages G, 2000, J BIOL CHEM, V275, P26484, DOI 10.1074/jbc.M002104200; Paget WJ, 1999, SOZ PRAVENTIV MED, V44, P1, DOI 10.1007/BF01624804; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; REYNOLDS JF, 1986, AM J MED GENET, V25, P413, DOI 10.1002/ajmg.1320250303; Rodriguez-Viciana P, 2006, SCIENCE, V311, P1287, DOI 10.1126/science.1124642; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Ruegg C, 2003, CELL MOL LIFE SCI, V60, P1135, DOI 10.1007/s00018-003-2297-3; Saba-El-Leil MK, 2003, EMBO REP, V4, P964, DOI 10.1038/sj.embor.embor939; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shin EY, 2001, EXP MOL MED, V33, P276, DOI 10.1038/emm.2001.45; St Croix B, 2000, SCIENCE, V289, P1197; Tamura K, 2000, CELL, V102, P221, DOI 10.1016/S0092-8674(00)00027-1; Tanaka N, 2002, EMBO REP, V3, P785, DOI 10.1093/embo-reports/kvf153; Tartaglia M, 2005, ANNU REV GENOM HUM G, V6, P45, DOI 10.1146/annurev.genom.6.080604.162305; Vitale G, 2000, BIOCHEM J, V352, P739, DOI 10.1042/0264-6021:3520739; Wang X, 2005, MOL CELL BIOL, V25, P336, DOI 10.1128/MCB.25.1.336-345.2005; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yan Lijun, 2003, BMC Dev Biol, V3, P11, DOI 10.1186/1471-213X-3-11; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Yang JH, 2000, NAT GENET, V24, P309, DOI 10.1038/73550	78	21	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2007	26	9					1290	1296		10.1038/sj.onc.1210198	http://dx.doi.org/10.1038/sj.onc.1210198			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DU	17322914	Bronze			2022-12-17	WOS:000244558700006
J	Liu, J; Grimison, B; Maller, JL				Liu, J.; Grimison, B.; Maller, J. L.			New insight into metaphase arrest by cytostatic factor: from establishment to release	ONCOGENE			English	Review						cytostatic factor; CSF; Xenopus; cyclin E/Cdk2; Mps1; Emi2	XENOPUS EGGS; VERTEBRATE EGGS; MEIOTIC EXIT; CELL-CYCLES; MEIOSIS-II; CHECKPOINT; INHIBITOR; FERTILIZATION; EMI2; MOS	Since the discovery of cytostatic factor (CSF) 35 years ago, significant progress has been made in identifying molecular components of CSF activity and the mechanism of CSF-induced metaphase II arrest (CSF arrest). This short review focuses on recent discoveries in the field and discusses the implication of these results for a general picture of CSF establishment and release. One recent focus is on the cyclin E/Cdk2 pathway. The discovery of a downstream target for cyclin E/Cdk2, the spindle checkpoint protein Mps1, provides insight into how cyclin E/Cdk2 contributes to CSF arrest. The anaphase promoting complex/cyclosome (APC/C) inhib itor Emi2 is another recent focus of work in the field. It is now clear that not only is degradation of Emi2 critical for CSF release, but its abrupt accumulation during meiosis II ( M II) is also required for the establishment of CSF arrest. Thus, by discrete pathways of APC/C inhibition operative during CSF arrest, the stability of cell cycle arrest in the egg appears to be reinforced by multiple mechanisms.	Univ Colorado, Sch Med, Dept Pharm, Howard Hughes Med Inst, Aurora, CO 80045 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus	Maller, JL (corresponding author), Univ Colorado, Sch Med, Dept Pharm, Howard Hughes Med Inst, 12801 E 17th Ave,Mail Stop F8303,POB 6511, Aurora, CO 80045 USA.	jim.maller@uchsc.edu						Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Bhatt RR, 1999, SCIENCE, V286, P1362, DOI 10.1126/science.286.5443.1362; D'Angiolella V, 2001, CURR BIOL, V11, P1221, DOI 10.1016/S0960-9822(01)00352-9; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Grimison B, 2006, CURR BIOL, V16, P1968, DOI 10.1016/j.cub.2006.08.055; Hansen DV, 2006, P NATL ACAD SCI USA, V103, P608, DOI 10.1073/pnas.0509549102; Liu JJ, 2005, CURR BIOL, V15, P1458, DOI 10.1016/j.cub.2005.07.030; Liu JJ, 2006, J BIOL CHEM, V281, P34736, DOI 10.1074/jbc.M606607200; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; Madgwick S, 2006, J CELL BIOL, V174, P791, DOI 10.1083/jcb.200604140; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; Ohsumi K, 2004, P NATL ACAD SCI USA, V101, P12531, DOI 10.1073/pnas.0405300101; Phillips KP, 2002, DEV BIOL, V247, P210, DOI 10.1006/dbio.2002.0680; Rauh NR, 2005, NATURE, V437, P1048, DOI 10.1038/nature04093; Reimann JDR, 2002, NATURE, V416, P850, DOI 10.1038/416850a; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; Roy LM, 1996, ONCOGENE, V12, P2203; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; Schmidt A, 2006, J CELL SCI, V119, P1213, DOI 10.1242/jcs.02919; Schmidt A, 2005, GENE DEV, V19, P502, DOI 10.1101/gad.320705; Sharp-Baker H, 2001, J CELL BIOL, V153, P1239, DOI 10.1083/jcb.153.6.1239; Shoji S, 2006, EMBO J, V25, P834, DOI 10.1038/sj.emboj.7600953; Tung JJ, 2005, P NATL ACAD SCI USA, V102, P4318, DOI 10.1073/pnas.0501108102; Tunquist BJ, 2003, J CELL BIOL, V163, P1231, DOI 10.1083/jcb.200306153; Tunquist BJ, 2003, GENE DEV, V17, P683, DOI 10.1101/gad.1071303; Tunquist BJ, 2002, CURR BIOL, V12, P1027, DOI 10.1016/S0960-9822(02)00894-1; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0	27	21	24	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	2007	26	9					1286	1289		10.1038/sj.onc.1210203	http://dx.doi.org/10.1038/sj.onc.1210203			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DU	17322913				2022-12-17	WOS:000244558700005
J	Silva, FP; Hamamoto, R; Furukawa, Y; Nakamura, Y				Silva, F. P.; Hamamoto, R.; Furukawa, Y.; Nakamura, Y.			TIPUH1 encodes a novel KRAB zinc-finger protein highly expressed in human hepatocellular carcinomas	ONCOGENE			English	Article						TIPUH1; hepatocellular carcinoma; TIF1 beta; hnRNPU; nucleolin	MECHANISMS; CANCER; GENE; CARCINOGENESIS; INVOLVEMENT; FAMILY	To achieve a better understanding of mechanisms that underlie hepatocarcinogenesis and to identify novel target molecules for diagnosis and therapy of hepatocellular carcinoma (HCC), we previously analysed gene-expression profiles of 20 HCC tissues on a cDNA microarray. Among the genes upregulated in the tumor tissues compared with their nontumor counterparts, we focused on a novel gene termed transcription-involved protein upregulated in HCC (TIPUH1) that putatively encoded a 500-amino-acid protein containing 12 zinc-finger domains and a Kruppel-associated box domain. Multiple-tissue northern blot analysis revealed it's testis- and placenta-specific expression in normal tissues. Colony-formation assay in soft agar showed that TIPUH1 conferred anchorage-independent growth to NIH3T3 cells, suggesting its oncogenic activity. Conversely, specific siRNA for TIPUH1 knocked down its expression in HCC cells, which resulted in their growth inhibition. We identified four TIPUH1-interacting proteins including TIF1 beta, a transcription-intermediary protein, and three involved in pre-mRNA processing (hnRNPU, hnRNPF, and Nucleolin), suggesting that overexpressed TIPUH1 may play a role in hepatocarcinogenesis by regulating transcription and/or RNA processing of growth control genes. These data may contribute to a better understanding of liver neoplasia, and to the development of novel strategy for treatment of HCCs.	Univ Tokyo, Inst Med Sci, Human Genome Ctr, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Human Genome Ctr, Mol Med Lab,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Hamamoto, Ryuji/AAF-9600-2019; Silva, Fabio Pittella/B-2621-2013	Hamamoto, Ryuji/0000-0002-2632-1334; Silva, Fabio Pittella/0000-0002-9644-7098				Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Feitelson MA, 2002, ONCOGENE, V21, P2593, DOI 10.1038/sj.onc.1205434; Ford LP, 2002, ONCOGENE, V21, P580, DOI 10.1038/sj.onc.1205086; Grisham JW, 2002, MOLECULAR BASIS OF HUMAN CANCER, P269; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Howell M, 2004, J BIOL CHEM, V279, P26300, DOI 10.1074/jbc.M401070200; Kim GJ, 2003, CANCER GENET CYTOGEN, V142, P129, DOI 10.1016/S0165-4608(02)00834-8; Looman C, 2002, MOL BIOL EVOL, V19, P2118, DOI 10.1093/oxfordjournals.molbev.a004037; Mark C, 1999, DNA CELL BIOL, V18, P381, DOI 10.1089/104454999315277; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; Oguri T, 1998, GENE, V222, P61, DOI 10.1016/S0378-1119(98)00464-8; Okabe H, 2001, CANCER RES, V61, P2129; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Raidl M, 2004, J HEPATOL, V40, P660, DOI 10.1016/j.jhep.2003.12.020; Reed R, 2001, NAT CELL BIOL, V3, pE201, DOI 10.1038/ncb0901-e201; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Shimokawa T, 2003, CANCER RES, V63, P6116; Silva FP, 2005, NEOPLASIA, V7, P348, DOI 10.1593/neo.04544; TANAKA S, 1993, CANCER RES, V53, P2884; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; Urrutia R, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-231; Wilkens L, 2001, J PATHOL, V193, P476, DOI 10.1002/path.825; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514	25	21	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					5063	5070		10.1038/sj.onc.1209517	http://dx.doi.org/10.1038/sj.onc.1209517			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568080				2022-12-17	WOS:000239921300012
J	Simbulan-Rosenthal, CM; Daher, A; Trabosh, V; Chen, WC; Gerstel, D; Soeda, E; Rosenthal, DS				Simbulan-Rosenthal, C. M.; Daher, A.; Trabosh, V.; Chen, W-C; Gerstel, D.; Soeda, E.; Rosenthal, D. S.			Id3 induces a caspase-3- and -9-dependent apoptosis and mediates UVB sensitization of HPV16 E6/7 immortalized human keratinocytes	ONCOGENE			English	Article						Id proteins; apoptosis; immortalization; caspases	LOOP-HELIX PROTEINS; SOLAR KERATOSES; ULTRAVIOLET-B; CELL-GROWTH; PROTEASE; BAX; IDENTIFICATION; TRANSCRIPTION; DIMERIZATION; EXPRESSION	Inhibitor of differentiation/DNA binding ( Id) proteins comprise a class of helix-loop-helix transcription factors involved in proliferation, differentiation, apoptosis, and carcinogenesis. We have shown that while Id2 is induced by UVB in primary keratinocytes, Id3 is upregulated only in immortalized cells. We have now determined that the consequences of ectopic expression of Id3 protein are strikingly different between immortalized and primary keratinocytes. Overexpression of Id3 induces a significant increase in apoptotic cells as revealed by Annexin V positivity as well as proteolytic processing of caspase-3 in immortalized, but not in primary keratinocytes. Id3-green fluorescent protein ( GFP)-positive cells exhibited a fivefold increase in apoptotic nuclear fragmentation compared to Id3-GFP-negative cells. These apoptotic responses were accompanied by activation of caspase-3, as shown by immunocytochemical staining with antibodies to active caspase-3. Immunostaining with antibodies to the active form of caspase-9 as well as to the active form of Bax further revealed that induction of apoptosis in Id3-overexpressing keratinocytes occurred via a mitochondrial-caspase-9-mediated pathway. Coexpression of dominant-negative caspase-9 with Id3 significantly suppressed apoptotic nuclear fragmentation, indicating that caspase-9 activation is essential for Id3-induced cell death. This response was also markedly attenuated by coexpression with the Bax antagonist antiapoptotic protein Bcl-2, confirming a role for Bax activation in this apoptotic response. Id3-induced Bax activation may result from increased expression of Bax protein. Furthermore, reduction of Id3 expression by small interfering RNAs abrogated the UVB-induced proteolytic activation of caspase- 3 in these cells. These data together suggest that UVB-induced apoptosis of immortalized keratinocytes is at least in part due to Id3 upregulation in these cells.	Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20007 USA	Georgetown University	Rosenthal, DS (corresponding author), Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Room 307,3900 Reservoir Rd WV, Washington, DC 20007 USA.	rosenthd@georgetown.edu	Simbulan-Rosenthal, Cynthia M./W-8429-2019; Rosenthal, Dean S/J-2360-2014; Daher, Ahmad/AAL-4605-2020	Rosenthal, Dean/0000-0002-7624-0209; Simbulan-Rosenthal, Ph.D, Cynthia M./0000-0002-5070-0342	NCI NIH HHS [R01 CA100443-05, R01 CA100443, 1R01 CA100443-01A1, R01 CA100443-01A1, R01 CA100443-03, R01 CA100443-02, R01 CA100443-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; Backvall H, 2005, MUTAT RES-FUND MOL M, V571, P65, DOI 10.1016/j.mrfmmm.2004.10.011; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Cleaver JE, 2002, FRONT BIOSCI-LANDMRK, V7, pD1024, DOI 10.2741/cleaver; Daher A, 2006, EXP DERMATOL, V15, P23, DOI 10.1111/j.0906-6705.2005.00384.x; Decraene D, 2004, J INVEST DERMATOL, V123, P207, DOI 10.1111/j.0022-202X.2004.22702.x; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; Frost C, 2000, J INVEST DERMATOL, V115, P273, DOI 10.1046/j.1523-1747.2000.00048.x; Harvey I, 1996, BRIT J CANCER, V74, P1302, DOI 10.1038/bjc.1996.534; Heisler GM, 2004, PHOTOCHEM PHOTOBIOL, V80, P422, DOI 10.1562/0031-8655(2004)080&lt;0422:SURIUE&gt;2.0.CO;2; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Kee BL, 2001, NAT IMMUNOL, V2, P242, DOI 10.1038/85303; Koyama T, 2004, ANTICANCER RES, V24, P1519; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Liu J, 2000, BIOCHEM BIOPH RES CO, V273, P1042, DOI 10.1006/bbrc.2000.3055; MARKS R, 1986, BRIT J DERMATOL, V115, P649, DOI 10.1111/j.1365-2133.1986.tb06644.x; MARKS R, 1988, LANCET, V1, P795, DOI 10.1016/s0140-6736(88)91658-3; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Mitchell KO, 2000, CANCER RES, V60, P6318; MIYASHITA T, 1995, CELL, V80, P293; Mueller C, 2002, CIRCULATION, V105, P2423, DOI 10.1161/01.CIR.0000016047.19488.91; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nickoloff BJ, 2000, J BIOL CHEM, V275, P27501; Norton JD, 2000, J CELL SCI, V113, P3897; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Park HR, 2004, J CUTAN PATHOL, V31, P544, DOI 10.1111/j.0303-6987.2004.00228.x; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Simbulan-Rosenthal CM, 2005, ONCOGENE, V24, P5443, DOI 10.1038/sj.onc.1208709; Simbulan-Rosenthal CM, 2002, J BIOL CHEM, V277, P24709, DOI 10.1074/jbc.M200281200; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Stratton S P, 2001, Curr Oncol Rep, V3, P295, DOI 10.1007/s11912-001-0080-x; Takehara T, 2003, CANCER RES, V63, P3054; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Van Laethem A, 2004, FASEB J, V18, P1946, DOI 10.1096/fj.04-2285fje	40	21	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3649	3660		10.1038/sj.onc.1209407	http://dx.doi.org/10.1038/sj.onc.1209407			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16449966				2022-12-17	WOS:000238448300004
J	Alabert, C; Rogers, L; Kahn, L; Niellez, S; Fafet, P; Cerulis, S; Blanchard, JM; Hipskind, RA; Vignais, ML				Alabert, C.; Rogers, L.; Kahn, L.; Niellez, S.; Fafet, P.; Cerulis, S.; Blanchard, J. M.; Hipskind, R. A.; Vignais, M. -L.			Cell type-dependent control of NF-Y activity by TGF-beta	ONCOGENE			English	Article						TGF-beta; NF-Y; MAPK	CCAAT-BINDING-FACTOR; CYCLIN-A EXPRESSION; P38 MAP KINASE; TRANSCRIPTION FACTOR; INDEPENDENT PATHWAYS; NUCLEAR-LOCALIZATION; SIGNAL-TRANSDUCTION; GENE-TRANSCRIPTION; B-SUBUNIT; CBF/NF-Y	Transforming growth factor b (TGF-beta) is a pluripotent cytokine that regulates cell growth and differentiation in a cell type-dependent fashion. TGF-beta exerts its effects through the activation of several signaling pathways. One involves membrane proximal events that lead to nuclear translocation of members of the Smad family of transcriptional regulators. TGF-beta can also activate MAPK cascades. Here, we show that TGF-beta induces nuclear translocation of the NF-YA subunit of the transcription factor NF-Y by a process that requires activation of the ERK cascade. This results in increased binding of endogenous NF-Y to chromatin and TGF-beta-dependent transcriptional regulation of the NF-Y target gene cyclin A2. Interestingly, the kinetics of NF-YA relocalization differs between epithelial cells and fibroblasts. NIH3T3 fibroblasts show an elevated basal level of phosphorylated p38 and delayed nuclear accumulation of NF-YA after TGF-beta treatment. In contrast, MDCK cells show low basal p38 activation, higher basal ERK phosphorylation and more rapid localization of NF-YA after induction. Thus, NF-Y activation by TGF-beta 1 involves ERK1/2 and potentially an interplay between MAPK pathways, thereby opening the possibility for finely tuned transcriptional regulation.	CNRS, Inst Mol Genet, UMR5535, IFR122, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Vignais, ML (corresponding author), CNRS, Inst Mol Genet, UMR5535, IFR122, 1919 Route Mende, F-34293 Montpellier 5, France.	vignais@igmm.cnrs.fr	Vignais, Marie Luce/D-5144-2017	Vignais, Marie Luce/0000-0002-0183-5953				Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; BARLAT I, 1995, ONCOGENE, V11, P1309; BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; Bhattacharya A, 2003, CANCER RES, V63, P8167; Bolognese F, 1999, ONCOGENE, V18, P1845, DOI 10.1038/sj.onc.1202494; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Cheung PCF, 2003, EMBO J, V22, P5793, DOI 10.1093/emboj/cdg552; Coustry F, 1996, J BIOL CHEM, V271, P14485, DOI 10.1074/jbc.271.24.14485; de Caestecker M, 2004, CYTOKINE GROWTH F R, V15, P1, DOI 10.1016/j.cytogfr.2003.10.004; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Efimova T, 2003, J BIOL CHEM, V278, P34277, DOI 10.1074/jbc.M302759200; Fajas L, 2001, MOL CELL BIOL, V21, P2956, DOI 10.1128/MCB.21.8.2956-2966.2001; Farina A, 1999, ONCOGENE, V18, P2818, DOI 10.1038/sj.onc.1202472; Frontini M, 2004, CELL CYCLE, V3, P217; Hall JP, 2002, J CELL BIOCHEM, V86, P1, DOI 10.1002/jcb.10187; Hu QH, 2000, J BIOL CHEM, V275, P4435, DOI 10.1074/jbc.275.6.4435; Huang WQ, 2005, J BIOL CHEM, V280, P10047, DOI 10.1074/jbc.M408680200; Huet X, 1996, MOL CELL BIOL, V16, P3789; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kahle J, 2005, MOL CELL BIOL, V25, P5339, DOI 10.1128/MCB.25.13.5339-5354.2005; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Lindahl GE, 2002, J BIOL CHEM, V277, P6153, DOI 10.1074/jbc.M108966200; MAITY SN, 1992, J BIOL CHEM, V267, P16574; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Marziali G, 1999, BLOOD, V93, P519, DOI 10.1182/blood.V93.2.519.402a01_519_526; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nicolas FJ, 2004, J CELL SCI, V117, P4113, DOI 10.1242/jcs.01289; Park SH, 2002, J BIOL CHEM, V277, P5168, DOI 10.1074/jbc.M106451200; Philips A, 1999, ONCOGENE, V18, P6222, DOI 10.1038/sj.onc.1203017; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Plet A, 1997, ONCOGENE, V14, P2575, DOI 10.1038/sj.onc.1201103; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Testa A, 2005, J BIOL CHEM, V280, P13606, DOI 10.1074/jbc.M414039200; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Wysocka J, 2001, MOL CELL BIOL, V21, P3820, DOI 10.1128/MCB.21.11.3820-3829.2001; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yingling JM, 2004, NAT REV DRUG DISCOV, V3, P1011, DOI 10.1038/nrd1580; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Yun JH, 2003, J BIOL CHEM, V278, P36966, DOI 10.1074/jbc.M305178200	51	21	21	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3387	3396		10.1038/sj.onc.1209385	http://dx.doi.org/10.1038/sj.onc.1209385			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16434965	Green Published			2022-12-17	WOS:000238448100004
J	Leszczyniecka, M; Bhatia, U; Cueto, M; Nirmala, NR; Towbin, H; Vattay, A; Wang, B; Zabludoff, S; Phillips, PE				Leszczyniecka, M; Bhatia, U; Cueto, M; Nirmala, NR; Towbin, H; Vattay, A; Wang, B; Zabludoff, S; Phillips, PE			MAP1D, a novel methionine aminopeptidase family member is overexpressed in colon cancer	ONCOGENE			English	Article						methionine aminopeptidase; MAP1D; colon cancer; shRNA	EUKARYOTIC PEPTIDE DEFORMYLASES; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; CELL-GROWTH; PROTEIN; IDENTIFICATION; UNIVERSALITY; EXPRESSION; INITIATION; EXCISION	N-terminal methionine removal is an important cellular process required for proper biological activity, subcellular localization, and eventual degradation of many proteins. The enzymes that catalyze this reaction are called Methionine Aminopeptidases (MAPs). To date, only two MAP family members, MAP1A and MAP2, have been well characterized and studied in mammals. In our studies, we have cloned a full length MAP1D gene. Expression and purification of full length recombinant protein shows that the sequence encodes an enzyme with MAP activity. MAP1D is overexpressed in colon cancer cell lines and in colon tumors as compared to matched normal tissue samples. Downregulation of MAP1D expression by shRNA in HCT-116 colon carcinoma cells reduces anchorage-independant growth in soft agar. These data suggest that MAP1D is a potentially oncogenic, novel member of the MAP gene family that may play an important role in colon tumorigenesis.	Novartis Inst Biomed Res, Cambridge, MA 02139 USA; Novartis Pharma AG, Basel, Switzerland	Novartis; Novartis	Leszczyniecka, M (corresponding author), Novartis Inst Biomed Res, Cambridge, MA 02139 USA.	magdalena.leszczyniecka@novartis.com		Nirmala, Nanguneri/0000-0003-0267-9793				Addlagatta A, 2005, BIOCHEMISTRY-US, V44, P7166, DOI 10.1021/bi0501176; ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; ARFIN SM, 1995, P NATL ACAD SCI USA, V92, P7714, DOI 10.1073/pnas.92.17.7714; BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; Bradshaw RA, 2002, ESSAYS BIOCHEM, V38, P65, DOI 10.1042/bse0380065; Catalano A, 2001, AM J PATHOL, V159, P721, DOI 10.1016/S0002-9440(10)61743-9; CHANG SYP, 1989, J BACTERIOL, V171, P4071, DOI 10.1128/jb.171.7.4071-4072.1989; CHANG YH, 1990, J BIOL CHEM, V265, P19892; Chen SP, 2002, ARCH BIOCHEM BIOPHYS, V398, P87, DOI 10.1006/abbi.2001.2675; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cutforth T, 1999, MECH DEVELOP, V82, P23, DOI 10.1016/S0925-4773(99)00006-4; Endo H, 2002, J BIOL CHEM, V277, P26396, DOI 10.1074/jbc.M202244200; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; Garrabrant Thomas, 2004, Angiogenesis, V7, P91, DOI 10.1007/s10456-004-6089-7; Giglione C, 2003, EMBO J, V22, P13, DOI 10.1093/emboj/cdg007; Giglione C, 2001, TRENDS PLANT SCI, V6, P566, DOI 10.1016/S1360-1385(01)02151-3; Giglione C, 2000, EMBO J, V19, P5916, DOI 10.1093/emboj/19.21.5916; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; Kanno T, 2002, LAB INVEST, V82, P893, DOI 10.1097/01.LAB.0000020419.25365.C4; Kinder FR, 2001, J MED CHEM, V44, P3692; Li X, 1995, P NATL ACAD SCI USA, V92, P12357, DOI 10.1073/pnas.92.26.12357; Lowther WT, 2000, BBA-PROTEIN STRUCT M, V1477, P157, DOI 10.1016/S0167-4838(99)00271-X; MEINNEL T, 1993, BIOCHIMIE, V75, P1061, DOI 10.1016/0300-9084(93)90005-D; MILLER CG, 1987, P NATL ACAD SCI USA, V84, P2718, DOI 10.1073/pnas.84.9.2718; Serero A, 2003, J BIOL CHEM, V278, P52953, DOI 10.1074/jbc.M309770200; Serero A, 2001, J MOL BIOL, V314, P695, DOI 10.1006/jmbi.2001.5175; SING N, 1997, P NATL ACAD SCI USA, V94, P6099; Towbin H, 2003, J BIOL CHEM, V278, P52964, DOI 10.1074/jbc.M309039200; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142	30	21	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 8	2006	25	24					3471	3478		10.1038/sj.onc.1209383	http://dx.doi.org/10.1038/sj.onc.1209383			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16568094				2022-12-17	WOS:000238448100012
J	Landis, MD; Seachrist, DD; Abdul-Karim, FW; Keri, RA				Landis, M. D.; Seachrist, D. D.; Abdul-Karim, F. W.; Keri, R. A.			Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors	ONCOGENE			English	Article						gene expression profiling; ErbB2/Neu/HER2; transgenic mice; parity; breast cancer; mammary gland	BREAST-CANCER RISK; ATOMIC-BOMB SURVIVORS; ACID-COA LIGASE-4; LUTEINIZING-HORMONE; TRANSIENT INCREASE; NEU PROTOONCOGENE; EXPRESSION; CARCINOGENESIS; RECEPTOR; MICE	Epidemiological studies indicate that parity enhances HER2/ErbB2/Neu-induced breast tumorigenesis. Furthermore, recent studies using multiparous, ErbB2/Neu-overexpressing mouse mammary tumor virus (MMTV-Neu) mice have shown that parity induces a population of cells that are targeted for ErbB2/Neuinduced transformation. Although parity accelerates mammary tumorigenesis, the pattern of tumor development in multiparous MMTV-Neu mice remains stochastic, suggesting that additional events are required for ErbB2/Neu to cause mammary tumors. Whether such events are genetic in nature or reflective of the dynamic hormonal control of the gland that occurs with pregnancy remains unclear. We postulated that young age at pregnancy initiation or chronic trophic maintenance of mammary epithelial cells might provide a cellular environment that significantly increases susceptibility toErbB2/Neu-induced tumorigenesis. MMTV-Neu mice that were maintained pregnant or lactating beginning at 3 weeks of age demonstrated accelerated tumorigenesis, but this process was still stochastic, indicating that early pregnancy does not provide the requisite events of tumorigenesis. However, bitransgenic mice that were generated by breeding MMTV-Neu mice with a luteinizing hormone-overexpressing mouse model of ovarian hyperstimulation developed multifocal mammary tumors in an accelerated, synchronous manner compared to virgin MMTV-Neu animals. This synchrony of tumor development in the bitransgenic mice suggests that trophic maintenance of the mammary gland provides the additional events required for tumor formation and maintains the population of cells that are targeted by ErbB2/Neu for transformation. Both the synchrony of tumor appearance and the ability to characterize a window of commitment by ovariectomy/palpation studies permitted microarray analysis to evaluate changes in gene expression over a defined timeline that spans the progression from normal to preneoplastic mammary tissue. These approaches led to identification of several candidate genes whose expression changes in the mammary gland with commitment to ErbB2/Neu-induced tumorigenesis, suggesting that they may either be regulated by ErbB2/Neu and/or contribute to tumor formation.	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Div Gen Med Sci Oncol, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Keri, RA (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 2109 Adelbert Rd RT300, Cleveland, OH 44106 USA.	ruth.keri@case.edu	Keri, Ruth/ABF-2209-2021	Keri, Ruth/0000-0002-1640-3088	NCI NIH HHS [R01-CA90398, P30 CA043703, R01 CA090398, P30-CA43703] Funding Source: Medline; NIGMS NIH HHS [GM08803, T32 GM008803] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090398, P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008803] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrechek ER, 2004, P NATL ACAD SCI USA, V101, P4984, DOI 10.1073/pnas.0306802101; Anisimov VN, 2003, CANCER LETT, V193, P49, DOI 10.1016/S0304-3835(02)00721-8; Beckmann MW, 1997, J MOL MED, V75, P429, DOI 10.1007/s001090050128; BOARD M, 1990, BIOCHEM J, V265, P503, DOI 10.1042/bj2650503; Boutros R, 2004, BIOCHEM BIOPH RES CO, V325, P1115, DOI 10.1016/j.bbrc.2004.10.112; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Cao Y, 2001, CANCER RES, V61, P8429; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244; DUTU R, 1980, ACTA CYTOL, V24, P160; Gebre-Medhin M, 2001, AM J PATHOL, V158, P1217, DOI 10.1016/S0002-9440(10)64071-0; GUNZBURG WH, 1992, BIOCHEM J, V283, P625; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HANCOCK SL, 1993, J NATL CANCER I, V85, P25, DOI 10.1093/jnci/85.1.25; Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8; HENNIPMAN A, 1987, TUMOR BIOL, V8, P251, DOI 10.1159/000217529; Henry MD, 2004, ONCOGENE, V23, P6980, DOI 10.1038/sj.onc.1207827; KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115; Kero J, 2000, J CLIN INVEST, V105, P633, DOI 10.1172/JCI7716; Kurokawa Y, 2004, J EXP CLIN CANC RES, V23, P135; LAMBE M, 1994, NEW ENGL J MED, V331, P5, DOI 10.1056/NEJM199407073310102; Land CE, 2003, RADIAT RES, V160, P707, DOI 10.1667/RR3082; Landis MD, 2005, ONCOGENE, V24, P5173, DOI 10.1038/sj.onc.1208712; Liang YC, 2005, WORLD J GASTROENTERO, V11, P2557, DOI 10.3748/wjg.v11.i17.2557; Liu Q, 2002, CANCER CAUSE CONTROL, V13, P299, DOI 10.1023/A:1015287208222; Macheda ML, 2005, J CELL PHYSIOL, V202, P654, DOI 10.1002/jcp.20166; Mazurek S, 2002, BRIT J NUTR, V87, pS23, DOI [10.1079/BJN2001454, 10.1079/BJN2001455]; MCDERMOTT EWM, 1990, BRIT J SURG, V77, P1179, DOI 10.1002/bjs.1800771029; Milliken EL, 2002, ENDOCRINOLOGY, V143, P3671, DOI 10.1210/en.2002-220228; Reed W, 2003, INT J SURG PATHOL, V11, P65, DOI 10.1177/106689690301100201; RISMA KA, 1995, P NATL ACAD SCI USA, V92, P1322, DOI 10.1073/pnas.92.5.1322; Robertson C, 1997, INT J CANCER, V73, P1; Russo IH, 1998, J MAMMARY GLAND BIOL, V3, P49, DOI 10.1023/A:1018770218022; Russo J, 1996, BREAST CANCER RES TR, V39, P7, DOI 10.1007/BF01806074; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SINGLETARY KW, 1991, NUTR CANCER, V16, P13, DOI 10.1080/01635589109514136; Stighall M, 2005, INT J CANCER, V115, P403, DOI 10.1002/ijc.20875; Sung YK, 2003, CANCER SCI, V94, P421, DOI 10.1111/j.1349-7006.2003.tb01458.x; TOKUNAGA M, 1979, J NATL CANCER I, V62, P1347; TREURNIET HF, 1992, CANCER RES, V52, P2344; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wu KD, 2002, CANCER RES, V62, P6376; Yang XH, 2003, CANCER RES, V63, P2425	46	21	22	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3325	3334		10.1038/sj.onc.1209365	http://dx.doi.org/10.1038/sj.onc.1209365			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16434967	Green Accepted			2022-12-17	WOS:000237951200011
J	Rouget-Quermalet, V; Giustiniani, J; Marie-Cardine, A; Beaud, G; Besnard, F; Loyaux, D; Ferrara, P; Leroy, K; Shimizu, N; Gaulard, P; Bensussan, A; Schmitt, C				Rouget-Quermalet, V; Giustiniani, J; Marie-Cardine, A; Beaud, G; Besnard, F; Loyaux, D; Ferrara, P; Leroy, K; Shimizu, N; Gaulard, P; Bensussan, A; Schmitt, C			Protocadherin 15 (PCDH15): a new secreted isoformand a potential marker for NK/T cell lymphomas	ONCOGENE			English	Article						NK/T lymphomas; isoforms; PCDH15; RT-PCR	T-CELL; EXPRESSION; RECEPTORS; MUTANT; LINES; GENE	Natural killer cells are well known to play an important role in immune defense against tumor development and viral infections. To further characterize new functionally relevant structures in these cells, we studied a series of monoclonal antibodies that we have raised against the NK cell line YT. One of these antibodies previously described as AY19, recognizes a 85 kD surface glycoprotein. Here we report the identification of a new secreted isoform of protocadherin 15, PCDH15C, which represents a potential associated protein for p85. Importantly, whereas protocadherins are absent from the surface of normal hematopoietic cells, we describe, for the first time, that PCDH15 is expressed in cytotoxic tumor-derived T- and NK-cell lines as well as in biopsies of nasal NK/T-cell lymphomas.	INSERM, Fac Med, U659, F-94010 Creteil, France; Sanofi Aventis, Rueil Malmaison, France; Sanofi Aventis, Labege, France; CHU Henri Mondor, Dept Pathol, INSERM, U 617,AP HP, F-94010 Creteil, France; Med Res Inst, Dept Virol, Tokyo, Japan	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Sanofi-Aventis; Sanofi-Aventis; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Schmitt, C (corresponding author), INSERM, Fac Med, U659, 8 Rue Gen Sarrail, F-94010 Creteil, France.	christian.schmitt@im3.inserm.fr	Leroy, Karen/E-9235-2011; Bensussan, Armand/E-5434-2017	Leroy, Karen/0000-0002-4379-0140; Giustiniani, Jerome/0000-0002-4612-0759; Bensussan, Armand/0000-0002-0409-2497				Ahmed ZM, 2003, HUM MOL GENET, V12, P3215, DOI 10.1093/hmg/ddg358; Ahmed ZM, 2001, AM J HUM GENET, V69, P25, DOI 10.1086/321277; Alagramam KN, 2001, NAT GENET, V27, P99, DOI 10.1038/83837; Chen MW, 2002, ONCOGENE, V21, P7861, DOI 10.1038/sj.onc.1205991; Frank M, 2002, CURR OPIN CELL BIOL, V14, P557, DOI 10.1016/S0955-0674(02)00365-4; Kanavaros P, 2000, LEUKEMIA LYMPHOMA, V38, P317, DOI 10.3109/10428190009087022; Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526; Le Bouteiller P, 2002, P NATL ACAD SCI USA, V99, P16963, DOI 10.1073/pnas.012681099; MANSUR IG, 1993, HUM IMMUNOL, V37, P31, DOI 10.1016/0198-8859(93)90140-V; Moretta L, 2004, EMBO J, V23, P255, DOI 10.1038/sj.emboj.7600019; Nagata H, 2001, BLOOD, V97, P708, DOI 10.1182/blood.V97.3.708; Nava VE, 2005, ADV ANAT PATHOL, V12, P27, DOI 10.1097/01.pap.0000151318.34752.80; Sherwood DR, 2005, CELL, V121, P951, DOI 10.1016/j.cell.2005.03.031; VILMER E, 1988, BLOOD, V72, P841; YING L, 2005, ONCOGENE, DOI DOI 10.1038	15	21	23	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2807	2811		10.1038/sj.onc.1209301	http://dx.doi.org/10.1038/sj.onc.1209301			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16369489				2022-12-17	WOS:000237272900012
J	Hoglund, M; Frigyesi, A; Mitelman, F				Hoglund, M; Frigyesi, A; Mitelman, F			A gene fusion network in human neoplasia	ONCOGENE			English	Article						gene fusion; network; cancer		Cancer is, at the cellular level, a genetic disease and acquired gene fusions play a causal role in the initiation of the neoplastic process either by activating proto-oncogenes or creating hybrid genes. We constructed a network by combining the 5' and 3' parts of all presently known gene fusions in human neoplasia and here we show that the observed network is fragmented and that the organization of the genes demonstrates a scale-free network topology with a power law degree distribution meeting the requirements of P( k) similar to k(-y), that is, conforming to the distributions found in naturally occurring networks such as the Internet and social or ecological networks. The results hence indicate that the complex system of pairwise interacting genes leading to neoplasia is governed by a universal principle.	Univ Lund Hosp, Dept Clin Genet, SE-22185 Lund, Sweden; Lund Univ, Ctr Math Sci Math Stat, Lund, Sweden	Lund University; Skane University Hospital; Lund University	Hoglund, M (corresponding author), Univ Lund Hosp, Dept Clin Genet, SE-22185 Lund, Sweden.	mattias.hoglund@med.lu.se		Hoglund, Mattias/0000-0001-9283-4421; Mitelman, Felix/0000-0002-3757-7212				Albert R, 2002, REV MOD PHYS, V74, P47, DOI 10.1103/RevModPhys.74.47; Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; Apic G, 2001, Bioinformatics, V17 Suppl 1, pS83; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Callaway DS, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.041902; Collins EC, 2002, TRENDS MOL MED, V8, P436, DOI 10.1016/S1471-4914(02)02397-3; Davison AC, 1997, BOOTSTRAP METHODS TH; ERDOS P, 1960, B INT STATIST INST, V38, P343; Holme P, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.056107; Johnson N., 1992, UNIVARIATE DISCRETE; Klemm K, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.036123; Liljeros F, 2001, NATURE, V411, P907, DOI 10.1038/35082140; Middendorf M, 2005, P NATL ACAD SCI USA, V102, P3192, DOI 10.1073/pnas.0409515102; Mitelman F, 2004, NAT GENET, V36, P331, DOI 10.1038/ng1335; Vazquez Alexei, 2003, ComPlexUs, V1, P38, DOI 10.1159/000067642; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Wuchty S, 2001, MOL BIOL EVOL, V18, P1694, DOI 10.1093/oxfordjournals.molbev.a003957; Wylie JL, 2001, SEX TRANSM DIS, V28, P14, DOI 10.1097/00007435-200101000-00005	20	21	21	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2674	2678		10.1038/sj.onc.1209290	http://dx.doi.org/10.1038/sj.onc.1209290			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16331252				2022-12-17	WOS:000237099400011
J	Marchetti, B; Ashrafi, GH; Dornan, ES; Araibi, EH; Ellis, SA; Campo, MS				Marchetti, B; Ashrafi, GH; Dornan, ES; Araibi, EH; Ellis, SA; Campo, MS			The E5 protein of BPV-4 interacts with the heavy chain of MHC class I and irreversibly retains the MHC complex in the Golgi apparatus	ONCOGENE			English	Article						BPV-4; E5; MHC class I; heavy chain; interaction; immunoevasion	BOVINE PAPILLOMAVIRUS TYPE-4; FACTOR-BETA RECEPTOR; GROWTH-FACTOR; CELL-TRANSFORMATION; DOWN-REGULATION; INTERCELLULAR COMMUNICATION; IMMUNE EVASION; E8 PROTEIN; ONCOPROTEIN; EXPRESSION	BPV-4 E5 inhibits transcription of the bovine MHC class I heavy chain (HC) gene, increases degradation of HC and downregulates surface expression of MHC class I by retaining the complex in the Golgi apparatus (GA). Here we report that transcription inhibition can be alleviated by interferon treatment and the degradation of HC can be reversed by treatment with inhibitors of proteasomes and lysosomes. However, the inhibition of transport of MHC class I to the cell surface is irreversible. We show that E5 is capable of physically interacting with HC. Together with the inhibition of the vacuolar ATPase ( due to the interaction between E5 and 16k subunit c), the interaction between E5 and HC is likely to be responsible for retention of MHC class I in the GA. C-terminus deletion mutants of E5 are incapable of either downregulating surface MHC class I or interacting with HC, establishing that the C-terminus domain of E5 is important in the inhibition of MHC class I.	Univ Glasgow, Inst Comparat Med, Div Pathol Sci, Glasgow G61 1QH, Lanark, Scotland; Inst Anim Hlth, Immunol & Pathol Div, Compton, Berks, England	University of Glasgow; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute	Campo, MS (corresponding author), Univ Glasgow, Inst Comparat Med, Div Pathol Sci, Glasgow G61 1QH, Lanark, Scotland.	s.campo@vet.gla.ac.uk		Ashrafi, G. Hossein/0000-0002-4516-5111				Agrawal S, 2000, J HEMATOTH STEM CELL, V9, P795, DOI 10.1089/152581600750062237; Anderson RA, 1997, VET J, V154, P69, DOI 10.1016/S1090-0233(05)80010-3; Araibi EH, 2004, J GEN VIROL, V85, P2809, DOI 10.1099/vir.0.80128-0; Ashby ADM, 2001, J GEN VIROL, V82, P2353, DOI 10.1099/0022-1317-82-10-2353; Ashrafi GH, 2005, INT J CANCER, V113, P276, DOI 10.1002/ijc.20558; Ashrafi GH, 2000, J GEN VIROL, V81, P689, DOI 10.1099/0022-1317-81-3-689; Ashrafi GH, 2002, ONCOGENE, V21, P248; Bartee E, 2004, J VIROL, V78, P1109, DOI 10.1128/JVI.78.3.1109-1120.2004; BENSAID A, 1989, ANIM GENET, V20, P241; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; Chevalier MS, 2002, J VIROL, V76, P8265, DOI 10.1128/JVI.76.16.8265-8275.2002; DiMaio D, 2001, ONCOGENE, V20, P7866, DOI 10.1038/sj.onc.1204915; Disbrow GL, 2005, J VIROL, V79, P5839, DOI 10.1128/JVI.79.9.5839-5846.2005; Ellis SA, 1996, IMMUNOGENETICS, V43, P156, DOI 10.1007/BF00176677; Faccini AM, 1996, J VIROL, V70, P9041, DOI 10.1128/JVI.70.12.9041-9045.1996; Furman MH, 2002, J VIROL, V76, P11753, DOI 10.1128/JVI.76.22.11753-11756.2002; Gaddum RM, 1996, IMMUNOGENETICS, V43, P238, DOI 10.1007/BF00587307; GOLDSTEIN DJ, 1992, J VIROL, V66, P405, DOI 10.1128/JVI.66.1.405-413.1992; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GRAHAM SP, 1995, J COMP PATHOL, V112, P185, DOI 10.1016/S0021-9975(05)80060-X; Grindlay GJ, 2005, VIRUS RES, V108, P29, DOI 10.1016/j.virusres.2004.07.010; Hewitt EW, 2002, EMBO J, V21, P2418, DOI 10.1093/emboj/21.10.2418; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; Kasper MR, 2003, J VIROL, V77, P3041, DOI 10.1128/JVI.77.5.3041-3049.2003; Klein O, 1999, J VIROL, V73, P3264, DOI 10.1128/JVI.73.4.3264-3272.1999; Klein O, 1998, J VIROL, V72, P8921, DOI 10.1128/JVI.72.11.8921-8932.1998; Lai CC, 2000, J BIOL CHEM, V275, P9832, DOI 10.1074/jbc.275.13.9832; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; Marchetti B, 2002, ONCOGENE, V21, P7808, DOI 10.1038/sj.onc.1205885; O'Brien PM, 2003, TRENDS MICROBIOL, V11, P300, DOI 10.1016/S0966-842X(03)00145-8; O'Brien V, 1999, VIROLOGY, V255, P385, DOI 10.1006/viro.1998.9563; O'Brien V, 2001, J BIOL CHEM, V276, P33861, DOI 10.1074/jbc.M100958200; PENNIE WD, 1993, VIROLOGY, V193, P614, DOI 10.1006/viro.1993.1169; PETTI L, 1994, J VIROL, V68, P3582, DOI 10.1128/JVI.68.6.3582-3592.1994; Petti LM, 1997, J VIROL, V71, P7318, DOI 10.1128/JVI.71.10.7318-7327.1997; Pichowski JS, 1996, IMMUNOGENETICS, V43, P253, DOI 10.1007/BF00587314; Piguet V, 2005, CURR TOP MICROBIOL, V285, P199; Sawhney SMS, 1996, GENE, V171, P281, DOI 10.1016/0378-1119(96)00096-0; SAWHNEY SMS, 1995, IMMUNOGENETICS, V41, P246, DOI 10.1007/BF00172066; Schapiro F, 2000, J CELL BIOL, V148, P305, DOI 10.1083/jcb.148.2.305; Tirabassi RS, 2002, J VIROL, V76, P6832, DOI 10.1128/JVI.76.13.6832-6835.2002; TOYE PG, 1990, IMMUNOLOGY, V70, P20; Williams M, 2005, J VIROL, V79, P632, DOI 10.1128/JVI.79.1.632-636.2005; Williams M, 2002, J VIROL, V76, P12173, DOI 10.1128/JVI.76.23.12173-12184.2002; Zago M, 2004, J GEN VIROL, V85, P3585, DOI 10.1099/vir.0.80313-0	46	21	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2254	2263		10.1038/sj.onc.1209245	http://dx.doi.org/10.1038/sj.onc.1209245			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16288210	Green Accepted			2022-12-17	WOS:000236581200012
J	de Abajo, AS; de la Hoya, M; van Puijenbroek, M; Godino, J; Diaz- Rubio, E; Morreau, H; Caldes, T				de Abajo, AS; de la Hoya, M; van Puijenbroek, M; Godino, J; Diaz- Rubio, E; Morreau, H; Caldes, T			Dual role of LOH at MMR loci in hereditary non-polyposis colorectal cancer?	ONCOGENE			English	Article						LOH; HNPCC; MMR	MISMATCH REPAIR DEFICIENCY; HMLH1 PROMOTER; MICROSATELLITE INSTABILITY; COLON-CANCER; GERMLINE MUTATIONS; CELL-LINES; TUMORS; HYPERMETHYLATION; MLH1; INACTIVATION	hMLH1 and hMSH2 can be considered tumor suppressor genes, as both alleles must be inactivated in order to lose the mismatch repair (MMR) function. In this regard, it has been proposed that LOH at MMR loci is a common Knudson's second-hit mechanism in HNPCC patients. However, experimental evidence supporting this view is scarcely found in the literature. We have performed a comprehensive analysis of LOH in 45 HNPCC tumors carrying a germline alteration in MMR loci. Overall, we have detected LOH at MMR loci in 56% of the cases. However, up to 40% of the LOH events targeted the mutant allele, arguing against a second-hit role in these tumors. Interestingly, the age at diagnosis was significantly older in these patients. To explain this and previous data, we propose a dual role for LOH at MMR loci in HNPCC.	Hosp Clin San Carlos, Oncol Mol Lab, E-28040 Madrid, Spain; Leiden Univ Ctr, Dept Pathol, Leiden, Netherlands; Hosp Clin San Carlos, Dept Clin Oncol, Madrid, Spain	Hospital Clinico San Carlos; Leiden University; Leiden University - Excl LUMC; Hospital Clinico San Carlos	Caldes, T (corresponding author), Hosp Clin San Carlos, Oncol Mol Lab, Martin Lagos S-N, E-28040 Madrid, Spain.	tcaldes@hcsc.es	de la Hoya, MIguel/Z-2911-2019; Godino, Javier/M-3753-2018	Godino, Javier/0000-0002-5653-2722; Diaz-Rubio, Eduardo/0000-0003-2792-5348				Ahuja N, 1998, CANCER RES, V58, P5489; Caldes T, 2002, INT J CANCER, V98, P774, DOI 10.1002/ijc.10240; Cunningham JM, 1998, CANCER RES, V58, P3455; de Jong AE, 2004, CLIN CANCER RES, V10, P972, DOI 10.1158/1078-0432.CCR-0956-3; de la Hoya M, 1999, CLIN CHEM, V45, P2028; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Kane MF, 1997, CANCER RES, V57, P808; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Lu SL, 1996, JPN J CANCER RES, V87, P279, DOI 10.1111/j.1349-7006.1996.tb00218.x; Lynch HT, 1999, J MED GENET, V36, P801; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Osorio A, 2002, INT J CANCER, V99, P305, DOI 10.1002/ijc.10337; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Peltomaki P, 1997, ADV CANCER RES, V71, P93, DOI 10.1016/S0065-230X(08)60097-4; Potocnik U, 2001, CANCER GENET CYTOGEN, V126, P85, DOI 10.1016/S0165-4608(00)00399-X; Tannergard P, 1997, HUM GENET, V101, P51, DOI 10.1007/s004390050585; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Wheeler JMD, 2000, J MED GENET, V37, P588, DOI 10.1136/jmg.37.8.588; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Yuen ST, 2002, ONCOGENE, V21, P7585, DOI 10.1038/sj.onc.1205968	24	21	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2124	2130		10.1038/sj.onc.1209233	http://dx.doi.org/10.1038/sj.onc.1209233			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16288214				2022-12-17	WOS:000236359700016
J	Villa-Morales, M; Santos, J; Fernandez-Piqueras, J				Villa-Morales, M; Santos, J; Fernandez-Piqueras, J			Functional Fas (Cd95/Apo-1) promoter polymorphisms in inbred mouse strains exhibiting different susceptibility to gamma-radiation-induced thymic lymphoma	ONCOGENE			English	Article						Fas (Apo-1/CD95); functional polymorphisms; cancer-genetic-susceptibility; thymic lymphoma	TUMOR-SUPPRESSOR GENE; NF-KAPPA-B; SELECTION IN-VIVO; NEGATIVE SELECTION; TRANSCRIPTIONAL REGULATION; INDUCED APOPTOSIS; T-CELLS; THYMOCYTES; EXPRESSION; LIGAND	The Fas death receptor is a cell surface molecule involved in apoptosis as well as in proliferative or activating signals of many cells types, including T lymphocytes. Using quantitative real-time reverse transcription - PCR analysis, we confirm that expression of this gene is scarcely perceptible in thymic lymphomas induced by c-irradiation in C57BL/6J mice. Notably, we also demonstrate for the first time that Fas expression is significantly upregulated in vivo both after single high dose of radiation and in thymic lymphoma-free mice. In addition, we determined its levels of expression in five mouse strains exhibiting different degrees of susceptibility (SPRET/Ei, SEG/Pas, BALB/cJ, C57BL/6J and RF/J). Interestingly, we found the highest levels of expression in SPRET/Ei and SEG/Pas strains ( both derived from the Mus spretus species), which are known to have the most resistant phenotype, and the lowest levels in the most susceptible strains C57BL/6J and RF/J. DNA sequencing of the Fas promoter in all five strains showed many polymorphisms that can be classified into three functional haplotypes by using luciferase assays: (1) C57BL/6J and RF/J, ( 2) BALB/cJ and ( 3) SPRET/Ei and SEG/Pas. Promoter activities in response to single high doses of radiation correlated well with the levels of Fas expression and are consistent with the degree of strain susceptibility.	Univ Autonoma Madrid, Dept Biol, Lab Genet Mol Humana, E-28049 Madrid, Spain	Autonomous University of Madrid	Fernandez-Piqueras, J (corresponding author), Univ Autonoma Madrid, Dept Biol, Lab Genet Mol Humana, E-28049 Madrid, Spain.	jf.piqueras@uam.es	VILLA-MORALES, MARIA C./H-8797-2015; Santos, Javier/ABF-5755-2021	VILLA-MORALES, MARIA C./0000-0001-7906-0169; Santos, Javier/0000-0002-4168-6251				Adachi M, 1996, P NATL ACAD SCI USA, V93, P2131, DOI 10.1073/pnas.93.5.2131; Booker JK, 1998, J IMMUNOL, V161, P4536; Castro JE, 1996, IMMUNITY, V5, P617, DOI 10.1016/S1074-7613(00)80275-7; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; DeRyckere D, 2003, J IMMUNOL, V171, P802, DOI 10.4049/jimmunol.171.2.802; Feuk L, 2003, HUM MUTAT, V21, P53, DOI 10.1002/humu.10148; Fleck M, 1998, J IMMUNOL, V160, P3766; Hettmann T, 2000, J IMMUNOL, V165, P5004, DOI 10.4049/jimmunol.165.9.5004; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Hoogendoorn B, 2003, HUM MOL GENET, V12, P2249, DOI 10.1093/hmg/ddg246; Kishimoto H, 1998, J EXP MED, V187, P1427, DOI 10.1084/jem.187.9.1427; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kurasawa K, 1999, CELL IMMUNOL, V194, P127, DOI 10.1006/cimm.1999.1502; Lai HC, 2003, INT J CANCER, V103, P221, DOI 10.1002/ijc.10800; Maas K, 2005, ARTHRITIS RHEUM-US, V52, P1047, DOI 10.1002/art.20931; Melendez B, 1999, ONCOGENE, V18, P4166, DOI 10.1038/sj.onc.1202826; Muschen M, 2000, J MOL MED-JMM, V78, P312, DOI 10.1007/s001090000112; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; NISHIMURA Y, 1995, J IMMUNOL, V154, P4395; OGASAWARA J, 1995, J EXP MED, V181, P485, DOI 10.1084/jem.181.2.485; Oukka M, 1998, IMMUNITY, V9, P295, DOI 10.1016/S1074-7613(00)80612-3; Pinkoski MJ, 1999, CELL DEATH DIFFER, V6, P1174, DOI 10.1038/sj.cdd.4400611; RATHMELL JC, 2002, CELL S, V109, P97; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; Santos J, 1996, ONCOGENE, V12, P669; Santos J, 2002, ONCOGENE, V21, P6680, DOI 10.1038/sj.onc.1205846; Santos J, 2001, ONCOGENE, V20, P2186, DOI 10.1038/sj.onc.1204297; Schmitz I, 2003, INT IMMUNOL, V15, P1237, DOI 10.1093/intimm/dxg125; Sibley K, 2003, CANCER RES, V63, P4327; Siegel RM, 2000, NAT IMMUNOL, V1, P469, DOI 10.1038/82712; Zheng Y, 2001, J IMMUNOL, V166, P4949, DOI 10.4049/jimmunol.166.8.4949	31	21	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2022	2029		10.1038/sj.onc.1209234	http://dx.doi.org/10.1038/sj.onc.1209234			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16301997				2022-12-17	WOS:000236359700005
J	Sankpal, NV; Moskaluk, CA; Hampton, GM; Powell, SM				Sankpal, NV; Moskaluk, CA; Hampton, GM; Powell, SM			Overexpression of CEBP beta correlates with decreased TFF1 in gastric cancer	ONCOGENE			English	Article						gastric cancer; c/EBP beta overexpression; TFF1	BINDING-PROTEIN-BETA; C/EBP-BETA; GENE-EXPRESSION; TRANSCRIPTION FACTOR; EPITHELIAL-CELLS; BREAST-CANCER; MICE LACKING; ACTIVATION; INVASIVENESS; ENHANCER	CCAAT element binding protein beta (C/EBP beta) is an important regulator of cell growth, differentiation and in promoting tumor invasiveness. C/EBP beta is located on chromosome 20q, which is amplified in many solid tumors including gastric cancers ( GC). We sought to characterize the status of C/EBP beta expression in GCs, which was recently found to repres TFF1 gene. Microarray analysis revealed overexpression of C/EBP beta in 25 of 27 (93%) GC when compared to 12 normal gastric tissue samples. RT-PCR analysis confirmed the overexpression of C/EBP beta b transcripts in 54 of 59 (91%) GC. In total, 15 of 18 gastric tumors exhibited at least fivefold higher C/EBPb transcript levels compared to their corresponding adjacent normal gastric tissue samples. Moreover, immunohistochemistry analysis demonstrated increased nuclear staining of C/EBP beta in 10 of 13 GC and at least fourfold overexpression of C/EBP beta in three primary GC compared to adjacent normal gastric tissue. Furthermore, a striking correlation of decreased TFF1 expression with increased C/EBP beta was observed in the gastric tumors studied. Microarray analysis demonstrated a loss of TFF1 expression in all 27 GC cases examined, of which 25 exhibited high C/EBP beta expression compared to normal gastric tissue. RT-PCR analysis revealed loss of TFF1 expression in 56 of 59 gastric tumors in which 54 of these tumors exhibited overexpression of C/EBP beta. Immunohistochemical analysis revealed overexpression of C/EBP beta in 10 of 13 gastric tumors that exhibited low expression of TFF1 at the protein level. Thus, overexpression of the transcription factor C/EBP beta in the majority of GCs is a novel finding.	Univ Virginia, Hlth Syst, Digest Hlth Ctr Excellence, Dept Internal Med, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Syst, Dept Pathol, Charlottesville, VA 22908 USA; Novartis Res Fdn, Genom Inst, San Diego, CA USA	University of Virginia; University of Virginia; Novartis	Powell, SM (corresponding author), Univ Virginia, Hlth Syst, Digest Hlth Ctr Excellence, Dept Internal Med, POB 800708, Charlottesville, VA 22908 USA.	powell@virginia.edu			NATIONAL CANCER INSTITUTE [R29CA067900, R01CA067900] Funding Source: NIH RePORTER; NCI NIH HHS [CA67900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beckler AD, 2003, CANCER, V98, P2184, DOI 10.1002/cncr.11789; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; Dossinger V, 2002, CELL PHYSIOL BIOCHEM, V12, P197, DOI 10.1159/000066279; El-Rifai W, 2001, GASTROENTEROLOGY, V121, P592, DOI 10.1053/gast.2001.27215; Gorgoni B, 2001, J BIOL CHEM, V276, P40769, DOI 10.1074/jbc.M106865200; Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200; Hasegawa S, 2002, CANCER RES, V62, P7012; Judd LM, 2004, GASTROENTEROLOGY, V126, P196, DOI 10.1053/j.gastro.2003.10.066; Kagan BL, 2003, CANCER RES, V63, P1696; Kang KW, 2003, J NATL CANCER I, V95, P53, DOI 10.1093/jnci/95.1.53; Kintscher J, 2004, ONCOGENE, V23, P5807, DOI 10.1038/sj.onc.1207722; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Li WL, 2005, CANCER RES, V65, P2592, DOI 10.1158/0008-5472.CAN-04-1532; Oya M, 2003, CLIN CANCER RES, V9, P1021; Rask K, 2000, INT J CANCER, V86, P337, DOI 10.1002/(SICI)1097-0215(20000501)86:3<337::AID-IJC6>3.3.CO;2-V; Sankpal NV, 2005, BBA-GENE STRUCT EXPR, V1728, P1, DOI 10.1016/j.bbaexp.2004.12.014; Sundfeldt K, 1999, BRIT J CANCER, V79, P1240, DOI 10.1038/sj.bjc.6690199; Tebbutt NC, 2002, NAT MED, V8, P1089, DOI 10.1038/nm763; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Zahnow CA, 1997, J NATL CANCER I, V89, P1887, DOI 10.1093/jnci/89.24.1887	23	21	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					643	649		10.1038/sj.onc.1209081	http://dx.doi.org/10.1038/sj.onc.1209081			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16247479				2022-12-17	WOS:000234897400015
J	Wattel, S; Mircescu, H; Venet, D; Burniat, A; Franc, B; Frank, S; Andry, G; Van Sande, J; Rocmans, P; Dumont, JE; Detours, V; Maenhaut, C				Wattel, S; Mircescu, H; Venet, D; Burniat, A; Franc, B; Frank, S; Andry, G; Van Sande, J; Rocmans, P; Dumont, JE; Detours, V; Maenhaut, C			Gene expression in thyroid autonomous adenomas provides insight into their physiopathology	ONCOGENE			English	Article						thyroid; autonomous adenoma; gene expression; microarray	THYROTROPIN RECEPTOR MUTATIONS; BLOOD CAPILLARY ENLARGEMENT; DOG PRIMARY THYROCYTES; C-MYC EXPRESSION; PROTEIN-KINASE-A; CYCLIC-AMP; TRANSGENIC MICE; MICROARRAY DATA; GROWTH-FACTORS; TSH RECEPTOR	The purpose of this study was to use the microarray technology to de. ne expression profiles characteristic of thyroid autonomous adenomas and relate these findings to physiological mechanisms. Experiments were performed on a series of separated adenomas and their normal counterparts on Micromax cDNA microarrays covering 2400 genes (analysis I), and on a pool of adenomatous tissues and their corresponding normal counterparts using microarrays of 18 000 spots (analysis II). Results for genes present on the two arrays corroborated and several gene regulations previously determined by Northern blotting or microarrays in similar lesions were confirmed. Five overexpressed and 24 underexpressed genes were also confirmed by real-time RT-PCR in some of the samples used for microarray analysis, and in additional tumor specimens. Our results show: (1) a change in the cell populations of the tumor, with a marked decrease in lymphocytes and blood cells and an increase in endothelial cells. The latter increase would correspond to the establishment of a close relation between thyrocytes and endothelial cells and is related to increased N-cadherin expression. It explains the increased blood flow in the tumor; (2) a homogeneity of tumor samples correlating with their common physiopathological mechanism: the constitutive activation of the thyrotropin (TSH)/cAMP cascade; (3) a low proportion of regulated genes consistent with the concept of a minimal deviation tumor; (4) a higher expression of genes coding for specific functional proteins, consistent with the functional hyperactivity of the tumors; (5) an increase of phosphodiesterase gene expression which explains the relatively low cyclic AMP levels measured in these tumors; (6) an overexpression of antiapoptotic genes and underexpression of proapoptotic genes compatible with their low apoptosis rate; (7) an overexpression of N-cadherin and downregulation of caveolins, which casts doubt about the use of these expressions as markers for malignancy.	Free Univ Brussels, Sch Med, IRIBHM, Int Interdisciplinary Res, B-1070 Brussels, Belgium; Univ Versailles, Hop Ambroise Pare, AP HP, Serv Anat & Cytol Pathol, St Quentin en Yvelines, France; Inst Jules Bordet, Dept Surg, B-1000 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Saclay; Institut Jules Bordet	Maenhaut, C (corresponding author), Free Univ Brussels, Sch Med, IRIBHM, Int Interdisciplinary Res, 808 Route Lennik,Campus Erasme,Bldg C, B-1070 Brussels, Belgium.	cmaenhau@ulb.ac.be						Aldred MA, 2004, J CLIN ONCOL, V22, P3531, DOI 10.1200/JCO.2004.08.127; Aldred MA, 2003, CANCER RES, V63, P2864; Aust G, 2001, J CLIN ENDOCR METAB, V86, P3368, DOI 10.1210/jc.86.7.3368; BAPTIST M, 1995, EXP CELL RES, V221, P160, DOI 10.1006/excr.1995.1363; Barden CB, 2003, CLIN CANCER RES, V9, P1792; Baris O, 2004, J CLIN ENDOCR METAB, V89, P994, DOI 10.1210/jc.2003-031238; Bauch K, 1998, EXP CLIN ENDOCR DIAB, V106, pS16, DOI 10.1055/s-0029-1212050; Becker D, 1997, J CLIN ULTRASOUND, V25, P63, DOI 10.1002/(SICI)1097-0096(199702)25:2<63::AID-JCU3>3.0.CO;2-H; Bourdeau I, 2004, ONCOGENE, V23, P1575, DOI 10.1038/sj.onc.1207277; Carver LA, 2003, NAT REV CANCER, V3, P571, DOI 10.1038/nrc1146; Cho-Chung YS, 2004, BBA-PROTEINS PROTEOM, V1697, P71, DOI 10.1016/j.bbapap.2003.11.014; Corvilain B, 2001, CLIN ENDOCRINOL, V55, P143, DOI 10.1046/j.1365-2265.2001.01365.x; Deleu S, 2000, THYROID, V10, P131, DOI 10.1089/thy.2000.10.131; Detours V, 2005, BRIT J CANCER, V92, P1545, DOI 10.1038/sj.bjc.6602521; DRALLE H, 1977, VIRCHOWS ARCH A, V374, P285, DOI 10.1007/BF00432652; Dremier S, 2002, ANN NY ACAD SCI, V968, P106, DOI 10.1111/j.1749-6632.2002.tb04330.x; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; Eggo MC, 1996, J CLIN ENDOCR METAB, V81, P3056, DOI 10.1210/jc.81.8.3056; ERMANS AM, 1972, ACTA ENDOCRINOL-COP, V70, P463, DOI 10.1530/acta.0.0700463; Eszlinger M, 2004, ONCOGENE, V23, P795, DOI 10.1038/sj.onc.1207186; Eszlinger M, 2001, J CLIN ENDOCR METAB, V86, P4834, DOI 10.1210/jc.86.10.4834; Finley DJ, 2004, J CLIN ENDOCR METAB, V89, P3214, DOI 10.1210/jc.2003-031811; Fuhrer D, 1997, J CLIN ENDOCR METAB, V82, P3885, DOI 10.1210/jc.82.11.3885; Gerard AC, 2002, J CLIN ENDOCR METAB, V87, P1291, DOI 10.1210/jc.87.3.1291; Goffard JC, 2004, MOL ENDOCRINOL, V18, P194, DOI 10.1210/me.2003-0249; HAMBURGER JI, 1987, ENDOCR REV, V8, P439, DOI 10.1210/edrv-8-4-439; HANASAKI K, 1995, J BIOL CHEM, V270, P7533, DOI 10.1074/jbc.270.13.7533; Haugen DRF, 2003, THYROID, V13, P613; Huang Y, 2001, P NATL ACAD SCI USA, V98, P15044, DOI 10.1073/pnas.251547398; Husmark J, 1999, INT J CANCER, V83, P692, DOI 10.1002/(SICI)1097-0215(19991126)83:5<692::AID-IJC21>3.0.CO;2-1; Karsten SL, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e4; KETELBANTBALASSE P, 1976, HORM METAB RES, V8, P212, DOI 10.1055/s-0028-1093662; Knudsen N, 2000, EUR J ENDOCRINOL, V143, P485, DOI 10.1530/eje.0.1430485; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Krohn K, 2000, J PATHOL, V192, P37; Krohn K, 1998, J CLIN ENDOCR METAB, V83, P130, DOI 10.1210/jc.83.1.130; Lania A, 1998, J CLIN ENDOCR METAB, V83, P1624, DOI 10.1210/jc.83.5.1624; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; Mazzanti C, 2004, CANCER RES, V64, P2898, DOI 10.1158/0008-5472.CAN-03-3811; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; NAMBA H, 1990, J CLIN INVEST, V86, P120, DOI 10.1172/JCI114673; NEVE P, 1970, Experimental Cell Research, V63, P285, DOI 10.1016/0014-4827(70)90215-6; NILSON JH, 1980, ENDOCRINOLOGY, V107, P262, DOI 10.1210/endo-107-1-262; O'Donovan N, 2002, J ENDOCRINOL, V174, P517, DOI 10.1677/joe.0.1740517; Persani L, 2000, J CLIN ENDOCR METAB, V85, P2872, DOI 10.1210/jc.85.8.2872; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; PIRSON I, 1994, EXP CELL RES, V210, P33, DOI 10.1006/excr.1994.1005; Pirson I, 1996, J CELL PHYSIOL, V168, P59, DOI 10.1002/(SICI)1097-4652(199607)168:1<59::AID-JCP8>3.0.CO;2-7; Puskas LG, 2002, BIOTECHNIQUES, V32, P1330, DOI 10.2144/02326mt04; REUSE S, 1990, EXP CELL RES, V189, P33, DOI 10.1016/0014-4827(90)90253-7; Rieger-Christ KM, 2004, ONCOGENE, V23, P4745, DOI 10.1038/sj.onc.1207629; ROGER PP, 1984, MOL CELL ENDOCRINOL, V36, P79, DOI 10.1016/0303-7207(84)90087-X; RUSSO D, 1995, J CLIN ENDOCR METAB, V80, P1347, DOI 10.1210/jc.80.4.1347; Savonet V, 1997, ANAL BIOCHEM, V247, P165, DOI 10.1006/abio.1997.2055; Taniguchi M, 2001, GENOMICS, V71, P34, DOI 10.1006/geno.2000.6427; Tonacchera M, 2000, J CLIN ENDOCR METAB, V85, P2270, DOI 10.1210/jc.85.6.2270; Tonacchera M, 1999, J CLIN ENDOCR METAB, V84, P4155, DOI 10.1210/jc.84.11.4155; VANDENHOVEVANDENBROUCKE MF, 1976, J CLIN ENDOCR METAB, V43, P178, DOI 10.1210/jcem-43-1-178; Vandeput F, 2003, ENDOCRINOLOGY, V144, P1341, DOI 10.1210/en.2001-211316; VANSANDE J, 1980, J CLIN ENDOCR METAB, V50, P776, DOI 10.1210/jcem-50-4-776; VANSANDE J, 1995, J CLIN ENDOCR METAB, V80, P2577, DOI 10.1210/jc.80.9.2577; VANSANDE J, 1988, J CLIN ENDOCR METAB, V66, P570, DOI 10.1210/jcem-66-3-570; Vanvooren V, 2002, EUR J ENDOCRINOL, V147, P287, DOI 10.1530/eje.0.1470287; Venet D, 2001, Bioinformatics, V17 Suppl 1, pS279; Venet D, 2003, BIOINFORMATICS, V19, P659, DOI 10.1093/bioinformatics/btg046; Voigt C, 2004, J ENDOCRINOL, V182, P173, DOI 10.1677/joe.0.1820173; Wang H, 1997, GENE, V199, P39, DOI 10.1016/S0378-1119(97)00343-0; Weber G, 2002, ADV ENZYME REGUL, V42, P83; WOLLMAN SH, 1982, ENDOCRINOLOGY, V111, P1867, DOI 10.1210/endo-111-6-1867; WOLLMAN SH, 1978, ENDOCRINOLOGY, V103, P2306, DOI 10.1210/endo-103-6-2306; Yamazaki K, 2003, THYROID, V13, P149, DOI 10.1089/105072503321319459; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Yano Y, 2004, CLIN CANCER RES, V10, P2035, DOI 10.1158/1078-0432.CCR-0807-03; Zeiger MA, 1997, ENDOCRINOLOGY, V138, P3133, DOI 10.1210/en.138.8.3133	74	21	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 20	2005	24	46					6902	6916		10.1038/sj.onc.1208849	http://dx.doi.org/10.1038/sj.onc.1208849			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16027733				2022-12-17	WOS:000232701700005
J	Krepulat, F; Lohler, J; Heinlein, C; Hermannstadter, A; Tolstonog, GV; Deppert, W				Krepulat, F; Lohler, J; Heinlein, C; Hermannstadter, A; Tolstonog, GV; Deppert, W			Epigenetic mechanisms affect mutant p53 transgene expression in WAP-mutp53 transgenic mice	ONCOGENE			English	Article						transgenic mice; whey acidic protein ( WAP) promoter; mutant p53; mammary carcinoma; SV40 T- antigen; epigenetics	LARGE T-ANTIGEN; PROTEIN GENE PROMOTER; MATRIX-ATTACHMENT REGIONS; BREAST-CANCER PATIENTS; MAMMARY-GLAND; VALPROIC ACID; MOUSE MODEL; CELL-DIFFERENTIATION; TUMOR-SUPPRESSOR; HYBRID GENE	We describe the construction and phenotypic characterization of 23 whey acidic protein (WAP)-mutp53 transgenic mouse lines. The mutp53-expressing lines showed a mosaic expression pattern for the transgenes, leading to a heterogeneous yet mouse line-specific expression pattern for mutp53 upon induction. Only fewlines were obtained, in which the majority of the induced mammary epithelial cells expressed the mutp53 transgene, most of the transgenic lines did not express mutp53, or expressed the transgene in less than 2% of the induced mammary epithelial cells. Hormone requirements for mutp53 transgene expression from the WAP-promoter differed in high and lowexpressing lines, being low in high expressing lines, and even lower in multiparous mutp53 mice, where persistent expression of the transgene occurred. Repeated induction of mutp53 expression through repeated parturition resulted in the formation of expanding mutp53-expressing foci within the mammary alveolar epithelium. The data suggest that epigenetic mechanisms play a role in modulating the expression of the mutp53 transgene. To support this idea, we crossed a nonexpressing WAP-mutp53 line with a strongly SV40 T-antigen-expressing WAP-T mouse line. In the bitransgenic mice, T-antigen-induced chromatin remodeling led to re-expression of epigenetically silenced mutp53 transgene(s). In these mice, mutp53 expression was much more variable compared to SV40 T-antigen expression, and seemed to depend on the coexpression of SV40 T-antigen. Mutp53 expression in this system thus resembles the situation in many human tumors, where one can observe a heterogeneous expression of mutp53, despite a homogeneous distribution of the p53 mutation in the tumor cells.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Deppert, W (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.	wolfgang.deppert@hpi.uni-hamburg.de						Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartoli A, 2003, PHARMACOL RES, V48, P111, DOI 10.1016/S1043-6618(03)00079-3; Borresen-Dale AL, 2003, HUM MUTAT, V21, P292, DOI 10.1002/humu.10174; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; BURDON T, 1991, J BIOL CHEM, V266, P6909; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; DEPPERT W, 1979, J VIROL, V31, P522, DOI 10.1128/JVI.31.2.522-536.1979; Deppert W, 2000, J CELL BIOCHEM, P115; Ebina M, 2001, ONCOGENE, V20, P2579, DOI 10.1038/sj.onc.1204351; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; FELIX CA, 1993, ONCOGENE, V8, P1203; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GOH HS, 1995, CANCER RES, V55, P5217; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Hanash S, 2004, NAT REV CANCER, V4, P638, DOI 10.1038/nrc1414; Heinrichs S, 2003, ONCOGENE, V22, P555, DOI 10.1038/sj.onc.1206138; Hogan B., 1986, MANIPULATING MOUSE E; HORIO Y, 1994, ONCOGENE, V9, P1231; JHAPPAN C, 1993, EMBO J, V12, P1835, DOI 10.1002/j.1460-2075.1993.tb05832.x; Jiao JF, 2003, J VIROL, V77, P12720, DOI 10.1128/JVI.77.23.12720-12728.2003; Klawitz I, 2001, INT J ONCOL, V19, P1325; Kramer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315; KRNACIK MJ, 1995, J BIOL CHEM, V270, P11119, DOI 10.1074/jbc.270.19.11119; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Lazar H, 2000, INT J CANCER, V85, P578, DOI 10.1002/(SICI)1097-0215(20000215)85:4<578::AID-IJC21>3.0.CO;2-S; LI BL, 1994, CELL GROWTH DIFFER, V5, P711; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; Li DW, 2003, NATURE, V423, P512, DOI 10.1038/nature01691; LI S, 1994, J BIOL CHEM, V269, P14235; LOZANO G, 1991, MOL CARCINOGEN, V4, P3, DOI 10.1002/mc.2940040103; MCKNIGHT RA, 1995, TRANSGENIC RES, V4, P39, DOI 10.1007/BF01976500; McKnight RA, 1996, MOL REPROD DEV, V44, P179, DOI 10.1002/(SICI)1098-2795(199606)44:2&lt;179::AID-MRD6&gt;3.0.CO;2-K; MCKNIGHT RA, 1992, P NATL ACAD SCI USA, V89, P6943, DOI 10.1073/pnas.89.15.6943; Milavetz BI, 2002, VIROLOGY, V294, P170, DOI 10.1006/viro.2001.1308; Murphy KL, 2000, ONCOGENE, V19, P1045, DOI 10.1038/sj.onc.1203274; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; PITTIUS CW, 1988, P NATL ACAD SCI USA, V85, P5874, DOI 10.1073/pnas.85.16.5874; PITTIUS CW, 1988, MOL ENDOCRINOL, V2, P1027, DOI 10.1210/mend-2-11-1027; Rahko E, 2003, EUR J CANCER, V39, P447, DOI 10.1016/S0959-8049(02)00499-9; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; SANDGREN EP, 1995, CANCER RES, V55, P3915; SCHIRMBECK R, 1991, J VIROL, V65, P2578, DOI 10.1128/JVI.65.5.2578-2588.1991; SCHMITT MK, 1987, VIROLOGY, V156, P268, DOI 10.1016/0042-6822(87)90407-7; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; Schulze-Garg C, 2000, ONCOGENE, V19, P1028, DOI 10.1038/sj.onc.1203281; Seinsoth S, 2003, EMBO REP, V4, P263, DOI 10.1038/sj.embor.embor770; Sherr CJ, 2000, CANCER RES, V60, P3689; Sigal A, 2000, CANCER RES, V60, P6788; Simmons DT, 2004, NUCLEIC ACIDS RES, V32, P1103, DOI 10.1093/nar/gkh236; Slack A, 1999, J BIOL CHEM, V274, P10105, DOI 10.1074/jbc.274.15.10105; Smalley MJ, 1998, IN VITRO CELL DEV-AN, V34, P711; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; TIEMANN F, 1994, ONCOGENE, V9, P1907; Tolstonog GV, 2000, DNA CELL BIOL, V19, P647, DOI 10.1089/10445490050199054; TZENG YJ, 1993, ONCOGENE, V8, P1965; Valls E, 2003, NUCLEIC ACIDS RES, V31, P3114, DOI 10.1093/nar/gkg418; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Zgouras D, 2004, BIOCHEM BIOPH RES CO, V316, P693, DOI 10.1016/j.bbrc.2004.02.105; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhou Q, 2002, BREAST CANCER RES TR, V75, P107, DOI 10.1023/A:1019698807564	64	21	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4645	4659		10.1038/sj.onc.1208557	http://dx.doi.org/10.1038/sj.onc.1208557			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15870706				2022-12-17	WOS:000230304500004
J	Schleiermacher, G; Bourdeaut, F; Combaret, V; Picrron, G; Raynal, V; Aurias, A; Ribeiro, A; Janoueix-Lerosey, I; Delattre, O				Schleiermacher, G; Bourdeaut, F; Combaret, V; Picrron, G; Raynal, V; Aurias, A; Ribeiro, A; Janoueix-Lerosey, I; Delattre, O			Stepwise occurrence of a complex unbalanced translocation in neuroblastoma leading to insertion of a telomere sequence and late chromosome 17q gain	ONCOGENE			English	Article						neuroblastoma; chromosome 17; translocation breakpoint; molecular cloning; interstitial telomere	ARM 17Q; PATIENT; REGION; BREAKPOINT; 5-KINASE; FAMILY; DOMAIN; TUMORS; GENES	In neuroblastoma, the most frequent genetic alterations are unbalanced translocations involving chromosome 17. To gain insights into these rearrangements, we have characterized a previously identified der(1)t(1;17) of the CLB-Bar cell line. The 17q breakpoint was mapped by FISH. Subsequently, a rearranged fragment was identified by Southern analysis, cloned in a lambda vector and sequenced. The chromosome rearrangement is more complex than expected due to the presence of an interstitial 4p telomeric sequence between chromosome 1p and 17q. Three different genes, which may play a role in neuroblastoma development, are disrupted by the translocation breakpoints. Indeed, the 3'UTR of the PIP5K2B gene on chromosome 17q is directly fused to the (TTAGGG)n repeat of the chromosome 4p telomere, and the ( 1; 4) fusion disrupts the MACF1 (microtubule-actin crosslinking factor 1) and POLN genes, respectively. Interestingly, the ( 1; 4) fusion was present at diagnosis and at relapse, whereas the ( 4; 17) fusion was detected at relapse only, leading to a secondary 17q gain confirmed by array CGH therefore indicating that 17q gain may not be a primary event in neuroblastoma. Finally, screening of a panel of neuroblastoma cell lines identified interstitial telomeric sequences in three other cases, suggesting that this may be a recurrent mechanism leading to unbalanced translocations in neuroblastoma.	Inst Curie, INSERM, Lab Pathol Mol Canc, Unite 509, F-75248 Paris, France; Ctr Leon Berard, Biol Cellulaire Lab, F-69373 Lyon, France; Inst Curie, Unite Genet Somat, F-75248 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UNICANCER; Centre Leon Berard; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Delattre, O (corresponding author), Inst Curie, INSERM, Lab Pathol Mol Canc, Unite 509, 26 Rue Ulm, F-75248 Paris, France.	delattre@curie.fr	Janoueix-Lerosey, Isabelle/G-1758-2018; , Bourdeaut/AAG-8494-2019	Janoueix-Lerosey, Isabelle/0000-0003-0434-3003; delattre, olivier/0000-0002-8730-2276				Bown N, 2001, J CLIN PATHOL, V54, P897, DOI 10.1136/jcp.54.12.897; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; CARON H, 1994, AM J HUM GENET, V55, P341; Castellino AM, 1997, J BIOL CHEM, V272, P5861, DOI 10.1074/jbc.272.9.5861; CHRISTIANSEN H, 1987, CANCER GENET CYTOGEN, V26, P235, DOI 10.1016/0165-4608(87)90057-4; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Gong TWL, 2001, MAMM GENOME, V12, P852, DOI 10.1007/s00335-001-3037-3; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; Lastowska M, 2002, GENE CHROMOSOME CANC, V34, P428, DOI 10.1002/gcc.10089; Lastowska M, 2001, J CLIN ONCOL, V19, P3080; Marini F, 2003, J BIOL CHEM, V278, P32014, DOI 10.1074/jbc.M305646200; Meddeb M, 1996, GENE CHROMOSOME CANC, V17, P156, DOI 10.1002/(SICI)1098-2264(199611)17:3<156::AID-GCC3>3.0.CO;2-3; Perri P, 2002, ONCOGENE, V21, P8356, DOI 10.1038/sj.onc.1206009; Roberts T, 1998, HUM MOL GENET, V7, P1169, DOI 10.1093/hmg/7.7.1169; Sambrook J.F., 2000, MOL CLONING LAB MANU; Schleiermacher G, 2004, GENE CHROMOSOME CANC, V39, P143, DOI 10.1002/gcc.10313; Schleiermacher G, 2003, CANCER GENET CYTOGEN, V141, P32, DOI 10.1016/S0165-4608(02)00644-1; Sossey-Alaoui K, 2002, ONCOGENE, V21, P5967, DOI 10.1038/sj.onc.1205734; Spitz R, 2003, CLIN CANCER RES, V9, P4835; Trakhtenbrot L, 2002, CANCER GENET CYTOGEN, V137, P95, DOI 10.1016/S0165-4608(02)00553-8; Van Roy N, 2002, GENE CHROMOSOME CANC, V35, P113, DOI 10.1002/gcc.10034; Yamazaki M, 2002, J BIOL CHEM, V277, P17226, DOI 10.1074/jbc.M109795200; Zhu XD, 2003, MOL CELL, V12, P1489, DOI 10.1016/S1097-2765(03)00478-7	24	21	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3377	3384		10.1038/sj.onc.1208486	http://dx.doi.org/10.1038/sj.onc.1208486			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735707	Bronze			2022-12-17	WOS:000228881800016
J	Tarrade, A; Bastien, J; Bruck, N; Bauer, A; Gianni, M; Rochette-Egly, C				Tarrade, A; Bastien, J; Bruck, N; Bauer, A; Gianni, M; Rochette-Egly, C			Retinoic acid and arsenic trioxide cooperate for apoptosis through phosphorylated RXR alpha	ONCOGENE			English	Article						arsenic; retinoic acic; phosphorylation; apoptosis; stress-kinases; RXR	OXIDATIVE DNA-DAMAGE; HISTONE H3 PHOSPHOACETYLATION; IMMEDIATE-EARLY GENE; N-TERMINAL KINASE; RECEPTOR-ALPHA; RAR-ALPHA; NUCLEAR RECEPTORS; CARCINOMA-CELLS; ACTIVATION; TRANSCRIPTION	Arsenite trioxide (AS(2)O(3)) induces apoptosis in several cell lines by disturbing key signal transduction pathways through its oxidative properties. Here, we report that AS(2)O(3) also induces the phosphorylation of the retinoid receptor RXR alpha, subsequent to oxidative damages and the activation of the stress-activated protein kinases cascade (JNKs). We also report that RA amplifies both AS(2)O(3)-induced phosphorylation of RXR alpha and apoptosis. Taking advantage of 'rescue' F9 cell lines expressing RXR alpha mutated at its phosphorylation sites, in an RXR alpha a null background, we provide evidence that RXR alpha is a key element involved in that potentiating effect. Finally, we demonstrate that AS(2)O(3) also abrogates the transactivation of RA-target genes.	IGBMC, CNRS, INSERM, ULP, F-67404 Illkirch Graffenstaden, France; Ist Ric Farmacol Mario Negri, Lab Biol Mol, I-20157 Milan, Italy	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Rochette-Egly, C (corresponding author), IGBMC, CNRS, INSERM, ULP, BP 10142, F-67404 Illkirch Graffenstaden, France.	cegly@igbmc.u-strasbg.fr	Gianni, Maurizio/ABG-6322-2020	Gianni, Maurizio/0000-0002-6945-708X				Adam-Stitah S, 1999, J BIOL CHEM, V274, P18932, DOI 10.1074/jbc.274.27.18932; Altucci L, 2001, TRENDS ENDOCRIN MET, V12, P460, DOI 10.1016/S1043-2760(01)00502-1; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; Bastien J, 2000, J BIOL CHEM, V275, P21896, DOI 10.1074/jbc.M001985200; Bastien J., 2002, J BIOL CHEM, V24, P24; Bebien M, 2003, ONCOGENE, V22, P1836, DOI 10.1038/sj.onc.1206334; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Benoit G, 1999, EMBO J, V18, P7011, DOI 10.1093/emboj/18.24.7011; Bernstam L, 2000, J TOXICOL ENV HEAL B, V3, P293, DOI 10.1080/109374000436355; Boudjelal M, 2002, EXP CELL RES, V274, P130, DOI 10.1006/excr.2001.5450; Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; Ghosh R, 1999, NUCLEIC ACIDS RES, V27, P3213, DOI 10.1093/nar/27.15.3213; Gianni M, 2002, J BIOL CHEM, V277, P24859, DOI 10.1074/jbc.C200230200; Gianni M, 2002, EMBO J, V21, P3760, DOI 10.1093/emboj/cdf374; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; GIANNI M, 2003, J BIOL CHEM, V5, P389; Hayakawa F, 2004, CANCER CELL, V5, P389, DOI 10.1016/S1535-6108(04)00082-0; He ZW, 2003, J BIOL CHEM, V278, P10588, DOI 10.1074/jbc.M208581200; Hong SH, 2001, MOL CELL BIOL, V21, P7172, DOI 10.1128/MCB.21.21.7172-7182.2001; Huang CS, 2004, MOL CELL BIOCHEM, V255, P57, DOI 10.1023/B:MCBI.0000007261.04684.78; Iordanov MS, 1999, J BIOL CHEM, V274, P25801, DOI 10.1074/jbc.274.36.25801; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Keriel A, 2002, CELL, V109, P125, DOI 10.1016/S0092-8674(02)00692-X; Kessel M, 2002, MOL CELL BIOCHEM, V234, P301, DOI 10.1023/A:1015927406142; Kitchin KT, 2003, TOXICOL LETT, V137, P3, DOI 10.1016/S0378-4274(02)00376-4; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Laudet V., 2001, NUCL RECEPTOR FACTSB; Lee HY, 2000, J BIOL CHEM, V275, P32193, DOI 10.1074/jbc.M005490200; Lee HY, 1999, MOL CELL BIOL, V19, P1973; Lerner L, 2003, GENE DEV, V17, P2564, DOI 10.1101/gad.1135003; Li J, 2003, J BIOL CHEM, V278, P13183, DOI 10.1074/jbc.M300269200; Li J, 2002, J BIOL CHEM, V277, P49504, DOI 10.1074/jbc.M207836200; Li QJ, 2003, EMBO J, V22, P281, DOI 10.1093/emboj/cdg028; Lim CP, 1998, ONCOGENE, V16, P2915, DOI 10.1038/sj.onc.1201834; Liu Q, 2003, BLOOD, V101, P4078, DOI 10.1182/blood-2002-10-3231; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Mologni L, 1999, BLOOD, V93, P1045, DOI 10.1182/blood.V93.3.1045.403k22_1045_1061; Na SY, 1998, J BIOL CHEM, V273, P30933, DOI 10.1074/jbc.273.47.30933; Nesnow S, 2002, CHEM RES TOXICOL, V15, P1627, DOI 10.1021/tx025598y; Oridate N, 1996, ONCOGENE, V12, P2019; Puccetti E, 2003, ONCOGENE, V22, P6900, DOI 10.1038/sj.onc.1206747; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; Rochette-Egly C, 2003, CELL SIGNAL, V15, P355, DOI 10.1016/S0898-6568(02)00115-8; Rochette-Egly C, 2001, HISTOL HISTOPATHOL, V16, P909, DOI 10.14670/HH-16.909; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; Roussel MJS, 2001, ONCOGENE, V20, P7287, DOI 10.1038/sj.onc.1204863; Sakaue M, 2001, CELL DEATH DIFFER, V8, P411, DOI 10.1038/sj.cdd.4400818; Schwerdtle T, 2003, CARCINOGENESIS, V24, P967, DOI 10.1093/carcin/bgg018; Shen ZX, 2004, P NATL ACAD SCI USA, V101, P5328, DOI 10.1073/pnas.0400053101; Shi HL, 2004, MOL CELL BIOCHEM, V255, P67, DOI 10.1023/B:MCBI.0000007262.26044.e8; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; Theodosiou A, 2002, ONCOGENE, V21, P2387, DOI 10.1038/sj.onc.1205309; Verma A, 2002, J BIOL CHEM, V277, P44988, DOI 10.1074/jbc.M207176200; Xi HK, 2003, J IMMUNOL, V170, P315, DOI 10.4049/jimmunol.170.1.315; Zhang TD, 2001, ONCOGENE, V20, P7146, DOI 10.1038/sj.onc.1204762; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807; Zhu J, 2002, NAT REV CANCER, V2, P705, DOI 10.1038/nrc887; Zhu J, 2001, ONCOGENE, V20, P7257, DOI 10.1038/sj.onc.1204852; Zhu Q, 2002, BLOOD, V99, P1014	67	21	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2277	2288		10.1038/sj.onc.1208402	http://dx.doi.org/10.1038/sj.onc.1208402			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15688020				2022-12-17	WOS:000227877400001
J	Jang, JH				Jang, JH			Reciprocal relationship in gene expression between FGFR1 and FGFR3: implication for tumorigenesis	ONCOGENE			English	Article						FGFR1; silencing; tumorigenesis; colon cancer; FGFR3	FIBROBLAST-GROWTH-FACTOR; FACTOR-RECEPTOR; MULTIPLE-MYELOMA; HEPARAN-SULFATE; HUMAN BREAST; COMMON	We have previously demonstrated that the expression of FGFR3 is frequently downregulated in colorectal carcinoma cells. Here we have shown that FGFR1 is over-expressed in colorectal carcinoma cells and the gene expressions between FGFR1 and FGFR3 are mutually exclusive. Moreover, we have also shown that the disruption of FGFR1 expression by introducing of FGFR1 siRNA was effective in elevating FGFR3 expression and tumor suppressive activities. Thus, FGFR1 may confer a selectable advantage on clones of cells in colorectal tumorigenesis, favoring proliferation, whereas FGFR3 may have the effect of an unfavorable negative regulation of progression of the carcinomas to malignancy, promoting differentiation. Our results indicate that the reciprocal relationship in gene expression between FGFR1 and FGFR3 in colorectal tissue plays an important role in the progression of the carcinomas to malignancy.	Inha Univ, Coll Med, Dept Biochem, Inchon 400712, South Korea	Inha University	Jang, JH (corresponding author), Inha Univ, Coll Med, Dept Biochem, 7-241 Shinheung Dong 3 Ga, Inchon 400712, South Korea.	juhjang@seoul.com						BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Cancilla B, 1999, KIDNEY INT, V56, P2025, DOI 10.1046/j.1523-1755.1999.00781.x; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; Dailey L, 2003, J CELL BIOL, V161, P1053, DOI 10.1083/jcb.200302075; Feng SJ, 1997, CANCER RES, V57, P5369; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Giri D, 1999, CLIN CANCER RES, V5, P1063; JACQUEMIER J, 1994, INT J CANCER, V59, P373, DOI 10.1002/ijc.2910590314; Jang JH, 2000, CANCER RES, V60, P4049; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kanai M, 1997, AM J PHYSIOL-GASTR L, V272, pG885, DOI 10.1152/ajpgi.1997.272.4.G885; Kornmann M, 2002, GASTROENTEROLOGY, V123, P301, DOI 10.1053/gast.2002.34174; LUQMANI YA, 1992, BRIT J CANCER, V66, P273, DOI 10.1038/bjc.1992.256; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; Oh LYS, 2003, J NEUROSCI, V23, P883; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; SHAOUL E, 1995, ONCOGENE, V10, P1553; SHI DL, 1994, DEV BIOL, V164, P173, DOI 10.1006/dbio.1994.1189; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Werner S, 1998, CYTOKINE GROWTH F R, V9, P153, DOI 10.1016/S1359-6101(98)00010-0; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484	28	21	23	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					945	948		10.1038/sj.onc.1208254	http://dx.doi.org/10.1038/sj.onc.1208254			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15558020				2022-12-17	WOS:000226577100020
J	Vetter, M; Blumenthal, SG; Lindemann, RK; Manns, J; Wesselborg, S; Dittmer, J				Vetter, M; Blumenthal, SG; Lindemann, RK; Manns, J; Wesselborg, S; Dittmer, J			Ets1 is an effector of protein kinase Ca in cancer cells	ONCOGENE			English	Article						Ets transcription factors; protein kinase C; breast cancer; RNA interference	HORMONE-RELATED PROTEIN; BREAST-CARCINOMA CELLS; TRANSCRIPTION FACTOR; PKC-ALPHA; INDUCED APOPTOSIS; GENE-EXPRESSION; PROMOTER; GROWTH; PHOSPHORYLATION; INVOLVEMENT	PKCalpha and Ets1 are both associated with breast cancer progression. Our previous studies suggested that these proteins are likely to functionally interact with one another. Here, we show that attenuation of endogenous PKCalpha expression (siPalpha) by RNA interference leads to reduced Ets1 protein expression in a variety of cancer cells. Pulse-chase experiments and treatment with proteasome inhibitor MG-132 revealed that siPa interferes with both Ets1 protein synthesis and stability. The effect of siPalpha on Ets1 expression could be partially prevented by KN-93, suggesting that calcium/calmodulin-dependent kinase II ( CaMKII), a modulator of Ets1 activity, may play a role in PKCalpha-dependent Ets1 regulation. In contrast, Ets1-regulating kinases ERK1/ 2 were not found to be involved in this process. To assess the importance of the PKCalpha/Ets1 interaction, we compared the biological responses of MDA-MB-231 cells to PKCalpha- and Ets1-specific siRNAs (siE1). While only siPalpha induced changes in cellular morphology and anchorage-independent growth, both siRNAs similarly affected cellular responses to the antitumor drug mithramycin A and to UV light. Microarray analyses further showed that the expression of a certain set of genes was equally affected by siPa and siE1. The data suggest that Ets1 serves as an effector for PKCalpha to fulfil certain functions in cancer cells.	Univ Halle Wittenberg, Univ Klin & Poliklin Gynakol, D-06097 Halle Saale, Saale, Germany; Univ Tubingen, Innere Med Abt 1, Med Klin, D-72076 Tubingen, Germany	Martin Luther University Halle Wittenberg; Eberhard Karls University of Tubingen	Dittmer, J (corresponding author), Univ Halle Wittenberg, Univ Klin & Poliklin Gynakol, Ernst Grube Str 40, D-06097 Halle Saale, Saale, Germany.	dittmer@medizin.uni-halle.de	Dittmer, Juergen/G-1160-2011; Manns, J/AAA-4986-2020	Wesselborg, Sebastian/0000-0002-5236-942X				Anilkumar N, 2003, EMBO J, V22, P5390, DOI 10.1093/emboj/cdg521; Asher G, 2003, P NATL ACAD SCI USA, V100, P15065, DOI 10.1073/pnas.2436329100; Baillat D, 2002, J BIOL CHEM, V277, P29386, DOI 10.1074/jbc.M200088200; Ballschmieter P, 2003, INT J ONCOL, V22, P849; Behrens P, 2001, J PATHOL, V194, P43, DOI 10.1002/path.844; Blumenthal SG, 1999, J BIOL CHEM, V274, P12910, DOI 10.1074/jbc.274.18.12910; Budworth J, 1997, BRIT J CANCER, V75, P1330, DOI 10.1038/bjc.1997.225; Carlier MF, 2003, BIOESSAYS, V25, P336, DOI 10.1002/bies.10257; Cowley DO, 2000, GENE DEV, V14, P366; DITTMER J, 1993, J VIROL, V67, P6087, DOI 10.1128/JVI.67.10.6087-6095.1993; DITTMER J, 1998, BIOCHIM BIOPHYS ACTA, V1377, P1; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; Foos G, 2004, HANDB EXP PHARM, V166, P259; Gardoni F, 2001, J BIOL CHEM, V276, P7609, DOI 10.1074/jbc.M009922200; Ghozi MC, 1996, P NATL ACAD SCI USA, V93, P1935, DOI 10.1073/pnas.93.5.1935; Goldstein AS, 2002, J BIOMED MATER RES, V59, P665, DOI 10.1002/jbm.1276; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Han SH, 2003, ONCOGENE, V22, P4035, DOI 10.1038/sj.onc.1206610; Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012; Huigsloot M, 2003, MOL PHARMACOL, V64, P965, DOI 10.1124/mol.64.4.965; Jiang Y, 2002, CANCER RES, V62, P1910; Kaneda A, 2002, INT J CANCER, V100, P57, DOI 10.1002/ijc.10464; Lee MP, 1998, CANCER RES, V58, P1052; Lin Q, 2003, CURR BIOL, V13, P1469, DOI 10.1016/S0960-9822(03)00613-4; Lindemann RK, 2003, INT J ONCOL, V22, P799; Lindemann RK, 2001, J BIOL CHEM, V276, P46661, DOI 10.1074/jbc.M105816200; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; Okabe H, 2003, CANCER RES, V63, P3043; Orlandi L, 2003, PROSTATE, V54, P133, DOI 10.1002/pros.10181; Otsubo T, 2004, MODERN PATHOL, V17, P461, DOI 10.1038/modpathol.3800062; Platet N, 1998, INT J CANCER, V75, P750, DOI 10.1002/(SICI)1097-0215(19980302)75:5<750::AID-IJC14>3.0.CO;2-A; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; Remsing LL, 2003, J AM CHEM SOC, V125, P5745, DOI 10.1021/ja034162h; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Samatar AA, 2002, J BIOL CHEM, V277, P28118, DOI 10.1074/jbc.M203686200; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Sesto A, 2002, P NATL ACAD SCI USA, V99, P2965, DOI 10.1073/pnas.052678999; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Sioud M, 1998, NAT BIOTECHNOL, V16, P556, DOI 10.1038/nbt0698-556; Soh Jae-Won, 2003, J Exp Ther Oncol, V3, P115, DOI 10.1046/j.1359-4117.2003.01087.x; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Song JC, 2002, AM J PHYSIOL-CELL PH, V283, pC1548, DOI 10.1152/ajpcell.00105.2002; Sunaga N, 2002, CANCER EPIDEM BIOMAR, V11, P730; Wasylyk C, 2002, MOL CELL BIOL, V22, P2687, DOI 10.1128/MCB.22.8.2687-2702.2002; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; Xu DK, 2002, EMBO J, V21, P4081, DOI 10.1093/emboj/cdf413; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yordy JS, 2004, ONCOGENE, V23, P6654, DOI 10.1038/sj.onc.1207891; Zhou JN, 1998, MOL CARCINOGEN, V21, P234, DOI 10.1002/(SICI)1098-2744(199804)21:4<234::AID-MC2>3.0.CO;2-K	54	21	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					650	661		10.1038/sj.onc.1208234	http://dx.doi.org/10.1038/sj.onc.1208234			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15531915				2022-12-17	WOS:000226420400012
J	Chan, EL; Peace, BE; Collins, MH; Toney-Earley, K; Waltz, SE				Chan, EL; Peace, BE; Collins, MH; Toney-Earley, K; Waltz, SE			Ron tyrosine kinase receptor regulates papilloma growth and malignant conversion in a murine model of skin carcinogenesis	ONCOGENE			English	Article						tyrosine kinase; Ras; hepatocyte growth factor-like protein (HGFL); macrophage-stimulating protein (MSP); Met; stem cell-derived tyrosine kinase (stk)	MACROPHAGE-STIMULATING PROTEIN; RAS GENE MUTATION; TRANSGENIC MOUSE; SPLICING VARIANT; POINT MUTATIONS; RETINOIC ACID; ACTIVATED RAS; MET; TRANSFORMATION; CARCINOMA	Recent studies demonstrate that the receptor tyrosine kinase (TK) Ron is tumorigenic when overexpressed and plays a role in regulating skin homeostasis. We hypothesized that Ron signaling promotes skin carcinogenesis. To test this hypothesis, mice deficient in the TK domain of Ron (TK-/- mice) were crossed with v-Ha-ras (Tg.AC) transgenic mice; the resulting TK-/- Tg.AC(+/-) mice, and their controls, we re utilized in a model of chemically induced Ras-mediated skin carcinogenesis. The mice were treated with 2.5 mug of 12-O-tetradecanoylphorbol-13-acetate applied weekly to the shaved back of 36 control (TK+/+ Tg.AC(+/-)) and 35 experimental (TK-/- Tg.AC(+/-)) mice. In an analysis of the resulting papillomas, a reduction in cellular proliferation and papilloma volume was found in the TK-/- Tg.AC(+/-) mice compared to controls. Further, Ron protein expression was upregulated during papilloma formation. Ablation of Ron signaling resulted in partial defects in MAPK and Akt signaling that may account for the decreased papilloma growth in the TK-/- Tg.AC(+/-) mice. The papilloma-bearing mice were monitored for the occurrence of malignant skin tumors and other malignant tumor types for a period of 48 weeks. Loss of Ron receptor signaling significantly reduced the percent of papillomas that underwent malignant conversion as well as the number of mice developing other malignant tumor types. In conclusion, these studies demonstrate that Ron signaling augments papilloma growth and malignant conversion in vivo.	Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Waltz, SE (corresponding author), Univ Cincinnati, Coll Med, Dept Surg, SRU-MSB G482,ML 0558,231 Albert Sabin Way, Cincinnati, OH 45267 USA.	susan.waltz@uc.edu		Waltz, Susan/0000-0003-3572-4642	NCI NIH HHS [R01 CA100002-02, R01 CA100002-01A1, R01 CA100002, R01 CA100002-03] Funding Source: Medline; NICHD NIH HHS [T32 HD43005-01, HD-36888, T32 HD043005, R01 HD036888-04, R01 HD036888, R01 HD036888-05] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036888, T32HD043005] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA100002] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agazie Y, 2002, ONCOGENE, V21, P697, DOI 10.1038/sj.onc.1205115; Bohle RM, 1996, AM J PATHOL, V148, P731; CARDIFF RD, 1993, AM J PATHOL, V142, P1199; Chen QY, 1997, HEPATOLOGY, V26, P59; Collesi C, 1996, MOL CELL BIOL, V16, P5518; Finkelstein LD, 2002, ONCOGENE, V21, P3562, DOI 10.1038/sj.onc.1205442; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Furge KA, 2001, P NATL ACAD SCI USA, V98, P10722, DOI 10.1073/pnas.191067898; HENNINGS H, 1985, CARCINOGENESIS, V6, P1607, DOI 10.1093/carcin/6.11.1607; HENNINGS H, 1990, CANCER RES, V50, P653; Ivan M, 1997, ONCOGENE, V14, P2417, DOI 10.1038/sj.onc.1201083; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; KULESZMARTIN MF, 1991, CANCER RES, V51, P4701; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Leonis NA, 2002, HEPATOLOGY, V36, P1053, DOI 10.1053/jhep.2002.36822; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; McDowell SA, 2002, AM J RESP CELL MOL, V26, P99, DOI 10.1165/ajrcmb.26.1.4621; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Nanney LB, 1998, J INVEST DERMATOL, V111, P573, DOI 10.1046/j.1523-1747.1998.00332.x; Okino T, 1999, INT J ONCOL, V15, P709; Peace BE, 2001, ONCOGENE, V20, P6142, DOI 10.1038/sj.onc.1204836; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sakamoto A, 2001, HUM PATHOL, V32, P1225, DOI 10.1053/hupa.2001.28953; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; SPALDING JW, 1993, CARCINOGENESIS, V14, P1335, DOI 10.1093/carcin/14.7.1335; Spalding JW, 1999, TOXICOL SCI, V49, P241, DOI 10.1093/toxsci/49.2.241; SPENCER JM, 1995, ARCH DERMATOL, V131, P796, DOI 10.1001/archderm.131.7.796; Waltz SE, 1998, ONCOGENE, V16, P27, DOI 10.1038/sj.onc.1201508; Waltz SE, 2001, J CLIN INVEST, V108, P567, DOI 10.1172/JCI200111881; Wang MH, 1996, ONCOGENE, V13, P2167; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; Wang MH, 2000, CARCINOGENESIS, V21, P1507, DOI 10.1093/carcin/21.8.1507; Webb CP, 1998, ONCOGENE, V17, P2019, DOI 10.1038/sj.onc.1202135; Willett CG, 1997, J CLIN INVEST, V99, P2979, DOI 10.1172/JCI119493	36	21	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					479	488		10.1038/sj.onc.1208231	http://dx.doi.org/10.1038/sj.onc.1208231			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15531916				2022-12-17	WOS:000226279700018
J	Tamura, Y; Maruyama, M; Mishima, Y; Fujisawa, H; Obata, M; Kodama, Y; Yoshikai, Y; Aoyagi, Y; Niwa, O; Schaffner, W; Kominami, R				Tamura, Y; Maruyama, M; Mishima, Y; Fujisawa, H; Obata, M; Kodama, Y; Yoshikai, Y; Aoyagi, Y; Niwa, O; Schaffner, W; Kominami, R			Predisposition to mouse thymic lymphomas in response to ionizing radiation depends on variant alleles encoding metal-responsive transcription factor-1 (Mtf-1)	ONCOGENE			English	Article						cancer susceptibility; lymphoma; positional cloning; gamma-radiation; radical scavenger	PLACENTAL GROWTH-FACTOR; TUMOR-SUSCEPTIBILITY; HOMOZYGOUS DELETIONS; GENETIC DISSECTION; POINT MUTATIONS; COMPLEX TRAITS; CANDIDATE; LOCUS; MICE; MODIFIER	Genetic predisposition to cancers is significant to public health because a high proportion of cancers probably arise in a susceptible human subpopulation. Using a mouse model of gamma-ray-induced thymic lymphomas, we performed linkage analysis and haplotype mapping that suggested Mtf-1, metal-responsive transcription factor-1 (Mtf-1), as a candidate lymphoma susceptibility gene. Sequence analysis revealed a polymorphism of Mtf-1 that alters the corresponding amino acid at position 424 in the proline-rich domain from a serine in susceptibility strains to proline in resistant strains. The transcriptional activity of Mtf-1 encoding serine and proline was compared by transfecting the DNA to Mtf-1-null cells, and the change to proline conferred a higher metal responsiveness in transfections. Furthermore, the resistant congenic strains possessing the Mtf-1 allele of proline type exhibited higher radiation inducibility of target genes than susceptible background strains having the Mtf-1 allele of serine type. Since products of the targets such as metallothionein are able to suppress cellular stresses generated by irradiation, these results suggest that highly inducible strains having Mtf-1 of proline type are refractory to radiation effects and hence are resistant to lymphoma development.	Niigata Univ, Grad Sch Med & Dent Sci, Dept Mol Genet, Niigata 9518122, Japan; Niigata Univ, Ctr Transdisciplinary Res, Niigata 9518122, Japan; Kyoto Univ, Ctr Radiat Biol, Sakyou Ku, Kyoto 6068315, Japan; Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland	Niigata University; Niigata University; Kyoto University; University of Zurich	Kominami, R (corresponding author), Niigata Univ, Grad Sch Med & Dent Sci, Dept Mol Genet, Asahimachi 1-757, Niigata 9518122, Japan.	rykomina@med.niigata-u.ac.jp		Maruyama, Masaki/0000-0002-9534-4652				Adini A, 2002, CANCER RES, V62, P2749; Andrews GK, 2000, BIOCHEM PHARMACOL, V59, P95, DOI 10.1016/S0006-2952(99)00301-9; Andrews GK, 2001, EMBO J, V20, P1114, DOI 10.1093/emboj/20.5.1114; Angel JM, 2002, MOL CARCINOGEN, V33, P105, DOI 10.1002/mc.10026; Balmain A, 2002, CELL, V108, P145, DOI 10.1016/S0092-8674(02)00622-0; Balmain A, 2003, NAT GENET, V33, P238, DOI 10.1038/ng1107; Berrington de Gonzalez A, 2004, LANCET, V363, P345, DOI 10.1016/S0140-6736(04)15433-0; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Criswell T, 2003, ONCOGENE, V22, P5813, DOI 10.1038/sj.onc.1206680; Darvasi A, 1998, NAT GENET, V18, P19, DOI 10.1038/ng0198-19; Demant P, 1992, Semin Cancer Biol, V3, P159; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Ghebranious N, 1998, ONCOGENE, V17, P3385, DOI 10.1038/sj.onc.1202573; Gould KA, 1998, EXP LUNG RES, V24, P437, DOI 10.3109/01902149809087379; Gunes C, 1998, EMBO J, V17, P2846, DOI 10.1093/emboj/17.10.2846; Hellsten E, 2001, DEV BIOL, V240, P641, DOI 10.1006/dbio.2001.0476; KAMMANN M, 1989, NUCLEIC ACIDS RES, V17, P5404, DOI 10.1093/nar/17.13.5404; KOROPATNICK J, 1989, RADIAT RES, V119, P356, DOI 10.2307/3577626; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Langmade SJ, 2000, J BIOL CHEM, V275, P34803, DOI 10.1074/jbc.M007339200; Lichtlen P, 2001, BIOESSAYS, V23, P1010, DOI 10.1002/bies.1146; Lichtlen P, 2001, NUCLEIC ACIDS RES, V29, P1514, DOI 10.1093/nar/29.7.1514; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Matsumoto Y, 1998, ONCOGENE, V16, P2747, DOI 10.1038/sj.onc.1201810; Nadeau JH, 2001, NAT REV GENET, V2, P165, DOI 10.1038/35056009; Okano H, 1999, ONCOGENE, V18, P6677, DOI 10.1038/sj.onc.1203100; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; RADTKE F, 1995, NUCLEIC ACIDS RES, V23, P2277, DOI 10.1093/nar/23.12.2277; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; Saito Y, 2001, ONCOGENE, V20, P5243, DOI 10.1038/sj.onc.1204675; Sato H, 2003, CANCER SCI, V94, P668, DOI 10.1111/j.1349-7006.2003.tb01500.x; Saydam N, 2001, J BIOL CHEM, V276, P25487, DOI 10.1074/jbc.M009154200; Smirnova IV, 2000, J BIOL CHEM, V275, P9377, DOI 10.1074/jbc.275.13.9377; TAMAI KT, 1993, P NATL ACAD SCI USA, V90, P8013, DOI 10.1073/pnas.90.17.8013; Wade CM, 2002, NATURE, V420, P574, DOI 10.1038/nature01252; Wakabayashi Y, 2003, NAT IMMUNOL, V4, P533, DOI 10.1038/ni927; Wakabayashi Y, 2003, BIOCHEM BIOPH RES CO, V301, P598, DOI 10.1016/S0006-291X(02)03069-3; Wang Y, 2004, FASEB J, V18, P1071, DOI 10.1096/fj.03-1282com; Wright AF, 2001, GENOME BIOL, V2; Zhang H, 2003, CURR BIOL, V13, P1625, DOI 10.1016/j.cub.2003.08.054	42	21	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					399	406		10.1038/sj.onc.1208197	http://dx.doi.org/10.1038/sj.onc.1208197			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15516976				2022-12-17	WOS:000226279700011
J	Vaghefi, H; Neet, KE				Vaghefi, H; Neet, KE			Deacetylation of p53 after nerve growth factor treatment in PC12 cells as a post-translational modification mechanism of neurotrophin-induced tumor suppressor activation	ONCOGENE			English	Article						acetylation; signal transduction; apoptosis; differentiation	PROTEIN-KINASE ACTIVITY; DNA-DAMAGE; PHEOCHROMOCYTOMA CELLS; HISTONE DEACETYLASE; MEDIATED APOPTOSIS; NEURITE OUTGROWTH; CARCINOMA-CELLS; TRICHOSTATIN-A; PHOSPHORYLATION; INHIBITOR	The tumor suppressor protein p53 is a transcription factor that regulates the response to cellular insults such as DNA damage and growth factor withdrawal. Transcriptional activity of p53 requires post-translational modification by phosphorylation and acetylation. This study used site-specific antibodies to demonstrate that nerve growth factor (NGF) treatment of PC12 cells results in p53 deacetylation at lysine (Lys) 382. Histone deacetylase (HDAC) activity, measured by a direct fluorescent assay, was increased after NGF treatment and peaked before p53 deacetylation. Inhibition of HDAC by trichostatin blocked the deacetylation of p53 and its transcriptional activity toward a reporter gene construct. Comparison of PC12 with PC12 cells containing a temperature-sensitive, dominant-negative construct showed that p53 deacetylation required functional p53. Inhibitors of MAP kinase that block p53 transactivation and inhibitors of TrkA receptor also abolished HDAC activation, indicating that deacetylation of p53 is an NGF-dependent post-translational mechanism of p53 activation. Finally, NGF or serum withdrawal did not lead to p53 deacetylation. A model is proposed in which the acetylation status of Lys 382 of p53 discriminates between cell cycle arrest and apoptosis.	Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Biochem & Mol Biol, N Chicago, IL 60064 USA	Chicago Medical School; Rosalind Franklin University Medical & Science	Neet, KE (corresponding author), Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Biochem & Mol Biol, 3333 Green Bay Rd, N Chicago, IL 60064 USA.	kenneth.neet@rosalindfranklin.edu			NINDS NIH HHS [NS24380] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024380] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; Bayle JH, 1997, CHEM BIOL, V4, P885, DOI 10.1016/S1074-5521(97)90296-9; BENDORI R, 1983, FEBS LETT, V162, P384; Billon N, 1996, ONCOGENE, V13, P2047; Blaydes JP, 2001, J BIOL CHEM, V276, P4699, DOI 10.1074/jbc.M003485200; BOONSTRA J, 1985, BIOCHIMIE, V67, P1177, DOI 10.1016/S0300-9084(85)80117-6; BOULIKAS T, 1995, CRIT REV EUKAR GENE, V5, P1; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CHANDRASEKARAN K, 1982, J CELL PHYSIOL, V113, P134, DOI 10.1002/jcp.1041130122; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Choi HS, 2002, BIOCHEM BIOPH RES CO, V296, P1005, DOI 10.1016/S0006-291X(02)02001-6; Craig AL, 1999, ONCOGENE, V18, P6305, DOI 10.1038/sj.onc.1203085; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Cregan SP, 1999, J NEUROSCI, V19, P7860; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Dornan D, 2003, J BIOL CHEM, V278, P13431, DOI 10.1074/jbc.M211460200; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Furumai R, 2001, P NATL ACAD SCI USA, V98, P87, DOI 10.1073/pnas.011405598; Gartenhaus RB, 1996, P NATL ACAD SCI USA, V93, P265, DOI 10.1073/pnas.93.1.265; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Gollapudi L, 1997, J NEUROSCI RES, V49, P461, DOI 10.1002/(SICI)1097-4547(19970815)49:4<461::AID-JNR7>3.3.CO;2-6; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Grimes JA, 2000, J BIOL CHEM, V275, P9461, DOI 10.1074/jbc.275.13.9461; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Heneka MT, 1998, J NEUROCHEM, V71, P88; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hughes AL, 2000, J BIOL CHEM, V275, P37829, DOI 10.1074/jbc.M003146200; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Iwasaki S, 1999, J BIOL CHEM, V274, P26503, DOI 10.1074/jbc.274.37.26503; Jabbur JR, 2001, INT J MOL MED, V7, P163; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Lad SP, 2003, CNS NEUROL DISORD-DR, V2, P315, DOI 10.2174/1568007033482724; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; LEE V, 1977, P NATL ACAD SCI USA, V74, P5021, DOI 10.1073/pnas.74.11.5021; Lehrmann H, 2002, ADV CANCER RES, V86, P41, DOI 10.1016/S0065-230X(02)86002-X; LIU M, 1995, ONCOGENE, V10, P1955; LUCKENBILLEDDS L, 1979, J NEUROCYTOL, V8, P493, DOI 10.1007/BF01214805; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; LUO Y, 1992, J BIOL CHEM, V267, P12275; MAKRIS A, 1995, LANCET, V345, P1181, DOI 10.1016/S0140-6736(95)91014-X; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; Mauser A, 2002, J VIROL, V76, P12503, DOI 10.1128/JVI.76.24.12503-12512.2002; Maxwell SA, 1996, ELECTROPHORESIS, V17, P1772, DOI 10.1002/elps.1150171115; MCGUIRE JC, 1979, J BIOL CHEM, V254, P3362; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; Merrick BA, 2001, BIOCHEMISTRY-US, V40, P4053, DOI 10.1021/bi002045i; Milczarek GJ, 1996, LIFE SCI, V60, P1, DOI 10.1016/S0024-3205(96)00479-1; Morrison RS, 2003, NEUROCHEM RES, V28, P15, DOI 10.1023/A:1021687810103; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Neet KE, 2001, CELL MOL LIFE SCI, V58, P1021, DOI 10.1007/PL00000917; OHMICHI M, 1992, BIOCHEMISTRY-US, V31, P4034, DOI 10.1021/bi00131a019; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Roeder RG, 1998, COLD SPRING HARB SYM, V63, P201, DOI 10.1101/sqb.1998.63.201; Scotto C, 1999, MOL CELL BIOL, V19, P7168; SELTER H, 1994, INT J BIOCHEM, V26, P145, DOI 10.1016/0020-711X(94)90139-2; Shiseki M, 2003, CANCER RES, V63, P2373; Simpson MTW, 2001, J NEUROSCI, V21, P7089, DOI 10.1523/JNEUROSCI.21-18-07089.2001; SLADEK TL, 1992, ONCOGENE, V7, P1305; Stefanis L, 1996, J BIOL CHEM, V271, P30663, DOI 10.1074/jbc.271.48.30663; TAPLEY P, 1992, ONCOGENE, V7, P371; TOGARI A, 1983, BIOCHEM BIOPH RES CO, V114, P1189, DOI 10.1016/0006-291X(83)90688-5; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Vaghefi H, 2004, J BIOL CHEM, V279, P15604, DOI 10.1074/jbc.M311500200; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; Wert MM, 2000, BIOCHEM J, V352, P175, DOI 10.1042/0264-6021:3520175; WOO SB, 1995, J BIOL CHEM, V270, P6278, DOI 10.1074/jbc.270.11.6278; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zeng LF, 2003, J BIOL CHEM, V278, P24594, DOI 10.1074/jbc.M301955200; ZHAN QM, 1994, ONCOGENE, V9, P3743; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	86	21	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8078	8087		10.1038/sj.onc.1207953	http://dx.doi.org/10.1038/sj.onc.1207953			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15361854				2022-12-17	WOS:000224692500005
J	Geahlen, RL; Handley, MD; Harrison, ML				Geahlen, RL; Handley, MD; Harrison, ML			Molecular interdiction of Src-family kinase signaling in hematopoietic cells	ONCOGENE			English	Review						Src-family kinase; kinase inhibitor; protein palmitoylation; protein myristoylation; lipid raft; SH2 domain	PROTEIN-TYROSINE KINASE; GPI-ANCHORED PROTEINS; FC-EPSILON-RI; AFFINITY PHOSPHOTYROSYL PEPTIDE; TRANSMEMBRANE ADAPTER PROTEIN; HETEROGENEOUS FATTY ACYLATION; CBL PROTOONCOGENE PRODUCT; LIPID RAFTS; N-MYRISTOYLTRANSFERASE; ANTIGEN RECEPTOR	The ability of Src-family kinases (SFKs) to mediate signaling from cell surface receptors in hematopoietic cells is a function of their catalytic activity, location and binding partners. Kinase activity is regulated in the cell by kinases and phosphatases that alter the state of phosphorylation of key tyrosine residues and by protein binding partners that stabilize the kinase in active or inactive conformations or localize the enzyme to specific subcellular or submembrane domains. Kinase activity and function can be modulated experimentally through the use of small molecule inhibitors designed to directly target catalytic or binding domains or regulate the location of the protein by altering its state of acylation.	Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Harrison, ML (corresponding author), Purdue Univ, Dept Med Chem & Mol Pharmacol, Hansen Life Sci Res Bldg,201 S Univ St, W Lafayette, IN 47907 USA.	harrison@pharmacy.purdue.edu		Geahlen, Robert/0000-0001-8400-2924	NCI NIH HHS [T32CA09634, CA37372] Funding Source: Medline; NIGMS NIH HHS [GM48099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037372, T32CA009634] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAND L, 1994, J BIOL CHEM, V269, P16701; Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; Arnold LD, 2000, BIOORG MED CHEM LETT, V10, P2167, DOI 10.1016/S0960-894X(00)00441-8; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bi K, 2001, SEMIN IMMUNOL, V13, P139, DOI 10.1006/smim.2000.0305; Bishop AC, 2000, NATURE, V407, P395, DOI 10.1038/35030148; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; Bolen JB, 1997, ANNU REV IMMUNOL, V15, P371, DOI 10.1146/annurev.immunol.15.1.371; Brdicka T, 2002, J EXP MED, V196, P1617, DOI 10.1084/jem.20021405; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Brdickova N, 2003, J EXP MED, V198, P1453, DOI 10.1084/jem.20031484; Burchat AF, 2002, BIOORG MED CHEM LETT, V12, P1687, DOI 10.1016/S0960-894X(02)00196-8; Burke TR, 2003, ACCOUNTS CHEM RES, V36, P426, DOI 10.1021/ar020127o; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; Das J, 2003, BIOORG MED CHEM LETT, V13, P2145, DOI 10.1016/S0960-894X(03)00380-9; Davidson D, 2003, MOL CELL BIOL, V23, P2017, DOI 10.1128/MCB.23.6.2017-2028.2003; De Vos ML, 2001, BIOCHEM PHARMACOL, V62, P985, DOI 10.1016/S0006-2952(01)00739-0; DEVADAS B, 1992, J BIOL CHEM, V267, P7224; Dietrich C, 2002, BIOPHYS J, V82, P274, DOI 10.1016/S0006-3495(02)75393-9; Dunphy JT, 2001, J BIOL CHEM, V276, P43300, DOI 10.1074/jbc.M104275200; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; Farazi TA, 2001, J BIOL CHEM, V276, P39501, DOI 10.1074/jbc.R100042200; Filipp D, 2003, J EXP MED, V197, P1221, DOI 10.1084/jem.20022112; Germain RN, 2001, J BIOL CHEM, V276, P35223, DOI 10.1074/jbc.R100025200; Giang DG, 1998, J BIOL CHEM, V273, P6595, DOI 10.1074/jbc.273.12.6595; GILMER T, 1994, J BIOL CHEM, V269, P31711; Glebov OO, 2004, NAT CELL BIOL, V6, P238, DOI 10.1038/ncb1103; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harder T, 2004, TRAFFIC, V5, P265, DOI 10.1111/j.1600-0854.2003.00163.x; Harrison SC, 2003, CELL, V112, P737, DOI 10.1016/S0092-8674(03)00196-X; Hawash IY, 2002, J BIOL CHEM, V277, P5683, DOI 10.1074/jbc.M110002200; Hawash IY, 2002, BBA-MOL CELL RES, V1589, P140, DOI 10.1016/S0167-4889(02)00165-9; Heerklotz H, 2002, BIOPHYS J, V83, P2693, DOI 10.1016/S0006-3495(02)75278-8; Hermiston ML, 2003, ANNU REV IMMUNOL, V21, P107, DOI 10.1146/annurev.immunol.21.120601.140946; Holowka D, 2001, SEMIN IMMUNOL, V13, P99, DOI 10.1006/smim.2000.0301; HOOEJSI V, 2003, IMMUNOL REV, V191, P148; Hur EM, 2003, J EXP MED, V198, P1463, DOI 10.1084/jem.20030232; Ilangumaran S, 2000, IMMUNOL TODAY, V21, P2, DOI 10.1016/S0167-5699(99)01494-2; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; JOHNSON DR, 1990, P NATL ACAD SCI USA, V87, P8511, DOI 10.1073/pnas.87.21.8511; Kabouridis PS, 2003, BIOCHEM J, V371, P907, DOI 10.1042/BJ20021578; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Kenworthy AK, 2000, MOL BIOL CELL, V11, P1645, DOI 10.1091/mbc.11.5.1645; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; Kwiatkowska K, 2003, J CELL SCI, V116, P537, DOI 10.1242/jcs.00254; Lafont F, 2001, P NATL ACAD SCI USA, V98, P3180, DOI 10.1073/pnas.051003498; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; Lawrence DS, 2003, ACCOUNTS CHEM RES, V36, P401, DOI 10.1021/ar020132s; Lawrence DS, 1999, J MED CHEM, V42, P4932, DOI 10.1021/jm980591s; Lee TR, 1999, J MED CHEM, V42, P784, DOI 10.1021/jm980663f; Leitenberg D, 2001, SEMIN IMMUNOL, V13, P129, DOI 10.1006/smim.2000.0304; Liang XQ, 2004, J BIOL CHEM, V279, P8133, DOI 10.1074/jbc.M311180200; Liang XQ, 2001, J BIOL CHEM, V276, P30987, DOI 10.1074/jbc.M104018200; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; Maly DJ, 2000, P NATL ACAD SCI USA, V97, P2419, DOI 10.1073/pnas.97.6.2419; Maurer-Stroh S, 2002, J MOL BIOL, V317, P523, DOI 10.1006/jmbi.2002.5425; Miceli MC, 2001, SEMIN IMMUNOL, V13, P115, DOI 10.1006/smim.2000.0303; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Mustelin T, 2003, IMMUNOL REV, V191, P139, DOI 10.1034/j.1600-065X.2003.00014.x; NADLER MJS, 1993, BIOCHEMISTRY-US, V32, P9250, DOI 10.1021/bi00086a034; OMURA S, 1976, BACTERIOL REV, V40, P681, DOI 10.1128/MMBR.40.3.681-697.1976; PAIGE LA, 1990, BIOCHEMISTRY-US, V29, P10566, DOI 10.1021/bi00498a021; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Pasquet JM, 1999, MOL CELL BIOL, V19, P8326; Pierce SK, 2004, NAT CELL BIOL, V6, P180, DOI 10.1038/ncb0304-180; Pizzo P, 2003, CURR OPIN IMMUNOL, V15, P255, DOI 10.1016/S0952-7915(03)00038-4; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Profit AA, 2001, J BIOL CHEM, V276, P9446, DOI 10.1074/jbc.M009262200; Rao N, 2002, J LEUKOCYTE BIOL, V71, P753; Rao NV, 2002, P NATL ACAD SCI USA, V99, P3794, DOI 10.1073/pnas.062055999; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Rickles RJ, 1998, CHEM BIOL, V5, P529, DOI 10.1016/S1074-5521(98)90112-0; Saitoh S, 2000, IMMUNITY, V12, P525, DOI 10.1016/S1074-7613(00)80204-6; Sawyer TK, 2002, MINI-REV MED CHEM, V2, P475, DOI 10.2174/1389557023405765; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; SCHLESINGER MJ, 1982, J BIOL CHEM, V257, P9887; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; Schutz GJ, 2000, EMBO J, V19, P892, DOI 10.1093/emboj/19.5.892; Sharma P, 2004, CELL, V116, P577, DOI 10.1016/S0092-8674(04)00167-9; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Stankovic CJ, 1997, BIOORG MED CHEM LETT, V7, P1909, DOI 10.1016/S0960-894X(97)00334-X; Straus DB, 1996, J BIOL CHEM, V271, P9976, DOI 10.1074/jbc.271.17.9976; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Sundaramoorthi R, 2003, BIOPOLYMERS, V71, P717, DOI 10.1002/bip.10600; Takai T, 2002, NAT REV IMMUNOL, V2, P580, DOI 10.1038/nri856; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; van't Hof W, 1999, J CELL BIOL, V145, P377, DOI 10.1083/jcb.145.2.377; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Veillette A, 2002, ANNU REV IMMUNOL, V20, P669, DOI 10.1146/annurev.immunol.20.081501.130710; Vrljic M, 2002, BIOPHYS J, V83, P2681, DOI 10.1016/S0006-3495(02)75277-6; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; Waltenberger J, 1999, CIRC RES, V85, P12; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Wilson BS, 2000, J CELL BIOL, V149, P1131, DOI 10.1083/jcb.149.5.1131; Wolven A, 1997, MOL BIOL CELL, V8, P1159, DOI 10.1091/mbc.8.6.1159; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yasuda K, 2002, J IMMUNOL, V169, P2813, DOI 10.4049/jimmunol.169.6.2813; Yeh RH, 2001, J BIOL CHEM, V276, P12235, DOI 10.1074/jbc.M011232200; Young RM, 2003, J BIOL CHEM, V278, P20746, DOI 10.1074/jbc.M211402200; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zhu XT, 1999, STRUCTURE, V7, P651, DOI 10.1016/S0969-2126(99)80086-0	117	21	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2004	23	48					8024	8032		10.1038/sj.onc.1208078	http://dx.doi.org/10.1038/sj.onc.1208078			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863JR	15489920				2022-12-17	WOS:000224558300013
J	Ramakrishnan, R; Fujimura, Y; Zou, JP; Liu, F; Lee, L; Rao, VN; Reddy, ESP				Ramakrishnan, R; Fujimura, Y; Zou, JP; Liu, F; Lee, L; Rao, VN; Reddy, ESP			Role of protein-protein interactions in the antiapoptotic function of EWS-Fli-1	ONCOGENE			English	Article						EWS-Fli-1; Ewing's sarcoma; Fli-1; CBP; RXR	CREB-BINDING-PROTEIN; EWINGS-SARCOMA CELLS; RUBINSTEIN-TAYBI SYNDROME; ACUTE MYELOID-LEUKEMIA; RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; CHIMERIC PROTEIN; TUMOR-CELLS; HISTONE ACETYLTRANSFERASE	In the majority of Ewing's family tumors, chromosomal translocation t(11; 22) leads to aberrant fusion of RNA-binding protein EWS with DNA-binding ETS transcriptional factor Fli-1. EWS-Fli-1 has altered the transcriptional activity and modulating its downstream target genes through this transcriptional activity is thought to be responsible for this tumor. We have previously shown that both EWS-Fli-1 and Fli-1 have antiapoptotic activity against several apoptotic inducers. Here, we show that the transcriptional activity of EWS-Fli-1 and Fli-1 is not essential for its antiapoptotic activity. We also demonstrate that EWS-Fli-1 and Fli-1 interact with CBP through its amino-terminal region and inhibit the CBP-dependent transcriptional activity of RXR. This activity appears to be independent of DNA-binding activity of EWS-Fli-1. Introduction of the dominant-negative form of CBP into Ewing's sarcoma cells sensitizes these cells against genotoxic or retinoic-acid induced apoptosis. These results suggest that the ability of EWS-Fli-1/Fli-1 to target transcriptional cofactor(s) and modulate apoptotic pathways may be responsible for its antiapoptotic and tumorigenic activities.	Georgia Canc Ctr Excellence, Morehouse Sch Med, Dept Med, Canc Biol Program, Atlanta, GA 30303 USA; Drexel Univ, Philadelphia, PA 19102 USA; SAIC, Frederick, MD 21702 USA	Morehouse School of Medicine; Drexel University; Science Applications International Corporation (SAIC); SAIC-Frederick	Reddy, ESP (corresponding author), Georgia Canc Ctr Excellence, Morehouse Sch Med, Dept Med, Canc Biol Program, 80 Jessie Hill Jr Dr, Atlanta, GA 30303 USA.	ereddy@msm.edu			NATIONAL CANCER INSTITUTE [R01CA057322, R01CA085343, P50CA083591] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 85642, CA 83591, R01 CA 85343, CA 57322] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Araya N, 2003, J BIOL CHEM, V278, P5427, DOI 10.1074/jbc.M210234200; Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Canaani E, 2004, BRIT J CANCER, V90, P756, DOI 10.1038/sj.bjc.6601639; Darby TG, 1997, ONCOGENE, V15, P3067, DOI 10.1038/sj.onc.1201503; Deneen B, 2003, MOL CELL BIOL, V23, P3897, DOI 10.1128/MCB.23.11.3897-3908.2003; Dhulipala PDK, 1998, ONCOGENE, V17, P1149, DOI 10.1038/sj.onc.1202030; Fujimura Y, 2001, ONCOGENE, V20, P6653, DOI 10.1038/sj.onc.1204684; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Goodman RH, 2000, GENE DEV, V14, P1553; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hong W, 2002, MOL CELL BIOL, V22, P3729, DOI 10.1128/MCB.22.11.3729-3743.2002; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; Javelaud D, 2000, ONCOGENE, V19, P61, DOI 10.1038/sj.onc.1203246; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Kung AL, 2000, GENE DEV, V14, P272; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Martini A, 2002, CANCER RES, V62, P5408; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MILLER RW, 1995, AM J MED GENET, V56, P112, DOI 10.1002/ajmg.1320560125; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; OUCHIDA M, 1995, ONCOGENE, V11, P1049; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; PRASAD DDK, 1994, ONCOGENE, V9, P669; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1993, ONCOGENE, V8, P2167; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; Rossow KL, 2001, CANCER RES, V61, P2690; Sargiannidou I, 2004, SEMIN THROMB HEMOST, V30, P127; Sarrazin S, 2002, BBA-MOL CELL RES, V1592, P123, DOI 10.1016/S0167-4889(02)00290-2; Satake N, 1997, GENE CHROMOSOME CANC, V20, P60, DOI 10.1002/(SICI)1098-2264(199709)20:1<60::AID-GCC9>3.3.CO;2-O; Shen WF, 2001, MOL CELL BIOL, V21, P7509, DOI 10.1128/MCB.21.21.7509-7522.2001; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; So CW, 2002, MOL CELL BIOL, V22, P6542, DOI 10.1128/MCB.22.18.6542-6552.2002; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Soldatenkov VA, 2002, ONCOGENE, V21, P2890, DOI 10.1038/sj.onc.1205393; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Truong AHL, 2000, ONCOGENE, V19, P6482, DOI 10.1038/sj.onc.1204042; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; WELFORD SM, 2001, J BIOL CHEM, V11, P11; Yang L, 2000, J BIOL CHEM, V275, P37612, DOI 10.1074/jbc.M005739200; Yang L, 2000, MOL CELL BIOL, V20, P3345, DOI 10.1128/MCB.20.10.3345-3354.2000; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; Yuan ZM, 1999, ONCOGENE, V18, P5714, DOI 10.1038/sj.onc.1202930; Zhao F, 2003, MOL CELL BIOL, V23, P3837, DOI 10.1128/MCB.23.11.3837-3846.2003; Zhou RR, 2002, CANCER GENE THER, V9, P407, DOI 10.1038/sj.cgt.7700449; Zhou ZC, 2001, CANCER RES, V61, P3394	56	21	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7087	7094		10.1038/sj.onc.1207927	http://dx.doi.org/10.1038/sj.onc.1207927			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15273724				2022-12-17	WOS:000223885100009
J	Bennett, RA; Izumi, H; Fukasawa, K				Bennett, RA; Izumi, H; Fukasawa, K			Induction of centrosome amplification and chromosome instability in p53-null cells by transient exposure to subtoxic levels of S-phase-targeting anticancer drugs	ONCOGENE			English	Article						centrosome amplification; chromosome instability; p53; DNA synthesis; anticancer drug	TUMOR-SUPPRESSOR GENE; P53; CANCER; HYPERAMPLIFICATION; OVEREXPRESSION; DUPLICATION; INHIBITOR; KINASES; CYCLE; P21	Chromosome instability (CIN) is one of the most important phenotypes in tumor progression, introducing multiple mutations required for acquisition of further malignant characteristics. Abnormal amplification of centrosomes, which is frequently observed in human cancer, has been shown to contribute to CIN by increasing the frequency of mitotic defects. Here, we show that transient exposure to subtoxic concentrations of commonly used anticancer drugs that target DNA synthesis induces centrosome amplification in cells lacking p53 tumor suppressor protein, by allowing continuous centrosome duplication in the absence of DNA synthesis. When these cells are released from cell cycle arrest by removal of drugs, cells suffer extensive destabilization of chromosomes. Considering that p53 is the most frequently mutated gene in human cancer and that CIN is known to be associated with acquisition of malignant phenotypes, our observations may explain why recurrent tumors, after chemotherapy, often exhibit more malignant characteristics than the original tumors. The tumor cells that are exposed to subtoxic levels of DNA synthesis-targeting drugs will be arrested and undergo centrosome amplification. Upon cessation of chemotherapy, these cells will re-enter cell cycling, and experience extensive CIN due to the presence of amplified centrosomes. This in turn promotes generation of tumor cells equipped with further malignant characteristics.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA	University of Cincinnati	Fukasawa, K (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, POB 670521,3125 Eden Ave, Cincinnati, OH 45267 USA.	kenji.fukasawa@uc.edu			NATIONAL CANCER INSTITUTE [R01CA090522] Funding Source: NIH RePORTER; NCI NIH HHS [CA90522] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; CHEN S, 1983, P NATL ACAD SCI-BIOL, V80, P5670, DOI 10.1073/pnas.80.18.5670; CHENG KC, 1993, ADV CANCER RES, V60, P121; Chiba S, 2000, EXP CELL RES, V258, P310, DOI 10.1006/excr.2000.4916; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fukasawa K, 2002, ONCOGENE, V21, P6140, DOI 10.1038/sj.onc.1205771; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Izumi H, 2002, NEOPLASIA, V4, P103, DOI 10.1038/sj.neo.7900205; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lange BMH, 1996, TRENDS CELL BIOL, V6, P348, DOI 10.1016/0962-8924(96)10033-7; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MAZIA D, 1987, INT REV CYTOL, V100, P49; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Nayak BK, 2002, ONCOGENE, V21, P7226, DOI 10.1038/sj.onc.1205889; OAKLEY A, 1996, EFFECTIVE HLTH CARE, V2, P1; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Vandre D.D., 1989, MITOSIS MOL MECHANIS, P39; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	29	21	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6823	6829		10.1038/sj.onc.1207561	http://dx.doi.org/10.1038/sj.onc.1207561			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15273731				2022-12-17	WOS:000223653600015
J	Lee, J; Ahnn, J; Bae, SC				Lee, J; Ahnn, J; Bae, SC			Homologs of RUNX and CBF beta/PEBP2 beta in C-elegans	ONCOGENE			English	Article						C. elegans; RUNX; BRO-1; evolution; TGF-beta	CORE-BINDING-FACTOR; CAENORHABDITIS-ELEGANS; EGF RECEPTOR; TGF-BETA; CBL PROTOONCOGENE; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; NEGATIVE REGULATOR; VULVAR DEVELOPMENT; PROTEIN PRODUCT	RUNX proteins are evolutionarily well-conserved transcription factors that are involved in essential aspects of the development of metazoan animals ranging from nematodes to humans. Geneticor epigenetic defects in any one of the three RUNX proteins in humans cause severe diseases. Although much is known about the functions and signaling pathways of the RUNX proteins through the use of mammalian systems, there are still gaps in our knowledge with regard to the functions of the RUNX proteins in normal development and disease states. Recently, the nematode Caenorhabditis elegans was revealed to bear one RUNX homolog (RNT-1) and one homolog of the RUNX protein partner CBFbeta/PEBP2beta (BRO-1). The expression patterns and biological functions of RNT-1 and the manner in which it is regulated are all comparable to what has been observed for the mammalian RUNX proteins. Thus, the nematode system is a promising model system for elucidating the functions and regulation of Runt proteins. In addition, it has recently emerged that the RNT-1 protein is involved in a transforming growth factor beta signaling pathway. The bro-1 gene encoding the CBFbeta homolog is exclusively expressed in the hypodermis, not in the intestine, which indicates that additional tissue-specific cofactors in the intestine might exist. The possible autoregulation of RNT1 expression by RNT-1/BRO-1 in the hypodermal cells is also discussed.	Yonsei Univ, Dept Biol, Natl Res Lab, Seoul 120749, South Korea; Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Chungbuk Natl Univ, Coll Med, Dept Biochem, Tumor Res Ctr, Cheongju 361763, South Korea	Yonsei University; Gwangju Institute of Science & Technology (GIST); Chungbuk National University	Lee, J (corresponding author), Yonsei Univ, Dept Biol, Natl Res Lab, 134 Shinchon, Seoul 120749, South Korea.	leej@yonsei.ac.kr						AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; Bae SC, 2000, GENE, V241, P255, DOI 10.1016/S0378-1119(99)00488-6; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; BRENNER S, 1974, GENETICS, V77, P71; Broome MA, 1999, ONCOGENE, V18, P2908, DOI 10.1038/sj.onc.1202873; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Coffman JA, 2003, CELL BIOL INT, V27, P315, DOI 10.1016/S1065-6995(03)00018-0; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GERGEN JP, 1985, DEV BIOL, V109, P321, DOI 10.1016/0012-1606(85)90459-2; HAN M, 1990, GENETICS, V126, P899; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; Hopper NA, 2000, MOL CELL, V6, P65, DOI 10.1016/S1097-2765(00)00008-3; Hwang SB, 2003, J MOL BIOL, V333, P237, DOI 10.1016/j.jmb.2003.08.055; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; JONGEWARD GD, 1995, GENETICS, V139, P1553; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Kataoka H, 2000, MECH DEVELOP, V98, P139, DOI 10.1016/S0925-4773(00)00445-7; Krishna S, 1999, DEVELOPMENT, V126, P251; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Li FQ, 2004, J BIOL CHEM, V279, P2873, DOI 10.1074/jbc.M310759200; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lupher ML, 1998, INT J BIOCHEM CELL B, V30, P439, DOI 10.1016/S1357-2725(97)00075-7; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Mao SF, 1999, MOL CELL BIOL, V19, P3635; Martensson A, 2001, EUR J IMMUNOL, V31, P3165, DOI 10.1002/1521-4141(200111)31:11<3165::AID-IMMU3165>3.0.CO;2-N; McCarthy TL, 2000, J BIOL CHEM, V275, P21746, DOI 10.1074/jbc.M002291200; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; Morita K, 2002, EMBO J, V21, P1063, DOI 10.1093/emboj/21.5.1063; Morita K, 1999, DEVELOPMENT, V126, P1337; Nam S, 2002, MOL CELL BIOL, V22, P547, DOI 10.1128/MCB.22.2.547-554.2002; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Otto F, 2003, J CELL BIOCHEM, V89, P9, DOI 10.1002/jcb.10491; Patterson GI, 2000, TRENDS GENET, V16, P27, DOI 10.1016/S0168-9525(99)01916-2; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; Smit L, 1997, CRIT REV ONCOGENESIS, V8, P359, DOI 10.1615/CritRevOncog.v8.i4.50; Suzuki Y, 1999, DEVELOPMENT, V126, P241; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	54	21	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4346	4352		10.1038/sj.onc.1207669	http://dx.doi.org/10.1038/sj.onc.1207669			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156192				2022-12-17	WOS:000221586000021
J	Ren, Y; Roy, S; Ding, Y; Iqbal, J; Broome, JD				Ren, Y; Roy, S; Ding, Y; Iqbal, J; Broome, JD			Methylation of the asparagine synthetase promoter in human leukemic cell lines is associated with a specific methyl binding protein	ONCOGENE			English	Article						methyl binding protein; asparagine synthetase; leukemia	SENSING RESPONSE PATHWAY; DNA METHYLATION; GENE; IDENTIFICATION; TRANSCRIPTION; EXPRESSION; REPRESSION; MEDIATOR; FAMILY; SITE	We have examined the methylation profiles of the asparagine synthetase (ASY) promoter in a number of human leukemic cell lines in relation to their asparagine (ASN) requirements in vitro. Cells in which the promoter is highly methylated are auxotrophs and express ASY at very low levels. Electromobility shift assays ( EMSA) of nuclear extracts with oligomers from the promoting region show, in addition to recognized transcription factor binding, a novel methyl binding protein specific for a 12 base consensus sequence, which includes a single methylated CpG. This sequence overlaps that of the amino-acid response unit of the ASY promoter, which is activated byATF4 and C/EBP. Competition by the methyl binding protein could account for the observed failure of the methylated promoter to bind these transcription factors and consequently, although other mechanisms can also be operative, for the specific repression of the gene. The ASY methyl binding protein (ASMB) is present in leukemic lymphoid and myeloid cells irrespective of their methylation status, and in normal lymphocytes after phytohemagglutinin stimulation. It has been purified by affinity chromatography and has a molecular size of 40 kDa in 10% SDS-polyacrylamide gels.	N Shore Univ Hosp, Dept Pathol, Manhasset, NY 11030 USA; NYU, Sch Med, Dept Pathol, New York, NY 10017 USA	Northwell Health; North Shore University Hospital; New York University	Broome, JD (corresponding author), N Shore Univ Hosp, Dept Pathol, Manhasset, NY 11030 USA.	jbroome@nshs.edu						ANDRULIS IL, 1987, MOL CELL BIOL, V7, P2435, DOI 10.1128/MCB.7.7.2435; Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BROOME JD, 1963, J EXP MED, V118, P99, DOI 10.1084/jem.118.1.99; BROOME JD, 1968, J EXP MED, V127, P1055, DOI 10.1084/jem.127.6.1055; Daniel JM, 2002, NUCLEIC ACIDS RES, V30, P2911, DOI 10.1093/nar/gkf398; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Drexler HG., 2001, LEUKEMIA LYMPHOMA CE, P2, DOI [10.1016/B978-012221970-2/50002-4, DOI 10.1016/B978-012221970-2/50002-4]; Ehrlich M., 1993, Experientia Supplementum (Basel), V64, P145; Feng Q, 2001, GENE DEV, V15, P827; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; GRECO A, 1989, MOL CELL BIOL, V9, P2350, DOI 10.1128/MCB.9.6.2350; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Jost J P, 1993, EXS, V64, P425; JOST JP, 1992, P NATL ACAD SCI USA, V89, P9499, DOI 10.1073/pnas.89.20.9499; KHAN R, 1988, J BIOL CHEM, V263, P14374; Matheson EC, 2003, CARCINOGENESIS, V24, P31, DOI 10.1093/carcin/24.1.31; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; Peng H, 2001, BRIT J CANCER, V85, P930, DOI 10.1054/bjoc.2001.2000; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Sengupta PK, 1999, J BIOL CHEM, V274, P36649, DOI 10.1074/jbc.274.51.36649; Siu F, 2001, J BIOL CHEM, V276, P48100, DOI 10.1074/jbc.M109533200; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Yoon HG, 2003, MOL CELL, V12, P723, DOI 10.1016/j.molcel.2003.08.008; ZHANG XY, 1993, MOL CELL BIOL, V13, P6810, DOI 10.1128/MCB.13.11.6810; Zhong C, 2003, BIOCHEM J, V372, P603, DOI 10.1042/BJ20030076	35	21	22	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3953	3961		10.1038/sj.onc.1207498	http://dx.doi.org/10.1038/sj.onc.1207498			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15048083				2022-12-17	WOS:000221382000007
J	Gascoyne, DM; Thomas, GR; Latchman, DS				Gascoyne, DM; Thomas, GR; Latchman, DS			The effects of Brn-3a on neuronal differentiation and apoptosis are differentially modulated by EWS and its oncogenic derivative EWS/Fli-1	ONCOGENE			English	Article						POU domain; Ewing's sarcoma; neuronal differentiation	TRANSCRIPTION FACTORS BRN-3A; RNA-POLYMERASE-II; DNA-BINDING; POU TRANSCRIPTION; GENE-EXPRESSION; FUSION PROTEIN; EWS/ETS FUSIONS; GROWTH ARREST; EWING FAMILY; CELL-LINES	The Brn-3 family of POU (Pit-Oct-Unc) homeodomain transcription factors regulate differentiation of neuronal cell types. The transcriptional activator Brn-3a is expressed in Ewing's sarcomas, which also express characteristic chimaeric proteins as a consequence of fusion of the TET family gene EWS to one of several ETS genes. We have previously demonstrated a physical interaction between Brn-3a and EWS proteins, and show here that the C-terminal POU domain but not N-terminal activation domain of Brn-3a can interact in vitro with the RNA-binding domain of EWS. Likely due to POU domain homology, the related factor Brn-3b can also interact with EWS, but to a lesser extent than Brn-3a. Importantly, Brn-3a but not Brn-3b interacts in vitro with chimaeric EWS/Fli-1, EWS/ATF-1 and EWS/ERG proteins. Furthermore, overexpression of EWS/Fli-1 but not EWS or Fli-1 inhibits Brn-3a-associated growth arrest and neurite outgrowth in neuronal cells, and specifically inhibits Brn-3a-dependent activation of p21 and SNAP-25 transcription. In contrast, upregulation of Bcl-2 expression and inhibition of apoptosis by Brn-3a is antagonized more by EWS than by EWS/Fli-1. These data demonstrate that oncogenic rearrangement of EWS to produce EWS/Fli-1 may enhance the antiapoptotic effect of Brn-3a and inhibit its ability to promote neuronal differentiation.	UCL, Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EHUCL, England	University of London; University College London	Gascoyne, DM (corresponding author), UCL, Inst Child Hlth, Med Mol Biol Unit, 30 Guilford St, London WC1N 1EHUCL, England.	d.gascoyne@ich.ucl.ac.uk			MRC [G9901318] Funding Source: UKRI; Medical Research Council [G9901318] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; Araya N, 2003, J BIOL CHEM, V278, P5427, DOI 10.1074/jbc.M210234200; Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; Budhram-Mahadeo V, 1999, ONCOGENE, V18, P6684, DOI 10.1038/sj.onc.1203072; Budhram-Mahadeo V, 1998, MOL CELL BIOL, V18, P1029, DOI 10.1128/MCB.18.2.1029; Budram-Mahadeo V, 2002, ONCOGENE, V21, P6123, DOI 10.1038/sj.onc.1205842; Chansky HA, 2001, CANCER RES, V61, P3586; COLLUM RG, 1992, NUCLEIC ACIDS RES, V20, P4919, DOI 10.1093/nar/20.18.4919; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; Eliazer S, 2003, MOL CELL BIOL, V23, P482, DOI 10.1128/MCB.23.2.482-492.2003; Ensor E, 2001, J BIOL CHEM, V276, P5204, DOI 10.1074/jbc.M007068200; Erkman L, 1996, NATURE, V381, P603, DOI 10.1038/381603a0; Frass B, 2002, BBA-GENE STRUCT EXPR, V1579, P207, DOI 10.1016/S0167-4781(02)00540-7; Gascoyne DM, 2003, J BIOL CHEM, V278, P18022, DOI 10.1074/jbc.M301812200; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Huang EJ, 1999, DEVELOPMENT, V126, P2869; Im YH, 2000, CANCER RES, V60, P1536; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; LAKIN ND, 1995, J BIOL CHEM, V270, P15858, DOI 10.1074/jbc.270.26.15858; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; Li KKC, 2000, J BIOL CHEM, V275, P23053, DOI 10.1074/jbc.M002961200; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; MAO XH, 1994, J BIOL CHEM, V269, P18216; Matsumoto Y, 2001, BRIT J CANCER, V84, P768, DOI 10.1054/bjoc.2000.1652; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; McEvilly RJ, 1996, NATURE, V384, P574, DOI 10.1038/384574a0; Melot T, 2001, EUR J BIOCHEM, V268, P3483, DOI 10.1046/j.1432-1327.2001.02251.x; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; Morris PJ, 1997, NEUROREPORT, V8, P2041, DOI 10.1097/00001756-199705260-00047; Nakatani F, 2003, J BIOL CHEM, V278, P15105, DOI 10.1074/jbc.M211470200; Ndisang D, 1999, J BIOL CHEM, V274, P28521, DOI 10.1074/jbc.274.40.28521; Nishimori H, 2002, ONCOGENE, V21, P8302, DOI 10.1038/sj.onc.1206025; OHNO T, 1994, ONCOGENE, V9, P3087; OUCHIDA M, 1995, ONCOGENE, V11, P1049; Perez-Sanchez C, 2002, NUCLEIC ACIDS RES, V30, P4872, DOI 10.1093/nar/gkf610; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; PLOUGASTEL B, 1993, GENOMICS, V18, P609, DOI 10.1016/S0888-7543(05)80363-5; Rossow KL, 2001, CANCER RES, V61, P2690; Ryabinin AE, 1995, J MOL NEUROSCI, V6, P201, DOI 10.1007/BF02736765; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Smith MD, 1996, INT J CANCER, V67, P653; Smith MD, 2001, MOL CELL NEUROSCI, V17, P460, DOI 10.1006/mcne.2000.0927; Smith MD, 1997, MOL CELL BIOL, V17, P345, DOI 10.1128/MCB.17.1.345; Smith MD, 1998, NUCLEIC ACIDS RES, V26, P4100, DOI 10.1093/nar/26.18.4100; Teitell MA, 1999, LAB INVEST, V79, P1535; THEIL T, 1993, NUCLEIC ACIDS RES, V21, P5921, DOI 10.1093/nar/21.25.5921; Thomas GR, 2002, CANCER BIOL THER, V1, P428, DOI 10.4161/cbt.1.4.23; Thompson AD, 1999, ONCOGENE, V18, P5506, DOI 10.1038/sj.onc.1202928; Uranishi H, 2001, J BIOL CHEM, V276, P13395, DOI 10.1074/jbc.M011176200; Wagner KD, 2003, GENE, V305, P217, DOI 10.1016/S0378-1119(02)01231-3; Welford SM, 2001, J BIOL CHEM, V276, P41977, DOI 10.1074/jbc.M106757200; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; Xiang MQ, 1996, P NATL ACAD SCI USA, V93, P11950, DOI 10.1073/pnas.93.21.11950; Yang L, 2000, J BIOL CHEM, V275, P37612, DOI 10.1074/jbc.M005739200; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099	59	21	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3830	3840		10.1038/sj.onc.1207497	http://dx.doi.org/10.1038/sj.onc.1207497			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15021903				2022-12-17	WOS:000221242500010
J	Marquez, N; Chappell, SC; Sansom, OJ; Clarke, AR; Court, J; Errington, RJ; Smith, PJ				Marquez, N; Chappell, SC; Sansom, OJ; Clarke, AR; Court, J; Errington, RJ; Smith, PJ			Single cell tracking reveals that Msh2 is a key component of an early-acting DNA damage-activated G2 checkpoint	ONCOGENE			English	Article						G2 checkpoint; Msh2; mouse embryonic fibroblasts; time-lapse microscopy; event analysis	REPAIR PROTEINS MSH2; MISMATCH REPAIR; DRUG-RESISTANCE; TUMOR-CELLS; APOPTOSIS; CISPLATIN; MUTATION; ARREST; P53; EXPRESSION	Dysfunction of cell-cycle checkpoints in DNA mismatch repair (MMR)- deficient cells in response to DNA damage has implications for anticancer therapy and genetic instability. We have studied the cell-cycle effects of MMR deficiency (Msh2(-/-)) in primary mouse embryonic fibroblasts (MEFs) exposed to cisplatin (10 muM x 1 h) using time-lapse microscopy. Kinetic responses of MEFs from different embryos and passage ages varied, but we report a consistent drug-induced inhibition of mitotic entry (approx. 50%). There was a loss of an early-acting (<5 h) delay in G2 to M transition in Msh2(-/-) cells, although a later-acting G2 arrest was apparently normal. This suggests that Msh2 primarily acts to delay mitotic entry of cells already in G2, that is, DNA damage incurred during G2 does not influence the cell once committed to mitotic traverse. Irrespective of Msh2 status, cisplatin treatment and the incurred DNA damage did not effect mitotic traverse or show any evidence for early ( within 24 h) cell death. The results indicate that Msh2(-/-) status can result in the premature commitment to mitosis of a cell subpopulation, determined by the fraction residing in G2 at the time of damage induction. The findings suggest a new route to MMR-driven genetic instability that does not rely primarily on the integrity of the late-acting checkpoint.	Cardiff Univ, Dept Pathol, Cardiff CF14 4XN, S Glam, Wales; Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales; Velindre NHS Trust, Canc Res Wales Lab, Cardiff CF14 2TL, S Glam, Wales; Cardiff Univ, Dept Med Biochem, Cardiff CF4 4XN, S Glam, Wales	Cardiff University; Cardiff University; Cardiff University	Smith, PJ (corresponding author), Cardiff Univ, Dept Pathol, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	smithpj2@cardiff.ac.uk	t, lf/AAJ-4924-2020; clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Clarke, Alan/0000-0002-4281-426X; Sansom, Owen J./0000-0001-9540-3010; Chapell, Sally/0000-0003-2712-2617				Aebi S, 1997, CLIN CANCER RES, V3, P1763; Aquilina G, 1999, CARCINOGENESIS, V20, P2317, DOI 10.1093/carcin/20.12.2317; Bellacosa A, 2001, CELL DEATH DIFFER, V8, P1076, DOI 10.1038/sj.cdd.4400948; Branch P, 2000, ONCOGENE, V19, P3138, DOI 10.1038/sj.onc.1203668; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Christmann M, 2002, NUCLEIC ACIDS RES, V30, P1959, DOI 10.1093/nar/30.9.1959; Christmann M, 2000, J BIOL CHEM, V275, P36256, DOI 10.1074/jbc.M005377200; delasAlas MM, 1997, J NATL CANCER I, V89, P1537, DOI 10.1093/jnci/89.20.1537; EPSTEIN RJ, 1988, CYTOMETRY, V9, P349, DOI 10.1002/cyto.990090412; EVANS DL, 1993, CANCER RES, V53, P2133; Fink D, 1996, CANCER RES, V56, P4881; Fink D, 1998, CLIN CANCER RES, V4, P1; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hirose Y, 2001, CANCER RES, V61, P1957; Karran P, 1999, FR MOLEC B, V22, P66; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; Kravtsov VD, 1999, AM J PATHOL, V155, P1327, DOI 10.1016/S0002-9440(10)65235-2; Lage H, 1999, INT J CANCER, V80, P744, DOI 10.1002/(SICI)1097-0215(19990301)80:5<744::AID-IJC19>3.0.CO;2-5; LIN X, 2001, CANCER RES, V15, P1508; Moreland NJ, 1999, CANCER RES, V59, P2102; Nehme A, 1999, BRIT J CANCER, V79, P1104, DOI 10.1038/sj.bjc.6690176; Sansom OJ, 2002, ONCOGENE, V21, P5934, DOI 10.1038/sj.onc.1205760; Sansom OJ, 2001, ONCOGENE, V20, P3580, DOI 10.1038/sj.onc.1204449; SORENSON CM, 1988, CANCER RES, V48, P6703; Strathdee G, 2001, ONCOGENE, V20, P1923, DOI 10.1038/sj.onc.1204276; Therneau T.M., 2000, STAT BIOL HEALTH; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; WATSON JV, 1987, CYTOMETRY, V8, P1, DOI 10.1002/cyto.990080101; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yan T, 2001, CANCER RES, V61, P8290; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	34	21	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2003	22	48					7642	7648		10.1038/sj.onc.1206876	http://dx.doi.org/10.1038/sj.onc.1206876			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576827				2022-12-17	WOS:000186113000012
J	Dorothee, G; Echchakir, H; Chansac, BL; Vergnon, I; El Hage, F; Moretta, A; Bensussan, A; Chouaib, S; Mami-Chouaib, F				Dorothee, G; Echchakir, H; Chansac, BL; Vergnon, I; El Hage, F; Moretta, A; Bensussan, A; Chouaib, S; Mami-Chouaib, F			Functional and molecular characterization of a KIR3DL2/p140 expressing tumor-specific cytotoxic T lymphocyte clone infiltrating a human lung carcinoma	ONCOGENE			English	Article						TIL; KIR3DL2; CTL; TCR	CLASS-I MOLECULES; CELL-MEDIATED CYTOTOXICITY; NATURAL-KILLER-CELLS; INHIBITORY RECEPTOR; DIFFERENTIAL EXPRESSION; KIR2DL4 CD158D; LYTIC ACTIVITY; NK CELLS; HLA-A; ANTIGEN	T lymphocytes infiltrating a human lung carcinoma stimulated in vitro with autologous tumor cell line showed a TCRVbeta13.6(+) T-cell expansion. This subset was isolated using TCRVbeta-specific antibody and several T-cell clones were generated. All these clones expressed a unique Vbeta13.6-Jbeta2.7 TCR with the same junctional region strongly suggesting that they derived from the same cell. They were CD8(+)/CD28(-) and expressed the MHC class I binding killer cell Ig-like receptor (KIR)3DL2/p140, but not KIR3DL1/p70, KIR2DL1/p58.1 and KIR2DL2/3/p58.2. Sequence analysis indicated that KIR3DL2/p140 cDNA was identical to the previously reported 3DL2*002 allele except for two nucleic acid substitutions. Functional studies showed that KIR3DL2/p140(+) CTL secrete a significant level of IFNgamma and mediate an HLA-A2-restricted cytotoxicity against the autologous and some allogeneic tumor cells but not towards the autologous EBV-B cells. Strikingly, both the lytic and the cytokine secretion activities induced upon specific cell interactions were unaffected by anti-KIR3DL2/p140 antibody. In addition, crosslinking KIR3DL2/p140 molecules on CTL did not result into the modi. cation of cytotoxicity and cytokine production triggered by anti-CD3 antibody. These results strongly suggest that, as opposed to distinct KIR expressed by CTL, the in vitro KIR3DL2/p140 engagement does not result into inhibitory (nor activatory) effects on tumor-specific CTL.	Inst Gustave Roussy, INSERM, U487, Lab Cytokines & Immunol Tumeurs Humaines, F-94805 Villejuif, France; Univ Genoa, Ctr Eccellenza Ric Biomed, I-16132 Genoa, Italy; Univ Genoa, Dipartimento Med Sperimentale, Sez Istol, I-16132 Genoa, Italy; Fac Med Creteil, INSERM, U448, F-94010 Creteil, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; University of Genoa; University of Genoa; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Mami-Chouaib, F (corresponding author), Inst Gustave Roussy, INSERM, U487, Lab Cytokines & Immunol Tumeurs Humaines, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		DOROTHEE, Guillaume/O-9760-2016; Bensussan, Armand/E-5434-2017; Chouaib, Salem/F-7939-2016; Mami-Chouaib, Fathia/E-5267-2016	DOROTHEE, Guillaume/0000-0001-5763-3632; Bensussan, Armand/0000-0002-0409-2497				Asselin-Paturel C, 1998, INT J CANCER, V77, P7, DOI 10.1002/(SICI)1097-0215(19980703)77:1<7::AID-IJC2>3.0.CO;2-Y; AZUMA M, 1993, J IMMUNOL, V150, P1147; Bagot M, 2001, BLOOD, V97, P1388, DOI 10.1182/blood.V97.5.1388; Bakker ABH, 1998, J IMMUNOL, V160, P5239; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Colonna M, 1997, J EXP MED, V186, P1809, DOI 10.1084/jem.186.11.1809; COLONNA M, 1995, SCIENCE, V268, P405, DOI 10.1126/science.7716543; Dohring C, 1996, J IMMUNOL, V156, P3098; Echchakir H, 2001, CANCER RES, V61, P4078; Echchakir H, 2002, P NATL ACAD SCI USA, V99, P9358, DOI 10.1073/pnas.142308199; Echchakir H, 2000, INT IMMUNOL, V12, P537, DOI 10.1093/intimm/12.4.537; Faure M, 2002, J IMMUNOL, V168, P6208, DOI 10.4049/jimmunol.168.12.6208; FERRINI S, 1994, EUR J IMMUNOL, V24, P2294, DOI 10.1002/eji.1830241005; Fry AM, 1996, J EXP MED, V184, P295, DOI 10.1084/jem.184.1.295; Gardiner CM, 2001, J IMMUNOL, V166, P2992, DOI 10.4049/jimmunol.166.5.2992; Gati A, 2001, CANCER RES, V61, P3240; Guerra N, 2000, BLOOD, V95, P2883, DOI 10.1182/blood.V95.9.2883.009k22_2883_2889; Ikeda H, 1997, IMMUNITY, V6, P199, DOI 10.1016/S1074-7613(00)80426-4; Le Drean E, 1998, EUR J IMMUNOL, V28, P264, DOI 10.1002/(SICI)1521-4141(199801)28:01<264::AID-IMMU264>3.0.CO;2-O; MINGARI MC, 1995, INT IMMUNOL, V7, P697, DOI 10.1093/intimm/7.4.697; MORETTA A, 1995, J EXP MED, V182, P875, DOI 10.1084/jem.182.3.875; MORETTA A, 1994, J EXP MED, V180, P545, DOI 10.1084/jem.180.2.545; Noppen C, 1998, EUR J IMMUNOL, V28, P1134, DOI 10.1002/(SICI)1521-4141(199804)28:04<1134::AID-IMMU1134>3.0.CO;2-G; Pende D, 1996, J EXP MED, V184, P505, DOI 10.1084/jem.184.2.505; PHILLIPS JH, 1995, SCIENCE, V268, P403, DOI 10.1126/science.7716542; Rajagopalan S, 2001, J IMMUNOL, V167, P1877, DOI 10.4049/jimmunol.167.4.1877; Shilling HG, 2002, J IMMUNOL, V168, P2307, DOI 10.4049/jimmunol.168.5.2307; Speiser DE, 1999, J EXP MED, V190, P775, DOI 10.1084/jem.190.6.775; STORKUS WJ, 1991, P NATL ACAD SCI USA, V88, P5989, DOI 10.1073/pnas.88.14.5989; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; Young NT, 2001, J IMMUNOL, V166, P3933, DOI 10.4049/jimmunol.166.6.3933; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	32	21	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 16	2003	22	46					7192	7198		10.1038/sj.onc.1206627	http://dx.doi.org/10.1038/sj.onc.1206627			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562047				2022-12-17	WOS:000185955000010
J	Ruivenkamp, CAL; Csikos, T; Klous, AM; van Wezel, T; Demant, P				Ruivenkamp, CAL; Csikos, T; Klous, AM; van Wezel, T; Demant, P			Five new mouse susceptibility to colon cancer loci, Scc11-Scc15	ONCOGENE			English	Article						susceptibility genes; colon cancer; genetic mapping; mouse genetics; AOM	TUMOR-SUSCEPTIBILITY; LINKAGE; MODELS; GENES	Although several genes causing familial cancer syndromes have been identified, susceptibility to sporadic cancer remains unsolved. Animal experiments have demonstrated a large number of quantitative trait loci affecting cancer susceptibility. Previously, we described in mouse strain CcS-19/Dem five susceptibility to colon cancer (Scc) loci, Scc1-Scc5 controlling tumor numbers. In the present study, we performed an independent identical mouse cross using a distinct carcinogen, azoxymethane, to induce colon tumors. We confirmed all five originally described Scc loci and detected five additional new Scc loci; Scc11 Scc15. All these loci were detected in two-way interactions.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Demant, P (corresponding author), Leiden Univ, Med Ctr, Dept Human & Clin Genet, POB 9600, NL-2300 RC Leiden, Netherlands.		van Wezel, Tom/A-9599-2008; van Wezel, Tom/AAL-5626-2021; van Wezel, Tom/Z-3092-2019	van Wezel, Tom/0000-0001-5773-7730; van Wezel, Tom/0000-0001-5773-7730				Balmain A, 2002, CELL, V108, P145, DOI 10.1016/S0092-8674(02)00622-0; Demant P, 1992, Semin Cancer Biol, V3, P159; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Mao JH, 2003, CURR OPIN GENET DEV, V13, P14, DOI 10.1016/S0959-437X(03)00005-4; MOEN CJA, 1992, ONCOGENE, V7, P563; MOEN CJA, 1991, MAMM GENOME, V1, P217, DOI 10.1007/BF00352328; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; Tripodis N, 2001, J NATL CANCER I, V93, P1484, DOI 10.1093/jnci/93.19.1484; van Wezel T, 1999, CANCER RES, V59, P4216; vanWezel T, 1996, NAT GENET, V14, P468, DOI 10.1038/ng1296-468	12	21	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 16	2003	22	46					7258	7260		10.1038/sj.onc.1207096	http://dx.doi.org/10.1038/sj.onc.1207096			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562056				2022-12-17	WOS:000185955000019
J	Rutter, JL; Goldstein, AM; Davila, MR; Tucker, MA; Struewing, JP				Rutter, JL; Goldstein, AM; Davila, MR; Tucker, MA; Struewing, JP			CDKN2A point mutations D153spl(c.457G > T) and IVS2+1G > T result in aberrant splice products affecting both p16(INK4a) and p14(ARF)	ONCOGENE			English	Article						melanoma; RT-PCR; alternate reading frame; cryptic splice site	CELL-CYCLE ARREST; PRONE FAMILIES; MELANOMA; P19(ARF); GENE; INHIBITION; LOCUS; MDM2; P53	The CDKN2A gene, which encodes the proteins p16(INK4a) and p14(ARF), is located on chromosome 9p21. Germline mutations at this locus increase susceptibility to cutaneous malignant melanoma (CMM). In general, missense and nonsense mutations are primarily responsible for defective p16(INK4a) and possibly p14(ARF) protein function and account for similar to20% of inherited CMM cases. We report a G>T transversion mutation in the last nucleotide of exon 2, affecting the aspartic acid residue at position 153 of CDKN2A-p16(INK4a) in a proband with melanoma. If splicing were unaffected, this mutation would change Asp to Tyr. RT-PCR analysis, however, revealed that this mutation, which we have termed D153spl(c.457G>T), and a previously described mutation at the next nucleotide, IVS2 + 1G > T, result in identical aberrant splicing affecting both p16(INK4a) and p14(ARF). The two main alternate splice products for each of the two normal transcripts includes a 74 bp deletion in exon 2, revealing a cryptic splice site, and the complete skipping of exon 2. The dual inactivation of p16(INK4a), and p14(ARF) may contribute to the CMM in these families.	NCI, Lab Populat Genet, NIH, DHHS,Ctr Canc Res, Bethesda, MD 20892 USA; NCI, Genet Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,DHHS, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Struewing, JP (corresponding author), NCI, Lab Populat Genet, NIH, DHHS,Ctr Canc Res, Bldg 41,Room D702,41 Library Dr,MSC 5060, Bethesda, MD 20892 USA.		Struewing, Jeffery P/C-3221-2008; Tucker, Margaret A/B-4297-2015; Struewing, Jeffery P/I-7502-2013	Struewing, Jeffery P/0000-0002-4848-3334; Rutter, Joni/0000-0002-6502-2361				Goldstein AM, 2000, J NATL CANCER I, V92, P1006, DOI 10.1093/jnci/92.12.1006; Goldstein AM, 2001, ARCH DERMATOL, V137, P1493; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; Harland M, 2001, HUM MOL GENET, V10, P2679, DOI 10.1093/hmg/10.23.2679; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kefford RF, 1999, J CLIN ONCOL, V17, P3245, DOI 10.1200/JCO.1999.17.10.3245; KRAWCZAK M, 1992, HUM GENET, V90, P41; Lynch HT, 2002, CANCER-AM CANCER SOC, V94, P84, DOI 10.1002/cncr.10159; Moskaluk C A, 1998, Hum Mutat, V12, P70; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Pesole G, 1999, NUCLEIC ACIDS RES, V27, P188, DOI 10.1093/nar/27.1.188; Petronzelli F, 2001, GENE CHROMOSOME CANC, V31, P398, DOI 10.1002/gcc.1159; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Rizos H, 1997, ONCOGENE, V15, P515, DOI 10.1038/sj.onc.1201217; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	21	21	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 10	2003	22	28					4444	4448		10.1038/sj.onc.1206564	http://dx.doi.org/10.1038/sj.onc.1206564			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853981				2022-12-17	WOS:000183978900014
J	Jiang, MR; Lie, YC; Yang, Y; Wu, JR				Jiang, MR; Lie, YC; Yang, Y; Wu, JR			C-Myc degradation induced by DNA damage results in apoptosis of CHO cells	ONCOGENE			English	Article						c-Myc; apoptosis; DNA damage; CHO cell; tripchlorolide	SISTER-CHROMATID EXCHANGE; STRAND-BREAK REPAIR; PROTEIN-DEGRADATION; TRIPTOLIDE; PROTEASOME; EXPRESSION; GROWTH; CHEMOTHERAPY; SUPPRESSION; INHIBITORS	Although tripchlorolide (TC), a compound purified from a Chinese herb Tripterygium Wilfordii Hook, has been demonstrated to be a potent antitumor agent, its mechanisms of action are unknown. The present study shows that TC induces apoptosis of Chinese Hamster Ovary (CHO) cells. Most strikingly, TC was particularly potent in inducing apoptosis of the UV41 mutant CHO cells, which are deficient in the ERCC4 gene encoding a nucleotide excision repair protein. TC caused a higher level of DNA damage in UV41 cells than those in the wildtype CHO cells or EM9 cells, which are deficient in single-strand break repair. These results provided a critical link between apoptotic hypersensitivity and DNA damage in defective nucleotide excision repair pathway of UV41 cells by TC treatment. Further analysis showed that degradation of the c-Myc protein in TC-treated UV41 cells was much stronger than those in the wild-type CHOAA8 and the EM9. A proteasome inhibitor, MG132, reduced both the degradation of c-Myc and apoptosis in TC-treated UV41 cells. Expression of exogenous c-Myc also inhibited apoptosis of TC-treated UV41 cells. These results indicate that c-Myc degradation induced by DNA damage in the presence of TC contributes to induction of apoptosis of UV41 cells.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, Shanghai 200031, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Mat Med, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Shanghai Institutes for Biological Sciences, CAS	Wu, JR (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.		Jiang, Manrong/E-6991-2011					Adachi S, 2001, MOL CELL BIOL, V21, P4929, DOI 10.1128/MCB.21.15.4929-4937.2001; Brookman KW, 1996, MOL CELL BIOL, V16, P6553; Chang WT, 2001, J BIOL CHEM, V276, P2221, DOI 10.1074/jbc.M009713200; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Dang CV, 1999, MOL CELL BIOL, V19, P1; Deroo BJ, 2002, MOL CELL BIOL, V22, P4113, DOI 10.1128/MCB.22.12.4113-4123.2002; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; GIBSON AW, 1995, EXP CELL RES, V218, P351, DOI 10.1006/excr.1995.1166; Gottlieb RA, 2002, METHODS, V26, P341, DOI 10.1016/S1046-2023(02)00040-3; Jiang MR, 2001, BIOCHEM BIOPH RES CO, V287, P775, DOI 10.1006/bbrc.2001.5655; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; KUPCHAN SM, 1972, J AM CHEM SOC, V94, P7194, DOI 10.1021/ja00775a078; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lee HY, 1997, GENE, V184, P177, DOI 10.1016/S0378-1119(96)00592-6; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LU XY, 1990, ACTA ACADEMIAE MED S, V12, P157; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Sgonc R, 1998, EXP GERONTOL, V33, P525, DOI 10.1016/S0531-5565(98)00031-X; Sonenshein GE, 1997, J IMMUNOL, V158, P1994; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Tajima K, 2001, FEBS LETT, V490, P59, DOI 10.1016/S0014-5793(01)02138-X; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Thompson LH, 1998, BIOESSAYS, V20, P589, DOI 10.1002/(SICI)1521-1878(199807)20:7<589::AID-BIES11>3.0.CO;2-W; THOMPSON LH, 1981, P NATL ACAD SCI-BIOL, V78, P3734, DOI 10.1073/pnas.78.6.3734; THOMPSON LH, 1982, MUTAT RES, V95, P427, DOI 10.1016/0027-5107(82)90276-7; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; THULASI R, 1993, J BIOL CHEM, V268, P18306; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WOOD AC, 1994, BRIT J CANCER, V69, P663, DOI 10.1038/bjc.1994.128; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZHANG T-M, 1981, Acta Pharmacologica Sinica, V2, P128	39	21	22	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 22	2003	22	21					3252	3259		10.1038/sj.onc.1206501	http://dx.doi.org/10.1038/sj.onc.1206501			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761495				2022-12-17	WOS:000183040000007
J	Gery, S; Yin, D; Xie, D; Black, KL; Koeffler, HP				Gery, S; Yin, D; Xie, D; Black, KL; Koeffler, HP			TMEFF1 and brain tumors	ONCOGENE			English	Article						brain cancer; epidermal growth factor and follistatin	EPIDERMAL GROWTH-FACTOR; PROSTATE-CANCER; FOLLISTATIN; CELLS	TMEFF1 is a novel transmembrane protein, containing two follisatin domains and an epidermal growth factor-like region. These structural domains suggest a role for TMEFF1 in growth factor signaling. TMEFF1 fused to enhanced green fluorescent protein revealed that TMEFF1 is expressed on the cell membrane. Northern analysis of normal human tissue showed that TMEFF1 is predominantly expressed in the brain. Study of cancer cell lines from different tissues including the brain, demonstrated moderate to low levels of TMEFF1 in most of these transformed cell lines. Furthermore, quantitative real-time RT-PCR analysis of 54 brain tumors showed that most of these tumors (96%) had lower levels of TMEFF1 expression than normal brain tissue. Interestingly, ectopic expression of TMEFF1 in brain cancer cells resulted in their growth inhibition. These data suggest that TMEFF1 may behave as a tumor suppressor gene in brain cancers.	Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Maxine Dunitz Neurosurg Inst, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center	Gery, S (corresponding author), Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA.			Black, Keith/0000-0002-0546-4934				Eib DW, 1996, J NEUROCHEM, V67, P1047; Eib DW, 1998, CYTOGENET CELL GENET, V81, P180, DOI 10.1159/000015023; EIB DW, 2000, MECH DEVELOP, V97, P67; ENGLER DA, 1990, FEBS LETT, V271, P47, DOI 10.1016/0014-5793(90)80368-S; Gery S, 2002, ONCOGENE, V21, P4739, DOI 10.1038/sj.onc.1205142; Glynne-Jones E, 2001, INT J CANCER, V94, P178, DOI 10.1002/ijc.1450; Horie M, 2000, GENOMICS, V67, P146, DOI 10.1006/geno.2000.6228; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; Patel K, 1998, INT J BIOCHEM CELL B, V30, P1087, DOI 10.1016/S1357-2725(98)00064-8; PATTHY L, 1993, TRENDS NEUROSCI, V16, P76, DOI 10.1016/0166-2236(93)90021-D; Westermark Bengt, 1995, Current Opinion in Oncology, V7, P220, DOI 10.1097/00001622-199505000-00005	11	21	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2723	2727		10.1038/sj.onc.1206351	http://dx.doi.org/10.1038/sj.onc.1206351			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743596				2022-12-17	WOS:000182569300003
J	Wertheim, JA; Miller, JP; Xu, LW; He, YP; Pear, WS				Wertheim, JA; Miller, JP; Xu, LW; He, YP; Pear, WS			The biology of chronic myelogenous leukemia: mouse models and cell adhesion	ONCOGENE			English	Article						CML; mouse model; cell adhesion; Philadelphia chromosome; BCR-ABL	CHRONIC MYELOID-LEUKEMIA; ABL TYROSINE KINASE; ACUTE LYMPHOBLASTIC-LEUKEMIA; BONE-MARROW STROMA; BCR-ABL; C-ABL; PHILADELPHIA-CHROMOSOME; TRANSGENIC MICE; MYELOPROLIFERATIVE DISEASE; HEMATOPOIETIC-CELLS	Chronic myelogenous leukemia (CML) is a biphasic neoplasm of the bone marrow that is precipitated by the Philadelphia chromosome, a t(9;22) balanced translocation that encodes a constitutively activated nonreceptor tyrosine kinase termed P210(BCR-ABL). This oncoprotein has several intracellular functions; however, the most important effect of P210(BCR-ABL) leading to cell transformation is phosphorylation of signaling molecules through a constitutively active tyrosine kinase domain. Despite extensive knowledge of the structure and functional domains of BCR-ABL, its precise function in transformation is not known. Progress has been hampered, in part, by the lack of relevant CML models, as cell culture and in vitro assays do not mimic the pathogenesis of CML. Recently, there has been significant progress toward improving murine models that closely resemble human CML. This has allowed researchers to evaluate critical functions of BCR-ABL and has provided a model to test the efficacy of therapeutic medications that block these pathways. Our laboratory has developed two intersecting research programs to better understand the functioning of P210(BCR-ABL) in leukemogenesis. In one approach, we have developed a murine CML model by transferring HSCs that express BCR-ABL from a retroviral vector. All recipients develop a rapidly fatal MPD that shares several important features with CML. This model has been extremely useful for studying the function of BCR-ABL in the pathogenesis of CML. A second approach utilizes a quantitative cell detachment apparatus capable of measuring small changes in cell adhesion to investigate the mechanism by which P210(BCR-ABL) causes abnormal cell binding. Altered cell adhesion may contribute to the imbalance between proliferation and self-renewal in the hematopoietic progenitor compartment. To better understand the role abnormal adhesion may play in the development of leukemia, we have attempted to correlate the effects of functional P210(BCR-ABL) mutants in regulating adhesion and oncogenicity.	Univ Penn, Inst Med & Engn, Philadelphia, PA 19104 USA; Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania	Pear, WS (corresponding author), Univ Penn, Inst Med & Engn, 611 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.		Wertheim, Jason/H-1275-2014	Wertheim, Jason/0000-0001-5680-1067	NCI NIH HHS [CA77570] Funding Source: Medline; NIDDK NIH HHS [P30-DK50306] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andreasson P, 1997, GENE CHROMOSOME CANC, V20, P299; Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1; Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; Bernasconi P, 2001, HAEMATOLOGICA, V86, P320; Bhatia R, 1999, EXP HEMATOL, V27, P1384, DOI 10.1016/S0301-472X(99)00084-3; Boettiger D, 2001, MOL BIOL CELL, V12, P1227, DOI 10.1091/mbc.12.5.1227; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Castillo DA, 2001, CR-NEW CENTEN REV, V1, P283, DOI 10.1353/ncr.2003.0033; Cobaleda C, 2000, BLOOD, V95, P1007, DOI 10.1182/blood.V95.3.1007.003k35_1007_1013; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; COZENSROBERTS C, 1990, BIOPHYS J, V58, P841, DOI 10.1016/S0006-3495(90)82430-9; COZENSROBERTS C, 1990, BIOPHYS J, V58, P857, DOI 10.1016/S0006-3495(90)82431-0; Cuenco GM, 2001, ONCOGENE, V20, P8236, DOI 10.1038/sj.onc.1205095; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1991, P NATL ACAD SCI USA, V88, P11335, DOI 10.1073/pnas.88.24.11335; Dash AB, 2002, P NATL ACAD SCI USA, V99, P7622, DOI 10.1073/pnas.102583199; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Garcia AJ, 1999, BIOMATERIALS, V20, P2427, DOI 10.1016/S0142-9612(99)00170-2; Garcia AJ, 1998, J BIOL CHEM, V273, P10988, DOI 10.1074/jbc.273.18.10988; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Golub TR, 1997, CURR TOP MICROBIOL, V220, P67; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Gordon MY, 1996, BRIT J HAEMATOL, V95, P10; Haskovec C, 1998, BRIT J HAEMATOL, V103, P1104, DOI 10.1046/j.1365-2141.1998.01098.x; HAWLEY RG, 1994, GENE THER, V1, P136; HAWLEY RG, 1993, J EXP MED, V178, P1175, DOI 10.1084/jem.178.4.1175; He YP, 2002, BLOOD, V99, P2957, DOI 10.1182/blood.V99.8.2957; Heaney C, 1997, BLOOD, V89, P297, DOI 10.1182/blood.V89.1.297.297_297_306; Heisterkamp N, 2000, BLOOD, V96, P2226; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; HURLEY RW, 1995, J CLIN INVEST, V96, P511, DOI 10.1172/JCI118063; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; Kramer A, 1999, P NATL ACAD SCI USA, V96, P2087, DOI 10.1073/pnas.96.5.2087; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lewis ID, 1998, BLOOD, V91, P630, DOI 10.1182/blood.V91.2.630.630_630_640; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, MOL CELL BIOL, V13, P1553; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; Melo JV, 1996, LEUKEMIA, V10, P751; Million RP, 2002, BLOOD, V99, P4568, DOI 10.1182/blood-2001-12-0244; Million RP, 2000, BLOOD, V96, P664; NOWELL PC, 1960, SCIENCE, V132, P1497; ODA T, 1994, J BIOL CHEM, V269, P22925; Okuda K, 1996, ONCOGENE, V13, P1147; Pane F, 1996, BLOOD, V88, P2410, DOI 10.1182/blood.V88.7.2410.bloodjournal8872410; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PEREGO R, 1991, ONCOGENE, V6, P1899; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SALGIA R, 1995, ONCOGENE, V11, P1149; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Schott B, 1996, SOMAT CELL MOLEC GEN, V22, P291, DOI 10.1007/BF02369568; Skourides PA, 1999, ONCOGENE, V18, P1165, DOI 10.1038/sj.onc.1202407; SPANGRUDE GJ, 1995, BLOOD, V85, P1006, DOI 10.1182/blood.V85.4.1006.bloodjournal8541006; Sparrow E.M., 1960, J HEAT TRANS-T ASME, V82, P294, DOI [10.1115/1.3679937, DOI 10.1115/1.3679937]; TACHIBANA N, 1987, BLOOD, V70, P1458; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; Tauchi T, 1997, J BIOL CHEM, V272, P1389, DOI 10.1074/jbc.272.2.1389; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; Van Limbergen H, 2001, GENE CHROMOSOME CANC, V30, P274, DOI 10.1002/1098-2264(2000)9999:9999<1::AID-GCC1089>3.3.CO;2-T; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; VERFAILLIE C, 1994, CRIT REV ONCOL HEMAT, V16, P201, DOI 10.1016/1040-8428(94)90071-X; Verfaillie CM, 1997, ACTA HAEMATOL-BASEL, V97, P40; Verfaillie CM, 1997, J LAB CLIN MED, V129, P584, DOI 10.1016/S0022-2143(97)90192-X; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985; VERFAILLIE CM, 1992, BLOOD, V79, P2821; Verstovsek S, 2002, CANCER, V94, P2416, DOI 10.1002/cncr.10490; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; WADA H, 1995, CANCER RES, V55, P3192; Wertheim JA, 2002, BLOOD, V99, P4122, DOI 10.1182/blood.V99.11.4122; Wolff NC, 2001, BLOOD, V98, P2808, DOI 10.1182/blood.V98.9.2808; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829; Zhang XW, 2001, BLOOD, V97, P277, DOI 10.1182/blood.V97.1.277; Zhang XW, 2001, MOL CELL BIOL, V21, P840, DOI 10.1128/MCB.21.3.840-853.2001; ZHAO X, 2002, NAT STRUCT BIOL, V7, P7	94	21	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	2002	21	56					8612	8628		10.1038/sj.onc.1206089	http://dx.doi.org/10.1038/sj.onc.1206089			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476308				2022-12-17	WOS:000179734300011
J	Joaquin, M; Bessa, M; Saville, MK; Watson, RJ				Joaquin, M; Bessa, M; Saville, MK; Watson, RJ			B-Myb overcomes a p107-mediated cell proliferation block by interacting with an N-terminal domain of p107	ONCOGENE			English	Article						B-Myb; p107 pocket protein; cell cycle; cyclin E/Cdk2; cyclin A2/Cdk2	CYCLIN A/CDK2; S-PHASE; REGULATED EXPRESSION; DEPENDENT KINASE; C-MYB; PROTEIN; PHOSPHORYLATION; TRANSCRIPTION; TRANSACTIVATION; INHIBITION	B-Myb is a cell-cycle regulated transcription factor which is implicated in cell proliferation and has an essential role in early embryonic development. In this study we examined the functions of B-Myb required to overcome G1 arrest in Saos-2 cells induced by the retinoblastoma-related p107 protein. Our results demonstrated that this activity was independent of B-Myb transactivation function, but correlated with its capacity to form an in vivo complex with p107. A large proportion of B-Myb formed complexes with p107 in cotransfected cells, however, B-Myb bound weakly to the related p130 protein and not at all to pRb. In contrast to the E2F transcription factors, which bind the p107 C-terminal pocket domain, B-Myb recognizes an N-terminal p107 region which overlaps the larger cyclin-binding domain. B-Myb and cyclin A2 formed mutually exclusive complexes with p107, and B-Myb enhanced the activity of co-transfected cyclin E kinase activity, implying that B-Myb affects the cell cycle by preventing sequestration of active cyclin/cdk2 complexes. This study defines a novel function of B-Myb and further suggests that the p107 N-terminus provides an interaction domain for transcription factors involved in cell cycle control.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Ludwig Inst Canc Res, Sect Virol & Cell Biol, London W2 1PG, England	Imperial College London; Ludwig Institute for Cancer Research	Watson, RJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Ludwig Inst Canc Res, Sect Virol & Cell Biol, St Marys Campus,Norfolk Pl, London W2 1PG, England.		Joaquin, Manel/O-6533-2019; Joaquin, Manel/E-2216-2015	Joaquin, Manel/0000-0001-8973-5916; Joaquin, Manel/0000-0001-8973-5916				Ansieau S, 1997, J MOL MED-JMM, V75, P815, DOI 10.1007/s001090050170; ARSURA M, 1992, BLOOD, V79, P2708; Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; Bessa M, 2001, BLOOD CELL MOL DIS, V27, P416, DOI 10.1006/bcmd.2001.0399; Bessa M, 2001, ONCOGENE, V20, P3376, DOI 10.1038/sj.onc.1204439; Bies J, 1996, ONCOGENE, V12, P355; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; Engelhard A, 2000, EXP CELL RES, V254, P153, DOI 10.1006/excr.1999.4742; Golay J, 1997, CELL GROWTH DIFFER, V8, P1305; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; JAULT FM, 1995, J VIROL, V69, P6697, DOI 10.1128/JVI.69.11.6697-6704.1995; Johnson RA, 1999, J GEN VIROL, V80, P1293, DOI 10.1099/0022-1317-80-5-1293; Johnson TK, 1999, J BIOL CHEM, V274, P36741, DOI 10.1074/jbc.274.51.36741; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; Robinson C, 1996, ONCOGENE, V12, P1855; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1996, J BIOL CHEM, V271, P28738, DOI 10.1074/jbc.271.46.28738; Sala A, 1999, J CELL PHYSIOL, V179, P245; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Saville MK, 1998, ADV CANCER RES, V72, P109; Sitzmann J, 1996, ONCOGENE, V12, P1889; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; ZHU LG, 1995, MOL CELL BIOL, V15, P3552; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	42	21	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 14	2002	21	52					7923	7932		10.1038/sj.onc.1206001	http://dx.doi.org/10.1038/sj.onc.1206001			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439743				2022-12-17	WOS:000179097200002
J	Wu, X; Lee, H				Wu, X; Lee, H			Human Dbf4/ASK promoter is activated through the Sp1 and MluI cell-cycle box (MCB) transcription elements	ONCOGENE			English	Article						Dbf4; ASK; promoter; Sp1; MluI cell-cycle box (MCB); gene structure; transcription initiation	HUMAN CDC7-RELATED KINASE; DNA-REPLICATION GENES; CDC7 PROTEIN-KINASE; S-PHASE; SACCHAROMYCES-CEREVISIAE; G(1)/S TRANSITION; POLYMERASE-ALPHA; CHECKPOINT; COMPLEX; IDENTIFICATION	Dbf4 is the regulatory subunit of Cdc7 kinase, which is essential for entry into and traversing through S phase. The level of Dbf4, which is critical for the activation of Cdc7, is regulated by transcription and protein degradation. To gain a better understanding as to how the transcription of human Dbf4 (HuDbf4) is regulated, we have cloned and characterized its promoter. We found that HuDbf4 core promoter is localized within -211 to -285 of the translation start-codon. This 75 bp DNA segment contains, among others, a putative Mlu1 Cell-cycle Box (MCB). A point mutation within the NICB dramatically reduced the promoter activity. This is the first example that an MCB element plays an essential role in the activation of a core promoter in mammalian cells. The auxiliary elements required for the full promoter activity are present within 162-bp upstream from the core promoter (i.e., -286/-447). A point mutation within the Sp1 element at -353/-361 resulted in a decrease of promoter activity to the basal level, while the deletion of the putative HES-1 at -326/ - 331 dramatically increased the promoter activity. Taken together, our data suggests that the NICB element is essential for the core promoter activation, while the SpI positive regulator and the HES-1 repressor coordinately determine the efficiency of the HuDbf4 promoter. We have also found: (i) that the major transcription initiations occur at -220, -235 and -245; (ii) that HuDbf4 gene consists of 12 exons, which spread over a 33-kb region.	Northeastern Ontario Reg Canc Ctr, Dept Res, Sudburg, ON P3E 5J1, Canada		Lee, H (corresponding author), Northeastern Ontario Reg Canc Ctr, Dept Res, 41 Ramsey Lake Rd, Sudburg, ON P3E 5J1, Canada.	hlee@neorcc.on.ca						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; Carey M, 2000, TRANSCRIPTIONAL REGU; CHAPMAN JW, 1989, EXP CELL RES, V180, P419, DOI 10.1016/0014-4827(89)90068-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COUDERC JL, 1987, NUCLEIC ACIDS RES, V15, P2549, DOI 10.1093/nar/15.6.2549; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; Ferreira MG, 2000, MOL CELL BIOL, V20, P242; GORDON CB, 1991, P NATL ACAD SCI USA, V88, P6058, DOI 10.1073/pnas.88.14.6058; Guo B, 2001, BIOTECHNIQUES, V31, P314, DOI 10.2144/01312st02; Guo BQ, 2001, GENE, V264, P249, DOI 10.1016/S0378-1119(01)00332-8; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; HILLARP A, 1993, J BIOL CHEM, V268, P15017; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; Jares P, 2000, GENE DEV, V14, P1528; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Kumagai H, 1999, MOL CELL BIOL, V19, P5083; Larner JM, 1999, NUCLEIC ACIDS RES, V27, P803, DOI 10.1093/nar/27.3.803; Lee HY, 1997, P NATL ACAD SCI USA, V94, P526, DOI 10.1073/pnas.94.2.526; Lepke M, 1999, MOL GEN GENET, V262, P220, DOI 10.1007/s004380051078; LEUTWILER LS, 1986, NUCLEIC ACIDS RES, V14, P4051, DOI 10.1093/nar/14.10.4051; Masai H, 2002, J CELL PHYSIOL, V190, P287, DOI 10.1002/jcp.10070; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; Masai H., 1999, FRONT BIOSCI, V4, pD834; Maxam A M, 1980, Methods Enzymol, V65, P499; MCINTOSH EM, 1993, CURR GENET, V24, P185, DOI 10.1007/BF00351790; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Nougarede R, 2000, MOL CELL BIOL, V20, P3795, DOI 10.1128/MCB.20.11.3795-3806.2000; Oshiro G, 1999, MOL CELL BIOL, V19, P4888; Owens JC, 1997, P NATL ACAD SCI USA, V94, P12521, DOI 10.1073/pnas.94.23.12521; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Perier RC, 2000, NUCLEIC ACIDS RES, V28, P302, DOI 10.1093/nar/28.1.302; RAJPUT B, 1994, J BIOL CHEM, V269, P9590; Sambrook J, 2001, MOL CLONING LAB MANU; SANICOLA M, 1990, J MOL BIOL, V212, P259, DOI 10.1016/0022-2836(90)90123-4; SCHAEFER BC, 1995, ANAL BIOCHEM, V227, P255, DOI 10.1006/abio.1995.1279; SIEDE W, 1994, GENETICS, V138, P271; Tercero JA, 2000, EMBO J, V19, P2082, DOI 10.1093/emboj/19.9.2082; Tomic-Canic M, 1996, Methods Mol Biol, V57, P259; Treuner K, 1998, J BIOL CHEM, V273, P31744, DOI 10.1074/jbc.273.48.31744; TREWITT PM, 1988, GENE, V69, P91, DOI 10.1016/0378-1119(88)90381-2; TSUJIMOTO Y, 1979, CELL, V16, P425, DOI 10.1016/0092-8674(79)90018-7; VERMA R, 1991, P NATL ACAD SCI USA, V88, P7155, DOI 10.1073/pnas.88.16.7155; VERMA R, 1992, P NATL ACAD SCI USA, V89, P9479, DOI 10.1073/pnas.89.20.9479; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	48	21	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2002	21	51					7786	7796		10.1038/sj.onc.1205914	http://dx.doi.org/10.1038/sj.onc.1205914			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420215				2022-12-17	WOS:000178946000003
J	David-Pfeuty, T; Nouvian-Dooghe, Y				David-Pfeuty, T; Nouvian-Dooghe, Y			Human p14(Arf): an exquisite sensor of morphological changes and of short-lived perturbations in cell cycle and in nucleolar function	ONCOGENE			English	Article						p14(Arf); cell cycle regulation; tumor suppression; cell morphology; cyclin-dependent kinase	ARF TUMOR-SUPPRESSOR; WILD-TYPE P53; RIBOSOMAL-RNA; P53-DEPENDENT APOPTOSIS; STABILIZES P53; P19(ARF); MDM2; TRANSCRIPTION; INHIBITORS; PROTEINS	The human Ink4a/Arf tumor suppressor locus encodes two distinct products: p16(Ink4a) which prevents phosphorylation and inactivation of the retinoblastoma protein and, p14(Arf), a nucleolar protein which activates the function of the tumor suppressor p53 protein in the nucleoplasm in response to oncogenic stimulation through an as yet ill-defined mechanism. Here we show that the level of endogenous p14(Arf) and its balance between the nucleolus and the nucleoplasm in HeLa cells are exquisitely sensitive to changes in cell morphology and to short-lived perturbations in cell cycle and in nucleolar function such as those induced by the cyclin-dependent kinase inhibitor, roscovitine, and the casein kinase II and RNA synthesis inhibitor, DRB. Most remarkably, whereas p14(Arf) predominantly concentrates in the nucleolus of interphase cells and transiently disappears between metaphase and early G1 under normal growth conditions, it massively and reversibly accumulates in the nucleoplasm of postmitotic and S-phase cells upon short-term treatment with roscovitine and, at a lesser extent, DRB. In line with the fact that the nuclear level of p53 reaches a peak between mid-G1 and the G1/S border in p53-expressor cells which lack Arf expression, these results provide a clue that, in p53+/Arf+ cells, Arf proteins might serve both to speed and to amplify p53-mediated responses in conditions and cell cycle periods in which the mechanisms involved in p53 stabilization and activation are not fully operational. They further suggest that human endogenous p14(Arf) might activate p53 pathways in physiologic situations by acting inside the nucleoplasm, especially when normal cell cycle progression and nucleolar function are compromised.	Ctr Univ, CNRS, UMR 146, Inst Curie Rech, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	David-Pfeuty, T (corresponding author), Ctr Univ, CNRS, UMR 146, Inst Curie Rech, Batiment 110, F-91405 Orsay, France.	Therese.Pfeuty@curie.u-psud.fr						Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; Cong F, 1999, ONCOGENE, V18, P7731, DOI 10.1038/sj.onc.1203290; David-Pfeuty T, 1999, ONCOGENE, V18, P7409, DOI 10.1038/sj.onc.1203103; David-Pfeuty T, 2001, ONCOGENE, V20, P5951, DOI 10.1038/sj.onc.1204741; DavidPfeuty T, 1996, CELL GROWTH DIFFER, V7, P1211; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Dundr M, 2000, J CELL BIOL, V150, P433, DOI 10.1083/jcb.150.3.433; Dundr M, 1998, MOL BIOL CELL, V9, P2407, DOI 10.1091/mbc.9.9.2407; DURO D, 1995, ONCOGENE, V11, P21; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; GAUTIER T, 1992, J CELL SCI, V102, P729; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; GRANICK D, 1975, J CELL BIOL, V65, P418, DOI 10.1083/jcb.65.2.418; Haaf T, 1996, EXP CELL RES, V224, P163, DOI 10.1006/excr.1996.0124; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Karayan L, 2001, ONCOGENE, V20, P836, DOI 10.1038/sj.onc.1204170; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; Khan SH, 1998, CANCER RES, V58, P396; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; MAO L, 1995, CANCER RES, V55, P2995; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; OConnor PM, 1997, CANCER SURV, V29, P151; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Savino TM, 1999, J CELL SCI, V112, P1889; Savino TM, 2001, J CELL BIOL, V153, P1097, DOI 10.1083/jcb.153.5.1097; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sirri V, 2002, J CELL BIOL, V156, P969, DOI 10.1083/jcb.200201024; Sirri V, 2000, J CELL BIOL, V148, P259, DOI 10.1083/jcb.148.2.259; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TAKAHASHI K, 1994, ONCOGENE, V9, P183; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WILSON GD, 1985, CYTOMETRY, V6, P641, DOI 10.1002/cyto.990060621; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	67	21	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2002	21	44					6779	6790		10.1038/sj.onc.1205871	http://dx.doi.org/10.1038/sj.onc.1205871			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360404				2022-12-17	WOS:000178315800008
J	Kopantzev, Y; Heller, M; Swaminathan, N; Rudikoff, S				Kopantzev, Y; Heller, M; Swaminathan, N; Rudikoff, S			IL-6 mediated activation of STAT3 bypasses Janus kinases in terminally differentiated B lineage cells	ONCOGENE			English	Article						IL-6; STAT3; MEK kinase; phosphorylation	SIGNAL TRANSDUCER GP130; JAK-TYK KINASES; TYROSINE KINASE; SERINE PHOSPHORYLATION; CYTOKINE RECEPTORS; INTERLEUKIN-6 FAMILY; PROTEIN-KINASES; IN-VIVO; INHIBITOR; ASSOCIATION	Cytokine signaling generally occurs through receptors lacking tyrosine kinase activity. Aggregation of receptors leads to activation of receptor associated Janus kinases (Jaks) which in turn phosphorylate members of a family of transcription factors (STATs) that translocate to the nucleus and regulate gene expression. In the case of Interleukin-6 (IL-6), the consensus for signaling in B lineage cells has been that Jak1, Jak2 and Tyk2 are all phosphorylated upon ligand binding and participate in activation of downstream elements, in particular STAT3. In other cell types, Jak1 has been demonstrated to be absolutely required for IL-6 mediated activation of STAT3. In the present studies, we have identified a series of end stage B cell (plasma cell) lines that fail to express Jak1, but phosphorylate STAT3 in response to IL-6. No evidence was found for a requirement of other Jak family members in the activation of STAT3. STAT3 tyrosine phosphorylation was inhibited in a dose dependent manner by the MEK inhibitor U0126, but not by inhibitors of PI-3K or Src kinases. Moreover, STAT3 phosphorylation was similarly inhibited in lines expressing Jak1 wherein Jak1 was phosphorylated upon IL-6 stimulation and Jakl phosphorylation was not inhibited by U0126. These results indicate that the MAPK pathway plays a critical role in IL-6 mediated tyrosine phosphorylation of STAT3 and suggests that Jak kinases may not be required in this cascade. Thus, it may be important to re-evaluate the role of Jak kinases in other cytokine signaling pathways as well.	NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rudikoff, S (corresponding author), NCI, Cellular & Mol Biol Lab, NIH, Bldg 37,Room 1D-18, Bethesda, MD 20892 USA.	rudikoff@helix.nih.gov						ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BERGER LC, 1994, BIOCHEM BIOPH RES CO, V202, P596, DOI 10.1006/bbrc.1994.1970; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; DAEIPOUR M, 1993, J IMMUNOL, V150, P4743; De Vos J, 2000, BRIT J HAEMATOL, V109, P823, DOI 10.1046/j.1365-2141.2000.02127.x; EILERS A, 1995, MOL CELL BIOL, V15, P3579; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gadina M, 2001, CURR OPIN IMMUNOL, V13, P363, DOI 10.1016/S0952-7915(00)00228-4; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Hallek M, 1997, EXP HEMATOL, V25, P1367; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HILBERT DM, 1995, J EXP MED, V182, P243, DOI 10.1084/jem.182.1.243; Hirano T, 1998, Int Rev Immunol, V16, P249; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Karaghiosoff M, 2000, IMMUNITY, V13, P549, DOI 10.1016/S1074-7613(00)00054-6; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Krishnan K, 1997, EUR J BIOCHEM, V247, P298, DOI 10.1111/j.1432-1033.1997.00298.x; KUMAR G, 1994, J IMMUNOL, V153, P4436; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; Nosaka T, 2000, INT J HEMATOL, V71, P309; Ogata A, 1997, J IMMUNOL, V159, P2212; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rane SG, 2000, ONCOGENE, V19, P5662, DOI 10.1038/sj.onc.1203925; Schuringa JJ, 2000, BIOCHEM J, V347, P89, DOI 10.1042/0264-6021:3470089; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Treon S P, 1998, Curr Opin Hematol, V5, P42; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; YANG YP, 1995, HUM GENE THER, V6, P1203, DOI 10.1089/hum.1995.6.9-1203; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	38	21	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2002	21	44					6791	6800		10.1038/sj.onc.1205815	http://dx.doi.org/10.1038/sj.onc.1205815			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360405				2022-12-17	WOS:000178315800009
J	Mueller, W; Mollenhauer, J; Stockhammer, F; Poustka, A; von Deimling, A				Mueller, W; Mollenhauer, J; Stockhammer, F; Poustka, A; von Deimling, A			Rare mutations of the DMBT1 gene in human astrocytic gliomas	ONCOGENE			English	Article						DMBT1; mutation; glioblastoma; pilocytic astrocytoma	TUMORS; PTEN; PROGRESSION; EXPRESSION; CANCER	The Deleted in Malignant Brain Tumors I gene (DMBT1) has been proposed as a tumor suppressor gene candidate in human brain tumors, based on the observation of homozygous deletions affecting the DMBT1 region or part of the gene. In order to support this hypothesis, we performed a mutational analysis of the entire coding region of DMBT1, employing SSCP analysis and direct DNA sequencing in a series of 79 astrocytic gliomas. Five somatic mutations were detected. Two mutations, one of which resulted in an amino acid exchange, occurred in glioblastomas. One pilocytic astrocytoma carried two missense mutations and another pilocytic astrocytoma contained a somatic mutation, not affecting the presumed protein. In addition, 21 of the 27 single nucleotide polymorphisms identified in this study have not been recognized previously. The data indicate, that small mutations are not a frequent finding in gliomas.	Charite Humboldt Univ, Inst Neuropathol, D-13353 Berlin, Germany; Deutsch Krebsforschungszentrum, Dept Mol Genome Anal, D-69120 Heidelberg, Germany; Charite Humboldt Univ, Dept Neurosurg, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; German Cancer Research Center (DKFZ); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	von Deimling, A (corresponding author), Charite Humboldt Univ, Inst Neuropathol, D-13353 Berlin, Germany.		von Deimling, Andreas/F-7774-2013; Mollenhauer, Jan/G-4452-2012	von Deimling, Andreas/0000-0002-5863-540X; Stockhammer, Florian/0000-0002-0525-5956				Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; Fujisawa H, 1999, AM J PATHOL, V155, P387, DOI 10.1016/S0002-9440(10)65135-8; Holmskov U, 1999, P NATL ACAD SCI USA, V96, P10794, DOI 10.1073/pnas.96.19.10794; Lualdi E, 2000, BIOCHEM BIOPH RES CO, V270, P673, DOI 10.1006/bbrc.2000.2478; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Mollenhauer J, 1999, ONCOGENE, V18, P6233, DOI 10.1038/sj.onc.1203071; Mollenhauer J, 2000, CANCER RES, V60, P1704; Mori M, 1999, BRIT J CANCER, V79, P211, DOI 10.1038/sj.bjc.6690035; Petersen S, 2000, INT J CANCER, V88, P71, DOI 10.1002/1097-0215(20001001)88:1<71::AID-IJC11>3.0.CO;2-X; Sasaki H, 2001, AM J PATHOL, V159, P359, DOI 10.1016/S0002-9440(10)61702-6; Somerville RPT, 1998, ONCOGENE, V17, P1755, DOI 10.1038/sj.onc.1202066; Steck PA, 1999, GENE CHROMOSOME CANC, V24, P135, DOI 10.1002/(SICI)1098-2264(199902)24:2<135::AID-GCC6>3.0.CO;2-A; Takeshita H, 1999, JPN J CANCER RES, V90, P903, DOI 10.1111/j.1349-7006.1999.tb00833.x; von Deimling A, 2000, J NEUROPATH EXP NEUR, V59, P544, DOI 10.1093/jnen/59.6.544; Wu WG, 1999, CANCER RES, V59, P1846	15	21	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5956	5959		10.1038/sj.onc.1205733	http://dx.doi.org/10.1038/sj.onc.1205733			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185598				2022-12-17	WOS:000177520900018
J	Redeuilh, G; Attia, A; Mester, J; Sabbah, M				Redeuilh, G; Attia, A; Mester, J; Sabbah, M			Transcriptional activation by the oestrogen receptor alpha is modulated through inhibition of cyclin-dependent kinases	ONCOGENE			English	Article						oestrogen receptor; p21(waf1); cell cycle; coactivators; cyclin-dependent kinases	CREB BINDING-PROTEIN; HISTONE ACETYLTRANSFERASE ACTIVITY; ESTROGEN-RECEPTOR; CELL-CYCLE; NUCLEAR RECEPTORS; BIOLOGICAL-ACTIVITY; P300 COACTIVATOR; DISTINCT ROLES; BREAST-CANCER; D1 EXPRESSION	We have investigated the interaction between the expression of p21(WAF1/CIP1/SDI1), a stoichiometric inhibitor of Cdk, and the transcriptional activity of the oestrogen receptor alpha (ERalpha). Transient transfection experiments demonstrated that the expression of p21(WAF1/CIP1/SDI1) amplified the transcriptional activation by ERalpha. A dominant negative mutant of Cdk2 also enhanced the ERa transcriptional activity, indicating that the underlying mechanism relies on the inhibition of Cdk2 activity and cell cycle arrest. In agreement with this conclusion, experiments with p21(WAF1/CIP1/SDI1) mutants demonstrated that the domain involved in the binding of p21(WAF1/CIP1/SDI1) to Cdks was indispensable for the modulation of ERa activity. In addition, we show that expression of p21(WAF1/CIP1/SDI1) alleviates the block on CBP function mediated by Cdk2 and in turn stimulates transcriptional activation by ERalpha in a CBP-histone acetyltransferase (HAT)-dependent manner. These results suggest a novel mechanism by which p21(WAF1/CIP1/SDI1) functions as an enhancer of ERalpha activity through the modulation of CBP function.	Hop St Antoine, INSERM, U482, F-75571 Paris 12, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Sabbah, M (corresponding author), Hop St Antoine, INSERM, U482, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.	sabbah@st-antoine.inserm.fr		SABBAH, Michele/0000-0001-5368-9022				Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Altucci L, 1996, ONCOGENE, V12, P2315; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Auwerx J, 1999, CELL, V97, P161; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen XM, 2000, J NATL CANCER I, V92, P1403, DOI 10.1093/jnci/92.17.1403; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Felzien LK, 1999, MOL CELL BIOL, V19, P4241; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; GAGNE D, 1994, J BIOLUM CHEMILUM, V9, P201, DOI 10.1002/bio.1170090314; Glass CK, 2000, GENE DEV, V14, P121; Goodman RH, 2000, GENE DEV, V14, P1553; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; ING NH, 1992, J BIOL CHEM, V267, P17617; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Mitra J, 1999, MOL CELL BIOL, V19, P3916; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; Oh YL, 2001, PATHOL INT, V51, P94, DOI 10.1046/j.1440-1827.2001.01173.x; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Planas-Silva MD, 2001, CANCER RES, V61, P3858; Polesskaya A, 2001, EMBO J, V20, P6816, DOI 10.1093/emboj/20.23.6816; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Sabbah M, 1996, BIOCHEM J, V314, P205, DOI 10.1042/bj3140205; Sabbah M, 1998, BIOCHEM J, V336, P639, DOI 10.1042/bj3360639; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WALDMAN T, 1995, CANCER RES, V55, P5187; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	69	21	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5773	5782		10.1038/sj.onc.1205753	http://dx.doi.org/10.1038/sj.onc.1205753			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173048				2022-12-17	WOS:000177463400013
J	Rochette, PJ; Bastien, N; McKay, BC; Therrien, JP; Drobetsky, EA; Drouin, R				Rochette, PJ; Bastien, N; McKay, BC; Therrien, JP; Drobetsky, EA; Drouin, R			Human cells bearing homozygous mutations in the DNA mismatch repair genes hMLH1 or hMSH2 are fully proficient in transcription-coupled nucleotide excision repair	ONCOGENE			English	Article						transcription-coupled nucleotide excision repair; DNA mismatch repair; ligation mediated PCR; cyclobutane pyrimidine dieter	COCKAYNE-SYNDROME; TUMOR-CELLS; UV; INVOLVEMENT; SUNLIGHT; LIGHT; MSH2; PHOTOPRODUCTS; DEFICIENCY; POLYMERASE	The transcription-coupled nucleotide excision repair (TONER) pathway maintains genomic stability by rapidly eliminating helix-distorting DNA adducts, such as UV-induced cyclobutane pyrimidine dimers (CPDs), specifically from the transcribed strands of active genes. DNA mismatch repair (MMR) constitutes yet another critical antimutagenic pathway that removes mispaired bases generated during semiconservative replication. It was previously reported that the human colon adenocarcinoma strains HCT11G and LoVo (bearing homozygous mutations in the MMR genes hMLH1 and hMSH2, respectively), besides manifesting hallmark phenotypes associated with defective DNA mismatch correction, are also completely deficient in TONER of UV-induced CPDs. This revealed a direct mechanistic link between MMR and TONER in human cells, although subsequent studies have either supported, or argued against, the validity of this important notion. Here, the ligation-mediated polymerase chain reaction was used to show at nucleotide resolution that MMR-deficient HCT11G and LoVo retain the ability to excise UV-induced CPDs much more rapidly from the transcribed vs the nontranscribed strands of active genes. Moreover, relative to DNA repair-proficient counterparts, MMR-deficient cells were not more sensitive to the cytotoxic effects of UV, and displayed equal ability to recover mRNA synthesis following UV challenge. These results conclusively demonstrate that hMLH1- and hMSH2-deficient human colon adenocarcinoma cells are fully proficient in TONER.	Univ Laval, Fac Med, Dept Med Biol, Div Pathol, Quebec City, PQ G1L 3L5, Canada; Univ Quebec, Cent Hosp, Hop St Francois Assise, Unite Rech Genet Humaine & Mol,Res Ctr, Quebec City, PQ G1L 3L5, Canada; Ottawa Reg Canc Ctr, Ctr Canc Therapeut, Ottawa, ON K1Y 4K7, Canada; Hop Maison Neuve Rosemont, Ctr Rech Guy Bernier, Montreal, PQ H1T 2M4, Canada; Univ Montreal, Fac Med, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada	Laval University; Laval University; University of Quebec; University of Ottawa; Ottawa Hospital Research Institute; Universite de Montreal; Universite de Montreal	Drobetsky, EA (corresponding author), Univ Laval, Fac Med, Dept Med Biol, Div Pathol, Quebec City, PQ G1L 3L5, Canada.	regen.drouin@crsfa.ulaval.ca	Rochette, Patrick/HHN-2300-2022; Therrien, Jean-Philippe/AAW-8912-2021; McKay, Bruce C/I-4081-2013	Therrien, Jean-Philippe/0000-0001-5878-6841; McKay, Bruce C/0000-0002-7921-1331; Rochette, Patrick/0000-0002-0678-8869				Adimoolam S, 2001, J BIOL CHEM, V276, P25813, DOI 10.1074/jbc.M102240200; AFZAL V, 1995, MUTAGENESIS, V10, P457, DOI 10.1093/mutage/10.5.457; ANDREWS AD, 1978, J INVEST DERMATOL, V70, P237, DOI 10.1111/1523-1747.ep12541383; Angers M, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.16.e83; Aquilina G, 2001, J CELL PHYSIOL, V187, P145, DOI 10.1002/jcp.1067; Berneburg M, 2001, ADV GENET, V43, P71, DOI 10.1016/S0065-2660(01)43004-5; Bertrand P, 1998, P NATL ACAD SCI USA, V95, P14278, DOI 10.1073/pnas.95.24.14278; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DROBETSKY EA, 1995, P NATL ACAD SCI USA, V92, P2350, DOI 10.1073/pnas.92.6.2350; Drouin R, 2001, Methods Mol Biol, V148, P175; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Fleck O, 1999, NAT GENET, V21, P314, DOI 10.1038/6838; GAO SW, 1994, SCIENCE, V263, P1438, DOI 10.1126/science.8128226; Glaab WE, 1998, CARCINOGENESIS, V19, P1931, DOI 10.1093/carcin/19.11.1931; Kirkpatrick DT, 1997, NATURE, V387, P929, DOI 10.1038/43225; KOI M, 1994, CANCER RES, V54, P4308; KRAEMER KH, 1984, CARCINOGENESIS, V5, P511, DOI 10.1093/carcin/5.4.511; Leadon SA, 1998, MUTAT RES-DNA REPAIR, V407, P177, DOI 10.1016/S0921-8777(98)00007-X; Leadon SA, 1997, CANCER RES, V57, P3784; Ljungman M, 1996, ONCOGENE, V13, P823; MAYNE LV, 1982, CANCER RES, V42, P1473; McKay Bruce C., 1999, Neoplasia (New York), V1, P276, DOI 10.1038/sj.neo.7900028; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; O'Driscoll M, 1999, CARCINOGENESIS, V20, P799, DOI 10.1093/carcin/20.5.799; Peltomaki P, 2001, MUTAT RES-REV MUTAT, V488, P77, DOI 10.1016/S1383-5742(00)00058-2; Reitmair AH, 1997, CANCER RES, V57, P3765; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; SELBY CP, 1995, J BIOL CHEM, V270, P4890, DOI 10.1074/jbc.270.9.4890; Sonneveld E, 2001, ONCOGENE, V20, P538, DOI 10.1038/sj.onc.1204125; Sweder KS, 1996, GENETICS, V143, P1127; Therrien JP, 1999, P NATL ACAD SCI USA, V96, P15038, DOI 10.1073/pnas.96.26.15038; Therrien JP, 2001, CANCER RES, V61, P3781; TORNALETTI S, 1993, ONCOGENE, V8, P2051; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; Tyrrell RM, 1996, BIOESSAYS, V18, P139, DOI 10.1002/bies.950180210; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; Wang HX, 1999, J BIOL CHEM, V274, P16894, DOI 10.1074/jbc.274.24.16894; You YH, 1999, J MOL BIOL, V293, P493, DOI 10.1006/jmbi.1999.3174	42	21	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5743	5752		10.1038/sj.onc.1205641	http://dx.doi.org/10.1038/sj.onc.1205641			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173044				2022-12-17	WOS:000177463400009
J	Cullingworth, J; Hooper, ML; Harrison, DJ; Mason, J; Sirard, C; Patek, CE; Clarke, AR				Cullingworth, J; Hooper, ML; Harrison, DJ; Mason, J; Sirard, C; Patek, CE; Clarke, AR			Carcinogen-induced pancreatic lesions in the mouse: effect of Smad4 and Apc genotypes	ONCOGENE			English	Article						pancreas; SMAD4; APC; mouse	GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR GENE; TGF-BETA; DIFFERENTIAL EXPRESSION; EXOCRINE PANCREAS; THYMIC LYMPHOMAS; MUTANT MICE; DPC4; CANCER; MUTATIONS	Mutations in the tumour suppressor genes SMAD4 (DPC4, deleted in pancreatic cancer locus 4) and adenomatous polyposis coli (APC) have been implicated in the development of pancreatic cancer in humans. Treatment of wild-type, Smad4(+/-), Apc(Min/+) or Apc(Min/+) Smad4(+/-) mice with N-Nitroso-N-Methyl Urea (NMU) results in abnormal foci in pancreatic acinar cells characterized by increased levels of beta-catenin. Previously such foci have been shown to be the precursors of pancreatic neoplasia. Interestingly, only NMU-treated Apc(Min/+) Smad4(+/-) mice exhibit a significant increase in abnormal pancreas, which was found to be due to increased number of abnormal foci rather than increased focus size. A, range of foci sizes were analysed, but only smaller abnormal foci were characterized by morphological nuclear atypia. These studies suggest functional co-operation between TGF-beta and Wnt signalling pathways in the suppression of pancreatic tumorigenesis in the mouse.	Western Gen Hosp, Sir Alastain Currie Canc Res UK Labs, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh Sch Med, Sect Biomed Sci, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Cardiff, Dept Biomed Sci, Cardiff CF10 3US, S Glam, Wales; McGill Univ, Brain Tumor Res Ctr, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada	University of Edinburgh; University of Edinburgh; Cardiff University; McGill University	Hooper, ML (corresponding author), Western Gen Hosp, Sir Alastain Currie Canc Res UK Labs, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland.		Clarke, Alan R/A-6256-2008; Mason, John O/A-1926-2010; clarke, alan r/P-2820-2014	Mason, John O/0000-0002-0489-2400; harrison, david/0000-0001-9041-9988; Clarke, Alan/0000-0002-4281-426X				Abraham SC, 2002, AM J PATHOL, V160, P953, DOI 10.1016/S0002-9440(10)64917-6; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; ASAMURA H, 1989, CANCER, V64, P1657, DOI 10.1002/1097-0142(19891015)64:8<1657::AID-CNCR2820640817>3.0.CO;2-4; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; BARKA T, 1982, J NATL CANCER I, V69, P1115; Bottinger EP, 1997, EMBO J, V16, P2621, DOI 10.1093/emboj/16.10.2621; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CLARKE AR, 1995, ONCOGENE, V11, P1913; COROMINAS M, 1991, CANCER RES, V51, P5129; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; DIAMOND LE, 1987, CELL IMMUNOL, V107, P115, DOI 10.1016/0008-8749(87)90271-1; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Grau AM, 1997, CANCER RES, V57, P3929; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1998, DIGESTION, V59, P493, DOI 10.1159/000007526; Hahn SA, 1996, CANCER RES, V56, P490; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Howe JR, 1997, SURG ONCOL, V6, P1, DOI 10.1016/S0960-7404(97)00001-7; KEIGHREN M, 1993, HISTOCHEM J, V25, P30, DOI 10.1007/BF00161042; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kito K, 1996, MOL CARCINOGEN, V17, P78, DOI 10.1002/(SICI)1098-2744(199610)17:2<78::AID-MC4>3.0.CO;2-P; Kongkanuntn R, 1999, ONCOGENE, V18, P7219, DOI 10.1038/sj.onc.1203181; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; MONIS B, 1991, INT J PANCREATOL, V8, P119; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; POLAKIS P, 1997, BIOCHIM BIOPHYS ACTA, V1332, P127; Rozenblum E, 1997, CANCER RES, V57, P1731; SCARPA A, 1993, AM J PATHOL, V142, P1534; Schutte M, 1996, CANCER RES, V56, P2527; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; SOKAL RR, 1995, BIOMETRY PRINCIPLES, P151; Suzuki K, 2000, ANTICANCER RES, V20, P1257; Takaku K, 1999, CANCER RES, V59, P6113; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667	44	21	24	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 11	2002	21	30					4696	4701		10.1038/sj.onc.1205673	http://dx.doi.org/10.1038/sj.onc.1205673			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	569WH	12096346				2022-12-17	WOS:000176625100011
J	Lambert, S; Lopez, BS				Lambert, S; Lopez, BS			Inactivation of the RAD51 recombination pathway stimulates UV-induced mutagenesis in mammalian cells	ONCOGENE			English	Article						mammalian RAD51; recombination; mutagenesis; DNA repair; UV-C	INTRACHROMOSOMAL HOMOLOGOUS RECOMBINATION; SACCHAROMYCES-CEREVISIAE; SPONTANEOUS MUTATION; DNA-POLYMERASES; REPAIR; RADIATION; CYCLE; P53	We have examined the impact of the RAD51 recombination pathway on recombination and mutagenesis induced by UV-C in mammalian cells. We used hamster CHO cell lines that express different forms of Rad51 protein, resulting in stimulation or inhibition of spontaneous gene conversion. Spontaneous mutagenesis was affected by none of the RAD51 forms. The wild-type mouse MmRAD51 affects neither UV-induced recombination nor UV-induced mutagenesis. In contrast, the dominant negative SMRAD51 strongly impairs UV-induced recombination while it stimulates UV-induced mutagenesis. Our results show that a defect in the RAD51 gene conversion pathway reveals (a) mutagenic alternative pathway(s) to repair UV-damage, in mammalian cells.	Dept Radiobiol & Radiopathol, Direct Sci Vivant, CEA, CNRS,UMR217, F-92265 Fontenay Aux Roses, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Lopez, BS (corresponding author), Dept Radiobiol & Radiopathol, Direct Sci Vivant, CEA, CNRS,UMR217, 60-68 Ave Gen Leclerc, F-92265 Fontenay Aux Roses, France.		Lopez, Bernard S/O-7308-2017; lambert, sarah/K-7750-2017	Lopez, Bernard S/0000-0001-5088-0155; lambert, sarah/0000-0002-1403-3204				BHATTACHARYYA NP, 1990, MUTAT RES, V234, P31, DOI 10.1016/0165-1161(90)90028-M; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; Chen FQ, 1997, MUTAT RES-DNA REPAIR, V384, P205, DOI 10.1016/S0921-8777(97)00020-7; FABRE F, 1984, MOL GEN GENET, V195, P139, DOI 10.1007/BF00332736; Hu T, 1999, MUTAT RES-FUND MOL M, V426, P51, DOI 10.1016/S0027-5107(99)00077-9; KADYK LC, 1992, GENETICS, V132, P387; Kannouche P, 2001, GENE DEV, V15, P158, DOI 10.1101/gad.187501; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Lambert S, 2001, ONCOGENE, V20, P6627, DOI 10.1038/sj.onc.1204813; Lehmann AR, 2000, GENE, V253, P1, DOI 10.1016/S0378-1119(00)00250-X; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Luria SE, 1943, GENETICS, V28, P491; QUAH SK, 1980, GENETICS, V96, P819; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Sambrook J, 1989, MOL CLONING LAB MANU; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TSUJIMURA T, 1990, P NATL ACAD SCI USA, V87, P1566, DOI 10.1073/pnas.87.4.1566; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; WANG YY, 1988, MOL CELL BIOL, V8, P196, DOI 10.1128/MCB.8.1.196; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191	20	21	21	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 6	2002	21	25					4065	4069		10.1038/sj.onc.1205535	http://dx.doi.org/10.1038/sj.onc.1205535			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037689				2022-12-17	WOS:000175869900013
J	Bisson, SA; Ujack, EE; Robbins, SM				Bisson, SA; Ujack, EE; Robbins, SM			Isolation and characterization of a novel, transforming allele of the c-Cbl proto-oncogene from a murine macrophage cell line	ONCOGENE			English	Article						E3-ubiquitin ligase; Src-family kinase; J-774; cells; Fc receptors	PHOSPHOTYROSINE-BINDING DOMAIN; GROWTH-FACTOR RECEPTOR; MEDIATED NEGATIVE REGULATION; SRC-FAMILY KINASES; FC-GAMMA-RI; TYROSINE KINASE; SH3 DOMAIN; PROTEIN PRODUCT; DOWN-REGULATION; IN-VIVO	The c-Cbl proto-oncogene acts as an E3 ubiquitin ligase via its RING finger domain to negatively regulate activated cellular signal transduction pathways. We have identified an aberrant Cbl-protein of approximately 95 kDa, which we have called p95Cbl, from the murine reticulum sarcoma cell-line, J-774. Cloning of the p95Cbl cDNA revealed that it contains a deletion resulting in the loss of 111 amino acids, eliminating two critical tyrosine residues in the linker region as well as the entire RING finger domain. p95Cbl displays a propensity for its interaction with the Src-family kinase Hck over cellular Cbl expressed in the same cells. Like its wildtype counterpart, p95Cbl is inducibly tyrosine phosphorylated in response to Fcgamma receptor engagement on hematopoietic cells, however this phosphorylation is sustained beyond that of cellular Cbl. NIH3T3 fibroblasts stably expressing p95Cbl acquire the typical refractile morphology associated with cellular transformation and form colonies in a focus-formation assay. The exogenously expressed mutant protein is constitutively phosphorylated in fibroblasts and partitions into the particulate fraction of cells, while cellular Cbl is exclusively cytoplasmic. p95Cbl is a novel, oncogenic mutant of the c-Cbl proto-oncogene, which might act in a dominant negative fashion to prolong normal cellular signaling responses by interfering with the down-regulation of activated signaling complexes through c-Cbl.	Univ Calgary, Dept Oncol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Robbins, SM (corresponding author), Univ Calgary, Dept Oncol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	srobbins@ucalgary.ca		Robbins, Stephen/0000-0001-7475-1665				Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Brizzi MF, 1998, EXP HEMATOL, V26, P1229; COHN M, 1967, COLD SPRING HARB SYM, V32, P211, DOI 10.1101/SQB.1967.032.01.029; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DURDEN DL, 1995, J IMMUNOL, V154, P4039; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; Hirst JW, 1971, J IMMUNOL, V107, P926; Horita DA, 1998, J MOL BIOL, V278, P253, DOI 10.1006/jmbi.1998.1690; Howlett CJ, 2002, ONCOGENE, V21, P1707, DOI 10.1038/sj.onc.1205228; Howlett CJ, 1999, BIOCHEM BIOPH RES CO, V257, P129, DOI 10.1006/bbrc.1999.0427; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JONGEWARD GD, 1995, GENETICS, V139, P1553; KAPLAN G, 1978, EXP CELL RES, V115, P53, DOI 10.1016/0014-4827(78)90401-9; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; Kuwae A, 2001, J BIOL CHEM, V276, P32230, DOI 10.1074/jbc.M103831200; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Levkowitz G, 1996, ONCOGENE, V12, P1117; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ojaniemi M, 1998, ONCOGENE, V16, P3159, DOI 10.1038/sj.onc.1201859; PAIGE CJ, 1978, J IMMUNOL, V121, P641; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; RALPH P, 1975, J IMMUNOL, V114, P898; RALPH P, 1975, NATURE, V257, P393, DOI 10.1038/257393a0; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Sato N, 1999, J IMMUNOL, V163, P6123; SAVAGE PD, 1991, CYTOGENET CELL GENET, V56, P112, DOI 10.1159/000133062; Scaife RM, 2000, J CELL SCI, V113, P215; SCHOLT G, 2000, J BIOL CHEM, V273, P14615; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Suzuki T, 2000, J IMMUNOL, V165, P473, DOI 10.4049/jimmunol.165.1.473; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; WANG AVT, 1994, J EXP MED, V180, P1165, DOI 10.1084/jem.180.3.1165; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zell T, 1998, CURR BIOL, V8, P814, DOI 10.1016/S0960-9822(98)70323-9	59	21	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3677	3687		10.1038/sj.onc.1205510	http://dx.doi.org/10.1038/sj.onc.1205510			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032836				2022-12-17	WOS:000175676000003
J	Hemmeryckx, B; Reichert, A; Watanabe, M; Kaartinen, V; de Jong, R; Pattengale, PK; Groffen, J; Heisterkamp, N				Hemmeryckx, B; Reichert, A; Watanabe, M; Kaartinen, V; de Jong, R; Pattengale, PK; Groffen, J; Heisterkamp, N			BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl	ONCOGENE			English	Article						Bcr/Abl P190; Crkl; Ph-positive; acute lymphoblastic leukemia; null mutant	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; BCR-ABL TRANSFORMATION; TYROSINE PHOSPHORYLATION; ADAPTER PROTEIN; LEUKEMOGENESIS; CELLS; GENE; PROLIFERATION; PEPTIDES	The Bcr/Abl fusion protein directly causes chronic myelogenous leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Multiple independent studies have implicated Crkl, a small adapter protein, in transduction of oncogenic signals of Bcr/Abl and CrkI tyro sine-phosphorylation is used as a diagnostic tool for Philadelphia-positive leukemia. To evaluate the contribution of CrkI to this type of leukemia, we generated mutant mice that lack CrkI expression. We found that the overall survival of P190 BCR/ABL crkl-/- mice was comparable to that of genetically matched P190 BCR/ABL crkl +/+ mice. Both genotypes developed lymphoid lineage leukemia/lymphoma. Western blot analysis of -/- and +/+ lymphomas showed that the related Crk protein was tyrosine phosphorylated and could be found complexed with Bcr-Abl P190. These data indicate that possible therapeutic approaches that target CrkI may be complicated by the presence of pathways that compensate for lack of CrkI function.	Childrens Hosp Los Angeles, Res Inst, Sect Mol Carcinogenesis, Div Hematol Oncol, Los Angeles, CA 90027 USA; Univ So Calif, Keck Sch Med, Sect Mol Carcinogenesis, Div Hematol Oncol, Los Angeles, CA 90027 USA; Childrens Hosp Los Angeles, Res Inst, Dept Pathol, Los Angeles, CA 90027 USA; Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; University of Southern California	Heisterkamp, N (corresponding author), Childrens Hosp Los Angeles, Res Inst, Sect Mol Carcinogenesis, Div Hematol Oncol, MS 54,4650 Sunset Blvd, Los Angeles, CA 90027 USA.		Kaartinen, Vesa/AAU-5396-2021; Hemmeryckx, Bianca/AAR-2360-2021; Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273; Kaartinen, Vesa/0000-0002-9432-510X	NCI NIH HHS [CA 90321, CA 50248] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050248, R01CA090321] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; DEJONG R, 1995, ONCOGENE, V11, P1469; deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Guris DL, 2001, NAT GENET, V27, P293, DOI 10.1038/85855; Heaney C, 1997, BLOOD, V89, P297, DOI 10.1182/blood.V89.1.297.297_297_306; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Hemmeryckx B, 2001, CANCER RES, V61, P1398; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; Kardinal C, 2000, FASEB J, V14, P1529, DOI 10.1096/fj.14.11.1529; Kardinal C, 2001, BLOOD, V98, P1773, DOI 10.1182/blood.V98.6.1773; Kolibaba KS, 1999, LEUKEMIA LYMPHOMA, V33, P119, DOI 10.3109/10428199909093732; Li SG, 2001, EMBO J, V20, P6793, DOI 10.1093/emboj/20.23.6793; Li SG, 2001, BLOOD, V97, P1442, DOI 10.1182/blood.V97.5.1442; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; NICHOLS GL, 1994, BLOOD, V84, P2912; ODA T, 1994, J BIOL CHEM, V269, P22925; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Tari AM, 1997, BIOCHEM BIOPH RES CO, V235, P383, DOI 10.1006/bbrc.1997.6791; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Uemura N, 1997, LEUKEMIA, V11, P376, DOI 10.1038/sj.leu.2400590; Voncken JW, 1998, ONCOGENE, V16, P2029, DOI 10.1038/sj.onc.1201730; VONCKEN JW, 1992, BLOOD, V79, P1029; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; VONCKEN JW, 1992, CANCER RES, V52, P4534; Voss J, 2000, ONCOGENE, V19, P1684, DOI 10.1038/sj.onc.1203467; VOSS J, 2001, SIGNAL TRANSDUCTION, V1, P1	36	21	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2002	21	20					3225	3231		10.1038/sj.onc.1205452	http://dx.doi.org/10.1038/sj.onc.1205452			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082638				2022-12-17	WOS:000175373600014
J	Soldatenkov, VA; Trofimova, IN; Rouzaut, A; McDermott, F; Dritschilo, A; Notario, V				Soldatenkov, VA; Trofimova, IN; Rouzaut, A; McDermott, F; Dritschilo, A; Notario, V			Differential regulation of the response to DNA damage in Ewing's sarcoma cells by ETS1 and EWS/FLI-1	ONCOGENE			English	Article						antisense apoptosis; ETS transcription factors; poly(ADP-ribose) polymerase	GROWTH-FACTOR-BETA; ANTISENSE RAF OLIGODEOXYRIBONUCLEOTIDE; HUMAN-TUMOR CELLS; EWS GENE; FUSION PROTEINS; DOWN-REGULATION; II RECEPTOR; EWS-FLI1; FAMILY; TRANSCRIPTION	Ewing's sarcoma (EWS) cells contain levels of poly (ADP-ribose) polymerase (PARP) significantly higher than other eukaryotic cells. Previously, we cloned the PARP gene promoter region from EWS cells, showed that it contained multiple ETS-binding sites and demonstrated a positive regulation of PARP by ETS1. We now report that, contrary to ETS1, EWS/FLI-1, an aberrant ETS transcription factor present in most EWS cells, is a negative effector of PARP transcription. Because PARP levels have been associated with cellular resistance or sensitivity to genotoxic agents, we studied the effect of modifying PARP levels in EWS cells on their response to DNA damage by modulating the expression of ETS1 or EWS/FLI-1 using antisense methodology. Results show that stable down-regulation of ETS1 increases the resistance of EWS cells to various genotoxic agents, whereas down-regulation of EWS/FLI-1 has pro-apoptotic effects. Because down-regulation EWS/FLI-1 does not dramatically change PARP levels, these results suggest a direct effect for EWS/FLI-1 in the DNA damage response of EWS cells. Since expression of the aberrant fusion proteins by EWS cells is essential for maintaining their neoplastic phenotype, our results suggest that the use of antisense oligonuleotides in combination with chemotherapeutic agents or radiation may be doubly effective by causing both an increase in sensitivity to therapeutic agents and a simultaneous down-regulation, or reversion, of the neoplastic phenotype of EWS cells.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Radiat Med,Expt Carcinogenesis Lab, Washington, DC 20007 USA	Georgetown University	Notario, V (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Radiat Med,Expt Carcinogenesis Lab, Res Bldg,Room E215,3970 Reservoir Rd NW, Washington, DC 20007 USA.	notariov@georgetown.edu	Rouzaut, Ana/I-2576-2017; /AFP-0764-2022; /AAB-6461-2022	Rouzaut, Ana/0000-0003-3226-9162; 	NCI NIH HHS [CA64472, P01-CA74175, P30-CA51008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064472, P01CA074175, P30CA051008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; de Alava E, 2000, AM J PATHOL, V156, P849, DOI 10.1016/S0002-9440(10)64953-X; Dohjima T, 2000, BRIT J CANCER, V82, P16, DOI 10.1054/bjoc.1998.0870; Gokhale PC, 1999, ANTISENSE NUCLEIC A, V9, P191, DOI 10.1089/oli.1.1999.9.191; Gokhale PC, 1997, GENE THER, V4, P1289, DOI 10.1038/sj.gt.3300543; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Huang CC, 1997, ONCOGENE, V15, P851, DOI 10.1038/sj.onc.1201408; Im YH, 2000, CANCER RES, V60, P1536; KELLAND LR, 1988, INT J RADIAT ONCOL, V14, P1239, DOI 10.1016/0360-3016(88)90403-8; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; LEITH JT, 1988, RADIAT RES, V114, P186, DOI 10.2307/3577154; Lin PP, 1999, CANCER RES, V59, P1428; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; Matsumoto Y, 2001, BRIT J CANCER, V84, P768, DOI 10.1054/bjoc.2000.1652; Ohmori T, 1998, EXP CELL RES, V245, P350, DOI 10.1006/excr.1998.4261; OHNO T, 1994, ONCOGENE, V9, P3087; OUCHIDA M, 1995, ONCOGENE, V11, P1049; PLOUGASTEL B, 1993, GENOMICS, V18, P609, DOI 10.1016/S0888-7543(05)80363-5; PRASAD SC, 1990, CANCER RES, V50, P38; RAO VN, 1993, ONCOGENE, V8, P2167; Raynal S, 1997, INT J CANCER, V72, P356, DOI 10.1002/(SICI)1097-0215(19970717)72:2<356::AID-IJC26>3.0.CO;2-C; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Seth A, 1999, CELL DEATH DIFFER, V6, P902, DOI 10.1038/sj.cdd.4400567; Soldatenkov VA, 1999, CANCER RES, V59, P5085; Soldatenkov VA, 1999, ONCOGENE, V18, P3954, DOI 10.1038/sj.onc.1202778; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; SUZUKI H, 1995, P NATL ACAD SCI USA, V92, P4442, DOI 10.1073/pnas.92.10.4442; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; THRAVES PJ, 1986, INT J RADIAT BIOL, V50, P961, DOI 10.1080/09553008614551381; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Wei G, 2000, CANCER-AM CANCER SOC, V89, P793, DOI 10.1002/1097-0142(20000815)89:4<793::AID-CNCR11>3.0.CO;2-M; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	37	21	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2890	2895		10.1038/sj.onc.1205393	http://dx.doi.org/10.1038/sj.onc.1205393			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973649				2022-12-17	WOS:000175063700014
J	Hsiang, CH; Straus, DS				Hsiang, CH; Straus, DS			Cyclopentenone causes cell cycle arrest and represses cyclin D1 promoter activity in MCF-7 breast cancer cells	ONCOGENE			English	Article						MCF-7 breast cancer cells; cyclopentenone; cyclin D1; BTEB	GROWTH-FACTOR-I; NF-KAPPA-B; GENE-EXPRESSION; GENOMIC ORGANIZATION; PROSTAGLANDIN A(2); CARCINOMA CELLS; KINASE-ACTIVITY; SERUM-ALBUMIN; TRANSCRIPTION; PROTEIN	Evidence indicates that overexpression of cyclin D1 is an important event in malignant transformation of breast cancer cells. Therefore, cyclin D1 is a potential target for mechanistically-based chemoprevention/treatment of breast cancer. Treatment of serum-stimulated quiescent MCF-7 breast cancer cells with cyclopentenone (2-cyclopenten-1-one) blocked progression through G(1) and into S phase. Growth arrest of the cyclopentenone-treated cells in G(1) was associated with changes in the levels of several proteins that control the cell cycle, including a dramatic decrease in cyclin D1 protein expression. Cyclopentenone also decreased the abundance of cyclin D1 mRNA and nuclear transcripts, indicating that it regulated cyclin D1 expression at the transcriptional level. Cyclopentenone selectively inhibited the activity of the cyclin D1 and cyclin A promoters but not the activity of several other control promoters. Deletion analysis indicated that the cyclopentenone response element was located in the cyclin D1 core promoter. Additional functional studies showed that a sequence within the core promoter (CycY, located downstream from the initiator element) played an important role in activation of the cyclin D1 promoter in MCF-7 cells. Electrophoretic mobility shift assays demonstrated specific binding of the transcription factor BTEB to the CycY site. The cyclopentenone response element did not correspond to the CycY site but rather mapped to the initiator element itself The overall results suggest that cyclopentenone interferes with the transcription initiation complex that assembles over the cyclin D1 initiator element, leading to selective inhibition of cyclin D1 gene transcription.	Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA; Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	Straus, DS (corresponding author), Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA.	daniel.straus@ucr.edu						Alle KM, 1998, CLIN CANCER RES, V4, P847; BAKER RT, 1989, AM J HUM GENET, V44, P534; Barnes DM, 1997, J PATHOL, V181, P267, DOI 10.1002/(SICI)1096-9896(199703)181:3<267::AID-PATH783>3.0.CO;2-X; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Bui T, 1997, ENDOCRINOLOGY, V138, P985, DOI 10.1210/en.138.3.985; Bui T, 1998, BBA-GENE STRUCT EXPR, V1397, P31, DOI 10.1016/S0167-4781(97)00214-5; Chen AP, 1999, J BIOL CHEM, V274, P158, DOI 10.1074/jbc.274.1.158; Ciufolini MA, 1998, J ORG CHEM, V63, P1668, DOI 10.1021/jo972073f; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fukami-Kobayashi J, 1998, EXP CELL RES, V241, P435, DOI 10.1006/excr.1998.4079; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; Gillett CE, 1998, J PATHOL, V184, P396; Gorospe M, 1996, MOL CELL BIOL, V16, P762; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HAYDEN JM, 1994, ENDOCRINOLOGY, V134, P760, DOI 10.1210/en.134.2.760; HERBER B, 1994, ONCOGENE, V9, P1295; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hsiang CH, 1999, BIOCHEM J, V338, P241, DOI 10.1042/0264-6021:3380241; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; LAMMIE GA, 1991, ONCOGENE, V6, P439; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Lin SK, 2000, MOL CELL BIOL, V20, P7903, DOI 10.1128/MCB.20.21.7903-7913.2000; Lyss G, 1998, J BIOL CHEM, V273, P33508, DOI 10.1074/jbc.273.50.33508; Marten NW, 1999, BBA-GENE STRUCT EXPR, V1447, P160, DOI 10.1016/S0167-4781(99)00165-7; MARTEN NW, 1994, FASEB J, V8, P538, DOI 10.1096/fasebj.8.8.8181673; Martin KM, 2000, BIOCHEM J, V345, P529, DOI 10.1042/0264-6021:3450529; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; Nenoi M, 1996, GENE, V175, P179, DOI 10.1016/0378-1119(96)00145-X; Nielsen SJ, 1998, BIOCHEM J, V333, P511, DOI 10.1042/bj3330511; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; Rossi A, 1996, J BIOL CHEM, V271, P32192, DOI 10.1074/jbc.271.50.32192; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Simpson JF, 1997, AM J PATHOL, V151, P161; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Smale ST, 2001, GENE DEV, V15, P2503, DOI 10.1101/gad.937701; SMITH R, 1995, GENOMICS, V25, P85, DOI 10.1016/0888-7543(95)80112-Y; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006; STRAUS DS, 1993, ENDOCRINOLOGY, V132, P1090, DOI 10.1210/en.132.3.1090; STRAUS DS, 1994, J NUTR, V124, P1041, DOI 10.1093/jn/124.7.1041; Suh NJ, 1999, CANCER RES, V59, P336; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142	58	21	22	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2212	2226		10.1038/sj.onc.1205293	http://dx.doi.org/10.1038/sj.onc.1205293			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948404				2022-12-17	WOS:000174555300010
J	Chen, Q; Ash, JD; Branton, P; Fromm, L; Overbeek, PA				Chen, Q; Ash, JD; Branton, P; Fromm, L; Overbeek, PA			Inhibition of crystallin expression and induction of apoptosis by lens-specific E1A expression in transgenic mice	ONCOGENE			English	Article						E1A; CBP/p300; crystallin; apoptosis; transgenic mice	MOUSE LENS; CELL-CYCLE; RETINOBLASTOMA PROTEIN; DIFFERENTIATION; GENE; BINDING; CBP; P53; P300; TRANSACTIVATION	Previous studies have shown that the adenovirus E1A oncoprotein can bind to and inactivate the retinoblastoma tumor suppressor protein (pRb) and the transcriptional coactivators CBP/p300. In this study, wild-type E1A12S or two deletion mutants (delN. which binds pRb but not CBP/p300; delCR2. which binds to CBP/p300 but not pRb) were linked to the lens-specific alphaA-crystallin promoter, and used to generate transgenic mice. Lens fiber cells expressing E1A12S or delCR2, both of which bind to CBP/p300, failed to upregulate beta-crystallin and gamma-crystallin expression. In contrast, lens fiber cells expressing delN showed significant expression of beta- and gamma-crystallins. Lens fiber cells expressing delN showed cell cycle entry, marked apoptosis, and evidence for p53 activation, while cells expressing either E1A12S or delCR2 showed limited apoptosis and no evidence for upregulation of the p53-inducible gene p21. Our results suggest that the transcriptional coactivators CBP and/or p300 are required for the dramatic increases in crystallin expression that accompany terminal differentiation in the lens, and also for activation of p53 in response to inactivation of pRb in the lens.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; NYU, Sch Med, Skirball Inst, New York, NY 10012 USA	Baylor College of Medicine; McGill University; New York University	Overbeek, PA (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.			Overbeek, Paul/0000-0001-9784-2084; Ash, John/0000-0002-8330-7301	NEI NIH HHS [EY-11348, EY-06708, EY-10803, EY-10448] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010803, R01EY011348, R01EY010448, F32EY006708] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BARBEAU D, 1994, ONCOGENE, V9, P359; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fromm L, 1996, ONCOGENE, V12, P69; FROMM L, 1994, MOL CELL BIOL, V14, P6743, DOI 10.1128/MCB.14.10.6743; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; JONES N, 1995, CURR TOP MICROBIOL, V199, P59; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; MCAVOY JW, 1978, J EMBRYOL EXP MORPH, V44, P149; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; Nishiguchi S, 1998, GENE DEV, V12, P776, DOI 10.1101/gad.12.6.776; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; Reynaud EG, 1999, MOL CELL BIOL, V19, P7621; Ring BZ, 2000, DEVELOPMENT, V127, P307; Robinson ML, 1996, INVEST OPHTH VIS SCI, V37, P2276; ROBINSON ML, 1995, DEVELOPMENT, V121, P505; Smith ML, 1997, EXP CELL RES, V230, P61, DOI 10.1006/excr.1996.3402; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; TRETON JA, 1991, DIFFERENTIATION, V47, P143, DOI 10.1111/j.1432-0436.1991.tb00232.x; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; Wigle JT, 1999, NAT GENET, V21, P318, DOI 10.1038/6844; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162	31	21	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					1028	1037		10.1038/sj.onc.1205050	http://dx.doi.org/10.1038/sj.onc.1205050			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850820				2022-12-17	WOS:000173580100006
J	Gao, YN; Lu, YJ; Xue, SA; Chen, HL; Wedderburn, N; Griffin, BE				Gao, YN; Lu, YJ; Xue, SA; Chen, HL; Wedderburn, N; Griffin, BE			Hypothesis: a novel route for immortalization of epithelial cells by Epstein-Barr virus	ONCOGENE			English	Article						'hit and run'; gene amplification; telomeres; chromosomal instability; double minute chromosomes (DMs)	DOUBLE-MINUTE CHROMOSOMES; HUMAN B-LYMPHOCYTES; NASOPHARYNGEAL CARCINOMA; RUN ONCOGENESIS; COMMON MARMOSET; GENE-EXPRESSION; KILOBASE PAIRS; SIMPLEX VIRUS; DNA-SEQUENCE; BAMHI-A	Transfection of primate tissue explants with a specific sub-fragment (p31) of EBV DNA results in epithelial (but no other) cells proliferating indefinitely (becoming 'immortalized') without evidence of a 'growth crisis'. Molecular evidence supports integration of viral information into the host chromosome, and an early genotypic alteration involving specific amplification of a subcomponent (IR1) of p31 DNA, followed by apparent loss of viral DNA from chromosomes, consistent with a 'hit and run' mechanism. However, analysis at the individual cell level during long-term culture, by FISH techniques, reveals chromosomal alferations, and viral sequences surviving within double minute (DM) bodies. Changing growth patterns occurring at different stages during propagation (>a year in culture) may be explained by sporadic reintegration of surviving viral DNA into the host chromosome. Notably, throughout culture, telomere lengths in chromosomal DNAs do not alter but rather retain the length observed in the primary cell populations. Introduction of a growth stimulating function of EBV, BARF1, into the immortalized, nonclonable epithelial cells under conditions which permit overexpression, allows clonal populations to be derived. Based on the data, mechanisms of immortalization, in the absence of a proven viral oncogene in p31 DNA, and possible genes involved, are considered.	Univ London Imperial Coll Sci Technol & Med, Dept Med, Viral Oncol Unit, London W2 1PG, England; Inst Canc Res, Sect Cell Biol & Expt Pathol, Sutton SM2 5NG, Surrey, England; Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China	Imperial College London; University of London; Institute of Cancer Research - UK; University of Hong Kong	Griffin, BE (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Med, Viral Oncol Unit, Norfolk Pl, London W2 1PG, England.	b.griffin@ic.ac.uk	Xue, Shao-An/A-2735-2011; Chen, Honglin/C-4224-2009	Chen, Honglin/0000-0001-5108-8338; Lu, Yong-Jie/0000-0001-6174-6621				Ambinder RF, 2000, AM J PATHOL, V156, P1, DOI 10.1016/S0002-9440(10)64697-4; Antunes SG, 1998, P NATL ACAD SCI USA, V95, P11745, DOI 10.1073/pnas.95.20.11745; ARRAND JR, 1981, NUCLEIC ACIDS RES, V9, P2999, DOI 10.1093/nar/9.13.2999; ARRAND JR, 1983, EMBO J, V2, P1673, DOI 10.1002/j.1460-2075.1983.tb01642.x; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAR AI, 1992, GENE CHROMOSOME CANC, V4, P314; BAUER G, 1992, INT J CANCER, V51, P754, DOI 10.1002/ijc.2910510515; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Brink AATP, 1998, J CLIN MICROBIOL, V36, P3164, DOI 10.1128/JCM.36.11.3164-3169.1998; BROERS JLV, 1986, J CELL SCI, V83, P37; CHEN HL, 1992, VIROLOGY, V191, P193, DOI 10.1016/0042-6822(92)90181-N; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; Cox C, 1996, J GEN VIROL, V77, P1173, DOI 10.1099/0022-1317-77-6-1173; Delecluse HJ, 1997, J PATHOL, V182, P475; EIJWUNMI AB, 1987, THESIS U OXFORD UK; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; Farrell PJ, 1997, J GEN VIROL, V78, P1417, DOI 10.1099/0022-1317-78-6-1417; Freshney R.I., 2016, CULTURE ANIMAL CELLS; FRESHNEY RI, 1996, CULTURE IMMORTALIZED; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FURUYA T, 1993, CANCER GENET CYTOGEN, V70, P132, DOI 10.1016/0165-4608(93)90183-M; GALLOWAY DA, 1983, NATURE, V302, P21, DOI 10.1038/302021a0; GALLOWAY DA, 1990, J MED VIROL, V31, P36, DOI 10.1002/jmv.1890310108; GELB L, 1984, J INVEST DERMATOL, V83, pS77, DOI 10.1111/1523-1747.ep12281388; GRIFFIN BE, 1984, NATURE, V309, P78, DOI 10.1038/309078a0; HAHN PJ, 1993, BIOESSAYS, V15, P477, DOI 10.1002/bies.950150707; Harris A., 1996, EPITHELIAL CELL CULT; Hayes DP, 1999, J CLIN PATHOL-MOL PA, V52, P97, DOI 10.1136/mp.52.2.97; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HITT MM, 1989, EMBO J, V8, P2639, DOI 10.1002/j.1460-2075.1989.tb08404.x; IWASAKA T, 1992, ACTA OBSTET GYN SCAN, V71, P219, DOI 10.3109/00016349209009922; JOX A, 1997, AM J PATHOL, V151, P1387; KARRAN L, 1990, INT J CANCER, V45, P763, DOI 10.1002/ijc.2910450432; KEMPKES B, 1995, J VIROL, V69, P231, DOI 10.1128/JVI.69.1.231-238.1995; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; LIN CT, 1993, LAB INVEST, V68, P716; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nakamura TM, 1998, SCIENCE, V282, P493, DOI 10.1126/science.282.5388.493; NIELSEN JL, 1993, CANCER GENET CYTOGEN, V65, P120, DOI 10.1016/0165-4608(93)90219-C; NOWELL P, 1983, NATURE, V306, P494, DOI 10.1038/306494a0; Rao PH, 1998, CANCER GENET CYTOGEN, V105, P160, DOI 10.1016/S0165-4608(98)00013-2; ROBERTSON E, 1995, J VIROL, V69, P983, DOI 10.1128/JVI.69.2.983-993.1995; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Russo I, 1998, ONCOGENE, V17, P3417, DOI 10.1038/sj.onc.1202261; Sambrook J., 1989, MOL CLONING LABORATO, V2, P916; Sedivy JM, 1998, P NATL ACAD SCI USA, V95, P9078, DOI 10.1073/pnas.95.16.9078; Shen YQ, 1997, P NATL ACAD SCI USA, V94, P3341, DOI 10.1073/pnas.94.7.3341; SKINNER GRB, 1976, BRIT J EXP PATHOL, V57, P361; SMITH KT, 1988, VIROLOGY, V164, P39, DOI 10.1016/0042-6822(88)90617-4; SMITH KT, 1993, ONCOGENE, V8, P151; Smith PR, 2000, J VIROL, V74, P3082, DOI 10.1128/JVI.74.7.3082-3092.2000; SMITH PR, 1993, J VIROL, V67, P3217, DOI 10.1128/JVI.67.6.3217-3225.1993; Srinivas SK, 1998, J INFECT DIS, V177, P1705, DOI 10.1086/517427; Steinberg Mark L., 1996, P95; Strockbine LD, 1998, J VIROL, V72, P4015, DOI 10.1128/JVI.72.5.4015-4021.1998; TRASK BJ, 1991, METHOD CELL BIOL, V35, P3; VANDERBLIEK AM, 1988, NUCLEIC ACIDS RES, V16, P4841, DOI 10.1093/nar/16.11.4841; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WEI MX, 1989, EMBO J, V8, P2897, DOI 10.1002/j.1460-2075.1989.tb08438.x; Wei MX, 1997, ONCOGENE, V14, P3073, DOI 10.1038/sj.onc.1201128; WEI MX, 1994, CANCER RES, V54, P1843; WOLF J, 1995, VIROLOGY, V212, P179, DOI 10.1006/viro.1995.1466; Xue SA, 2000, J VIROL, V74, P2793, DOI 10.1128/JVI.74.6.2793-2803.2000; YAO K, 1990, INT J CANCER, V45, P83, DOI 10.1002/ijc.2910450116; ZHANG CX, 1988, J VIROL, V62, P1862, DOI 10.1128/JVI.62.6.1862-1869.1988; Zhang JX, 1998, J MED VIROL, V55, P227, DOI 10.1002/(SICI)1096-9071(199807)55:3<227::AID-JMV8>3.0.CO;2-3	68	21	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2002	21	5					825	835		10.1038/sj.onc.1205130	http://dx.doi.org/10.1038/sj.onc.1205130			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850810				2022-12-17	WOS:000173427000013
J	Santilli, G; Cervellera, MN; Johnson, TK; Lewis, RE; Iacobelli, S; Sala, A				Santilli, G; Cervellera, MN; Johnson, TK; Lewis, RE; Iacobelli, S; Sala, A			PARP co-activates B-MYB through enhanced phosphorylation at cyclin/cdk2 sites	ONCOGENE			English	Article						cell cycle; transformation; transcription; promoter	CELL-CYCLE REGULATION; POLY(ADP-RIBOSE) POLYMERASE; DNA-BINDING; IN-VIVO; S-PHASE; EXPRESSION; TRANSCRIPTION; PROTEIN; PROLIFERATION; TRANSACTIVATION	PARP is a multifunctional protein that can affect genome stability, transcription control, telomere length and cell death. Recently we have reported that PARP binds to and enhances B-MYB transactivating potential. B-MYB is a potentially oncogenic transcription factor involved in mammalian cell proliferation, survival and differentiation. B-MYB gene expression is growth regulated and B-MYB protein is phosphorylated during S phase by cyclin A or E/cdk2 kinase, resulting in augmented transactivating potential. Here we show that PARP induces phosphorylation of B-MVB protein at cdk2 phosphorylation sites, since a B-MYB protein with mutated cdk2 phosphorylation sites is refractory to PARP-induced phosphorylation and co-activation in mammalian cells. We propose that PARP functions as a B-MYB co-factor by promoting cyclin/cdk2-dependent B-MYB phosphorylation. These results highlight a novel role for PARP as a factor that integrates cyclin-dependent kinases signaling with gene transcription.	Inst Child Hlth, Mol Haematol & Canc Biol Unit, London WC1N, England; Univ G DAnnunzio, Dept Oncol & Neurosci, Sect Med Oncol, I-66100 Chieti, Italy; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	G d'Annunzio University of Chieti-Pescara; University of Nebraska System; University of Nebraska Medical Center	Sala, A (corresponding author), Inst Child Hlth, Mol Haematol & Canc Biol Unit, 30 Guilford St, London WC1N, England.		Lewis, Robert E./H-3404-2019; sala, arturo/C-4959-2008	Sala, Arturo/0000-0002-2841-7866				Ansieau S, 1997, J MOL MED-JMM, V75, P815, DOI 10.1007/s001090050170; ARSURA M, 1992, BLOOD, V79, P2708; Cervellera M, 2000, J BIOL CHEM, V275, P21055, DOI 10.1074/jbc.M002055200; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Johnson TK, 1999, J BIOL CHEM, V274, P36741, DOI 10.1074/jbc.274.51.36741; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; Kim T, 1999, FEBS LETT, V460, P363, DOI 10.1016/S0014-5793(99)01375-7; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Menegazzi M, 1999, MOL CARCINOGEN, V25, P256, DOI 10.1002/(SICI)1098-2744(199908)25:4<256::AID-MC4>3.0.CO;2-W; Miyamoto T, 1999, MOL CELL BIOL, V19, P2644; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Plaza S, 1999, ONCOGENE, V18, P1041, DOI 10.1038/sj.onc.1202406; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; Raschella G, 1999, CANCER RES, V59, P3365; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; Robinson C, 1996, ONCOGENE, V12, P1855; Sala A, 1999, ONCOGENE, V18, P1333, DOI 10.1038/sj.onc.1202421; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1999, J CELL PHYSIOL, V179, P245; Saville MK, 1998, ADV CANCER RES, V72, P109; Simbulan-Rosenthal CM, 2000, P NATL ACAD SCI USA, V97, P11274, DOI 10.1073/pnas.200285797; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; Soldatenkov VA, 1999, ONCOGENE, V18, P3954, DOI 10.1038/sj.onc.1202778; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	36	21	21	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2001	20	57					8167	8174		10.1038/sj.onc.1204943	http://dx.doi.org/10.1038/sj.onc.1204943			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	498KC	11781832				2022-12-17	WOS:000172507800001
J	Wang, Y; Hu, L; Yao, RS; Wang, M; Crist, KA; Grubbs, CJ; Johanning, GL; Lubet, RA; You, M				Wang, Y; Hu, L; Yao, RS; Wang, M; Crist, KA; Grubbs, CJ; Johanning, GL; Lubet, RA; You, M			Altered gene expression profile in chemically induced rat mammary adenocarcinomas and its modulation by an aromatase inhibitor	ONCOGENE			English	Article						rat; mammary; adenocarcinoma; gene expression; competitive cDNA library screening; vorozole; chemoprevention	CYCLIN D1; BREAST-CARCINOMA; DNA MICROARRAY; CANCER; MODELS; CELLS; DIFFERENTIATION; CLASSIFICATION; TRANSFORMATION; MASPIN	In the present study, competitive cDNA library screening (CCLS) and cDNA microarray analyses were employed to identify differentially expressed genes in methylnitrosourea-induced rat mammary adenocarcinomas. The preliminary screening of 100 000 plaques by CCLS identified 1217 clones with differential expression. Dot-blot analysis of the isolated clones verified differential expression in 471 distinct genes. Confirmation of these 471 genes was conducted by performing reverse transcription-polymerase chain reactions, and a total of 160 genes were confirmed after comparing six rat mammary adenocarcinomas and three normal rat mammary glands. Fifty-nine of these showed lower expression in the adenocarcinomas while the remaining 101 were overexpressed in the tumors. Employing a cDNA microarray containing 588 known genes revealed an additional 33 differentially expressed genes in these tumors. Importantly, most of the identified genes demonstrated relatively reproducible overexpression or underexpression in individual tumors. Many of the altered genes determined by cDNA microarray analysis were oncogenes, tumor suppressor genes, or genes involved in cell cycle control and apoptosis. CCLS identified many others not previously associated with mammary carcinogenesis, including a novel gene named RMT-7. Preliminary studies to determine the applicability of this gene expression approach for detecting potential biomarkers for cancer chemoprevention was evaluated in rat mammary tumors obtained from animals treated with vorozole, a potent aromatase inhibitor. When genes exhibiting differential expression as determined by CCLS or cDNA microarray analysis were examined in control and vorozole-treated tumors, expression of 19 genes was found to be modulated significantly in tumors treated with vorozole. Further investigations into these identified genes should contribute significantly to our understanding of the molecular mechanisms of rat mammary tumorigenesis. In addition, the identified genes may become useful targets for drug development and potential biomarkers for monitoring treatment and prevention of breast cancer in humans.	Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Sch Publ Hlth, Columbus, OH 43210 USA; Med Coll Ohio, Toledo, OH 43614 USA; Ohio State Univ, Div Human Canc Genet, Ctr Comprehens Canc, Columbus, OH 43210 USA; Univ Alabama Birmingham, Chemoprevent Ctr, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA; NCI, Chemoprevent Branch, Bethesda, MD 20892 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	You, M (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Sch Publ Hlth, Columbus, OH 43210 USA.		Johanning, Gary L/A-9671-2008		NCI NIH HHS [CN05113, CA58554, CA16058, CA78797] Funding Source: Medline; DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005113] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R29CA058554, R01CA078797, P30CA016058, R01CA058554] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; Burk RF, 1997, HISTOCHEM CELL BIOL, V108, P11, DOI 10.1007/s004180050141; Chen H, 2001, MOL CARCINOGEN, V30, P79, DOI 10.1002/1098-2744(200102)30:2<79::AID-MC1016>3.0.CO;2-F; Christov K, 2000, BREAST CANCER RES TR, V60, P117, DOI 10.1023/A:1006384026252; COLE PA, 1990, J MED CHEM, V33, P2933, DOI 10.1021/jm00173a001; DECOSTER R, 1992, CANCER RES, V52, P1240; DEVILEE P, 1994, CRIT REV ONCOGENESIS, V5, P247, DOI 10.1615/CritRevOncog.v5.i2-3.70; Dukes M, 1997, ONCOLOGY, V54, P6; EASTON DF, 1993, AM J HUM GENET, V52, P678; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; FILMUS J, 1994, ONCOGENE, V9, P3627; Gilles C, 1997, CLIN EXP METASTAS, V15, P519, DOI 10.1023/A:1018427027270; GOULD MN, 1995, SEMIN CANCER BIOL, V6, P147, DOI 10.1006/scbi.1995.0023; GRUBBS CJ, 1974, EUR J CANCER, V10, P707, DOI 10.1016/0014-2964(74)90108-X; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hu L, 1997, J CELL BIOCHEM, P117; HU L, 1997, J CELL BIOCHEM, P28; Kelly DL, 2000, MOL REPROD DEV, V56, P113, DOI 10.1002/(SICI)1098-2795(200006)56:2&lt;113::AID-MRD1&gt;3.0.CO;2-Q; Koga M, 1998, BIOL REPROD, V58, P261, DOI 10.1095/biolreprod58.1.261; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Lubet RA, 1998, CARCINOGENESIS, V19, P1345, DOI 10.1093/carcin/19.8.1345; LUBET RA, 1994, CARCINOGENESIS, V15, P2775, DOI 10.1093/carcin/15.12.2775; Maass N, 2000, ACTA ONCOL, V39, P931; MARTIKAINEN H, 1992, FERTIL STERIL, V58, P543; Martin K, 2000, CANCER RES, V60, P2232; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Nacht M, 1999, CANCER RES, V59, P5464; Popovici RM, 2000, ENDOCRINOLOGY, V141, P3510, DOI 10.1210/en.141.9.3510; RAMACHANDRA S, 1990, J PATHOL, V161, P7, DOI 10.1002/path.1711610104; Russo J, 1996, BREAST CANCER RES TR, V39, P7, DOI 10.1007/BF01806074; Russo J, 2000, J MAMMARY GLAND BIOL, V5, P187, DOI 10.1023/A:1026443305758; Sager R, 1996, CURR TOP MICROBIOL, V213, P51; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; Sallinen SL, 2000, CANCER RES, V60, P6617; Schedin P, 2000, J MAMMARY GLAND BIOL, V5, P211, DOI 10.1023/A:1026447506666; Schultz Linda B., 1999, Current Opinion in Oncology, V11, P429, DOI 10.1097/00001622-199911000-00002; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STEELE VE, 1994, J CELL BIOCHEM, P32; SUIKKARI AM, 1991, FERTIL STERIL, V55, P895; Thompson HJ, 2000, J MAMMARY GLAND BIOL, V5, P201, DOI 10.1023/A:1026495322596; VANDEVIJVER MJ, 1991, BIOCHIM BIOPHYS ACTA, V1072, P33, DOI 10.1016/0304-419X(91)90005-6; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WOUTERS W, 1990, J STEROID BIOCHEM, V37, P1049, DOI 10.1016/0960-0760(90)90464-V; YAMASHITA H, 1993, JPN J CANCER RES, V84, P871, DOI 10.1111/j.1349-7006.1993.tb02060.x	46	21	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2001	20	53					7710	7721		10.1038/sj.onc.1204941	http://dx.doi.org/10.1038/sj.onc.1204941			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE	11753649				2022-12-17	WOS:000172161700002
J	Yu, JJ; Thornton, K; Guo, Y; Kotz, H; Reed, E				Yu, JJ; Thornton, K; Guo, Y; Kotz, H; Reed, E			An ERCC1 splicing variant involving the 5 '-UTR of the mRNA may have a transcriptional modulatory function	ONCOGENE			English	Article						ERCC1; nucleotide excision repair; ovarian cancer; transcriptional factor	NUCLEOTIDE EXCISION-REPAIR; OVARIAN-CANCER CELLS; MESSENGER-RNA LEVELS; CISPLATIN; CHEMOTHERAPY; EXPRESSION; ACID	Human ovarian cancer cells and tissues were examined for the presence or absence of a 42-bp splicing variant of ERCC1 gene, and for a possible functional role of this 42-bp sequence. This specific sequence exists in exon I, the 5'-UTR of the gene. Loss of this 42-bp sequence was associated with increased ERCC1 mRNA expression, in an assessment of 121 ovarian cancer specimens (p2 < 10(-6)). In cells in tissue culture, the absence of the 42-bp segment was associated with a twofold increased ability to drive transcription in a Luciferase reporter system. Protein can be demonstrated in ovarian cancer cells based on EMSA analysis. Computer analysis shows that this 42-bp sequence contains several binding sites, including a core-binding domain for protein RFX1, transcriptional repressor. These preliminary results lay the groundwork in determination of potential roles for a negative regulatory element in NER repair pathway.	W Virginia Univ, Mary Babb Randolph Canc Ctr, Robert C Byrd Hlth Sci Ctr, Morgantown, WV 26506 USA	West Virginia University	Reed, E (corresponding author), W Virginia Univ, Mary Babb Randolph Canc Ctr, Robert C Byrd Hlth Sci Ctr, 1801 Hlth Sci S,POB 9300, Morgantown, WV 26506 USA.	ereed@hsc.wvu.edu						BEHRENS BC, 1987, CANCER RES, V47, P414; BONOVICH M, 2000, P AM ASSOC CANC RES, V41, P399; DABHOLKAR M, 1994, J CLIN INVEST, V94, P703, DOI 10.1172/JCI117388; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Li QD, 1998, J BIOL CHEM, V273, P23419, DOI 10.1074/jbc.273.36.23419; Metzger R, 1998, J CLIN ONCOL, V16, P309, DOI 10.1200/JCO.1998.16.1.309; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; PALMITER RD, 1974, BIOCHEMISTRY-US, V13, P3606, DOI 10.1021/bi00714a032; PARKER RJ, 1991, J CLIN INVEST, V87, P772, DOI 10.1172/JCI115080; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Reed E, 1998, CANCER TREAT REV, V24, P331, DOI 10.1016/S0305-7372(98)90056-1; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; VANVUUREN AJ, 1995, MUTAT RES-DNA REPAIR, V337, P25, DOI 10.1016/0921-8777(95)00009-9; Yang LY, 2000, CLIN CANCER RES, V6, P773	15	21	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2001	20	52					7694	7698		10.1038/sj.onc.1204977	http://dx.doi.org/10.1038/sj.onc.1204977			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	491TC	11753647				2022-12-17	WOS:000172124100012
J	Bieche, I; Parfait, B; Nogues, C; Andrieu, C; Vidaud, D; Spyratos, F; Lidereau, R; Vidaud, M				Bieche, I; Parfait, B; Nogues, C; Andrieu, C; Vidaud, D; Spyratos, F; Lidereau, R; Vidaud, M			The CGA gene as new predictor of the response to endocrine therapy in ER alpha-positive postmenopausal breast cancer patients	ONCOGENE			English	Article						postmenopausal breast cancer; CGA; real-time RT-PCR quantification; endocrine therapy	OVEREXPRESSION; TAMOXIFEN	We recently identified CGA (coding for the alpha subunit of glycoprotein hormones) as a new estrogen receptor alpha (ER alpha)-responsive gene in human breast tumors. Here, we assessed the relationship between CGA status (as determined by real-time quantitative RT-PCR) and the response to tamoxifen therapy in a well-defined cohort of 125 ER alpha -positive postmenopausal breast cancer patients treated with primary surgery followed by adjuvant tamoxifen alone. CGA overexpression, observed in 37.6% of patients, was associated with good relapse-free survival (P=0.037; univariate analysis). CGA status, combined with ERBB2 status (a marker of poor outcome), was an independent predictor of the response to tamoxifen (P=0.020; multivariate analysis). CGA status, especially when combined with ERBB2 status, may thus provide useful predictive information on tamoxifen responsiveness in breast cancer.	Univ Paris 05, Fac Sci Pharmaceut & Biol, Genet Mol Lab, UPRES JE 2195, F-75006 Paris, France; Ctr Rene Huguenin, Lab Oncobiol, F-92211 St Cloud, France; INSERM, E0017, Lab Oncogenet, F-75654 Paris, France	UDICE-French Research Universities; Universite Paris Cite; Rene Huguenin Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm)	Vidaud, M (corresponding author), Univ Paris 05, Fac Sci Pharmaceut & Biol, Genet Mol Lab, UPRES JE 2195, 4 Ave Observ, F-75006 Paris, France.		Bièche, Ivan/O-7399-2017; PARFAIT, Beatrice/O-7392-2017; VIDAUD, Dominique/O-7357-2017; Vidaud, Michel/O-7346-2017	Bièche, Ivan/0000-0002-2430-5429; 				Bieche I, 2001, CANCER RES, V61, P1652; Bieche I, 1999, CLIN CHEM, V45, P1148; BORG A, 1994, CANCER LETT, V81, P137, DOI 10.1016/0304-3835(94)90194-5; Carlomagno C, 1996, J CLIN ONCOL, V14, P2702, DOI 10.1200/JCO.1996.14.10.2702; COX DR, 1972, J R STAT SOC B, V34, P187; Diab SG, 2000, J NATL CANCER I, V92, P550, DOI 10.1093/jnci/92.7.550; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; McGuire W L, 1980, Recent Prog Horm Res, V36, P135; Sjogren S, 1998, J CLIN ONCOL, V16, P462; TETU B, 1994, CANCER, V73, P2359, DOI 10.1002/1097-0142(19940501)73:9<2359::AID-CNCR2820730919>3.0.CO;2-9	10	21	23	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6955	6959		10.1038/sj.onc.1204739	http://dx.doi.org/10.1038/sj.onc.1204739			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687975				2022-12-17	WOS:000171641000017
J	Jennings, R; Alsarraj, M; Wright, KL; Munoz-Antonia, T				Jennings, R; Alsarraj, M; Wright, KL; Munoz-Antonia, T			Regulation of the human transforming growth factor beta type II receptor gene promoter by novel Sp1 sites	ONCOGENE			English	Article						transforming growth factor-beta (TGF beta); TGF beta receptors; promoter; Sp1 transcription factor	THYMIDINE KINASE PROMOTER; NF-Y; TRANSCRIPTION FACTORS; CARCINOMA-CELLS; REPRESS TRANSCRIPTION; TUMOR-SUPPRESSOR; SMAD PATHWAY; MCF-7 CELLS; EXPRESSION; BINDING	The transforming growth factor-beta (TGF beta) type II receptor (T betaR-II) is responsible for transducing the growth inhibitory signals of TGF beta. The T betaR-II gene promoter lacks both a TATA box and a CAAT box near the transcription initiation site, and has been shown to contain binding sequences for several transcription factors (Sp1, AP1, NF-Y, Cut and ERT) which are important for T betaR-II gene promoter activity in vitro. However, it is still not clear which interactions are important for the regulation of T betaR-II gene promoter activity in vivo. Using in viro genomic DNA footprinting of normal human epithelial cells (HaCaT), we have identified two novel identical and strongly protected sites (ggggctgg) at positions -59 and - 102 of the T betaR-II gene promoter. Mutation of either site significantly reduced promoter activity in transient transfections. Protein binding to these sites, as determined by electrophoretic mobility shift assays (EMSA), was specifically competed with consensus Sp1 oligonucleotides. Furthermore, anti-Sp1/3 antibodies produced band shifts when incubated with the T betaR-II - 59 and - 102 DNA probes. Importantly, Sp1 protein binding was influenced by the presence of an intact NF-Y binding site at position -83. Our data suggests that both Sp1 and NF-Y may play an important role in regulating T betaR-II gene promoter basal activity in vivo.	Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Biochem & Mol Biol, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Biochem & Mol Biol, Program Immunol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol, Program Immunol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Munoz-Antonia, T (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.							Ammanamanchi S, 1998, J BIOL CHEM, V273, P16527, DOI 10.1074/jbc.273.26.16527; Ammanamanchi S, 2001, J BIOL CHEM, V276, P3348, DOI 10.1074/jbc.M002462200; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; Baker JC, 1997, CURR OPIN GENET DEV, V7, P467, DOI 10.1016/S0959-437X(97)80072-X; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3982; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; HUMPHRIES DE, 1994, BIOCHEM BIOPH RES CO, V203, P1020, DOI 10.1006/bbrc.1994.2284; Jackson RJ, 1999, ARCH BIOCHEM BIOPHYS, V371, P290, DOI 10.1006/abbi.1999.1459; Ji CH, 1996, J CELL BIOCHEM, V63, P478; Kelly D, 1998, J BIOL CHEM, V273, P21115, DOI 10.1074/jbc.273.33.21115; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu Y, 2000, J BIOL CHEM, V275, P12231, DOI 10.1074/jbc.275.16.12231; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; MunozAntonia T, 1996, CANCER RES, V56, P4831; Periyasamy S, 2000, ONCOGENE, V19, P4660, DOI 10.1038/sj.onc.1203822; Roder K, 1999, GENE, V234, P61, DOI 10.1016/S0378-1119(99)00180-8; Roder K, 1997, J BIOL CHEM, V272, P21616, DOI 10.1074/jbc.272.34.21616; Rotheneder H, 1999, J MOL BIOL, V293, P1005, DOI 10.1006/jmbi.1999.3213; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sorensen P, 1999, J BIOL CHEM, V274, P30943, DOI 10.1074/jbc.274.43.30943; Sowa Y, 1999, ANN NY ACAD SCI, V886, P195, DOI 10.1111/j.1749-6632.1999.tb09415.x; Steffen ML, 1999, BIOCHEM J, V340, P425, DOI 10.1042/0264-6021:3400425; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978	39	21	25	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6899	6909		10.1038/sj.onc.1204808	http://dx.doi.org/10.1038/sj.onc.1204808			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687969	Green Published, Green Submitted			2022-12-17	WOS:000171641000011
J	Plo, I; Lautier, D; Casteran, N; Dubreuil, P; Arock, M; Laurent, G				Plo, I; Lautier, D; Casteran, N; Dubreuil, P; Arock, M; Laurent, G			Kit signaling and negative regulation of daunorubicin-induced apoptosis: role of phospholipase C gamma	ONCOGENE			English	Article						c-Kit; daunorubicin; apoptosis; PKC; PLC gamma; ceramide	PROTEIN-KINASE-C; STEM-CELL FACTOR; CERAMIDE-INDUCED APOPTOSIS; MYELOID-LEUKEMIA CELLS; GROWTH-FACTOR; NEUTRAL SPHINGOMYELINASE; TRANSDUCTION PATHWAY; ACTIVATION; EXPRESSION; LIGAND	Previous studies have demonstrated that activation of Kit by stem cell factor (SCF), its natural ligand, or by gain-of-function point mutation in its intracellular domain, confers significant protection against apoptosis induced by growth factor deprivation or radiation. However, the effects of Kit activation on the cellular response to antitumor agents have not been so extensively documented. This study shows that daunorubicin-induced apoptosis and cytotoxicity were reduced in the murine Ba/F3 cells transfected with Kit (Ba/F3-Kit) in the presence of SCF and in Ba/F3 cells transfected with a constitutively active Kit variant (Ba/F3-Kit Delta 27), compared to either parental Ba/F3 (Ba/F3-wt) or unstimulated Ba/F3-Kit cells. In Ba/F3-wt and in Ba/F3-Kit cells, daunorubicin stimulated within 8-15 min neutral sphingomyelinase and ceramide production but not in SCF-stimulated Ba/F3-Kit or in Ba/F3-Kit Delta 27 whereas all Ba/F3 cells were equally sensitive to exogenous cell-permeant C6-ceramide. In Ba/F3-Kit, SCF-induced Kit activation resulted in a rapid phospholipase C gamma (PLC gamma) tyrosine phosphorylation followed by diacylglycerol release and protein kinase C (PKC) stimulation. U-73122, a PLC gamma inhibitor, not only blocked diacylglycerol production and PKC stimulation but also restored daunorubicin-induced sphingomyelinase stimulation, ceramide production, and apoptosis. These results suggest that Kit activation results in PLC gamma -mediated PKC-dependent sphingomyelinase inhibition which contributes to drug resistance in Kit-related malignancies.	INSERM, Inst Claudius Regaud, E9910, F-31052 Toulouse, France; Inst Natl St & Rech Med, Lab Cancerol Expt, F-13009 Marseille, France; Lab Hematol Cellulaire & Mol, UPRES, EA2509, Fac Pharm, F-75006 Paris, France; Ctr Hosp Univ Purpan, Serv Hematol, F-31059 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Plo, I (corresponding author), INSERM, Inst Claudius Regaud, E9910, 20,Rue Pont St Pierre, F-31052 Toulouse, France.	plo@icr.fnclcc.fn	dubreuil, patrice/F-5346-2011; Lautier, Dominique/G-3959-2017; Plo, Isabelle/AAT-6742-2021; Dubreuil, Patrice/V-4816-2019; Plo, Isabelle/C-9056-2017	dubreuil, patrice/0000-0003-1155-1150; Dubreuil, Patrice/0000-0003-1155-1150; Plo, Isabelle/0000-0002-5915-6910				Allouche M, 2000, BLOOD, V96, P1187, DOI 10.1182/blood.V96.3.1187.015k01_1187_1190; Allouche M, 1997, ONCOGENE, V14, P1837, DOI 10.1038/sj.onc.1201023; ASHMAN LK, 1988, LEUKEMIA RES, V12, P923, DOI 10.1016/0145-2126(88)90020-3; Bettaieb A, 1999, MOL PHARMACOL, V55, P118, DOI 10.1124/mol.55.1.118; BLEASDALE JE, 1989, ADV PROSTAG THROMB L, V19, P590; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; BLUMEJENSEN P, 1994, J BIOL CHEM, V269, P21793; Bruno AP, 1998, CELL DEATH DIFFER, V5, P172, DOI 10.1038/sj.cdd.4400330; Burow ME, 2000, J BIOL CHEM, V275, P9628, DOI 10.1074/jbc.275.13.9628; CARSON WE, 1994, P NATL ACAD SCI USA, V91, P7553, DOI 10.1073/pnas.91.16.7553; Caruana G, 1999, ONCOGENE, V18, P5573, DOI 10.1038/sj.onc.1202939; CHABNER BA, 1989, CANCER PRINCIPLES PR, P349; CHEN SJ, 1993, BIOCHEMISTRY-US, V32, P1032, DOI 10.1021/bi00055a006; Chmura SJ, 1996, CANCER RES, V56, P2711; Cole SR, 1996, LEUKEMIA, V10, P288; Come MG, 1999, INT J CANCER, V81, P580, DOI 10.1002/(SICI)1097-0215(19990517)81:4<580::AID-IJC13>3.0.CO;2-T; De Sepulveda P, 1999, EMBO J, V18, P904; FAN D, 1992, ANTICANCER RES, V12, P661; Feng HL, 1998, MOL REPROD DEV, V49, P317, DOI 10.1002/(SICI)1098-2795(199803)49:3&lt;317::AID-MRD12&gt;3.0.CO;2-T; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Haslauer M, 1999, BLOOD, V94, P114, DOI 10.1182/blood.V94.1.114.413k21_114_126; Hassan HT, 1996, ACTA HAEMATOL-BASEL, V95, P257; HERBST R, 1995, BIOCHEMISTRY-US, V34, P5971, DOI 10.1021/bi00017a026; IKEDA H, 1991, BLOOD, V78, P2962; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; KOIKE T, 1993, J IMMUNOL, V151, P359; Kozawa O, 1997, EUR J BIOCHEM, V248, P149, DOI 10.1111/j.1432-1033.1997.00149.x; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LEIGH BR, 1995, RADIAT RES, V142, P12, DOI 10.2307/3578961; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Mansat V, 1997, FASEB J, V11, P695, DOI 10.1096/fasebj.11.8.9240970; Mansat V, 1997, CANCER RES, V57, P5300; Nagata H, 1997, INT ARCH ALLERGY IMM, V113, P184, DOI 10.1159/000237541; NETA R, 1993, BLOOD, V81, P324; QuilletMary A, 1996, LEUKEMIA, V10, P417; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; REUSSBORST MA, 1994, LEUKEMIA, V8, P258; RHEE SG, 1991, BIOCHEM SOC T, V19, P337, DOI 10.1042/bst0190337; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RIZZO MT, 1991, CELL SIGNAL, V3, P311, DOI 10.1016/0898-6568(91)90060-8; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; SCHUENING FG, 1993, BLOOD, V81, P20; Sette C, 1998, J CELL BIOL, V142, P1063, DOI 10.1083/jcb.142.4.1063; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Yang JM, 1997, BIOCHEM PHARMACOL, V53, P1597, DOI 10.1016/S0006-2952(97)82451-3; YEE NS, 1994, J EXP MED, V179, P1777, DOI 10.1084/jem.179.6.1777; YOUNG S, 1988, EUR J BIOCHEM, V173, P247, DOI 10.1111/j.1432-1033.1988.tb13991.x; ZSEBO KM, 1992, P NATL ACAD SCI USA, V89, P9464, DOI 10.1073/pnas.89.20.9464	51	21	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2001	20	46					6752	6763		10.1038/sj.onc.1204877	http://dx.doi.org/10.1038/sj.onc.1204877			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709710				2022-12-17	WOS:000171551600012
J	Sugai, T; Habano, W; Uesugi, N; Jiao, YF; Nakamura, S; Yoshida, T; Higuchi, T				Sugai, T; Habano, W; Uesugi, N; Jiao, YF; Nakamura, S; Yoshida, T; Higuchi, T			Frequent allelic imbalance at the ATM locus in DNA multiploid colorectal carcinomas	ONCOGENE			English	Article						allelic imbalance; ATM; colorectal carcinogenesis; DNA multiploidy; PCR	CRYPT-ISOLATION TECHNIQUE; ATAXIA-TELANGIECTASIA GENE; TUMOR-SUPPRESSOR GENES; CHROMOSOME 11Q23; HETEROZYGOSITY; CANCER; REGION; DAMAGE; IDENTIFICATION; ANEUPLOIDY	DNA multiploidy may involve specific DNA ploidy states with respect to genetic alterations such as oncogenes, tumor suppressor gene mutation and microsatellite instability. To clarify the role of DNA multiploidy in colorectal cancer, we analysed allelic imbalance involving the ATM gene, localized to chromosome 11q22-23 and thought to be involved in genetic stability, in a series of multiploid colorectal carcinomas. In addition, p53 gene mutation (exons 5 - 8) and allelic imbalance at 11q24 loci distal to the ATM locus were also examined. The crypt isolation technique coupled with DNA cytometric sorting and polymerase chain reaction assay using 10 microsatellite markers tightly linked to the ATM gene were used to study ATM allelic imbalance in 55 colorectal carcinomas (15 diploid, 13 aneuploid, 27 multiploid). While allelic imbalance at the ATM locus was rarely observed in diploid and aneuploid carcinomas, multiploid carcinomas exhibited a high frequency of ATM allelic imbalance. In multiploid carcinoma samples, diploid subpopulations showed a smaller range of allelic imbalance at the loci tested compared to aneuploid subpopulations that demonstrated allelic imbalance over a relatively large region. Also, the frequency of AI at 11q24 showed a similar tendency to that at the ATM locus for each DNA ploidy state. An association between p53 gene mutation and ATM allelic imbalance in multiploid carcinoma was also observed. Our results suggest that ATM allelic imbalance and p53 gene mutations occur during the progression from diploid to aneuploid cell populations in multiploid colorectal carcinomas.	Iwate Med Univ, Sch Med, Cent Clin Lab, Div Pathol, Morioka, Iwate 0208505, Japan; Iwate Med Univ, Sch Med, Dept Surg 1, Morioka, Iwate 0208505, Japan	Iwate Medical University; Iwate Medical University	Sugai, T (corresponding author), Iwate Med Univ, Sch Med, Cent Clin Lab, Div Pathol, 19-1 Morioka, Morioka, Iwate 0208505, Japan.							BAFFA R, 1995, P NATL ACAD SCI USA, V92, P4922, DOI 10.1073/pnas.92.11.4922; Baysal BE, 1997, GENOMICS, V44, P214, DOI 10.1006/geno.1997.4880; BETHWAITE PB, 1995, BRIT J CANCER, V71, P814, DOI 10.1038/bjc.1995.157; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; CARDER PJ, 1995, BRIT J CANCER, V71, P215, DOI 10.1038/bjc.1995.46; CARTER SL, 1994, CANCER RES, V54, P6270; Connolly KC, 1999, CANCER RES, V59, P2806; Davis M, 1996, CANCER RES, V56, P741; GUSTAFSON CE, 1994, BRIT J CANCER, V70, P395, DOI 10.1038/bjc.1994.315; Japanese Society for Cancer of the Colon and Rectum, 1997, JAP CLASS COL CARC, P30; KELDYSH PL, 1993, GENE CHROMOSOME CANC, V6, P45, DOI 10.1002/gcc.2870060109; LANGE E, 1995, AM J HUM GENET, V57, P112; Meyn MS, 1999, CLIN GENET, V55, P289, DOI 10.1034/j.1399-0004.1999.550501.x; MEYN MS, 1995, CANCER RES, V55, P5991; Monaco C, 1997, GENOMICS, V46, P217, DOI 10.1006/geno.1997.5036; NAKAMURA S, 1994, GASTROENTEROLOGY, V106, P100, DOI 10.1016/S0016-5085(94)94651-5; OFFERHAUS GJA, 1992, GASTROENTEROLOGY, V102, P1612, DOI 10.1016/0016-5085(92)91721-F; RASIO D, 1995, CANCER RES, V55, P6053; RASIO D, 1995, CANCER RES, V55, P3988; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sugai T, 2000, INT J CANCER, V88, P614, DOI 10.1002/1097-0215(20001115)88:4<614::AID-IJC15>3.3.CO;2-S; Sugai T, 2000, HUM PATHOL, V31, P925, DOI 10.1053/hupa.2000.9087; Sugai T, 2000, ARCH PATHOL LAB MED, V124, P382; Sugai T, 2000, PATHOL RES PRACT, V196, P145, DOI 10.1016/S0344-0338(00)80094-1; Takagi M, 1998, CANCER RES, V58, P4923; TURNBULL RB, 1967, ANN SURG, V166, P420; Uhrhammer N, 1999, ONCOL REP, V6, P655; VANAGAITE L, 1995, HUM GENET, V95, P451; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; Xie GF, 1998, ONCOGENE, V16, P721, DOI 10.1038/sj.onc.1201793; ZBIERANOWSKI I, 1993, ANAL CELL PATHOL, V5, P69	33	21	21	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					6095	6101		10.1038/sj.onc.1204731	http://dx.doi.org/10.1038/sj.onc.1204731			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593417				2022-12-17	WOS:000171056300017
J	Ikeguchi, A; Yang, HY; Gao, GX; Goff, SP				Ikeguchi, A; Yang, HY; Gao, GX; Goff, SP			Inhibition of v-Abl transformation in 3T3 cells overexpressing different forms of the Abelson interactor protein Abi-1	ONCOGENE			English	Article						Abelson murine leukemia virus; interacting protein	TYROSINE KINASE-ACTIVITY; LEUKEMIA-VIRUS VARIANTS; C-ABL; INDUCED ACTIVATION; BINDING; GROWTH; EPS8; RAS; ABL-INTERACTOR-1; IDENTIFICATION	The abi-1 gene encodes a protein that binds and is phosphorylated by the Abelson protein tyrosine kinase. Constructs expressing a full-length abi-1 cDNA, and a smaller cDNA arising from an alternatively spliced form, were generated and tested for their effect on transformation of NIH3T3 cells by the Abelson murine leukemia virus. Overexpression of both forms of the protein strongly inhibited transformation by the wild-type P160 strain of the virus, but not by the non-interacting mutant P90A strain. The inhibition required the SH3 domain of Abi-1, suggesting that a direct interaction was required for the effect. Rare breakthrough P160 transformants of the Abi-1 overexpressing lines were found to have downregulated Abi-1 protein levels by a post-transcriptional mechanism.	Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; Columbia University	Goff, SP (corresponding author), Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA.		Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547	NCI NIH HHS [P01 CA 23767] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELSON HT, 1970, CANCER RES, V30, P2213; BERGOLD PJ, 1987, J VIROL, V61, P1193, DOI 10.1128/JVI.61.4.1193-1202.1987; Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; Fan PD, 2000, MOL CELL BIOL, V20, P7591, DOI 10.1128/MCB.20.20.7591-7601.2000; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; GOFF SP, 1981, J VIROL, V38, P460, DOI 10.1128/JVI.38.2.460-468.1981; Juang JL, 1999, ONCOGENE, V18, P5138, DOI 10.1038/sj.onc.1202911; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Maniatis T., 1982, MOL CLONING LAB MANU; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MURTAGH K, 1986, J VIROL, V60, P599, DOI 10.1128/JVI.60.2.599-606.1986; NICHOLS GL, 1994, BLOOD, V84, P2912; Raffel GD, 1996, J BIOL CHEM, V271, P4640; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROSENBERG N, 1980, J VIROL, V33, P340, DOI 10.1128/JVI.33.1.340-348.1980; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; So CW, 2000, LEUKEMIA, V14, P594, DOI 10.1038/sj.leu.2401692; Taki T, 1998, BLOOD, V92, P1125, DOI 10.1182/blood.V92.4.1125.416k40_1125_1130; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3	29	21	25	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					4926	4934		10.1038/sj.onc.1204502	http://dx.doi.org/10.1038/sj.onc.1204502			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526477				2022-12-17	WOS:000170439800002
J	Keating, KE; Gueven, N; Watters, D; Rodemann, HP; Lavin, MF				Keating, KE; Gueven, N; Watters, D; Rodemann, HP; Lavin, MF			Transcriptional downregulation of ATM by EGF is defective in ataxia-telangiectasia cells expressing mutant protein	ONCOGENE			English	Article						ataxia-telangiectasia ATM; transcriptional downregulation; EGF; Sp1 transcriptional factor	EPIDERMAL GROWTH-FACTOR; DAMAGE-INDUCED PHOSPHORYLATION; CYCLE CHECKPOINT PATHWAY; DOUBLE-STRAND BREAKS; DNA-DAMAGE; GENE-PRODUCT; DEPENDENT PHOSPHORYLATION; IONIZING-RADIATION; SP1-MEDIATED TRANSCRIPTION; SIGNAL-TRANSDUCTION	There is evidence that ATM plays a wider role in intracellular signalling in addition to DNA damage recognition and cell cycle control, In this report we show that activation of the EGF receptor is defective in ataxia-telangiectasia (A-T) cells and that sustained stimulation of cells with EGF downregulates ATM protein in control cells but not in A-T cells expressing mutant protein, Concomitant with the downregulation of ATM, DNA-binding activity of the transcription factor Spl decreased in controls after EGF treatment but increased from a lower basal level in A-T cells to that in untreated control cells, Mutation in two Spl consensus sequences in the ATM promoter reduced markedly the capacity of the promoter to support luciferase activity in a reporter assay. Overexpression of anti-sense ATM cDNA in control cells decreased the;basal level of Spl, which in turn was increased by subsequent treatment of cells with EGF, similar to that observed in,A-T cells. On the other hand full-length ATM cDNA increased the basal level of Spl binding in A-T cells, and in response to EGF Spl binding decreased, confirming that this is an ATR I-dependent process. Contrary to that observed in control cells there was no radiation-induced change in ATM protein in EGF-treated A-T cells and likewise no alteration in Spl binding activity. The results demonstrate that EGF-induced downregulation of ATM (mutant) protein in A-T cells is defective and this appears to be due to less efficient EGFR activation and abnormal Spl regulation.	PO Royal Brisbane Hosp, Queensland Inst Med Res, Queensland Canc Fund Res Lab, Brisbane, Qld 4029, Australia; Sect Radiobiol & Mol Environm Res, D-72076 Tubingen, Germany; Univ Queensland, PO Royal Brisbane Hosp, Dept Surg, Brisbane, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Royal Brisbane & Women's Hospital; University of Queensland	Lavin, MF (corresponding author), PO Royal Brisbane Hosp, Queensland Inst Med Res, Queensland Canc Fund Res Lab, Brisbane, Qld 4029, Australia.		Lavin, Martin F/F-5961-2014; Watters, Dianne J/E-6007-2010	Lavin, Martin F/0000-0002-5940-4769; Watters, Dianne J/0000-0002-2555-5825				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Balaban N, 1996, BBA-MOL CELL RES, V1314, P147, DOI 10.1016/S0167-4889(96)00068-7; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Barlow C, 1998, DEVELOPMENT, V125, P4007; Barlow C, 2000, P NATL ACAD SCI USA, V97, P871, DOI 10.1073/pnas.97.2.871; Barlow C, 1999, P NATL ACAD SCI USA, V96, P9915, DOI 10.1073/pnas.96.17.9915; Baskaran R, 1997, J BIOL CHEM, V272, P18905, DOI 10.1074/jbc.272.30.18905; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Byrd PJ, 1996, HUM MOL GENET, V5, P145, DOI 10.1093/hmg/5.1.145; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Clarke RA, 1998, J CLIN PATHOL-MOL PA, V51, P224, DOI 10.1136/mp.51.4.224; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Dittmann KH, 1998, INT J RADIAT BIOL, V74, P225, DOI 10.1080/095530098141609; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELMORE E, 1976, J CELL PHYSIOL, V89, P429, DOI 10.1002/jcp.1040890308; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; Fukao T, 1999, BLOOD, V94, P1998; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; GOTOFF SP, 1967, AM J DIS CHILD, V114, P617, DOI 10.1001/archpedi.1967.02090270073006; Gueven N, 2001, J BIOL CHEM, V276, P8884, DOI 10.1074/jbc.M006190200; Imai T, 1996, GENOME RES, V6, P439, DOI 10.1101/gr.6.5.439; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1995, ONCOGENE, V11, P609; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; KHANNA KK, 1997, J BIOL CHEM, V271, P29335; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KONDO N, 1993, SCAND J IMMUNOL, V38, P45, DOI 10.1111/j.1365-3083.1993.tb01692.x; KWOK TT, 1992, INT J RADIAT ONCOL, V22, P525, DOI 10.1016/0360-3016(92)90867-H; KWOK TT, 1991, INT J CANCER, V19, P73; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lim DS, 1998, P NATL ACAD SCI USA, V95, P10146, DOI 10.1073/pnas.95.17.10146; Lynn WS, 1997, NEUROIMMUNOMODULAT, V4, P277, DOI 10.1159/000097348; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Mortensen ER, 1997, J BIOL CHEM, V272, P16540, DOI 10.1074/jbc.272.26.16540; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; NELSON J, 1989, EUR J CANC CLIN ONCO, V12, P1851; OCONNOR RD, 1980, CLIN IMMUNOL IMMUNOP, V15, P66, DOI 10.1016/0090-1229(80)90021-5; Oka A, 1998, NEUROSCI LETT, V252, P195, DOI 10.1016/S0304-3940(98)00576-X; Peretz S, 2001, P NATL ACAD SCI USA, V98, P1676, DOI 10.1073/pnas.041416598; Rhodes N, 1998, GENE DEV, V12, P3686, DOI 10.1101/gad.12.23.3686; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Saito T, 1998, MAMM GENOME, V9, P769, DOI 10.1007/s003359900861; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SEDGWICK RP, 1991, HEREDITARY NEUROPATH, P347; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHILOH Y, 1982, CARCINOGENESIS, V3, P815, DOI 10.1093/carcin/3.7.815; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Watters D, 1999, J BIOL CHEM, V274, P34277, DOI 10.1074/jbc.274.48.34277; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; WOLTMAN R, 1994, INT J RADIAT ONCOL, V30, P91; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Yamabe Y, 1998, MOL CELL BIOL, V18, P6191, DOI 10.1128/MCB.18.11.6191; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Zhang N, 1998, ONCOGENE, V17, P811, DOI 10.1038/sj.onc.1202007; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	70	21	23	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4281	4290		10.1038/sj.onc.1204527	http://dx.doi.org/10.1038/sj.onc.1204527			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466608				2022-12-17	WOS:000169912600001
J	Yui, D; Yoneda, T; Oono, K; Katayama, T; Imaizumi, K; Tohyama, M				Yui, D; Yoneda, T; Oono, K; Katayama, T; Imaizumi, K; Tohyama, M			Interchangeable binding of Bcl10 to TRAF2 and cIAPs regulates apoptosis signaling	ONCOGENE			English	Article						Bcl10; TRAF2; cIAPs; phosphorylation; apoptosis	NECROSIS-FACTOR-ALPHA; CELL-DEATH; PROTEINS; GENE; LYMPHOMA; CASPASES; KINASE; RECRUITMENT; ACTIVATION; MUTATIONS	Bcl10 was identified as a candidate gene responsible for low grade B cell lymphomas of mucosa-associated lymphoid tissue. Overexpression of Bcl10 in cultured cells was reported to promote apoptosis, however, the mechanism of regulation of apoptosis mediated by Bcl10 has not been demonstrated. In the present study, we analysed the apoptosis signaling pathway mediated by Bcl10, focusing on phosphorylation of Bcl10 and the dynamic interaction with its binding partners during apoptosis, Previously, we have demonstrated that Bcl10 potentially interacts with the other apoptosis regulator, TNF receptor associated factor-2 (TRAF2) and inhibitor of apoptosis proteins (cIAPs), The present results showed that the complex formation of these molecules was regulated by phosphorylation of Bcl10, that is, phosphorylation of Bcl10 resulted in binding of Bcl10 to cIAPs and the dissociation of it from TRAFZ. Moreover, hyperphosphorylation of Bcl10 enhanced apoptosis, suggesting that changes in the binding partners of Bcl10 were correlated to the promotion of apoptosis as mediated by Bcl10, Indeed, the mutant which was deleted from the binding site of Bcl10 for cIAPs, could not induce apoptosis, These findings indicate that Bcl10 is a mediator of apoptosis signaling, by switching over binding to cIAPs from TRAFZ through the events of Bcl10 phosphorylation.	Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Suita, Osaka 5650871, Japan; Nara Inst Sci & Technol, Grad Sch Biol Sci, Dept Cellular & Struct Biol, Nara 6300101, Japan; JST, Japan Sci & Technol Corp, CREST, Suita, Osaka 5650871, Japan	Osaka University; Nara Institute of Science & Technology; Japan Science & Technology Agency (JST)	Yui, D (corresponding author), Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Bertin J, 2000, J BIOL CHEM, V275, P41082, DOI 10.1074/jbc.C000726200; Bertoni F, 1999, ANN ONCOL, V10, P1259, DOI 10.1023/A:1008309631480; Cecconi F, 1999, CELL DEATH DIFFER, V6, P1087, DOI 10.1038/sj.cdd.4400602; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Du MQ, 2000, BLOOD, V95, P3885; HOFFMAN K, 1997, TRENDS BIOCHEM SCI, V22, P155; Hofmann K, 1999, CELL MOL LIFE SCI, V55, P1113, DOI 10.1007/s000180050361; KIZAKI H, 1989, J BIOCHEM-TOKYO, V105, P673, DOI 10.1093/oxfordjournals.jbchem.a122724; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Koseki T, 1999, J BIOL CHEM, V274, P9955, DOI 10.1074/jbc.274.15.9955; Laouar A, 1999, J BIOL CHEM, V274, P23526, DOI 10.1074/jbc.274.33.23526; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Simms LA, 2000, CELL DEATH DIFFER, V7, P236, DOI 10.1038/sj.cdd.4400650; Takada Y, 1999, J BIOL CHEM, V274, P28286, DOI 10.1074/jbc.274.40.28286; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Thome M, 1999, J BIOL CHEM, V274, P9962, DOI 10.1074/jbc.274.15.9962; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Yamamoto H, 2000, CELL DEATH DIFFER, V7, P238, DOI 10.1038/sj.cdd.4400651; Yan MH, 1999, J BIOL CHEM, V274, P10287, DOI 10.1074/jbc.274.15.10287; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yoneda T, 2000, J BIOL CHEM, V275, P11114, DOI 10.1074/jbc.275.15.11114; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767	27	21	26	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4317	4323		10.1038/sj.onc.1204576	http://dx.doi.org/10.1038/sj.onc.1204576			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466612				2022-12-17	WOS:000169912600005
J	Mercalli, E; Ghizzoni, S; Arighi, E; Alberti, L; Sangregorio, R; Radice, MT; Gishizky, ML; Pierotti, MA; Borrello, MG				Mercalli, E; Ghizzoni, S; Arighi, E; Alberti, L; Sangregorio, R; Radice, MT; Gishizky, ML; Pierotti, MA; Borrello, MG			Key role of Shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein	ONCOGENE			English	Article						Ret; Shc; oncogene; thyroid carcinoma	RECEPTOR TYROSINE KINASES; NEUROTROPHIC FACTOR; TRANSDUCTION PATHWAYS; PHOSPHORYLATION SITES; RET MUTATIONS; DOCKING SITE; PROTEIN; ACTIVATION; BINDING; DOMAIN	The RET/PTC oncogenes, generated by chromosomal rearrangements in papillary thyroid carcinomas, are constitutively activated versions of protoRET, a gene encoding two protein isoforms of a transmembrane tyrosine kinase receptor, By using Ret/ptc2 short isoform (iso9), we have previously demonstrated that Tyr586 (Tyr1062 of protoRet) is the docking site for both the PTB and the SH2 domains of Shc. To determine the relevance of this interaction for the transforming activity of Ret/ptc oncogenes, we have generated and characterized novel Ret/ptc mutants unable to activate Shc: Ret/ptc2 long isoform (iso51)-Y586F and both isoforms of Ret/ptc2-N583A, These mutants neither activate Shc nor transform NIH3T3 cells. Since Tyr1062 shows features of a multifunctional docking site, we have used a Shc mutant (Shc Y317F) to directly assess Shc role, We have demonstrated that in our cell syst-ern Shc Y317F behaves like a dominant interfering mutant on the activation of the Grb2-Sos pathway by endogenous Shc triggered by Ret/ptc2, A strong reduction of the transforming activity of Ret/ptc2 in presence of this mutant was also demonstrated. Our data suggest that Shc activation play a key role in the transforming pathways triggered by Ret/ptc oncoproteins. Moreover, we have shown that coexpression of the Shc-Y317F mutant with Ret/ptc2 specifically causes apoptosis, and that the surviving cells lose the long-term expression of one of the two genes.	Ist Nazl Tumori, Dept Expt Oncol, Res Unit 3, I-20133 Milan, Italy; SUGEN, San Francisco, CA 94080 USA	Fondazione IRCCS Istituto Nazionale Tumori Milan; Pfizer	Pierotti, MA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Res Unit 3, Via G Venezian 1, I-20133 Milan, Italy.		Pierotti, Marco Alessandro/AAC-4728-2022; Borrello, Maria Grazia/C-3161-2017	Pierotti, Marco Alessandro/0000-0002-7431-8332; Borrello, Maria Grazia/0000-0002-6854-2848				Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; BONGARZONE I, 1989, ONCOGENE, V4, P1457; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BORRELLO MG, 1994, ONCOGENE, V9, P1661; Creedon DJ, 1997, P NATL ACAD SCI USA, V94, P7018, DOI 10.1073/pnas.94.13.7018; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Fischer AH, 1998, AM J PATHOL, V153, P1443, DOI 10.1016/S0002-9440(10)65731-8; FIXMAN ED, 1995, ONCOGENE, V10, P237; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Hennige AM, 2000, MOL CELL ENDOCRINOL, V167, P69, DOI 10.1016/S0303-7207(00)00283-5; Hill RJ, 1996, CELL GROWTH DIFFER, V7, P1125; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Thomas D, 1997, J BIOL CHEM, V272, P22293, DOI 10.1074/jbc.272.35.22293; TRUB T, 1995, J BIOL CHEM, V270, P18205; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; vanWeering DHJ, 1997, J BIOL CHEM, V272, P249	50	21	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2001	20	27					3475	3485		10.1038/sj.onc.1204462	http://dx.doi.org/10.1038/sj.onc.1204462			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429694				2022-12-17	WOS:000169478300003
J	Yin, ZN; Babaian, RJ; Troncoso, P; Strom, SS; Spitz, MR; Caudell, JJ; Stein, JD; Kagan, J				Yin, ZN; Babaian, RJ; Troncoso, P; Strom, SS; Spitz, MR; Caudell, JJ; Stein, JD; Kagan, J			Limiting the location of putative human prostate cancer tumor suppressor genes on chromosome 18q	ONCOGENE			English	Article						chromosome 18q; prostate cancer; loss of heterozygosity; tumor suppressor gene; Smad2; Smad4; DCC	IN-VIVO ALTERATIONS; GROWTH-FACTOR-BETA; HUMAN LUNG CANCERS; ALLELIC LOSS; DCC GENE; MUTATIONAL ANALYSIS; FREQUENT LOSS; COLORECTAL CARCINOMAS; CELL CARCINOMA; P53 PROTEIN	We studied loss of heterozygosity (LOH) on the long arm of human chromosome 18 in prostate cancer to determine the location of a putative tumor suppressor gene (TSG) and to correlate these losses with the pathological grade and stage of the cancer, Of 48 specimens analysed 17 (35.4%) lost at least one allele on chromosome 18q, All the specimens with allelic losses lost at least one allele within chromosomal region 18q21, Allelic losses picked at D18S51 (19%) and D18S858 (17%), A 0.58 cM DNA segment that includes the D18S858 locus and is flanked by the microsatellite loci D18S41 and D18S381, was lost in eight (47%) of 17 specimens with allelic losses, This segment was designated as a LOH cluster region 1 (LCR 1), Although Smad2 resides within LCR 1, it was not mutated in any of the six prostate cell lines (five prostate cancer cell lines and one immortalized prostate epithelial cell line) analysed, suggesting that it is not a candidate TSG in prostate cancer. A second LCR at 18q21, LCR 2, includes the D18S51 locus and is flanked by the D18S1109 and D18S68 loci, which are separated by 7.64 cM, LCR 2 was lost in six (35%) of the 17 specimens with chromosome 18q losses. These results suggest that chromosome 18q21 may harbor two candidate prostate cancer TSGs, The candidate TSGs DCC and Smad4 are located centromeric to the LCRs, No alleles were lost within or in close proximity to these genes, suggesting that they are not targets for inactivation by allelic losses in prostate cancer. Although there was no obvious correlation between chromosome 18q LOH and the pathological grade or stage, three (37.5%) of eight low-grade cancers and nine (32.1%) of 28 organ-confined cancers lost alleles at 18q21, suggesting that allelic losses are relatively early events in the development of invasive prostate cancer.	Univ Texas, MD Anderson Canc Ctr, Div Pathol & Lab Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kagan, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Pathol & Lab Med, 1515 Holcombe Blvd,Box 054, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA068578] Funding Source: NIH RePORTER; NCI NIH HHS [CA68578-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROW MG, 1995, CANCER RES, V55, P1452; [Anonymous], 1997, AJCC CANC STAGING MA; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BOVA GS, 1993, CANCER RES, V53, P3869; BREWSTER SF, 1994, BRIT J CANCER, V70, P697, DOI 10.1038/bjc.1994.376; Brooks JD, 1996, CANCER RES, V56, P3814; Cairns P, 1997, CANCER RES, V57, P5356; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CHENEVIXTRENCH G, 1992, ONCOGENE, V7, P1059; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CLIBY W, 1993, CANCER RES, V53, P2393; Collins A, 1996, P NATL ACAD SCI USA, V93, P14771, DOI 10.1073/pnas.93.25.14771; Cooney KA, 1996, CANCER RES, V56, P1142; CROPP CS, 1990, P NATL ACAD SCI USA, V87, P7737, DOI 10.1073/pnas.87.19.7737; Crundwell MC, 1996, INT J CANCER, V69, P295, DOI 10.1002/(SICI)1097-0215(19960822)69:4<295::AID-IJC10>3.3.CO;2-#; Cunningham JM, 1996, CANCER RES, V56, P4475; DEGEORGES A, 1995, INT J CANCER, V62, P724, DOI 10.1002/ijc.2910620613; DEVILEE P, 1991, ONCOGENE, V6, P311; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GAO X, 1995, CANCER RES, V55, P1002; GAO X, 1993, CANCER RES, V53, P2723; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; Goggins M, 1998, CANCER RES, V58, P5329; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1998, CANCER RES, V58, P1124; HAHN SA, 1995, CANCER RES, V55, P4670; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HUANG Y, 1992, CANCER RES, V52, P6525; Ittmann M, 1996, CANCER RES, V56, P2143; Jenkins R, 1998, GENE CHROMOSOME CANC, V21, P131, DOI 10.1002/(SICI)1098-2264(199802)21:2<131::AID-GCC9>3.0.CO;2-1; KAGAN J, 1995, ONCOGENE, V11, P2121; Kim SK, 1996, CANCER RES, V56, P2519; Kong XT, 1997, CANCER RES, V57, P3772; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; Latil A, 1999, PROSTATE, V40, P225, DOI 10.1002/(SICI)1097-0045(19990901)40:4<225::AID-PROS3>3.0.CO;2-3; LATIL A, 1994, GENE CHROMOSOME CANC, V11, P119, DOI 10.1002/gcc.2870110208; Li CD, 1998, ONCOGENE, V16, P481, DOI 10.1038/sj.onc.1201554; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; MACOSKA JA, 1995, CANCER RES, V55, P5390; Melamed J, 1997, CLIN CANCER RES, V3, P1867; Mottaz AE, 1997, PROSTATE, V31, P209; Nagatake M, 1996, CANCER RES, V56, P2718; NAVONE NM, 1993, J NATL CANCER I, V85, P1657, DOI 10.1093/jnci/85.20.1657; Raff T, 1997, BIOTECHNIQUES, V23, P456, DOI 10.2144/97233st02; REALE MA, 1994, CANCER RES, V54, P4493; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Salem CE, 1997, J UROLOGY, V158, P510, DOI 10.1016/S0022-5347(01)64520-8; Schutte M, 1996, CANCER RES, V56, P2527; SHIBAGAKI L, 1994, CANCER RES, V54, P2995; SHISEKI M, 1994, CANCER RES, V54, P5643; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; SUZUKI H, 1995, GENE CHROMOSOME CANC, V13, P168, DOI 10.1002/gcc.2870130306; TAKITA J, 1995, ONCOGENE, V11, P1829; Teng DHF, 1997, CANCER RES, V57, P5221; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; TRAPMAN J, 1994, CANCER RES, V54, P6061; Uchida K, 1996, CANCER RES, V56, P5583; UCHINO S, 1992, CANCER RES, V52, P3099; Ueda T, 1997, GENE CHROMOSOME CANC, V20, P140, DOI 10.1002/(SICI)1098-2264(199710)20:2<140::AID-GCC4>3.0.CO;2-3; VISAKORPI T, 1995, CANCER RES, V55, P342; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Yin ZN, 1999, ONCOGENE, V18, P7576, DOI 10.1038/sj.onc.1203203; ZAR JH, 1991, BIOSTATISTICAL ANAL; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	70	21	23	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2001	20	18					2273	2280		10.1038/sj.onc.1204310	http://dx.doi.org/10.1038/sj.onc.1204310			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402322				2022-12-17	WOS:000168404500009
J	Harris, VK; Kagan, BL; Ray, R; Coticchia, CM; Liaudet-Coopman, ED; Wellstein, A; Riegel, AT				Harris, VK; Kagan, BL; Ray, R; Coticchia, CM; Liaudet-Coopman, ED; Wellstein, A; Riegel, AT			Serum induction of the fibroblast growth factor-binding protein (FGF-BP) is mediated through ERK and p38 MAP kinase activation and C/EBP-regulated transcription	ONCOGENE			English	Article						FGF-BP; serum; p38 MAPK; C/EBP; transcription	SIGNAL-TRANSDUCTION PATHWAYS; GENE-EXPRESSION; PHOSPHORYLATION; ISOFORMS; ELEMENT	The fibroblast growth factor-binding protein (FGF-BP) modulates FGF activity through binding and release from the extracellular matrix, Consequently, the expression of FGF-BP in certain tumor types is a rate-limiting regulator of FGF-mediated angiogenesis. FGF-BP is upregulated in squamous cell carcinoma by treatment with mitogens such as EGF or TPA, In this study, we investigated the regulation of FGF-BP gene expression by serum. Treatment of serum-starved ME-180 cells with fetal bovine serum (FBS) resulted in a rapid increase in steady-state levels of FGF-BP mRNA and in the rate of FGF-BP gene transcription. Serum induction of FGF-BP mRNA was not mediated through EGF receptor activation but was dependent on PKC, as well as ERK kinase (MEK) and p38 MAP kinase activation. Promoter analysis showed that C/EBP is the main promoter element required for the serum response. Unlike EGF-activation of FGF-BP, transcriptional induction by serum is not significantly regulated through the AP-I or E-box sites in the promoter. These results illustrate differences between the mechanism of induction in response to serum and EGF.	Georgetown Univ, Dept Oncol, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; Georgetown Univ, Dept Pharmacol, Washington, DC 20007 USA	Georgetown University; Georgetown University	Harris, VK (corresponding author), CUNY, Mt Sinai Med Ctr, Derald H Ruttenberg Canc Ctr, 1425 Madison Ave,Box 1130,East Bldg,Rm 15-52, New York, NY 10029 USA.		Liaudet-Coopman, Emmanuelle/N-4744-2017	Liaudet-Coopman, Emmanuelle/0000-0001-9313-9690; Wellstein, Anton/0000-0002-0570-4950	NCI NIH HHS [CA71508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071508] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Harris VK, 2000, J BIOL CHEM, V275, P28539, DOI 10.1074/jbc.M001677200; Harris VK, 2000, J BIOL CHEM, V275, P10802, DOI 10.1074/jbc.275.15.10802; Harris VK, 1998, J BIOL CHEM, V273, P19130, DOI 10.1074/jbc.273.30.19130; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kurtz A, 1997, ONCOGENE, V14, P2671, DOI 10.1038/sj.onc.1201117; LiaudetCoopman EDE, 1996, J BIOL CHEM, V271, P21303, DOI 10.1074/jbc.271.35.21303; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WU DQ, 1991, J BIOL CHEM, V266, P16778	24	21	21	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1730	1738		10.1038/sj.onc.1204249	http://dx.doi.org/10.1038/sj.onc.1204249			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313920				2022-12-17	WOS:000167750900006
J	Fukuhara, H; Maruyama, T; Nomura, S; Oshimura, M; Kitamura, T; Sekiya, T; Murakami, Y				Fukuhara, H; Maruyama, T; Nomura, S; Oshimura, M; Kitamura, T; Sekiya, T; Murakami, Y			Functional evidence for the presence of tumor suppressor gene on chromosome 10p15 in human prostate cancers	ONCOGENE			English	Article						prostate cancer; tumor suppressor gene; chromosome 10p15; microcell-mediated chromosome transfer	CELL-LINE; ALLELIC LOSS; SHORT ARM; MALIGNANT PHENOTYPE; METASTASIS; LOCI; FRAGMENTS; CARCINOMA; DELETION; HETEROZYGOSITY	Loss of heterozygosity on chromosome 10p was observed frequently in human prostate cancers. Studies have demonstrated that the introduction of the short arm of human chromosome 10 into a human prostate cancer cell line, PPC-I, by microcell-mediated chromosome transfer (MMCT), suppressed the malignant phenotype, suggesting the presence of a prostate tumor suppressor gene(s) within a region of 17 cM at distal 10p, To narrow down the candidate region harboring the tumor suppressor gene, a series of 10p fragments were transferred into PPC-1 cells by MMCT using a panel of hamster-human hybrid cells containing various portions of 10p, Pour of the six hybrid tells obtained showed decreased tumorigenicity when injected subcutaneously irate athymic nude mice. Tumors developed only at six of 40 injection sites for these four hybrid cells. In contrast, the other two hybrid cells, as well as parental PPC-1 cells, were judged to he fully tumorigenic because tumors appeared at a total 26 of 32 sites for the two hybrid cells and 15 of 16 sites for PPC-I, Allelotyping of 10p combined with fluorescence in situ hybridization in these hybrid cells suggested that a prostate tumor suppressor gene was located within a fragment of approximately 1.2 Mb flanked by D10S1172 and D10S226 on 10p15.1.	Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Chuo Ku, Tokyo 1040045, Japan; BML, R&D Ctr, Kawagoe, Saitama 3501101, Japan; Tottori Univ, Fac Med, Sch Life Sci, Yonago, Tottori 6838503, Japan; Univ Tokyo, Sch Med, Dept Urol, Tokyo 1138655, Japan	National Cancer Center - Japan; Tottori University; University of Tokyo	Murakami, Y (corresponding author), Natl Canc Ctr, Res Inst, Tumor Suppress & Funct Genom Project, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.		Nomura, Sachio/GYU-4930-2022; Kitamura, Toshio/AAA-2071-2021	Nomura, Sachio/0000-0001-9214-4041; 				ALBERTSEN H, 1994, AM J HUM GENET, V54, P516; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BOVA GS, 1993, CANCER RES, V53, P3869; BROTHMAN AR, 1989, INT J CANCER, V44, P898, DOI 10.1002/ijc.2910440525; BROTHMAN AR, 1991, J UROLOGY, V145, P1088, DOI 10.1016/S0022-5347(17)38540-3; BROTHMAN AR, 1990, CANCER RES, V50, P3795; BROTHMAN AR, 1995, GENE CHROMOSOME CANC, V13, P278, DOI 10.1002/gcc.2870130408; BROTHMAN AR, 1992, CYTOGENET CELL GENET, V60, P8, DOI 10.1159/000133283; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; EFFERT PJ, 1992, J UROLOGY, V147, P789, DOI 10.1016/S0022-5347(17)37387-1; FOURNIER REK, 1981, P NATL ACAD SCI-BIOL, V78, P6349, DOI 10.1073/pnas.78.10.6349; Gao AC, 1999, PROSTATE, V38, P46, DOI 10.1002/(SICI)1097-0045(19990101)38:1<46::AID-PROS6>3.0.CO;2-9; ICHIKAWA T, 1994, CANCER RES, V54, P2299; ICHIKAWA T, 1992, CANCER RES, V52, P3486; ISAACS WB, 1991, CANCER RES, V51, P4716; Ittmann M, 1996, CANCER RES, V56, P2143; Kawana Y, 1997, PROSTATE, V32, P205; Kimmelman AC, 1996, GENOMICS, V34, P250, DOI 10.1006/geno.1996.0277; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; Kon H, 1998, ONCOGENE, V16, P257, DOI 10.1038/sj.onc.1201488; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MACOSKA JA, 1993, GENE CHROMOSOME CANC, V8, P88, DOI 10.1002/gcc.2870080205; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; MURAKAMI Y, 2000, IN PRESS J HUM GENET; Murakami YS, 1996, CANCER RES, V56, P2157; MURAKAMI YS, 1995, CANCER RES, V55, P3389; NIHEI N, 1995, GENE CHROMOSOME CANC, V14, P112, DOI 10.1002/gcc.2870140205; Nihei N, 1996, GENE CHROMOSOME CANC, V17, P260, DOI 10.1002/(SICI)1098-2264(199612)17:4<260::AID-GCC8>3.0.CO;2-1; Nihei N, 1999, GENE CHROMOSOME CANC, V24, P1, DOI 10.1002/(SICI)1098-2264(199901)24:1<1::AID-GCC1>3.0.CO;2-A; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; PHILLIPS SMA, 1994, BRIT J UROL, V73, P390, DOI 10.1111/j.1464-410X.1994.tb07602.x; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; RINKERSCHAEFFER CW, 1994, CANCER RES, V54, P6249; Robertson GP, 1999, CANCER RES, V59, P3596; Sanchez Y, 1996, P NATL ACAD SCI USA, V93, P2551, DOI 10.1073/pnas.93.6.2551; Shimura M, 1999, CANCER RES, V59, P2259; Sonoda Y, 1996, JPN J CANCER RES, V87, P363, DOI 10.1111/j.1349-7006.1996.tb00231.x; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; Trybus TM, 1996, CANCER RES, V56, P2263; VISAKORPI T, 1995, CANCER RES, V55, P342; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816	48	21	21	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					314	319		10.1038/sj.onc.1204079	http://dx.doi.org/10.1038/sj.onc.1204079			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313960				2022-12-17	WOS:000166411000005
J	Mixon, M; Kittrell, F; Medina, D				Mixon, M; Kittrell, F; Medina, D			Expression of Brca1 and splice variant Brca1 Delta 11 RNA levels in mouse mammary gland during normal development and tumorigenesis	ONCOGENE			English	Article						genes; Brca1; breast neoplasms; gene expression	HEREDITARY BREAST-CANCER; DNA-DAMAGE; CELL-CYCLE; MEIOTIC CELLS; IN-VIVO; DIFFERENTIATION; REPAIR; MUTATIONS; TISSUES; GENE	Expression of Brca1 in mouse mammary cancer has yet to be analysed. We use a progressive model of neoplasia based on several mouse epithelial cell lines that represent distinct steps toward the fully tumorigenic state. Using RNase protection analysis because acceptable anti-Brca1 antibodies are not available we investigated the expression of Brca1 and a splice variant, Brca1 Delta 11, in several mammary hyperplasias and tumors that arose from them, and in normal mammary gland through pregnancy and involution, Expression of Brca1 was highest in rapidly proliferating cells. Expression of the full-length Brca1 was detectable in the virgin gland, was slightly elevated in the midpregnant gland, and decreased to levels similar to the age-matched virgin gland in the completely involuted gland, Expression of both forms of Brca1 was detectable in 9/9 paired hyperplasias and tumors, with levels of total Brca1, but not the splice variant Brca1 Delta 11, in tumors higher than those in the hyperplasias. While in disagreement with the observation that Brca1 levels decrease in human breast cancer progression, these patterns support the notion that Brca1 expression is associated with proliferating cells, and suggests that the link with differentiation seen in normal cells can be removed when cells become tumorigenic.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine	Medina, D (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.				NCI NIH HHS [CA64255] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA064255] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chen YM, 1996, CANCER RES, V56, P3168; EASTON D, 1993, CANCER SURV, V18, P95; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Husain A, 1998, CANCER RES, V58, P1120; Jiang C, 1997, CARCINOGENESIS, V18, P2085, DOI 10.1093/carcin/18.11.2085; Kainu T, 1996, CANCER RES, V56, P2912; KITTRELL FS, 1992, CANCER RES, V52, P1924; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Lu ML, 1996, CANCER RES, V56, P4578; LYNCH HT, 1994, WORLD J SURG, V18, P21, DOI 10.1007/BF00348188; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; Marks JR, 1997, ONCOGENE, V14, P115, DOI 10.1038/sj.onc.1200808; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; Medina D, 1996, Cancer Treat Res, V83, P37; Medina D, 1998, MOL CARCINOGEN, V22, P199, DOI 10.1002/(SICI)1098-2744(199807)22:3<199::AID-MC8>3.0.CO;2-G; MEDINA D, 1993, CANCER RES, V53, P663; Merajver SD, 1995, CLIN CANCER RES, V1, P539; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shao NS, 1996, ONCOGENE, V13, P1; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Xu CF, 1997, GENE CHROMOSOME CANC, V18, P102, DOI 10.1002/(SICI)1098-2264(199702)18:2<102::AID-GCC4>3.3.CO;2-A	34	21	21	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 2	2000	19	46					5237	5243		10.1038/sj.onc.1203905	http://dx.doi.org/10.1038/sj.onc.1203905			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077440				2022-12-17	WOS:000165059700004
J	Gaitonde, SV; Riley, JR; Qiao, DH; Martinez, JD				Gaitonde, SV; Riley, JR; Qiao, DH; Martinez, JD			Conformational phenotype of p53 is linked to nuclear translocation	ONCOGENE			English	Article						p53; conformation; subcellular localization	WILD-TYPE P53; CELL-CYCLE; CYTOPLASMIC SEQUESTRATION; MONOCLONAL-ANTIBODY; HUMAN NEUROBLASTOMA; DNA-BINDING; PROTEIN; LOCALIZATION; SUPPRESSOR; GENE	P53 is inactivated in tumors by mechanisms other than mutations in the p53 gene itself, To gain insight into the mechanisms by which this inactivation occurs, we chemically mutagenized A1-5 cells expressing high levels of temperature sensitive p53(val135) (tsp53) and selected for clones that were capable of growth at the permissive temperature for p53 activation. We expanded 22 clones (ALTR cells for (A) under bar 1-5 (L) under bar ow (T) under bar emperature (R) under bar esistant) that could grow at the permissive temperature. Most exhibited cytoplasmic sequestration as the mechanism by which p53 was inactivated. We show here that this cytoplasmically sequestered tsp53 protein is maintained in a mutant conformation. Only in clones with nuclear localized p53 is it also expressed in the wild-type conformation suggesting that subcellular localization of tsp53 is important in determining the conformation of the protein. Consistent with this, we show that the changes in conformation of p53 in A1-5 and SK-N-SH cells induced by ionizing radiation also correlate with nuclear translocation of p53, We suggest that nuclear translocation of p53 can result in a change in the conformation from mutant to wild-type but that these may be two separable events.	Univ Arizona, Dept Radiat Oncol, Arizona Canc Ctr, Tucson, AZ 85724 USA; Univ Arizona, Canc Biol Interdisciplinary Program, Grad Program, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona; University of Arizona	Martinez, JD (corresponding author), Univ Arizona, Dept Radiat Oncol, Arizona Canc Ctr, POB 245024,1515 N Campbell Ave, Tucson, AZ 85724 USA.				NCI NIH HHS [CA64842] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064842] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOSARI S, 1995, AM J PATHOL, V147, P790; BROWN JP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Goldman SC, 1996, AM J PATHOL, V148, P1381; HAINAUT P, 1993, CANCER RES, V53, P1739; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; McLure KG, 1996, ONCOGENE, V13, P1297; McLure KG, 1999, EMBO J, V18, P763, DOI 10.1093/emboj/18.3.763; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1990, ONCOGENE, V5, P1683; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAULSKY G, 1991, CELL GROWTH DIFFER, V2, P661; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; Wolkowicz R, 1998, CANCER DETECT PREV, V22, P1, DOI 10.1046/j.1525-1500.1998.00003.x; Zaika A, 1999, J BIOL CHEM, V274, P27474, DOI 10.1074/jbc.274.39.27474; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZERRAHN J, 1992, ONCOGENE, V7, P1371	42	21	21	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2000	19	35					4042	4049		10.1038/sj.onc.1203756	http://dx.doi.org/10.1038/sj.onc.1203756			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962561	Bronze			2022-12-17	WOS:000088825300010
J	White, JR; Weston, K				White, JR; Weston, K			Myb is required for self-renewal in a model system of early hematopoiesis	ONCOGENE			English	Article						Myb; hematopoiesis; differentiation; apoptosis; bcl-2	C-MYB; STEM-CELLS; B-CELLS; PROGENITOR CELLS; LEUKEMIA-VIRUS; V-MYB; DIFFERENTIATION; EXPRESSION; APOPTOSIS; GENE	In hematopoiesis, self-renewal, proliferation, differentiation and apoptosis represent opposing decisions made by stem cells and progenitor cells, which when dysregulated can result in leukaemia, Here, we have investigated the function of;Myb proteins in regulating these key cellular decisions, using the cell line FDCP-mix A4 as a model of early hematopoiesis, High concentrations of IL-3 in these cells favour self-renewal ol er differentiation and apoptosis, However when endogenous Myb activity was inhibited with an inducible dominant interfering protein, self-renewal was replaced by apoptosis and differentiation. Differentiation was to granulocytes and monocyte/macrophages and was closely associated with a G(1)-S phase block in the cell cycle. As for normal hematopoiesis, cytokine-induced terminal differentiation of FDCP-mix cells is associated with concomitant proliferation prior to its completion, However, when Myb activity was inhibited during this process, proliferation and survival were both reduced, resulting in a much lower yield of mature cells. These results indicate multiple cellular roles of Myb proteins during normal hematopoiesis.	Inst Canc Res, CRC, Ctr Cell & Mol Biol, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Weston, K (corresponding author), Inst Canc Res, CRC, Ctr Cell & Mol Biol, London SW3 6JB, England.							Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FORD AM, 1992, BLOOD, V79, P1962, DOI 10.1182/blood.V79.8.1962.bloodjournal7981962; FRAMPTON J, 1995, EMBO J, V14, P2866, DOI 10.1002/j.1460-2075.1995.tb07286.x; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; HATHCOCK KS, 1992, J IMMUNOL, V149, P2286; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; Heyworth CM, 1990, GROWTH FACTORS, V2, P197, DOI 10.3109/08977199009071506; HEYWORTH CM, 1995, BRIT J HAEMATOL, V91, P15, DOI 10.1111/j.1365-2141.1995.tb05238.x; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; Lagasse E, 1996, J IMMUNOL METHODS, V197, P139, DOI 10.1016/0022-1759(96)00138-X; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MCMAHON J, 1988, ONCOGENE, V3, P717; METCALF D, 1980, P NATL ACAD SCI-BIOL, V77, P5327, DOI 10.1073/pnas.77.9.5327; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIYAJIMA I, 1995, BLOOD, V85, P1246, DOI 10.1182/blood.V85.5.1246.bloodjournal8551246; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Necas E, 1998, STEM CELLS, V16, P107; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; Ratajczak MZ, 1998, BLOOD, V91, P1934, DOI 10.1182/blood.V91.6.1934.1934_1934_1946; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; SCHMID I, 1991, CYTOMETRY, V12, P279, DOI 10.1002/cyto.990120312; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SPANGRUDE GJ, 1990, P NATL ACAD SCI USA, V87, P7433, DOI 10.1073/pnas.87.19.7433; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; TESTA NG, 1993, HAEMOPOIESIS PRACTIC, P267; Weston K, 1999, ONCOGENE, V18, P3034, DOI 10.1038/sj.onc.1202728; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0	41	21	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2000	19	9					1196	1205		10.1038/sj.onc.1203394	http://dx.doi.org/10.1038/sj.onc.1203394			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713708				2022-12-17	WOS:000085567800010
J	Hennighausen, L				Hennighausen, L			Mouse models for breast cancer	ONCOGENE			English	Article						mammary; cancer; mouse models; transgenic; knock-out	TRANSGENIC MICE; GENES		NIDDKD, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hennighausen, L (corresponding author), NIDDKD, Lab Genet & Physiol, NIH, Bldg 8,Room 101, Bethesda, MD 20892 USA.			Hennighausen, Lothar/0000-0001-8319-9841	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK061000, Z01DK061000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743	4	21	26	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		966	967		10.1038/sj.onc.1203346	http://dx.doi.org/10.1038/sj.onc.1203346			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713679	Green Published			2022-12-17	WOS:000085796400001
J	Hutton, FG; Turnell, AS; Gallimore, PH; Grand, RJA				Hutton, FG; Turnell, AS; Gallimore, PH; Grand, RJA			Consequences of disruption of the interaction between p53 and the larger adenovirus early region 1B protein in adenovirus E1 transformed human cells	ONCOGENE			English	Article						p53; adenovirus E1B; penetratin peptides	WILD-TYPE P53; TUMOR-SUPPRESSOR; CELLULAR PROTEIN; APOPTOSIS; EXPRESSION; ONCOGENICITY; LOCALIZATION; ASSOCIATION; FRAGMENTS; BINDING	The adenovirus early region 1B (Ad E1B) genes have no transforming capability of their own but markedly increase the transformation frequency of Ad EIA following co-transfection into mammalian cells, The larger E1B proteins of both Ad2/5 and Ad12 bind to p53 and inhibit its ability to transcriptionally activate other genes. We have previously demonstrated that synthetic peptides identical to the binding sites for p53 on both the Ad2 and Ad12 E1B proteins will disrupt the interaction in vivo and in vitro . in the work presented here we have examined the effects of complex dissociation on Ad El-transformed human cells, If has been shown, using confocal microscopy, that when the peptide identical to the p53 binding site was added to Ad5 E1-transformed cells it initally located in the cytoplasmic dense bodies where it caused disruption of the p53/E1B complex. Peptide and p53 then translocated to the nucleus, In Ad12 El-transformed cells the peptide localized in the nucleus directly and there caused a reorganization of p53 staining from a highly organized, 'flecke' distribution to one in vc which nuclear staining was homogeneous and diffuse. Peptides added to either Ad5 El or Ad12 El transformed cells resulted in the release of transcriptionally active p53, interestingly, the level of p53 then fell presumably as a result of proteasomal action - this was probably a reflection of the short half-life of 'free' (i.e. dissociated) p53 compared to that of the bound protein, Free p53 did not cause apoptosis in target cells probably due to the presence of the smaller (19K) E1B proteins. However, addition of peptide leads to a significant reduction in cell growth rate. We have further demonstrated that a significant proportion of those cells which had taken up peptide had ceased DNA synthesis, probably due to a p53-induced cell cycle arrest. The role of the larger E1B protein during transformation is considered in view of these data.	Univ Birmingham, CRC Inst Canc Studies, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Grand, RJA (corresponding author), Univ Birmingham, CRC Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.			Hutton, Fiona/0000-0002-9707-2988				BAYLEY ST, 1994, INT J ONCOL, V5, P425; BERNARDS R, 1984, BIOCHIM BIOPHYS ACTA, V783, P187, DOI 10.1016/0167-4781(84)90029-0; Chinnadurai G, 1998, SEMIN VIROL, V8, P399, DOI 10.1006/smvy.1997.0139; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; Gabler S, 1998, J VIROL, V72, P7960, DOI 10.1128/JVI.72.10.7960-7971.1998; GALLIMORE PH, 1986, ANTICANCER RES, V6, P499; Gallimore PH, 1997, J VIROL, V71, P6629, DOI 10.1128/JVI.71.9.6629-6640.1997; GALLIMORE PH, 1985, CANCER RES, V45, P2670; GALLIMORE PH, 1985, SOC GEN MICROBIOL S, V37, P125; Grand RJA, 1999, ONCOGENE, V18, P955, DOI 10.1038/sj.onc.1202358; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; Grand RJA, 1996, VIROLOGY, V218, P23, DOI 10.1006/viro.1996.0162; GRAND RJA, 1993, VIROLOGY, V193, P579, DOI 10.1006/viro.1993.1166; HUEN DS, 1995, ONCOGENE, V10, P549; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MAK I, 1988, VIROLOGY, V163, P201, DOI 10.1016/0042-6822(88)90248-6; MERRICK RM, 1991, J GEN VIROL, V72, P955, DOI 10.1099/0022-1317-72-4-955; MORAN E, 1994, SEMIN VIROL, V5, P327, DOI 10.1006/smvy.1994.1037; Prochiantz A, 1996, CURR OPIN NEUROBIOL, V6, P629, DOI 10.1016/S0959-4388(96)80095-X; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Turnell AS, 1999, J VIROL, V73, P2074, DOI 10.1128/JVI.73.3.2074-2083.1999; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; White E, 1998, SEMIN VIROL, V8, P505, DOI 10.1006/smvy.1998.0155; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAJDEL MEB, 1988, ONCOGENE, V2, P579; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	37	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					452	462		10.1038/sj.onc.1203316	http://dx.doi.org/10.1038/sj.onc.1203316			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656694				2022-12-17	WOS:000084873700017
J	Roy, G; Horton, JK; Roy, R; Denning, T; Mitra, S; Boldogh, I				Roy, G; Horton, JK; Roy, R; Denning, T; Mitra, S; Boldogh, I			Acquired alkylating drug resistance of a human ovarian carcinoma cell line is unaffected by altered levels of pro- and anti-apoptotic proteins	ONCOGENE			English	Article						drug resistance; apoptosis; alkylating drugs; pro- and anti-apoptotic proteins; bcl-2 family	GENE O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; BASE EXCISION-REPAIR; APURINIC/APYRIMIDINIC ENDONUCLEASE; CYTOCHROME-C; DNA; BCL-2; MITOCHONDRIA; RECOGNITION; EXPRESSION; ACTIVATION	In a systematic study to elucidate the involvement of pro-and anti-apoptotic proteins in alkylating drug resistance of tumor cells, we utilized the A2780(100) line, that was selected by repeated exposure of A2780 cell line (human ovarian carcinoma line) to chlorambucil (CBL), A2780(100) was 5-10-fold more resistant to nitrogen mustards (IC,, of 50-60 mu M) and other DNA crosslinking agents, e,g,, cisplatin, and also to DNA topoisomerase inhibitor etoposide (ETO) than A2780. CEL (125 mu M) induced extensive apoptosis in A2780 associated with mitochondrial damage but not in A2780(100). No significant differences were observed between A2780 and A2780(100) cells in the basal levels, or the enhanced levels in some cases after CBL treatment, of DNA repair proteins involved in repair of alkyl base adducts or in repair of DNA crosslinks or double strand break repair. However, the basal levels of anti-apoptotic proteins Bcl-x(L), and Mcl-1 were 4-8-fold higher in A2780(100) than in A2780 neither of which expressed Bcl-2, In contrast, the levels of pro-apoptotic Bas and Bak were 3-5-fold higher in the CBL-treated A2780 but not in A2780(100). ETO (5 mu M) induced apoptosis in A2780 without altering the levels of Bax and Bak in these cells. lit the same time, neither ol expression of Bcl-x(L), in A2780, nor its antisense expression in A2780(100), and nor overexpression of Bas in A2780(100), significantly affected drug sensitivity of either line. Our results suggest that a change in an early step in DNA damage processing which affects intracellular signaling, such as enhanced DNA double-strand break repair, could be the primary cause for development of resistance in A2780(100) cells to drugs which induce DNA crosslinks or double strand-breaks.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Mitra, S (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, Route 1079, Galveston, TX 77555 USA.		Denning, Timothy/F-2271-2011	Denning, Timothy/0000-0002-1072-7444	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676, R01ES007572] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES07572, ES06676] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Begleiter A, 1996, LEUKEMIA LYMPHOMA, V23, P187, DOI 10.3109/10428199609054821; Boldogh I, 1998, CANCER RES, V58, P3950; Bresnahan WA, 1997, VIROLOGY, V231, P239, DOI 10.1006/viro.1997.8489; Brookman KW, 1996, MOL CELL BIOL, V16, P6553; Chen KH, 1998, NUCLEIC ACIDS RES, V26, P2001, DOI 10.1093/nar/26.8.2001; Chen ZF, 1998, J PHARMACOL EXP THER, V285, P608; COLVIN OM, 1993, ADV ENZYME REGUL, V33, P19; Decaudin D, 1997, CANCER RES, V57, P62; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hazra TK, 1997, BIOCHEMISTRY-US, V36, P5769, DOI 10.1021/bi963085i; Horton JK, 1999, BIOCHEM PHARMACOL, V58, P693, DOI 10.1016/S0006-2952(99)00142-2; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; KAMESAKI S, 1993, CANCER RES, V53, P4251; KOHN KW, 1966, J MOL BIOL, V19, P266, DOI 10.1016/S0022-2836(66)80004-9; Krokan HE, 1997, BIOCHEM J, V325, P1; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; MITRA S, 1993, PROG NUCLEIC ACID RE, V44, P109, DOI 10.1016/S0079-6603(08)60218-4; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; Robertson KA, 1997, CELL GROWTH DIFFER, V8, P443; Roy R, 1998, BIOCHEMISTRY-US, V37, P580, DOI 10.1021/bi972313l; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Stahelin BJ, 1998, J CLIN PATHOL-MOL PA, V51, P204; Tano K, 1997, J BIOL CHEM, V272, P13250, DOI 10.1074/jbc.272.20.13250; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	33	21	23	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					141	150		10.1038/sj.onc.1203318	http://dx.doi.org/10.1038/sj.onc.1203318			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644989				2022-12-17	WOS:000084844300016
J	Crusius, K; Kaszkin, M; Kinzel, V; Alonso, A				Crusius, K; Kaszkin, M; Kinzel, V; Alonso, A			The human papillomavirus type 16 E5 protein modulates phospholipase C-gamma-1 activity and phosphatidyl inositol turnover in mouse fibroblasts	ONCOGENE			English	Article						phospholipids; phospholipases; membranes; kinases	EPIDERMAL-GROWTH-FACTOR; EPITHELIAL-CELL LINE; KINASE-C ACTIVATION; SIGNAL-TRANSDUCTION; FACTOR RECEPTOR; A431 CELLS; KERATINOCYTES; HYDROLYSIS; GENE; COMMUNICATION	The human papillomavirus type 16 E5 (HPV16-E5) protein is a membrane protein that has been associated with malignant growth. The protein affects growth factor-mediated signal transduction in a ligand-dependent manner. We show now that E5 expression in A31 fibroblasts results in an increased level of diacylglycerol (DAG) and inositol phosphates. Immunoprecipitation of phospholipase C-gamma-1 (PLC-gamma-1) with specific antibodies and immunoblotting with anti-phosphotyrosine antibodies reveal a large increase in tyrosine phosphorylation of the enzyme in ES-expressing cells compared to control vector-transfected cells. This activation of tyrosine phosphorylation is growth factor independent. In addition, an enhanced formation of phosphatidic acid (PA) was observed in E5 cells. This increase did not result from activation of phospholipase D (PLD), although the enzyme was activatable by treatment with phorbol ester. Thus, a phosphohydrolase-mediated DAG synthesis from PLD-produced PA can be excluded. The observed effects were not further enhanced by EGF showing that the presence of the growth factor is not necessary for maintaining permanent activation of PLC-gamma-1 in E5-expressing cells. The DAG- and inositol phosphate-mediated signal cascade within the cells is thus effectively uncoupled from external control via EGF and its receptor in the presence of E5 protein.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Alonso, A (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.							Auvinen E, 1997, INT J ONCOL, V11, P1297; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOUVARD V, 1994, VIROLOGY, V203, P73, DOI 10.1006/viro.1994.1456; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Crusius K, 1998, EXP CELL RES, V241, P76, DOI 10.1006/excr.1998.4024; Crusius K, 1997, ONCOGENE, V15, P1437, DOI 10.1038/sj.onc.1201312; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; Exton JH, 1998, BBA-MOL CELL BIOL L, V1436, P105, DOI 10.1016/S0005-2760(98)00124-6; Faccini AM, 1996, J VIROL, V70, P9041, DOI 10.1128/JVI.70.12.9041-9045.1996; FAULKNERVALLE G, 1995, J GEN VIROL, V76, P1239; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAUSEN HZ, 1989, CANCER RES, V49, P4677; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; Homma MK, 1996, CELL GROWTH DIFFER, V7, P281; Kaszkin M, 1996, BIOCHEM J, V314, P129, DOI 10.1042/bj3140129; KASZKIN M, 1992, BIOCHEM J, V287, P51, DOI 10.1042/bj2870051; Katan M, 1996, CANCER SURV, V27, P199; Khare S, 1997, J CLIN INVEST, V99, P1831, DOI 10.1172/JCI119350; Kiss Z, 1998, BBA-LIPID LIPID MET, V1392, P109, DOI 10.1016/S0005-2760(98)00030-7; KOBAYASHI M, 1987, J NEUROCHEM, V48, P1597, DOI 10.1111/j.1471-4159.1987.tb05707.x; Lambeth JD., 1996, NEW COMPREHENSIVE BI, P237; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; Liscovitch M, 1996, J LIPID MEDIAT CELL, V14, P215, DOI 10.1016/0929-7855(96)00528-7; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; PIM D, 1992, ONCOGENE, V7, P27; Rahimi N, 1996, CELL GROWTH DIFFER, V7, P263; REYNOLDS NJ, 1993, BIOCHEM J, V294, P535, DOI 10.1042/bj2940535; Sakane F, 1997, INT J BIOCHEM CELL B, V29, P1139, DOI 10.1016/S1357-2725(97)00037-X; Schmidt M, 1998, J BIOL CHEM, V273, P7413, DOI 10.1074/jbc.273.13.7413; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; WAGNER H, 1962, J LIPID RES, V3, P177; WAHL M, 1988, J BIOL CHEM, V263, P7581; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980	36	21	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	1999	18	48					6714	6718		10.1038/sj.onc.1203075	http://dx.doi.org/10.1038/sj.onc.1203075			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597278				2022-12-17	WOS:000083792000012
J	Kurasawa, Y; Todokoro, K				Kurasawa, Y; Todokoro, K			Identification of human APC10/Doc1 as a subunit of anaphase promoting complex	ONCOGENE			English	Article						APC; APC10; centromere; Doc1; ubiquitin	SISTER-CHROMATID SEPARATION; CHECKPOINT PROTEIN MAD2; XENOPUS EGG EXTRACTS; SPINDLE CHECKPOINT; FISSION YEAST; CYCLIN PROTEOLYSIS; SACCHAROMYCES-CEREVISIAE; UBIQUITIN LIGASE; MITOTIC SPINDLE; MAMMALIAN-CELLS	Anaphase-promoting complex or cyclosome (APC) is a ubiquitin ligase which specifically targets mitotic regulatory factors such as Pds1/Cut2 and cyclin B. Identification of the subunits of multiprotein complex APC in several species revealed the highly conserved composition of APC from yeast to human. It has been reported, however, that vertebrate APC is composed of at least eight subunits, APC1 to APC8, while budding yeast APC is constituted of at least 12 components, Apc1 to Apc13. It has not Set been clearly understood whether additional components found in budding yeast, Apc9 to Apc13, are actually composed of mammalian APC. Here we isolated and characterized human APC10/Doc1, and found that APC10/Doc1 binds to APC core subunits throughout the cell cycle. Further, it was found that APC10/Doc1 is localized in centrosomes and mitotic spindles throughout mitosis, while it is also localized in kinetochores from prophase to anaphase and in midbody in telophase and cytokinesis. These results strongly support the notion that human APC10/Doc1 may be one of the APC core subunits rather than the transiently associated regulatory factor.	RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Tsukuba, Ibaraki 3050074, Japan	RIKEN	Todokoro, K (corresponding author), RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, 3-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.							Alexandru G, 1999, EMBO J, V18, P2707, DOI 10.1093/emboj/18.10.2707; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Fesquet D, 1999, EMBO J, V18, P2424, DOI 10.1093/emboj/18.9.2424; Fraschini R, 1999, J CELL BIOL, V145, P979, DOI 10.1083/jcb.145.5.979; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; Grossberger R, 1999, J BIOL CHEM, V274, P14500, DOI 10.1074/jbc.274.20.14500; Harlow E, 1998, ANTIBODIES LAB MANUA; He XW, 1997, P NATL ACAD SCI USA, V94, P7965, DOI 10.1073/pnas.94.15.7965; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; Hwang LH, 1997, MOL BIOL CELL, V8, P1877, DOI 10.1091/mbc.8.10.1877; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; Ishii K, 1996, EMBO J, V15, P6629, DOI 10.1002/j.1460-2075.1996.tb01053.x; Jiang W, 1998, MOL CELL, V2, P877, DOI 10.1016/S1097-2765(00)80302-0; Jorgensen PM, 1998, MOL CELL BIOL, V18, P468; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Kominami K, 1998, EMBO J, V17, P5388, DOI 10.1093/emboj/17.18.5388; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; KOTANI S, 1999, IN PRESS J CELL BIOL; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Nagata Y, 1997, J CELL BIOL, V139, P449, DOI 10.1083/jcb.139.2.449; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Weinstein J, 1997, J BIOL CHEM, V272, P28501, DOI 10.1074/jbc.272.45.28501; Yamada H, 1997, J CELL SCI, V110, P1793; Yamashita YM, 1996, NATURE, V384, P276, DOI 10.1038/384276a0; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216	49	21	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	1999	18	37					5131	5137		10.1038/sj.onc.1203133	http://dx.doi.org/10.1038/sj.onc.1203133			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498862				2022-12-17	WOS:000082555700001
J	Pajalunga, D; Tognozzi, D; Tiainen, M; D'Angelo, M; Ferrantelli, F; Helin, K; Sacchi, A; Crescenzi, M				Pajalunga, D; Tognozzi, D; Tiainen, M; D'Angelo, M; Ferrantelli, F; Helin, K; Sacchi, A; Crescenzi, M			E2F activates late-G1 events but cannot replace E1A in inducing S phase in terminally differentiated skeletal muscle cells	ONCOGENE			English	Article						differentiation; recombinant adenovirus; cell cycle; transcription; p27	CARDIAC GENE-TRANSCRIPTION; CYCLIN-A; RETINOBLASTOMA PROTEIN; NUCLEAR-LOCALIZATION; ADENOVIRUS E1A; SUBCELLULAR-LOCALIZATION; DEREGULATED EXPRESSION; VENTRICULAR MYOCYTES; FAMILY MEMBERS; GROWTH	We have previously shown that the adenovirus E1A oncogene can reactivate the cell cycle in terminally differentiated cells. Current models imply that much or all of this E1A activity is mediated by the release of the E2F transcription factors from pocket-protein control. In contrast, me show here that overexpression of E2F-1, E2F-2 and E2F-4, or a chimeric E2F-4 tethered to a nuclear localization signal cannot reactivate postmitotic skeletal muscle cells (myotubes). This is not due to lack of transcriptional activity, as demonstrated on both a reporter construct and a number of endogenous target genes. Although cyclin E was strongly overexpressed in E2F-transduced myotubes, it lacked associated kinase activity, possibly explaining the inability of the myotubes to enter S phase and accumulate cyclin A. Although E2F is not sufficient to trigger DNA synthesis in myotubes, its activity is necessary even in the presence of E1A, as dominant-negative DP-1 mutants inhibit E1A-mediated cell cycle reentry. Our data show that, to reactivate myotubes, E1A must exert other functions, in addition to releasing E2F. They also establish mouse myotubes as an experimental system uniquely suited to study the most direct E2F functions in the absence of downstream cell cycle effects.	Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Rome, Italy; European Inst Oncol, Dept Expt Oncol, Milan, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS European Institute of Oncology (IEO)	Crescenzi, M (corresponding author), Ist Super Sanita, Lab Compared Toxicol & Ecotoxicol, Viale Regina Elena 299, I-00161 Rome, Italy.		Crescenzi, Marco/J-3603-2018; Ferrantelli, Flavia/J-7794-2016; pajalunga, deborah/K-2423-2018; Helin, Kristian/K-2526-2019; Helin, Kristian/HDM-8306-2022	Crescenzi, Marco/0000-0003-0156-1494; Ferrantelli, Flavia/0000-0002-0768-1078; pajalunga, deborah/0000-0003-4892-8396; Helin, Kristian/0000-0003-1975-6097	Telethon [761] Funding Source: Medline	Telethon(Fondazione Telethon)		Alevizopoulos K, 1998, EMBO J, V17, P5987, DOI 10.1093/emboj/17.20.5987; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CRESCENZI M, 1995, J CELL PHYSIOL, V162, P26, DOI 10.1002/jcp.1041620105; CRESCENZI M, 1995, ANN NY ACAD SCI, V752, P9, DOI 10.1111/j.1749-6632.1995.tb17402.x; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; delaLuna S, 1996, J CELL SCI, V109, P2443; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Endo T., 1989, CELLULAR MOL BIOL MU, P95; FOGEL M, 1967, P NATL ACAD SCI USA, V58, P967, DOI 10.1073/pnas.58.3.967; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; Kirshenbaum LA, 1996, DEV BIOL, V179, P402, DOI 10.1006/dbio.1996.0270; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Magae J, 1996, J CELL SCI, V109, P1717; Muller H, 1997, MOL CELL BIOL, V17, P5508; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OKAZAKI K, 1966, P NATL ACAD SCI USA, V56, P1484, DOI 10.1073/pnas.56.5.1484; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Puri PL, 1998, CANCER RES, V58, P1325; Puri PL, 1997, ONCOGENE, V14, P1171, DOI 10.1038/sj.onc.1200941; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Tiainen M, 1996, CELL GROWTH DIFFER, V7, P1039; Tiainen M, 1996, MOL CELL BIOL, V16, P5302; TRIVEDI RA, 1995, J NEUROCHEM, V64, P2230; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; Wu CL, 1996, MOL CELL BIOL, V16, P3698; YAFFE D, 1967, NATURE, V215, P421, DOI 10.1038/215421a0; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407	40	21	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	1999	18	36					5054	5062		10.1038/sj.onc.1202897	http://dx.doi.org/10.1038/sj.onc.1202897			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490842				2022-12-17	WOS:000082497100005
J	Reddy, DE; Sandhu, AK; DeRiel, JK; Athwal, RS; Kaur, GP				Reddy, DE; Sandhu, AK; DeRiel, JK; Athwal, RS; Kaur, GP			Identification of a gene at 16q24.3 that restores cellular senescence in immortal mammary tumor cells	ONCOGENE			English	Article						cell senescence; gene mapping; immortalization; breast cancer; chromosome transfer	MEDIATED CHROMOSOME TRANSFER; SPORADIC BREAST-CANCER; HUMAN-FIBROBLASTS; INDEFINITE DIVISION; MOUSE CELLS; ALLELE LOSS; CARCINOMA; TUMORIGENICITY; MAP; COMPLEMENTATION	We have mapped a cellular senescence gene, SEN16, within a genetic distance of 3-7 cM, at 16q24.3. Microcell mediated transfer of a normal human chromosome 16, 16q22-qter or 16q23-qter restored cellular senescence in four immortal cell lines, derived from human and rat mammary tumors. The resumption of indefinite cell proliferation, concordant with the segregation of the donor chromosome, confirmed the presence of a senescence gene at 16q23-qter. While microcell hybrids were maintained in selection medium to retain the donor chromosome, sporadic immortal revertant clones arose among senescent cells. Reversion to immortal growth could occur due to inactivation of the senescence gene either by a mutation or a deletion. The analysis for chromosome 16 specific DNA markers, in revertant clones of senescent microcell hybrids, revealed a consensus deletion, spanning a genetic interval of approximately 3-7 cM at 16q24.3.	Temple Univ, Sch Med, Fels Inst Canc Res, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Kaur, GP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res, 3307 N Broad St,AHB Room 201, Philadelphia, PA 19140 USA.							Adams S. M., 1992, Human Molecular Genetics, V1, P91, DOI 10.1093/hmg/1.2.91; ATHWAL RS, 1985, SOMAT CELL MOLEC GEN, V11, P177, DOI 10.1007/BF01534706; AUSTRUY E, 1993, GENOMICS, V15, P684, DOI 10.1006/geno.1993.1126; BARRETT JC, 1978, P NATL ACAD SCI USA, V75, P3761, DOI 10.1073/pnas.75.8.3761; Brenner AJ, 1997, PROG CLIN BIOL RES, V396, P63; BUN CL, 1980, EXP CELL RES, V127, P385; CLETONJANSEN AM, 1994, GENE CHROMOSOME CANC, V9, P101, DOI 10.1002/gcc.2870090205; DANIEL CW, 1983, MECH AGEING DEV, V23, P259, DOI 10.1016/0047-6374(83)90026-X; DEVILEE P, 1991, ONCOGENE, V6, P1705; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DOGGETT NA, 1995, NATURE, V377, P335; EHMANN UK, 1991, IN VITRO CELL DEV B, V27, P749, DOI 10.1007/BF02633221; GANTZ I, 1994, GENOMICS, V19, P394, DOI 10.1006/geno.1994.1080; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GOOLSBY CL, 1991, CANCER GENET CYTOGEN, V49, P231; GOTOH S, 1979, J GEN VIROL, V42, P409, DOI 10.1099/0022-1317-42-2-409; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GUALANDI F, 1994, GENE CHROMOSOME CANC, V10, P77, DOI 10.1002/gcc.2870100202; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; HUBBARDSMITH K, 1992, MOL CELL BIOL, V12, P2273, DOI 10.1128/MCB.12.5.2273; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; KAUR GP, 1993, SOMAT CELL MOLEC GEN, V19, P83, DOI 10.1007/BF01233957; KOZMAN HM, 1995, GENOMICS, V25, P44, DOI 10.1016/0888-7543(95)80108-X; Latil A, 1997, CANCER RES, V57, P1058; LI S, 1995, CANCER RES, V55, P3992; LIDA A, 1997, BRIT J CANCER, V75, P254; LINDBLOM A, 1993, CANCER RES, V53, P3707; MAW MA, 1992, CANCER RES, V52, P3094; MEDINA D, 1993, CANCER RES, V53, P663; MEDINA D, 1996, J MAMMARY GLAND BIOL, V1, P21; NEGRINI M, 1994, CANCER RES, V54, P1331; NEUFELD DS, 1987, MOL CELL BIOL, V7, P2794, DOI 10.1128/MCB.7.8.2794; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; OBRIEN W, 1986, P NATL ACAD SCI USA, V83, P8659; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; Oshimura M, 1997, EUR J CANCER, V33, P710, DOI 10.1016/S0959-8049(97)00090-7; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PRONK JC, 1995, NAT GENET, V11, P338, DOI 10.1038/ng1195-338; PULLMAN WE, 1992, NATURE, V356, P529, DOI 10.1038/356529a0; RIMESSI P, 1994, ONCOGENE, V9, P3467; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Sandhu AK, 1996, ONCOGENE, V12, P247; SATO T, 1991, CANCER RES, V51, P5794; Scott IC, 1996, GENE, V174, P135, DOI 10.1016/0378-1119(96)00510-0; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; STAMPS AC, 1992, EUR J CANCER, V28A, P1495, DOI 10.1016/0959-8049(92)90552-D; STANBRIDGE EJ, 1992, TUMOR SUPPRESSOR GEN, P5; Steenbergen RDM, 1998, INT J CANCER, V76, P412, DOI 10.1002/(SICI)1097-0215(19980504)76:3<412::AID-IJC20>3.0.CO;2-B; TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791, DOI 10.1073/pnas.87.17.6791; TSUDA H, 1994, CANCER RES, V54, P513; UEJIMA H, 1995, GENE CHROMOSOME CANC, V14, P120, DOI 10.1002/gcc.2870140206; WANG E, 1995, CANCER RES, V55, P2284; WANG XW, 1992, CARCINOGENESIS, V13, P555, DOI 10.1093/carcin/13.4.555; WEBER JL, 1989, AM J HUM GENET, V44, P388; WELCH DR, 1994, ONCOGENE, V9, P255; Whitmore SA, 1998, GENOMICS, V50, P1, DOI 10.1006/geno.1998.5316; YAMADA H, 1990, ONCOGENE, V5, P1141; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163	64	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5100	5107		10.1038/sj.onc.1202888	http://dx.doi.org/10.1038/sj.onc.1202888			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490846				2022-12-17	WOS:000082497100009
J	Lorenzi, MV; Castagnino, P; Chen, Q; Hori, Y; Miki, T				Lorenzi, MV; Castagnino, P; Chen, Q; Hori, Y; Miki, T			Distinct expression patterns and transforming properties of multiple isoforms of Ost, an exchange factor for RhoA and Cdc42	ONCOGENE			English	Article						expression cloning; cell cycle; alternative splicing; embryogenesis	CELL-CYCLE PROGRESSION; ACTIN STRESS FIBERS; PROTEIN-KINASE-C; RAS TRANSFORMATION; ACTIVATION; GTPASES; ONCOGENE; RAC1; FAMILY; GENE	A search for transforming genes expressed in brain led to the identification of a no, el isoform of Ost. an exchange factor for RhoA and Cdc42, In addition to the Dbl-homology (DH) and pleckstrin-homology (PH) domains identified in the original Ost, this isoform contained a SH3 domain and a novel) HIV-Tat related (TR) domain. The presence or absence of these domains in Ost defined multiple isoforms of the protein. RT-PCR and in situ hybridization analysis revealed that these isoforms were generated by tissue-specific and developmentally restricted alternative splicing events. Whereas deletion of the N-terminus activated the transforming properties of Ost, the presence of the SH3 domain reduced the transforming activity of the protein. This inhibition mas relieved by the presence of a TR domain, which contained a potential SH3 ligand sequence. The transforming activity of all Ost isoforms was inhibited by dominant negative forms of the Rho family proteins. Expression of Ost isoforms potently induced the formation of actin stress fibers and filopodia as well as JNK activity and AP1- and SRF-regulated transcriptional pathways. Ost transfectants also displayed elevated levels of cyclins A and D1, suggesting that the de-regulation of these cyclins is linked to Oat-mediated transformation.	NCI, Cellular & Mol Biol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Miki, T (corresponding author), NCI, Cellular & Mol Biol Lab, Bldg 37 Room 1E24,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.							Alam MR, 1996, J BIOL CHEM, V271, P28636, DOI 10.1074/jbc.271.45.28636; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Choi DJ, 1997, AIDS RES HUM RETROV, V13, P357, DOI 10.1089/aid.1997.13.357; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; HAMILTONANDREOT.A, 1997, NATURE, V385, P93; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KIESS M, 1995, ONCOGENE, V10, P61; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lorenzi MV, 1996, P NATL ACAD SCI USA, V93, P8956, DOI 10.1073/pnas.93.17.8956; Lorenzi MV, 1997, ONCOGENE, V15, P817, DOI 10.1038/sj.onc.1201242; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SASSOON D, 1993, METHOD ENZYMOL, V225, P384; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Tolkacheva T, 1997, ONCOGENE, V15, P727, DOI 10.1038/sj.onc.1201229; Viel A, 1996, CURR OPIN CELL BIOL, V8, P49, DOI 10.1016/S0955-0674(96)80048-2; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; WHITEHEAD I, 1995, ONCOGENE, V10, P713; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	35	21	21	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	1999	18	33					4742	4755		10.1038/sj.onc.1202851	http://dx.doi.org/10.1038/sj.onc.1202851			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467422	Bronze			2022-12-17	WOS:000082154400012
J	Labbaye, C; Valtieri, M; Grignani, F; Luchetti, L; Masella, B; Alcalay, M; Testa, U; Peschle, C				Labbaye, C; Valtieri, M; Grignani, F; Luchetti, L; Masella, B; Alcalay, M; Testa, U; Peschle, C			Expression and role of PML gene in normal adult hematopoiesis: functional interaction between PML and Rb proteins in erythropoiesis	ONCOGENE			English	Article						HPCs; PML; RB; erythropoiesis	ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; ZINC FINGER GENE; RAR-ALPHA; ERYTHROID-DIFFERENTIATION; RETINOBLASTOMA PROTEIN; RECEPTOR-ALPHA; HUMAN CYTOMEGALOVIRUS; BINDING DOMAINS; HOXB GENES	The expression of the PML gene was investigated in purified early hematopoietic progenitor cells (HPCs) induced to unilineage erythroid or granulocytic differentiation. PML mRNA and protein, while barely detectable in quiescent HPCs, are consistently induced by growth factor stimulation through the erythroid or granulocytic lineage. Thereafter, PML is downmodulated in late granulocytic maturation, whereas it is sustainably expressed through the erythroid pathway. In functional studies, PML expression was inhibited by addition of antisense oligomers targeting PML mRNA (alpha-PML). Interestingly, early treatment (day 0 HPCs) with cr-PML reduced the number of both erythroid and granulocytic colonies, whereas late treatment (day 5 culture) reduced erythroid, but not granulocytic, clonogenesis. These findings suggest that PML is required for early hematopoiesis and erythroid, but not granulocytic maturation. The pattern of PML expression in normal hematopoiesis mimics that of retinoblastoma pRb 105. Combined treatment of HPCs with alpha-PML and alpha-Rb oligomers inhibited both PML and Rb protein expression and completely blocked erythroid colony development. Furthermore, PML and pRb 105 were co-immunoprecipitated in cellular lysates derived from erythroid precursors indicating that this functional interaction may have a biochemical basis. These results suggest a key functional role of PML in early hematopoiesis and late erythropoiesis: the latter phenomenon may be related to the molecular and functional interaction of PML with pRb 105.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Ist Super Sanita, Dept Hematol & Oncol, I-00161 Rome, Italy; Univ Perugia, Dept Clin Med, I-06100 Perugia, Italy; European Inst Oncol, Dept Expt Oncol, Milan, Italy	Jefferson University; Istituto Superiore di Sanita (ISS); University of Perugia; IRCCS European Institute of Oncology (IEO)	Peschle, C (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Bluemle Life Sci Bldg,233 S 10th St, Philadelphia, PA 19107 USA.		valtieri, mauro/H-1044-2016; Alcalay, Myriam/AAB-4300-2019; Testa, Ugo/J-6472-2016; Labbaye, Catherine/J-9930-2016; Alcalay, Myriam/B-3182-2016; Puglisi, Rossella/M-7120-2017; Grignani, Francesco/AAC-2565-2022	valtieri, mauro/0000-0002-9139-6754; Alcalay, Myriam/0000-0002-5558-4272; Testa, Ugo/0000-0001-7900-8942; Alcalay, Myriam/0000-0002-5558-4272; Puglisi, Rossella/0000-0003-1680-1032; Labbaye, Catherine/0000-0003-1255-4396				Ahn JH, 1997, J VIROL, V71, P4599, DOI 10.1128/JVI.71.6.4599-4613.1997; Ahn JH, 1998, MOL CELL BIOL, V18, P4899, DOI 10.1128/MCB.18.8.4899; ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Borden KLB, 1996, P NATL ACAD SCI USA, V93, P1601, DOI 10.1073/pnas.93.4.1601; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; CARE A, 1994, MOL CELL BIOL, V14, P4872, DOI 10.1128/MCB.14.7.4872; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CONDORELLI GL, 1995, P NATL ACAD SCI USA, V92, P4808, DOI 10.1073/pnas.92.11.4808; DANIEL MT, 1993, BLOOD, V82, P1858; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; FAGIOLI M, 1992, ONCOGENE, V7, P1083; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GIAMPAOLO A, 1994, BLOOD, V84, P3637, DOI 10.1182/blood.V84.11.3637.bloodjournal84113637; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1995, CANCER RES, V55, P440; GRIGNANI F, 1994, BLOOD, V83, P10; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; GUIOCHONMANTEL A, 1995, MOL ENDOCRINOL, V9, P1791, DOI 10.1210/me.9.12.1791; He DL, 1997, CANCER RES, V57, P1868; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LABBAYE C, 1994, BLOOD, V83, P651; LABBAYE C, 1995, J CLIN INVEST, V95, P2346, DOI 10.1172/JCI117927; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; NEVINS JR, 1992, SCIENCE, V258, P424; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; ROUSSELOT P, 1994, ONCOGENE, V9, P545; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; VALTIERI M, 1989, BLOOD, V74, P460; VALTIERI M, 1991, BLOOD, V77, P1181; Wang ZG, 1998, SCIENCE, V279, P1547; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109	58	21	21	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 10	1999	18	23					3529	3540		10.1038/sj.onc.1202682	http://dx.doi.org/10.1038/sj.onc.1202682			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376531				2022-12-17	WOS:000080850600011
J	Helou, K; Wallenius, V; Qiu, Y; Ohman, F; Stahl, F; Klinga-Levan, K; Kindblom, LG; Mandahl, N; Jansson, JO; Levan, G				Helou, K; Wallenius, V; Qiu, Y; Ohman, F; Stahl, F; Klinga-Levan, K; Kindblom, LG; Mandahl, N; Jansson, JO; Levan, G			Amplification and overexpression of the hepatocyte growth factor receptor (HGFR/MET) in rat DMBA sarcomas	ONCOGENE			English	Article						rat DMBA sarcoma; HGF receptor; Met gene amplification	MET PROTOONCOGENE PRODUCT; FACTOR SCATTER FACTOR; HGF RECEPTOR; C-MET; GENE AMPLIFICATION; SOLID TUMORS; HA-RAS; EXPRESSION; CANCER; CELLS	In the present study subcutaneous fibrosarcomas were induced by the carcinogen 7,12-dimethylbenz(a)anthracene (DMBA) in rats from F1 generation cross breedings of two different inbred strains. Comparative genomic hybridization (CGH) analysis, which allows detection of DNA sequence copy changes, was applied to one of the tumors and it was found that there were increased copy numbers of sequences at chromosome 4q12-q21 in this tumor. We have previously determined that the loci for the hepatocyte growth factor (Hgf) and hepatocyte growth factor receptor (Hgfr/Met), a protooncogene, are situated in this particular chromosome region, Using probes for the two genes in FISH (fluorescence in situ hybridization) and in Southern blots we found that the Hgfr/Met gene was amplified in five of the 19 sarcomas studied, and that the Hgf gene,vas coamplified in two of them. Northern and Western blots and tyrosine phosphorylation analysis showed that the HGF receptor was overexpressed and functional in all five tumors, as well as in two additional tumors. In summary, both amplification and overexpression of the Hgfr/Met gene was found in about 25% of DMBA-induced experimental rat sarcomas, and HGF receptor overexpression alone was seen in two additional tumors. Possibly this reflects an involvement in paracrine or autocrine stimulation of growth and invasiveness by HGF. Our finding could provide a rodent model system to increased knowledge about causality and therapy, which may be applicable to the sizeable fraction of human musculoskeletal tumors displaying MET overexpression.	Univ Gothenburg, Dept Mol & Cell Biol, Gothenburg, Sweden; Univ Gothenburg, Res Ctr Endocrinol & Metab, Gothenburg, Sweden; Univ Gothenburg, Dept Pathol, Gothenburg, Sweden; Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden	University of Gothenburg; University of Gothenburg; University of Gothenburg; Lund University; Skane University Hospital	Helou, K (corresponding author), Univ Gothenburg, Dept Mol & Cell Biol, Gothenburg, Sweden.		Wallenius, Ville Raymond/C-5486-2014	Wallenius, Ville Raymond/0000-0001-8668-3196				BIEDLER JL, 1976, SCIENCE, V191, P185, DOI 10.1126/science.942798; Comoglio PM, 1996, GENES CELLS, V1, P347, DOI 10.1046/j.1365-2443.1996.37037.x; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; DUMANOIR S, 1993, HUM GENET, V90, P590, DOI 10.1007/BF00202476; Ferracini R, 1996, ONCOGENE, V12, P1697; FISCHER U, 1995, GENE CHROMOSOME CANC, V12, P63, DOI 10.1002/gcc.2870120111; GALEAZZI E, 1997, EUR ARCH OTO-RHINO-L, V1, pS138; HOULDSWORTH J, 1990, CANCER RES, V50, P6417; ISLAM MQ, 1987, HEREDITAS, V107, P127, DOI 10.1111/j.1601-5223.1987.tb00277.x; Iwazawa T, 1996, JPN J CANCER RES, V87, P1134, DOI 10.1111/j.1349-7006.1996.tb03123.x; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; KALLIONIEMI OP, 1994, GENE CHROMOSOME CANC, V10, P231, DOI 10.1002/gcc.2870100403; Kito K, 1996, MOL CARCINOGEN, V17, P78, DOI 10.1002/(SICI)1098-2744(199610)17:2<78::AID-MC4>3.0.CO;2-P; KUNIYASU H, 1992, BIOCHEM BIOPH RES CO, V189, P227, DOI 10.1016/0006-291X(92)91548-5; LEVAN G, 1976, HEREDITAS, V83, P83; Maggiora P, 1997, J CELL PHYSIOL, V173, P183, DOI 10.1002/(SICI)1097-4652(199711)173:2<183::AID-JCP18>3.3.CO;2-Y; Maniatis T., 1982, MOL CLONING LAB MANU; MATSUMOTO K, 1996, J BIOCH, V119, P519; MITELMAN F, 1972, SCIENCE, V176, P1340, DOI 10.1126/science.176.4041.1340; MITELMAN F, 1972, HEREDITAS-GENETISK A, V71, P325; Mitelman F, 1997, CANCER GENET CYTOGEN, V95, P1, DOI 10.1016/S0165-4608(96)00252-X; Naka T, 1997, MODERN PATHOL, V10, P832; NISSON PE, 1992, FOCUS, V14, P119; NUNBERG JH, 1978, P NATL ACAD SCI USA, V75, P5553, DOI 10.1073/pnas.75.11.5553; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; RUGGERI B, 1993, P NATL ACAD SCI USA, V90, P1013, DOI 10.1073/pnas.90.3.1013; SCHWAB M, 1985, NATURE, V315, P345, DOI 10.1038/315345a0; Scotlandi K, 1996, AM J PATHOL, V149, P1209; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; Wallenius VR, 1997, MAMM GENOME, V8, P661, DOI 10.1007/s003359900533; Yamanouchi K, 1995, LASER CHEM, V16, P1, DOI 10.1155/1995/74390; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	36	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 27	1999	18	21					3226	3234		10.1038/sj.onc.1202658	http://dx.doi.org/10.1038/sj.onc.1202658			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359528				2022-12-17	WOS:000080523800005
J	Morley, GM; Uden, M; Gullick, WJ; Dibb, NJ				Morley, GM; Uden, M; Gullick, WJ; Dibb, NJ			Cell specific transformation by c-fms activating loop mutations is attributable to constitutive receptor degradation	ONCOGENE			English	Article						c-fms; M-CSF; CSF-1; oncogene; transformation	COLONY-STIMULATING FACTOR; FACTOR-INDEPENDENT GROWTH; PROTO-ONCOGENE PRODUCT; HUMAN CSF-1 RECEPTOR; FACTOR-I RECEPTOR; TYROSINE KINASE; SURFACE EXPRESSION; FDC-P1 CELLS; MURINE; GENE	Expression of a receptor for human macrophage-colony stimulating factor (M-CSF or CSF-1), containing a point mutation which changes an aspartate to a valine at position 802 of the activating loop of the kinase domain, potently transforms the haemopoietic cell line FDC-P1 Set prevents Rat-2 fibroblast transformation, In order to understand this apparent paradox, aspartate 802 was changed by cassette mutagenesis to each of the other 19 amino acids, AU hydrophobic amino acid substitutions were transforming when tested in FDC-P1 cells yet inactivating when tested in Rat-2 fibroblasts. These same amino acid substitutions also activated receptor degradation, strongly suggesting a causal relationship between receptor degradation and inactivation in fibroblasts, Point mutations or small deletions of Y708 within the kinase insert region of the mutant D802V receptor partly inhibited receptor degradation, The more stable D802V receptor derivatives were able to transform both FDC-P1 cells and Rat-2 fibroblasts, so establishing that the cell specific effect of the c-fmsD802V activating loop mutation is attributable to receptor degradation which accompanies kinase activation and prevents the transformation of Rat-2 hut not of FDC-P1 cells.	Hammersmith Hosp, Imperial Coll, Sch Med, Cell Signalling Unit,Div Paediat Obstet & Gynaeco, London W12 0NN, England; Hammersmith Hosp, Imperial Coll, Sch Med, ICRF Mol Oncol Unit, London W12 0NN, England	Imperial College London; Imperial College London	Dibb, NJ (corresponding author), Hammersmith Hosp, Imperial Coll, Sch Med, Cell Signalling Unit,Div Paediat Obstet & Gynaeco, Du Cane Rd, London W12 0NN, England.							BAKER DA, 1994, LEUKEMIA, V8, P1970; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Dibb NJ, 1990, GROWTH FACTORS, V2, P301, DOI 10.3109/08977199009078018; DUBREUIL P, 1988, BLOOD, V72, P1081; GLOVER HR, 1995, ONCOGENE, V11, P1347; HADWIGER A, 1986, EMBO J, V5, P689, DOI 10.1002/j.1460-2075.1986.tb04268.x; HALENBECK R, 1989, BIO-TECHNOL, V7, P710, DOI 10.1038/nbt0789-710; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Hubbard S. R., 1997, EMBO J, V16, P5573; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kacinski BM, 1997, MOL REPROD DEV, V46, P71, DOI 10.1002/(SICI)1098-2795(199701)46:1<71::AID-MRD11>3.0.CO;2-6; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; LADNER MB, 1987, EMBO J, V6, P2693, DOI 10.1002/j.1460-2075.1987.tb02561.x; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; MINOR DL, 1994, NATURE, V371, P264, DOI 10.1038/371264a0; NICHOLS EJ, 1985, MOL CELL BIOL, V5, P3467, DOI 10.1128/MCB.5.12.3467; Novak U, 1996, ONCOGENE, V13, P2607; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; RAMBALDI A, 1988, J CLIN INVEST, V81, P1030, DOI 10.1172/JCI113413; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; Roth P, 1992, Curr Top Microbiol Immunol, V181, P141; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; Sambrook J, 1989, MOL CLONING LAB MANU; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SMITH CK, 1994, BIOCHEMISTRY-US, V33, P5510, DOI 10.1021/bi00184a020; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; TROULIARIS S, 1995, ARCH VIROL, V140, P179, DOI 10.1007/BF01309733; TSUJIMURA T, 1995, INT ARCH ALLERGY IMM, V106, P377, DOI 10.1159/000236870; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VERON M, 1993, P NATL ACAD SCI USA, V90, P10618, DOI 10.1073/pnas.90.22.10618; WHEELER EF, 1987, MOL CELL BIOL, V7, P1673, DOI 10.1128/MCB.7.5.1673	43	21	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3076	3084		10.1038/sj.onc.1202646	http://dx.doi.org/10.1038/sj.onc.1202646			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340379				2022-12-17	WOS:000080388000003
J	Robertson, GP; Goldberg, EK; Lugo, TG; Fountain, JW				Robertson, GP; Goldberg, EK; Lugo, TG; Fountain, JW			Functional localization of a melanoma tumor suppressor gene to a small (<= 2 Mb) region on 11q23	ONCOGENE			English	Article						melanoma; tumor suppressor gene; chromosome 11 (11q23); functional cloning; DNA-damage checkpoint control gene (CHK1)	HUMAN PROSTATE-CANCER; MALIGNANT-MELANOMA; CHROMOSOME 11Q; BREAST-CANCER; ATAXIA-TELANGIECTASIA; OVARIAN-CANCER; ALLELIC LOSSES; HUMAN GENOME; HETEROZYGOSITY; MAP	We have previously demonstrated the existence of a melanoma tumor suppressor gene(s) on the long arm of chromosome 11 through suppression of tumorigenicity assays. Although loss of heterozygosity studies also support this finding, only a large critical region (44 cM) has been identified to date on 11q22-25, To further localize a tumor suppressor gene(s) within this region, we have now generated and characterized nine melanoma microcell hybrids, each retaining an introduced fragment of 11q, Of the nine hybrids, four were suppressed for tumor formation in nude mice, while five formed tumors at the same rate as the parental melanoma cell line (UACC 903), Molecular analysis of the hybrids with 118 microsatellite markers narrowed the location of a putative suppressor gene to a small (less than or equal to 2 Mb) candidate region on 11q23 between the markers D11S1786 and D11S2077 and within the larger region frequently deleted in melanoma tumors and cell fines. While multiple tumor suppressor genes are likely to reside on 11q22-25, the presence of this region in all four suppressed hybrids supports the simplest model that a single locus is responsible for the suppressed phenotype observed in UACC 903.	Univ So Calif, Inst Med Genet, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA	University of Southern California; University of California System; University of California Riverside	Fountain, JW (corresponding author), Univ So Calif, Inst Med Genet, Dept Biochem & Mol Biol, 2250 Alcazar St,CSC-IGM240, Los Angeles, CA 90033 USA.		Robertson, Gavin P./A-6106-2017	Robertson, Gavin P./0000-0003-0152-2997	NATIONAL CANCER INSTITUTE [R01CA066021] Funding Source: NIH RePORTER; NCI NIH HHS [CA66021] Funding Source: Medline; CIT NIH HHS [CCT0197] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CIT NIH HHS		Arai Y, 1996, GENOMICS, V35, P196, DOI 10.1006/geno.1996.0339; BARCH MJ, 1991, ACT CYTOGENETICS LAB, P180; Baysal BE, 1997, GENOMICS, V44, P214, DOI 10.1006/geno.1997.4880; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Dahiya R, 1997, INT J CANCER, V72, P283, DOI 10.1002/(SICI)1097-0215(19970717)72:2<283::AID-IJC14>3.0.CO;2-H; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Evans Glen A., 1996, American Journal of Human Genetics, V59, pA66; FOULKES WD, 1993, BRIT J CANCER, V67, P268, DOI 10.1038/bjc.1993.51; FOUNTAIN JW, 1998, GENETIC FACTORS CUTA, P475; Gabra H, 1996, CANCER RES, V56, P950; GUDMUNDSSON J, 1995, BRIT J CANCER, V72, P696, DOI 10.1038/bjc.1995.396; HAMPTON GM, 1994, CANCER RES, V54, P4586; HERBST RA, 1995, CANCER RES, V55, P2494; IIZUKA M, 1995, GENE CHROMOSOME CANC, V13, P40; JAMES MR, 1994, NAT GENET, V8, P70, DOI 10.1038/ng0994-70; Kawana Y, 1997, PROSTATE, V32, P205; KELDYSH PL, 1993, GENE CHROMOSOME CANC, V6, P45, DOI 10.1002/gcc.2870060109; KILLARY AM, 1995, METHOD ENZYMOL, V254, P133; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; LUGO TG, 1987, MOL CELL BIOL, V7, P2814, DOI 10.1128/MCB.7.8.2814; Manickam P, 1997, HUM GENET, V101, P102, DOI 10.1007/s004390050595; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; NEGRINI M, 1995, CANCER RES, V55, P3003; RASIO D, 1995, CANCER RES, V55, P6053; Robertson G, 1996, CANCER RES, V56, P4487; Robertson GP, 1997, CYTOGENET CELL GENET, V79, P53, DOI 10.1159/000134682; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SHAW ME, 1995, GENE CHROMOSOME CANC, V13, P1, DOI 10.1002/gcc.2870130102; THOMPSON FH, 1995, CANCER GENET CYTOGEN, V83, P93, DOI 10.1016/0165-4608(95)00057-V; TOMLINSON IPM, 1995, J CLIN PATHOL, V48, P424, DOI 10.1136/jcp.48.5.424; TOMLINSON IPM, 1993, GENE CHROMOSOME CANC, V7, P169, DOI 10.1002/gcc.2870070310; Tomlinson IPM, 1996, EUR J CANCER, V32A, P1797, DOI 10.1016/0959-8049(96)00198-0; TRASK B, 1990, FLUORESCENCE IN SITU, P383; VANAGAITE L, 1995, HUM GENET, V95, P451; WALKER GJ, 1995, GENE CHROMOSOME CANC, V12, P134, DOI 10.1002/gcc.2870120208; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; WINQVIST R, 1995, CANCER RES, V55, P2660	41	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3173	3180		10.1038/sj.onc.1202664	http://dx.doi.org/10.1038/sj.onc.1202664			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340390				2022-12-17	WOS:000080388000014
J	Woo, ES; Rice, RL; Lazo, JS				Woo, ES; Rice, RL; Lazo, JS			Cell cycle dependent subcellular distribution of Cdc25B subtypes	ONCOGENE			English	Article						Cdc25; green fluorescent protein; nuclear localization; phosphorylation; etoposide; cell cycle	CDK REGULATION; PHOSPHATASE; MITOSIS; PHOSPHORYLATION; ACTIVATION; PHASE; TRIGGERS; BINDING; DOMAIN; ROLES	The dual specificity phosphatase and oncogene Cdc25B has been implicated in the G2/M cell cycle checkpoint, but the mode by which it is regulated remains poorly understood, Regional subcellular redistribution of proteins represents a unique potential regulatory mechanism. Thus, we examined in live cells the subcellular localization characteristics of Cdc25B(2) and Cdc25B(3) fused to green fluorescent protein. Cdc25B(2) partitioned primarily in the cytoplasm during G1 and progressively migrated to the nucleus as cells transited from S to G2/M phase. In contrast, Cdc25B(3) maintained a homogeneously staining diffuse phenotype irrespective of cell cycle phase. Treatment of the Cdc25B(2)-green fluorescent protein stable transfectants with vanadate inhibited the cell cycle dependency of intracellular distribution, while okadaic acid had little effect except in G1, suggesting regulation by at least one phosphorylation-dependent pathway. The DNA topoisomerase II poison and DNA damaging agent, etoposide, inhibited nuclear localization of Cdc25B(2) in S phase, possibly by invoking a sequestration cascade. Thus, differences in the spatial distribution of Cdc25B subtypes exist within cells and the 41 amino acid insert in the N-terminus of the Cdc25B(3) splice variant encodes an important inhibitory determinant for such regulation. The subcellular redistribution of Cdc25B(2) could be functionally important for G2/M checkpoint regulation.	Univ Pittsburgh, Inst Canc, Dept Pharmacol, Mol Therapeut Drug Discovery Program, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lazo, JS (corresponding author), Univ Pittsburgh, Inst Canc, Dept Pharmacol, Mol Therapeut Drug Discovery Program, Pittsburgh, PA 15261 USA.				NCI NIH HHS [CA61299, CA78039] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061299, P01CA078039] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; Gabrielli BG, 1997, ONCOGENE, V15, P749, DOI 10.1038/sj.onc.1201254; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Kruk PA, 1997, BIOCHEM BIOPH RES CO, V233, P717, DOI 10.1006/bbrc.1997.6549; Lammer C, 1998, J CELL SCI, V111, P2445; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; PASTAN I, 1979, METHOD ENZYMOL, V58, P233; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Woo ES, 1997, CANCER RES, V57, P4236; Xu X, 1996, J BIOL CHEM, V271, P5118; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766	25	21	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2770	2776		10.1038/sj.onc.1202614	http://dx.doi.org/10.1038/sj.onc.1202614			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348352	Bronze			2022-12-17	WOS:000080124900013
J	Li, L; Peterson, CA; Kanter-Smoler, G; Wei, YF; Ramagli, LS; Sunnerhagen, P; Siciliano, MJ; Legerski, RJ				Li, L; Peterson, CA; Kanter-Smoler, G; Wei, YF; Ramagli, LS; Sunnerhagen, P; Siciliano, MJ; Legerski, RJ			hRAD17, a structural homolog of the Schizosaccharomyces pombe RAD17 cell cycle checkpoint gene, stimulates p53 accumulation	ONCOGENE			English	Article						cell cycle checkpoint; DNA damage; p53; fission yeast S-Pombe; RAD17; human homolog	DNA-DAMAGE CHECKPOINT; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; S-PHASE; PROTEIN-KINASE; BUDDING YEAST; ATAXIA-TELANGIECTASIA; ACCESSORY PROTEINS; REPAIR; REPLICATION	The RAD17 gene product of S. Pombe is an essential component of the checkpoint control pathway which responds to both DNA damage and disruption of replication. We have identified a human cDNA that encodes a polypeptide which is structurally conserved with the S, Pombe Rad17 protein. The human gene, designated hRAD17, predicts an encoded protein of 590 amino acids and a molecular weight of 69 kD. Amino acid sequence alignment revealed that hRad17 has 28.3% and 52.5% similarity with the S. Pombe Rad17 protein, and 21.8% identity and 45.8% similarity to the budding yeast cell cycle checkpoint protein, Rad 24. When introduced into the S. Pombe rad17 mutant, hRAD17 was able to partially revert its hydroxyurea and ionizing radiation hypersensitivity, but not its UV hypersensitivity. Permanent overexpression of the kRAD17 gene in human fibrosarcoma cells resulted in p53 activation and a significant reduction of S- and G2/M-phase cells accompanied by an accumulation of the G1-phase population, suggesting that hRAD17 may have a role in cell cycle checkpoint control, Immunostaining of HT-1080 cells transiently transfected with a hRAD17 construct confirmed the nuclear accumulation of p53, which mimics the induction caused by DNA damage. Using FISH analysis, we have mapped the hRAD17 locus to human chromosome 5q11.2.	Univ Texas, MD Anderson Cancer Ctr, Dept Mol Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Gothenburg, Dept Biol Mol, Lundberg Lab, SE-40530 Gothenburg, Sweden; Human Genome Sci Inc, Rockville, MD 20850 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Gothenburg; GlaxoSmithKline; Human Genome Sciences Inc	Legerski, RJ (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Mol Genet, Houston, TX 77030 USA.		Sunnerhagen, Per/G-1696-2012	Sunnerhagen, Per/0000-0002-0967-8729	NATIONAL CANCER INSTITUTE [R01CA076172, R29CA076172, P01CA034936, R01CA052461] Funding Source: NIH RePORTER; NCI NIH HHS [CA76172, CA52461, CA34936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; Barrett MT, 1996, ONCOGENE, V13, P1867; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; CARR AM, 1995, SEMIN CELL BIOL, V6, P65, DOI 10.1016/1043-4682(95)90002-0; DAHLKVIST A, 1995, MOL GEN GENET, V246, P316, DOI 10.1007/BF00288604; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOWARD DL, 1998, GENE DEV, V12, P382; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lieberman HB, 1996, P NATL ACAD SCI USA, V93, P13890, DOI 10.1073/pnas.93.24.13890; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Lydall D, 1997, MOL GEN GENET, V256, P638, DOI 10.1007/s004380050612; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; McAlear MA, 1996, GENETICS, V142, P65; MIURA I, 1992, CANCER RES, V52, P1322; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; PAN ZQ, 1993, P NATL ACAD SCI USA, V90, P6, DOI 10.1073/pnas.90.1.6; Parker AE, 1998, J BIOL CHEM, V273, P18340, DOI 10.1074/jbc.273.29.18340; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PETERSON C, 1991, GENE, V107, P279, DOI 10.1016/0378-1119(91)90328-9; Plug AW, 1997, NAT GENET, V17, P457, DOI 10.1038/ng1297-457; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; SIEDE W, 1994, GENETICS, V138, P271; STALLINGS RL, 1988, AM J HUM GENET, V43, P144; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; Sugimoto K, 1996, P NATL ACAD SCI USA, V93, P7048, DOI 10.1073/pnas.93.14.7048; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	56	21	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	1999	18	9					1689	1699		10.1038/sj.onc.1202469	http://dx.doi.org/10.1038/sj.onc.1202469			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208430				2022-12-17	WOS:000079025000004
J	Ghorbel, MT; Seugnet, I; Hadj-Sahraoui, N; Topilko, P; Levi, G; Demeneix, B				Ghorbel, MT; Seugnet, I; Hadj-Sahraoui, N; Topilko, P; Levi, G; Demeneix, B			Thyroid hormone effects on Krox-24 transcription in the post-natal mouse brain are developmentally regulated but are not correlated with mitosis	ONCOGENE			English	Article						non viral gene transfer; polyethylenimine; thyroid hormone; Krox-24; mouse; central nervous system	A GENE-EXPRESSION; NGFI-A; GROWTH-FACTORS; RAT-BRAIN; IN-VIVO; DIFFERENTIATION; RECEPTOR; CELLS; POLYETHYLENIMINE; PROLIFERATION	Krox-24 (NGFI-A, Egr-1) is an immediate-early gene encoding a zinc finger transcription factor. As Krox-24 is expressed in brain areas showing post-natal neurogenesis during a thyroid hormone (T-3)-sensitive period, we followed T-3 effects on Krox-24 expression in newborn mice. We analysed whether regulation was associated,vith changes in mitotic activity in the subventricular zone and the cerebellum, In vivo T-3-dependent Krox-24 transcription was studied by polyethylenimine-based gene transfer. T-3 increased transcription from the Krox-24 promoter in both areas studied at post-natal day 2, but was without effect at day 6, An intact thyroid hormone response element (TRE) in the Krox-24 promoter was necessary for these inductions. These stage-dependent effects were also seen in endogenous Krox-24 mRNA levels: activation at day 2 and no effect at day 6, Moreover, similar results were obtained by examining beta-galactosidase expression in heterozygous mice in which one allele of the Krox-24 gene was disrupted with an in-frame Lac-Z insertion. However, bromodeoxyuridine incorporation showed mitosis to continue through to day 6. We conclude first, that T-3 activates Krox-24 transcription during early post-natal mitosis but that this effect is extinguished as development proceeds and second, loss of T-3-dependent Krox-24 expression is not correlated with loss of mitotic activity.	Museum Natl Hist Nat, Lab Physiol Gen & Comparee, CNRS, URA 90, F-75231 Paris 5, France; Ecole Normale Super, INSERM, U368, F-75230 Paris, France; IST, CBA, Mol Biol Lab, Genoa, Italy	Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Demeneix, B (corresponding author), Museum Natl Hist Nat, Lab Physiol Gen & Comparee, CNRS, URA 90, F-75231 Paris 5, France.		Levi, Giovanni/B-4416-2013	Levi, Giovanni/0000-0002-7041-6787				Abdallah B, 1996, HUM GENE THER, V7, P1947, DOI 10.1089/hum.1996.7.16-1947; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BRADLEY DJ, 1992, J NEUROSCI, V12, P2288; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; DEMENEIX BA, 1978, GEN COMP ENDOCR, V35, P77, DOI 10.1016/0016-6480(78)90170-3; FORREST D, 1994, SEMIN CANCER BIOL, V5, P167; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Ghorbel M, 1997, NEUROSCI LETT, V231, P127, DOI 10.1016/S0304-3940(97)00541-7; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GUISSOUMA H, IN PRESS FASEB J; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; Lebel JM, 1994, CURR OPIN ENDOCRINOL, V1, P167; Lee SL, 1996, MOL CELL BIOL, V16, P4566; LEE SL, 1995, J BIOL CHEM, V270, P9971, DOI 10.1074/jbc.270.17.9971; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEZOUALCH F, 1992, MOL ENDOCRINOL, V6, P1797, DOI 10.1210/me.6.11.1797; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; MELLSTROM B, 1994, ENDOCRINOLOGY, V135, P583, DOI 10.1210/en.135.2.583; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NICHOLSO.JL, 1972, BRAIN RES, V44, P13, DOI 10.1016/0006-8993(72)90362-9; PIPAON C, 1992, J BIOL CHEM, V267, P21, DOI 10.1016/S0021-9258(18)48449-9; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; ROHRER H, 1990, EUR J NEUROSCI, V2, P1005, DOI 10.1111/j.1460-9568.1990.tb00013.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Topilko P, 1998, MOL ENDOCRINOL, V12, P107, DOI 10.1210/mend.12.1.0049; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	33	21	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	1999	18	4					917	924		10.1038/sj.onc.1202378	http://dx.doi.org/10.1038/sj.onc.1202378			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023667	Bronze			2022-12-17	WOS:000078510600008
J	Pupa, SM; Howard, CM; Invernizzi, AM; De Vecchi, R; Giani, C; Claudio, PP; Colnaghi, MI; Giordano, A; Menard, S				Pupa, SM; Howard, CM; Invernizzi, AM; De Vecchi, R; Giani, C; Claudio, PP; Colnaghi, MI; Giordano, A; Menard, S			Ectopic expression of pRb2/p130 suppresses the tumorigenicity of the c-erbB-2-overexpressing SKOV3 tumor cell line	ONCOGENE			English	Article						Rb2; oncosuppressor; c-erbB-2; oncogene; ovary carcinoma; tumorigenicity	RETINOBLASTOMA-SUSCEPTIBILITY GENE; TRANSCRIPTIONAL REPRESSION; NEU PROTOONCOGENE; FAMILY MEMBERS; PROTEIN FAMILY; RB2/P130 GENE; CYCLE; PRODUCT; ONCOGENE; E1A	We investigated the in vitro and in vivo effects of the ectopic expression of the pRb2/p130 cell cycle regulator on c-erbB-2-associated tumorigenicity. SKOV3 ovarian cancer cells, which display c-erbB-2 gene amplification and oncoprotein (p185(HER2)) overexpression, were stably transfected with a plasmid containing the coding sequence for human wild-type pRb2/p130 (wtRb2), or with pcDNA3 empty vector. Three wtRb2-transfected clones (cl. 24, cl. 19, cl. 100) and one empty vector-transfected clone (cl, mock) were randomly picked and further analysed, Western blot analysis revealed high levels of pRb2/p130 in the three clones compared to mock cells. Levels of p185(HER2) and the extent of its tyrosine phosphorylation were similar in all transfectant clones, as were levels of pRb1 and p107, In anchorage-independent growth assays, the number of colonies from wtRb2 clone-transfectants was about 90% less than that arising from mock cells (P < 0.001). Tumor take rates of the three wtRb2-transfected clones xenografted in nu/nu mice were much lower than those of mock cells, and tumor volume was decreased by 80% (P < 0.001). A mutant version of pRb2/p130 deleted of the pocket region (mut-Rb2) was also transfected into SKOV3 cells and studied in parallel with the wtRb2-transfected and pcDNA empty vector-transfected bulk populations. mut-Rb2 transfected cells showed no inhibition of in vitro colony formation and were fully tumorigenic. Together, these findings indicate that Rb2 acts as a tumor suppressor gene in vivo and in vitro in SKOV3 cells and that the intact pocket region is required for the suppressor activity.	Ist Nazl Tumori, Div Expt Oncol E, I-20133 Milan, Italy; Thomas Jefferson Univ, Jefferson Med Coll, Sbarro Inst Canc Res & Mol Med, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Fondazione IRCCS Istituto Nazionale Tumori Milan; Jefferson University	Menard, S (corresponding author), Ist Nazl Tumori, Div Expt Oncol E, Via Venezian 1, I-20133 Milan, Italy.		menard, sylvie mm/C-7940-2011; Giordano, Antonio/F-1927-2010; Claudio, Pier Paolo/AAW-7282-2021; Pupa, Serenella/K-6388-2016	Giordano, Antonio/0000-0002-5959-016X; Claudio, Pier Paolo/0000-0001-7790-1622; Pupa, Serenella/0000-0002-4592-6830; Howard, Candace/0000-0001-6537-3551	NATIONAL CANCER INSTITUTE [R01CA060999] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA60999-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Baldi A, 1996, P NATL ACAD SCI USA, V93, P4629, DOI 10.1073/pnas.93.10.4629; Baldi A, 1997, CLIN CANCER RES, V3, P1691; BALDI A, 1996, CLIN CANCER RES, V2, P1; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; FRISCH SM, 1995, CANCER RES, V55, P5551; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; KERN JA, 1994, J CLIN INVEST, V93, P516, DOI 10.1172/JCI117001; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; MATIN A, 1994, ONCOGENE, V9, P1333; MAYOL X, 1993, ONCOGENE, V8, P2561; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Susini T, 1998, J CLIN ONCOL, V16, P1085, DOI 10.1200/JCO.1998.16.3.1085; TAGLIABUE E, 1991, INT J CANCER, V47, P933, DOI 10.1002/ijc.2910470625; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; YEUNG RS, 1993, ONCOGENE, V8, P3465; YU DH, 1994, CELL GROWTH DIFFER, V5, P431; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1992, J BIOL CHEM, V267, P10203; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	31	21	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					651	656		10.1038/sj.onc.1202363	http://dx.doi.org/10.1038/sj.onc.1202363			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989815				2022-12-17	WOS:000078394400010
J	Peters, UR; Hasse, U; Oppliger, E; Tschan, M; Ong, ST; Rassool, FV; Borisch, B; Tobler, A; Fey, MF				Peters, UR; Hasse, U; Oppliger, E; Tschan, M; Ong, ST; Rassool, FV; Borisch, B; Tobler, A; Fey, MF			Aberrant FHIT mRNA transcripts are present in malignant and normal haematopoiesis, but absence of FHIT protein is restricted to leukaemia	ONCOGENE			English	Article						FHIT; FRA3B; leukaemia; lymphoma	TUMOR-SUPPRESSOR LOCUS; RENAL-CELL CARCINOMA; COMMON FRAGILE SITE; LUNG-CANCER; HOMOZYGOUS DELETIONS; BREAST CARCINOMAS; FRA3B REGION; SHORT ARM; GENE; 3P14.2	Alterations of the recently cloned fragile histidine triad (FHIT) gene at chromosome 3p14.2 are frequent in a variety of solid tumours and cancer cell lines. Based on these findings, FHIT has been proposed as a putative tumour-suppressor gene. We evaluated the mRNA expression of the FHIT gene in samples from 55 patients with various haematological malignancies (21 AML, 8 CML, 10 CLL, seven low-grade and nine high-grade Non-Hodgkin's lymphomas), in a panel of 16 leukaemia cell lines, in normal mature haematopoietic cells of both myeloid and lymphoid lineage, as well as in CD34(+) haematopoietic progenitor cells. Aberrant FHIT mRNA transcripts were observed in 14/16 (88%) leukaemia cell lines, 43/55 (78%) primary haematological neoplasms, but also in 17/22 (77%) normal controls. 1/16 (6%) cell lines and 7/55 (13%) neoplasms did not express and FHIT mRNA. cDNA sequencing revealed exonic deletions, small DNA insertions and combinations of both. Analysis of genomic DNA showed gene deletions in two myeloid leukaemia cell lines. In contrast to all normal types of haematopoietic cells, FHIT protein was clearly reduced or absent in 8/18 (44%) neoplastic samples tested. Our data indicate that whilst aberrant FHIT mRNA transcripts are seen both in normal and malignant cells, lack of FHIT protein is restricted to leukaemia. Absent FHIT protein expression might contribute to leukaemogenesis.	Univ Bern, Dept Clin Res, Bern, Switzerland; Univ Bern, Inst Med Oncol, Bern, Switzerland; Univ Bern, Cent Haematol Lab, Bern, Switzerland; Inselspital Bern, CH-3010 Bern, Switzerland; Univ Geneva, Dept Pathol, CH-1211 Geneva 4, Switzerland; Univ Chicago, Med Ctr, Sect Haematol Oncol, Chicago, IL 60637 USA	University of Bern; University of Bern; University of Bern; University of Geneva; University of Chicago; University of Chicago Medical Center	Fey, MF (corresponding author), Univ Bern, Dept Clin Res, Bern, Switzerland.		Borisch, Bettina/AAG-8212-2019; Oppliger Leibundgut, Elisabeth/AGG-5030-2022	Borisch, Bettina/0000-0002-9902-324X; Tschan, Mario P./0000-0001-5897-3647; Ong, S. Tiong/0000-0001-9460-3483; Oppliger Leibundgut, Elisabeth/0000-0002-6652-4160				Ahmadian M, 1997, CANCER RES, V57, P3664; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; Carapeti M., 1996, Blood, V88, p578A; Druck T, 1997, CANCER RES, V57, P504; Fong KM, 1997, CANCER RES, V57, P2256; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; Gemma A, 1997, CANCER RES, V57, P1435; Greenspan DL, 1997, CANCER RES, V57, P4692; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Hayashi S, 1997, CANCER RES, V57, P1981; Inoue H, 1997, P NATL ACAD SCI USA, V94, P14584, DOI 10.1073/pnas.94.26.14584; Kastury K, 1996, CANCER RES, V56, P978; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; Le Beau MM, 1998, GENE CHROMOSOME CANC, V21, P281, DOI 10.1002/(SICI)1098-2264(199804)21:4<281::AID-GCC1>3.0.CO;2-V; LEBEAU MM, 1984, NATURE, V308, P607, DOI 10.1038/308607a0; Lima CD, 1997, SCIENCE, V278, P286, DOI 10.1126/science.278.5336.286; Lin PM, 1997, BRIT J HAEMATOL, V99, P612, DOI 10.1046/j.1365-2141.1997.4223235.x; Mao L, 1998, J NATL CANCER I, V90, P412, DOI 10.1093/jnci/90.6.412; Mao L, 1996, CANCER RES, V56, P5128; Michael D, 1997, ONCOGENE, V15, P1653; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Negrini M, 1996, CANCER RES, V56, P3173; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Ong ST, 1997, GENE CHROMOSOME CANC, V20, P16, DOI 10.1002/(SICI)1098-2264(199709)20:1<16::AID-GCC3>3.0.CO;2-C; Otterson GA, 1998, J NATL CANCER I, V90, P426, DOI 10.1093/jnci/90.6.426; Panagopoulos I, 1997, GENE CHROMOSOME CANC, V19, P215, DOI 10.1002/(SICI)1098-2264(199708)19:4<215::AID-GCC2>3.0.CO;2-#; Rassool FV, 1996, GENOMICS, V35, P109, DOI 10.1006/geno.1996.0329; SANCHEZ Y, 1994, P NATL ACAD SCI USA, V91, P3383, DOI 10.1073/pnas.91.8.3383; Schwaller J, 1997, BRIT J HAEMATOL, V99, P896, DOI 10.1046/j.1365-2141.1997.4863289.x; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Sozzi G, 1997, CANCER RES, V57, P5207; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Sugimoto K, 1997, STEM CELLS, V15, P223, DOI 10.1002/stem.150223; Thiagalingam S, 1996, CANCER RES, V56, P2936; Uguccioni M, 1996, J EXP MED, V183, P2379, DOI 10.1084/jem.183.5.2379; vandenBerg A, 1997, GENE CHROMOSOME CANC, V19, P220, DOI 10.1002/(SICI)1098-2264(199708)19:4<220::AID-GCC3>3.0.CO;2-Z; Wang L, 1998, ONCOGENE, V16, P635, DOI 10.1038/sj.onc.1201576; Yeung R. S., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P422; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; Zimonjic DB, 1997, CANCER RES, V57, P1166	42	21	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					79	85		10.1038/sj.onc.1202256	http://dx.doi.org/10.1038/sj.onc.1202256			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926922				2022-12-17	WOS:000078166000009
J	Varadhachary, AS; Salgame, P				Varadhachary, AS; Salgame, P			CD95 mediated T cell apoptosis and its relevance to immune deviation	ONCOGENE			English	Article						T cells; CD95; immune; deviation	ACTIVATION-INDUCED CELL; TUMOR-NECROSIS-FACTOR; B7-2 COSTIMULATORY MOLECULES; PROTEIN-TYROSINE-PHOSPHATASE; SIGNALING COMPLEX DISC; FAS-INDUCED APOPTOSIS; DIFFERENTIAL ABILITY; MONOCLONAL-ANTIBODY; FUNCTIONAL SUBSETS; DEATH DOMAIN	The CD95/CD95L pair plays a manifold role in regulating life and death in the function of the immune system, Examples include CD95/CD95L acting as cytotoxic CD8+ T cell effector molecules, or functioning on CD4+ T helper cells to maintain peripheral tolerance or reestablishing homeostasis, Current understanding of the CD95 signaling pathway reveals several potential regulatory targets, acting both receptor proximally and distally, that can terminate or amplify the receptor's signal, The important and possibly nonredundant role of CD95 is highlighted both in how deficiencies in functional CD95 or its ligand manifest themselves in autoimmune syndromes, and how uncontrolled cell death results in insufficient, or inappropriate immune responses against immune challenge. This review examines CD95-mediated signal transduction, and the effect preferential apoptosis of T helper cell subsets has on immune system biasing.	Temple Univ, Dept Microbiol & Immunol, Sch Med, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Salgame, P (corresponding author), Temple Univ, Dept Microbiol & Immunol, Sch Med, Philadelphia, PA 19140 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055972] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 55972] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKBAR AN, 1993, J EXP MED, V178, P427, DOI 10.1084/jem.178.2.427; AMEISEN JC, 1994, IMMUNOL REV, V142, P9, DOI 10.1111/j.1600-065X.1994.tb00882.x; Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; BLOOM BR, 1992, ANNU REV IMMUNOL, V10, P453, DOI 10.1146/annurev.iy.10.040192.002321; BOISE LH, 1995, CURR OPIN IMMUNOL, V7, P620, DOI 10.1016/0952-7915(95)80067-0; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CHAN J, 1994, IMMUNE MECH PROTECTI, pCH24; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CHIU VK, 1995, J IMMUNOL, V154, P2023; CLERICI M, 1993, SCIENCE, V262, P1721, DOI 10.1126/science.7903123; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; GAJEWSKI TF, 1990, J IMMUNOL, V144, P4110; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1997, P NATL ACAD SCI USA, V94, P5986, DOI 10.1073/pnas.94.12.5986; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; IRLMER M, 1997, NATURE, V388, P461; ITOH N, 1993, J BIOL CHEM, V268, P10932; JAATTELA M, 1995, ONCOGENE, V10, P2297; JANEWAY CA, 1988, IMMUNOL REV, V101, P39, DOI 10.1111/j.1600-065X.1988.tb00732.x; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Ledru E, 1998, J IMMUNOL, V160, P3194; Lee RK, 1996, INT IMMUNOL, V8, P991, DOI 10.1093/intimm/8.7.991; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; LYNCH DH, 1995, IMMUNOL TODAY, V16, P569, DOI 10.1016/0167-5699(95)80079-4; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; MEMON SA, 1995, J IMMUNOL, V155, P4644; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NOVAK TJ, 1990, P NATL ACAD SCI USA, V87, P9353, DOI 10.1073/pnas.87.23.9353; Okura T, 1996, J IMMUNOL, V157, P4277; Peter ME, 1997, EUR J IMMUNOL, V27, P1207, DOI 10.1002/eji.1830270523; PFEIFFER C, 1991, IMMUNOL REV, V123, P65, DOI 10.1111/j.1600-065X.1991.tb00606.x; POWRIE F, 1993, EUR J IMMUNOL, V23, P3043, DOI 10.1002/eji.1830231147; RAMSDELL F, 1994, INT IMMUNOL, V6, P1545, DOI 10.1093/intimm/6.10.1545; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; SALGAME P, 1992, CHEM IMMUNOL, V54, P44; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SCAFFIDI C, 1998, IN PRESS J BIOL CHEM; Scott P, 1998, IMMUNOL RES, V17, P229, DOI 10.1007/BF02786447; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; STADECKER MJ, 1994, IMMUNOL TODAY, V15, P571, DOI 10.1016/0167-5699(94)90219-4; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; SU X, 1995, IMMUNITY, V2, P353, DOI 10.1016/1074-7613(95)90143-4; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; SWAIN SL, 1990, J IMMUNOL, V145, P3796; Szabo SJ, 1997, J EXP MED, V185, P817, DOI 10.1084/jem.185.5.817; Takayama H, 1995, ADV IMMUNOL, V60, P289, DOI 10.1016/S0065-2776(08)60588-X; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Trinchieri G, 1998, IMMUNOL RES, V17, P269, DOI 10.1007/BF02786451; Van Parijs L, 1998, SCIENCE, V280, P243; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; vanParijs L, 1996, CURR OPIN IMMUNOL, V8, P355, DOI 10.1016/S0952-7915(96)80125-7; Varadhachary AS, 1997, P NATL ACAD SCI USA, V94, P5778, DOI 10.1073/pnas.94.11.5778; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; VILLANUEVA POF, 1994, J IMMUNOL, V153, P5190; WEAVER CT, 1988, P NATL ACAD SCI USA, V85, P8181, DOI 10.1073/pnas.85.21.8181; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang XH, 1997, J EXP MED, V185, P1837, DOI 10.1084/jem.185.10.1837	98	21	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 24	1998	17	25					3271	3276		10.1038/sj.onc.1202572	http://dx.doi.org/10.1038/sj.onc.1202572			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916989				2022-12-17	WOS:000078048200008
J	Hartl, M; Bister, K				Hartl, M; Bister, K			Structure and transcriptional regulation of BKJ, a novel AP-1 target gene activated during jun- or fos-induced fibroblast transformation	ONCOGENE			English	Article						cell transformation; oncogenes; transcription factor AP-1; keratin; cell differentiation	AVIAN KERATIN GENES; C-JUN; DNA-BINDING; V-JUN; CELL-TRANSFORMATION; EMBRYO FIBROBLASTS; RNA-POLYMERASE; BASIC REGION; EXPRESSION; PROTEIN	The BKJ gene was originally identified based on its specific transcriptional activation in jun-transformed avian fibroblasts. We now show that BKJ is a direct transcriptional target of the AP-1 transcription factor components Jun and Fos. The complete structural organization of the quail BKJ gene was determined by nucleotide sequence analysis and transcriptional mapping. The gene contains three exons with the coding region confined to the third exon. A major mRNA species of 0.8 kb and a minor one of 1.3 kb are produced by variable usage of two transcriptional initiation sites. The BKJ promoter region contains two authentic AP-1 binding sites. By transactivation of reporter gene constructs and direct binding of Jun recombinant protein, the proximal AP-T element was shown to be essential for BKJ promoter activation. Using polyclonal antiserum directed against recombinant BKJ protein, the activation of BKJ in jun-transformed avian fibroblasts was also demonstrated at the protein level. BKJ is a novel gene related to the avian beta-keratin gene family whose members display highly specific expression patterns during embryogenesis and epidermal development. Activation of BKJ in fibroblasts by retroviral or deregulated cellular jun or fos alleles may contribute to cell transformation.	Univ Innsbruck, Inst Biochem, A-6020 Innsbruck, Austria	University of Innsbruck	Hartl, M (corresponding author), Univ Innsbruck, Inst Biochem, Peter Mayr Str 1A, A-6020 Innsbruck, Austria.		Bister, Klaus/AFA-9400-2022; Hartl, Markus/O-4655-2014	Hartl, Markus/0000-0001-7447-5920; Bister, Klaus/0000-0001-6545-5653				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BISTER K, 1987, ONCOGENE, V1, P97; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BRUN G, 1989, NUCLEIC ACIDS RES, V17, P6393, DOI 10.1093/nar/17.15.6393; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; Crittenden L, 1995, Trends Genet, P33; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Gao MH, 1996, CANCER RES, V56, P4229; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Hadman M, 1996, ONCOGENE, V12, P135; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; HARTL M, 1995, VIROLOGY, V207, P321, DOI 10.1006/viro.1995.1086; HARTL M, 1991, ONCOGENE, V6, P1623; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; Jefferies D, 1998, BBA-GENE STRUCT EXPR, V1396, P237, DOI 10.1016/S0167-4781(97)00234-0; JURDIC P, 1995, ONCOGENE, V11, P1699; KERKHOFF E, 1991, ONCOGENE, V6, P93; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Martin ML, 1996, MOL CELL BIOL, V16, P2110; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; MOLDERS H, 1987, ONCOGENE, V1, P377; MORGAN IM, 1993, ONCOGENE, V8, P1135; MORGAN IM, 1992, ONCOGENE, V7, P1119; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHIZAWA M, 1987, J VIROL, V61, P3733, DOI 10.1128/JVI.61.12.3733-3740.1987; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; Oshima RG, 1996, CANCER METAST REV, V15, P445, DOI 10.1007/BF00054012; PANKOV R, 1994, P NATL ACAD SCI USA, V91, P873, DOI 10.1073/pnas.91.3.873; PAPOULAS O, 1992, J BIOL CHEM, V267, P10470; PATSCHINSKY T, 1986, J VIROL, V59, P341, DOI 10.1128/JVI.59.2.341-353.1986; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PRESLAND RB, 1989, J MOL BIOL, V209, P549, DOI 10.1016/0022-2836(89)90593-7; PRESLAND RB, 1989, J MOL BIOL, V209, P561, DOI 10.1016/0022-2836(89)90594-9; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TIKHONENKO AT, 1992, J VIROL, V66, P946, DOI 10.1128/JVI.66.2.946-955.1992; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198; Weiskirchen R, 1997, GENOMICS, V44, P83, DOI 10.1006/geno.1997.4855; WEISKIRCHEN R, 1993, GENE, V128, P269, DOI 10.1016/0378-1119(93)90573-L; WEISKIRCHEN R, 1993, ONCOGENE, V8, P2317; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WONG WY, 1992, ONCOGENE, V7, P2077	64	21	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 3	1998	17	22					2901	2913		10.1038/sj.onc.1202219	http://dx.doi.org/10.1038/sj.onc.1202219			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	143ZA	9879996				2022-12-17	WOS:000077286400010
J	Cohen, SB; Nicol, R; Stavnezer, E				Cohen, SB; Nicol, R; Stavnezer, E			A domain necessary for the transforming activity of SnoN is required for specific DNA binding, transcriptional repression and interaction with TAF(II)110	ONCOGENE			English	Article						oncogene; repression; SnoN; transcription; transformation	THYROID-HORMONE RECEPTOR; ADENOVIRUS E1A PROTEIN; FUNCTIONAL-ANALYSIS; CDNA CLONES; GENE; ACTIVATION; SKI; GAL4; OVEREXPRESSION; IDENTIFICATION	sno is a member of the ski oncogene family and shares ski's ability to transform avian fibroblasts and induce muscle differentiation. Ski and Sno are nuclear proteins that form homodimers and heterodimers, Ski activates transcription of cellular and viral enhancers and we have identified a DNA binding site (GTCTAGAC) through which it represses transcription. In this work, we show that SnoN binds this site and represses transcription of reporters a with this binding site as an upstream element. Using fusions with the Gal4-DNA binding domain in a heterologous reporter assay, we identify a tripartite repression domain in SnoN, A 107 amino acid stretch of the SnoN repression domain, that contains two of the subdomains, is closely related to the minimal region of Ski required for transformation. The third subdomain is unique to SnoN, By analysing deletions involving each of the subdomains, we show that subdomains II and III are also required for DNA binding and cellular transformation. We provide evidence for a quenching mechanism of transcriptional repression by which subdomain II binds to TAF(II)11O.	Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	Case Western Reserve University; University System of Ohio; University of Cincinnati	Stavnezer, E (corresponding author), Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA.				NCI NIH HHS [CA43600] Funding Source: Medline; NIGMS NIH HHS [T32-GM08056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BOYER PL, 1993, ONCOGENE, V8, P457; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; Chen CMA, 1996, CELL, V86, P731, DOI 10.1016/S0092-8674(00)80148-8; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Fondell JD, 1996, MOL CELL BIOL, V16, P281; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GIVOL I, 1995, GENE, V156, P271, DOI 10.1016/0378-1119(95)00066-F; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HEYMAN HC, 1994, J BIOL CHEM, V269, P26996; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Liang SD, 1996, MOL CELL BIOL, V16, P3773; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LYONS GE, 1994, TRENDS CARDIOVAS MED, V4, P70, DOI 10.1016/1050-1738(94)90012-4; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; Mimura N, 1996, FEBS LETT, V397, P253, DOI 10.1016/S0014-5793(96)01165-9; Nicol R, 1998, J BIOL CHEM, V273, P3588, DOI 10.1074/jbc.273.6.3588; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; PearsonWhite S, 1997, NUCLEIC ACIDS RES, V25, P2930, DOI 10.1093/nar/25.14.2930; Pelzer T, 1996, DEV DYNAM, V205, P114; QIAN Z, 1995, J VIROL, V69, P4037, DOI 10.1128/JVI.69.7.4037-4044.1995; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; UM M, 1995, MOL CELL BIOL, V15, P5007; Zheng GX, 1997, ONCOGENE, V15, P459, DOI 10.1038/sj.onc.1201205	35	21	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2505	2513		10.1038/sj.onc.1202177	http://dx.doi.org/10.1038/sj.onc.1202177			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824161				2022-12-17	WOS:000076927300010
J	Magnusson, KP; Satalino, R; Qian, W; Klein, G; Wiman, KG				Magnusson, KP; Satalino, R; Qian, W; Klein, G; Wiman, KG			Is conversion of solid into more anoxic ascites tumors associated with p53 inactivation?	ONCOGENE			English	Article						hypoxia; tumor progression; alternative spliced p53; p53 mutation	ALTERNATIVELY SPLICED P53; DNA-BINDING; MESSENGER-RNA; PROTEIN; CELLS; MICE	Most solid tumors are unable to grow in the ascites form, unless selected by prolonged serial transfer of peritoneal fluid (Klein, 1955), Established ascites tumor cells grow under highly crowded, virtually anoxic conditions (Warburg and Hiepler, 1953), Hypoxia was recently identified as a powerful inducer of p53 dependent apoptosis (Graeber et nl,, 1996), We wished to examine whether the conversion of relatively well-vascularized solid mouse tumors into freely growing ascitic cell variants favors cell with mutated or deleted p53, We have sequenced exons 4-9 of p53 cDNA from two serially transplanted methylcholanthrene induced sarcomas (MCIM and MSWBS) that were available in the original solid and the gradually converted ascites form, We have also examined five additional solid tumors, four carcinomas and one sarcoma and six additional ascites tumors, five carcinomas and one sarcoma, Sequence analysis showed that all solid tumors carried exclusively wild type p53, Among the eight ascites tumors, five carried mutant p53 and three had only the wild type gene. In one of the two isogenic pairs, the original solid tumor line had only wild type, whereas the derived ascites line had only mutant p53, In the second pair, the solid tumor was mild type whereas the ascitic variant was heterozygous, The naturally occurring alternatively spliced p53 (p53as) mRNA was detected in all solid tumors, but not in five of the eight ascites tumors. Our findings indicate that conversion of solid into ascites tumors favors the selection of cell variants with mutated p53 and of cells that lack the alternatively spliced form of p53.	Karolinska Inst, Microbiol & Tumor Biol Ctr, S-17177 Stockholm, Sweden; CODE Genet, IS-110 Reykjavik, Iceland; Univ Bari, Dept Anat, I-70124 Bari, Italy	Karolinska Institutet; Universita degli Studi di Bari Aldo Moro	Magnusson, KP (corresponding author), Karolinska Inst, Microbiol & Tumor Biol Ctr, Box 280, S-17177 Stockholm, Sweden.		Magnusson, Kristinn/A-6479-2011; Magnusson, Kristinn P Pétur/X-4907-2019; Wiman, Klas/AAB-8399-2021	Magnusson, Kristinn/0000-0003-4528-6826; Magnusson, Kristinn P Pétur/0000-0003-4528-6826; Wiman, Klas/0000-0002-7113-524X				BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HELLSTROM U, 1978, EUR J CANCER, V14, P1265, DOI 10.1016/0014-2964(78)90234-7; KLEIN E, 1955, EXP CELL RES, V8, P188, DOI 10.1016/0014-4827(55)90056-2; KLEIN E, 1955, EXP CELL RES, V8, P213, DOI 10.1016/0014-4827(55)90057-4; KLEIN G, 1951, CANCER RES, V11, P466; KLEIN G, 1960, CANCER RES, V20, P1561; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; KUZUMAKI N, 1980, EUR J CANCER, V16, P1181, DOI 10.1016/0014-2964(80)90177-2; LAVIGUEUR A, 1991, ONCOGENE, V6, P2197; LETTRE H, 1950, Z KREBSFORSCH, V57, P1; Provencher DM, 1997, TUMOR BIOL, V18, P167, DOI 10.1159/000218027; PURDOM L, 1958, NATURE, V181, P1586, DOI 10.1038/1811586a0; RINGERTZ N, 1957, J NATL CANCER I, V18, P173; Schumacher U, 1997, EXP MOL PATHOL, V64, P103, DOI 10.1006/exmp.1997.2213; THOMLINSON RH, 1955, BRIT J CANCER, V9, P539, DOI 10.1038/bjc.1955.55; Wang Q, 1997, J GEN VIROL, V78, P893, DOI 10.1099/0022-1317-78-4-893; WARBURG O, 1952, Z NATURFORSCH B, V7, P193; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WOLKOWICZ R, 1995, P NATL ACAD SCI USA, V92, P6842, DOI 10.1073/pnas.92.15.6842; Wu Y, 1997, P NATL ACAD SCI USA, V94, P8982, DOI 10.1073/pnas.94.17.8982; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x	25	21	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	1998	17	18					2333	2337		10.1038/sj.onc.1202149	http://dx.doi.org/10.1038/sj.onc.1202149			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811464				2022-12-17	WOS:000076723300007
J	Zhang, LJ; Zhan, SL; Navid, F; Li, QD; Choi, YH; Kim, M; Seth, P; Helman, LJ				Zhang, LJ; Zhan, SL; Navid, F; Li, QD; Choi, YH; Kim, M; Seth, P; Helman, LJ			AP-2 may contribute to IGF-II overexpression in rhabdomyosarcoma	ONCOGENE			English	Article						IGF-II; AP-2; tumor cells	TRANSCRIPTION FACTOR AP-2; GROWTH FACTOR-II; GENE-EXPRESSION; INDUCIBLE ENHANCER; MAMMARY-CARCINOMA; CYCLIC-AMP; CELL-LINE; PROMOTER; EMBRYOGENESIS; ACTIVATION	The human insulin-like growth factor II gene is regulated in a development-dependent manner and is not expressed in most adult tissues. However, high levels of insulin-like growth factor II mRNA are detected in many human tumors including rhabdomyosarcoma, an embryonal tumor of skeletal muscle origin. In this study, we demonstrate that the developmentally regulated transcription factor AP-2 is expressed at higher levels in human fetal skeletal muscle and rhabdomyosarcoma cells compared to human adult skeletal muscle, Endogenous insulin-like growth factor II mRNA derived from the P3 as well as transfected P3 promoter activity were modestly and consistently increased to the same extent following treatment of the rhabdomyosarcoma cell line RD with forskolin, a compound implicated in AP-2 transactivation, This effect of AP-2 on increased transcriptional activity was confirmed by nuclear run-on assays. Expression of AP-2B, a dominant-negative inhibitor of AP-2, suppressed the P3 promoter activity in AP-2 expressing RD cells. Furthermore, five AP-2 protected regions corresponding to six AP-2 specific binding sites were detected in the insulin-like growth factor II P3 promoter. These data together suggest that AP-2 may contribute to the high expression of IGF-II in rhabdomyosarcoma cells.	NCI, Mol Oncol Sect, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA; NCI, Med Ovarian Canc Sect, NIH, Bethesda, MD 20892 USA; NCI, Cell Signaling & Oncogenesis Sect, NIH, Bethesda, MD 20892 USA; NCI, Med Breast Canc Sect, Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Helman, LJ (corresponding author), NCI, Mol Oncol Sect, Pediat Oncol Branch, NIH, Bldg 10,Rm 13N240, Bethesda, MD 20892 USA.			Choi, Yung Hyun/0000-0002-1454-3124				BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; BYRNE C, 1994, DEVELOPMENT, V120, P2369; CROUCH GD, 1993, EXP CELL RES, V204, P210, DOI 10.1006/excr.1993.1026; DAUGHADAY WH, 1990, ENDOCRINOLOGY, V127, P1; DOUGLASS EC, 1987, CYTOGENET CELL GENET, V45, P148, DOI 10.1159/000132446; DUAN CM, 1995, J BIOL CHEM, V270, P24844, DOI 10.1074/jbc.270.42.24844; ELBADRY OM, 1989, J CLIN INVEST, V84, P829, DOI 10.1172/JCI114243; Gong DW, 1996, J BIOL CHEM, V271, P3971; HASLINGER A, 1985, P NATL ACAD SCI USA, V82, P8572, DOI 10.1073/pnas.82.24.8572; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MEIER P, 1995, DEV BIOL, V169, P1, DOI 10.1006/dbio.1995.1121; MINNITI CP, 1994, AM J CLIN PATHOL, V101, P198, DOI 10.1093/ajcp/101.2.198; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NYBORG JK, 1990, J BIOL CHEM, V265, P8230; RAJ NBK, 1983, P NATL ACAD SCI-BIOL, V80, P3923, DOI 10.1073/pnas.80.13.3923; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; Zhang LJ, 1996, CANCER RES, V56, P1367	31	21	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1261	1270		10.1038/sj.onc.1202050	http://dx.doi.org/10.1038/sj.onc.1202050			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771969				2022-12-17	WOS:000075803300008
J	Mukhopadhyay, T; Multani, AS; Roth, JA; Pathak, S				Mukhopadhyay, T; Multani, AS; Roth, JA; Pathak, S			Reduced telomeric signals and increased telomeric associations in human lung cancer cell lines undergoing p53-mediated apoptosis	ONCOGENE			English	Article						p53; lung cancer; apoptosis; telomere; gene expression	WILD-TYPE P53; ACTIVATION; DEATH; INDUCTION; LENGTH; GROWTH	Transduction of a p53-negative H1299 human non-small cell lung cancer cell line with an adenoviral vector containing wild-type p53 (Ad5p53) induced apoptosis, Analysis of the Ad5p53-infected H1299 cells showed high levels of telomeric association prior to apoptotic nuclear fragmentation. Similar telomeric association was observed in stably transfected clones of the wtH226b cell line, which expressed exogenous wild-type p53 protein and also showed complex chromosomal abnormalities including dicentrics, rings and fragments, Fluorescence ill situ hybridization (FISH) analysis using a human telomeric DNA probe indicated reductions in telomere signals in both Ad5p53-infected H1299 cells and wtH226b-S cells. In contrast, stably transfected wtH226b-AS clones expressing antisense p53 cDNA showed no telomeric association and had high levels of telomeric signals associated with a faster growing phenotype, These results suggest that wild-type p53 is involved in shortening telomeres, a possibly early event in the p53-mediated apoptotic process and in the subsequent telomeric association that predisposes a cell to genetic instability and DNA fragmentation resulting in apoptotic cell death. Moreover, loss of telomeric signals may indicate a cell's decision to undergo programmed cell death and, if so, could, serve as a sensitive marker of p53-mediated apoptosis.	Univ Texas, MD Anderson Cancer Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Cell Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mukhopadhyay, T (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [R01 CA45187, P50-CA70907, CA 16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P50CA070907, R01CA045187] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Broccoli D, 1996, MOL CELL BIOL, V16, P3765; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; HEALY KC, 1995, ONCOL RES, V7, P121; HIYAMA K, 1995, ONCOGENE, V10, P937; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MUKHOPADHYAY T, 1993, CANCER RES, V53, P4362; Mukhopadhyay T, 1997, ONCOGENE, V14, P379, DOI 10.1038/sj.onc.1200835; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; PATHAK S, 1994, INT J ONCOL, V4, P323; Pathak S., 1994, In Vivo (Attiki), V8, P843; Pathak S., 1996, Archivos de Zootecnia, V45, P141; PATHAK S, 1976, J REPROD MED, V17, P25; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; Seegers JC, 1997, J STEROID BIOCHEM, V62, P253, DOI 10.1016/S0960-0760(97)00043-5; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1996, ONCOGENE, V12, P2197; ZHANG WW, 1995, HUM GENE THER, V6, P155, DOI 10.1089/hum.1995.6.2-155; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868	24	21	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					901	906		10.1038/sj.onc.1202011	http://dx.doi.org/10.1038/sj.onc.1202011			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780006				2022-12-17	WOS:000075448800011
J	Sacchi, N; Tamanini, F; Willemsen, R; Denis-Donini, S; Campiglio, S; Hoogeveen, AT				Sacchi, N; Tamanini, F; Willemsen, R; Denis-Donini, S; Campiglio, S; Hoogeveen, AT			Subcellular localization of the oncoprotein MTG8 (CDR/ETO) in neural cells	ONCOGENE			English	Article						MTG8 protein; neural cells; cellular localization	ACUTE MYELOID-LEUKEMIA; FETAL LIVER HEMATOPOIESIS; FUSION TRANSCRIPT; AML1; GENE; IDENTIFICATION; PROTEIN; ETO; TRANSLOCATIONS; BREAKPOINTS	The t(8;21) translocation associated with acute myeloid leukemia (AML) disrupts two genes, the AML1 gene also known as the core binding factor A2 (CBFA2) on chromosome 21, and a gene on chromosome 8, hereafter referred to as MTG8, but also known as CDR and ETO, Extensive information is available on AML1, a member of the CBF family of transcription factors, containing a highly conserved domain, the runt box, of the Drosophila segmentation gene runt. This gene is essential for the hematopoietic development and is found disrupted in several leukemias, In contrast, the function of the MTG8 gene is poorly understood. The predicted protein sequence shows two unusual, putative zinc-fingers, three proline-rich regions, a PEST domain and several phosphorylation sites. In addition, we found a region encompassing aa 443-514 predicted to have a significant propensity to form coiled coil structures. MTG8 displays a high degree of similarity with nervy, a homeotic target gene of Drosophila, expressed in the nervous system. Human and mouse wild-type MTG8 are also highly expressed in brain relative to other tissues. For these reasons, we set out to investigate the expression and subcellular localization of the MTG8 protein in neural cells. Immunohistochemical experiments in a 12.5-day-old mouse embryo clearly showed that the protein was expressed in the neural cells of the developing brain and the spinal cord. In primary cultures of hippocampal neurons of 2-3 day-old mice, MTG8 was found in the nucleus, in the cytoplasm and as fine granules in the neurites, Cytoplasmic localization of the protein was observed in Purkinje cells of both human and mouse cerebellum. The molecular mass of MTG8 in total human and mouse brain was analysed by immunoblotting and determined to be between 70 and 90 kDa, Isoforms with the same molecular mass were demonstrated in synaptosomes isolated from mouse forebrain, The evidence of MTG8 in the nucleus and cytoplasm of neural cells suggests a specific mechanism regulating the subcellular localization of the protein.	Univ Milan, Sch Med, Dept Biol & Genet, Milan, Italy; Univ Milan, Sch Biol Sci, Dept Biol, Milan, Italy; Erasmus Univ, Sch Med, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands; CNR, Ctr Cytopharmacol, I-20133 Milan, Italy	University of Milan; University of Milan; Erasmus University Rotterdam; Consiglio Nazionale delle Ricerche (CNR)	Sacchi, N (corresponding author), Univ Milan, Sch Med, Dept Biol & Genet, Milan, Italy.							Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; ERA T, 1995, LEUKEMIA, V9, pS26; ERA T, 1995, GENE CHROMOSOME CANC, V13, P25, DOI 10.1002/gcc.2870130105; ERICKSON P, 1992, BLOOD, V80, P1825; ERICKSON PF, 1994, CANCER RES, V54, P1782; Erickson PF, 1996, BLOOD, V88, P1813; FEINSTEIN PG, 1995, GENETICS, V140, P573; HARLOW E, 1988, ANTIBODIES; Ito Y, 1996, J CANCER RES CLIN, V122, P266, DOI 10.1007/BF01261402; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; LI CY, 1987, J HISTOCHEM CYTOCHEM, V35, P1457, DOI 10.1177/35.12.2824601; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; NUCIFORA G, 1993, BLOOD, V82, P712; NUCIFORA G, 1995, BLOOD, V86, P1; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; RAO A, 1991, J NEUROSCI, V11, P2881; Sacchi N, 1996, ONCOGENE, V12, P437; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Saunders MJ, 1996, LEUKEMIA, V10, P1139; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; Tamanini F, 1997, HUM MOL GENET, V6, P1315, DOI 10.1093/hmg/6.8.1315; TIGHE JE, 1994, BLOOD, V84, P2115, DOI 10.1182/blood.V84.7.2115.bloodjournal8472115; VANDELOCHT LTF, 1994, LEUKEMIA, V8, P1780; WANG J, 1997, CANCER RES, V12, P2951; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303	34	21	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	1998	16	20					2609	2615		10.1038/sj.onc.1201824	http://dx.doi.org/10.1038/sj.onc.1201824			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632137				2022-12-17	WOS:000073698200005
J	Anderson, DH; Ismail, PM				Anderson, DH; Ismail, PM			V-fps causes transformation by inducing tyrosine phosphorylation and activation of the PDGF beta receptor	ONCOGENE			English	Article						Fps/Fes; PDGF beta receptor; down-regulation; tyrosine phosphorylation	GROWTH-FACTOR RECEPTORS; COLONY-STIMULATING FACTOR; FUJINAMI SARCOMA-VIRUS; C-FES PROTEIN; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS; TRANSGENIC MICE; KINASE FUNCTION; SRC ONCOGENE; FACTOR-I	The v-fps oncogene encodes an activated tyrosine kinase which is capable of transforming fibroblasts. In this report, we provide evidence that within a few minutes of activation of the tyrosine kinase activity of v-Fps, tyrosine phosphorylation of the platelet derived growth factor (PDGF) beta receptor is observed. Further, sustained expression of activated v-Fps results in a downregulation of the PDGF receptor both at the level of the mRNA (similar to 4-8-fold), but even more markedly at the level of the receptor protein (>100-fold). The kinase activity of the v-Fps oncoprotein was found to be required for both the induction of PDGF receptor tyrosine phosphorylation and ultimately the reduced receptor protein levels. Tyrosine phosphorylation of a kinase inactive PDGF receptor was also demonstrated in cells which also express v-fps, but this was not sufficient to induce transformation. Only cells expressing both v-fps and a wild type PDGF receptor were able to form colonies in soft agar. These findings suggest that wild type v-fps may use tyrosine phosphorylation of the PDGF beta receptor to constitutively activate the kinase activity of the receptor, resulting in a sustained proliferative signal and fibroblast transformation.	Saskatoon Canc Ctr, Res Unit, Saskatoon, SK S7N 4H4, Canada	University of Saskatchewan	Anderson, DH (corresponding author), Saskatoon Canc Ctr, Res Unit, 20 Campus Dr, Saskatoon, SK S7N 4H4, Canada.							BOWENPOPE DF, 1984, P NATL ACAD SCI-BIOL, V81, P2396, DOI 10.1073/pnas.81.8.2396; Brizzi MF, 1996, J BIOL CHEM, V271, P3562; CARE A, 1994, ONCOGENE, V9, P739; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FOSTER DA, 1985, CELL, V42, P105, DOI 10.1016/S0092-8674(85)80106-9; FUKUI Y, 1991, ONCOGENE, V6, P407; GARRETT JS, 1984, P NATL ACAD SCI-BIOL, V81, P7466, DOI 10.1073/pnas.81.23.7466; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GREER P, 1990, MOL CELL BIOL, V10, P2521, DOI 10.1128/MCB.10.6.2521; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; Hawking F, 1978, Adv Pharmacol Chemother, V15, P289, DOI 10.1016/S1054-3589(08)60486-X; HELDIN CH, 1982, J BIOL CHEM, V257, P4216; HJERMSTAD SJ, 1993, ONCOGENE, V8, P2283; HUANG SS, 1988, J BIOL CHEM, V263, P12608; INGMANBAKER J, 1984, J VIROL, V50, P572, DOI 10.1128/JVI.50.2.572-578.1984; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOZMA LM, 1990, MOL CELL BIOL, V10, P3626, DOI 10.1128/MCB.10.7.3626; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LANFRANCONE L, 1989, INT J CANCER, P35; LETWIN K, 1988, ONCOGENE, V3, P621; LIN AH, 1988, MOL CELL BIOL, V8, P5052, DOI 10.1128/MCB.8.11.5052; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MARU Y, 1995, MOL CELL BIOL, V15, P835; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MORAN MF, 1988, ONCOGENE, V3, P665; NILSON LA, 1993, MOL CELL BIOL, V13, P4137, DOI 10.1128/MCB.13.7.4137; NILSSON J, 1983, P NATL ACAD SCI-BIOL, V80, P5592, DOI 10.1073/pnas.80.18.5592; PANTAZIS P, 1990, EUR J HAEMATOL, V45, P127; PANTAZIS P, 1991, P NATL ACAD SCI USA, V88, P2481, DOI 10.1073/pnas.88.6.2481; PARK WY, 1995, BIOCHEM BIOPH RES CO, V211, P447, DOI 10.1006/bbrc.1995.1834; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAKE JB, 1991, J BIOL CHEM, V266, P5348; ROSENFELD ME, 1984, J CELL PHYSIOL, V121, P263, DOI 10.1002/jcp.1041210202; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAMARUT J, 1985, MOL CELL BIOL, V5, P1067, DOI 10.1128/MCB.5.5.1067; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SIEGBAHN A, 1990, J CLIN INVEST, V85, P916, DOI 10.1172/JCI114519; SMITHGALL TE, 1988, J BIOL CHEM, V263, P15050; SODROSKI JG, 1984, P NATL ACAD SCI-BIOL, V81, P3039, DOI 10.1073/pnas.81.10.3039; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; TZENG DY, 1985, BLOOD, V66, P179; VAZIRI C, 1995, MOL CELL BIOL, V15, P1244; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WILLIAMS LT, 1984, J BIOL CHEM, V259, P5287; YAN XQ, 1993, J IMMUNOL, V150, P2440; YAN XQ, 1994, ONCOGENE, V9, P163; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YOUNG JC, 1984, J VIROL, V52, P913, DOI 10.1128/JVI.52.3.913-918.1984; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	64	21	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	1998	16	18					2321	2331		10.1038/sj.onc.1201780	http://dx.doi.org/10.1038/sj.onc.1201780			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620549				2022-12-17	WOS:000073428000004
J	Purrello, M; Di Pietro, C; Viola, A; Rapisarda, A; Stevens, S; Guermah, M; Tao, Y; Bonaiuto, C; Arcidiacono, A; Messina, A; Sichel, G; Grzeschik, KH; Roeder, R				Purrello, M; Di Pietro, C; Viola, A; Rapisarda, A; Stevens, S; Guermah, M; Tao, Y; Bonaiuto, C; Arcidiacono, A; Messina, A; Sichel, G; Grzeschik, KH; Roeder, R			Genomics and transcription analysis of human TFIID	ONCOGENE			English	Article						TAF(II)s; regulation of gene expression; signal transduction; cell proliferation and differentiation; oncogenesis; Cancer Genome Anatomy Project	TATA-BOX-BINDING; RNA-POLYMERASE-II; FUNCTIONAL INTERACTION; MULTIPLE INTERACTIONS; CCG1 GENE; SUBUNIT; PROTEIN; LOCALIZATION; ACTIVATION; COMPLEX	TFIID, a multisubunit protein comprised of TBP (TATA box-binding protein) and TAF(II)s (TBP-associated factors), has a central role in transcription initiation at class II promoters. TAF(II)s role as mediators of regulatory transcription factors, such as pRb and p53, and their involvement in signal transduction pathways suggest that some may participate in the control of cell proliferation and differentiation: therefore, they could be considered potential protooncogenes or antioncogenes. With the aim of starting to analyse these potential roles, we have determined the genomic position of nine human TAF(II) genes (TAF(II)250, TAF(II)135, TAF(II)100, TAF(II)80, TAF(II)55, TAF(II)43, TAF(II)31, TAF(II)28, TAF(II)20/15) and of two previously unknown sequences related to TAF(II)250 and TAF(II)31, respectively. Except for those encoding TAF(II)250 and TAF(II)31, these genes are present in a single copy and, with the exclusion of those for TAF(II)43 and TAF(II)28 (both at 6p21), are localized in different segments of the genome. Indeed, six of them map to a chromosomal region commonly altered in specific neoplasias, which defines them as candidates for in oncogenesis. Our experiments also that TAF(II) transcripts are synthesized ubiquitously, mostly at low levels similar to those of TBP. Interestingly, the amount of the major mRNA species detected by TAF(II)20/15 cDNA is higher, which suggests that the polypeptide it encodes may also perform functions independently of TFIID. TAF(II) isoforms, indicated by additional bands on Northern blots, may play a role in modulation of TFIID function. These data will be useful for analysing variations of TAF(II) mRNA phenotype during cell proliferation, differentiation and development, both normal and pathological.	Univ Catania, Ist Biol Gen, I-95124 Catania, Italy; Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA; Univ Catania, Ist Patol Gen, I-95124 Catania, Italy; Univ Marburg, Med Zentrum Humangenet, D-35037 Marburg, Germany; Univ Catania, Dept Anim Biol, I-95124 Catania, Italy	University of Catania; Rockefeller University; University of Catania; Philipps University Marburg; University of Catania	Purrello, M (corresponding author), Univ Catania, Ist Biol Gen, I-95124 Catania, Italy.		Agatea, Lisa/L-8267-2016	DI PIETRO, Cinzia Santa/0000-0002-6036-4469				Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; BOYER TG, 1993, GENE DEV, V7, P1810, DOI 10.1101/gad.7.9.1810; BROWN CJ, 1989, SOMAT CELL MOLEC GEN, V15, P93, DOI 10.1007/BF01534674; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; Dubrovskaya V, 1996, GENOMICS, V36, P556, DOI 10.1006/geno.1996.0509; Dubrovskaya V, 1996, EMBO J, V15, P3702, DOI 10.1002/j.1460-2075.1996.tb00740.x; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HISATAKE K, 1995, P NATL ACAD SCI USA, V92, P8195, DOI 10.1073/pnas.92.18.8195; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; Hoffmann A, 1996, J BIOL CHEM, V271, P18194, DOI 10.1074/jbc.271.30.18194; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Kazmierczak B, 1996, J NATL CANCER I, V88, P1234, DOI 10.1093/jnci/88.17.1234; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; Lavigne AC, 1996, J BIOL CHEM, V271, P19774, DOI 10.1074/jbc.271.33.19774; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUBBERT M, 1991, BLOOD, V77, P909; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; PURRELLO M, 1994, GENOMICS, V23, P253, DOI 10.1006/geno.1994.1488; Purrello M, 1996, CYTOGENET CELL GENET, V75, P186, DOI 10.1159/000134479; PURRELLO M, 1994, GENOMICS, V22, P94, DOI 10.1006/geno.1994.1349; PURRELLO M, 1995, CYTOGENET CELL GENET, V69, P75, DOI 10.1159/000133942; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Sanchez Y, 1996, P NATL ACAD SCI USA, V93, P2551, DOI 10.1073/pnas.93.6.2551; Sauer F, 1996, CELL, V87, P1271, DOI 10.1016/S0092-8674(00)81822-X; SCHEER E, 1995, GENOMICS, V29, P269, DOI 10.1006/geno.1995.1243; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; Shao ZH, 1997, ONCOGENE, V15, P385, DOI 10.1038/sj.onc.1201204; Strausberg RL, 1997, NAT GENET, V15, P415, DOI 10.1038/ng0497supp-415; SUZUKI S, 1997, MOL CELL BIOL, V17, P3284; Tansey WP, 1997, CELL, V88, P729, DOI 10.1016/S0092-8674(00)81916-9; Tao Y, 1997, J BIOL CHEM, V272, P6714, DOI 10.1074/jbc.272.10.6714; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Xiao S, 1997, AM J PATHOL, V150, P901	40	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1633	1638		10.1038/sj.onc.1201673	http://dx.doi.org/10.1038/sj.onc.1201673			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569032				2022-12-17	WOS:000072743200015
J	Fournes, B; Monier, R; Michiels, F; Milgrom, E; Misrahi, M; Feunteun, J				Fournes, B; Monier, R; Michiels, F; Milgrom, E; Misrahi, M; Feunteun, J			Oncogenic potential of a mutant human thyrotropin receptor expressed in FRTL-5 cells	ONCOGENE			English	Article						FRTL-5 cells; TSH receptor; Gsp; malignant transformation	HYPERFUNCTIONING THYROID ADENOMAS; SOMATIC MUTATIONS; CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE; GERMLINE MUTATIONS; EPITHELIAL-CELLS; FOLLICULAR CELLS; TRANSGENIC MICE; TSH RECEPTOR; GS-ALPHA; GENE	An abnormal stimulation of the cAMP pathway has been recognized as the primary event in various pathological situations that lead to goitrogenesis or thyroid tumors, Thyroid adenomas are monoclonal neoplasms that become independent of thyroid stimulating hormone (TSH) in their secretory function and growth, Mutated forms of the TSH receptor (TSHR) and the adenylyl cyclase-activating Gs alpha protein, which confer a constitutive activity on these proteins, have been observed in human adenomas, The FRTL-5 rat thyroid cell line is a permanent but untransformed line; the growth of which depends on the presence of TSH, and at least in part, on the stimulation of the cAMP pathway, In order to compare the oncogenic potential of the activated mutant Gs alpha protein and the constitutively activated TSHR, we have transfected FRTL-5 cells with an expression vector bearing either the cDNA of the Gs alpha gene carrying the A201S mutation or the cDNA of the TSH receptor carrying the M453T mutation recently identified in a case of congenital hyperthyroidism. The expression of these two cDNAs was driven by the bovine thyroglobulin gene promoter, We show that, although the expression of both the Gs alpha or TSHR mutant proteins leads to TSH-independent proliferation and to constitutive cAMP accumulation in FRTL-5 cells, only the mutant TSHR is able to induce neoplastic transformation, as demonstrated by growth in semi-solid medium and tumorigenesis in nude mice.	Inst Gustave Roussy, CNRS, URA 1967, Lab Genet Oncol, F-94805 Villejuif, France; Ctr Hosp Bicetre, INSERM, U135, F-94270 Le Kremlin Bicetre, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Feunteun, J (corresponding author), Inst Gustave Roussy, CNRS, URA 1967, Lab Genet Oncol, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		Feunteun, Jean/AAZ-1267-2020	Feunteun, Jean/0000-0003-1212-9189				AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; DeRoux N, 1996, J CLIN ENDOCR METAB, V81, P2023, DOI 10.1210/jc.81.6.2023; DERWAHL M, 1992, BIOCHEM BIOPH RES CO, V183, P220, DOI 10.1016/0006-291X(92)91631-Y; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; FUSCO A, 1982, CANCER RES, V42, P618; GORETZKI PE, 1992, WORLD J SURG, V16, P576, DOI 10.1007/BF02067325; HEN R, 1989, P NATL ACAD SCI USA, V86, P4785, DOI 10.1073/pnas.86.12.4785; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; KOPP P, 1995, NEW ENGL J MED, V332, P150, DOI 10.1056/NEJM199501193320304; Laglia G, 1996, ENDOCRINOLOGY, V137, P3170, DOI 10.1210/en.137.8.3170; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Laugwitz KL, 1996, P NATL ACAD SCI USA, V93, P116, DOI 10.1073/pnas.93.1.116; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; LEDENT C, 1990, P NATL ACAD SCI USA, V87, P6176, DOI 10.1073/pnas.87.16.6176; LOOSFELT H, 1992, P NATL ACAD SCI USA, V89, P3765, DOI 10.1073/pnas.89.9.3765; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; MUCA C, 1994, ONCOGENE, V9, P647; OSSENDORP FA, 1990, ENDOCRINOLOGY, V127, P419, DOI 10.1210/endo-127-1-419; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PASCHKE R, 1994, J CLIN ENDOCR METAB, V79, P1785, DOI 10.1210/jc.79.6.1785; PETER HJ, 1991, ENDOCRINOLOGY, V128, P211, DOI 10.1210/endo-128-1-211; RUSSO D, 1995, J CLIN ENDOCR METAB, V80, P1347, DOI 10.1210/jc.80.4.1347; RUSSO D, 1995, ONCOGENE, V11, P1907; SAJI M, 1994, SURGERY, V116, P1048; SANTISTEBAN P, 1987, J BIOL CHEM, V262, P4048; SUAREZ HG, 1991, ONCOGENE, V6, P677; Tonacchera M, 1996, J CLIN ENDOCR METAB, V81, P547, DOI 10.1210/jc.81.2.547; TSUZAKI S, 1991, ENDOCRINOLOGY, V128, P1359, DOI 10.1210/endo-128-3-1359; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WEIGEL RJ, 1993, CANCER RES, V53, P3472; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K; Zeiger MA, 1996, ENDOCRINOLOGY, V137, P5392, DOI 10.1210/en.137.12.5392	39	21	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	1998	16	8					985	990		10.1038/sj.onc.1201626	http://dx.doi.org/10.1038/sj.onc.1201626			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519872				2022-12-17	WOS:000072335900004
J	Wang, Q; Driouch, K; Courtois, S; Champeme, MH; Bieche, I; Treilleux, I; Briffod, M; Rimokh, R; Magaud, JP; Curmi, P; Lidereau, R; Puisieux, A				Wang, Q; Driouch, K; Courtois, S; Champeme, MH; Bieche, I; Treilleux, I; Briffod, M; Rimokh, R; Magaud, JP; Curmi, P; Lidereau, R; Puisieux, A			Low frequency of TSG101/CC2 gene alterations in invasive human breast cancers	ONCOGENE			English	Article						human breast cancer; TSG101/CC2; rearrangement; mutation	HETEROZYGOSITY; CHROMOSOME-11; PHOSPHORYLATION; ADENOCARCINOMA; PHOSPHOPROTEIN; ONCOPROTEIN-18; INSTABILITY; PROGRESSION; EXPRESSION; STATHMIN	Large intragenic deletions of the TSG101/CC2 gene were recently reported in seven of 15 primary metastatic breast cancers. Although the number of samples was small, this observation suggested that TSG101/CC2 alterations were a major event in breast carcinogenesis. To study the frequency of these deletions in invasive breast cancers we analysed 189 primary invasive breast tumours and 59 breast cancer metastases. We detected intragenic rearrangements in only three samples (two primary tumours and one metastasis). Northern blot analysis of 43 tumours without rearrangements failed to detect any abnormalities. Furthermore, we studied TSG101/CC2 in 11 human breast adenocarcinoma cell lines by Southern blot, RT-PCR and sequencing of the entire coding region of the gene, and detected no abnormalities. These results show that genetic alteration of TSG101/CC2 is a rare event in breast cancer.	Ctr Leon Berard, Unite Oncol Mol, INSERM, U453, F-69373 Lyon 08, France; Ctr Rene Huguenin, Lab Oncogenet, F-92210 St Cloud, France; Ctr Leon Berard, Dept Anat & Cytol Pathol, F-69373 Lyon 08, France; Ctr Rene Huguenin, Lab Anatomocytopathol, F-92210 St Cloud, France; INSERM, U440, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Rene Huguenin Hospital; UNICANCER; Centre Leon Berard; Rene Huguenin Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm)	Puisieux, A (corresponding author), Ctr Leon Berard, Unite Oncol Mol, INSERM, U453, F-69373 Lyon 08, France.		Bièche, Ivan/O-7399-2017; CURMI, Patrick/G-4036-2013; Rimokh, Ruth/G-7506-2014	Bièche, Ivan/0000-0002-2430-5429; CURMI, Patrick A./0000-0001-5045-8501; PUISIEUX, Alain/0000-0002-9938-3798				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Baffa R, 1996, CANCER RES, V56, P268; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; BRATTSAND G, 1993, LEUKEMIA, V7, P569; CHENG KC, 1993, ADV CANCER RES, V60, P121; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FRIEDRICH B, 1995, PROSTATE, V27, P102, DOI 10.1002/pros.2990270207; GUDMUNDSSON J, 1995, BRIT J CANCER, V72, P696, DOI 10.1038/bjc.1995.396; HANASH SM, 1988, J BIOL CHEM, V263, P12813; KARNIK P, 1995, HUM MOL GENET, V4, P1889, DOI 10.1093/hmg/4.10.1889; LARSSON N, 1995, J BIOL CHEM, V270, P14175, DOI 10.1074/jbc.270.23.14175; Lee MP, 1997, CANCER RES, V57, P3131; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Lu KH, 1997, CANCER RES, V57, P387; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; Steiner P, 1997, NAT GENET, V16, P332, DOI 10.1038/ng0897-332; STRAHLER JR, 1992, BIOCHEM BIOPH RES CO, V185, P197, DOI 10.1016/S0006-291X(05)80975-1; Tran YK, 1996, CANCER RES, V56, P2916; WEBER JL, 1989, AM J HUM GENET, V44, P388; WINQVIST R, 1995, CANCER RES, V55, P2660	24	21	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					677	679		10.1038/sj.onc.1201563	http://dx.doi.org/10.1038/sj.onc.1201563			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482115				2022-12-17	WOS:000071816600014
J	Pyles, RB; Santoro, IM; Groden, J; Parysek, LM				Pyles, RB; Santoro, IM; Groden, J; Parysek, LM			Novel protein isoforms of the APC tumor suppressor in neural tissue	ONCOGENE			English	Article						APC; tumor suppressor; neural tissue; protein isoforms	MULTIPLE INTESTINAL NEOPLASIA; COLORECTAL-CANCER; BRAIN-TUMORS; GENE-PRODUCT; WILD-TYPE; ASSOCIATION; COLI; IDENTIFICATION; EXPRESSION; MUTATIONS	The conventional protein isoform of the APC tumor suppressor is 310 kD and is encoded by exons 1-15 of the APC gene, Other RNAs are expressed from the APC gene and include one form that contains an exon upstream of exon 1, designated BS, but this transcript does not include exon 1, This transcript recently has been shown to be enriched in non-dividing, terminally-differentiated cells (Santoro and Groden, 1997). To determine if the BS-containing transcript encoded an alternate APC protein isoform, we generated and affinity-purified a polyclonal antibody directed to protein sequence predicted by exon BS, The BS antibody labeled a band of similar to 300 kD on immunoblots of cerebral and cerebellar tissue from adult human, baboon, rat and mouse, These same tissue lysates also contained prominent BS-reactive proteins of 290 kD, 200 kD and 150 kD, Lysates from mitotically active cells did not contain these APC isoforms, To verify that BS-reactive proteins were APC isoforms, BS-immunoprecipitates were blotted and labeled with commercially available APC antibodies, All four high molecular weight BS-antibody-precipitated proteins were recognized by antibodies directed against epitopes encoded by APC exons 2 and 15. BS isoforms were not, however, labeled with antibodies to an epitope encoded by APC exon 1, consistent with the prediction that BS-APC isoforms lack the domain encoded by these sequences, Like conventional APC, at least one of the four BS-APC protein isoforms also interacts with beta-catenin. BS-APC isoforms that lack exon 1-encoded sequences are incapable of dimerization with the conventional form of APC, yet retain the ability to bind beta-catenin, Such isoforms are likely to be functionally distinct from the conventional APC protein.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Neurobiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Anat, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Biochem & Microbiol, Cincinnati, OH 45267 USA	University of Cincinnati; University of Cincinnati; University of Cincinnati; University of Cincinnati; University of Cincinnati	Pyles, RB (corresponding author), Childrens Hosp Res Fdn, 3333 Burnet Ave, Cincinnati, OH 45229 USA.				NATIONAL CANCER INSTITUTE [R29CA063507, R01CA063507] Funding Source: NIH RePORTER; NCI NIH HHS [CA-63507] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BHAT RV, 1994, J NEUROSCI, V14, P3059; CARRARO U, 1983, BIOCHEM BIOPH RES CO, V116, P793, DOI 10.1016/S0006-291X(83)80212-5; GRODEN J, 1995, CANCER RES, V55, P1531; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GRODEN J, 1995, NEW ENGL J MED, V332, P884, DOI 10.1056/NEJM199503303321310; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HORII A, 1993, HUM MOL GENET, V2, P283, DOI 10.1093/hmg/2.3.283; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; Kraus C, 1996, INT J CANCER, V65, P383, DOI 10.1002/(SICI)1097-0215(19960126)65:3<383::AID-IJC18>3.3.CO;2-U; LUONGO C, 1994, CANCER RES, V54, P5947; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MIYASHIRO I, 1995, ONCOGENE, V11, P89; MORI T, 1994, GENE CHROMOSOME CANC, V9, P168, DOI 10.1002/gcc.2870090304; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Santoro IM, 1997, CANCER RES, V57, P488; SMITH KJ, 1994, CANCER RES, V54, P3672; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1993, CANCER RES, V53, P2728; SULEKOVA Z, 1995, INT J CANCER, V63, P435, DOI 10.1002/ijc.2910630323; TAINER JA, 1984, NATURE, V312, P127, DOI 10.1038/312127a0; THLIVERIS A, 1994, CANCER RES, V54, P2991; Yamamoto H, 1996, CANCER RES, V56, P3605	31	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					77	82		10.1038/sj.onc.1201505	http://dx.doi.org/10.1038/sj.onc.1201505			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467945				2022-12-17	WOS:000071236800009
J	Kato, K; Ueoka, Y; Kato, K; Hachiya, T; Nishida, J; Wake, N				Kato, K; Ueoka, Y; Kato, K; Hachiya, T; Nishida, J; Wake, N			Contribution of enhanced transcriptional activation by ER to [(12)Val] K-Ras mediated NIH3T3 cell transformation	ONCOGENE			English	Article						Ras; transformation; ER; PR	STEROID-HORMONE RECEPTORS; HUMAN ESTROGEN-RECEPTOR; PROTEIN; PHOSPHORYLATION; STIMULATION; BINDING; REGION; KINASE; GROWTH	We investigated the biological significance of estrogen receptors (ER) in NM3T3 cell transformation by the [(12)Val] K-Ras mutant, This mutant enhanced the steady state level of ER, Cells expressing mutant K-Ras (K12V cell) were tumorigenic, To determine the role of ER accumulation in Ras-transformed cells, we developed cells (KwtER cells) that overexpressed both wild-type (wt) K-Ras and ER, and found these cells were also tumorigenic. E-2 stimulated the transcriptional activity by ER dominantly in K12V cells, However, only partial activation of ER by E-2 was seen in KwtER cells, In the presence of 10% serum in media, the activation of ER appeared only in transformed KtwER and K12V cells, suggesting that two independently transmitted signals, the E-2-ER binding and the ER-AF1 activation, are necessary for ER activation and that the dominant activation of ER might be involved in Ras-mediated cell transformation, Co-expression of progesterone receptor (PR) with mutant K-Ras led to suppression of tumorigenicity and inhibition of the activation of ER, The antisense oligomers complementary to the ER suppressed proliferation and transformed phenotypes of K12V cells, These observations support the importance of ER in aas-mediated cell transformation.	Kyushu Univ, Med Inst Bioregulat, Dept Reprod Physiol & Endocrinol, Beppu, Oita 874, Japan	Kyushu University	Wake, N (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Reprod Physiol & Endocrinol, 4546 Tsurumihara, Beppu, Oita 874, Japan.							ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CICATIELLO L, 1992, J STEROID BIOCHEM, V41, P523, DOI 10.1016/0960-0760(92)90377-U; COEZY E, 1982, CANCER RES, V42, P317; DUBIK D, 1987, CANCER RES, V47, P6517; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; INOUE S, 1993, P NATL ACAD SCI USA, V90, P11117, DOI 10.1073/pnas.90.23.11117; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KRAUS WL, 1995, MOL CELL BIOL, V15, P1847; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; PETRANGELI E, 1994, J STEROID BIOCHEM, V49, P327, DOI 10.1016/0960-0760(94)90275-5; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOJEK AB, 1993, CELL, V74, P205; WALMER DK, 1995, CANCER RES, V55, P1168; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	20	21	22	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	1997	15	25					3037	3046		10.1038/sj.onc.1201497	http://dx.doi.org/10.1038/sj.onc.1201497			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444952				2022-12-17	WOS:000070968000004
J	Zong, WX; Farrell, M; Bash, J; Gelinas, C				Zong, WX; Farrell, M; Bash, J; Gelinas, C			v-Rel prevents apoptosis in transformed lymphoid cells and blocks TNF alpha-induced cell death	ONCOGENE			English	Article						v-Rel; apoptosis; cell transformation; tetracycline-regulation	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; RECEPTOR FUSION PROTEIN; CHICKEN SPLEEN-CELLS; RETICULOENDOTHELIOSIS VIRUS; ESTROGEN-RECEPTOR; MAMMALIAN-CELLS; GENE-EXPRESSION; FAMILY; DNA	The v-Rel oncoprotein belongs to the Rel/NF-kappa B family of transcription factors, It transforms chicken lymphoid cells in vitro and induces fatal lymphomas in vivo, In this study, we used a tetracycline-regulated system to characterize the role of v-Rel in cell transformation. We show that the continued expression of v-Rel is necessary to maintain the viability of transformed lymphoid cells and enables primary spleen cells to escape apoptosis in vitro culture. In agreement with a possible role for v-Rel in the inhibition of programmed cell death, its inducible expression in HeLa cells prevented TNF alpha-induced apoptosis, While the repression of v-Rel was accompanied by the rapid degradation of I kappa B alpha, changes in the steady-state levels of the apoptosis inhibitors Bcl-2 and Bcl-X-L were only observed following the onset of cell death in transformed lymphoid cells. This suggests that the anti-apoptotic activity of v-Rel may affect other apoptosis inhibitors or other factors in the death pathway, Together, these findings demonstrate that v-Rel blocks apoptosis and suggest that this activity may be an important component of its transforming function.	UNIV MED & DENT NEW JERSEY,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,GRAD PROGRAM BIOCHEM & MOL BIOL,PISCATAWAY,NJ 08854; RUTGERS STATE UNIV,GRAD PROGRAM MICROBIOL & MOL GENET,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,CANC INST NEW JERSEY,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey					NCI NIH HHS [CA54999] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA054999, R01CA054999] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BERNARD HU, 1985, EXP CELL RES, V158, P237, DOI 10.1016/0014-4827(85)90446-X; BHAT GV, 1990, ONCOGENE, V5, P625; BOEHMELT G, 1995, CELL, V80, P341, DOI 10.1016/0092-8674(95)90417-4; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cai ZZ, 1997, J BIOL CHEM, V272, P96; CAPOBIANCO AJ, 1993, VIROLOGY, V193, P160, DOI 10.1006/viro.1993.1112; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAVIS JN, 1990, ONCOGENE, V5, P1109; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; Gilmore TD, 1996, ONCOGENE, V13, P1367; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HALDAR S, 1989, NATURE, V342, P195, DOI 10.1038/342195a0; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HOLTMANN H, 1988, IMMUNOBIOLOGY, V177, P7, DOI 10.1016/S0171-2985(88)80087-1; Houldsworth J, 1996, BLOOD, V87, P25; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LU D, 1991, ONCOGENE, V6, P1235; LUQUE I, 1997, IN PRESS SEMIN CANC, V8; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1989, ONCOGENE, V4, P677; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RUBIN BY, 1988, CANCER RES, V48, P6006; SACHDEV S, 1997, IN PRESS ONCOGENE, V14; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; WHITE DW, 1993, J VIROL, V67, P6876, DOI 10.1128/JVI.67.11.6876-6881.1993; White DW, 1996, MOL CELL BIOL, V16, P1169; White DW, 1996, ONCOGENE, V13, P891; WHITE DW, 1995, ONCOGENE, V10, P857; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733	54	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					971	980		10.1038/sj.onc.1201266	http://dx.doi.org/10.1038/sj.onc.1201266			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285692				2022-12-17	WOS:A1997XR76700010
J	Persengiev, SP; Kondova, II; Millette, CF; Kilpatrick, DL				Persengiev, SP; Kondova, II; Millette, CF; Kilpatrick, DL			Gli family members are differentially expressed during the mitotic phase of spermatogenesis	ONCOGENE			English	Article						proto-oncogenes; spermatogonia; DNA binding proteins; male germ line	GREIG CEPHALOPOLYSYNDACTYLY SYNDROME; GENE CUBITUS-INTERRUPTUS; ZINC-FINGER PROTEIN; EXTRA-TOES XT; CELL-DIFFERENTIATION; KRUPPEL FAMILY; MESSENGER-RNA; MOUSE; RAT; TRANSCRIPTION	The Cli family of DNA binding proteins has been implicated in multiple neoplasias and developmental abnormalities, suggesting a primary involvement in cell development and differentiation, However, to date their specific roles and mechanisms of action remain obscure, and a drawback has been the lack of a model system in which to study their normal function, Here we demonstrate that Gli family members are differentially expressed during spermatogenesis in mice, Specifically, Gli and Gli3 mRNAs were detected in mouse germ cells, while Gli2 was not, Further, both Gli and Gli3 exhibited stage-dependent patterns of expression selectively in type A and B spermatogonia, Gli expression was somewhat higher in type B spermatogonia,while the abundance of Gli3 transcripts was similar in type A and B cells, Gel-shift analyses also demonstrated the enrichment of DNA binding activity specific for the Gli target sequence in spermatogonial cells, These results indicate a selective role for Gli and Gli3 during mitotic stages of male germ cell development, Spermatogenesis may thus provide a unique opportunity to identify downstream targets and explore the normal function of Gli family proteins.	WORCESTER FDN BIOMED RES, NEUROBIOL GRP, SHREWSBURY, MA 01545 USA; UNIV S CAROLINA, SCH MED, DEPT CELL BIOL & NEUROSCI, COLUMBIA, SC 29208 USA	Worcester Foundation for Biomedical Research; University of South Carolina; University of South Carolina System; University of South Carolina Columbia					NICHD NIH HHS [HD15269] Funding Source: Medline; NIDDK NIH HHS [DK36468] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD015269] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036468] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALCIVAR AA, 1991, MOL REPROD DEV, V30, P187, DOI 10.1002/mrd.1080300304; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BELLVE AR, 1977, J HISTOCHEM CYTOCHEM, V25, P480, DOI 10.1177/25.7.893996; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; GALCHEVAGARGOVA Z, 1993, MOL ENDOCRINOL, V7, P979, DOI 10.1210/me.7.8.979; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; KEW D, 1990, MOL ENDOCRINOL, V4, P337, DOI 10.1210/mend-4-2-337; KEW D, 1989, MOL ENDOCRINOL, V3, P1191, DOI 10.1210/mend-3-8-1191; KILPATRICK DL, 1990, MOL CELL BIOL, V10, P3717, DOI 10.1128/MCB.10.7.3717; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Kleene KC, 1996, MOL REPROD DEV, V43, P268, DOI 10.1002/(SICI)1098-2795(199602)43:2&lt;268::AID-MRD17&gt;3.0.CO;2-#; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; ROBERTS WM, 1989, CANCER RES, V49, P5407; RUPPERT JM, 1990, MOL CELL BIOL, V10, P5408, DOI 10.1128/MCB.10.10.5408; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; SCHIMMANG T, 1992, DEVELOPMENT, V116, P799; TORRY DS, 1992, AM J REPROD IMMUNOL, V27, P167, DOI 10.1111/j.1600-0897.1992.tb00745.x; VORTKAMP A, 1992, MAMM GENOME, V3, P461, DOI 10.1007/BF00356157; VORTKAMP A, 1995, DNA CELL BIOL, V14, P629, DOI 10.1089/dna.1995.14.629; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; WALTERHOUSE D, 1993, DEV DYNAM, V196, P91, DOI 10.1002/aja.1001960203; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; ZARKOWER D, 1993, NUCLEIC ACIDS RES, V21, P3691, DOI 10.1093/nar/21.16.3691	32	21	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	1997	14	19					2259	2264		10.1038/sj.onc.1201068	http://dx.doi.org/10.1038/sj.onc.1201068			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178901				2022-12-17	WOS:A1997WY88300002
J	Jones, TL; Karavanova, I; Chong, L; Zhou, RP; Daar, IO				Jones, TL; Karavanova, I; Chong, L; Zhou, RP; Daar, IO			Identification of XLerk, an Eph family ligand regulated during mesoderm induction and neurogenesis in Xenopus laevis	ONCOGENE			English	Article						Eph ligand; xenopus development; nervous system	RECEPTOR TYROSINE KINASES; GROWTH-FACTOR; NEURAL CREST; MOLECULAR-CLONING; CDNA CLONING; EXPRESSION; PROTEIN; EMBRYOS; GENES; TRANSITION	We have isolated and characterized the first Xenopus transmembrane Eph ligand, XLerk (Xenopus Ligand for Eph Receptor Tyrosine Kinases). While this ligand has 72% identity with the closest mammalian family member, Lerk-2, it is the cytoplasmic domain of this molecule that is the most conserved domain with 95% identity, XLerk exists as a maternally expressed mRNA, however, expression of transcripts and protein increase during gastrulation and again in the late swimming tadpole stage. In the adult, XLerk is expressed at low levels in mast adult tissues with increased levels observed in the kidney, oocytes, ovary and testis. While low levels of XLerk expression are observed in the adult brain, ill situ hybridization analysis demonstrates prominent expression in the developing olfactory system, retina, hindbrain, cranial ganglia, and somites, Furthermore, we have shown that XLerk transcripts are significantly elevated during mesoderm induction caused by activin and FGF, but not during noggin-induced neuralization. These results suggest a role for XLerk in the developing mesenchymal and nervous tissue.	NCI,FREDERICK CANC RES & DEV CTR,LAB LEUKOCYTE BIOL,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,COMPARAT CARCINOGENESIS LAB,FREDERICK,MD 21702; RUTGERS STATE UNIV,CANC RES LAB,PISCATAWAY,NJ 08855	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Rutgers State University New Brunswick				Daar, Ira/0000-0003-2657-526X				BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; Bohme B, 1996, J BIOL CHEM, V271, P24747, DOI 10.1074/jbc.271.40.24747; BOUILLET P, 1995, DEV BIOL, V170, P420, DOI 10.1006/dbio.1995.1226; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; BRANDLI AW, 1995, DEV DYNAM, V203, P119; CARPENTER MK, 1995, J NEUROSCI RES, V42, P199, DOI 10.1002/jnr.490420207; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Doniach T, 1995, CELL, V83, P1067, DOI 10.1016/0092-8674(95)90133-7; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; EASTY DJ, 1995, CANCER RES, V55, P2528; FLETCHER FA, 1994, ONCOGENE, V9, P3241; Gale NW, 1996, ONCOGENE, V13, P1343; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Gao PP, 1996, P NATL ACAD SCI USA, V93, P11161, DOI 10.1073/pnas.93.20.11161; HEMMATIBRIVANLOU A, 1992, NEURON, V9, P417, DOI 10.1016/0896-6273(92)90180-L; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; HENS MD, 1995, DEV BIOL, V170, P274, DOI 10.1006/dbio.1995.1214; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; HOLLAND PWH, 1988, DEVELOPMENT, V102, P150; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; JONES TL, 1995, ONCOGENE, V10, P1111; Kenny D, 1995, DEV BIOL, V172, P708, DOI 10.1006/dbio.1995.8083; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KROTOSKI D, 1990, J EXP ZOOL, V253, P139, DOI 10.1002/jez.1402530204; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; LEFCORT F, 1992, DEVELOPMENT, V116, P767; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NIEUWKOOP PD, 1976, NORMAL TABLE XENOPUS, P252; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; RANSOM DG, 1993, DEV BIOL, V160, P265, DOI 10.1006/dbio.1993.1304; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SHAO HN, 1995, J BIOL CHEM, V270, P3467, DOI 10.1074/jbc.270.8.3467; SIMONNEAU L, 1992, DEV DYNAM, V194, P247, DOI 10.1002/aja.1001940402; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; TOMASELLI KJ, 1989, ASSEMBLY NERVOUS SYS, P81; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; Weinstein DC, 1996, MECH DEVELOP, V57, P133, DOI 10.1016/0925-4773(96)00536-9; WINNING RS, 1994, MECH DEVELOP, V46, P219, DOI 10.1016/0925-4773(94)90072-8; Winning RS, 1996, DEV BIOL, V179, P309, DOI 10.1006/dbio.1996.0262; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; Xu QL, 1995, DEVELOPMENT, V121, P4005	57	21	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 8	1997	14	18					2159	2166		10.1038/sj.onc.1201082	http://dx.doi.org/10.1038/sj.onc.1201082			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WX938	9174051				2022-12-17	WOS:A1997WX93800004
J	Lohman, FP; Gibbs, S; Fischer, DF; Borgstein, AMB; vandePutte, P; Backendorf, C				Lohman, FP; Gibbs, S; Fischer, DF; Borgstein, AMB; vandePutte, P; Backendorf, C			Involvement of c-JUN in the regulation of terminal differentiation genes in normal and malignant keratinocytes	ONCOGENE			English	Article						keratinocytes; terminal differentiation; c-JUN; SPRR2; involucrin	CORNIFIED CELL-ENVELOPE; PROLINE-RICH PROTEINS; DELETION MUTANT; FOS; CULTURE; TRANSFORMATION; PROTOONCOGENE; EXPRESSION; EVOLUTION; PROMOTER	In stratifying cultures of human keratinocytes, expression of the proto-oncoprotein c-JUN and the small proline rich 2 (SPRR2) protein, a precursor of the cornified cell envelope, are inversely related. Whereas c-JUN is typically found in basal proliferating cells, SPRR2 is restricted to suprabasal differentiating layers. Malignant keratinocytes (derived from squamous cell carcinoma, SCC) have reduced sprr2 expression, consistent with their low potential to differentiate, and express c-jun at higher levels than normal keratinocytes. A direct relation between c-jun and sprr2 expression was shown in several ways: transient ectopic expression of c-jun inhibits sprr2a promoter activity in normal differentiating cells, whereas in malignant keratinocytes a dominant negative c-jun mutant restored at least partially both the low promoter activity and the expression of endogenous sprr2. These effects are mediated via a 134 bp promoter fragment which does not include the sprr2a AP-1 binding site. Interestingly, in an SCC cell line, constitutively expressing the dominant c-jun mutant, expression of the terminal differentiation marker involucrin is also strongly increased, suggesting that c-JUN is a general modulator of keratinocyte terminal differentiation rather than only affecting the expression of sprr2.	LEIDEN INST CHEM, GENET MOL LAB, NL-2300 RA LEIDEN, NETHERLANDS; LEIDEN UNIV HOSP, DEPT DERMATOL, NL-2300 RC LEIDEN, NETHERLANDS	Leiden University; Leiden University; Leiden University Medical Center (LUMC)				Fischer, David/0000-0002-6690-0197				ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BOISJOYEUX B, 1995, J BIOL CHEM, V270, P10204, DOI 10.1074/jbc.270.17.10204; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DOMANN FE, 1994, MOL CARCINOGEN, V9, P61, DOI 10.1002/mc.2940090202; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; FRANCASTEL C, 1994, ONCOGENE, V9, P1957; GIBBS S, 1990, NUCLEIC ACIDS RES, V18, P4401, DOI 10.1093/nar/18.15.4401; GIBBS S, 1993, GENOMICS, V16, P630, DOI 10.1006/geno.1993.1240; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HILBERG F, 1992, ONCOGENE, V7, P2371; HOHL D, 1995, J INVEST DERMATOL, V104, P902, DOI 10.1111/1523-1747.ep12606176; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LICHTENAUERKALIGIS EGR, 1993, HUM MOL GENET, V2, P173, DOI 10.1093/hmg/2.2.173; PONEC M, 1989, IN VITRO CELL DEV B, V25, P689, DOI 10.1007/BF02623721; RHEINWALD JG, 1980, CELL, V22, P629, DOI 10.1016/0092-8674(80)90373-6; RHEINWALD JG, 1981, CANCER RES, V41, P1657; RHEINWALD JG, 1983, HUMAN CARCINOGENESIS, P85; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; WATT FM, 1991, J CELL SCI, V99, P397	30	21	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	1997	14	13					1623	1627		10.1038/sj.onc.1200974	http://dx.doi.org/10.1038/sj.onc.1200974			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129155				2022-12-17	WOS:A1997WQ54800015
J	Bansal, A; Ramirez, RD; Minna, JD				Bansal, A; Ramirez, RD; Minna, JD			Mutation analysis of the coding sequences of MEK-1 and MEK-2 genes in human lung cancer cell lines	ONCOGENE			English	Article						MAP kinase pathway; MEK; human lung cancer	MAP KINASE KINASE; PROTEIN-KINASE; MYC GENE; INSULIN; TRANSFORMATION; PHOSPHORYLATES; AMPLIFICATION; EXPRESSION; ACTIVATOR; PATHWAY	Recently, constitutively active mutants of MEK (MAP/ ERI( kinase) were shown to be capable of transforming cells to tumorigenicity suggesting that MEK can function as a dominant oncogene and potentially play a role in human carcinogenesis, Human lung cancer cells exhibit mutations in other components of the MAP kinase signaling pathway such as the Her-2/neu and ras oncogenes. Thus, the coding sequences of both MEK-1 and MEK-2 cDNAs from human lung cancer cell lines were screened by single strand conformation polymorphism analysis and DNA sequencing for alterations in these two genes. In 37 lung cancer cell lines we found: an allelic variant in MEK-1 cDNA, nt 783 G-->A, (no amino acid change); a MEK-2 cDNA change (nt 977 C-->T mutation leading to 298 Pro-->Leu change); a MEK-2 cDNA change nt 537 C-->T (no amino acid change); and a frequent MEK-2 cDNA germline polymorphism nt 744, A-->C (no amino acid change) with an allele frequency of 0.5 for each form. These results suggest that mutations in the MEK-1 and MEK-2 gene occur at a very low frequency in human lung cancer.	UNIV TEXAS,SW MED CTR,HAMON CTR THERAPEUT ONCOL RES,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								BLUMER KJ, 1994, P NATL ACAD SCI USA, V91, P4925, DOI 10.1073/pnas.91.11.4925; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRUNET A, 1994, ONCOGENE, V9, P3379; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; GAZDAR AF, 1994, COLD SPRING HARB SYM, V59, P565, DOI 10.1101/SQB.1994.059.01.063; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MINNA J, 1994, LUNG CANC PRINCIPLES, P143; MINNA JD, 1993, CHEST, V103, pS449, DOI 10.1378/chest.103.4_Supplement.449S; MINNA JD, 1997, CANC PRINCIPLES PRAC; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEKIDO Y, 1994, ONCOGENE, V9, P1599; SEKIDO Y, 1995, CANCER RES, V55, P1227; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	26	21	24	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1231	1234		10.1038/sj.onc.1200947	http://dx.doi.org/10.1038/sj.onc.1200947			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121773				2022-12-17	WOS:A1997WM78200013
J	Hart, KC; Donoghue, DJ				Hart, KC; Donoghue, DJ			Derivatives of activated H-ras lacking C-terminal lipid modifications retain transforming ability if targeted to the correct subcellular location	ONCOGENE			English	Article						ras; subcellular localization; transformation	GUANINE-NUCLEOTIDE-BINDING; MURINE SARCOMA-VIRUS; SRC-GENE-PRODUCT; PLASMA-MEMBRANE; POSTTRANSLATIONAL MODIFICATION; ONCOGENE PROTEIN; GOLGI-COMPLEX; P21; DOMAIN; SIGNAL	To examine the ability of uas to activate signal transduction pathways in the absence of lipid modifications, fusion proteins were constructed that target ras(WT) or activated ras(61L) to cellular membranes as integral membrane proteins, using the first transmembrane domain of the El protein of avian infectious bronchitis virus (IBV), which contains a cis-Golgi targeting signal. Golgi-targeted derivatives of activated ras were completely inactive in transformation assays. However, when examined in focus formation assays, transformation of NIH3T3 cells were seen with derivatives of vas(61L) containing a mutated El targeting sequence that results in plasma membrane localization. Removal of the lipid modification sites in and upstream of the CAAX motif did not abrogate the transforming activity of plasma membrane-localized ras(61L) derivatives, indicating that these lipid modifications are not essential for ras activity, as long as the protein is correctly localized to the plasma membrane. Interestingly, the activity of integral membrane versions of vas(61L) was strictly dependent on a minimum distance between the transmembrane domain anchor region and the coding sequence of vas. Derivatives with only a 3-amino acid linker were inactive, while linkers of either 11- or 22-amino acids were sufficient to restore transforming activity. These results demonstrate that: (1) activated ras targeted to Golgi membranes is unable to cause transformation; (2) lipid modifications at the C-terminus are not required for the transforming activity of plasma membrane-anchored ras(61L) derivatives, and serve primarily a targeting function; (3) a transmembrane domain can effectively substitute for C-terminal modifications that would normally target uas to the inner surface of the plasma membrane, indicating that ras(61L) does not need to reversibly dissociate from the membrane as might be allowed by the normal lipidation; and (4) in order to function properly, there exists a critical distance that the ras protein must reside from the plasma membrane.	UNIV CALIF SAN DIEGO,SCH MED,DEPT CHEM & BIOCHEM,CTR GENET MOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,MOL PATHOL PROGRAM,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego								BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRANDTRAUF PW, 1990, J PROTEIN CHEM, V9, P137, DOI 10.1007/BF01025304; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Hart K C, 1995, Genet Eng (N Y), V17, P181; HART KC, 1994, J CELL BIOL, V127, P1843, DOI 10.1083/jcb.127.6.1843; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JOHN J, 1989, J BIOL CHEM, V264, P13086; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LACAL PM, 1988, ONCOGENE, V2, P533; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LOWY DR, 1986, CANCER SURV, V5, P275; MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; Okada T, 1996, J BIOL CHEM, V271, P4671; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; SEKIYA T, 1984, P NATL ACAD SCI-BIOL, V81, P4771, DOI 10.1073/pnas.81.15.4771; SHIH TY, 1980, NATURE, V287, P686, DOI 10.1038/287686a0; SHIH TY, 1982, J VIROL, V42, P253, DOI 10.1128/JVI.42.1.253-261.1982; SHIH TY, 1984, CANCER INVEST, V2, P109, DOI 10.3109/07357908409020294; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TEMELES GL, 1985, NATURE, V313, P700, DOI 10.1038/313700a0; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; XU YF, 1993, J CELL BIOL, V123, P549, DOI 10.1083/jcb.123.3.549; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	50	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 27	1997	14	8					945	953		10.1038/sj.onc.1200908	http://dx.doi.org/10.1038/sj.onc.1200908			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050994	Green Published, Bronze			2022-12-17	WOS:A1997WK34400008
J	Park, S; Sanchez, MP				Park, S; Sanchez, MP			The Eek receptor, a member of the Eph family of tyrosine protein kinases, can be activated by three different Eph family ligands	ONCOGENE			English	Article						receptor tyrosine kinase; Eph family; brain	GENE; EXPRESSION; BRAIN; IDENTIFICATION; CLONING; MOUSE; TRKB; ELK; OVEREXPRESSION; HINDBRAIN	The Eph family of receptors, the largest subgroup within the tyrosine protein kinase receptor family, are comprised of at least thirteen members, many of which are predominantly expressed in the developing and adult nervous system. In this study, we have isolated a full-length cDNA, encoding the mouse homologue of a previous partially characterized Eek protein, a member of Eph receptor tyrosine kinase family. In a comparison of the amino acid sequences of various Eph family members, Eek is most similar to Ehk-3/MDK1, Sek/Cek8, Ehk-2, Hek/Mek4/Cek4, and Bsk/Ehk1/Rek7/Cek7, which are predominantly expressed in the nervous system. Additionally, we have used a low-stringency PCR cloning technique to identify ligands, related to B61, that may interact with Eek. Three different GPI-linked ligands, namely Elf-1/Cek7-L, Ehk1-L/Efl-2/Lerk3 and AL-1/RAGS, were isolated from mouse brain. To study the functional interactions between these ligands and the Eek receptors, rye have constructed chimeric ligands consisting of the Fc portion of human IgG fused to their carboxyl-terminus. These chimeric ligands bound to, and activated both the Eek receptors and the Eek-TrkB chimeric receptors expressed in NIH3T3 cells. These findings suggest that Eek receptor can be activated by at least three different GPI-Linked ligands.			Park, S (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOL BIOL,POB 4000,PRINCETON,NJ 08543, USA.		Sanchez, Marina P/A-2453-2011	Sanchez, Marina P/0000-0003-1905-3842; Park, Soochul/0000-0002-7029-3414				ANDRES AC, 1994, ONCOGENE, V9, P1461; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1994, J BIOL CHEM, V269, P14211; BOHME B, 1993, ONCOGENE, V8, P2857; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; CHAN J, 1991, ONCOGENE, V6, P1057; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CIOSSEK T, 1995, ONCOGENE, V9, P97; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Friedman GC, 1996, CURR OPIN NEUROBIOL, V6, P127, DOI 10.1016/S0959-4388(96)80018-3; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KIYOKAWA E, 1994, CANCER RES, V54, P3645; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MARU Y, 1990, ONCOGENE, V5, P445; NIETO MA, 1992, DEVELOPMENT, V116, P1137; OBRIAN JP, 1991, MOL CELL BIOL, V11, P5016; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; SHAO HN, 1995, J BIOL CHEM, V270, P3467, DOI 10.1074/jbc.270.8.3467; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; VALENZUELA DM, 1995, ONCOGENE, V10, P1573; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; ZETTLMEISSL G, 1990, DNA CELL BIOL, V9, P347, DOI 10.1089/dna.1990.9.347; ZHOU R, 1994, J NEUROSCI RES, V37, P129, DOI 10.1002/jnr.490370117	50	21	31	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					533	542		10.1038/sj.onc.1200857	http://dx.doi.org/10.1038/sj.onc.1200857			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053851				2022-12-17	WOS:A1997WF52400004
J	Blaszyk, H; Hartmann, A; Tamura, Y; Saitoh, S; Cunningham, JM; McGovern, RM; Schroeder, JJ; Schaid, DJ; Ii, K; Monden, Y; Morimoto, T; Komaki, K; Sasa, M; Hirata, K; Okazaki, M; Kovach, JS; Sommer, SS				Blaszyk, H; Hartmann, A; Tamura, Y; Saitoh, S; Cunningham, JM; McGovern, RM; Schroeder, JJ; Schaid, DJ; Ii, K; Monden, Y; Morimoto, T; Komaki, K; Sasa, M; Hirata, K; Okazaki, M; Kovach, JS; Sommer, SS			Molecular epidemiology of breast cancers in northern and southern Japan: The frequency, clustering, and patterns of p53 gene mutations differ among these two low-risk populations	ONCOGENE			English	Article						Japan; molecular epidemiology; p53; breast cancer	TUMOR-SUPPRESSOR GENE; FACTOR-IX GENE; CPG DINUCLEOTIDES; CARCINOMAS; WOMEN; ETIOLOGY; PROTEIN; RATES	Comparison of acquired mutations in the p53 tumor suppressor gene can illuminate factors contributing to carcinogenesis among cancer cohorts. Japan has an ethnically homogeneous population with a low incidence of breast cancer. Previously we reported an unusual frequency, allelic status, and clustering of mutations in breast cancers from the northern part of the main Japanese island. To extend these findings, exons 2-11 and adjacent intronic sequences were analysed in tumors of women from northern (Hokkaido) and southern (Tokushima) Japan. The frequency of breast cancers with p53 gene mutations in the Hokkaido group is the highest reported (81%) while that in Tokushima (28%) is similar to most other populations. Thirteen of the 19 mutations (68.4%) in the Hokkaido cohort were heterozygous, an unusually high frequency for p53 mutations in any tumor type. There were three missense mutations at codon 175, a known hotspot for alterations in the p53 gene, and three missense mutations at codon 179, a rare site for p53 changes. In addition, the patterns of p53 gene mutation differed between the two Japanese cohorts (P=0.04). The multiple differences in acquired p53 mutations suggest unsuspected biological differences among breast cancers in northern and southern Japan. In addition, the high frequency of p53 mutations in breast cancers from Hokkaido predicted a poorer prognosis for this population which was confirmed on examination of mortality data.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT ONCOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT LAB MED & PATHOL,ROCHESTER,MN 55905; HIROSAKI UNIV,SCH MED,DEPT INTERNAL MED 1,HIROSAKI,AOMORI 036,JAPAN; UNIV TOKUSHIMA,SCH MED,DEPT PATHOL 1,TOKUSHIMA 770,JAPAN; SAPPORO MED UNIV,DEPT SURG 1,CHUO KU,SAPPORO,HOKKAIDO 060,JAPAN	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Hirosaki University; Tokushima University; Sapporo Medical University					NATIONAL CANCER INSTITUTE [R01CA056881] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA56881, CA15086] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSEN TI, 1993, BRIT J CANCER, V68, P540, DOI 10.1038/bjc.1993.383; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; BIGGS PJ, 1993, MUTAGENESIS, V8, P275, DOI 10.1093/mutage/8.4.275; BLASZYK H, 1995, BIOTECHNIQUES, V18, P256; BLASZYK H, 1994, LANCET, V343, P1195, DOI 10.1016/S0140-6736(94)92403-1; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BORRESEN AL, 1992, CANCER RES, V52, P3234; BOTTEMA CDK, 1993, HUM GENET, V91, P496; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CALEFFI M, 1994, CANCER, V73, P2147, DOI 10.1002/1097-0142(19940415)73:8<2147::AID-CNCR2820730820>3.0.CO;2-5; CHIBA I, 1990, ONCOGENE, V5, P1603; COLEMAN MP, 1993, IARC SCI PUBL, V121, P1; COLES C, 1992, CANCER RES, V52, P5291; COOPER DN, 1990, HUM GENET, V85, P55; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DeVries EMG, 1996, HUM MUTAT, V7, P202, DOI 10.1002/(SICI)1098-1004(1996)7:3<202::AID-HUMU4>3.3.CO;2-5; GLEBOV OK, 1994, CANCER RES, V54, P3703; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; Hartmann A, 1996, BRIT J CANCER, V73, P896, DOI 10.1038/bjc.1996.179; HARTMANN A, 1995, ONCOGENE, V10, P681; HARTMANN A, 1995, J CLIN INVEST, V95, P686, DOI 10.1172/JCI117714; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; JONES PA, 1991, CANCER RES, V51, P3617; KETTERLING RP, 1994, AM J HUM GENET, V54, P831; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; Kovach JS, 1996, P NATL ACAD SCI USA, V93, P1093, DOI 10.1073/pnas.93.3.1093; KUROISHI T, 1994, CANC MORTALITY MORBI, P96; MAZARS R, 1992, CANCER RES, V52, P3918; MOLES JP, 1993, ONCOGENE, V8, P583; SAITOH S, 1994, ONCOGENE, V9, P2869; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; SASA M, 1993, BREAST CANCER RES TR, V27, P247, DOI 10.1007/BF00665694; SHIELDS PG, 1991, JAMA-J AM MED ASSOC, V266, P681, DOI 10.1001/jama.266.5.681; SHIMIZU H, 1991, BRIT J CANCER, V63, P963, DOI 10.1038/bjc.1991.210; SOMMER SS, 1990, NATURE, V346, P22, DOI 10.1038/346022b0; SOMMER SS, 1992, J NATL CANCER I, V84, P246, DOI 10.1093/jnci/84.4.246; Sommer Steve S., 1994, P214; SOUSSI T, 1990, ONCOGENE, V5, P945; STEMMERMANN GN, 1991, BREAST CANCER RES TR, V18, pS67, DOI 10.1007/BF02633531; THORLACIUS S, 1993, CANCER RES, V53, P1637; TOMINAGA S, 1995, CANCER LETT, V90, P75, DOI 10.1016/0304-3835(94)03680-H; TOMINAGA S, 1993, GANN TOKEI HAKUSHO R, P86; TOMINAGA S, 1994, CANC MORTALITY MORBI, P120; TORNALETTI S, 1995, ONCOGENE, V10, P1493; TSUDA H, 1993, JPN J CANCER RES, V84, P394, DOI 10.1111/j.1349-7006.1993.tb00149.x; UMEKITA Y, 1994, JPN J CANCER RES, V85, P825, DOI 10.1111/j.1349-7006.1994.tb02954.x	48	21	21	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2159	2166						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950983				2022-12-17	WOS:A1996VV14500013
J	Maier, JAM; Mariotti, M; Comoglio, PM; Soria, MR				Maier, JAM; Mariotti, M; Comoglio, PM; Soria, MR			Interleukin 1 induces an autocrine loop hepatocyte growth factor c-Met in murine Kaposi-like spindle cells	ONCOGENE			English	Article						hepatocyte growth factor; c-Met; autocrine loop; interleukin-1 alpha; Kaposi's sarcoma	FACTOR-SCATTER-FACTOR; COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASE; TAT TRANSGENIC MICE; FACTOR-RECEPTOR; MESSENGER-RNA; FACTOR GENE; HUMAN KERATINOCYTES; EXPRESSION; PROTOONCOGENE	Several cytokines, growth factors and the HIV transactivator Tat were shown to be involved in the pathogenesis of Kaposi's sarcoma, BKV/tat transgenic mice develop Kaposi's sarcoma-like lesions, and spindle-shaped cells (TTB) have been derived from these lesions, Here we show that TTB cells co-express hepatocyte growth factor (HGF) and its receptor, the product of the oncogene c-Met. An autocrine loop HGF/Met sustains spindle cell proliferation in vitro; indeed, an antisense oligomer targeted against HGF markedly inhibited cell growth, Moreover, HGF and Met are overexpressed after exposing TTB cells to the proinflammatory cytokine interleukin 1 (IL-1), We argue that upon exposure to IL-1, an HGF/Met autocrine loop is induced which could explain the appearance of multiple foci of uncontrolled growth, In addition, due to its angiogenic activity, HGF may also sustain the neovascularization typical of Kaposi's sarcoma lesions.	SAN RAFFAELE SCI INST,DEPT BIOL & TECHNOL RES,DIBIT,I-20132 MILAN,ITALY; UNIV TURIN,SCH MED,DEPT BIOMED SCI & TECHNOL,I-10126 TURIN,ITALY	University of Turin	Maier, JAM (corresponding author), UNIV MILAN,HSR,DEPT BIOMED SCI & TECHNOL,MILAN,ITALY.		Maier, Jeanette AM/H-4820-2012	Maier, Jeanette AM/0000-0002-6326-9221; Comoglio, Paolo/0000-0002-7056-5328				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BARBANTIBRODANO G, 1994, ANTIBIOT CHEMOTHER, V46, P88; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CAMPIONI D, 1995, AIDS RES HUM RETROV, V11, P1039, DOI 10.1089/aid.1995.11.1039; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Comoglio P M, 1993, EXS, V65, P131; CORALLINI A, 1993, CANCER RES, V53, P5569; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1992, ONCOGENE, V7, P2549; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; ELLER MS, 1995, J CELL SCI, V108, P2741; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; FALKENBURG JHF, 1990, J IMMUNOL, V144, P4657; FRIESEL R, 1987, J CELL BIOL, V104, P689, DOI 10.1083/jcb.104.3.689; GALIMI F, 1994, J CELL BIOL, V127, P1743, DOI 10.1083/jcb.127.6.1743; GAMBAROTTA G, 1994, J BIOL CHEM, V269, P12852; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; JUNG W, 1994, J CELL BIOL, V126, P485, DOI 10.1083/jcb.126.2.485; KUPPER TS, 1986, J EXP MED, V164, P2095, DOI 10.1084/jem.164.6.2095; KUPPER TS, 1988, J CLIN INVEST, V82, P1787, DOI 10.1172/JCI113792; LIBBY P, 1988, J CLIN INVEST, V81, P487, DOI 10.1172/JCI113346; LIU YH, 1993, BIOCHIM BIOPHYS ACTA, V1216, P299, DOI 10.1016/0167-4781(93)90159-B; LIU YH, 1994, J BIOL CHEM, V269, P4152; Maier JAM, 1996, INT J CANCER, V65, P168, DOI 10.1002/(SICI)1097-0215(19960117)65:2<168::AID-IJC7>3.0.CO;2-X; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MATSUMOTO K, 1992, BIOCHEM BIOPH RES CO, V188, P235, DOI 10.1016/0006-291X(92)92375-8; MOGHUL A, 1994, ONCOGENE, V9, P2045; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAIDU YM, 1994, P NATL ACAD SCI USA, V91, P5281, DOI 10.1073/pnas.91.12.5281; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NORIOKA K, 1987, BIOCHEM BIOPH RES CO, V145, P969, DOI 10.1016/0006-291X(87)91060-6; OKAJIMA A, 1993, EUR J BIOCHEM, V213, P113, DOI 10.1111/j.1432-1033.1993.tb17740.x; POLVERINI PJ, 1995, ADV CANCER RES, V66, P235, DOI 10.1016/S0065-230X(08)60256-0; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; RAGHOW R, 1994, FASEB J, V8, P823, DOI 10.1096/fasebj.8.11.8070631; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONSIN C, 1993, ONCOGENE, V8, P1195; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; Sambrook J, 1989, MOL CLONING LAB MANU; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAMURA M, 1993, J BIOL CHEM, V268, P8140; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WOOLF AS, 1995, J CELL BIOL, V128, P171, DOI 10.1083/jcb.128.1.171; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	56	21	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					1009	1015						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806690				2022-12-17	WOS:A1996VG76600014
J	Leiter, LM; Chen, JJ; Marathe, T; Tanaka, M; Dutta, A				Leiter, LM; Chen, JJ; Marathe, T; Tanaka, M; Dutta, A			Loss of transactivation and transrepression function, and not RPA binding, alters growth suppression by p53	ONCOGENE			English	Article						p53; RPA; transcription; cell cycle; DNA replication	WILD-TYPE P53; DNA-REPLICATION INVITRO; SIMIAN VIRUS-40 DNA; TRANSCRIPTIONAL ACTIVATION; SACCHAROMYCES-CEREVISIAE; GENE AMPLIFICATION; MULTIPLE STAGES; SV40 ORIGIN; PROTEIN-A; INHIBITION	The tumor suppressor protein p53 activates transcription from promoters with specific p53 binding elements, represses transcription from promoters without such elements and interacts with and inhibits the single-stranded DNA binding activity of the human DNA replication factor RPA, All these activities involve the N terminal 70 amino acids of p53, Dissection of the domains of p53 which,bind RPA suggest that multiple sub-domains of the protein synergize to give strong RPA binding, Point-mutations in one of these sub-domains of p53 significantly diminish its ability to interact with RPA, A multimer of a peptide from p53 which includes these residues, or of a peptide from the acidic activation domain of the prototypic trans-activator protein VP16, can itself bind to RPA, Comparison of sequences of these multimeric peptides suggests that aromatic amino acids flanked by negatively charged residues are important for binding RPA, Several alleles of p53 with point mutations in the N terminal region were analysed for their relative abilities to bind RPA, activate or repress transcription, and suppress growth of p53 null SaOs2 and H1299 cells, Both mutants of p53 with decreased RPA binding suppressed cell growth as well as wild-type p53, suggesting that p53 can suppress growth without interacting with RPA, The allele that lost most of the transcription activation function also lost most of its transcription repression activity suggesting that interaction with the same basal transcription factors are involved in both functions, This same allele bound RPA well but was defective in growth suppression. Therefore, transcription activation and/or repression appear to be more important for the growth suppression function of p53 than RPA binding.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,DIV MOL ONCOL,BOSTON,MA 02115; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Cold Spring Harbor Laboratory			Dutta, Anindya/P-3203-2016	Dutta, Anindya/0000-0002-4319-0073	NCI NIH HHS [CA 60499, R01 CA060499, R01 CA060499-02S1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060499] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DELSAL G, 1995, MOL CELL BIOL, V15, P7152; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; EL DW, 1993, CELL, V75, P817; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Sambrook J, 1989, MOL CLONING LAB MANU; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shen F, 1996, J BIOL CHEM, V271, P4819; Shen F, 1996, J BIOL CHEM, V271, P4827; Steel R.G.D., 1980, PRINCIPLES STAT; SUBLER MA, 1994, ONCOGENE, V9, P1351; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P3839, DOI 10.1128/MCB.9.9.3839; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; WU X, 1993, GENE DEV, V8, P1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	43	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2661	2668						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700525				2022-12-17	WOS:A1996UW48700020
J	Zhu, D; Bourguignon, L				Zhu, D; Bourguignon, L			Overexpression of CD44 in p185(neu)-transfected NIH3T3 cells promotes an up-regulation of hyaluronic acid-mediated membrane-cytoskeleton interaction and cell adhesion	ONCOGENE			English	Article						CD44; p184(neu); hyaluronic acid; cytoskeleton; cell adhesion	TRANSMEMBRANE GLYCOPROTEIN; PROTO-ONCOGENE; RECEPTOR CD44; HUMAN-BREAST; EXPRESSION; BINDING; NEU; MOLECULE; GP85; AMPLIFICATION	CD44 is a transmembrane glycoprotein known to bind hyaluronic acid (HA) in its extracellular domain and to contain at least one ankyrin-binding site in its cytoplasmic domain. In this study we have examined CD44 expression in a mouse fibroblast cell line transfected with the p185(neu) oncogene cDNA. The results of RT-PCR and Southern blot analyses reveal that CD44s (CD44 standard form) transcript is expressed in both p185(neu)-transfected cells and untransfected cells. Using surface iodination, anti-CD44 immunoprecipitation and immune-binding assays, we have found that the number of CD44s molecules expressed on the surface of p185(neu)-transfected cells are at least 4.5-fold higher than those detected on untransfected cells. Overexpression of surface CD44s in p185(neu)-transfected cells results in a dramatic enhancement of HA-mediated cell adhesion. Scatchard plot analysis indicates that CD44s in p185(neu)-transfected cells binds directly and specifically to ankyrin. The binding affinity between CD44s and ankyrin in p185(neu)-transfected cells (K-d approximate to 0.19 nM) appears to be somewhat higher than that found in the untransfected cells (K-d approximate to 0.30 nM). Double immunofluorescence staining and confocal microscopic analyses indicate that HA induces the HA receptor (i.e. CD44s) to form adhesion plaque-like structures, and causes an accumulation of intracellular ankyrin directly underneath HA receptor (CD44s)-adhesion plaque-like structures in p185(neu)-transfected cells (but not in untransfected cells). These findings suggest that overexpression of CD44s and up-regulation of CD44s-ankyrin interaction by p185(neu) oncogene may be one of the pre-requisite steps in regulating tumor cell behavior.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,MIAMI,FL 33101	University of Miami					NATIONAL CANCER INSTITUTE [R01CA066163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036353] Funding Source: NIH RePORTER; NCI NIH HHS [CA66163] Funding Source: Medline; NIGMS NIH HHS [GM36353] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BERGER MS, 1988, CANCER RES, V48, P1238; BOURGUIGNON LYW, 1991, J BIOL CHEM, V266, P11761; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; CARTER WG, 1988, J BIOL CHEM, V263, P4193; COOPER DL, 1995, NAT MED, V1, P635, DOI 10.1038/nm0795-635; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; DIGIOVANNA MP, 1995, CANCER RES, V55, P1646; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HAYNES BF, 1991, CANCER CELL-MON REV, V3, P347; HIRANO H, 1994, INT IMMUNOL, V6, P49, DOI 10.1093/intimm/6.1.49; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; IIDA N, 1995, J CELL PHYSIOL, V162, P127, DOI 10.1002/jcp.1041620115; ISACKE CM, 1994, J CELL SCI, V107, P2353; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; JAMAL HH, 1994, ONCOGENE, V9, P417; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; KALOMIRIS EL, 1988, J CELL BIOL, V106, P317; KUPPNER MC, 1992, INT J CANCER, V50, P572, DOI 10.1002/ijc.2910500414; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P22073; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; LOKESHWAR VB, 1991, J BIOL CHEM, V266, P17983; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PARK JB, 1989, CANCER RES, V49, P6605; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; RALL CJN, 1995, CANCER RES, V55, P1831; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SHI DR, 1992, MOL CARCINOGEN, V5, P213, DOI 10.1002/mc.2940050308; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; UNDERHILL C, 1992, J CELL SCI, V103, P293; WELSH CF, 1995, J CELL PHYSIOL, V164, P605, DOI 10.1002/jcp.1041640319; XIE YM, 1994, BIOCHEM BIOPH RES CO, V203, P1589, DOI 10.1006/bbrc.1994.2368; YU DH, 1992, J BIOL CHEM, V267, P10203; YU DH, 1994, CANCER RES, V54, P3260; YU DH, 1991, ONCOGENE, V6; ZHANG LR, 1995, CANCER RES, V55, P428	45	21	22	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2309	2314						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649770				2022-12-17	WOS:A1996UQ22000007
J	Srivenugopal, KS; AliOsman, F				Srivenugopal, KS; AliOsman, F			Deletions and rearrangements inactivate the p16(INK4) gene in human glioma cells	ONCOGENE			English	Article						p16(INK4); cell cycle; human glioma; CdK inhibitor; retinoblastoma protein		Structural alterations in the p16(INK4) gene were examined in early passage human glioma cell lines and related to the expression of p16 transcripts and protein. Using the Southern blot approach, we observed both homozygous and hemizygous deletions, as well as rearrangements of the p16 and p15 genes in 5 of the 7 cell lines (71%). Two cell lines, MGR3 and HBT28, revealed hemizygous deletion of the p16 and p15 genes combined with indistinguishable rearrangements of the remaining p15-p16 locus that resulted in loss of exon 2 sequences for p15 and p16, but retention of p16 exon 1; neither of these cell lines expressed p16 mRNA. Data for a third cell line, MGR2, indicated a similar, but rearrangement involving the p15 and p16 MGR2, which retained a single wild-type p15-p16 locus, showed expression of p16 transcript, but not of p16 protein as indicated by Western blot analysis. All the glioma cell lines expressed similar levels of the retinoblastoma protein and no amplification of the cyclin-dependent kinase 4 gene. These results demonstrate that human glioma cells contain p16 gene microdeletions and rearrangements that contribute to inactivation of the cell cycle regulatory protein.			Srivenugopal, KS (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPT PEDIAT,BOX 169,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.				NATIONAL CANCER INSTITUTE [R01CA064900] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALIOSMAN F, 1987, J NEUROPATH EXP NEUR, V46, P371, DOI 10.1097/00005072-198705000-00126; ALIOSMAN F, 1990, CANCER RES, V50, P6976; ARAP W, 1995, CANCER RES, V55, P1351; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DURO D, 1995, ONCOGENE, V11, P21; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HE J, 1994, CANCER RES, V54, P5804; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; HERMAN JG, 1995, CANCER RES, V55, P4525; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V265, P416, DOI 10.1126/science.265.5170.416; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; LI Y, 1994, CANCER RES, V54, P6078; LI YJ, 1995, ONCOGENE, V11, P597; LIU Q, 1995, ONCOGENE, V10, P1061; MAO L, 1995, CANCER RES, V55, P2995; MEAD LJ, 1994, CANCER RES, V54, P2307; MORI T, 1994, CANCER RES, V54, P3396; NISHIKAWA R, 1995, CANCER RES, V55, P1941; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1995, ONCOGENE, V11, P1211; OTTERSON GA, 1994, ONCOGENE, V9, P3375; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SONODA Y, 1995, ONCOGENE, V11, P2145; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; STONE S, 1995, ONCOGENE, V11, P987; STONE S, 1995, CANCER RES, V55, P2988; Ueki K, 1996, CANCER RES, V56, P150; WALKER DG, 1995, CANCER RES, V55, P20; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XU L, 1994, CANCER RES, V54, P5262; YEUDALL WA, 1994, CARCINOGENESIS, V15, P2683, DOI 10.1093/carcin/15.12.2683	40	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					2029	2034						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649864				2022-12-17	WOS:A1996UK49800022
J	Juang, SH; Carvajal, ME; Whitney, M; Liu, YC; Carraway, CAC				Juang, SH; Carvajal, ME; Whitney, M; Liu, YC; Carraway, CAC			Tyrosine phosphorylation at the membrane-microfilament interface: A p185(neu)-associated signal transduction particle containing Src, Abl and phosphorylated p58, a membrane- and microfilament-associated retroviral gag-like protein	ONCOGENE			English	Article						signal transduction particle; tyrosine kinase; src; Ab1; p185(neu); membrane microfilament	EPIDERMAL GROWTH-FACTOR; RAT MAMMARY ADENOCARCINOMA; TUMOR-CELL MICROVILLI; ROUS-SARCOMA VIRUS; C-ABL; GENE-PRODUCT; ASCITES ADENOCARCINOMA; GLYCOPROTEIN COMPLEX; SIALOMUCIN COMPLEX; PHALLOIDIN SHIFT	Microfilaments are associated with the microvillar membrane in the 13762 ascites rat mammary carcinoma cells by stable interaction with a large, multimeric signal transduction particle (STP) containing the (proto)oncogene receptor p185(neu). In vitro kinase assays on isolated microvilli and microvillar fractions enriched in the putative signal transduction particle showed a high specific activity of tyrosine kinase activity compared to that of membranes from EGF receptor-overexpressing A431 cells maximally activated by EGF. Assays of velocity sedimentation fractions from microvillar lysates in the presence and absence of the exogenous tyrosine kinase substrate poly-glu-tyr polypeptide (poly-E(4)Y) suggested association of the tyrosine kinase activity with STP-enriched microvillar fractions. The particulate fractions also contained discrete endogenous tyrosine-phosphorylated proteins, including prominent bands of approximate to 42 and 58 kDa. Addition of ATP to these fractions resulted in a rapid increase in tyrosine phosphorylation of these and several other proteins, as detected by antiphosphotyrosine blots. Immunoprecipitation and immunoblotting with anti-phosphotyrosine antibody of SDS-solubilized ascites cells and microfilament core fractions showed nine major bands; the electrophoretic mobilities of most of these in the cell immunoprecipitate and microfilament core were the same. In vivo and in situ phosphorylation, phosphoamino acid analysis, immunoprecipitation, 2-dimensional isoelectric focusing/SDS PAGE and immunoblot analysis showed that one of the prominent substrates is p58E(gag), a retroviral Gag-like cytoplasmic STP component implicated in stabilizing microfilament-membrane interactions. Immunoblotting identified two peripheral membrane tyrosine kinases, p60(src) and p120(abl), stably associated with the p185(neu)-containing signal transduction particle. These results provide further evidence for the constitutive activation of this aggressive mammary tumor and suggest a role for phosphorylation of p58S(gag) in organization of the STP at the membrane-microfilament interface in these cells.	UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,MIAMI,FL 33101	University of Miami; University of Miami			Rolle, Marsha W/D-8286-2012		NATIONAL CANCER INSTITUTE [R01CA052498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033795] Funding Source: NIH RePORTER; NCI NIH HHS [CA 52498] Funding Source: Medline; NIGMS NIH HHS [GM 33795] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRAUN S, 1984, J BIOL CHEM, V259, P2051; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; CARRAWAY C A C, 1992, P123; CARRAWAY CAC, 1983, P NATL ACAD SCI-BIOL, V80, P430, DOI 10.1073/pnas.80.2.430; CARRAWAY CAC, 1986, BIOCHIM BIOPHYS ACTA, V885, P68, DOI 10.1016/0167-4889(86)90039-X; CARRAWAY CAC, 1985, EXP CELL RES, V161, P150, DOI 10.1016/0014-4827(85)90499-9; CARRAWAY CAC, 1982, BIOCHIM BIOPHYS ACTA, V719, P126; CARRAWAY CAC, 1991, J BIOL CHEM, V266, P16238; CARRAWAY CAC, 1985, EXP CELL RES, V157, P71, DOI 10.1016/0014-4827(85)90153-3; CARRAWAY CAC, 1993, J BIOL CHEM, V268, P5582; CARRAWAY CAC, 1996, IN PRESS TREATISE CY; CARRAWAY CAC, 1983, EXP CELL RES, V143, P301; CARRAWAY KL, 1980, NATURE, V285, P508, DOI 10.1038/285508a0; CARRAWAY KL, 1982, J CELL BIOL, V94, P624, DOI 10.1083/jcb.94.3.624; CARRAWAY KL, 1995, BIOESSAYS, V17, P171, DOI 10.1002/bies.950170212; CARRAWAY KL, 1989, BIOCHIM BIOPHYS ACTA, V988, P147, DOI 10.1016/0304-4157(89)90017-8; CARRAWAY KL, 1979, J CELL BIOL, V83, P529, DOI 10.1083/jcb.83.3.529; CHINKERS M, 1979, J CELL BIOL, V83, P260, DOI 10.1083/jcb.83.1.260; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; HOWARD SC, 1982, JNCI-J NATL CANCER I, V69, P33; HUGGINS JW, 1980, EXP CELL RES, V127, P27; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JUANG SH, 1994, J BIOL CHEM, V269, P15067; JUNG G, 1985, J CELL BIOCHEM, V28, P243, DOI 10.1002/jcb.240280402; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; KELLIE S, 1988, BIOESSAYS, V8, P25, DOI 10.1002/bies.950080107; KRUEGER JG, 1983, CURR TOP MICROBIOL I, V107, P52; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; LUI Y, 1989, J BIOL CHEM, V264, P1208; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OKAMURA H, 1994, ONCOGENE, V9, P2293; PELECH SL, 1986, BIOCHEMISTRY-US, V25, P8348, DOI 10.1021/bi00374a002; PLUSKAL MG, 1986, BIOTECHNIQUES, V4, P272; RIJKEN PJ, 1991, J CELL SCI, V100, P491; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SOBUE K, 1988, BIOCHEM BIOPH RES CO, V157, P1383, DOI 10.1016/S0006-291X(88)81028-3; SRIVASTAVA AK, 1989, BIOCHIM BIOPHYS ACTA, V996, P13, DOI 10.1016/0167-4838(89)90087-3; TAKATA K, 1988, J CELL BIOL, V106, P1757, DOI 10.1083/jcb.106.5.1757; THOM D, 1977, BIOCHEM J, V168, P187, DOI 10.1042/bj1680187; VANDERPUYE OA, 1988, EXP CELL RES, V178, P211, DOI 10.1016/0014-4827(88)90392-8; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325	54	21	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1033	1042						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649794				2022-12-17	WOS:A1996UA88400011
J	Weih, F; Lira, SA; Bravo, R				Weih, F; Lira, SA; Bravo, R			Overexpression of RelB in transgenic mice does not affect I kappa B alpha levels: Differential regulation of RelA and RelB by the inhibitor protein	ONCOGENE			English	Article						RelB; I kappa B alpha; transgenic mice	TRANSCRIPTION FACTORS; ACTIVATION; INTERACTS; ENCODES; FAMILY	In mouse lymphoid tissues, RelB heterodimers represent the constitutive kappa B-binding activity, whereas RelA and c-Rel complexes most likely are involved in inducible kappa B-binding and gene activation. Our laboratory has previously shown that the potential excess of NF-kappa B activity in transgenic mice overexpressing RelA is counteracted by a dramatic increase in I kappa B alpha, mainly due to its increased stability through association with RelA. As an attempt to elucidate the in vivo mechanisms that lead to the constitutive DNA-binding activity of RelB heterodimers, we have generated mouse lines overexpressing a relB transgene in a position-independent and copy number-dependent manner, Expression of RelB in these transgenic animals is very high in immature thymocytes and restricted to T cell areas in secondary lymphoid tissues, In contrast to the results obtained with RelA-transgenic thymocytes, we demonstrate here that overexpression of RelB results in a dramatic increase in overall kappa B-binding activity, Interestingly, I kappa B alpha protein levels are not altered in the RelB-transgenic animals, indicating that within the same cell type RelA and RelB complexes are differentially regulated by I kappa B alpha.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC ONCOL,PRINCETON,NJ 08543	Bristol-Myers Squibb								ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; ALLEN JM, 1992, MOL CELL BIOL, V12, P2758, DOI 10.1128/MCB.12.6.2758; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; CARRASCO D, 1994, DEVELOPMENT, V120, P2991; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DIDONATO JA, 1993, MOL CELL BIOL, V13, P1572; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P1184; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GRILLI M, 1993, INT REV CYTOL, V143, P1; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; LANG G, 1991, NUCLEIC ACIDS RES, V19, P5851, DOI 10.1093/nar/19.21.5851; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LERNBECHER T, 1994, EMBO J, V13, P4069; LEWIS DB, 1991, J EXP MED, V173, P89, DOI 10.1084/jem.173.1.89; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; PEREZ P, 1995, MOL CELL BIOL, V15, P3523; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; WEIH F, 1994, ONCOGENE, V9, P3289; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0	40	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					445	449						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570223				2022-12-17	WOS:A1996TR53800025
J	CHEN, RH; FIELDS, S; LIPSICK, JS				CHEN, RH; FIELDS, S; LIPSICK, JS			DISSOCIATION OF TRANSCRIPTIONAL ACTIVATION AND ONCOGENIC TRANSFORMATION BY V-MYB	ONCOGENE			English	Article						MYB; TRANSCRIPTION; LEUKEMIA	HIGH-EFFICIENCY TRANSFORMATION; AVIAN-MYELOBLASTOSIS VIRUS; DNA-BINDING DOMAIN; C-MYB; GENE-EXPRESSION; FUNCTIONAL DOMAINS; MAMMALIAN-CELLS; SV40 ENHANCER; MIM-1 GENE; TRANSACTIVATION	nuclear oncoprotein v-Myb is a transcriptional activator in both animal cells and the budding yeast Saccharomyces cerevisiae. Previous studies have suggested that an acidic domain of approximately 50 amino acids (amino acids 204-254 of v-Myb) is necessary and sufficient for transcriptional activation by v-Myb, c-Myb and GAL4-Myb fusion proteins. However, we find that first, none of the acidic residues within this region is essential for transcriptional activation in either animal cells or yeast. Second, transcriptional activation requires cooperation among multiple domains of v-Myb. In animal cells, transcriptional activation by v-Myb requires a central domain (amino acids 234-295), a C-terminal domain (amino acids 295-356), plus either of two more N-terminal domains (amino acids 163-197 or 198-232); in yeast, it requires the central domain plus either the C-terminal domain or a more N-terminal domain (amino acids 163-233). Third, although various subsets of these domains are sufficient for transcriptional activation by v-Myb, all of the domains must be present for transformation of primary hematopoietic cells. These results demonstrate that transcriptional activation by v-Myb is not sufficient for oncogenic transformation.	SUNY STONY BROOK,DEPT MOLEC GENET & MICROBIOL,STONY BROOK,NY 11794; STANFORD UNIV,SCH MED,DEPT PATHOL,STANFORD,CA 94305	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stanford University					NCI NIH HHS [CA43592] Funding Source: Medline; NIGMS NIH HHS [GM49065] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049065] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BORTNER DM, 1991, NUCLEIC ACIDS RES, V19, P1533, DOI 10.1093/nar/19.7.1533; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ENGELKE U, 1995, VIROLOGY; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; FRAMPTON J, 1993, EMBO J, V12, P1333, DOI 10.1002/j.1460-2075.1993.tb05778.x; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GONDA TJ, 1989, EMBO J, P1777; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; GRASSER FA, 1992, ONCOGENE, V7, P1005; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; IWABUCHI K, 1993, ONCOGENE, V8, P1693; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIPSICK JS, 1987, J VIROL, V61, P933, DOI 10.1128/JVI.61.3.933-936.1987; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NERLOV C, 1994, GENE DEV, V8, P250; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUNYAMMALEE B, 1991, ONCOGENE, V6, P11; RAMSAY RG, 1991, ONCOGENE, V6, P1875; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; TANAKA M, 1994, MOL CELL BIOL, V14, P6046, DOI 10.1128/MCB.14.9.6046; TANAKA M, 1994, MOL CELL BIOL, V14, P6056, DOI 10.1128/MCB.14.9.6056; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	51	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1771	1779						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478605				2022-12-17	WOS:A1995TD09400012
J	ONODERA, M; KUNISADA, T; NISHIKAWA, S; SAKIYAMA, Y; MATSUMOTO, S; NISHIKAWA, S				ONODERA, M; KUNISADA, T; NISHIKAWA, S; SAKIYAMA, Y; MATSUMOTO, S; NISHIKAWA, S			OVEREXPRESSION OF RETINOIC ACID RECEPTOR-ALPHA SUPPRESSES MYELOID CELL-DIFFERENTIATION AT THE PROMYELOCYTE STAGE	ONCOGENE			English	Article						RAR-ALPHA; RETROVIRAL-MEDIATED GENE TRANSFER; BONE MARROW CELLS; MYELOID; APL	ZINC FINGER GENE; THYROID-HORMONE; RAR-ALPHA; ALL-TRANS; MONOCLONAL-ANTIBODIES; BINDING-PROPERTIES; RESPONSE ELEMENTS; NUCLEAR RECEPTOR; DNA-BINDING; STEM-CELLS	Retinoic acid receptor (RAR) alpha is required to heterodimerize with retinoid X receptor (RXRs) in order to regulate myeloid differentiation. If so, it is expected that overexpression of normal RAR alpha may perturb the RAR alpha/ RXR heterodimer formation and also the differentiation of myeloid cells. We have described here the morphology and the RA response of human RAR alpha cDNA transduced murine bone marrow cells using a retroviral vector. Most of RAR alpha transduced cells displayed promyelocyte like morphology and their proportion of c-kit expressing population was increased remarkably compared with the control (Neo(r) gene transduced cells). Furthermore, this morphology was observed even after these cells were brought into the semisolid culture containing IL-3 alone. Interestingly, immature RAR alpha transduced cells differentiated into mature granulocytes under the condition of the high concentration of RA(10(-6)M). We did not observe any effect of RAR alpha on monocytes. These results indicate that overexpression of normal RAR alpha is sufficient for inducing maturation arrest of myeloid cell lineage that is similar to the phenotype found in the acute promyelocytic leukemia bearing PML-RAR alpha translocation.	KYOTO UNIV,FAC MED,DEPT MOLEC GENET,SAKYO KU,KYOTO 06001,JAPAN; HOKKAIDO UNIV,SCH MED,DEPT PEDIAT,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN	Kyoto University; Hokkaido University								BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHOMIENNE C, 1990, BLOOD, V76, P1710; CHOMIENNE C, 1990, LEUKEMIA, V4, P802; Coffman R L, 1982, Immunol Rev, V69, P5; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DAWSON MI, 1994, BLOOD, V84, P446; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; HAYASHI SI, 1990, J EXP MED, V171, P1683, DOI 10.1084/jem.171.5.1683; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KODAMA HA, 1982, J CELL PHYSIOL, V112, P89, DOI 10.1002/jcp.1041120114; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KRIEGLER M, 1990, LABORATORY MANUAL, P161; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROWLEY JD, 1987, LANCET, V5, P549; RUBERTE E, 1990, DEVELOPMENT, V108, P213; RUBERTE E, 1991, DEVELOPMENT, V111, P45; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; SUDO T, 1989, J EXP MED, V170, P333, DOI 10.1084/jem.170.1.333; TOHDA S, 1992, LEUKEMIA, V6, P656; TSAI S, 1992, GENE DEV, V6, P2258, DOI 10.1101/gad.6.12a.2258; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VARTDAL F, 1987, TRANSPLANTATION, V43, P366, DOI 10.1097/00007890-198703000-00010; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	53	21	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1291	1298						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478549				2022-12-17	WOS:A1995RY96700009
J	MURRELL, AM; BOCKAMP, EO; GOTTGENS, B; CHAN, YS; CROSS, MA; HEYWORTH, CM; GREEN, AR				MURRELL, AM; BOCKAMP, EO; GOTTGENS, B; CHAN, YS; CROSS, MA; HEYWORTH, CM; GREEN, AR			DISCORDANT REGULATION OF SCL/TAL-1 MESSENGER-RNA AND PROTEIN DURING ERYTHROID-DIFFERENTIATION	ONCOGENE			English	Article						SCL/TAL-1; ERYTHROID DIFFERENTIATION	SCL GENE-PRODUCT; LOOP-HELIX GENE; T-CELL LEUKEMIA; SELF-RENEWAL; TRANSLOCATION; EXPRESSION; HEMATOPOIESIS; ENCODES; TAL-1; LINES	SCL/TAL1 gene was originally identified by virtue of its rearrangement and transcriptional activation in patients with T cell acute lymphoblastic leukaemia, It encodes a helix-loop-helix transcription factor, is not normally expressed in T cells, but is expressed in erythroid, mast, megakaryocytic and progenitor cells, Over-expression of sense and antisense constructs have implicated SCL as a positive regulator of erythroid differentiation, In addition we have previously shown that SCL mRNA levels undergo biphasic modulation during induced erythroid differentiation of murine erythroleukaemia (MEL) cells with a transient early fall followed by a late rise, In this paper we have studied expression of the SCL protein during erythroid differentiation and also the molecular basis for the raised SCL mRNA levels that accompany erythroid differentiation, We have generated an anti-SCL antiserum and used it to demonstrate that an early transient fall in SCL protein does not occur during induced differentiation of MEL cells, Furthermore SCL protein levels underwent a late fall in three different models of erythroid differentiation and in two models of myeloid differentiation, The fall in SCL protein levels during induced erythroid differentiation contrasted with the concomitant marked rise in SCL mRNA levels. These observations have significant implications for the mechanism by which SCL may regulate erythropoiesis. In addition we have demonstrated that the stability of SCL mRNA was only marginally enhanced during erythroid differentiation of MEL cells, whereas the activity of a luciferase reporter construct driven by the SCL promoter was increased 11- to 17-fold, Up-regulation of transcription therefore accounted for most of the increase in SCL mRNA levels during erythroid differentiation.	UNIV CAMBRIDGE,CTR MRC,DEPT HAEMATOL,CAMBRIDGE CB2 2QH,ENGLAND; CHRISTIE HOSP NHS TRUST,PATERSON INST CANC RES,CRC,DEPT EXPTL HAEMATOL,MANCHESTER M20 9BX,LANCS,ENGLAND	University of Cambridge; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research				Cross, Michael/0000-0002-8815-7621; Gottgens, Berthold/0000-0001-6302-5705; Bockamp, Ernesto/0000-0002-6181-1734; Green, Anthony/0000-0002-9795-0218	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BEGLEY CG, 1994, GENE, V138, P93, DOI 10.1016/0378-1119(94)90787-0; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1991, ONCOGENE, V6, P1477; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; CHENG JT, 1993, ONCOGENE, V8, P677; CROSS MA, 1994, ONCOGENE, V9, P3013; ELWOOD NJ, 1994, LEUKEMIA, V8, P106; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; GOLDFARB AN, 1992, BLOOD, V80, P2858; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, ONCOGENE, V7, P653; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; GREEN AR, 1993, EXP HEMATOL, V21, P525; Heyworth CM, 1990, GROWTH FACTORS, V2, P197, DOI 10.3109/08977199009071506; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HWANG LY, 1993, ONCOGENE, V8, P3043; KAIHO SI, 1985, ANAL BIOCHEM, V149, P117, DOI 10.1016/0003-2697(85)90483-X; KAN O, 1993, HAEMOPOIEISIS PRACTI; KIM KJ, 1979, J IMMUNOL, V122, P549; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; MITSUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322; MOUTHON MA, 1993, BLOOD, V81, P647; MURRELL AM, 1995, ONCOGENE, V10, P631; PROUD CG, 1994, NATURE, V371, P747, DOI 10.1038/371747a0; Sambrook J., 1989, MOL CLONING LAB MANU; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VISVADER J, 1991, ONCOGENE, V6, P195; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x	41	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					131	139						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624120				2022-12-17	WOS:A1995RJ29500016
J	HALL, AR; MILNER, J				HALL, AR; MILNER, J			STRUCTURAL AND KINETIC-ANALYSIS OF P53-DNA COMPLEXES AND COMPARISON OF HUMAN AND MURINE P53	ONCOGENE			English	Article						P53-DNA INTERACTION; KINETICS; P53 CONFORMATION	TUMOR SUPPRESSOR PROTEIN; WILD-TYPE; DNA-BINDING; MUTANT CONFORMATION; SIMIAN VIRUS-40; SEQUENCE; DOMAIN; SITE	Sequence-specific DNA binding by p53 is dependent upon protein conformation. The 1620(+) form correlates with wild type p53 suppressor function and is a prerequisite for binding to the DNA consensus p53-CON in vitro. It has been reported that murine p53 changes conformation on interaction with high affinity DNA target sequences and in the present Study we have analysed p53-DNA complexes using conformation-specific monoclonal antibodies against p53. For murine p53 (mp53) we show (i) the 1620(+) form is retained and stabilised in complex,vith DNA, and (ii) the complexes are dissociated by the PAb1620 monoclonal antibody. In contrast, PAb1620 did not detect nor dissociate human p53-DNA complexes nor did it interfere with complex formation. In competition experiments murine p53 replaced human p53 (hp53) in p53-DNA complexes and this correlated with the greater lability observed for hp53-DNA complexes at a given temperature. Mixed human-murine p53 oligomers were competent for DNA binding,vith an estimated affinity around 5x10(-10)M, similar to that observed for either human or murine p53 alone, The potential significance of these observations is discussed in relation p53 function in vivo.			HALL, AR (corresponding author), UNIV YORK,DEPT BIOL,YORK YO1 5DD,N YORKSHIRE,ENGLAND.							BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BUTCHER S, 1994, BIOCHEM J, V298, P513, DOI 10.1042/bj2980513; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FREIDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1591; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1994, ONCOGENE, V9, P299; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; MEDCALF EA, 1992, ONCOGENE, V7, P71; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1990, ONCOGENE, V5, P1683; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SRINIVASAN R, 1993, CANCER RES, V53, P5361; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; ZABEL U, 1991, J BIOL CHEM, V266, P252; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	33	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					561	567						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845681				2022-12-17	WOS:A1995QF64800017
J	ADNANE, J; ROBBINS, PD				ADNANE, J; ROBBINS, PD			THE RETINOBLASTOMA SUSCEPTIBILITY GENE-PRODUCT REGULATES MYC-MEDIATED TRANSCRIPTION	ONCOGENE			English	Article						RETINOBLASTOMA PROTEIN; MYC; TRANSCRIPTION	APOPTOTIC CELL-DEATH; VIRUS-40 LARGE-T; C-MYC; DNA-BINDING; MOLECULAR-CLONING; FACTOR E2F; PROTEIN; MAX; DOMAIN; ACTIVATION	The protein product of the retinoblastoma tumor suppressor gene (RE) has been demonstrated to bind c-Myc protein (Myc) in vitro. To determine whether RE regulates Myc transcriptional activity in vivo, GAL4-Myc chimeric expression plasmids were generated and cotransfected with a RE expression plasmid and a GAL4-dependent reporter plasmid. RE stimulated GAL4-Myc-mediated transcription, dependent upon a domain(s) in the amino-terminus of Myc. The stimulation of Myc-mediated transcription by RE was cell-type specific and was inhibited by SV40 T-antigen, but not by a T-antigen mutant defective in RE-binding. Moreover, RE mutants containing mutations in domain B of RE pocket were significantly reduced in their ability to stimulate GAL4-Myc mediated transcription. To determine whether RE and Myc interact in vivo either directly or indirectly, a two hybrid system was used where GAL4-Rb and Myc-VP16 expression constructs were cotransfected with a GAL4-dependent reporter plasmid. A significant increase of GAL4-dependent transcription was observed, dependent upon the presence of both GAL4-Rb and Myc-VP16 fusion proteins, Mutational analysis of the Myc-VP16 chimeric proteins suggests that the amino-terminus of Myc is essential for the interaction with RE. These results demonstrate that RE can regulate Myc-mediated transcription in vivo in a cell-type specific manner through protein-protein interactions.	UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NCI NIH HHS [CA55227] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055227] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BENEDICT WF, 1988, CANCER, V62, P1691, DOI 10.1002/1097-0142(19881015)62:1+<1691::AID-CNCR2820621306>3.0.CO;2-5; BENEDICT WF, 1990, J CLIN INVEST, V85, P988, DOI 10.1172/JCI114575; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHENG J, 1990, BLOOD, V75, P730; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KRATZKE RA, 1992, J BIOL CHEM, V267, P25998; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LUCHER B, 1990, I MYC GENES DEV, V4, P2025; MAYOL X, 1993, ONCOGENE, V8, P2561; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SRINIVASAN A, 1989, J VIROL, P5459; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	62	21	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					381	387						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838535				2022-12-17	WOS:A1995QC62400017
J	KONDOH, G; HAYASAKA, N; LI, Q; NISHIMUNE, Y; HAKURA, A				KONDOH, G; HAYASAKA, N; LI, Q; NISHIMUNE, Y; HAKURA, A			AN IN-VIVO MODEL FOR RECEPTOR TYROSINE KINASE AUTOCRINE/PARACRINE ACTIVATION - AUTO-STIMULATED KIT RECEPTOR ACTS AS A TUMOR-PROMOTING FACTOR IN PAPILLOMAVIRUS-INDUCED TUMORIGENESIS	ONCOGENE			English	Article						HPV16 TRANSGENIC MOUSE; C-KIT SLF; AUTOSTIMULATION; TUMORIGENESIS	STEM-CELL FACTOR; AUTOCRINE GROWTH-FACTORS; C-KIT; W-LOCUS; LUNG-CANCER; TRANSMEMBRANE FORM; PROTO-ONCOGENE; SERTOLI CELLS; GENE-PRODUCT; MUTANT MICE	Constitutive overactivation of growth factor receptors through autocrinelparacrine mechanisms occurs frequently in cancer cells and are thought to play a critical role in carcinogenesis. In the present report, we propose a refined in vivo model which explains the significance of these mechanisms in tumour development. We have previously established transgenic mouse lines containing human papillomavirus type 16 (HPV16) E6E7 oncogenes, in male mice of which a Leydig cell tumor developes with a very high incidence, Not only HPV transgene but also the c-kit proto-oncogene receptor tyrosine kinase and its ligand Steel Factor (SLF) were coexpressed in all tumors analysed. This coexpression of c-kit/SLF was also found in two other Leydig cell tumor lines. Moreover, the proliferation of transgenic tumor cells was attenuated by treatment with a c-kit neutralizing antibody in vitro, strongly suggesting that tumorigenesis is closely related to stimulation of receptors through ligand induction, To confirm the significance of these findings, a defective mutation of the SLF gene in a laboratory mouse, the Steel-Dickey (Sld) mutation, was introduced into a line of transgenic mice showing 100% incidence of the tumor. In Sl(d)-E6E7 transgenic mice, tumorigenesis was initiated but numbers of tumor cells were markedly reduced compared with transgenic mice carrying both wild type SLP allele, showing that c-kit activation through the induction of SLF is essential for testicular tumorigenesis, especially in tumour promotion. This transgenic mice system should be a useful in vivo model for clarifying the implication of growth factor autostimulation in carcinogenesis.	OSAKA UNIV,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN	Osaka University	KONDOH, G (corresponding author), OSAKA UNIV,GENOME INFORMAT RES CTR,SUITA,OSAKA 565,JAPAN.							ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BERDEL WE, 1992, CANCER RES, V52, P3498; BERNSTEIN SE, 1960, MOUSE NEWS LETT, V23, P33; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BROWDER TM, 1989, CANCER CELL-MON REV, V1, P9; BROXMEYER HE, 1991, CANCER CELL-MON REV, V3, P480; CACERESCORTES JR, 1992, CANCER RES, V52, P5208; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HAYASHI SI, 1991, NUCLEIC ACIDS RES, V13, P2485; HIBI K, 1991, ONCOGENE, V6, P2291; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; INOUE M, 1994, CANCER RES, V54, P3049; KANDA T, 1988, VIROLOGY, V165, P321, DOI 10.1016/0042-6822(88)90694-0; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KONDOH G, 1991, J VIROL, V65, P3335, DOI 10.1128/JVI.65.6.3335-3339.1991; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; MANOVA K, 1993, DEV BIOL, V157, P85, DOI 10.1006/dbio.1993.1114; MANOVA K, 1990, DEVELOPMENT, V110, P1057; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MARZIALI G, 1993, DEV BIOL, V157, P182, DOI 10.1006/dbio.1993.1122; MOTRO B, 1991, DEVELOPMENT, V113, P1207; MUNGER K, 1989, J VIROL, V63, P4417; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; QIE F, 1988, EMBO J, V7, P1003; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, GENES PHENOTYPES GEN, V5, P105; RUSSELL NH, 1992, BLOOD REV, V6, P149, DOI 10.1016/0268-960X(92)90026-M; SARVELLA PATRICIA A., 1956, JOUR HEREDITY, V47, P123; SATO B, 1987, ENDOCRINOLOGY, V120, P1112, DOI 10.1210/endo-120-3-1112; SEKIDO Y, 1991, CANCER RES, V51, P2416; SEKIDO Y, 1993, CANCER RES, V53, P1709; SHIN SI, 1967, ENDOCRINOLOGY, V81, P440, DOI 10.1210/endo-81-3-440; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STROHMEYER T, 1991, CANCER RES, V51, P1811; TAJIMA Y, 1991, DEVELOPMENT, V113, P1031; TOKSOZ D, 1992, P NATL ACAD SCI USA, V89, P7350, DOI 10.1073/pnas.89.16.7350; WILLIAMS DE, 1992, DEV BIOL, V151, P368, DOI 10.1016/0012-1606(92)90176-H; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	46	21	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					341	347						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7530826				2022-12-17	WOS:A1995QC62400013
J	RASCLE, A; GHYSDAEL, J; SAMARUT, J				RASCLE, A; GHYSDAEL, J; SAMARUT, J			C-ERBA, BUT NOT V-ERBA, COMPETES WITH A PUTATIVE ERYTHROID REPRESSOR FOR BINDING TO THE CARBONIC-ANHYDRASE-II PROMOTER	ONCOGENE			English	Article							THYROID-HORMONE RECEPTOR; RETINOID-X-RECEPTOR; BETA-GLOBIN GENE; ACID RECEPTORS; RESPONSE ELEMENT; NUCLEAR RECEPTORS; VITAMIN-D; TRANSCRIPTION; PROTEIN; CELLS	The carbonic anhydrase II (CAII) gene is the only known gene identified as direct target for v-ErbA-mediated repression in avian erythroleukemic cells transformed by Avian Erythroblastosis Virus (AEV). This gene is transcriptionally activated by thyroid hormone (T3) in normal erythrocytic cells. In this work we have analysed the molecular basis of the transcriptional control of the CAII gene by c-ErbA and v-ErbA. We show that several domains in the promoter control hormonal regulation of transcription. One domain proximal to the TATA box mediates T3 response but contains no identified binding site for c-ErbA. An other domain termed PAL2 is approximately 600 bp upstream the transcription initiation site and contains a c-ErbA binding site. We show that when it is associated to a heterologous promoter this site mediates transcriptional repression in erythrocytic cells but not in HeLa cells. Moreover, this site binds a nuclear erythrocyte-specific factor that we called NFX, which is different from c-ErbA. Heterodimers between c-ErbA and the 9-cis retinoic acid receptor (RXR) compete with NFX for binding to PAL2. In contrast, v-ErbA alone or in association with RXR is a very poor competitor and is unable to chase NFX out of the PAL2 site. We propose that NFX is a transcription repressor whose activity is inhibited by c-ErbA but not v-ErbA. This mechanism might contribute to the overall regulation of the carbonic anhydrase II promoter. These data illustrate another possible mechanism through which v-ErbA might antagonize the function of c-ErbA in controlling gene expression.	ECOLE NORMALE SUPER LYON,INRA,BIOL MOLEC & CELLULAIRE LAB,CNRS,UMR49,F-69364 LYON 07,FRANCE; CTR UNIV ORSAY,INST CURIE,BIOL SECT,F-91405 ORSAY,FRANCE	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); INRAE; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay			Samarut, Jacques/AAD-2587-2019; GHYSDAEL, Jacques/F-3377-2013; Rascle, Anne/AAC-1904-2019	Rascle, Anne/0000-0001-7464-8545				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; BIGLER J, 1988, MOL CELL BIOL, V8, P4155, DOI 10.1128/MCB.8.10.4155; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; CHOI OR, 1986, NATURE, V323, P731, DOI 10.1038/323731a0; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; CRENON I, 1993, ONCOGENE, V8, P867; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; EMERSON BM, 1987, P NATL ACAD SCI USA, V84, P4786, DOI 10.1073/pnas.84.14.4786; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; GANDRILLON O, 1994, ONCOGENE, V9, P749; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HALLENBECK PL, 1993, J BIOL CHEM, V268, P3825; HARDING PP, 1992, J BIOL CHEM, V267, P14145; HENTZEN D, 1987, MOL CELL BIOL, V7, P2416, DOI 10.1128/MCB.7.7.2416; HERMANN T, 1993, ONCOGENE, V8, P55; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEHMANN JM, 1993, MOL CELL BIOL, V13, P7698, DOI 10.1128/MCB.13.12.7698; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LIEBER MR, 1987, J CELL BIOL, V105, P1055, DOI 10.1083/jcb.105.3.1055; LU XP, 1993, MOL CELL BIOL, V13, P6509, DOI 10.1128/MCB.13.10.6509; LUCAS PC, 1991, MOL CELL BIOL, V11, P5164, DOI 10.1128/MCB.11.10.5164; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; PAIN B, 1990, New Biologist, V2, P284; PARK HY, 1993, MOL ENDOCRINOL, V7, P319, DOI 10.1210/me.7.3.319; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; SANDE S, 1993, J VIROL, V67, P1067, DOI 10.1128/JVI.67.2.1067-1074.1993; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SCHROEDER C, 1992, ONCOGENE, V7, P217; SEGARS JH, 1993, MOL CELL BIOL, V13, P2258, DOI 10.1128/MCB.13.4.2258; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; VENNSTROM B, 1980, J VIROL, V36, P575; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILLIAMS GR, 1992, MOL ENDOCRINOL, V6, P1527, DOI 10.1210/me.6.10.1527; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	54	21	21	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2853	2867						15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	7916146				2022-12-17	WOS:A1994PG82200011
J	ROMANO, A; WONG, WT; SANTORO, M; WIRTH, PJ; THORGEIRSSON, SS; DIFIORE, PP				ROMANO, A; WONG, WT; SANTORO, M; WIRTH, PJ; THORGEIRSSON, SS; DIFIORE, PP			THE HIGH TRANSFORMING POTENCY OF ERBB-2 AND RET IS ASSOCIATED WITH PHOSPHORYLATION OF PAXILLIN AND A 23 KDA PROTEIN	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; GUANINE-NUCLEOTIDE EXCHANGE; DNA-BINDING PROTEINS; NIH 3T3 CELLS; SIGNAL-TRANSDUCTION; TYROSINE KINASE; EGF RECEPTOR; INTERFERON-GAMMA; ADAPTER PROTEIN; RAS	Two-dimensional gel maps of proteins phosphorylated by the epidermal growth factor receptor (EGFR) and erbB-2 kinases were obtained, to investigate the molecular basis of the different biological properties of these two molecules. Several proteins were phosphorylated by EGFR or erbB-2 with different stoichiometry. Differences were either quantitative or qualitative. In NIH3T3 cells, erbB-2 is 100-fold more transforming than EGFR. In the same cell line several proteins were preferentially phosphorylated by erbB-2, as compared to EGFR. To identify which of these substrates might be directly involved in mitogenic signaling, we obtained two-dimensional maps of proteins phosphorylated on tyrosine by EGFR/ret and an EGFR/erbB-2(TK) chimeric receptors. Both these chimerae behaved indistinguishably from erbB-2 in a number of bioassays and potently transformed NIH3T3 cells. Paxillin and a 23 kDa substrate were invariably phosphorylated to higher stoichiometry whenever potent mitogenic and transforming signals were activated. We propose that paxillin and the 23 kDa substrate are important elements in the erbB-2 and ret-activated mitogenic and transforming signaling.	NCI,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20892; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,I-80125 NAPLES,ITALY; FAC MED & CHIRURG NAPLES,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC L CAL,NAPLES,ITALY; FAC MED & CHIRURG BARI,IST MICROBIOL,BARI,ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita degli Studi di Bari Aldo Moro			Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIFIORE PP, 1992, EMBO J, V11, P3927, DOI 10.1002/j.1460-2075.1992.tb05486.x; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HART MJ, 1990, J BIOL CHEM, V265, P5990; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P424, DOI 10.1016/0003-2697(88)90209-6; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LONARDO F, 1990, New Biologist, V2, P992; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MONTMINY M, 1993, SCIENCE, V261, P1694, DOI 10.1126/science.8397444; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SORKIN A, 1993, ONCOGENE, V8, P3021; TAVERNA D, 1991, CELL GROWTH DIFFER, V2, P145; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WIRTH PJ, 1991, ELECTROPHORESIS, V12, P931, DOI 10.1002/elps.1150121112	50	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2923	2933						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	7916147				2022-12-17	WOS:A1994PG82200018
J	MUSHINSKI, JF; GOODNIGHT, J; RUDIKOFF, E; MORSE, HC; LANGDON, WY				MUSHINSKI, JF; GOODNIGHT, J; RUDIKOFF, E; MORSE, HC; LANGDON, WY			EXPRESSION OF C-CBL PROTOONCOGENE IS MODULATED DURING DIFFERENTIATION BUT NOT DURING INDUCTION OF PROLIFERATION	ONCOGENE			English	Article							MURINE IMMUNE-SYSTEM; NF-KAPPA-B; V-CBL; POLYCLONAL ACTIVATION; TRANSCRIPTION FACTOR; DNA-BINDING; ZINC FINGER; CELLS; IDENTIFICATION; TRUNCATION	The proto-oncogene c-cbl is expressed as two mRNAs, ca. 10.5 and 3.1 kb, both of which appear to be functional inasmuch as both can be found on polyribosomes in tissues that express both mRNAs. The function of the 120 kDa c-cbl protein is not known, but its primary structure resembles that of a DNA-binding transcription factor with a basic region, a nuclear localization sequence, a zinc finger-like motif and a leucine zipper. To test whether expression of this protein resembles that of regulatory proteins, we studied expression of c-cbl mRNA and protein in differentiating cells and in proliferating cells, conditions in which expression of regulatory proteins commonly is modulated. Differentiation of both erythroleukemia cells and teratocarcinoma cells showed a decrease in c-cbl expression, with kinetics similar to those of transcription factors that are immediate early response genes. Unlike early response genes, however, c-cbl mRNA showed a very long half life in B lymphocytes. Further, in fibroblasts and spleen cells that were induced to proliferate, c-cbl mRNA expression did not change, and expression of c-cbl protein did not change during any stage of the cell cycle. These characteristics indicate that c-cbl does not belong to the immediate early response type of transcription factor. Yet when c-cbl is truncated, as in v-cbl, the protein does enter the nucleus and bind DNA, and it contributes to neoplastic transformation of B lymphocytes and fibroblasts. These findings indicate that the regulation of the c-cbl proto-oncogene is different from that of the proto-oncogenes identified to date and suggest that c-cbl belongs to a new class of proto-oncogenes.	NIAID,IMMUNOPATHOL LAB,BETHESDA,MD 20892; UNIV WESTERN AUSTRALIA,DEPT BIOCHEM,NEDLANDS,WA 6009,AUSTRALIA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Western Australia	MUSHINSKI, JF (corresponding author), NCI,MOLEC GENET SECT,BETHESDA,MD 20892, USA.			Morse, Herbert/0000-0002-9331-3705				BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BRAUN J, 1983, J IMMUNOL, V130, P2113; FINKELMAN FD, 1982, J IMMUNOL, V129, P638; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRIEND C, 1978, P NATL ACAD SCI USA, V81, P378; GRUMONT RJ, 1990, CELL GROWTH DIFFER, V1, P345; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LAVU S, 1985, CANCER CELLS, V2, P301; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MATHERLY LH, 1989, ANAL BIOCHEM, V182, P338, DOI 10.1016/0003-2697(89)90605-2; MOUNTZ JD, 1987, J IMMUNOL, V139, P2172; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PETERS R, 1986, BIOCHIM BIOPHYS ACTA, V864, P305, DOI 10.1016/0304-4157(86)90003-1; REGNIER DC, 1989, J VIROL, V63, P3678, DOI 10.1128/JVI.63.9.3678-3682.1989; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; TUNNACLIFFE A, 1990, GENOMICS, V8, P447, DOI 10.1016/0888-7543(90)90030-X; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9	30	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2489	2497						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058312				2022-12-17	WOS:A1994PC05400008
J	CASSARMALEK, I; MARCHAL, S; ALTABEF, M; WRUTNIAK, C; SAMARUT, J; CABELLO, G				CASSARMALEK, I; MARCHAL, S; ALTABEF, M; WRUTNIAK, C; SAMARUT, J; CABELLO, G			V-ERBA STIMULATES QUAIL MYOBLAST DIFFERENTIATION IN A T3 INDEPENDENT, CELL-SPECIFIC MANNER	ONCOGENE			English	Article							THYROID-HORMONE RECEPTOR; AVIAN ERYTHROBLASTOSIS VIRUS; RETINOIC ACID RECEPTOR; DNA-BINDING DOMAIN; C-ERBA; GENE-EXPRESSION; ERYTHROID-DIFFERENTIATION; SKI ONCOGENE; TRANSCRIPTIONAL ACTIVATION; TERMINAL DIFFERENTIATION	The v-erbA oncoprotein represents a mutated version of a thyroid hormone receptor, responsible for the induction of a differentiation arrest in chicken erythroid cells. We have studied the influence of v-erbA on proliferation and differentiation of avian myoblasts. Secondary quail myoblast cultures were infected either with an avian retrovirus carrying the v-erbA oncogene in association with the neomycin resistance gene, or with a control deleted v-erbA/neo(R) retrovirus. We report here that v-erbA expression led to an increase in myoblast proliferation and to a surprising stimulation of quail myoblast terminal differentiation. In addition, these effects occurred in the presence or absence of T3, and v-erbA did not suppress T3 influence on myoblasts. Transient transfection assays demonstrated that, in contrast to its action in HeLa cells, v-erbA was unable to repress the transcriptional activation of a TRE-CAT reporter gene by liganded c-erbA alpha receptors in quail myoblasts. We also observed that the AP-1/c-erbA/v-erbA interactions are not functional in quail myoblasts. These data suggest that, in these cells, v-erbA action does not interfere with T3 induced mechanisms. They also demonstrate a cell specificity for the v-erbA pathway. Lastly, expression of c-erbA/v-erbA chimeric proteins and of the S61G v-erbA mutant indicates that the DNA binding domain of v-erbA, and more specifically serine 61, is directly involved in the enhancement of myoblast differentiation by the oncoprotein.	INRA, DIFFERENCIAT CELLULAIRE & CROISSANCE LAB, UNITE ENDOCRINOL CELLULAIRE, F-34060 MONTPELLIER 01, FRANCE; ECOLE NORMALE SUPER LYON, INRA, BIOL CELLULAIRE & MOLEC LAB, CNRS, UMR40, F-69364 LYON 07, FRANCE	INRAE; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); INRAE			Samarut, Jacques/AAD-2587-2019; , Cassar-Malek/AAW-6386-2020	, Cassar-Malek/0000-0001-7407-1408				ANTIN PB, 1991, DEV BIOL, V143, P111, DOI 10.1016/0012-1606(91)90058-B; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; CARNAC G, 1992, MOL ENDOCRINOL, V6, P1185, DOI 10.1210/me.6.8.1185; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DESBOIS C, 1991, ONCOGENE, V6, P2129; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DEVERNEUIL H, 1990, NUCLEIC ACIDS RES, V18, P4489; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; FALCONE G, 1990, CIBA F SYMP, V150, P250; FORMAN BM, 1988, MOL ENDOCRINOL, V2, P902, DOI 10.1210/mend-2-10-902; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; GANDRILLON O, 1994, ONCOGENE, V9, P749; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GAZZOLO L, 1980, CELL, V22, P683, DOI 10.1016/0092-8674(80)90544-9; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GROSSI M, 1991, ONCOGENE, V6, P1767; GROSSI M, 1989, PATHOLOGY GENE EXPRE, P313; HERMANN T, 1993, ONCOGENE, V8, P55; KHAZAIE K, 1991, ONCOGENE, V6, P21; KING DB, 1987, J EXP ZOOL, P291; LARSEN J, 1992, ONCOGENE, V7, P1903; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCHAL S, 1993, BIOL CELL, V78, P191, DOI 10.1016/0248-4900(93)90129-3; Markwell M A, 1981, Methods Enzymol, V72, P296; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; MUSCAT GEO, 1994, NUCLEIC ACIDS RES, V22, P583, DOI 10.1093/nar/22.4.583; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; PAIN B, 1990, New Biologist, V2, P284; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SCHROEDER C, 1992, ONCOGENE, V7, P217; SCOW RO, 1951, ENDOCRINOLOGY, V49, P641, DOI 10.1210/endo-49-5-641; SHAINBERG A, 1984, J ENDOCRINOL, V101, P141, DOI 10.1677/joe.0.1010141; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SHARIF M, 1992, ONCOGENE, V7, P953; SMITMCBRIDE Z, 1993, ONCOGENE, V8, P1465; SNEDECOR GW, 1961, STATISTICAL METHODS; STOCKDALE FE, 1977, REGULATION CELL PROL, P165; SU HY, 1991, ONCOGENE, V6, P1759; SUTRAVE P, 1991, ONCOGENE, V6, P353; VENNSTROM B, 1980, J VIROL, V36, P575; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YAMAMOTO T, 1983, CELL, V34, P225, DOI 10.1016/0092-8674(83)90153-8; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	60	21	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1994	9	8					2197	2206						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	7913543				2022-12-17	WOS:A1994NX62900011
J	MEERABUX, JM; COTTER, FE; KEARNEY, L; NIZETIC, D; DHUT, S; GIBBONS, B; LISTER, TA; YOUNG, BD				MEERABUX, JM; COTTER, FE; KEARNEY, L; NIZETIC, D; DHUT, S; GIBBONS, B; LISTER, TA; YOUNG, BD			MOLECULAR-CLONING OF A NOVEL 11Q23 BREAKPOINT ASSOCIATED WITH NON-HODGKINS-LYMPHOMA	ONCOGENE			English	Article							B-CELL LYMPHOMA; ACUTE LEUKEMIAS; CHROMOSOME-TRANSLOCATION; DROSOPHILA-TRITHORAX; INSITU HYBRIDIZATION; GENE; ABNORMALITIES; T(4-11); IDENTIFICATION; DISTINCT	Chromosomal analysis of a non-Hodgkin's lymphoma revealed a t(11;14)(q23;q32) translocation amongst other abnormalities. To investigate the molecular basis of this translocation, a cosmid library was constructed from the tumour DNA and the rearranged IGH locus was isolated in a single cosmid. Fluorescence in situ hybridization confirmed that the cloned region contained sequences from chromosome 11q23 fused to chromosome 14q32. Sequence analysis identified the breakpoint as a fusion between a region from the switch segment of the C gamma 4 gene of the IGH locus and an unknown sequence on chromosome 11. The chromosome 11 sequence maps proximal to the CD3 gene cluster and is therefore distinct from both the HTRX1 gene (rearranged in acute leukaemias) and the RCK gene (rearranged in a cell line derived from a histiocytic B-cell lymphoma). This newly identified region contains a cluster of rare cutting restriction enzyme sites located within 200 bases of the breakpoint, suggestive of a CpG island. Although this t(11;14)(q23;q32) translocation and that in the RC-K8 cell line affect different regions on chromosome 11, the breakpoints on chromosome 14 were found to have occurred at equivalent positions of S gamma 2 and S gamma 4 segments.	ST BARTHOLOMEWS HOSP,DEPT MED ONCOL,IMPERIAL CANC RES FUND,LONDON EC1A 7BE,ENGLAND; INST CHILD HLTH,LONDON WC1N 1EH,ENGLAND; IMPERIAL CANC RES FUND,GENOME ANAL LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK; University of London; Queen Mary University London; University of London; University College London; Cancer Research UK; The Genome Analysis Centre (TGAC)			Nizetic, Dean/F-9509-2015	Nizetic, Dean/0000-0001-5486-5761				AKAO Y, 1991, CANCER RES, V51, P1574; AKAO Y, 1992, CANCER RES, V52, P6083; AKAO Y, 1990, CANCER RES, V50, P4856; BLOOMFIELD CD, 1983, CANCER RES, V43, P2975; CABANILLAS F, 1988, BLOOD, V71, P1615; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COTTER FE, 1990, GENOMICS, V7, P257, DOI 10.1016/0888-7543(90)90548-9; DAS S, 1992, GENE CHROMOSOME CANC, V5, P244, DOI 10.1002/gcc.2870050312; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIBSON TJ, 1987, GENE, V53, P275, DOI 10.1016/0378-1119(87)90016-3; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; ICHIHARA Y, 1988, EMBO J, V7, P4141, DOI 10.1002/j.1460-2075.1988.tb03309.x; KEARNEY L, 1992, BLOOD, V80, P1659; KIEVITS T, 1990, CYTOGENET CELL GENET, V53, P134, DOI 10.1159/000132913; KUBONISHI I, 1986, CANCER, V58, P1453, DOI 10.1002/1097-0142(19861001)58:7<1453::AID-CNCR2820580713>3.0.CO;2-B; LEVINE EG, 1985, BLOOD, V66, P1414; MCKEITHAN TW, 1990, GENE CHROMOSOME CANC, V1, P247, DOI 10.1002/gcc.2870010310; MILLS FC, 1990, NUCLEIC ACIDS RES, V18, P7305, DOI 10.1093/nar/18.24.7305; MOLLER P, 1986, VIRCHOWS ARCH A, V409, P79, DOI 10.1007/BF00705408; NISHIDA Y, 1982, P NATL ACAD SCI-BIOL, V79, P3833, DOI 10.1073/pnas.79.12.3833; NIZETIC D, 1991, P NATL ACAD SCI USA, V88, P3233, DOI 10.1073/pnas.88.8.3233; PARRY P, 1993, P NATL ACAD SCI USA, V90, P4738, DOI 10.1073/pnas.90.10.4738; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; RADICE P, 1992, GENE CHROMOSOME CANC, V5, P50, DOI 10.1002/gcc.2870050108; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARPA A, 1987, VIRCHOWS ARCH A, V412, P17, DOI 10.1007/BF00750725; SCARPA A, 1991, BLOOD, V78, P780; TAKAHASHI N, 1980, NUCLEIC ACIDS RES, V8, P5983, DOI 10.1093/nar/8.24.5983; TAKAHASHI N, 1982, CELL, V29, P671, DOI 10.1016/0092-8674(82)90183-0; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TOMLINSON IM, 1992, J MOL BIOL, V227, P776, DOI 10.1016/0022-2836(92)90223-7; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	34	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					893	898						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108133				2022-12-17	WOS:A1994MW55100026
J	BOYER, MJ; GUTMANN, DH; COLLINS, FS; BARSAGI, D				BOYER, MJ; GUTMANN, DH; COLLINS, FS; BARSAGI, D			CROSS-LINKING OF THE SURFACE-IMMUNOGLOBULIN RECEPTOR IN B-LYMPHOCYTES INDUCES A REDISTRIBUTION OF NEUROFIBROMIN BUT NOT P120-GAP	ONCOGENE			English	Article							TYPE-1 GENE-PRODUCT; RAS PROTEINS; CELLS; GAP; P21; IDENTIFICATION; MUTATIONS; SEQUENCE; ENCODES; MUTANTS	The activation of Ras proteins is a key step in the signal transduction pathways triggered by ligand-bound cell surface receptors. The GTPase activating proteins (GAPs) p120-GAP and neurofibromin, the neurofibromatosis-type 1 (NF1) gene product, are thought to play an essential role in the regulation of Ras activity by increasing the GTPase activity of wild type, but not activated Ras in vitro. Both GAPs are widely expressed in mammalian tissues thus raising the question of whether or not they have different regulatory functions. In this study, we have analysed the distribution of p120-GAP and neurofibromin in splenic B lymphocytes by immunofluorescent staining. Crosslinking of surface immunoglobulin (sig), the B-lymphocyte antigen receptor, induced the redistribution of neurofibromin. In contrast, no apparent change in the cellular localization of p120-GAP occurred followed the cross-linking of sig. The redistribution of neurofibromin coincided both spatially and temporally with the relocalization of crosslinked slg and was inhibited by the cytoskeletal disrupting agents colchicine and cytochalasin D. These findings indicated that neurofibromin and p120-GAP can be differentially regulated in vivo and suggest that neurofibromin is a component of the signaling pathway initiated by crosslinking of B lymphocyte sig. Furthermore, our observations that cocapping neurofibromin with sig is independent of the p21(ras) redistribution suggests that the role of neurofibromin in B cells is not solely related to its ability to act as a Ras regulator.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; UNIV MICHIGAN,DEPT NEUROL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109	Cold Spring Harbor Laboratory; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan				Bar-Sagi, Dafna/0000-0003-2597-8948; Gutmann, David/0000-0002-3127-5045	NATIONAL CANCER INSTITUTE [R37CA055360, R01CA055360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001590] Funding Source: NIH RePORTER; NCI NIH HHS [CA55360] Funding Source: Medline; NINDS NIH HHS [NS-01590, NS02340] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADCOCK MR, 1993, NATURE, V363, P83; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOLLAG G, 1993, EMBO J, V12, P1923, DOI 10.1002/j.1460-2075.1993.tb05841.x; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BORISY GG, 1967, J CELL BIOL, V34, P525, DOI 10.1083/jcb.34.2.525; BOURGUIGNON LYW, 1978, J CELL PHYSIOL, V95, P239, DOI 10.1002/jcp.1040950302; BRAUN J, 1980, IMMUNOL REV, V52, P3, DOI 10.1111/j.1600-065X.1980.tb00328.x; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; DATSON MM, 1992, NEURON, V8, P415; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; EDELMAN GM, 1973, P NATL ACAD SCI USA, V70, P1442, DOI 10.1073/pnas.70.5.1442; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GABBIANI G, 1977, NATURE, V269, P697, DOI 10.1038/269697a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOLD MR, 1993, J IMMUNOL, V150, P377; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; GRAZIADEI L, 1990, NATURE, V347, P396, DOI 10.1038/347396a0; GREGORY PE, 1993, SOMAT CELL MOLEC GEN, V19, P265, DOI 10.1007/BF01233074; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; GUTMANN DH, 1993, J NEUROSCI RES, V36, P206; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; QIU MS, 1991, J CELL BIOL, V115, P795, DOI 10.1083/jcb.115.3.795; SEVERSON CD, 1987, IMMUNOL LETT, V15, P291, DOI 10.1016/0165-2478(87)90130-1; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; TAYLOR RB, 1971, NATURE-NEW BIOL, V233, P225, DOI 10.1038/newbio233225a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; Weihing R R, 1979, Methods Achiev Exp Pathol, V8, P42; WESSELLS NK, 1971, SCIENCE, V171, P135, DOI 10.1126/science.171.3967.135; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YAHARA I, 1978, CELL, V15, P251, DOI 10.1016/0092-8674(78)90100-9	41	21	21	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					349	357						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290249				2022-12-17	WOS:A1994MW24800002
J	MAVROTHALASSITIS, G; FISHER, RJ; SMYTH, F; WATSON, DK; PAPAS, TS				MAVROTHALASSITIS, G; FISHER, RJ; SMYTH, F; WATSON, DK; PAPAS, TS			STRUCTURAL INFERENCES OF THE ETS1 DNA-BINDING DOMAIN DETERMINED BY MUTATIONAL ANALYSIS	ONCOGENE			English	Article							GENE FAMILY; C-FOS; TRANSCRIPTION FACTORS; ONCOGENIC ACTIVITY; PROTEIN; C-ETS-1; CELLS; MOTIF; PROTOONCOGENE; SEQUENCE	The ets family of transcription factors is characterized by a conserved region that harbors the DNA-binding activity. We performed extensive deletion and mutational analyses, as well as DNA-peptide interaction studies necessary to identify the determinants of the DNA-binding activity of the ETS1 oncoprotein. We found that amino acids beyond the 85 amino acid conserved region are required in order to afford maximum DNA-binding activity in a heterologous system. Mutation throughout the binding domain can have a detrimental effect on binding activity, indicating that proper folding of the entire domain is necessary for DNA binding. A peptide, as small as 37 residues (K37N), derived from the basic region of the ETS1 binding domain, is sufficient to exhibit sequence-specific DNA recognition. Total randomization of Lysine 379, Lysine 381 and Arginine 391 within this region fails to provide functional substitutions, indicating that these specific amino acids within the basic region are required for binding. Transactivation activity of the ETS1 proteins bearing mutations was consistent with their DNA-binding activity, indicating that the primary (if not only) function of this domain is to provide sequence-specific DNA recognition activity. Our mutational analysis, as well as modeling predictions, lead us to propose a helix-turn-helix structure for the basic region of the ETS1 binding domain that is able to interact directly with DNA. We also propose that the hydrophobic alpha-helical region, surrounding tryptophan 338, is fundamental for proper protein folding and;functioning of the ets binding domain.	PROGRAM RESOURCES INC,DYNCORP,FREDERICK,MD 21701		MAVROTHALASSITIS, G (corresponding author), NCI,MOLEC ONCOL LAB,POB B,FREDERICK,MD 21702, USA.		Fisher, Robert/B-1431-2009					BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1989, J IMMUNOL, V142, P672; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; FISHER RJ, 1991, ONCOGENE, V6, P2249; FISHER RJ, 1992, J BIOL CHEM, V267, P17957; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Leung DW, 1989, TECHNIQUE, V1, P11; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WERNERT N, 1992, AM J PATHOL, V140, P119; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	35	21	21	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					425	435						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290254				2022-12-17	WOS:A1994MW24800009
J	COGLIATI, T; DUNN, BK; BARNER, M; CULTRARO, CM; SEGAL, S				COGLIATI, T; DUNN, BK; BARNER, M; CULTRARO, CM; SEGAL, S			TRANSFECTED WILD-TYPE AND MUTANT MAX REGULATE CELL-GROWTH AND DIFFERENTIATION OF MURINE ERYTHROLEUKEMIA-CELLS	ONCOGENE			English	Article							C-MYC; DNA-BINDING; ERYTHROID-DIFFERENTIATION; EXPRESSION; COMMITMENT; GENE; PROTEIN; G0/G1	Max protein forms specific DNA-binding dimeric complexes with itself and with proteins of the c-myc gene family. A large volume of data has accumulated on the role of the c-myc proto-oncogene in cell proliferation, differentiation and tumorigenesis. To elucidate the role of max in regulating c-myc functions and the effect of both proteins on cell proliferation and differentiation, we transfected murine erythroleukemia (MEL) cells with a full-length wild-type (wt) human max gene and a mutant containing a double point mutation in the basic region (bm), which abolishes specific DNA binding. All clones expressing wt-max grow slowly, and the process of inducer-mediated differentiation is delayed. Furthermore, cells transfected with the mutated max exhibit growth retardation, accumulation in the G0/G1 phase of the cell cycle and spontaneous differentiation. Our findings are consistent with a model in which a large excess of wt-Max in the cells enhances the formation of Max-Max growth-suppressor complexes, while elevated bm-Max deprives the cell of growth-promoting Myc-Max heterodimers in a dominant-negative manner, presumably by inactivating endogenous Myc and Max.	UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814; NCI,MED ONCOL BRANCH,BETHESDA,MD 20889	Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BARNER M, 1992, CELL GROWTH DIFFER, V3, P183; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BIRRER MJ, 1989, MOL CELL BIOL, V9, P2734, DOI 10.1128/MCB.9.6.2734; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CUTTITTA F, 1988, J CLIN ENDOCR METAB, V67, P576, DOI 10.1210/jcem-67-3-576; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DAVIS LG, 1986, METHODS MOL BIOL; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DUBE SK, 1974, DIFFERENTIATION CONT, P99; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; FRIED J, 1978, J HISTOCHEM CYTOCHEM, V26, P921, DOI 10.1177/26.11.82573; GELLER R, 1978, J CELL PHYSIOL, V95, P213, DOI 10.1002/jcp.1040950211; GUSELLA J, 1976, CELL, V9, P221, DOI 10.1016/0092-8674(76)90113-6; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KAHN S M, 1990, Technique (Philadelphia), V2, P27; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; Sambrook J., 1989, MOL CLONING LAB MANU; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TERADA M, 1977, P NATL ACAD SCI USA, V74, P248, DOI 10.1073/pnas.74.1.248; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x	37	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1263	1268						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479748				2022-12-17	WOS:A1993KY32800018
J	OTTERSON, GA; KRATZKE, RA; LIN, AY; JOHNSTON, PG; KAYE, FJ				OTTERSON, GA; KRATZKE, RA; LIN, AY; JOHNSTON, PG; KAYE, FJ			ALTERNATIVE SPLICING OF THE RBP1 GENE CLUSTERS IN AN INTERNAL EXON THAT ENCODES POTENTIAL PHOSPHORYLATION SITES	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; CELL-CYCLE; TRANSCRIPTION FACTOR; PRODUCT; PROTEINS; BINDING; EXPRESSION; CARCINOMA; COMPLEX; IDENTIFICATION	We have isolated cDNA and genomic clones for the human retinoblastoma binding protein 1 (RBP1) gene, and have identified alternative splicing of RBP1 clustered within a 207-nucleotide internal exon. Three of the predicted RPB1 peptides share amino-terminal and carboxy-terminal domains, while a fourth species encodes a distinct carboxy-terminal domain. Functional analysis of these peptides demonstrated that they are capable of precipitating retinoblastoma (RB) protein in vitro from K562 cell lysates, but cannot bind to mutant RB protein. However, each of the RBP1 peptides differed within an internal exon that contains potential casein kinase II and p34cdc2 phosphorylation sites. Immunoblot analysis using polyclonal alpha-RBP1 antiserum revealed that the RBP1 protein is expressed in a wide range of cell lines of differing histologic type and migrates on sodium dodecyl sulfate-polyacrylamide gel electrophoresis predominantly as a 200-kDa protein. Immunohistochemical analysis using the alpha-RBP1 antiserum demonstrated a distinct nuclear staining pattern that was eliminated when the antiserum was preabsorbed with RBP1 peptide. The RBP1 gene encodes a widely expressed 200-kDa nuclear protein and undergoes alternative splicing that predicts a family of RB-binding peptides.	USN HOSP,NCI,NAVY ONCOL BRANCH,BLDG 8,RM 5101,BETHESDA,MD 20889; UNIV HLTH SCI,UNIFORMED SERV,BETHESDA,MD 20889	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy			kaye, frederic/E-2437-2011					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; Battey, 1986, BASIC METHODS MOL BI; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; CARNEY DN, 1985, CANCER RES, V45, P2913; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KRATZKE RA, 1992, J BIOL CHEM, V267, P25998; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; NEVINS JR, 1991, TRENDS BIOCHEM SCI, V16, P435, DOI 10.1016/0968-0004(91)90171-Q; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YOKOTA J, 1988, ONCOGENE, V3, P471	38	21	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					949	957						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455946				2022-12-17	WOS:A1993KT22000017
J	TELERMAN, A; DODEMONT, H; DEGRAEF, C; GALAND, P; BAUWENS, S; VANOOSTVELDT, P; AMSON, RB				TELERMAN, A; DODEMONT, H; DEGRAEF, C; GALAND, P; BAUWENS, S; VANOOSTVELDT, P; AMSON, RB			IDENTIFICATION OF THE CELLULAR PROTEIN ENCODED BY THE HUMAN WILMS-TUMOR (WT1) GENE	ONCOGENE			English	Note							HUMAN CHROMOSOME-11; PHYSICAL MAP; PRODUCT; DELETION; BINDING; REGION; GROWTH; LOCUS	A putative tumor-suppressor gene (wt1) located at chromosome 11p13 and involved in Wilms' tumor development has recently been identified as a zinc finger polypeptide-encoding gene. The purpose of this study was to characterize the protein encoded by the human wt1 gene. The region spanning the entire zinc finger domain was amplified by polymerase chain reaction (PCR) and subcloned in the pATH 3 expression vector. Polyclonal antibodies against the fused TrpE-WT protein were raised. These antibodies immunoprecipitated a 49- to 51-kDa protein from hematopoietic tumor cells labeled in vivo with [S-35]methionine. Subcellular fractionation and immunohistochemistry followed by confocal microscopy indicated that the Wilms' tumor gene product (WT1) is mainly localized within the nucleus.	FREE UNIV BRUSSELS,SCH MED,INST INTERDISCIPLINARY RES,CAMPUS ERASME,BLDG C,ROUTE LENNIK 808,B-1070 BRUSSELS,BELGIUM; MAX PLANCK INST BIOPHYS CHEM,DEPT BIOCHEM,W-3400 GOTTINGEN,GERMANY; FREE UNIV BRUSSELS,SCH MED,CYTOL & EXPTL ONCOL LAB,B-1050 BRUSSELS,BELGIUM; STATE UNIV GHENT,GENET LAB,B-9000 GENT,BELGIUM; STATE UNIV GHENT,BIOCHEM LAB,B-9000 GENT,BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Max Planck Society; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Ghent University; Ghent University								AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; AMSON RB, 1989, ONCOGENE, V4, P243; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COMPTON DA, 1988, CELL, V55, P827, DOI 10.1016/0092-8674(88)90138-9; GALAND P, 1989, CELL TISSUE KINET, V22, P383, DOI 10.1111/j.1365-2184.1989.tb00223.x; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TELERMAN A, 1988, MOL CELL BIOL, V8, P1498, DOI 10.1128/MCB.8.4.1498; VANHEYNINGEN V, 1990, P NATL ACAD SCI USA, V87, P5383, DOI 10.1073/pnas.87.14.5383	19	21	28	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2545	2548						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1334252				2022-12-17	WOS:A1992KA85600023
J	METZ, T; GRAF, T				METZ, T; GRAF, T			THE NUCLEAR ONCOGENES V-ERBA AND V-ETS COOPERATE IN THE INDUCTION OF AVIAN ERYTHROLEUKEMIA	ONCOGENE			English	Article							THYROID-HORMONE RECEPTOR; CHICKEN ERYTHROID-CELLS; MONOCLONAL-ANTIBODIES; LEUKEMIA VIRUSES; MYELOID CELLS; GROWTH-FACTOR; PROTEIN; DIFFERENTIATION; TRANSFORMATION; GENE	The nuclear oncogenes v-erbA and v-ets are known to cooperate with other viral oncogenes in the induction of avian erythroleukemia. Thus, in the case of avian erythroblastosis virus (AEV), v-erbA enhances the effect of the tyrosine kinase-encoding v-erbB oncogene by blocking the terminal differentiation of erythroid cells. In the case of E26 virus a fusion of the product from v-ets to that of the nuclear oncogene v-myb is a prerequisite for leukemogenicity. Here we show that an artificial virus carrying both v-erbA and v-ets induces a rapid, acute erythroleukemia phenotypically similar to that induced by AEV. In contrast, virus constructs containing either v-erbA or v-ets alone are non-leukemogenic, although they are capable of transforming erythroid cells in vitro. Analysis of in vitro-transformed cells showed that v-erbA induces a block of differentiation without abrogating dependence on anemic serum, while v-ets predominantly causes anemic serum independence. As expected, cells transformed by both oncogenes exhibit an increased proliferative potential, are blocked in differentiation and are anemic serum independent. These data demonstrate that two separately expressed nuclear oncoproteins can complement each other in vitro and in vivo. They also show that the v-Ets protein on its own can contribute to leukemogenesis.			METZ, T (corresponding author), EUROPEAN MOLEC BIOL LAB, DIFFERENTIAT PROGRAMME, POSTFACH 102209, W-6900 HEIDELBERG, GERMANY.		Graf, Thomas/B-4252-2015	Graf, Thomas/0000-0003-2774-4117				BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BEUG H, 1982, J CELL PHYSIOL, P195; BEUG H, 1989, EUR J CLIN INVEST, V19, P491, DOI 10.1111/j.1365-2362.1989.tb00265.x; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BIGLER J, 1988, MOL CELL BIOL, V8, P4155, DOI 10.1128/MCB.8.10.4155; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; Frykberg L, 1988, Oncogene Res, V3, P313; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HENTZEN D, 1987, MOL CELL BIOL, V7, P2416, DOI 10.1128/MCB.7.7.2416; JANSSON M, 1987, ONCOGENE, V1, P167; KAHN P, 1984, P NATL ACAD SCI-BIOL, V81, P7122, DOI 10.1073/pnas.81.22.7122; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; LAI MMC, 1980, VIROLOGY, V100, P475, DOI 10.1016/0042-6822(80)90537-1; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; METZ T, 1991, EMBO J, V10, P837, DOI 10.1002/j.1460-2075.1991.tb08016.x; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; PAPAS TS, 1986, CANCER INVEST, V4, P555, DOI 10.3109/07357908609039835; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0	42	21	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1992	7	3					597	605						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1347919				2022-12-17	WOS:A1992HK00500030
J	STOREY, A; GREENFIELD, I; BANKS, L; PIM, D; CROOK, T; CRAWFORD, L; STANLEY, M				STOREY, A; GREENFIELD, I; BANKS, L; PIM, D; CROOK, T; CRAWFORD, L; STANLEY, M			LACK OF IMMORTALIZING ACTIVITY OF A HUMAN PAPILLOMAVIRUS TYPE-16 VARIANT DNA WITH A MUTATION IN THE E2 GENE ISOLATED FROM NORMAL HUMAN CERVICAL KERATINOCYTES	ONCOGENE			English	Article							HUMAN FORESKIN KERATINOCYTES; EPITHELIAL-CELLS; TRANSCRIPTIONAL REPRESSOR; REGULATORY REGION; ACTIVATED RAS; TRANSFORMATION; CARCINOMA; PRODUCT; PROTEIN; LINE	The oncogenic potential of a human papillomavirus type 16 (HPV16) variant cloned from normal human cervical keratinocytes has been tested in vitro using primary rodent epithelial cells and human cervical keratinocytes. The HPV16 variant was able to extend the lifespan of, but failed to immortalize, human keratinocytes. It could however cooperate with an activated ras oncogene to transform primary rodent cells. Radioimmunoprecipitation assays of the rodent cells showed that they expressed the E7 protein. DNA sequence analysis of the URR/E6/E7 and E5 regions of the HPV16 showed them to be fully functional, but a deletion in the viral E2 open reading frame was detected. This truncated E2 only weakly stimulated transcription of the viral regulatory region. Complementation assays using the HPV16 variant and a full-length E2 enabled the cloned variant to immortalize human cervical keratinocytes with wild-type efficiency. These results suggest that other viral gene products in addition to E6/E7 may play an important role in the in vitro immortalization of cervical keratinocytes in HPV16 and the development of cervical cancer.	UNIV CAMBRIDGE, DEPT PATHOL, IMPERIAL CANC RES FUND TUMOR VIRUS GRP, CAMBRIDGE CB2 1QP, ENGLAND; ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, LONDON W2 1PG, ENGLAND	University of Cambridge; Imperial College London; Ludwig Institute for Cancer Research	STOREY, A (corresponding author), INT CTR GENET ENGN & BIOTECHNOL, PADRICIANO 99, I-34012 TRIESTE, ITALY.			Storey, Alan/0000-0003-2001-9772				ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; BARBOSA MS, 1989, ONCOGENE, V4, P1529; CHAN WK, 1989, J VIROL, V63, P3261, DOI 10.1128/JVI.63.8.3261-3269.1989; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOE J, 1989, J VIROL, V63, P1743, DOI 10.1128/JVI.63.4.1743-1755.1989; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; DEVILLIERS EM, 1987, LANCET, V2, P703; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DURST M, 1987, ONCOGENE, V1, P251; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FARR A, 1987, CANCER CELL, V5, P171; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GERGELY L, 1987, LANCET, V2, P513; GISSMANN L, 1983, P NATL ACAD SCI-BIOL, V80, P560, DOI 10.1073/pnas.80.2.560; GLOSS B, 1990, J VIROL, V64, P5577, DOI 10.1128/JVI.64.11.5577-5584.1990; GLOSS B, 1987, EMBO J, V6, P3735, DOI 10.1002/j.1460-2075.1987.tb02708.x; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KAUR P, 1989, J GEN VIROL, V70, P1261, DOI 10.1099/0022-1317-70-5-1261; LAMBERT PF, 1987, CELL, V50, P69, DOI 10.1016/0092-8674(87)90663-5; LEES E, 1990, J GEN VIROL, V71, P183, DOI 10.1099/0022-1317-71-1-183; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; OLTERSDORF T, 1987, J GEN VIROL, V68, P2933, DOI 10.1099/0022-1317-68-11-2933; PECORARO G, 1989, P NATL ACAD SCI USA, V86, P563, DOI 10.1073/pnas.86.2.563; PHELPS WC, 1987, J VIROL, V61, P1630, DOI 10.1128/JVI.61.5.1630-1638.1987; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; ROMANCZUK H, 1990, J VIROL, V64, P2849, DOI 10.1128/JVI.64.6.2849-2859.1990; ROMANCZUK H, 1991, J VIROL, V65, P2739, DOI 10.1128/JVI.65.5.2739-2744.1991; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPALHOLZ BA, 1985, CELL, V42, P183, DOI 10.1016/S0092-8674(85)80114-8; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; STANLEY MA, 1979, INT J CANCER, V24, P407, DOI 10.1002/ijc.2910240406; STERLING J, 1990, J VIROL, V64, P6305, DOI 10.1128/JVI.64.12.6305-6307.1990; STOREY A, 1990, J GEN VIROL, V71, P165, DOI 10.1099/0022-1317-71-1-165; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; THIERRY F, 1987, EMBO J, V6, P3391, DOI 10.1002/j.1460-2075.1987.tb02662.x; VANDENBRULE AJC, 1989, J MED VIROL, V29, P20, DOI 10.1002/jmv.1890290105; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989	51	21	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1992	7	3					459	465						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1312701				2022-12-17	WOS:A1992HK00500009
J	RAMEH, LE; ARMELIN, MCS				RAMEH, LE; ARMELIN, MCS			T-ANTIGENS ROLE IN POLYOMAVIRUS TRANSFORMATION - C-MYC BUT NOT C-FOS OR C-JUN EXPRESSION IS A TARGET FOR MIDDLE-T	ONCOGENE			English	Article							PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; EARLY-RESPONSE GENES; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; ONCOGENIC TRANSFORMATION; MOLECULAR-CLONING; PP60C-SRC KINASE; TRANSGENIC MICE; PHOSPHOLIPASE-C; EARLY PROTEINS	Polyoma virus (Py) causes neoplastic transformation in vitro and multiple tumors in vivo. The role played by large and middle T antigens (LT, MT) and their mechanisms of action are focused here. Py-transformed Balb-3T3 cells become independent of platelet-derived growth factor (PDGF) for growth. JE, c-fos, c-jun and c-myc are 'immediate early' genes induced in response to PDGF. To test whether these cellular genes play a role in malignant transformation by Py, we generated a number of transfectant cell lines overexpressing LT, MT or both. Characterization of these cell lines revealed that: (a) MT but not LT causes morphological transformation, ability to grow in PDGF-free plasma medium and ability to grow in agarose suspension; (b) cooperation between LT and MT is evident in vitro, however, high and simultaneous LT and MT expression does not warrant tumorigenic potential; (c) MT expression does not correlate with tumorigenic potential but alters the probability of eliciting tumors; (d) JE and c-myc (but not c-fos or c-jun) are constitutively expressed in MT transfectants. MT induction is followed by c-myc induction 1.5 h later. We conclude that some of the 'immediate-early' genes may play pivotal roles in Py transformation.	UNIV SAO PAULO,INST QUIM,DEPT BIOQUIM,CP 20780,BR-01498 SAO PAULO,BRAZIL	Universidade de Sao Paulo	ARMELIN, MCS (corresponding author), UNIV SAO PAULO,INST QUIM,DEPT BIOQUIM,CP 20780,BR-01498 SAO PAULO,BRAZIL.							ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ARMELIN HA, 1973, P NATL ACAD SCI USA, V70, P2702, DOI 10.1073/pnas.70.9.2702; ARMELIN MCS, 1985, COLD SPRING HARBOR C, V3, P195; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; BENJAMIN T, 1990, VIROLOGY, P317; BOUCHARD L, 1984, VIROLOGY, V135, P53, DOI 10.1016/0042-6822(84)90116-8; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; CHERINGTON V, 1986, P NATL ACAD SCI USA, V83, P4307, DOI 10.1073/pnas.83.12.4307; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; EK B, 1982, NATURE, V295, P419, DOI 10.1038/295419a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GELINAS C, 1989, VIROLOGY, V170, P193, DOI 10.1016/0042-6822(89)90366-8; GLENN GM, 1990, J VIROL, V64, P2193, DOI 10.1128/JVI.64.5.2193-2201.1990; GORGA FR, 1990, J VIROL, V64, P105, DOI 10.1128/JVI.64.1.105-112.1990; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; ITO Y, 1977, P NATL ACAD SCI USA, V74, P4666, DOI 10.1073/pnas.74.10.4666; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAPLAN DR, 1985, MOL CELL BIOL, V5, P1795, DOI 10.1128/MCB.5.7.1795; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; METCALF D, 1987, EMBO J, V6, P3703, DOI 10.1002/j.1460-2075.1987.tb02704.x; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MUSER J, 1989, ONCOGENE, V4, P1433; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; SONOBE MH, 1991, IN PRESS ONCOGENE; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WELHAM MJ, 1990, ONCOGENE, V5, P161; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5; ZULLO J, 1987, P NATL ACAD SCI USA, V84, P1210, DOI 10.1073/pnas.84.5.1210	55	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1049	1056						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1648700				2022-12-17	WOS:A1991GU62200022
J	WILLEMS, L; KETTMANN, R; BURNY, A				WILLEMS, L; KETTMANN, R; BURNY, A			THE AMINO-ACID (157-197) PEPTIDE SEGMENT OF BOVINE LEUKEMIA-VIRUS P34TAX ENCOMPASS A LEUCINE-RICH GLOBALLY NEUTRAL ACTIVATION DOMAIN	ONCOGENE			English	Note							TRANSCRIPTIONAL ACTIVATOR; MAMMALIAN-CELLS; FUNCTIONAL DISSECTION; GENE-EXPRESSION; TRANS-ACTIVATOR; GAL4; PROTEINS; YEAST; ELEMENTS; ESTROGEN	The specific DNA-binding Ga14 amino-terminal portion (amino acids 1 to 147) was fused to protein segments of BLV transactivator p34tax and tested for its capacity to activate CAT-gene expression in mammalian cells. The p34tax peptide segment 157 to 197 encompasses an activating region. The segment is approximately located in the middle of p34tax and is globally neutral (net charge zero). The tax (157-197) domain contains 24% of leucine residues, possibly involved in heterologous protein interactions.	UNIV BRUSSELS,DEPT MOLEC BIOL,B-1640 RHODE ST GENESE,BELGIUM; FAC AGRON GEMBLOUX,DEPT MOLEC BIOL,B-5030 GEMBLOUX,BELGIUM	University of Liege	WILLEMS, L (corresponding author), FAC AGRON GEMBLOUX,DEPT MOLEC BIOL,B-5800 GEMBLOUX,BELGIUM.			Willems, Luc/0000-0002-0563-2213				BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BURNY A, 1987, CANCER SURV, V6, P139; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DERSE D, 1987, J VIROL, V61, P2462, DOI 10.1128/JVI.61.8.2462-2471.1987; DERSE D, 1988, J VIROL, V62, P1115, DOI 10.1128/JVI.62.4.1115-1119.1988; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KETTMANN R, 1982, P NATL ACAD SCI-BIOL, V79, P2465, DOI 10.1073/pnas.79.8.2465; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MILLER JM, 1969, JNCI-J NATL CANCER I, V43, P1297; PORTETELLE D, 1978, ANN RECH VET, V9, P667; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAGATA N, 1985, P NATL ACAD SCI USA, V82, P677, DOI 10.1073/pnas.82.3.677; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WILLEMS L, 1987, EMBO J, V6, P3385, DOI 10.1002/j.1460-2075.1987.tb02661.x; WILLEMS L, 1987, VIROLOGY, V160, P55, DOI 10.1016/0042-6822(87)90043-2; WILLEMS L, 1989, VIROLOGY, V171, P615, DOI 10.1016/0042-6822(89)90633-8; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557	31	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					159	163						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1846955				2022-12-17	WOS:A1991EY03900023
J	HEBERLEIN, C; KAWAI, M; FRANZ, MJ; BECKENGESER, G; DANIEL, CP; OSTERTAG, W; STOCKING, C				HEBERLEIN, C; KAWAI, M; FRANZ, MJ; BECKENGESER, G; DANIEL, CP; OSTERTAG, W; STOCKING, C			RETROTRANSPOSONS AS MUTAGENS IN THE INDUCTION OF GROWTH AUTONOMY IN HEMATOPOIETIC-CELLS	ONCOGENE			English	Article							STIMULATING FACTOR GENE; A-PARTICLE GENE; BONE-MARROW CULTURES; NUCLEOTIDE-SEQUENCE; AUTOCRINE STIMULATION; INTERLEUKIN-3 GENE; SARCOMA-VIRUS; LINE WEHI-3B; LEUKEMIA; STEM	Factor-independent mutants of hematopoietic cells, especially of multipotent cells, are valuable tools to identify genes that regulate stem cell proliferation and differentiation and thus may be important in leukemogenesis. Factor-independent mutants from both myeloid precursor and hematopoietic stem cell lines were isolated. The frequency of such mutants in a given cell population was one to two orders of magnitude lower for the multipotent cell line FDC-Pmix (3.6 x 10(-9)) than for the myeloid precursors, FDC-P1-M (1.7 x 10(-8)) and D35 (2.2 x 10(-7)). Analysis of these mutants revealed several mechanisms by which growth autonomy was obtained, either with or without direct contribution of growth factor gene activation. The molecular basis of spontaneous activation of the Multi-CSF (Interleukin3) gene was determined and compared to activation of the GM-CSF gene in a previous study. Multi-CSF gene activation in both precursor and stem cells was caused by the insertion of an intracisternal A particle (IAP) provirus. In two independent mutants of the D35 cell line, activation of the Multi-CSF or the GM-CSF gene was caused by almost identical IAPs with a 99% homology in the U3 and R region of the long terminal repeat. This result demonstrates that only one class of IAPs, or perhaps a single provirus, is involved in transposition and gene activation in a particular cell line. A unique example of anti-sense promotion from an IAP provirus in one Multi-CSF mutant underlines the versatility of these elements as natural insertional mutagens.	UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY; AICHI MED UNIV,DEPT MICROBIOL,NAGAKUTE,AICHI 48011,JAPAN; CHRISTIE HOSP & HOLT RADIUM INST,PATERSON LAB,MANCHESTER M20 9BX,LANCS,ENGLAND	Heinrich Pette Institute; University of Hamburg; Aichi Medical University; Christie NHS Foundation Trust; Christie Hospital								AOTA S, 1987, GENE, V56, P1, DOI 10.1016/0378-1119(87)90153-3; Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BREINDL M, 1984, CELL, V38, P9, DOI 10.1016/0092-8674(84)90521-X; BROWDER TM, 1989, MOL CELL BIOL, V9, P204, DOI 10.1128/MCB.9.1.204; CHRISTY RJ, 1985, NUCLEIC ACIDS RES, V13, P289, DOI 10.1093/nar/13.1.289; CHRISTY RJ, 1988, MOL CELL BIOL, V8, P1093, DOI 10.1128/MCB.8.3.1093; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DUHRSEN U, 1988, LEUKEMIA, V2, P334; DUHRSEN U, 1988, LEUKEMIA, V2, P329; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FALZON M, 1988, J VIROL, V62, P4070, DOI 10.1128/JVI.62.11.4070-4077.1988; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GREENBERGER JS, 1980, VIROLOGY, V105, P425, DOI 10.1016/0042-6822(80)90043-4; HAEUPTLE MT, 1989, J CELL BIOL, V108, P1227, DOI 10.1083/jcb.108.4.1227; HOROWITZ M, 1984, EMBO J, V3, P2937, DOI 10.1002/j.1460-2075.1984.tb02235.x; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KLUGE NK, 1986, LEUKEMIA RES, V10, P187, DOI 10.1016/0145-2126(86)90041-X; KOLLEK R, 1984, J VIROL, V50, P717, DOI 10.1128/JVI.50.3.717-724.1984; KOURY MJ, 1982, NATURE, V299, P638, DOI 10.1038/299638a0; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LAKER C, 1989, MOL CELL BIOL, V9, P5746, DOI 10.1128/MCB.9.12.5746; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; METCALF D, 1984, HEMOPOIETIC COLONIES; MIYATAKE S, 1985, P NATL ACAD SCI USA, V82, P316, DOI 10.1073/pnas.82.2.316; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; NUSSE R, 1988, CELLULAR ONCOGENE AC, P95; ONO M, 1985, J VIROL, V55, P387, DOI 10.1128/JVI.55.2.387-394.1985; ONO M, 1986, J VIROL, V60, P589, DOI 10.1128/JVI.60.2.589-598.1986; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SHANNON MF, 1988, P NATL ACAD SCI USA, V85, P674, DOI 10.1073/pnas.85.3.674; SHENONG GLC, 1984, J VIROL, V49, P171, DOI 10.1128/JVI.49.1.171-177.1984; SKOWRONSKI J, 1986, COLD SPRING HARB SYM, V51, P457, DOI 10.1101/SQB.1986.051.01.055; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; SPOONCER E, 1984, NATURE, V310, P228, DOI 10.1038/310228a0; SPOONCER E, 1989, CURR TOP MICROBIOL I, V149, P108; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; SUEMATSU S, 1990, IN PRESS; TOKSOZ D, 1980, BLOOD, V55, P931; WONG GG, 1988, IMMUNOL TODAY, V9, P137, DOI 10.1016/0167-5699(88)91200-5; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798; WYKE JA, 1986, MOL CELL BIOL, V6, P959, DOI 10.1128/MCB.6.3.959; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0; YMER S, 1986, NUCLEIC ACIDS RES, V14, P5901, DOI 10.1093/nar/14.14.5901; YOUNG DC, 1987, J CLIN INVEST, V79, P100, DOI 10.1172/JCI112769	53	21	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1990	5	12					1799	1807						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET436	2178239				2022-12-17	WOS:A1990ET43600009
J	BOUCHER, P; PRIVALSKY, ML				BOUCHER, P; PRIVALSKY, ML			MAPPING OF FUNCTIONAL DOMAINS WITHIN THE V-ERB A ONCOGENE PROTEIN - THE REMNANTS OF THE HORMONE BINDING DOMAIN PLAY MULTIPLE, VITAL ROLES IN PROTEIN ACTION	ONCOGENE			English	Article											BOUCHER, P (corresponding author), UNIV CALIF DAVIS,DEPT MICROBIOL,DAVIS,CA 95616, USA.							BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERG JM, 1989, CELL, V57, P1065, DOI 10.1016/0092-8674(89)90042-1; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BIGLER J, 1988, MOL CELL BIOL, V8, P4155, DOI 10.1128/MCB.8.10.4155; BONDE BG, 1990, J VIROL, V64, P1314, DOI 10.1128/JVI.64.3.1314-1320.1990; BOUCHER P, 1988, J VIROL, V62, P534, DOI 10.1128/JVI.62.2.534-544.1988; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DANG CV, 1989, J BIOL CHEM, V264, P18019; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DENIS M, 1988, NATURE, V333, P686, DOI 10.1038/333686a0; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; EUL J, 1989, EMBO J, V8, P83, DOI 10.1002/j.1460-2075.1989.tb03351.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FLUG F, 1987, J BIOL CHEM, V262, P6373; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORREST D, IN PRESS ONCOGENE; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HORROWITZ ZD, 1989, MOL ENDOCRINOL, V3, P148; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KLEINHITPASS L, 1989, MOL CELL BIOL, V9, P43, DOI 10.1128/MCB.9.1.43; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAVIN TN, 1988, J BIOL CHEM, V263, P9418; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MEISELD R, 1987, SCIENCE, V263, P423; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; NORMAN MF, 1989, J BIOL CHEM, V264, P12063; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHAUER M, 1989, P NATL ACAD SCI USA, V86, P1123, DOI 10.1073/pnas.86.4.1123; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZHENG SY, 1987, J BIOL CHEM, V262, P6313	48	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1990	5	9					1303	1311						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	2170895				2022-12-17	WOS:A1990EC24100005
J	PATSCHINSKY, T; DEPPERT, W				PATSCHINSKY, T; DEPPERT, W			PHOSPHORYLATION OF P53 IN PRIMARY, IMMORTALIZED AND TRANSFORMED BALB/C MOUSE CELLS	ONCOGENE			English	Note											PATSCHINSKY, T (corresponding author), UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY.							CHEN S, 1983, P NATL ACAD SCI-BIOL, V80, P5670, DOI 10.1073/pnas.80.18.5670; CRAWFORD L, 1983, INT REV EXP PATHOL, V25, P1; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DEPPERT W, 1989, ONCOGENE, V4, P1103; DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453; DEPPERT W, 1986, MOL CELL BIOL, V6, P223; DEPPERT W, 1989, NATO ASI SERIES H, V34, P399; ELIYAHU D, 1988, ONCOGENE, V3, P313; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALEVY O, 1989, MOL CELL BIOL, V9, P3385, DOI 10.1128/MCB.9.8.3385; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, ONCOGENE HDB, P403; KLEIN G, 1982, ADV VIRAL ONCOLOGY, V2; LEMISCHKA IR, 1981, J MOL BIOL, V151, P101, DOI 10.1016/0022-2836(81)90223-0; Maniatis T., 1982, MOL CLONING; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MORA PT, 1980, NATURE, V288, P722, DOI 10.1038/288722a0; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; PATSCHINSKY T, 1988, ONCOGENE, V3, P357; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; ROTTER V, 1985, ADV CANCER RES, V43, P113, DOI 10.1016/S0065-230X(08)60944-6; ROTTER V, 1983, P NATL ACAD SCI-BIOL, V80, P2613, DOI 10.1073/pnas.80.9.2613; RUBIN H, 1989, P NATL ACAD SCI USA, V86, P1860, DOI 10.1073/pnas.86.6.1860; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SHOHAT O, 1987, ONCOGENE, V1, P277; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; STEINMEYER K, 1988, ONCOGENE, V3, P501; STURZBECHER HW, 1987, VIROLOGY, V160, P445; VANROY F, 1981, J VIROL, V40, P28, DOI 10.1128/JVI.40.1.28-44.1981; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	40	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1990	5	7					1071	1076						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	2142761				2022-12-17	WOS:A1990DP41500019
J	MILNER, J; GAMBLE, J; COOK, A				MILNER, J; GAMBLE, J; COOK, A			P53 IS ASSOCIATED WITH A 35KD PROTEIN IN CELLS TRANSFORMED BY SIMIAN VIRUS-40	ONCOGENE			English	Note											MILNER, J (corresponding author), UNIV CAMBRIDGE,DEPT PATHOL,DIV VIROL,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND.							BOSSERT A, 1985, J VIROL, V56, P325, DOI 10.1128/JVI.56.1.325-327.1985; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; COFFMAN RL, 1981, J EXP MED, V153, P269, DOI 10.1084/jem.153.2.269; CRAWFORD L, 1983, INT REV EXP PATHOL, V25, P1; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GRUSSENMEYER T, 1987, J VIROL, V61, P3902, DOI 10.1128/JVI.61.12.3902-3909.1987; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KACZMAREK L, 1986, EXP CELL RES, V162, P268, DOI 10.1016/0014-4827(86)90445-3; KLEIN G, 1982, ADV VIRAL ONCOLOGY, V2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MCCORMICK F, 1980, J VIROL, V34, P213, DOI 10.1128/JVI.34.1.213-224.1980; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; METCALFE S, 1984, BRIT J CANCER, V49, P337, DOI 10.1038/bjc.1984.53; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1985, VIROLOGY, V147, P206, DOI 10.1016/0042-6822(85)90240-5; MILNER J, 1986, VIROLOGY, V150, P265, DOI 10.1016/0042-6822(86)90286-2; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; POHL J, 1988, MOL CELL BIOL, V8, P2078, DOI 10.1128/MCB.8.5.2078; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; ROTTER V, 1985, ADV CANCER RES, V43, P113, DOI 10.1016/S0065-230X(08)60944-6; RUNDELL K, 1987, J VIROL, V61, P1240, DOI 10.1128/JVI.61.4.1240-1243.1987; RUSCETTI SK, 1983, J VIROL, V46, P1022, DOI 10.1128/JVI.46.3.1022-1026.1983; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; STURZBECHER HW, 1987, ONCOGENE, V1, P201; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	43	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1989	4	5					665	668						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U7688	2542865				2022-12-17	WOS:A1989U768800019
J	EICK, D; POLACK, A; KOFLER, E; BORNKAMM, GW				EICK, D; POLACK, A; KOFLER, E; BORNKAMM, GW			THE BLOCK OF ELONGATION IN C-MYC EXON-1 IS ABOLISHED IN BURKITTS-LYMPHOMA CELL-LINES WITH VARIANT TRANSLOCATION	ONCOGENE			English	Article											EICK, D (corresponding author), UNIV FREIBURG,INST MED MIKROBIOL & HYG,VIROL ABT,HERMANN HERDER STR 11,D-7800 FREIBURG,FED REP GER.							AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BORNKAMM GW, 1980, BLUT, V40, P167, DOI 10.1007/BF01008574; BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; BOYM A, 1968, SCAND J CLIN LAB S97, V21, P77; BROOME HE, 1987, MOL CELL BIOL, V7, P2988, DOI 10.1128/MCB.7.8.2988; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHUNG J, 1987, CELL, V51, P1001, DOI 10.1016/0092-8674(87)90586-1; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DENNY CT, 1985, MOL CELL BIOL, V5, P3199, DOI 10.1128/MCB.5.11.3199; EICK D, 1987, ONCOGENE, V2, P61; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERRE F, 1987, ONCOGENE, V1, P387; FONATSCH C, 1982, INT J CANCER, V30, P321, DOI 10.1002/ijc.2910300311; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GAZIN C, 1986, EMBO J, V5, P2241, DOI 10.1002/j.1460-2075.1986.tb04491.x; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; HALUSKA FG, 1986, NATURE, V324, P158, DOI 10.1038/324158a0; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HARTL P, 1987, MOL CELL BIOL, V7, P2037, DOI 10.1128/MCB.7.6.2037; HOLLIS GF, 1984, NATURE, V307, P752, DOI 10.1038/307752a0; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P3283, DOI 10.1073/pnas.71.8.3283; LACY J, 1987, P NATL ACAD SCI USA, V84, P5838, DOI 10.1073/pnas.84.16.5838; LENOIR GM, 1982, NATURE, V298, P474, DOI 10.1038/298474a0; LENOIR GM, 1985, IARC SCI PUBL, V60, P309; LEY TJ, 1982, P NATL ACAD SCI-BIOL, V79, P4775, DOI 10.1073/pnas.79.15.4775; MANIATIS T, 1982, MOL CLONING LABORATO; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MENGLEGAW L, 1987, EMBO J, V6, P1959, DOI 10.1002/j.1460-2075.1987.tb02458.x; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NEPVEU A, 1987, ONCOGENE, V1, P243; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; POLACK A, 1987, EMBO J, V6, P2959, DOI 10.1002/j.1460-2075.1987.tb02601.x; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RUPPERT C, 1986, EMBO J, V5, P1897, DOI 10.1002/j.1460-2075.1986.tb04442.x; SCHNEIDERSCHAULIES J, 1987, EUR J IMMUNOL, V17, P713, DOI 10.1002/eji.1830170521; SHOWE LC, 1987, P NATL ACAD SCI USA, V84, P2824, DOI 10.1073/pnas.84.9.2824; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUN LK, 1986, NUCLEIC ACIDS RES, V14, P4037, DOI 10.1093/nar/14.10.4037; SZAJNERT MF, 1987, NUCLEIC ACIDS RES, V15, P4553, DOI 10.1093/nar/15.11.4553; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; WALDMANN TA, 1982, ADV IMMUNOL, V32, P1, DOI 10.1016/S0065-2776(08)60720-8; WIMAN KG, 1984, P NATL ACAD SCI-BIOL, V81, P6798, DOI 10.1073/pnas.81.21.6798; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x	52	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					397	403						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	3078949				2022-12-17	WOS:A1988Q773900007
J	KNIGHT, J; BEUG, H; MARSHALL, J; HAYMAN, MJ				KNIGHT, J; BEUG, H; MARSHALL, J; HAYMAN, MJ			ABNORMAL GLYCOSYLATION OF THE ENV-SEA ONCOGENE PRODUCT INHIBITS ITS PROTEOLYTIC CLEAVAGE AND BLOCKS ITS TRANSFORMING ABILITY	ONCOGENE			English	Article									SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794; EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-6900 HEIDELBERG,FED REP GER	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; European Molecular Biology Laboratory (EMBL)				Marshall, John/0000-0003-1361-2869	NATIONAL CANCER INSTITUTE [P01CA028146, R01CA042573] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42573, CA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENEDICT SH, 1985, VIROLOGY, V145, P154, DOI 10.1016/0042-6822(85)90210-7; BEUG H, 1986, J VIROL, V57, P1127, DOI 10.1128/JVI.57.3.1127-1138.1986; BEUG H, 1985, VIROLOGY, V145, P141, DOI 10.1016/0042-6822(85)90209-0; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; BEUG H, 1982, J CELL PHYSL, V115, P295; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BOSCH JV, 1982, VIROLOGY, V119, P122; BOSCH JV, 1984, VIROLOGY, V132, P95; CHAN AML, 1987, ONCOGENE, V1, P229; DEAN M, 1985, NATURE, V318, P285; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FLIESLER SJ, 1986, P NATL ACAD SCI USA, V83, P6435, DOI 10.1073/pnas.83.17.6435; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; GROSS V, 1983, J BIOL CHEM, V258, P12201; HADWIGER A, 1986, EMBO J, V5, P689, DOI 10.1002/j.1460-2075.1986.tb04268.x; HAYMAN M, 1978, VIROLOGY, V85, P475, DOI 10.1016/0042-6822(78)90454-3; HAYMAN MJ, 1986, VIROLOGY, V150, P270, DOI 10.1016/0042-6822(86)90287-4; HAYMAN MJ, 1984, NATURE, V309, P460, DOI 10.1038/309460a0; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; HORI H, 1984, ARCH BIOCHEM BIOPHYS, V228, P525, DOI 10.1016/0003-9861(84)90019-5; KOWENZ E, 1987, MODERN TRENDS HUMAN, V11, P119; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; LYMAN SD, 1987, MOL CELL BIOL, V7, P3287, DOI 10.1128/MCB.7.9.3287; MCDOWELL W, 1987, VIROLOGY, V161, P37, DOI 10.1016/0042-6822(87)90168-1; NICHOLS EJ, 1985, MOL CELL BIOL, V5, P3467, DOI 10.1128/MCB.5.12.3467; NICKAMEYER WS, 1985, J VIROL, V53, P879; PALMERI S, 1982, VIROLOGY, V123, P209; PAN YT, 1983, BIOCHEMISTRY-US, V22, P3975, DOI 10.1021/bi00285a038; PEREZ LG, 1987, J VIROL, V61, P1609, DOI 10.1128/JVI.61.5.1609-1614.1987; PEYRIERAS N, 1983, EMBO J, V2, P823, DOI 10.1002/j.1460-2075.1983.tb01509.x; REPP R, 1985, J BIOL CHEM, V260, P5873; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; ROYERPOKORA B, 1978, CELL, V13, P751, DOI 10.1016/0092-8674(78)90225-8; SAUL R, 1985, P NATL ACAD SCI USA, V82, P93, DOI 10.1073/pnas.82.1.93; SCHLESSINGER S, 1987, VIRUS RES, V2, P139; SCHMIDT JA, 1985, EMBO J, V4, P105, DOI 10.1002/j.1460-2075.1985.tb02323.x; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; Stubbs EL, 1935, J EXP MED, V61, P593, DOI 10.1084/jem.61.5.593; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0	43	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1988	2	4					317	326						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	2834683				2022-12-17	WOS:A1988M947200003
J	KOENEN, M; SIPPEL, AE; TRACHMANN, C; BISTER, K				KOENEN, M; SIPPEL, AE; TRACHMANN, C; BISTER, K			PRIMARY STRUCTURE OF THE CHICKEN C-MIL PROTEIN - IDENTIFICATION OF DOMAINS SHARED WITH OR ABSENT FROM THE RETROVIRAL V-MIL PROTEIN	ONCOGENE			English	Article									MAX PLANCK INST MOLEC GENET,OTTO WARBURG LAB,D-1000 BERLIN 33,FED REP GER; UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,NEUENHEIMER FELD 282,D-6900 HEIDELBERG,FED REP GER	Max Planck Society; Ruprecht Karls University Heidelberg			Bister, Klaus/AFA-9400-2022	Bister, Klaus/0000-0001-6545-5653				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BIEGALKE B, 1987, J VIROL, V61, P1949, DOI 10.1128/JVI.61.6.1949-1956.1987; BISTER K, 1986, ADV CANCER RES, V47, P99, DOI 10.1016/S0065-230X(08)60199-2; BISTER K, 1987, ADV VIRAL ONCOL, V6, P45; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BRYANT DL, 1984, MOL CELL BIOL, V4, P862, DOI 10.1128/MCB.4.5.862; CARPENTER D, 1987, NATURE, V325, P107, DOI 10.1038/325107a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLL J, 1983, EMBO J, V2, P2189, DOI 10.1002/j.1460-2075.1983.tb01722.x; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DOZIER C, 1987, MOL CELL BIOL, V7, P1995, DOI 10.1128/MCB.7.5.1995; FLORDELLIS CS, 1985, VIROLOGY, V141, P267, DOI 10.1016/0042-6822(85)90257-0; FUKUI M, 1987, MOL CELL BIOL, V7, P1776, DOI 10.1128/MCB.7.5.1776; GALIBERT F, 1984, EMBO J, V3, P1333, DOI 10.1002/j.1460-2075.1984.tb01972.x; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOELET P, 1982, P NATL ACAD SCI-BIOL, V79, P5818, DOI 10.1073/pnas.79.19.5818; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ISHIKAWA F, 1986, P NATL ACAD SCI USA, V83, P3209, DOI 10.1073/pnas.83.10.3209; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; JANSEN HW, 1985, VIROLOGY, V142, P248, DOI 10.1016/0042-6822(85)90333-2; JANSEN HW, 1983, J VIROL, V48, P61, DOI 10.1128/JVI.48.1.61-73.1983; JANSEN HW, 1985, VIROLOGY, V143, P359, DOI 10.1016/0042-6822(85)90376-9; JANSEN HW, 1984, VIROLOGY, V137, P217, DOI 10.1016/0042-6822(84)90028-X; JANSEN HW, 1983, EMBO J, V2, P1969, DOI 10.1002/j.1460-2075.1983.tb01686.x; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KAN NC, 1983, P NATL ACAD SCI-BIOL, V80, P6566, DOI 10.1073/pnas.80.21.6566; KAN NC, 1984, P NATL ACAD SCI-BIOL, V81, P3000, DOI 10.1073/pnas.81.10.3000; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; LAPEYRE B, 1985, GENE, V37, P215, DOI 10.1016/0378-1119(85)90275-6; MANIATIS T, 1982, MOL CLONING LABORATO; MCDONNELL DP, 1987, SCIENCE, V235, P1214, DOI 10.1126/science.3029866; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MOELDERS H, 1985, EMBO (European Molecular Biology Organization) Journal, V4, P693; MURRAY AW, 1987, TRENDS BIOCHEM SCI, V12, P53, DOI 10.1016/0968-0004(87)90026-0; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; PALMIERI S, 1987, J VIROL, V61, P1717, DOI 10.1128/JVI.61.5.1717-1721.1987; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PATSCHINSKY T, 1986, MOL CELL BIOL, V6, P739, DOI 10.1128/MCB.6.2.739; RAMSAY G, 1982, EMBO J, V1, P1111, DOI 10.1002/j.1460-2075.1982.tb01305.x; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; SUTRAVE P, 1984, NATURE, V309, P85, DOI 10.1038/309085a0; TAHIRA T, 1987, NUCLEIC ACIDS RES, V15, P4809, DOI 10.1093/nar/15.12.4809; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; VANBEVEREN C, 1986, CURR TOP MICROBIOL, V123, P73; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WALTHER N, 1986, VIROLOGY, V154, P219, DOI 10.1016/0042-6822(86)90444-7; WALTHER N, 1985, J VIROL, V54, P576, DOI 10.1128/JVI.54.2.576-585.1985; WEINBERGER C, 1985, NATURE, V318, P670, DOI 10.1038/318670a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0	62	21	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1988	2	2					179	185						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	3285296				2022-12-17	WOS:A1988M086000012
J	Yu, ZY; Jiang, XY; Qin, L; Deng, HX; Wang, JL; Ren, W; Li, HB; Zhao, L; Liu, HX; Yan, H; Shi, WG; Wang, Q; Luo, CJ; Long, B; Zhou, HN; Sun, H; Jiao, ZY				Yu, Zeyuan; Jiang, Xiangyan; Qin, Long; Deng, Haixiao; Wang, Jianli; Ren, Wen; Li, Hongbin; Zhao, Lei; Liu, Huanxiang; Yan, Hong; Shi, Wengui; Wang, Qi; Luo, Changjiang; Long, Bo; Zhou, Huinian; Sun, Hui; Jiao, Zuoyi			A novel UBE2T inhibitor suppresses Wnt/beta-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination	ONCOGENE			English	Article							CONJUGATING ENZYME UBE2T; E2; WNT; METHYLATION; PROMOTER; PATHWAY; FANCD2; BINDS; DNA	Dysregulation of the Wnt/beta-catenin signaling pathway is critically involved in gastric cancer (GC) progression. However, current Wnt pathway inhibitors being studied in preclinical or clinical settings for other cancers such as colorectal and pancreatic cancers are either too cytotoxic or insufficiently efficacious for GC. Thus, we screened new potent targets from beta-catenin destruction complex associated with GC progression from clinical samples, and found that scaffolding protein RACK1 deficiency plays a significant role in GC progression, but not APC, AXIN, and GSK3 beta. Then, we identified its upstream regulator UBE2T which promotes GC progression via hyperactivating the Wnt/beta-catenin signaling pathway through the ubiquitination and degradation of RACK1 at the lysine K172, K225, and K257 residues independent of an E3 ligase. Indeed, UBE2T protein level is negatively associated with prognosis in GC patients, suggesting that UBE2T is a promising target for GC therapy. Furthermore, we identified a novel UBE2T inhibitor, M435-1279, and suggested that M435-1279 acts inhibit the Wnt/beta-catenin signaling pathway hyperactivation through blocking UBE2T-mediated degradation of RACK1, resulting in suppression of GC progression with lower cytotoxicity in the meantime. Overall, we found that increased UBE2T levels promote GC progression via the ubiquitination of RACK1 and identified a novel potent inhibitor providing a balance between growth inhibition and cytotoxicity as well, which offer a new opportunity for the specific GC patients with aberrant Wnt/beta-catenin signaling.	[Yu, Zeyuan; Jiang, Xiangyan; Deng, Haixiao; Luo, Changjiang; Long, Bo; Zhou, Huinian; Jiao, Zuoyi] Lanzhou Univ, Hosp 2, Dept Gen Surg, Lanzhou 730000, Gansu, Peoples R China; [Qin, Long; Wang, Jianli; Ren, Wen; Li, Hongbin; Zhao, Lei; Shi, Wengui; Sun, Hui; Jiao, Zuoyi] Lanzhou Univ, Hosp 2, Cuiying Expt Ctr, Lanzhou 730000, Gansu, Peoples R China; [Liu, Huanxiang] Lanzhou Univ, Sch Pharm, Lanzhou 730000, Gansu, Peoples R China; [Yan, Hong] Lanzhou Univ, Hosp 2, Dept Pathol, Lanzhou 730000, Gansu, Peoples R China; [Wang, Qi] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Canc Ctr, Boston, MA 02215 USA	Lanzhou University; Lanzhou University; Lanzhou University; Lanzhou University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Jiao, ZY (corresponding author), Lanzhou Univ, Hosp 2, Dept Gen Surg, Lanzhou 730000, Gansu, Peoples R China.; Sun, H; Jiao, ZY (corresponding author), Lanzhou Univ, Hosp 2, Cuiying Expt Ctr, Lanzhou 730000, Gansu, Peoples R China.	yaohy04@126.com; jiaozy@lzu.edu.cn	ZHOU, Huinian/AAD-9279-2022	Liu, Huanxiang/0000-0002-9284-3667; Jiang, Xiangyan/0000-0002-2685-2899; Jiao, Zuoyi/0000-0003-1942-0905	National Natural Science Foundation of China [31670847]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (31670847).	Abdi E, 2019, CANCER MED-US, V8, P6114, DOI 10.1002/cam4.2497; Ajani JA, 2016, J NATL COMPR CANC NE, V14, P1286, DOI 10.6004/jnccn.2016.0137; Al-Batran SE, 2019, LANCET, V393, P1948, DOI 10.1016/S0140-6736(18)32557-1; Alagpulinsa DA, 2019, BLOOD ADV, V3, P3968, DOI 10.1182/bloodadvances.2019000181; Alpi A, 2007, MOL CELL BIOL, V27, P8421, DOI 10.1128/MCB.00504-07; Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Bang YJ, 2010, LANCET, V376, P1302; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cats A, 2018, LANCET ONCOL, V19, P616, DOI 10.1016/S1470-2045(18)30132-3; Chiurillo MA, 2015, WORLD J EXP MED, V5, P84, DOI [DOI 10.5493/WJEM.V5.I2.84, 10.5493/wjem.v5.i2.84]; Clement G, 2004, CANCER RES, V64, P6867, DOI 10.1158/0008-5472.CAN-03-2503; Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012; Day JP, 2018, FUTUR SCI OA, V4, DOI 10.4155/fsoa-2018-0022; Deng YZ, 2012, GASTROENTEROLOGY, V142, P812, DOI 10.1053/j.gastro.2011.12.046; Dzobo K, 2019, OMICS, V23, P517, DOI 10.1089/omi.2019.0147; Fischer AS, 2019, BIOMEDICINES, V7, DOI 10.3390/biomedicines7020044; Flanagan DJ, 2019, CANCER RES, V79, P5901, DOI 10.1158/0008-5472.CAN-19-1362; Fomenkov A, 2004, CELL CYCLE, V3, P1285, DOI 10.4161/cc.3.10.1155; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Gomez-Martin C, 2012, J CLIN PATHOL, V65, P751, DOI 10.1136/jclinpath-2012-200774; Jung YS, 2020, EXP MOL MED, V52, P183, DOI 10.1038/s12276-020-0380-6; Lee DG, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5423; Liu LL, 2019, CANCER MANAG RES, V11, P8359, DOI 10.2147/CMAR.S202631; Liu NN, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2351-9; Longerich S, 2009, J BIOL CHEM, V284, P23182, DOI 10.1074/jbc.C109.038075; Luo CJ, 2017, ONCOTARGET, V8, P32639, DOI 10.18632/oncotarget.15947; Machida YJ, 2006, MOL CELL, V23, P589, DOI 10.1016/j.molcel.2006.06.024; Mao J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.515; Mazzoni SM, 2014, CANCER LETT, V355, P1, DOI 10.1016/j.canlet.2014.09.018; Morreale FE, 2017, J MED CHEM, V60, P8183, DOI 10.1021/acs.jmedchem.7b01071; Morreale FE, 2017, J MED CHEM, V60, P4093, DOI 10.1021/acs.jmedchem.7b00147; Murata-Kamiya N, 2007, ONCOGENE, V26, P4617, DOI 10.1038/sj.onc.1210251; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; Palle J, 2020, DRUGS, V80, P401, DOI 10.1007/s40265-020-01272-5; Pan KF, 2008, WORLD J GASTROENTERO, V14, P1570, DOI 10.3748/wjg.14.1570; Perez-Pena J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17836-7; Rickman KA, 2015, CELL REP, V12, P35, DOI 10.1016/j.celrep.2015.06.014; Sadowski M, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-19; Tan CQ, 2014, PHARMACOECONOMICS, V32, P235, DOI 10.1007/s40273-013-0065-2; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Ueki T, 2009, CANCER RES, V69, P8752, DOI 10.1158/0008-5472.CAN-09-1809; van Kappel EC, 2017, BRIT J PHARMACOL, V174, P4575, DOI 10.1111/bph.13922; Vila IK, 2017, CANCER CELL, V31, P208, DOI 10.1016/j.ccell.2017.01.003; Voloshanenko O, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3610; Yang HJ, 2018, GASTRIC CANCER, V21, P237, DOI 10.1007/s10120-017-0741-6; Yin J, 2020, J ENVIRON SCI, V89, P65, DOI 10.1016/j.jes.2019.09.025	47	20	22	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2021	40	5					1027	1042		10.1038/s41388-020-01572-w	http://dx.doi.org/10.1038/s41388-020-01572-w		DEC 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC5NB	33323973	hybrid, Green Published			2022-12-17	WOS:000599126500004
J	Suo, DQ; Wang, ZF; Li, L; Chen, QY; Zeng, TT; Liu, RY; Yun, JP; Guan, XY; Li, Y				Suo, Daqin; Wang, Zifeng; Li, Lei; Chen, Qingyun; Zeng, Tingting; Liu, Ranyi; Yun, Jingping; Guan, Xin-Yuan; Li, Yan			HOXC10 upregulation confers resistance to chemoradiotherapy in ESCC tumor cells and predicts poor prognosis	ONCOGENE			English	Article							GENE-EXPRESSION; DNA-REPAIR; CANCER; ACTIVATION; OVEREXPRESSION; CHEMOTHERAPY; INHIBITION; INVASION	Esophageal squamous cell carcinoma (ESCC) is a malignant disease and is a common cause of death in China. By performing an integrative study investigating public databases and clinical samples collected by our group, we found that HOXC10 (homeobox C10) is upregulated in ESCC tumor tissues compared with nontumor tissues and that the upregulation of HOXC10 is correlated with the poor prognosis of patients with ESCC. The enforced expression of HOXC10 promoted ESCC cell proliferation in vitro and in vivo. Our study revealed that HOXC10 could bind the promoter region of human Erb-b2 receptor tyrosine kinase 3 (ERBB3/HER3) and activate the PI3K/AKT pathway. In addition, by immunoprecipitation and mass spectrometry analysis, we found that HOXC10 could bind X-ray repair cross complementing 6 (Ku70) and accelerate the DNA repair mechanism via the nonhomologous end-joining (NHEJ) pathway. We further evaluated HOXC10 expression in ESCC patients receiving adjuvant radiotherapy or platinum-based chemotherapy. The results demonstrate that HOXC10 upregulation predicts the poor prognosis of ESCC patients receiving adjuvant radiotherapy or chemotherapy. Our study reveals that HOXC10 upregulation reflects the poor prognosis of ESCC patients and directs the selection of postoperative therapy regimens.	[Suo, Daqin; Wang, Zifeng; Li, Lei; Chen, Qingyun; Zeng, Tingting; Liu, Ranyi; Yun, Jingping; Guan, Xin-Yuan; Li, Yan] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou, Peoples R China; [Li, Lei; Guan, Xin-Yuan] Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; University of Hong Kong	Guan, XY; Li, Y (corresponding author), Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou, Peoples R China.; Guan, XY (corresponding author), Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China.	xyguan@hku.hk; liy6@mail.sysu.edu.cn		Li, Yan/0000-0002-8856-4083	National Key R&D Program of China [2017YFC1309000]; NSFC [81672357, 81871903, 81772554]; Open funds of State Key Laboratory of Oncology in South China [HN2019-06]	National Key R&D Program of China; NSFC(National Natural Science Foundation of China (NSFC)); Open funds of State Key Laboratory of Oncology in South China	This work was supported by National Key R&D Program of China (2017YFC1309000), NSFC (81672357, 81871903, and 81772554), and Open funds of State Key Laboratory of Oncology in South China (HN2019-06).	Akbas GE, 2004, BIOL REPROD, V70, P39, DOI 10.1095/biolreprod.102.014969; Bedenne L, 2007, J CLIN ONCOL, V25, P1160, DOI 10.1200/JCO.2005.04.7118; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cantile M, 2003, ONCOGENE, V22, P6462, DOI 10.1038/sj.onc.1206808; Cao MF, 2019, CANCER BIOL MED, V16, P595, DOI 10.20892/j.issn.2095-3941.2018.0277; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chu MC, 2004, CANCER BIOL THER, V3, P568, DOI 10.4161/cbt.3.6.848; CILLO C, 1992, INT J CANCER, V51, P892, DOI 10.1002/ijc.2910510610; Dai BW, 2019, J CANCER, V10, P4540, DOI 10.7150/jca.30645; Damia G, 2019, CANCERS, V11, DOI 10.3390/cancers11010119; de Stanchina E, 2000, J MOL BIOL, V299, P667, DOI 10.1006/jmbi.2000.3782; DEVITA G, 1993, EUR J CANCER, V29A, P887, DOI 10.1016/S0959-8049(05)80432-0; FAIELLA A, 1994, P NATL ACAD SCI USA, V91, P5335, DOI 10.1073/pnas.91.12.5335; Feng XY, 2015, MOL BIOSYST, V11, P2946, DOI 10.1039/c5mb00253b; Finn RS, 2019, CLIN CANCER RES, V19, P751; Hafner A, 2019, NAT REV MOL CELL BIO, V20, P199, DOI 10.1038/s41580-019-0110-x; Hostikka SL, 2009, INT J BIOL SCI, V5, P397; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jain AK, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.158360; Koyama FC, 2018, BRIT J SURG, V105, pE192, DOI 10.1002/bjs.10695; Lagergren J, 2017, LANCET, V390, P2383, DOI 10.1016/S0140-6736(17)31462-9; Leng X, 2019, ANN SURG, V12, P4932; Li JF, 2019, J WATER REUSE DESAL, V9, P1, DOI 10.2166/wrd.2017.019; Li S, 2017, ONCOTARGET, V8, P88974, DOI 10.18632/oncotarget.21634; Li Y, 2011, CANCER RES, V71, P6106, DOI 10.1158/0008-5472.CAN-10-4291; Lieber MR, 2010, ANNU REV BIOCHEM, V79, P181, DOI 10.1146/annurev.biochem.052308.093131; Lin DC, 2018, GASTROENTEROLOGY, V154, P374, DOI 10.1053/j.gastro.2017.06.066; Ma J, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-105; Ma M, 2020, MOL CELL PROBE, V49, DOI 10.1016/j.mcp.2019.101491; Miwa T, 2019, ANN SURG ONCOL, V26, P1535, DOI 10.1245/s10434-019-07166-5; Nemoz C, 2018, NAT STRUCT MOL BIOL, V25, P971, DOI 10.1038/s41594-018-0133-6; Ohashi S, 2015, GASTROENTEROLOGY, V149, P1700, DOI 10.1053/j.gastro.2015.08.054; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Ponz-Sarvise M, 2019, CLIN CANCER RES, V25, P11; Sadik H, 2016, CANCER RES, V76, P4443, DOI 10.1158/0008-5472.CAN-16-0774; Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Takahashi O, 2007, ONCOL REP, V17, P753; Tan ZY, 2018, THERANOSTICS, V8, P5143, DOI 10.7150/thno.27310; Tang XL, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00557; Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430; Waltregny D, 2002, PROSTATE, V50, P162, DOI 10.1002/pros.10045; Wang C, 2013, INT J RADIAT ONCOL, V86, P440, DOI 10.1016/j.ijrobp.2013.01.011; Wang XC, 2019, CLIN CANCER RES, V25, P4567, DOI 10.1158/1078-0432.CCR-18-3735; Yan T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09255-1; Yang G, 2018, NUCLEIC ACIDS RES, V46, P3446, DOI 10.1093/nar/gky088; Yang H, 2018, J CLIN ONCOL, V36, P2796, DOI 10.1200/JCO.2018.79.1483; Yao S, 2018, BIOCHEM BIOPH RES CO, V501, P628, DOI 10.1016/j.bbrc.2018.05.019; Zhang LZ, 2017, CHINESE J CANCER RES, V29, P149, DOI 10.21147/j.issn.1000-9604.2017.02.08	50	20	20	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2020	39	32					5441	5454		10.1038/s41388-020-1375-4	http://dx.doi.org/10.1038/s41388-020-1375-4		JUN 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW4DS	32587398				2022-12-17	WOS:000543299500001
J	Koyen, AE; Madden, MZ; Park, D; Minten, EV; Kapoor-Vazirani, P; Werner, E; Pfister, NT; Haji-Seyed-Javadi, R; Zhang, H; Xu, J; Deng, N; Duong, DM; Pecen, TJ; Frazier, Z; Nagel, ZD; Lazaro, JB; Mouw, KW; Seyfried, NT; Moreno, CS; Owonikoko, TK; Deng, XM; Yu, DS				Koyen, Allyson E.; Madden, Matthew Z.; Park, Dongkyoo; Minten, Elizabeth, V; Kapoor-Vazirani, Priya; Werner, Erica; Pfister, Neil T.; Haji-Seyed-Javadi, Ramona; Zhang, Hui; Xu, Jie; Deng, Nikita; Duong, Duc M.; Pecen, Turner J.; Frazier, Zoe; Nagel, Zachary D.; Lazaro, Jean-Bernard; Mouw, Kent W.; Seyfried, Nicholas T.; Moreno, Carlos S.; Owonikoko, Taofeek K.; Deng, Xingming; Yu, David S.			EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair	ONCOGENE			English	Article							OVARIAN-CANCER CELLS; GROUP PROTEIN EZH2; LUNG-CANCER; IN-VIVO; NONCANONICAL FUNCTION; SELECTIVE-INHIBITION; GENE-EXPRESSION; DNA-REPAIR; POLYCOMB; METHYLATION	Small cell lung cancer (SCLC) is a highly aggressive malignancy with poor outcomes associated with resistance to cisplatin-based chemotherapy. Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of polycomb repressive complex 2 (PRC2), which silences transcription through trimethylation of histone H3 lysine 27 (H3K27me3) and has emerged as an important therapeutic target with inhibitors targeting its methyltransferase activity under clinical investigation. Here, we show that EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair (NER) and govern cisplatin resistance in SCLC. Using a synthetic lethality screen, we identified important regulators of cisplatin resistance in SCLC cells, including EZH2. EZH2 depletion causes cellular cisplatin and UV hypersensitivity in an epistatic manner with DDB1-DDB2. EZH2 complexes with DDB1-DDB2 and promotes DDB2 stability by impairing its ubiquitination independent of methyltransferase activity or PRC2, thereby facilitating DDB2 localization to cyclobutane pyrimidine dimer crosslinks to govern their repair. Furthermore, targeting EZH2 for depletion with DZNep strongly sensitizes SCLC cells and tumors to cisplatin. Our findings reveal a non-catalytic and PRC2-independent function for EZH2 in promoting NER through DDB2 stabilization, suggesting a rationale for targeting EZH2 beyond its catalytic activity for overcoming cisplatin resistance in SCLC.	[Koyen, Allyson E.; Madden, Matthew Z.; Park, Dongkyoo; Minten, Elizabeth, V; Kapoor-Vazirani, Priya; Werner, Erica; Pfister, Neil T.; Haji-Seyed-Javadi, Ramona; Zhang, Hui; Xu, Jie; Deng, Nikita; Deng, Xingming; Yu, David S.] Emory Univ, Dept Radiat Oncol, Sch Med, Atlanta, GA 30322 USA; [Duong, Duc M.; Seyfried, Nicholas T.] Emory Univ, Dept Biochem, Sch Med, Atlanta, GA 30322 USA; [Pecen, Turner J.; Nagel, Zachary D.] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; [Frazier, Zoe; Lazaro, Jean-Bernard; Mouw, Kent W.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA; [Moreno, Carlos S.] Emory Univ, Dept Pathol & Lab Med, Sch Med, Atlanta, GA 30322 USA; [Owonikoko, Taofeek K.] Emory Univ, Dept Hematol & Med Oncol, Sch Med, Atlanta, GA 30322 USA	Emory University; Emory University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Emory University; Emory University	Yu, DS (corresponding author), Emory Univ, Dept Radiat Oncol, Sch Med, Atlanta, GA 30322 USA.	dsyu@emory.edu	Classen, Scott/AAY-8176-2020; Moreno, Carlos S/B-3863-2009	Moreno, Carlos S/0000-0002-5582-0028; Werner, Erica/0000-0002-8183-1601; Madden, Matthew/0000-0003-4062-4427; Mouw, Kent/0000-0001-7939-7343	NCI NIH HHS [R01 CA178999, R01 CA193828, P01 CA092584, F31 CA225119] Funding Source: Medline; NIEHS NIH HHS [U01 ES029520] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barakat BM, 2010, INT J CANCER, V127, P977, DOI 10.1002/ijc.25112; Barckhausen C, 2014, ONCOGENE, V33, P1964, DOI 10.1038/onc.2013.141; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Byers LA, 2012, CANCER DISCOV, V2, P798, DOI 10.1158/2159-8290.CD-12-0112; Byrski T, 2008, BREAST CANCER RES TR, V108, P289, DOI 10.1007/s10549-007-9600-1; Byrski T, 2014, BREAST CANCER RES TR, V147, P401, DOI 10.1007/s10549-014-3100-x; Campbell S, 2013, CELL CYCLE, V12, P2675, DOI 10.4161/cc.25795; Ceccaldi R, 2015, NATURE, V518, P258, DOI 10.1038/nature14184; Chang JW, 2016, ORAL ONCOL, V52, P66, DOI 10.1016/j.oraloncology.2015.11.002; Chen XA, 2001, J BIOL CHEM, V276, P48175, DOI 10.1074/jbc.M106808200; Chen YT, 2016, CANCER CHEMOTH PHARM, V77, P757, DOI 10.1007/s00280-016-2990-1; Chou DM, 2010, P NATL ACAD SCI USA, V107, P18475, DOI 10.1073/pnas.1012946107; Chute JP, 1999, J CLIN ONCOL, V17, P1794, DOI 10.1200/JCO.1999.17.6.1794; Coe BP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071670; Colbert LE, 2014, CANCER RES, V74, P2677, DOI 10.1158/0008-5472.CAN-13-1996; Crea F, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-40; El-Mahdy MA, 2006, J BIOL CHEM, V281, P13404, DOI 10.1074/jbc.M511834200; Fei J, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001183; Fischer ES, 2011, CELL, V147, P1024, DOI 10.1016/j.cell.2011.10.035; Fitch ME, 2003, J BIOL CHEM, V278, P46906, DOI 10.1074/jbc.M307254200; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gardner EE, 2017, CANCER CELL, V31, P286, DOI 10.1016/j.ccell.2017.01.006; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; He AB, 2012, GENE DEV, V26, P37, DOI 10.1101/gad.173930.111; Horita N, 2015, SCI REP-UK, V5, DOI 10.1038/srep18113; Hu S, 2010, CANCER BIOL THER, V10, P788, DOI 10.4161/cbt.10.8.12913; Huang S, 2017, CANCER RES, V77, P6562, DOI 10.1158/0008-5472.CAN-17-1570; Huang YX, 2017, MOL CARCINOGEN, V56, P447, DOI 10.1002/mc.22507; Hubaux R, 2013, J THORAC ONCOL, V8, P1102, DOI 10.1097/JTO.0b013e318298762f; Jansson M, 2008, NAT CELL BIOL, V10, P1431, DOI 10.1038/ncb1802; Jiang FZ, 2015, ONCOTARGET, V6, P44660, DOI 10.18632/oncotarget.6350; KEENEY S, 1993, J BIOL CHEM, V268, P21293; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Kim J, 2018, CELL REP, V25, P2808, DOI 10.1016/j.celrep.2018.11.035; Knutson SK, 2014, MOL CANCER THER, V13, P842, DOI 10.1158/1535-7163.MCT-13-0773; Lee JM, 2012, MOL CELL, V48, P572, DOI 10.1016/j.molcel.2012.09.004; Lei AH, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00422; Li H, 2010, MOL CANCER RES, V8, P1610, DOI 10.1158/1541-7786.MCR-10-0398; Li ZW, 2013, ONCOTARGET, V4, P2532, DOI 10.18632/oncotarget.1503; Liu HD, 2016, ONCOTARGET, V7, P56338, DOI 10.18632/oncotarget.10841; Marteijn JA, 2014, NAT REV MOL CELL BIO, V15, P465, DOI 10.1038/nrm3822; Matsumoto S, 2015, NUCLEIC ACIDS RES, V43, P1700, DOI 10.1093/nar/gkv038; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013; Murai F, 2015, CELL DISCOV, V1, DOI 10.1038/celldisc.2015.26; Nagel ZD, 2014, P NATL ACAD SCI USA, V111, pE1823, DOI 10.1073/pnas.1401182111; Nienstedt JC, 2018, J ORAL PATHOL MED, V47, P240, DOI 10.1111/jop.12673; Owonikoko TK, 2014, CANCER MED-US, V3, P1579, DOI 10.1002/cam4.317; Pines A, 2012, J CELL BIOL, V199, P235, DOI 10.1083/jcb.201112132; Puppe J, 2019, CLIN CANCER RES, V25, P4351, DOI 10.1158/1078-0432.CCR-18-4024; Qi W, 2012, P NATL ACAD SCI USA, V109, P21360, DOI 10.1073/pnas.1210371110; Rao ZY, 2010, CARCINOGENESIS, V31, P1576, DOI 10.1093/carcin/bgq150; Rondinelli B, 2017, NAT CELL BIOL, V19, P1371, DOI 10.1038/ncb3626; Sanulli S, 2015, MOL CELL, V57, P769, DOI 10.1016/j.molcel.2014.12.020; Sato T, 2013, SCI REP-UK, V3, DOI 10.1038/srep01911; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21601, 10.3322/caac.21590]; Smith SC, 2014, NUCLEIC ACIDS RES, V42, P11517, DOI 10.1093/nar/gku840; Stefansson OA, 2012, EPIGENETICS-US, V7, P1225, DOI 10.4161/epi.22561; Stoyanova T, 2008, MOL CELL BIOL, V28, P177, DOI 10.1128/MCB.00880-07; Stoyanova T, 2009, P NATL ACAD SCI USA, V106, P10690, DOI 10.1073/pnas.0812254106; Sun S, 2018, CANCER SCI, V109, P1853, DOI 10.1111/cas.13599; Takedachi A, 2010, MOL CELL BIOL, V30, P2708, DOI 10.1128/MCB.01460-09; Vasanthakumar A, 2017, EMBO REP, V18, P619, DOI 10.15252/embr.201643237; Vaswani RG, 2016, J MED CHEM, V59, P9928, DOI 10.1021/acs.jmedchem.6b01315; Wan LX, 2018, MOL CELL, V69, P279, DOI 10.1016/j.molcel.2017.12.024; Wang QE, 2007, NUCLEIC ACIDS RES, V35, P5338, DOI 10.1093/nar/gkm550; Wu Z, 2011, CELL DEATH DIFFER, V18, P1771, DOI 10.1038/cdd.2011.48; Xa H, 2012, ONCOL LETT, V4, P135, DOI 10.3892/ol.2012.696; Xie HF, 2016, CANCER DISCOV, V6, P1237, DOI 10.1158/2159-8290.CD-15-1439; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Xu L, 2019, MOL MED REP, V19, P4249, DOI 10.3892/mmr.2019.10075; Yamaguchi H, 2018, ONCOGENE, V37, P208, DOI 10.1038/onc.2017.311; Yan JL, 2016, BLOOD, V128, P948, DOI 10.1182/blood-2016-01-690701; Yap DB, 2011, BLOOD, V117, P2451, DOI 10.1182/blood-2010-11-321208; Zeidler M, 2005, NEOPLASIA, V7, P1011, DOI 10.1593/neo.05472; Zhang L, 2012, CELL CYCLE, V11, P4378, DOI 10.4161/cc.22688; Zhao R, 2015, NUCLEIC ACIDS RES, V43, P7838, DOI 10.1093/nar/gkv667	77	20	20	3	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	2020	39	25					4798	4813		10.1038/s41388-020-1332-2	http://dx.doi.org/10.1038/s41388-020-1332-2			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LZ3HT	32457468	Green Accepted			2022-12-17	WOS:000541119400002
J	Misawa, K; Mai, A; Matsui, H; Kanai, A; Misawa, Y; Mochizuki, D; Mima, M; Yamada, S; Kurokawa, T; Nakagawa, T; Mineta, H				Misawa, Kiyoshi; Mai, Atsushi; Matsui, Hirotaka; Kanai, Akinori; Misawa, Yuki; Mochizuki, Daiki; Mima, Masato; Yamada, Satoshi; Kurokawa, Tomoya; Nakagawa, Takuya; Mineta, Hiroyuki			Identification of novel methylation markers in HPV-associated oropharyngeal cancer: genome-wide discovery, tissue verification and validation testing in ctDNA	ONCOGENE			English	Article							CALMODULIN-LIKE PROTEIN; HUMAN-PAPILLOMAVIRUS; CLINICAL-SIGNIFICANCE; DNA METHYLATION; NECK-CANCER; HEAD; SURVIVAL; SERUM; STAGE	Human papilloma virus (HPV)-associated oropharyngeal cancer (OPC) is an independent tumour type with regard to cellular, biological, and clinical features. The use of non-invasive biomarkers such as circulating tumour DNA (ctDNA) may be relevant in early diagnosis and eventually improve the outcomes of patients with head and neck squamous cell carcinoma (HNSCC). Genome-wide discovery using RNA sequencing and reduced representation bisulfite sequencing yielded 21 candidates for methylation-targeted genes. A verification study (252 HNSCC patients) using quantitative methylation-specific PCR (Q-MSP) identified 10 genes (ATP2A1, CALML5, DNAJC5G, GNMT, GPT, LY6D, LYNX1, MAL, MGC16275, and MRGPRF) that showed a significant increase recurrence in methylation groups with OPC. Further study on ctDNA using Q-MSP in HPV-associated OPC showed that three genes (CALML5, DNAJC5G, and LY6D) had a high predictive ability as emerging biomarkers for a validation set, each capable of discriminating between the plasma of the patients from healthy individuals. Among the 42 ctDNA samples, methylated CALML5, DNAJC5G, and LY6D were observed in 31 (73.8%), 19 (45.2%), and 19 (45.2%) samples, respectively. Among pre-treatment ctDNA samples, methylated CALML5, DNAJC5G, and LY6D were observed in 8/8 (100%), 7/8 (87.5%), and 7/8 (87.5%) samples, respectively. Methylated CALML5, DNAJC5G, and LY6D were found in 2/8 (25.0%), 0/8 (0%), and 1/8 (12.5%) of the final samples in the series, respectively. Here, we present the relationship between the methylation status of three specific genes and cancer recurrence for risk classification of HPV-associated OPC cases. In conclusion, ctDNA analysis has the potential to aid in determining patient prognosis and real-time surveillance for disease recurrences and serves as an alternative method of screening for HPV-associated OPC.	[Misawa, Kiyoshi; Mai, Atsushi; Misawa, Yuki; Mochizuki, Daiki; Mima, Masato; Yamada, Satoshi; Mineta, Hiroyuki] Hamamatsu Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Shizuoka, Japan; [Matsui, Hirotaka] Kumamoto Univ, Grad Sch Med Sci, Dept Mol Lab Med, Kumamoto, Japan; [Kanai, Akinori] Hiroshima Univ, Res Inst Radiat Biol & Med, Hiroshima, Japan; [Kurokawa, Tomoya; Nakagawa, Takuya] Chiba Univ, Grad Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Chiba, Japan	Hamamatsu University School of Medicine; Kumamoto University; Hiroshima University; Chiba University	Misawa, K (corresponding author), Hamamatsu Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Shizuoka, Japan.	kiyoshim@hama-med.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology of Japan [16K11228, 16K20239, 17K16904, 17K16903, 19K09866, 19K09906, 19K18728]	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study was funded by a Grant-in-Aid for Scientific Research (No. 16K11228, No. 16K20239, 17K16904, 17K16903, 19K09866, 19K09906 and 19K18728) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	Akalin A, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-r87, 10.1186/gb-2012-13-10-R87]; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Barros-Silva JD, 2018, CELL REP, V25, P3504, DOI 10.1016/j.celrep.2018.11.069; Berman TA, 2017, CANCER-AM CANCER SOC, V123, P2219, DOI 10.1002/cncr.30588; Bose P, 2013, INT J CANCER, V133, P2013, DOI 10.1002/ijc.28112; Chera BS, 2020, J CLIN ONCOL, V38, P1050, DOI 10.1200/JCO.19.02444; Chera BS, 2019, CLIN CANCER RES, V25, P4682, DOI 10.1158/1078-0432.CCR-19-0211; Cree IA, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3693-7; Damerla RR, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.18.00276; Debald M, 2013, J CANCER RES CLIN, V139, P2125, DOI 10.1007/s00432-013-1541-y; Fakhry C, 2019, CANCER-AM CANCER SOC, V125, P2027, DOI 10.1002/cncr.32025; Fici P, 2019, METHODS MOL BIOL, V1909, P47, DOI 10.1007/978-1-4939-8973-7_4; Garnaes E, 2016, INT J CANCER, V139, P2598, DOI 10.1002/ijc.30389; Golusinski P, 2019, ORAL ONCOL, V88, P145, DOI 10.1016/j.oraloncology.2018.11.020; Gonda TA, 2012, GASTROENTEROLOGY, V142, P824, DOI 10.1053/j.gastro.2011.12.058; Granata R, 2012, ANN ONCOL, V23, P1832, DOI 10.1093/annonc/mdr544; IJzerman MJ, 2018, EXPERT REV PHARM OUT, V18, P593, DOI 10.1080/14737167.2018.1505505; Jeannot E, 2016, J PATHOL CLIN RES, V2, P201, DOI 10.1002/cjp2.47; Kong HK, 2012, BMB REP, V45, P595, DOI 10.5483/BMBRep.2012.45.11.210; Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167; Kurokawa T, 2020, CANCER SCI, V111, P1407, DOI 10.1111/cas.14338; Ludwig ML, 2018, ORAL ONCOL, V87, P144, DOI 10.1016/j.oraloncology.2018.10.031; Mayama A, 2018, CANCER SCI, V109, P3350, DOI 10.1111/cas.13770; Mazurek AM, 2019, HEAD NECK-J SCI SPEC, V41, P632, DOI 10.1002/hed.25368; Mehul B, 2000, J BIOL CHEM, V275, P12841, DOI 10.1074/jbc.275.17.12841; Misawa K, 2020, SCI REP, V10; Misawa K, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0363-1; Misawa K, 2016, ONCOTARGET, V7, P26087, DOI 10.18632/oncotarget.8317; Moss J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07466-6; Mydlarz WK, 2016, HEAD NECK-J SCI SPEC, V38, P9, DOI 10.1002/hed.23842; Nakagawa T, 2020, INT J CANCER, V146, P2460, DOI 10.1002/ijc.32890; Nieuwenhuis EJC, 2003, LAB INVEST, V83, P1233, DOI 10.1097/01.LAB.0000083532.46536.56; Ossandon MR, 2018, JNCI-J NATL CANCER I, V110, P929, DOI 10.1093/jnci/djy105; Ribeiro IP, 2019, MOL CYTOGENET, V12, DOI 10.1186/s13039-019-0447-z; Schilling B, 1998, VIROLOGY, V247, P74, DOI 10.1006/viro.1998.9220; Schmidt H, 2018, DIAGNOSTICS, V8, DOI 10.3390/diagnostics8040079; Schrock A, 2017, CLIN CHEM, V63, P1288, DOI 10.1373/clinchem.2016.270207; Seyhan AA, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1864-9; Shen SY, 2018, NATURE, V563, P579, DOI 10.1038/s41586-018-0703-0; Sullivan CS, 2001, VIROLOGY, V287, P1, DOI 10.1006/viro.2001.1038; Sun BK, 2015, GENE DEV, V29, P2225, DOI 10.1101/gad.267708.115; Swiecicki PL, 2019, LARYNGOSCOPE, V129, P1836, DOI 10.1002/lary.27725; Terai H, 2015, INT J ONCOL, V46, P430, DOI 10.3892/ijo.2014.2733; Urano E, 2013, JAIDS-J ACQ IMM DEF, V64, P154, DOI 10.1097/QAI.0b013e31829a2ef8; van Ginkel JH, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3424-0; Volik S, 2016, MOL CANCER RES, V14, P898, DOI 10.1158/1541-7786.MCR-16-0044	46	20	20	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	24					4741	4755		10.1038/s41388-020-1327-z	http://dx.doi.org/10.1038/s41388-020-1327-z		MAY 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LY0HO	32415241	Green Published, hybrid			2022-12-17	WOS:000533041900001
J	Arnold, JM; Gu, F; Ambati, CR; Rasaily, U; Ramirez-Pena, E; Joseph, R; Manikkam, M; San Martin, R; Charles, C; Pan, YH; Chatterjee, SS; Den Hollander, P; Zhang, WJ; Nagi, C; Sikora, AG; Rowley, D; Putluri, N; Zhang, XHF; Karanam, B; Mani, SA; Sreekumar, A				Arnold, James M.; Gu, Franklin; Ambati, Chandrashekar R.; Rasaily, Uttam; Ramirez-Pena, Esmeralda; Joseph, Robiya; Manikkam, Mohan; San Martin, Rebeca; Charles, Christy; Pan, Yinghong; Chatterjee, Sujash S.; Den Hollander, Petra; Zhang, Weijie; Nagi, Chandandeep; Sikora, Andrew G.; Rowley, David; Putluri, Nagireddy; Zhang, Xiang H-F; Karanam, Balasubramanyam; Mani, Sendurai A.; Sreekumar, Arun			UDP-glucose 6-dehydrogenase regulates hyaluronic acid production and promotes breast cancer progression	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; SURVIVAL; CELLS; METASTASIS; REVEALS; FOXC2	An improved understanding of the biochemical alterations that accompany tumor progression and metastasis is necessary to inform the next generation of diagnostic tools and targeted therapies. Metabolic reprogramming is known to occur during the epithelial-mesenchymal transition (EMT), a process that promotes metastasis. Here, we identify metabolic enzymes involved in extracellular matrix remodeling that are upregulated during EMT and are highly expressed in patients with aggressive mesenchymal-like breast cancer. Activation of EMT significantly increases production of hyaluronic acid, which is enabled by the reprogramming of glucose metabolism. Using genetic and pharmacological approaches, we show that depletion of the hyaluronic acid precursor UDP-glucuronic acid is sufficient to inhibit several mesenchymal-like properties including cellular invasion and colony formation in vitro, as well as tumor growth and metastasis in vivo. We found that depletion of UDP-glucuronic acid altered the expression of PPAR-gamma target genes and increased PPAR-gamma DNA-binding activity. Taken together, our findings indicate that the disruption of EMT-induced metabolic reprogramming affects hyaluronic acid production, as well as associated extracellular matrix remodeling and represents pharmacologically actionable target for the inhibition of aggressive mesenchymal-like breast cancer progression.	[Arnold, James M.; Gu, Franklin; Charles, Christy; Sreekumar, Arun] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Arnold, James M.; Gu, Franklin; Rasaily, Uttam; Manikkam, Mohan; San Martin, Rebeca; Charles, Christy; Zhang, Weijie; Rowley, David; Putluri, Nagireddy; Zhang, Xiang H-F; Sreekumar, Arun] Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza, Houston, TX 77030 USA; [Arnold, James M.; Gu, Franklin; Ambati, Chandrashekar R.; Rasaily, Uttam; Charles, Christy; Putluri, Nagireddy; Sreekumar, Arun] Baylor Coll Med, Alkek Ctr Mol Discovery, Houston, TX 77030 USA; [Ramirez-Pena, Esmeralda; Joseph, Robiya; Den Hollander, Petra; Mani, Sendurai A.] MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Ramirez-Pena, Esmeralda] NCI, Div Canc Prevent, Rockville, MD 20850 USA; [Pan, Yinghong; Chatterjee, Sujash S.] Univ Houston, Dept Biol & Biochem, Seq N Edit Core, Houston, TX 77004 USA; [Pan, Yinghong] UPMC, Genome Ctr, Pittsburgh, PA 15232 USA; [Zhang, Weijie; Zhang, Xiang H-F] Baylor Coll Med, Lester & Sue Smith Breast Ctr, One Baylor Plaza, Houston, TX 77030 USA; [Zhang, Weijie] Baylor Coll Med, Duncan L Canc Ctr, One Baylor Plaza, Houston, TX 77030 USA; [Nagi, Chandandeep] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Sikora, Andrew G.] Baylor Coll Med, Dept Otolaryngol Head & Neck Surg, Houston, TX 77030 USA; [Karanam, Balasubramanyam] Tuskegee Univ, Dept Biol & Canc Res, Tuskegee, AL 36088 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Houston System; University of Houston; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Tuskegee University	Sreekumar, A (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA.; Sreekumar, A (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza, Houston, TX 77030 USA.; Sreekumar, A (corresponding author), Baylor Coll Med, Alkek Ctr Mol Discovery, Houston, TX 77030 USA.	sreekuma@bcm.edu	Mani, Sendurai A./A-7244-2009	Mani, Sendurai A./0000-0002-5918-4276; Pan, Yinghong/0000-0001-7334-1787; Zhang, Weijie/0000-0002-6462-6067; Putluri, Nagireddy/0000-0003-4488-7400; Joseph, Robiya/0000-0003-3214-890X; San Martin, Rebeca/0000-0001-7249-3922				Battula VL, 2010, STEM CELLS, V28, P1435, DOI 10.1002/stem.467; Bhowmik SK, 2015, ONCOTARGET, V6, P42651, DOI 10.18632/oncotarget.4765; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dasgupta S, 2015, J CLIN INVEST, V125, P1174, DOI 10.1172/JCI76029; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hollier BG, 2013, CANCER RES, V73, P1981, DOI 10.1158/0008-5472.CAN-12-2962; Jacobetz MA, 2013, GUT, V62, P112, DOI 10.1136/gutjnl-2012-302529; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Kultti A, 2009, EXP CELL RES, V315, P1914, DOI 10.1016/j.yexcr.2009.03.002; Li M, 2015, JOVE-J VIS EXP, V104, P52411; Lucena MC, 2016, J BIOL CHEM, V291, P12917, DOI 10.1074/jbc.M116.729236; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marshall J, 2011, METHODS MOL BIOL, V769, P97, DOI 10.1007/978-1-61779-207-6_8; Misra S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00201; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Oyinlade O, 2018, ONCOGENE, V37, P2615, DOI 10.1038/s41388-018-0138-y; Putluri N, 2014, NEOPLASIA, V16, P390, DOI 10.1016/j.neo.2014.05.007; Putluri N, 2011, CANCER RES, V71, P7376, DOI 10.1158/0008-5472.CAN-11-1154; Ricciardelli C, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-476; Saito T, 2013, ONCOL LETT, V5, P1068, DOI 10.3892/ol.2013.1124; Sato N, 2016, CANCER SCI, V107, P569, DOI 10.1111/cas.12913; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Toole BP, 2009, CLIN CANCER RES, V15, P7462, DOI 10.1158/1078-0432.CCR-09-0479; van der Horst EH, 2004, BIOTECHNIQUES, V37, P940, DOI 10.2144/04376ST02; Vigetti D, 2014, MATRIX BIOL, V35, P8, DOI 10.1016/j.matbio.2013.10.002; Werden SJ, 2016, ONCOGENE, V35, P5977, DOI 10.1038/onc.2016.203; Yates TJ, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv085	29	20	20	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	15					3089	3101		10.1038/s41388-019-0885-4	http://dx.doi.org/10.1038/s41388-019-0885-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LB8NS	31308490	Green Accepted			2022-12-17	WOS:000524887800004
J	De Piano, M; Manuelli, V; Zadra, G; Otte, J; Edqvist, PHD; Ponten, F; Nowinski, S; Niaouris, A; Grigoriadis, A; Loda, M; Van Hemelrijck, M; Wells, CM				De Piano, Mario; Manuelli, Valeria; Zadra, Giorgia; Otte, Jonathan; Edqvist, Per-Henrik D.; Ponten, Fredrik; Nowinski, Salpie; Niaouris, Athanasios; Grigoriadis, Anita; Loda, Massimo; Van Hemelrijck, Mieke; Wells, Claire M.			Lipogenic signalling modulates prostate cancer cell adhesion and migration via modification of Rho GTPases	ONCOGENE			English	Article							FATTY-ACID SYNTHASE; CDC42; EXPRESSION	Fatty acid synthase (FASN) is commonly overexpressed in prostate cancer and associated with tumour progression. FASN is responsible for de novo synthesis of the fatty acid palmitate; the building block for protein palmitoylation. Recent work has suggested that alongside its established role in promoting cell proliferation FASN may also promote invasion. We now find depletion of FASN expression increases prostate cancer cell adhesiveness, impairs HGF-mediated cell migration and reduces 3D invasion. These changes in motility suggest that FASN can mediate actin cytoskeletal remodelling; a process known to be downstream of Rho family GTPases. Here, we demonstrate that modulation of FASN expression specifically impacts on the palmitoylation of the atypical GTPase RhoU. Impaired RhoU activity in FASN depleted cells leads to reduced adhesion turnover downstream of paxillin serine phosphorylation, which is rescued by addition of exogenous palmitate. Moreover, canonical Cdc42 expression is dependent on the palmitoylation status of RhoU. Thus we uncover a novel relationship between FASN, RhoU and Cdc42 that directly influences cell migration potential. These results provide compelling evidence that FASN activity directly promotes cell migration and supports FASN as a potential therapeutic target in metastatic prostate cancer.	[De Piano, Mario; Manuelli, Valeria; Nowinski, Salpie; Niaouris, Athanasios; Grigoriadis, Anita; Van Hemelrijck, Mieke; Wells, Claire M.] Kings Coll London, Sch Canc & Pharmaceut Sci, London SE1 1UL, England; [Zadra, Giorgia; Loda, Massimo] Harvard Med Sch, Dana Farber Canc Inst, Dept Oncol Pathol, Boston, MA 02215 USA; [Zadra, Giorgia; Loda, Massimo] Harvard Med Sch, Dana Farber Canc Inst, Dept Pathol, Boston, MA 02215 USA; [Zadra, Giorgia; Loda, Massimo] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02215 USA; [Otte, Jonathan] Uppsala Univ, Dept Surg Sci, Uppsala, Sweden; [Edqvist, Per-Henrik D.; Ponten, Fredrik] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden	University of London; King's College London; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Uppsala University; Uppsala University	Wells, CM (corresponding author), Kings Coll London, Sch Canc & Pharmaceut Sci, London SE1 1UL, England.	claire.wells@kcl.ac.uk		Wells, Claire/0000-0003-1926-6282; Van Hemelrijck, Mieke/0000-0002-7317-0858; Grigoriadis, Anita/0000-0003-3434-201X; Ponten, Fredrik/0000-0003-0703-3940	Prostate UK [S12-008]; Medical Research Council; U-CAN; DoD [PC150263]; Claudia Adams Barr Award in Innovative Basic Cancer Research	Prostate UK; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); U-CAN; DoD(United States Department of Defense); Claudia Adams Barr Award in Innovative Basic Cancer Research	MDP was supported by Prostate UK (S12-008). VM is supported by the Medical Research Council. This study was supported by U-CAN. GZ is a recipient of the DoD Idea Development Award for New Investigators (PC150263) and a Claudia Adams Barr Award in Innovative Basic Cancer Research.	Alinezhad S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155901; American Cancer Society, 2016, SURV RAT PROST CANC; Baenke F, 2013, DIS MODEL MECH, V6, P1353, DOI 10.1242/dmm.011338; Berzat AC, 2005, J BIOL CHEM, V280, P33055, DOI 10.1074/jbc.M507362200; Bright RK, 1997, CANCER RES, V57, P995; Coleman DT, 2009, MOL CANCER THER, V8, P214, DOI 10.1158/1535-7163.MCT-08-0722; Czuchra A, 2005, MOL BIOL CELL, V16, P4473, DOI 10.1091/mbc.E05-01-0061; Dart AE, 2015, J CELL BIOL, V211, P863, DOI 10.1083/jcb.201501072; Dasgupta Subhamoy, 2012, J Carcinog, V11, P4, DOI 10.4103/1477-3163.93001; De Piano M, 2017, STANDARD SUPER RESOL, P173; Flavin R, 2010, FUTURE ONCOL, V6, P551, DOI [10.2217/fon.10.11, 10.2217/FON.10.11]; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Glimelius B, 2018, ACTA ONCOL, V57, P187, DOI 10.1080/0284186X.2017.1337926; Hodge Richard G, 2020, Small GTPases, V11, P8, DOI 10.1080/21541248.2017.1362495; Kampf C, 2012, JOVE-J VIS EXP, V63; Lawson CD, 2017, J CELL BIOL, P2; Li N, 2012, NUTR CANCER, V64, P864, DOI 10.1080/01635581.2012.701704; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; NC I, CANC GEN ATL; Pascual G, 2017, NATURE, V541, P41, DOI 10.1038/nature20791; Reymond N, 2012, J CELL BIOL, V199, P653, DOI 10.1083/jcb.201205169; Swinnen JV, 2002, INT J CANCER, V98, P19, DOI 10.1002/ijc.10127; Team RC, 2015, LANG ENV STAT COMP; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Van de Sande T, 2005, J PATHOL, V206, P214, DOI 10.1002/path.1760; Wen SM, 2016, MOL CARCINOGEN, V55, P2278, DOI 10.1002/mc.22468; Whale AD, 2013, ONCOGENE, V32, P2114, DOI 10.1038/onc.2012.233; Zadra G, 2019, P NATL ACAD SCI USA, V116, P631, DOI 10.1073/pnas.1808834116; Zhang BL, 1998, J BIOL CHEM, V273, P25728, DOI 10.1074/jbc.273.40.25728	29	20	20	4	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	18					3666	3679		10.1038/s41388-020-1243-2	http://dx.doi.org/10.1038/s41388-020-1243-2		MAR 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LI5XR	32139877	Green Published, hybrid			2022-12-17	WOS:000518240300001
J	Li, K; Zhang, JW; Tian, YH; He, YQ; Xu, XL; Pan, WT; Gao, Y; Chen, FF; Wei, L				Li, Kai; Zhang, Jingwei; Tian, Yihao; He, Yanqi; Xu, Xiaolong; Pan, Wenting; Gao, Yang; Chen, Fangfang; Wei, Lei			The Wnt/beta-catenin/VASP positive feedback loop drives cell proliferation and migration in breast cancer	ONCOGENE			English	Article							VASODILATOR-STIMULATED PHOSPHOPROTEIN; BETA-CATENIN; DIFFERENTIAL EXPRESSION; ENA/VASP PROTEINS; RNA-SEQ; VASP; INVASION; ADHESION; PATHWAY; RAC1	Previous studies have shown that the main function of VASP is to regulate the cytoskeleton and play an important role in promoting tumor cell metastasis. In this study, we first reveal that VASP is located in the nucleus of breast cancer cells and elucidate a Wnt/beta-catenin/VASP positive feedback loop. We identify that VASP is a target gene of Wnt/beta-catenin signaling pathway, and activation of Wnt/beta-catenin signaling pathway can significantly upregulate VASP protein expression, while upregulated VASP protein can in turn promote translocation of beta-catenin and DVL3 proteins into the nucleus. In the nucleus, VASP, DVL3, beta-catenin, and TCF4 can form VASP/DVL3/beta-catenin/TCF4 protein complex, activating Wnt/beta-catenin signaling pathway, and promoting the expression of target genes VASP, c-myc, and cyclin D1. Thus, our study reveals that there is a Wnt/beta-catenin/VASP malignant positive feedback loop in breast cancer, which promotes the proliferation and migration of breast cancer cells, and breaking this positive feedback loop may provide new strategy for breast cancer treatment.	[Li, Kai; He, Yanqi; Xu, Xiaolong; Pan, Wenting; Gao, Yang; Wei, Lei] Wuhan Univ, Sch Basic Med Sci, Dept Pathol & Pathophysiol, Hubei Prov Key Lab Developmentally Originated Dis, 185 Donghu Rd, Wuhan 430071, Hubei, Peoples R China; [Li, Kai] Nanyang Inst Technol, Zhang Zhongjing Coll Chinese Med, Henan Key Lab Zhang Zhongjing Formulae & Herbs Im, Nanyang 473004, Henan, Peoples R China; [Zhang, Jingwei; Chen, Fangfang] Wuhan Univ, Zhongnan Hosp, Hubei Canc Clin Study Ctr, Dept Breast & Thyroid Surg,Hubei Key Lab Tumor Bi, Wuhan 430071, Hubei, Peoples R China; [Tian, Yihao] Wuhan Univ, Sch Basic Med Sci, Dept Anat, Wuhan 430071, Hubei, Peoples R China	Wuhan University; Nanyang Institute of Technology; Wuhan University; Wuhan University	Wei, L (corresponding author), Wuhan Univ, Sch Basic Med Sci, Dept Pathol & Pathophysiol, Hubei Prov Key Lab Developmentally Originated Dis, 185 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.	leiwei@whu.edu.cn	Li, Kai/ABD-6377-2020	Li, Kai/0000-0002-0318-7064				Arend RC, 2013, GYNECOL ONCOL, V131, P772, DOI 10.1016/j.ygyno.2013.09.034; Arques O, 2016, CLIN CANCER RES, V22, P644, DOI 10.1158/1078-0432.CCR-14-3081; Ball LJ, 2000, EMBO J, V19, P4903, DOI 10.1093/emboj/19.18.4903; Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; Bruhmann S, 2017, P NATL ACAD SCI USA, V114, pE5815, DOI 10.1073/pnas.1703145114; Chen XJ, 2014, DEV CELL, V30, P569, DOI 10.1016/j.devcel.2014.08.001; Chen YH, 2016, EMBO J, V35, P668, DOI 10.15252/embj.201592810; Daniels DL, 2005, NAT STRUCT MOL BIOL, V12, P364, DOI 10.1038/nsmb912; Dertsiz L, 2005, THORAX, V60, P576, DOI 10.1136/thx.2004.037622; Gan XQ, 2008, J CELL BIOL, V180, P1087, DOI 10.1083/jcb.200710050; Gkretsi V, 2017, EXP CELL RES, V352, P281, DOI 10.1016/j.yexcr.2017.02.019; Grabherr MG, 2011, NAT BIOTECHNOL, V29, P644, DOI 10.1038/nbt.1883; Han G, 2008, ONCOL REP, V20, P929, DOI 10.3892/or_00000093; Hansen SD, 2015, ELIFE, V4, DOI 10.7554/eLife.06585; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Kanehisa M, 2008, NUCLEIC ACIDS RES, V36, pD480, DOI 10.1093/nar/gkm882; Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7; Krause M, 2002, J CELL SCI, V115, P4721, DOI 10.1242/jcs.00218; Krause M, 2003, ANNU REV CELL DEV BI, V19, P541, DOI 10.1146/annurev.cellbio.19.050103.103356; Kuang CC, 2017, ONCOL LETT, V13, P3253, DOI 10.3892/ol.2017.5825; Li K, 2018, CANCER MED-US, V7, P3875, DOI 10.1002/cam4.1568; Li K, 2018, J CANCER, V9, P1821, DOI 10.7150/jca.24934; Liu AB, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0669-9; Liu ZK, 2018, THERANOSTICS, V8, P4649, DOI 10.7150/thno.26789; Lu Y, 2017, CELL RES, V27, P1422, DOI 10.1038/cr.2017.107; Ma F, 2016, J CLIN INVEST, V126, P1745, DOI 10.1172/JCI78815; Marioni JC, 2008, GENOME RES, V18, P1509, DOI 10.1101/gr.079558.108; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; Renfranz PJ, 2002, CURR OPIN CELL BIOL, V14, P88, DOI 10.1016/S0955-0674(01)00299-X; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Runowicz CD, 2016, CA-CANCER J CLIN, V66, P44, DOI 10.3322/caac.21319; Stewart DJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt356; Su K, 2016, ONCOTARGET, V7, P45849, DOI 10.18632/oncotarget.9968; Su K, 2012, DNA CELL BIOL, V31, P1078, DOI 10.1089/dna.2011.1563; Sun SM, 2019, FISH SHELLFISH IMMUN, V86, P832, DOI 10.1016/j.fsi.2018.12.028; Tago K, 2000, GENE DEV, V14, P1741; Takemaru KI, 2003, NATURE, V422, P905, DOI 10.1038/nature01570; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Tian YH, 2018, ONCOL LETT, V16, P2151, DOI 10.3892/ol.2018.8930; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Townsley FM, 2004, NAT CELL BIOL, V6, P626, DOI 10.1038/ncb1141; Varghese F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096801; Wang GZ, 2017, CLIN CANCER RES, V23, P6640, DOI 10.1158/1078-0432.CCR-17-0774; Wang J, 2012, EUR J CANCER, V48, P1904, DOI 10.1016/j.ejca.2011.11.026; Wang WQ, 2015, DEV CELL, V32, P707, DOI 10.1016/j.devcel.2015.01.031; Wang YP, 2010, EUR J PHARMACOL, V635, P40, DOI 10.1016/j.ejphar.2010.03.017; Wang ZY, 2016, P NATL ACAD SCI USA, V113, P13150, DOI 10.1073/pnas.1616336113; Xue GD, 2016, CANCER TREAT REV, V49, P1, DOI 10.1016/j.ctrv.2016.06.009; Zhang JW, 2013, ACTA PHARMACOL SIN, V34, P1084, DOI 10.1038/aps.2013.15; Zhang LJ, 2007, EUR J PHARMACOL, V563, P69, DOI 10.1016/j.ejphar.2007.01.073	50	20	22	3	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2258	2274		10.1038/s41388-019-1145-3	http://dx.doi.org/10.1038/s41388-019-1145-3			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31831834				2022-12-17	WOS:000519440400003
J	Rebollido-Rios, R; Venton, G; Sanchez-Redondo, S; Felip, CII; Fournet, G; Gonzalez, E; Fernandez, WR; Escuela, DOB; Di Stefano, B; Penarroche-Diaz, R; Martin, G; Ceylan, I; Costello, R; Perez-Alea, M				Rebollido-Rios, Rocio; Venton, Geoffroy; Sanchez-Redondo, Sara; Iglesias i Felip, Carmela; Fournet, Guy; Gonzalez, Elena; Fernandez, Wilber Romero; Escuela, Dasiel Oscar Borroto; Di Stefano, Barbara; Penarroche-Diaz, Reinier; Martin, Guillaume; Ceylan, Ismail; Costello, Regis; Perez-Alea, Mileidys			Dual disruption of aldehyde dehydrogenases 1 and 3 promotes functional changes in the glutathione redox system and enhances chemosensitivity in nonsmall cell lung cancer	ONCOGENE			English	Article							STEM-CELLS; EXPRESSION; MECHANISM; 1A1; INHIBITORS; MARKER; APOPTOSIS; SUBSTRATE; REDUCTASE; ALDH1A3	Aldehyde dehydrogenases (ALDHs) are multifunctional enzymes that oxidize diverse endogenous and exogenous aldehydes. We conducted a meta-analysis based on The Cancer Genome Atlas and Gene Expression Omnibus data and detected genetic alterations in ALDH1A1, ALDH1A3, or ALDH3A1, 86% of which were gene amplification or mRNA upregulation, in 31% of nonsmall cell lung cancers (NSCLCs). The expression of these isoenzymes impacted chemoresistance and shortened survival times in patients. We hypothesized that these enzymes provide an oxidative advantage for the persistence of NSCLC. To test this hypothesis, we used genetic and pharmacological approaches with DIMATE, an irreversible inhibitor of ALDH1/3. DIMATE showed cytotoxicity in 73% of NSCLC cell lines tested and demonstrated antitumor activity in orthotopic xenografts via hydroxynonenal-protein adduct accumulation, GSTO1-mediated depletion of glutathione and increased H2O2. Consistent with this result, ALDH1/3 disruption synergized with ROS-inducing agents or glutathione synthesis inhibitors to trigger cell death. In lung cancer xenografts with high to moderate cisplatin resistance, combination treatment with DIMATE promoted strong synergistic responses with tumor regression. These results indicate that NSCLCs with increased expression of ALDH1A1, ALDH1A3, or ALDH3A1 may be targeted by strategies involving inhibitors of these isoenzymes as monotherapy or in combination with chemotherapy to overcome patient-specific drug resistance.	[Rebollido-Rios, Rocio] Univ Cologne, Fac Med, Dept Internal Med 1, Cologne, Germany; [Rebollido-Rios, Rocio] Univ Cologne, Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany; [Venton, Geoffroy; Costello, Regis] Ctr Hosp Univ La Conception, Serv Haematol & Cellular Therapy, Marseille, France; [Sanchez-Redondo, Sara] Spanish Natl Canc Res Ctr CNIO, Microenvironm & Metastasis Lab, Mol Oncol Programme, Madrid, Spain; [Iglesias i Felip, Carmela] Barcelona UAB, Dept Anat Pathol, Vall dHebron Hosp, Barcelona, Spain; [Fournet, Guy] Univ Claude Bernard Lyon1, Inst Chim & Biochim Mol & Supramol, CNRS, UMR 5246,Univ Lyon, Villeurbanne, France; [Gonzalez, Elena; Perez-Alea, Mileidys] Vall dHebron Res Inst, Oncol Res Program, Barcelona, Spain; [Fernandez, Wilber Romero; Escuela, Dasiel Oscar Borroto] Uppsala Univ, Dept Cell & Mol Biol, Computat Biol & Bioinformat, Uppsala, Sweden; [Di Stefano, Barbara] Univ Palermo, Dichirons Dept Surg, Lab Biol & Regenerat Med Plast Surg BIOPLAST, Oncol & Stomatol Sci, Palermo, Italy; [Penarroche-Diaz, Reinier] Reixmor, Barcelona, Spain; [Martin, Guillaume; Ceylan, Ismail; Perez-Alea, Mileidys] Adv Biodesign ABD, Unit Res Cellular & Mol Biol, St Priest, France	University of Cologne; University of Cologne; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Centro Nacional de Investigaciones Oncologicas (CNIO); Hospital Universitari Vall d'Hebron; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Institut National des Sciences Appliquees de Lyon - INSA Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Uppsala University; University of Palermo	Perez-Alea, M (corresponding author), Vall dHebron Res Inst, Oncol Res Program, Barcelona, Spain.; Perez-Alea, M (corresponding author), Adv Biodesign ABD, Unit Res Cellular & Mol Biol, St Priest, France.	mileidys.perez@gmail.com	Borroto-Escuela, Dasiel Oscar/F-3627-2014; Rebollido-Rios, Rocio/ABD-5458-2020; di stefano, anna barbara/K-1447-2016	Borroto-Escuela, Dasiel Oscar/0000-0002-5736-373X; Rebollido-Rios, Rocio/0000-0002-8910-867X; di stefano, anna barbara/0000-0003-4323-8564; fournet, guy/0000-0002-2478-4810; Romero-Fernandez, Wilber/0000-0001-9868-8074; PEREZ, Mileidys/0000-0002-8739-8087	La Marato TV3 Foundation program of Catalonia, Spain; Prometheus program of SENESCYT	La Marato TV3 Foundation program of Catalonia, Spain; Prometheus program of SENESCYT	The authors are grateful to Dr Gerard Quash, who has been a motivation and inspiration for this work. The authors also thank Alessandro Ventura for imaging support, Dr Alberto Indacochea for his advice and support in database analysis and Dr Yokota Jun for kindly providing the H441, H23, H2122, Hop62, and H829 cell lines. This work was partially funded by the La Marato TV3 Foundation program of Catalonia, Spain and the Prometheus program of SENESCYT.	AHMAD T, 1985, J LAB CLIN MED, V105, P464; Alamgeer M, 2013, THORAX, V68, P1095, DOI 10.1136/thoraxjnl-2012-203021; Alison MR, 2010, J PATHOL, V222, P335, DOI 10.1002/path.2772; Ayala A, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/360438; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Barta JA, 2019, ANN GLOB HEALTH, V85, DOI 10.5334/aogh.2419; Canino C, 2015, ONCOTARGET, V6, P12637, DOI 10.18632/oncotarget.3703; Castro JP, 2017, FREE RADICAL BIO MED, V111, P309, DOI 10.1016/j.freeradbiomed.2016.10.497; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Choi YM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135083; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Cvek B, 2011, CURR CANCER DRUG TAR, V11, P332, DOI 10.2174/156800911794519806; Eramo A, 2010, ONCOGENE, V29, P4625, DOI 10.1038/onc.2010.207; Fournet G, 2013, CURR MED CHEM, V20, P527; Franco R, 2009, CELL DEATH DIFFER, V16, P1303, DOI 10.1038/cdd.2009.107; Franklin CC, 2002, AM J PATHOL, V160, P1887, DOI 10.1016/S0002-9440(10)61135-2; Gene Expression Omnibus (GEO), GEN EXPR OMN GEO; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; Gyorff B, 2019, KAPLAN MEIER PLOTTER; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Jackson Brian, 2011, Human Genomics, V5, P283; Jiang F, 2009, MOL CANCER RES, V7, P330, DOI 10.1158/1541-7786.MCR-08-0393; JONES P, 1968, BIOCHEM J, V110, P621, DOI 10.1042/bj1100621; Koppaka V, 2012, PHARMACOL REV, V64, P520, DOI 10.1124/pr.111.005538; Levi BP, 2009, BLOOD, V113, P1670, DOI 10.1182/blood-2008-05-156752; Li X, 2012, J THORAC ONCOL, V7, P1235, DOI 10.1097/JTO.0b013e318257cc6d; Ma I, 2011, STEM CELL REV REP, V7, P292, DOI 10.1007/s12015-010-9208-4; Mahmood T, 2012, N AM J MED SCI, V4, P429, DOI 10.4103/1947-2714.100998; Marcato P, 2011, CELL CYCLE, V10, P1378, DOI 10.4161/cc.10.9.15486; Marchitti SA, 2008, EXPERT OPIN DRUG MET, V4, P697, DOI [10.1517/17425255.4.6.697, 10.1517/17425255.4.6.697 ]; Marullo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081162; MCKENNA R, 1983, J LAB CLIN MED, V102, P102; Mordant P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026073; Morgan CA, 2015, CHEM-BIOL INTERACT, V234, P18, DOI 10.1016/j.cbi.2014.12.008; Muller M, 2002, FREE RADICAL BIO MED, V33, P1527, DOI 10.1016/S0891-5849(02)01087-0; Oncomine Platform, 2015, ONCOMINE PLATFORM; Patel M, 2008, LUNG CANCER, V59, P340, DOI 10.1016/j.lungcan.2007.08.033; Perez-Alea M, 2017, ONCOGENE, V36, P5695, DOI 10.1038/onc.2017.160; Ponten F, 2011, J INTERN MED, V270, P428, DOI 10.1111/j.1365-2796.2011.02427.x; Pors K, 2014, DRUG DISCOV TODAY, V19, P1953, DOI 10.1016/j.drudis.2014.09.009; Postmus PE, 2017, ANN ONCOL, V28, P1, DOI 10.1093/annonc/mdx222; Quash G, 1999, ADV EXP MED BIOL, V463, P97; R Core Team, 2017, R LANG ENV STAT COMP; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rodriguez-Torres M, 2016, CLIN EXP METASTAS, V33, P97, DOI 10.1007/s10585-015-9755-9; Shao CL, 2014, CLIN CANCER RES, V20, P4154, DOI 10.1158/1078-0432.CCR-13-3292; Shien K, 2012, LUNG CANCER, V77, P162, DOI 10.1016/j.lungcan.2012.02.006; Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X; Singh S, 2013, FREE RADICAL BIO MED, V56, P89, DOI 10.1016/j.freeradbiomed.2012.11.010; Sullivan JP, 2010, CANCER RES, V70, P9937, DOI 10.1158/0008-5472.CAN-10-0881; Tomita H, 2016, ONCOTARGET, V7, P11018, DOI 10.18632/oncotarget.6920; Vasiliou V, 2013, CHEM-BIOL INTERACT, V202, P2, DOI 10.1016/j.cbi.2012.10.026; Vassalli G, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/3904645; Wei D, 2015, HEART LUNG CIRC, V24, P780, DOI 10.1016/j.hlc.2015.03.021; Yang HT, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0909-x; Zhou L, 2019, CELL BIOL TOXICOL, V35, P161, DOI 10.1007/s10565-018-9444-y	56	20	20	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2756	2771		10.1038/s41388-020-1184-9	http://dx.doi.org/10.1038/s41388-020-1184-9		FEB 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32015486	Green Published, hybrid			2022-12-17	WOS:000510820900001
J	Kumarasamy, V; Ruiz, A; Nambiar, R; Witkiewicz, AK; Knudsen, ES				Kumarasamy, Vishnu; Ruiz, Amanda; Nambiar, Ram; Witkiewicz, Agnieszka K.; Knudsen, Erik S.			Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer	ONCOGENE			English	Article							GEMCITABINE; REPLICATION; SUPPRESSION; PROGRESSION; RESISTANCE; APOPTOSIS; PATHWAY; REPAIR; CELLS; E2F	Pancreatic ductal adenocarcinoma (PDAC) is a therapy recalcitrant disease characterized by the aberrations in multiple genes that drive pathogenesis and limit therapeutic response. While CDK4/6 represents a downstream target of both KRAS mutation and loss of the CDKN2A tumor suppressor in PDAC, clinical and preclinical studies indicate that pharmacological CDK4/6 inhibitors are only modestly effective. Since chemotherapy represents the established backbone of PDAC treatment we evaluated the interaction of CDK4/6 inhibitors with gemcitabine and taxanes that are employed in the treatment of PDAC. Herein, we demonstrate that the difference in mechanisms of actions of chemotherapeutic agents elicit distinct effects on the cellular response to CDK4/6 inhibition. Gemcitabine largely ablates the function of CDK4/6 inhibition in S-phase arrested cells when administered contemporaneously; although, when cells recover from S-phase block they exhibit sensitivity to CDK4/6 inhibition. In contrast, pharmacological inhibition of CDK4/6 yields a cooperative cytostatic effect in combination with docetaxel and prevents adaptation and cell cycle re-entry, which is a common basis for resistance to such agents. Importantly, using organoid and PDX models we could confirm the cooperative effects between chemotherapy and CDK4/6 inhibition in vivo. These data indicate that the combination of cytotoxic and cytostatic agents could represent an important modality in those tumor types that are relatively resistant to CDK4/6 inhibitors.	[Kumarasamy, Vishnu; Nambiar, Ram; Witkiewicz, Agnieszka K.; Knudsen, Erik S.] Roswell Park Canc Inst, Ctr Personalized Med, Buffalo, NY 14263 USA; [Kumarasamy, Vishnu; Nambiar, Ram; Knudsen, Erik S.] Roswell Park Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; [Ruiz, Amanda] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA; [Witkiewicz, Agnieszka K.] Roswell Park Canc Inst, Dept Pathol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute; Arizona Center Cancer Care; University of Arizona; Roswell Park Cancer Institute	Witkiewicz, AK; Knudsen, ES (corresponding author), Roswell Park Canc Inst, Ctr Personalized Med, Buffalo, NY 14263 USA.; Knudsen, ES (corresponding author), Roswell Park Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA.; Witkiewicz, AK (corresponding author), Roswell Park Canc Inst, Dept Pathol, Buffalo, NY 14263 USA.	Agnieszka.Witkiewicz@Roswellpark.org; Erik.Knudsen@roswellpark.org	Kumarasamy, Vishnu/AAV-8896-2021		National Cancer Institute (NCI)	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The author thanks all members of the laboratory group and colleagues in the discussion and preparation of the manuscript. The research was supported by a grant to AKW and ESK from National Cancer Institute (NCI).	ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu, 2017, Cancer Cell, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Cao J, 2019, ONCOGENE, V38, P4125, DOI 10.1038/s41388-019-0708-7; Cappella P, 2001, INT J CANCER, V93, P401, DOI 10.1002/ijc.1351; Cheema AR, 2016, SURG CLIN N AM, V96, P1391, DOI 10.1016/j.suc.2016.07.011; Chou A, 2018, GUT, V67, P2142, DOI 10.1136/gutjnl-2017-315144; Clark AS, 2019, CLIN CANCER RES, V25, P2072, DOI 10.1158/1078-0432.CCR-18-0790; Cowan RW, 2014, CANCER J, V20, P80, DOI 10.1097/PPO.0000000000000011; Dean JL, 2012, J BIOL CHEM, V287, P29075, DOI 10.1074/jbc.M112.365494; Duronio Robert J, 2013, Cold Spring Harb Perspect Biol, V5, pa008904, DOI 10.1101/cshperspect.a008904; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Ewald B, 2007, MOL CANCER THER, V6, P1239, DOI 10.1158/1535-7163.MCT-06-0633; Francis AM, 2017, MOL CANCER THER, V16, P1751, DOI 10.1158/1535-7163.MCT-17-0040; Franco J, 2014, ONCOTARGET, V5, P6512, DOI 10.18632/oncotarget.2270; Haines Eric, 2018, Oncotarget, V9, P31572, DOI 10.18632/oncotarget.25803; He SH, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3986; HEINEMANN V, 1995, SEMIN ONCOL, V22, P11; Hernandez-Vargas H, 2007, ONCOGENE, V26, P2902, DOI 10.1038/sj.onc.1210102; Herrera-Abreu MT, 2016, CANCER RES, V76, P2301, DOI 10.1158/0008-5472.CAN-15-0728; Hidalgo M, 2015, PANCREATOLOGY, V15, P8, DOI 10.1016/j.pan.2014.10.001; Hoskins EE, 2008, ONCOGENE, V27, P4798, DOI 10.1038/onc.2008.121; Iyengar Mangala, 2018, Oncotarget, V9, P15658, DOI 10.18632/oncotarget.24585; Jansen VM, 2017, CANCER RES, V77, P2488, DOI 10.1158/0008-5472.CAN-16-2653; Johnson SM, 2010, J CLIN INVEST, V120, P2528, DOI 10.1172/JCI41402; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Knudsen ES, 2019, ONCOGENE, V38, P3355, DOI 10.1038/s41388-018-0650-0; Knudsen ES, 2018, GUT, V67, P508, DOI 10.1136/gutjnl-2016-313133; Knudsen ES, 2016, GASTROENTEROLOGY, V150, P48, DOI 10.1053/j.gastro.2015.08.056; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; McClendon AK, 2012, CELL CYCLE, V11, P2747, DOI 10.4161/cc.21127; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; O'Hayer KM, 2016, DISCOV MED, V21, P117; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; Pienta KJ, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.26892; Pontano LL, 2009, CELL CYCLE, V8, P824, DOI 10.4161/cc.8.6.7889; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Schutte M, 1997, CANCER RES, V57, P3126; Shangguan WJ, 2014, ONCOL REP, V31, P305, DOI 10.3892/or.2013.2815; Shen H, 2010, J BIOL CHEM, V285, P23103, DOI 10.1074/jbc.M110.124990; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Taylor-Harding B, 2015, ONCOTARGET, V6, P696, DOI 10.18632/oncotarget.2673; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Witkiewicz AK, 2018, CELL REP, V22, P1185, DOI 10.1016/j.celrep.2018.01.022; Witkiewicz AK, 2015, ONCOTARGET, V6, P15788, DOI 10.18632/oncotarget.3819; Witkiewicz AK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7744	48	20	20	1	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					1831	1845		10.1038/s41388-019-1102-1	http://dx.doi.org/10.1038/s41388-019-1102-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31745297	Green Accepted			2022-12-17	WOS:000516579800001
J	Zhou, BJ; Zong, SM; Zhong, WL; Tian, YX; Wang, LM; Zhang, Q; Zhang, RY; Li, L; Wang, W; Zhao, JM; Chen, X; Feng, YJ; Zhai, BH; Sun, T; Liu, YR				Zhou, Bijiao; Zong, Shumin; Zhong, Weilong; Tian, Yixuan; Wang, Lumeng; Zhang, Qian; Zhang, Renya; Li, Lei; Wang, Wei; Zhao, Jianmin; Chen, Xin; Feng, Yaju; Zhai, Binghui; Sun, Tao; Liu, Yanrong			Interaction between laminin-5 gamma 2 and integrin beta 1 promotes the tumor budding of colorectal cancer via the activation of Yes-associated proteins	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; POOR-PROGNOSIS; THERAPEUTIC TARGET; CELL-ADHESION; INVASION; SURVIVAL; LAMININ; METASTASIS; EXPRESSION; MIGRATION	Colorectal cancer (CRC) is a common cancer type and a threat to human health. Tumor budding (TB) is the presence of a single cancer cell or clusters of up to five cancer cells prior to the invasive front of an aggressive carcinoma and is an independent prognosis factor for CRC. The molecular mechanism of TB is still unclear, and drugs that inhibit this process are still in the blank stage. This study found that TBs exhibit characteristics of partial EMT with a decreased expression of E-cadherin and no substantial differences in the expression of N-cadherin and vimentin. We also observed the interaction of integrin with extracellular matrix components, laminin-5 gamma 2 (LN-5 gamma 2), play essential roles in the TB of CRC. We then verified that the interaction between LN-5 gamma 2 and integrin beta 1 promotes the TB of CRC via the activation of FAK and Yes-associated proteins (YAP). A natural drug monomer, cucurbitacin B, was screened using virtual screening methods for the interaction interface of proteins. We found that this monomer could block the interaction interface between LN-5 gamma 2 and integrin beta 1 and substantially inhibit the TB of CRC cells via inactivation of YAP. This study provides new insights into the mechanism of TB mechanism and the development of drugs targeting the TB of CRC.	[Zhou, Bijiao; Zhang, Renya; Li, Lei; Wang, Wei; Liu, Yanrong] Jining Med Univ, Mol Pathol Inst Gastrointestinal Tumors, Affiliated Hosp, Jining 272029, Shandong, Peoples R China; [Zhou, Bijiao; Zong, Shumin; Tian, Yixuan; Wang, Lumeng; Zhang, Qian; Chen, Xin; Feng, Yaju; Zhai, Binghui; Sun, Tao; Liu, Yanrong] Nankai Univ, State Key Lab Med Chem Biol, Tianjin 300350, Peoples R China; [Zhou, Bijiao; Zong, Shumin; Tian, Yixuan; Wang, Lumeng; Zhang, Qian; Chen, Xin; Feng, Yaju; Zhai, Binghui; Sun, Tao; Liu, Yanrong] Nankai Univ, Coll Pharm, Tianjin 300350, Peoples R China; [Zhou, Bijiao; Zong, Shumin; Tian, Yixuan; Wang, Lumeng; Zhang, Qian; Chen, Xin; Feng, Yaju; Zhai, Binghui; Sun, Tao; Liu, Yanrong] Tianjin Int Joint Acad Biomed, Tianjin Key Lab Early Druggabil Evaluat Innovat D, Tianjin 300457, Peoples R China; [Zhou, Bijiao; Zong, Shumin; Tian, Yixuan; Wang, Lumeng; Zhang, Qian; Chen, Xin; Feng, Yaju; Zhai, Binghui; Sun, Tao; Liu, Yanrong] Tianjin Int Joint Acad Biomed, Tianjin Key Lab Mol Drug Res, Tianjin 300457, Peoples R China; [Zhong, Weilong] Tianjin Med Univ, Dept Gastroenterol & Hepatol, Gen Hosp, Tianjin 300052, Peoples R China; [Zhao, Jianmin] Hosp Shun Yi Dist, Dept Pathol, Beijing, Peoples R China	Jining Medical University; Nankai University; Nankai University; Tianjin International Joint Academy of Biomedicine; Tianjin International Joint Academy of Biomedicine; Tianjin Medical University	Liu, YR (corresponding author), Jining Med Univ, Mol Pathol Inst Gastrointestinal Tumors, Affiliated Hosp, Jining 272029, Shandong, Peoples R China.; Sun, T; Liu, YR (corresponding author), Nankai Univ, State Key Lab Med Chem Biol, Tianjin 300350, Peoples R China.; Sun, T; Liu, YR (corresponding author), Nankai Univ, Coll Pharm, Tianjin 300350, Peoples R China.; Sun, T; Liu, YR (corresponding author), Tianjin Int Joint Acad Biomed, Tianjin Key Lab Early Druggabil Evaluat Innovat D, Tianjin 300457, Peoples R China.; Sun, T; Liu, YR (corresponding author), Tianjin Int Joint Acad Biomed, Tianjin Key Lab Mol Drug Res, Tianjin 300457, Peoples R China.	sunrockmia@hotmail.com; liuyanrong1984@163.com			National Natural Science Funds of China [81972629, 81802945, 81872374, 81572838]; Taishan Scholar Project Special Funding; National Science and Technology Major Project [2018ZX09736-005]	National Natural Science Funds of China(National Natural Science Foundation of China (NSFC)); Taishan Scholar Project Special Funding; National Science and Technology Major Project	This work was funded by the following: National Natural Science Funds of China (81972629, 81802945, 81872374, and 81572838), the Taishan Scholar Project Special Funding and the National Science and Technology Major Project (2018ZX09736-005).	Almangush A, 2014, HISTOPATHOLOGY, V65, P587, DOI 10.1111/his.12471; Attramadal CG, 2015, ANTICANCER RES, V35, P6111; Belkin AM, 2015, MICROSC RES TECHNIQ, V51, P280; Bolos V, 2010, ONCOTARGETS THER, V3, P83; Bronsert P, 2014, J PATHOL, V234, P410, DOI 10.1002/path.4416; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; Chai YT, 2018, MED SCI MONITOR, V24, P9251, DOI 10.12659/MSM.911594; Cheng DT, 2016, ONCOTARGET, V7, P45199, DOI 10.18632/oncotarget.9900; Decline F, 2001, J CELL SCI, V114, P811; GABBERT HE, 1992, INT J CANCER, V50, P202, DOI 10.1002/ijc.2910500208; Graves ML, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-015-0670-4; Grigore AD, 2016, J CLIN MED, V5, P51, DOI 10.3390/jcm5050051; Haggar Fatima A, 2009, Clin Colon Rectal Surg, V22, P191, DOI 10.1055/s-0029-1242458; Han JX, 2019, CANCER RES, V79, P1451, DOI 10.1158/0008-5472.CAN-18-2238; Hillig T, 2012, APMIS, V120, P1000, DOI 10.1111/j.1600-0463.2012.02929.x; Jensen DH, 2015, J PATHOL, V236, P505, DOI 10.1002/path.4550; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Khan N, 2017, CARCINOGENESIS, V38, P184, DOI 10.1093/carcin/bgw124; KIKKAWA Y, 1994, J BIOCHEM-TOKYO, V116, P862, DOI 10.1093/oxfordjournals.jbchem.a124608; Kim NG, 2015, J CELL BIOL, V210, P503, DOI 10.1083/jcb.201501025; Koelzer VH, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1106677; Koelzer VH, 2015, HUM PATHOL, V46, P1573, DOI 10.1016/j.humpath.2015.07.010; Kohler I, 2015, J GASTROEN HEPATOL, V30, P78, DOI 10.1111/jgh.12752; Lachowski D, 2018, FASEB J, V32, P1099, DOI 10.1096/fj.201700721R; Landau MS, 2014, MODERN PATHOL, V27, P1578, DOI 10.1038/modpathol.2014.66; Lenander C, 2008, INT J CLIN EXP PATHO, V1, P254; Li J, 2019, J CELL MOL MED, V23, P6283, DOI 10.1111/jcmm.14514; Liang FL, 2013, PATHOL RES PRACT, V209, P269, DOI 10.1016/j.prp.2013.01.009; Liang J, 2019, PHYTOTHER RES, V33, P618, DOI 10.1002/ptr.6250; Lugli A, 2017, MODERN PATHOL, V30, P1299, DOI 10.1038/modpathol.2017.46; Masugi Y, 2010, HUM PATHOL, V41, P1061, DOI 10.1016/j.humpath.2010.01.016; MIYAZAKI K, 1993, P NATL ACAD SCI USA, V90, P11767, DOI 10.1073/pnas.90.24.11767; Moon YW, 2015, CELL DEATH DIFFER, V22, P1341, DOI 10.1038/cdd.2014.228; NIESSEN CM, 1994, EXP CELL RES, V211, P360, DOI 10.1006/excr.1994.1099; Nishiuchi R, 2006, MATRIX BIOL, V25, P189, DOI 10.1016/j.matbio.2005.12.001; Niwa Y, 2014, J SURG ONCOL, V110, P764, DOI 10.1002/jso.23694; Oh BY, 2018, ANN SURG ONCOL, V25, P204, DOI 10.1245/s10434-017-6135-5; Ohike N, 2010, AM J SURG PATHOL, V34, P1417, DOI 10.1097/PAS.0b013e3181f0b05a; Rogers AC, 2014, MODERN PATHOL, V27, P156, DOI 10.1038/modpathol.2013.124; Roh MS, 2004, DIS ESOPHAGUS, V17, P333, DOI 10.1111/j.1442-2050.2004.00436.x; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; Scott RW, 2011, JOVE-J VIS EXP, V58, P3525; Shen J, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0850-z; Shukla S, 2016, SCI REP-UK, V6, DOI 10.1038/srep21860; Shukla S, 2015, CANCER PREV RES, V8, P552, DOI 10.1158/1940-6207.CAPR-14-0286; Song JM, 2015, ONCOL REP, V33, P1867, DOI 10.3892/or.2015.3749; Sy J, 2010, DIS COLON RECTUM, V53, P301, DOI 10.1007/DCR.0b013e3181c3ed05; Tiwari N, 2012, SEMIN CANCER BIOL, V22, P194, DOI 10.1016/j.semcancer.2012.02.013; Ueno H, 2002, HISTOPATHOLOGY, V40, P127, DOI 10.1046/j.1365-2559.2002.01324.x; van Wyk HC, 2015, CANCER TREAT REV, V41, P151, DOI 10.1016/j.ctrv.2014.12.007; Venderbosch S, 2012, PROGNOSTIC VALUE RES, P3252; Wang C, 2011, J ORAL PATHOL MED, V40, P545, DOI 10.1111/j.1600-0714.2011.01041.x; Wang LM, 2009, AM J SURG PATHOL, V33, P134, DOI 10.1097/PAS.0b013e318184cd55; Wu JI, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37443-4; Xiang XY, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-017-0045-7; Yamada N, 2017, HUM PATHOL, V60, P151, DOI 10.1016/j.humpath.2016.10.007; Yamaguchi Y, 2010, J THORAC ONCOL, V5, P1361, DOI 10.1097/JTO.0b013e3181eaf2f3; Yang T, 2017, ONCOTARGET, V8, P5800, DOI 10.18632/oncotarget.10584; Yasuda S, 2010, MOL NUTR FOOD RES, V54, P559, DOI 10.1002/mnfr.200900165; Zhang Q, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1282-6; Zhong WL, 2018, EBIOMEDICINE, V37, P246, DOI 10.1016/j.ebiom.2018.10.041	61	20	20	3	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1527	1542		10.1038/s41388-019-1082-1	http://dx.doi.org/10.1038/s41388-019-1082-1			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31676872				2022-12-17	WOS:000513289600010
J	Zhang, JC; Lin, XX; Wu, LF; Huang, JJ; Jiang, WQ; Kipps, TJ; Zhang, SP				Zhang, Jianchao; Lin, Xinxin; Wu, Liufeng; Huang, Jia-Jia; Jiang, Wen-Qi; Kipps, Thomas J.; Zhang, Suping			Aurora B induces epithelial-mesenchymal transition by stabilizing Snail1 to promote basal-like breast cancer metastasis	ONCOGENE			English	Article							OCT4 INTERACTION; POOR-PROGNOSIS; STEM-CELLS; EXPRESSION; PHOSPHORYLATION; OVEREXPRESSION; EMT; TRANSCRIPTION; REPRESSION; PLASTICITY	Aurora B is a serine/threonine kinase that has been implicated in regulating cell proliferation in distinct cancers, including breast cancer. Here we show that Aurora B expression is elevated in basal-like breast cancer (BLBC) compared with other breast cancer subtypes. This high level of expression seems to correlate with poor metastasis-free survival and relapse-free survival in affected patients. Mechanistically, we show that elevated Aurora B expression in breast cancer cells activates AKT/GSK3 beta to stabilize Snail1 protein, a master regulator of epithelial-mesenchymal transition (EMT), leading to EMT induction in a kinase-dependent manner. Conversely, Aurora B knock down by short-hairpin RNAs (shRNAs) suppresses AKT/GSK3 beta/Snail1 signaling, reverses EMT and reduces breast cancer metastatic potential in vitro and in vivo. Finally, we identified a specific OCT4 phosphorylation site (T343) responsible for mediating Aurora B-induced AKT/GSK3 beta/Snail1 signaling and EMT that could be attenuated by Aurora B kinase inhibitor treatment. These findings support that Aurora B induces EMT to promote breast cancer metastasis via OCT4/AKT/GSK3 beta/Snail1 signaling. Pharmacologic Aurora B inhibition might be a potential effective treatment for breast cancer patients with metastatic disease.	[Zhang, Jianchao; Lin, Xinxin; Wu, Liufeng; Zhang, Suping] Shenzhen Univ, Hlth Sci Ctr, Int Canc Ctr,Dept Pharmacol,Guangdong Key Lab Gen, Base Int Sci & Technol Cooperat Carson Canc Stem, Shenzhen 518055, Peoples R China; [Huang, Jia-Jia; Jiang, Wen-Qi] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Med Oncol,State Key Lab Oncol South China, Guangzhou 510060, Peoples R China; [Kipps, Thomas J.; Zhang, Suping] Univ Calif San Diego, Moores UCSD Canc Ctr, 9310 Athena Circle, San Diego, CA 92093 USA	Shenzhen University; State Key Lab Oncology South China; Sun Yat Sen University; University of California System; University of California San Diego	Zhang, SP (corresponding author), Shenzhen Univ, Hlth Sci Ctr, Int Canc Ctr,Dept Pharmacol,Guangdong Key Lab Gen, Base Int Sci & Technol Cooperat Carson Canc Stem, Shenzhen 518055, Peoples R China.; Zhang, SP (corresponding author), Univ Calif San Diego, Moores UCSD Canc Ctr, 9310 Athena Circle, San Diego, CA 92093 USA.	s9zhang@szu.edu.cn	jiang, wen/GYI-9662-2022		National Natural Science Foundation of China [81672912, 81972753, 81502537]; Science and Technology Program of Guangdong Province, China [2017B030301016, 2016A030310128]; Shenzhen Basic Research Program [JCYJ20170818143630465, JCYJ20170818101638620, JCYJ20180507182203049]; Shenzhen Peacock Innovation Team Project [KQTD20140630100658078]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Program of Guangdong Province, China; Shenzhen Basic Research Program; Shenzhen Peacock Innovation Team Project	This study was supported by the National Natural Science Foundation of China (81672912, 81972753, and 81502537), the Science and Technology Program of Guangdong Province, China (2017B030301016 and 2016A030310128), the Shenzhen Basic Research Program (JCYJ20170818143630465, JCYJ20170818101638620, and JCYJ20180507182203049) and the Shenzhen Peacock Innovation Team Project (KQTD20140630100658078). The authors would like to thank Dr Jessica Tamanini (Shenzhen University, ETediting) for editing the paper prior to submission. We acknowledge the help of the Instrumental Analysis Center of Shenzhen University (Xili Campus) for technical assistance.	Abulaiti X, 2017, STEM CELL REP, V9, P1630, DOI 10.1016/j.stemcr.2017.09.001; Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118; Brumbaugh J, 2012, P NATL ACAD SCI USA, V109, P7162, DOI 10.1073/pnas.1203874109; Calabro A, 2009, BREAST CANCER RES TR, V116, P69, DOI 10.1007/s10549-008-0105-3; Campbell PA, 2013, STEM CELLS, V31, P1107, DOI 10.1002/stem.1365; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Chieffi P, 2006, PROSTATE, V66, P326, DOI 10.1002/pros.20345; Chin SF, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r215; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Fernandez-Miranda G, 2011, DEVELOPMENT, V138, P2661, DOI 10.1242/dev.066381; Goldenson B, 2015, ONCOGENE, V34, P537, DOI 10.1038/onc.2014.14; Gonzalez-Loyola A, 2015, MOL CELL BIOL, V35, P3566, DOI 10.1128/MCB.01286-14; Guise AJ, 2012, MOL CELL PROTEOMICS, V11, P1220, DOI 10.1074/mcp.M112.021030; Gully CP, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-42; Jezequel P, 2012, BREAST CANCER RES TR, V131, P765, DOI 10.1007/s10549-011-1457-7; Jin Y, 2015, CANCER LETT, V362, P70, DOI 10.1016/j.canlet.2015.03.037; Kai K, 2015, MOL CANCER THER, V14, P2687, DOI 10.1158/1535-7163.MCT-15-0096; Krenn V, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00225; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lin YJ, 2012, MOL CELL, V48, P627, DOI 10.1016/j.molcel.2012.08.030; Liu ZC, 2014, BBA-GEN SUBJECTS, V1840, P3096, DOI 10.1016/j.bbagen.2014.07.018; Ma YX, 2015, J MOL MED, V93, P427, DOI 10.1007/s00109-014-1228-0; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mittal V, 2018, ANNU REV PATHOL-MECH, V13, P395, DOI 10.1146/annurev-pathol-020117-043854; Nadler Y, 2008, CLIN CANCER RES, V14, P4455, DOI 10.1158/1078-0432.CCR-07-5268; Pattabiraman DR, 2016, COLD SH Q B, V81, P11, DOI 10.1101/sqb.2016.81.030957; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Porcelli L, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0385-4; Portella G, 2011, CURR MED CHEM, V18, P482, DOI 10.2174/092986711794480203; Rakha EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748; Riaz M, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3415; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Schmidt JM, 2015, CELL REP, V10, P131, DOI 10.1016/j.celrep.2014.12.032; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Shin J, 2016, ELIFE, V5, DOI 10.7554/eLife.10877; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sorrentino R, 2005, J CLIN ENDOCR METAB, V90, P928, DOI 10.1210/jc.2004-1518; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Vargo-Gogola T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193; Vinas-Castells R, 2010, J BIOL CHEM, V285, P3794, DOI 10.1074/jbc.M109.065995; Vischioni B, 2006, MOL CANCER THER, V5, P2905, DOI 10.1158/1535-7163.MCT-06-0301; Wang C, 2016, EUR J PHARMACOL, V779, P1, DOI 10.1016/j.ejphar.2015.11.049; Wang D, 2014, ONCOTARGET, V5, P10803, DOI 10.18632/oncotarget.2506; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Zeng QQ, 2012, P NATL ACAD SCI USA, V109, P1127, DOI 10.1073/pnas.1111053108; Zeng WFF, 2007, J CLIN PATHOL, V60, P218, DOI 10.1136/jcp.2006.036806; Zhang A, 2013, ONCOL LETT, V6, P339, DOI 10.3892/ol.2013.1385; Zhang YQ, 2015, INT J CLIN EXP PATHO, V8, P751; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zhu XP, 2014, EXP THER MED, V7, P560, DOI 10.3892/etm.2014.1491	56	20	19	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2550	2567		10.1038/s41388-020-1165-z	http://dx.doi.org/10.1038/s41388-020-1165-z		JAN 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	31996785				2022-12-17	WOS:000510136400002
J	Chauhan, SS; Toth, RK; Jensen, CC; Casillas, AL; Kashatus, DF; Warfel, NA				Chauhan, Shailender S.; Toth, Rachel K.; Jensen, Corbin C.; Casillas, Andrea L.; Kashatus, David F.; Warfel, Noel A.			PIM kinases alter mitochondrial dynamics and chemosensitivity in lung cancer	ONCOGENE			English	Article							DEPENDENT PROTEIN-KINASE; CYTOCHROME-C; SMALL-CELL; FISSION; DRP1; PHOSPHORYLATION; FUSION; RESISTANCE; REGULATORS; SURVIVAL	Resistance to chemotherapy represents a major obstacle to the successful treatment of non-small-cell lung cancer (NSCLC). The goal of this study was to determine how PIM kinases impact mitochondrial dynamics, ROS production, and response to chemotherapy in lung cancer. Live-cell imaging and microscopy were used to determine the effect of PIM loss or inhibition on mitochondrial phenotype and ROS. Inhibition of PIM kinases caused excessive mitochondrial fission and significant upregulation of mitochondrial superoxide, increasing intracellular ROS. Mechanistically, we define a signaling axis linking PIM1 to Drp1 and mitochondrial fission in lung cancer. PIM inhibition significantly increased the protein levels and mitochondrial localization of Drp1, causing marked fragmentation of mitochondria. An inverse correlation between PIM1 and Drp1 was confirmed in NSCLC patient samples. Inhibition of PIM sensitized NSCLC cells to chemotherapy and produced a synergistic antitumor response in vitro and in vivo. Immunohistochemistry and transmission electron microscopy verified that PIM inhibitors promote mitochondrial fission and apoptosis in vivo. These data improve our knowledge about how PIM1 regulates mitochondria and provide justification for combining PIM inhibition with chemotherapy in NSCLC.	[Chauhan, Shailender S.; Warfel, Noel A.] Univ Arizona, Dept Cellular & Mol Med, Tucson, AZ 85721 USA; [Toth, Rachel K.; Warfel, Noel A.] Univ Arizona, Canc Ctr, Tucson, AZ 85721 USA; [Jensen, Corbin C.; Casillas, Andrea L.] Univ Arizona, Dept Canc Biol, Tucson, AZ USA; [Kashatus, David F.] Univ Virginia, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA USA; [Warfel, Noel A.] Levy Canc Ctr, Rm 0977,1515 N Campbell Ave, Tucson, AZ 85724 USA	University of Arizona; University of Arizona; University of Arizona; University of Virginia	Warfel, NA (corresponding author), Univ Arizona, Dept Cellular & Mol Med, Tucson, AZ 85721 USA.; Warfel, NA (corresponding author), Univ Arizona, Canc Ctr, Tucson, AZ 85721 USA.; Warfel, NA (corresponding author), Levy Canc Ctr, Rm 0977,1515 N Campbell Ave, Tucson, AZ 85724 USA.	warfelna@email.arizona.edu	Chauhan, Shailender Singh/AAM-5269-2020; Kashatus, David/D-8299-2012	Chauhan, Shailender Singh/0000-0002-1975-2734; Casillas, Andrea L/0000-0002-2059-3048; Kashatus, David/0000-0001-8007-0612	American Cancer Society [RSG-16-159-01-CDD]; American Lung Association [LCD-504131]; Department of Defense PCRP Award [W81XWH-19-1-0455]; Cancer Center Support Grant [P30CA023074]	American Cancer Society(American Cancer Society); American Lung Association; Department of Defense PCRP Award(United States Department of Defense); Cancer Center Support Grant	We would like to thank Donna Zhang (University of Arizona) for providing the H1299 Keap1<SUP>-/-</SUP>cell line and assistance with the acquisition and analysis of EPR results. We thank Adam R. Kohr for his assistance with graphic design. The research was supported by American Cancer Society grant RSG-16-159-01-CDD, American Lung Association grant LCD-504131, and Department of Defense PCRP Award (W81XWH-19-1-0455) to NAW. Cancer Center Support Grant P30CA023074 also provided support for this research.	Bordt EA, 2017, DEV CELL, V40, P583, DOI 10.1016/j.devcel.2017.02.020; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Cao LJ, 2019, CANCER LETT, V444, P116, DOI 10.1016/j.canlet.2018.12.015; Chang CR, 2007, J BIOL CHEM, V282, P21583, DOI 10.1074/jbc.C700083200; Choi YM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135083; Cribbs JT, 2007, EMBO REP, V8, P939, DOI 10.1038/sj.embor.7401062; Cristofani R, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0866-5; Din S, 2013, P NATL ACAD SCI USA, V110, P5969, DOI 10.1073/pnas.1213294110; Estaquier J, 2007, CELL DEATH DIFFER, V14, P1086, DOI 10.1038/sj.cdd.4402107; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Jezek J, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7010013; Joseph B, 1999, BIOCHEM BIOPH RES CO, V262, P381, DOI 10.1006/bbrc.1999.1191; Kashatus DF, 2011, NAT CELL BIOL, V13, P1108, DOI 10.1038/ncb2310; Kashatus JA, 2015, MOL CELL, V57, P537, DOI 10.1016/j.molcel.2015.01.002; Kong B, 2014, J BIOL CHEM, V289, P27134, DOI 10.1074/jbc.M114.594812; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Li X, 2017, SCI REP-UK, V7, DOI 10.1038/srep42748; Lilly M, 1999, ONCOGENE, V18, P4022, DOI 10.1038/sj.onc.1202741; Lin JJ, 2016, TRENDS CANCER, V2, P350, DOI 10.1016/j.trecan.2016.05.010; Macdonald A, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-1; Mikkers H, 2004, MOL CELL BIOL, V24, P6104, DOI 10.1128/MCB.24.13.6104-6115.2004; Nagdas S, 2019, CELL REP, V28, P1845, DOI 10.1016/j.celrep.2019.07.031; Qian W, 2014, ONCOTARGET, V5, P4180, DOI 10.18632/oncotarget.1944; Rambold AS, 2011, P NATL ACAD SCI USA, V108, P10190, DOI 10.1073/pnas.1107402108; Roberts ER, 2013, COMPUT STRUCT BIOTEC, V6, DOI 10.5936/csbj.201303019; Senft D, 2016, CURR OPIN CELL BIOL, V39, P43, DOI 10.1016/j.ceb.2016.02.001; Song JH, 2015, ONCOGENE, V34, P3728, DOI 10.1038/onc.2014.306; Song Jin H, 2018, Mol Cancer Ther, V17, P2710, DOI 10.1158/1535-7163.MCT-18-0374; Song JH, 2016, ONCOTARGET, V7, P20152, DOI 10.18632/oncotarget.7918; Thomas KJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045319; Trotta AP, 2017, CELL MOL LIFE SCI, V74, P1999, DOI 10.1007/s00018-016-2451-3; Tu ML, 2011, LIFE SCI, V88, P233, DOI 10.1016/j.lfs.2010.12.001; von Eyss B, 2015, CANCER CELL, V28, P743, DOI 10.1016/j.ccell.2015.10.013; Wan J, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0665-1; Warfel NA, 2016, MOL CANCER THER, V15, P1637, DOI 10.1158/1535-7163.MCT-15-1018; Warfel NA, 2015, PHARMACOL THERAPEUT, V151, P41, DOI 10.1016/j.pharmthera.2015.03.001; Warfel NA, 2011, J BIOL CHEM, V286, P19777, DOI 10.1074/jbc.M111.237081; Westermann B, 2010, NAT REV MOL CELL BIO, V11, P872, DOI 10.1038/nrm3013; Xie LL, 2018, CANCER SCI, V109, P3686, DOI 10.1111/cas.13830; Zappa C, 2016, TRANSL LUNG CANCER R, V5, P288, DOI 10.21037/tlcr.2016.06.07; Zemskova M, 2008, J BIOL CHEM, V283, P20635, DOI 10.1074/jbc.M709479200; Zhao J, 2013, ONCOGENE, V32, P4814, DOI 10.1038/onc.2012.494	42	20	20	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2597	2611		10.1038/s41388-020-1168-9	http://dx.doi.org/10.1038/s41388-020-1168-9		JAN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	31992853	Green Accepted, Green Submitted			2022-12-17	WOS:000509838800001
J	Zhang, MH; Zhang, HH; Du, XH; Gao, J; Li, C; Shi, HR; Li, SZ				Zhang, Ming-Hui; Zhang, Hui-Hui; Du, Xue-Hua; Gao, Jie; Li, Chao; Shi, Hui-Rong; Li, Shang-Ze			UCHL3 promotes ovarian cancer progression by stabilizing TRAF2 to activate the NF-kappa B pathway	ONCOGENE			English	Article							C-TERMINAL HYDROLASES; TARGETS TRAF2; UBIQUITIN; INFLAMMATION; METASTASIS; EXPRESSION; PROGNOSIS; NEDD8; GAIN; MICE	The inflammatory response plays an important role in carcinogenesis. However, the functional role and mechanism of the UCHL3-associated inflammatory response in ovarian cancer remain to be characterized. Here, we report that increased expression of UCHL3 facilitates tumourigenesis by targeting TRAF2 protein, thereby enhancing the inflammatory response. The expression of UCHL3 is elevated in ovarian cancer patients and is associated with an unfavourable prognosis. Genetic ablation of UCHL3 was found to markedly block ovarian cancer cell proliferation, viability and migration both in vitro and in vivo. Mechanistically, luciferase pathway screening results show that NF-kappa B signalling is clearly activated compared with other pathways. UCHL3 was found to activate NF-kappa B signalling by deubiquitinating and stabilizing TRAF2, leading to tumourigenesis. Our results indicate that highly expressed UCHL3 enhances inflammation by stabilizing TRAF2, which in turn facilitates tumourigenesis in ovarian cancer, and that UCHL3 is a potential target for ovarian cancer patients with increased inflammation.	[Zhang, Ming-Hui; Shi, Hui-Rong; Li, Shang-Ze] Zhengzhou Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Zhengzhou 450052, Henan, Peoples R China; [Zhang, Hui-Hui] Hunan Normal Univ, Coll Med, Changsha 410013, Hunan, Peoples R China; [Du, Xue-Hua; Gao, Jie; Li, Chao] Wuhan Univ, Coll Life Sci, Hubei Key Lab Cell Homeostasis, Wuhan 430072, Hubei, Peoples R China; [Li, Shang-Ze] Wuhan Univ, Zhongnan Hosp, Med Sci Res Ctr, Wuhan 430071, Hubei, Peoples R China	Zhengzhou University; Hunan Normal University; Wuhan University; Wuhan University	Li, SZ (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Zhengzhou 450052, Henan, Peoples R China.; Li, SZ (corresponding author), Wuhan Univ, Zhongnan Hosp, Med Sci Res Ctr, Wuhan 430071, Hubei, Peoples R China.	shangze.li@whu.edu.cn	li, shangze/AAW-6317-2021	li, shangze/0000-0003-3134-532X	National Natural Science Foundation of China [81602450]; Fundamental Research Funds for the Central Universities [413000099]; Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund Project [cxpy2017005]; Foundation of Hunan Educational Committee [16B161]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund Project; Foundation of Hunan Educational Committee	This work was supported by grants from the National Natural Science Foundation of China [81602450] and the Fundamental Research Funds for the Central Universities [413000099] and Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund Project [cxpy2017005] and Foundation of Hunan Educational Committee (16B161).	Artavanis-Tsakonas K, 2010, J BIOL CHEM, V285, P6857, DOI 10.1074/jbc.M109.072405; Borghi A, 2016, BIOCHEM PHARMACOL, V116, P1, DOI 10.1016/j.bcp.2016.03.009; Browning L, 2018, CANCER MANAG RES, V10, P6685, DOI 10.2147/CMAR.S179189; Cheong KM, 2011, LANCET ONCOL, V12, P1183, DOI 10.1016/S1470-2045(11)70351-5; Etemadi N, 2015, ELIFE, V4, DOI 10.7554/eLife.10592; Fang Y, 2010, BBA-REV CANCER, V1806, P1, DOI 10.1016/j.bbcan.2010.03.001; Frickel EM, 2007, CELL MICROBIOL, V9, P1601, DOI 10.1111/j.1462-5822.2007.00896.x; Gupta KK, 2019, INT J GYNECOL CANCER, V29, P195, DOI 10.1136/ijgc-2018-000016; Gupta M, 2016, HUM PATHOL, V54, P82, DOI 10.1016/j.humpath.2016.03.006; Habelhah H, 2002, EMBO J, V21, P5756, DOI 10.1093/emboj/cdf576; Kim JY, 2011, FEBS LETT, V585, P1121, DOI 10.1016/j.febslet.2011.03.053; Kisielewski R, 2013, GINEKOL POL, V84, P293; Li LY, 2009, BBA-MOL CELL RES, V1793, P346, DOI 10.1016/j.bbamcr.2008.09.013; Li S, 2018, FASEB J, V32, P230, DOI 10.1096/fj.201700415RR; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Lin TB, 2015, J NEUROSCI, V35, P16545, DOI 10.1523/JNEUROSCI.2301-15.2015; Maccio A, 2012, CYTOKINE, V58, P133, DOI 10.1016/j.cyto.2012.01.015; Menon U, 2014, GYNECOL ONCOL, V132, P490, DOI 10.1016/j.ygyno.2013.11.030; Moufarrij S, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-018-0602-0; Mtango NR, 2012, J CELL PHYSIOL, V227, P2022, DOI 10.1002/jcp.22931; Mtango NR, 2012, J CELL PHYSIOL, V227, P1592, DOI 10.1002/jcp.22876; Nishi R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36235-0; Omori E, 2006, J BIOL CHEM, V281, P19610, DOI 10.1074/jbc.M603384200; Peramuhendige P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18327-5; Popp MW, 2009, J BIOL CHEM, V284, P3593, DOI 10.1074/jbc.M807172200; Reyes-Turcu FE, 2009, ANNU REV BIOCHEM, V78, P363, DOI 10.1146/annurev.biochem.78.082307.091526; Riedlinger T, 2017, BBA-MOL CELL RES, V1864, P1785, DOI 10.1016/j.bbamcr.2017.07.005; Sano Y, 2006, AM J PATHOL, V169, P132, DOI 10.2353/ajpath.2006.060085; Setsuie R, 2010, NEUROCHEM INT, V56, P911, DOI 10.1016/j.neuint.2010.03.021; Song HM, 2014, BIOCHEM BIOPH RES CO, V452, P722, DOI 10.1016/j.bbrc.2014.08.144; Suzuki M, 2009, ENDOCRINOLOGY, V150, P5230, DOI 10.1210/en.2009-0332; Tesio M, 2015, J EXP MED, V212, P525, DOI 10.1084/jem.20141438; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Wada H, 1998, BIOCHEM BIOPH RES CO, V251, P688, DOI 10.1006/bbrc.1998.9532; Wei BB, 2017, MED SCI MONITOR, V23, DOI 10.12659/MSM.903500; Wei BB, 2017, BIOMED PHARMACOTHER, V93, P462, DOI 10.1016/j.biopha.2017.05.145; White KL, 2012, CANCER RES, V72, P1064, DOI 10.1158/0008-5472.CAN-11-3512; Wood MA, 2005, HIPPOCAMPUS, V15, P610, DOI 10.1002/hipo.20082; Wu CJ, 2005, EMBO J, V24, P1886, DOI 10.1038/sj.emboj.7600649; Xiao N, 2012, BIOCHEM J, V441, P979, DOI 10.1042/BJ20111358; Zhang J, 2015, INT J CLIN EXP PATHO, V8, P14228; Zhang YN, 2013, NAT CHEM BIOL, V9, P51, DOI [10.1038/NCHEMBIO.1134, 10.1038/nchembio.1134]; Zhao JJ, 2018, J GASTROEN HEPATOL, V33, P431, DOI 10.1111/jgh.13818; Zhao P, 2017, ANTIVIR RES, V144, P120, DOI 10.1016/j.antiviral.2017.06.002; Zhong HJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080976	45	20	22	2	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					322	333		10.1038/s41388-019-0987-z	http://dx.doi.org/10.1038/s41388-019-0987-z			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31477831				2022-12-17	WOS:000507766400006
J	Jallow, F; O'Leary, KA; Rugowski, DE; Guerrero, JF; Ponik, SM; Schuler, LA				Jallow, Fatou; O'Leary, Kathleen A.; Rugowski, Debra E.; Guerrero, Jorge F.; Ponik, Suzanne M.; Schuler, Linda A.			Dynamic interactions between the extracellular matrix and estrogen activity in progression of ER plus breast cancer	ONCOGENE			English	Article							ENDOCRINE THERAPY; TAMOXIFEN RESISTANCE; DNA-BINDING; IN-VIVO; COLLAGEN; AP-1; GROWTH; CELLS; ASSOCIATION; TUMORS	Metastatic, antiestrogen resistant estrogen receptor a positive (ER+) breast cancer is the leading cause of breast cancer deaths in USA women. While studies have demonstrated the importance of the stomal tumor microenvironment in cancer progression and therapeutic responses, effects on the responses of ER+ cancers to estrogen and antiestrogens are poorly understood, particularly in the complex in vivo environment. In this study, we used an estrogen responsive syngeneic mouse model to interrogate how a COL1A1-enriched fibrotic ECM modulates integrated hormonal responses in cancer progression. We orthotopically transplanted the ER+ TC11 cell line into wild-type (WT) or collagen-dense (Col1a1(t)(m1Jae/+),mCol1a1 syngeneic FVB/N female mice. Once tumors were established, recipients were supplemented with 17 beta-estradiol (E2), tamoxifen, or left untreated. Although the dense/stiff environment in mCol1a1 recipients did not alter the rate of E2-induced proliferation of the primary tumor, it fostered the agonist activity of tamoxifen to increase proliferation and AP-1 activity. Manipulation of estrogen activity did not alter the incidence of lung lesions in either WT or mCol1a1 hosts. However, the mCol1a1 environment enabled tamoxifen-stimulated growth of pulmonary metastases and further fueled estrogen-driven growth. Moreover, E2 remodeled peritumoral ECM architecture in WT animals, modifying alignment of collagen fibers and altering synthesis of ECM components associated with increased alignment and stiffness, and increasing FN1 and POSTN expression in the pulmonary metastatic niche. These studies demonstrate dynamic interactions between ECM properties and estrogen activity in progression of ER+ breast cancer, and support the need for therapeutics that target both ER and the tumor microenvironment.	[Jallow, Fatou; O'Leary, Kathleen A.; Rugowski, Debra E.; Schuler, Linda A.] Univ Wisconsin, Dept Comparat Biosci, 2015 Linden Dr W, Madison, WI 53706 USA; [Jallow, Fatou] Univ Wisconsin, Endocrinol Reprod Physiol Program, Madison, WI USA; [Guerrero, Jorge F.; Ponik, Suzanne M.] Univ Wisconsin, Dept Cell & Regenerat Biol, Madison, WI USA; [Ponik, Suzanne M.; Schuler, Linda A.] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Schuler, LA (corresponding author), Univ Wisconsin, Dept Comparat Biosci, 2015 Linden Dr W, Madison, WI 53706 USA.; Schuler, LA (corresponding author), Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53706 USA.	linda.schuler@wisc.edu	Ponik, Suzanne/AAF-5572-2020	Ponik, Suzanne/0000-0003-1367-4349	National Institutes of Health [R01 CA157675, R01 CA179556, T32 HD041921, R25 GM083252, P30CA014520]; UWCCC Breast Disease Oriented Team; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD041921] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA179556, R01CA206458, P30CA014520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM083252] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UWCCC Breast Disease Oriented Team; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the National Institutes of Health [R01 CA157675 (LAS) and R01 CA179556 (LAS, SMP), T32 HD041921 and R25 GM083252 (FJ), and P30CA014520 (University of Wisconsin Carbone Cancer Center)], and funds from the UWCCC Breast Disease Oriented Team.	ALADNANI MS, 1975, BRIT J CANCER, V31, P653, DOI 10.1038/bjc.1975.112; Anderson WF, 2011, J NATL CANCER I, V103, P1397, DOI 10.1093/jnci/djr257; Barcus CE, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0801-1; Barcus CE, 2016, ONCOTARGET, V7, P48093, DOI 10.18632/oncotarget.10137; Barcus CE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116891; Barcus CE, 2013, J BIOL CHEM, V288, P12722, DOI 10.1074/jbc.M112.447631; Bertrand KA, 2018, HORM CANCER-US, V9, P117, DOI 10.1007/s12672-017-0321-6; Burstein HJ, 2014, J CLIN ONCOL, V32, P2255, DOI 10.1200/JCO.2013.54.2258; Byrne C, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx001; Calvo E, 2012, BREAST CANCER RES TR, V134, P625, DOI 10.1007/s10549-012-2104-7; Campbell KM, 2019, CELL REP, V28, P1526, DOI 10.1016/j.celrep.2019.06.098; Cheung E, 2005, P NATL ACAD SCI USA, V102, P559, DOI 10.1073/pnas.0407113102; Clark IA, 2008, INT J BIOCHEM CELL B, V40, P1362, DOI 10.1016/j.biocel.2007.12.006; Conklin MW, 2011, AM J PATHOL, V178, P1221, DOI 10.1016/j.ajpath.2010.11.076; Cox TR, 2014, CLIN CANCER RES, V20, P3637, DOI 10.1158/1078-0432.CCR-13-1059; Dabrosin C, 2003, INT J CANCER, V107, P535, DOI 10.1002/ijc.11398; Dumont JA, 1996, CELL GROWTH DIFFER, V7, P351; Dupont S, 2016, EXP CELL RES, V343, P42, DOI 10.1016/j.yexcr.2015.10.034; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Esbona K, 2018, AM J PATHOL, V188, P559, DOI 10.1016/j.ajpath.2017.10.025; Evans A, 2018, BREAST CANCER RES TR, V171, P383, DOI 10.1007/s10549-018-4836-5; Gerard C, 2017, J MAMMARY GLAND BIOL, V22, P1, DOI 10.1007/s10911-016-9368-1; Goddard ET, 2017, CANCER DISCOV, V7, P177, DOI 10.1158/2159-8290.CD-16-0822; Gyorfi AH, 2018, MATRIX BIOL, V68-69, P8, DOI 10.1016/j.matbio.2017.12.016; Haslam SZ, 2001, BREAST CANCER RES, V3, P365, DOI 10.1186/bcr324; Hattar R, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2220; He H, 2018, ONCOGENE, V37, P2586, DOI 10.1038/s41388-018-0165-8; Helleman J, 2008, CLIN CANCER RES, V14, P5555, DOI 10.1158/1078-0432.CCR-08-0555; Holm C, 2006, JNCI-J NATL CANCER I, V98, P671, DOI 10.1093/jnci/djj185; Houthuijzen JM, 2018, CANCER METAST REV, V37, P577, DOI 10.1007/s10555-018-9768-3; Insua-Rodriguez J, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201809003; Jakacka M, 2001, J BIOL CHEM, V276, P13615, DOI 10.1074/jbc.M008384200; Jallow F, 2018, J ENDOCR SOC, V2, P293, DOI 10.1210/js.2017-00399; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Kang JS, 2009, BIOL PHARM BULL, V32, P150, DOI 10.1248/bpb.32.150; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Kaushik S, 2016, CANCER METAST REV, V35, P655, DOI 10.1007/s10555-016-9650-0; Keely PJ, 2011, J MAMMARY GLAND BIOL, V16, P205, DOI 10.1007/s10911-011-9226-0; Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820; Kim KK, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a022293; Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; LIU X, 1995, J CELL BIOL, V130, P227, DOI 10.1083/jcb.130.1.227; Liu YM, 2017, METHODS MOL BIOL, V1627, P429, DOI 10.1007/978-1-4939-7113-8_28; Lupien M, 2010, GENE DEV, V24, P2219, DOI 10.1101/gad.1944810; Malorni L, 2016, MOL CANCER RES, V14, P470, DOI 10.1158/1541-7786.MCR-15-0423; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; Molnar IA, 2017, VIRCHOWS ARCH, V470, P275, DOI 10.1007/s00428-017-2065-7; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Nagaraj G, 2015, BREAST CANCER RES TR, V150, P231, DOI 10.1007/s10549-015-3316-4; Nardone A, 2015, BREAST, V24, pS60, DOI 10.1016/j.breast.2015.07.015; Nelson ER, 2013, SCIENCE, V342, P1094, DOI 10.1126/science.1241908; O'Leary KA, 2015, ADV EXP MED BIOL, V846, P201, DOI 10.1007/978-3-319-12114-7_9; Ong CC, 2011, P NATL ACAD SCI USA, V108, P7177, DOI 10.1073/pnas.1103350108; Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379; Pan HC, 2017, NEW ENGL J MED, V377, P1836, DOI 10.1056/NEJMoa1701830; Pontiggia O, 2012, BREAST CANCER RES TR, V133, P459, DOI 10.1007/s10549-011-1766-x; Provenzano PP, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-11; Provenzano PP, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-38; Robertson C, 2016, EXP CELL RES, V343, P73, DOI 10.1016/j.yexcr.2015.11.009; Sampayo RG, 2018, J CELL BIOL, V217, P2777, DOI 10.1083/jcb.201703037; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shea MP, 2018, CANCER LETT, V433, P1, DOI 10.1016/j.canlet.2018.06.025; Shen Q, 2008, ONCOGENE, V27, P366, DOI 10.1038/sj.onc.1210643; Smid M, 2008, CANCER RES, V68, P3108, DOI 10.1158/0008-5472.CAN-07-5644; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; Socovich AM, 2019, SEMIN CELL DEV BIOL, V89, P157, DOI 10.1016/j.semcdb.2018.06.005; Svoronos N, 2017, CANCER DISCOV, V7, P72, DOI 10.1158/2159-8290.CD-16-0502; Tomko LA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31126-w; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Walker RA, 2001, BREAST CANCER RES, V3, P143, DOI 10.1186/bcr287; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Wegner KA, 2017, J HISTOCHEM CYTOCHEM, V65, P479, DOI 10.1369/0022155417718541; Wernig G, 2017, P NATL ACAD SCI USA, V114, P4757, DOI 10.1073/pnas.1621375114; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhou YM, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-59	78	20	20	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2019	38	43					6913	6925		10.1038/s41388-019-0941-0	http://dx.doi.org/10.1038/s41388-019-0941-0			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JH4GX	31406251	Green Accepted			2022-12-17	WOS:000492728000003
J	Beyes, S; Andrieux, G; Schrempp, M; Aicher, D; Wenzel, J; Anton-Garcia, P; Boerries, M; Hecht, A				Beyes, Sven; Andrieux, Geoffroy; Schrempp, Monika; Aicher, David; Wenzel, Janna; Anton-Garcia, Pablo; Boerries, Melanie; Hecht, Andreas			Genome-wide mapping of DNA-binding sites identifies stemness-related genes as directly repressed targets of SNAIL1 in colorectal cancer cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; EPHB3 TUMOR-SUPPRESSOR; COMPETITIVE DISPLACEMENT; SMALL-INTESTINE; EXPRESSION; MYB; TRANSCRIPTION; ASCL2; RNA; EMT	At the molecular level, epithelial-to-mesenchymal transition (EMT) necessitates extensive transcriptional reprogramming which is orchestrated by a small group of gene-regulatory factors that include the zinc-finger DNA-binding protein SNAIL1. Although SNAIL1 is a well-known master regulator of EMT, knowledge of its immediate target genes is incomplete. Here, we used ChIP-seq to identify genes directly regulated by SNAIL1 in colorectal adenocarcinoma cells. When comparing the genomic distribution of SNAIL1 to that of the intestinal stem cell (ISC) transcription factors ASCL2 and TCF7L2, we observed a significant overlap. Furthermore, SNAIL1 ChIP-seq peaks are associated with a substantial fraction of ISC signature genes. In two colorectal cancer cell lines, we verified that SNAIL1 decreases ISC marker expression. Likewise, SNAIL1 directly represses the proto-oncogene MYB, and the long noncoding RNA (lncRNA) WiNTRLINC1, a recently described regulator of ASCL2. SNAIL1 targets multiple regulatory elements at the MYB and WiNTRLINC1 loci, and displaces ASCL2 and TCF7L2 from their binding regions at a MYB downstream regulatory element. Correlation analyses and expression profiling showed antiparallel expression of SNAIL1 and MYB in colorectal and breast cancer cell lines and tumor transcriptomes, suggesting that SNAIL1 controls MYB expression in different tissues. MYB loss-of-function attenuated proliferation and impaired clonogenicity in two- and three-dimensional cell cultures. Therefore, SNAIL1-mediated downregulation of MYB and ISC markers like WiNTRLINC1 likely contributes to the decrease in proliferation known to be associated with EMT, while simultaneously abrogating stemness features of colorectal cancer cells. Apparently, the relationship between EMT and stemness varies in different tumor entities.	[Beyes, Sven; Andrieux, Geoffroy; Schrempp, Monika; Aicher, David; Wenzel, Janna; Anton-Garcia, Pablo; Boerries, Melanie; Hecht, Andreas] Univ Freiburg, Fac Med, Inst Mol Med & Cell Res, Freiburg, Germany; [Beyes, Sven; Wenzel, Janna; Anton-Garcia, Pablo; Hecht, Andreas] Univ Freiburg, Fac Biol, Freiburg, Germany; [Andrieux, Geoffroy; Boerries, Melanie] Univ Freiburg, Univ Med Ctr Freiburg, Fac Med, Inst Med Bioinformat & Syst Med, Freiburg, Germany; [Andrieux, Geoffroy; Boerries, Melanie] German Canc Consortium DKTK, Partner Site Freiburg, Freiburg, Germany; [Andrieux, Geoffroy; Boerries, Melanie] German Canc Res Ctr, Heidelberg, Germany; [Boerries, Melanie] Univ Freiburg, Univ Med Ctr, Fac Med, CCCF, Freiburg, Germany; [Hecht, Andreas] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, Freiburg, Germany	University of Freiburg; University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg; University of Freiburg	Hecht, A (corresponding author), Univ Freiburg, Fac Med, Inst Mol Med & Cell Res, Freiburg, Germany.; Hecht, A (corresponding author), Univ Freiburg, Fac Biol, Freiburg, Germany.; Hecht, A (corresponding author), Univ Freiburg, BIOSS Ctr Biol Signalling Studies, Freiburg, Germany.	andreas.hecht@mol-med.uni-freiburg.de	Boerries, Melanie/AAM-2602-2021	ANDRIEUX, GEOFFROY/0000-0002-5389-9481	Deutsche Forschungsgemeinschaft [DFG HE2004/11-1, CRC-850, GRK2344]; German Federal Ministry of Education and Research (BMBF) [FKZ 01ZX1708F]; Deutsche Forschungsgemeinschaft Research Training Group [GRK2344]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft Research Training Group(German Research Foundation (DFG))	The authors are grateful to K. Geiger and D. Herchenbach for excellent technical assistance, and to the team of the Genomics and Proteomics Core Facility, German Cancer Research Center/DKFZ, Heidelberg, Germany, for their sequencing service. This work was financially supported by the Deutsche Forschungsgemeinschaft (DFG HE2004/11-1 to AH; CRC-850 subprojects B5 to AH and Z1 to MB; GRK2344 subprojects B02 to MB and B03 to AH), and by the German Federal Ministry of Education and Research (BMBF) within the framework of the e:Med research and funding concept CoNfirm (FKZ 01ZX1708F to MB). JW and PAG were funded by the Deutsche Forschungsgemeinschaft Research Training Group GRK2344 "MeInBio-BioInMe".	Afgan E, 2016, NUCLEIC ACIDS RES, V44, pW3, DOI 10.1093/nar/gkw343; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Beck B, 2015, CELL STEM CELL, V16, P67, DOI 10.1016/j.stem.2014.12.002; Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Caja L, 2018, ONCOGENE, V37, P2515, DOI 10.1038/s41388-018-0136-0; Celia-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218; Cheasley D, 2011, STEM CELLS, V29, P2042, DOI 10.1002/stem.761; Ciznadija D, 2009, CELL DEATH DIFFER, V16, P1530, DOI 10.1038/cdd.2009.94; Fabregat I, 2016, J CLIN MED, V5, DOI 10.3390/jcm5030037; Fellmann C, 2013, CELL REP, V5, P1704, DOI 10.1016/j.celrep.2013.11.020; Giakountis A, 2016, CELL REP, V15, P2588, DOI 10.1016/j.celrep.2016.05.038; Giresi PG, 2007, GENOME RES, V17, P877, DOI 10.1101/gr.5533506; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Haraguchi M, 2008, J BIOL CHEM, V283, P23514, DOI 10.1074/jbc.M801125200; Hsu DSS, 2014, CANCER CELL, V26, P534, DOI 10.1016/j.ccell.2014.09.002; Hsu PD, 2013, NAT BIOTECHNOL, V31, P827, DOI 10.1038/nbt.2647; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Hugo HJ, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3580; Hwang WL, 2014, NAT CELL BIOL, V16, P268, DOI 10.1038/ncb2910; Hwang WL, 2011, GASTROENTEROLOGY, V141, P279, DOI 10.1053/j.gastro.2011.04.008; Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389; Jagle S, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007109; Jagle S, 2014, P NATL ACAD SCI USA, V111, P4886, DOI 10.1073/pnas.1314523111; Javaid S, 2013, CELL REP, V5, P1679, DOI 10.1016/j.celrep.2013.11.034; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lambert SA, 2018, CELL, V172, P650, DOI 10.1016/j.cell.2018.01.029; Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63; Malaterre J, 2016, ONCOGENE, V35, P2475, DOI 10.1038/onc.2015.305; Malaterre J, 2007, P NATL ACAD SCI USA, V104, P3829, DOI 10.1073/pnas.0610055104; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Maturi V, 2018, MOL ONCOL, V12, P1153, DOI 10.1002/1878-0261.12317; Meyer-Schaller N, 2019, DEV CELL, V48, P539, DOI 10.1016/j.devcel.2018.12.023; Miao RY, 2011, CANCER RES, V71, P7029, DOI 10.1158/0008-5472.CAN-11-1015; Millanes-Romero A, 2013, MOL CELL, V52, P746, DOI 10.1016/j.molcel.2013.10.015; Mokry M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015092; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Preca BT, 2015, INT J CANCER, V137, P2566, DOI 10.1002/ijc.29642; Ramsay RG, 2008, NAT REV CANCER, V8, P523, DOI 10.1038/nrc2439; Rembold M, 2014, GENE DEV, V28, P167, DOI 10.1101/gad.230953.113; Ronsch K, 2015, MOL ONCOL, V9, P335, DOI 10.1016/j.molonc.2014.08.016; Rosmaninho P, 2018, EMBO J, V37, DOI 10.15252/embj.201797115; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Schnappauf O, 2016, BBA-GENE REGUL MECH, V1859, P1353, DOI 10.1016/j.bbagrm.2016.08.002; Schuijers J, 2015, CELL STEM CELL, V16, P158, DOI 10.1016/j.stem.2014.12.006; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Soleimani VD, 2012, MOL CELL, V47, P457, DOI 10.1016/j.molcel.2012.05.046; Srivastava SK, 2015, BRIT J CANCER, V113, P1694, DOI 10.1038/bjc.2015.400; Stanisavljevic J, 2011, J CELL SCI, V124, P4159, DOI 10.1242/jcs.078824; Stemmer V, 2008, ONCOGENE, V27, P5075, DOI 10.1038/onc.2008.140; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tran DD, 2011, MOL CANCER RES, V9, P1644, DOI 10.1158/1541-7786.MCR-11-0371; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Van der Auwera, 2013, CURR PROTOC BIOINFOR, V43; van der Flier LG, 2009, CELL, V136, P903, DOI 10.1016/j.cell.2009.01.031; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Weise A, 2010, NUCLEIC ACIDS RES, V38, P1964, DOI 10.1093/nar/gkp1197; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Yu GC, 2015, BIOINFORMATICS, V31, P2382, DOI 10.1093/bioinformatics/btv145; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhu P, 2018, NAT CELL BIOL, V1134	75	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2019	38	40					6647	6661		10.1038/s41388-019-0905-4	http://dx.doi.org/10.1038/s41388-019-0905-4			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JC0EY	31391555	hybrid			2022-12-17	WOS:000488953500001
J	Alasiri, G; Jiramongkol, Y; Zona, S; Fan, LYN; Mahmud, Z; Gong, G; Lee, HJ; Lam, EWF				Alasiri, Glowi; Jiramongkol, Yannasittha; Zona, Stefania; Fan, Lavender Y. N.; Mahmud, Zimam; Gong, Gyungyub; Lee, Hee Jin; Lam, Eric W-F			Regulation of PERK expression by FOXO3: a vulnerability of drug-resistant cancer cells	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; DNA-DAMAGE RESPONSE; ER STRESS; BREAST-CANCER; TRANSCRIPTION FACTOR; FOXM1 EXPRESSION; GEFITINIB IRESSA; KINASE; INHIBITOR; AUTOPHAGY	The major impediment to effective cancer therapy has been the development of drug resistance. The tumour suppressive transcription factor FOXO3 promotes cell cycle arrest, senescence and cell death, and mediates the cytotoxic and cytostatic functions of cancer therapeutics. In consequence, FOXO3 is often downregulated as an adaptive response in cancer and particularly in chemotherapeutic drug-resistant cells. Consistently, we find that FOXO3 expression is attenuated in the drug-resistant MCF-7-Epi(R) and MCF-7-Tax(R) compared to the parental MCF-7 breast cancer cells. Using ChIP, short-interfering RNA (siRNA) knockdown, and overexpression assays as well as Foxo(1/3/4-/-) MEFs, we establish the endoplasmic reticulum (ER)-stress defence modulator PERK (eIF2AK3) as a direct downstream transcriptional target of FOXO3. In agreement, there is also a positive correlation between FOXO3 and PERK expression at the protein and RNA levels in breast cancer patient samples. We uncover that PERK expression is downregulated but its activity constitutively elevated in the drug-resistant cells. With this in mind, we exploit this adaptive response of low FOXO3 and PERK expression, and high PERK activity in drug-resistant breast cancer cells and show that these drug-resistant cells are specifically sensitive to PERK inhibition. In support of this finding, we show that ectopic overexpression of FOXO3 can reduce the sensitivity of the resistant cells to the PERK inhibitor GSK2606414, while the Foxo(1/3/4-/-) MEFs expressing lower levels of PERK are more sensitive to PERK inhibition compared to wild-type MEFs. PERK inhibitor-titration and -time course experiments showed that the drug-resistant cells, which express lower expression and higher activity levels of PERK, are more sensitive to the increasing concentrations of PERK inhibitor compared to parental MCF-7 cells. Our present work thus reveals a chemotherapeutic drug-resistant cancer cell vulnerability in PERK and suggests PERK as a potential target for cancer therapy, specifically in the context of drug-resistant cancers.	[Alasiri, Glowi; Jiramongkol, Yannasittha; Zona, Stefania; Fan, Lavender Y. N.; Mahmud, Zimam; Lam, Eric W-F] Imperial Coll London, Dept Surg & Canc, Hammersmith Hosp Campus, London W12 0NN, England; [Gong, Gyungyub; Lee, Hee Jin] Univ Ulsan, Asan Med Ctr, Dept Pathol, Coll Med, Seoul, South Korea	Imperial College London; University of Ulsan; Asan Medical Center	Lam, EWF (corresponding author), Imperial Coll London, Dept Surg & Canc, Hammersmith Hosp Campus, London W12 0NN, England.	eric.lam@imperial.ac.uk	Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576; Jiramongkol, Yannasittha/0000-0003-1824-4313; Lee, Hee Jin/0000-0002-4963-6603	MRC [MR/N012097/1]; CRUK [C37/A12011]; Breast Cancer Now [2012MayPR070, 2012NovPhD016, 2014NovPhD326]; Cancer Research UK Imperial Centre; NIHR Imperial BRC; Saudi Arabian Cultural Bureau in London [MSU434]; Medical Research Council (MRC) of UK [MR/N012097/1]; Commonwealth Scholarship Commission [BDCS-2015-63]; Korean Health Technology R&D Project, Ministry of Health Welfare [HI15C0708, HI17C0337]; Basic Science Research Programs through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning, Republic of Korea [NRF-2017R1D1A1B03027977]; Imperial ECMC	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); CRUK(Cancer Research UK); Breast Cancer Now; Cancer Research UK Imperial Centre; NIHR Imperial BRC; Saudi Arabian Cultural Bureau in London; Medical Research Council (MRC) of UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Commonwealth Scholarship Commission; Korean Health Technology R&D Project, Ministry of Health Welfare; Basic Science Research Programs through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning, Republic of Korea; Imperial ECMC	Eric W.-F. Lam's work is supported by MRC (MR/N012097/1), CRUK (C37/A12011), Breast Cancer Now (2012MayPR070; 2012NovPhD016; 2014NovPhD326), the Cancer Research UK Imperial Centre, Imperial ECMC and NIHR Imperial BRC. Glowi Alasiri is a recipient of a scholarship from the Saudi Arabian Cultural Bureau in London (MSU434). Stefania Zona was a post-doctoral research associate supported by the Medical Research Council (MRC) of UK (MR/N012097/1) and Breast Cancer Now (2012MayPR070). Zimam Mahmud was supported by a fellowship from the Commonwealth Scholarship Commission (BDCS-2015-63). Gyungyub Gong and Hee Jin Lee are supported by The Korean Health Technology R&D Project, Ministry of Health & Welfare (HI15C0708 and HI17C0337) and Basic Science Research Programs through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning, Republic of Korea (NRF-2017R1D1A1B03027977).	Alasiri G, 2018, MOL CELL ENDOCRINOL, V462, P67, DOI 10.1016/j.mce.2017.05.027; Axten JM, 2012, J MED CHEM, V55, P7193, DOI 10.1021/jm300713s; Bella L, 2014, SEMIN CANCER BIOL, V29, P32, DOI 10.1016/j.semcancer.2014.07.008; Bhattacharyya S, 2014, NAT REV MOL CELL BIO, V15, P122, DOI 10.1038/nrm3741; Bines J, 2014, ANN ONCOL, V25, P1079, DOI 10.1093/annonc/mdu007; Bobrovnikova-Marjon E, 2012, MOL CELL BIOL, V32, P2268, DOI 10.1128/MCB.00063-12; Bu YW, 2016, J CELL PHYSIOL, V231, P2088, DOI 10.1002/jcp.25336; Chen JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013704; Clarke HJ, 2014, CANCER CELL, V25, P563, DOI 10.1016/j.ccr.2014.03.015; de Moraes GN, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.26; de Moraes GN, 2016, CURR DRUG TARGETS, V17, P164, DOI 10.2174/1389450115666141122211549; de Olano N, 2012, MOL CANCER RES, V10, P1189, DOI 10.1158/1541-7786.MCR-11-0559; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Eijkelenboom A, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2012.74; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; Essaghir A, 2009, J BIOL CHEM, V284, P10334, DOI 10.1074/jbc.M808848200; Francis RE, 2009, INT J ONCOL, V35, P57, DOI 10.3892/ijo_00000313; Garg Abhishek D, 2015, Mol Cell Oncol, V2, pe975089, DOI 10.4161/23723556.2014.975089; Guertin DA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe24; Ho KK, 2008, ONCOGENE, V27, P2300, DOI 10.1038/onc.2008.23; Ho KK, 2012, J BIOL CHEM, V287, P1545, DOI 10.1074/jbc.M111.284224; Hui RCY, 2008, MOL CANCER THER, V7, P670, DOI 10.1158/1535-7163.MCT-07-0397; Im J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0652-4; Intuyod K, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1235-0; Ji GR, 2015, INT J BIOL SCI, V11, P803, DOI 10.7150/ijbs.11100; Jiang YQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065756; Kajihara T, 2006, MOL ENDOCRINOL, V20, P2444, DOI 10.1210/me.2006-0118; Karadedou CT, 2012, ONCOGENE, V31, P1845, DOI 10.1038/onc.2011.368; Khongkow M, 2013, CARCINOGENESIS, V34, P1476, DOI 10.1093/carcin/bgt098; Khongkow P, 2016, ONCOGENE, V35, P990, DOI 10.1038/onc.2015.152; Khongkow P, 2014, ONCOGENE, V33, P4144, DOI 10.1038/onc.2013.457; Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755; Koo CY, 2012, BBA-GENE REGUL MECH, V1819, P28, DOI 10.1016/j.bbagrm.2011.09.004; Krol J, 2007, MOL CANCER THER, V6, P3169, DOI 10.1158/1535-7163.MCT-07-0507; Kwok JMM, 2008, MOL CANCER THER, V7, P2022, DOI 10.1158/1535-7163.MCT-08-0188; Lam EWF, 2006, BIOCHEM SOC T, V34, P722, DOI 10.1042/BST0340722; Lam EWF, 2013, NAT REV CANCER, V13, P482, DOI 10.1038/nrc3539; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lee HJ, 2015, VIRCHOWS ARCH, V467, P701, DOI 10.1007/s00428-015-1861-1; Lee JJ, 2016, INT J EXP PATHOL, V97, P170, DOI 10.1111/iep.12187; Ma XH, 2014, J CLIN INVEST, V124, P1406, DOI 10.1172/JCI70454; Mahoney E, 2013, AUTOPHAGY, V9, P434, DOI 10.4161/auto.23027; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; McGovern UB, 2009, MOL CANCER THER, V8, P582, DOI 10.1158/1535-7163.MCT-08-0805; Mujtaba T, 2011, DISCOV MED, V12, P471; Myatt S.S., 2008, CANCER, V8, P242, DOI DOI 10.1038/NRC2223-C2; Nabholtz JM, 2001, ONCOLOGIST, V6, P5, DOI 10.1634/theoncologist.6-suppl_3-5; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Pytel D, 2016, ONCOGENE, V35, P1207, DOI 10.1038/onc.2015.178; Salaroglio IC, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0657-0; Sunters A, 2006, CANCER RES, V66, P212, DOI 10.1158/0008-5472.CAN-05-1997; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Urra H, 2016, TRENDS CANCER, V2, P252, DOI 10.1016/j.trecan.2016.03.007; van der Vos KE, 2012, NAT CELL BIOL, V14, P829, DOI 10.1038/ncb2536; Varghese V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38017-0; Xie J, 2010, ONCOGENE, V29, P2499, DOI 10.1038/onc.2010.18; Yecies JL, 2011, CANCER RES, V71, P2815, DOI 10.1158/0008-5472.CAN-10-4158; Zhang W, 2015, CELL SIGNAL, V27, P436, DOI 10.1016/j.cellsig.2014.12.010; Zhang W, 2013, GENE DEV, V27, P441, DOI 10.1101/gad.201731.112; Zona S, 2014, BBA-GENE REGUL MECH, V1839, P1316, DOI 10.1016/j.bbagrm.2014.09.016	60	20	20	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2019	38	36					6382	6398		10.1038/s41388-019-0890-7	http://dx.doi.org/10.1038/s41388-019-0890-7			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IX6EX	31312024	Green Published, hybrid			2022-12-17	WOS:000485776800005
J	Gomez, ML; Shah, N; Kenny, TC; Jenkins, EC; Germain, D				Gomez, Maria L.; Shah, Nagma; Kenny, Timothy C.; Jenkins, Edmund C., Jr.; Germain, Doris			SOD1 is essential for oncogene-driven mammary tumor formation but dispensable for normal development and proliferation	ONCOGENE			English	Article							SUPEROXIDE-DISMUTASE 1; TRANSGENIC MICE; ESTROGEN-RECEPTOR; CANCER; BREAST; UPRMT; NEU; ADENOCARCINOMA; IDENTIFICATION; ACTIVATION	We previously reported that the dismutase SOD1 is overexpressed in breast cancer. However, whether SOD1 plays an active role in tumor formation in vivo has never been demonstrated. Further, as luminal cells of normal breast epithelial cells are enriched in SOD1, whether SOD1 is essential for normal mammary gland development has never been determined. We initiated this study to investigate the role of SOD1 in mammary gland tumorigenesis as well as in normal mammary gland development. We crossed the inducible erbB2 (MMTV-iErbB2) and Wnt (MMTV-Wnt) transgenic mice to the SOD1 heterozygote or knockout mice. Our results show that SOD1 is essential for oncogene-driven proliferation, but not normal proliferation of the mammary gland associated with pregnancy or other normal proliferative tissues such as skin and intestines. We show that activation of the oncogene ErbB2 is associated with increased ROS and that high ROS subpopulation of ErbB2 cancer cells show elevated SOD1. In the same cells, decrease in SOD1 is associated with an elevation in both apoptosis as well as oncogene-induced senescence. Based on these results, we suggest that SOD1 carries a housekeeping function that maintains ROS levels below a threshold that supports oncogene-dependent proliferation, while allowing escape from oncogene-induced senescence, independently of the oncogene driving tumor formation. These results identify SOD1 as an ideal target for cancer therapy as SOD1 inhibitors hold the potential to prevent the growth of cancers cells of diverse genotypes, activate multiple modes of cell death therefore making acquired resistance more difficult, while sparing normal tissues.	[Gomez, Maria L.; Shah, Nagma; Kenny, Timothy C.; Jenkins, Edmund C., Jr.; Germain, Doris] Icahn Sch Med Mt Sinai, Dept Med, Div Hematol Oncol, Tisch Canc Inst, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Germain, D (corresponding author), Icahn Sch Med Mt Sinai, Dept Med, Div Hematol Oncol, Tisch Canc Inst, New York, NY 10029 USA.	doris.germain@mssm.edu		Jenkins, Edmund/0000-0002-6448-090X; Gomez, Maria Lucia/0000-0003-3682-9219; Kenny, Timothy Cole/0000-0001-8258-5716	NIH [R01CA172046]; NIH; P30 grant [CA196521]; NATIONAL CANCER INSTITUTE [F31CA228259, P30CA196521, R01CA172046] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); P30 grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank all members of the Germain lab and of the Mount Sinai Flow Cytometry Core, Microscopy Core and Biorepository Core Facility. This study was supported by the NIH R01CA172046 to DG and the NIH supplement to MG. The core facilities used in this study are supported by P30 grant CA196521.	Bae J, 2000, MCL 1S SPLICING VARI, DOI [10.1074/JBC.M909826199, DOI 10.1074/JBC.M909826199]; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Elster N, 2015, BREAST CANCER RES TR, V149, P5, DOI 10.1007/s10549-014-3250-x; Finley LWS, 2011, CANCER CELL, V19, P416, DOI 10.1016/j.ccr.2011.02.014; Germain D, 2017, J BIOENERG BIOMEMBR, V49, P291, DOI 10.1007/s10863-017-9716-x; Glasauer A, 2014, J CLIN INVEST, V124, P117, DOI 10.1172/JCI71714; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hart PC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7053; He CX, 2016, TRENDS BIOCHEM SCI, V41, P568, DOI 10.1016/j.tibs.2016.04.004; Hempel N, 2011, ANTI-CANCER AGENT ME, V11, P191, DOI 10.2174/187152011795255911; Ho YS, 1998, J BIOL CHEM, V273, P7765, DOI 10.1074/jbc.273.13.7765; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Kannan N, 2014, P NATL ACAD SCI USA, V111, P7789, DOI 10.1073/pnas.1403813111; Kenny TC, 2017, ONCOGENE, V36, P4393, DOI 10.1038/onc.2017.52; Kenny TC, 2017, J BIOENERG BIOMEMBR, V49, P297, DOI 10.1007/s10863-017-9722-z; Kenny TC, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00159; Kenny TC, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00037; Li S., 2018, INT J CHEM REACT ENG, V16, P1; Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273; Lombard David B, 2011, Handb Exp Pharmacol, V206, P163, DOI 10.1007/978-3-642-21631-2_8; Matzuk MM, 1998, ENDOCRINOLOGY, V139, P4008, DOI 10.1210/en.139.9.4008; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; Moullan N, 2015, CELL REP, V10, P1681, DOI 10.1016/j.celrep.2015.02.034; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; OBERLEY LW, 1979, CANCER RES, V39, P1141; Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200; Palechor-Ceron N, 2013, AM J PATHOL, V183, P1862, DOI 10.1016/j.ajpath.2013.08.009; Papa Luena, 2014, Genes Cancer, V5, P15; Papa L, 2014, J BIOL CHEM, V289, P5412, DOI 10.1074/jbc.C113.526475; Papa L, 2014, MOL CELL BIOL, V34, P699, DOI 10.1128/MCB.01337-13; Papa L, 2011, J CELL SCI, V124, P1396, DOI 10.1242/jcs.078220; Pelicano H, 2006, J CELL BIOL, V175, P913, DOI 10.1083/jcb.200512100; Reddi AR, 2013, CELL, V152, P224, DOI 10.1016/j.cell.2012.11.046; Riar AK, 2017, HUM MOL GENET, V26, P1318, DOI 10.1093/hmg/ddx049; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Sajesh BV, 2015, ONCOTARGET, V6, P27907, DOI 10.18632/oncotarget.4875; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Somwar R, 2011, P NATL ACAD SCI USA, V108, P16375, DOI 10.1073/pnas.1113554108; Somwar R, 2009, J BIOMOL SCREEN, V14, P1176, DOI 10.1177/1087057109350919; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; Tao RD, 2010, MOL CELL, V40, P893, DOI 10.1016/j.molcel.2010.12.013; Tsang CK, 2018, MOL CELL, V70, P502, DOI 10.1016/j.molcel.2018.03.029; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Wang Y, 2018, J CELL BIOL, V217, P1915, DOI 10.1083/jcb.201708007; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107	50	20	21	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2019	38	29					5751	5765		10.1038/s41388-019-0839-x	http://dx.doi.org/10.1038/s41388-019-0839-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IQ4WS	31222103	Green Accepted			2022-12-17	WOS:000480752800001
J	Mishra, S; Bernal, C; Silvano, M; Anand, S; Altaba, ARI				Mishra, Sonakshi; Bernal, Carolina; Silvano, Marianna; Anand, Santosh; Altaba, Ariel Ruiz i			The protein secretion modulator TMED9 drives CNIH4/TGF alpha/GLI signaling opposing TMED3-WNT-TCF to promote colon cancer metastases	ONCOGENE			English	Article							GROWTH-FACTOR-ALPHA; TGF-ALPHA; FACTOR RECEPTOR; P24 FAMILY; BETA-CATENIN; COLORECTAL-CANCER; EXOCYTIC VESICLES; CARGO RECEPTORS; PROTGF-ALPHA; TUMOR-GROWTH	How cells in primary tumors initially become pro-metastatic is not understood. A previous genome-wide RNAi screen uncovered colon cancer metastatic suppressor and WNT promoting functions of TMED3, a member of the p24 ER-to-Golgi protein secretion family. Repression of canonical WNT signaling upon knockdown (kd) of TMED3 might thus be sufficient to drive metastases. However, searching for transcriptional influences on other family members here we find that TMED3 kd leads to enhanced TMED9, that TMED9 acts downstream of TMED3 and that TMED9 kd compromises metastasis. Importantly, TMED9 pro-metastatic function is linked to but distinct from the repression of TMED3-WNT-TCF signaling. Functional rescue of the migratory deficiency of TMED9 kd cells identifies TGF alpha as a mediator of TMED9 pro-metastatic activity. Moreover, TMED9 kd compromises the biogenesis, and thus function, of TGF alpha. Analyses in three colon cancer cell types highlight a TMED9-dependent gene set that includes CNIH4, a member of the CORNICHON family of TGF alpha exporters. Our data indicate that TGFA and CNIH4, which display predictive value for disease-free survival, promote colon cancer cell metastatic behavior, and suggest that TMED9 pro-metastatic function involves the modulation of the secretion of TGF alpha ligand. Finally, TMED9/TMED3 antagonism impacts WNT-TCF and GLI signaling, where TMED9 primacy over TMED3 leads to the establishment of a positive feedback loop together with CNIH4, TGF alpha, and GLI1 that enhances metastases. We propose that primary colon cancer cells can transition between two states characterized by secretion-transcription regulatory loops gated by TMED3 and TMED9 that modulate their metastatic proclivities.	[Mishra, Sonakshi; Bernal, Carolina; Silvano, Marianna; Anand, Santosh; Altaba, Ariel Ruiz i] Univ Geneva, Dept Genet Med & Dev, Fac Med, Med Sch, 1 Rue Michel Servet, CH-1211 Geneva, Switzerland	University of Geneva	Altaba, ARI (corresponding author), Univ Geneva, Dept Genet Med & Dev, Fac Med, Med Sch, 1 Rue Michel Servet, CH-1211 Geneva, Switzerland.	Ariel.RuizAltaba@unige.ch		Anand, Santosh/0000-0003-2287-0229	Swiss Government pre-doctoral grant; Swiss National Science Foundation; Swiss Cancer League; Departement d'Instruction Publique de Geneve	Swiss Government pre-doctoral grant; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Cancer League; Departement d'Instruction Publique de Geneve	We are grateful to R. Coffey for the kind gift of HA/FLAG-tagged TGFa, to all Ruiz i Altaba lab members for discussion, to M. Kuciak and A. Conod for comments on the manuscript and to I. Borges Grazina for technical help. This work was supported by a Swiss Government pre-doctoral grant to SM and by grants from the Swiss National Science Foundation and the Swiss Cancer League, and by funds from the Departement d'Instruction Publique de Geneve to ARA.	Aberger F, 2014, SEMIN CELL DEV BIOL, V33, P93, DOI 10.1016/j.semcdb.2014.05.003; Adolf A, 2018, PROTEOMIC PROFILING; Ahn Y, 2010, DEVELOPMENT, V137, P3221, DOI 10.1242/dev.054668; ALISON MR, 1993, CELL PROLIFERAT, V26, P449, DOI 10.1111/j.1365-2184.1993.tb00132.x; Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Azzolin L, 2014, CELL, V158, P157, DOI 10.1016/j.cell.2014.06.013; Azzolin L, 2012, CELL, V151, P1443, DOI 10.1016/j.cell.2012.11.027; Barr FA, 2001, J CELL BIOL, V155, P885, DOI 10.1083/jcb.200108102; Bokel C, 2006, DEVELOPMENT, V133, P459, DOI 10.1242/dev.02219; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; Buechling T, 2011, EMBO REP, V12, P1265, DOI 10.1038/embor.2011.212; Cao Z, 2008, MOL CELL PROTEOMICS, V7, P1651, DOI 10.1074/mcp.M700155-MCP200; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; Connolly DJ, 2013, J BIOL CHEM, V288, P5616, DOI 10.1074/jbc.M112.403899; De Jong KP, 1998, HEPATOLOGY, V28, P971, DOI 10.1002/hep.510280411; Denzel A, 2000, CURR BIOL, V10, P55, DOI 10.1016/S0960-9822(99)00266-3; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; Desnoyers L, 2008, ONCOGENE, V27, P85, DOI 10.1038/sj.onc.1210623; Dhawan P, 2011, ONCOGENE, V30, P3234, DOI 10.1038/onc.2011.43; Doyle SL, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1706; Duquet A, 2014, EMBO MOL MED, V6, P882, DOI 10.15252/emmm.201303799; Eberl M, 2012, EMBO MOL MED, V4, P218, DOI 10.1002/emmm.201100201; El-Hariry I, 2001, INT J CANCER, V94, P652, DOI 10.1002/ijc.1515; Emery G, 2000, J CELL SCI, V113, P2507; Fraisier V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082223; Freeman TJ, 2012, GASTROENTEROLOGY, V142, P562, DOI 10.1053/j.gastro.2011.11.026; Fullekrug J, 1999, MOL BIOL CELL, V10, P1939, DOI 10.1091/mbc.10.6.1939; Giancotti FG, 2013, CELL, V155, P750, DOI 10.1016/j.cell.2013.10.029; Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064; Gregorieff A, 2015, NATURE, V526, P715, DOI 10.1038/nature15382; Gu XH, 2012, CLIN EXP MED, V12, P195, DOI 10.1007/s10238-011-0155-4; Gwak J, 2016, ONCOTARGET, V7, P48250, DOI 10.18632/oncotarget.10198; Hu TH, 2010, J BIOL CHEM, V285, P13561, DOI 10.1074/jbc.M109.075945; HUANG F, 1995, EXP CELL RES, V219, P8, DOI 10.1006/excr.1995.1198; Jenne N, 2002, J BIOL CHEM, V277, P46504, DOI 10.1074/jbc.M206989200; Jerome-Majewska LA, 2010, DEV BIOL, V341, P154, DOI 10.1016/j.ydbio.2010.02.019; Kho DH, 2009, GUT, V58, P509, DOI 10.1136/gut.2008.150938; Krausova M, 2014, CELL SIGNAL, V26, P570, DOI 10.1016/j.cellsig.2013.11.032; Kuo A, 2000, EMBO J, V19, P6427, DOI 10.1093/emboj/19.23.6427; Lai W, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0566-z; LaLonde DP, 2006, CURR BIOL, V16, P1375, DOI 10.1016/j.cub.2006.05.057; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lau TS, 2017, ONCOGENE, V36, P3576, DOI 10.1038/onc.2016.509; Lavoie C, 1999, J CELL BIOL, V146, P285, DOI 10.1083/jcb.146.2.285; Li CX, 2007, MOL BIOL CELL, V18, P3081, DOI 10.1091/mbc.E07-02-0172; Li CX, 2004, P NATL ACAD SCI USA, V101, P5571, DOI 10.1073/pnas.0401294101; Li X, 2015, BIOCHEM BIOPH RES CO, V463, P483, DOI 10.1016/j.bbrc.2015.04.151; Liao XY, 2015, INT J MOL SCI, V16, P17655, DOI 10.3390/ijms160817655; Liaunardy-Jopeace A, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005275; Liu Q, 2016, ONCOTARGET, V7, P36800, DOI 10.18632/oncotarget.9191; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Luo WB, 2007, J BIOL CHEM, V282, P30246, DOI 10.1074/jbc.M703205200; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Maye P, 2004, J BIOL CHEM, V279, P24659, DOI 10.1074/jbc.M311724200; Mayor S, 2004, NAT REV MOL CELL BIO, V5, P110, DOI 10.1038/nrm1309; MILLER W, 1985, CLIN EXP METASTAS, V3, P189, DOI 10.1007/BF01786762; Mitrovic S, 2008, MOL BIOL CELL, V19, P1976, DOI 10.1091/mbc.E07-10-0989; Najdi R, 2012, DIFFERENTIATION, V84, P203, DOI 10.1016/j.diff.2012.06.004; Pagant S, 2015, CURR BIOL, V25, P403, DOI 10.1016/j.cub.2014.11.070; Park HW, 2015, CELL, V162, P780, DOI 10.1016/j.cell.2015.07.013; Perez Castro C, 2007, J CELL SCI, V120, P2454, DOI 10.1242/jcs.004200; Pobbati AV, 2013, CANCER BIOL THER, V14, P390, DOI 10.4161/cbt.23788; Port F, 2011, EMBO REP, V12, P1144, DOI 10.1038/embor.2011.165; Price MA, 2011, PIGM CELL MELANOMA R, V24, P1148, DOI 10.1111/j.1755-148X.2011.00929.x; Qin W, 2014, INT J ONCOL, V45, P1225, DOI 10.3892/ijo.2014.2506; Radaelli E, 2009, HISTOL HISTOPATHOL, V24, P879, DOI 10.14670/HH-24.879; REPESH LA, 1989, INVAS METAST, V9, P192; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Rieger ME, 2010, MOL CELL BIOL, V30, P4267, DOI 10.1128/MCB.01418-09; Riku M, 2016, ONCOTARGET, V7, P5690, DOI 10.18632/oncotarget.6788; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Romagnoli M, 2014, EMBO MOL MED, V6, P278, DOI 10.1002/emmm.201303373; Ruifrok ACC, 1997, RADIAT RES, V147, P1, DOI 10.2307/3579436; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012; Sasaki T, 2008, AM J PATHOL, V173, P205, DOI 10.2353/ajpath.2008.071147; Sauvageau E, 2014, TRAFFIC, V15, P383, DOI 10.1111/tra.12148; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; Seth C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150697; Singh Bhuminder, 2016, F1000Res, V5, DOI 10.12688/f1000research.9025.1; Singh B, 2014, ANNU REV PHYSIOL, V76, P275, DOI 10.1146/annurev-physiol-021113-170406; Singovski G, 2016, J MOL CELL BIOL, V8, P157, DOI 10.1093/jmcb/mjv034; Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Stecca B, 2010, J MOL CELL BIOL, V2, P84, DOI 10.1093/jmcb/mjp052; Strating JRPM, 2009, BIOL CELL, V101, P495, DOI 10.1042/BC20080233; Sukhotnik I, 2008, PEDIATR SURG INT, V24, P1303, DOI 10.1007/s00383-008-2271-0; Tada M, 2000, DEVELOPMENT, V127, P2227; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; Takida S, 2008, BIOCHEM J, V409, P555, DOI 10.1042/BJ20070234; Uysal-Onganer P, 2012, ACTA PHYSIOL, V204, P52, DOI 10.1111/j.1748-1716.2011.02297.x; Varnat F, 2010, EMBO MOL MED, V2, P440, DOI 10.1002/emmm.201000098; Varnat F, 2009, EMBO MOL MED, V1, P338, DOI 10.1002/emmm.200900039; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Voloshanenko O, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3610; von Karstedt S, 2015, CANCER CELL, V27, P561, DOI 10.1016/j.ccell.2015.02.014; Wajapeyee N, 2009, MOL CANCER THER, V8, P3009, DOI 10.1158/1535-7163.MCT-09-0470; Wang P, 2015, BIOCHEM BIOPH RES CO, V460, P314, DOI 10.1016/j.bbrc.2015.03.032; Wang XC, 2012, PANCREAS, V41, P10, DOI 10.1097/MPA.0b013e318223c7e4; Wang YW, 2017, ONCOTARGET, V8, P34429, DOI 10.18632/oncotarget.16260; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Wong SF, 2005, CLIN THER, V27, P684, DOI 10.1016/j.clinthera.2005.06.003; Zeelenberg IS, 2003, CANCER RES, V63, P3833; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333; Zhang PC, 2016, MOL BIOL CELL, V27, P1938, DOI 10.1091/mbc.E16-02-0090; Zheng H, 2016, SCI REP-UK, V6, DOI 10.1038/srep37070	106	20	20	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2019	38	29					5817	5837		10.1038/s41388-019-0845-z	http://dx.doi.org/10.1038/s41388-019-0845-z			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IQ4WS	31253868	hybrid, Green Published			2022-12-17	WOS:000480752800006
J	Kim, M; Gwak, J; Hwang, S; Yang, S; Jeong, SM				Kim, Minjoong; Gwak, Jihye; Hwang, Sunsook; Yang, Seungyeon; Jeong, Seung Min			Mitochondrial GPT2 plays a pivotal role in metabolic adaptation to the perturbation of mitochondrial glutamine metabolism	ONCOGENE			English	Article							PANCREATIC-CANCER GROWTH; UP-REGULATION; SUPPRESSION; INHIBITION; SURVIVAL; PATHWAY	Cancer cells exhibit metabolic dependence on mitochondrial glutamine metabolism that provides them with the substrates required for rapid proliferation. Despite the extensive efforts to target this glutamine addiction for therapeutic purposes, the adaptive metabolic responses and the mechanisms whereby cells maintain their unlimited growth remain areas of active investigation. Here we report that mitochondrial glutamate-pyruvate transaminase 2 (GPT2) contributes to cell survival and growth by sustaining the tricarboxylic acid (TCA) cycle anaplerosis after the inhibition of glutaminase (GLS), the first enzyme for mitochondrial glutamine metabolism. We found that elevated reactive oxygen species upon GLS inhibition induce GPT2 expression via activating transcription factor 4. Moreover, inhibition of GPT2 synergized with suppression of GLS activity to induce a pronounced reduction in proliferation and an increase in cell death of cancer cells. Our data uncover GPT2 as an important component of the adaptive metabolic response for glutamine deprivation and indicate that targeting this pathway in combination with GLS inhibition may be an effective therapeutic approach for cancer treatment.	[Kim, Minjoong; Gwak, Jihye; Hwang, Sunsook; Yang, Seungyeon; Jeong, Seung Min] Catholic Univ Korea, Coll Med, Dept Biochem, 222 Banpo Daero, Seoul 06591, South Korea; [Kim, Minjoong; Gwak, Jihye; Hwang, Sunsook; Yang, Seungyeon; Jeong, Seung Min] Catholic Univ Korea, Coll Med, Dept Biomed & Hlth Sci, 222 Banpo Daero, Seoul 06591, South Korea; [Kim, Minjoong; Gwak, Jihye; Hwang, Sunsook; Yang, Seungyeon; Jeong, Seung Min] Catholic Univ Korea, Coll Med, Inst Aging & Metab Dis, 222 Banpo Daero, Seoul 06591, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Jeong, SM (corresponding author), Catholic Univ Korea, Coll Med, Dept Biochem, 222 Banpo Daero, Seoul 06591, South Korea.; Jeong, SM (corresponding author), Catholic Univ Korea, Coll Med, Dept Biomed & Hlth Sci, 222 Banpo Daero, Seoul 06591, South Korea.; Jeong, SM (corresponding author), Catholic Univ Korea, Coll Med, Inst Aging & Metab Dis, 222 Banpo Daero, Seoul 06591, South Korea.	smjeong@catholic.ac.kr		Kim, Minjoong/0000-0003-1065-7914	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [2015R1C1A1A01052548, 2018R1D1A1B07040961]	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2015R1C1A1A01052548 and 2018R1D1A1B07040961).	Altman BJ, 2016, NAT REV CANCER, V16, P619, DOI 10.1038/nrc.2016.71; Biancur DE, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15965; Byun JK, 2017, CELL REP, V20, P586, DOI 10.1016/j.celrep.2017.06.066; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Ferguson J, 2017, ONCOTARGET, V8, P32946, DOI 10.18632/oncotarget.16514; Gross MI, 2014, MOL CANCER THER, V13, P890, DOI 10.1158/1535-7163.MCT-13-0870; Hao YJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11971; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Jeong SM, 2016, SCI REP-UK, V6, DOI 10.1038/srep30767; Jeong SM, 2013, CANCER CELL, V23, P450, DOI 10.1016/j.ccr.2013.02.024; Lu SC, 2009, MOL ASPECTS MED, V30, P42, DOI 10.1016/j.mam.2008.05.005; Panieri E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.105; Patel D, 2016, J BIOL CHEM, V291, P9322, DOI 10.1074/jbc.M115.710145; Polet F, 2016, ONCOTARGET, V7, P1765, DOI 10.18632/oncotarget.6426; Robinson MM, 2007, BIOCHEM J, V406, P407, DOI 10.1042/BJ20070039; Salgado MC, 2014, BBA-GENE REGUL MECH, V1839, P288, DOI 10.1016/j.bbagrm.2014.01.005; Shanware NP, 2011, J MOL MED, V89, P229, DOI 10.1007/s00109-011-0731-9; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Sun LC, 2015, CELL RES, V25, P429, DOI 10.1038/cr.2015.33; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Toda K, 2016, NEOPLASIA, V18, P654, DOI 10.1016/j.neo.2016.09.004; Wang SF, 2016, ONCOTARGET, V7, P74132, DOI 10.18632/oncotarget.12356; Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Wong D T, 1973, Adv Enzyme Regul, V11, P139, DOI 10.1016/0065-2571(73)90013-7; Yang S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0089-1; Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81; Zhang J, 2014, MOL CELL, V56, P205, DOI 10.1016/j.molcel.2014.08.018	28	20	20	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4729	4738		10.1038/s41388-019-0751-4	http://dx.doi.org/10.1038/s41388-019-0751-4			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30765862				2022-12-17	WOS:000471160500006
J	Yang, CY; Chang, PW; Hsu, WH; Chang, HC; Chen, CL; Lai, CC; Chiu, WT; Chen, HC				Yang, Cheng-Yi; Chang, Po-Wei; Hsu, Wen-Hsin; Chang, Hsuan-Chia; Chen, Chien-Lin; Lai, Chien-Chen; Chiu, Wen-Tai; Chen, Hong-Chen			Src and SHP2 coordinately regulate the dynamics and organization of vimentin filaments during cell migration	ONCOGENE			English	Article							MICROTUBULE-DEPENDENT TRANSPORT; INTERMEDIATE-FILAMENTS; PHOSPHORYLATION; KINASE; ADHESION; ACTIN; RHO; REORGANIZATION; SITE; CYTOSKELETON	Vimentin intermediate filaments (VIFs), expressed in most mesenchymal and cancer cells, undergo dramatic reorganization during cell migration; however, the mechanism remains obscure. This study demonstrates that upon growth-factor stimulation, Src directly phosphorylates vimentin at Tyr117, leading to VIF disassembly into squiggles and particles at the cell edge during lamellipodia formation. The protein tyrosine phosphatase SHP2 counteracted the Src effects on VIF tyrosine phosphorylation and organization. VIFs formed by vimentin Y117D mutant were more soluble and dynamic than those formed by the wild-type and Y117F mutant. Increased expression of vimentin promoted growth-factor induced lamellipodia formation and cell migration, whereas the mutants suppressed both. The vimentin-induced increase in lamellipodia formation correlated with the activation of Rac and Vav2, with the latter associated with VIFs and recruited to the plasma membrane upon growth-factor stimulation. These results reveal a novel mechanism for regulating VIF dynamics through Src and SHP2 and demonstrate that proper VIF dynamics are important for Rac activation and cell migration.	[Yang, Cheng-Yi; Chang, Po-Wei; Chen, Chien-Lin] Natl Chung Hsing Univ, Dept Life Sci, Taichung, Taiwan; [Hsu, Wen-Hsin; Chen, Hong-Chen] Natl Yang Ming Univ, Canc Progress Res Ctr, Taipei, Taiwan; [Chang, Hsuan-Chia; Chen, Hong-Chen] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei, Taiwan; [Lai, Chien-Chen] Natl Chung Hsing Univ, Inst Mol Biol, Taichung, Taiwan; [Chiu, Wen-Tai] Natl Cheng Kung Univ, Dept Biomed Engn, Tainan, Taiwan	National Chung Hsing University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Chung Hsing University; National Cheng Kung University	Chen, HC (corresponding author), Natl Yang Ming Univ, Canc Progress Res Ctr, Taipei, Taiwan.; Chen, HC (corresponding author), Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei, Taiwan.; Lai, CC (corresponding author), Natl Chung Hsing Univ, Inst Mol Biol, Taichung, Taiwan.; Chiu, WT (corresponding author), Natl Cheng Kung Univ, Dept Biomed Engn, Tainan, Taiwan.	lailai@dragon.nchu.edu.tw; wtchiu@mail.ncku.edu.tw; hcchen1029@ym.edu.tw	/AGZ-4617-2022	/0000-0002-7133-8266; Chiu, Wen-Tai/0000-0003-0310-0675; Hsu, Wen-Hsin/0000-0001-6050-6255	Ministry of Science and Technology, Taiwan [105-2320-B-005-005-MY3, 106-2320-B-005-011-MY3, 107-2923-B-005-002-MY3]; Cancer Progression Research Center, National Yang-Ming University from the Featured Areas Research Center Program	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); Cancer Progression Research Center, National Yang-Ming University from the Featured Areas Research Center Program	We thank the Bio-image Core Facility Program for Biotechnology, the Ministry of Science and Technology, Taiwan, for the support of advanced microscopy and the International Institute of Macromolecular Analysis and Nanomedicine Innovation (i-MANI), National Cheng Kung University, Taiwan, for cryo-EM. We are grateful to Dr. Shang-Rung Wu for her technical support. This work was supported by the Ministry of Science and Technology, Taiwan (grant number 105-2320-B-005-005-MY3, 106-2320-B-005-011-MY3, and 107-2923-B-005-002-MY3) and the Cancer Progression Research Center, National Yang-Ming University from the Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan.	Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; ANDO S, 1989, BIOCHEMISTRY-US, V28, P2974, DOI 10.1021/bi00433a035; ANDO S, 1991, BIOCHEM BIOPH RES CO, V175, P955, DOI 10.1016/0006-291X(91)91658-Y; Chan PC, 2003, J BIOL CHEM, V278, P44075, DOI 10.1074/jbc.M305745200; Chan PC, 2014, J CELL BIOL, V204, P19, DOI 10.1083/jcb.201306083; Chan PC, 2012, CANCER RES, V72, P2405, DOI 10.1158/0008-5472.CAN-11-3078; Chang L, 2004, NAT REV MOL CELL BIO, V5, P601, DOI 10.1038/nrm1438; Cheng TJ, 2003, J CELL BIOCHEM, V89, P589, DOI 10.1002/jcb.10511; CHOU YH, 1991, J BIOL CHEM, V266, P7325; Chung BM, 2013, CURR OPIN CELL BIOL, V25, P600, DOI 10.1016/j.ceb.2013.06.008; DELLAGI K, 1985, BLOOD, V65, P1444, DOI 10.1182/blood.V65.6.1444.bloodjournal6561444; Eriksson JE, 2004, J CELL SCI, V117, P919, DOI 10.1242/jcs.00906; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728; Goto H, 2002, GENES CELLS, V7, P91, DOI 10.1046/j.1356-9597.2001.00504.x; Goto H, 2003, J BIOL CHEM, V278, P8526, DOI 10.1074/jbc.M210892200; Gregor M, 2014, FASEB J, V28, P715, DOI 10.1096/fj.13-231829; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANSSON GK, 1984, P NATL ACAD SCI-BIOL, V81, P3103, DOI 10.1073/pnas.81.10.3103; Havel LS, 2015, ONCOGENE, V34, P1979, DOI 10.1038/onc.2014.123; Helfand BT, 2011, MOL BIOL CELL, V22, P1274, DOI 10.1091/mbc.E10-08-0699; Herrmann H, 2004, ANNU REV BIOCHEM, V73, P749, DOI 10.1146/annurev.biochem.73.011303.073823; Herrmann H, 2009, J CLIN INVEST, V119, P1772, DOI 10.1172/JCI38214; Hesse M, 2001, J CELL SCI, V114, P2569; Hookway C, 2015, MOL BIOL CELL, V26, P1675, DOI 10.1091/mbc.E14-09-1398; HUANG TJ, 1994, J PROTEIN CHEM, V13, P517, DOI 10.1007/BF01901533; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; Ivaska J, 2005, EMBO J, V24, P3834, DOI 10.1038/sj.emboj.7600847; Jiu Y, 2017, J CELL SCI, V130, P892, DOI 10.1242/jcs.196881; Kirmse R, 2007, J BIOL CHEM, V282, P18563, DOI 10.1074/jbc.M701063200; Leduc C, 2017, J CELL BIOL, V216, P1689, DOI 10.1083/jcb.201607045; Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a; Lowery J, 2015, J BIOL CHEM, V290, P17145, DOI 10.1074/jbc.R115.640359; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; Margiotta A, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5020020; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Meier M, 2009, J MOL BIOL, V390, P245, DOI 10.1016/j.jmb.2009.04.067; Mendez MG, 2010, FASEB J, V24, P1838, DOI 10.1096/fj.09-151639; Meriane M, 2000, J BIOL CHEM, V275, P33046, DOI 10.1074/jbc.M001566200; Mucke N, 2004, J MOL BIOL, V340, P97, DOI 10.1016/j.jmb.2004.04.039; Nakamura Y, 2000, GENES CELLS, V5, P823, DOI 10.1046/j.1365-2443.2000.00372.x; Nieminen M, 2006, NAT CELL BIOL, V8, P156, DOI 10.1038/ncb1355; Niki T, 1999, HEPATOLOGY, V29, P520, DOI 10.1002/hep.510290232; Pan YR, 2013, J CELL SCI, V126, P657, DOI 10.1242/jcs.116624; Pan YR, 2011, J CELL BIOL, V195, P113, DOI 10.1083/jcb.201103016; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Robert A, 2016, BIOESSAYS, V38, P232, DOI 10.1002/bies.201500142; Robert A, 2015, P NATL ACAD SCI USA, V112, pE3505, DOI 10.1073/pnas.1505303112; Robert A, 2014, FASEB J, V28, P2879, DOI 10.1096/fj.14-250019; Rogel MR, 2011, FASEB J, V25, P3873, DOI 10.1096/fj.10-170795; Rotty JD, 2012, J CELL BIOL, V197, P381, DOI 10.1083/jcb.201107078; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Satelli A, 2011, CELL MOL LIFE SCI, V68, P3033, DOI 10.1007/s00018-011-0735-1; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Schoumacher M, 2010, J CELL BIOL, V189, P541, DOI 10.1083/jcb.200909113; Schweizer J, 2006, J CELL BIOL, V174, P169, DOI 10.1083/jcb.200603161; Snider NT, 2013, J BIOL CHEM, V288, P31329, DOI 10.1074/jbc.M113.502724; Tamas P, 2003, J BIOL CHEM, V278, P5163, DOI 10.1074/jbc.M207555200; Tang DD, 2005, BIOCHEM J, V388, P773, DOI 10.1042/BJ20050065; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Toivola DM, 2010, TRENDS CELL BIOL, V20, P79, DOI 10.1016/j.tcb.2009.11.004; Tsai WC, 2015, ONCOTARGET, V6, P23845, DOI 10.18632/oncotarget.4313; TSUJIMURA K, 1994, J BIOL CHEM, V269, P31097; Tsuruta D, 2003, J CELL SCI, V116, P4977, DOI 10.1242/jcs.00823; Valgeirsdottir S, 1998, J CELL SCI, V111, P1973; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; Yamaguchi T, 2005, J CELL BIOL, V171, P431, DOI 10.1083/jcb.200504091; Zhang X, 2010, J MED CHEM, V53, P2482, DOI 10.1021/jm901645u; Zhou Q, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013538; Zhu QS, 2011, ONCOGENE, V30, P457, DOI 10.1038/onc.2010.421	71	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4075	4094		10.1038/s41388-019-0705-x	http://dx.doi.org/10.1038/s41388-019-0705-x			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30696956	Green Published, hybrid			2022-12-17	WOS:000468740200008
J	Tiemann, K; Garri, C; Lee, SB; Malihi, PD; Park, M; Alvarez, RM; Yap, LP; Ma, P; Katz, JE; Gross, ME; Kani, K				Tiemann, Katrin; Garri, Carolina; Lee, Sang Bok; Malihi, Paymaneh D.; Park, Mincheol; Alvarez, Ruth M.; Yap, Li Peng; Ma, Parag; Katz, Jonathan E.; Gross, Mitchell E.; Kani, Kian			Loss of ER retention motif of AGR2 can impact mTORC signaling and promote cancer metastasis	ONCOGENE			English	Article							ANTERIOR GRADIENT 2; PROSTATE-CANCER; ISOMERASE AGR2; HIPPO PATHWAY; SERUM AGR2; PROTEIN; EXPRESSION; GROWTH; BIOMARKER; GENE	Anterior gradient 2 (AGR2) is a member of the protein disulfide isomerase (PDI) family, which plays a role in the regulation of protein homeostasis and the unfolded protein response pathway (UPR). AGR2 has also been characterized as a protooncogene and a potential cancer biomarker. Cellular localization of AGR2 is emerging as a key component for understanding the role of AGR2 as a proto-oncogene. Here, we provide evidence that extracellular AGR2 (eAGR2) promotes tumor metastasis in various in vivo models. To further characterize the role of the intracellular-resident versus extracellular protein, we performed a comprehensive protein-protein interaction screen. Based on these results, we identify AGR2 as an interacting partner of the mTORC2 pathway. Importantly, our data indicates that eAGR2 promotes increased phosphorylation of RICTOR (T1135), while intracellular AGR2 (iAGR2) antagonizes its levels and phosphorylation. Localization of AGR2 also has opposing effects on the Hippo pathway, spheroid formation, and response to chemotherapy in vitro. Collectively, our results identify disparate phenotypes predicated on AGR2 localization. Our findings also provide credence for screening of eAGR2 to guide therapeutic decisions.	[Tiemann, Katrin; Garri, Carolina; Lee, Sang Bok; Malihi, Paymaneh D.; Park, Mincheol; Alvarez, Ruth M.; Katz, Jonathan E.; Gross, Mitchell E.; Kani, Kian] Univ Southern Calif, Keck Sch Med, Lawrence J Ellison Inst Transformat Med, Los Angeles, CA 90007 USA; [Yap, Li Peng] Keck Sch Med, Dept Radiol, Los Angeles, CA USA; [Ma, Parag] Stanford Univ, Dept Radiol, Los Angeles, CA USA	University of Southern California; Stanford University	Kani, K (corresponding author), Univ Southern Calif, Keck Sch Med, Lawrence J Ellison Inst Transformat Med, Los Angeles, CA 90007 USA.	Kani@usc.edu		Kani, Kian/0000-0001-7774-265X	Lawrence J. Ellison Medical Foundation	Lawrence J. Ellison Medical Foundation	Drs. Philip Roux and Dos Sarbossov provided valuable insight and reagents (Roux) on the mTOR pathway. We are grateful for the guidance of Dr. David Agus and the generous financial support of the Lawrence J. Ellison Medical Foundation. We appreciate the support of Autumn Beemer, Lisa Flashner, Laura Ng, and Jeffrey Wang.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013; Arumugam T, 2015, MOL CANCER THER, V14, P941, DOI 10.1158/1535-7163.MCT-14-0470; Boulbes D, 2010, MOL CANCER RES, V8, P896, DOI 10.1158/1541-7786.MCR-09-0409; Brychtova V, 2015, SEMIN CANCER BIOL, V33, P16, DOI 10.1016/j.semcancer.2015.04.005; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Chen R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-149; Chung K, 2011, CANCER BIOMARK, V10, P101, DOI 10.3233/CBM-2012-0234; Clarke C, 2015, MOL CELL BIOCHEM, V408, P245, DOI 10.1007/s11010-015-2502-3; Darb-Esfahani S, 2012, VIRCHOWS ARCH, V461, P109, DOI 10.1007/s00428-012-1273-4; Dong AW, 2011, J BIOL CHEM, V286, P18301, DOI 10.1074/jbc.M110.215707; Fan R, 2013, P NATL ACAD SCI USA, V110, P2569, DOI 10.1073/pnas.1216462110; Fessart D, 2016, ELIFE, V5, DOI 10.7554/eLife.13887; Fletcher GC, 2003, BRIT J CANCER, V88, P579, DOI 10.1038/sj.bjc.6600740; Fritzsche FR, 2007, HISTOL HISTOPATHOL, V22, P703, DOI 10.14670/HH-22.703; Fritzsche FR, 2006, CLIN CANCER RES, V12, P1728, DOI 10.1158/1078-0432.CCR-05-2057; Garri Carolina, 2018, Oncotarget, V9, P27363, DOI 10.18632/oncotarget.25221; Gray TA, 2013, PROTEIN SCI, V22, P1266, DOI 10.1002/pro.2299; Guo H, 2017, ONCOGENE, V36, P5098, DOI 10.1038/onc.2017.132; Hengel SM, 2011, J PROTEOME RES, V10, P4567, DOI 10.1021/pr2004117; Higa A, 2011, J BIOL CHEM, V286, P44855, DOI 10.1074/jbc.M111.275529; Jia MQ, 2018, BBA-MOL BASIS DIS, V1864, P1622, DOI 10.1016/j.bbadis.2018.01.021; Jiang YQ, 2010, CLIN CHEM, V56, P1492, DOI 10.1373/clinchem.2010.143297; Julien LA, 2010, MOL CELL BIOL, V30, P908, DOI 10.1128/MCB.00601-09; Kani K, 2017, MOL CANCER THER, V16, P1645, DOI 10.1158/1535-7163.MCT-16-0564; Kani K, 2013, PROSTATE, V73, P306, DOI 10.1002/pros.22569; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lee S, 2006, ONCOL REP, V16, P747; Liu D, 2005, CANCER RES, V65, P3796, DOI 10.1158/0008-5472.CAN-04-3823; Lundberg E, 2010, PROTEOMICS, V10, P3984, DOI 10.1002/pmic.201000125; Maslon MM, 2010, J MOL BIOL, V404, P418, DOI 10.1016/j.jmb.2010.09.035; Matoulkova E, 2017, EXP CELL RES, V356, P40, DOI 10.1016/j.yexcr.2017.04.011; Mellacheruvu D, 2013, NAT METHODS, V10, P730, DOI 10.1038/nmeth.2557; Mohtar MA, 2018, MOL CELL PROTEOMICS, V17, P737, DOI 10.1074/mcp.RA118.000573; Muniz VP, 2011, MOL CANCER RES, V9, P867, DOI 10.1158/1541-7786.MCR-10-0475; Park K, 2011, EXP MOL MED, V43, P91, DOI 10.3858/emm.2011.43.2.011; Park SW, 2009, P NATL ACAD SCI USA, V106, P6950, DOI 10.1073/pnas.0808722106; Patel P, 2013, J MOL BIOL, V425, P929, DOI 10.1016/j.jmb.2012.12.009; Rice GE, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-62; Riener MO, 2009, HISTOL HISTOPATHOL, V24, P1121, DOI 10.14670/HH-24.1121; Roux Kyle J, 2013, Curr Protoc Protein Sci, V74, DOI 10.1002/0471140864.ps1923s74; Roux KJ, 2012, J CELL BIOL, V196, P801, DOI 10.1083/jcb.201112098; Ryu J, 2013, BIOCHEM BIOPH RES CO, V430, P610, DOI 10.1016/j.bbrc.2012.11.105; Salmans ML, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3408; Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487; Skarra DV, 2011, PROTEOMICS, V11, P1508, DOI 10.1002/pmic.201000770; Smirnov DA, 2005, CANCER RES, V65, P4993, DOI 10.1158/0008-5472.CAN-04-4330; Tackett AJ, 2005, J PROTEOME RES, V4, P1752, DOI 10.1021/pr050225e; Tian SB, 2018, EXP CELL RES, V364, P198, DOI 10.1016/j.yexcr.2018.02.004; Tohti M, 2017, CLIN NEUROL NEUROSUR, V154, P19, DOI 10.1016/j.clineuro.2017.01.004; Wang Z, 2008, CANCER RES, V68, P492, DOI 10.1158/0008-5472.CAN-07-2930; Xu CH, 2016, TUMOR BIOL, V37, P6091, DOI 10.1007/s13277-015-4481-0; Zhang JS, 2005, GENE CHROMOSOME CANC, V43, P249, DOI 10.1002/gcc.20188; Zweitzig DR, 2007, MOL CELL BIOCHEM, V306, P255, DOI 10.1007/s11010-007-9562-y	55	20	21	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					3003	3018		10.1038/s41388-018-0638-9	http://dx.doi.org/10.1038/s41388-018-0638-9			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30575818	Green Accepted			2022-12-17	WOS:000465167600010
J	Causse, SZ; Marcion, G; Chanteloup, G; Uyanik, B; Boudesco, C; Grigorash, BB; Douhard, R; Dias, AMM; Dumetier, B; Dondaine, L; Gozzi, GJ; Moussay, E; Paggetti, J; Mirjolet, C; de Thonel, A; Dubrez, L; Demidov, ON; Gobbo, J; Garrido, C				Causse, Sebastien Z.; Marcion, Guillaume; Chanteloup, Gaetan; Uyanik, Burhan; Boudesco, Christophe; Grigorash, Bogdan B.; Douhard, Romain; Dias, Alexandre M. M.; Dumetier, Baptiste; Dondaine, Lucile; Gozzi, Gustavo J.; Moussay, Etienne; Paggetti, Jerome; Mirjolet, Celine; de Thonel, Aurelie; Dubrez, Laurence; Demidov, Oleg N.; Gobbo, Jessica; Garrido, Carmen			HSP110 translocates to the nucleus upon genotoxic chemotherapy and promotes DNA repair in colorectal cancer cells	ONCOGENE			English	Article							HEAT-SHOCK PROTEINS; EXPRESSION; HSP70	A multicenter clinical study demonstrated the presence of a loss-of-function HSP110 mutation in about 15% of colorectal cancers, which resulted from an alternative splicing and was produced at the detriment of wild-type HSP110. Patients expressing low levels of wild-type HSP110 had excellent outcomes (i.e. response to an oxaliplatin-based chemotherapy). Here, we show in vitro, in vivo, and in patients' biopsies that HSP110 co-localizes with DNA damage (gamma-H2AX). In colorectal cancer cells, HSP110 translocates into the nucleus upon treatment with genotoxic chemotherapy such as oxaliplatin. Furthermore, we show that HSP110 interacts with the Ku70/Ku80 heterodimer, an essential element of the nonhomologous end joining (NHEJ) repair machinery. We also demonstrate by evaluating the resolved 53BP1 foci that depletion in HSP110 impairs repair steps of the NHEJ pathway, which is associated with an increase in DNA double-strand breaks and in the cells' sensitivity to oxaliplatin. HSP110-depleted cells sensitization to oxaliplatin-induced DNA damage is abolished upon re-expression of HSP110. Confirming a role for HSP110 in DNA non-homologous repair, SCR7 and NU7026, two inhibitors of the NHEJ pathway, circumvents HSP110-induced resistance to chemotherapy. In conclusion, HSP110 through its interaction with the Ku70/80 heterodimer may participate in DNA repair, thereby inducing a protection against genotoxic therapy.	[Causse, Sebastien Z.; Marcion, Guillaume; Chanteloup, Gaetan; Uyanik, Burhan; Boudesco, Christophe; Grigorash, Bogdan B.; Douhard, Romain; Dias, Alexandre M. M.; Dumetier, Baptiste; Dondaine, Lucile; Gozzi, Gustavo J.; Dubrez, Laurence; Demidov, Oleg N.; Gobbo, Jessica; Garrido, Carmen] INSERM, Equipe Labellisee Ligue Natl Canc, UMR 1231, Dijon, France; [Causse, Sebastien Z.; Marcion, Guillaume; Chanteloup, Gaetan; Uyanik, Burhan; Boudesco, Christophe; Grigorash, Bogdan B.; Douhard, Romain; Dias, Alexandre M. M.; Dumetier, Baptiste; Dondaine, Lucile; Gozzi, Gustavo J.; Dubrez, Laurence; Demidov, Oleg N.; Gobbo, Jessica; Garrido, Carmen] Lab Excellence LipSTIC, Dijon, France; [Causse, Sebastien Z.; Marcion, Guillaume; Chanteloup, Gaetan; Uyanik, Burhan; Boudesco, Christophe; Grigorash, Bogdan B.; Douhard, Romain; Dias, Alexandre M. M.; Dumetier, Baptiste; Dondaine, Lucile; Gozzi, Gustavo J.; Dubrez, Laurence; Demidov, Oleg N.; Gobbo, Jessica; Garrido, Carmen] Univ Bourgogne Franche Comte, Dijon, France; [Moussay, Etienne; Paggetti, Jerome] Luxembourg Inst Hlth, 84 Val Fleuri, L-1526 Luxembourg, Luxembourg; [Mirjolet, Celine; Gobbo, Jessica; Garrido, Carmen] Anticanc Ctr Georges Francois Leclerc Unicanc, Dijon, France; [de Thonel, Aurelie] Univ Paris Diderot, Unite Epigenet & Destin Cellulaire, Paris, France	Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Luxembourg Institute of Health; UDICE-French Research Universities; Universite Paris Cite	Garrido, C (corresponding author), INSERM, Equipe Labellisee Ligue Natl Canc, UMR 1231, Dijon, France.; Garrido, C (corresponding author), Lab Excellence LipSTIC, Dijon, France.; Garrido, C (corresponding author), Univ Bourgogne Franche Comte, Dijon, France.; Garrido, C (corresponding author), Anticanc Ctr Georges Francois Leclerc Unicanc, Dijon, France.	cgarrido@u-bourgogne.fr	Demidov, Oleg/AAC-4462-2021; Causse, Sebastien Zwe/AAZ-7365-2021; Garrido, carmen/G-1633-2018; Moussay, Etienne/I-3729-2019; Paggetti, Jerome/I-2786-2019; Laurence, Dubrez/P-9472-2019; Garrido, Carolina/GWM-5557-2022	Demidov, Oleg/0000-0003-4323-7174; Garrido, carmen/0000-0003-1368-1493; Moussay, Etienne/0000-0002-0879-8067; Paggetti, Jerome/0000-0001-9460-5876; Laurence, Dubrez/0000-0002-7030-2181; Mirjolet Didelot, Celine/0000-0003-0047-9421; de Thonel, Aurelie/0000-0003-0405-0745; DUMETIER, Baptiste/0000-0001-9087-2344; Causse, Sebastien/0000-0003-3246-3491; Marcion, Guillaume/0000-0002-3634-6316	Institut National du Cancer; Ligue Nationale Contre le Cancer; Conseil Regional de Bourgogne; French Government [ANR-11-LABX-0021]; European Union programme FEDER; La Ligue Nationale contre le Cancer; Association pour la Recherche sur le Cancer; "Fondation de France"; "Fondation pour la Recherche Medicale [ECO20160736090]	Institut National du Cancer(Institut National du Cancer (INCA) France); Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Conseil Regional de Bourgogne(Region Bourgogne-Franche-Comte); French Government; European Union programme FEDER(European Commission); La Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); "Fondation de France"(Fondation de France); "Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	We are grateful professor Gorbunova for allowing us using her NHEJ DNA repair system and to Alex Duval and Ada Collura for helpful discussions. We also thank the Platforms of cytometry Cellimap. This work was supported by grants from the Institut National du Cancer, Ligue Nationale Contre le Cancer, and the Conseil Regional de Bourgogne. The work was also supported by a French Government grant managed by the French National Research Agency under the program "Investissements d'Avenir" with reference ANR-11-LABX-0021 (LabEX LipSTIC). We thank the European Union programme FEDER for their financial support. SC had a fellowship from La Ligue Nationale contre le Cancer, GM from the Association pour la Recherche sur le Cancer, GG from the "Fondation de France", and GC from the "Fondation pour la Recherche Medicale (ECO20160736090)".	Berthenet K, 2017, ONCOGENE, V36, P2328, DOI 10.1038/onc.2016.403; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Collura A, 2014, GASTROENTEROLOGY, V146, P401, DOI 10.1053/j.gastro.2013.10.054; Dorard C, 2011, NAT MED, V17, P1283, DOI 10.1038/nm.2457; Dufour A, 2011, IEEE T IMAGE PROCESS, V20, P1925, DOI 10.1109/TIP.2010.2099125; Garrido C, 2006, CELL CYCLE, V5, P2592, DOI 10.4161/cc.5.22.3448; Gravina GL, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0085-1; Guttmann DM, 2011, CANCER BIOL THER, V12, P1023, DOI 10.4161/cbt.12.12.18374; Kai M, 2003, ONCOL REP, V10, P1777; Kimura A, 2016, ONCOTARGET, V7, P18415, DOI 10.18632/oncotarget.7821; Mao ZY, 2008, CELL CYCLE, V7, P2902, DOI 10.4161/cc.7.18.6679; Mattoo RUH, 2013, J BIOL CHEM, V288, P21399, DOI 10.1074/jbc.M113.479253; Olivo-Marin JC, 2002, PATTERN RECOGN, V35, P1989, DOI 10.1016/S0031-3203(01)00127-3; Panier S, 2014, NAT REV MOL CELL BIO, V15, P7, DOI 10.1038/nrm3719; Rampelt H, 2012, EMBO J, V31, P4221, DOI 10.1038/emboj.2012.264; Saito Y, 2007, EXP CELL RES, V313, P3707, DOI 10.1016/j.yexcr.2007.06.009; Thomas X, 2005, LEUKEMIA RES, V29, P1049, DOI 10.1016/j.leukres.2005.02.010; Willmore E, 2004, BLOOD, V103, P4659, DOI 10.1182/blood-2003-07-2527; Yang ZG, 2015, INT J MED SCI, V12, P256, DOI 10.7150/ijms.10735; Yu N, 2015, MOL CELL BIOL, V35, P1390, DOI 10.1128/MCB.01307-14	20	20	21	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2767	2777		10.1038/s41388-018-0616-2	http://dx.doi.org/10.1038/s41388-018-0616-2			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30542121				2022-12-17	WOS:000464121600007
J	Gomes, AM; Carron, EC; Mills, KL; Dow, AM; Gray, Z; Fecca, CR; Lakey, MA; Carmeliet, P; Kittrell, F; Medina, D; Machado, HL				Gomes, Angelica M.; Carron, Emily C.; Mills, Kylie L.; Dow, Alexa M.; Gray, Zane; Fecca, Christopher R.; Lakey, Meredith A.; Carmeliet, Peter; Kittrell, Frances; Medina, Daniel; Machado, Heather L.			Stromal Gas6 promotes the progression of premalignant mammary cells	ONCOGENE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; TO-MESENCHYMAL TRANSITION; RECEPTOR TYROSINE KINASE; AXL KINASE; CANCER; GROWTH; ACTIVATION; EXPRESSION; SURVIVAL; MODEL	Tumor progression is regulated by a complex interplay between neoplastic cells and the tumor microenvironment. Tumor-associated macrophages have been shown to promote breast cancer progression in advanced disease and more recently, in early stage cancers. However, little is known about the macrophage-derived factors that promote tumor progression in early stage lesions. Using a p53-null model of early stage mammary tumor progression, we found that Gas6 is highly expressed in pre-invasive lesions associated with increased infiltrating macrophages, as compared with those with few recruited macrophages. We show that F4/80(+)CD11b(+ )macrophages produce Gas6 in premalignant lesions in vivo, and that macrophage-derived Gas6 induces a tumor-like phenotype ex vivo. Using a 3-D co-culture system, we show that macrophage-derived Gas6 activates its receptor Axl and downstream survival signals including Akt and STAT3, which was accompanied by altered E-cadherin expression to induce a malignant morphology. In vivo studies demonstrated that deletion of stromal Gas6 delays early stage progression and decreases tumor formation, while tumor growth in established tumors remains unaffected. These studies suggest that macrophage-derived Gas6 is a critical regulator of the transition from premalignant to invasive cancer, and may lead to the development of unique biomarkers of neoplastic progression for patients with early stage breast cancer, including ductal carcinoma in situ.	[Gomes, Angelica M.; Mills, Kylie L.; Dow, Alexa M.; Gray, Zane; Fecca, Christopher R.; Machado, Heather L.] Tulane Sch Med, Tulane Canc Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; [Carron, Emily C.] La Jolla Inst Allergy & Immunol, Div Cellular Biol, La Jolla, CA USA; [Lakey, Meredith A.] Ochsner Clin Fdn, Ochsner Biorepository, Dept Res, New Orleans, LA USA; [Carmeliet, Peter] VIB, Vesalius Res Ctr, Lab Angiogenesis & Vasc Metab, Ctr Canc Biol, B-3000 Leuven, Belgium; [Carmeliet, Peter] Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongsan Ophthalm Ctr, Guangzhou, Guangdong, Peoples R China; [Carmeliet, Peter] Katholieke Univ Leuven, Lab Angiogenesis & Vasc Metab, Dept Oncol, B-3000 Leuven, Belgium; [Carmeliet, Peter] Katholieke Univ Leuven, Leuven Canc Inst LKI, B-3000 Leuven, Belgium; [Kittrell, Frances; Medina, Daniel] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Tulane University; La Jolla Institute for Immunology; Ochsner Health System; Flanders Institute for Biotechnology (VIB); Sun Yat Sen University; KU Leuven; KU Leuven; Baylor College of Medicine	Machado, HL (corresponding author), Tulane Sch Med, Tulane Canc Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA.	hmachado@tulane.edu	Carmeliet, Peter/AAQ-5140-2020	Carmeliet, Peter/0000-0001-7961-1821	Susan G. Komen [CCR16377665]; NIH [R01 CA212518]; Tulane Cancer Center through the Cancer Crusaders of New Orleans; NATIONAL CANCER INSTITUTE [R01CA212518] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM114732] Funding Source: NIH RePORTER	Susan G. Komen(Susan G. Komen Breast Cancer Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Tulane Cancer Center through the Cancer Crusaders of New Orleans; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by Susan G. Komen CCR16377665 (HLM), NIH R01 CA212518 (HLM), and the Tulane Cancer Center through the Cancer Crusaders of New Orleans. We would like to thank Dr. Dorota Wyczechowska from the LCRC Cell Immunology and Metabolism Core (NIH/NIGMS 1P30GM114732-01) for assistance with FACS and Dr. Leann Myers for help with statistical analysis. We would like to acknowledge Alexandra Giardina at the LCRC Biospecimen Core and Dr. Lyndsey Buckner Baiamonte, Jeannine Ascani, and Dr. Michelle Ponder at the Oschner Biorepository Unit for human DCIS tissues.	Angelillo-Scherrer A, 2001, NAT MED, V7, P215, DOI 10.1038/84667; Asiedu MK, 2014, ONCOGENE, V33, P1316, DOI 10.1038/onc.2013.57; Behbod F, 2018, J MAMMARY GLAND BIOL, V23, P269, DOI 10.1007/s10911-018-9408-0; Ben-Batalla I, 2013, BLOOD, V122, P2443, DOI 10.1182/blood-2013-03-491431; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; Bohrer LR, 2014, CANCER RES, V74, P374, DOI 10.1158/0008-5472.CAN-13-2469; Bohrer LR, 2012, MOL CANCER RES, V10, P1294, DOI 10.1158/1541-7786.MCR-12-0275; Bottai G, 2016, NPJ BREAST CANCER, V2, P1, DOI 10.1038/npjbcancer.2016.33; Braunger J, 1997, ONCOGENE, V14, P2619, DOI 10.1038/sj.onc.1201123; Buehler M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/238284; Carron EC, 2017, ONCOTARGET, V8, P50731, DOI 10.18632/oncotarget.14913; Geng K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01521; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Gocheva V, 2010, GENE DEV, V24, P241, DOI 10.1101/gad.1874010; Goruppi S, 1996, ONCOGENE, V12, P471; Goruppi S, 2001, MOL CELL BIOL, V21, P902, DOI 10.1128/MCB.21.3.902-915.2001; Goyette MA, 2018, CELL REP, V23, P1476, DOI 10.1016/j.celrep.2018.04.019; Holland SJ, 2010, CANCER RES, V70, P1544, DOI 10.1158/0008-5472.CAN-09-2997; Ishimoto Y, 2000, J BIOCHEM-TOKYO, V127, P411, DOI 10.1093/oxfordjournals.jbchem.a022622; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; Jerry DJ, 1998, ONCOGENE, V17, P2305, DOI 10.1038/sj.onc.1202157; Kariolis MS, 2017, J CLIN INVEST, V127, P183, DOI 10.1172/JCI85610; Kirane A, 2015, CANCER RES, V75, P3699, DOI 10.1158/0008-5472.CAN-14-2887-T; LaMarca HL, 2010, STEM CELLS, V28, P535, DOI 10.1002/stem.297; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Lew ED, 2014, ELIFE, V3, DOI 10.7554/eLife.03385; Lin Elaine Y, 2004, Novartis Found Symp, V256, P158; Lin EY, 2006, CANCER RES, V66, P11238, DOI 10.1158/0008-5472.CAN-06-1278; Loges S, 2010, BLOOD, V115, P2264, DOI 10.1182/blood-2009-06-228684; Lyons TR, 2011, NAT MED, V17, P1109, DOI 10.1038/nm.2416; Mc Cormack O, 2008, BRIT J CANCER, V98, P1141, DOI 10.1038/sj.bjc.6604260; Medina D, 2005, CANCER RES, V65, P3493, DOI 10.1158/0008.5472.CAN-04-3869; Medina D, 2002, FASEB J, V16, P881, DOI 10.1096/fj.01-0885fje; Medrek C, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-306; Meyer AS, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004155; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Paccez JD, 2013, ONCOGENE, V32, P689, DOI 10.1038/onc.2012.89; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Shieh YS, 2005, NEOPLASIA, V7, P1058, DOI 10.1593/neo.05640; Shiozawa Y, 2010, NEOPLASIA, V12, P116, DOI 10.1593/neo.91384; Tjwa M, 2008, BLOOD, V111, P4096, DOI 10.1182/blood-2007-05-089565; Tsou WI, 2014, J BIOL CHEM, V289, P25750, DOI 10.1074/jbc.M114.569020; Vouri M, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.66; Wang W, 2015, MOL MED REP, V11, P2397, DOI 10.3892/mmr.2014.3018; Weischenfeldt Joachim, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot5080; Wu GL, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.113; Wu XL, 2017, J CANCER RES CLIN, V143, P1947, DOI 10.1007/s00432-017-2408-4; Wu XL, 2014, ONCOTARGET, V5, P9546, DOI 10.18632/oncotarget.2542; Xue J, 2014, IMMUNITY, V40, P274, DOI 10.1016/j.immuni.2014.01.006; Yanagita M, 2001, J BIOL CHEM, V276, P42364, DOI 10.1074/jbc.M107488200; Zhang X., 2008, CURR PROTOC IMMUNOL; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330; Zucca LE, 2018, UROL ONCOL-SEMIN ORI, V36, DOI 10.1016/j.urolonc.2017.09.003	55	20	22	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2437	2450		10.1038/s41388-018-0593-5	http://dx.doi.org/10.1038/s41388-018-0593-5			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30531835	Green Accepted			2022-12-17	WOS:000463335200001
J	Kuhlen, M; Taeubner, J; Brozou, T; Wieczorek, D; Siebert, R; Borkhardt, A				Kuhlen, Michaela; Taeubner, Julia; Brozou, Triantafyllia; Wieczorek, Dagmar; Siebert, Reiner; Borkhardt, Arndt			Family-based germline sequencing in children with cancer	ONCOGENE			English	Review							DE-NOVO MUTATIONS; LI-FRAUMENI SYNDROME; UNIPARENTAL DISOMY; PARENTAL AGE; PREDISPOSITION GENES; RISK; RATES; ASSOCIATION; DISEASES; VARIANTS	The discovery of cancer-predisposing syndromes (CPSs) using next-generation sequencing (NGS) technologies is of increasing importance in pediatric oncology with regard to diagnosis, treatment, surveillance, family counselling and research. Recent studies indicate that a considerable percentage of childhood cancers are associated with CPSs. However, the ratio of CPSs that are caused by inherited vs. de novo mutations (DNMs), the risk of recurrence, and even the total number of genes, which should be considered as a true cancer-predisposing gene, are still unknown. In contrast to sequencing only single index patients, family-based NGS of the germline is a very powerful tool for providing unique insights into inheritance patterns (e.g., DNMs, parental mosaicism) and types of aberrations (e.g., SNV, CNV, indels, SV). Furthermore, functional perturbations of key cancer pathways (e.g., TP53, FA/BRCA) by at least two co-inherited heterozygous digenic mutations from each parent and currently unrecognized rare variants and unmeasured genetic interactions between common and rare variants may be a widespread genetic phenomenon in the germline of affected children. Therefore, family-based trio sequencing has the potential to reveal a striking new landscape of inheritance in childhood cancer and to facilitate the integration and efforts of individualized treatment strategies, including personalized and preventive medicine and cancer surveillance programs. Consequently, cancer genetics is becoming an increasingly common approach in modern oncology, so trio-sequencing should also be routinely integrated into pediatric oncology.	[Kuhlen, Michaela; Taeubner, Julia; Brozou, Triantafyllia; Borkhardt, Arndt] Heinrich Heine Univ, Univ Childrens Hosp, Med Fac, Dept Pediat Oncol Hematol & Clin Immunol, Dusseldorf, Germany; [Wieczorek, Dagmar] Heinrich Heine Univ, Inst Human Genet, Med Fac, Dusseldorf, Germany; [Siebert, Reiner] Ulm Univ, Inst Human Genet, Ulm, Germany; [Siebert, Reiner] Ulm Univ, Med Ctr, Ulm, Germany	Heinrich Heine University Dusseldorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Heinrich Heine University Dusseldorf; Ulm University; Ulm University	Kuhlen, M (corresponding author), Heinrich Heine Univ, Univ Childrens Hosp, Med Fac, Dept Pediat Oncol Hematol & Clin Immunol, Dusseldorf, Germany.	Michaela.Kuhlen@med.uni-duesseldorf.de	Wieczorek, Dagmar/AAU-6008-2021; Siebert, Reiner/A-8049-2010	Wieczorek, Dagmar/0000-0003-2812-6492; Borkhardt, Arndt/0000-0002-6121-4737	German Research Consortium of Translational Cancer Research, DKTK; BMBF [01KU1505G]; KinderKrebsInitiative Buchholz/Holm-Seppensen	German Research Consortium of Translational Cancer Research, DKTK; BMBF(Federal Ministry of Education & Research (BMBF)); KinderKrebsInitiative Buchholz/Holm-Seppensen	The authors thank Stewart Boden for providing English editing. AB is supported by the German Research Consortium of Translational Cancer Research, DKTK. The research of RS on germline alterations in pediatric cancer is supported by the BMBF in the framework of the ICGC-DE-Mining consortium (01KU1505G) and the KinderKrebsInitiative Buchholz/Holm-Seppensen. AB is supported by the German Research Consortium of Translational Cancer Research, DKTK. The research of RS on germline alterations in pediatric cancer is supported by the BMBF in the framework of the ICGC-DE-Mining consortium (01KU1505G) and the KinderKrebsInitiative Buchholz/Holm-Seppensen.	Acuna-Hidalgo R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1110-1; Acuna-Hidalgo R, 2015, AM J HUM GENET, V97, P67, DOI 10.1016/j.ajhg.2015.05.008; Ariffin H, 2014, P NATL ACAD SCI USA, V111, P15497, DOI 10.1073/pnas.1417322111; Bainbridge MN, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju384; Ballinger ML, 2016, LANCET ONCOL, V17, P1261, DOI 10.1016/S1470-2045(16)30147-4; Bardai A, 2016, NEW ENGL J MED, V374, P1390, DOI 10.1056/NEJMc1600338; Bell RJA, 2016, MOL CANCER RES, V14, P315, DOI 10.1158/1541-7786.MCR-16-0003; Besenbacher S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6969; Betts MJ, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1094; Brozou T, 2018, EUR J PEDIATR, V177, P53, DOI 10.1007/s00431-017-2997-6; Campbell CD, 2013, TRENDS GENET, V29, P575, DOI 10.1016/j.tig.2013.04.005; Campbell IM, 2014, AM J HUM GENET, V95, P173, DOI 10.1016/j.ajhg.2014.07.003; Cerrato F, 2008, HUM MOL GENET, V17, P1427, DOI 10.1093/hmg/ddn031; Chamary JV, 2006, NAT REV GENET, V7, P98, DOI 10.1038/nrg1770; Chubb D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11883; Conrad DF, 2011, NAT GENET, V43, P712, DOI 10.1038/ng.862; Conti SL, 2016, ASIAN J ANDROL, V18, P420, DOI 10.4103/1008-682X.175097; Crow JF, 2000, NAT REV GENET, V1, P40, DOI 10.1038/35049558; de Kock L, 2018, GENE CHROMOSOME CANC, V57, P223, DOI 10.1002/gcc.22523; Diets IJ, 2018, CLIN CANCER RES, V24, P1594, DOI 10.1158/1078-0432.CCR-17-1725; Dorairaj JJ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-421; Eyre-Walker A, 2007, NAT REV GENET, V8, P610, DOI 10.1038/nrg2146; Farwell KD, 2015, GENET MED, V17, P578, DOI 10.1038/gim.2014.154; Franceschi S, 2017, CARCINOGENESIS, V38, P938, DOI 10.1093/carcin/bgx069; Francioli LC, 2015, NAT GENET, V47, P822, DOI 10.1038/ng.3292; Fremerey J, 2017, FAM CANCER, V16, P401, DOI 10.1007/s10689-016-9958-5; Gilissen C, 2014, NATURE, V511, P344, DOI [10.1038/nature13394, 10.3389/fnhum.2013.00444]; Goldmann JM, 2016, NAT GENET, V48, P935, DOI 10.1038/ng.3597; Goriely A, 2012, AM J HUM GENET, V90, P175, DOI 10.1016/j.ajhg.2011.12.017; Hadizadeh H, 2017, PEDIAT ALLERG IMM-UK, V28, P280, DOI 10.1111/pai.12685; Heidemann S, 2012, BREAST CANCER RES TR, V134, P1229, DOI 10.1007/s10549-012-2050-4; Hemminki K, 1999, EPIDEMIOLOGY, V10, P271, DOI 10.1097/00001648-199905000-00014; Iossifov I, 2012, NEURON, V74, P285, DOI 10.1016/j.neuron.2012.04.009; Johnson KJ, 2009, EPIDEMIOLOGY, V20, P475, DOI 10.1097/EDE.0b013e3181a5a332; King DA, 2014, GENOME RES, V24, P673, DOI 10.1101/gr.160465.113; Kloosterman WP, 2015, GENOME RES, V25, P792, DOI 10.1101/gr.185041.114; Knapke Sara, 2012, Am Soc Clin Oncol Educ Book, P576, DOI 10.14694/EdBook_AM.2012.32.576; Kong A, 2012, NATURE, V488, P471, DOI 10.1038/nature11396; Korbel JO, 2007, SCIENCE, V318, P420, DOI 10.1126/science.1149504; Kotzot D, 2008, J MED GENET, V45, P545, DOI 10.1136/jmg.2008.058016; Kratz CP, 2017, CLIN CANCER RES, V23, pE38, DOI 10.1158/1078-0432.CCR-17-0408; Kresak JL, 2016, J PEDIATR GENET, V5, P98, DOI 10.1055/s-0036-1579766; Kuhlen M, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708641; Lee H, 2014, JAMA-J AM MED ASSOC, V312, P1880, DOI 10.1001/jama.2014.14604; Lelieveld SH, 2016, NAT NEUROSCI, V19, P1194, DOI 10.1038/nn.4352; Martin-Lorenzo A, 2015, CANCER DISCOV, V5, P1328, DOI 10.1158/2159-8290.CD-15-0892; McBride KA, 2014, NAT REV CLIN ONCOL, V11, P260, DOI 10.1038/nrclinonc.2014.41; Mcrae JF, 2017, NATURE, V542, P433, DOI 10.1038/nature21062; Mestek-Boukhibar L, 2018, J MED GENET, V55, P721, DOI 10.1136/jmedgenet-2018-105396; Mussa A, 2016, J PEDIATR-US, V176, P142, DOI 10.1016/j.jpeds.2016.05.038; Nagy R, 2004, ONCOGENE, V23, P6445, DOI 10.1038/sj.onc.1207714; Natacci F, 2008, AM J MED GENET A, V146A, P784, DOI 10.1002/ajmg.a.32228; Neale BM, 2012, NATURE, V485, P242, DOI 10.1038/nature11011; Ng SB, 2010, NAT GENET, V42, P790, DOI 10.1038/ng.646; O'Roak BJ, 2011, NAT GENET, V43, P585, DOI 10.1038/ng.835; Papenhausen P, 2011, AM J MED GENET A, V155A, P757, DOI 10.1002/ajmg.a.33939; Rahbari R, 2016, NAT GENET, V48, P126, DOI 10.1038/ng.3469; Rauch A, 2012, LANCET, V380, P1674, DOI 10.1016/S0140-6736(12)61480-9; Rauen KA, 2013, ANNU REV GENOM HUM G, V14, P355, DOI 10.1146/annurev-genom-091212-153523; Renaux-Petel M, 2018, J MED GENET, V55, P173, DOI 10.1136/jmedgenet-2017-104976; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Rivera B, 2016, ACTA NEUROPATHOL, V131, P847, DOI 10.1007/s00401-016-1549-x; Robles-Espinoza CD, 2014, NAT GENET, V46, P478, DOI 10.1038/ng.2947; Rotunno M, 2016, HAEMATOLOGICA, V101, P853, DOI 10.3324/haematol.2015.135475; Salem B, 2016, J PEDIAT HEMATOL ONC, V38, pE278, DOI 10.1097/MPH.0000000000000566; Sanders SJ, 2012, NATURE, V485, P237, DOI 10.1038/nature10945; Sauna ZE, 2011, NAT REV GENET, V12, P683, DOI 10.1038/nrg3051; Schwaederle M, 2017, CANCER, V124, P1288; Shi JX, 2014, NAT GENET, V46, P482, DOI 10.1038/ng.2941; Shlien A, 2008, P NATL ACAD SCI USA, V105, P11264, DOI 10.1073/pnas.0802970105; Speedy HE, 2016, BLOOD, V128, P2319, DOI 10.1182/blood-2016-01-695692; Strauss BS, 2000, MUTAT RES-FUND MOL M, V457, P93, DOI 10.1016/S0027-5107(00)00135-4; Taeubner J, 2018, TRENDS CANCER, V4, P718, DOI 10.1016/j.trecan.2018.09.002; Taeubner J, 2018, EUR J HUM GENET, V26, P137, DOI 10.1038/s41431-017-0048-4; Veltman JA, 2012, NAT REV GENET, V13, P565, DOI 10.1038/nrg3241; Villani A, 2011, LANCET ONCOL, V12, P559, DOI 10.1016/S1470-2045(11)70119-X; Vislovukh Andrii, 2014, World J Biol Chem, V5, P40, DOI 10.4331/wjbc.v5.i1.40; Vissers LELM, 2010, NAT GENET, V42, P1109, DOI 10.1038/ng.712; Wang R, 2017, AM J EPIDEMIOL, V186, P843, DOI 10.1093/aje/kwx160; Waszak SM, 2017, BIORXIV, DOI [10.1101/208330, DOI 10.1101/208330]; Yamazawa K, 2010, AM J MED GENET C, V154C, P329, DOI 10.1002/ajmg.c.30270; Zhang JH, 2015, NEW ENGL J MED, V373, P2336, DOI 10.1056/NEJMoa1508054; Zhong Q, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.80; Zhu XL, 2015, GENET MED, V17, P774, DOI 10.1038/gim.2014.191; Zlotogora J, 2004, HUM GENET, V114, P521, DOI 10.1007/s00439-004-1105-y	85	20	20	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1367	1380		10.1038/s41388-018-0520-9	http://dx.doi.org/10.1038/s41388-018-0520-9			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30305723	Green Published, hybrid			2022-12-17	WOS:000459945800001
J	Feng, JB; Zhang, Y; She, XL; Sun, YN; Fan, L; Ren, X; Fu, HJ; Liu, CH; Li, PY; Zhao, CH; Liu, Q; Liu, Q; Li, GY; Wu, MH				Feng, Jianbo; Zhang, Yan; She, Xiaoling; Sun, Yingnan; Fan, Li; Ren, Xing; Fu, Haijuan; Liu, Changhong; Li, Peiyao; Zhao, Chunhua; Liu, Qiang; Liu, Qing; Li, Guiyuan; Wu, Minghua			Hypermethylated gene ANKDD1A is a candidate tumor suppressor that interacts with FIH1 and decreases HIF1 alpha stability to inhibit cell autophagy in the glioblastoma multiforme hypoxia microenvironment	ONCOGENE			English	Article							MIR-101 REVERSES; ANKYRIN REPEAT; EXPRESSION; CANCER; HIF-1; METHYLATION; HIF-1-ALPHA; PROMOTER; IMPACT; GROWTH	Ectopic epigenetic mechanisms play important roles in facilitating tumorigenesis. Here, we first demonstrated that ANKDD1A is a functional tumor suppressor gene, especially in the hypoxia microenvironment. ANKDD1A directly interacts with FIH1 and inhibits the transcriptional activity of HIF1 alpha by upregulating FIH1. In addition, ANKDD1A decreases the half-life of HIF1 alpha by upregulating FIH1, decreases glucose uptake and lactate production, inhibits glioblastoma multiforme (GBM) autophagy, and induces apoptosis in GBM cells under hypoxia. Moreover, ANKDD1A is highly frequently methylated in GBM. The tumor-specific methylation of ANKDD1A indicates that it could be used as a potential epigenetic biomarker as well as a possible therapeutic target.	[Feng, Jianbo; Zhang, Yan; Sun, Yingnan; Ren, Xing; Fu, Haijuan; Liu, Changhong; Li, Peiyao; Zhao, Chunhua; Li, Guiyuan; Wu, Minghua] Cent S Univ, Hunan Prov Tumor Hosp, Changsha 410013, Hunan, Peoples R China; [Feng, Jianbo; Zhang, Yan; Sun, Yingnan; Ren, Xing; Fu, Haijuan; Liu, Changhong; Li, Peiyao; Zhao, Chunhua; Li, Guiyuan; Wu, Minghua] Cent S Univ, Affiliated Tumor Hosp, Xiangya Med Sch, Changsha 410013, Hunan, Peoples R China; [Feng, Jianbo; Zhang, Yan; Ren, Xing; Fu, Haijuan; Liu, Changhong; Li, Peiyao; Zhao, Chunhua; Li, Guiyuan; Wu, Minghua] Cent S Univ, Key Lab Carcinogenesis, Chinese Minist Hlth,Canc Res Inst, Key Lab Carcinogenesis & Canc Invas,Chinese Minis, Changsha 410008, Hunan, Peoples R China; [She, Xiaoling] Cent S Univ, Second Xiangya Hosp, Changsha 410011, Hunan, Peoples R China; [Fan, Li] Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA; [Liu, Qiang] Cent S Univ, Third Xiangya Hosp, Changsha 410011, Hunan, Peoples R China; [Liu, Qing] Cent S Univ, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China	Central South University; Central South University; Central South University; Central South University; University of California System; University of California Riverside; Central South University; Central South University	Wu, MH (corresponding author), Cent S Univ, Hunan Prov Tumor Hosp, Changsha 410013, Hunan, Peoples R China.; Wu, MH (corresponding author), Cent S Univ, Affiliated Tumor Hosp, Xiangya Med Sch, Changsha 410013, Hunan, Peoples R China.; Wu, MH (corresponding author), Cent S Univ, Key Lab Carcinogenesis, Chinese Minist Hlth,Canc Res Inst, Key Lab Carcinogenesis & Canc Invas,Chinese Minis, Changsha 410008, Hunan, Peoples R China.	wuminghua554@aliyun.com			National Science Foundation of China [81272297]; National Key Technology Research and Development program of the Ministry of Science and Technology of China [2014BAI04B02]; 111 Project [111-2]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Technology Research and Development program of the Ministry of Science and Technology of China(National Key Technology R&D Program); 111 Project(Ministry of Education, China - 111 Project)	This work was supported by grants from the National Science Foundation of China (81272297), National Key Technology Research and Development program of the Ministry of Science and Technology of China under Grant 2014BAI04B02; 111 Project under Grant number 111-2.	Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09; Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Beyer AR, 2017, CELL MICROBIOL, V19, DOI 10.1111/cmi.12727; Bhardwaj A, 2003, J CLIN IMMUNOL, V23, P317, DOI 10.1023/A:1025319031417; Bordoli MR, 2011, ONCOGENE, V30, P548, DOI 10.1038/onc.2010.433; Bourguignon LYW, 2000, J CELL BIOL, V150, P177, DOI 10.1083/jcb.150.1.177; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Cheng J, 2007, CELL, V131, P584, DOI 10.1016/j.cell.2007.08.045; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Christensen BC, 2011, JNCI-J NATL CANCER I, V103, DOI 10.1093/jnci/djq497; Chung AS, 2005, MOL CELL BIOL, V25, P4716, DOI 10.1128/MCB.25.11.4716-4726.2005; Cockman ME, 2009, ANN NY ACAD SCI, V1177, P9, DOI 10.1111/j.1749-6632.2009.05042.x; Du WY, 2017, CHIN J CANCER, V36, DOI 10.1186/s40880-017-0180-0; Duyndam MCA, 2003, J BIOL CHEM, V278, P6885, DOI 10.1074/jbc.M206320200; Eales KL, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.50; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Kim Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10347; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lei QQ, 2016, ONCOTARGET, V7, P5007, DOI 10.18632/oncotarget.6652; Liu CJ, 2010, CANCER RES, V70, P1635, DOI 10.1158/0008-5472.CAN-09-2291; Liu XP, 2015, ONCOTARGET, V6, P7930, DOI 10.18632/oncotarget.3181; Liu ZJ, 2015, J ZHEJIANG UNIV-SC B, V16, P32, DOI 10.1631/jzus.B1400221; Madsen CD, 2015, EMBO REP, V16, P1394, DOI 10.15252/embr.201540107; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3515, DOI 10.4161/cc.9.17.12928; Mehrmohamadi M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13666; Mikeska T, 2014, GENES-BASEL, V5, P821, DOI 10.3390/genes5030821; Nguyen LK, 2015, J CELL SCI, V128, P422, DOI 10.1242/jcs.167304; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Pelletier J, 2012, ONCOGENE, V31, P2989, DOI 10.1038/onc.2011.471; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Uhlmann K, 2003, INT J CANCER, V106, P52, DOI 10.1002/ijc.11175; Vakil L, 2016, TUMOR BIOL, V37, P8841, DOI 10.1007/s13277-015-4723-1; Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1; Vordermark D, 2002, CANCER, V94, P2317, DOI 10.1002/cncr.10462; Wajant H, 2003, ESSAYS BIOCHEM, V39, P53, DOI 10.1042/bse0390053; Wang EF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086102; Wang ZY, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0355-1; Weidemann A, 2008, CELL DEATH DIFFER, V15, P621, DOI 10.1038/cdd.2008.12; Wiestler B, 2014, NEURO-ONCOLOGY, V16, P1630, DOI 10.1093/neuonc/nou138; Wilkins SE, 2009, INT J BIOCHEM CELL B, V41, P1563, DOI 10.1016/j.biocel.2009.01.005; Xiaoping L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.197; Xu G, 2015, J NEUROSCI, V35, P7153, DOI 10.1523/JNEUROSCI.4726-14.2015; Yan B, 2011, MOL CELL BIOCHEM, V348, P1, DOI 10.1007/s11010-010-0631-2; Yang M, 2011, J BIOL CHEM, V286, P7648, DOI 10.1074/jbc.M110.193540; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200; Zhang N, 2010, CELL METAB, V11, P364, DOI 10.1016/j.cmet.2010.03.001; Zhang ZP, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-124; Zhang ZP, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-99; Zheng X, 2008, P NATL ACAD SCI USA, V105, P3368, DOI 10.1073/pnas.0711591105	53	20	21	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2019	38	1					103	119		10.1038/s41388-018-0423-9	http://dx.doi.org/10.1038/s41388-018-0423-9			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG2EL	30082910	Green Published, hybrid			2022-12-17	WOS:000454775900008
J	Park, JW; Chae, YC; Kim, JY; Oh, H; Seo, SB				Park, Jin Woo; Chae, Yun-Cheol; Kim, Ji-Young; Oh, Hyein; Seo, Sang-Beom			Methylation of Aurora kinase A by MMSET reduces p53 stability and regulates cell proliferation and apoptosis	ONCOGENE			English	Article							HISTONE METHYLTRANSFERASE; LYSINE METHYLATION; INHIBITION; PROTEIN	The histone methyltransferase multiple myeloma SET domain protein (MMSET/WHSC1) is highly expressed in diverse tumor types, and its expression appears to be involved in cell proliferation. In this study, we report that MMSET interacts with and methylates Aurora kinase A (AURKA). We show that MMSET-mediated methylation of AURKA induces interaction with p53 as well as enhanced kinase activity of AURKA, which results in the proteasomal degradation of p53. MMSET-mediated p53 degradation increases cell proliferation and results in oncogenic activity. Furthermore, knockdown of MMSET potently inhibits tumorigenic cells and renders them sensitive to growth inhibition by the therapeutic drug, alisertib (AURKA inhibitor). Taken together, our results suggest that MMSET is a regulator of p53 stability via methylation of AURKA in proliferating cells and might be a potential therapeutic target in solid tumors.	[Park, Jin Woo; Chae, Yun-Cheol; Kim, Ji-Young; Oh, Hyein; Seo, Sang-Beom] Chung Ang Univ, Dept Life Sci, Coll Nat Sci, Seoul 06974, South Korea	Chung Ang University	Seo, SB (corresponding author), Chung Ang Univ, Dept Life Sci, Coll Nat Sci, Seoul 06974, South Korea.	sangbs@cau.ac.kr			National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning [NRF-2016R1A4A1008035, NRF-2017R1A2B4004407]	National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Ministry of Science, ICT & Future Planning NRF-2016R1A4A1008035 and NRF-2017R1A2B4004407)	Nguyen AT, 2011, GENE DEV, V25, P1345, DOI 10.1101/gad.2057811; Asangani IA, 2013, MOL CELL, V49, P80, DOI 10.1016/j.molcel.2012.10.008; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Dar AA, 2010, MOL CANCER THER, V9, P268, DOI 10.1158/1535-7163.MCT-09-0765; De Luca M, 2006, CELL CYCLE, V5, P296; Ertych N, 2014, NAT CELL BIOL, V16, P779, DOI 10.1038/ncb2994; Esteve PO, 2009, P NATL ACAD SCI USA, V106, P5076, DOI 10.1073/pnas.0810362106; Hudlebusch HR, 2011, CLIN CANCER RES, V17, P2919, DOI 10.1158/1078-0432.CCR-10-1302; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Kim JY, 2008, MOL CELL BIOL, V28, P2023, DOI 10.1128/MCB.02130-07; Kurash JK, 2008, MOL CELL, V29, P392, DOI 10.1016/j.molcel.2007.12.025; Laurent B, 2015, MOL CELL, V57, P957, DOI 10.1016/j.molcel.2015.01.010; Lee DF, 2012, CELL STEM CELL, V11, P179, DOI 10.1016/j.stem.2012.05.020; Lee YF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106661; Li N, 2017, J CLIN INVEST, V127, P1284, DOI 10.1172/JCI91144; Martinez-Garcia E, 2011, BLOOD, V117, P211, DOI 10.1182/blood-2010-07-298349; Marxer M, 2014, ONCOGENE, V33, P3550, DOI 10.1038/onc.2013.325; Maxwell CA, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001199; Moll UM, 2003, MOL CANCER RES, V1, P1001; Morishita M, 2014, BMC STRUCT BIOL, V14, DOI 10.1186/s12900-014-0025-x; Nimura K, 2009, NATURE, V460, P287, DOI 10.1038/nature08086; Park JW, 2015, SCI REP-UK, V5, DOI 10.1038/srep12485; Pei HD, 2011, NATURE, V470, P124, DOI 10.1038/nature09658; Sammons MA, 2015, GENOME RES, V25, P179, DOI 10.1101/gr.181883.114; Shen C, 2015, MOL CELL, V60, P847, DOI 10.1016/j.molcel.2015.10.033; Subramanian K, 2008, MOL CELL, V30, P336, DOI 10.1016/j.molcel.2008.03.022; Yang XD, 2009, EPIGENETICS-US, V4, P429, DOI 10.4161/epi.4.7.9787; Yang XD, 2009, EMBO J, V28, P1055, DOI 10.1038/emboj.2009.55	30	20	22	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2018	37	48					6212	6224		10.1038/s41388-018-0393-y	http://dx.doi.org/10.1038/s41388-018-0393-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC2HE	30013191				2022-12-17	WOS:000451622100002
J	Brough, R; Gulati, A; Haider, S; Kumar, R; Campbell, J; Knudsen, E; Pettitt, SJ; Ryan, CJ; Lord, CJ				Brough, Rachel; Gulati, Aditi; Haider, Syed; Kumar, Rahul; Campbell, James; Knudsen, Erik; Pettitt, Stephen J.; Ryan, Coim J.; Lord, Christopher J.			Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer	ONCOGENE			English	Article							COP9 SIGNALOSOME; CELL-CYCLE; NEOADJUVANT CHEMOTHERAPY; PATHWAY DISRUPTION; PROTEIN EXPRESSION; OVARIAN-CANCER; LARGE-SCALE; P53; ASSOCIATION; INHIBITORS	Although defects in the RB1 tumour suppressor are one of the more common driver alterations found in triple-negative breast cancer (TNBC), therapeutic approaches that exploit this have not been identified. By integrating molecular profiling data with data from multiple genetic perturbation screens, we identified candidate synthetic lethal (SL) interactions associated with RB1 defects in TNBC. We refined this analysis by identifying the highly penetrant effects, reasoning that these would be more robust in the face of molecular heterogeneity and would represent more promising therapeutic targets. A significant proportion of the highly penetrant RB1 SL effects involved proteins closely associated with RB1 function, suggesting that this might be a defining characteristic. These included nuclear pore complex components associated with the MAD2 spindle checkpoint protein, the kinase and bromodomain containing transcription factor TAF1, and multiple components of the SCFSKP Cullin F box containing complex. Small-molecule inhibition of SCFSKP elicited an increase in p27Kip levels, providing a mechanistic rationale for RB1 SL. Transcript expression of SKP2, a SCFSKP component, was elevated in RB1-defective TNBCs, suggesting that in these tumours, SKP2 activity might buffer the effects of RB1 dysfunction.	[Brough, Rachel; Gulati, Aditi; Haider, Syed; Kumar, Rahul; Campbell, James; Pettitt, Stephen J.; Lord, Christopher J.] Breast Canc Now Toby Robins Breast Canc Res Ctr, London SW3 6JB, England; [Brough, Rachel; Gulati, Aditi; Kumar, Rahul; Campbell, James; Pettitt, Stephen J.; Lord, Christopher J.] Inst Canc Res, CRUK Gene Funct Lab, London SW3 6JB, England; [Knudsen, Erik] Univ Arizona, Dept Med, Tucson, AZ 85721 USA; [Ryan, Coim J.] Univ Coll Dublin, Syst Biol Ireland, Dublin, Ireland; [Ryan, Coim J.] Univ Coll Dublin, Sch Comp Sci, Dublin, Ireland	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Arizona; University College Dublin; University College Dublin	Lord, CJ (corresponding author), Breast Canc Now Toby Robins Breast Canc Res Ctr, London SW3 6JB, England.; Lord, CJ (corresponding author), Inst Canc Res, CRUK Gene Funct Lab, London SW3 6JB, England.; Ryan, CJ (corresponding author), Univ Coll Dublin, Syst Biol Ireland, Dublin, Ireland.; Ryan, CJ (corresponding author), Univ Coll Dublin, Sch Comp Sci, Dublin, Ireland.	Colm.RyanRyan@ucd.ie; Chris.Lord@icr.ac.uk	Lord, Christopher/AAX-7130-2021; kumar, rahul/GZG-2171-2022; Kumar, Rahul/ABB-3530-2020; Lord, Christopher/B-3295-2012	Pettitt, Stephen/0000-0003-3313-3857; Lord, Christopher/0000-0002-3226-0515; Ryan, Colm/0000-0003-2750-9854; Kumar, Rahul/0000-0002-6927-5390	Breast Cancer Now and Cancer Research UK Programme; Science Foundation Ireland; Health Research Board; Wellcome Trust under the SFI-HRB-Wellcome Trust Biomedical Research Partnership [103049/Z/13/Z]; NHS; Cancer Research UK; British Columbia Cancer Agency Branch; NATIONAL CANCER INSTITUTE [P30CA023074] Funding Source: NIH RePORTER	Breast Cancer Now and Cancer Research UK Programme; Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Health Research Board; Wellcome Trust under the SFI-HRB-Wellcome Trust Biomedical Research Partnership(Wellcome Trust); NHS; Cancer Research UK(Cancer Research UK); British Columbia Cancer Agency Branch; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by Breast Cancer Now and Cancer Research UK Programme Grants to CJL. CJR was a Sir Henry Wellcome Fellow jointly funded by Science Foundation Ireland, the Health Research Board and the Wellcome Trust (grant number 103049/Z/13/Z) under the SFI-HRB-Wellcome Trust Biomedical Research Partnership. We acknowledge NHS funding to the NIHR Biomedical Research Centre at the Royal Marsden Hospital. This study makes use of data generated by the Molecular Taxonomy of Breast Cancer International Consortium, which was funded by Cancer Research UK and the British Columbia Cancer Agency Branch. The results published here are based, in part, upon data generated by The Cancer Genome Atlas pilot project established by the NCI and NHGRI. Information about TCGA and the investigators and institutions who constitute the TCGA research network can be found at http://cancergenome.nih.gov/.	Asghar US, 2017, CLIN CANCER RES, V23, P5561, DOI 10.1158/1078-0432.CCR-17-0369; Ashworth A, 2011, CELL, V145, P30, DOI 10.1016/j.cell.2011.03.020; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bernad R, 2006, J BIOL CHEM, V281, P19378, DOI 10.1074/jbc.M512585200; Bianchini G, 2016, NAT REV CLIN ONCOL, V13, P674, DOI 10.1038/nrclinonc.2016.66; Blower MD, 2005, CELL, V121, P223, DOI 10.1016/j.cell.2005.02.016; Bouche L, 2017, J MED CHEM, V60, P4002, DOI 10.1021/acs.jmedchem.7b00306; Brough R, 2011, CANCER DISCOV, V1, P260, DOI 10.1158/2159-8290.CD-11-0107; Campbell J, 2016, CELL REP, V14, P2490, DOI 10.1016/j.celrep.2016.02.023; Ceron J, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-30; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Chen X, 2012, CANCER INFORM, V11, P147, DOI 10.4137/CIN.S9983; Choi W, 2017, EUR UROL, V72, P354, DOI 10.1016/j.eururo.2017.03.010; Chung D, 2015, BIOMOLECULES, V5, P2388, DOI 10.3390/biom5042388; Corney DC, 2008, ADV EXP MED BIOL, V622, P99, DOI 10.1007/978-0-387-68969-2_9; Crawford TD, 2016, J MED CHEM, V59, P5391, DOI 10.1021/acs.jmedchem.6b00264; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Ertel A, 2010, CELL CYCLE, V9, P4153, DOI 10.4161/cc.9.20.13454; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Feingold EA, 2004, SCIENCE, V306, P636, DOI 10.1126/science.1105136; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Goldhoff P, 2012, J NEUROPATH EXP NEUR, V71, P83, DOI 10.1097/NEN.0b013e31823fe8f1; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; Haverty PM, 2016, NATURE, V533, P333, DOI 10.1038/nature17987; Herschkowitz JI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2142; HIGASHIYAMA M, 1994, ONCOLOGY-BASEL, V51, P544; Ji P, 2004, MOL CELL, V16, P47, DOI 10.1016/j.molcel.2004.09.029; Jiang Z, 2011, CELL CYCLE, V10, P1563, DOI 10.4161/cc.10.10.15703; Johnson J, 2016, ONCOGENE, V35, P4829, DOI 10.1038/onc.2016.32; Jones RA, 2016, J CLIN INVEST, V126, P3739, DOI 10.1172/JCI81568; Knudsen ES, 2015, CELL CYCLE, V14, P109, DOI 10.4161/15384101.2014.967118; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lawrence RT, 2015, CELL REP, V11, P630, DOI 10.1016/j.celrep.2015.03.050; Lehmann BD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157368; Li P, 2017, J CELL PHYSIOL, V232, P1246, DOI 10.1002/jcp.25696; Lin CY, 2002, CURR BIOL, V12, P2142, DOI 10.1016/S0960-9822(02)01389-1; Lingaraju GM, 2014, NATURE, V512, P161, DOI 10.1038/nature13566; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Lord CJ, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-38; Lu ZL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4463; Marcotte R, 2016, CELL, V164, P293, DOI 10.1016/j.cell.2015.11.062; Marcotte R, 2012, CANCER DISCOV, V2, P172, DOI 10.1158/2159-8290.CD-11-0224; McDonald ER, 2017, CELL, V170, P577, DOI 10.1016/j.cell.2017.07.005; Nittner D, 2012, NAT CELL BIOL, V14, P958, DOI 10.1038/ncb2556; Orjalo AV, 2006, MOL BIOL CELL, V17, P3806, DOI 10.1091/mbc.e05-11-1061; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Reed SI, 2003, NAT REV MOL CELL BIO, V4, P855, DOI 10.1038/nrm1246; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robinson TJW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078641; Rodriguez-Bravo V, 2014, CELL, V156, P1017, DOI 10.1016/j.cell.2014.01.010; Russnes HG, 2017, AM J PATHOL, V187, P2152, DOI 10.1016/j.ajpath.2017.04.022; Schvartzman JM, 2011, CANCER CELL, V19, P701, DOI 10.1016/j.ccr.2011.04.017; Sdelci S, 2016, NAT CHEM BIOL, V12, P504, DOI 10.1038/nchembio.2080; Searle JS, 2010, ONCOTARGET, V1, P228; Semczuk A, 2000, PATHOL RES PRACT, V196, P41, DOI 10.1016/S0344-0338(00)80020-5; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; Shao ZH, 1997, ONCOGENE, V15, P385, DOI 10.1038/sj.onc.1201204; Stefansson OA, 2011, EPIGENETICS-US, V6, P638, DOI 10.4161/epi.6.5.15667; Takada M, 2014, BREAST CANCER RES TR, V145, P143, DOI 10.1007/s10549-014-2907-9; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Trere D, 2009, ANN ONCOL, V20, P1818, DOI 10.1093/annonc/mdp209; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Wang HB, 2010, NAT GENET, V42, P83, DOI 10.1038/ng.498; Witkiewicz AK, 2012, CLIN CANCER RES, V18, P5110, DOI 10.1158/1078-0432.CCR-12-0903; Wu L, 2012, CHEM BIOL, V19, P1515, DOI 10.1016/j.chembiol.2012.09.015; Wu ZG, 2016, CELL BIOL INT, V40, P968, DOI 10.1002/cbin.10633; Xu XLL, 2014, NATURE, V514, P385, DOI 10.1038/nature13813; Zhao H, 2017, ONCOGENE, V36, P60, DOI 10.1038/onc.2016.175	68	20	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2018	37	43					5701	5718		10.1038/s41388-018-0368-z	http://dx.doi.org/10.1038/s41388-018-0368-z			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY1KL	29915391	Green Published, hybrid			2022-12-17	WOS:000448288200001
J	Roh, E; Lee, MH; Zykova, TA; Zhu, F; Nadas, J; Kim, HG; Bae, KB; Li, Y; Cho, YY; Curiel-Lewandrowski, C; Einspahr, J; Dickinson, SE; Bode, AM; Dong, ZG				Roh, Eunmiri; Lee, Mee-Hyun; Zykova, Tatyana A.; Zhu, Feng; Nadas, Janos; Kim, Hong-Gyum; Bae, Ki Beom; Li, Yan; Cho, Yong Yeon; Curiel-Lewandrowski, Clara; Einspahr, Janine; Dickinson, Sally E.; Bode, Ann M.; Dong, Zigang			Targeting PRPK and TOPK for skin cancer prevention and therapy	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; CYCLIN D1 EXPRESSION; BETAMETHASONE VALERATE; GROWTH-FACTOR; RISK-FACTORS; PROTEIN; KINASE; CARCINOGENESIS; METASTASIS; PHOSPHORYLATION	Solar ultraviolet (sUV) irradiation is a major environmental carcinogen that can cause inflammation and skin cancer. The costs and morbidity associated with skin cancer are increasing, and therefore identifying molecules that can help prevent skin carcinogenesis is important. In this study, we identified the p53-related protein kinase (PRPK) as a novel oncogenic protein that is phosphorylated by the T-LAK cell-originated protein kinase (TOPK). Knockdown of TOPK inhibited PRPK phosphorylation and conferred resistance to solar-simulated light (SSL)-induced skin carcinogenesis in mouse models. In the clinic, acute SSL irradiation significantly increased epidermal thickness as well as total protein and phosphorylation levels of TOPK and PRPK in human skin tissues. We identified two PRPK inhibitors, FDA-approved rocuronium bromide (Zemuron (R)) or betamethasone 17-valerate (Betaderm (R)) that could attenuate TOPK-dependent PRPK signaling. Importantly, topical application of either rocuronium bromide or betamethasone decreased SSL-induced epidermal hyperplasia, neovascularization, and cutaneous squamous cell carcinoma (cSCC) development in SKH1 (Crl: SKH1-Hr(hr)) hairless mice by inhibiting PRPK activation, and also reduced expression of the proliferation and oncogenesis markers, COX-2, cyclin D1, and MMP-9. This study is the first to demonstrate that targeting PRPK could be useful against sUV-induced cSCC development.	[Roh, Eunmiri; Lee, Mee-Hyun; Zykova, Tatyana A.; Zhu, Feng; Nadas, Janos; Kim, Hong-Gyum; Bae, Ki Beom; Li, Yan; Bode, Ann M.; Dong, Zigang] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA; [Lee, Mee-Hyun] China US Hormel Canc Inst, Zhengzhou 45008, Henan, Peoples R China; [Zhu, Feng] Huazhong Univ Sci & Technol, Sch Basic Med, Wuhan 430030, Hubei, Peoples R China; [Cho, Yong Yeon] Catholic Univ Korea, Coll Pharm, Bucheon 420743, South Korea; [Curiel-Lewandrowski, Clara; Einspahr, Janine; Dickinson, Sally E.] Univ Arizona, Ctr Canc, Tucson, AZ USA	University of Minnesota System; Huazhong University of Science & Technology; Catholic University of Korea; University of Arizona	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu	Cho, Yong-Yeon/AAD-4263-2020; ZHU, Feng/C-1303-2010	Zhu, Feng/0000-0003-1172-0102; Cho, Yong-Yeon/0000-0003-1107-2651	Hormel Foundation; National of Institutes of Health [CA027502, CA166011, CA187027, CA196639]; NATIONAL CANCER INSTITUTE [R01CA166011, P01CA027502, R01CA196639, P30CA023074, R01CA187027] Funding Source: NIH RePORTER	Hormel Foundation; National of Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by The Hormel Foundation and National of Institutes of Health grants CA027502, CA166011, CA187027, and CA196639 (ZD). We thank Dr. Lorenzo A. Pinna (Universita di Padova, Italy) for the pQE-81L-PRPK plasmid, Alyssa Langfald for confocal microscopy analysis, and Dr. Tia Rai and Nicki Brickman for assistance with manuscript submission.	Abe Y, 2006, BIOCHEM BIOPH RES CO, V344, P377, DOI 10.1016/j.bbrc.2006.03.071; Abe Y, 2001, J BIOL CHEM, V276, P44003, DOI 10.1074/jbc.M105669200; Allanson M, 2007, CANCER IMMUNOL IMMUN, V56, P1807, DOI 10.1007/s00262-007-0324-1; Atzmony L, 2016, AM J CLIN DERMATOL, V17, P11, DOI 10.1007/s40257-015-0160-6; Bode AM, 2006, MOL CARCINOGEN, V45, P422, DOI 10.1002/mc.20222; BOYLE JO, 1993, CANCER RES, V53, P4477; Brantsch KD, 2008, LANCET ONCOL, V9, P713, DOI 10.1016/S1470-2045(08)70178-5; Burton KA, 2016, AM J CLIN DERMATOL, V17, P491, DOI 10.1007/s40257-016-0207-3; Chang CF, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071007; Cherpelis BS, 2002, DERMATOL SURG, V28, P268, DOI 10.1046/j.1524-4725.2002.01169.x; Dobrev H, 2001, PHOTODERMATOL PHOTO, V17, P184, DOI 10.1034/j.1600-0781.2001.170408.x; Edlund K, 2012, P NATL ACAD SCI USA, V109, P9551, DOI 10.1073/pnas.1200019109; Facchin S, 2007, CELL MOL LIFE SCI, V64, P2680, DOI 10.1007/s00018-007-7179-7; Fan XM, 2016, ONCOTARGET, V7, P24633, DOI 10.18632/oncotarget.8260; Farasat S, 2011, J AM ACAD DERMATOL, V64, P1051, DOI 10.1016/j.jaad.2010.08.033; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Gao G, 2017, MOL CANCER THER, V16, P1843, DOI 10.1158/1535-7163.MCT-17-0212; Girardini JE, 2011, CANCER CELL, V20, P79, DOI 10.1016/j.ccr.2011.06.004; Guy GP, 2014, AM J PUBLIC HEALTH, V104, pE69, DOI [10.2105/AJPH.2013.301850, 10.1016/j.amepre.2014.08.036]; Hensler S, 2013, CANCER J, V19, P517, DOI 10.1097/PPO.0000000000000010; Huang K, 2012, CLIN EXP DERMATOL, V37, P411, DOI 10.1111/j.1365-2230.2011.04275.x; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Jensen JM, 2012, ALLERGY, V67, P413, DOI 10.1111/j.1398-9995.2011.02747.x; Joel M, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0398-x; Katiyar SK, 2007, TOXICOL APPL PHARM, V224, P220, DOI 10.1016/j.taap.2006.11.017; Katiyar SK, 2015, PHOTOCHEM PHOTOBIOL, V91, P156, DOI 10.1111/php.12330; Kim JE, 2016, ONCOGENE, V35, P4091, DOI 10.1038/onc.2015.471; Kim JE, 2016, ONCOTARGET, V7, P14616, DOI 10.18632/oncotarget.7524; Kwon JY, 2009, CARCINOGENESIS, V30, P1932, DOI 10.1093/carcin/bgp216; Li Y, 2016, ONCOTARGET, V7, P6748, DOI 10.18632/oncotarget.6826; Lohmann CM, 2001, ADV ANAT PATHOL, V8, P27, DOI 10.1097/00125480-200101000-00005; Loyo M, 2013, HEAD NECK-J SCI SPEC, V35, P454, DOI 10.1002/hed.23100; Marcil I, 2000, ARCH DERMATOL, V136, P1524, DOI 10.1001/archderm.136.12.1524; Matsuo Y, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3010277; Missero C, 2014, EXP DERMATOL, V23, P143, DOI 10.1111/exd.12320; Muller-Decker K, 2011, CANCER METAST REV, V30, P343, DOI 10.1007/s10555-011-9306-z; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; Oh SM, 2007, CANCER RES, V67, P5186, DOI 10.1158/0008-5472.CAN-06-4506; Panelos J, 2008, MODERN PATHOL, V21, P316, DOI 10.1038/modpathol.3801007; Park JH, 2014, CELL SIGNAL, V26, P849, DOI 10.1016/j.cellsig.2014.01.004; Peterson D, 2010, CANCER RES, V70, P6325, DOI 10.1158/0008-5472.CAN-10-0015; Ratushny V, 2012, J CLIN INVEST, V122, P464, DOI 10.1172/JCI57415; Ridley AJ, 2009, INT J RADIAT BIOL, V85, P177, DOI 10.1080/09553000902740150; Rogers HW, 2015, JAMA DERMATOL, V151, P1081, DOI 10.1001/jamadermatol.2015.1187; Runger TM, 2007, J INVEST DERMATOL, V127, P2103, DOI 10.1038/sj.jid.5700988; Saraceno R, 2010, J DERMATOL TREAT, V21, P363, DOI 10.3109/09546630903386606; Schwarz A, 2005, J EXP MED, V201, P173, DOI 10.1084/jem.20041212; Shen YY, 2014, MOL CLIN ONCOL, V2, P545, DOI 10.3892/mco.2014.273; Shih MC, 2012, ONCOGENE, V31, P2389, DOI 10.1038/onc.2011.419; Thompson AK, 2016, JAMA DERMATOL, V152, P419, DOI 10.1001/jamadermatol.2015.4994; Trifan OC, 2003, J CELL MOL MED, V7, P207, DOI 10.1111/j.1582-4934.2003.tb00222.x; Yano K, 2004, J INVEST DERMATOL, V122, P201, DOI 10.1046/j.0022-202X.2003.22101.x; Yokogawa M, 2013, MOL CARCINOGEN, V52, P760, DOI 10.1002/mc.21901; Zhu F, 2007, GASTROENTEROLOGY, V133, P219, DOI 10.1053/j.gastro.2007.04.048	54	20	21	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2018	37	42					5633	5647		10.1038/s41388-018-0350-9	http://dx.doi.org/10.1038/s41388-018-0350-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX3JJ	29904102	Green Accepted			2022-12-17	WOS:000447619100004
J	Lee, GW; Park, JB; Park, SY; Seo, J; Shin, SH; Park, JW; Kim, SJ; Watanabe, M; Chun, YS				Lee, Gun-Woo; Park, Jun Bum; Park, Sung Yeon; Seo, Jieun; Shin, Seung-Hyun; Park, Jong-Wan; Kim, Sang Jung; Watanabe, Masatoshi; Chun, Yang-Sook			The E3 ligase C-CBL inhibits cancer cell migration by neddylating the proto-oncogene c-Src	ONCOGENE			English	Article							NEDD8-ACTIVATING ENZYME-INHIBITOR; PROTEIN NEDDYLATION; NEDD8 CONJUGATION; IN-VITRO; MLN4924; EXPRESSION; PATHWAY; TARGET; ACTIVATION; APOPTOSIS	Neddylation is a cellular process that covalently conjugates substrate proteins with the small ubiquitin-like molecule NEDD8. As neddylation is required for fast turnover of proteins in proliferating cancer cells, the neddylation process is currently regarded as a potential target for cancer therapy. However, little is known about the role of neddylation in cancer invasion and metastasis. Unexpectedly, we here found that the neddylation blockade stimulates migration of lung cancer and glioblastoma cells. Mechanistically, C-CBL acts as the E3 ligase for neddylation of the proto-oncogene c-Src. After neddylation, c-Src is poly-ubiquitinated and degraded through the proteasome, which inhibits the PI3K-AKT pathway responsible for cell migration. In human lung cancer tissues, the downregulation of C-CBL was associated with c-Src/AKT, cancer metastasis, and poor survival in patients. Therefore, C-CBL is likely to play a tumor suppressive role by antagonizing a robust oncogenic signaling driven by c-Src. This study provides new insight about the role of neddylation in cancer metastasis. It also implies that the metastasis risk should be carefully evaluated before the clinical application of neddylation inhibitors as anticancer regimens.	[Lee, Gun-Woo; Park, Jun Bum; Park, Sung Yeon; Seo, Jieun; Shin, Seung-Hyun; Park, Jong-Wan; Kim, Sang Jung; Chun, Yang-Sook] Dept Biomed Sci, Seoul 110799, South Korea; [Park, Sung Yeon; Park, Jong-Wan; Kim, Sang Jung; Chun, Yang-Sook] Ischem Hypox Dis Inst, Seoul 110799, South Korea; [Kim, Sang Jung; Chun, Yang-Sook] Seoul Natl Univ, Dept Physiol, Coll Med, Seoul 110799, South Korea; [Watanabe, Masatoshi] Yokohama Natl Univ, Grad Sch Engn, Lab Med Engn, Yokohama, Kanagawa 2408501, Japan	Seoul National University (SNU)	Chun, YS (corresponding author), Dept Biomed Sci, Seoul 110799, South Korea.; Chun, YS (corresponding author), Ischem Hypox Dis Inst, Seoul 110799, South Korea.; Chun, YS (corresponding author), Seoul Natl Univ, Dept Physiol, Coll Med, Seoul 110799, South Korea.	chunys@snu.ac.kr		Seo, Jieun/0000-0003-1319-832X; Park, Jong-Wan/0000-0003-4676-5191; Kim, Sang Jeong/0000-0001-8931-3713	Korean Health Technology RD grant [HI15C2695]; National Research Foundation grants from the Korean government [2016R1AB4013377, 2012R1A5A2A44671346]	Korean Health Technology RD grant; National Research Foundation grants from the Korean government(National Research Foundation of Korea)	This work was supported by a Korean Health Technology R&D grant (HI15C2695), and National Research Foundation grants from the Korean government (2016R1AB4013377, 2012R1A5A2A44671346).	Abidi N, 2015, ENDOCR-RELAT CANCER, V22, pT55, DOI 10.1530/ERC-14-0315; Aoki I, 2013, ONCOGENE, V32, P3954, DOI 10.1038/onc.2012.428; Bennett EJ, 2010, CELL, V143, P951, DOI 10.1016/j.cell.2010.11.017; Cheng CY, 2010, BRIT J PHARMACOL, V160, P1595, DOI 10.1111/j.1476-5381.2010.00858.x; Duncan K, 2012, FUTURE ONCOL, V8, P1461, DOI [10.2217/FON.12.131, 10.2217/fon.12.131]; Embade N, 2012, HEPATOLOGY, V55, P1237, DOI 10.1002/hep.24795; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Katzav S, 2015, ONCOTARGET, V6, P10689, DOI 10.18632/oncotarget.3986; Korrodi-Gregorio L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165973; Kuo KL, 2015, CANCER LETT, V363, P127, DOI 10.1016/j.canlet.2015.01.015; Kuo LY, 2006, J CELL PHYSIOL, V207, P729, DOI 10.1002/jcp.20616; Lo FY, 2011, CANCER-AM CANCER SOC, V117, P5344, DOI 10.1002/cncr.26153; Luo ZG, 2012, CANCER RES, V72, P3360, DOI 10.1158/0008-5472.CAN-12-0388; Milhollen MA, 2010, BLOOD, V116, P1515, DOI 10.1182/blood-2010-03-272567; Nawrocki ST, 2013, CLIN CANCER RES, V19, P3577, DOI 10.1158/1078-0432.CCR-12-3212; Noguchi K, 2011, CARCINOGENESIS, V32, P995, DOI 10.1093/carcin/bgr068; Ohh Michael, 2003, Methods Mol Biol, V222, P167; Oved S, 2006, J BIOL CHEM, V281, P21640, DOI 10.1074/jbc.M513034200; Park HS, 2016, CELL DEATH DIFFER, V23, P1296, DOI 10.1038/cdd.2016.6; Ryu JH, 2011, J BIOL CHEM, V286, P6963, DOI 10.1074/jbc.M110.188706; Salon C, 2007, J PATHOL, V213, P303, DOI 10.1002/path.2223; Sanada M, 2009, NATURE, V460, P904, DOI 10.1038/nature08240; Sandilands E, 2012, NAT CELL BIOL, V14, P51, DOI 10.1038/ncb2386; Sarkaria I, 2006, CANCER RES, V66, P9437, DOI 10.1158/0008-5472.CAN-06-2074; Seong MW, 2014, BIOCHEM BIOPH RES CO, V455, P153, DOI 10.1016/j.bbrc.2014.10.129; Soucy Teresa A, 2010, Genes Cancer, V1, P708, DOI 10.1177/1947601910382898; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Stickle NH, 2004, MOL CELL BIOL, V24, P3251, DOI 10.1128/MCB.24.8.3251-3261.2004; Tan YHC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008972; Truitt L, 2010, CANCER RES, V70, P1141, DOI 10.1158/0008-5472.CAN-09-1710; Wang XF, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/974309; Wu X, 2016, INT J MOL MED, V37, P639, DOI 10.3892/ijmm.2016.2472; Xie P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4733; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Zhang LY, 2012, ONCOL LETT, V3, P395, DOI 10.3892/ol.2011.487; Zhou XC, 2016, P NATL ACAD SCI USA, V113, pE2935, DOI 10.1073/pnas.1522367113	37	20	20	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2018	37	41					5552	5568		10.1038/s41388-018-0354-5	http://dx.doi.org/10.1038/s41388-018-0354-5			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GW5QO	29899407				2022-12-17	WOS:000446991200006
J	Grun, D; Adhikary, G; Eckert, RL				Grun, Daniel; Adhikary, Gautam; Eckert, Richard L.			NRP-1 interacts with GIPC1 and alpha 6/beta 4-integrins to increase YAP1/Delta Np63 alpha-dependent epidermal cancer stem cell survival	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; SKIN-CANCER; ISOFORM EXPRESSION; HIPPO PATHWAY; TUMOR-CELLS; NEUROPILIN-1; VEGF; CARCINOMA; ANGIOGENESIS; PROMOTE	We have identified an epidermal cancer stem (ECS) cell population that drives formation of rapidly growing and highly invasive and vascularized tumors. VEGF-A and neuropilin-1 (NRP-1) are highly expressed in ECS cell tumors and VEGF-A/NRP-1 interaction is required for ECS cell survival and tumor vascularization. We now identify a novel signaling cascade that is triggered by VEGF-A/NRP-1. We show that NRP-1 forms a complex with GIPC1 and alpha 6/beta 4-integrin to activate FAK/Src signaling, which leads to stabilization of a YAP1/Delta Np63 alpha to enhance ECS cell survival, invasion, and angiogenesis. Loss of NRP-1, GIPC1, alpha 6/beta 4-integrins, YAP1, or Delta Np63 alpha reduces these responses. Moreover, restoration of constituently active YAP1 or Delta Np63 alpha in NRP-1 null cells restores the ECS cell phenotype. Tumor xenograft experiments show that NRP-1 knockout ECS cells form small tumors characterized by reduced vascularization as compared to wild-type cells. The NRP-1 knockout tumors display signaling changes consistent with a role for the proposed signaling cascade. These studies suggest that VEGF-A interacts with NRP-1 and GIPC1 to regulate alpha 6/beta 4-integrin, FAK, Src, PI3K/PDK1, LATS1 signaling to increase YAP1/Delta Np63 alpha accumulation to drive ECS cell survival, angiogenesis, and tumor formation.	[Grun, Daniel; Adhikary, Gautam; Eckert, Richard L.] Univ Maryland, Dept Biochem & Mol Biol, Sch Med, Baltimore, MD 21201 USA; [Eckert, Richard L.] Univ Maryland, Dept Dermatol, Sch Med, Baltimore, MD 21201 USA; [Eckert, Richard L.] Univ Maryland, Sch Med, Dept Reprod Biol, Baltimore, MD 21201 USA; [Eckert, Richard L.] Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Eckert, RL (corresponding author), Univ Maryland, Dept Biochem & Mol Biol, Sch Med, Baltimore, MD 21201 USA.; Eckert, RL (corresponding author), Univ Maryland, Dept Dermatol, Sch Med, Baltimore, MD 21201 USA.; Eckert, RL (corresponding author), Univ Maryland, Sch Med, Dept Reprod Biol, Baltimore, MD 21201 USA.; Eckert, RL (corresponding author), Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA.	reckert@umaryland.edu			NIH [CA131074, CA184027]; Greenebaum Comprehensive Cancer Center [P30 CA134274]; NATIONAL CANCER INSTITUTE [R01CA184027, R01CA131074, P30CA134274] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Greenebaum Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the NIH (CA131074 and CA184027) to RLE and a pilot grant from the Greenebaum Comprehensive Cancer Center (P30 CA134274).	Adhikary G, 2015, CARCINOGENESIS, V36, P800, DOI 10.1093/carcin/bgv064; Adhikary G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084324; American Cancer Society, CANC FACTS FIG; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Beck B, 2011, NATURE, V478, P399, DOI 10.1038/nature10525; Bickers DR, 2006, J AM ACAD DERMATOL, V55, P490, DOI 10.1016/j.jaad.2006.05.048; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Bowden J, 2002, J CUTAN PATHOL, V29, P585, DOI 10.1034/j.1600-0560.2002.291003.x; Cao Y, 2012, CANCER RES, V72, P3912, DOI 10.1158/0008-5472.CAN-11-4058; Casanova ML, 2002, CANCER RES, V62, P3402; Chew YC, 2013, J BIOL CHEM, V288, P17759, DOI 10.1074/jbc.M113.477133; Claesson-Welsh L, 2013, J INTERN MED, V273, P114, DOI 10.1111/joim.12019; Djordjevic S, 2013, DRUG DISCOV TODAY, V18, P447, DOI 10.1016/j.drudis.2012.11.013; El Mourabit H, 2002, MATRIX BIOL, V21, P207, DOI 10.1016/S0945-053X(01)00198-6; Elbediwy A, 2016, DEVELOPMENT, V143, P1674, DOI 10.1242/dev.133728; Fisher ML, 2016, CANCER RES, V76, P7265, DOI 10.1158/0008-5472.CAN-16-2032; Fisher ML, 2016, MOL CARCINOGEN, V55, P2024, DOI 10.1002/mc.22448; Fisher ML, 2015, ONCOTARGET, V6, P20525, DOI 10.18632/oncotarget.3890; Fisher ML, 2015, MOL CANCER RES, V13, P1083, DOI 10.1158/1541-7786.MCR-14-0685-T; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Gray MJ, 2005, CANCER RES, V65, P3664, DOI 10.1158/0008-5472.CAN-04-2229; Grun D, 2016, ONCOGENE, V35, P4379, DOI 10.1038/onc.2015.507; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hirakawa S, 2005, J EXP MED, V201, P1089, DOI 10.1084/jem.20041896; Jarvis A, 2010, J MED CHEM, V53, P2215, DOI 10.1021/jm901755g; Jia H, 2010, BRIT J CANCER, V102, P541, DOI 10.1038/sj.bjc.6605539; Johnson KE, 2012, J SKIN CANCER, V2012, DOI 10.1155/2012/483439; Katoh M, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.49; Kim J, 2017, J CLIN INVEST, V127, P3447, DOI 10.1172/JCI93825; Koch S, 2011, BIOCHEM J, V437, P169, DOI 10.1042/BJ20110301; Kostera MI, 2004, J DERMATOL SCI, V34, P3, DOI 10.1016/j.jdermsci.2003.10.003; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Lampropoulou A, 2014, BIOCHEM SOC T, V42, P1623, DOI 10.1042/BST20140244; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; Li M, 2004, CANCER-AM CANCER SOC, V101, P2341, DOI 10.1002/cncr.20634; Lichtenberger BM, 2010, CELL, V140, P268, DOI 10.1016/j.cell.2009.12.046; Linde N, 2012, J PATHOL, V227, P17, DOI 10.1002/path.3989; Mamluk R, 2002, J BIOL CHEM, V277, P24818, DOI 10.1074/jbc.M200730200; Man XY, 2006, MOL MED, V12, P127, DOI 10.2119/2006-00024.Man; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Rogers HW, 2010, ARCH DERMATOL, V146, P283, DOI 10.1001/archdermatol.2010.19; Shahrabi-Farahani S, 2016, AM J PATHOL, V186, P1055, DOI 10.1016/j.ajpath.2015.11.021; Siegle JM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5511; Sniezek JC, 2004, LARYNGOSCOPE, V114, P2063, DOI 10.1097/01.mlg.0000149437.35855.4b; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Tani TT, 2001, J BIOL CHEM, V276, P36535, DOI 10.1074/jbc.M105785200; Thurfjell N, 2004, INT J ONCOL, V25, P27; Valdembri D, 2009, PLOS BIOL, V7, P115, DOI 10.1371/journal.pbio.1000025; Wang XH, 2017, DEV CELL, V42, P462, DOI 10.1016/j.devcel.2017.08.002; Yang XH, 2006, BIOCHEM BIOPH RES CO, V349, P31, DOI 10.1016/j.bbrc.2006.07.213; Yoshida A, 2015, BIOL OPEN, V4, P1063, DOI 10.1242/bio.010918; Zhang GL, 2016, TUMOR BIOL, V37, P13777, DOI 10.1007/s13277-016-5138-3; Zhao Y, 2011, INT J DEV BIOL, V55, P477, DOI 10.1387/ijdb.103225yz; Zhu JW, 2012, INT J BIOCHEM CELL B, V44, P246, DOI 10.1016/j.biocel.2011.10.022	55	20	21	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2018	37	34					4711	4722		10.1038/s41388-018-0290-4	http://dx.doi.org/10.1038/s41388-018-0290-4			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GR3SE	29755126	Green Accepted			2022-12-17	WOS:000442514400006
J	Pentimalli, F; Forte, IM; Esposito, L; Indovina, P; Iannuzzi, CA; Alfano, L; Costa, C; Barone, D; Rocco, G; Giordano, A				Pentimalli, Francesca; Forte, Iris M.; Esposito, Luca; Indovina, Paola; Iannuzzi, Carmelina A.; Alfano, Luigi; Costa, Caterina; Barone, Daniela; Rocco, Gaetano; Giordano, Antonio			RBL2/p130 is a direct AKT target and is required to induce apoptosis upon AKT inhibition in lung cancer and mesothelioma cell lines	ONCOGENE			English	Article							TUMOR-SUPPRESSOR PROTEIN; RETINOBLASTOMA FAMILY; PRB2/P130 EXPRESSION; GENE-EXPRESSION; CDK INHIBITORS; CYCLE; PHOSPHORYLATION; KINASE; RB; ACTIVATION	The retinoblastoma (RB) protein family includes RB1/p105, RBL1/p107, and RBL2/p130, which are key factors in cell-cycle regulation and stand at the crossroads of multiple pathways dictating cell fate decisions. The role of RB proteins in apoptosis is controversial because they can inhibit or promote apoptosis depending on the context, on the apoptotic stimuli and on their intrinsic status, impacting on the response to antitumoral treatments. Here we identified RBL2/p130 as a direct substrate of the AKT kinase, a key antiapoptotic factor hyperactive in multiple cancer types. We showed that RBL2/p130 and AKT1 physically interact and AKT phosphorylates RBL2/p130 Ser941, located in the pocket domain, but not when this residue is mutated into Ala. We found that pharmacological inhibition of AKT, through the highly selective AKT inhibitor VIII (AKTiVIII), impairs RBL2/p130 Ser941 phosphorylation and increases RBL2/p130 stability, mRNA expression and nuclear levels in both lung cancer and mesothelioma cell lines, mirroring the more extensively studied effects on the p27 cell-cycle inhibitor. Consistently, AKT inhibition reduced cell viability, induced cell accumulation in G0/G1, and triggered apoptosis, which proved to be largely dependent on RBL2/p130 itself, as shown upon RBL2/p130 silencing. AKT inhibition induced RBL2/p130-dependent apoptosis also in HEK-293 cells, in which re-expression of a short hairpin-resistant RBL2/p130 was able to rescue AKTiVIII-induced apoptosis upon RBL2/p130 silencing. Our data also showed that the combination of AKT and cyclin-dependent kinases (CDK) inhibitors, which converge on the re-activation of RBL2/p130 antitumoral potential, could be a promising anticancer strategy.	[Pentimalli, Francesca; Forte, Iris M.; Esposito, Luca; Iannuzzi, Carmelina A.; Alfano, Luigi; Costa, Caterina; Barone, Daniela] Fdn G Pascale, Ist Nazl Tumori IRCCS, Oncol Res Ctr Mercogliano CROM, I-80131 Naples, Italy; [Indovina, Paola; Giordano, Antonio] Temple Univ, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Coll Sci & Technol, Philadelphia, PA 19122 USA; [Iannuzzi, Carmelina A.; Barone, Daniela; Giordano, Antonio] Univ Siena, Dept Med Surg & Neurosci, I-53100 Siena, Italy; [Rocco, Gaetano] Fdn G Pascale, Div Thorac Surg, Dept Thorac Surg & Oncol, Ist Nazl Tumori, I-80131 Naples, Italy; [Rocco, Gaetano] IRCCS, I-80131 Naples, Italy	IRCCS Fondazione Pascale; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Siena; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Fondazione Pascale; IRCCS Fondazione Pascale	Pentimalli, F (corresponding author), Fdn G Pascale, Ist Nazl Tumori IRCCS, Oncol Res Ctr Mercogliano CROM, I-80131 Naples, Italy.; Giordano, A (corresponding author), Temple Univ, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Coll Sci & Technol, Philadelphia, PA 19122 USA.; Giordano, A (corresponding author), Univ Siena, Dept Med Surg & Neurosci, I-53100 Siena, Italy.	f.pentimalli@istitutotumori.na.it; president@shro.org	Costa, Caterina/N-1742-2019; Forte, Iris Maria/K-7588-2016; Costa, Caterina/ABE-2452-2020; Giordano, Antonio/AAU-1201-2020; Pentimalli, Francesca/K-4936-2014; Alfano, Luigi/B-8330-2015; Barone, Daniela/N-1024-2015; Iannuzzi, CarmelinaAntonella/K-3131-2018; Rocco, Gaetano/K-4801-2016	Costa, Caterina/0000-0003-0909-7366; Forte, Iris Maria/0000-0001-9490-5844; Giordano, Antonio/0000-0002-5959-016X; Pentimalli, Francesca/0000-0003-4740-6801; Alfano, Luigi/0000-0002-4516-9956; Barone, Daniela/0000-0002-5543-7686; Iannuzzi, CarmelinaAntonella/0000-0002-4445-9687; Rocco, Gaetano/0000-0003-4150-8604; Indovina, Paola/0000-0001-8416-435X	AIRC-Associazione Italiana per la Ricerca sul Cancro [IG 2014-15690]; Italian Ministry of Health; Sbarro Health Research Organization [phosphoRBL2/p130S941]	AIRC-Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health(Ministry of Health, Italy); Sbarro Health Research Organization	This work was supported by the AIRC-Associazione Italiana per la Ricerca sul Cancro, IG 2014-15690 to AG and by the Italian Ministry of Health. We are grateful to the Sbarro Health Research Organization (www.shro.org) for its support and for providing the custom phosphoRBL2/p130S941 antibody, and to the Commonwealth of Pennsylvania. We are grateful to our intern students Flora Magnotti, Michela Napolitano, Caterina Miro and Sonia Sodano for technical help. We are grateful to Flavio Rizzolio for sharing RBL2/p130 silencing vectors and to Enrico Bucci for helpful discussion. AG is also Director of the Cell Cycle and Cancer Research Line at CROM, Istituto Nazionale Tumori; Naples. FP is also Adjunct Associate professor at Temple University, Department of Biology, Philadelphia, PA, USA.	Abate AA, 2013, EXPERT OPIN INV DRUG, V22, P895, DOI 10.1517/13543784.2013.798641; Alessio N, 2013, CELL MOL LIFE SCI, V70, P1637, DOI 10.1007/s00018-012-1224-x; Altomare DA, 2005, ONCOGENE, V24, P6080, DOI 10.1038/sj.onc.1208744; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; Bellan C, 2002, INVEST OPHTH VIS SCI, V43, P3602; Bhattacharya S, 2003, ONCOGENE, V22, P2443, DOI 10.1038/sj.onc.1206339; Busacca S, 2010, AM J RESP CELL MOL, V42, P312, DOI 10.1165/rcmb.2009-0060OC; Calleja V, 2009, PLOS BIOL, V7, P189, DOI 10.1371/journal.pbio.1000017; Caputi M, 2002, CLIN CANCER RES, V8, P3850; Chestukhin A, 2002, MOL CELL BIOL, V22, P453, DOI 10.1128/MCB.22.2.453-468.2002; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Cirillo D, 2011, CURR MED CHEM, V18, P2854, DOI 10.2174/092986711796150496; D'Andrilli G, 2004, CLIN CANCER RES, V10, P3098, DOI 10.1158/1078-0432.CCR-03-0524; David O, 2004, CLIN CANCER RES, V10, P6865, DOI 10.1158/1078-0432.CCR-04-0174; De Falco G, 2006, ONCOGENE, V25, P5333, DOI 10.1038/sj.onc.1209614; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Di Marzo D, 2014, CELL CYCLE, V13, P652, DOI 10.4161/cc.27546; Dick FA, 2013, NAT REV MOL CELL BIO, V14, P297, DOI 10.1038/nrm3567; Ecker K, 2009, NAT CELL BIOL, V11, P377, DOI [10.1038/ncb1859, 10.1038/ncb0409-377]; Engeland K, 2018, CELL DEATH DIFFER, V25, P114, DOI 10.1038/cdd.2017.172; Helmbold H, 2012, J CELL PHYSIOL, V227, P508, DOI 10.1002/jcp.22786; Henley SA, 2012, CELL DIV, V7, DOI 10.1186/1747-1028-7-10; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Ho VM, 2009, ONCOGENE, V28, P1393, DOI 10.1038/onc.2008.491; Howard CM, 2000, CANCER RES, V60, P2737; Indovina P, 2012, ONCOGENE, V31, P929, DOI 10.1038/onc.2011.286; Indovina P, 2015, ONCOTARGET, V6, P17873, DOI 10.18632/oncotarget.4286; Indovina P, 2013, J CELL PHYSIOL, V228, P525, DOI 10.1002/jcp.24170; Jorl FP, 2005, CELL DEATH DIFFER, V12, P65, DOI 10.1038/sj.cdd.4401499; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Knudsen ES, 2010, CLIN CANCER RES, V16, P1094, DOI 10.1158/1078-0432.CCR-09-0787; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; La Sala D, 2003, ONCOGENE, V22, P3518, DOI 10.1038/sj.onc.1206487; Lapenna S, 2009, NAT REV DRUG DISCOV, V8, P547, DOI 10.1038/nrd2907; Lindsley CW, 2005, BIOORG MED CHEM LETT, V15, P761, DOI 10.1016/j.bmcl.2004.11.011; Litovchick L, 2004, MOL CELL BIOL, V24, P8970, DOI 10.1128/MCB.24.20.8970-8980.2004; Liu DX, 2005, GENE DEV, V19, P719, DOI 10.1101/gad.1296405; Liu PD, 2014, CELL CYCLE, V13, P2162, DOI 10.4161/cc.29584; Liu PD, 2014, NATURE, V508, P541, DOI 10.1038/nature13079; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Logie L, 2007, DIABETES, V56, P2218, DOI 10.2337/db07-0343; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Masciullo V, 2008, CLIN CANCER RES, V14, P4775, DOI 10.1158/1078-0432.CCR-07-4055; MAYOL X, 1993, ONCOGENE, V8, P2561; Meuillet EJ, 2011, CURR MED CHEM, V18, P2727; Ming LH, 2008, CARCINOGENESIS, V29, P1878, DOI 10.1093/carcin/bgn150; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Pentimalli F, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-LB-080; Pentimalli F, 2010, CANCER DRUG DISCOV D, P109, DOI 10.1007/978-1-60761-178-3_8; Pucci B, 2002, ONCOGENE, V21, P5897, DOI 10.1038/sj.onc.1205750; Qiu ZX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081451; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Rizzolio F, 2012, CELL DEATH DIFFER, V19, P1152, DOI 10.1038/cdd.2011.202; Sadasivam S, 2013, NAT REV CANCER, V13, P585, DOI 10.1038/nrc3556; Saharia A, 2008, CURR BIOL, V18, P496, DOI 10.1016/j.cub.2008.02.071; Simpson DS, 2009, CANCER RES, V69, P8733, DOI 10.1158/0008-5472.CAN-09-1359; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Tsurutani J, 2006, J CLIN ONCOL, V24, P306, DOI 10.1200/JCO.2005.02.4133; Yang H, 2006, ONCOGENE, V25, P4585, DOI 10.1038/sj.onc.1209481; Zhang XB, 2011, BBA-MOL CELL RES, V1813, P1978, DOI 10.1016/j.bbamcr.2011.03.010; Zhou S, 2014, BRIT J CANCER, V110, P2479, DOI 10.1038/bjc.2014.220	61	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2018	37	27					3657	3671		10.1038/s41388-018-0214-3	http://dx.doi.org/10.1038/s41388-018-0214-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM3CM	29606701				2022-12-17	WOS:000437975200004
J	Sun, LX; Xu, XH; Chen, YJ; Zhou, YX; Tan, R; Qiu, HT; Jin, LT; Zhang, WY; Fan, R; Hong, WJ; Wang, TL				Sun, Lixiang; Xu, Xiaohui; Chen, Yongjun; Zhou, Yuxia; Tan, Ran; Qiu, Hantian; Jin, Liting; Zhang, Wenyi; Fan, Rong; Hong, Wanjin; Wang, Tuanlao			Rab34 regulates adhesion, migration, and invasion of breast cancer cells	ONCOGENE			English	Article							VESICLE TRAFFICKING; ALPHA-5-BETA-1 INTEGRIN; 3D MICROENVIRONMENTS; SRC KINASE; ENDOCYTOSIS; GTPASES; MACROPINOCYTOSIS; PATHWAY; DISEASE; PROTEIN	The small GTPase Rab34 regulates spatial distribution of the lysosomes, secretion, and macropinocytosis. In this study, we found that Rab34 is over-expressed in aggressive breast cancer cells, implying a potential role of Rab34 in breast cancer. Silencing Rab34 by shRNA inhibits cell migration, invasion, and adhesion of breast cancer cells. Rab34 specifically binds to the cytoplasmic tail of integrin beta 3, and depletion of Rab34 promotes the degradation of integrin beta 3. Interestingly, EGF induces the translocation of Rab34 to the membrane ruffle, which is greatly enhanced by the expression of Src kinase. Accordingly, Rab34 is tyrosine phosphorylated by Src at Y247 residue. A mutant mimicking phosphorylated form of Rab34 (Rab34Y247D) promotes cell migration and invasion. Importantly, the tyrosine phosphorylation of Rab34 is inhibited in cells in suspension, and increased with the cells re-adhesion. In addition, Rab34Y247D promotes cell adhesion, and enhances integrin beta 3 endocytosis and recycling. The results uncover a role of Rab34 in migration and invasion of breast cancer cells and its involvement in cancer metastasis, and provide a novel mechanism of tyrosine phosphorylation of Rab34 in regulating cell migration, invasion, and adhesion through modulating the endocytosis, stability, and recycling of integrin beta 3.	[Sun, Lixiang; Xu, Xiaohui; Chen, Yongjun; Zhou, Yuxia; Qiu, Hantian; Jin, Liting; Zhang, Wenyi; Fan, Rong; Hong, Wanjin; Wang, Tuanlao] Xiamen Univ, Sch Pharmaceut Sci, State Key Lab Cellular Stress Biol, Fujian Prov Key Lab Innovat Drug Target Res, Xiamen 361005, Peoples R China; [Tan, Ran] State Ocean Adm, Inst Oceanog 3, Xiamen 361005, Peoples R China; [Hong, Wanjin] ASTAR, Inst Mol & Cell Biol, 61 Biopolis Dr, Singapore 138673, Singapore	Xiamen University; State Oceanic Administration; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Hong, WJ; Wang, TL (corresponding author), Xiamen Univ, Sch Pharmaceut Sci, State Key Lab Cellular Stress Biol, Fujian Prov Key Lab Innovat Drug Target Res, Xiamen 361005, Peoples R China.; Hong, WJ (corresponding author), ASTAR, Inst Mol & Cell Biol, 61 Biopolis Dr, Singapore 138673, Singapore.	mcbhwj@imcb.a-star.edu.sg; xmuibrwtl@xmu.edu.cn		Sun, Lixiang/0000-0002-0287-4831	National Natural Science Foundation of China [31371353, 31671478]; International Science & Technology Cooperation Program of China [2013DFG32730]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); International Science & Technology Cooperation Program of China	This work was supported by National Natural Science Foundation of China (No. 31371353 and No. 31671478) and International Science & Technology Cooperation Program of China (No. 2013DFG32730). The cDNA of integrin beta 1 and integrin beta 3 were kindly provided by Dr. Jiahuai Han (State Key Laboratory of Cellular Stress Biology, Xiamen University, China).	Agola JO, 2011, CLIN GENET, V80, P305, DOI 10.1111/j.1399-0004.2011.01724.x; Alanko J, 2016, TRENDS CELL BIOL, V26, P391, DOI 10.1016/j.tcb.2016.02.001; Alanko J, 2015, NAT CELL BIOL, V17, P1412, DOI 10.1038/ncb3250; Amyere M, 2002, INT J MED MICROBIOL, V291, P487; Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Balzac F, 2005, J CELL SCI, V118, P4765, DOI 10.1242/jcs.02584; Bhuin T, 2014, EXP CELL RES, V328, P1, DOI 10.1016/j.yexcr.2014.07.027; Bravo-Cordero JJ, 2007, EMBO J, V26, P1499, DOI 10.1038/sj.emboj.7601606; Caswell PT, 2008, J CELL BIOL, V183, P143, DOI 10.1083/jcb.200804140; Caswell PT, 2007, DEV CELL, V13, P496, DOI 10.1016/j.devcel.2007.08.012; Chavez Kathryn J, 2010, Breast Dis, V32, P35, DOI 10.3233/BD-2010-0307; Cheng KW, 2005, CANCER RES, V65, P2516, DOI 10.1158/0008-5472.CAN-05-0573; Cheng KW, 2004, NAT MED, V10, P1251, DOI 10.1038/nm1125; Chodniewicz D, 2004, EXP CELL RES, V301, P31, DOI 10.1016/j.yexcr.2004.08.006; Coyne CB, 2007, CELL HOST MICROBE, V2, P181, DOI 10.1016/j.chom.2007.07.003; Di Florio A, 2007, ENDOCR-RELAT CANCER, V14, P111, DOI 10.1677/erc.1.01318; Edinger AL, 2003, DEV CELL, V5, P571, DOI 10.1016/S1534-5807(03)00291-0; Gardel ML, 2010, ANNU REV CELL DEV BI, V26, P315, DOI 10.1146/annurev.cellbio.011209.122036; Goldenberg NM, 2007, MOL BIOL CELL, V18, P4762, DOI 10.1091/mbc.E06-11-0991; Gu ZZ, 2011, J CELL BIOL, V193, P61, DOI 10.1083/jcb.201007003; Harris KP, 2011, CURR BIOL, V21, pR841, DOI 10.1016/j.cub.2011.08.061; Hawes CR, 1999, CURR OPIN PLANT BIOL, V2, P454, DOI 10.1016/S1369-5266(99)00023-0; Igarashi T, 2017, ONCOTARGET, V8, P12290, DOI 10.18632/oncotarget.14703; Ihemelandu CU, 2008, AM J SURG, V195, P153, DOI 10.1016/j.amjsurg.2007.09.033; Iwamoto DV, 2015, CURR OPIN CELL BIOL, V36, P41, DOI 10.1016/j.ceb.2015.06.009; Lee U, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082125; Lin XS, 2017, CELL SIGNAL, V35, P84, DOI 10.1016/j.cellsig.2017.03.006; Luo HC, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-82; Mettlen M, 2006, TRAFFIC, V7, P589, DOI 10.1111/j.1600-0854.2006.00412.x; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Pellinen T, 2006, J CELL BIOL, V173, P767, DOI 10.1083/jcb.200509019; Porther N, 2015, Small GTPases, V6, P135, DOI 10.1080/21541248.2015.1050152; Redig AJ, 2013, J INTERN MED, V274, P113, DOI 10.1111/joim.12084; SALISBURY JL, 1983, INT REV EXP PATHOL, V24, P1; Spang A, 2008, CELL MOL LIFE SCI, V65, P2781, DOI 10.1007/s00018-008-8349-y; Speight P, 2005, TRAFFIC, V6, P858, DOI 10.1111/j.1600-0854.2005.00321.x; Starling GP, 2016, EMBO REP, V17, P823, DOI 10.15252/embr.201541382; Stein MP, 2003, ADV DRUG DELIVER REV, V55, P1421, DOI 10.1016/j.addr.2003.07.009; Stenmark H, 2009, NAT REV MOL CELL BIO, V10, P513, DOI 10.1038/nrm2728; Subramani D, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-312; Sun P, 2003, J BIOL CHEM, V278, P4063, DOI 10.1074/jbc.M208699200; Tang BL, 2009, CELL MOTIL CYTOSKEL, V66, P365, DOI 10.1002/cm.20376; Valdembri D, 2012, CURR OPIN CELL BIOL, V24, P582, DOI 10.1016/j.ceb.2012.08.004; Voulgari A, 2009, BBA-REV CANCER, V1796, P75, DOI 10.1016/j.bbcan.2009.03.002; Wang HJ, 2015, TUMOR BIOL, V36, P1573, DOI 10.1007/s13277-014-2732-0; Wang TL, 2004, MOL BIOL CELL, V15, P815, DOI 10.1091/mbc.E03-06-0413; Wang TL, 2002, MOL BIOL CELL, V13, P4317, DOI 10.1091/mbc.E02-05-0280; Wang TL, 2012, J CELL PHYSIOL, V227, P2788, DOI 10.1002/jcp.23023; Wright PK, 2008, RECENT PAT ANTI-CANC, V3, P137, DOI 10.2174/157489208784638730; Xiao R, 2013, BLOOD, V121, P700, DOI 10.1182/blood-2012-07-440644; Zhang B, 2015, GENET TEST MOL BIOMA, V19, P69, DOI 10.1089/gtmb.2014.0210; Zhang JX, 2016, THERANOSTICS, V6, P2099, DOI 10.7150/thno.16587; Zhang XD, 2017, NANOSCALE, V9, P150, DOI 10.1039/c6nr07866d	55	20	20	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2018	37	27					3698	3714		10.1038/s41388-018-0202-7	http://dx.doi.org/10.1038/s41388-018-0202-7			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM3CM	29622794				2022-12-17	WOS:000437975200007
J	Stebbing, J; Shah, K; Lit, LC; Gagliano, T; Ditsiou, A; Wang, TT; Wendler, F; Simon, T; Szabo, KS; O'Hanlon, T; Dean, M; Roslani, AC; Cheah, SH; Lee, SC; Giamas, G				Stebbing, Justin; Shah, Kalpit; Lit, Lei Cheng; Gagliano, Teresa; Ditsiou, Angeliki; Wang, Tingting; Wendler, Franz; Simon, Thomas; Szabo, Krisztina Sara; O'Hanlon, Timothy; Dean, Michael; Roslani, April Camilla; Cheah, Swee Hung; Lee, Soo-Chin; Giamas, Georgios			LMTK3 confers chemo-resistance in breast cancer	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; LEMUR TYROSINE KINASE-3; COMET ASSAY; DNA-DAMAGE; NEOADJUVANT CHEMOTHERAPY; HISTONE H2AX; THERAPEUTIC TARGET; PROGNOSTIC ROLE; ACTIVATES ATM; CELL-DEATH	Lemur tyrosine kinase 3 (LMTK3) is an oncogenic kinase that is involved in different types of cancer (breast, lung, gastric, colorectal) and biological processes including proliferation, invasion, migration, chromatin remodeling as well as innate and acquired endocrine resistance. However, the role of LMTK3 in response to cytotoxic chemotherapy has not been investigated thus far. Using both 2D and 3D tissue culture models, we found that overexpression of LMTK3 decreased the sensitivity of breast cancer cell lines to cytotoxic (doxorubicin) treatment. In a mouse model we showed that ectopic overexpression of LMTK3 decreases the efficacy of doxorubicin in reducing tumor growth. Interestingly, breast cancer cells overexpressing LMTK3 delayed the generation of double strand breaks (DSBs) after exposure to doxorubicin, as measured by the formation of gamma H2AX foci. This effect was at least partly mediated by decreased activity of ataxia-telangiectasia mutated kinase (ATM) as indicated by its reduced phosphorylation levels. In addition, our RNA-seq analyses showed that doxorubicin differentially regulated the expression of over 700 genes depending on LMTK3 protein expression levels. Furthermore, these genes were found to promote DNA repair, cell viability and tumorigenesis processes / pathways in LMTK3-overexpressing MCF7 cells. In human cancers, immunohistochemistry staining of LMTK3 in pre- and postchemotherapy breast tumor pairs from four separate clinical cohorts revealed a significant increase of LMTK3 following both doxorubicin and docetaxel based chemotherapy. In aggregate, our findings show for the first time a contribution of LMTK3 in cytotoxic drug resistance in breast cancer.	[Stebbing, Justin; Lit, Lei Cheng] Imperial Coll London, Dept Surg & Canc, Div Canc, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England; [Shah, Kalpit; Dean, Michael] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA; [Lit, Lei Cheng; Cheah, Swee Hung] Univ Malaya, Fac Med, Dept Physiol, Kuala Lumpur 50603, Malaysia; [Gagliano, Teresa; Ditsiou, Angeliki; Wendler, Franz; Simon, Thomas; Szabo, Krisztina Sara; Giamas, Georgios] Univ Sussex, Sch Life Sci, Dept Biochem & Biomed, Brighton BN1 9QG, E Sussex, England; [Wang, Tingting; Lee, Soo-Chin] Canc Sci Inst Singapore, Ctr Life Sci, 28 Med Dr 02-15, Singapore, Singapore; [O'Hanlon, Timothy] Leidos Biomed Res Inc, NCI, Canc Genom Res Lab, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; [Roslani, April Camilla] Univ Malaya, Fac Med, Dept Surg, Kuala Lumpur 50603, Malaysia	Imperial College London; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Universiti Malaya; University of Sussex; National University of Singapore; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Universiti Malaya	Giamas, G (corresponding author), Univ Sussex, Sch Life Sci, Dept Biochem & Biomed, Brighton BN1 9QG, E Sussex, England.	g.giamas@sussex.ac.uk	Giamas, Georgios/AAP-3487-2021; Lee, Soo Chin/S-9111-2016; Lit, Lei Cheng/AAS-9778-2021; Dean, Michael/R-7501-2019; Dean, Michael C/G-8172-2012; Gagliano, Teresa/G-1645-2015; wang, tingting/AAK-2640-2020; Roslani, April Camilla/B-8245-2010	Lee, Soo Chin/0000-0002-5835-6419; Lit, Lei Cheng/0000-0002-3210-4491; Dean, Michael C/0000-0003-2234-0631; Gagliano, Teresa/0000-0002-4877-6292; Roslani, April Camilla/0000-0003-2458-965X; Stebbing, Justin/0000-0002-1117-6947; Simon, Thomas/0000-0002-3280-2716; O'Hanlon, Timothy/0000-0003-2759-733X; Giamas, Georgios/0000-0002-4417-2707	High Impact Research Chancellery Grant [UM.C/625/1/HIR/179]; Action Against Cancer; National Institute for Health Research (NIHR); Colin McDavid Family Trust; Swire Charitable Trust; intramural research program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health	High Impact Research Chancellery Grant; Action Against Cancer; National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); Colin McDavid Family Trust; Swire Charitable Trust; intramural research program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health	This work was supported by grants from: (i) The High Impact Research Chancellery Grant UM.C/625/1/HIR/179 (University of Malaya); (ii) Action Against Cancer; (iii) The National Institute for Health Research (NIHR); (iv) The Colin McDavid Family Trust; (v) The Swire Charitable Trust; (vi) Charles and Diane Herlinger; (vii) Mr Alessandro Dusi and (viii) The intramural research program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health. Infrastructure support was provided by Imperial Experimental Cancer Medicine Centre, Cancer Research UK Imperial Centre, the Imperial Biomedical Research Centre (BRC) and the University of Sussex. This work utilized the computational resources of the NIH HPC Biowulf cluster and DCEG CCAD cluster. (http://hpc.nih.gov). We thank Sara Bass for her assistance in library preparation and sequencing.	Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Azqueta A, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00288; Bakkenist Christopher J, 2015, Oncoscience, V2, P542; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bertucci F, 2016, LANCET ONCOL, V17, P600, DOI 10.1016/S1470-2045(16)00011-5; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Brum G, 2013, INT J ONCOL, V42, P211, DOI 10.3892/ijo.2012.1680; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Carbon S, 2017, NUCLEIC ACIDS RES, V45, pD331, DOI 10.1093/nar/gkw1108; Chen J, 2010, BRIT J CANCER, V102, P351, DOI 10.1038/sj.bjc.6605486; Cheung-Ong K, 2013, CHEM BIOL, V20, P648, DOI 10.1016/j.chembiol.2013.04.007; Collins AR, 2004, MOL BIOTECHNOL, V26, P249, DOI 10.1385/MB:26:3:249; Davies AR, 2014, J CLIN ONCOL, V32, P2983, DOI 10.1200/JCO.2014.55.9070; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Eom YW, 2005, ONCOGENE, V24, P4765, DOI 10.1038/sj.onc.1208627; Fernandez-Capetillo O, 2003, DEV CELL, V4, P497, DOI 10.1016/S1534-5807(03)00093-5; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Giamas G, 2007, BIOCHEM J, V406, P389, DOI 10.1042/BJ20070091; Giamas G, 2011, NAT MED, V17, P715, DOI 10.1038/nm.2351; Gianni L, 2014, LANCET ONCOL, V15, P640, DOI 10.1016/S1470-2045(14)70080-4; Gundry C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14646; Gyori BM, 2014, REDOX BIOL, V2, P457, DOI 10.1016/j.redox.2013.12.020; Hatzis C, 2016, CLIN CANCER RES, V22, P26, DOI 10.1158/1078-0432.CCR-14-3304; Jacob J, 2016, CANCER LETT, V372, P137, DOI 10.1016/j.canlet.2015.12.026; Jung EJ, 2008, EXP MOL MED, V40, P276, DOI 10.3858/emm.2008.40.3.276; Kurz EU, 2004, J BIOL CHEM, V279, P53272, DOI 10.1074/jbc.M406879200; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Lee SC, 2009, PHARMACOGENET GENOM, V19, P181, DOI 10.1097/FPC.0b013e32831ebb5d; Lee YK, 2007, J BIOL CHEM, V282, P1595, DOI 10.1074/jbc.M606306200; Li HP, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-196; Li X, 2007, J BIOL CHEM, V282, P36177, DOI 10.1074/jbc.M706912200; Li ZG, 2014, MOL CLIN ONCOL, V2, P756, DOI 10.3892/mco.2014.301; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lucas X, 2013, NUCLEIC ACIDS RES, V41, pD1130, DOI 10.1093/nar/gks1253; Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6; Nitiss John L, 2002, Curr Opin Investig Drugs, V3, P1512; Nunes J, 2016, ONCOTARGET, V7, P27599, DOI 10.18632/oncotarget.8504; Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5; Pan YZ, 2011, CLIN CANCER RES, V17, P3248, DOI 10.1158/1078-0432.CCR-10-0890; Peng ZH, 2015, J AM CHEM SOC, V137, P6726, DOI 10.1021/jacs.5b00922; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Senavirathna LK, 2013, THERANOSTICS, V3, P687, DOI 10.7150/thno.6381; Shah K, 2015, ONCOTARGET, V6, P14233, DOI 10.18632/oncotarget.3899; Shaw KRM, 2004, J MAMMARY GLAND BIOL, V9, P297, DOI 10.1007/s10911-004-1402-z; Shi HB, 2014, INT J CLIN EXP PATHO, V7, P1101; Shi HB, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0754-x; Smart DJ, 2008, MUTAT RES-FUND MOL M, V641, P43, DOI 10.1016/j.mrfmmm.2008.03.005; So SR, 2009, J CELL BIOL, V187, P977, DOI 10.1083/jcb.200906064; Stebbing J, 2013, ONCOGENE, V32, P3371, DOI 10.1038/onc.2012.343; Stebbing J, 2012, BREAST CANCER RES TR, V132, P537, DOI 10.1007/s10549-011-1622-z; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Thorn CF, 2011, PHARMACOGENET GENOM, V21, P440, DOI 10.1097/FPC.0b013e32833ffb56; Tyner JW, 2009, P NATL ACAD SCI USA, V106, P8695, DOI 10.1073/pnas.0903233106; Vidi Pierre-Alexandre, 2013, Methods Mol Biol, V945, P193, DOI 10.1007/978-1-62703-125-7_13; von Minckwitz G, 2016, EUR J CANCER, V64, P12, DOI 10.1016/j.ejca.2016.05.015; Wakatsuki T, 2013, MOL CANCER THER, V12, P2261, DOI 10.1158/1535-7163.MCT-12-1134; Wang X, 2013, BIOMATERIALS, V34, P4667, DOI 10.1016/j.biomaterials.2013.03.008; White DE, 2006, CANCER RES, V66, P11594, DOI 10.1158/0008-5472.CAN-06-4138; Xu YC, 2015, CELL REP, V12, P837, DOI 10.1016/j.celrep.2015.06.073; Xu YC, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005170; Xu ZG, 2014, TUMOR BIOL, V35, P5007, DOI 10.1007/s13277-014-1660-3; Yamasaki M, 2017, ANN ONCOL, V28, P116, DOI 10.1093/annonc/mdw439; Yang F, 2014, BBA-REV CANCER, V1845, P84, DOI 10.1016/j.bbcan.2013.12.002; Yu KD, 2013, CLIN CANCER RES, V19, P2723, DOI 10.1158/1078-0432.CCR-12-2986; Zhang KX, 2015, INT J CLIN EXP PATHO, V8, P629; Zhao GQ, 2013, DNA CELL BIOL, V32, P699, DOI 10.1089/dna.2013.2130; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446	70	20	21	1	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	23					3113	3130		10.1038/s41388-018-0197-0	http://dx.doi.org/10.1038/s41388-018-0197-0			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GI6VO	29540829	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000434641400006
J	Browne, AL; Charmsaz, S; Vareslija, D; Fagan, A; Cosgrove, N; Cocchiglia, S; Purcell, S; Ward, E; Bane, F; Hudson, L; Hill, AD; Carroll, JS; Redmond, AM; Young, LS				Browne, Alacoque L.; Charmsaz, Sara; Vareslija, Damir; Fagan, Ailis; Cosgrove, Nicola; Cocchiglia, Sinead; Purcell, Siobhan; Ward, Elspeth; Bane, Fiona; Hudson, Lance; Hill, Arnold D.; Carroll, Jason S.; Redmond, Aisling M.; Young, Leonie S.			Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer	ONCOGENE			English	Article							STEROID-RECEPTOR COACTIVATOR-1; PROTEIN METHYLTRANSFERASE; MEDIATED TRANSACTIVATIONS; P160 COACTIVATORS; GENE-EXPRESSION; SOLID TUMORS; STAT FAMILY; FACTOR-I; ER; METASTASIS	Steroid receptor coactivator 1 (SRC-1) interacts with nuclear receptors and other transcription factors (TFs) to initiate transcriptional networks and regulate downstream genes which enable the cancer cell to evade therapy and metastasise. Here we took a top-down discovery approach to map out the SRC-1 transcriptional network in endocrine resistant breast cancer. First, rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) was employed to uncover new SRC-1 TF partners. Next, RNA sequencing (RNAseq) was undertaken to investigate SRC-1 TF target genes. Molecular and patientderived xenograft studies confirmed STAT1 as a new SRC-1 TF partner, important in the regulation of a cadre of four SRC-1 transcription targets, NFIA, SMAD2, E2F7 and ASCL1. Extended network analysis identified a downstream 79 gene network, the clinical relevance of which was investigated in RNAseq studies from matched primary and local-recurrence tumours from endocrine resistant patients. We propose that SRC-1 can partner with STAT1 independently of the estrogen receptor to initiate a transcriptional cascade and control regulation of key endocrine resistant genes.	[Browne, Alacoque L.; Charmsaz, Sara; Vareslija, Damir; Fagan, Ailis; Cosgrove, Nicola; Cocchiglia, Sinead; Purcell, Siobhan; Ward, Elspeth; Bane, Fiona; Hudson, Lance; Hill, Arnold D.; Young, Leonie S.] Royal Coll Surg, Dept Surg, Endocrine Oncol Res Grp, Dublin, Ireland; [Carroll, Jason S.; Redmond, Aisling M.] Univ Cambridge, Cambridge Inst, Canc Res UK, Cambridge, England	Royal College of Surgeons - Ireland; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Young, LS (corresponding author), Royal Coll Surg, Dept Surg, Endocrine Oncol Res Grp, Dublin, Ireland.	lyoung@rcsi.ie		Ward, Elspeth/0000-0002-7530-2279; Carroll, Jason/0000-0003-3643-0080; Cosgrove, Nicola/0000-0002-8296-115X; Vareslija, Damir/0000-0003-1000-0357	Science Foundation Ireland [08-IN1-B1853, 12/1A/1294]; Health Research Board of Ireland [HRB/POR/2012/101]; Irish Cancer Society Collaborative Cancer Research Centre grant [CCRC13GAL, BREASTPREDICT]; Cancer Research UK [20411] Funding Source: researchfish	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Health Research Board of Ireland; Irish Cancer Society Collaborative Cancer Research Centre grant; Cancer Research UK(Cancer Research UK)	We kindly acknowledge the funding support from the Science Foundation Ireland (08-IN1-B1853 and 12/1A/1294), the Health Research Board of Ireland (HRB/POR/2012/101). This work was partly supported by the Irish Cancer Society Collaborative Cancer Research Centre grant, BREASTPREDICT, CCRC13GAL.	Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013; BRONZERT DA, 1985, ENDOCRINOLOGY, V117, P1409, DOI 10.1210/endo-117-4-1409; Carroll JS, 2016, EUR J ENDOCRINOL, V175, pR41, DOI 10.1530/EJE-16-0124; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chu JJ, 2015, ONCOTARGET, V6, P31944, DOI 10.18632/oncotarget.5128; Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7; Dammer EB, 2007, MOL ENDOCRINOL, V21, P415, DOI 10.1210/me.2006-0361; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dieci MV, 2013, ANN ONCOL, V24, P101, DOI 10.1093/annonc/mds248; Durinck S, 2009, NAT PROTOC, V4, P1184, DOI 10.1038/nprot.2009.97; Fleming FJ, 2004, J CLIN PATHOL, V57, P1069, DOI 10.1136/jcp.2004.016733; Giraud S, 2002, J BIOL CHEM, V277, P8004, DOI 10.1074/jbc.M111486200; Glasgow SM, 2013, J NEUROSCI, V33, P13560, DOI 10.1523/JNEUROSCI.0321-13.2013; Grabowska MM, 2014, MOL ENDOCRINOL, V28, P949, DOI 10.1210/me.2013-1213; Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064; Hoefnagel LDC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2645; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Janky R, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003731; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; Kim J, 2016, ONCOTARGET, V7, P85021, DOI 10.18632/oncotarget.13116; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Kolde R., 2015, PHEATMAP PRETTY HEAT; Kulakovskiy IV, 2013, NUCLEIC ACIDS RES, V41, pD195, DOI 10.1093/nar/gks1089; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Litterst CM, 2003, J BIOL CHEM, V278, P45340, DOI 10.1074/jbc.M303644200; Litterst CM, 2001, J BIOL CHEM, V276, P45713, DOI 10.1074/jbc.M108132200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maeda Y, 2006, J BIOL CHEM, V281, P9600, DOI 10.1074/jbc.M510435200; Mathelier A, 2014, NUCLEIC ACIDS RES, V42, pD142, DOI 10.1093/nar/gkt997; McBryan J, 2015, CLIN CANCER RES, V21, P5371, DOI 10.1158/1078-0432.CCR-14-2155; McBryan J, 2012, CANCER RES, V72, P548, DOI 10.1158/0008-5472.CAN-11-2073; McCartan D, 2012, CANCER RES, V72, P220, DOI 10.1158/0008-5472.CAN-11-1976; McIlroy M, 2010, CANCER RES, V70, P1585, DOI 10.1158/0008-5472.CAN-09-3713; Meissl K, 2017, CYTOKINE, V89, P12, DOI 10.1016/j.cyto.2015.11.011; Mohammed H, 2016, NAT PROTOC, V11, P316, DOI 10.1038/nprot.2016.020; Mohammed H, 2013, CELL REP, V3, P342, DOI 10.1016/j.celrep.2013.01.010; Myers E, 2005, CLIN CANCER RES, V11, P2111, DOI 10.1158/1078-0432.CCR-04-1192; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; O'Leary B, 2016, NAT REV CLIN ONCOL, V13, P417, DOI 10.1038/nrclinonc.2016.26; Priedigkeit N, 2017, JAMA ONCOL, V3, P666, DOI 10.1001/jamaoncol.2016.5630; Qin L, 2014, CANCER RES, V74, P3477, DOI 10.1158/0008-5472.CAN-13-2639; Qin L, 2011, CANCER RES, V71, P1742, DOI 10.1158/0008-5472.CAN-10-3453; Qin L, 2009, CANCER RES, V69, P3819, DOI 10.1158/0008-5472.CAN-08-4389; Ravasi T, 2010, CELL, V140, P744, DOI 10.1016/j.cell.2010.01.044; Redmond AM, 2015, ONCOGENE, V34, P3871, DOI 10.1038/onc.2014.323; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shaw FL, 2012, J MAMMARY GLAND BIOL, V17, P111, DOI 10.1007/s10911-012-9255-3; Sheppard HM, 2001, MOL CELL BIOL, V21, P39, DOI 10.1128/MCB.21.1.39-50.2001; Stashi E, 2014, TRENDS ENDOCRIN MET, V25, P337, DOI 10.1016/j.tem.2014.05.004; Thomas SJ, 2015, BRIT J CANCER, V113, P365, DOI 10.1038/bjc.2015.233; Uysal-Onganer P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-55; Vareslija D, 2017, METHODS MOL BIOL, V1501, P327, DOI 10.1007/978-1-4939-6475-8_17; Vareslija D, 2016, CLIN CANCER RES, V22, P2765, DOI 10.1158/1078-0432.CCR-15-1583; Verfaillie A., 2015, CURR PROTOC BIOINFOR, V52, P1; Vinnedge LMP, 2015, ONCOGENE, V34, P2325, DOI 10.1038/onc.2014.173; Walsh CA, 2014, CANCER RES, V74, P2533, DOI 10.1158/0008-5472.CAN-13-2133; Walsh CA, 2012, INT J BIOL SCI, V8, P470, DOI 10.7150/ijbs.4125; Wang L, 2016, HORM CANCER-US, V7, P229, DOI 10.1007/s12672-016-0261-6; Wang S, 2009, P NATL ACAD SCI USA, V106, P151, DOI 10.1073/pnas.0808703105; Weirauch MT, 2014, CELL, V158, P1431, DOI 10.1016/j.cell.2014.08.009; Wu LL, 2014, ONCOTARGET, V5, P7677, DOI 10.18632/oncotarget.2291; Xu Y, 2014, INT J BIOL SCI, V10, P396, DOI 10.7150/ijbs.8193; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Ye Y, 2009, MOL CANCER RES, V7, P1984, DOI 10.1158/1541-7786.MCR-09-0119	64	20	20	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	15					2008	2021		10.1038/s41388-017-0042-x	http://dx.doi.org/10.1038/s41388-017-0042-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GC6KH	29367763	Green Published, hybrid			2022-12-17	WOS:000429899400005
J	Li, N; Truong, S; Nouri, M; Moore, J; Al Nakouzi, N; Lubik, AA; Buttyan, R				Li, Na; Truong, Sarah; Nouri, Mannan; Moore, Jackson; Al Nakouzi, Nader; Lubik, Amy Anne; Buttyan, Ralph			Non-canonical activation of hedgehog in prostate cancer cells mediated by the interaction of transcriptionally active androgen receptor proteins with Gli3	ONCOGENE			English	Article							SIGNALING PATHWAY; PROLIFERATION; TARGET; STEROIDOGENESIS; INTERFERENCE; DEGRADATION; MECHANISMS; PROTEASOME; RESISTANCE; PROMOTER	Hedgehog (Hh) is an oncogenic signaling pathway that regulates the activity of Gli transcription factors. Canonical Hh is a Smoothened-(Smo-) driven process that alters the post-translational processing of Gli2/Gli3 proteins. Though evidence supports a role for Gli action in prostate cancer (PCa) cell growth and progression, there is little indication that Smo is involved. Here we describe a non-canonical means for activation of Gli transcription in PCa cells mediated by the binding of transcriptionally-active androgen receptors (ARs) to Gli3. Androgens stimulated reporter expression from a Gli-dependent promoter in a variety of AR + PCa cells and this activity was suppressed by an anti-androgen, Enz, or by AR knockdown. Androgens also upregulated expression of endogenous Gli-dependent genes. This activity was associated with increased intranuclear binding of Gli3 to AR that was antagonized by Enz. Fine mapping of the AR binding domain on Gli2 showed that AR recognizes the Gli protein processing domain (PPD) in the C-terminus. Mutations in the arginine-/serine repeat elements of the Gli2 PPD involved in phosphorylation and ubiquitinylation blocked the binding to AR. beta-TrCP, a ubiquitin ligase that recognizes the Gli PPD, competed with AR for binding to this site. AR binding to Gli3 suppressed its proteolytic processing to the Gli3 repressor form (Gli3R) whereas AR knockdown increased Gli3R. Both full-length and truncated ARs were able to activate Gli transcription. Finally, we found that an ARbinding decoy polypeptide derived from the Gli2 Cterminus can compete with Gli3 for binding to AR. Exogenous overexpression of this decoy suppressed Gli transcriptional activity in PCa cells. Collectively, this work identifies a novel pathway for non-canonical activation of Hh signaling in PCa cells and identifies a means for interference that may have clinical relevance for PCa patients.	[Li, Na; Truong, Sarah; Moore, Jackson; Al Nakouzi, Nader; Lubik, Amy Anne] Vancouver Prostate Ctr, Vancouver, BC, Canada; [Truong, Sarah; Nouri, Mannan; Buttyan, Ralph] Univ British Columbia, Interdisciplinary Oncol Program, Vancouver, BC, Canada; [Buttyan, Ralph] Univ British Columbia, Urol Sci, Vancouver, BC, Canada	University of British Columbia; University of British Columbia	Buttyan, R (corresponding author), Univ British Columbia, Interdisciplinary Oncol Program, Vancouver, BC, Canada.; Buttyan, R (corresponding author), Univ British Columbia, Urol Sci, Vancouver, BC, Canada.	rbuttyan@prostatecentre.com		Nouri, Mannan/0000-0002-7442-9251	Canadian Institutes of Health Research [CIHR258931]; Prostate Cancer Canada-Movember Team [T2103]; US Department of Defense [PCRP W81XWH-10-1-0493]; Terry Fox Research Institute New Frontiers [PPG 1062]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Prostate Cancer Canada-Movember Team; US Department of Defense(United States Department of Defense); Terry Fox Research Institute New Frontiers	The authors acknowledge the helpful assistance of Dr Mengqian Chen of the South Carolina School of Pharmacy in the generation of the human Gli3 expression vector. Sources of Support: Canadian Institutes of Health Research (CIHR258931); Prostate Cancer Canada-Movember Team T2103; US Department of Defense PCRP W81XWH-10-1-0493; Terry Fox Research Institute New Frontiers PPG 1062.	Agathocleous M, 2007, CELL CYCLE, V6, P156, DOI 10.4161/cc.6.2.3745; Altaba ARI, 2002, NAT REV NEUROSCI, V3, P24; Briscoe J, 2013, NAT REV MOL CELL BIO, V14, P416, DOI 10.1038/nrm3598; Chen MQ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-89; Chen M, 2009, CELL CYCLE, V8, P149, DOI 10.4161/cc.8.1.7532; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Dehm SM, 2006, J CELL BIOCHEM, V99, P333, DOI 10.1002/jcb.20794; Evangelista M, 2006, CLIN CANCER RES, V12, P5924, DOI 10.1158/1078-0432.CCR-06-1736; Finco I, 2015, ANNU REV PHYSIOL, V77, P105, DOI 10.1146/annurev-physiol-061214-111754; Han BC, 2015, CELL REP, V13, P1046, DOI 10.1016/j.celrep.2015.09.063; Hui CC, 2011, ANNU REV CELL DEV BI, V27, P513, DOI 10.1146/annurev-cellbio-092910-154048; Ikram MS, 2004, J INVEST DERMATOL, V122, P1503, DOI 10.1111/j.0022-202X.2004.22612.x; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jiang J, 2008, DEV CELL, V15, P801, DOI 10.1016/j.devcel.2008.11.010; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kasper M, 2006, EUR J CANCER, V42, P437, DOI 10.1016/j.ejca.2005.08.039; Koebernick K, 2002, DIFFERENTIATION, V70, P69, DOI 10.1046/j.1432-0436.2002.700201.x; Lauth M, 2007, CELL CYCLE, V6, P2458, DOI 10.4161/cc.6.20.4808; Levina E, 2012, PROSTATE, V72, P817, DOI 10.1002/pros.21500; Li N, 2014, PROSTATE, V74, P1400, DOI 10.1002/pros.22855; Lubik AA, 2017, INT J CANCER, V140, P358, DOI 10.1002/ijc.30450; Pan Y, 2007, J BIOL CHEM, V282, P10846, DOI 10.1074/jbc.M608599200; Penning TM, 2015, J STEROID BIOCHEM, V153, P105, DOI 10.1016/j.jsbmb.2015.05.010; Robbins DJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002906; Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086; Ryan CJ, 2011, J CLIN ONCOL, V29, P3651, DOI 10.1200/JCO.2011.35.2005; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Schrader EK, 2011, J BIOL CHEM, V286, P39051, DOI 10.1074/jbc.M111.274993; Sirab N, 2012, INT J CANCER, V131, P1297, DOI 10.1002/ijc.27384; Stecca B, 2005, TRENDS MOL MED, V11, P199, DOI 10.1016/j.molmed.2005.03.004; Tickle C, 2013, WIRES DEV BIOL, V2, P275, DOI 10.1002/wdev.70; Toftgard R, 2000, CELL MOL LIFE SCI, V57, P1720, DOI 10.1007/PL00000654; Wang BW, 2006, P NATL ACAD SCI USA, V103, P33, DOI 10.1073/pnas.0509927103; Ware KE, 2014, ENDOCR-RELAT CANCER, V21, pT87, DOI 10.1530/ERC-13-0470; Wijgerde M, 2002, GENE DEV, V16, P2849, DOI 10.1101/gad.1025702; Winklmayr M, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471-2199-11-2; Xavier GM, 2016, DEV BIOL, V415, P198, DOI 10.1016/j.ydbio.2016.02.009; Yang L, 2010, ONCOGENE, V29, P469, DOI 10.1038/onc.2009.392; Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235; Zhou JC, 2016, CANCER LETT, V370, P313, DOI 10.1016/j.canlet.2015.11.006; Zhou PB, 2000, MOL CELL, V6, P751, DOI 10.1016/S1097-2765(00)00074-5; Zhu ML, 2010, FASEB J, V24, P769, DOI 10.1096/fj.09-136994	42	20	21	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	17					2313	2325		10.1038/s41388-017-0098-7	http://dx.doi.org/10.1038/s41388-017-0098-7			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE3FW	29429990	hybrid, Green Published			2022-12-17	WOS:000431100200008
J	Serio, J; Ropa, J; Chen, W; Mysliwski, M; Saha, N; Chen, L; Wang, J; Miao, H; Cierpicki, T; Grembecka, J; Muntean, AG				Serio, J.; Ropa, J.; Chen, W.; Mysliwski, M.; Saha, N.; Chen, L.; Wang, J.; Miao, H.; Cierpicki, T.; Grembecka, J.; Muntean, A. G.			The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia	ONCOGENE			English	Article							RNA-POLYMERASE-II; ACUTE MYELOID-LEUKEMIA; JAW TUMOR SYNDROME; ARGININE-METHYLTRANSFERASE; H2B UBIQUITYLATION; MOUSE DEVELOPMENT; GENE-EXPRESSION; CELLS; TRANSCRIPTION; METHYLATION	Acute myeloid leukemia (AML) is a disease associated with epigenetic dysregulation. 11q23 translocations involving the H3K4 methyltransferase MLL1 (KMT2A) generate oncogenic fusion proteins with deregulated transcriptional potential. The polymeraseassociated factor complex (PAFc) is an epigenetic co-activator complex that makes direct contact with MLL fusion proteins and is involved in AML, however, its functions are not well understood. Here, we explored the transcriptional targets regulated by the PAFc that facilitate leukemia by performing RNA-sequencing after conditional loss of the PAFc subunit Cdc73. We found Cdc73 promotes expression of an early hematopoietic progenitor gene program that prevents differentiation. Among the target genes, we confirmed the protein arginine methyltransferase Prmt5 is a direct target that is positively regulated by a transcriptional unit that includes the PAFc, MLL1, HOXA9 and STAT5 in leukemic cells. We observed reduced PRMT5-mediated H4R3me2s following excision of Cdc73 placing this histone modification downstream of the PAFc and revealing a novel mechanism between the PAFc and Prmt5. Knockdown or pharmacologic inhibition of Prmt5 causes a G1 arrest and reduced proliferation resulting in extended leukemic disease latency in vivo. Overall, we demonstrate the PAFc regulates Prmt5 to facilitate leukemic progression and is a potential therapeutic target for AMLs.	[Serio, J.; Ropa, J.; Chen, W.; Mysliwski, M.; Saha, N.; Chen, L.; Wang, J.; Miao, H.; Cierpicki, T.; Grembecka, J.; Muntean, A. G.] Univ Michigan, Dept Pathol, Med Sch, 7520B Med Sci Res Bldg 1,1301 Catherine Rd, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Muntean, AG (corresponding author), Univ Michigan, Dept Pathol, Med Sch, 7520B Med Sci Res Bldg 1,1301 Catherine Rd, Ann Arbor, MI 48109 USA.	andrewmu@umich.edu	Saha, Nirmalya/AEF-3616-2022	SAHA, NIRMALYA/0000-0002-5624-8879; Chen, Wei/0000-0002-8316-1728; Ropa, James/0000-0001-6120-1859; Muntean, Andrew/0000-0003-3034-0682	NIH [R00 CA158136]; American Society of Hematology Scholar Award; Leukemia Research Foundation award; American Cancer Society Scholar Award [RSG-15-046]; Children's Leukemia Research Association; NATIONAL CANCER INSTITUTE [R00CA158136, R01CA207272, T32CA140044, R01CA160467] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Society of Hematology Scholar Award; Leukemia Research Foundation award; American Cancer Society Scholar Award(American Cancer Society); Children's Leukemia Research Association; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Dong-Er Zhang (UCSD), Dr Wei Xu (University of Wisconsin), Dr Jean-Francois Rual and Dr Tao Xu (University of Michigan) for providing the Prmt1, Prmt4 and Prmt5 constructs, respectively, Dr Yali Dou (University of Michigan) for the MLLc antibody. This work was supported by NIH grants R00 CA158136 (AGM), an American Society of Hematology Scholar Award (AGM), a Leukemia Research Foundation award (AGM), an American Cancer Society Scholar Award RSG-15-046 (AGM) and Children's Leukemia Research Association (AGM).	Aplan PD, 2006, DNA REPAIR, V5, P1265, DOI 10.1016/j.dnarep.2006.05.034; Bandyopadhyay S, 2012, MOL CELL BIOL, V32, P1202, DOI 10.1128/MCB.05977-11; Brewin J, 2013, NEW ENGL J MED, V369, P1472, DOI 10.1056/NEJMc1308782; Carpten JD, 2002, NAT GENET, V32, P676, DOI 10.1038/ng1048; Chan-Penebre E, 2015, NAT CHEM BIOL, V11, P432, DOI [10.1038/NCHEMBIO.1810, 10.1038/nchembio.1810]; Chaudhary K, 2007, ONCOGENE, V26, P7499, DOI 10.1038/sj.onc.1210582; Chen CW, 2015, NAT MED, V21, P335, DOI 10.1038/nm.3832; Chen FX, 2015, CELL, V162, P1003, DOI 10.1016/j.cell.2015.07.042; Chen L, 2015, LEUKEMIA, V29, P1290, DOI 10.1038/leu.2015.18; Chen LL, 2016, ONCOTARGET, V7, P25208, DOI 10.18632/oncotarget.8199; Cheung N, 2007, NAT CELL BIOL, V9, P1208, DOI 10.1038/ncb1642; Cheung N, 2016, CANCER CELL, V29, P32, DOI 10.1016/j.ccell.2015.12.007; Collins CT, 2016, ONCOGENE, V35, P1090, DOI 10.1038/onc.2015.174; Daser A, 2005, SEMIN CANCER BIOL, V15, P175, DOI 10.1016/j.semcancer.2005.01.007; Dey P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026926; Garcia-Cuellar MP, 2016, CELL REP, V15, P310, DOI 10.1016/j.celrep.2016.03.018; Girardot M, 2014, NUCLEIC ACIDS RES, V42, P235, DOI 10.1093/nar/gkt884; Hanks S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5398; He NH, 2011, P NATL ACAD SCI USA, V108, pE636, DOI 10.1073/pnas.1107107108; Huang YS, 2012, BLOOD, V119, P388, DOI 10.1182/blood-2011-03-341081; Jaehning JA, 2010, BBA-GENE REGUL MECH, V1799, P379, DOI 10.1016/j.bbagrm.2010.01.001; Jin YL, 2016, J CLIN INVEST, V126, P3961, DOI 10.1172/JCI85239; Kim J, 2010, CELL, V140, P491, DOI 10.1016/j.cell.2009.12.050; Kim J, 2009, CELL, V137, P459, DOI 10.1016/j.cell.2009.02.027; Kim M, 2004, EMBO J, V23, P354, DOI 10.1038/sj.emboj.7600053; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Kryukov GV, 2016, SCIENCE, V351, P1214, DOI 10.1126/science.aad5214; Laslo P, 2006, CELL, V126, P755, DOI 10.1016/j.cell.2006.06.052; Li Li, 2003, Cancer Immun, V3, P8; Li Y, 2015, CANCER DISCOV, V5, P288, DOI 10.1158/2159-8290.CD-14-0625; Liu F, 2015, J CLIN INVEST, V125, P3532, DOI 10.1172/JCI81749; Marjon K, 2016, CELL REP, V15, P574, DOI 10.1016/j.celrep.2016.03.043; Migliori V, 2012, NAT STRUCT MOL BIOL, V19, P136, DOI 10.1038/nsmb.2209; Milne TA, 2010, MOL CELL, V38, P853, DOI 10.1016/j.molcel.2010.05.011; Mongiardi MP, 2015, SCI REP-UK, V5, DOI 10.1038/srep15494; Moniaux N, 2006, ONCOGENE, V25, P3247, DOI 10.1038/sj.onc.1209353; Mueller CL, 2002, MOL CELL BIOL, V22, P1971, DOI 10.1128/MCB.22.7.1971-1980.2002; Muntean AG, 2013, BLOOD, V122, P1914, DOI 10.1182/blood-2013-02-486977; Muntean AG, 2010, CANCER CELL, V17, P609, DOI 10.1016/j.ccr.2010.04.012; Newey PJ, 2010, HUM MUTAT, V31, P295, DOI 10.1002/humu.21188; Pal S, 2004, MOL CELL BIOL, V24, P9630, DOI 10.1128/MCB.24.21.9630-9645.2004; Pal S, 2007, EMBO J, V26, P3558, DOI 10.1038/sj.emboj.7601794; Pavri R, 2006, CELL, V125, P703, DOI 10.1016/j.cell.2006.04.029; Pawlak MR, 2000, MOL CELL BIOL, V20, P4859, DOI 10.1128/MCB.20.13.4859-4869.2000; Penheiter KL, 2005, MOL CELL, V20, P213, DOI 10.1016/j.molcel.2005.08.023; Qiu HF, 2006, MOL CELL BIOL, V26, P3135, DOI 10.1128/MCB.26.8.3135-3148.2006; Shia WJ, 2012, BLOOD, V119, P4953, DOI 10.1182/blood-2011-04-347476; Tarighat SS, 2016, LEUKEMIA, V30, P789, DOI 10.1038/leu.2015.308; Tee WW, 2010, GENE DEV, V24, P2772, DOI 10.1101/gad.606110; Tomson BN, 2013, BBA-GENE REGUL MECH, V1829, P116, DOI 10.1016/j.bbagrm.2012.08.011; Van Oss SB, 2016, MOL CELL, V64, P815, DOI 10.1016/j.molcel.2016.10.008; Vu LP, 2013, CELL REP, V5, P1625, DOI 10.1016/j.celrep.2013.11.025; Wade PA, 1996, PROTEIN EXPRES PURIF, V8, P85, DOI 10.1006/prep.1996.0077; Wang L, 2008, MOL CELL BIOL, V28, P6262, DOI 10.1128/MCB.00923-08; Wang L, 2014, CANCER CELL, V25, P21, DOI 10.1016/j.ccr.2013.12.007; Wei H, 2013, P NATL ACAD SCI USA, V110, P13516, DOI 10.1073/pnas.1311784110; Yadav N, 2003, P NATL ACAD SCI USA, V100, P6464, DOI 10.1073/pnas.1232272100; Yang H, 2016, ONCOTARGET, V7, P72131, DOI 10.18632/oncotarget.12351; Yang YZ, 2013, NAT REV CANCER, V13, P37, DOI 10.1038/nrc3409; Youn MY, 2007, J BIOL CHEM, V282, P34727, DOI 10.1074/jbc.M705411200; Yu M, 2015, SCIENCE, V350, P1383, DOI 10.1126/science.aad2338; Zeng H, 2015, GENE DEV, V29, P2153, DOI 10.1101/gad.268722.115; Zhang BL, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0721-8; Zuber J, 2011, NAT BIOTECHNOL, V29, P79, DOI 10.1038/nbt.1720	64	20	20	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2018	37	4					450	460		10.1038/onc.2017.337	http://dx.doi.org/10.1038/onc.2017.337			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT7KP	28945229	Green Accepted			2022-12-17	WOS:000423331600004
J	Yun, MR; Choi, HM; Kang, HN; Lee, Y; Joo, HS; Kim, DH; Kim, HR; Hong, MH; Yoon, SO; Cho, BC				Yun, M. R.; Choi, H. M.; Kang, H. N.; Lee, Yw; Joo, H-S; Kim, D. H.; Kim, H. R.; Hong, M. H.; Yoon, S. O.; Cho, B. C.			ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma	ONCOGENE			English	Article							I PI3K INHIBITOR; PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR; EPITHELIAL-MESENCHYMAL TRANSITION; PHASE-I; BUPARLISIB BKM120; LUNG-CANCER; EGFR INHIBITORS; DOSE-ESCALATION; METASTATIC HEAD; COMBINATION	Hyperactivation of phosphatidylinositol 3-kinase (PI3K) pathway occurs frequently in head and neck squamous cell carcinoma (HNSCC). However, clinical outcomes of targeting the PI3K pathway have been underwhelming. In present study, we investigated the resistant mechanisms and potential combination therapeutic strategy to overcome adaptive resistance to PI3K inhibitor in HNSCC. Treatment of NVP-BKM120, a pan-PI3K inhibitor, led to upregulation of interleukin-6 (IL-6) and subsequent activation of either extracellular signal-regulated kinase (ERK) or signal transducers and activators of transcription 3 (STAT3), causing modest antitumor effects on the growth of HNSCC cells. Blockade of autocrine IL-6 signaling with siRNA or neutralizing antibody for IL-6 receptor (IL-6R) completely abolished NVP-BKM120-induced activation of ERK and STAT3 as well as expression of c-Myc oncogene, which resulted in enhanced sensitivity to NVP-BKM120. Moreover, when compared with a pharmacologic inhibitor or silencing of STAT3, trametinib, a MEK inhibitor, in combination with NVP-BKM120 yielded more potent anti-proliferative effects by inhibiting S phase transition, arresting cells at G0/G1 phase, and downregulating IL-6 and c-Myc expression. Furthermore, as compared with either agent alone, combination of NVP-BKM120 with trametinib or tocilizumab, a humanized anti-IL-6R antibody, significantly suppressed tumor growth in NVP-BKM120-resistant patient-derived tumor xenograft (PDTX) models, which was also confirmed in PDTX-derived cell lines. Collectively, these results suggested that IL-6/ERK signaling is closely involved in adaptive resistance of NVP-BKM120 in HNSCC cells, providing a rationale for a novel combination therapy to overcome resistance to PI3K inhibitors.	[Yun, M. R.; Kang, H. N.; Joo, H-S; Kim, D. H.; Cho, B. C.] JEUK Co Ltd, JEUK Inst Canc Res, Gumi, Kyungbuk, South Korea; [Yun, M. R.; Choi, H. M.; Kang, H. N.; Lee, Yw; Kim, H. R.; Hong, M. H.; Cho, B. C.] Yonsei Univ, Div Med Oncol, Yonsei Canc Ctr, Coll Med, Seoul, South Korea; [Yoon, S. O.] Yonsei Univ, Dept Pathol, Coll Med, Seoul, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Cho, BC (corresponding author), Yonsei Univ, Coll Med, Dept Internal Med, Yonsei Canc Ctr,Div Med Oncol, 50 Yonsei Ro, Seoul 120752, South Korea.	cbc1971@yuhs.ac		Cho, Byoung Chul/0000-0002-5562-270X; Hong, Min Hee/0000-0003-3490-2195; Kim, Hye Ryun/0000-0002-1842-9070	National Research Foundation of Korea (NRF) - Korea government [NRF-2014R1A1A1006865, 2015R1A2A1A15055817]	National Research Foundation of Korea (NRF) - Korea government(National Research Foundation of Korea)	This work was supported by the National Research Foundation of Korea (NRF) funded by the Korea government (NRF-2014R1A1A1006865 to MR Yun and 2015R1A2A1A15055817 to BC Cho).	Awad Mark M, 2014, Clin Adv Hematol Oncol, V12, P429; Bendell JC, 2012, J CLIN ONCOL, V30, P282, DOI 10.1200/JCO.2011.36.1360; Bhattacharya N, 2009, J ORAL PATHOL MED, V38, P759, DOI 10.1111/j.1600-0714.2009.00781.x; Bonner JA, 2010, LANCET ONCOL, V11, P21, DOI 10.1016/S1470-2045(09)70311-0; Brachmann SM, 2012, MOL CANCER THER, V11, P1747, DOI 10.1158/1535-7163.MCT-11-1021; Du L, 2012, J ONCOL, V2012, DOI 10.1155/2012/450179; Eichten A, 2016, CANCER RES, V76, P2327, DOI 10.1158/0008-5472.CAN-15-1443; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Fallahi-Sichani M, 2017, MOL SYST BIOL, V13, DOI 10.15252/msb.20166796; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Giudice FS, 2013, J CARCINOG MUTAGEN, V2, P5; Grana B, 2011, J CLIN ONCOL, V29; Guo YQ, 2012, CANCER TREAT REV, V38, P904, DOI 10.1016/j.ctrv.2012.04.007; Haddad R, 2013, LANCET ONCOL, V14, P257, DOI 10.1016/S1470-2045(13)70011-1; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Heo TH, 2016, ONCOTARGET, V7, P15460, DOI 10.18632/oncotarget.7102; Hidalgo M, 2014, CANCER DISCOV, V4, P998, DOI 10.1158/2159-8290.CD-14-0001; Hong DS, 2012, CLIN CANCER RES, V18, P4173, DOI 10.1158/1078-0432.CCR-12-0714; Hyman DM, 2015, CANCER CHEMOTH PHARM, V75, P747, DOI 10.1007/s00280-015-2693-z; Jimeno A, 2015, ORAL ONCOL, V51, P383, DOI 10.1016/j.oraloncology.2014.12.013; Kim HS, 2015, CLIN CANCER RES, V21, P544, DOI 10.1158/1078-0432.CCR-14-1756; Kim HR, 2015, CO CLIN TRIALS DEMON; Kim SM, 2012, MOL CANCER THER, V11, P2254, DOI 10.1158/1535-7163.MCT-12-0311; Klempner SJ, 2013, CANCER DISCOV, V3, P1345, DOI 10.1158/2159-8290.CD-13-0063; Koul D, 2012, CLIN CANCER RES, V18, P184, DOI 10.1158/1078-0432.CCR-11-1558; Leon X, 2005, CLIN ONCOL-UK, V17, P418, DOI 10.1016/j.clon.2005.02.014; Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Liu XF, 2012, AM J PATHOL, V180, P599, DOI 10.1016/j.ajpath.2011.10.036; Lovly CM, 2014, CLIN CANCER RES, V20, P2249, DOI 10.1158/1078-0432.CCR-13-1610; Ma PF, 2016, THERANOSTICS, V6, P1232, DOI 10.7150/thno.14409; Maira SM, 2012, MOL CANCER THER, V11, P317, DOI 10.1158/1535-7163.MCT-11-0474; Massarelli E, 2015, ANN ONCOL, V26, P1476, DOI 10.1093/annonc/mdv194; Michmerhuizen Nicole L, 2016, Otorhinolaryngol Head Neck Surg, V1, P44; Miller A, 2015, ONCOGENE, V34, P1510, DOI 10.1038/onc.2014.99; Mohan S, 2015, CLIN CANCER RES, V21, P3946, DOI 10.1158/1078-0432.CCR-14-3377; Munster PN, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.3018; Nagasaki T, 2014, RECEPTORS CLIN INVES, V1, pe202; Neel DS, 2013, CLIN CANCER RES, V19, P3, DOI 10.1158/1078-0432.CCR-12-3232; Patel JD, 2014, J CLIN ONCOL, V32, P129, DOI 10.1200/JCO.2013.53.7076; Ren H, 2016, ONCOTARGET, V7, P67277, DOI 10.18632/oncotarget.11645; Ren H, 2012, CANCER LETT, V325, P139, DOI 10.1016/j.canlet.2012.06.018; Rodon J, 2014, INVEST NEW DRUG, V32, P670, DOI 10.1007/s10637-014-0082-9; Roper J, 2014, CANCER LETT, V347, P204, DOI 10.1016/j.canlet.2014.02.018; Rosell R, 2013, TRANSL LUNG CANCER R, V2, P152, DOI 10.3978/j.issn.2218-6751.2012.12.08; Scherzad A, 2015, INT J ONCOL, V47, P391, DOI 10.3892/ijo.2015.3009; Shapiro GI, 2014, CLIN CANCER RES, V20, P233, DOI 10.1158/1078-0432.CCR-13-1777; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shi YJ, 2011, J BIOL CHEM, V286, P67, DOI 10.1074/jbc.M110.153221; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sos ML, 2014, CELL REP, V8, P1037, DOI 10.1016/j.celrep.2014.07.010; Stanam A, 2015, MOL ONCOL, V9, P1371, DOI 10.1016/j.molonc.2015.03.008; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Sun SY, 2014, CANCER RES, V74, P7546, DOI 10.1158/0008-5472.CAN-14-0826; Vansteenkiste JF, 2015, J THORAC ONCOL, V10, P1319, DOI 10.1097/JTO.0000000000000607; Vermorken JB, 2008, CANCER-AM CANCER SOC, V112, P2710, DOI 10.1002/cncr.23442; Von Hoff DD, 2010, J CLIN ONCOL, V28, P2541; Vyse S, 2017, J MOL BIOL, V429, P1767, DOI 10.1016/j.jmb.2017.04.018; Wei W, 2016, CANCER CELL, V29, P563, DOI 10.1016/j.ccell.2016.03.012; Yadav A, 2011, MOL CANCER RES, V9, P1658, DOI 10.1158/1541-7786.MCR-11-0271; Yang L, 2014, BIOCHEM BIOPH RES CO, V453, P582, DOI 10.1016/j.bbrc.2014.09.129; Zhang H, 2015, ONCOTARGET, V6, P3085, DOI 10.18632/oncotarget.3099	62	20	21	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2018	37	3					377	388		10.1038/onc.2017.339	http://dx.doi.org/10.1038/onc.2017.339			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS9QS	28945228				2022-12-17	WOS:000422753900010
J	Kim, ES; Kim, SY; Koh, M; Lee, HM; Kim, K; Jung, J; Kim, HS; Moon, WK; Hwang, S; Moon, A				Kim, E-S; Kim, S. Y.; Koh, M.; Lee, H-M; Kim, K.; Jung, J.; Kim, H. S.; Moon, W. K.; Hwang, S.; Moon, A.			C-reactive protein binds to integrin alpha 2 and Fc gamma receptor I, leading to breast cell adhesion and breast cancer progression	ONCOGENE			English	Article							EPITHELIAL-CELLS; H-RAS; INVASIVE PHENOTYPE; ACUTE APPENDICITIS; TUMOR-GROWTH; EXPRESSION; PAXILLIN; KINASE; METASTASIS; INTERLEUKIN-6	C-reactive protein (CRP) is an acute phase protein synthesized upon the inflammatory responses, associated with breast cancer. The process of tumor cell invasion and metastasis involves the adherence of cells to the extracellular matrix via integrin as a receptor for matrix molecules. The present study investigated the role of CRP in the adhesive phenotype of breast cells and the underlying mechanisms. Here, we first showed that CRP induces adhesion of MCF10A human breast epithelial cells through the activation of integrin alpha 2 signaling. Expression of integrin alpha 2 was induced by CRP in which transcription factors c-fos and SP1 may be involved. Binding of CRP with integrin alpha 2 leads to the activation of focal adhesion kinase (FAK), paxillin and ERKs. CRP also binds to an Fc gamma receptor Fc gamma receptor I (Fc gamma RI), and induces activation of paxillin, FAK and ERKs. Integrin alpha 2 and FAK have crucial roles in the adhesive and invasive phenotypes as well as MMP-9 upregulation induced by CRP in MCF10A cells. Treatment with an inflammatory lipid sphingosine-1-phosphate induced CRP, which may be secreted and exert an autocrine effect by binding to Fc gamma RI and integrin alpha 2. Involvement of CRP in adhesion, invasion, anchorage-independent growth and upregulation of integrin alpha 2, paxillin and FAK was observed in MDA-MB-231 triple-negative human breast cancer (TNBC) cells. Using an in vivo invasion model and an orthotopic mouse tumor model with MDA-MB-231 cells, we showed that CRP has an important role in intravasation and tumor growth in vivo, demonstrating the in vivo relevance of our in vitro results. The present study elucidates a critical molecular basis between CRP, integrin alpha 2 and Fc gamma RI pathways in MCF10A breast cells and MDA-MB-231 TNBC cells, thereby providing useful information on CRP-induced aggressiveness of breast cells in the inflammatory microenvironment.	[Kim, E-S; Kim, S. Y.; Koh, M.; Lee, H-M; Kim, K.; Jung, J.; Moon, A.] Duksung Womens Univ, Coll Pharm, Duksung Innovat Drug Ctr, Seoul 132714, South Korea; [Kim, H. S.; Moon, W. K.] Seoul Natl Univ Hosp, Dept Radiol, Seoul, South Korea; [Hwang, S.] Hanyang Univ, Coll Med, Seoul, South Korea	Duksung Women's University; Seoul National University (SNU); Seoul National University Hospital; Hanyang University	Moon, A (corresponding author), Duksung Womens Univ, Coll Pharm, Duksung Innovat Drug Ctr, Seoul 132714, South Korea.	armoon@duksung.ac.kr			Priority Research Centers Program [2016R1A6A1A03007648]; Bio & Medical Technology Development Program [2015M3A9B6074045]; Basic Science Program of the NRF - Korean government [2014R1A6A3A01059908]	Priority Research Centers Program; Bio & Medical Technology Development Program; Basic Science Program of the NRF - Korean government	The present study was supported by Priority Research Centers Program (no. 2016R1A6A1A03007648), the Bio & Medical Technology Development Program (no. 2015M3A9B6074045) and Basic Science Program (no. 2014R1A6A3A01059908) of the NRF funded by the Korean government.	Allin KH, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2891; AMES BN, 1995, P NATL ACAD SCI USA, V92, P5258, DOI 10.1073/pnas.92.12.5258; Andre F, 2012, ANN ONCOL, V23, P46, DOI 10.1093/annonc/mds195; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Bartolome RA, 2014, ONCOGENE, V33, P1658, DOI 10.1038/onc.2013.117; Bendas G, 2012, INT J CELL BIOL, V2012; Cance WG, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.120pe22; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chi M, 2002, J IMMUNOL, V168, P1413, DOI 10.4049/jimmunol.168.3.1413; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; DEPRAETERE S, 1991, AGENTS ACTIONS, V34, P369, DOI 10.1007/BF01988730; Fujita M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093738; Galon J, 1996, J IMMUNOL, V157, P1184; Golubovskaya VM, 2012, CARCINOGENESIS, V33, P1004, DOI 10.1093/carcin/bgs120; Guo Yan, 2014, Biomed Res Int, V2014, P248090, DOI 10.1155/2014/248090; GURLEYIK E, 1995, DIS COLON RECTUM, V38, P1270, DOI 10.1007/BF02049151; Haimovich B, 1996, J BIOL CHEM, V271, P16332, DOI 10.1074/jbc.271.27.16332; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; Hojilla CV, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1980; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Hwang HS, 2015, BMB REP, V48, P407, DOI 10.5483/BMBRep.2015.48.7.050; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ibaragi S, 2011, ANTICANCER RES, V31, P1307; INDIK ZK, 1994, EXP HEMATOL, V22, P599; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kim ES, 2014, ONCOGENE, V33, P3583, DOI 10.1038/onc.2013.319; Kim ES, 2011, J CELL SCI, V124, P2220, DOI 10.1242/jcs.076794; Kim KM, 2017, INT J NANOMED, V12, P1917, DOI 10.2147/IJN.S132043; Kim MS, 2003, CANCER RES, V63, P5454; Knupfer H, 2007, BREAST CANCER RES TR, V102, P129, DOI 10.1007/s10549-006-9328-3; Koh M, 2015, INT J CANCER, V136, pE508, DOI 10.1002/ijc.29154; KOUKOULIS GK, 1993, J SUBMICR CYTOL PATH, V25, P285; Lee HM, 2016, BIOMOL THER, V24, P62, DOI 10.4062/biomolther.2015.172; MAEMURA M, 1995, CLIN EXP METASTAS, V13, P223, DOI 10.1007/BF00133478; Maric G, 2015, ONCOGENE, V34, P5494, DOI 10.1038/onc.2015.8; Mego M, 2010, NAT REV CLIN ONCOL, V7, P693, DOI 10.1038/nrclinonc.2010.171; Metzger O, 2012, J CLIN ONCOL, V30, P1879, DOI 10.1200/JCO.2011.38.2010; Mira E, 2002, CLIN EXP METASTAS, V19, P313, DOI 10.1023/A:1015563031769; Monteiro RC, 2003, ANNU REV IMMUNOL, V21, P177, DOI 10.1146/annurev.immunol.21.120601.141011; Moon A, 2000, INT J CANCER, V85, P176, DOI 10.1002/(SICI)1097-0215(20000115)85:2<176::AID-IJC5>3.0.CO;2-E; Ortiz-Stern A, 2003, IMMUNOL LETT, V90, P137, DOI 10.1016/j.imlet.2003.08.004; Pierce BL, 2009, J CLIN ONCOL, V27, P3437, DOI 10.1200/JCO.2008.18.9068; Platz Elizabeth A., 2004, Journal of Urology, V171, pS36, DOI 10.1097/01.ju.0000108131.43160.77; Qu Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131285; Ramirez NE, 2011, J CLIN INVEST, V121, P226, DOI 10.1172/JCI42328; Ravishankaran P, 2011, WORLD J SURG ONCOL, V9, DOI 10.1186/1477-7819-9-18; Ridker PM, 2016, CIRC RES, V118, P145, DOI 10.1161/CIRCRESAHA.115.306656; Rodriguez-Sanjuan JC, 1999, DIS COLON RECTUM, V42, P1325, DOI 10.1007/BF02234223; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sawhney RS, 2003, J BIOL CHEM, V278, P19861, DOI 10.1074/jbc.M213162200; Schaller MD, 2004, J CELL BIOL, V166, P157, DOI 10.1083/jcb.200406151; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Schmidt RE, 2005, IMMUNOL LETT, V100, P56, DOI 10.1016/j.imlet.2005.06.022; Song H, 2006, CANCER RES, V66, P10487, DOI 10.1158/0008-5472.CAN-06-1461; SOULE HD, 1990, CANCER RES, V50, P6075; Tsaur I, 2012, BRIT J CANCER, V107, P847, DOI 10.1038/bjc.2012.313; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Venugopal SK, 2005, AM J PATHOL, V166, P1265, DOI 10.1016/S0002-9440(10)62345-0; WENG ZG, 1993, J BIOL CHEM, V268, P14956; Woollard KJ, 2005, INFLAMM RES, V54, P485, DOI 10.1007/s00011-005-1382-5; Yang CQ, 2003, CANCER RES, V63, P8312; Yang J, 2007, CANCER CELL, V12, P252, DOI 10.1016/j.ccr.2007.08.008; Ye JP, 1996, MOL CELL BIOL, V16, P6178; Yoshimura K, 2009, CANCER RES, V69, P7320, DOI 10.1158/0008-5472.CAN-09-0315; YOUNG B, 1991, PATHOLOGY, V23, P118, DOI 10.3109/00313029109060809; Zou Cai-Yan, 2008, Zhongguo Dang Dai Er Ke Za Zhi, V10, P386; ZUTTER MM, 1994, J BIOL CHEM, V269, P463	67	20	20	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2018	37	1					28	38		10.1038/onc.2017.298	http://dx.doi.org/10.1038/onc.2017.298			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS7YF	28846105				2022-12-17	WOS:000422625000004
J	Padilla, L; Dakhel, S; Adan, J; Masa, M; Martinez, JM; Roque, L; Coll, T; Hervas, R; Calvis, C; Llinas, L; Buenestado, S; Castellsague, J; Messeguer, R; Mitjans, F; Hernandez, JL				Padilla, L.; Dakhel, S.; Adan, J.; Masa, M.; Martinez, J. M.; Roque, L.; Coll, T.; Hervas, R.; Calvis, C.; Llinas, L.; Buenestado, S.; Castellsague, J.; Messeguer, R.; Mitjans, F.; Hernandez, J. L.			S100A7: from mechanism to cancer therapy	ONCOGENE			English	Article							GLYCATION END-PRODUCTS; INVASIVE BREAST-CANCER; TUMOR MICROENVIRONMENT; ENDOTHELIAL-CELLS; BINDING ASSAY; PSORIASIN; RECEPTOR; METASTASIS; EXPRESSION; RAGE	Within the tumor, malignant and stromal cells support each other by secreting a wide variety of growth factors and cytokines, allowing tumor growth and disease progression. The identification and regulation of those key factors in this crosstalk has opened the opportunity to develop new therapeutic strategies that not only act on the tumor cells but also on the stroma. Among these factors, S100A7 protein has gained interest in the last years. With key roles in cell motility its expression correlates with increased tumor growth, angiogenesis and metastatic potential. This work aims to deepen in the role played by extracellular S100A7 in the tumor microenvironment, offering a new integrative insight of its mechanism of action on each cellular compartment (tumor, endothelial, immune and fibroblast). As a result, we demonstrate its implication in cell migration and invasion, and its important contribution to the formation of a proinflammatory and proangiogenic environment that favors tumor progression and metastasis. Furthermore, we define its possible role in the pre-metastatic niche formation. Considering the relevance of S100A7 in cancer progression, we have developed neutralizing monoclonal antibodies, reporting for the first time the proof of principle of this promising therapeutic strategy for cancer treatment.	[Padilla, L.; Dakhel, S.; Adan, J.; Masa, M.; Martinez, J. M.; Roque, L.; Coll, T.; Hervas, R.; Calvis, C.; Llinas, L.; Buenestado, S.; Castellsague, J.; Messeguer, R.; Mitjans, F.; Hernandez, J. L.] LEITAT Technol Ctr, Biomed Div, C Baldiri Reixach 15-21,Barcelona Sci Pk, Barcelona 08028, Spain		Hernandez, JL (corresponding author), LEITAT Technol Ctr, Biomed Div, C Baldiri Reixach 15-21,Barcelona Sci Pk, Barcelona 08028, Spain.	jlhernandez@leitat.org	Padilla, Leo/GYU-4775-2022; Masa, Marc/AAO-6133-2021; Mitjans, Francesc/AAZ-8922-2020; Buenestado, Silvia/AAB-3361-2019	Buenestado, Silvia/0000-0002-2715-9383; hernandez, jose luis/0000-0002-9172-6004; Mitjans, Francesc/0000-0001-8331-9954	Spanish MINECO [RTC-2015-3318-1]	Spanish MINECO(Spanish Government)	The work was partially supported by Grants from the Spanish MINECO (RTC-2015-3318-1).	Al-Haddad S, 1999, AM J PATHOL, V155, P2057, DOI 10.1016/S0002-9440(10)65524-1; Bettum IJ, 2014, CANCER LETT, V344, P28, DOI 10.1016/j.canlet.2013.10.036; Bresnick AR, 2015, NAT REV CANCER, V15, P96, DOI 10.1038/nrc3893; Chen F, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0278-7; Chen HY, 2014, AM J CANCER RES, V4, P89; Chen L, 2015, J HEPATOL, V62, P156, DOI 10.1016/j.jhep.2014.07.035; Choi SH, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-016-0374-6; Dakhel S, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.7; Donato R, 2013, CURR MOL MED, V13, P24, DOI 10.2174/156652413804486214; Ducharme A, 2000, J CLIN INVEST, V106, P55, DOI 10.1172/JCI8768; Emberley ED, 2003, CLIN CANCER RES, V9, P2627; Emberley ED, 2003, CANCER RES, V63, P1954; Heldin CH, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-97; Huber J, 2006, J LIPID RES, V47, P1054, DOI 10.1194/jlr.M500555-JLR200; Jin QE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019375; JUNQUEIRA LCU, 1979, HISTOCHEM J, V11, P447, DOI 10.1007/BF01002772; Kataoka K, 2012, ONCOL LETT, V3, P1149, DOI 10.3892/ol.2012.612; Klingelhofer J, 2012, NEOPLASIA, V14, P1260, DOI 10.1593/neo.121554; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Krop I, 2005, CANCER RES, V65, P11326, DOI 10.1158/0008-5472.CAN-05-1523; Laenkholm AV, 2012, MOL ONCOL, V6, P428, DOI 10.1016/j.molonc.2012.04.003; Leclerc E, 2015, BBA-MOL BASIS DIS, V1852, P2706, DOI 10.1016/j.bbadis.2015.09.022; Limaverde-Sousa G, 2014, CANCER TREAT REV, V40, P548, DOI 10.1016/j.ctrv.2013.11.009; McCullough KC, 1999, IMMUNOLOGY, V98, P203, DOI 10.1046/j.1365-2567.1999.00867.x; McKeown SR, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20130676; Moserle L, 2014, CANCER DISCOV, V4, P31, DOI 10.1158/2159-8290.CD-13-0199; Nasser MW, 2015, CANCER RES, V75, P974, DOI 10.1158/0008-5472.CAN-14-2161; Nasser MW, 2012, CANCER RES, V72, P604, DOI 10.1158/0008-5472.CAN-11-0669; Padilla L, 2014, BIOCHEM BIOPH RES CO, V446, P404, DOI 10.1016/j.bbrc.2014.02.143; Peng QX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075328; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rich L, 2005, BRAZ J MORPHOL SCI, V22, P7; Robinson MJ, 2002, J BIOL CHEM, V277, P3658, DOI 10.1074/jbc.M102950200; Schweizer MT, 2013, CANCER J, V19, P99, DOI 10.1097/PPO.0b013e31827e0b86; Shubbar E, 2012, BREAST CANCER RES TR, V134, P71, DOI 10.1007/s10549-011-1920-5; Sorci G, 2004, J CELL PHYSIOL, V199, P274, DOI 10.1002/jcp.10462; Tan JQ, 1996, J INVEST DERMATOL, V107, P5, DOI 10.1111/1523-1747.ep12294284; Torres I, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0068434, 10.1371/journal.pone.0072480]; Tripathi SC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011939; Vegfors J, 2016, BRIT J DERMATOL, V175, P1263, DOI 10.1111/bjd.14718; West NR, 2010, ONCOGENE, V29, P2083, DOI 10.1038/onc.2009.488; Wolf R, 2008, J IMMUNOL, V181, P1499, DOI 10.4049/jimmunol.181.2.1499; Wolf S, 2011, AMINO ACIDS, V41, P809, DOI 10.1007/s00726-010-0822-x; Yamada T, 2012, J THORAC ONCOL, V7, P272, DOI 10.1097/JTO.0b013e3182398e69; Zhang H, 2008, THORAX, V63, P352, DOI 10.1136/thx.2007.087015; Zhang H, 2007, LUNG CANCER, V57, P37, DOI 10.1016/j.lungcan.2007.02.020	46	20	21	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2017	36	49					6749	6761		10.1038/onc.2017.283	http://dx.doi.org/10.1038/onc.2017.283			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FP0IK	28825725				2022-12-17	WOS:000417282500001
J	Kim, J; Xu, S; Xiong, L; Yu, L; Fu, X; Xu, Y				Kim, J.; Xu, S.; Xiong, L.; Yu, L.; Fu, X.; Xu, Y.			SALL4 promotes glycolysis and chromatin remodeling via modulating HP1 alpha-Glut1 pathway	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; MURINE HOMOLOG; CELL; CANCER; GENE; ATM; EXPRESSION; PROLIFERATION; PLURIPOTENCY; METABOLISM	SALL4 has recently been identified to promote chemo-resistance in multiple types of cancer, but the underlying mechanism remains to be fully established. Open chromatin structure is important for DNA damage response (DDR) and DNA repair. Here, we demonstrate that SALL4 promotes open chromatin by destabilizing heterochromatin protein 1a (HP1a) by recruiting ubiquitin E3 ligase CUL4B to HP1 alpha. The silencing of SALL4 in cancer cells decreased the expression levels of Glut1 and inhibited glycolysis in cancer cells. The upregulation of HP1 alpha in human cancer cells suppressed open chromatin, glycolysis and Glut1 expression levels. Therefore, SALL4 promotes the expression of Glut1 and open chromatin through a HP1 alpha-dependent mechanism. Impaired DDR in SALL4-deficient human cancer cells can be rescued by the restored expression of Glut1, indicating the importance of HP1 alpha-Glut1 axis in SALL4-mediated DDR. These findings demonstrate that SALL4 could induce drug resistance by enhancing DDR and DNA repair through promoting glycolysis and subsequent chromatin remodeling.	[Kim, J.; Xu, S.; Yu, L.; Xu, Y.] Southern Med Univ, Canc Res Inst, Sch Basic Med Sci, Guangzhou, Guangdong, Peoples R China; [Kim, J.; Xiong, L.; Xu, Y.] Univ Calif San Diego, Div Biol Sci, 9500 Gilman Dr, La Jolla, CA 92093 USA; [Yu, L.; Fu, X.] Sun Yat Sen Univ, Affiliated Hosp 8, Shenzhen, Peoples R China	Southern Medical University - China; University of California System; University of California San Diego; Sun Yat Sen University	Xu, Y (corresponding author), Univ Calif San Diego, Div Biol Sci, 9500 Gilman Dr, La Jolla, CA 92093 USA.	yangxu@ucsd.edu		Xu, Yang/0000-0001-5574-921X; Xiong, Lingyun/0000-0003-4594-4120	National Natural Science Foundation of China [815300045, 81373166, 81430032]; National High-tech R&D Program (863 Program) [2015AA020310]; Guangdong Provincial Key Laboratory of Tumor Immunotherapy, South Wisdom Valley Innovative Research Team Program [365]; Major basic research developmental project of the Natural Science Foundation of Guangdong Province; Shenzhen Municipal Science and Technology Innovation Council [20140405201035]; California Institute for Regenerative Medicine [TR3-05559, RT3-07899]; Guangzhou Key Laboratory of Tumor Immunology Research, South Wisdom Valley Innovative Research Team Program [365]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High-tech R&D Program (863 Program)(National High Technology Research and Development Program of China); Guangdong Provincial Key Laboratory of Tumor Immunotherapy, South Wisdom Valley Innovative Research Team Program; Major basic research developmental project of the Natural Science Foundation of Guangdong Province; Shenzhen Municipal Science and Technology Innovation Council; California Institute for Regenerative Medicine(California Institute for Regenerative Medicine); Guangzhou Key Laboratory of Tumor Immunology Research, South Wisdom Valley Innovative Research Team Program	We thank Michael Qiu for technical support. This study is supported by the National Natural Science Foundation of China (No. 815300045, 81373166, 81430032), a grant from the National High-tech R&D Program (863 Program No. 2015AA020310), Guangdong Provincial Key Laboratory of Tumor Immunotherapy and Guangzhou Key Laboratory of Tumor Immunology Research, South Wisdom Valley Innovative Research Team Program (2014) No. 365, Major basic research developmental project of the Natural Science Foundation of Guangdong Province, Shenzhen Municipal Science and Technology Innovation Council (20140405201035), and grants from California Institute for Regenerative Medicine (TR3-05559, RT3-07899).	Abmayr Susan M, 2006, Curr Protoc Pharmacol, VChapter 12, DOI [10.1002/0471142727.mb1201s75, 10.1002/0471141755.ph1203s35]; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bleau AM, 2009, CELL STEM CELL, V4, P226, DOI 10.1016/j.stem.2009.01.007; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Bouwman P, 2012, NAT REV CANCER, V12, P587, DOI 10.1038/nrc3342; Chen YY, 2016, BMC MOL BIOL, V17, DOI 10.1186/s12867-016-0055-y; Cheng J, 2016, ONCOTARGET, V7, P24314, DOI 10.18632/oncotarget.8237; Chiou SH, 2010, CANCER RES, V70, P10433, DOI 10.1158/0008-5472.CAN-10-2638; Faucher D, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001082; Forghanifard MM, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-6; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Goodarzi AA, 2008, MOL CELL, V31, P167, DOI 10.1016/j.molcel.2008.05.017; Han SX, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/262385; Housman G, 2014, CANCERS, V6, P1769, DOI 10.3390/cancers6031769; Kim J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.87; Kim JA, 2007, J CELL BIOL, V178, P209, DOI 10.1083/jcb.200612031; Kim YC, 2009, NAT CELL BIOL, V11, P92, DOI 10.1038/ncb1817; Kohlhase J, 2002, CYTOGENET GENOME RES, V98, P274, DOI 10.1159/000071048; Latham T, 2012, NUCLEIC ACIDS RES, V40, P4794, DOI 10.1093/nar/gks066; Li A, 2015, ONCOGENE, V34, P63, DOI 10.1038/onc.2013.529; Liu L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138515; Liu XS, 2015, ONCOTARGET, V6, P4214, DOI 10.18632/oncotarget.2929; Lu JY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005577; Lu X, 2014, ONCOGENE, V33, P2655, DOI 10.1038/onc.2013.209; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Mai V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020647; Masuda S, 2013, NEW ENGL J MED, V369, P1171, DOI 10.1056/NEJMc1308785; Miettinen M, 2014, AM J SURG PATHOL, V38, P410, DOI 10.1097/PAS.0000000000000116; Molina-Serrano D, 2013, NUCLEUS-AUSTIN, V4, P343, DOI 10.4161/nucl.26051; Murga M, 2007, J CELL BIOL, V178, P1101, DOI 10.1083/jcb.200704140; Oikawa T, 2013, HEPATOLOGY, V57, P1469, DOI 10.1002/hep.26159; Olaussen KA, 2006, NEW ENGL J MED, V355, P983, DOI 10.1056/NEJMoa060570; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sakaki-Yumoto M, 2006, DEVELOPMENT, V133, P3005, DOI 10.1242/dev.02457; Shiloh Y, 2013, NAT REV MOL CELL BIO, V14, P197, DOI 10.1038/nrm3546; Sulli G, 2012, NAT REV CANCER, V12, DOI 10.1038/nrc3344; Xiong JH, 2015, J CELL BIOL, V208, P513, DOI 10.1083/jcb.201408106; Yanagihara N, 2015, INT J ONCOL, V46, P1527, DOI 10.3892/ijo.2015.2866; Yang MY, 2016, ONCOL REP, V35, P1796, DOI 10.3892/or.2016.4545; Zhang JQ, 2006, NAT CELL BIOL, V8, P1114, DOI 10.1038/ncb1481; Zhang L, 2014, ONCOGENE, V33, P5491, DOI 10.1038/onc.2013.495; Zhong L, 2010, CELL, V140, P280, DOI 10.1016/j.cell.2009.12.041; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446	44	20	21	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6472	6479		10.1038/onc.2017.265	http://dx.doi.org/10.1038/onc.2017.265			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28759035				2022-12-17	WOS:000415622900010
J	Provenzano, L; Ryan, Y; Hilton, DA; Lyons-Rimmer, J; Dave, F; Maze, EA; Adams, CL; Rigby-Jones, R; Ammoun, S; Hanemann, CO				Provenzano, L.; Ryan, Y.; Hilton, D. A.; Lyons-Rimmer, J.; Dave, F.; Maze, E. A.; Adams, C. L.; Rigby-Jones, R.; Ammoun, S.; Hanemann, C. O.			Cellular prion protein (PrPC) in the development of Merlin-deficient tumours	ONCOGENE			English	Article							UBIQUITIN LIGASE CRL4(DCAF1); LAMININ RECEPTOR; HUMAN SCHWANNOMA; C-JUN; GENE-EXPRESSION; AMYLOID-BETA; CANCER-CELLS; ACTIVATION; PROLIFERATION; MENINGIOMAS	Loss of function mutations in the neurofibromatosis Type 2 (NF2) gene, coding for a tumour suppressor, Merlin, cause multiple tumours of the nervous system such as schwannomas, meningiomas and ependymomas. These tumours may occur sporadically or as part of the hereditary condition neurofibromatosis Type 2 (NF2). Current treatment is confined to (radio) surgery and no targeted drug therapies exist. NF2 mutations and/or Merlin inactivation are also seen in other cancers including some mesothelioma, breast cancer, colorectal carcinoma, melanoma and glioblastoma. To study the relationship between Merlin deficiency and tumourigenesis, we have developed an in vitro model comprising human primary schwannoma cells, the most common Merlin-deficient tumour and the hallmark for NF2. Using this model, we show increased expression of cellular prion protein (PrPC) in schwannoma cells and tissues. In addition, a strong overexpression of PrPC is observed in human Merlin-deficient mesothelioma cell line TRA and in human Merlin-deficient meningiomas. PrPC contributes to increased proliferation, cell-matrix adhesion and survival in schwannoma cells acting via 37/67 kDa non-integrin laminin receptor (LR/37/67 kDa) and downstream ERK1/2, PI3K/AKT and FAK signalling pathways. PrPC protein is also strongly released from schwannoma cells via exosomes and as a free peptide suggesting that it may act in an autocrine and/or paracrine manner. We suggest that PrPC and its interactor, LR/37/67 kDa, could be potential therapeutic targets for schwannomas and other Merlin-deficient tumours.	[Provenzano, L.; Ryan, Y.; Lyons-Rimmer, J.; Dave, F.; Maze, E. A.; Adams, C. L.; Ammoun, S.; Hanemann, C. O.] Plymouth Univ, Inst Translat & Stratified Med, Peninsula Sch Med, John Bull Bldg,Tamar Sci Pk,Res Way, Plymouth PL6 8BU, Devon, England; [Provenzano, L.; Ryan, Y.; Lyons-Rimmer, J.; Dave, F.; Maze, E. A.; Adams, C. L.; Ammoun, S.; Hanemann, C. O.] Plymouth Univ, Inst Translat & Stratified Med, Peninsula Sch Dent, John Bull Bldg,Tamar Sci Pk,Res Way, Plymouth PL6 8BU, Devon, England; [Hilton, D. A.; Rigby-Jones, R.] Derriford Hosp, Dept Cellular & Anat Pathol, Plymouth, Devon, England	University of Plymouth; University of Plymouth; Derriford Hospital	Ammoun, S (corresponding author), Plymouth Univ, Inst Translat & Stratified Med, Peninsula Sch Med, John Bull Bldg,Tamar Sci Pk,Res Way, Plymouth PL6 8BU, Devon, England.; Ammoun, S (corresponding author), Plymouth Univ, Inst Translat & Stratified Med, Peninsula Sch Dent, John Bull Bldg,Tamar Sci Pk,Res Way, Plymouth PL6 8BU, Devon, England.	sylwia.ammoun@plymouth.ac.uk	Hanemann, C Oliver/AAV-6257-2020; Atangana Maze, Emmanuel/HHC-2713-2022	Hanemann, C Oliver/0000-0002-1951-1025; Atangana Maze, Emmanuel/0000-0003-4632-6324; Ryan, Yan/0000-0002-4708-5350; Provenzano, Lucy/0000-0002-2922-0109; Adams, Claire/0000-0003-3871-9267	Laura Crane Youth Cancer Trust; Brain Tumour Research	Laura Crane Youth Cancer Trust; Brain Tumour Research	We thank Mario Salmona for mock PrP peptide and Joseph Testa for Merlin adenovirus. This work was supported by The Laura Crane Youth Cancer Trust and Brain Tumour Research.	Alais S, 2008, BIOL CELL, V100, P603, DOI 10.1042/BC20080025; Altmeppen HC, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-36; Ammoun S, 2014, ONCOGENE, V33, P336, DOI 10.1038/onc.2012.587; Ammoun S, 2012, ONCOGENE, V31, P1710, DOI 10.1038/onc.2011.357; Ammoun S, 2015, MOL ONCOL, V9, P236, DOI 10.1016/j.molonc.2014.08.005; Ammoun S, 2008, CANCER RES, V68, P5236, DOI 10.1158/0008-5472.CAN-07-5849; Ammoun S, 2010, NEUROBIOL DIS, V37, P141, DOI 10.1016/j.nbd.2009.09.017; Arsenault RJ, 2012, PRION, V6, DOI 10.4161/pri.21914; Bacot SM, 2003, J LEUKOCYTE BIOL, V74, P118, DOI 10.1189/jlb.1102521; Blakeley Jaishri O, 2012, Am J Med Genet A, V158A, P24, DOI 10.1002/ajmg.a.34359; Bourteele S, 2007, CELL MICROBIOL, V9, P2202, DOI 10.1111/j.1462-5822.2007.00950.x; Bremer J, 2010, NAT NEUROSCI, V13, P310, DOI 10.1038/nn.2483; Carimalo J, 2005, EUR J NEUROSCI, V21, P2311, DOI 10.1111/j.1460-9568.2005.04080.x; Clark VE, 2013, SCIENCE, V339, P1077, DOI 10.1126/science.1233009; Deguen B, 1998, INT J CANCER, V77, P554, DOI 10.1002/(SICI)1097-0215(19980812)77:4<554::AID-IJC14>3.0.CO;2-6; Faure J, 2006, MOL CELL NEUROSCI, V31, P642, DOI 10.1016/j.mcn.2005.12.003; Fevrier B, 2004, P NATL ACAD SCI USA, V101, P9683, DOI 10.1073/pnas.0308413101; Flaiz C, 2009, BRAIN PATHOL, V19, P27, DOI 10.1111/j.1750-3639.2008.00165.x; Ford MJ, 2002, NEUROSCIENCE, V113, P177, DOI 10.1016/S0306-4522(02)00155-0; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; Gerber MA, 2006, CANCER RES, V66, P5295, DOI 10.1158/0008-5472.CAN-05-1628; Godsave SF, 2015, VIRUS RES, V207, P136, DOI 10.1016/j.virusres.2015.02.004; Gu YP, 2002, J BIOL CHEM, V277, P2275, DOI 10.1074/jbc.M104345200; Guillot-Sestier MV, 2009, J BIOL CHEM, V284, P35973, DOI 10.1074/jbc.M109.051086; Guo BB, 2016, J BIOL CHEM, V291, P5128, DOI 10.1074/jbc.M115.684258; Hanemann CO, 2008, BRAIN, V131, P606, DOI 10.1093/brain/awm249; Hanemann CO, 2006, NEUROPATH APPL NEURO, V32, P605, DOI 10.1111/j.1365-2990.2006.00769.x; Hilton DA, 2016, NEUROPATHOLOGY, V36, P250, DOI 10.1111/neup.12266; Kimata A, 2007, J MED CHEM, V50, P5053, DOI 10.1021/jm070688r; Klyubin I, 2014, J NEUROSCI, V34, P6140, DOI 10.1523/JNEUROSCI.3526-13.2014; Li W, 2010, CELL CYCLE, V9, P4433, DOI 10.4161/cc.9.22.13838; Li W, 2010, CELL, V140, P477, DOI 10.1016/j.cell.2010.01.029; Liang J, 2007, FASEB J, V21, P2247, DOI 10.1096/fj.06-7799com; Lin Y, 2010, EXPERT OPIN THER TAR, V14, P45, DOI 10.1517/14728220903431069; Linden R, 2008, PHYSIOL REV, V88, P673, DOI 10.1152/physrev.00007.2007; Lopes JP, 2009, CELL CYCLE, V8, P97, DOI 10.4161/cc.8.1.7506; Loubet D, 2012, FASEB J, V26, P678, DOI 10.1096/fj.11-185579; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Maretzky T, 2005, P NATL ACAD SCI USA, V102, P9182, DOI 10.1073/pnas.0500918102; Nunes F, 2005, CANCER GENET CYTOGEN, V162, P135, DOI 10.1016/j.cancergencyto.2005.04.003; Parkin ET, 2004, J BIOL CHEM, V279, P11170, DOI 10.1074/jbc.M312105200; Parkinson DB, 2008, J CELL BIOL, V181, P625, DOI 10.1083/jcb.200803013; Parkinson DB, 2004, J CELL BIOL, V164, P385, DOI 10.1083/jcb.200307132; Petrilli AM, 2016, ONCOGENE, V35, P537, DOI 10.1038/onc.2015.125; Pflanzner T, 2012, J CEREBR BLOOD F MET, V32, P628, DOI 10.1038/jcbfm.2012.7; Robb VA, 2005, ONCOGENE, V24, P1946, DOI 10.1038/sj.onc.1208335; Robertson C, 2006, BLOOD, V107, P3907, DOI 10.1182/blood-2005-02-0802; Rosenbaum C, 1998, NEUROBIOL DIS, V5, P55, DOI 10.1006/nbdi.1998.0179; Santos TG, 2015, PRION, V9, P165, DOI 10.1080/19336896.2015.1027855; Sarnataro D, 2016, SCI REP-UK, V6, DOI 10.1038/srep24457; Satoh J, 2000, AM J PATHOL, V157, P59, DOI 10.1016/S0002-9440(10)64517-8; Shivane A, 2013, HISTOPATHOLOGY, V62, P651, DOI 10.1111/his.12062; Singh N, 2010, ANTIOXID REDOX SIGN, V12, P1271, DOI 10.1089/ars.2009.2628; Steele AD, 2006, P NATL ACAD SCI USA, V103, P3416, DOI 10.1073/pnas.0511290103; Stella R, 2010, MOL CELL BIOL, V30, P4864, DOI 10.1128/MCB.01040-09; Utermark T, 2003, BRAIN PATHOL, V13, P352; van den Munckhof P, 2012, NEUROGENETICS, V13, P1, DOI 10.1007/s10048-011-0300-y; Watts JC, 2007, BBA-MOL BASIS DIS, V1772, P654, DOI 10.1016/j.bbadis.2007.05.001; Weise J, 2008, RESTOR NEUROL NEUROS, V26, P57; Westergard L, 2007, BBA-MOL BASIS DIS, V1772, P629, DOI 10.1016/j.bbadis.2007.02.011; Wozniak K, 2008, CANCER GENET CYTOGEN, V183, P14, DOI 10.1016/j.cancergencyto.2008.01.020; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Yap YHY, 2011, CANCER LETT, V306, P111, DOI 10.1016/j.canlet.2011.02.040; Yuzawa S, 2016, BRAIN TUMOR PATHOL, V33, P237, DOI 10.1007/s10014-016-0271-7; Zeng L, 2015, INT J CLIN EXP MED, V8, P8042; Zhou L, 2012, FEBS LETT, V586, P1403, DOI 10.1016/j.febslet.2012.03.016; Zhou L, 2011, NEOPLASIA, V13, P1101, DOI 10.1593/neo.111060; Zhou XM, 2008, MICROB PATHOGENESIS, V44, P129, DOI 10.1016/j.micpath.2007.08.014; Zuber C, 2008, MOL IMMUNOL, V45, P144, DOI 10.1016/j.molimm.2007.04.030	69	20	20	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2017	36	44					6132	6142		10.1038/onc.2017.200	http://dx.doi.org/10.1038/onc.2017.200			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FL5CU	28692055	Green Submitted			2022-12-17	WOS:000414249800007
J	Rupp, M; Hagenbuchner, J; Rass, B; Fiegl, H; Kiechl-Kohlendorfer, U; Obexer, P; Ausserlechner, MJ				Rupp, M.; Hagenbuchner, J.; Rass, B.; Fiegl, H.; Kiechl-Kohlendorfer, U.; Obexer, P.; Ausserlechner, M. J.			FOXO3-mediated chemo-protection in high-stage neuroblastoma depends on wild-type TP53 and SESN3	ONCOGENE			English	Article							FOXO TRANSCRIPTION FACTORS; MULTIDRUG-RESISTANCE; GENE-EXPRESSION; CELLS; AKT; ACTIVATION; MUTATIONS; APOPTOSIS; CANCER; BIM	Forkhead box O class transcription factors are homeostasis regulators that control cell death, longevity and therapy-resistance. In neuroblastoma (NB), nuclear FOXO3 correlates with stage M disease and poor prognosis. To analyze whether FOXO3 contributes to drug-resistance in this childhood cancer, we investigated how different high-stage-derived NB cells respond to the activation of an ectopic FOXO3 allele. We found endogenous FOXO3 mostly localized to the nucleus-upon activation of an ectopic, 4OHTactivated FOXO3(A3) ER fusion protein two of the cell lines underwent apoptosis, whereas in the others FOXO3-activation even increased survival during drug-treatment. In the latter cell type, FOXO3 did not induce the BH3-only protein BCL2L11/BIM due to impaired binding of FOXO3 to the BIM-promoter, but still activated other FOXO3 targets. It was shown before that FOXO3 and TP53 physically interact with each other at two different regions-the TP53-N-terminus binds to the FOXO3-DNA binding domain (DBD) and the FOXO3-C-terminus interacts with the TP53-DBD. Interestingly, cell lines that undergo FOXO3-induced cell death carry homozygous point mutations in the TP53-DBD near the structural hotspot-mutation-site R175H, which abrogated FOXO3-TP53 interaction. In contrast, in FOXO3-death-resistant cells no point mutations in the TP53-DBD were found-in these cells FOXO3-TP53 complexes are formed and FOXO3-binding to the BIM-promoter, but not the induction of the detoxifying protein SESN3, were prevented, which in turn increased chemo-protection in this type of high-stage-derived NB cells. Our combined data suggest that FOXO3 steps in as a death inducer in case of TP53-mutation, whereas functional TP53 alters FOXO3-target-promoter-recognition, which prevents death induction by FOXO3 and instead increases chemo-protection and survival of NB cells. This novel mechanism may explain the low incidence of TP53 mutation in high-stage NB at diagnosis and suggests FOXO3 as a therapeutic target for this childhood malignancy.	[Rupp, M.; Hagenbuchner, J.; Kiechl-Kohlendorfer, U.; Obexer, P.] Med Univ Innsbruck, Dept Pediat 2, A-6020 Innsbruck, Austria; [Rupp, M.; Rass, B.; Ausserlechner, M. J.] Med Univ Innsbruck, Dept Pediat 1, A-6020 Innsbruck, Austria; [Rupp, M.; Obexer, P.] Tyrolean Canc Res Inst, A-6020 Innsbruck, Austria; [Fiegl, H.] Med Univ Innsbruck, Dept Obstet & Gynecol, Innsbruck, Austria	Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck	Hagenbuchner, J; Obexer, P (corresponding author), Med Univ Innsbruck, Dept Pediat 2, A-6020 Innsbruck, Austria.; Ausserlechner, MJ (corresponding author), Med Univ Innsbruck, Dept Pediat 1, A-6020 Innsbruck, Austria.; Obexer, P (corresponding author), Tyrolean Canc Res Inst, A-6020 Innsbruck, Austria.	judith.hagenbuchner@i-med.ac.at; petra.obexer@i-med.ac.at; michael.j.ausserlechner@i-med.ac.at	Zeimet, Alain/AFK-2441-2022; Zeimet, Alain/AAF-9688-2022; Fiegl, Heidi/K-4445-2017	Hagenbuchner, Judith/0000-0003-1396-3407; Fiegl, Heidi/0000-0002-1236-6806; Ausserlechner, Michael/0000-0002-1015-2302	intramural funding program of the Medical University Innsbruck for young scientists MUI-START [P2012032014]; Kinderkrebshilfe fur Tirol und Vorarlberg; Sudtiroler Krebshilfe; Kinderkrebshilfe Sudtirol-Regenbogen; Austrian Wirtschaftsservice [PRIZE P1308459]; Provita Kinderleukamiestiftung; MFF-Tirol [246]; Krebshilfe Tirol [16004]; Austrian Science Fund (FWF) [I 3089 - B28]; Tirol-Kliniken GmbH	intramural funding program of the Medical University Innsbruck for young scientists MUI-START; Kinderkrebshilfe fur Tirol und Vorarlberg; Sudtiroler Krebshilfe; Kinderkrebshilfe Sudtirol-Regenbogen; Austrian Wirtschaftsservice; Provita Kinderleukamiestiftung; MFF-Tirol; Krebshilfe Tirol; Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Tirol-Kliniken GmbH	We thank Drs Peter Ambros, Todd Waldmann and Andreas Villunger for providing NB cell lines and plasmids. This work was supported by the intramural funding program of the Medical University Innsbruck for young scientists MUI-START (P2012032014), by grants from the 'Kinderkrebshilfe fur Tirol und Vorarlberg', 'Sudtiroler Krebshilfe', 'Kinderkrebshilfe Sudtirol-Regenbogen', the Austrian Wirtschaftsservice (PRIZE P1308459), the 'Provita Kinderleukamiestiftung', the MFF-Tirol (Project Nr. 246), the 'Krebshilfe Tirol (Nr 16004)' the Austrian Science Fund (FWF) (I 3089 - B28) and the 'Tirol-Kliniken GmbH'.	Arden KC, 2002, ARCH BIOCHEM BIOPHYS, V403, P292, DOI 10.1016/S0003-9861(02)00207-2; Ausserlechner MJ, 2012, NEUROBLASTOMA PRESEN, P325; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Chen JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013704; de Brachene AC, 2016, CELL MOL LIFE SCI, V73, P1159, DOI 10.1007/s00018-015-2112-y; de Keizer PLJ, 2011, ANTIOXID REDOX SIGN, V14, P1093, DOI 10.1089/ars.2010.3403; Gaviraghi M, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-56; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Gomes AR, 2008, CELL CYCLE, V7, P3133, DOI 10.4161/cc.7.20.6920; Grignani F, 1998, CANCER RES, V58, P14; Hagenbuchner J, 2016, ONCOGENE, V35, P2052, DOI 10.1038/onc.2015.264; Hagenbuchner J, 2013, ONCOGENE, V32, P4748, DOI 10.1038/onc.2012.500; Hagenbuchner J, 2017, ONCOTARGET, V8, P32009, DOI 10.18632/oncotarget.16434; Hagenbuchner Judith, 2016, Oncotarget, V7, P77591, DOI 10.18632/oncotarget.12728; Hagenbuchner J, 2013, ONCOTARGET, V4, P1241, DOI 10.18632/oncotarget.1147; Hagenbuchner J, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00147; Hagenbuchner J, 2012, J CELL SCI, V125, P1191, DOI 10.1242/jcs.092098; Ho KK, 2008, ONCOGENE, V27, P2300, DOI 10.1038/onc.2008.23; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Hui RCY, 2008, MOL CELL BIOL, V28, P5886, DOI 10.1128/MCB.01265-07; Hui RCY, 2008, MOL CANCER THER, V7, P670, DOI 10.1158/1535-7163.MCT-07-0397; Keniry M, 2013, GENE DEV, V27, P916, DOI 10.1101/gad.214049.113; Keshelava N, 2001, CANCER RES, V61, P6185; Kim JS, 2007, MOL CELL BIOL, V27, P662, DOI 10.1128/MCB.00537-06; Krytska K, 2016, CLIN CANCER RES, V22, P948, DOI 10.1158/1078-0432.CCR-15-0379; Lin Hung-Yu, 2008, Int J Biomed Sci, V4, P248; Liu DP, 2010, ONCOGENE, V29, P949, DOI 10.1038/onc.2009.376; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Miyaguchi Y, 2009, CELL BIOL INT, V33, P853, DOI 10.1016/j.cellbi.2009.04.017; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Obexer P, 2007, CELL DEATH DIFFER, V14, P534, DOI 10.1038/sj.cdd.4402017; Obexer P, 2009, MOL BIOL CELL, V20, P2041, DOI 10.1091/mbc.E08-07-0699; Obsilova V, 2008, PHYSIOL RES, V57, pS11, DOI 10.33549/physiolres.931598; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Salcher S, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0661-4; Salcher S, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-224; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Thiele CJ, 1999, HUMAN CELL CULTURE, V1, P21; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Tseng AHH, 2013, FREE RADICAL BIO MED, V63, P222, DOI 10.1016/j.freeradbiomed.2013.05.002; Tweddle DA, 2001, CANCER RES, V61, P8; Tzivion G, 2011, BBA-MOL CELL RES, V1813, P1938, DOI 10.1016/j.bbamcr.2011.06.002; Wang F, 2007, AGING CELL, V6, P505, DOI 10.1111/j.1474-9726.2007.00304.x; Wang F, 2008, J MOL BIOL, V384, P590, DOI 10.1016/j.jmb.2008.09.025; Wilson MSC, 2011, CURR DRUG TARGETS, V12, P1256; Xie X, 2016, ONCOGENE, V35, P4798, DOI 10.1038/onc.2016.12; Zilfou JT, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001883	56	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2017	36	44					6190	6203		10.1038/onc.2017.288	http://dx.doi.org/10.1038/onc.2017.288			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FL5CU	28869600	hybrid, Green Published			2022-12-17	WOS:000414249800012
J	Manent, J; Banerjee, S; de Matos Simoes, R; Zoranovic, T; Mitsiades, C; Penninger, JM; Simpson, KJ; Humbert, PO; Richardson, HE				Manent, J.; Banerjee, S.; de Matos Simoes, R.; Zoranovic, T.; Mitsiades, C.; Penninger, J. M.; Simpson, K. J.; Humbert, P. O.; Richardson, H. E.			Autophagy suppresses Ras-driven epithelial tumourigenesis by limiting the accumulation of reactive oxygen species	ONCOGENE			English	Article							CELL-DEATH; DROSOPHILA-MELANOGASTER; TUMOR PROGRESSION; GENETIC SCREEN; ONCOGENIC RAS; CANCER; PROMOTES; EXPRESSION; GROWTH; TRANSFORMATION	Activation of Ras signalling occurs in similar to 30% of human cancers; however, activated Ras alone is not sufficient for tumourigenesis. In a screen for tumour suppressors that cooperate with oncogenic Ras (Ras(V12)) in Drosophila, we identified genes involved in the autophagy pathway. Bioinformatic analysis of human tumours revealed that several core autophagy genes, including GABARAP, correlate with oncogenic KRAS mutations and poor prognosis in human pancreatic cancer, supporting a potential tumour-suppressive effect of the pathway in Ras-driven human cancers. In Drosophila, we demonstrate that blocking autophagy at any step of the pathway enhances Ras(V12)-driven epithelial tissue overgrowth via the accumulation of reactive oxygen species and activation of the Jun kinase stress response pathway. Blocking autophagy in Ras(V12) clones also results in non-cell-autonomous effects with autophagy, cell proliferation and caspase activation induced in adjacent wild-type cells. Our study has implications for understanding the interplay between perturbations in Ras signalling and autophagy in tumourigenesis, which might inform the development of novel therapeutics targeting Ras-driven cancers.	[Manent, J.; Richardson, H. E.] La Trobe Univ, Sch Mol Sci, La Trobe Inst Mol Sci, Cell Polar & Signaling Lab,Dept Biochem & Genet, Melbourne, Vic 3086, Australia; [Manent, J.; Banerjee, S.; Richardson, H. E.] Peter MacCallum Canc Ctr, Cell Cycle & Dev Lab, Melbourne, Vic, Australia; [Manent, J.; Banerjee, S.; Humbert, P. O.] Peter MacCallum Canc Ctr, Cell Cycle & Canc Genet Lab, Melbourne, Vic, Australia; [Manent, J.; Banerjee, S.; Simpson, K. J.] Peter MacCallum Canc Ctr, Victorian Ctr Funct Gen, Melbourne, Vic, Australia; [Manent, J.; Banerjee, S.; Simpson, K. J.; Humbert, P. O.; Richardson, H. E.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [de Matos Simoes, R.; Mitsiades, C.] Harvard Med Sch, Dept Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA; [Zoranovic, T.; Penninger, J. M.] Inst Mol Biotechnol, Vienna, Austria; [Humbert, P. O.; Richardson, H. E.] Univ Melbourne, Dept Biochem & Mol Biol, Melbourne, Vic, Australia; [Humbert, P. O.] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia; [Humbert, P. O.] La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem & Genet, Canc Biol Cell Polar & Tissue Architecture Lab, Melbourne, Vic, Australia; [Richardson, H. E.] Univ Melbourne, Dept Anat & Neurobiol, Melbourne, Vic, Australia; [Manent, J.] Monash Univ, Dept Anat & Dev Biol, Clayton, Vic, Australia; [Zoranovic, T.] Max Planck Inst Infect Biol, Berlin, Germany	La Trobe University; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); University of Melbourne; University of Melbourne; La Trobe University; University of Melbourne; Monash University; Max Planck Society	Richardson, HE (corresponding author), La Trobe Univ, Sch Mol Sci, La Trobe Inst Mol Sci, Cell Polar & Signaling Lab,Dept Biochem & Genet, Melbourne, Vic 3086, Australia.	h.richardson@latrobe.edu.au	Pryjda, Tamara/O-5714-2019; Penninger, Josef M/I-6860-2013; Humbert, Patrick O/L-4264-2016; Richardson, Helena E/A-8080-2013	Penninger, Josef M/0000-0002-8194-3777; Humbert, Patrick O/0000-0002-1366-6691; Richardson, Helena E/0000-0003-3852-4953; zoranovic, tamara/0000-0002-5369-6385; de Matos Simoes, Ricardo/0000-0002-1700-5276; Simpson, Kaylene/0000-0001-9136-1781; Manent, Jan/0000-0001-9152-5459	National Health and Medical Research Council (NHMRC) [1020525]; PeterMac Foundation; LIMS; La Trobe University; NHMRC [1020525]; Australian Postgraduate Research Award; Marie Curie Excellence grant; NHMRC	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); PeterMac Foundation; LIMS; La Trobe University; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Australian Postgraduate Research Award; Marie Curie Excellence grant(European Commission); NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	We thank Donna Denton, Sharad Kumar, Louise Cheng, Tor Erik Rusten, Lee Jun, Gabor Juhasz, Tom Neufeld, Stephen Gregory and Zeeshan Shaukat for reagents, and Tor Erik Rusten, Andreas Bergmann, Donna Denton, Sharad Kumar and Stephen Gregory for discussions. We thank Edwina McGlinn for critical reading of the manuscript. We are grateful to the Peter MacCallum Microscopy core and the LIMS Bioimaging facility for their help with imaging and analysis. We are grateful to OzDros and to Peter Burke for quarantine, shipment and maintenance of Drosophila stocks. The project was supported by grants from the National Health and Medical Research Council (NHMRC, no. 1020525) and from the PeterMac Foundation to HER, JMP, KJS and POH, and funds from LIMS and La Trobe University. JM was supported by an NHMRC grant (no. 1020525) and LIMS and La Trobe University, SB by a Australian Postgraduate Research Award and TZ by a Marie Curie Excellence grant. HER and POH are supported by fellowships of the (NHMRC) and funds from LIMS and La Trobe University.	Alves S, 2015, ONCOTARGET, V6, P30787, DOI 10.18632/oncotarget.5021; [Anonymous], MODELLING CANC DROSO; Avalos Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/603980; Belaid A, 2013, CANCER RES, V73, P4311, DOI 10.1158/0008-5472.CAN-12-4142; Bellot GL, 2013, MITOCHONDRION, V13, P155, DOI 10.1016/j.mito.2012.06.007; Brumby AM, 2005, NAT REV CANCER, V5, P626, DOI 10.1038/nrc1671; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Brumby AM, 2011, GENETICS, V188, P105, DOI 10.1534/genetics.111.127910; Byun JY, 2009, CARCINOGENESIS, V30, P1880, DOI 10.1093/carcin/bgp235; Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416; Cianfanelli V, 2015, NAT CELL BIOL, V17, P20, DOI 10.1038/ncb3072; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; Colombani J, 2012, SCIENCE, V336, P582, DOI 10.1126/science.1216689; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Denton D, 2012, CELL DEATH DIFFER, V19, P1299, DOI 10.1038/cdd.2012.43; Denton D, 2009, CURR BIOL, V19, P1741, DOI 10.1016/j.cub.2009.08.042; DiMauro T, 2010, CURR CANCER DRUG TAR, V10, P869, DOI 10.2174/156800910793357998; Doggett K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132987; Doggett K, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-57; Fernandez-Medarde Alberto, 2011, Genes Cancer, V2, P344, DOI 10.1177/1947601911411084; Fogarty CE, 2016, CURR BIOL, V26, P575, DOI 10.1016/j.cub.2015.12.064; Fuja TJ, 2004, CANCER RES, V64, P942, DOI 10.1158/0008-5472.CAN-03-2100; Furuta S, 2004, ONCOGENE, V23, P3898, DOI 10.1038/sj.onc.1207539; Galko MJ, 2004, PLOS BIOL, V2, P1114, DOI 10.1371/journal.pbio.0020239; Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784; Gargini R, 2016, ONCOL REP, V35, P3689, DOI 10.3892/or.2016.4699; Gonzalez C, 2013, NAT REV CANCER, V13, P172, DOI 10.1038/nrc3461; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Guruharsha KG, 2011, CELL, V147, P690, DOI 10.1016/j.cell.2011.08.047; Halfar K, 2001, DEVELOPMENT, V128, P1687; Hu YH, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-357; Hu YM, 2012, CELL RES, V22, P399, DOI 10.1038/cr.2011.145; Juhasz G, 2008, J CELL BIOL, V181, P655, DOI 10.1083/jcb.200712051; Karim FD, 1998, DEVELOPMENT, V125, P1; Karim FD, 1996, GENETICS, V143, P315; Katheder NS, 2017, NATURE, V541, P417, DOI 10.1038/nature20815; Khoo P, 2013, DIS MODEL MECH, V6, P661, DOI 10.1242/dmm.010066; Kim MJ, 2011, J BIOL CHEM, V286, P12924, DOI 10.1074/jbc.M110.138958; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lee TM, 2001, TRENDS NEUROSCI, V24, P251, DOI 10.1016/S0166-2236(00)01791-4; Leong GR, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-62; Li ML, 2016, BMC BIOL, V14, DOI 10.1186/s12915-016-0293-y; Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006; Liu ZY, 2014, J NEURO-ONCOL, V116, P465, DOI 10.1007/s11060-013-1325-x; Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Martinez-Lopez N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3799; Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107; Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Mauvezin C, 2014, METHODS, V68, P134, DOI 10.1016/j.ymeth.2014.03.014; Menut L, 2007, GENETICS, V177, P1667, DOI 10.1534/genetics.107.078360; Morelli E, 2014, AUTOPHAGY, V10, P2251, DOI 10.4161/15548627.2014.981913; Morgan MJ, 2014, AUTOPHAGY, V10, P1814, DOI 10.4161/auto.32135; Murrow L, 2013, ANNU REV PATHOL-MECH, V8, P105, DOI 10.1146/annurev-pathol-020712-163918; Nagy P, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003664; Nakamura M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6264; O'Farrell F, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001612; Ohsawa S, 2012, NATURE, V490, P547, DOI 10.1038/nature11452; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Perez E, 2015, ONCOGENE, V34, P3369, DOI 10.1038/onc.2014.285; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Qin WJ, 2015, ONCOTARGET, V6, P39839, DOI 10.18632/oncotarget.5674; Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056; Sacco E, 2012, EXPERT OPIN THER PAT, V22, P1263, DOI 10.1517/13543776.2012.728586; Santabarbara-Ruiz P, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005595; Schmukler E, 2014, ONCOTARGET, V5, P577, DOI 10.18632/oncotarget.1775; Shaukat Z, 2015, ONCOGENE, V34, P4044, DOI 10.1038/onc.2014.344; Su TT, 2015, AIMS GENET, V2, P54, DOI 10.3934/genet.2015.1.54; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Takats S, 2013, J CELL BIOL, V201, P531, DOI 10.1083/jcb.201211160; Tomiyama L, 2015, ONCOGENE, V34, P1141, DOI 10.1038/onc.2014.31; Wang YH, 2012, P NATL ACAD SCI USA, V109, P13325, DOI 10.1073/pnas.1120193109; Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011; White E, 2013, GENE DEV, V27, P2065, DOI 10.1101/gad.228122.113; White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262; Willecke M, 2011, ONCOGENE, V30, P4067, DOI 10.1038/onc.2011.125; Wong CH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009996; Wu H, 2009, MECH DEVELOP, V126, P624, DOI 10.1016/j.mod.2009.06.1082; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709; Zhou ZH, 2015, EXP CELL RES, V331, P399, DOI 10.1016/j.yexcr.2014.11.015	85	20	20	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2017	36	40					5576	5592		10.1038/onc.2017.175	http://dx.doi.org/10.1038/onc.2017.175			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI8ZW	28581519	Green Published, hybrid			2022-12-17	WOS:000412293600003
J	Batisse-Lignier, M; Sahut-Barnola, I; Tissier, F; Dumontet, T; Mathieu, M; Drelon, C; Pointud, JC; Damon-Soubeyrand, C; Marceau, G; Kemeny, JL; Bertherat, J; Tauveron, I; Val, P; Martinez, A; Lefrancois-Martinez, AM				Batisse-Lignier, M.; Sahut-Barnola, I.; Tissier, F.; Dumontet, T.; Mathieu, M.; Drelon, C.; Pointud, J-C; Damon-Soubeyrand, C.; Marceau, G.; Kemeny, J-L; Bertherat, J.; Tauveron, I.; Val, P.; Martinez, A.; Lefrancois-Martinez, A-M			P53/Rb inhibition induces metastatic adrenocortical carcinomas in a preclinical transgenic model	ONCOGENE			English	Article							BETA-CATENIN; GENOMIC CHARACTERIZATION; PROGNOSTIC ROLE; TUMORS; CANCER; TUMORIGENESIS; MUTATIONS; PATHWAYS; REVEALS; GROWTH	Adrenocortical carcinoma (ACC) is a rare cancer with poor prognosis. Pan-genomic analyses identified p53/Rb and WNT/beta-catenin signaling pathways as main contributors to the disease. However, isolated beta-catenin constitutive activation failed to induce malignant progression in mouse adrenocortical tumors. Therefore, there still was a need for a relevant animal model to study ACC pathogenesis and to test new therapeutic approaches. Here, we have developed a transgenic mice model with adrenocortical specific expression of SV40 large T-antigen (AdTAg mice), to test the oncogenic potential of p53/Rb inhibition in the adrenal gland. All AdTAg mice develop large adrenal carcinomas that eventually metastasize to the liver and lungs, resulting in decreased overall survival. Consistent with ACC in patients, adrenal tumors in AdTAg mice autonomously produce large amounts of glucocorticoids and spontaneously activate WNT/beta-catenin signaling pathway during malignant progression. We show that this activation is associated with downregulation of secreted frizzled related proteins (Sfrp) and Znrf3 that act as inhibitors of the WNT signaling. We also show that mTORC1 pathway activation is an early event during neoplasia expansion and further demonstrate that mTORC1 pathway is activated in ACC patients. Preclinical inhibition of mTORC1 activity induces a marked reduction in tumor size, associated with induction of apoptosis and inhibition of proliferation that results in normalization of corticosterone plasma levels in AdTAg mice. Altogether, these data establish AdTAg mice as the first preclinical model for metastatic ACC.	[Batisse-Lignier, M.; Sahut-Barnola, I.; Dumontet, T.; Mathieu, M.; Drelon, C.; Pointud, J-C; Damon-Soubeyrand, C.; Tauveron, I.; Val, P.; Martinez, A.; Lefrancois-Martinez, A-M] Univ Clermont Auvergne, CNRS UMR6293, INSERM U1103, GReD, Campus Univ Cezeaux,10 Ave Blaise Pascal, F-63178 Aubiere, France; [Batisse-Lignier, M.; Tauveron, I.] Ctr Hosp Univ, Endocrinol Diabetol & Metab Dis Dept, Sch Med, Clermont Ferrand, France; [Tissier, F.; Bertherat, J.] Hop Cochin, Assistance Publ Hop Paris, Reference Ctr Rare Adrenal Dis, Dept Pathol, Paris, France; [Tissier, F.] Univ Paris 06, Hop Pitie Salpetriere, Dept Pathol, Paris, France; [Marceau, G.] Ctr Hosp Univ, Dept Biochem & Mol Biol, Clermont Ferrand, France; [Kemeny, J-L] Clermont Ferrand Hosp, Dept Anatomopathol, Clermont Ferrand, France; [Bertherat, J.] Univ Paris 05, CNRS UMR8104, INSERM U1016, Inst Cochin, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Clermont Auvergne (UCA); CHU Clermont Ferrand; Universite de Franche-Comte; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Clermont Ferrand; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Martinez, A; Lefrancois-Martinez, AM (corresponding author), Univ Clermont Auvergne, CNRS UMR6293, INSERM U1103, GReD, Campus Univ Cezeaux,10 Ave Blaise Pascal, F-63178 Aubiere, France.	antoine.martinez@uca.fr; a-marie.lefrancois-martinez@uca.fr	Dumontet, Typhanie/AAA-3605-2022	BERTHERAT, Jerome/0000-0003-2551-3008; MARCEAU, GEOFFROY/0000-0003-4713-7162	Universite Blaise Pascal; Universite d'Auvergne; CNRS; INSERM; Agence National de la Recherche [ANR-14-CE12-0007]; Fondation ARC pour la Recherche sur le Cancer [PJA 20141201894]; La Fondation de France	Universite Blaise Pascal; Universite d'Auvergne; CNRS(Centre National de la Recherche Scientifique (CNRS)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Agence National de la Recherche(French National Research Agency (ANR)); Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); La Fondation de France(Fondation de France)	We thank Lucile Mounier for technical assistance and Sandrine Plantade, Khirredine Ouchen and Philippe Mazuel for animal care. Tissue analyses were performed at Anipath Clermont core facility. This work was supported by Universite Blaise Pascal, Universite d'Auvergne, CNRS, INSERM, Agence National de la Recherche (grant ANR-14-CE12-0007), grants from Fondation ARC pour la Recherche sur le Cancer (PJA 20141201894) and from La Fondation de France. We thank the Cochin tumor bank and COMETE (COrtico MEdullo Tumeurs Endocrines) network for the provision of ACA and ACC tissue samples.	Abiven G, 2006, J CLIN ENDOCR METAB, V91, P2650, DOI 10.1210/jc.2005-2730; Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Allolio B, 2006, J CLIN ENDOCR METAB, V91, P2027, DOI 10.1210/jc.2005-2639; Assie G, 2014, NAT GENET, V46, P607, DOI 10.1038/ng.2953; Assie G, 2010, TRENDS ENDOCRIN MET, V21, P325, DOI 10.1016/j.tem.2009.12.009; Baudin E, 2015, ENDOCRIN METAB CLIN, V44, P411, DOI 10.1016/j.ecl.2015.03.001; Bernichtein S, 2008, ENDOCRINOLOGY, V149, P651, DOI 10.1210/en.2007-0925; Berruti A, 2014, EUR UROL, V65, P832, DOI 10.1016/j.eururo.2013.11.006; Berthon A, 2010, HUM MOL GENET, V19, P1561, DOI 10.1093/hmg/ddq029; Beuschlein F, 2015, J CLIN ENDOCR METAB, V100, P841, DOI 10.1210/jc.2014-3182; Bocchetta M, 2008, CANCER RES, V68, P1022, DOI 10.1158/0008-5472.CAN-07-5203; De Martino MC, 2012, ENDOCR-RELAT CANCER, V19, P351, DOI 10.1530/ERC-11-0270; de Reynies A, 2009, J CLIN ONCOL, V27, P1108, DOI 10.1200/JCO.2008.18.5678; Doghman M, 2012, MOL CELL ENDOCRINOL, V364, P101, DOI 10.1016/j.mce.2012.08.014; Doghman M, 2010, CANCER RES, V70, P4666, DOI 10.1158/0008-5472.CAN-09-3970; Drelon C, 2016, HUM MOL GENET, V25, P2789, DOI 10.1093/hmg/ddw136; Drelon C, 2013, J CLIN ENDOCR METAB, V98, P505, DOI 10.1210/jc.2012-3310; Drelon C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044171; Else T, 2014, ENDOCR REV, V35, P282, DOI 10.1210/er.2013-1029; Faillot S, 2016, EUR J ENDOCRINOL, V174, pR249, DOI 10.1530/EJE-15-1118; Fassnacht M, 2015, LANCET ONCOL, V16, P426, DOI 10.1016/S1470-2045(15)70081-1; Fassnacht M, 2012, NEW ENGL J MED, V366, P2189, DOI 10.1056/NEJMoa1200966; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Feng ZH, 2010, TRENDS CELL BIOL, V20, P427, DOI 10.1016/j.tcb.2010.03.004; Fraenkel M, 2013, ENDOCRINE, V44, P187, DOI 10.1007/s12020-013-9878-1; Gangadhar TC, 2011, CLIN CANCER RES, V17, P1956, DOI 10.1158/1078-0432.CCR-10-2061; Gaujoux S, 2011, CLIN CANCER RES, V17, P328, DOI 10.1158/1078-0432.CCR-10-2006; Gibb N, 2013, DEVELOPMENT, V140, P1537, DOI 10.1242/dev.088047; Giordano TJ, 2009, CLIN CANCER RES, V15, P668, DOI 10.1158/1078-0432.CCR-08-1067; Heaton JH, 2012, AM J PATHOL, V181, P1017, DOI 10.1016/j.ajpath.2012.05.026; Heikkila M, 2002, ENDOCRINOLOGY, V143, P4358, DOI 10.1210/en.2002-220275; Heinze B, 2014, EUR J ENDOCRINOL, V170, P707, DOI 10.1530/EJE-13-0788; Hershkovitz L, 2007, ENDOCRINOLOGY, V148, P976, DOI 10.1210/en.2006-1100; Hisada M, 1998, JNCI-J NATL CANCER I, V90, P606, DOI 10.1093/jnci/90.8.606; Juhlin CC, 2015, J CLIN ENDOCR METAB, V100, pE493, DOI 10.1210/jc.2014-3282; Kananen K, 1996, MOL ENDOCRINOL, V10, P1667, DOI 10.1210/me.10.12.1667; Lambert-Langlais S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007309; Latronico AC, 2001, J CLIN ENDOCR METAB, V86, P4970, DOI 10.1210/jc.86.10.4970; Libe R, 2005, EUR J ENDOCRINOL, V153, P477, DOI 10.1530/eje.1.02004; Libe R, 2007, CLIN CANCER RES, V13, P844, DOI 10.1158/1078-0432.CCR-06-2085; Martino MCD, 2014, ENDOCR-RELAT CANCER, V21, P601; Naing A, 2011, CLIN CANCER RES, V17, P6052, DOI 10.1158/1078-0432.CCR-10-2979; Paglin S, 2006, AUTOPHAGY, V2, P291, DOI 10.4161/auto.2835; Papotti Mauro, 2011, Hormones & Cancer, V2, P333, DOI 10.1007/s12672-011-0088-0; Ragazzon B, 2006, ENDOCRINOLOGY, V147, P1805, DOI 10.1210/en.2005-1279; Ragazzon B, 2014, EUR J ENDOCRINOL, V170, P385, DOI 10.1530/EJE-13-0778; Ragazzon B, 2010, CANCER RES, V70, P8276, DOI 10.1158/0008-5472.CAN-10-2014; REINCKE M, 1994, J CLIN ENDOCR METAB, V78, P790, DOI 10.1210/jc.78.3.790; Ribeiro RC, 2001, P NATL ACAD SCI USA, V98, P9330, DOI 10.1073/pnas.161479898; Romero DG, 2007, ENDOCRINOLOGY, V148, P2644, DOI 10.1210/en.2006-1509; Sun Y, 2016, ONCOGENE, V35, P4321, DOI 10.1038/onc.2015.494; Surana R, 2014, BBA-REV CANCER, V1845, P53, DOI 10.1016/j.bbcan.2013.11.004; Tissier F, 2004, EUR J ENDOCRINOL, V150, P809, DOI 10.1530/eje.0.1500809; Tissier F, 2012, AM J SURG PATHOL, V36, P1194, DOI 10.1097/PAS.0b013e31825a6308; Yamamura S, 2010, MOL CANCER THER, V9, P1680, DOI 10.1158/1535-7163.MCT-10-0012; Zheng SY, 2016, CANCER CELL, V29, P723, DOI 10.1016/j.ccell.2016.04.002	56	20	20	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4445	4456		10.1038/onc.2017.54	http://dx.doi.org/10.1038/onc.2017.54			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368424				2022-12-17	WOS:000406806000007
J	Zhang, W; Hong, R; Xue, L; Ou, Y; Liu, X; Zhao, Z; Xiao, W; Dong, D; Dong, L; Fu, M; Ma, L; Lu, N; Chen, H; Song, Y; Zhan, Q				Zhang, W.; Hong, R.; Xue, L.; Ou, Y.; Liu, X.; Zhao, Z.; Xiao, W.; Dong, D.; Dong, L.; Fu, M.; Ma, L.; Lu, N.; Chen, H.; Song, Y.; Zhan, Q.			Piccolo mediates EGFR signaling and acts as a prognostic biomarker in esophageal squamous cell carcinoma	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; PRESYNAPTIC ACTIVE ZONES; NEUROTRANSMITTER RELEASE; EPITHELIAL-CELLS; CANCER GENOMICS; PROTEIN; BASSOON; OVEREXPRESSION; MUTATIONS; SYNAPSE	The presynaptic cytomatrix protein Piccolo, encoded by PCLO, is frequently mutated and amplified in esophageal squamous cell carcinoma (ESCC), but its exact roles in ESCC remain unclear. Here we report that Piccolo expression correlates significantly with clinical stage, patient survival and tumor embolus. Functional studies demonstrate that PCLO knockdown remarkably attenuates ESCC malignancy in vitro and in vivo, and ectopic EGFR expression partially compensates for Piccolo loss. PCLO knockdown promotes ubiquitination and degradation of EGFR, which is associated with the negative regulatory effect of Piccolo on E3 ligase Siah1. An anti-Piccolo monoclonal antibody inhibited tumor proliferation in a mouse model of ESCC. These results demonstrate that Piccolo contributes to tumor aggressiveness in ESCC, likely by stabilizing EGFR and promoting EGFR-dependent signaling. Our results further suggest that Piccolo may represent a novel prognostic biomarker and therapeutic target for patients with ESCC.	[Zhang, W.; Ou, Y.; Liu, X.; Zhao, Z.; Xiao, W.; Dong, D.; Dong, L.; Fu, M.; Ma, L.; Song, Y.; Zhan, Q.] Chinese Acad Med Sci, Canc Inst & Canc Hosp, State Key Lab Mol Oncol, Beijing 100021, Peoples R China; [Zhang, W.; Liu, X.; Zhao, Z.; Xiao, W.; Dong, D.; Dong, L.; Fu, M.; Ma, L.; Song, Y.; Zhan, Q.] Peking Union Med Coll, Beijing 100021, Peoples R China; [Zhang, W.; Zhan, Q.] Sichuan Univ, West China Hosp, Collaborat Innovat Ctr Biotherapy, Sichuan, Peoples R China; [Zhang, W.; Chen, H.] Guangdong Koheala Precis Med Inst, Guangzhou, Guangdong, Peoples R China; [Hong, R.] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Xue, L.; Lu, N.] Peking Union Med Coll, Canc Inst & Canc Hosp, Dept Pathol, Beijing, Peoples R China; [Xue, L.; Lu, N.] Chinese Acad Med Sci, Beijing, Peoples R China; [Ou, Y.] Capital Med Univ, Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China; [Liu, X.] Dalian Med Univ, Canc Ctr, Inst Canc Stem Cell, Dalian, Peoples R China; [Zhan, Q.] Peking Univ Canc Hosp & Inst, Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Sichuan University; State Key Lab Oncology South China; Sun Yat Sen University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Capital Medical University; Dalian Medical University; Peking University	Zhan, Q (corresponding author), Chinese Acad Med Sci, Canc Inst & Canc Hosp, State Key Lab Mol Oncol, Beijing 100021, Peoples R China.; Zhan, Q (corresponding author), Peking Union Med Coll, Beijing 100021, Peoples R China.	zhanqimin@bjmu.edu.cn	Dong, Dezuo/EUE-3308-2022		National 973 Program [2015CB553904]; National Natural Fund of China [81230047, 81321091]	National 973 Program(National Basic Research Program of China); National Natural Fund of China	We appreciated Jie Chen and Tian Lan for revising this manuscript and offering constructive advices. This work is supported by the National 973 Program (2015CB553904) and National Natural Fund of China (81230047 and 81321091).	Abedi-Ardekani B, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-602; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Cao HH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106007; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cremona O, 2001, J CELL SCI, V114, P1041; Fenster SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1; Fujimoto A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7120; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gao ZH, 2014, ONCOL LETT, V7, P1118, DOI 10.3892/ol.2014.1881; Garcia J, 2004, NAT STRUCT MOL BIOL, V11, P45, DOI 10.1038/nsmb707; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Gerber SH, 2001, EMBO J, V20, P1605, DOI 10.1093/emboj/20.7.1605; Hanawa M, 2006, INT J CANCER, V118, P1173, DOI 10.1002/ijc.21454; Kalabis J, 2012, NAT PROTOC, V7, P235, DOI 10.1038/nprot.2011.437; Lehman HL, 2015, AM J PATHOL, V185, P240, DOI 10.1016/j.ajpath.2014.09.008; Limbach C, 2011, P NATL ACAD SCI USA, V108, pE392, DOI 10.1073/pnas.1101707108; Lin DC, 2014, NAT GENET, V46, P467, DOI 10.1038/ng.2935; Lohr JG, 2012, P NATL ACAD SCI USA, V109, P3879, DOI 10.1073/pnas.1121343109; Navarini D, 2012, GASTROENT RES PRACT, V2012; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Sander JD, 2014, NAT BIOTECHNOL, V32, P347, DOI 10.1038/nbt.2842; Shang L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111045; Shen ZY, 2002, WORLD J GASTROENTERO, V8, P357; Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Sunpaweravong P, 2005, J CANCER RES CLIN, V131, P111, DOI 10.1007/s00432-004-0610-7; Takao-Rikitsu E, 2004, J CELL BIOL, V164, P301, DOI 10.1083/jcb.200307101; Waites CL, 2013, EMBO J, V32, P954, DOI 10.1038/emboj.2013.27; Wang QF, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-278; Wang XL, 1999, J CELL BIOL, V147, P151, DOI 10.1083/jcb.147.1.151; Xue LY, 2012, MODERN PATHOL, V25, P1364, DOI 10.1038/modpathol.2012.89; Yang F, 2013, J BIOL CHEM, V288, P6552, DOI 10.1074/jbc.M112.418335; Yang YL, 2012, CHINESE MED J-PEKING, V125, P450, DOI 10.3760/cma.j.issn.0366-6999.2012.03.009; Zhai RG, 2001, NEURON, V29, P131, DOI 10.1016/S0896-6273(01)00185-4; Zhang H, 2006, CANCER GENET CYTOGEN, V165, P25, DOI 10.1016/j.cancergencyto.2005.07.016; Zhang YN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100854	39	20	20	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2017	36	27					3890	3902		10.1038/onc.2017.15	http://dx.doi.org/10.1038/onc.2017.15			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EZ6SM	28263981				2022-12-17	WOS:000404848200009
J	Tsuruta-Kishino, T; Koya, J; Kataoka, K; Narukawa, K; Sumitomo, Y; Kobayashi, H; Sato, T; Kurokawa, M				Tsuruta-Kishino, T.; Koya, J.; Kataoka, K.; Narukawa, K.; Sumitomo, Y.; Kobayashi, H.; Sato, T.; Kurokawa, M.			Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; TYROSINE KINASE JAK2; MYELOPROLIFERATIVE NEOPLASMS; GENOMIC INSTABILITY; ACTIVATING MUTATION; PROGENITOR CELLS; GENETIC-ANALYSIS; MOUSE MODEL; DNA-DAMAGE	As leukemic transformation of myeloproliferative neoplasms (MPNs) worsens the clinical outcome, reducing the inherent risk of the critical event in MPN cases could be beneficial. Among genetic alterations concerning the transformation, the frequent one is TP53 mutation. Here we show that retroviral overexpression of Jak2 V617F mutant into wild-type p53 murine bone marrow cells induced polycythemia vera (PV) in the recipient mice, whereas Jak2 V617F-transduced p53-null mice developed lethal leukemia after the preceding PV phase. The leukemic mice had severe anemia, hepatosplenomegaly, pulmonary hemorrhage and expansion of dysplastic erythroid progenitors. Primitive leukemia cells (c-kit+ Sca1+ Lin-(KSL) and CD34-CD16/32c- kit+ Sca1-Lin-(megakaryocyte-erythroid progenitor; MEP)) and erythroid progenitors (CD71+) from Jak2 V617F-transduced p53-null leukemic mice had leukemia-initiating capacity, however, myeloid differentiated populations (Mac-1+) could not recapitulate the disease. Interestingly, recipients transplanted with CD71+ cells rapidly developed erythroid leukemia, which was in sharp contrast to leukemic KSL cells to cause lethal leukemia after the polycythemic state. The leukemic CD71+ cells were more sensitive to INCB18424, a potent JAK inhibitor, than KSL cells. p53 restoration could ameliorate Jak2 V617F-transduced p53-null erythroleukemia. Taken together, our results show that p53 loss is sufficient for inducing leukemic transformation in Jak2 V617Fpositive MPN.	[Tsuruta-Kishino, T.; Koya, J.; Kataoka, K.; Narukawa, K.; Sumitomo, Y.; Kobayashi, H.; Sato, T.; Kurokawa, M.] Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan; [Sumitomo, Y.] Kyowa Hakko Kirin Co, Oncol Res Labs, Machida, Tokyo, Japan; [Sato, T.] Univ Tokyo Hosp, Dept Transfus Med, Bunkyo Ku, Tokyo, Japan; [Kurokawa, M.] Univ Tokyo Hosp, Dept Cell Therapy & Transplantat, Bunkyo Ku, Tokyo, Japan	University of Tokyo; Kyowa Kirin Ltd; University of Tokyo; University of Tokyo	Kurokawa, M (corresponding author), Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kurokawa-tky@umin.ac.jp	Kataoka, Keisuke/AAS-2546-2020	Kataoka, Keisuke/0000-0002-8263-9902; Koya, Junji/0000-0002-0605-1226; Sato, Tomohiko/0000-0002-8244-075X	Ministry of Education, Culture, Sports, Science and Technology of Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank T Kitamura for Plat-E packaging cells; H Nakauchi and M Onodera for pGCDNsam-IRES-EGFP and Kusabira Orange retroviral vector; S Aizawa for p53 knockout mice (RIKEN BRC, Acc. no. CDB 0001K); A Berns for p53 conditional knockout mice; J Takeda for Mx1-Cre transgenic mice; F Ueki, R Takizawa-Toyama and Y Oikawa for expert for technical assistance. This study was supported by the Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Abdel-Wahab O, 2010, CANCER RES, V70, P447, DOI 10.1158/0008-5472.CAN-09-3783; Akala OO, 2008, NATURE, V453, P228, DOI 10.1038/nature06869; [Anonymous], 2015, JAKAVI TABLETS 5 MG; Barlow JL, 2010, NAT MED, V16, P59, DOI 10.1038/nm.2063; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Beer PA, 2010, BLOOD, V115, P2891, DOI 10.1182/blood-2009-08-236596; Campbell PJ, 2006, NEW ENGL J MED, V355, P2452, DOI 10.1056/NEJMra063728; Chen JC, 2008, EXP HEMATOL, V36, P1236, DOI 10.1016/j.exphem.2008.04.012; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Santos Leonardo Caires dos, 2011, Rev. Bras. Hematol. Hemoter., V33, P417, DOI 10.5581/1516-8484.20110116; Gibbs KD, 2012, CELL STEM CELL, V10, P210, DOI 10.1016/j.stem.2012.01.004; Goardon N, 2011, CANCER CELL, V19, P138, DOI 10.1016/j.ccr.2010.12.012; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Haase D, 2007, BLOOD, V110, P4385, DOI 10.1182/blood-2007-03-082404; Harrison C, 2012, NEW ENGL J MED, V366, P787, DOI 10.1056/NEJMoa1110556; Harutyunyan A, 2011, NEW ENGL J MED, V364, P488, DOI 10.1056/NEJMc1012718; Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Kennedy JA, 2013, BLOOD, V121, P2725, DOI 10.1182/blood-2012-10-464248; Klampfl T, 2013, NEW ENGL J MED, V369, P2379, DOI 10.1056/NEJMoa1311347; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Kumar C Chandra, 2011, Genes Cancer, V2, P95, DOI 10.1177/1947601911408076; Lacout C, 2006, BLOOD, V108, P1652, DOI 10.1182/blood-2006-02-002030; Lee HJ, 2013, CLIN CANCER RES, V19, P327, DOI 10.1158/1078-0432.CCR-12-2087; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Liu Y, 2009, CELL STEM CELL, V4, P37, DOI 10.1016/j.stem.2008.11.006; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Marino S, 2000, GENE DEV, V14, P994; Marty C, 2010, BLOOD, V116, P783, DOI 10.1182/blood-2009-12-257063; Mullally A, 2012, BLOOD, V120, P166, DOI 10.1182/blood-2012-01-402396; Mullally A, 2010, CANCER CELL, V17, P584, DOI 10.1016/j.ccr.2010.05.015; Nakatake M, 2012, ONCOGENE, V31, P1323, DOI 10.1038/onc.2011.313; Nam C, 2010, HISTOL HISTOPATHOL, V25, P485, DOI 10.14670/HH-25.485; Nangalia J, 2013, NEW ENGL J MED, V369, P2391, DOI 10.1056/NEJMoa1312542; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Pant V, 2012, BLOOD, V120, P5118, DOI 10.1182/blood-2012-05-356014; Pei SS, 2012, BEST PRACT RES CL HA, V25, P415, DOI 10.1016/j.beha.2012.10.003; Peller S, 2003, HUM MUTAT, V21, P277, DOI 10.1002/humu.10190; Pellicano F, 2014, STEM CELLS, V32, P1373, DOI 10.1002/stem.1678; Pikman Y, 2006, PLOS MED, V3, P1140, DOI 10.1371/journal.pmed.0030270; Rampal R, 2014, P NATL ACAD SCI USA, V111, pE5401, DOI 10.1073/pnas.1407792111; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Saito Y, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000349; Sarry JE, 2011, J CLIN INVEST, V121, P384, DOI 10.1172/JCI41495; Shimabe M, 2009, ONCOGENE, V28, P4364, DOI 10.1038/onc.2009.288; Shin DM, 2001, CANCER EPIDEM BIOMAR, V10, P603; Tefferi A, 2012, BLOOD, V119, P2721, DOI 10.1182/blood-2011-11-395228; TeKippe M, 2003, EXP HEMATOL, V31, P521, DOI 10.1016/S0301-472X(03)00072-9; TSUKADA T, 1993, ONCOGENE, V8, P3313; Verstovsek S, 2012, NEW ENGL J MED, V366, P799, DOI 10.1056/NEJMoa1110557; Wagner K, 2006, P NATL ACAD SCI USA, V103, P6338, DOI 10.1073/pnas.0508143103; Wernig G, 2006, BLOOD, V107, P4274, DOI 10.1182/blood-2005-12-4824; Xu HM, 2012, BLOOD, V120, P3089, DOI 10.1182/blood-2012-01-405332; Zhang SJ, 2012, BLOOD, V119, P4480, DOI 10.1182/blood-2011-11-390252; Zhao WK, 2012, EXP HEMATOL ONCOL, V1, DOI 10.1186/2162-3619-1-15; Zhao Z, 2010, GENE DEV, V24, P1389, DOI 10.1101/gad.1940710	60	20	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3300	3311		10.1038/onc.2016.478	http://dx.doi.org/10.1038/onc.2016.478			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	28068330				2022-12-17	WOS:000402869800009
J	Huang, PH; Lu, PJ; Ding, LY; Chu, PC; Hsu, WY; Chen, CS; Tsao, CC; Chen, BH; Lee, CT; Shan, YS; Chen, CS				Huang, P-H; Lu, P-J; Ding, L-Y; Chu, P-C; Hsu, W-Y; Chen, C-S; Tsao, C-C; Chen, B-H; Lee, C-T; Shan, Y-S; Chen, C-S			TGF beta promotes mesenchymal phenotype of pancreatic cancer cells, in part, through epigenetic activation of VAV1	ONCOGENE			English	Article							NUCLEOTIDE EXCHANGE ACTIVITY; GROWTH-FACTOR-BETA; TUMOR-MICROENVIRONMENT; PROTOONCOGENE PRODUCT; PROSTATE-CANCER; LUNG-CANCER; EXPRESSION; METHYLATION; PROTEIN; ADENOCARCINOMA	The highly homeostasis-resistant nature of cancer cells leads to their escape from treatment and to liver metastasis, which in turn makes pancreatic ductal adenocarcinoma (PDAC) difficult to treat, especially the squamous/epithelial-to-mesenchymal transition (EMT)-like subtype. As the molecular mechanisms underlying tumour heterogeneity remain elusive, we investigated whether epigenetic regulation might explain inter-individual differences in the progression of specific subtypes. DNA methylation profiling performed on cancer tissues prior to chemo/radiotherapy identified one hypermethylated CpG site (CpG6882469) in the VAV1 gene body that was correlated with demethylation of two promoter CpGs (CpG6772370/CpG6772811) in both PDAC and peripheral blood. Transforming growth factor beta treatment induced gene-body hypermethylation, dissociation of DNMT1 from the promoter, and VAV1 expression via SMAD4 and mutant Kras(G12D). Pharmacological inhibition of TGF beta-VAV1 signalling decreased the squamous/EMT-like cancer cells, promoted nuclear VAV1 localization, and enhanced the efficacy of gemcitabine in prolonging the survival of (KPC)-C-fl/fl mice. Together, the three VAV1 CpGs serve as biomarkers for prognosis and early detection, and the TGF beta-VAV1 axis represents a therapeutic target.	[Huang, P-H; Ding, L-Y; Hsu, W-Y; Chen, C-S; Chen, B-H] Natl Cheng Kung Univ, Dept Biochem & Mol Biol, Coll Med, Tainan, Taiwan; [Huang, P-H; Lu, P-J; Ding, L-Y; Chu, P-C; Chen, C-S; Shan, Y-S; Chen, C-S] Natl Cheng Kung Univ, Inst Basic Med Sci, Coll Med, Tainan, Taiwan; [Lu, P-J; Tsao, C-C; Shan, Y-S] Natl Cheng Kung Univ, Inst Clin Med, Coll Med, 1 Univ Rd, Tainan 701, Taiwan; [Chu, P-C; Chen, C-S] Acad Sinica, Inst Biol Chem, 128,Acad Rd Sect 2, Taipei 115, Taiwan; [Lee, C-T] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Pathol, Tainan, Taiwan; [Shan, Y-S] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Surg, Tainan, Taiwan; [Chen, C-S] Ohio State Univ, Coll Pharm, Div Med Chem & Pharmacognosy, 500 W 12Th Ave, Columbus, OH 43210 USA	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; Academia Sinica - Taiwan; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital; University System of Ohio; Ohio State University	Shan, YS (corresponding author), Natl Cheng Kung Univ, Inst Clin Med, Coll Med, 1 Univ Rd, Tainan 701, Taiwan.; Chen, CS (corresponding author), Acad Sinica, Inst Biol Chem, 128,Acad Rd Sect 2, Taipei 115, Taiwan.	ysshan@mail.ncku.edu.tw; chencs@gate.sinica.edu.tw			Bi-institutional Collaborative Pancreatic Cancer Research grant from the College of Medicine of National Cheng Kung University; Ministry of Science and Technology, Taiwan [MOST102-2320-B-006-050, MOST104-2320-B-006-028-]; Ministry of Health and Welfare, Taiwan [MOHW104-TDU-B-211-124-003]; Team of Excellent Research Program of the Ministry of Science and Technology, Taiwan [MOST 105-2321-B-001-064]	Bi-institutional Collaborative Pancreatic Cancer Research grant from the College of Medicine of National Cheng Kung University; Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); Ministry of Health and Welfare, Taiwan; Team of Excellent Research Program of the Ministry of Science and Technology, Taiwan	The authors acknowledge the assistance of Yi-Chen Chen, Pei-Rong Gu, and Hui-Ling Tung, as well as assistance from the following core facilities: the Clinical Medicine Research Center of National Cheng Kung University Hospital, the Animal Center of National Cheng Kung University, and the National Center for Genome Medicine (technical/bioinformatics). The authors would like to thank Drs Yi-Chuang Liao and Po-Min Chiang for pathological consultations and Dr Cindy Lee for manuscript editing. This work is supported by the Bi-institutional Collaborative Pancreatic Cancer Research grant from the College of Medicine of National Cheng Kung University to PJL and CSC; and grants MOST102-2320-B-006-050 and MOST104-2320-B-006-028- from the Ministry of Science and Technology, Taiwan, to PHH; MOHW104-TDU-B-211-124-003 from the Ministry of Health and Welfare, Taiwan, to YSS; and MOST 105-2321-B-001-064 from the Team of Excellent Research Program of the Ministry of Science and Technology, Taiwan, to CSC.	Achyut BR, 2011, GASTROENTEROLOGY, V141, P1167, DOI 10.1053/j.gastro.2011.07.048; Bai LY, 2013, BIOCHEM PHARMACOL, V86, P1430, DOI 10.1016/j.bcp.2013.09.002; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Bertagnolo V, 2005, EXP CELL RES, V306, P56, DOI 10.1016/j.yexcr.2004.12.001; Brugnoli F, 2010, EXP CELL RES, V316, P38, DOI 10.1016/j.yexcr.2009.09.004; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; Collazo J, 2014, CANCER RES, V74, P2362, DOI 10.1158/0008-5472.CAN-13-3058; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Dong ZJ, 2012, IMMUNITY, V36, P974, DOI 10.1016/j.immuni.2012.03.023; Ebert MPA, 2002, BRIT J CANCER, V86, P257, DOI 10.1038/sj/bjc/6600031; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Fernandez-Zapico ME, 2005, CANCER CELL, V7, P39, DOI 10.1016/j.ccr.2004.11.024; Gaspar NJ, 2007, MOL PHARMACOL, V72, P152, DOI 10.1124/mol.106.029025; Gore AJ, 2014, J CLIN INVEST, V124, P338, DOI 10.1172/JCI71526; Grassilli S, 2014, ONCOTARGET, V5, P4320, DOI 10.18632/oncotarget.2011; Grimmer MR, 2014, EPIGENOMICS-UK, V6, P493, DOI [10.2217/EPI.14.30, 10.2217/epi.14.30]; Gunawan M, 2015, NAT IMMUNOL, V16, P505, DOI 10.1038/ni.3125; Hezel AF, 2012, CANCER RES, V72, P4840, DOI 10.1158/0008-5472.CAN-12-0634; Hou YC, 2014, CANCER-AM CANCER SOC, V120, P2766, DOI 10.1002/cncr.28774; Houlard M, 2005, ONCOGENE, V24, P28, DOI 10.1038/sj.onc.1208043; Houlard M, 2002, J EXP MED, V195, P1115, DOI 10.1084/jem.20011701; Huang PH, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003816; Huang PH, 2011, MOL PHARMACOL, V79, P197, DOI 10.1124/mol.110.067702; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Kataoka K, 2015, NAT GENET, V47, P1304, DOI 10.1038/ng.3415; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Katzav S, 2015, ONCOTARGET, V6, P28731, DOI 10.18632/oncotarget.5086; Krohn A, 2012, AM J PATHOL, V181, P401, DOI 10.1016/j.ajpath.2012.04.026; Ksionda O, 2012, J CELL SCI, V125, P5302, DOI 10.1242/jcs.105148; Li RM, 2009, CANCER BIOL THER, V8, P1402, DOI 10.4161/cbt.8.14.8882; Lindsey JC, 2015, ONCOGENE, V34, P4746, DOI 10.1038/onc.2014.405; Garcia JL, 2012, J NEURO-ONCOL, V110, P69, DOI 10.1007/s11060-012-0936-y; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; Miletic AV, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006599; Nakajima S, 2004, CLIN CANCER RES, V10, P4125, DOI 10.1158/1078-0432.CCR-0578-03; Nolz JC, 2005, TRENDS CELL BIOL, V15, P514, DOI 10.1016/j.tcb.2005.08.003; Ostapoff KT, 2014, CANCER RES, V74, P4996, DOI 10.1158/0008-5472.CAN-13-1807; Qi Y, 2015, AM J CANCER RES, V5, P2491; Razanadrakoto L, 2015, ONCOTARGET, V6, P2524, DOI 10.18632/oncotarget.2629; Razidlo GL, 2015, CANCER RES, V75, P2907, DOI 10.1158/0008-5472.CAN-14-3103; Razidlo GL, 2013, DEV CELL, V24, P573, DOI 10.1016/j.devcel.2013.02.010; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Saveliev A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000420; Sebban S, 2014, ONCOTARGET, V5, P9214, DOI 10.18632/oncotarget.2400; Su I, 2005, CELL, V121, P425, DOI 10.1016/j.cell.2005.02.029; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thillainadesan G, 2012, MOL CELL, V46, P636, DOI 10.1016/j.molcel.2012.03.027; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Vidakovic AT, 2015, CELL REP, V13, P2480, DOI 10.1016/j.celrep.2015.11.040; Yang XJ, 2014, CANCER CELL, V26, P577, DOI 10.1016/j.ccr.2014.07.028	51	20	20	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2017	36	16					2202	2214		10.1038/onc.2016.378	http://dx.doi.org/10.1038/onc.2016.378			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DM	27893715				2022-12-17	WOS:000399782700002
J	Sizemore, GM; Balakrishnan, S; Hammer, AM; Thies, KA; Trimboli, AJ; Wallace, JA; Sizemore, ST; Kladney, RD; Woelke, SA; Yu, L; Fernandez, SA; Chakravarti, A; Leone, G; Ostrowski, MC				Sizemore, G. M.; Balakrishnan, S.; Hammer, A. M.; Thies, K. A.; Trimboli, A. J.; Wallace, J. A.; Sizemore, S. T.; Kladney, R. D.; Woelke, S. A.; Yu, L.; Fernandez, S. A.; Chakravarti, A.; Leone, G.; Ostrowski, M. C.			Stromal PTEN inhibits the expansion of mammary epithelial stem cells through Jagged-1	ONCOGENE			English	Article							TUMOR-INITIATING CELLS; BREAST-CANCER; STEM/PROGENITOR CELLS; GLAND DEVELOPMENT; GENE-EXPRESSION; TRANSGENIC MICE; THY NEIGHBOR; SELF-RENEWAL; NICHE; TUMORIGENESIS	Fibroblasts within the mammary tumor microenvironment are active participants in carcinogenesis mediating both tumor initiation and progression. Our group has previously demonstrated that genetic loss of phosphatase and tensin homolog (PTEN) in mammary fibroblasts induces an oncogenic secretome that remodels the extracellular milieu accelerating ErbB2-driven mammary tumor progression. While these prior studies highlighted a tumor suppressive role for stromal PTEN, how the adjacent normal epithelium transforms in response to PTEN loss was not previously addressed. To identify these early events, we have evaluated both phenotypic and genetic changes within the pre-neoplastic mammary epithelium of mice with and without stromal PTEN expression. We report that fibroblast-specific PTEN deletion greatly restricts mammary ductal elongation and induces aberrant alveolar side-branching. These mice concomitantly exhibit an expansion of the mammary epithelial stem cell (MaSC) enriched basal/myoepithelial population and an increase in in vitro stem cell activity. Further analysis revealed that NOTCH signaling, specifically through NOTCH3, is diminished in these cells. Mechanistically, JAGGED-1, a transmembrane ligand for the NOTCH receptor, is downregulated in the PTEN-null fibroblasts leading to a loss in the paracrine activation of NOTCH signaling from the surrounding stroma. Reintroduction of JAGGED-1 expression within the PTEN-null fibroblasts was sufficient to abrogate the observed increase in colony forming activity implying a direct role for stromal JAGGED-1 in regulation of MaSC properties. Importantly, breast cancer patients whose tumors express both low stromal JAG1 and low stromal PTEN exhibit a shorter time to recurrence than those whose tumors express low levels of either alone suggesting similar stromal signaling in advanced disease. Combined, these results unveil a novel stromal PTEN-to-JAGGED-1 axis in maintaining the MaSC niche, and subsequently inhibiting breast cancer initiation and disease progression.	[Sizemore, G. M.; Balakrishnan, S.; Hammer, A. M.; Thies, K. A.; Trimboli, A. J.; Wallace, J. A.; Sizemore, S. T.; Kladney, R. D.; Woelke, S. A.; Leone, G.; Ostrowski, M. C.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Sizemore, G. M.; Balakrishnan, S.; Hammer, A. M.; Thies, K. A.; Trimboli, A. J.; Kladney, R. D.; Leone, G.; Ostrowski, M. C.] Ohio State Univ, Dept Canc Biol & Genet, Columbus, OH 43210 USA; [Sizemore, S. T.; Chakravarti, A.] Ohio State Univ, Dept Radiat Oncol, Columbus, OH 43210 USA; [Yu, L.; Fernandez, S. A.] Ohio State Univ, Dept Biomed Informat, Ctr Biostat, Columbus, OH 43210 USA; [Leone, G.] Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Sizemore, GM; Ostrowski, MC (corresponding author), Ohio State Univ, Dept Canc Biol & Genet, Comprehens Canc, 570A Biomed Res Tower,460W 12th Ave, Columbus, OH 43210 USA.	gina.sizemore@osumc.edu; michael.ostrowski@osumc.edu	Sizemore, Gina/ABI-7542-2020; yu, lianbo/B-3472-2010; Ostrowski, Michael/H-3108-2011	Ostrowski, Michael/0000-0003-2948-6297	NIH [PO1CA097189]; Department of Defense [W81XWH-14-1-0040]; Pelotonia Fellowship Program; NATIONAL CANCER INSTITUTE [P30CA016058, P01CA097189] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Pelotonia Fellowship Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Jason Bice and Daphne Bryant (Solid Tumor Biology Program-Histology Core), Bryan McElwain and Katrina Miller (OSUCCC-Analytic Cytometry) and Sarah Warner (OSUCCC-Genomics) for technical support. This study was supported by the NIH (PO1CA097189, MCO and GL), the Department of Defense (W81XWH-14-1-0040, GMS) and the Pelotonia Fellowship Program (SB and GMS).	Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bernardo GM, 2010, DEVELOPMENT, V137, P2045, DOI 10.1242/dev.043299; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bissell MJ, 2003, CURR OPIN CELL BIOL, V15, P753, DOI 10.1016/j.ceb.2003.10.016; Bocker W, 2002, LAB INVEST, V82, P737, DOI 10.1097/01.LAB.0000017371.72714.C5; Boquest AC, 2005, MOL BIOL CELL, V16, P1131, DOI 10.1091/mbc.E04-10-0949; Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001; Bronisz A, 2012, NAT CELL BIOL, V14, P159, DOI 10.1038/ncb2396; Callahan R, 2004, J MAMMARY GLAND BIOL, V9, P145, DOI 10.1023/B:JOMG.0000037159.63644.81; Chiba S, 2006, STEM CELLS, V24, P2437, DOI 10.1634/stemcells.2005-0661; Clarke RB, 2005, DEV BIOL, V277, P443, DOI 10.1016/j.ydbio.2004.07.044; Dontu G, 2003, CELL PROLIFERAT, V36, P59, DOI 10.1046/j.1365-2184.36.s.1.6.x; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Forster N, 2014, DEV CELL, V28, P147, DOI 10.1016/j.devcel.2013.11.019; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Ghiabi P, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0386-3; Ghiabi P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112424; Ha HY, 2001, CANCER RES, V61, P984; Jeselsohn R, 2010, CANCER CELL, V17, P65, DOI 10.1016/j.ccr.2009.11.024; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kessenbrock K, 2015, MATRIX BIOL, V44-46, P184, DOI 10.1016/j.matbio.2015.01.022; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Liu JC, 2007, CANCER RES, V67, P8671, DOI 10.1158/0008-5472.CAN-07-1486; Liu JC, 2012, P NATL ACAD SCI USA, V109, P5832, DOI 10.1073/pnas.1201105109; Lo PK, 2012, ONCOGENE, V31, P2614, DOI [10.1038/onc.2012.147, 10.1038/onc.2011.439]; Lobry C, 2014, BLOOD, V123, P2451, DOI 10.1182/blood-2013-08-355818; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Ohlstein B, 2004, CURR OPIN CELL BIOL, V16, P693, DOI 10.1016/j.ceb.2004.09.003; Parsonage G, 2005, TRENDS IMMUNOL, V26, P150, DOI 10.1016/j.it.2004.11.014; Patel PH, 2015, NAT CELL BIOL, V17, P1182, DOI 10.1038/ncb3214; Plaks V, 2015, CELL STEM CELL, V16, P225, DOI 10.1016/j.stem.2015.02.015; Polyak K, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003244; Qiu M, 2013, CANCER LETT, V328, P261, DOI 10.1016/j.canlet.2012.09.023; Radisky DC, 2004, SCIENCE, V303, P775, DOI 10.1126/science.1094412; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Richert MM, 2000, J MAMMARY GLAND BIOL, V5, P227, DOI 10.1023/A:1026499523505; Rios AC, 2014, NATURE, V506, P322, DOI 10.1038/nature12948; Robinson GW, 2008, CELL STEM CELL, V3, P359, DOI 10.1016/j.stem.2008.09.014; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; SOULE HD, 1986, IN VITRO CELL DEV B, V22, P6, DOI 10.1007/BF02623435; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Tlsty TD, 2001, CURR OPIN GENET DEV, V11, P54, DOI 10.1016/S0959-437X(00)00156-8; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; Vaillant F, 2007, STEM CELL REV, V3, P114, DOI 10.1007/s12015-007-0018-2; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; Xing F, 2011, ONCOGENE, V30, P4075, DOI 10.1038/onc.2011.122; Xing F, 2013, EMBO MOL MED, V5, P384, DOI 10.1002/emmm.201201623; Xu KL, 2012, CANCER CELL, V21, P626, DOI 10.1016/j.ccr.2012.03.041; Yamamoto M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3299	58	20	21	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2017	36	16					2297	2308		10.1038/onc.2016.383	http://dx.doi.org/10.1038/onc.2016.383			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DM	27797378	Green Accepted			2022-12-17	WOS:000399782700010
J	Jeffery, JM; Kalimutho, M; Johansson, P; Cardenas, DG; Kumar, R; Khanna, KK				Jeffery, J. M.; Kalimutho, M.; Johansson, P.; Cardenas, D. G.; Kumar, R.; Khanna, K. K.			FBXO31 protects against genomic instability by capping FOXM1 levels at the G2/M transition	ONCOGENE			English	Article							E3 UBIQUITIN LIGASES; F-BOX; TRANSCRIPTION FACTOR; CELL-CYCLE; MITOTIC PROGRESSION; TUMOR-SUPPRESSOR; POOR-PROGNOSIS; DEGRADATION; PROTEOLYSIS; CDT1	F-box proteins in conjunction with Skp1, Cul1 and Rbx1 generate SCF complexes that are responsible for the ubiquitination of proteins, leading to their activation or degradation. Here we show that the F-box protein FBXO31 is required for normal mitotic progression and genome stability due to its role in regulating FOXM1 levels during the G2/M transition. FBXO31-depleted cells undergo a transient delay in mitosis due to an activated spindle checkpoint concomitant with an increase in lagging chromosomes and anaphase bridges. FBXO31 regulates mitosis in part by controlling the levels of FOXM1, a transcription factor and master regulator of mitosis. FBXO31 specifically interacts with FOXM1 during the G2/M transition, resulting in FOXM1 ubiquitination and degradation. FBXO31 depletion results in increased expression of FOXM1 transcriptional targets and mimics the FOXM1 overexpression. In contrast, co-depletion of FBXO31 and FOXM1 restores the genomic instability phenotype but not the delay in mitosis, indicating that FBXO31 probably has additional mitotic substrates. Thus, FBXO31 is the first described negative regulator of FOXM1 during the G2/M transition.	[Jeffery, J. M.; Kalimutho, M.; Cardenas, D. G.; Khanna, K. K.] QIMR Berghofer Med Res Inst, Signal Transduct Lab, Dept Cell & Mol Biol, Brisbane, Qld, Australia; [Johansson, P.] Univ Gothenburg, Dept Clin Chem & Transfus Med, Sahlgrenska Acad, Gothenburg, Sweden; [Kumar, R.] Univ Adelaide, Dept Paediat, Sch Med, Adelaide, SA, Australia; [Kumar, R.] Univ Adelaide, Robinson Res Inst, Adelaide, SA 5000, Australia	QIMR Berghofer Medical Research Institute; University of Gothenburg; University of Adelaide; Robinson Research Institute; University of Adelaide	Kumar, R (corresponding author), Univ Adelaide, Robinson Res Inst, Adelaide, SA 5000, Australia.; Kumar, R (corresponding author), Univ Adelaide, Sch Med, Adelaide, SA 5000, Australia.; Khanna, KK (corresponding author), Queensland Inst Med Res, Dept Cell & Mol Biol, 300 Herston Rd, Herston, Qld 4006, Australia.	raman.sharma@adelaide.edu.au; kumkum.khanna@qimrberghofer.edu.au	Kumar, Raman/AHE-0538-2022; Kalimutho, Murugan/AAD-1441-2019	Kumar, Raman/0000-0001-7976-8386; Khanna, Kum Kum/0000-0001-8650-5381; Kalimutho, Murugan/0000-0002-0772-8673	NHMRC; Cancer Council of Queensland; Cancer Council of South Australia; Cancer Council Queensland	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council of Queensland(Cancer Council Queensland); Cancer Council of South Australia(Cancer Council South Australia); Cancer Council Queensland(Cancer Council Queensland)	This work is funded by the NHMRC (Program Grant), the Cancer Council of Queensland and the Cancer Council of South Australia. Murugan Kalimutho is supported by project grant from the Cancer Council Queensland. Pegah Johansson is a Swedish Research Council (Vetenskapsradet) post-doctoral fellow. We thank Professor Michele Pagano for the Skp1, Cul1 and Rbx1 antibodies, and the FLAG-Skp2, FLAG-FBW9, FLAG-HAFBXO10, FLAG-HA-FBXO24 and FLAG-beta-Trcp1 constructs; Dr Sabine Elowe for BUBR1 pS676 antibody; and Stephen Miles for tissue culture assistance.	Anders L, 2011, CANCER CELL, V20, P620, DOI 10.1016/j.ccr.2011.10.001; Carter SL, 2009, Patent No. [US20090215054 A1, 20090215054]; Chen C, 2006, MOL CANCER RES, V4, P695, DOI 10.1158/1541-7786.MCR-06-0182; Chen DT, 2010, BREAST CANCER RES TR, V119, P335, DOI 10.1007/s10549-009-0344-y; Cheng WY, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002920; D'Angiolella V, 2012, CELL, V149, P1023, DOI 10.1016/j.cell.2012.03.043; Fu Z, 2008, NAT CELL BIOL, V10, P1076, DOI 10.1038/ncb1767; Fujita M, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-22; Gemenetzidis E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004849; Halasi M, 2009, CELL CYCLE, V8, P1966, DOI 10.4161/cc.8.12.8708; Heix J, 1998, EMBO J, V17, P7373, DOI 10.1093/emboj/17.24.7373; Huang HL, 2010, ONCOL REP, V24, P715, DOI 10.3892/or_00000912; Jeffery JM, 2010, ONCOGENE, V29, P2649, DOI 10.1038/onc.2010.37; Johansson P, 2014, J BIOL CHEM, V289, P18514, DOI 10.1074/jbc.M114.559930; Klein J, 1999, P NATL ACAD SCI USA, V96, P6096, DOI 10.1073/pnas.96.11.6096; Kogo R, 2011, INT J ONCOL, V39, P155, DOI 10.3892/ijo.2011.1018; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; Kumar R, 2005, CANCER RES, V65, P11304, DOI 10.1158/0008-5472.CAN-05-0936; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Laoukili J, 2008, CELL CYCLE, V7, P2720, DOI 10.4161/cc.7.17.6580; Lee EK, 2014, ONCOGENE, V33, P2011, DOI 10.1038/onc.2013.144; Leung TWC, 2001, FEBS LETT, V507, P59, DOI 10.1016/S0014-5793(01)02915-5; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Liu J, 2014, J BIOL CHEM, V289, P21508, DOI 10.1074/jbc.M114.560342; Malonia SK, 2015, P NATL ACAD SCI USA, V112, P8632, DOI 10.1073/pnas.1510929112; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Montero-Conde C, 2008, ONCOGENE, V27, P1554, DOI 10.1038/sj.onc.1210792; Nishitani H, 2006, EMBO J, V25, P1126, DOI 10.1038/sj.emboj.7601002; Park HJ, 2008, MOL CELL BIOL, V28, P5162, DOI 10.1128/MCB.00387-08; Pyronnet S, 2001, GENE DEV, V15, P2083, DOI 10.1101/gad.889201; Santra MK, 2009, NATURE, V459, P722, DOI 10.1038/nature08011; Seki A, 2008, J CELL BIOL, V181, P65, DOI 10.1083/jcb.200712027; Sivan G, 2008, CELL CYCLE, V7, P741, DOI 10.4161/cc.7.6.5596; Skaar JR, 2013, NAT REV MOL CELL BIO, V14, P369, DOI 10.1038/nrm3582; Teh MT, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-45; Vadhvani M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057530; van der Horst A, 2006, NAT CELL BIOL, V8, P1064, DOI 10.1038/ncb1469; Zhang XC, 2014, ONCOTARGET, V5, P6178, DOI 10.18632/oncotarget.2183; Zhou W, 2013, CANCER CELL, V23, P48, DOI 10.1016/j.ccr.2012.12.001	39	20	20	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	2017	36	7					1012	1022		10.1038/onc.2016.268	http://dx.doi.org/10.1038/onc.2016.268			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8JG	27568981				2022-12-17	WOS:000394169100013
J	Kao, YC; Jheng, JR; Pan, HJ; Liao, WY; Lee, CH; Kuo, PL				Kao, Y-C; Jheng, J-R; Pan, H-J; Liao, W-Y; Lee, C-H; Kuo, P-L			Elevated hydrostatic pressure enhances the motility and enlarges the size of the lung cancer cells through aquaporin upregulation mediated by caveolin-1 and ERK1/2 signaling	ONCOGENE			English	Article							INTERSTITIAL FLUID PRESSURE; PROGNOSTIC-FACTORS; CERVIX CANCER; METASTASIS; TUMOR; MIGRATION; ACTIVATION; MELANOMA; INVASION; PATHWAYS	The mechanical characteristics presented in cancer microenvironment are known to have pivotal roles in cancer metastasis, which accounts for the leading cause of death from malignant tumors. However, while a uniformly distributed high interstitial fluid pressure (IFP) is a common feature in solid tumors, the effects of high IFP on the motility and invasiveness of cancer cells remain obscure. Using cell-culture devices that simulated increased IFP conditions by applying hydrostatic pressure (HP) ranging from 0 to 20 mm Hg to the cells, we found that the elevated HPs increased the migration speeds, invasiveness, cell volume, filopodial number and aquaporin-1 (AQP1), Snail and vinculin expression levels, as well as phosphorylation of caveolin-1 and extracellular signalregulated kinase1/2 (ERK1/2), in the lung cancer cells CL1-5 and A549. The increases of migration speed and cell volume correlated temporally with the increase of AQP1 expression. The elevated HP-induced migration acceleration was hindered by AQP1 knockdown using small interfering RNA (siRNA) transfection. Inhibition of ERK1/2 phosphorylation using the mitogen-activated protein kinase kinase inhibitor PD98059 abrogated the elevated HP-induced AQP1 upregulation and migration acceleration in the cancer cells. Caveolin-1 knockdown by siRNA transfection attenuated the HP-induced, ERK1/2-depedent AQP1 upregulation and migration acceleration. Further biochemical studies revealed that the caveolin-1 activation-driven ERK1/2 signaling is mediated by Akt1/2 phosphorylation. By contrast, the elevated HPs had negligible effects on the migration speed and volume of normal bronchial epithelial cells. These results disclose a novel mechanism relating high IFP to the invasiveness of cancer cells and highlight potential targets to impede cancer spreading.	[Kao, Y-C; Jheng, J-R; Kuo, P-L] Natl Taiwan Univ, Grad Inst Biomed Elect & Bioinformat, 1,Sec 4,Roosevelt Rd, Taipei 10617, Taiwan; [Kao, Y-C; Pan, H-J; Lee, C-H] Acad Sinica, Res Ctr Appl Sci, 128,Sec 2,Acad Rd, Taipei 11529, Taiwan; [Liao, W-Y] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan; [Liao, W-Y] Natl Taiwan Univ, Coll Med, Taipei, Taiwan; [Lee, C-H] Natl Yang Ming Univ, Inst Biophoton, Taipei, Taiwan; [Lee, C-H] Natl Taiwan Univ, Dept Phys, Taipei, Taiwan; [Kuo, P-L] Natl Taiwan Univ, Dept Elect Engn, Taipei, Taiwan; [Kuo, P-L] Natl Taiwan Univ Hosp, Dept Rehabil, Taipei, Taiwan	National Taiwan University; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Yang Ming Chiao Tung University; National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital	Kuo, PL (corresponding author), Natl Taiwan Univ, Grad Inst Biomed Elect & Bioinformat, 1,Sec 4,Roosevelt Rd, Taipei 10617, Taiwan.; Lee, CH (corresponding author), Acad Sinica, Res Ctr Appl Sci, 128,Sec 2,Acad Rd, Taipei 11529, Taiwan.	clee@gate.sinica.edu.tw; poling@ntu.edu.tw	Liao, Wei-Yu/HGE-3881-2022; Lee, Chau-Hwang/B-2204-2008	Lee, Chau-Hwang/0000-0001-5013-7062; LIAO, WEI-YU/0000-0001-6383-3470	Taiwan Ministry of Science of Technology [MOST 102-2221-E-002-066, 103-2320-B-002-004-MY3, 103-2112-M-001-019-MY3]	Taiwan Ministry of Science of Technology	This work was supported by the grants from the Taiwan Ministry of Science of Technology (Grant Nos. MOST 102-2221-E-002-066, 103-2320-B-002-004-MY3 and 103-2112-M-001-019-MY3).	Adjei AA, 2008, J CLIN ONCOL, V26, P2139, DOI 10.1200/JCO.2007.14.4956; Arciszewski MB, 2011, ANN ANAT, V193, P81, DOI 10.1016/j.aanat.2010.11.003; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Bekaii-Saab T, 2011, J CLIN ONCOL, V29, P2357, DOI 10.1200/JCO.2010.33.9473; BOUCHER Y, 1990, CANCER RES, V50, P4478; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; CURTI BD, 1993, CANCER RES, V53, P2204; Deschenes-Simard X, 2014, CANCER RES, V74, P412, DOI 10.1158/0008-5472.CAN-13-2381; Dubroca C, 2007, CARDIOVASC RES, V73, P190, DOI 10.1016/j.cardiores.2006.10.020; Eikenes L, 2004, CANCER RES, V64, P4768, DOI 10.1158/0008-5472.CAN-03-1472; Fyles A, 2006, RADIOTHER ONCOL, V80, P132, DOI 10.1016/j.radonc.2006.07.014; Gomes LR, 2015, ONCOGENE, V34, P5329, DOI 10.1038/onc.2014.461; Gortazar AR, 2013, J BIOL CHEM, V288, P8168, DOI 10.1074/jbc.M112.437921; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hoque MO, 2006, AM J PATHOL, V168, P1345, DOI 10.2353/ajpath.2006.050596; Hu J, 2006, FASEB J, V20, P1892, DOI 10.1096/fj.06-5930fje; Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389; JAIN RK, 1994, SCI AM, V271, P58, DOI 10.1038/scientificamerican0794-58; Ji L, 2008, NAT CELL BIOL, V10, P1393, DOI 10.1038/ncb1797; Joshi B, 2008, CANCER RES, V68, P8210, DOI 10.1158/0008-5472.CAN-08-0343; Kelley LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013847; Kovbasnjuk O, 2005, P NATL ACAD SCI USA, V102, P19087, DOI 10.1073/pnas.0506474102; Leong HS, 2014, CELL REP, V8, P1558, DOI 10.1016/j.celrep.2014.07.050; Liao WY, 2015, J PATHOL, V235, P50, DOI 10.1002/path.4421; Liou YR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089767; Loitto VM, 2002, J LEUKOCYTE BIOL, V71, P212; Luo DX, 2010, BIOCHEM BIOPH RES CO, V391, P1693, DOI 10.1016/j.bbrc.2009.12.132; MacGrath SM, 2012, J CELL SCI, V125, P1621, DOI 10.1242/jcs.093781; Machesky LM, 2008, FEBS LETT, V582, P2102, DOI 10.1016/j.febslet.2008.03.039; Merikallio H, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-104; Milosevic M, 2001, CANCER RES, V61, P6400; Muriel O, 2011, J CELL SCI, V124, P2763, DOI 10.1242/jcs.080804; Nicchia GP, 2013, J MOL MED, V91, P613, DOI 10.1007/s00109-012-0977-x; Pan SH, 2011, J CLIN INVEST, V121, P3189, DOI 10.1172/JCI42975; Papadopoulos MC, 2008, PFLUG ARCH EUR J PHY, V456, P693, DOI 10.1007/s00424-007-0357-5; Parton RG, 2013, NAT REV MOL CELL BIO, V14, P98, DOI 10.1038/nrm3512; Radel C, 2005, AM J PHYSIOL-HEART C, V288, pH936, DOI 10.1152/ajpheart.00519.2004; Ribatti D, 2014, BBA-GEN SUBJECTS, V1840, P1550, DOI 10.1016/j.bbagen.2013.09.025; Rizzo V, 2003, AM J PHYSIOL-HEART C, V285, pH1720, DOI 10.1152/ajpheart.00344.2002; Rofstad EK, 2002, CANCER RES, V62, P661; Rubashkin MG, 2014, CANCER RES, V74, P4597, DOI 10.1158/0008-5472.CAN-13-3698; Rubin K, 2000, INT J CANCER, V86, P636, DOI 10.1002/(SICI)1097-0215(20000601)86:5<636::AID-IJC6>3.0.CO;2-R; Saadoun S, 2005, NATURE, V434, P786, DOI 10.1038/nature03460; Sinha B, 2011, CELL, V144, P402, DOI 10.1016/j.cell.2010.12.031; Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325; Stroka KM, 2014, CELL, V157, P611, DOI 10.1016/j.cell.2014.02.052; Umenishi F, 2003, J BIOL CHEM, V278, P15765, DOI 10.1074/jbc.M209980200; Verkman AS, 2014, NAT REV DRUG DISCOV, V13, P259, DOI 10.1038/nrd4226; Wang CC, 2011, LAB CHIP, V11, P695, DOI 10.1039/c0lc00155d; Wang CC, 2009, OPT LETT, V34, P3538, DOI 10.1364/OL.34.003538; Wirtz D, 2011, NAT REV CANCER, V11, P512, DOI 10.1038/nrc3080; Zhang BF, 2007, CELL SIGNAL, V19, P1690, DOI 10.1016/j.cellsig.2007.03.005	52	20	20	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					863	874		10.1038/onc.2016.255	http://dx.doi.org/10.1038/onc.2016.255			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27499095				2022-12-17	WOS:000394168200013
J	Bianchi-Smiraglia, A; Bagati, A; Fink, EE; Moparthy, S; Wawrzyniak, JA; Marvin, EK; Battaglia, S; Jowdy, P; Kolesnikova, M; Foley, CE; Berman, AE; Kozlova, NI; Lipchick, BC; Paul-Rosner, LM; Bshara, W; Ackroyd, JJ; Shewach, DS; Nikiforov, MA				Bianchi-Smiraglia, A.; Bagati, A.; Fink, E. E.; Moparthy, S.; Wawrzyniak, J. A.; Marvin, E. K.; Battaglia, S.; Jowdy, P.; Kolesnikova, M.; Foley, C. E.; Berman, A. E.; Kozlova, N. I.; Lipchick, B. C.; Paul-Rosner, L. M.; Bshara, W.; Ackroyd, J. J.; Shewach, D. S.; Nikiforov, M. A.			Microphthalmia-associated transcription factor suppresses invasion by reducing intracellular GTP pools	ONCOGENE			English	Article							MELANOMA-CELL INVASION; MATRIX-METALLOPROTEINASE; LINEAGE SURVIVAL; RHO-GTPASES; MITF; EXPRESSION; PROLIFERATION; METASTASIS; RESISTANCE; DEPLETION	Melanoma progression is associated with increased invasion and, often, decreased levels of microphthalmia-associated transcription factor (MITF). Accordingly, downregulation of MITF induces invasion in melanoma cells; however, little is known about the underlying mechanisms. Here, we report for the first time that depletion of MITF results in elevation of intracellular GTP levels and increased amounts of active (GTP-bound) RAC1, RHO-A and RHO-C. Concomitantly, MITF-depleted cells display larger number of invadopodia and increased invasion. We further demonstrate that the gene for guanosine monophosphate reductase (GMPR) is a direct MITF target, and that the partial repression of GMPR accounts mostly for the above phenotypes in MITF-depleted cells. Reciprocally, transactivation of GMPR is required for MITF-dependent suppression of melanoma cell invasion, tumorigenicity and lung colonization. Moreover, loss of GMPR accompanies downregulation of MITF in vemurafenib-resistant BRAF(V600E)-melanoma cells and underlies the increased invasion in these cells. Our data uncover novel mechanisms linking MITF-dependent inhibition of invasion to suppression of guanylate metabolism.	[Bianchi-Smiraglia, A.; Bagati, A.; Fink, E. E.; Moparthy, S.; Wawrzyniak, J. A.; Marvin, E. K.; Jowdy, P.; Kolesnikova, M.; Foley, C. E.; Lipchick, B. C.; Paul-Rosner, L. M.; Nikiforov, M. A.] Roswell Pk Canc Inst, Dept Cell Stress Biol, BLSC L3-317, Buffalo, NY 14263 USA; [Battaglia, S.] Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; [Berman, A. E.; Kozlova, N. I.] Orekhovich Inst Biomed Chem, Moscow, Russia; [Bshara, W.] Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA; [Ackroyd, J. J.; Shewach, D. S.] Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; [Wawrzyniak, J. A.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Wawrzyniak, J. A.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute; Russian Academy of Medical Sciences; Institute of Biomedical Chemistry; Roswell Park Cancer Institute; University of Michigan System; University of Michigan; University of California System; University of California San Diego; University of California System; University of California San Diego	Nikiforov, MA (corresponding author), Roswell Pk Canc Inst, Dept Cell Stress Biol, BLSC L3-317, Buffalo, NY 14263 USA.	mikhail.nikiforov@roswellpark.org	Kozlova, Nadezda/ABD-7878-2020; EBerman, Albert/F-5042-2017	Ackroyd, Jeffrey/0000-0003-3796-4447; Bianchi-Smiraglia, Anna/0000-0002-5963-103X; Kolesnikova, Masha/0000-0001-7803-9632; Fink, Emily/0000-0003-2738-5732	NIH [CA120244, CA190533, CA083081]; Ruth L Kirschstein National Research Service Award [F32CA189622]; American Cancer Society [RSG-10-121-01]; Jennifer Linscott Tietgen Foundation; NCI Cancer Center [CA016056]; NATIONAL CANCER INSTITUTE [R01CA120244, P30CA016056, R01CA190533, F32CA189622, R01CA083081] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ruth L Kirschstein National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Jennifer Linscott Tietgen Foundation; NCI Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr Dominic Smiraglia (Roswell Park Cancer Institute) for critical reading of the manuscript and to the Pathology Resource Network and the Clinical Data Network at Roswell Park Cancer Institute for providing human specimens. This work has been supported by NIH grants CA120244 and CA190533 (MAN), CA083081 (DSS), Ruth L Kirschstein National Research Service Award F32CA189622 (AB-S); American Cancer Society grant RSG-10-121-01 (MAN) and Jennifer Linscott Tietgen Foundation (MAN). This work was also supported in part by NCI Cancer Center Support Grant CA016056 to the Roswell Park Cancer Institute.	Arozarena I, 2011, ONCOGENE, V30, P4531, DOI 10.1038/onc.2011.162; Arozarena I, 2011, CANCER CELL, V19, P45, DOI 10.1016/j.ccr.2010.10.029; Bartolome RA, 2004, CANCER RES, V64, P2534, DOI 10.1158/0008-5472.CAN-03-3398; Bauer NN, 2007, EXP CELL RES, V313, P3832, DOI 10.1016/j.yexcr.2007.08.017; Bianchi-Smiraglia A, 2015, CELL DEATH DIFFER, V22, P1858, DOI 10.1038/cdd.2015.47; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cheli Y, 2012, ONCOGENE, V31, P2461, DOI 10.1038/onc.2011.425; Cheli Y, 2011, ONCOGENE, V30, P2307, DOI 10.1038/onc.2010.598; Cheli Y, 2010, PIGM CELL MELANOMA R, V23, P27, DOI 10.1111/j.1755-148X.2009.00653.x; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Felicetti F, 2008, CANCER RES, V68, P2745, DOI 10.1158/0008-5472.CAN-07-2538; Fink EE, 2016, LEUKEMIA, V30, P104, DOI 10.1038/leu.2015.190; FRANKLIN TJ, 1977, EUR J BIOCHEM, V77, P113, DOI 10.1111/j.1432-1033.1977.tb11648.x; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Golan T, 2015, MOL CELL, V59, P664, DOI 10.1016/j.molcel.2015.06.028; Halaban R, 2015, CLIN THER, V37, P682, DOI 10.1016/j.clinthera.2014.10.027; Hallett MA, 2003, AM J PHYSIOL-CELL PH, V285, pC129, DOI 10.1152/ajpcell.00007.2003; Hoek KS, 2008, PIGM CELL MELANOMA R, V21, P665, DOI 10.1111/j.1755-148X.2008.00505.x; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Imamura H, 2009, P NATL ACAD SCI USA, V106, P15651, DOI 10.1073/pnas.0904764106; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Javelaud D, 2011, PIGM CELL MELANOMA R, V24, P932, DOI 10.1111/j.1755-148X.2011.00893.x; Ji ZY, 2015, J INVEST DERMATOL, V135, P1863, DOI 10.1038/jid.2015.105; Kamai T, 2003, CLIN CANCER RES, V9, P2632; Kollareddy M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8389; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Mannava S, 2013, AM J PATHOL, V182, P142, DOI 10.1016/j.ajpath.2012.09.011; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Mondin M, 2007, BIOCHEM PHARMACOL, V73, P1491, DOI 10.1016/j.bcp.2006.12.025; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; O'Connell MP, 2013, CANCER DISCOV, V3, P1378, DOI 10.1158/2159-8290.CD-13-0005; Paraiso KHT, 2015, CANCER DISCOV, V5, P264, DOI 10.1158/2159-8290.CD-14-0293; Salti GI, 2000, CANCER RES, V60, P5012; Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106; Shibahara S, 2001, J INVEST DERM SYMP P, V6, P99, DOI 10.1046/j.0022-202x.2001.00010.x; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Vachtenheim J, 2015, EXP DERMATOL, V24, P481, DOI 10.1111/exd.12724; van Horssen R, 2009, J BIOL CHEM, V284, P1620, DOI 10.1074/jbc.M806974200; Wang JH, 2015, J INVEST DERMATOL, V135, P532, DOI 10.1038/jid.2014.418; Wawrzyniak JA, 2013, CELL REP, V5, P493, DOI 10.1016/j.celrep.2013.09.015; Weaver AM, 2006, CLIN EXP METASTAS, V23, P97, DOI 10.1007/s10585-006-9014-1; Wellbrock C, 2005, J CELL BIOL, V170, P703, DOI 10.1083/jcb.200505059; Wellbrock C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002734; Zubrilov I, 2015, CANCER LETT, V361, P86, DOI 10.1016/j.canlet.2015.02.041	50	20	21	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2017	36	1					84	96		10.1038/onc.2016.178	http://dx.doi.org/10.1038/onc.2016.178			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK6XJ	27181209	Green Accepted			2022-12-17	WOS:000394069100008
J	Shou, P; Chen, Q; Jiang, J; Xu, C; Zhang, J; Zheng, C; Jiang, M; Velletri, T; Cao, W; Huang, Y; Yang, Q; Han, X; Zhang, L; Wei, L; Rabson, AB; Chin, YE; Wang, Y; Shi, Y				Shou, P.; Chen, Q.; Jiang, J.; Xu, C.; Zhang, J.; Zheng, C.; Jiang, M.; Velletri, T.; Cao, W.; Huang, Y.; Yang, Q.; Han, X.; Zhang, L.; Wei, L.; Rabson, A. B.; Chin, Y. E.; Wang, Y.; Shi, Y.			Type I interferons exert anti-tumor effect via reversing immunosuppression mediated by mesenchymal stromal cells	ONCOGENE			English	Article							NF-KAPPA-B; DOUBLE-EDGED-SWORD; STEM-CELLS; NITRIC-OXIDE; IFN-GAMMA; IMMUNE-RESPONSES; INOS GENE; ALPHA; PHOSPHORYLATION; ACETYLATION	Mesenchymal stromal cells (MSCs) are strongly immunosuppressive via producing nitric oxide (NO) and known to migrate into tumor sites to promote tumor growth, but the underlying mechanisms remain largely elusive. Here, we found that interferon alpha (IFN alpha)-secreting MSCs showed more dramatic inhibition effect on tumor progression than that of IFN alpha alone. Interestingly, IFN alpha primed MSCs could also effectively suppress tumor growth. Mechanistically, we demonstrated that both IFN alpha and IFN beta (type I IFNs) reversed the immunosuppressive effect of MSCs on splenocyte proliferation. This effect of type I IFNs was exerted through inhibiting inducible NO synthase (iNOS) expression in IFN. and TNFa-stimulated MSCs. Notably, only NO production was inhibited by IFN alpha; production of other cytokines or chemokines tested was not suppressed. Furthermore, IFN alpha promoted the switch from signal transducer and activator of transcription 1 (Stat1) homodimers to Stat1-Stat2 heterodimers. Studies using the luciferase reporter system and chromatin immunoprecipitation assay revealed that IFN alpha suppressed iNOS transcription through inhibiting the binding of Stat1 to iNOS promoter. Therefore, the synergistic anti-tumor effects of type I IFNs and MSCs were achieved by inhibiting NO production. This study provides essential information for understanding the mechanisms of MSC-mediated immunosuppression and for the development of better clinical strategies using IFNs and MSCs for cancer immunotherapy.	[Shou, P.; Chen, Q.; Xu, C.; Zheng, C.; Jiang, M.; Velletri, T.; Cao, W.; Huang, Y.; Yang, Q.; Han, X.; Chin, Y. E.; Wang, Y.; Shi, Y.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Key Lab Stem Cell Biol, Shanghai, Peoples R China; [Shou, P.; Chen, Q.; Xu, C.; Zheng, C.; Jiang, M.; Velletri, T.; Cao, W.; Huang, Y.; Yang, Q.; Han, X.; Chin, Y. E.; Wang, Y.; Shi, Y.] Shanghai Jiao Tong Univ, Sch Med, Shanghai, Peoples R China; [Chen, Q.; Zhang, L.; Shi, Y.] Soochow Univ, Affiliated Hosp 1, Inst Translat Med, 199 Renai Rd, Suzhou 215123, Jiangsu, Peoples R China; [Jiang, J.] Soochow Univ, Affiliated Hosp 3, Changzhou, Jiangsu, Peoples R China; [Zhang, J.; Zhang, L.; Rabson, A. B.; Shi, Y.] Rutgers State Univ, Robert Wood Johnson Med Sch, Child Hlth Inst New Jersey, New Brunswick, NJ USA; [Wei, L.] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Tumor Immunol & Gene Therapy Ctr, Shanghai, Peoples R China; [Shou, P.] Univ Chinese Acad Sci, Beijing, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Soochow University - China; Soochow University - China; Rutgers State University New Brunswick; Rutgers State University Medical Center; Naval Medical University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Shi, Y (corresponding author), Soochow Univ, Affiliated Hosp 1, Inst Translat Med, 199 Renai Rd, Suzhou 215123, Jiangsu, Peoples R China.; Wang, Y (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	yingwang@sibs.ac.cn; yfshi@suda.edu.cn	Shou, Peishun/J-7985-2014; Shi, Yufang/AAE-4431-2020; HUANG, YIN/AAH-6871-2020; Xu, Chunliang/R-7065-2018	Shou, Peishun/0000-0001-7685-7471; Shi, Yufang/0000-0001-8964-319X; HUANG, YIN/0000-0001-5602-9871; Wei, Lixin/0000-0002-9526-5348; wang, ying/0000-0002-2571-9367; Chen, Qing/0000-0002-2088-0370	Ministry of Science and Technology of China [2015CB964400, 2012CBA01303]; Scientific Innovation Project of the Chinese Academy of Science [XDA01040110, XDA01040107]; External Cooperation Program of Bureau of International Cooperation, Chinese Academy of Sciences [GJHZ201307]; Programs of National Natural Science of China [81330046, 81171653, 31570877, 31570908]; National Institutes of Health of the United States of America [GM866889]; Robert Wood Johnson Foundation [67038]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM866889] Funding Source: NIH RePORTER	Ministry of Science and Technology of China(Ministry of Science and Technology, China); Scientific Innovation Project of the Chinese Academy of Science; External Cooperation Program of Bureau of International Cooperation, Chinese Academy of Sciences; Programs of National Natural Science of China(National Natural Science Foundation of China (NSFC)); National Institutes of Health of the United States of America(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Ms Fengying Li and Ms Jingjing Li for technical assistances in breeding the mice; Ms Yanyan Han, Mr Jianchang Cao, Mr Shijia Wang, Ms Qing Li and Ms Chenxi Zhang for technical assistances and helpful discussion. This work was supported by grants from the Ministry of Science and Technology of China (2015CB964400, 2012CBA01303), Scientific Innovation Project of the Chinese Academy of Science (XDA01040110, XDA01040107), the External Cooperation Program of Bureau of International Cooperation, Chinese Academy of Sciences (GJHZ201307), the Programs of National Natural Science of China (81330046, 81171653, 31570877, 31570908), grants from the National Institutes of Health of the United States of America (GM866889) and a grant to the Child Health Institute from the Robert Wood Johnson Foundation (67038).	Beckermann BM, 2008, BRIT J CANCER, V99, P622, DOI 10.1038/sj.bjc.6604508; Begitt A, 2014, NAT IMMUNOL, V15, P168, DOI 10.1038/ni.2794; Burke SJ, 2013, MOL ENDOCRINOL, V27, P1724, DOI 10.1210/me.2013-1159; Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168; Chen Q, 2014, STEM CELLS, V32, P327, DOI 10.1002/stem.1567; De Stefano D, 2006, J MOL MED, V84, P65, DOI 10.1007/s00109-005-0713-x; Djouad F, 2003, BLOOD, V102, P3837, DOI 10.1182/blood-2003-04-1193; Du JC, 2012, INT J BIOCHEM CELL B, V44, P1305, DOI 10.1016/j.biocel.2012.04.015; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Elzaouk L, 2006, EXP DERMATOL, V15, P865, DOI 10.1111/j.1600-0625.2006.00479.x; Frasca L, 2011, THESCIENTIFICWORLDJO, V11, P2071, DOI 10.1100/2011/873895; Galderisi Umberto, 2010, World J Stem Cells, V2, P5, DOI 10.4252/wjsc.v2.i1.5; Gao JJ, 1997, J BIOL CHEM, V272, P1226, DOI 10.1074/jbc.272.2.1226; Ghislain JJ, 2001, J INTERF CYTOK RES, V21, P379, DOI 10.1089/107999001750277853; Guo L, 2007, SURGERY, V142, P156, DOI 10.1016/j.surg.2007.02.016; Han X, 2014, CELL DEATH DIFFER, V21, P1758, DOI 10.1038/cdd.2014.85; Huang Y, 2014, ONCOGENE, V33, P3830, DOI 10.1038/onc.2013.355; Karp JM, 2009, CELL STEM CELL, V4, P206, DOI 10.1016/j.stem.2009.02.001; Khakoo AY, 2006, J EXP MED, V203, P1235, DOI 10.1084/jem.20051921; Kim MO, 2004, J NEUROCHEM, V90, P297, DOI 10.1111/j.1471-4159.2004.02487.x; Kleinert H, 1998, BRIT J PHARMACOL, V125, P193, DOI 10.1038/sj.bjp.0702039; Kramer OH, 2009, GENE DEV, V23, P223, DOI 10.1101/gad.479209; KretzRemy C, 1996, J CELL BIOL, V133, P1083, DOI 10.1083/jcb.133.5.1083; Lee ST, 2002, BRIT J HAEMATOL, V118, P1128, DOI 10.1046/j.1365-2141.2002.03767.x; Li W, 2012, CELL DEATH DIFFER, V19, P1505, DOI 10.1038/cdd.2012.26; Li YZ, 2005, J BIOL CHEM, V280, P10001, DOI 10.1074/jbc.M410972200; Liu H, 2006, J IMMUNOL, V176, P2864, DOI 10.4049/jimmunol.176.5.2864; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(01)00269-0; Ohkouchi S, 2012, MOL THER, V20, P417, DOI 10.1038/mt.2011.259; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; Pestka S, 2007, J BIOL CHEM, V282, P20047, DOI 10.1074/jbc.R700004200; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Qiao L, 2008, CANCER LETT, V269, P67, DOI 10.1016/j.canlet.2008.04.032; Qiao L, 2008, CELL RES, V18, P500, DOI 10.1038/cr.2008.40; Rayamajhi M, 2010, J EXP MED, V207, P327, DOI 10.1084/jem.20091746; Ren CC, 2008, STEM CELLS, V26, P2332, DOI 10.1634/stemcells.2008-0084; Ren G, 2014, ONCOGENE, V33, P4016, DOI 10.1038/onc.2013.387; Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014; Ren GW, 2012, CELL STEM CELL, V11, P812, DOI 10.1016/j.stem.2012.08.013; Ren GW, 2009, STEM CELLS, V27, P1954, DOI 10.1002/stem.118; Salam MT, 2012, J ALLERGY CLIN IMMUN, V129, P232, DOI 10.1016/j.jaci.2011.09.037; Shi YF, 2012, TRENDS IMMUNOL, V33, P136, DOI 10.1016/j.it.2011.11.004; Tanos T, 2005, J BIOL CHEM, V280, P18842, DOI 10.1074/jbc.M500620200; Torrone DZ, 2012, CLIN EPIGENETICS, V4, DOI 10.1186/1868-7083-4-3; Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395; Uddin S, 2000, J BIOL CHEM, V275, P27634; Wang KW, 2011, BBA-MOL CELL RES, V1813, P1395, DOI 10.1016/j.bbamcr.2011.04.004; Wang Y, 2014, NAT IMMUNOL, V15, P1009, DOI 10.1038/ni.3002; Wieczorek M, 2012, CYTOKINE GROWTH F R, V23, P293, DOI 10.1016/j.cytogfr.2012.06.005; Wu TR, 2002, J BIOL CHEM, V277, P47572, DOI 10.1074/jbc.M207536200; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Xu C, 2014, ONCOGENE, V33, P5047, DOI 10.1038/onc.2013.458; Xu CL, 2014, J IMMUNOL, V192, P103, DOI 10.4049/jimmunol.1302164; Yu ZY, 2006, AM J PHYSIOL-RENAL, V290, pF496, DOI 10.1152/ajprenal.00316.2005; Zou WB, 2012, CANCER RES, V72, P2980, DOI 10.1158/0008-5472.CAN-11-4216	55	20	22	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2016	35	46					5953	5962		10.1038/onc.2016.128	http://dx.doi.org/10.1038/onc.2016.128			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CA	27109100	Green Accepted, hybrid, Green Published			2022-12-17	WOS:000388509400003
J	Rai, R; Zhang, F; Colavita, K; Leu, NA; Kurosaka, S; Kumar, A; Birnbaum, MD; Gyorffy, B; Dong, DW; Shtutman, M; Kashina, A				Rai, R.; Zhang, F.; Colavita, K.; Leu, N. A.; Kurosaka, S.; Kumar, A.; Birnbaum, M. D.; Gyorffy, B.; Dong, D. W.; Shtutman, M.; Kashina, A.			Arginyltransferase suppresses cell tumorigenic potential and inversely correlates with metastases in human cancers	ONCOGENE			English	Article							RNA-PROTEIN TRANSFERASE; END RULE PATHWAY; IN-VIVO; ARGINYLATION; EXPRESSION; FORMS; ATE1	Arginylation is an emerging post-translational modification mediated by arginyltransferase (ATE1) that is essential for mammalian embryogenesis and regulation of the cytoskeleton. Here, we discovered that Ate1-knockout (KO) embryonic fibroblasts exhibit tumorigenic properties, including abnormally rapid contact-independent growth, reduced ability to form cell-cell contacts and chromosomal aberrations. Ate1-KO fibroblasts can form large colonies in Matrigel and exhibit invasive behavior, unlike wild-type fibroblasts. Furthermore, Ate1-KO cells form tumors in subcutaneous xenograft assays in immunocompromised mice. Abnormal growth in these cells can be partially rescued by reintroduction of stably expressed specific Ate1 isoforms, which also reduce the ability of these cells to form tumors. Tumor array studies and bioinformatics analysis show that Ate1 is downregulated in several types of human cancer samples at the protein level, and that its transcription level inversely correlates with metastatic progression and patient survival. We conclude that Ate1-KO results in carcinogenic transformation of cultured fibroblasts, suggesting that in addition to its previously known activities Ate1 gene is essential for tumor suppression and also likely participates in suppression of metastatic growth.	[Rai, R.; Zhang, F.; Colavita, K.; Leu, N. A.; Kurosaka, S.; Kashina, A.] Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA; [Zhang, F.; Kumar, A.; Birnbaum, M. D.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; [Gyorffy, B.] MTA TTK Lendulet Canc Biomarker Res Grp, Budapest, Hungary; [Gyorffy, B.] Semmelweis Univ, Dept Pediat 2, Budapest, Hungary; [Dong, D. W.] Univ Penn, Perelman Sch Med, Inst Biomed Informat, Philadelphia, PA 19104 USA; [Shtutman, M.] Univ South Carolina, Columbia, SC 29208 USA	University of Pennsylvania; University of Miami; Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences; Semmelweis University; University of Pennsylvania; Pennsylvania Medicine; University of South Carolina System; University of South Carolina Columbia	Kashina, A (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA.	akashina@vet.upenn.edu	Shtutman, Michael/AAB-8391-2020; Gyorffy, Balazs/AAA-9135-2021	Shtutman, Michael/0000-0002-2458-3226; Gyorffy, Balazs/0000-0002-5772-3766	NIH [GM104003, GM117984, GM109091]; Pilot Grant from the Mari Lowe Center for Comparative Oncology; OTKA grant [K108655]; Developmental Grant from Sylvester Comprehensive Cancer Center; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM109091, R01GM108744, R01GM104003] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pilot Grant from the Mari Lowe Center for Comparative Oncology; OTKA grant(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); Developmental Grant from Sylvester Comprehensive Cancer Center; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH grants GM104003 and GM117984 and the Pilot Grant from the Mari Lowe Center for Comparative Oncology to AK. BG was supported by the OTKA K108655 grant. MS was supported by NIH grant GM109091. FZ, MDB and A Kumar were partly supported by a Developmental Grant from Sylvester Comprehensive Cancer Center.	BALZI E, 1990, J BIOL CHEM, V265, P7464; Eisenach PA, 2014, J BIOL CHEM, V289, P35376, DOI 10.1074/jbc.M114.578674; Gyorffy B, 2015, ONCOTARGET, V6, P13334; KAJI H, 1963, BIOCHIM BIOPHYS ACTA, V76, P477; Karakozova M, 2006, SCIENCE, V313, P192, DOI 10.1126/science.1129344; Kurosaka S, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000878; Kwon YT, 1999, MOL CELL BIOL, V19, P182; Kwon YT, 2002, SCIENCE, V297, P96, DOI 10.1126/science.1069531; Mihaly Z, 2013, BREAST CANCER RES TR, V140, P219, DOI 10.1007/s10549-013-2622-y; Piatkov KI, 2012, P NATL ACAD SCI USA, V109, pE1839, DOI 10.1073/pnas.1207786109; Rai R, 2005, P NATL ACAD SCI USA, V102, P10123, DOI 10.1073/pnas.0504500102; Rai R, 2006, EMBO REP, V7, P800, DOI 10.1038/sj.embor.7400747; Saha S, 2011, CHEM BIOL, V18, P1369, DOI 10.1016/j.chembiol.2011.08.019; Saha S, 2011, DEV BIOL, V358, P1, DOI 10.1016/j.ydbio.2011.06.043; Wang JL, 2014, CHEM BIOL, V21, P331, DOI 10.1016/j.chembiol.2013.12.017; Wang JL, 2011, CHEM BIOL, V18, P121, DOI 10.1016/j.chembiol.2010.10.016; Wong CCL, 2007, PLOS BIOL, V5, P2231, DOI 10.1371/journal.pbio.0050258; Zhang FL, 2012, J CELL BIOL, V197, P819, DOI 10.1083/jcb.201112129	18	20	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 4	2016	35	31					4058	4068		10.1038/onc.2015.473	http://dx.doi.org/10.1038/onc.2015.473			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8GG	26686093	Green Submitted, Green Accepted			2022-12-17	WOS:000381020900004
J	Yan, H; Tang, G; Wang, H; Hao, L; He, T; Sun, X; Ting, AH; Deng, A; Sun, S				Yan, H.; Tang, G.; Wang, H.; Hao, L.; He, T.; Sun, X.; Ting, A. H.; Deng, A.; Sun, S.			DNA methylation reactivates GAD1 expression in cancer by preventing CTCF-mediated polycomb repressive complex 2 recruitment	ONCOGENE			English	Article							MUCINOUS HISTOLOGY PREDICTS; METASTATIC COLON-CANCER; GAMMA-AMINOBUTYRIC-ACID; COLORECTAL-CANCER; GENE-EXPRESSION; AIRWAY EPITHELIUM; INDUCED APOPTOSIS; BINDING REGIONS; PROTEINS; SURVIVAL	Levels of gamma-aminobutyric acid (GABA) and glutamic acid decarboxylase 1 (GAD1), the enzyme that synthesizes GABA, are significantly increased in neoplastic tissues. However, the mechanism underlying this increase remains elusive. Instead of silencing gene transcription, we showed that the GAD1 promoter was hypermethylated in both colon and liver cancer cells, leading to the production of high levels of GAD1. GAD1 is a target gene that is silenced by H3K27me3. The key locus responsible for GAD1 reactivation was mapped to a DNA methylation-sensitive CTCF-binding site (CTCF-BS3) within the third intron of GAD1. Chromosome configuration capture (3C) analysis indicated that an intrachromosomal loop was formed by CTCF self-dimerisation in normal cells (CTCF binds to both unmethylated CTCF-BS3 and CTCF-BS2). The CTCF dimer then interacted with suppressor of zeste 12 homologue (SUZ12), which is a domain of Polycomb repressive complex 2 (PRC2), promoting the methylation of H3K27 and the silencing of GAD1 expression. This silencing was shown to be inhibited by DNA methylation in cancer cells. These findings strongly suggest that GAD1 is reactivated by DNA methylation, which provided a model for DNA methylation and the active orchestration of oncogenic gene expression by CTCF in cancer cells.	[Yan, H.; Sun, X.; Deng, A.] Second Mil Med Univ, Changhai Hosp, Dept Lab Med, 168 Changhai Rd, Shanghai 200433, Peoples R China; [Tang, G.; Sun, S.] Second Mil Med Univ, Inst Genet, Shanghai, Peoples R China; [Wang, H.; Hao, L.] Second Mil Med Univ, Changhai Hosp, Dept Colorectal Surg, Shanghai, Peoples R China; [He, T.] Second Mil Med Univ, Changhai Hosp, Div Hepatopancreatobiliary Surg, Shanghai, Peoples R China; [Ting, A. H.] Cleveland Clin Fdn, Genom Med Inst, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA	Naval Medical University; Naval Medical University; Naval Medical University; Naval Medical University; Cleveland Clinic Foundation	Yan, H; Deng, A; Sun, S (corresponding author), Second Mil Med Univ, Changhai Hosp, Dept Lab Med, 168 Changhai Rd, Shanghai 200433, Peoples R China.	hongliyan@smmu.edu.cn; amdeng70@163.com; shsun@vip.sina.com			National Natural Science Foundation of China Shanghai Pujiang Outstanding Young Scientist Project [81071680, 81272280, 81172307]	National Natural Science Foundation of China Shanghai Pujiang Outstanding Young Scientist Project	This work was supported by grants from the National Natural Science Foundation of China (grants no. 81071680, 81272280, 81172307) Shanghai Pujiang Outstanding Young Scientist Project.	Andang M, 2008, NATURE, V451, P460, DOI 10.1038/nature06488; Azuma H, 2003, CANCER RES, V63, P8090; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913; Catalano V, 2009, BRIT J CANCER, V100, P881, DOI 10.1038/sj.bjc.6604955; Cotter PD, 2001, MOL MICROBIOL, V40, P465, DOI 10.1046/j.1365-2958.2001.02398.x; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Du WB, 2004, DIS COLON RECTUM, V47, P78, DOI 10.1007/s10350-003-0014-9; Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909; Euskirchen GM, 2007, GENOME RES, V17, P898, DOI 10.1101/gr.5583007; Fu XW, 2011, AM J RESP CELL MOL, V44, P222, DOI 10.1165/rcmb.2010-0109OC; Gatenby RA, 2006, CANCER RES, V66, P5216, DOI 10.1158/0008-5472.CAN-05-4193; Gius D, 2004, CANCER CELL, V6, P361, DOI 10.1016/j.ccr.2004.08.029; Ha M, 2011, GENOME RES, V21, P590, DOI 10.1101/gr.116467.110; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Hernandez A, 2012, CURR PHARM DESIGN, V18, P1317, DOI 10.2174/138161212799504894; HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098; Huang HS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000809; Huerta S, 2003, INT J ONCOL, V22, P663; Jaraj SJ, 2011, SCAND J UROL NEPHROL, V45, P39, DOI 10.3109/00365599.2010.521189; JOH TH, 1985, FED PROC, V44, P2773; Jorissen RN, 2008, CLIN CANCER RES, V14, P8061, DOI 10.1158/1078-0432.CCR-08-1431; Kim BN, 2005, INT J ONCOL, V26, P1217; Kimura R, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-555; Kobayashi T, 2003, BBA-GENE STRUCT EXPR, V1628, P156, DOI 10.1016/S0167-4781(03)00138-6; Labrador M, 2002, CELL, V111, P151, DOI 10.1016/S0092-8674(02)01004-8; Lai AY, 2010, J EXP MED, V207, P1939, DOI 10.1084/jem.20100204; Leopoldo S, 2008, ANN SURG ONCOL, V15, P1429, DOI 10.1245/s10434-007-9757-1; Li CM, 2004, AM J PATHOL, V165, P1943, DOI 10.1016/S0002-9440(10)63246-4; Li T, 2008, MOL CELL BIOL, V28, P6473, DOI 10.1128/MCB.00204-08; Maemura K, 2003, J GASTROEN HEPATOL, V18, P1089, DOI 10.1046/j.1440-1746.2003.03131.x; Maisano R, 2012, J CHEMOTHERAPY, V24, P212, DOI 10.1179/1973947812Y.0000000013; Matuszek M, 2001, Med Sci Monit, V7, P377; Negri FV, 2005, ANN ONCOL, V16, P1305, DOI 10.1093/annonc/mdi244; Nozoe T, 2000, J SURG ONCOL, V75, P103, DOI 10.1002/1096-9098(200010)75:2<103::AID-JSO6>3.3.CO;2-3; Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402; Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001; Rago C, 2007, NAT PROTOC, V2, P2734, DOI 10.1038/nprot.2007.408; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; Ren LC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031416; Renaud S, 2007, NUCLEIC ACIDS RES, V35, P1245, DOI 10.1093/nar/gkl1125; Rodriguez C, 2010, BIOCHEM BIOPH RES CO, V392, P129, DOI 10.1016/j.bbrc.2009.12.159; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Stuhmer T, 2002, CEREB CORTEX, V12, P75, DOI 10.1093/cercor/12.1.75; Wang ZH, 2009, METHODS MOL BIOL, V567, P87, DOI 10.1007/978-1-60327-414-2_6; West AG, 2004, MOL CELL, V16, P453, DOI 10.1016/j.molcel.2004.10.005; Xiang YY, 2007, NAT MED, V13, P862, DOI 10.1038/nm1604; Xu YM, 2012, GENOME RES, V22, P283, DOI 10.1101/gr.122788.111; Yan HL, 2009, EMBO J, V28, P2719, DOI 10.1038/emboj.2009.214; Zhang JW, 2016, GUT, V65, P1482, DOI 10.1136/gutjnl-2014-308614	50	20	20	5	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					3995	4008		10.1038/onc.2015.423	http://dx.doi.org/10.1038/onc.2015.423			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	26549033				2022-12-17	WOS:000381013100011
J	Heltemes-Harris, LM; Larson, JD; Starr, TK; Hubbard, GK; Sarver, AL; Largaespada, DA; Farrar, MA				Heltemes-Harris, L. M.; Larson, J. D.; Starr, T. K.; Hubbard, G. K.; Sarver, A. L.; Largaespada, D. A.; Farrar, M. A.			Sleeping Beauty transposon screen identifies signaling modules that cooperate with STAT5 activation to induce B-cell acute lymphoblastic leukemia	ONCOGENE			English	Article							HEMATOPOIETIC STEM-CELLS; PROTEIN-KINASE PATHWAYS; CANCER GENE DISCOVERY; NF-KAPPA-B; LYSINE METHYLATION; REGULATED KINASE; BCR-ABL; SENESCENCE; SELECTION; IKAROS	Signal transducer and activator of transcription 5 (STAT5) activation occurs frequently in human progenitor B-cell acute lymphoblastic leukemia (B-ALL). To identify gene alterations that cooperate with STAT5 activation to initiate leukemia, we crossed mice expressing a constitutively active form of STAT5 (Stat5b-CA) with mice in which a mutagenic Sleeping Beauty transposon (T2/Onc) was mobilized only in B cells. Stat5b-CA mice typically do not develop B-ALL (<2% penetrance); in contrast, 89% of Stat5b-CA mice in which the T2/Onc transposon had been mobilized died of B-ALL by 3 months of age. High-throughput sequencing approaches were used to identify genes frequently targeted by the T2/Onc transposon; these included Sos1 (74%), Kdm2a (35%), Jak1 (26%), Bmi1 (19%), Prdm14 or Ncoa2 (13%), Cdkn2a (10%), Ikzf1 (8%), Caap1 (6%) and Klf3 (6%). Collectively, these mutations target three major cellular processes: (i) the Janus kinase/STAT5 pathway (ii) progenitor B-cell differentiation and (iii) the CDKN2A tumor-suppressor pathway. Transposon insertions typically resulted in altered expression of these genes, as well as downstream pathways including STAT5, extracellular signal-regulated kinase (Erk) and p38. Importantly, expression of Sos1 and Kdm2a, and activation of p38, correlated with survival, further underscoring the role these genes and associated pathways have in B-ALL.	[Heltemes-Harris, L. M.; Hubbard, G. K.; Farrar, M. A.] Univ Minnesota, Ctr Immunol, Minneapolis, MN USA; [Heltemes-Harris, L. M.; Hubbard, G. K.; Farrar, M. A.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; [Heltemes-Harris, L. M.; Larson, J. D.; Starr, T. K.; Hubbard, G. K.; Sarver, A. L.; Largaespada, D. A.; Farrar, M. A.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA; [Larson, J. D.; Starr, T. K.] Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN USA; [Starr, T. K.] Univ Minnesota, Dept Obstet Gynecol & Womens Hlth, Minneapolis, MN USA; [Starr, T. K.; Largaespada, D. A.] Univ Minnesota, Ctr Genome Engn, Minneapolis, MN USA; [Largaespada, D. A.] Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Farrar, MA (corresponding author), Univ Minnesota, Ctr Immunol, Minneapolis, MN USA.; Farrar, MA (corresponding author), Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.; Farrar, MA (corresponding author), Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA.; Farrar, MA (corresponding author), Univ Minnesota, Dept Lab Med & Pathol, Ctr Immunol, Masonic Canc Ctr, 2101 6th St SE,2-116 WMBB, Minneapolis, MN 55455 USA.	farra005@umn.edu	Starr, Tim/AAX-9342-2021; Farrar, Michael A/M-7802-2013	Farrar, Michael/0000-0002-5569-0366; Starr, Timothy/0000-0002-6308-3451; Heltemes Harris, Lynn/0000-0002-2668-8005	University of Minnesota Masonic Cancer Center; NIH [R01 CA154998, CA151845, 5R00CA151672-04, R01 CA113636]; NIH Institutional Shared Resource grant [P30-CA77598]; NATIONAL CANCER INSTITUTE [R01CA151845, R00CA151672, R01CA154998, U01CA084221, R01CA113636, P30CA077598] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000114] Funding Source: NIH RePORTER	University of Minnesota Masonic Cancer Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Institutional Shared Resource grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank Peter Schoettler, Chris Reis, Alyssa Kne, Amy Mack and Emilea Sykes for assistance with animal husbandry, Maya Raghunandan for technical assistance, Paul Champoux for assistance with Flow cytometry and Dr Richard Williams for helpful comments. This work was supported by a Brainstorm grant from the University of Minnesota Masonic Cancer Center (MAF and DAL), NIH grants R01 CA154998 and CA151845 to MAF, NIH grant 5R00CA151672-04 to TKS, NIH R01 CA113636 to DAL, an NIH Institutional Shared Resource grant to the Masonic Cancer Center P30-CA77598 and a Leukemia and Lymphoma Society Scholar award (MAF).	Abbott KL, 2015, NUCLEIC ACIDS RES, V43, pD844, DOI 10.1093/nar/gku770; Arranz L, 2012, CELL CYCLE, V11, P65, DOI 10.4161/cc.11.1.18097; Berquam-Vrieze KE, 2011, BLOOD, V118, P4646, DOI 10.1182/blood-2011-03-343947; Brett BT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024668; Bulavin DV, 2003, MOL CELL BIOL, V23, P3859, DOI 10.1128/MCB.23.11.3859-3871.2003; Burchill MA, 2003, J IMMUNOL, V171, P5853, DOI 10.4049/jimmunol.171.11.5853; Chen ZS, 2015, NATURE, V521, P357, DOI 10.1038/nature14231; Cheng ZJ, 2014, GENE DEV, V28, P1758, DOI 10.1101/gad.246561.114; Collier LS, 2005, NATURE, V436, P272, DOI 10.1038/nature03681; Cornall RJ, 1998, IMMUNITY, V8, P497, DOI 10.1016/S1074-7613(00)80554-3; Diehl NL, 2000, J EXP MED, V191, P321, DOI 10.1084/jem.191.2.321; Dupuy AJ, 2009, CANCER RES, V69, P8150, DOI 10.1158/0008-5472.CAN-09-1135; Dupuy AJ, 2005, NATURE, V436, P221, DOI 10.1038/nature03691; Evelyn CR, 2014, CHEM BIOL, V21, P1618, DOI 10.1016/j.chembiol.2014.09.018; Heltemes-Harris LM, 2011, J EXP MED, V208, P1135, DOI 10.1084/jem.20101947; Hobeika E, 2006, P NATL ACAD SCI USA, V103, P13789, DOI 10.1073/pnas.0605944103; Inaba H, 2013, LANCET, V381, P1943, DOI 10.1016/S0140-6736(12)62187-4; Irving J, 2014, BLOOD, V124, P3420, DOI 10.1182/blood-2014-04-531871; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jun JE, 2013, MOL CELL BIOL, V33, P2470, DOI 10.1128/MCB.01593-12; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Li Q, 2013, NATURE, V504, P143, DOI 10.1038/nature12830; Lu T, 2013, P NATL ACAD SCI USA, V110, P13510, DOI 10.1073/pnas.1311770110; Lu T, 2010, P NATL ACAD SCI USA, V107, P46, DOI 10.1073/pnas.0912493107; Mandal M, 2009, NAT IMMUNOL, V10, P1110, DOI 10.1038/ni.1785; Mullighan CG, 2008, GENE DEV, V22, P1411, DOI 10.1101/gad.1673908; Mullighan CG, 2008, NATURE, V453, P110, DOI 10.1038/nature06866; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Mullighan CG, 2013, SEMIN HEMATOL, V50, P314, DOI 10.1053/j.seminhematol.2013.10.001; Mullighan CG, 2009, NEW ENGL J MED, V360, P470, DOI 10.1056/NEJMoa0808253; Nakayama J, 2009, BLOOD, V113, P1483, DOI 10.1182/blood-2008-07-166355; Oguro H, 2010, CELL STEM CELL, V6, P279, DOI 10.1016/j.stem.2010.01.005; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Roberts KG, 2015, NAT REV CLIN ONCOL, V12, P344, DOI 10.1038/nrclinonc.2015.38; Sarver AL, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-154; Schwickert TA, 2014, NAT IMMUNOL, V15, P283, DOI 10.1038/ni.2828; Shojaee S, 2015, CANCER CELL, V28, P1; Starr TK, 2009, SCIENCE, V323, P1747, DOI 10.1126/science.1163040; Starr TK, 2005, CELL CYCLE, V4, P1744, DOI 10.4161/cc.4.12.2223; Vu TT, 2011, J IMMUNOL, V187, P5032, DOI 10.4049/jimmunol.1101450; Vougioukalaki M, 2011, CANCER LETT, V304, P80, DOI 10.1016/j.canlet.2011.02.004; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Williams RT, 2008, COLD SH Q B, V73, P461, DOI 10.1101/sqb.2008.73.039; Xu H, 2013, JNCI-J NATL CANCER I, V105, P733, DOI 10.1093/jnci/djt042; Zhang JH, 2011, BLOOD, V118, P3080, DOI 10.1182/blood-2011-03-341412	46	20	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2016	35	26					3454	3464		10.1038/onc.2015.405	http://dx.doi.org/10.1038/onc.2015.405			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DQ5UI	26500062	Green Accepted			2022-12-17	WOS:000379270100010
J	Yu, EJ; Kim, SH; Kim, HJ; Heo, K; Ou, CY; Stallcup, MR; Kim, JH				Yu, E. J.; Kim, S-H; Kim, H. J.; Heo, K.; Ou, C-Y; Stallcup, M. R.; Kim, J. H.			Positive regulation of beta-catenin-PROX1 signaling axis by DBC1 in colon cancer progression	ONCOGENE			English	Article							BETA-CATENIN; WNT/BETA-CATENIN; COLORECTAL TUMORIGENESIS; ANDROGEN RECEPTOR; GENE ACTIVATION; GROWTH; P53; PROX1; CELLS; SIRT1	Aberrant activation of Wnt/beta-catenin pathway contributes to colorectal cancer (CRC) progression. However, little is known about regulatory mechanisms of the beta-catenin activity in cancer progression. Here we investigated the role of DBC1, which was recently reported as a negative regulator of SIRT1 and a transcriptional coactivator, in the regulation of Wnt/beta-catenin signaling. We identified the genome-wide targets of DBC1 and found that loss of DBC1 inhibits the expression of beta-catenin target genes including PROX1, a transcription factor linked to CRC progression. Mechanistically, DBC1 stabilizes LEF1-beta-catenin interaction by inhibiting SIRT1-mediated beta-catenin deacetylation, thereby enhancing LEF1-beta-catenin complex formation and long-range chromatin looping at the PROX1 locus. Furthermore, DBC1 is also required for the transcriptional activity of PROX1, suggesting that DBC1 has a dual function in regulating beta-catenin-PROX1 signaling axis: as a coactivator for both beta-catenin and PROX1. Importantly, loss of DBC1 inhibited growth and tumorigenic potential of colon cancer cells, and DBC1 expression correlated with shorter relapse-free survival in patients with advanced CRC. Our results firmly establish DBC1 as a critical positive regulator of beta-catenin-PROX1 signaling axis and a key factor in beta-catenin-PROX1-mediated CRC progression.	[Yu, E. J.; Kim, S-H; Kim, H. J.; Kim, J. H.] Sungkyunkwan Univ, Samsung Canc Ctr, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Seoul 135710, South Korea; [Yu, E. J.; Kim, H. J.; Kim, J. H.] Samsung Med Ctr, Samsung Biomed Res Inst, Dept Biomed Sci, Seoul, South Korea; [Kim, S-H] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, Seoul, South Korea; [Heo, K.] Dongnam Inst Radiol & Med Sci, Dept Clin Res, Busan, South Korea; [Ou, C-Y; Stallcup, M. R.] Univ Southern Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Korea Institute of Radiological & Medical Sciences; University of Southern California	Kim, JH (corresponding author), Sungkyunkwan Univ, Samsung Canc Ctr, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Seoul 135710, South Korea.; Kim, JH (corresponding author), Samsung Med Ctr, Samsung Biomed Res Inst, Dept Biomed Sci, Seoul, South Korea.; Stallcup, MR (corresponding author), Univ Southern Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA.	stallcup@usc.edu; jeongkim@skku.edu	Ou, Chenyin/AAM-7473-2020	Ou, Chenyin/0000-0002-8036-7317; Heo, Kyu/0000-0001-8833-4731	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning (MISP) [NRF-2013R1A1A2059697]; National R&D Program through the Dongnam Institute of Radiological and Medical Sciences (DIRAMS) - MISP [50590-2015]; National Institutes of Health [DK043093]; NATIONAL CANCER INSTITUTE [P30CA014089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043093] Funding Source: NIH RePORTER	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning (MISP); National R&D Program through the Dongnam Institute of Radiological and Medical Sciences (DIRAMS) - MISP; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Woo-Young Seo (Sungkyunkwan University) for expert technical assistance and Dr Yong-Kwon Hong (University of Southern California) for providing PROX1 expression and reporter constructs. This work was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (MISP) (NRF-2013R1A1A2059697 to JHK), National R&D Program through the Dongnam Institute of Radiological and Medical Sciences (DIRAMS) funded by MISP (50590-2015), and the National Institutes of Health (DK043093 to MRS).	BAKER SJ, 1990, CANCER RES, V50, P7717; Chini EN, 2013, BIOSCIENCE REP, V33, P637, DOI 10.1042/BSR20130062; Elyada E, 2011, NATURE, V470, P409, DOI 10.1038/nature09673; Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020; Hoppler S, 2007, J CELL SCI, V120, P385, DOI 10.1242/jcs.03363; Kanwar SS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-212; Kim HJ, 2015, ONCOGENE, V34, P4500, DOI 10.1038/onc.2014.381; Kim JE, 2008, NATURE, V451, P583, DOI 10.1038/nature06500; Kim JH, 2008, MOL CELL, V31, P510, DOI 10.1016/j.molcel.2008.08.001; Kim SH, 2012, HISTOL HISTOPATHOL, V27, P49, DOI 10.14670/HH-27.49; Levy L, 2004, MOL CELL BIOL, V24, P3404, DOI 10.1128/MCB.24.8.3404-3414.2004; Li HW, 2004, J BIOL CHEM, V279, P4212, DOI 10.1074/jbc.M311374200; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Neumann H, 2009, MOL CELL, V36, P153, DOI 10.1016/j.molcel.2009.07.027; Ou CY, 2009, J BIOL CHEM, V284, P20629, DOI 10.1074/jbc.M109.014332; Pangon L, 2015, INT J CANCER, V136, P55, DOI 10.1002/ijc.28967; Petrova TV, 2008, CANCER CELL, V13, P407, DOI 10.1016/j.ccr.2008.02.020; Qin B, 2015, CELL REP, V10, P1324, DOI 10.1016/j.celrep.2015.01.066; Ragusa S, 2014, CELL REP, V8, P1957, DOI 10.1016/j.celrep.2014.08.041; Sebio A, 2014, EXPERT OPIN THER TAR, V18, P611, DOI 10.1517/14728222.2014.906580; Seo WY, 2013, NUCLEIC ACIDS RES, V41, P8526, DOI 10.1093/nar/gkt644; SINICROPE FA, 1995, CANCER RES, V55, P237; Skog M, 2011, BRIT J CANCER, V105, P1346, DOI 10.1038/bjc.2011.297; Todaro M, 2010, GASTROENTEROLOGY, V138, P2151, DOI 10.1053/j.gastro.2009.12.063; Tutter AV, 2001, GENE DEV, V15, P3342, DOI 10.1101/gad.946501; Wiener Z, 2014, CELL REP, V8, P1943, DOI 10.1016/j.celrep.2014.08.034; Xu WQ, 2007, J CELL SCI, V120, P3337, DOI 10.1242/jcs.013771; Yang CK, 2006, J BIOL CHEM, V281, P3389, DOI 10.1074/jbc.M510403200; Yu EJ, 2013, ONCOGENE, V32, P4160, DOI 10.1038/onc.2012.420; Yu EJ, 2011, NUCLEIC ACIDS RES, V39, P6932, DOI 10.1093/nar/gkr347; Zhang YG, 2014, INT J CLIN ONCOL, V19, P106, DOI 10.1007/s10147-012-0506-5	31	20	21	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2016	35	26					3410	3418		10.1038/onc.2015.401	http://dx.doi.org/10.1038/onc.2015.401			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DQ5UI	26477307	Green Accepted			2022-12-17	WOS:000379270100006
J	Cheng, H; Liu, P; Ohlson, C; Xu, E; Symonds, L; Isabella, A; Muller, WJ; Lin, NU; Krop, IE; Roberts, TM; Winer, EP; Arteaga, CL; Zhao, JJ				Cheng, H.; Liu, P.; Ohlson, C.; Xu, E.; Symonds, L.; Isabella, A.; Muller, W. J.; Lin, N. U.; Krop, I. E.; Roberts, T. M.; Winer, E. P.; Arteaga, C. L.; Zhao, J. J.			PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling	ONCOGENE			English	Article							HUMAN BREAST-CANCER; PIK3CA MUTATIONS; TRASTUZUMAB RESISTANCE; ADJUVANT CHEMOTHERAPY; METABOLIC-REGULATION; UP-REGULATION; INHIBITION; EXPRESSION; PATHWAY; IMPACT	Human breast cancers that have HER2 amplification/overexpression frequently carry PIK3CA mutations, and are often associated with a worse prognosis. However, the role of PIK3CA mutations in the initiation and maintenance of these breast cancers remains elusive. In the present study, we generated a compound mouse model that genetically mimics HER2-positive breast cancer with coexisting PIK3CA(H1047R). Induction of PIK3CA(H1047R) expression in mouse mammary glands with constitutive expression of activated Her2/Neu resulted in accelerated mammary tumorigenesis with enhanced metastatic potential. Interestingly, inducible expression of mutant PIK3CA resulted in a robust activation of phosphatidylinositol-3-kinase (PI3K)/AKT signaling but attenuation of Her2/Her3 signaling, and this can be reversed by deinduction of PIK3CA(H1047R) expression. Strikingly, although these Her2(+) PIK3CA(H1047R) initiated primary mammary tumors are refractory to HER2-targeted therapy, all tumors responded to inactivation of the oncogenic PIK3CA(H1047R), a situation closely mimicking the use of a highly effective inhibitor specifically targeting the mutant PIK3CA/p110a. Notably, these tumors eventually resumed growth, and a fraction of them escaped PI3K dependence by compensatory ERK activation, which can be blocked by combined inhibition of Her2 and MEK. Together, these results suggest that PIK3CA-specific inhibition as a monotherapy followed by combination therapy targeting MAPK and HER2 in a timely manner may be an effective treatment approach against HER2-positive cancers with coexisting PIK3CA-activating mutations.	[Cheng, H.] Dalian Med Univ, Hosp 2, Inst Canc, Dalian 116023, Peoples R China; [Cheng, H.; Liu, P.; Ohlson, C.; Xu, E.; Symonds, L.; Isabella, A.; Roberts, T. M.; Zhao, J. J.] Dana Farber Canc Inst, Dept Canc Biol, 450 Brookline Ave Smith 936, Boston, MA 02215 USA; [Muller, W. J.] McGill Univ, Goodman Canc Res Ctr, Dept Biochem, Montreal, PQ, Canada; [Lin, N. U.] Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA; [Krop, I. E.; Winer, E. P.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Arteaga, C. L.] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Dept Med, 221 Kirkland Hall, Nashville, TN 37235 USA	Dalian Medical University; Harvard University; Dana-Farber Cancer Institute; McGill University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Vanderbilt University	Cheng, H (corresponding author), Dalian Med Univ, Hosp 2, Inst Canc, Dalian 116023, Peoples R China.; Zhao, JJ (corresponding author), Dana Farber Canc Inst, Dept Canc Biol, 450 Brookline Ave Smith 936, Boston, MA 02215 USA.	hailingcheng_dmu@163.com; jean_zhao@dfci.harvard.edu			Susan G. Komen Breast Cancer Foundation [CCR12225834]; Susan G. Komen Breast Cancer Foundation; Breast Cancer Research Foundation; ACS [CRP-07-234-06-COUN]; NIH [CA187918, CA172461-01, 1P50CA168504]; NATIONAL CANCER INSTITUTE [R01CA187918, P50CA168504, R01CA172461] Funding Source: NIH RePORTER	Susan G. Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); Susan G. Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); Breast Cancer Research Foundation; ACS(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Roderick Bronson and the Dana-Farber/Harvard Cancer Center Rodent Histoplathology Core for histopathological analyses. We thank L. Chodosh (University of Pennsylvania School of Medicine) for providing MMTVrtTAmice. This work was supported by the Susan G. Komen Breast Cancer Foundation CCR12225834 (HC), Susan G. Komen Breast Cancer Foundation (IEK), Breast Cancer Research Foundation (NUL, EPW and JJZ), ACS grant CRP-07-234-06-COUN (CLA), NIH grants CA187918 (TMR and JJZ), CA172461-01 (JJZ) and 1P50CA168504 (TMR, IEK, EPW, NUL and JJZ).	Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Baselga J, 2013, P 104 ANN M AM ASS C; Baselga J, 2013, 27 SEPT 1 OCT 2013 E; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Chakrabarty A, 2012, P NATL ACAD SCI USA, V109, P2718, DOI 10.1073/pnas.1018001108; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Cizkova M, 2013, BRIT J CANCER, V108, P1807, DOI 10.1038/bjc.2013.164; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Foukas LC, 2006, NATURE, V441, P366, DOI 10.1038/nature04694; Garcia-Echeverria C, 2008, ONCOGENE, V27, P5511, DOI 10.1038/onc.2008.246; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; Ghosh R, 2011, CANCER RES, V71, P1871, DOI 10.1158/0008-5472.CAN-10-1872; Gunther EJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0551com; Hanker AB, 2013, P NATL ACAD SCI USA, V110, P14372, DOI 10.1073/pnas.1303204110; Hynes NE, 2009, CANCER CELL, V15, P353, DOI 10.1016/j.ccr.2009.04.004; Jensen JD, 2012, ANN ONCOL, V23, P2034, DOI 10.1093/annonc/mdr546; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lerma E, 2008, VIRCHOWS ARCH, V453, P133, DOI 10.1007/s00428-008-0643-4; Liu PX, 2011, NAT MED, V17, P1116, DOI 10.1038/nm.2402; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Miron A, 2010, CANCER RES, V70, P5674, DOI 10.1158/0008-5472.CAN-08-2660; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nahta R, 2006, NAT CLIN PRACT ONCOL, V3, P269, DOI 10.1038/ncponc0509; Perez EA, 2013, J CLIN ONCOL, V31, P2115, DOI 10.1200/JCO.2012.42.2642; Perez EA, 2012, JNCI-J NATL CANCER I, V104, P159, DOI 10.1093/jnci/djr490; Perez EA, 2011, J CLIN ONCOL, V29, P4491, DOI 10.1200/JCO.2011.36.7045; Razis E, 2011, BREAST CANCER RES TR, V128, P447, DOI 10.1007/s10549-011-1572-5; Serra V, 2011, ONCOGENE, V30, P2547, DOI 10.1038/onc.2010.626; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; Sopasakis VR, 2010, CELL METAB, V11, P220, DOI 10.1016/j.cmet.2010.02.002; Stachler MD, 2015, APPL IMMUNOHISTOCHEM; Ursini-Siegel J, 2008, EMBO J, V27, P910, DOI 10.1038/emboj.2008.22; Yuan TL, 2008, P NATL ACAD SCI USA, V105, P9739, DOI 10.1073/pnas.0804123105	36	20	20	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2016	35	23					2961	2970		10.1038/onc.2015.377	http://dx.doi.org/10.1038/onc.2015.377			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0NB	26640141	Green Accepted			2022-12-17	WOS:000377474500002
J	Berbegall, AP; Villamon, E; Piqueras, M; Tadeo, I; Djos, A; Ambros, PF; Martinsson, T; Ambros, IM; Canete, A; Castel, V; Navarro, S; Noguera, R				Berbegall, A. P.; Villamon, E.; Piqueras, M.; Tadeo, I.; Djos, A.; Ambros, P. F.; Martinsson, T.; Ambros, I. M.; Canete, A.; Castel, V.; Navarro, S.; Noguera, R.			Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors	ONCOGENE			English	Article							COPY-NUMBER; METASTATIC NEUROBLASTOMA; INTEGRATIVE GENOMICS; 17Q GAIN; AMPLIFICATION; SURVIVAL; RISK; IDENTIFICATION; EXPRESSION; PHENOTYPE	Intratumoral heterogeneous MYCN amplification (hetMNA) is an unusual event in neuroblastoma with unascertained biological and clinical implications. Diagnosis is based on the detection of MYCN amplification surrounded by non-amplified tumor cells by fluorescence in situ hybridization (FISH). To better define the genetic features of hetMNA tumors, we studied the Spanish cohort of neuroblastic tumors by FISH and single nucleotide polymorphism arrays. We compared hetMNA tumors with homogeneous MNA (homMNA) and nonMNA tumors with 11q deletion (nonMNA w11q-). Of 1091 primary tumors, 28 were hetMNA by FISH. Intratumoral heterogeneity of 1p, 2p, 11q and 17q was closely associated with hetMNA tumors when analyzing different pieces for each case. For chromosome 2, 16 cases showed 2p intact, 4 focal gain at 2p24.3 and 8 MNA. The lengths of the smallest regions of overlap (SROs) for 2p gains and 1p deletions were between the SRO lengths observed in homMNA and nonMNA w11q- tumors. Co-occurrence of 11q- and +17q was frequently found with the largest SROs for both aberrations. The evidence for and frequency of different genetic subpopulations representing a hallmark of the hetMNA subgroup of NB indicates, on one hand, the presence of a considerable genetic instability with different SRO of either gains and losses compared with those of the other NB groups and highlights and, on the other hand, the need for multiple sampling from distant and macroscopically and microscopically distinct tumor areas. Narrowing down the different SRO for both deletions and gains in NB groups would be crucial to pinpointing the candidate gene(s) and the critical gene dosage with prognostic and therapeutic significance. This complexity of segmental chromosomal aberration patterns reinforces the necessity for a larger cohort study using FISH and pangenomic techniques to develop a suitable therapeutic strategy for these patients.	[Berbegall, A. P.; Villamon, E.; Piqueras, M.; Tadeo, I.; Navarro, S.; Noguera, R.] Univ Valencia, Med Res Fdn, INCLIVA, Pathol Dept,Med Sch, Valencia, Spain; [Djos, A.; Martinsson, T.] Univ Gothenburg, Sahlgrenska Acad, Dept Med & Clin Genet, Gothenburg, Sweden; [Ambros, P. F.; Ambros, I. M.] St Anna Kinderkrebsforschung, Childrens Canc Res Inst, Vienna, Austria; [Ambros, P. F.; Canete, A.; Castel, V.] Hosp Univ & Politecn La Fe, Pediat Oncol Unit, Valencia, Spain	University of Valencia; University of Gothenburg; Saint Anna Children's Hospital; Hospital Universitari i Politecnic La Fe	Noguera, R (corresponding author), Univ Valencia, Sch Med, Dept Pathol, INCLIVA, Avda Blasco Ibanez 15, Valencia 46010, Spain.	rosa.noguera@uv.es	Navarro, Samuel/AAD-2021-2020; Piqueras, Marta/ABH-1866-2020; Ambros, Peter/AAA-1266-2021; Martinsson, Tommy/J-4140-2013; Cañete, Adela/ABG-7558-2020; canete, adela/G-5903-2016; Tadeo, Irene/M-1639-2016; Berbegall, Ana/AAB-2258-2020	Navarro, Samuel/0000-0001-5016-5653; Piqueras, Marta/0000-0002-3748-7444; Ambros, Peter/0000-0002-5507-7211; Martinsson, Tommy/0000-0002-9403-3123; canete, adela/0000-0002-5669-5097; Tadeo, Irene/0000-0003-3690-5007; Berbegall, Ana/0000-0002-8798-3286; Djos, Anna/0000-0002-5250-2163; Villamon, Eva/0000-0003-0636-3358; Castel, Victoria/0000-0002-3792-0615	FIS [PI10/15]; RTICC, Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation & European Regional Development Fund [RD12/36/20, RD06/20/102]	FIS(Instituto de Salud Carlos III); RTICC, Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation & European Regional Development Fund	Spanish Society of Hematology and Pediatric Oncology and Desiree Ramal (Pediatric Oncology Unit, Hospital Universitario y Politecnico La Fe, Valencia, Spain) are gratefully acknowledged for patient data management. We thank members of the International Society of Pediatric Oncology Europe Neuroblastoma Biology Group for validation of the genetic diagnosis. We also thank David Harrison for English language editing. This work was supported by FIS (contract PI10/15) and RTICC (contracts RD12/36/20 and RD06/20/102), Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation & European Regional Development Fund.	Ambros IM, 2003, J CLIN ONCOL, V21, P2077, DOI 10.1200/JCO.2003.03.025; Ambros IM, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00202; Ambros IM, 2011, CLIN CANCER RES, V17, P792, DOI 10.1158/1078-0432.CCR-10-0830; Ambros PF, 2009, BRIT J CANCER, V100, P1471, DOI 10.1038/sj.bjc.6605014; Ambros PF, 2001, MED PEDIATR ONCOL, V36, P1; Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; Barone G, 2013, CLIN CANCER RES, V19, P5814, DOI 10.1158/1078-0432.CCR-13-0680; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bishop MW, 2014, J PEDIAT HEMATOL ONC, V36, pE31, DOI 10.1097/MPH.0b013e3182847376; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brodeur GM, 2002, MED PEDIATR ONCOL, V38, P112, DOI 10.1002/mpo.1282.abs; Brodeur GM, 2002, J PEDIAT HEMATOL ONC, V24, P608, DOI 10.1097/00043426-200211000-00002; Buckley PG, 2010, CLIN CANCER RES, V16, P2971, DOI 10.1158/1078-0432.CCR-09-3215; Canete A, 2009, J CLIN ONCOL, V27, P1014, DOI 10.1200/JCO.2007.14.5839; Capasso M, 2010, CANCER TREAT RES, V155, P65, DOI 10.1007/978-1-4419-6033-7_4; Caren H, 2010, P NATL ACAD SCI USA, V107, P4323, DOI 10.1073/pnas.0910684107; Cetinkaya C, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-231; Coco S, 2012, INT J CANCER, V131, P1591, DOI 10.1002/ijc.27432; Fix A, 2004, GENE CHROMOSOME CANC, V40, P266, DOI 10.1002/gcc.20041; Fix A, 2008, GENE CHROMOSOME CANC, V47, P819, DOI 10.1002/gcc.20583; Fujita T, 2008, JNCI-J NATL CANCER I, V100, P940, DOI 10.1093/jnci/djn176; George RE, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000255; Guimier A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101990; Kerbl R, 2002, MED PEDIATR ONCOL, V38, P109, DOI 10.1002/mpo.1281.abs; Kumps C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052321; Lastowska M, 2007, ONCOGENE, V26, P7432, DOI 10.1038/sj.onc.1210552; Lastowska M, 2002, GENE CHROMOSOME CANC, V34, P428, DOI 10.1002/gcc.10089; Lundberg G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059268; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Matthay KK, 2003, J CLIN ONCOL, V21, P2486, DOI 10.1200/JCO.2003.09.122; Morowitz M, 2003, MODERN PATHOL, V16, P1248, DOI 10.1097/01.MP.0000097364.64566.81; Mosse YP, 2007, GENE CHROMOSOME CANC, V46, P936, DOI 10.1002/gcc.20477; Piqueras M, 2011, BRIT J CANCER, V105, P89, DOI 10.1038/bjc.2011.188; Santo EE, 2012, ONCOGENE, V31, P1571, DOI 10.1038/onc.2011.344; Schleiermacher G, 2007, BRIT J CANCER, V97, P238, DOI 10.1038/sj.bjc.6603820; Schleiermacher G, 2012, BRIT J CANCER, V107, P1418, DOI 10.1038/bjc.2012.375; Shimada H, 1999, CANCER, V86, P364, DOI 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.3.CO;2-Z; Speleman F, 2011, SEMIN CANCER BIOL, V21, P238, DOI 10.1016/j.semcancer.2011.07.003; Spitz R, 2004, EUR J CANCER, V40, P2753, DOI 10.1016/j.ejca.2004.05.002; Squire, 1996, Mol Diagn, V1, P281, DOI 10.1016/S1084-8592(96)70010-3; Theissen J, 2014, GENE CHROMOSOME CANC, V53, P639, DOI 10.1002/gcc.22174; Theissen J, 2009, CLIN CANCER RES, V15, P2085, DOI 10.1158/1078-0432.CCR-08-1648; Thorner PS, 2006, AM J SURG PATHOL, V30, P635, DOI 10.1097/01.pas.0000202163.82525.5c; Valent A, 2004, CANCER GENET CYTOGEN, V153, P10, DOI 10.1016/j.cancergencyto.2003.12.007; Vandesompele J, 2008, INT J CANCER, V122, P1177, DOI 10.1002/ijc.23156; Villamon E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053740; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618; Westermark UK, 2011, SEMIN CANCER BIOL, V21, P256, DOI 10.1016/j.semcancer.2011.08.001; White PS, 2005, ONCOGENE, V24, P2684, DOI 10.1038/sj.onc.1208306	50	20	20	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2016	35	11					1423	1432		10.1038/onc.2015.200	http://dx.doi.org/10.1038/onc.2015.200			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG6LQ	26119945				2022-12-17	WOS:000372196400008
J	Lee, YS; Bae, SC				Lee, Y-S; Bae, S-C			How do K-RAS-activated cells evade cellular defense mechanisms?	ONCOGENE			English	Review							LUNG-CANCER; TRANSFORMING GENE; STEM-CELLS; RESTRICTION POINT; P53; CARCINOMA; ONCOGENE; ORIGIN; DIFFERENTIATION; ADENOCARCINOMA	Lung adenocarcinomas, like other cancers, develop through the accumulation of epigenetic and genetic alterations. Numerous studies have shown that K-RAS mutation is among the most important early events in carcinogenesis of the lung. However, it is also well established that growth-stimulating signals feed back into growth-suppressing pathways, and any imbalance in these signaling networks will cause the cell to exit the cell cycle, thereby preventing uncontrolled cell growth. How, then, do K-RAS-activated cells evade cellular defense mechanisms? To answer this question, it is necessary to identify the molecular event(s) responsible for the development of early dysplastic lesions that are unable to defend against aberrant oncogene activation. Lineage-determining transcriptional regulators govern differentiation status during normal lung development, as well as in lung adenocarcinoma. Among the genes involved in K-RAS-induced lung tumorigenesis, RUNX3 is unique: inactivation of Runx3 in mouse lung induces lung adenoma and abrogates the ARF-p53 pathway. This observation raises the possibility of intimate cross-talk between the differentiation program and oncogene surveillance. In this review, we summarized evidences suggesting that K-RAS-activated cells do not evade cellular defense mechanisms per se; instead, cells with K-RAS mutations are selected only if they occur in cells in which defense mechanism is abrogated.	[Lee, Y-S; Bae, S-C] Chungbuk Natl Univ, Dept Biochem, Sch Med, Cheongju 361763, South Korea; [Lee, Y-S; Bae, S-C] Chungbuk Natl Univ, Inst Tumor Res, Cheongju, South Korea	Chungbuk National University; Chungbuk National University	Bae, SC (corresponding author), Chungbuk Natl Univ, Dept Biochem, Sch Med, Cheongju 361763, South Korea.; Bae, SC (corresponding author), Chungbuk Natl Univ, Inst Tumor Res, Cheongju, South Korea.	scbae@chungbuk.ac.kr		Bae, Sang-Cheol/0000-0003-4658-1093	Creative Research Grant [2014R1A3A2030690]; Basic Science Research Program through National Research Foundation (NRF) - Ministry of Education of Korea [2013R1A1A2057659]	Creative Research Grant; Basic Science Research Program through National Research Foundation (NRF) - Ministry of Education of Korea	S-CB is supported by a Creative Research Grant (2014R1A3A2030690) and Y-SL is supported by Basic Science Research Program (2013R1A1A2057659) through the National Research Foundation (NRF) funded by the Ministry of Education of Korea.	Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Barkauskas CE, 2013, J CLIN INVEST, V123, P3025, DOI 10.1172/JCI68782; Bishop AE, 2004, CELL PROLIFERAT, V37, P89, DOI 10.1111/j.1365-2184.2004.00302.x; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Blagosklonny MV, 2002, CELL CYCLE, V1, P103, DOI 10.4161/cc.1.2.108; Blanpain C, 2013, NAT CELL BIOL, V15, P126, DOI 10.1038/ncb2657; Cho HC, 2011, CANCER RES, V71, P7250, DOI 10.1158/0008-5472.CAN-11-0903; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Efeyan A, 2007, CELL CYCLE, V6, P1006, DOI 10.4161/cc.6.9.4211; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; Garraway LA, 2006, NAT REV CANCER, V6, P593, DOI 10.1038/nrc1947; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HARVEY JJ, 1964, NATURE, V204, P1104, DOI 10.1038/2041104b0; Ito Y, 2015, NAT REV CANCER, V15, P81, DOI 10.1038/nrc3877; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; Keijzer R, 2001, DEVELOPMENT, V128, P503; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kim WJ, 2011, J UROLOGY, V185, P2366, DOI 10.1016/j.juro.2011.02.017; KIRSTEN WH, 1967, J NATL CANCER I, V39, P311; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Lee KS, 2010, ONCOGENE, V29, P3349, DOI 10.1038/onc.2010.79; Lee YS, 2013, CANCER CELL, V24, P603, DOI 10.1016/j.ccr.2013.10.003; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Maeda Y, 2007, PHYSIOL REV, V87, P219, DOI 10.1152/physrev.00028.2006; Maeda Y, 2012, J CLIN INVEST, V122, P4388, DOI 10.1172/JCI64048; Marchetti A, 1996, J PATHOL, V179, P254, DOI 10.1002/(SICI)1096-9896(199607)179:3<254::AID-PATH589>3.0.CO;2-J; Meuwissen R, 2005, GENE DEV, V19, P643, DOI 10.1101/gad.1284505; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Park SY, 2012, J CELL PHYSIOL, V227, P899, DOI 10.1002/jcp.22799; PULCIANI S, 1982, P NATL ACAD SCI-BIOL, V79, P2845, DOI 10.1073/pnas.79.9.2845; Rauen KA, 2007, CLIN GENET, V71, P101, DOI 10.1111/j.1399-0004.2007.00743.x; Reddy R, 2004, AM J PHYSIOL-LUNG C, V286, pL658, DOI 10.1152/ajplung.00159.2003; Rock JR, 2011, ANNU REV CELL DEV BI, V27, P493, DOI 10.1146/annurev-cellbio-100109-104040; Rock JR, 2009, P NATL ACAD SCI USA, V106, P12771, DOI 10.1073/pnas.0906850106; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P383, DOI 10.1073/pnas.80.2.383; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Snyder EL, 2013, MOL CELL, V50, P185, DOI 10.1016/j.molcel.2013.02.018; SUGIO K, 1994, CANCER RES, V54, P5811; Sutherland KD, 2014, P NATL ACAD SCI USA, V111, P4952, DOI 10.1073/pnas.1319963111; Sutherland KD, 2010, MOL ONCOL, V4, P397, DOI 10.1016/j.molonc.2010.05.002; Travis WD, 2002, CLIN CHEST MED, V23, P65, DOI 10.1016/S0272-5231(03)00061-3; Travis WD., 2004, TRAVIS WB WHO CLASSI; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Weinberg RA, 2007, BIOL CANC; Westcott PMK, 2015, NATURE, V517, P489, DOI 10.1038/nature13898; Winslow MM, 2011, NATURE, V473, P101, DOI 10.1038/nature09881; Wistuba II, 2006, ANNU REV PATHOL-MECH, V1, P331, DOI 10.1146/annurev.pathol.1.110304.100103; Xu X, 2012, P NATL ACAD SCI USA, V109, P4910, DOI 10.1073/pnas.1112499109; Yin Z, 2006, AM J PHYSIOL-LUNG C, V291, pL191, DOI 10.1152/ajplung.00385.2005; Zhang YZ, 2007, DEVELOPMENT, V134, P189, DOI 10.1242/dev.02720	68	20	20	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2016	35	7					827	832		10.1038/onc.2015.153	http://dx.doi.org/10.1038/onc.2015.153			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RO	25961920	Green Published, hybrid			2022-12-17	WOS:000370332200003
J	Wang, W; Liao, P; Shen, M; Chen, T; Chen, Y; Li, Y; Lin, X; Ge, X; Wang, P				Wang, W.; Liao, P.; Shen, M.; Chen, T.; Chen, Y.; Li, Y.; Lin, X.; Ge, X.; Wang, P.			SCP1 regulates c-Myc stability and functions through dephosphorylating c-Myc Ser62	ONCOGENE			English	Article							TERMINAL DOMAIN PHOSPHATASE; PROTEIN-KINASE CK2; GENE-EXPRESSION; BREAST-CANCER; DNA-BINDING; DEGRADATION; CELLS; COMPLEX; ACTIVATION; SUBUNIT	Serine 62 (Ser62) phosphorylation affects the c-Myc protein stability in cancer cells. However, the mechanism for dephosphorylating c-Myc is not well understood. In this study, we identified carboxyl-terminal domain RNA polymerase II polypeptide A small phosphatase 1 (SCP1) as a novel phosphatase specifically dephosphorylating c-Myc Ser62. Ectopically expressed SCP1 strongly dephosphorylated c-Myc Ser62, destabilized c-Myc protein and suppressed c-Myc transcriptional activity. Knockdown of SCP1 increased the c-Myc protein levels in liver cancer cells. SCP1 interacted with c-Myc both in vivo and in vitro. In addition, Ser245 at the C-terminus of SCP1 was essential for its phosphatase activity towards c-Myc. Functionally, SCP1 negatively regulated the cancer cell proliferation. Collectively, our findings indicate that SCP1 is a potential tumor suppressor for liver cancers through dephosphorylating c-Myc Ser62.	[Wang, W.; Liao, P.; Ge, X.; Wang, P.] Tongji Univ, Dept Cent Lab, Shanghai Peoples Hosp 10, Shanghai 200092, Peoples R China; [Wang, W.; Liao, P.; Shen, M.; Chen, T.; Chen, Y.; Li, Y.; Wang, P.] E China Normal Univ, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200062, Peoples R China; [Wang, W.; Liao, P.; Shen, M.; Chen, T.; Chen, Y.; Li, Y.; Wang, P.] E China Normal Univ, Sch Life Sci, Shanghai 200062, Peoples R China; [Lin, X.] Baylor Coll Med, Dept Surg, Houston, TX 77030 USA; [Wang, P.] Tongji Univ, Sch Life Sci & Technol, Shanghai 200092, Peoples R China	Tongji University; East China Normal University; East China Normal University; Baylor College of Medicine; Tongji University	Ge, X; Wang, P (corresponding author), Tongji Univ, Dept Cent Lab, Shanghai Peoples Hosp 10, Shanghai 200092, Peoples R China.; Wang, P (corresponding author), E China Normal Univ, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200062, Peoples R China.; Wang, P (corresponding author), E China Normal Univ, Sch Life Sci, Shanghai 200062, Peoples R China.	gexx0019@163.com; pwangecnu@163.com	Liao, Peng/Y-1896-2019	Liao, Peng/0000-0002-8409-5574	National Basic Research Program of China (973 program) [2012CB910404, 2010CB529704]; National Natural Science Foundation of China [30971521, 31171338, 31222037]; Shanghai Municipal Education Commission; Shanghai Education Development Foundation [11SG27]; Shanghai Key Laboratory of Regulatory Biology [11DZ2260300]; Shanghai Rising-Star program [09QA1401900, 13QH1401300]; scholar of the Program for New Century Excellent Talents in University [NCET-10-0387]	National Basic Research Program of China (973 program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Education Commission(Shanghai Municipal Education Commission (SHMEC)); Shanghai Education Development Foundation; Shanghai Key Laboratory of Regulatory Biology; Shanghai Rising-Star program; scholar of the Program for New Century Excellent Talents in University	This work was supported by grants from National Basic Research Program of China (973 program 2012CB910404 and 2010CB529704), National Natural Science Foundation of China (30971521, 31171338 and 31222037), 'Shu Guang' project supported by Shanghai Municipal Education Commission and Shanghai Education Development Foundation (11SG27), Shanghai Key Laboratory of Regulatory Biology (11DZ2260300) and Shanghai Rising-Star program (09QA1401900 and 13QH1401300). PW is a scholar of the Program for New Century Excellent Talents in University (NCET-10-0387).	Amanchy R, 2007, NAT BIOTECHNOL, V25, P285, DOI 10.1038/nbt0307-285; Amati B, 2004, P NATL ACAD SCI USA, V101, P8843, DOI 10.1073/pnas.0403046101; Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Arnold HK, 2009, EMBO J, V28, P500, DOI 10.1038/emboj.2008.279; Barford D, 1996, TRENDS BIOCHEM SCI, V21, P407, DOI 10.1016/S0968-0004(96)10060-8; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Conacci-Sorrell M, 2011, CELL CYCLE, V10, P604, DOI 10.4161/cc.10.4.14794; CROUCH DH, 1993, ONCOGENE, V8, P1849; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Farrell A.S., 2014, COLD SPRING HARB PER, V4; Farrell AS, 2013, MOL CELL BIOL, V33, P2930, DOI 10.1128/MCB.01455-12; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; Janghorban M, 2014, P NATL ACAD SCI USA, V111, P9157, DOI 10.1073/pnas.1317630111; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Kops O, 2002, FEBS LETT, V513, P305, DOI 10.1016/S0014-5793(02)02288-3; Liao P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.536; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; Liu LD, 2012, NATURE, V483, P608, DOI 10.1038/nature10927; Liu Lingfeng, 2012, Genes Cancer, V3, P23, DOI 10.1177/1947601912448067; Liu N, 2010, J BIOL CHEM, V285, P18858, DOI 10.1074/jbc.M109.099440; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; Stolk M, 2005, BIOCHEM J, V386, P281, DOI 10.1042/BJ20041571; Strack S, 1999, FEBS LETT, V460, P462, DOI 10.1016/S0014-5793(99)01377-0; Tan J, 2010, CANCER CELL, V18, P459, DOI 10.1016/j.ccr.2010.10.021; Wang XY, 2011, CANCER RES, V71, P925, DOI 10.1158/0008-5472.CAN-10-1032; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Wrighton KH, 2006, J BIOL CHEM, V281, P38365, DOI 10.1074/jbc.M607246200; Wu YD, 2009, J BIOL CHEM, V284, P640, DOI 10.1074/jbc.M806916200; Xue Y, 2005, NUCLEIC ACIDS RES, V33, pW184, DOI 10.1093/nar/gki393; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yeo M, 2003, J BIOL CHEM, V278, P26078, DOI 10.1074/jbc.M301791200; Yeo M, 2005, SCIENCE, V307, P596, DOI 10.1126/science.1100801; Zhang MM, 2010, PROTEIN SCI, V19, P974, DOI 10.1002/pro.375; Zhang XL, 2012, P NATL ACAD SCI USA, V109, P2790, DOI 10.1073/pnas.1100764108; Zhang Y, 2006, MOL CELL, V24, P759, DOI 10.1016/j.molcel.2006.10.027	45	20	20	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2016	35	4					491	500		10.1038/onc.2015.106	http://dx.doi.org/10.1038/onc.2015.106			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OT	25893300				2022-12-17	WOS:000369056700009
J	Koch, DC; Jang, HS; O'Donnell, EF; Punj, S; Kopparapu, PR; Bisson, WH; Kerkvliet, NI; Kolluri, SK				Koch, D. C.; Jang, H. S.; O'Donnell, E. F.; Punj, S.; Kopparapu, P. R.; Bisson, W. H.; Kerkvliet, N. I.; Kolluri, S. K.			Anti-androgen flutamide suppresses hepatocellular carcinoma cell proliferation via the aryl hydrocarbon receptor mediated induction of transforming growth factor-beta 1	ONCOGENE			English	Article							BREAST-CANCER CELLS; AH-RECEPTOR; ESTROGEN-RECEPTOR; DIOXIN-RECEPTOR; CYCLE CONTROL; IN-VIVO; EXPRESSION; PROTEIN; GROWTH; MECHANISM	The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor and a member of the basic helix-loop-helix PER/ARNT/SIM family of chemosensors and developmental regulators. The AhR is widely known as a mediator of dioxin toxicity; however, it also suppresses cancer cell proliferation and recent findings have implicated its role as a tumor suppressor. We conducted a chemical library screen to identify nontoxic AhR ligands with anti-cancer effects and discovered flutamide (Eulexin) as a putative AhR ligand. Flutamide is an androgen receptor (AR) antagonist approved by the United States Food and Drug Administration for the treatment of prostate cancer. We found that flutamide inhibited the growth of several cancer cell lines independent of AR status, and that suppression of AhR expression reversed the anti-proliferative effects of flutamide. We investigated the AhR-dependent mechanism of action of flutamide in human hepatocellular carcinoma cells and identified that transforming growth factor-beta 1 (TGF-beta 1) is induced by flutamide in an AhR-dependent manner. In contrast, the potent AhR agonist 2,3,7,8-Tetrachlorodibenzo-p-dioxin had no effect on TGF-beta 1 expression, indicating the ligand specificity of AhR activation. We also determined that TGF-beta 1 induction is required for the AhR-dependent growth inhibitory effects of flutamide. Therefore, flutamide may be effective in AhR-positive cancers that are sensitive to TGF-beta 1 signaling, such as hepatocellular carcinoma.	[Koch, D. C.; Jang, H. S.; O'Donnell, E. F.; Punj, S.; Kopparapu, P. R.; Kolluri, S. K.] Oregon State Univ, Dept Environm & Mol Toxicol, Canc Res Lab, Corvallis, OR 97331 USA; [Koch, D. C.; Jang, H. S.; O'Donnell, E. F.; Punj, S.; Kopparapu, P. R.; Bisson, W. H.; Kerkvliet, N. I.; Kolluri, S. K.] Oregon State Univ, Dept Environm & Mol Toxicol, Environm Hlth Sci Ctr, Corvallis, OR 97331 USA	Oregon State University; Oregon State University	Kolluri, SK (corresponding author), Oregon State Univ, Dept Environm & Mol Toxicol, Canc Res Lab, 1007 ALS Bldg, Corvallis, OR 97331 USA.	siva.kolluri@oregonstate.edu		Jang, Hyo Sang/0000-0003-0460-9924; /0000-0001-9516-9690	American Cancer Society [RSG-13-132-01-CDD]; National Institute of Environmental Health Sciences (NIEHS) [ES016651, ES019000]; US Army Medical Research and Material Command; Cell Imaging and Analysis Facility Cores of the Environmental Health Sciences Center, NIEHS [P30 ES00210]; National Cancer Institute [1F31CA144571-01]; Burroughs Wellcome Fund post-doctoral enrichment program; Department of Defense Breast Cancer Research Program [W81XWH-10-1-0160]; NIEHS [T32ES07060]; NATIONAL CANCER INSTITUTE [F31CA144571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016651, R21ES019000, P30ES000210, T32ES007060] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); National Institute of Environmental Health Sciences (NIEHS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); US Army Medical Research and Material Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); Cell Imaging and Analysis Facility Cores of the Environmental Health Sciences Center, NIEHS; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Burroughs Wellcome Fund post-doctoral enrichment program; Department of Defense Breast Cancer Research Program(United States Department of Defense); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by American Cancer Society (RSG-13-132-01-CDD), the National Institute of Environmental Health Sciences (NIEHS) grant numbers ES016651 and ES019000, The US Army Medical Research and Material Command and The Cell Imaging and Analysis Facility Cores of the Environmental Health Sciences Center, NIEHS grant number P30 ES00210. DCK was supported by a National Research Service Award (1F31CA144571-01) pre-doctoral fellowship from the National Cancer Institute. DCK is currently supported by the Burroughs Wellcome Fund post-doctoral enrichment program. EFO was supported by a pre-doctoral fellowship from the Department of Defense Breast Cancer Research Program (W81XWH-10-1-0160). DCK and EFO were previously supported by NIEHS training grant (T32ES07060). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. We thank Samuel Bradford for excellent flow cytometry assistance, Sammy Khalil, Cathy Duong and Viktor Dikov for laboratory assistance.	ABBOTT BD, 1994, TOXICOL APPL PHARM, V126, P16, DOI 10.1006/taap.1994.1085; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Beischlag TV, 2008, CRIT REV EUKAR GENE, V18, P207, DOI 10.1615/CritRevEukarGeneExpr.v18.i3.20; Bertazzi PA, 1997, EPIDEMIOLOGY, V8, P646, DOI 10.1097/00001648-199710000-00006; Bisson WH, 2009, J MED CHEM, V52, P5635, DOI 10.1021/jm900199u; Bock KW, 2006, BIOCHEM PHARMACOL, V72, P393, DOI 10.1016/j.bcp.2006.01.017; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; Carvajal-Gonzalez JM, 2009, J CELL SCI, V122, P1823, DOI 10.1242/jcs.047274; Carver LA, 1997, J BIOL CHEM, V272, P11452; Chang XQ, 2007, MOL CELL BIOL, V27, P6127, DOI 10.1128/MCB.00323-07; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; Dohr O, 1997, BIOCHEM BIOPH RES CO, V241, P86, DOI 10.1006/bbrc.1997.7773; EGELAND GM, 1994, AM J EPIDEMIOL, V139, P272, DOI 10.1093/oxfordjournals.aje.a116994; Elizondo G, 2000, MOL PHARMACOL, V57, P1056; Fan YX, 2010, CANCER RES, V70, P212, DOI 10.1158/0008-5472.CAN-09-3090; Fanayan S, 2002, J BIOL CHEM, V277, P7255, DOI 10.1074/jbc.M108038200; Felts SJ, 2003, CELL STRESS CHAPERON, V8, P108, DOI 10.1379/1466-1268(2003)008<0108:PASPWC>2.0.CO;2; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FernandezSalguero PM, 1996, TOXICOL APPL PHARM, V140, P173, DOI 10.1006/taap.1996.0210; Fritz WA, 2007, CARCINOGENESIS, V28, P497, DOI 10.1093/carcin/bgl179; Funatake CJ, 2008, J IMMUNOTOXICOL, V5, P81, DOI 10.1080/15476910802019037; Gasiewicz TA, 2008, CRIT REV EUKAR GENE, V18, P279, DOI 10.1615/CritRevEukarGeneExpr.v18.i4.10; Ge NL, 1998, J BIOL CHEM, V273, P22708, DOI 10.1074/jbc.273.35.22708; Gomez-Duran A, 2009, BIOCHEM PHARMACOL, V77, P700, DOI 10.1016/j.bcp.2008.08.032; Hall JM, 2010, MOL ENDOCRINOL, V24, P359, DOI 10.1210/me.2009-0346; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hsu EL, 2007, TOXICOL SCI, V98, P436, DOI 10.1093/toxsci/kfm125; Hu WY, 2007, MOL PHARMACOL, V71, P1475, DOI 10.1124/mol.106.032748; Jin UH, 2012, J PHARMACOL EXP THER, V343, P333, DOI 10.1124/jpet.112.195339; Kharat I, 1996, J BIOL CHEM, V271, P10533, DOI 10.1074/jbc.271.18.10533; Kolluri SK, 2001, CANCER RES, V61, P8534; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Lai IK, 2012, TOXICOLOGY, V302, P25, DOI 10.1016/j.tox.2012.07.007; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Mitsuhashi T, 2010, P NATL ACAD SCI USA, V107, P16331, DOI 10.1073/pnas.1002960107; Mullen AC, 2011, CELL, V147, P565, DOI 10.1016/j.cell.2011.08.050; Murray IA, 2014, NAT REV CANCER, V14, P801, DOI 10.1038/nrc3846; O'Donnell EF, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.549; O'Donnell EF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040926; O'Donnell EF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013128; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; Perdew GH, 1996, BIOCHEM MOL BIOL INT, V39, P589; Perkins Arden, 2014, Biology (Basel), V3, P645, DOI 10.3390/biology3040645; Puga A, 2002, CHEM-BIOL INTERACT, V141, P117, DOI 10.1016/S0009-2797(02)00069-8; Puga A, 2009, BIOCHEM PHARMACOL, V77, P713, DOI 10.1016/j.bcp.2008.08.031; Punj S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088726; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RIER SE, 1993, FUND APPL TOXICOL, V21, P433, DOI 10.1006/faat.1993.1119; Robson CN, 1999, J ENDOCRINOL, V160, P257, DOI 10.1677/joe.0.1600257; Safe S, 2001, TOXICOL LETT, V120, P1, DOI 10.1016/S0378-4274(01)00301-0; Safe S, 2013, TOXICOL SCI, V135, P1, DOI 10.1093/toxsci/kft128; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Warner M, 2002, AM J EPIDEMIOL, V155, ps102; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; Zhang S, 2012, MOL CANCER THER, V11, P108, DOI 10.1158/1535-7163.MCT-11-0548	56	20	24	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2015	34	50					6092	6104		10.1038/onc.2015.55	http://dx.doi.org/10.1038/onc.2015.55			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RQ	25867062				2022-12-17	WOS:000366113800006
J	Kaur, J; Tikoo, K				Kaur, J.; Tikoo, K.			Ets1 identified as a novel molecular target of RNA aptamer selected against metastatic cells for targeted delivery of nano-formulation	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; CANCER; EXPRESSION; NANOPARTICLES	Nanomedicine era is not far from its realization, but a major concern of targeted delivery still stands tall in its way. Herein we demonstrate the mechanism underlying the anticancer activity of an RNA aptamer (Apt) conjugated to gefitinib-loaded poly (lactic co-glycolic acid) nanoparticles (GNPs). Apt was selected through Cell-SELEX (systemic evolution of ligands by exponential enrichment) process against gefitinib-resistant H1975 lung cancer cells. The selected aptamer exhibited high specificity toward H1975 cells, both qualitatively as well as quantitatively. Software analysis using the MATCH tool predicted Ets1, a proto-oncoprotein, to be the target of the selected aptamer. Interestingly, the localization of identified aptamer varied in descending order of Ets1 expression, wherein maximum localization was observed in H1975 cells than in MDA-MB231, DU-145, H23, H460, A431, A549 and MCF-7 cells, and minimum in L132 cells. Furthermore, Apt-GNP bio-conjugate showed augmented anticancer activity specifically in Ets1-overexpressing cells. In addition, partial depletion of Ets1 in H1975 cells and overexpression of Ets1 in L132 cells reversed the targeting efficacy of the aptamer. Notably, a single intratumoral injection of the Apt-GNP bio-conjugate abrogated the growth of tumor in H1975 xenograft nude mice. Altogether, we present a pioneering platform, involving aptamers, which can be clinically used as a diagnostic marker for metastasis as well as an effective delivery system to escort the pharmaceutical cargo specifically to Ets1-overexpressing highly progressive tumors.	[Kaur, J.; Tikoo, K.] Natl Inst Pharmaceut Educ & Res, Dept Pharmacol & Toxicol, Lab Epigenet & Dis, Sas Nagar 160062, Punjab, India	National Institute of Pharmaceutical Education & Research (NIPER); National Institute of Pharmaceutical Education & Research, S.A.S. Nagar (Mohali)	Tikoo, K (corresponding author), Natl Inst Pharmaceut Educ & Res, Dept Pharmacol & Toxicol, Lab Epigenet & Dis, Phase 10, Sas Nagar 160062, Punjab, India.	tikoo.k@gmail.com		Tikoo, Kulbhushan/0000-0003-3061-9739				Arteaga CL, 2001, CURR OPIN ONCOL, V13, P491, DOI 10.1097/00001622-200111000-00012; Buggy Y, 2004, BRIT J CANCER, V91, P1308, DOI 10.1038/sj.bjc.6602128; Chu TC, 2006, CANCER RES, V66, P5989, DOI 10.1158/0008-5472.CAN-05-4583; Dassie JP, 2014, MOL THER, V22, P1910, DOI 10.1038/mt.2014.117; Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Farokhzad OC, 2004, CANCER RES, V64, P7668, DOI 10.1158/0008-5472.CAN-04-2550; Farokhzad OC, 2006, P NATL ACAD SCI USA, V103, P6315, DOI 10.1073/pnas.0601755103; Guo KT, 2008, INT J MOL SCI, V9, P668, DOI 10.3390/ijms9040668; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Kaur J, 2013, BBA-MOL CELL RES, V1833, P1028, DOI 10.1016/j.bbamcr.2013.01.029; Keefe AD, 2010, NAT REV DRUG DISCOV, V9, P537, DOI 10.1038/nrd3141; Kel AE, 2003, NUCLEIC ACIDS RES, V31, P3576, DOI 10.1093/nar/gkg585; Kim Y, 2013, CANCER RES, V73, P4923, DOI 10.1158/0008-5472.CAN-12-4556; Li N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020299; Li R, 2000, ONCOGENE, V19, P55; Lupold SE, 2002, CANCER RES, V62, P4029; Meert AP, 2002, EUR RESPIR J, V20, P975, DOI 10.1183/09031936.02.00296502; Mi J, 2010, NAT CHEM BIOL, V6, P22, DOI [10.1038/NCHEMBIO.277, 10.1038/nchembio.277]; Nakayama T, 2001, MODERN PATHOL, V14, P415, DOI 10.1038/modpathol.3880328; Petros RA, 2010, NAT REV DRUG DISCOV, V9, P615, DOI 10.1038/nrd2591; SACCHI N, 1988, LEUKEMIA, V2, P12; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Shangguan DH, 2008, ANAL CHEM, V80, P721, DOI 10.1021/ac701962v; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Valter MM, 1999, CANCER RES, V59, P5608; Van Simaeys D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013770; Xiao ZY, 2012, ACS NANO, V6, P696, DOI 10.1021/nn204165v	30	20	22	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2015	34	41					5216	5228		10.1038/onc.2014.447	http://dx.doi.org/10.1038/onc.2014.447			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CT1QL	25639877	Green Published			2022-12-17	WOS:000362575400002
J	Hayashi, K; Momoi, Y; Tanuma, N; Kishimoto, A; Ogoh, H; Kato, H; Suzuki, M; Sakamoto, Y; Inoue, Y; Nomura, M; Kiyonari, H; Sakayori, M; Fukamachi, K; Kakugawa, Y; Yamashita, Y; Ito, S; Sato, I; Suzuki, A; Nishio, M; Suganuma, M; Watanabe, T; Shima, H				Hayashi, K.; Momoi, Y.; Tanuma, N.; Kishimoto, A.; Ogoh, H.; Kato, H.; Suzuki, M.; Sakamoto, Y.; Inoue, Y.; Nomura, M.; Kiyonari, H.; Sakayori, M.; Fukamachi, K.; Kakugawa, Y.; Yamashita, Y.; Ito, S.; Sato, I.; Suzuki, A.; Nishio, M.; Suganuma, M.; Watanabe, T.; Shima, H.			Abrogation of protein phosphatase 6 promotes skin carcinogenesis induced by DMBA	ONCOGENE			English	Article							MOUSE SKIN; TNF-ALPHA; KAPPA-B; CANCER DEVELOPMENT; TUMOR PROMOTION; OKADAIC ACID; CYCLIN D1; MICE; PROGRESSION; ACTIVATION	Somatic mutations in the gene encoding the catalytic subunit of protein phosphatase 6 (Ppp6c) have been identified in malignant melanoma and are thought to function as a driver in B-raf-or N-ras-driven tumorigenesis. To assess the role of Ppp6c in carcinogenesis, we generated skin keratinocyte-specific Ppp6c conditional knockout mice and performed two-stage skin carcinogenesis analysis. Ppp6c deficiency induced papilloma formation with 7,12-dimethylbenz (a) anthracene (DMBA) only, and development of those papillomas was significantly accelerated compared with that seen following DMBA/TPA (12-O-tetradecanoylphorbol 13-acetate) treatment of wild-type mice. NF-kappa B activation either by tumor necrosis factor (TNF)-alpha or interleukin (IL)-1 beta was enhanced in Ppp6c-deficient keratinocytes. Overall, we conclude that Ppp6c deficiency predisposes mice to skin carcinogenesis initiated by DMBA. This is the first report showing that such deficiency promotes tumor formation in mice.	[Hayashi, K.; Momoi, Y.; Tanuma, N.; Kato, H.; Sakamoto, Y.; Inoue, Y.; Nomura, M.; Sakayori, M.; Fukamachi, K.; Kakugawa, Y.; Yamashita, Y.; Shima, H.] Miyagi Canc Ctr, Res Inst, Div Canc Chemotherapy, Natori, Miyagi 9811293, Japan; [Hayashi, K.; Tanuma, N.; Kato, H.; Shima, H.] Tohoku Univ, Sch Med, Div Canc Mol Biol, Sendai, Miyagi 980, Japan; [Kishimoto, A.; Ogoh, H.; Suzuki, M.; Watanabe, T.] Nara Womens Univ, Dept Biol Sci, Grad Sch Humanities & Sci, Nara 630, Japan; [Kiyonari, H.] RIKEN Ctr Dev Biol, Lab Anim Resources & Genet Engn, Kobe, Hyogo, Japan; [Ito, S.; Sato, I.] Miyagi Canc Ctr, Div Pathol, Natori, Miyagi 9811293, Japan; [Suzuki, A.; Nishio, M.] Kyushu Univ, Med Inst Bioregulat, Div Canc Genet, Fukuoka 812, Japan; [Suganuma, M.] Saitama Canc Ctr, Res Inst Clin Oncol, Saitama, Japan	Miyagi Cancer Center; Tohoku University; Nara Womens University; RIKEN; Miyagi Cancer Center; Kyushu University	Shima, H (corresponding author), Miyagi Canc Ctr, Res Inst, Div Canc Chemotherapy, 47-1 Nodayama, Natori, Miyagi 9811293, Japan.	shima@med.tohoku.ac.jp	Kiyonari, Hiroshi/N-7936-2015		JSPS KAKENHI [24591928, 25861168, 22590298]; Women's University Intramural Grant for Project Research	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Women's University Intramural Grant for Project Research	We thank Dr Hirota Fujiki for critical advice and Dr Yoshikazu Nishino for statistical analyses. We thank Nozomi Sasaki, Kuniko Komuro and Miyuki Ueki for technical assistance. We thank Dr Elise Lamar for English editing. This work was supported by JSPS KAKENHI grant numbers 24591928 to Yoichiro Kakugawa, 25861168 to Kayoko Fukamachi and 22590298 to Hiroshi Shima and by a Nara Women's University Intramural Grant for Project Research to Toshio Watanabe.	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Afshar K, 2010, DEVELOPMENT, V137, P237, DOI 10.1242/dev.042754; Ancrile BB, 2008, MOL INTERV, V8, P22, DOI 10.1124/mi.8.1.6; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bastians H, 1996, J CELL SCI, V109, P2865; Brautigan DL, 2013, FEBS J, V280, P324, DOI 10.1111/j.1742-4658.2012.08609.x; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Davalos AR, 2010, CANCER METAST REV, V29, P273, DOI 10.1007/s10555-010-9220-9; Fimmel S, 2007, ANN NY ACAD SCI, V1119, P176, DOI 10.1196/annals.1404.016; Fujiki H, 2011, ANTI-CANCER AGENT ME, V11, P4, DOI 10.2174/187152011794941163; Goshima G, 2003, EMBO J, V22, P2752, DOI 10.1093/emboj/cdg266; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Kajino T, 2006, J BIOL CHEM, V281, P39891, DOI 10.1074/jbc.M608155200; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kolar M, 2012, BIOL CELL, V104, P738, DOI 10.1111/boc.201200018; KOMORI A, 1993, CANCER RES, V53, P3462; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Lichti U, 2008, NAT PROTOC, V3, P799, DOI 10.1038/nprot.2008.50; Luke MM, 1996, MOL CELL BIOL, V16, P2744; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Masuda K, 2010, BIOCHEM BIOPH RES CO, V393, P201, DOI 10.1016/j.bbrc.2010.01.097; Mi J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004395; Omori E, 2008, J BIOL CHEM, V283, P26161, DOI 10.1074/jbc.M804513200; Schioppa T, 2011, P NATL ACAD SCI USA, V108, P10662, DOI 10.1073/pnas.1100994108; Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006; Stefansson B, 2008, BIOCHEMISTRY-US, V47, P1442, DOI 10.1021/bi7022877; Stefansson B, 2006, J BIOL CHEM, V281, P22624, DOI 10.1074/jbc.M601772200; Suganuma M, 1999, CANCER RES, V59, P4516; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; Sundberg JP, 1997, MOL CARCINOGEN, V20, P19, DOI 10.1002/(SICI)1098-2744(199709)20:1<19::AID-MC4>3.0.CO;2-D; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; Suzuki JS, 2003, CARCINOGENESIS, V24, P1123, DOI 10.1093/carcin/bgg052; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; Valdiglesias V, 2013, MUTAT RES-REV MUTAT, V753, P24, DOI 10.1016/j.mrrev.2013.02.001; Vandercappellen J, 2008, CANCER LETT, V267, P226, DOI 10.1016/j.canlet.2008.04.050; Zhang BX, 1998, CANCER RES, V58, P4044	37	20	20	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2015	34	35					4647	4655		10.1038/onc.2014.398	http://dx.doi.org/10.1038/onc.2014.398			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BS	25486434				2022-12-17	WOS:000360189300010
J	Truesdell, P; Ahn, J; Chander, H; Meens, J; Watt, K; Yang, X; Craig, AWB				Truesdell, P.; Ahn, J.; Chander, H.; Meens, J.; Watt, K.; Yang, X.; Craig, A. W. B.			CIP4 promotes lung adenocarcinoma metastasis and is associated with poor prognosis	ONCOGENE			English	Article							CDC42-INTERACTING PROTEIN 4; GROWTH-FACTOR RECEPTOR; EPITHELIAL-MESENCHYMAL TRANSITION; CANCER-CELL INVASION; ACTIN CYTOSKELETON; MEMBRANE INVAGINATION; TUMOR PROGRESSION; DOWN-REGULATION; KINASE DOMAIN; BAR PROTEINS	Aberrant epidermal growth factor receptor (EGFR) signaling in non-small cell lung cancer (NSCLC) is linked to tumor progression, metastasis and poor survival rates. Here we report the role of Cdc42-interacting protein 4 (CIP4) in the regulation of NSCLC cell invasiveness and tumor metastasis. CIP4 was highly expressed in a panel of NSCLC cell lines and normal lung epithelial cell lines. Stable knockdown (KD) of CIP4 in lung adenocarcinoma H1299 cells, expressing wild-type EGFR, led to increased EGFR levels on the cell surface and defects in sustained activation of Erk kinase in H1299 cells treated with EGF. CIP4 localized to leading edge projections in NSCLC cells, and CIP4 KD cells displayed defects in EGF-induced cell motility and invasion through extracellular matrix. This correlated with reduced expression and activity of matrix metalloproteinase-2 (MMP-2) in CIP4 KD cells compared with control. In xenograft assays, CIP4 silencing had no effect on tumor growth but resulted in significant defects in spontaneous metastases to the lungs from these subcutaneous tumors. This correlated with reduced expression of the Erk target gene Zeb1 and the Zeb1 target gene MMP-2 in CIP4 KD tumors compared with control. CIP4 also enhanced rates of metastasis to the liver and lungs in an intrasplenic experimental metastasis model. In human NSCLC tumor sections, CIP4 expression was elevated greater than or equal to twofold in 43% of adenocarcinomas and 32% of squamous carcinomas compared with adjacent normal lung tissues. Analysis of microarray data for NSCLC patients also revealed that high CIP4 transcript levels correlated with reduced overall survival. Together, these results identify CIP4 as a positive regulator of NSCLC metastasis and a potential poor prognostic biomarker in lung adenocarcinoma.	[Truesdell, P.; Ahn, J.; Chander, H.; Meens, J.; Watt, K.; Craig, A. W. B.] Queens Univ, Dept Biomed & Mol Sci, Kingston, ON K7L 3N6, Canada; [Truesdell, P.; Ahn, J.; Chander, H.; Meens, J.; Watt, K.; Craig, A. W. B.] Queens Canc Res Inst, Canc Biol & Genet, Kingston, ON, Canada; [Yang, X.] Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada	Queens University - Canada; McMaster University; Queens University - Canada	Craig, AWB (corresponding author), Queens Univ, Dept Biomed & Mol Sci & Canc Biol & Genet, 18 Stuart St, Kingston, ON K7L 3N6, Canada.	andrew.craig@queensu.ca	Craig, Andrew/AAC-6923-2019; Craig, Andrew/G-2312-2017	Craig, Andrew/0000-0002-2039-2393; Craig, Andrew/0000-0002-2039-2393; Watt, Kathleen/0000-0001-6642-9756	Canadian Cancer Society Research Institute; Canadian Institutes for Health Research [MOP119562]	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR))	We thank Stephanie Everingham for technical assistance, Jeff Mewburn for help with time-lapse confocal microscopy and Lee Boudreau (Queen's Laboratory for Molecular Pathology) for help in optimizing IHC staining. Thanks also to Lois Mulligan, Peter Greer and Chris Nicol for sharing reagents and equipment. This research was supported by operating grants from Canadian Cancer Society Research Institute and Canadian Institutes for Health Research to AWBC (MOP119562).	Ahn J, 2013, MOL CANCER RES, V11, P952, DOI 10.1158/1541-7786.MCR-13-0003-T; Aspenstrom P, 1997, CURR BIOL, V7, P479, DOI 10.1016/S0960-9822(06)00219-3; Aspenstrom P, 2006, TRENDS BIOCHEM SCI, V31, P670, DOI 10.1016/j.tibs.2006.10.001; Aspenstrom P, 2006, EXP CELL RES, V312, P2180, DOI 10.1016/j.yexcr.2006.03.013; Bae GY, 2013, ONCOTARGET, V4, P2512, DOI 10.18632/oncotarget.1463; Bai SJ, 2012, INT J BIOL SCI, V8, P859, DOI 10.7150/ijbs.3490; Dong QZ, 2013, AM J PATHOL, V182, P954, DOI 10.1016/j.ajpath.2012.11.019; Downward J, 2008, NAT MED, V14, P1315, DOI 10.1038/nm1208-1315; Feng YM, 2010, J BIOL CHEM, V285, P4348, DOI 10.1074/jbc.M109.041038; Frost A, 2008, CELL, V132, P807, DOI 10.1016/j.cell.2007.12.041; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hirsch FR, 2008, J CLIN ONCOL, V26, P3351, DOI 10.1200/JCO.2007.14.0111; Hsu CC, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-12; Hu JH, 2011, J CELL SCI, V124, P1739, DOI 10.1242/jcs.078014; Hu JH, 2009, CELL SIGNAL, V21, P1686, DOI 10.1016/j.cellsig.2009.07.007; Huang MS, 2002, CLIN EXP METASTAS, V19, P359, DOI 10.1023/A:1015562532564; Ishikawa D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062104; Itoh T, 2005, DEV CELL, V9, P791, DOI 10.1016/j.devcel.2005.11.005; Kao SJ, 2012, TOXICOL APPL PHARM, V261, P105, DOI 10.1016/j.taap.2012.03.020; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Koduru S, 2010, P NATL ACAD SCI USA, V107, P16252, DOI 10.1073/pnas.1002747107; Koshkina NV, 2013, CURR CANCER DRUG TAR, V13, P48; Leibfried A, 2008, CURR BIOL, V18, P1639, DOI 10.1016/j.cub.2008.09.063; Li ZX, 2012, MOL CARCINOGEN, V51, P522, DOI 10.1002/mc.20815; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Malet-Engra G, 2013, CANCER RES, V73, P3412, DOI 10.1158/0008-5472.CAN-12-3564; Mitsudomi T, 2010, FEBS J, V277, P301, DOI 10.1111/j.1742-4658.2009.07448.x; Pichot CS, 2010, CANCER RES, V70, P8347, DOI 10.1158/0008-5472.CAN-09-4149; Richnau N, 2001, J BIOL CHEM, V276, P35060, DOI 10.1074/jbc.M103540200; Rosell R, 2010, CLIN TRANSL ONCOL, V12, P75, DOI 10.1007/S12094-010-0473-0; Rusch V, 1997, CLIN CANCER RES, V3, P515; Saengsawang W, 2013, J CELL SCI, V126, P2411, DOI 10.1242/jcs.117473; Saengsawang W, 2012, CURR BIOL, V22, P494, DOI 10.1016/j.cub.2012.01.038; Shimada A, 2007, CELL, V129, P761, DOI 10.1016/j.cell.2007.03.040; Takano K, 2008, EMBO J, V27, P2817, DOI 10.1038/emboj.2008.216; Taylor MJ, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000604; Tian L, 2000, J BIOL CHEM, V275, P7854, DOI 10.1074/jbc.275.11.7854; Tsuji E, 2006, BIOCHEM BIOPH RES CO, V339, P1083, DOI 10.1016/j.bbrc.2005.11.117; Tsujita K, 2006, J CELL BIOL, V172, P269, DOI 10.1083/jcb.200508091; Yang MM, 2013, INT J CANCER, V132, pE74, DOI 10.1002/ijc.27813; Zhang J, 2013, RENAL FAILURE, V35, P989, DOI 10.3109/0886022X.2013.808957; Zhao M, 2002, FASEB J, V16, P857, DOI 10.1096/fj.01-0811fje; Zhou Z, 2011, ONCOGENE, V30, P2181, DOI 10.1038/onc.2010.606	44	20	20	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	27					3527	3535		10.1038/onc.2014.280	http://dx.doi.org/10.1038/onc.2014.280			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM1IQ	25174397	Green Accepted, Bronze			2022-12-17	WOS:000357434900005
J	Purayil, HT; Zhang, Y; Dey, A; Gersey, Z; Espana-Serrano, L; Daaka, Y				Purayil, H. T.; Zhang, Y.; Dey, A.; Gersey, Z.; Espana-Serrano, L.; Daaka, Y.			Arrestin2 modulates androgen receptor activation	ONCOGENE			English	Article							NUCLEAR EXPORT SIGNAL; PROSTATE-CANCER; BETA-ARRESTINS; BETA-ARRESTIN1; PROGRESSION; EXPRESSION; IDENTIFICATION; ESTABLISHMENT; LOCALIZATION; ENDOCYTOSIS	Androgen receptor (AR) has a pivotal role in the growth and survival of prostate cancer (PCa). Arrestin2 (Arr2) is a ubiquitous scaffolding/adaptor protein first characterized as a regulator of G protein-coupled receptor signaling. In this study, we report that Arr2 additionally functions as a positive regulator of AR expression and function in PCa cells. Expression level of Arr2 correlates with that of AR, and knockdown of Arr2 inhibits the expression of AR and its effectors prostate-specific antigen, transmembrane protease serine 2, FK506-binding protein 51 and fatty acid synthase. Mechanistically, the knockdown of Arr2 attenuates the binding of AR to androgen response elements and consequently decreases transcription of AR-regulated genes. The inhibition of AR by Arr2 knockdown occurs in both androgen-dependent and castration-resistant PCa (CRPC) cells, although the effect is more prominent in CRPC. Arr2 knockdown inhibits the in vitro CRPC cell proliferation, prostasphere growth and invasion, as well as the in vivo prostate tumor formation, local invasion and distant metastasis. These results illustrate a new role for Arr2 in the expression and activation of AR and its potential relevance as a target for therapeutic intervention and monitoring of disease progression.	[Purayil, H. T.; Zhang, Y.; Dey, A.; Gersey, Z.; Espana-Serrano, L.; Daaka, Y.] Univ Florida, Dept Anat & Cell Biol, Coll Med, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Daaka, Y (corresponding author), Univ Florida, Dept Anat & Cell Biol, 1333 Ctr Dr,B1-004, Gainesville, FL 32610 USA.	ydaaka@ufl.edu	PURAYIL, HAMSA THAYELE/E-7533-2015	THAYELE PURAYIL, HAMSA/0000-0002-7211-3659				Attard G, 2011, CLIN CANCER RES, V17, P1649, DOI 10.1158/1078-0432.CCR-10-0567; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Boorjian SA, 2009, ENDOCR-RELAT CANCER, V16, P123, DOI 10.1677/ERC-08-0124; Buchanan FG, 2006, P NATL ACAD SCI USA, V103, P1492, DOI 10.1073/pnas.0510562103; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen W, 2003, SCIENCE, V301, P1391, DOI 10.1126/science.1082808; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; Chen Y, 2008, CURR OPIN PHARMACOL, V8, P440, DOI 10.1016/j.coph.2008.07.005; Chen Y, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002595; Debes JD, 2004, NEW ENGL J MED, V351, P1488, DOI 10.1056/NEJMp048178; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Friedrich J, 2009, NAT PROTOC, V4, P309, DOI 10.1038/nprot.2008.226; Gregory CW, 2001, CANCER RES, V61, P2892; Hara T, 2008, CANCER RES, V68, P1128, DOI 10.1158/0008-5472.CAN-07-1929; Harma V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010431; HOBISCH A, 1995, CANCER RES, V55, P3068; Hoeppner CZ, 2012, J BIOL CHEM, V287, P8932, DOI 10.1074/jbc.M111.294058; Kang JH, 2005, CELL, V123, P833, DOI 10.1016/j.cell.2005.09.011; Khaitan D, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-12; Lakshmikanthan V, 2009, P NATL ACAD SCI USA, V106, P9379, DOI 10.1073/pnas.0900258106; Lamont KR, 2010, ADV CANCER RES, V107, P137, DOI 10.1016/S0065-230X(10)07005-3; Lang SH, 2001, BRIT J CANCER, V85, P590, DOI 10.1054/bjoc.2001.1967; Lefkowitz RJ, 2004, CURR OPIN CELL BIOL, V16, P162, DOI 10.1016/j.ceb.2004.01.001; Liu YN, 2008, MOL CELL BIOL, V28, P7096, DOI 10.1128/MCB.00449-08; Ma L, 2007, J CELL SCI, V120, P213, DOI 10.1242/jcs.03338; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Matsumoto T, 2013, ANNU REV PHYSIOL, V75, P201, DOI 10.1146/annurev-physiol-030212-183656; Mo W, 2008, MOL CELL, V31, P695, DOI 10.1016/j.molcel.2008.06.017; Rosano L, 2013, ONCOGENE, V32, P5066, DOI 10.1038/onc.2012.527; Saraon P, 2011, CLIN CHEM, V57, P1366, DOI 10.1373/clinchem.2011.165977; Sartor O, 2002, UROLOGY, V60, P138; Scott MGH, 2002, J BIOL CHEM, V277, P37693, DOI 10.1074/jbc.M207552200; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Shenoy SK, 2012, ONCOGENE, V31, P282, DOI 10.1038/onc.2011.238; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Snoek R, 2009, CLIN CANCER RES, V15, P39, DOI 10.1158/1078-0432.CCR-08-1726; TILLEY WD, 1994, CANCER RES, V54, P4096; Vinci M, 2012, BMC BIOL, V10, DOI 10.1186/1741-7007-10-29; Wang LG, 2012, ASIAN PAC J CANCER P, V13, P5671, DOI 10.7314/APJCP.2012.13.11.5671; Wang P, 2003, J BIOL CHEM, V278, P11648, DOI 10.1074/jbc.M208109200; Wilbanks AM, 2004, SCIENCE, V306, P2264, DOI 10.1126/science.1104193; Witherow DS, 2004, P NATL ACAD SCI USA, V101, P8603, DOI 10.1073/pnas.0402851101; Xiao K, 2007, P NATL ACAD SCI USA, V104, P12011, DOI 10.1073/pnas.0704849104; Zou L, 2008, FASEB J, V22, P355, DOI 10.1096/fj.07-9046com	44	20	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2015	34	24					3144	3151		10.1038/onc.2014.252	http://dx.doi.org/10.1038/onc.2014.252			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3FD	25109335				2022-12-17	WOS:000356101100006
J	Zhang, X; Ma, W; Cui, J; Yao, H; Zhou, H; Ge, Y; Xiao, L; Hu, X; Liu, BH; Yang, J; Li, YY; Chen, S; Eaves, CJ; Wu, D; Zhao, Y				Zhang, X.; Ma, W.; Cui, J.; Yao, H.; Zhou, H.; Ge, Y.; Xiao, L.; Hu, X.; Liu, B-H; Yang, J.; Li, Y-Y; Chen, S.; Eaves, C. J.; Wu, D.; Zhao, Y.			Regulation of p21 by TWIST2 contributes to its tumor-suppressor function in human acute myeloid leukemia	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; ACUTE LYMPHOBLASTIC-LEUKEMIA; HELIX TRANSCRIPTION FACTOR; ADULT HEMATOPOIETIC STEM; SAETHRE-CHOTZEN SYNDROME; MYELODYSPLASTIC SYNDROMES; GENE-EXPRESSION; CELLS; PROTEIN; CANCER	TWIST2 has a dual function in tumors. Its implication in the initiation and metastasis of various solid tumors is well established, and its tumor-suppressor role in murine osteosarcoma cells has been reported recently. However, the function of TWIST2 and its underlying mechanisms in human normal and malignant hematopoiesis remain unclear. In the present study, we found that TWIST2 directly regulated p21 in human hematopoietic cells and whose silence promoted cell proliferation and cell cycle progression. Hypermethylation of TWIST2 occurred to 23 out of the 75 adult acute myeloid leukemia (AML) patients and resulted in the impaired expression of both TWIST2 and p21. Conversely, TWIST2 overexpression inhibited the growth of AML cells partially through its direct activation of p21 with intact HLH (helix-loop-helix) domain. The microarray data and gene expression validation showed that TWIST2 was sufficient to activate known tumor-suppressor genes, whereas suppress known oncogenes, which further supported its inhibitory effect against AML cells. Taken together, our data have identified a novel TWIST2-p21 axis that modulates the cell cycle of both normal and leukemic cells and demonstrated that the direct regulation of p21 by TWIST2 has a role in its tumor-suppressor function in AML.	[Zhang, X.; Ma, W.; Cui, J.; Yao, H.; Ge, Y.; Xiao, L.; Zhao, Y.] Soochow Univ, Cyrus Tang Hematol Ctr, Suzhou 215123, Jiangsu, Peoples R China; [Zhang, X.; Ma, W.; Chen, S.; Wu, D.; Zhao, Y.] Soochow Univ, Collaborat Innovat Ctr Hematol, Suzhou 215123, Jiangsu, Peoples R China; [Cui, J.; Yao, H.; Zhou, H.; Hu, X.; Chen, S.; Wu, D.] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Key Lab Thrombosis & Hemostatis, Suzhou 215123, Jiangsu, Peoples R China; [Liu, B-H; Yang, J.; Li, Y-Y] Shanghai Ctr Bioinformat Technol, Shanghai, Peoples R China; [Eaves, C. J.] British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada	Soochow University - China; Soochow University - China; Soochow University - China; Chinese Academy of Sciences; British Columbia Cancer Agency	Wu, D (corresponding author), Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Key Lab Thrombosis & Hemostatis, Suzhou 215123, Jiangsu, Peoples R China.	wudepei@medmail.com.cn; zhaoy@suda.edu.cn		, Yun/0000-0002-0065-4675; Eaves, Connie/0000-0002-3452-1926	National Natural Science Foundation of China [31170755]; National Key Scientific Project of China (973 Program) [2011CB933501]; Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP) [20113201120017]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Jiangsu Province's Key Medical Center [ZX201102]; National Public Health Grand Research Foundation [201202017]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Scientific Project of China (973 Program); Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Jiangsu Province's Key Medical Center; National Public Health Grand Research Foundation	This work was funded by National Natural Science Foundation of China (no. 31170755), National Key Scientific Project of China (973 Program no. 2011CB933501), Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP, no. 20113201120017), the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Jiangsu Province's Key Medical Center (ZX201102) and National Public Health Grand Research Foundation (No. 201202017).	Ansieau S, 2010, ONCOGENE, V29, P3173, DOI 10.1038/onc.2010.92; Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; APLAN PD, 1992, BLOOD, V79, P1327; Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9; Cakouros D, 2012, MOL CELL BIOL, V32, P1433, DOI 10.1128/MCB.06315-11; Capron C, 2006, BLOOD, V107, P4678, DOI 10.1182/blood-2005-08-3145; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Cosset E, 2011, BLOOD, V117, P1673, DOI 10.1182/blood-2009-11-254680; Duriez C, 2002, GENE, V282, P207, DOI 10.1016/S0378-1119(01)00825-3; ElGhouzzi V, 1997, NAT GENET, V15, P42; Eppert K, 2011, NAT MED, V17, P1086, DOI 10.1038/nm.2415; Fang X, 2011, ONCOGENE, V30, P4707, DOI 10.1038/onc.2011.181; Franco HL, 2011, NUCLEIC ACIDS RES, V39, P1177, DOI 10.1093/nar/gkq890; Gong XQ, 2002, J BIOL CHEM, V277, P12310, DOI 10.1074/jbc.M110228200; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; Isenmann S, 2009, STEM CELLS, V27, P2457, DOI 10.1002/stem.181; Ishikawa T, 2013, CANCER SCI, V104, P880, DOI 10.1111/cas.12163; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kawagoe H, 2007, CANCER RES, V67, P10677, DOI 10.1158/0008-5472.CAN-07-1118; Kee BL, 2009, NAT REV IMMUNOL, V9, P175, DOI 10.1038/nri2507; Kennah E, 2009, BLOOD, V113, P4646, DOI 10.1182/blood-2008-08-174037; Kim MS, 2013, MOL CELLS, V36, P177, DOI 10.1007/s10059-013-0061-6; Ko J, 2008, P NATL ACAD SCI USA, V105, P12967, DOI 10.1073/pnas.0805073105; Li X, 2013, HAEMATOLOGICA, V98, P414, DOI 10.3324/haematol.2012.071753; Li XA, 2010, BLOOD, V116, P2304, DOI 10.1182/blood-2009-09-242313; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Liu JH, 2004, LEUKEMIA LYMPHOMA, V45, P2419, DOI 10.1080/10428190400003317; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Meng YS, 2005, LEUKEMIA, V19, P1941, DOI 10.1038/sj.leu.2403836; Nagel S, 2007, BLOOD, V109, P3015, DOI 10.1182/blood-2006-08-044347; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Piccinin S, 2012, CANCER CELL, V22, P404, DOI 10.1016/j.ccr.2012.08.003; Qin Q, 2012, CELL RES, V22, P90, DOI 10.1038/cr.2011.144; Raval A, 2005, J CLIN ONCOL, V23, P3877, DOI 10.1200/JCO.2005.02.196; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Sandmann T, 2007, GENE DEV, V21, P436, DOI 10.1101/gad.1509007; Sharabi AB, 2008, PLOS BIOL, V6, P2786, DOI 10.1371/journal.pbio.0060316; Sharif MN, 2006, J EXP MED, V203, P1891, DOI 10.1084/jem.20051725; Shiota M, 2008, ONCOGENE, V27, P5543, DOI 10.1038/onc.2008.176; Shiota M, 2008, CANCER RES, V68, P98, DOI 10.1158/0008-5472.CAN-07-2981; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3; Souroullas GP, 2009, CELL STEM CELL, V4, P180, DOI 10.1016/j.stem.2009.01.001; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thathia SH, 2012, HAEMATOL-HEMATOL J, V97, P371, DOI 10.3324/haematol.2011.049593; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; Tukel T, 2010, AM J HUM GENET, V87, P289, DOI 10.1016/j.ajhg.2010.07.009; Ueda K, 2003, ONCOGENE, V22, P5586, DOI 10.1038/sj.onc.1206845; Wang M, 2009, LEUKEMIA, V23, P1320, DOI 10.1038/leu.2009.19; Yang DC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023965; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yin B, 2009, BLOOD, V113, P1075, DOI 10.1182/blood-2008-03-144436; Zhang WQ, 2014, BIOMATERIALS, V35, P567, DOI 10.1016/j.biomaterials.2013.09.102; Zhang WJ, 2014, CELL RES, V24, P331, DOI 10.1038/cr.2014.10; Zhou HX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086195	57	20	22	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	2015	34	23					3000	3010		10.1038/onc.2014.241	http://dx.doi.org/10.1038/onc.2014.241			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3EX	25088197				2022-12-17	WOS:000356100500006
J	Espinosa, L; Margalef, P; Bigas, A				Espinosa, L.; Margalef, P.; Bigas, A.			Non-conventional functions for NF-kappa B members: the dark side of NF-kappa B	ONCOGENE			English	Review							DEPENDENT GENE-EXPRESSION; SQUAMOUS-CELL CARCINOMAS; CHAIN ASSEMBLY COMPLEX; TUMOR-NECROSIS-FACTOR; NUCLEAR IKK ACTIVITY; KINASE-ALPHA; NF-KAPPA-B2 P100; SIGNALING PATHWAY; UBIQUITIN LIGASE; MICE LACKING	NF-kappa B pathway exerts an essential function in the regulation of the immune response, which has been the nucleus of numerous studies for the past 25 years. Both activation of the pathway and termination of the NF-kappa B response are tightly regulated events, which is essential to prevent exacerbated inflammatory responses. Thus, alterations in NF-kappa B regulatory elements might result in tissue damage and cancer in different systems. In addition, several of the proteins involved in NF-kappa B regulation display additional, and much less studied, functions that connect with specific NF-kappa B-unrelated pathways. Many of these pathways are in turn regulators of particular physiologic and/or pathologic responses. Which are the principal non-conventional functions that have been identified for specific NF-kappa B elements, how they connect with other signaling pathways and what is their potential impact on cancer is the focus of this review.	[Espinosa, L.; Margalef, P.; Bigas, A.] Inst Hosp del Mar Invest Med IMIM, Stem Cells & Canc Res Lab, Barcelona 08003, Spain	Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar	Espinosa, L (corresponding author), Inst Hosp del Mar Invest Med IMIM, Stem Cells & Canc Res Lab, Dr Aiguader 88, Barcelona 08003, Spain.	lespinosa@imim.es	Bigas, Anna/A-7457-2014; Espinosa, Lluis/ABA-4564-2020	Espinosa, Lluis/0000-0002-2897-4099; Bigas, Anna/0000-0003-4801-6899	AGAUR [SGR23]; ISCIII [PI13/00448]; RTICC [RD12/0036/0054]	AGAUR(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); ISCIII(Instituto de Salud Carlos III); RTICC(Instituto de Salud Carlos III)	We thank the members of our laboratory for helpful discussions. This work has been supported by AGAUR (SGR23), ISCIII (PI13/00448) and RTICC (RD12/0036/0054).	Aguilera C, 2004, P NATL ACAD SCI USA, V101, P16537, DOI 10.1073/pnas.0404429101; Amir RE, 2004, ONCOGENE, V23, P2540, DOI 10.1038/sj.onc.1207366; Ammirante M, 2010, NATURE, V464, P302, DOI 10.1038/nature08782; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Anest V, 2004, J BIOL CHEM, V279, P31183, DOI 10.1074/jbc.M404380200; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Barre B, 2007, EMBO J, V26, P4841, DOI 10.1038/sj.emboj.7601899; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Bettermann K, 2010, CANCER CELL, V17, P481, DOI 10.1016/j.ccr.2010.03.021; Betts JC, 1996, MOL CELL BIOL, V16, P6363; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Comb WC, 2011, ONCOGENE, V30, P1727, DOI 10.1038/onc.2010.553; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Criollo A, 2010, EMBO J, V29, P619, DOI 10.1038/emboj.2009.364; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Descargues P, 2008, P NATL ACAD SCI USA, V105, P2487, DOI 10.1073/pnas.0712044105; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Espinosa L, 2010, CANCER CELL, V18, P268, DOI 10.1016/j.ccr.2010.08.006; Fernandez-Majada V, 2007, P NATL ACAD SCI USA, V104, P276, DOI 10.1073/pnas.0606476104; Fernandez-Majada V, 2007, CELL CYCLE, V6, P1748, DOI 10.4161/cc.6.14.4429; Gerlach B, 2011, NATURE, V471, P591, DOI 10.1038/nature09816; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Haas TL, 2009, MOL CELL, V36, P831, DOI 10.1016/j.molcel.2009.10.013; Hao L, 2010, ONCOGENE, V29, P201, DOI 10.1038/onc.2009.323; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hoberg JE, 2004, MOL CELL, V16, P245, DOI 10.1016/j.molcel.2004.10.010; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Ikeda F, 2011, NATURE, V471, P637, DOI 10.1038/nature09814; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Klement JF, 1996, MOL CELL BIOL, V16, P2341; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Li L, 2011, J EXP MED, V208, P787, DOI 10.1084/jem.20091346; Li M, 2000, J VIROL, V74, P7470, DOI 10.1128/JVI.74.16.7470-7477.2000; Li QS, 2013, NAT MED, V19, P722, DOI 10.1038/nm.3190; Liu BG, 2006, P NATL ACAD SCI USA, V103, P17202, DOI 10.1073/pnas.0604481103; Liu L, 2006, J BIOL CHEM, V281, P1506, DOI 10.1074/jbc.M510402200; Luo JL, 2007, NATURE, V446, P690, DOI 10.1038/nature05656; Margalef P, 2012, CELL REP, V2, P840, DOI 10.1016/j.celrep.2012.08.028; Marinari B, 2008, P NATL ACAD SCI USA, V105, P17091, DOI 10.1073/pnas.0809288105; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mulero MC, 2013, CANCER CELL, V24, P1; Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116; O'Donnell MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041238; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Park E, 2007, CANCER RES, V67, P9158, DOI 10.1158/0008-5472.CAN-07-0590; Park GY, 2006, J BIOL CHEM, V281, P18684, DOI 10.1074/jbc.M600733200; Park KJ, 2005, MOL CELL, V18, P71, DOI 10.1016/j.molcel.2005.03.006; Prajapati S, 2006, CELL CYCLE, V5, P2371, DOI 10.4161/cc.5.20.3359; Rao P, 2010, NATURE, V466, P1115, DOI 10.1038/nature09283; Rebholz B, 2007, IMMUNITY, V27, P296, DOI 10.1016/j.immuni.2007.05.024; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Sakamoto K, 2013, ONCOGENE, V32, P1854, DOI 10.1038/onc.2012.192; Schrofelbauer B, 2012, MOL CELL, V47, P111, DOI 10.1016/j.molcel.2012.04.020; Seitz CS, 2000, CANCER RES, V60, P4085; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Seitz CS, 2000, J CLIN INVEST, V105, P253, DOI 10.1172/JCI7630; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shiha VFS, 2009, P NATL ACAD SCI USA, V106, P9619, DOI 10.1073/pnas.0812367106; Sil AK, 2004, NATURE, V428, P660, DOI 10.1038/nature02421; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Song LL, 2008, ONCOGENE, V27, P5833, DOI 10.1038/onc.2008.190; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Suzuki K, 2008, CELL, V134, P485, DOI 10.1016/j.cell.2008.05.050; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Temmerman ST, 2012, J CLIN INVEST, V122, P315, DOI 10.1172/JCI42534; Teo HL, 2010, NAT CELL BIOL, V12, P758, DOI 10.1038/ncb2080; Tokunaga F, 2011, NATURE, V471, P633, DOI 10.1038/nature09815; Tokunaga F, 2009, NAT CELL BIOL, V11, P123, DOI 10.1038/ncb1821; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Tsuchiya Y, 2010, MOL CELL, V39, P570, DOI 10.1016/j.molcel.2010.07.030; Tu Z, 2006, J BIOL CHEM, V281, P6699, DOI 10.1074/jbc.M512439200; Vallabhapurapu S, 2008, NAT IMMUNOL, V9, P1364, DOI 10.1038/ni.1678; van Hogerlinden M, 1999, CANCER RES, V59, P3299; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Vilimas T, 2007, NAT MED, V13, P70, DOI 10.1038/nm1524; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Wuerzberger-Davis SM, 2011, IMMUNITY, V34, P188, DOI 10.1016/j.immuni.2011.01.014; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang WZ, 2013, CANCER CELL, V23, P647, DOI 10.1016/j.ccr.2013.03.012; Zhu F, 2007, MOL CELL, V27, P214, DOI 10.1016/j.molcel.2007.05.042	96	20	20	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2279	2287		10.1038/onc.2014.188	http://dx.doi.org/10.1038/onc.2014.188			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	24975576				2022-12-17	WOS:000353824800001
J	Olsson, M; Forsberg, J; Zhivotovsky, B				Olsson, M.; Forsberg, J.; Zhivotovsky, B.			Caspase-2: the reinvented enzyme	ONCOGENE			English	Review							DNA-DAMAGE; OXIDATIVE STRESS; CELL-DEATH; CHROMOSOMAL INSTABILITY; METABOLIC-REGULATION; ER STRESS; APOPTOSIS; ACTIVATION; P53; PHOSPHORYLATION	On the basis of evidences that caspase-2 gene targeting in several generated mouse models accelerates tumor formation, this enzyme was recently implicated in tumor suppression. The observed function, however, compels other molecular perturbations harboring tumorigenic properties. Therefore, the question remains as to whether or not caspase-2 can be considered a true tumor suppressor? The traditional view of caspase-2 being vital for the apoptotic response to induced cell stress in some systems is in line with these findings. Yet, caspase-2 has also been associated with other processes which equally might interfere with tumorigenic potential, including the oxidative stress response, aging and genome surveillance. By different mechanisms, this enzyme has been proposed to function as a checkpoint regulator in the cell cycle. Together, these data indicate that caspase-2 is a highly versatile factor, a view that is contrasted by the alternative explanation where the enzyme harbors a mechanism affecting a discrete process, which in turn is functionally connected to other cell systems. In any case, it is clear that the general view of caspase-2 as a protein mainly involved in apoptotic cell death is shattered. Hence, we wish to discuss the perspectives of recent achievements in caspase-2-related research.	[Olsson, M.; Forsberg, J.; Zhivotovsky, B.] Karolinska Inst, Inst Environm Med, Div Toxicol, SE-17177 Stockholm, Sweden; [Zhivotovsky, B.] Moscow MV Lomonosov State Univ, Fac Fundamental Med, Moscow, Russia	Karolinska Institutet; Lomonosov Moscow State University	Zhivotovsky, B (corresponding author), Karolinska Inst, Inst Environm Med, Div Toxicol, Nobels Vag 13, SE-17177 Stockholm, Sweden.	Boris.Zhivotovsky@ki.se	Olsson, Magnus/E-3140-2012; Zhivotovsky, Boris/A-4346-2014	Olsson, Magnus/0000-0002-6370-8423; Zhivotovsky, Boris/0000-0002-2238-3482	Swedish Cancer Society; Stockholm Cancer Society; Swedish Childhood Cancer Foundation; Swedish Research Council; Russian Science Foundation	Swedish Cancer Society(Swedish Cancer Society); Stockholm Cancer Society; Swedish Childhood Cancer Foundation(European Commission); Swedish Research Council(Swedish Research CouncilEuropean Commission); Russian Science Foundation(Russian Science Foundation (RSF))	This work was supported by grants from the Swedish and the Stockholm Cancer Societies, the Swedish Childhood Cancer Foundation, the Swedish Research Council and Russian Science Foundation.	Andersen JL, 2009, EMBO J, V28, P3216, DOI 10.1038/emboj.2009.253; Ando K, 2012, MOL CELL, V47, P681, DOI 10.1016/j.molcel.2012.06.024; Baptiste-Okoh N, 2008, CELL CYCLE, V7, P1133, DOI 10.4161/cc.7.9.5805; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Berube C, 2005, P NATL ACAD SCI USA, V102, P14314, DOI 10.1073/pnas.0506475102; Boros LG, 2002, DRUG DISCOV TODAY, V7, P364, DOI 10.1016/S1359-6446(02)02179-7; Bouchier-Hayes L, 2009, MOL CELL, V35, P830, DOI 10.1016/j.molcel.2009.07.023; Braga M, 2008, APOPTOSIS, V13, P822, DOI 10.1007/s10495-008-0216-7; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Chen CC, 2013, J BIOL CHEM, V288, P11689, DOI 10.1074/jbc.M112.401844; Cosentino C, 2011, EMBO J, V30, P546, DOI 10.1038/emboj.2010.330; Dorstyn L, 2012, CELL DEATH DIFFER, V19, P1288, DOI 10.1038/cdd.2012.36; Farber-Katz SE, 2014, CELL, V156, P413, DOI 10.1016/j.cell.2013.12.023; Ho LH, 2008, ONCOGENE, V27, P3393, DOI 10.1038/sj.onc.1211005; Ho LH, 2009, P NATL ACAD SCI USA, V106, P5336, DOI 10.1073/pnas.0811928106; Imre G, 2012, EMBO J, V31, P2615, DOI 10.1038/emboj.2012.93; Jean YY, 2013, BIOCHEM J, V455, P15, DOI 10.1042/BJ20130556; Johnson ES, 2013, J BIOL CHEM, V288, P14463, DOI 10.1074/jbc.M112.437210; Lavrik IN, 2006, BLOOD, V108, P559, DOI 10.1182/blood-2005-07-007096; Lee SA, 2001, J BIOL CHEM, V276, P11783, DOI 10.1074/jbc.M004517200; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Lopez-Cruzan M, 2013, BIOGERONTOLOGY, V14, P121, DOI 10.1007/s10522-013-9415-x; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Manzl C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.470; Manzl C, 2012, CELL DEATH DIFFER, V19, P1722, DOI 10.1038/cdd.2012.54; Manzl C, 2009, J CELL BIOL, V185, P291, DOI 10.1083/jcb.200811105; McClelland SE, 2009, CELL CYCLE, V8, P3262, DOI 10.4161/cc.8.20.9690; McCoy F, 2013, J BIOL CHEM, V288, P8838, DOI 10.1074/jbc.M112.437186; Mendelsohn AR, 2002, P NATL ACAD SCI USA, V99, P6871, DOI 10.1073/pnas.072290599; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Nutt LK, 2005, CELL, V123, P89, DOI 10.1016/j.cell.2005.07.032; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Oliver TG, 2011, MOL CELL, V43, P57, DOI 10.1016/j.molcel.2011.06.012; Olshavsky NA, 2008, ONCOGENE, V27, P3111, DOI 10.1038/sj.onc.1210981; Parsons MJ, 2013, CELL DEATH DIFFER, V20, P1174, DOI 10.1038/cdd.2013.38; Puccini J, 2013, P NATL ACAD SCI USA, V110, P19920, DOI 10.1073/pnas.1311947110; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Ren KQ, 2012, J BIOL CHEM, V287, P14792, DOI 10.1074/jbc.M112.347625; Sandow JJ, 2014, CELL DEATH DIFFER, V21, P475, DOI 10.1038/cdd.2013.168; Santini S, 2014, ONCOGENE, V33, P1113, DOI 10.1038/onc.2013.52; Shalini S, 2012, CELL DEATH DIFFER, V19, P1370, DOI 10.1038/cdd.2012.13; Sidi S, 2008, CELL, V133, P864, DOI 10.1016/j.cell.2008.03.037; Sohn D, 2011, CELL DEATH DIFFER, V18, P1664, DOI 10.1038/cdd.2011.34; Song T, 2013, J CANCER RES CLIN, V139, P1189, DOI 10.1007/s00432-013-1392-6; Swanton C, 2009, P NATL ACAD SCI USA, V106, P8671, DOI 10.1073/pnas.0811835106; Taghiyev Agshin F, 2011, Genes Cancer, V2, P745, DOI 10.1177/1947601911426007; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tse AN, 2007, CLIN CANCER RES, V13, P1955, DOI 10.1158/1078-0432.CCR-06-2793; Upton JP, 2012, SCIENCE, V338, P818, DOI 10.1126/science.1226191; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P555, DOI 10.1038/sj.cdd.4402286; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47; Vakifahmetoglu H, 2006, ONCOGENE, V25, P5683, DOI 10.1038/sj.onc.1209569; Wu ZH, 2005, CELL, V123, P980, DOI 10.1016/j.cell.2005.11.025; Zhang YP, 2007, MECH AGEING DEV, V128, P213, DOI 10.1016/j.mad.2006.11.030; Zhivotovsky B, 2005, BIOCHEM BIOPH RES CO, V331, P859, DOI 10.1016/j.bbrc.2005.03.191	55	20	20	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					1877	1882		10.1038/onc.2014.139	http://dx.doi.org/10.1038/onc.2014.139			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24882576				2022-12-17	WOS:000352725600001
J	Yim, DGR; Ghosh, S; Guy, GR; Virshup, DM				Yim, D. G. R.; Ghosh, S.; Guy, G. R.; Virshup, D. M.			Casein kinase 1 regulates Sprouty2 in FGF-ERK signaling	ONCOGENE			English	Article						growth factor signaling; SPRY; casein kinase 1; neurite outgrowth; gastric cancer	FACTOR RECEPTOR STIMULATION; KERATINOCYTE GROWTH-FACTOR; TRANSLOCATION DOMAIN; GASTRIC-CARCINOMA; TYROSINE KINASES; CANCER-CELLS; PHOSPHORYLATION; PATHWAY; PROTEIN; INHIBITION	Sprouty2 (SPRY2) is a potent negative regulator of receptor tyrosine kinase signaling, and is implicated as a tumor suppressor. SPRY2 inhibits FGF-RAS-ERK signaling by binding to growth factor receptor bound protein 2 (GRB2) during fibroblast growth factor receptor (FGFR) activation, disrupting the GRB2-SOS (son of sevenless) complex that transduces signals from FGFR to RAS. SPRY2 binding to GRB2 is modulated by phosphorylation but the key regulatory kinase(s) are not known. Prior studies identified the frequent presence of CK1 phosphorylation motifs on SPRY2. We therefore tested if CK1 has a role in SPRY2 phosphorylation and function. Loss of CK1 binding and inhibition of CK1 activity by two structurally distinct small molecules abrogated SPRY2 inhibition of FGF-ERK signaling, leading to decreased SPRY2 interaction with GRB2. Moreover, CK1 activity and binding are necessary for SPRY2 inhibition of FGF-stimulated neurite outgrowth in PC12 cells. Consistent with its proposed role as an inhibitor of FGF signaling, we find that CSNK1E transcript abundance negatively correlates with FGF1/FGF7 message in human gastric cancer samples. Modulation of CK1 activity may be therapeutically useful in the treatment of FGF/SPRY2-related diseases.	[Yim, D. G. R.; Virshup, D. M.] Duke NUS Grad Med Sch, Program Canc & Stem Cell Biol, Singapore 169857, Singapore; [Yim, D. G. R.; Guy, G. R.] Biopolis, Inst Mol & Cellular Biol, Signal Transduct Lab, Singapore, Singapore; [Ghosh, S.] Duke NUS Grad Med Sch, Ctr Computat Biol, Singapore 169857, Singapore; [Virshup, D. M.] Natl Univ Singapore, YYL Sch Med, Dept Biochem, Singapore 117548, Singapore; [Yim, D. G. R.] Biopolis, Genome Inst Singapore, Singapore, Singapore	National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)	Virshup, DM (corresponding author), Duke NUS Grad Med Sch, Program Canc & Stem Cell Biol, 8 Coll Rd, Singapore 169857, Singapore.	david.virshup@duke-nus.edu.sg	Ghosh, Sujoy/I-3729-2017; Virshup, David M/C-1449-2009; Yim, Daniel/J-8834-2013	Ghosh, Sujoy/0000-0002-7601-165X; Virshup, David M/0000-0001-6976-850X; Yim, Daniel/0000-0001-6153-4725	National Medical Research Council of Singapore; A*STAR Graduate Scholarship; Agency for Science, Technology and Research, Singapore	National Medical Research Council of Singapore(National Medical Research Council, Singapore); A*STAR Graduate Scholarship(Agency for Science Technology & Research (A*STAR)); Agency for Science, Technology and Research, Singapore(Agency for Science Technology & Research (A*STAR))	We thank Dr Permeen Yusoff and Dr Jit Kong Cheong for advice. This research was supported by the National Medical Research Council of Singapore under its STaR Award program to DMV, the A*STAR Graduate Scholarship (to DGRY) and by the Agency for Science, Technology and Research, Singapore.	Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Aranda S, 2008, MOL CELL BIOL, V28, P5899, DOI 10.1128/MCB.00394-08; Badura L, 2007, J PHARMACOL EXP THER, V322, P730, DOI 10.1124/jpet.107.122846; Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792; Belch J, 2011, LANCET, V377, P1929, DOI 10.1016/S0140-6736(11)60394-2; Birrer MJ, 2007, J CLIN ONCOL, V25, P2281, DOI 10.1200/JCO.2006.09.0795; Casaletto JB, 2012, NAT REV CANCER, V12, P386, DOI 10.1038/nrc3277; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; CEGIELSKA A, 1993, MOL CELL BIOL, V13, P1202, DOI 10.1128/MCB.13.2.1202; Chandramouli S, 2008, J BIOL CHEM, V283, P1679, DOI 10.1074/jbc.M705457200; Cheong JK, 2011, ONCOGENE, V30, P2558, DOI 10.1038/onc.2010.627; Cheong JK, 2011, INT J BIOCHEM CELL B, V43, P465, DOI 10.1016/j.biocel.2010.12.004; Chow SY, 2009, J BIOL CHEM, V284, P19623, DOI 10.1074/jbc.M109.021600; DaSilva J, 2006, MOL CELL BIOL, V26, P1898, DOI 10.1128/MCB.26.5.1898-1907.2006; Edwin F, 2009, MOL PHARMACOL, V76, P679, DOI 10.1124/mol.109.055848; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Fong CW, 2006, CANCER RES, V66, P2048, DOI 10.1158/0008-5472.CAN-05-1072; Greer YE, 2011, J CELL BIOL, V192, P993, DOI 10.1083/jcb.201011111; Gross I, 2007, CELL DEATH DIFFER, V14, P1802, DOI 10.1038/sj.cdd.4402188; Guy GR, 2009, J ENDOCRINOL, V203, P191, DOI 10.1677/JOE-09-0110; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Hausott B, 2009, MOL CELL NEUROSCI, V42, P328, DOI 10.1016/j.mcn.2009.08.005; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Lao DH, 2007, J BIOL CHEM, V282, P9117, DOI 10.1074/jbc.M607563200; Lao DH, 2006, J BIOL CHEM, V281, P29993, DOI 10.1074/jbc.M604044200; Lei ZD, 2013, GASTROENTEROLOGY, V145, P554, DOI 10.1053/j.gastro.2013.05.010; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Lim J, 2000, J BIOL CHEM, V275, P32837, DOI 10.1074/jbc.M002156200; Lim J, 2002, MOL CELL BIOL, V22, P7953, DOI 10.1128/MCB.22.22.7953-7966.2002; Liu F, 2002, J BIOL CHEM, V277, P45393, DOI 10.1074/jbc.M204499200; Lo TL, 2004, CANCER RES, V64, P6127, DOI 10.1158/0008-5472.CAN-04-1207; Lord C, 2011, NATURE, V473, P181, DOI 10.1038/nature09969; Meng QJ, 2008, NEURON, V58, P78, DOI 10.1016/j.neuron.2008.01.019; Metzger RJ, 2008, NATURE, V453, P745, DOI 10.1038/nature07005; Nakazawa K, 2003, CANCER RES, V63, P8848; Okamura H, 2004, MOL CELL BIOL, V24, P4184, DOI 10.1128/MCB.24.10.4184-4195.2004; Ooi CH, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000676; Patel R, 2013, J CLIN INVEST, V123, P1157, DOI 10.1172/JCI63672; Pullar CE, 2003, J BIOL CHEM, V278, P22555, DOI 10.1074/jbc.M300205200; Rena G, 2004, EMBO REP, V5, P60, DOI 10.1038/sj.embor.7400048; Rubinfeld B, 2001, J BIOL CHEM, V276, P39037, DOI 10.1074/jbc.M105148200; Smith G, 2012, BRIT J CANCER, V107, P1327, DOI 10.1038/bjc.2012.410; Swiatek W, 2004, J BIOL CHEM, V279, P13011, DOI 10.1074/jbc.M304682200; Tang N, 2011, SCIENCE, V333, P342, DOI 10.1126/science.1204831; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; Toyokawa T, 2009, ONCOL REP, V21, P875, DOI 10.3892/or_00000297; Tsai IC, 2007, DEV CELL, V12, P335, DOI 10.1016/j.devcel.2007.02.009; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Wong ESM, 2001, J BIOL CHEM, V276, P5866, DOI 10.1074/jbc.M006945200; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200	52	20	20	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					474	484		10.1038/onc.2013.564	http://dx.doi.org/10.1038/onc.2013.564			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24469046				2022-12-17	WOS:000348451300008
J	Zhi, H; Zahoor, MA; Shudofsky, AMD; Giam, CZ				Zhi, H.; Zahoor, M. A.; Shudofsky, A. M. D.; Giam, C-Z			KSHV vCyclin counters the senescence/G1 arrest response triggered by NF-kappa B hyperactivation	ONCOGENE			English	Article						NF-kappa B hyperactivation; senescence; G1 cyclin-dependent kinase; CDK inhibitors; Kaposi's sarcoma herpesvirus; human T-lymphotropic virus type 1	SARCOMA-ASSOCIATED HERPESVIRUS; T-CELL LEUKEMIA; VIRUS TYPE-I; TAX TRANSFORMING PROTEIN; RIBOSOME ENTRY SITE; KAPOSIS-SARCOMA; IKK-GAMMA; CONSTITUTIVE ACTIVATION; INHIBITORY PROTEIN; MULTIPLE-MYELOMA	Many oncogenic viruses activate nuclear factor-kappa B (NF-kappa B) as a part of their replicative cycles. We have shown recently that persistent and potentially oncogenic activation of NF-kappa B by the human T-lymphotropic virus 1 (HTLV-1) oncoprotein Tax immediately triggers a host senescence response mediated by cyclin-dependent kinase inhibitors: p21(CIP1/WAF1) (p21) and p27(Kip1) (p27) Here we demonstrate that RelA/NF-kappa B activation by Kaposi sarcoma herpesvirus (KSHV) latency protein vFLIP also leads to p21/p27 upregulation and G1 cell cycle arrest. Remarkably, KSHV vCyclin, another latency protein coexpressed with vFLIP from a bicistronic latency-specific mRNA, was found to prevent the senescence and G1 arrest induced by HTLV-1 Tax and vFLIP, respectively. This is because of the known ability of vCyclin/cyclin-dependent kinase 6 complex to resist p21 and p27 inhibition and cause p27 degradation. In KSHV-transformed BCBL-1 cells, sustained vFLIP expression with small hairpin RNAs-mediated vCyclin depletion resulted in G1 arrest. The functional interdependence of vFLIP and vCyclin explains why they are cotranslated from the same viral mRNA. Importantly, deregulation of the G1 cyclin-dependent kinase can facilitate chronic I-kappa B kinases/NF-kappa B activation.	[Zhi, H.; Zahoor, M. A.; Shudofsky, A. M. D.; Giam, C-Z] Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Giam, CZ (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	chou-zen.giam@usuhs.edu	Zahoor, Muhammad/ADH-5812-2022	Zahoor, Muhammad/0000-0003-2302-3689	National Institutes of Health [R01CA140963, RO1CA115884]; USU intramural research program [RO73NV]; NATIONAL CANCER INSTITUTE [R01CA115884, R01CA140963] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); USU intramural research program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Mary Collins, Johnan Kaleeba and Emmy Verschuren for the vFLIP antibody, vFLIP cDNA and vCyclin expression plasmid, respectively. This work was supported by grants from the National Institutes of Health (R01CA140963 and RO1CA115884) and the USU intramural research program (RO73NV).	Bagneris C, 2008, MOL CELL, V30, P620, DOI 10.1016/j.molcel.2008.04.029; Bieleski L, 2001, J VIROL, V75, P1864, DOI 10.1128/JVI.75.4.1864-1869.2001; Cereseto A, 1999, ONCOGENE, V18, P2441, DOI 10.1038/sj.onc.1202567; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Dittmer D, 1998, J VIROL, V72, P8309, DOI 10.1128/JVI.72.10.8309-8315.1998; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; Field N, 2003, J CELL SCI, V116, P3721, DOI 10.1242/jcs.00691; Fujimuro M, 2007, REV MED VIROL, V17, P405, DOI 10.1002/rmv.549; Ganem D, 2006, ANNU REV PATHOL-MECH, V1, P273, DOI 10.1146/annurev.pathol.1.110304.100133; Ganem D, 2010, J CLIN INVEST, V120, P939, DOI 10.1172/JCI40567; Godfrey A, 2005, BLOOD, V105, P2510, DOI 10.1182/blood-2004-08-3052; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Grossmann C, 2006, J VIROL, V80, P7179, DOI 10.1128/JVI.01603-05; Grundhoff A, 2001, J VIROL, V75, P1857, DOI 10.1128/JVI.75.4.1857-1863.2001; Guasparri I, 2004, J EXP MED, V199, P993, DOI 10.1084/jem.20031467; Hasegawa H, 2006, NAT MED, V12, P466, DOI 10.1038/nm1389; Hatta Y, 2002, LEUKEMIA, V16, P1069, DOI 10.1038/sj.leu.2402458; Hayward S Diane, 2006, Sci STKE, V2006, pre4; Jarviluoma A, 2004, BLOOD, V104, P3349, DOI 10.1182/blood-2004-05-1798; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Koopal S, 2007, PLOS PATHOG, V3, P1348, DOI 10.1371/journal.ppat.0030140; Kuo YL, 2006, EMBO J, V25, P1741, DOI 10.1038/sj.emboj.7601054; Lee JS, 2009, NAT CELL BIOL, V11, P1355, DOI 10.1038/ncb1980; Leida AM, 2012, CELL HOST MICROBE, V11, P167, DOI 10.1016/j.chom.2012.01.005; Liu JY, 2007, J VIROL, V81, P10451, DOI 10.1128/JVI.00804-07; Liu MH, 2008, J VIROL, V82, P8442, DOI 10.1128/JVI.00091-08; Low W, 2001, J VIROL, V75, P2938, DOI 10.1128/JVI.75.6.2938-2945.2001; Mann DJ, 1999, EMBO J, V18, P654, DOI 10.1093/emboj/18.3.654; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; Matta H, 2004, P NATL ACAD SCI USA, V101, P9399, DOI 10.1073/pnas.0308016101; Mitsiades N, 2002, BLOOD, V99, P4079, DOI 10.1182/blood.V99.11.4079; Ojala PM, 1999, CANCER RES, V59, P4984; Oshiro A, 2006, BLOOD, V107, P4500, DOI 10.1182/blood-2005-09-3801; Rivas C, 2001, J VIROL, V75, P429, DOI 10.1128/JVI.75.1.429-438.2001; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Shimizu A, 2011, J VIROL, V85, P7444, DOI 10.1128/JVI.02337-10; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Swanton C, 1997, NATURE, V390, P184, DOI 10.1038/36606; Verschuren EW, 2004, J GEN VIROL, V85, P1347, DOI 10.1099/vir.0.79812-0; Verschuren EW, 2002, CANCER CELL, V2, P229, DOI 10.1016/S1535-6108(02)00123-X; Xiao GT, 2000, ONCOGENE, V19, P5198, DOI 10.1038/sj.onc.1203894; Yamada Y, 1997, J CLIN ONCOL, V15, P1778, DOI 10.1200/JCO.1997.15.5.1778; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang LP, 2011, J VIROL, V85, P3001, DOI 10.1128/JVI.00086-10; Zhang L, 2006, J VIROL, V80, P7459, DOI 10.1128/JVI.00130-06; Zhi HJ, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002025	49	20	20	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					496	505		10.1038/onc.2013.567	http://dx.doi.org/10.1038/onc.2013.567			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24469036	Green Accepted			2022-12-17	WOS:000348451300010
J	Zaganjor, E; Osborne, JK; Weil, LM; Diaz-Martinez, LA; Gonzales, JX; Singel, SM; Larsen, JE; Girard, L; Minna, JD; Cobb, MH				Zaganjor, E.; Osborne, J. K.; Weil, L. M.; Diaz-Martinez, L. A.; Gonzales, J. X.; Singel, S. M.; Larsen, J. E.; Girard, L.; Minna, J. D.; Cobb, M. H.			Ras regulates kinesin 13 family members to control cell migration pathways in transformed human bronchial epithelial cells	ONCOGENE			English	Article						kinesin; K-Ras; MAPK; ERK; microtubules	ACTIVATED PROTEIN-KINASE; SUPERFAMILY PROTEIN; MEDIATED TRANSFORMATION; MORPHOLOGICAL-CHANGES; SIGNALING PATHWAYS; TUMOR-SUPPRESSOR; GENE-EXPRESSION; CANCER-CELLS; LUNG-CANCER; K-RAS	We show that expression of the microtubule depolymerizing kinesin KIF2C is induced by transformation of immortalized human bronchial epithelial cells (HBEC) by expression of K-Ras(G12V) and knockdown of p53. Further investigation demonstrates that this is due to the K-Ras/ERK1/2 MAPK pathway, as loss of p53 had little effect on KIF2C expression. In addition to KIF2C, we also found that the related kinesin KIF2A is modestly upregulated in this model system; both proteins are expressed more highly in many lung cancer cell lines compared to normal tissue. As a consequence of their depolymerizing activity, these kinesins increase dynamic instability of microtubules. Depletion of either of these kinesins impairs the ability of cells transformed with mutant K-Ras to migrate and invade matrigel. However, depletion of these kinesins does not reverse the epithelial to mesenchymal transition (EMT) caused by mutant K-Ras. Our studies indicate that increased expression of microtubule destabilizing factors can occur during oncogenesis to support enhanced migration and invasion of tumor cells.	[Zaganjor, E.; Osborne, J. K.; Weil, L. M.; Diaz-Martinez, L. A.; Gonzales, J. X.; Girard, L.; Minna, J. D.; Cobb, M. H.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA; [Singel, S. M.] Univ Texas SW Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA; [Larsen, J. E.; Girard, L.; Minna, J. D.] Hamon Canc Ctr Therapeut Oncol Res, Dallas, TX USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Pharmacol, 6001 Forest Pk, Dallas, TX 75390 USA.	Melanie.Cobb@UTSouthwestern.edu	Larsen, Jill E/G-3787-2010	Larsen, Jill E/0000-0001-7806-3931; Cobb, Melanie/0000-0003-0833-5473; Diaz-Martinez, Laura/0000-0002-7226-7068	National Institutes of Health [R37 DK34128, P50CA70907]; Cancer Prevention and Research Institute of Texas (CPRIT); DOD PROSPECT; Longenbaugh Foundation; Robert A. Welch Foundation [I1243]; NIGMS Pharmacological Sciences Training Grant [5-T32 GM007062]; NHMRC Biomedical Fellowship [494511]; TSANZ/Allen & Hanburys Respiratory Research Fellowship; NATIONAL CANCER INSTITUTE [P50CA070907, P30CA142543] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas (CPRIT); DOD PROSPECT; Longenbaugh Foundation; Robert A. Welch Foundation(The Welch Foundation); NIGMS Pharmacological Sciences Training Grant; NHMRC Biomedical Fellowship(National Health and Medical Research Council (NHMRC) of Australia); TSANZ/Allen & Hanburys Respiratory Research Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Andres Lorente-Rodriguez and Michael Kalwat in the Cobb lab for comments and suggestions and Dionne Ware for administrative assistance. This work was supported by grants from the National Institutes of Health (R37 DK34128 to MHC and P50CA70907 to JDM), grants from the Cancer Prevention and Research Institute of Texas (CPRIT) to JDM, DOD PROSPECT and Longenbaugh Foundation to JDM, and the Robert A. Welch Foundation I1243 to MHC. JKO was supported by NIGMS Pharmacological Sciences Training Grant 5-T32 GM007062. JEL was supported by NHMRC Biomedical Fellowship (494511)TSANZ/Allen & Hanburys Respiratory Research Fellowship.	Ahmed SM, 2012, J CELL BIOL, V199, P951, DOI 10.1083/jcb.201206051; Bodemann BO, 2008, NAT REV CANCER, V8, P133, DOI 10.1038/nrc2296; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Ding LH, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn234; Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; Duesbery NS, 2001, P NATL ACAD SCI USA, V98, P4089, DOI 10.1073/pnas.061031898; Fotiadou PP, 2007, MOL CELL BIOL, V27, P6742, DOI 10.1128/MCB.00234-07; Fukazawa H, 2000, CANCER RES, V60, P2104; Ganem NJ, 2004, J CELL BIOL, V166, P473, DOI 10.1083/jcb.200404012; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; Groth-Pedersen L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045381; Harrison RE, 2001, NEOPLASIA, V3, P385, DOI 10.1038/sj.neo.7900180; Helenius J, 2006, NATURE, V441, P115, DOI 10.1038/nature04736; Homma N, 2003, CELL, V114, P229, DOI 10.1016/S0092-8674(03)00522-1; Humbert PO, 2008, ONCOGENE, V27, P6888, DOI 10.1038/onc.2008.341; Jimenez C, 2000, J CELL BIOL, V151, P249, DOI 10.1083/jcb.151.2.249; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kolsch V, 2008, J CELL SCI, V121, P551, DOI 10.1242/jcs.023333; Korolchuk VI, 2011, NAT CELL BIOL, V13, P453, DOI 10.1038/ncb2204; Larsen JE, 2011, CLIN CHEST MED, V32, P703, DOI 10.1016/j.ccm.2011.08.003; Leinweber BD, 1999, BIOCHEM J, V344, P117, DOI 10.1042/0264-6021:3440117; LIAO GJ, 1995, J CELL SCI, V108, P3473; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; Maeda M, 2005, J CELL SCI, V118, P873, DOI 10.1242/jcs.01634; Manning AL, 2007, MOL BIOL CELL, V18, P2970, DOI 10.1091/mbc.E07-02-0110; Maor-Nof M, 2013, CELL REP, V3, P971, DOI 10.1016/j.celrep.2013.03.005; Miki H, 2005, TRENDS CELL BIOL, V15, P467, DOI 10.1016/j.tcb.2005.07.006; Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398; Moore AT, 2005, J CELL BIOL, V169, P391, DOI 10.1083/jcb.200411089; Olsen MK, 1998, J CELL PHYSIOL, V176, P525, DOI 10.1002/(SICI)1097-4652(199809)176:3<525::AID-JCP9>3.0.CO;2-Q; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; Pollock CB, 2005, CANCER RES, V65, P1244, DOI 10.1158/0008-5472.CAN-04-1911; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Rogers GC, 2004, NATURE, V427, P364, DOI 10.1038/nature02256; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sanhaji M, 2011, ONCOTARGET, V2, P935; Sato M, 2006, CANCER RES, V66, P2116, DOI 10.1158/0008-5472.CAN-05-2521; Sato M, 2013, MOL CANCER RES, V11, P638, DOI 10.1158/1541-7786.MCR-12-0634-T; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Sunaga N, 2011, MOL CANCER THER, V10, P336, DOI 10.1158/1535-7163.MCT-10-0750; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P10499, DOI 10.1073/pnas.95.18.10499; Tanuma N, 2009, ONCOGENE, V28, P752, DOI 10.1038/onc.2008.431; Tiwari N, 2012, SEMIN CANCER BIOL, V22, P194, DOI 10.1016/j.semcancer.2012.02.013; van Es JH, 2001, EXP CELL RES, V264, P126, DOI 10.1006/excr.2000.5142; VASILIEV JM, 1970, J EMBRYOL EXP MORPH, V24, P625; Wang CQ, 2010, ORAL ONCOL, V46, P65, DOI 10.1016/j.oraloncology.2009.11.003; Yamashita J, 2012, ACTA DERM-VENEREOL, V92, P593, DOI 10.2340/00015555-1416; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	57	20	20	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2014	33	47					5457	5466		10.1038/onc.2013.486	http://dx.doi.org/10.1038/onc.2013.486			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MG	24240690	Green Accepted			2022-12-17	WOS:000345120700008
J	Tan, M; Li, H; Sun, Y				Tan, M.; Li, H.; Sun, Y.			Endothelial deletion of Sag/Rbx2/Roc2 E3 ubiquitin ligase causes embryonic lethality and blocks tumor angiogenesis	ONCOGENE			English	Article						angiogenesis; anti-angiogenesis therapy; MLN4924; Sag cKO mouse model; SAG-CRL E3 ligase; vasculogenesis	CULLIN-RING LIGASES; FOCAL ADHESION KINASE; NEDD8-ACTIVATING ENZYME; CELL-GROWTH; NEOPLASTIC TRANSFORMATION; APOPTOSIS PROTECTION; ANTIOXIDANT PROTEIN; ANTICANCER TARGETS; CANCER CELLS; SCF	SAG (Sensitive to Apoptosis Gene), also known as RBX2 or ROC2, is a RING protein required for the activity of Cullin-RING ligase (CRL). Our recent study showed that Sag total knockout caused embryonic lethality at E11.5-12.5 days with associated defects in vasculogenesis. Whether Sag is required for de novo vasculogenesis in embryos and angiogenesis in tumors is totally unknown. Here, we report that Sag endothelial deletion also causes embryonic lethality at E15.5 with poor vasculogenesis. Sag deletion in primary endothelial cells (ECs) or knockdown in MS-1 ECs inhibits migration, proliferation and tube formation, with p27 accumulation being responsible for the suppression of migration and proliferation. Furthermore, Sag deletion significantly inhibits angiogenesis in an in vivo Matrigel plug assay, and tumor angiogenesis and tumorigenesis in a B16F10 melanoma model. Finally, MLN4924, an investigational small molecule inhibitor of NEDD8-activating enzyme (NAE) that inhibits CRL, suppresses in vitro migration, proliferation and tube formation, as well as in vivo angiogenesis and tumorigenesis. Taken together, our study, using both genetic and pharmaceutical approaches, demonstrates that Sag is essential for embryonic vasculogenesis and tumor angiogenesis, and provides the proof-of-concept evidence that targeting Sag E3 ubiquitin ligase may have clinical value for anti-angiogenesis therapy of human cancer.	[Tan, M.; Li, H.; Sun, Y.] Univ Michigan, Div Radiat & Canc Biol, Dept Radiat Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Sun, Y (corresponding author), Univ Michigan, Div Radiat & Canc Biol, Dept Radiat Oncol, 4424B MS-1,1301 Catherine St, Ann Arbor, MI 48109 USA.	sunyi@umich.edu	Sun, Yi/K-1025-2014	Sun, Yi/0000-0002-5841-4287	NCI [CA118762, CA156744, CA170995, CA171277]; NATIONAL CANCER INSTITUTE [R21CA170995, R01CA156744, R01CA171277, R01CA118762] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Millennium Pharmaceuticals, Inc. for providing MLN4924. This work is supported by the NCI grants (CA118762, CA156744, CA170995, and CA171277) to YS.	Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025; Bockbrader KM, 2005, ONCOGENE, V24, P7381, DOI 10.1038/sj.onc.1208888; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Deshaies RJ, 2010, SUBCELL BIOCHEM, V54, P41, DOI 10.1007/978-1-4419-6676-6_4; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Diez-Juan Antonio, 2003, Current Vascular Pharmacology, V1, P99; Duan HJ, 1999, MOL CELL BIOL, V19, P3145; Duan HJ, 2001, MOL CARCINOGEN, V30, P37, DOI 10.1002/1098-2744(200101)30:1<37::AID-MC1011>3.0.CO;2-7; Duda DM, 2008, CELL, V134, P995, DOI 10.1016/j.cell.2008.07.022; FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Goldenberg SJ, 2004, CELL, V119, P517, DOI 10.1016/j.cell.2004.10.019; Grunstein J, 1999, CANCER RES, V59, P1592; Gu QY, 2007, J CELL BIOL, V178, P1009, DOI 10.1083/jcb.200612067; Gu QY, 2007, CANCER RES, V67, P3616, DOI 10.1158/0008-5472.CAN-06-4020; He HB, 2008, CARCINOGENESIS, V29, P858, DOI 10.1093/carcin/bgn021; Huang YH, 2001, MOL CARCINOGEN, V30, P62, DOI 10.1002/1098-2744(200101)30:1<62::AID-MC1014>3.3.CO;2-1; Jia L, 2011, CURR CANCER DRUG TAR, V11, P347, DOI 10.2174/156800911794519734; Jia LJ, 2010, CLIN CANCER RES, V16, P814, DOI 10.1158/1078-0432.CCR-09-1592; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Nawrocki ST, 2012, EXPERT OPIN INV DRUG, V21, P1563, DOI 10.1517/13543784.2012.707192; Park AYJ, 2009, J BIOL CHEM, V284, P9418, DOI 10.1074/jbc.M809040200; Rabut G, 2008, EMBO REP, V9, P969, DOI 10.1038/embor.2008.183; Schiappacassi M, 2008, MOL CANCER THER, V7, P1164, DOI 10.1158/1535-7163.MCT-07-2154; Shen TL, 2005, J CELL BIOL, V169, P941, DOI 10.1083/jcb.200411155; Soucy Teresa A, 2010, Genes Cancer, V1, P708, DOI 10.1177/1947601910382898; Soucy TA, 2009, CLIN CANCER RES, V15, P3912, DOI 10.1158/1078-0432.CCR-09-0343; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Sun Y, 2001, ANTIOXID REDOX SIGN, V3, P635, DOI 10.1089/15230860152542989; Sun Y, 1999, CARCINOGENESIS, V20, P1899, DOI 10.1093/carcin/20.10.1899; Sun Y, 2013, PROTEIN CELL, V4, P103, DOI 10.1007/s13238-012-2105-7; Swaroop M, 2000, ONCOGENE, V19, P2855, DOI 10.1038/sj.onc.1203635; Tan M, 2008, ONCOGENE, V27, P1404, DOI 10.1038/sj.onc.1210780; Tan MJ, 2006, NEOPLASIA, V8, P1042, DOI 10.1593/neo.06568; Tan MJ, 2011, DEV CELL, V21, P1062, DOI 10.1016/j.devcel.2011.09.014; Tan MJ, 2010, FREE RADICAL BIO MED, V49, P976, DOI 10.1016/j.freeradbiomed.2010.05.030; Tan M, 2009, P NATL ACAD SCI USA, V106, P6203, DOI 10.1073/pnas.0812425106; Wander SA, 2011, CLIN CANCER RES, V17, P12, DOI 10.1158/1078-0432.CCR-10-0752; Wang XQ, 2008, TUMOR BIOL, V29, P217, DOI 10.1159/000152939; Wei DP, 2012, CANCER RES, V72, P282, DOI 10.1158/0008-5472.CAN-11-2866; Willems AR, 2004, BBA-MOL CELL RES, V1695, P133, DOI 10.1016/j.bbamcr.2004.09.027; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; Xirodimas DP, 2008, BIOCHEM SOC T, V36, P802, DOI 10.1042/BST0360802; Yamoah K, 2008, P NATL ACAD SCI USA, V105, P12230, DOI 10.1073/pnas.0806155105; Yang GY, 2001, J CEREBR BLOOD F MET, V21, P722, DOI 10.1097/00004647-200106000-00010; Zhao XF, 2010, J CELL BIOL, V189, P955, DOI 10.1083/jcb.200912094; Zhao YC, 2013, CURR PHARM DESIGN, V19, P3215, DOI 10.2174/13816128113199990300; Zhu Y, 2001, GENE DEV, V15, P859, DOI 10.1101/gad.862101	49	20	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2014	33	44					5211	5220		10.1038/onc.2013.473	http://dx.doi.org/10.1038/onc.2013.473			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR9RZ	24213570	Green Accepted			2022-12-17	WOS:000343914900008
J	Dudley, A; Sater, M; Le, PU; Trinh, G; Sadr, MS; Bergeron, J; Deleavey, GF; Bedell, B; Damha, MJ; Petrecca, K				Dudley, A.; Sater, M.; Le, P. U.; Trinh, G.; Sadr, M. S.; Bergeron, J.; Deleavey, G. F.; Bedell, B.; Damha, M. J.; Petrecca, K.			DRR regulates AKT activation to drive brain cancer invasion	ONCOGENE			English	Article						brain cancer; glioblastoma; invasion; AKT; DRR	TYROSINE KINASE INHIBITOR; FOCAL ADHESION KINASE; PHASE I/II TRIAL; GLIOBLASTOMA-MULTIFORME; GROWTH; PATHWAY; CELLS; THERAPY; AKT/PKB; SRC	Glioblastoma (GBM) is the most common and invasive adult brain cancer. The rapid invasion of cancer cells into the normal brain is a major cause of treatment failure, yet the mechanisms that regulate this process are poorly understood. We have identified a novel mechanism of brain cancer invasion. We show that downregulated in renal cell carcinoma (DRR), which is newly expressed in invasive gliomas, recruits AKT to focal adhesions. This DRR-induced pathological relocalization of AKT bypasses commonly altered upstream signaling events and leads to AKT activation and invasion. We also developed an oligonucleotide therapeutic that reduces DRR expression and prevents glioma invasion in an in vivo preclinical model of the disease. Our findings identify DRR as a novel GBM target and show that oligonucleotides targeting DRR is a novel therapeutic approach for the treatment of DRR-positive GBMs.	[Dudley, A.; Sater, M.; Le, P. U.; Trinh, G.; Sadr, M. S.; Bergeron, J.; Bedell, B.; Petrecca, K.] McGill Univ, Montreal Neurol Inst & Hosp, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; [Deleavey, G. F.; Damha, M. J.] McGill Univ, Dept Chem, Montreal, PQ H3A 2B4, Canada	McGill University; McGill University	Petrecca, K (corresponding author), McGill Univ, Montreal Neurol Inst & Hosp, Dept Neurol & Neurosurg, 3801 Univ Ave,Suite 109c, Montreal, PQ H3A 2B4, Canada.	kevin.petrecca@mcgill.ca			Industry Canada, Centre of Excellence for Commercialization; Canadian Institutes for Health Research-Proof-of-Principle Grant; Canadian Institutes for Health Research-Operating Grant; McGill University Faculty of Medicine Scholarship; Vanier Canada Graduate Scholarship	Industry Canada, Centre of Excellence for Commercialization; Canadian Institutes for Health Research-Proof-of-Principle Grant; Canadian Institutes for Health Research-Operating Grant(Canadian Institutes of Health Research (CIHR)); McGill University Faculty of Medicine Scholarship; Vanier Canada Graduate Scholarship	This work was supported in part by grants from Industry Canada, Centre of Excellence for Commercialization (KP), Canadian Institutes for Health Research-Proof-of-Principle Grant (KP and MJD) and Canadian Institutes for Health Research-Operating Grant (MJD). AD was supported by a McGill University Faculty of Medicine Scholarship. GT was supported by a McGill University Faculty of Medicine Scholarship. GFD was supported by a Vanier Canada Graduate Scholarship.	AHMED NN, 1993, ONCOGENE, V8, P1957; Akhavan D, 2010, NEURO-ONCOLOGY, V12, P882, DOI 10.1093/neuonc/noq052; Anderson NG, 2001, INT J CANCER, V94, P774, DOI 10.1002/ijc.1557; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Asano Y, 2010, BIOCHEM BIOPH RES CO, V394, P829, DOI 10.1016/j.bbrc.2010.03.085; Barkovich KJ, 2012, CANCER DISCOV, V2, P450, DOI 10.1158/2159-8290.CD-11-0287; Bogdahn U, 2011, NEURO-ONCOLOGY, V13, P132, DOI 10.1093/neuonc/noq142; Brandes AA, 2008, CLIN CANCER RES, V14, P957, DOI 10.1158/1078-0432.CCR-07-1810; Brown PD, 2008, J CLIN ONCOL, V26, P5603, DOI 10.1200/JCO.2008.18.0612; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chin YR, 2009, CELL SIGNAL, V21, P470, DOI 10.1016/j.cellsig.2008.11.015; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; Del Re DP, 2008, J BIOL CHEM, V283, P35622, DOI 10.1074/jbc.M804036200; Dillon RL, 2007, ONCOGENE, V26, P1338, DOI 10.1038/sj.onc.1210202; Fan QW, 2011, CURR TOP MICROBIOL, V347, P279, DOI 10.1007/82_2010_67; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Franceschi E, 2012, NEURO-ONCOLOGY, V14, P1503, DOI 10.1093/neuonc/nos256; Gan HK, 2007, J BIOL CHEM, V282, P2840, DOI 10.1074/jbc.M605136200; Genot EM, 2000, MOL CELL BIOL, V20, P5469, DOI 10.1128/MCB.20.15.5469-5478.2000; Guarino M, 2010, J CELL PHYSIOL, V223, P14, DOI 10.1002/jcp.22011; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hers I, 2011, CELL SIGNAL, V23, P1515, DOI 10.1016/j.cellsig.2011.05.004; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Kelly JJP, 2009, STEM CELLS, V27, P1722, DOI 10.1002/stem.98; Le PU, 2010, ONCOGENE, V29, P4636, DOI 10.1038/onc.2010.216; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Liu Q, 2009, ONCOL REP, V22, P1069, DOI 10.3892/or_00000538; Lu KV, 2009, CANCER RES, V69, P6889, DOI 10.1158/0008-5472.CAN-09-0347; Lu-Emerson C, 2011, J NEURO-ONCOL, V104, P287, DOI 10.1007/s11060-010-0489-x; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Maret D, 2010, NEOPLASIA, V12, P1066, DOI 10.1593/neo.10954; Martelli AM, 2006, CELL SIGNAL, V18, P1101, DOI 10.1016/j.cellsig.2006.01.011; Milano V, 2009, MOL CANCER THER, V8, P394, DOI 10.1158/1535-7163.MCT-08-0669; Molina JR, 2010, NEOPLASIA, V12, P453, DOI 10.1593/neo.10126; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Petrecca K, 2013, J NEURO-ONCOL, V111, P19, DOI 10.1007/s11060-012-0983-4; Rexer BN, 2009, CLIN CANCER RES, V15, P4518, DOI 10.1158/1078-0432.CCR-09-0872; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schmidt MV, 2011, P NATL ACAD SCI USA, V108, P17213, DOI 10.1073/pnas.1103318108; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2010, J CLIN ONCOL, V28, P2712, DOI 10.1200/JCO.2009.26.6650; van den Bent MJ, 2009, J CLIN ONCOL, V27, P5881, DOI 10.1200/JCO.2009.24.1034; Villavicencio AT, 2009, NEUROSURG REV, V32, P417, DOI 10.1007/s10143-009-0212-6; Vivanco I, 2012, CANCER DISCOV, V2, P458, DOI 10.1158/2159-8290.CD-11-0284; Wang HM, 2004, LAB INVEST, V84, P941, DOI 10.1038/labinvest.3700123; Wang L, 2000, GENE CHROMOSOME CANC, V27, P1, DOI 10.1002/(SICI)1098-2264(200001)27:1<1::AID-GCC1>3.0.CO;2-6; Wang SY, 2011, ANTI-CANCER AGENT ME, V11, P993, DOI 10.2174/187152011797927661; Wolfrum S, 2004, ARTERIOSCL THROM VAS, V24, P1842, DOI 10.1161/01.ATV.0000142813.33538.82	53	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2014	33	41					4952	4960		10.1038/onc.2013.436	http://dx.doi.org/10.1038/onc.2013.436			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OA	24141773				2022-12-17	WOS:000343767900008
J	Dong, L; Jin, L; Tseng, HY; Wang, CY; Wilmott, JS; Yosufi, B; Yan, XG; Jiang, CC; Scolyer, RA; Zhang, XD; Guo, ST				Dong, L.; Jin, L.; Tseng, H-Y; Wang, C. Y.; Wilmott, J. S.; Yosufi, B.; Yan, X. G.; Jiang, C. C.; Scolyer, R. A.; Zhang, X. D.; Guo, S. T.			Oncogenic suppression of PHLPP1 in human melanoma	ONCOGENE			English	Article						PHLPP1; Akt; melanoma; DNA methylation	TUMOR-SUPPRESSOR; SIGNALING PATHWAYS; PHOSPHATASE PHLPP; CPG METHYLATION; PH DOMAIN; PROTEIN; AKT; PTEN; ACTIVATION; PI3K	Akt is constitutively activated in up to 70% of human melanomas and has an important role in the pathogenesis of the disease. However, little is known about protein phosphatases that dephosphorylate and thereby inactivate it in melanoma cells. Here we report that suppression of pleckstrin homology domain and leucine-rich repeat Ser/Thr protein phosphatase 1 (PHLPP1) by DNA methylation promotes Akt activation and has an oncogenic role in melanoma. While it is commonly downregulated, overexpression of PHLPP1 reduces Akt activation and inhibits melanoma cell proliferation in vitro, and retards melanoma growth in a xenograft model. In contrast, knockdown of PHLPP1 increases Akt activation, enhances melanoma cell and melanocyte proliferation, and results in anchorage-independent growth of melanocytes. Suppression of PHLPP1 involves blockade of binding of the transcription factor Sp1 to the PHLPP1 promoter. Collectively, these results suggest that suppression of PHLPP1 by DNA methylation contributes to melanoma development and progression.	[Dong, L.; Jin, L.; Tseng, H-Y; Yan, X. G.; Jiang, C. C.; Zhang, X. D.] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW 2308, Australia; [Wang, C. Y.; Guo, S. T.] Shanxi Med Univ, Shanxi Canc Hosp & Inst, Dept Mol Biol, Affiliated Hosp, Taiyuan, Peoples R China; [Wilmott, J. S.; Yosufi, B.; Scolyer, R. A.] Melanoma Inst Australia, Sydney, NSW, Australia; [Wilmott, J. S.; Scolyer, R. A.] Univ Sydney, Discipline Pathol, Sydney, NSW 2006, Australia; [Scolyer, R. A.] Royal Prince Alfred Hosp, Sydney, NSW, Australia	University of Newcastle; Shanxi Medical University; Melanoma Institute Australia; University of Sydney; University of Sydney	Zhang, XD (corresponding author), Univ Newcastle, Prior Res Ctr Canc Res, Sch Med & Publ Hlth, LS3-49,Life Sci Bldg, Newcastle, NSW 2308, Australia.	Xu.Zhang@newcastle.edu.au; gsutang@gmail.com	Scolyer, Richard/AAE-8511-2019; Tseng, Cindy Hsin-Yi/AAB-8958-2022; zhang, xu/GRX-9733-2022; zhang, xian/GYA-0290-2022; Wilmott, James/AGA-8227-2022; Jin, Lei/J-1896-2019; Jin, Lei/K-2315-2019; Zhang, xiaoyu/GXA-3206-2022; zhang, xu/GYE-3558-2022	Scolyer, Richard/0000-0002-8991-0013; Tseng, Cindy Hsin-Yi/0000-0002-7499-7515; Wilmott, James/0000-0002-6750-5244; Jin, Lei/0000-0001-7187-9671; Zhang, Xu Dong/0000-0001-9457-8003	National Health and Medical Research Council (NHMRC); Cancer Council NSW; Cancer Institute NSW; Hunter Medical Research Institute, Australia; National Natural Science Foundation of China; NHMRC; Cancer Institute NSW Fellowship Program	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council NSW(Cancer Council New South Wales); Cancer Institute NSW; Hunter Medical Research Institute, Australia; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute NSW Fellowship Program	This work was supported by the National Health and Medical Research Council (NHMRC), the Cancer Council NSW, Cancer Institute NSW and Hunter Medical Research Institute, Australia; and National Natural Science Foundation of China. XDZ is supported by senior research fellowships of NHMRC. RAS is supported by the Cancer Institute NSW Fellowship Program. We thank Dr Tianyan Gao (Markey Cancer Center, University of Kentucky) for the pcDNA3-PHLPP1-HA constructs.	Beezhold K, 2011, TOXICOL SCI, V123, P411, DOI 10.1093/toxsci/kfr188; Bozulic L, 2009, CURR OPIN CELL BIOL, V21, P256, DOI 10.1016/j.ceb.2009.02.002; Bradley EW, 2013, J BIOL CHEM, V288, P9572, DOI 10.1074/jbc.M112.423723; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chen MH, 2011, CANCER CELL, V20, P173, DOI 10.1016/j.ccr.2011.07.013; Cheung M, 2008, CANCER RES, V68, P3429, DOI 10.1158/0008-5472.CAN-07-5867; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Curtin JA, 2006, J INVEST DERMATOL, V126, P1660, DOI 10.1038/sj.jid.5700311; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Davies MA, 2009, CLIN CANCER RES, V15, P7538, DOI 10.1158/1078-0432.CCR-09-1985; Fayard E, 2005, J CELL SCI, V118, P5675, DOI 10.1242/jcs.02724; Fedele CG, 2010, P NATL ACAD SCI USA, V107, P22231, DOI 10.1073/pnas.1015245107; Ferte C, 2010, NAT REV CLIN ONCOL, V7, P367, DOI 10.1038/nrclinonc.2010.84; Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Gao T, 2008, J BIOL CHEM, V283, P6300, DOI 10.1074/jbc.M707319200; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Gewinner C, 2009, CANCER CELL, V16, P115, DOI 10.1016/j.ccr.2009.06.006; Gillespie S, 2005, MOL CANCER THER, V4, P668, DOI 10.1158/1535-7163.MCT-04-0332; Govindarajan B, 2007, J CLIN INVEST, V117, P719, DOI 10.1172/JCI30102; Guo ST, 2013, ONCOGENE, V32, P1910, DOI 10.1038/onc.2012.214; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Houslay MD, 2011, CANCER CELL, V19, P3, DOI 10.1016/j.ccr.2011.01.004; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Jiang CC, 2011, CLIN CANCER RES, V17, P721, DOI 10.1158/1078-0432.CCR-10-2225; Jin L, 2011, P NATL ACAD SCI USA, V108, P15840, DOI 10.1073/pnas.1019312108; Karreth FA, 2011, CELL, V147, P382, DOI 10.1016/j.cell.2011.09.032; Klug M, 2006, EPIGENETICS-US, V1, P127, DOI 10.4161/epi.1.3.3327; Li L, 2010, ANN ANAT, V192, P275, DOI 10.1016/j.aanat.2010.07.010; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Liu J, 2009, ONCOGENE, V28, P994, DOI 10.1038/onc.2008.450; Liu JY, 2011, MOL CELL BIOL, V31, P4917, DOI 10.1128/MCB.05799-11; Madhunapantula SV, 2009, PIGM CELL MELANOMA R, V22, P400, DOI 10.1111/j.1755-148X.2009.00585.x; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; Mirmohammadsadegh A, 2006, CANCER RES, V66, P6546, DOI 10.1158/0008-5472.CAN-06-0384; Molina JR, 2012, ONCOGENE, V31, P1264, DOI 10.1038/onc.2011.324; Nitsche C, 2012, GASTROENTEROLOGY, V142, P377, DOI 10.1053/j.gastro.2011.10.026; O'Hayre M, 2012, LEUKEMIA, V26, P1689, DOI 10.1038/leu.2012.6; O'Neill AK, 2013, FEBS J, V280, P572, DOI 10.1111/j.1742-4658.2012.08537.x; Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954; Park SJ, 2001, J BIOL CHEM, V276, P4781, DOI 10.1074/jbc.M010177200; Patterson SJ, 2011, J IMMUNOL, V186, P5533, DOI 10.4049/jimmunol.1002126; Poulikakos PI, 2011, CANCER CELL, V19, P11, DOI 10.1016/j.ccr.2011.01.008; Qiao M, 2010, MOL CELL, V38, P512, DOI 10.1016/j.molcel.2010.03.017; Ribas A, 2011, NAT REV CLIN ONCOL, V8, P426, DOI 10.1038/nrclinonc.2011.69; Rishi V, 2010, P NATL ACAD SCI USA, V107, P20311, DOI 10.1073/pnas.1008688107; Saavedra A, 2010, CELL DEATH DIFFER, V17, P324, DOI 10.1038/cdd.2009.127; Shimizu K, 2003, J BIOL CHEM, V278, P14920, DOI 10.1074/jbc.M213214200; Smalley KSM, 2010, J INVEST DERMATOL, V130, P28, DOI 10.1038/jid.2009.177; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Stark M, 2007, CANCER RES, V67, P2632, DOI 10.1158/0008-5472.CAN-06-4152; Tay KH, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.79; Warfel NA, 2012, J BIOL CHEM, V287, P3610, DOI 10.1074/jbc.R111.318675; Warfel NA, 2011, J BIOL CHEM, V286, P19777, DOI 10.1074/jbc.M111.237081; Ye Y, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2489; Zhuang LQ, 2009, HISTOPATHOLOGY, V54, P462, DOI 10.1111/j.1365-2559.2009.03242.x	60	20	20	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2014	33	39					4756	4766		10.1038/onc.2013.420	http://dx.doi.org/10.1038/onc.2013.420			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0ED	24121273	Green Submitted			2022-12-17	WOS:000343239500006
J	Drost, R; Jonkers, J				Drost, R.; Jonkers, J.			Opportunities and hurdles in the treatment of BRCA1-related breast cancer	ONCOGENE			English	Review						BRCA1; breast cancer; treatment	DNA-DAMAGE RESPONSE; INHIBITS HOMOLOGOUS RECOMBINATION; ANTICANCER DRUG CISPLATIN; CELL-CYCLE CHECKPOINT; BRCA1 MESSENGER-RNA; INTERACT IN-VIVO; POLY(ADP-RIBOSE) POLYMERASE; SPORADIC BREAST; PARP INHIBITOR; MAMMARY-TUMORS	BRCA1 functions as a classical tumor suppressor in breast and ovarian cancer. While the role of BRCA1 in homology-directed repair of DNA double-strand breaks contributes to its tumor suppressive activity, it also renders BRCA1-deficient cells highly sensitive to DNA-damaging agents. Although BRCA1 deficiency is therefore considered to be an attractive therapeutic target, re-activation of BRCA1 by secondary mutations has been shown to cause therapy resistance. In this review, we will assess the role of BRCA1 in both hereditary and sporadic breast cancer and discuss how different functionalities of the BRCA1 protein can contribute to its tumor suppressor function. In addition, we will discuss how this knowledge on BRCA1 function can help to overcome the hurdles encountered in the clinic and improve current treatment strategies for patients with BRCA1-related breast cancer.	[Jonkers, J.] Netherlands Canc Inst, Div Mol Pathol, NL-1066 CX Amsterdam, Noord Holland, Netherlands; Netherlands Canc Inst, Canc Genom Ctr Netherlands, NL-1066 CX Amsterdam, Noord Holland, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Jonkers, J (corresponding author), Netherlands Canc Inst, Div Mol Pathol, Plesmanlaan 121, NL-1066 CX Amsterdam, Noord Holland, Netherlands.	j.jonkers@nki.nl	Jonkers, Jos/AAG-3246-2019	Jonkers, Jos/0000-0002-9264-9792	European Union; TI Center for Translational Molecular Medicine (CTMM); Netherlands Organization for Scientific Research (NWO); Cancer Systems Biology Center; Cancer Genomics Centre Netherlands; Dutch Cancer Society (KWF)	European Union(European Commission); TI Center for Translational Molecular Medicine (CTMM); Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); Cancer Systems Biology Center; Cancer Genomics Centre Netherlands; Dutch Cancer Society (KWF)(KWF Kankerbestrijding)	We thank Peter Bouwman and Sven Rottenberg for helpful discussions and comments on the manuscript. This work was supported by grants from the European Union, the TI Center for Translational Molecular Medicine (CTMM), the Netherlands Organization for Scientific Research (NWO), the Cancer Systems Biology Center, the Cancer Genomics Centre Netherlands and the Dutch Cancer Society (KWF).	Althuis MD, 2005, INT J EPIDEMIOL, V34, P405, DOI 10.1093/ije/dyh414; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8; Baldassarre G, 2003, MOL CELL BIOL, V23, P2225, DOI 10.1128/MCB.23.7.2225-2238.2003; Baldwin RL, 2000, CANCER RES, V60, P5329; Ben David Y, 2002, J CLIN ONCOL, V20, P463, DOI 10.1200/JCO.2002.20.2.463; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Birkbak NJ, 2012, CANCER DISCOV, V2, P366, DOI 10.1158/2159-8290.CD-11-0206; Bordeleau L, 2010, BREAST CANCER RES TR, V119, P13, DOI 10.1007/s10549-009-0566-z; Bouwman P, 2012, NAT REV CANCER, V12, P587, DOI 10.1038/nrc3342; Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831; Boyd J, 2000, JAMA-J AM MED ASSOC, V283, P2260, DOI 10.1001/jama.283.17.2260; Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Brzovic PS, 2003, P NATL ACAD SCI USA, V100, P5646, DOI 10.1073/pnas.0836054100; Brzovic PS, 2006, MOL CELL, V21, P873, DOI 10.1016/j.molcel.2006.02.008; Bunting SF, 2012, MOL CELL, V46, P125, DOI 10.1016/j.molcel.2012.02.015; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Byrski T, 2008, BREAST CANCER RES TR, V108, P289, DOI 10.1007/s10549-007-9600-1; Byrski T, 2009, BREAST CANCER RES TR, V115, P359, DOI 10.1007/s10549-008-0128-9; Byrski T, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3231; Byrski T, 2010, J CLIN ONCOL, V28, P375, DOI 10.1200/JCO.2008.20.7019; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Cass I, 2003, CANCER, V97, P2187, DOI 10.1002/cncr.11310; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Catteau A, 2002, SEMIN CANCER BIOL, V12, P359, DOI 10.1016/S1044-579X(02)00056-1; Chabalier C, 2006, CELL CYCLE, V5, P1001, DOI 10.4161/cc.5.9.2726; Chalmers AJ, 2009, BRIT MED BULL, V89, P23, DOI 10.1093/bmb/ldp005; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen LC, 2008, J BIOL CHEM, V283, P7713, DOI 10.1074/jbc.M710245200; Chetrit A, 2008, J CLIN ONCOL, V26, P20, DOI 10.1200/JCO.2007.11.6905; Christensen DE, 2007, NAT STRUCT MOL BIOL, V14, P941, DOI 10.1038/nsmb1295; Clark AS, 2011, J MAMMARY GLAND BIOL, V16, P17, DOI 10.1007/s10911-011-9200-x; Clark CC, 2012, MOL CANCER THER, V11, P1948, DOI 10.1158/1535-7163.MCT-11-0597; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; Deans AJ, 2006, CANCER RES, V66, P8219, DOI 10.1158/0008-5472.CAN-05-3945; Deans AJ, 2011, NAT REV CANCER, V11, P467, DOI 10.1038/nrc3088; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; Dobrovic A, 1997, CANCER RES, V57, P3347; Donawho CK, 2007, CLIN CANCER RES, V13, P2728, DOI 10.1158/1078-0432.CCR-06-3039; Drost R, 2011, CANCER CELL, V20, P797, DOI 10.1016/j.ccr.2011.11.014; Dungey FA, 2009, MOL CANCER THER, V8, P2243, DOI 10.1158/1535-7163.MCT-09-0201; Edwards SL, 2008, NATURE, V451, P1111, DOI 10.1038/nature06548; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Evers B, 2008, CLIN CANCER RES, V14, P3916, DOI 10.1158/1078-0432.CCR-07-4953; Evers B, 2010, CLIN CANCER RES, V16, P99, DOI 10.1158/1078-0432.CCR-09-2434; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fong PC, 2010, J CLIN ONCOL, V28, P2512, DOI 10.1200/JCO.2009.26.9589; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Galizia E, 2010, ANAL QUANT CYTOL, V32, P24; Gelmon KA, 2011, LANCET ONCOL, V12, P852, DOI 10.1016/S1470-2045(11)70214-5; Glover JNM, 2006, FAM CANCER, V5, P89, DOI 10.1007/s10689-005-2579-z; Guha M, 2011, NAT BIOTECHNOL, V29, P373, DOI 10.1038/nbt0511-373; Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Holloman WK, 2011, NAT STRUCT MOL BIOL, V18, P748, DOI 10.1038/nsmb.2096; Holstege H, 2009, CANCER RES, V69, P3625, DOI 10.1158/0008-5472.CAN-08-3426; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; Huen MSY, 2010, NAT REV MOL CELL BIO, V11, P138, DOI 10.1038/nrm2831; Ibrahim YH, 2012, CANCER DISCOV, V2, P1036, DOI 10.1158/2159-8290.CD-11-0348; Ishida S, 2010, CANCER CELL, V17, P574, DOI 10.1016/j.ccr.2010.04.011; Jacquemont C, 2007, CANCER RES, V67, P7395, DOI 10.1158/0008-5472.CAN-07-1015; Jaspers JE, 2013, CANCER DISCOV, V3, P68, DOI 10.1158/2159-8290.CD-12-0049; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jensen RB, 2010, NATURE, V467, P678, DOI 10.1038/nature09399; Jones P, 2009, J MED CHEM, V52, P7170, DOI 10.1021/jm901188v; Joukov V, 2006, CELL, V127, P539, DOI 10.1016/j.cell.2006.08.053; Juvekar A, 2012, CANCER DISCOV, V2, P1048, DOI 10.1158/2159-8290.CD-11-0336; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kass EM, 2013, P NATL ACAD SCI USA, V110, P5564, DOI 10.1073/pnas.1216824110; Kennedy RD, 2004, JNCI-J NATL CANCER I, V96, P1659, DOI 10.1093/jnci/djh312; Kimbung S, 2012, CANCER LETT, V319, P232, DOI 10.1016/j.canlet.2012.01.015; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Krawczyk PM, 2011, P NATL ACAD SCI USA, V108, P9851, DOI 10.1073/pnas.1101053108; Kriege M, 2012, CANCER-AM CANCER SOC, V118, P899, DOI 10.1002/cncr.26351; Kummar S, 2012, CLIN CANCER RES, V18, P1726, DOI 10.1158/1078-0432.CCR-11-2821; Lafarge S, 2001, ONCOGENE, V20, P6597, DOI 10.1038/sj.onc.1204812; Li LP, 2008, CANCER RES, V68, P9141, DOI 10.1158/0008-5472.CAN-08-1127; Li ML, 2012, TRENDS BIOCHEM SCI, V37, P418, DOI 10.1016/j.tibs.2012.06.007; Liu J, 2010, NAT STRUCT MOL BIOL, V17, P1260, DOI 10.1038/nsmb.1904; Liu XS, 2012, CLIN CANCER RES, V18, P510, DOI 10.1158/1078-0432.CCR-11-1973; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; Metcalfe KA, 2010, J CLIN ONCOL, V28, P387, DOI 10.1200/JCO.2009.25.0712; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 2010, NAT REV MOL CELL BIO, V11, P196, DOI 10.1038/nrm2851; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Norquist B, 2011, J CLIN ONCOL, V29, P3008, DOI 10.1200/JCO.2010.34.2980; O'Shaughnessy J, 2011, NEW ENGL J MED, V364, P205, DOI 10.1056/NEJMoa1011418; Ohta T, 2011, FEBS LETT, V585, P2836, DOI 10.1016/j.febslet.2011.05.005; Osher DJ, 2011, J CLIN PATHOL, V64, P924, DOI 10.1136/jcp.2010.086405; Ouchi T, 2006, CANCER BIOL THER, V5, P470, DOI 10.4161/cbt.5.5.2845; Pajic M, 2010, CELL CYCLE, V9, P3780, DOI 10.4161/cc.9.18.13002; Patel AG, 2012, CLIN CANCER RES, V18, P1655, DOI 10.1158/1078-0432.CCR-11-2890; Pathania S, 2011, MOL CELL, V44, P235, DOI 10.1016/j.molcel.2011.09.002; Penning TD, 2009, J MED CHEM, V52, P514, DOI 10.1021/jm801171j; Piccart MJ, 2001, ANN ONCOL, V12, P1195, DOI 10.1023/A:1012259625746; Plummer R, 2008, CLIN CANCER RES, V14, P7917, DOI 10.1158/1078-0432.CCR-08-1223; Quinn JE, 2003, CANCER RES, V63, P6221; Rabik CA, 2007, CANCER TREAT REV, V33, P9, DOI 10.1016/j.ctrv.2006.09.006; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; Rakha EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748; Reis-Filho JS, 2008, HISTOPATHOLOGY, V52, P108, DOI 10.1111/j.1365-2559.2007.02889.x; Reis JS, 2011, LANCET, V378, P1812, DOI 10.1016/S0140-6736(11)61539-0; Rennert G, 2007, NEW ENGL J MED, V357, P115, DOI 10.1056/NEJMoa070608; Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761; Risch HA, 2006, JNCI-J NATL CANCER I, V98, P1694, DOI 10.1093/jnci/djj465; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; Rodriguez JA, 2004, EXP CELL RES, V293, P14, DOI 10.1016/j.yexcr.2003.09.027; Rottenberg S, 2008, P NATL ACAD SCI USA, V105, P17079, DOI 10.1073/pnas.0806092105; Rottenberg S, 2007, P NATL ACAD SCI USA, V104, P12117, DOI 10.1073/pnas.0702955104; Rottenberg S, 2012, CANCER RES, V72, P2350, DOI 10.1158/0008-5472.CAN-11-4201; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Russell PA, 2000, INT J CANCER, V87, P317, DOI 10.1002/1097-0215(20000801)87:3<317::AID-IJC2>3.0.CO;2-B; Saal LH, 2008, NAT GENET, V40, P102, DOI 10.1038/ng.2007.39; Sakai W, 2008, NATURE, V451, P1116, DOI 10.1038/nature06633; Sakai W, 2009, CANCER RES, V69, P6381, DOI 10.1158/0008-5472.CAN-09-1178; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shabbeer S, 2013, ONCOGENE, V32, P5005, DOI 10.1038/onc.2012.522; Shafee N, 2008, CANCER RES, V68, P3243, DOI 10.1158/0008-5472.CAN-07-5480; Shakya R, 2008, P NATL ACAD SCI US; Shakya R, 2011, SCIENCE, V334, P525, DOI 10.1126/science.1209909; Shuen AY, 2011, J MAMMARY GLAND BIOL, V16, P3, DOI 10.1007/s10911-011-9213-5; Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; Swisher EM, 2008, CANCER RES, V68, P2581, DOI 10.1158/0008-5472.CAN-08-0088; Sy SMH, 2009, P NATL ACAD SCI USA, V106, P7155, DOI 10.1073/pnas.0811159106; Tassone P, 2003, BRIT J CANCER, V88, P1285, DOI 10.1038/sj.bjc.6600859; Tassone P, 2009, CANCER BIOL THER, V8, P648, DOI 10.4161/cbt.8.7.7968; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Thompson D, 2002, JNCI-J NATL CANCER I, V94, P1358, DOI 10.1093/jnci/94.18.1358; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Thompson ME, 2005, J BIOL CHEM, V280, P21854, DOI 10.1074/jbc.M502676200; Thorslund T, 2010, NAT STRUCT MOL BIOL, V17, P1263, DOI 10.1038/nsmb.1905; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Vollebergh MA, 2011, ANN ONCOL, V22, P1561, DOI 10.1093/annonc/mdq624; Wang B, 2007, SCIENCE, V316, P1194, DOI 10.1126/science.1139476; Wang B, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-6; Weaver Z, 2002, ONCOGENE, V21, P5097, DOI 10.1038/sj.onc.1205636; Whittemore AS, 1997, AM J HUM GENET, V60, P496; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Wysocki PJ, 2008, MED SCI MONITOR, V14, pSC7; Xia B, 2006, MOL CELL, V22, P719, DOI 10.1016/j.molcel.2006.05.022; Xiang T, 2011, ONCOGENE, V30, P2443, DOI 10.1038/onc.2010.603; Xiang T, 2008, CANCER RES, V68, P10040, DOI 10.1158/0008-5472.CAN-08-3009; Xu B, 2002, CANCER RES, V62, P4588; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yang ES, 2012, CANCER RES, V72, P5547, DOI 10.1158/0008-5472.CAN-12-0934; Yang ES, 2010, FEBS J, V277, P3079, DOI 10.1111/j.1742-4658.2010.07734.x; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zamble DB, 1996, BIOCHEMISTRY-US, V35, P10004, DOI 10.1021/bi960453+; Zander SAL, 2010, CANCER RES, V70, P1700, DOI 10.1158/0008-5472.CAN-09-3367; Zhang F, 2009, MOL CANCER RES, V7, P1110, DOI 10.1158/1541-7786.MCR-09-0123; Zhang F, 2009, CURR BIOL, V19, P524, DOI 10.1016/j.cub.2009.02.018; Zhu Q, 2011, NATURE, V477, P179, DOI 10.1038/nature10371	172	20	22	0	38	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3753	3763		10.1038/onc.2013.329	http://dx.doi.org/10.1038/onc.2013.329			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	23955079				2022-12-17	WOS:000339394100001
J	Xu, Z; Pei, L; Wang, L; Zhang, F; Hu, X; Gui, Y				Xu, Z.; Pei, L.; Wang, L.; Zhang, F.; Hu, X.; Gui, Y.			Snail1-dependent transcriptional repression of Cezanne2 in hepatocellular carcinoma	ONCOGENE			English	Article						Snail1; Cezanne2; HCC; metastasis	NF-KAPPA-B; EPITHELIAL-MESENCHYMAL TRANSITIONS; GENE-EXPRESSION; SNAIL; MICROENVIRONMENT; HEPATOCYTES; COOPERATION; MECHANISMS; ICAM-1; CELLS	High malignancy and early metastasis are the hallmarks of hepatocellular carcinoma (HCC). Here, we report that Cezanne2 expression is downregulated in HCC cells and in HCC patients' tumorous tissues and that Cezanne2 is inversely associated with Snail1 expression in HCC patients' tumorous tissues. Chromatin immunoprecipitation assays and the reporter gene assay showed that Snail1 binds to the promoter of the Cezanne2 gene and mediates the direct consequence of Cezanne2 repression. Enhanced expression of Cezanne2 could suppress proliferation, migration and invasion in HCC cells. Further, Cezanne2 could regulate MMP (matrix metalloproteinase) 2, MMP9 and ICAM1 (intercellular adhesion molecule) levels through modulation of the NF-kappa B (nuclear factor kappa-light-chain-enhancer of activated B cell) signaling cascade. Co-immunoprecipitation and in vivo deubiquitination assay indicated that Cezanne2 interacts with TNF receptor-associated factor (TRAF) 6 and cleaves the polyubiquitin from TRAF6 substrates. Our data reveal that Snail1-mediated suppression of Cezanne2 may have a key role in HCC malignancy.	[Xu, Z.; Pei, L.; Zhang, F.] ZhongCheng Translat Med Inc, Dept Mol Diag, Shanghai 2, Peoples R China; [Wang, L.] Shanghai Jiao Tong Univ, Sch Med, Shanghai 200030, Peoples R China; [Hu, X.; Gui, Y.] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Hangzhou 310027, Zhejiang, Peoples R China	Shanghai Jiao Tong University; Zhejiang University	Xu, Z (corresponding author), Univ Chicago, Dept Med, JFK R322, BSLC, 57th St, Chicago, IL 60637 USA.	Xuzhonping@gmail.com		GUI, YAXING/0000-0002-0466-3608	Institute of Health Science, Shanghai Institutes for Biological Sciences; Chinese Academy of Sciences; Department of Medicine, University of Chicago; Startup Package of Zhongcheng Translational- Medicine Incorporation, Shanghai, China; SLRC laboratory animal company, Shanghai, China	Institute of Health Science, Shanghai Institutes for Biological Sciences; Chinese Academy of Sciences(Chinese Academy of Sciences); Department of Medicine, University of Chicago(University of Chicago); Startup Package of Zhongcheng Translational- Medicine Incorporation, Shanghai, China; SLRC laboratory animal company, Shanghai, China	Dr Zhongping Xu obtained his PhD in January 2011 from the Institute of Health Science, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, and at present he works as a postdoctoral fellow at the Department of Medicine, University of Chicago. Dr Zhongping Xu started to found Zhongcheng Translational-medicine Incorporation in June 2011. This study was sponsored by the Startup Package of Zhongcheng Translational-Medicine Incorporation, Shanghai, China. The nude mice were supplied by SLRC laboratory animal company, Shanghai, China.	Astarci E, 2012, FEBS J, V279, P2966, DOI 10.1111/j.1742-4658.2012.08677.x; Bu W, 1997, Zhonghua Yi Xue Za Zhi, V77, P661; Budhu A, 2006, CANCER CELL, V10, P99, DOI 10.1016/j.ccr.2006.06.016; Chaffer CL, SCIENCE, V331, P1559; Doreau A, 2009, NAT IMMUNOL, V10, P778, DOI 10.1038/ni.1741; Enesa K, 2008, J BIOL CHEM, V283, P7036, DOI 10.1074/jbc.M708690200; Evans PC, 2001, BIOCHEM J, V357, P617, DOI 10.1042/0264-6021:3570617; Evans PC, 2003, J BIOL CHEM, V278, P23180, DOI 10.1074/jbc.M301863200; Gao JM, 2008, J BIOL CHEM, V283, P8802, DOI 10.1074/jbc.M708470200; de Herreros AG, 2010, J MAMMARY GLAND BIOL, V15, P135, DOI 10.1007/s10911-010-9179-8; Gotzmann J, 2002, J CELL SCI, V115, P1189; Katzenellenbogen M, 2006, CANCER RES, V66, P4001, DOI 10.1158/0008-5472.CAN-05-2937; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Khetchoumian K, 2007, NAT GENET, V39, P1500, DOI 10.1038/ng.2007.15; La Starza R, 2007, CANCER GENET CYTOGEN, V175, P73, DOI 10.1016/j.cancergencyto.2007.01.011; Massoumi R, 2009, J EXP MED, V206, P221, DOI 10.1084/jem.20082044; Nguyen H, 2006, VIROLOGY, V354, P58, DOI 10.1016/j.virol.2006.04.028; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Shalom-Barak T, 1998, J BIOL CHEM, V273, P27467, DOI 10.1074/jbc.273.42.27467; Sun HC, 2004, J CANCER RES CLIN, V130, P307, DOI 10.1007/s00432-003-0530-y; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Xu ZP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014514; Xue JP, 2009, PHYSIOL GENOMICS, V38, P42, DOI 10.1152/physiolgenomics.00012.2009; Yang P, 2009, HEPATOL RES, V39, P1169, DOI 10.1111/j.1872-034X.2009.00563.x	24	20	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2014	33	22					2836	2845		10.1038/onc.2013.243	http://dx.doi.org/10.1038/onc.2013.243			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EI	23792447				2022-12-17	WOS:000337231800003
J	Rosebeck, S; Rehman, AO; Apel, IJ; Kohrt, D; Appert, A; O'Donnell, MA; Ting, AT; Du, MQ; Baens, M; Lucas, PC; McAllister-Lucas, LM				Rosebeck, S.; Rehman, A. O.; Apel, I. J.; Kohrt, D.; Appert, A.; O'Donnell, M. A.; Ting, A. T.; Du, M-Q; Baens, M.; Lucas, P. C.; McAllister-Lucas, L. M.			The API2-MALT1 fusion exploits TNFR pathway-associated RIP1 ubiquitination to promote oncogenic NF-kappa B signaling	ONCOGENE			English	Article						MALT1; TRAF2; RIP1; lymphoma; ubiquitination	NECROSIS-FACTOR RECEPTOR; MALT LYMPHOMA; CELL LYMPHOMA; DNA-DAMAGE; ACTIVATION; KINASE; APOPTOSIS; BCL10; PROTEIN; POLYUBIQUITINATION	The API2-MALT1 fusion oncoprotein is created by the recurrent t(11;18)(q21;q21) chromosomal translocation in mucosa-associated lymphoid tissue (MALT) lymphoma. We identified receptor interacting protein-1 (RIP1) as a novel API2-MALT1-associated protein, and demonstrate that RIP1 is required for API2-MALT1 to stimulate canonical nuclear factor kappa B (NF-kappa B). API2-MALT1 promotes ubiquitination of RIP1 at lysine (K) 377, which is necessary for full NF-kappa B activation. Furthermore, we found that TNF receptor-associated factor 2 (TRAF2) recruitment is required for API2-MALT1 to induce RIP1 ubiquitination, NF-kappa B activation and cellular transformation. Although both TRAF2 and RIP1 interact with the API2 moiety of API2-MALT1, this moiety alone is insufficient to induce RIP1 ubiquitination or activate NF-kappa B, indicating that API2-MALT1-dependent RIP1 ubiquitination represents a gain of function requiring the concerted actions of both the API2 and MALT1 moieties of the fusion. Intriguingly, constitutive RIP1 ubiquitination was recently demonstrated in several solid tumors, and now our study implicates RIP1 ubiquitination as a critical component of API2-MALT1-dependent lymphomagenesis.	[Rosebeck, S.; Rehman, A. O.; Kohrt, D.; McAllister-Lucas, L. M.] Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, Ann Arbor, MI USA; [Apel, I. J.; Lucas, P. C.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA; [Du, M-Q] Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Div Mol Histopathol, Cambridge CB2 2QQ, England; [O'Donnell, M. A.; Ting, A. T.] Icahn Sch Med Mt Sinai, Inst Immunol, New York, NY USA; [Baens, M.] Catholic Univ Louvain, Ctr Human Genet, Human Genome Lab, B-3000 Louvain, Belgium; [Baens, M.] VIB, Dept Mol & Dev Genet, Human Genome Lab, Louvain, Belgium	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Icahn School of Medicine at Mount Sinai; Universite Catholique Louvain; Flanders Institute for Biotechnology (VIB)	Lucas, PC (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Pathol, 5123 Rangos Res Bldg,4401 Penn Ave, Pittsburgh, PA 15224 USA.	lucaspc@upmc.edu; linda.mcallister@chp.edu		Du, Ming-Qing/0000-0002-1017-5045; Lucas, Peter/0000-0003-4880-7172	Shirley K Schlafer Foundation; Elizabeth Caroline Crosby Fund; University of Michigan Comprehensive Cancer Center [G007839]; National Cancer Institute, NIH [R01CA124540]; National Heart, Lung and Blood Institute, NIH [T32-HL007622-21A2]; Nancy Newton Loeb Pediatric Cancer Research Award; AACI Fellowship for Translational Cancer Research; NATIONAL CANCER INSTITUTE [R01CA124540] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082914, T32HL007622] Funding Source: NIH RePORTER	Shirley K Schlafer Foundation; Elizabeth Caroline Crosby Fund; University of Michigan Comprehensive Cancer Center; National Cancer Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Heart, Lung and Blood Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Nancy Newton Loeb Pediatric Cancer Research Award; AACI Fellowship for Translational Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Gabriel Nunez for contributing plasmids, Shaomeng Wang for providing smac mimetic compounds and Linda Klei for laboratory management. This work was supported by the Shirley K Schlafer Foundation, the Elizabeth Caroline Crosby Fund, and grants from the University of Michigan Comprehensive Cancer Center (G007839) and the National Cancer Institute, NIH (R01CA124540). SR was supported by the National Heart, Lung and Blood Institute, NIH (T32-HL007622-21A2), the Nancy Newton Loeb Pediatric Cancer Research Award and the AACI Fellowship for Translational Cancer Research.	Akagi T, 1999, ONCOGENE, V18, P5785, DOI 10.1038/sj.onc.1203018; Alvarez SE, 2010, NATURE, V465, P1084, DOI 10.1038/nature09128; Baens M, 2006, CANCER RES, V66, P5270, DOI 10.1158/0008-5472.CAN-05-4590; Bellail AC, 2012, CANCER DISCOV, V2, P140, DOI 10.1158/2159-8290.CD-11-0172; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Biton S, 2011, CELL, V145, P92, DOI 10.1016/j.cell.2011.02.023; Cardamone MD, 2012, MOL CELL, V46, P91, DOI 10.1016/j.molcel.2012.01.025; Conze DB, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000518; Coornaert B, 2008, NAT IMMUNOL, V9, P263, DOI 10.1038/ni1561; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Duprez L, 2012, J BIOL CHEM, V287, P14863, DOI 10.1074/jbc.M111.288670; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Garrison JB, 2009, ONCOGENE, V28, P1584, DOI 10.1038/onc.2009.17; Gerlach B, 2011, NATURE, V471, P591, DOI 10.1038/nature09816; Hasegawa M, 2008, EMBO J, V27, P373, DOI 10.1038/sj.emboj.7601962; Hoffmann A, 2006, IMMUNOL REV, V210, P171, DOI 10.1111/j.0105-2896.2006.00375.x; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Lee TH, 2004, J BIOL CHEM, V279, P33185, DOI 10.1074/jbc.M404206200; Li HX, 2006, J BIOL CHEM, V281, P13636, DOI 10.1074/jbc.M600620200; Liu HX, 2001, BLOOD, V98, P1182, DOI 10.1182/blood.V98.4.1182; Liu HX, 2002, GASTROENTEROLOGY, V122, P1286, DOI 10.1053/gast.2002.33047; Lu JF, 2008, CANCER RES, V68, P9384, DOI 10.1158/0008-5472.CAN-08-2655; Lucas PC, 2007, ONCOGENE, V26, P5643, DOI 10.1038/sj.onc.1210342; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; Morgan JA, 1999, CANCER RES, V59, P6205; Noels H, 2007, J BIOL CHEM, V282, P10180, DOI 10.1074/jbc.M611038200; O'Donnell MA, 2007, CURR BIOL, V17, P418, DOI 10.1016/j.cub.2007.01.027; Oeckinghaus A, 2007, EMBO J, V26, P4634, DOI 10.1038/sj.emboj.7601897; Peng C, 2012, J BIOL CHEM, V287, P25881, DOI 10.1074/jbc.M112.359521; Rosebeck S, 2011, SCIENCE, V331, P468, DOI 10.1126/science.1198946; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Shembade N, 2010, SCIENCE, V327, P1135, DOI 10.1126/science.1182364; Staal J, 2011, EMBO J, V30, P1742, DOI 10.1038/emboj.2011.85; Stoffel A, 2004, P NATL ACAD SCI USA, V101, P9079, DOI 10.1073/pnas.0402415101; Streubel B, 2003, BLOOD, V101, P2335, DOI 10.1182/blood-2002-09-2963; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Thome M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003004; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(00)00094-0; Varfolomeev E, 2008, J BIOL CHEM, V283, P24295, DOI 10.1074/jbc.C800128200; Vince JE, 2009, J BIOL CHEM, V284, P35906, DOI 10.1074/jbc.M109.072256; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Wu CJ, 2006, NAT CELL BIOL, V8, P398, DOI 10.1038/ncb1384; Yang YB, 2011, MOL CELL BIOL, V31, P2774, DOI 10.1128/MCB.01139-10; Yin Q, 2009, BIOCHEMISTRY-US, V48, P10558, DOI 10.1021/bi901462e; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767; Zhou HL, 2005, CANCER CELL, V7, P425, DOI 10.1016/j.ccr.2005.04.012; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	53	20	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2520	2530		10.1038/onc.2013.195	http://dx.doi.org/10.1038/onc.2013.195			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23770847	Green Accepted			2022-12-17	WOS:000336033600012
J	Ito, K; Maruyama, Z; Sakai, A; Izumi, S; Moriishi, T; Yoshida, CA; Miyazaki, T; Komori, H; Takada, K; Kawaguchi, H; Komori, T				Ito, K.; Maruyama, Z.; Sakai, A.; Izumi, S.; Moriishi, T.; Yoshida, C. A.; Miyazaki, T.; Komori, H.; Takada, K.; Kawaguchi, H.; Komori, T.			Overexpression of Cdk6 and Ccnd1 in chondrocytes inhibited chondrocyte maturation and caused p53-dependent apoptosis without enhancing proliferation	ONCOGENE			English	Article						Cdk6; cyclin D1; chondrocyte; apoptosis; p53; Rb	INTEGRIN-LINKED KINASE; CYCLIN D1; CELL-CYCLE; MICE LACKING; P53 LOSS; EXPRESSION; DIFFERENTIATION; OSTEOSARCOMA; P57(KIP2); PROTEIN	Cell proliferation and differentiation are closely coupled. However, we previously showed that overexpression of cyclin-dependent kinase (Cdk6) blocks chondrocyte differentiation without affecting cell-cycle progression in vitro. To investigate whether Cdk6 inhibits chondrocyte differentiation in vivo, we generated chondrocyte-specific Cdk6 transgenic mice using Col2a1 promoter. Unexpectedly, differentiation and cell-cycle progression of chondrocytes in the Cdk6 transgenic mice were similar to those in wildtype mice. Then, we generated chondrocyte-specific Ccnd1 transgenic mice and Cdk6/Ccnd1 double transgenic mice to investigate the possibility that Cdk6 inhibits chondrocyte differentiation through E2f activation. Bromodeoxyuridine (BrdU)-positive chondrocytes and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive chondrocytes were increased in number, and chondrocyte maturation was inhibited only in Cdk6/Ccnd1 transgenic mice (K6H/D1H mice), which showed dwarfism. Retinoblastoma protein (pRb) was highly phosphorylated but p107 was upregulated, and the expression of E2f target genes was dysregulated as shown by upregulation of Cdc6 but downregulation of cyclin E, dihydrofolate reductase (dhfr), Cdc25a and B-Myb in chondrocytes of K6H/D1H mice. Similarly, overexpression of Cdk6/Ccnd1 in a chondrogenic cell line ATDC5 highly phosphorylated pRb, upregulated p107, induced apoptosis, upregulated Cdc6 and downregulated cyclin E, dhfr and B-Myb and p107 small interfering RNA reversed the expression of downregulated genes. Further, introduction of kinase-negative Cdk6 and cyclin D1 abolished all effects by Cdk6/cyclin D1 in ATDC5 cells, indicating the requirement of the kinase activity on these effects. p53 deletion partially restored the size of the skeleton and almost completely rescued chondrocyte apoptosis, but failed to enhance chondrocyte proliferation in K6(H)/D1(H) mice. These findings indicated that Cdk6/Ccnd1 overexpression inhibited chondrocyte maturation and enhanced G1/S cell-cycle transition by phosphorylating pRb, but the chondrocytes failed to accomplish the cell cycle, and underwent p53-dependent apoptosis probably due to the dysregulation of E2f target genes. Our findings also indicated that p53 deletion in addition to the inactivation of Rb was not sufficient to accelerate chondrocyte proliferation, suggesting the resistance of chondrocytes to sarcomagenesis.	[Ito, K.; Maruyama, Z.; Sakai, A.; Izumi, S.; Moriishi, T.; Yoshida, C. A.; Miyazaki, T.; Komori, H.; Komori, T.] Nagasaki Univ, Grad Sch Biomed Sci, Dept Cell Biol, Nagasaki 8528588, Japan; [Ito, K.] Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol Bone Biol, Nagasaki 8528588, Japan; [Ito, K.] Nagasaki Univ, NRGIC, Ctr Genom Instabil & Carcinogenesis, Nagasaki 8528588, Japan; [Maruyama, Z.; Kawaguchi, H.] Univ Tokyo, Fac Med, Dept Orthopaed Surg, Tokyo 113, Japan; [Sakai, A.; Takada, K.] Osaka Univ, Grad Sch Dent, Dept Orthodont & Dentofacial Orthoped, Suita, Osaka, Japan	Nagasaki University; Nagasaki University; Nagasaki University; University of Tokyo; Osaka University	Komori, T (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Cell Biol, 1-7-1 Sakamoto, Nagasaki 8528588, Japan.	komorit@nagasaki-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan; President's Discretionary Fund of Nagasaki University	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); President's Discretionary Fund of Nagasaki University	We thank H Okayama and T Ogasawara for providing DNA plasmids for gene expression, M Hirakawa, M Mori and Y Matsuo for technical assistance, and C Fukuda for secretarial assistance. This work was supported by a grant from the Ministry of Education, Culture, Sports, Science and Technology, Japan, and the President's Discretionary Fund of Nagasaki University.	Beier F, 2001, MOL BIOL CELL, V12, P3852, DOI 10.1091/mbc.12.12.3852; Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105; Burkhart DL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001003; Chen QH, 2003, ONCOGENE, V22, P992, DOI 10.1038/sj.onc.1206193; Clark JCM, 2008, J CANCER RES CLIN, V134, P281, DOI 10.1007/s00432-007-0330-x; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Erhardt JA, 1998, J BIOL CHEM, V273, P23517, DOI 10.1074/jbc.273.36.23517; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fiaschi-Taesch NM, 2010, DIABETES, V59, P1926, DOI 10.2337/db09-1776; Garcia-Espana A, 2005, CANCER RES, V65, P1150, DOI 10.1158/0008-5472.CAN-04-2074; Grashoff C, 2003, EMBO REP, V4, P432, DOI 10.1038/sj.embor.embor801; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.0.CO;2-W; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; JIANG W, 1993, ONCOGENE, V8, P3447; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; Li MT, 1997, J VIROL, V71, P1984, DOI 10.1128/JVI.71.3.1984-1991.1997; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Long FX, 2001, DEVELOPMENT, V128, P5099; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Moro T, 2005, J CELL PHYSIOL, V204, P927, DOI 10.1002/jcp.20350; Mueller A, 1997, CANCER RES, V57, P5542; Musgrove EA, 2011, NAT REV CANCER, V11, P558, DOI 10.1038/nrc3090; Ohnuma S, 1999, CELL, V99, P499, DOI 10.1016/S0092-8674(00)81538-X; Ojala PM, 2000, NAT CELL BIOL, V2, P819, DOI 10.1038/35041064; Ojala PM, 1999, CANCER RES, V59, P4984; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rossi F, 2002, DEV BIOL, V247, P271, DOI 10.1006/dbio.2002.0691; Schnell JR, 2004, ANNU REV BIOPH BIOM, V33, P119, DOI 10.1146/annurev.biophys.33.110502.133613; SHIMOMURA Y, 1975, CALC TISS RES, V19, P179, DOI 10.1007/BF02564002; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sunters A, 1998, DEV GENET, V22, P386, DOI 10.1002/(SICI)1520-6408(1998)22:4<386::AID-DVG8>3.0.CO;2-2; Takahashi K, 2000, J BIOCHEM-TOKYO, V127, P73, DOI 10.1093/oxfordjournals.jbchem.a022586; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Terpstra L, 2003, J CELL BIOL, V162, P139, DOI 10.1083/jcb.200302066; Ueta C, 2001, J CELL BIOL, V153, P87, DOI 10.1083/jcb.153.1.87; Verschuren EW, 2004, CANCER RES, V64, P581, DOI 10.1158/0008-5472.CAN-03-1863; Verschuren EW, 2002, CANCER CELL, V2, P229, DOI 10.1016/S1535-6108(02)00123-X; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; Wang GY, 2004, J BIOL CHEM, V279, P13205, DOI 10.1074/jbc.M311427200; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Whelan J, 2012, INT J CANCER, V131, pE508, DOI 10.1002/ijc.26426; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Yang YZ, 2003, DEVELOPMENT, V130, P1003, DOI 10.1242/dev.00324; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0	55	20	21	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2014	33	14					1862	1871		10.1038/onc.2013.130	http://dx.doi.org/10.1038/onc.2013.130			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RE	23624920				2022-12-17	WOS:000334345500012
J	Watanabe, K; Fallahi, M; Dai, X				Watanabe, K.; Fallahi, M.; Dai, X.			Chromatin effector Pygo2 regulates mammary tumor initiation and heterogeneity in MMTV-Wnt1 mice	ONCOGENE			English	Article						MMTV-Wnt1; pygopus 2; Pygo2; mammary gland; tumor heterogeneity; cancer stem cells	CANCER STEM-CELLS; GENE-EXPRESSION; GLAND HYPERPLASIA; MYELOID-LEUKEMIA; BINDING-PROTEIN; TRANSGENIC MICE; BREAST-CANCER; INDUCE; POPULATIONS; CONTRIBUTE	Little is known about chromatin mechanisms that regulate tumor-initiating cells that are proposed to be responsible for tumor recurrence and relapse. We have previously shown that Pygopus 2 (Pygo2), a chromatin effector and context-dependent Wnt signaling coactivator, regulates mammary gland development by expanding epithelial stem/progenitor cells. However, the role of Pygo2 in mammary tumorigenesis in vivo remains to be addressed. In this study, we show that epithelia-specific ablation of Pygo2 in MMTV-Wnt1 transgenic mice results in delayed mammary ductal elongation, but the hyperbranching phenotype, aberrant accumulation of stem/progenitor-like cells, and canonical Wnt signaling output are largely unaffected. Chronic loss of Pygo2 significantly delays mammary tumor onset in MMTV-Wnt1 females, whereas acute deletion of Pygo2 in MMTV-Wnt1 tumor cells leads to a significant decrease in their tumor-initiating capability upon transplantation. Finally, we provide evidence supporting a role for Pygo2 in modulating the lineage potential of MMTV-Wnt1 tumor initiating cells. Collectively, our results suggest that Pygo2 acts at a step downstream of mammary stem cell accumulation to facilitate transformation, and that it regulates the tumor initiating capacity and lineage preference of the already transformed mammary cells, in MMTV-Wnt1 mice. These findings offer valuable insights into our understanding of the molecular basis of heterogeneity within breast tumors.	[Watanabe, K.; Fallahi, M.; Dai, X.] Univ Calif Irvine, Sch Med, Dept Biol Chem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Dai, X (corresponding author), Univ Calif Irvine, Sch Med, Dept Biol Chem, D250 Med Sci 1, Irvine, CA 92697 USA.	xdai@uci.edu	Watanabe, Kazuhide/C-9667-2017	Watanabe, Kazuhide/0000-0002-5331-0593; Dai, Xing/0000-0001-8134-1365	Susan G Komen grant [KG110897]; NIH [R01-GM083089]; U.S. Department of Defense Breast Cancer Research Program; (DOD BCRP) Postdoctoral Fellowship [W81XWH-10-1-0383]; NATIONAL CANCER INSTITUTE [P30CA062203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM083089] Funding Source: NIH RePORTER	Susan G Komen grant(Susan G. Komen Breast Cancer Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Defense Breast Cancer Research Program(United States Department of Defense); (DOD BCRP) Postdoctoral Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the UCI Genomics High Throughput Facility and Sue and Bill Gross Stem Cell Research Center Core Facility (Vanessa Scarfone) for expert service, Yi Li and Julie Serge for the generous gifts of MMTV-Wnt1 mice and keratin antibodies, respectively, and Eva Lee for discussions. This work was supported by Susan G Komen grant KG110897 and NIH Grant R01-GM083089 (to XD). KW was supported by a U.S. Department of Defense Breast Cancer Research Program. (DOD BCRP) Postdoctoral Fellowship (W81XWH-10-1-0383).	Andrews PGP, 2007, INT J ONCOL, V30, P357; Andrews PGP, 2009, BIOCHEM J, V422, P493, DOI 10.1042/BJ20090134; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Baker R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008854; Belenkaya TY, 2002, DEVELOPMENT, V129, P4089; Bocchinfuso WP, 1999, CANCER RES, V59, P1869; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Chen JK, 2010, MOL CELL BIOL, V30, P5621, DOI 10.1128/MCB.00465-10; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; Fiedler M, 2008, MOL CELL, V30, P507, DOI 10.1016/j.molcel.2008.03.011; Gjorevski N, 2011, NAT REV MOL CELL BIO, V12, P581, DOI 10.1038/nrm3168; Gu BN, 2012, CELL CYCLE, V11, P79, DOI 10.4161/cc.11.1.18402; Gu BN, 2010, J CELL BIOCHEM, V110, P1279, DOI 10.1002/jcb.22650; Gu BN, 2009, J CELL BIOL, V185, P811, DOI 10.1083/jcb.200810133; Guo W, 2008, NATURE, V453, P529, DOI 10.1038/nature06933; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Jagani Z, 2010, CELL CYCLE, V9, P3449, DOI 10.4161/cc.9.17.12945; Karantza-Wadsworth V, 2008, METHOD ENZYMOL, V446, P61, DOI 10.1016/S0076-6879(08)01604-2; Khalil S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033421; Kim S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019310; Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7; LaMarca HL, 2010, STEM CELLS, V28, P535, DOI 10.1002/stem.297; Li B, 2007, GENESIS, V45, P318, DOI 10.1002/dvg.20299; Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Lindeman GJ, 2010, ASIA-PAC J CLIN ONCO, V6, P89, DOI 10.1111/j.1743-7563.2010.01279.x; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; MUNN RJ, 1995, SEMIN CANCER BIOL, V6, P153, DOI 10.1006/scbi.1995.0020; Parker DS, 2002, DEVELOPMENT, V129, P2565; Raaphorst FM, 2003, TRENDS IMMUNOL, V24, P522, DOI 10.1016/S1471-4906(03)00241-2; Schwab KR, 2007, BMC BIOL, V5, DOI 10.1186/1741-7007-5-15; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; SMITH GH, 1990, CELL GROWTH DIFFER, V1, P161; Song N, 2007, DEVELOPMENT, V134, P1873, DOI 10.1242/dev.001495; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun P, 2010, HISTOCHEM CELL BIOL, V133, P213, DOI 10.1007/s00418-009-0662-5; Teissedre B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004537; Tepera SB, 2003, J CELL SCI, V116, P1137, DOI 10.1242/jcs.00334; Thompson B, 2002, NAT CELL BIOL, V4, P367, DOI 10.1038/ncb786; Thorne CA, 2010, NAT CHEM BIOL, V6, P829, DOI 10.1038/NCHEMBIO.453; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786	54	20	21	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					632	642		10.1038/onc.2012.620	http://dx.doi.org/10.1038/onc.2012.620			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23334328	Green Accepted, Green Submitted			2022-12-17	WOS:000331125100011
J	Beggs, AD; Domingo, E; Abulafi, M; Hodgson, SV; Tomlinson, IPM				Beggs, A. D.; Domingo, E.; Abulafi, M.; Hodgson, S. V.; Tomlinson, I. P. M.			A study of genomic instability in early preneoplastic colonic lesions	ONCOGENE			English	Article						colorectal cancer; gland; heterogeneity; methylation; microsatellite instability	MICROSATELLITE INSTABILITY; COLORECTAL ADENOMAS; NORMAL MUCOSA; CANCER; METHYLATION; HYPERMETHYLATION; PROMOTER; POLYPS; MUTATIONS; TUMORS	It is difficult to explain the differential rates of progression of premalignant colonic lesions and differences in behaviour of morphologically similar lesions. Heterogeneity for microsatellite instability (MSI) and promoter methylation in driving these phenomena forward may explain this; however, no previous analysis has examined this in detail at the gland level, the smallest unit of colorectal premalignant lesions. We aimed to carry out an analysis of gland level genomic instability for MSI and promoter methylation. MSI occurred significantly more frequently (20%) in colonic glands than has previously been observed in whole colorectal polyps. Significant promoter methylation was seen in MLH1, PMS2, MLH3 and MSH3 as well as significant heterogeneity for both MSI and promoter methylation. Methylation and MSI may have a significant role in driving forward colorectal carcinogenesis, although in the case of MSI, this association is less clear as it occurs significantly more frequently than previously thought, and may simply be a passenger in the adenoma-carcinoma sequence. Promoter methylation in MLH1, MLH3, MSH3 and PMS2 was also found to be significantly associated with MSI and should be investigated further. A total of 273 colorectal glands (126 hyperplastic, 147 adenomatous) were isolated via laser capture microdissection (targeted at regions of MLH1 loss) from 93 colonic polyps and tested for MSI, and promoter methylation of the DNA mismatch repair genes MLH1, MSH2, MLH3, MSH6, PMS2, MGMT and MLH3 via methylation specific multiplex ligation-dependent probe amplification. Logistic regression modelling was then used to identify significant associations between promoter methylation and gland histological type and MSI status.	[Beggs, A. D.; Domingo, E.; Tomlinson, I. P. M.] Univ Oxford, Mol & Populat Genet Lab, Oxford OX3 7BN, England; [Beggs, A. D.; Domingo, E.; Tomlinson, I. P. M.] Univ Oxford, NIHR Comprehens Biomed Res Ctr, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; [Beggs, A. D.; Abulafi, M.] Croydon Univ Hosp, Dept Surg, Croydon, England; [Hodgson, S. V.] St Georges Univ London, Dept Med Genet, London, England	University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; Croydon University Hospital; St Georges University London	Beggs, AD (corresponding author), Univ Oxford, Mol & Populat Genet Lab, Roosevelt Dr, Oxford OX3 7BN, England.	a.beggs@bham.ac.uk	Beggs, Andrew D/A-6912-2013; Domingo, Enric/A-9099-2018	Beggs, Andrew D/0000-0003-0784-2967; Domingo, Enric/0000-0003-4390-8767	Mason Medical Foundation; Peel Medical Research Trust; St George's Hospital Charity; Cancer Research UK; Wellcome Trust [090532/Z/09/Z]; Cancer Research UK [16459] Funding Source: researchfish	Mason Medical Foundation; Peel Medical Research Trust; St George's Hospital Charity; Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission); Cancer Research UK(Cancer Research UK)	ADB was funded by a Mason Medical Foundation Research Fellowship and grants from the Peel Medical Research Trust and St George's Hospital Charity; IPMT acknowledges funding from Cancer Research UK and the Wellcome Trust 090532/Z/09/Z.	AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Ahlquist T, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-94; Belshaw NJ, 2010, CARCINOGENESIS, V31, P1158, DOI 10.1093/carcin/bgq077; Brueckl WM, 2000, INT J COLORECTAL DIS, V15, P189, DOI 10.1007/s003840000241; Cunningham JM, 1998, CANCER RES, V58, P3455; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; Guerrette S, 1998, MOL CELL BIOL, V18, P6616, DOI 10.1128/MCB.18.11.6616; Jeuken JW, 2007, LAB INVEST, V87, P1055, DOI 10.1038/labinvest.3700664; Kloor M, 2012, LANCET ONCOL, V13, P598, DOI 10.1016/S1470-2045(12)70109-2; Koh DC, 2007, COLORECTAL DIS, V9, P521, DOI 10.1111/j.1463-1318.2007.01175.x; Lanza G, 2002, MODERN PATHOL, V15, P741, DOI 10.1097/01.MP.0000018979.68686.B2; Lipkin SM, 2000, NAT GENET, V24, P27, DOI 10.1038/71643; LOTHE RA, 1995, GENE CHROMOSOME CANC, V14, P182, DOI 10.1002/gcc.2870140305; Park CK, 2011, NEURO-ONCOLOGY, V13, P195, DOI 10.1093/neuonc/noq162; Poynter JN, 2008, CANCER EPIDEM BIOMAR, V17, P3208, DOI 10.1158/1055-9965.EPI-08-0512; Rashid A, 1999, GUT, V44, P826, DOI 10.1136/gut.44.6.826; Samowitz WS, 1997, AM J PATHOL, V151, P33; Samowitz WS, 1997, GASTROENTEROLOGY, V112, P1515, DOI 10.1016/S0016-5085(97)70032-5; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Umetani N, 2006, MOL CANCER RES, V4, P303, DOI 10.1158/1541-7786.MCR-05-0199; Yurgelun MB, 2012, CANCER PREV RES, V5, P574, DOI 10.1158/1940-6207.CAPR-11-0519	21	20	21	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2013	32	46					5333	5337		10.1038/onc.2012.584	http://dx.doi.org/10.1038/onc.2012.584			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251IU	23246972	hybrid, Green Published			2022-12-17	WOS:000326922400003
J	Chen, Y; Soong, J; Mohanty, S; Xu, L; Scott, G				Chen, Y.; Soong, J.; Mohanty, S.; Xu, L.; Scott, G.			The neural guidance receptor Plexin C1 delays melanoma progression	ONCOGENE			English	Article						melanoma; semaphorin; plexin; R-Ras; melanocyte	R-RAS GAP; CELL-MIGRATION; SEMAPHORIN 7A; TUMOR-SUPPRESSOR; DENDRITE FORMATION; AXON GUIDANCE; RHO; ACTIVATION; SIGNALS; ROLES	Plexin C1 is a type I transmembrane receptor with intrinsic R-Ras GTPase activity, which regulates cytoskeletal remodeling and adhesion in normal human melanocytes. Melanocytes are pigment-producing cells of the epidermis, precursors for melanoma, and express high levels of Plexin C1, which is lost in melanoma in vitro and in vivo. To determine if Plexin C1 is a tumor suppressor for melanoma, we introduced Plexin C1 into a primary human melanoma cell line, and phenotypes including migration, apoptosis, proliferation and tumor growth in mice were analyzed. Complimentary studies in which Plexin C1 was silenced in human melanocytes were performed. Plexin C1 significantly inhibited migration and proliferation in melanoma, whereas in melanocytes, loss of Plexin C1 increased migration and proliferation. In mouse xenografts, Plexin C1 delayed tumor growth of melanoma at early time points, but tumors eventually escaped the suppressive effects of Plexin C1, due to Plexin C1-dependent activation of the pro-survival protein Akt. R-Ras activation stimulates melanoma migration. Plexin C1 lowered R-Ras activity in melanoma and melanocytes, consistent with inhibitory effects of Plexin C1 on migration of melanocytes and melanoma. To determine if R-Ras is expressed in melanocytic lesions in vivo, staining of tissue microarrays of nevi and melanoma were performed. R-Ras expression was highly limited in melanocytic lesions, being essentially confined to primary melanoma, and almost completely absent in nevi and metastatic melanoma. These data suggest that loss of Plexin C1 in melanoma may promote early steps in melanoma progression through suppression of migration and proliferation, but pro-survival effects of Plexin C1 ultimately abrogate the tumor suppressive effects of Plexin C1. In primary melanoma, loss of Plexin C1 may function in early steps of melanoma progression by releasing inhibition of R-Ras activation, and stimulating migration.	[Chen, Y.; Soong, J.; Scott, G.] Univ Rochester, Sch Med, Dept Dermatol, Rochester, NY 14618 USA; [Soong, J.; Scott, G.] Univ Rochester, Sch Med, Dept Pathol, Rochester, NY 14618 USA; [Mohanty, S.; Xu, L.] Univ Rochester, Sch Med, Dept Biomed Genet, Rochester, NY 14618 USA	University of Rochester; University of Rochester; University of Rochester	Scott, G (corresponding author), Univ Rochester, Sch Med, Dept Dermatol, Box 697,601 Elmwood Ave, Rochester, NY 14618 USA.	Glynis_Scott@urmc.rochester.edu			NIH [5T32AR007472]; Department of Biogenetics, University of Rochester;  [R01CA136499]; NATIONAL CANCER INSTITUTE [R01CA136499] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Biogenetics, University of Rochester; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by R01CA136499 (GS), by NIH training Grant 5T32AR007472 (JS), and by the Department of Biogenetics, University of Rochester (LX). We also thank Lori Moll (Oncogene Inc.,) for assistance with subcloning of Plexin C1.	Abi-Habib RJ, 2005, MOL CANCER THER, V4, P1303, DOI 10.1158/1535-7163.MCT-05-0145; Argast GM, 2009, ONCOGENE, V28, P2697, DOI 10.1038/onc.2009.133; Artigiani S, 1999, IUBMB LIFE, V48, P477, DOI 10.1080/713803563; Aurandt J, 2002, P NATL ACAD SCI USA, V99, P12085, DOI 10.1073/pnas.142433199; Balakrishnan A, 2009, HUM MUTAT, V30, P1167, DOI 10.1002/humu.21017; Barberis D, 2005, J CELL SCI, V118, P4689, DOI 10.1242/jcs.02590; Barton WA, 2004, ADV PROTEIN CHEM, V68, P65; Comeau MR, 1998, IMMUNITY, V8, P473, DOI 10.1016/S1074-7613(00)80552-X; Gao L, 2006, CANCER RES, V66, P7880, DOI 10.1158/0008-5472.CAN-06-0254; Gawecka JE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011269; Giger RJ, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001867; HARA M, 1994, J CELL SCI, V107, P2739; Holly SP, 2005, MOL BIOL CELL, V16, P2458, DOI 10.1091/mbc.E03-12-0917; Itahana Koji, 2007, Methods Mol Biol, V371, P21; Iwasawa N, 2012, MOL BIOL CELL, V23, P2793, DOI 10.1091/mbc.E12-02-0103; Iwashita S, 2007, J BIOL CHEM, V282, P3413, DOI 10.1074/jbc.C600293200; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; Lallier TE, 2004, J DENT RES, V83, P677, DOI 10.1177/154405910408300904; Lazova R, 2009, AM J DERMATOPATH, V31, P177, DOI 10.1097/DAD.0b013e318196672d; Liu HL, 2010, CELL, V142, P749, DOI 10.1016/j.cell.2010.07.040; Maddodi N, 2008, PHOTOCHEM PHOTOBIOL, V84, P528, DOI 10.1111/j.1751-1097.2007.00283.x; Messina A, 2011, HUM MOL GENET, V20, P4759, DOI 10.1093/hmg/ddr403; Oinuma I, 2006, J CELL BIOL, V173, P601, DOI 10.1083/jcb.200508204; Pasterkamp RJ, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-98; Pasterkamp RJ, 2003, NATURE, V424, P398, DOI 10.1038/nature01790; Perala N, 2012, DIFFERENTIATION, V83, P77, DOI 10.1016/j.diff.2011.08.001; Puschel AW, 2007, ADV EXP MED BIOL, V600, P12; Scott G, 2002, PIGM CELL RES, V15, P322, DOI 10.1034/j.1600-0749.2002.02056.x; Scott G, 2003, PIGM CELL RES, V16, P139, DOI 10.1034/j.1600-0749.2003.00022.x; Scott GA, 2008, J INVEST DERMATOL, V128, P151, DOI 10.1038/sj.jid.5700974; Scott GA, 2009, J INVEST DERMATOL, V129, P954, DOI 10.1038/jid.2008.329; Stevens L, 2010, J INVEST DERMATOL, V130, P1636, DOI 10.1038/jid.2010.13; Suzuki K, 2007, J SYN ORG CHEM JPN, V65, P1; Uesugi K, 2009, J BIOL CHEM, V284, P6743, DOI 10.1074/jbc.M805213200; Walzer T, 2005, INT IMMUNOL, V17, P943, DOI 10.1093/intimm/dxh274; Wang YX, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002636; Winograd-Katz SE, 2006, ONCOGENE, V25, P7381, DOI 10.1038/sj.onc.1209737; Wozniak MA, 2005, MOL BIOL CELL, V16, P84, DOI 10.1091/mbc.E04-04-0277; Xu C, 2007, MOL ENDOCRINOL, V21, P1234, DOI 10.1210/me.2007-0034; Yang D, 2011, ONCOGENE, V30, P4590, DOI [10.1038/onc.2011.541, 10.1038/onc.2011.166]; Yazdani U, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-3-211; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	42	20	21	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4941	4949		10.1038/onc.2012.511	http://dx.doi.org/10.1038/onc.2012.511			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23160370	Green Accepted			2022-12-17	WOS:000325717800010
J	Kim, KJ; Moon, SM; Kim, SA; Kang, KW; Yoon, JH; Ahn, SG				Kim, K-J; Moon, S-M; Kim, S-A; Kang, K-W; Yoon, J-H; Ahn, S-G			Transcriptional regulation of MDR-1 by HOXC6 in multidrug-resistant cells	ONCOGENE			English	Article						HOXC6; MDR-1; multidrug resistance (MDR); apoptosis	CANCER-CELLS; GENE-EXPRESSION; PROSTATE-CANCER; HOMEOBOX B3; MORPHOGENESIS; GROWTH; PHENOTYPE; BINDING; TISSUE; GLAND	Resistance to chemotherapeutic drugs is a significant clinical problem in the treatment of cancer and this resistance has been linked to the cellular expression of multidrug-efflux transporters. The aim of this study was to explore the role of HOXC6 in the regulation of multidrug resistance (MDR) to chemotherapeutic drugs. The HOXC6 gene was identified as being overexpressed in drug-resistant cells compared with parental cell lines. Transfection assays demonstrated that HOXC6 activated MDR-1 promoter activity. A series of MDR-1 promoter deletion mutants was examined and the minimal HOXC6-responsive region was identified to be in the TAAT motif (-2243 bp) of the MDR-1 promoter. Interestingly, overexpression of HOXC6 in the parental cell lines resulted in the upregulation of MDR-1 expression. The inhibition of HOXC6 using small interfering RNA led to the repression of MDR-1. We determined that knockdown of HOXC6 expression in MDR cells increased their sensitivity to paclitaxel. Flow cytometry analysis suggested that siHOXC6 could induce paclitaxel-induced apoptosis and that this was accompanied by an increased accumulation and a decreased release of paclitaxel. Taken together, our findings suggest that HOXC6 expression is an important mechanism of chemotherapeutic drug resistance via its regulation of MDR-1.	[Kim, K-J; Moon, S-M; Ahn, S-G] Chosun Univ, Dept Pathol, Sch Dent, Kwangju 501759, South Korea; [Kim, S-A] Dongguk Univ, Dept Biochem, Gyeongju, South Korea; [Kang, K-W] Seoul Natl Univ, Coll Pharm, Seoul, South Korea; [Yoon, J-H] Wonkwang Univ, Daejeon Dent Hosp, Dept Oral Pathol, Taejon, South Korea	Chosun University; Dongguk University; Seoul National University (SNU); Wonkwang University	Ahn, SG (corresponding author), Chosun Univ, Dept Pathol, Sch Dent, 375 Seosuk Dong, Kwangju 501759, South Korea.	ahnsg@chosun.ac.kr		Kim, Soo-A/0000-0001-6777-739X	National Research Foundation of Korea (NRF); Ministry of Education, Science and Technology [R13-2008-010-00000-0, 2011-0029091]	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This research was supported by National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (No. R13-2008-010-00000-0; No. 2011-0029091).	Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Bodey B, 2000, ANTICANCER RES, V20, P3281; Bodey B, 2000, ANTICANCER RES, V20, P2717; CASTRONOVO V, 1994, BIOCHEM PHARMACOL, V47, P137, DOI 10.1016/0006-2952(94)90447-2; Chen HX, 2003, CANCER BIOL THER, V2, P524, DOI 10.4161/cbt.2.5.525; Cho S, 2011, P NATL ACAD SCI USA, V108, P20778, DOI 10.1073/pnas.1019452108; Deeley RG, 2006, FEBS LETT, V580, P1103, DOI 10.1016/j.febslet.2005.12.036; DEVITA G, 1993, EUR J CANCER, V29A, P887, DOI 10.1016/S0959-8049(05)80432-0; Ernst T, 2002, AM J PATHOL, V160, P2169, DOI 10.1016/S0002-9440(10)61165-0; FRIEDMANN Y, 1994, CANCER RES, V54, P5981; Fujiki K, 2008, GASTROENTEROLOGY, V135, P907, DOI 10.1053/j.gastro.2008.06.034; Garcia-Gasca A, 2000, DEV DYNAM, V219, P261, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1048>3.0.CO;2-3; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Grishina IB, 2005, DEV BIOL, V288, P334, DOI 10.1016/j.ydbio.2005.08.018; Guo CC, 2005, INT J CANCER, V116, P155, DOI 10.1002/ijc.20919; Haimeur A, 2004, CURR DRUG METAB, V5, P21, DOI 10.2174/1389200043489199; JONES FS, 1993, P NATL ACAD SCI USA, V90, P6557, DOI 10.1073/pnas.90.14.6557; Kim SA, 2012, J CELL PHYSIOL, V227, P1, DOI 10.1002/jcp.22948; Lin YS, 2007, DEVELOPMENT, V134, P723, DOI 10.1242/dev.02765; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; McCabe CD, 2008, CANCER RES, V68, P1988, DOI 10.1158/0008-5472.CAN-07-5843; Miller GJ, 2003, CANCER RES, V63, P5879; Ramachandran S, 2005, ONCOGENE, V24, P188, DOI 10.1038/sj.onc.1207906; Ricort JM, 2002, J BIOL CHEM, V277, P19448, DOI 10.1074/jbc.M200439200; Svingen T, 2006, HEREDITY, V97, P88, DOI 10.1038/sj.hdy.6800847; Szakacs G, 2004, CANCER CELL, V6, P129, DOI 10.1016/j.ccr.2004.06.026; TIBERIO C, 1994, INT J CANCER, V58, P608, DOI 10.1002/ijc.2910580426; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Veraksa A, 2000, MOL GENET METAB, V69, P85, DOI 10.1006/mgme.2000.2963	29	20	20	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 11	2013	32	28					3339	3349		10.1038/onc.2012.354	http://dx.doi.org/10.1038/onc.2012.354			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	180TM	22907429				2022-12-17	WOS:000321620200004
J	Kim, W; Kim, SY; Kim, T; Kim, M; Bae, DJ; Choi, HI; Kim, IS; Jho, E				Kim, W.; Kim, S. Y.; Kim, T.; Kim, M.; Bae, D-J; Choi, H-I; Kim, I-S; Jho, E.			ADP-ribosylation factors 1 and 6 regulate Wnt/beta-catenin signaling via control of LRP6 phosphorylation	ONCOGENE			English	Article						ADP-ribosylation factor (Arf); Wnt; signal transduction; phosphatidylinositol 4,5 bisphosphate (PtdIns (4,5)P-2); LRP6	NUCLEOTIDE-EXCHANGE FACTORS; BETA-CATENIN; ARF FAMILY; ACTIVATION; MEMBRANE; PROTEINS; PATHWAY; COMPLEX; ENDOCYTOSIS; MECHANISM	It has been shown that inhibition of GTPase-activating protein of ADP-ribosylation factor (Arf), ArfGAP, with a small molecule (QS11) results in synergistic activation of Wnt/beta-catenin signaling. However, the role of Arf in Wnt/b-catenin signaling has not yet been elucidated. Here, we show that activation of Arf is essential for Wnt/beta-catenin signaling. The level of the active form of Arf (Arf-GTP) transiently increased in the presence of Wnt, and this induction event was abrogated by blocking the interaction between Wnt and Frizzled (Fzd). In addition, knockdown of Fzds, Dvls or LRP6 blocked the Wnt-mediated activation of Arf. Consistently, depletion of Arf led to inhibition of Wnt-mediated membrane PtdIns (4,5)P-2 (phosphatidylinositol 4,5-bisphosphate) synthesis and LRP6 phosphorylation. Overall, our data suggest that transient activation of Arf modulates LRP6 phosphorylation for the transduction of Wnt/beta-catenin signaling.	[Kim, W.; Kim, T.; Kim, M.; Jho, E.] Univ Seoul, Dept Life Sci, Seoul, South Korea; [Kim, S. Y.; Bae, D-J; Choi, H-I; Kim, I-S] Kyungpook Natl Univ, Sch Med, Dept Biochem & Cell Biol, Cell & Matrix Res Inst, Taegu 700422, South Korea; [Kim, I-S] Korea Inst Sci & Technol, Biomed Res Inst, Seoul, South Korea	University of Seoul; Kyungpook National University; Korea Institute of Science & Technology (KIST)	Kim, IS (corresponding author), Kyungpook Natl Univ, Sch Med, Dept Biochem & Cell Biol, Cell & Matrix Res Inst, 101 Dongin 2Ga, Taegu 700422, South Korea.	iskim@knu.ac.kr; ej70@uos.ac.kr	김, 인산/I-8988-2014	Jho, Eek-hoon/0000-0003-2414-6234; Choi, Hee-Jung/0000-0002-1167-1526	National Research Foundation of Korea; Ministry of Education, Science and Technology [2006-2004046, 2012R1A2A2A01012472, 2010-0029206, 2011-0003980]; Brain Korea 21 program	National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Brain Korea 21 program(Ministry of Education & Human Resources Development (MOEHRD), Republic of Korea)	This work was supported by grants from the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (2006-2004046 and 2012R1A2A2A01012472 to E-HJ; 2010-0029206 to I-SK; 2011-0003980 to S-YK). WK, TK, and MK were supported by the Brain Korea 21 program.	Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; Davidson G, 2005, NATURE, V438, P867, DOI 10.1038/nature04170; Gagliardi M, 2008, TRAFFIC, V9, P1, DOI 10.1111/j.1600-0854.2007.00662.x; Giguere P, 2006, CELL SIGNAL, V18, P1988, DOI 10.1016/j.cellsig.2006.03.003; Gillingham AK, 2007, ANNU REV CELL DEV BI, V23, P579, DOI 10.1146/annurev.cellbio.23.090506.123209; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Hall B, 2008, ANAL BIOCHEM, V374, P243, DOI 10.1016/j.ab.2007.11.032; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Kahn RA, 2006, J CELL BIOL, V172, P645, DOI 10.1083/jcb.200512057; Kumari S, 2008, NAT CELL BIOL, V10, P30, DOI 10.1038/ncb1666; Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002; Liu XX, 2005, CURR BIOL, V15, P1989, DOI 10.1016/j.cub.2005.10.050; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; MacDonald BT, 2008, J BIOL CHEM, V283, P16115, DOI 10.1074/jbc.M800327200; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Naslavsky N, 2004, MOL BIOL CELL, V15, P3542, DOI 10.1091/mbc.E04-02-0151; Nishida K, 2011, J IMMUNOL, V187, P932, DOI 10.4049/jimmunol.1100360; Nishioka T, 2008, MOL BIOL CELL, V19, P4213, DOI 10.1091/mbc.E08-03-0315; Pan WJ, 2008, SCIENCE, V321, P1350, DOI 10.1126/science.1160741; Perez-Mansilla B, 2006, BBA-MOL CELL BIOL L, V1761, P1429, DOI 10.1016/j.bbalip.2006.09.006; Sakane H, 2010, J CELL SCI, V123, P360, DOI 10.1242/jcs.058008; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Sawano A, 2000, Nucleic Acids Res, V28, pE78, DOI 10.1093/nar/28.16.e78; Shin HW, 2004, J BIOCHEM, V136, P761, DOI 10.1093/jb/mvh185; Suzuki T, 2006, MOL CELL BIOL, V26, P6149, DOI 10.1128/MCB.00298-06; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Tiscornia G, 2003, P NATL ACAD SCI USA, V100, P1844, DOI 10.1073/pnas.0437912100; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097-2765(03)00427-1; Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052; Yamamoto H, 2006, DEV CELL, V11, P213, DOI 10.1016/j.devcel.2006.07.003; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185; Zhang QS, 2007, P NATL ACAD SCI USA, V104, P7444, DOI 10.1073/pnas.0702136104	40	20	20	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 11	2013	32	28					3390	3396		10.1038/onc.2012.373	http://dx.doi.org/10.1038/onc.2012.373			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	180TM	22907437				2022-12-17	WOS:000321620200009
J	Sully, K; Akinduro, O; Philpott, MP; Naeem, AS; Harwood, CA; Reeve, VE; O'Shaughnessy, RF; Byrne, C				Sully, K.; Akinduro, O.; Philpott, M. P.; Naeem, A. S.; Harwood, C. A.; Reeve, V. E.; O'Shaughnessy, R. F.; Byrne, C.			The mTOR inhibitor rapamycin opposes carcinogenic changes to epidermal Akt1/PKB alpha isoform signaling	ONCOGENE			English	Article						mTOR; rapamycin; epidermis; Akt/PKB; squamous cell carcinoma; ultraviolet radiation	INSULIN-RECEPTOR SUBSTRATE-1; PROTEIN-KINASE B; SKIN-CANCER; KERATINOCYTE DIFFERENTIATION; TRANSPLANT RECIPIENTS; 3-KINASE/AKT PATHWAY; MAMMALIAN TARGET; GROWTH-FACTOR; MOUSE SKIN; AKT	Epidermal squamous cell carcinoma (SCC) is the most aggressive non-melanoma skin cancer and is dramatically increased in patients undergoing immunosuppression following solid organ transplantation, contributing substantially to morbidity and mortality. Recent clinical studies show that use of the mammalian target of rapamycin (mTOR) inhibitor rapamycin as a post-transplantation immunosuppressive significantly reduces SCC occurrence compared with other immunosuppressives, though the mechanism is not fully understood. We show that rapamycin selectively upregulates epidermal Akt1, while failing to upregulate epidermal Akt2. Rapamycin increases epidermal Akt1 phosphorylation via inhibition of the mTOR complex 1-dependent regulation of insulin receptor substrate-1. Epidermal Akt1 is commonly downregulated in SCC while Akt2 is upregulated. We now demonstrate similar Akt1 downregulation and Akt2 upregulation by ultraviolet (UV) radiation, the most important skin carcinogen. Hence, rapamycin's upregulation of Akt1 signaling could potentially oppose the effects of UV radiation and/or tumor-associated changes on Akt1 signaling. We show in skin culture that rapamycin does enhance restoration of Akt1 phosphorylation in skin recovering from UV radiation, suggesting a mechanism for rapamycin's antitumor activity in epidermis in spite of its efficient immunosuppressive properties.	[Sully, K.; Akinduro, O.; Philpott, M. P.; Harwood, C. A.; Byrne, C.] Queen Mary Univ London, Blizard Inst, Ctr Cutaneous Res, Barts & London Sch Med & Dent, London E1 2AT, England; [Naeem, A. S.; O'Shaughnessy, R. F.] UCL, Inst Child Hlth, London, England; [Reeve, V. E.] Univ Sydney, Fac Vet Sci, Sydney, NSW 2006, Australia	University of London; Queen Mary University London; University of London; University College London; University of Sydney	Byrne, C (corresponding author), Queen Mary Univ London, Blizard Inst, Ctr Cutaneous Res, Barts & London Sch Med & Dent, London E1 2AT, England.	c.r.byrne@qmul.ac.uk		O'Shaughnessy, Ryan/0000-0002-3701-0267; Harwood, Catherine/0000-0002-1375-0965; Philpott, Michael/0000-0002-1255-4612; Nevin, Katherine/0000-0003-4710-2592	British Skin Foundation [941S]; Medical Research Council DTA studentship; Royal Society International Outgoing Short Visit [VO0872438]; Cancer Research UK [13044] Funding Source: researchfish; Great Ormond Street Hospital Childrens Charity [W1039, W0907] Funding Source: researchfish	British Skin Foundation; Medical Research Council DTA studentship; Royal Society International Outgoing Short Visit; Cancer Research UK(Cancer Research UK); Great Ormond Street Hospital Childrens Charity	This work was supported by the British Skin Foundation 941S, a Medical Research Council DTA studentship for OA and a Royal Society International Outgoing Short Visit VO0872438.	Alberu J, 2011, TRANSPLANTATION, V92, P303, DOI 10.1097/TP.0b013e3182247ae2; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BADEN HP, 1983, J INVEST DERMATOL, V80, P124, DOI 10.1111/1523-1747.ep12532899; Berg CE, 2002, BIOCHEM BIOPH RES CO, V293, P1021, DOI 10.1016/S0006-291X(02)00333-9; Boura-Halfon S, 2009, AM J PHYSIOL-ENDOC M, V296, P26; Calautti E, 2005, J BIOL CHEM, V280, P32856, DOI 10.1074/jbc.M506119200; Cao C, 2009, J CELL PHYSIOL, V220, P277, DOI 10.1002/jcp.21780; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; de Gruijl FR, 2010, INT J CANCER, V8, P8; Demehri S, 2009, CANCER CELL, V16, P55, DOI 10.1016/j.ccr.2009.05.016; Esposito DL, 2001, ENDOCRINOLOGY, V142, P2833, DOI 10.1210/en.142.7.2833; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Gan XQ, 2011, J BIOL CHEM, V286, P10998, DOI 10.1074/jbc.M110.195016; Geissler EK, 2010, NAT REV NEPHROL, V6, P639, DOI 10.1038/nrneph.2010.130; Gonzalez E, 2009, CELL CYCLE, V8, P2502, DOI 10.4161/cc.8.16.9335; Gual P, 2005, BIOCHIMIE, V87, P99, DOI 10.1016/j.biochi.2004.10.019; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Haratake A, 1997, J INVEST DERMATOL, V108, P769, DOI 10.1111/1523-1747.ep12292163; Harrington LS, 2005, TRENDS BIOCHEM SCI, V30, P35, DOI 10.1016/j.tibs.2004.11.003; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hsieh AC, 2004, NUCLEIC ACIDS RES, V32, P893, DOI 10.1093/nar/gkh238; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Janes SM, 2004, J CELL SCI, V117, P4157, DOI 10.1242/jcs.01302; Kim MA, 2009, ONCOGENE, V19, P19; Koehl GE, 2010, ONCOGENE, V29, P1553, DOI 10.1038/onc.2009.435; Kovacina KS, 2003, J BIOL CHEM, V278, P10189, DOI 10.1074/jbc.M210837200; Lu ZH, 2010, CANCER RES, V70, P3287, DOI 10.1158/0008-5472.CAN-09-3467; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Mao JH, 2004, GENE DEV, V18, P1800, DOI 10.1101/gad.1213804; Meeran SM, 2009, NEOPLASIA, V11, P846, DOI 10.1593/neo.09528; Mitchell C, 2010, AM J TRANSPLANT, V10, P1343, DOI 10.1111/j.1600-6143.2010.03133.x; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; O'Shaughnessy RFL, 2007, CANCER RES, V67, P8207, DOI 10.1158/0008-5472.CAN-07-0755; O'Shaughnessy RFL, 2007, J BIOL CHEM, V282, P17297, DOI 10.1074/jbc.M610386200; O'Shaughnessy RFL, 2009, DEVELOPMENT, V136, P3423, DOI 10.1242/dev.037010; Pfeifer GP, 2012, PHOTOCH PHOTOBIO SCI, V11, P90, DOI 10.1039/c1pp05144j; Pirola L, 2003, J BIOL CHEM, V278, P15641, DOI 10.1074/jbc.M208984200; Rao RR, 2010, IMMUNITY, V32, P67, DOI 10.1016/j.immuni.2009.10.010; Reeve VE, 2006, PHOTOCHEM PHOTOBIOL, V82, P406, DOI 10.1562/2005-09-29-RA-703; Sadagurski M, 2006, MOL CELL BIOL, V26, P2675, DOI 10.1128/MCB.26.7.2675-2687.2006; Sadagurski M, 2007, J CELL PHYSIOL, V213, P519, DOI 10.1002/jcp.21131; Salgo R, 2010, AM J TRANSPLANT, V10, P1385, DOI 10.1111/j.1600-6143.2009.02997.x; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Tabernero J, 2008, J CLIN ONCOL, V26, P1603, DOI 10.1200/JCO.2007.14.5482; Tato I, 2011, J BIOL CHEM, V286, P6128, DOI 10.1074/jbc.M110.166991; Thrash BR, 2006, J BIOL CHEM, V281, P12155, DOI 10.1074/jbc.M512116200; Tzatsos A, 2006, MOL CELL BIOL, V26, P63, DOI 10.1128/MCB.26.1.63-76.2006; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; Wang HQ, 2003, J BIOL CHEM, V278, P45737, DOI 10.1074/jbc.M300574200; Wang Z, 2010, ONCOGENE, V29, P3362, DOI 10.1038/onc.2010.95; Wertheimer E, 2001, ENDOCRINOLOGY, V142, P1234, DOI 10.1210/en.142.3.1234; Wulff BC, 2008, J INVEST DERMATOL, V128, P2467, DOI 10.1038/jid.2008.121; YAMAMOTO A, 1991, ARCH DERMATOL RES, V283, P219, DOI 10.1007/BF01106105; Yuan ZQ, 2002, J BIOL CHEM, V277, P29973, DOI 10.1074/jbc.M203636200; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002; Zhao L, 2008, ONCOGENE, V27, P5486, DOI 10.1038/onc.2008.244; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	63	20	21	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 4	2013	32	27					3254	3262		10.1038/onc.2012.338	http://dx.doi.org/10.1038/onc.2012.338			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	176JZ	22890326				2022-12-17	WOS:000321301600005
J	Jacque, E; Billot, K; Authier, H; Bordereaux, D; Baud, V				Jacque, E.; Billot, K.; Authier, H.; Bordereaux, D.; Baud, V.			RelB inhibits cell proliferation and tumor growth through p53 transcriptional activation	ONCOGENE			English	Article						RelB; NF-kappa B; cell proliferation; p53	NF-KAPPA-B; NUCLEAR-FACTOR; KINASE-ALPHA; MULTIPLE-MYELOMA; GENE-EXPRESSION; PROMOTES; PATHWAYS; DEATH; CARCINOMAS; SUPPRESSOR	The alternative nuclear factor-kappaB (NF-kappa B) - activation pathway proceeds via inducible p100 processing, leading to the activation of RelB-containing dimers. This pathway is aberrantly activated in several types of tumors; however, a direct role for RelB in the control of cell proliferation is still largely unexplored. Here, we demonstrate that RelB provides cell proliferation-inhibitory signals in murine fibroblasts. In agreement with these results, RelB ectopic expression inhibits xenograft tumor growth in vivo, whereas RelB knockdown enhances it. Significantly, we show that RelB inhibits cell proliferation and tumor growth in a p53-dependent manner. Mechanistic studies indicate that RelB regulates the transcription of the p53 tumor-suppressor gene through direct recruitment to the p53 promoter, thus increasing both p53 protein levels and expression of p53 target genes such as p21. Our findings define a novel link between NF-kappa B and growth-inhibitory pathways involving the RelB-dependent transcriptional upregulation of p53. Furthermore, they suggest that inhibition of RelB in some tumor types that retain wild-type p53 may diminish rather than improve therapeutic responses.	[Jacque, E.; Billot, K.; Authier, H.; Bordereaux, D.; Baud, V.] INSERM, Dept Immunol Hematol, Inst Cochin, U1016, F-75014 Paris, France; [Jacque, E.; Billot, K.; Authier, H.; Bordereaux, D.; Baud, V.] CNRS, UMR 8104, Paris, France; [Jacque, E.; Billot, K.; Authier, H.; Bordereaux, D.; Baud, V.] Univ Paris 05, Sorbonne Paris Cite, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Baud, V (corresponding author), INSERM, Dept Immunol Hematol, Inst Cochin, U1016, 123 Blvd Port Royal, F-75014 Paris, France.	veronique.baud@inserm.fr	Baud, Veronique/F-7699-2013; Baud, Veronique/AAL-3950-2020	Baud, Veronique/0000-0002-4090-718X; Baud, Veronique/0000-0002-4090-718X; authier, helene/0000-0002-5556-4570	Agence Nationale pour la Recherche (ANR); Association pour la Recherche sur le Cancer; Belgian InterUniversity Attraction Pole; Canceropole Ile-deFrance and Universite Paris Descartes,; Ministere de la Recherche et des Technologies; Ligue Nationale contre le Cancer; Societe Francaise du Cancer; Bettencourt-Schueller Fundation	Agence Nationale pour la Recherche (ANR)(French National Research Agency (ANR)); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Belgian InterUniversity Attraction Pole(Belgian Federal Science Policy Office); Canceropole Ile-deFrance and Universite Paris Descartes,; Ministere de la Recherche et des Technologies; Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Societe Francaise du Cancer; Bettencourt-Schueller Fundation	D Reisman, G Kroemer, JL Perfettini, M Korner, LA Martinez, T Tchenio, J Browning and I Verma for valuable material; G Piton for technical assistance; N Boggetto for cell sorting (ImagoSeine, Institut Monod, France, Region Ile-de-France grant no. E539); and LL Pritchard for critically reading the manuscript. This work was supported by grants to VB from Agence Nationale pour la Recherche (ANR), Association pour la Recherche sur le Cancer, Belgian InterUniversity Attraction Pole, Canceropole Ile-deFrance and Universite Paris Descartes, post-doctoral funding from ANR (HA and KB), doctoral fellowships from Ministere de la Recherche et des Technologies, Ligue Nationale contre le Cancer, and Societe Francaise du Cancer (EJ), and an award from the Bettencourt-Schueller Fundation (EJ).	Ak P, 2010, FASEB J, V24, P3643, DOI 10.1096/fj.10-160549; An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Barre B, 2010, MOL CELL, V38, P524, DOI 10.1016/j.molcel.2010.03.018; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; Chen F, 2007, CANCER RES, V67, P11093, DOI 10.1158/0008-5472.CAN-07-1576; Chen F, 2006, J BIOL CHEM, V281, P37142, DOI 10.1074/jbc.M603631200; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Dejardin E, 2006, BIOCHEM PHARMACOL, V72, P1161, DOI 10.1016/j.bcp.2006.08.007; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Fan YJ, 2008, ADV EXP MED BIOL, V615, P223, DOI 10.1007/978-1-4020-6554-5_11; Gapuzan MER, 2002, ONCOGENE, V21, P2484, DOI 10.1038/sj.onc.1205333; Hailfinger S, 2011, P NATL ACAD SCI USA, V108, P14596, DOI 10.1073/pnas.1105020108; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Huang WC, 2007, MOL CELL, V26, P75, DOI 10.1016/j.molcel.2007.02.019; Jacque E, 2005, P NATL ACAD SCI USA, V102, P14635, DOI 10.1073/pnas.0507342102; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Kieusseian A, 2006, BLOOD, V107, P492, DOI 10.1182/blood-2005-02-0529; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Liu BG, 2006, P NATL ACAD SCI USA, V103, P17202, DOI 10.1073/pnas.0604481103; Maeda G, 2007, CLIN CANCER RES, V13, P5041, DOI 10.1158/1078-0432.CCR-07-0463; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Mauro C, 2011, NAT CELL BIOL, V13, P1272, DOI 10.1038/ncb2324; Mise N, 2006, ONCOGENE, V25, P6637, DOI 10.1038/sj.onc.1209669; Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020; Oeckinghaus A, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000034; Park E, 2007, CANCER RES, V67, P9158, DOI 10.1158/0008-5472.CAN-07-0590; Perkins ND, 2004, TRENDS CELL BIOL, V14, P64, DOI 10.1016/j.tcb.2003.12.004; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Roy B, 1996, ONCOGENE, V13, P2359; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Saccani S, 2003, MOL CELL, V11, P1563, DOI 10.1016/S1097-2765(03)00227-2; Schumm K, 2006, EMBO J, V25, P4820, DOI 10.1038/sj.emboj.7601343; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang XB, 2007, NAT CELL BIOL, V9, P470, DOI 10.1038/ncb1559; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Wu L, 1998, IMMUNITY, V9, P839, DOI 10.1016/S1074-7613(00)80649-4; Xia YF, 2009, P NATL ACAD SCI USA, V106, P2629, DOI 10.1073/pnas.0812256106; Xu Y, 2009, CANCER RES, V69, P3267, DOI 10.1158/0008-5472.CAN-08-4635; Zhang JY, 2004, GENE DEV, V18, P17, DOI 10.1101/gad.1160904	45	20	21	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 23	2013	32	21					2661	2669		10.1038/onc.2012.282	http://dx.doi.org/10.1038/onc.2012.282			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FH	22777360				2022-12-17	WOS:000319806700007
J	Scribner, KC; Behbod, F; Porter, WW				Scribner, K. C.; Behbod, F.; Porter, W. W.			Regulation of DCIS to invasive breast cancer progression by Singleminded-2s (SIM2s)	ONCOGENE			English	Article						SIM2s; breast cancer; DCIS; differentiation	CARCINOMA IN-SITU; MAMMARY-GLAND DEVELOPMENT; GENE-EXPRESSION PROFILES; LUMINAL CELL FATE; SINGLE-MINDED 2S; ABERRANT ACTIVATION; SONIC HEDGEHOG; DIFFERENTIATION; PATHWAY; NOTCH	Singleminded-2s (SIM2s) is a member of the bHLH/ PAS family of transcription factors and a key regulator of mammary epithelial cell differentiation. SIM2s is highly expressed in mammary epithelial cells and downregulated in human breast cancer. Loss of Sim2s causes aberrant mouse mammary ductal development, with features suggestive of malignant transformation, whereas overexpression of SIM2s promotes precocious alveolar differentiation in nulliparous mouse mammary glands, suggesting that SIM2s is required for establishing and enhancing mammary gland differentiation. To test the hypothesis that SIM2s regulates tumor cell differentiation, we analyzed SIM2s expression in human primary breast ductal carcinoma in situ (DCIS) samples and found that SIM2s is lost with progression from DCIS to invasive ductal cancer (IDC). Using a MCF10DCIS. COM progression model, we have shown that SIM2s expression is decreased in MCF10DCIS. COM cells compared with MCF10A cells, and reestablishment of SIM2s in MCF10DCIS. COM cells significantly inhibits growth and invasion both in vitro and in vivo. Analysis of SIM2s-MCF10DCIS. com tumors showed that SIM2s promoted a more differentiated tumor phenotype including the expression of a broad range of luminal markers (CSN2 (beta-casein), CDH1 (E-cadherin), and KER18 (keratin-18)) and suppressed genes associated with stem cell maintenance and a basal phenotype (SMO (smoothened), p63, SLUG (snail-2), KER14 (keratin-14) and VIM (vimentin)). Furthermore, loss of SIM2s expression in MCF10DCIS. COM xenografts resulted in a more invasive phenotype and increased lung metastasis likely due to an increase in Hedgehog signaling and matrix metalloproteinase expression. Together, these exciting new data support a role for SIM2s in promoting human breast tumor differentiation and maintaining epithelial integrity.	[Scribner, K. C.; Porter, W. W.] Texas A&M Univ, Coll Vet Med, Dept Integrat Biosci, College Stn, TX 77843 USA; [Behbod, F.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66103 USA	Texas A&M University System; Texas A&M University College Station; University of Kansas; University of Kansas Medical Center	Porter, WW (corresponding author), Texas A&M Univ, Coll Vet Med, Depertment Integrat Biosci, Mail Stop 4458, College Stn, TX 77843 USA.	wporter@cvm.tamu.edu			National Cancer Institute (NCI) [R01CA111551]; Department of Defence (DOD-CDMRP) [W81XWH-11-1-0158]; NCI [5R00CA127462-06]; NATIONAL CANCER INSTITUTE [R00CA127462, R01CA111551] Funding Source: NIH RePORTER	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defence (DOD-CDMRP); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Daniel Medina (Baylor College of Medicine, Houston, TX, USA) for providing the MCF10DCIS.com cell line and the Histology Core Facility at Texas A&M University College of Veterinary Medicine & Biomedical Sciences for tissue preparation and hematoxylin and eosin staining. DCIS and IDC tissue sections were provided by the University of KansasCancer Center Biospecimen Share Resources at the University of KansasMedical Center. This work was supported by grants R01CA111551 from the National Cancer Institute (NCI) to WWP, W81XWH-11-1-0158 from the Department of Defence (DOD-CDMRP) to KCS and 5R00CA127462-06 from the NCI to FB.	Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Behbod F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2358; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Bond J, 1996, ONCOGENE, V13, P2097; Burstein HJ, 2004, NEW ENGL J MED, V350, P1430, DOI 10.1056/NEJMra031301; Chin K, 2004, NAT GENET, V36, P984, DOI 10.1038/ng1409; Cocker R, 2007, MED HYPOTHESES, V69, P57, DOI 10.1016/j.mehy.2006.11.042; Cody HS, 2007, ANN SURG ONCOL, V14, P2179, DOI 10.1245/s10434-006-9300-9; de Biase D, 2010, VIRCHOWS ARCH, V456, P395, DOI 10.1007/s00428-010-0900-1; Du ZJ, 2010, CANCER SCI, V101, P2417, DOI 10.1111/j.1349-7006.2010.01700.x; Dubois-Marshall S, 2011, CLIN EXP METASTASIS; Grimm SL, 2003, J MAMMARY GLAND BIOL, V8, P191, DOI 10.1023/A:1025900908026; Gustafson TL, 2009, ONCOGENE; Hettinger AM, 2001, BIOL REPROD, V65, P507, DOI 10.1095/biolreprod65.2.507; Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007; Ioachim EE, 1998, ANTICANCER RES, V18, P1665; Kallergi G, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2896; Kasper M, 2009, CARCINOGENESIS, V30, P903, DOI 10.1093/carcin/bgp048; Kasperczyk H, 2009, FASEB J, V23, P21, DOI 10.1096/fj.08-111096; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kiaris H, 2004, AM J PATHOL, V165, P695, DOI 10.1016/S0002-9440(10)63333-0; Koodie L, 2010, AM J PATHOL, V177, P984, DOI 10.2353/ajpath.2010.090621; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Kwak HI, 2007, CARCINOGENESIS, V28, P259, DOI 10.1093/carcin/bgl122; Laffin B, 2008, MOL CELL BIOL, V28, P1936, DOI 10.1128/MCB.01701-07; LaMarca HL, 2010, STEM CELLS, V28, P535, DOI 10.1002/stem.297; Liao XY, 2009, CARCINOGENESIS, V30, P131, DOI 10.1093/carcin/bgn230; Liu D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031251; Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Maffuz A, 2006, J EXP CLIN CANC RES, V25, P223; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; McDaniel SM, 2006, AM J PATHOL, V168, P608, DOI 10.2353/ajpath.2006.050677; Mendes O, 2005, CLIN EXP METASTAS, V22, P237, DOI 10.1007/s10585-005-8115-6; Metz RP, 2006, J BIOL CHEM, V281, P10839, DOI 10.1074/jbc.M508858200; Miller FR, 2000, J NATL CANCER I, V92, P1185, DOI 10.1093/jnci/92.14.1185A; Moraes RC, 2007, DEVELOPMENT, V134, P1231, DOI 10.1242/dev.02797; Oakes SR, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1411; Pellikainen JM, 2004, CLIN CANCER RES, V10, P7621, DOI 10.1158/1078-0432.CCR-04-1061; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Politi K, 2004, SEMIN CANCER BIOL, V14, P341, DOI 10.1016/j.semcancer.2004.04.013; Porter D, 2003, MOL CANCER RES, V1, P362; Schedin P, 2004, MOL CARCINOGEN, V41, P207, DOI 10.1002/mc.20058; Scribner KC, 2011, MOL ENDOCRINOL; Shekhar MPV, 2008, CANCER BIOL THER, V7, P1774, DOI 10.4161/cbt.7.11.6781; Sims JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018848; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Stockmann C, 2008, NATURE, V456, P814, DOI 10.1038/nature07445; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Tait LR, 2007, INT J CANCER, V120, P2127, DOI 10.1002/ijc.22572; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Visbal AP, 2011, DEV BIOL, V352, P116, DOI 10.1016/j.ydbio.2011.01.025; Walsh LA, 2012, J CELL COMMUN SIGNAL, V6, P87, DOI 10.1007/s12079-011-0157-8; Wang C, 2011, J CANCER RES CLIN, V137, P985, DOI 10.1007/s00432-010-0963-z; Wellberg E, 2010, DEVELOPMENT, V137, P945, DOI 10.1242/dev.041657; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Witty Jean P., 1995, Molecular Biology of the Cell, V6, P1287; Yalcin-Ozuysal O, 2010, CELL DEATH DIFFER, V17, P1600, DOI 10.1038/cdd.2010.37; Yao J, 2006, CANCER RES, V66, P4065, DOI 10.1158/0008-5472.CAN-05-4083; Yoo YA, 2011, CANCER RES, V71, P7061, DOI 10.1158/0008-5472.CAN-11-1338; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zhou J, 2005, EMBO J, V24, P635, DOI 10.1038/sj.emboj.7600538; Zuo SG, 2012, J CANCER RES CLIN, V138, P1045, DOI 10.1007/s00432-012-1153-y	64	20	21	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 23	2013	32	21					2631	2639		10.1038/onc.2012.286	http://dx.doi.org/10.1038/onc.2012.286			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FH	22777354	Green Accepted			2022-12-17	WOS:000319806700004
J	Garcia, I; Crowther, AJ; Gama, V; Miller, CR; Deshmukh, M; Gershon, TR				Garcia, I.; Crowther, A. J.; Gama, V.; Miller, C. Ryan; Deshmukh, M.; Gershon, T. R.			Bax deficiency prolongs cerebellar neurogenesis, accelerates medulloblastoma formation and paradoxically increases both malignancy and differentiation	ONCOGENE			English	Article						Bax; CGNPs; cerebellar neurogenesis; medulloblastoma; SmoA1 transgenic mouse	PROGRAMMED CELL-DEATH; KNOCK-OUT MICE; SONIC HEDGEHOG; NERVOUS-SYSTEM; POSTNATAL-DEVELOPMENT; TUMOR SUPPRESSORS; GRANULE CELLS; BCL-2 FAMILY; MOUSE MODEL; DAP-KINASE	Neurogenesis requires negative regulation through differentiation of progenitors or their programmed cell death (PCD). Growth regulation is particularly important in the postnatal cerebellum, where excessive progenitor proliferation promotes medulloblastoma, the most common malignant brain tumor in children. We present evidence that PCD operates alongside differentiation to regulate cerebellar granule neuron progenitors (CGNPs) and to prevent medulloblastoma. Here, we show that genetic deletion of pro-apoptotic Bax disrupts regulation of cerebellar neurogenesis and promotes medulloblastoma formation. In Bax(-/-) mice, the period of neurogenesis was extended into the third week of postnatal life, and ectopic neurons and progenitors collected in the molecular layer of the cerebellum and adjacent tectum. Importantly, genetic deletion of Bax in medulloblastoma-prone ND2:SmoA1 transgenic mice greatly accelerated tumorigenesis. Bax-deficient medulloblastomas exhibited strikingly distinct pathology, with reduced apoptosis, increased neural differentiation and tectal migration. Comparing Bax(-/-) and Bax(-/-) medulloblastomas, we were able to identify upregulation of Bcl-2 and nuclear exclusion of p27 as tumorigenic changes that are required to mitigate the tumor suppressive effect of Bax. Studies on human tumors confirmed the importance of modulating Bax in medulloblastoma pathogenesis. Our results demonstrate that Bax-dependent apoptosis regulates postnatal cerebellar neurogenesis, suppresses medulloblastoma formation and imposes selective pressure on tumors that form. Functional resistance to Bax-mediated apoptosis, required for medulloblastoma tumorigenesis, may be a tumor-specific vulnerability to be exploited for therapeutic benefit.	[Garcia, I.; Crowther, A. J.; Miller, C. Ryan; Gershon, T. R.] Univ N Carolina, Sch Med, Dept Neurol, Chapel Hill, NC 27599 USA; [Gama, V.; Deshmukh, M.] Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; [Miller, C. Ryan] Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Div Neuropathol, Chapel Hill, NC 27599 USA; [Miller, C. Ryan; Deshmukh, M.; Gershon, T. R.] Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Miller, C. Ryan; Deshmukh, M.; Gershon, T. R.] Univ N Carolina, Sch Med, Ctr Neurosci, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Gershon, TR (corresponding author), Univ N Carolina, Sch Med, Dept Neurol, 170 Manning Dr CB7025, Chapel Hill, NC 27599 USA.	gershont@neurology.unc.edu	Gershon, Timothy/H-5398-2019; , Pathology Services Core/CEZ-2246-2022; Miller, Ryan/B-9365-2008	Gershon, Timothy/0000-0001-7034-6400; Miller, Ryan/0000-0002-0096-8762; Crowther, Andrew/0000-0001-9269-6188; Gama, Vivian/0000-0002-1201-1394	National Cancer Institute [3P30CA016086]; National Institute of Environmental Health Sciences [3P30ES010126]; Department of Defense [W81XWH-09-2-0042]; UNC University Cancer Research Fund (UCRF); Clinical Investigator award from the Damon Runyon Cancer Research Foundation [CI-45-09]; St Baldrick's Foundation; Morgan Adams Foundation; Matthew Larson Brain Tumor Foundation; NATIONAL CANCER INSTITUTE [P30CA016086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078366] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS077978] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Department of Defense(United States Department of Defense); UNC University Cancer Research Fund (UCRF); Clinical Investigator award from the Damon Runyon Cancer Research Foundation; St Baldrick's Foundation; Morgan Adams Foundation; Matthew Larson Brain Tumor Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank James Olson, Fred Hutchinson Cancer Research Center for generously sharing ND2:SmoA1 mice; and Mervi Eeva, Jackie Kylander and Stephanie Cohen in the UNC Translational Pathology Laboratory (TPL) for expert technical assistance. The UNC TPL is supported, in part, by grants from the National Cancer Institute (3P30CA016086), National Institute of Environmental Health Sciences (3P30ES010126), Department of Defense (W81XWH-09-2-0042), and the UNC University Cancer Research Fund (UCRF). CRM is supported in part by a Clinical Investigator award from the Damon Runyon Cancer Research Foundation (CI-45-09). TRG is supported by a Scholar Award from the St Baldrick's Foundation. Major portions of this work were supported by the Morgan Adams Foundation and the Matthew Larson Brain Tumor Foundation.	Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; Ayrault O, 2009, MOL CANCER RES, V7, P33, DOI 10.1158/1541-7786.MCR-08-0369; Bhatia B, 2010, CELL CYCLE, V9, P4307, DOI 10.4161/cc.9.21.13441; Bolduc ME, 2011, DEV MED CHILD NEUROL, V53, P409, DOI 10.1111/j.1469-8749.2011.03929.x; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Di Marcotullio L, 2004, P NATL ACAD SCI USA, V101, P10833, DOI 10.1073/pnas.0400690101; Dicou E, 2009, INT J DEV NEUROSCI, V27, P299, DOI 10.1016/j.ijdevneu.2009.02.005; Fan HB, 2001, J COMP NEUROL, V436, P82; Gershon TR, 2006, CURR NEUROL NEUROSCI, V6, P200, DOI 10.1007/s11910-006-0006-y; Gershon TR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007491; Guenebeaud C, 2010, MOL CELL, V40, P863, DOI 10.1016/j.molcel.2010.11.021; Hallahan AR, 2004, CANCER RES, V64, P7794, DOI 10.1158/0008-5472.CAN-04-1813; Hatten ME, 1999, ANNU REV NEUROSCI, V22, P511, DOI 10.1146/annurev.neuro.22.1.511; Heine VM, 2009, J CLIN INVEST, V119, P267, DOI 10.1172/JCI36376; Jung AR, 2008, J NEUROSCI, V28, P2941, DOI 10.1523/JNEUROSCI.3897-07.2008; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Kenney AM, 2000, MOL CELL BIOL, V20, P9055, DOI 10.1128/MCB.20.23.9055-9067.2000; Kessler JD, 2009, GENE DEV, V23, P157, DOI 10.1101/gad.1759909; Kim WR, 2007, J NEUROSCI, V27, P14392, DOI 10.1523/JNEUROSCI.3903-07.2007; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Lindsten T, 2005, NEUROSCIENTIST, V11, P10, DOI 10.1177/1073858404269267; Lindsten T, 2003, J NEUROSCI, V23, P11112; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Llambi F, 2005, EMBO J, V24, P1192, DOI 10.1038/sj.emboj.7600584; Machold R, 2005, NEURON, V48, P17, DOI 10.1016/j.neuron.2005.08.028; Matei V, 2005, DEV DYNAM, V234, P633, DOI 10.1002/dvdy.20551; Noguchi KK, 2008, CELL DEATH DIFFER, V15, P1582, DOI 10.1038/cdd.2008.97; Oliver TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793; Packer RJ, 2008, J CHILD NEUROL, V23, P1122, DOI 10.1177/0883073808320758; Parathath SR, 2010, CELL CYCLE, V9, P4013, DOI 10.4161/cc.9.19.13325; Pfaff E, 2010, J CLIN ONCOL, V28, P5188, DOI 10.1200/JCO.2010.31.1670; Preusser M, 2011, ANN NEUROL, V70, P9, DOI 10.1002/ana.22425; Sato T, 2008, MOL CELL NEUROSCI, V39, P569, DOI 10.1016/j.mcn.2008.08.003; Tanaka S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005922; Uziel T, 2005, GENE DEV, V19, P2656, DOI 10.1101/gad.1368605; Valerie AW, 1999, CURR BIOL, V9, P445; Wang H, 2008, BIOCHEM BIOPH RES CO, V370, P594, DOI 10.1016/j.bbrc.2008.03.152; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0	39	20	20	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2013	32	18					2304	2314		10.1038/onc.2012.248	http://dx.doi.org/10.1038/onc.2012.248			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140VF	22710714	Green Accepted, Green Submitted			2022-12-17	WOS:000318683600007
J	Kawabata, KC; Ehata, S; Komuro, A; Takeuchi, K; Miyazono, K				Kawabata, K. C.; Ehata, S.; Komuro, A.; Takeuchi, K.; Miyazono, K.			TGF-beta-induced apoptosis of B-cell lymphoma Ramos cells through reduction of MS4A1/CD20	ONCOGENE			English	Article						B-cell lymphoma; apoptosis; TGF-beta; MS4A1/CD20; rituximab	BURKITT-LYMPHOMA; RITUXIMAB; INVOLVEMENT; RESISTANCE; EXPRESSION; ANTIBODIES; THERAPY; PROTEIN; LINES; NHL	Transforming growth factor-beta (TGF-beta) exhibits growth inhibitory effects on various types of tumor cells, including B-cell lymphoma cells. In the present study, the role of TGF-beta in the survival of Epstein-Barr virus-negative B-cell lymphoma Ramos cells was investigated. As TGF-beta-induced apoptosis of Ramos cells in vitro and in vivo, we attempted to identify novel target gene(s) responsible for their survival. Oligonucleotide microarray analysis and chromatin immunoprecipitation revealed that Smad proteins directly regulated the transcription of membrane-spanning 4-domains, subfamily A, member 1 (MS4A1), also known as CD20, in Ramos cells upon TGF-beta stimulation. In addition, immunohistochemical analysis using clinical samples from B-cell lymphoma patients showed an inverse correlation between the expression of MS4A1/CD20 and phosphorylation of Smad3. Although knockdown of MS4A1/CD20 in Ramos cells resulted in an increase of apoptotic cells, Ramos cells stably expressing MS4A1/CD20 were resistant to TGF-beta-induced apoptosis. This suggests that MS4A1/CD20 is responsible for TGF-beta-induced apoptosis of B-cell lymphoma cells. Moreover, downregulation of MS4A1/CD20 by TGF-beta attenuated the effects of the monoclonal anti-MS4A1/CD20 antibody, rituximab, on Ramos cells. Our findings suggest that the sensitivity of B-cell lymphoma cells to rituximab may be affected by TGF-beta signaling. Oncogene (2013) 32, 2096-2106; doi:10.1038/onc.2012.219; published online 4 June 2012	[Kawabata, K. C.; Ehata, S.; Komuro, A.; Miyazono, K.] Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Tokyo 1130033, Japan; [Takeuchi, K.] Japanese Fdn Canc Res, Inst Canc, Pathol Project Mol Targets, Tokyo 170, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Miyazono, K (corresponding author), Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono@m.u-tokyo.ac.jp	; Takeuchi, Kengo/C-3614-2008	Ehata, Shogo/0000-0002-6740-9391; Takeuchi, Kengo/0000-0002-1599-5800	KAKENHI; Global Center of Excellence Program 'Integrative Life Science Based on the Study of Biosignaling Mechanisms' from the Ministry of Education, Culture, Sports, Science and Technology (MEXT); Japan Society for the Promotion of Science (JSPS) Core-to-Core Program 'Cooperative International Framework in TGF-beta Family Signaling; Grants-in-Aid for Scientific Research [22112002] Funding Source: KAKEN	KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Global Center of Excellence Program 'Integrative Life Science Based on the Study of Biosignaling Mechanisms' from the Ministry of Education, Culture, Sports, Science and Technology (MEXT); Japan Society for the Promotion of Science (JSPS) Core-to-Core Program 'Cooperative International Framework in TGF-beta Family Signaling(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank D Koinuma (the University of Tokyo) and Y Morishita (the University of Tokyo) for technical assistance and H Miyoshi (RIKEN) for the lentiviral vectors. This work was supported by KAKENHI (Grants-in-Aid for Scientific Research on Innovative Areas 'Integrative Research on Cancer Microenvironment Network' (to KM) Grant-in-Aid for Young Scientists (to SE)) and the Global Center of Excellence Program 'Integrative Life Science Based on the Study of Biosignaling Mechanisms' from the Ministry of Education, Culture, Sports, Science and Technology (MEXT). This work was also supported by Japan Society for the Promotion of Science (JSPS) Core-to-Core Program 'Cooperative International Framework in TGF-beta Family Signaling'.	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ANDERSON KC, 1984, BLOOD, V63, P1424, DOI 10.1182/blood.V63.6.1424.1424; Bellan C, 2005, BLOOD, V106, P1031, DOI 10.1182/blood-2005-01-0168; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Blackford A, 2009, CLIN CANCER RES, V15, P4674, DOI 10.1158/1078-0432.CCR-09-0227; Daniel D, 2007, BLOOD, V110, P4037, DOI 10.1182/blood-2007-02-076075; Daniels I, 2008, BRIT J HAEMATOL, V142, P394, DOI 10.1111/j.1365-2141.2008.07193.x; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Ehata S, 2011, ONCOGENE, V30, P1693, DOI 10.1038/onc.2010.546; Ehata S, 2007, CANCER RES, V67, P9694, DOI 10.1158/0008-5472.CAN-07-1522; Ehata S, 2007, CANCER SCI, V98, P127, DOI 10.1111/j.1349-7006.2006.00357.x; Ernst JA, 2005, BIOCHEMISTRY-US, V44, P15150, DOI 10.1021/bi0511078; Fujita M, 2000, PATHOL INT, V50, P696, DOI 10.1046/j.1440-1827.2000.01108.x; Gopal AK, 2004, BLOOD, V103, P3516, DOI 10.1182/blood-2003-08-2795; Goyama S, 2009, CANCER SCI, V100, P990, DOI 10.1111/j.1349-7006.2009.01152.x; Guikema JEJ, 2006, GENE CHROMOSOME CANC, V45, P808, DOI 10.1002/gcc.20345; Hoshino Y, 2011, J BIOCHEM, V149, P55, DOI 10.1093/jb/mvq114; Ikushima H, 2012, CELL TISSUE RES, V347, P37, DOI 10.1007/s00441-011-1179-5; Inman GJ, 2000, J GEN VIROL, V81, P1567, DOI 10.1099/0022-1317-81-6-1567; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Jaffe ES, 2009, HEMATOL-AM SOC HEMAT, V2009, P523, DOI DOI 10.1182/ASHEDUCATI0N-2009.1.523; Koinuma D, 2009, MOL CELL BIOL, V29, P172, DOI 10.1128/MCB.01038-08; Lin HK, 2005, ONCOGENE, V24, P5693, DOI 10.1038/sj.onc.1208923; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; Mancao C, 2005, BLOOD, V106, P4339, DOI 10.1182/blood-2005-06-2341; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148; MYEROFF LL, 1995, CANCER RES, V55, P5545; Polyak MJ, 2002, BLOOD, V99, P3256, DOI 10.1182/blood.V99.9.3256; Saltzman A, 1998, EXP CELL RES, V242, P244, DOI 10.1006/excr.1998.4096; Shan DM, 2000, CANCER IMMUNOL IMMUN, V48, P673, DOI 10.1007/s002620050016; SHIRAMIZU B, 1991, BLOOD, V77, P1516; Spender LC, 2009, J BIOL CHEM, V284, P1435, DOI 10.1074/jbc.M808080200; Stolz C, 2009, LEUKEMIA LYMPHOMA, V50, P873, DOI 10.1080/10428190902878471; Sugimoto T, 2009, BIOCHEM BIOPH RES CO, V390, P48, DOI 10.1016/j.bbrc.2009.09.059; Suzuki E, 2007, ONCOGENE, V26, P6184, DOI 10.1038/sj.onc.1210448; Uchiyama S, 2010, CANCER SCI, V101, P201, DOI 10.1111/j.1349-7006.2009.01392.x; van Meerten T, 2009, NETH J MED, V67, P251; Vega MI, 2009, CLIN CANCER RES, V15, P6582, DOI 10.1158/1078-0432.CCR-09-1234; Witzig TE, 2005, J CLIN ONCOL, V23, P1103, DOI 10.1200/JCO.2005.12.052; Wolfraim LA, 2004, NEW ENGL J MED, V351, P552, DOI 10.1056/NEJMoa031197	42	20	23	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2013	32	16					2096	2106		10.1038/onc.2012.219	http://dx.doi.org/10.1038/onc.2012.219			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130LY	22665052				2022-12-17	WOS:000317919900011
J	Jin, W; Wu, K; Li, YZ; Yang, WT; Zou, B; Zhang, F; Zhang, J; Wang, KK				Jin, W.; Wu, K.; Li, Y-Z; Yang, W-T; Zou, B.; Zhang, F.; Zhang, J.; Wang, K-K			AML1-ETO targets and suppresses cathepsin G, a serine protease, which is able to degrade AML1-ETO in t(8;21) acute myeloid leukemia	ONCOGENE			English	Article						cathepsin G; AML1-ETO; t(8;21) AML	FUSION PROTEIN; NEUTROPHIL ELASTASE; GENE-EXPRESSION; EMBRYONIC LETHALITY; TRANSCRIPTION; DIFFERENTIATION; APOPTOSIS; CELLS; PU.1; PROMOTER	Although the significance of cathepsin G (CTSG) in host defense has been intensively investigated, little is known about its potential roles in granulopoiesis or leukemogenesis. We report here that CTSG is directly targeted and suppressed by AML1-ETO in t(8;21) acute myeloid leukemia (AML). Luciferase assays demonstrate that the CTSG promoter is strongly transactivated by AML1 and the AML1-dependent transactivation is suppressed by AML1-ETO. We also define a novel regulatory mechanism by which AML1-ETO-mediated transrepression requires both AML1-ETO and AML1 binding at adjacent sites, instead of the replacement of AML1 by AML1-ETO, and wild-type AML1 binding is a prerequisite for the repressive effect caused by AML1-ETO. Further evidence shows that CTSG, as a hematopoietic serine protease, can degrade AML1-ETO both in vitro and in vivo. Restoration of CTSG induces partial differentiation, growth inhibition and apoptosis in AML1-ETO-positive cells. In addition to t(8; 21) AML, CTSG downregulation is observed in AML patients with other cytogenetic/genetic abnormalities that potentially interrupt normal AML1 function, that is, inv(16) and EVI1 overexpression. Thus, the targeting and suppression of CTSG by AML1-ETO in t(8; 21) AML may provide a mechanism for leukemia cells to escape from the intracellular surveillance system by preventing degradation of foreign proteins. Oncogene (2013) 32, 1978-1987; doi:10.1038/onc.2012.204; published online 28 May 2012	[Jin, W.; Wu, K.; Li, Y-Z; Yang, W-T; Zou, B.; Zhang, F.; Zhang, J.; Wang, K-K] SJTU SM, Ruijin Hosp, State Key Lab Med Genom, Shanghai 200025, Peoples R China; [Jin, W.; Wu, K.; Li, Y-Z; Yang, W-T; Zou, B.; Zhang, F.; Zhang, J.; Wang, K-K] SJTU SM, Ruijin Hosp, Shanghai Inst Hematol, Shanghai 200025, Peoples R China; [Zhang, J.] Chinese Acad Sci, Inst Hlth Sci, Key Lab Stem Cell Biol, Shanghai Inst Biol Sci, Shanghai, Peoples R China; [Zhang, J.] SJTU SM, Shanghai 200025, Peoples R China	Chinese Academy of Sciences; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University	Wang, KK (corresponding author), SJTU SM, Ruijin Hosp, State Key Lab Med Genom, 197 Ruijin Er Rd, Shanghai 200025, Peoples R China.	kankanwang@shsmu.edu.cn		Wu, Kang/0000-0002-9024-795X	Ministry of Science and Technology Grants of China [2009CB825607, 2012AA02A211, 2011CB910202]; National Natural Science Foundation Grants of China [31171257, 90919059, 30971623]	Ministry of Science and Technology Grants of China; National Natural Science Foundation Grants of China(National Natural Science Foundation of China (NSFC))	We thank Dr Lubbert M for providing the AML1-ETO-inducible cell line, U937-A/E9/14/18. This work was supported in part by the Ministry of Science and Technology Grants of China (2009CB825607, 2012AA02A211 and 2011CB910202) and National Natural Science Foundation Grants of China (31171257, 90919059 and 30971623).	Biggs JR, 2001, P NATL ACAD SCI USA, V98, P3814, DOI 10.1073/pnas.071057398; BITTER MA, 1987, HUM PATHOL, V18, P211, DOI 10.1016/S0046-8177(87)80002-3; Corsello SM, 2009, BLOOD, V113, P6193, DOI 10.1182/blood-2008-07-166090; DENGLER R, 1995, BRIT J HAEMATOL, V89, P250, DOI 10.1111/j.1365-2141.1995.tb03297.x; Dunne J, 2006, ONCOGENE, V25, P6067, DOI 10.1038/sj.onc.1209638; Fliegauf M, 2004, ONCOGENE, V23, P9070, DOI 10.1038/sj.onc.1208042; Frank R, 1995, ONCOGENE, V11, P2667; Gardini A, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000275; Garwicz D, 1998, BLOOD, V92, P1415, DOI 10.1182/blood.V92.4.1415.416k28_1415_1422; Heidenreich O, 2003, BLOOD, V101, P3157, DOI 10.1182/blood-2002-05-1589; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Howcroft TK, 2005, J IMMUNOL, V174, P2106, DOI 10.4049/jimmunol.174.4.2106; Hug BA, 2004, ONCOGENE, V23, P4270, DOI 10.1038/sj.onc.1207674; Igney FH, 2002, J LEUKOCYTE BIOL, V71, P907; Jiang Y, 2005, LEUKEMIA, V19, P1239, DOI 10.1038/sj.leu.2403734; Kadkol SS, 2004, J MOL DIAGN, V6, P22, DOI 10.1016/S1525-1578(10)60487-4; Kitareewan S, 2007, J NATL CANCER I, V99, P41, DOI 10.1093/jnci/djk004; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Korkmaz B, 2008, BIOCHIMIE, V90, P227, DOI 10.1016/j.biochi.2007.10.009; Lane AA, 2003, CELL, V115, P305, DOI 10.1016/S0092-8674(03)00852-3; Laricchia-Robbio L, 2009, CANCER RES, V69, P1633, DOI 10.1158/0008-5472.CAN-08-2562; Lausen J, 2006, ONCOGENE, V25, P1349, DOI 10.1038/sj.onc.1209181; Lennartsson A, 2005, GENE, V356, P193, DOI 10.1016/j.gene.2005.05.004; Licht JD, 2001, ONCOGENE, V20, P5660, DOI 10.1038/sj.onc.1204593; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; McGhee L, 2003, J CELL BIOCHEM, V89, P1005, DOI 10.1002/jcb.10548; Mulloy JC, 2005, P NATL ACAD SCI USA, V102, P4016, DOI 10.1073/pnas.0404701102; Mulloy JC, 2003, BLOOD, V102, P4369, DOI 10.1182/blood-2003-05-1762; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Okumura AJ, 2008, BLOOD, V112, P1392, DOI 10.1182/blood-2007-11-124735; Peterson LF, 2004, ONCOGENE, V23, P4255, DOI 10.1038/sj.onc.1207727; Pham CTN, 2006, NAT REV IMMUNOL, V6, P541, DOI 10.1038/nri1841; Piazza F, 2000, BLOOD, V96, P1358, DOI 10.1182/blood.V96.4.1358.h8001358_1358_1365; Puissant A, 2010, LEUKEMIA, V24, P115, DOI 10.1038/leu.2009.233; Senyuk V, 2007, CANCER RES, V67, P5658, DOI 10.1158/0008-5472.CAN-06-3962; Shimada H, 2002, LEUKEMIA, V16, P874, DOI 10.1038/sj.leu.2402465; Tomasson MH, 2008, BLOOD, V111, P4797, DOI 10.1182/blood-2007-09-113027; Traver D, 1998, IMMUNITY, V9, P47, DOI 10.1016/S1074-7613(00)80587-7; Uchida H, 1997, J IMMUNOL, V158, P2251; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Wang KK, 2010, CANCER CELL, V17, P186, DOI 10.1016/j.ccr.2009.12.045; Wang L, 2007, CELL DEATH DIFFER, V14, P306, DOI 10.1038/sj.cdd.4401996; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Wingender E, 2008, BRIEF BIOINFORM, V9, P326, DOI 10.1093/bib/bbn016; Wouters BJ, 2009, BLOOD, V113, P3088, DOI 10.1182/blood-2008-09-179895; Yang G, 2007, ONCOGENE, V26, P91, DOI 10.1038/sj.onc.1209760; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Zhou GB, 2007, BLOOD, V109, P3441, DOI 10.1182/blood-2006-06-032250	51	20	22	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2013	32	15					1978	1987		10.1038/onc.2012.204	http://dx.doi.org/10.1038/onc.2012.204			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126GB	22641217				2022-12-17	WOS:000317599900012
J	Takada, Y; Gresh, L; Bozec, A; Ikeda, E; Kamiya, K; Watanabe, M; Kobayashi, K; Asano, K; Toyama, Y; Wagner, EF; Matsuo, K				Takada, Y.; Gresh, L.; Bozec, A.; Ikeda, E.; Kamiya, K.; Watanabe, M.; Kobayashi, K.; Asano, K.; Toyama, Y.; Wagner, E. F.; Matsuo, K.			Interstitial lung disease induced by gefitinib and Toll-like receptor ligands is mediated by Fra-1	ONCOGENE			English	Article						Fra-1; gefitinib; interstitial lung disease; MCP-1; AP-1; TLR	SYSTEMIC INFLAMMATORY RESPONSE; DOUBLE-EDGED-SWORD; NF-KAPPA-B; PULMONARY-FIBROSIS; C-FOS; OSTEOCLAST DIFFERENTIATION; TYROSINE KINASE; INNATE IMMUNITY; BONE-FORMATION; JUN PROTEINS	The role of the AP-1 transcription factor Fra-1 (encoded by Fosl1) in inflammatory responses associated with lung disease is largely unknown. Here, we show that Fra-1 overexpression in mice reduced proinflammatory cytokine production in response to injection of lipopolysaccharide (LPS), a Toll-like receptor (TLR)-ligand. Unexpectedly, Fra-1 transgenic mice died rapidly following LPS treatment, showing severe interstitial lung disease and displaying massive accumulation of macrophages and overproduction of several chemokines, including macrophage chemoattractant protein-1 (MCP-1, encoded by Ccl2). To assess the clinical relevance of Fra-1 in lung pathology, mice were treated with the anticancer drug gefitinib (Iressa), which can lead to interstitial lung disease in patients. Gefitinib-treated mice showed increased Fosl1 and Ccl2 expression and developed interstitial lung disease in response to LPS, endogenous TLR ligands and chemotherapy. Moreover, deletion of Fra-1 or blocking MCP-1 receptor signaling in mice attenuated gefitinib-enhanced lethality in response to LPS. Importantly, human alveolar macrophages showed enhanced LPS-induced FOSL1 and CCL2 expression after gefitinib treatment. These results indicate that Fra-1 is an important mediator of interstitial lung disease following gefitinib treatment. Oncogene (2011) 30, 3821-3832;doi:10.1038/onc.2011.101; published online 4 April 2011	[Matsuo, K.] Keio Univ, Lab Cell & Tissue Biol, Sch Med, Shinjuku Ku, Tokyo 1608582, Japan; [Gresh, L.] Res Inst Mol Pathol IMP, Vienna, Austria; [Bozec, A.; Wagner, E. F.] Spanish Natl Canc Res Ctr CNIO, Canc Cell Biol Programme, Madrid, Spain; [Ikeda, E.] Keio Univ, Dept Pathol, Sch Med, Tokyo 1608582, Japan; [Kamiya, K.; Watanabe, M.; Kobayashi, K.] Keio Univ, Dept Surg, Sch Med, Tokyo 1608582, Japan; [Asano, K.] Keio Univ, Dept Med, Sch Med, Tokyo 1608582, Japan; [Toyama, Y.] Keio Univ, Dept Orthopaed Surg, Sch Med, Tokyo 1608582, Japan	Keio University; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Centro Nacional de Investigaciones Oncologicas (CNIO); Keio University; Keio University; Keio University; Keio University	Matsuo, K (corresponding author), Keio Univ, Lab Cell & Tissue Biol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	matsuo@sc.itc.keio.ac.jp	Toyama, Yoshiaki/K-5743-2013; Matsuo, Koichi/K-5695-2012	Matsuo, Koichi/0000-0002-1490-8955; Wagner, Erwin F/0000-0001-7872-0196; Gresh, Lionel/0000-0002-2333-1748	global COE; MEXT of Japan [21390425]; Naito Foundation; EMBO; Boehringer Ingelheim; Grants-in-Aid for Scientific Research [23791663] Funding Source: KAKEN	global COE(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); MEXT of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Naito Foundation(Naito Memorial Foundation); EMBO(European Molecular Biology Organization (EMBO)); Boehringer Ingelheim(Boehringer Ingelheim); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank A Oide, M Asakawa and S Fukuse for technical support; T Yamaguchi for Fra-1 mouse maintenance; A Dent, A Ueda and M Busslinger for plasmids; H Daub for AX14596; and H Handa, S Sakamoto, K Maruyama, T Mitsudomi and L Bakiri for helpful input. We thank the Core Instrumentation Facility, Keio University School of Medicine, for technical assistance. This work was funded by a grant-in-aid from the global COE program, a grant-in-aid for Scientific Research (B) from MEXT of Japan (21390425), and a grant-in-aid for Scientific Research on Priority Areas and the Naito Foundation (YT). LG was funded by an EMBO Long-Term Fellowship. IMP is funded by Boehringer Ingelheim.	Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Bakiri L, 2007, BONE, V40, P867, DOI 10.1016/j.bone.2006.11.005; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; Bozec A, 2008, NATURE, V454, P221, DOI 10.1038/nature07019; Bozec A, 2010, J CELL BIOL, V190, P1093, DOI 10.1083/jcb.201002111; Brehmer D, 2005, CANCER RES, V65, P379; Cohen MH, 2003, ONCOLOGIST, V8, P303, DOI 10.1634/theoncologist.8-4-303; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eferl R, 2004, EMBO J, V23, P2789, DOI 10.1038/sj.emboj.7600282; Eferl R, 2008, P NATL ACAD SCI USA, V105, P10525, DOI 10.1073/pnas.0801414105; Finzer P, 2000, ONCOGENE, V19, P3235, DOI 10.1038/sj.onc.1203643; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Giaccone G, 2004, J CLIN ONCOL, V22, P777, DOI 10.1200/JCO.2004.08.001; Guinea-Viniegra J, 2009, GENE DEV, V23, P2663, DOI 10.1101/gad.543109; Han JH, 2005, NAT IMMUNOL, V6, P1198, DOI 10.1038/ni1274; Inoue A, 2003, LANCET, V361, P137, DOI 10.1016/S0140-6736(03)12190-3; Ishii Y, 2006, AM J RESP CRIT CARE, V174, P550, DOI 10.1164/rccm.200509-1534OC; Ishizaka A, 2001, CRIT CARE MED, V29, P896, DOI 10.1097/00003246-200104000-00043; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; Johnson GB, 2004, J IMMUNOL, V172, P20, DOI 10.4049/jimmunol.172.1.20; Katzenstein ALA, 1998, AM J RESP CRIT CARE, V157, P1301, DOI 10.1164/ajrccm.157.4.9707039; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kida H, 2005, AM J PHYSIOL-LUNG C, V288, pL342, DOI 10.1152/ajplung.00016.2004; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Lee DH, 2010, CLIN CANCER RES, V16, P1307, DOI 10.1158/1078-0432.CCR-09-1903; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Mollen KP, 2006, SHOCK, V26, P430, DOI 10.1097/01.shk.0000228797.41044.08; Morishita H, 2009, INT IMMUNOL, V21, P457, DOI 10.1093/intimm/dxp015; PAINE R, 1993, J IMMUNOL, V150, P4561; PETERSGOLDEN M, 1987, AM REV RESPIR DIS, V135, P1020; Pircher A, 2010, LUNG CANCER, V69, P265, DOI 10.1016/j.lungcan.2010.01.017; Ray N, 2006, INT IMMUNOL, V18, P671, DOI 10.1093/intimm/dxl004; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Salojin KV, 2006, J IMMUNOL, V176, P1899, DOI 10.4049/jimmunol.176.3.1899; Suzuki H, 2003, CANCER RES, V63, P5054; Takada Y, 2004, J BIOL CHEM, V279, P39541, DOI 10.1074/jbc.M403449200; Takada Y, 2010, J IMMUNOL, V184, P1014, DOI 10.4049/jimmunol.0901196; Tallquist MD, 2000, GENESIS, V26, P113, DOI 10.1002/(SICI)1526-968X(200002)26:2<113::AID-GENE3>3.0.CO;2-2; Toney LM, 2000, NAT IMMUNOL, V1, P214, DOI 10.1038/79749; ULICH TR, 1991, AM J PATHOL, V138, P1485; Vogl T, 2007, NAT MED, V13, P1042, DOI 10.1038/nm1638; Watanabe M, 2003, ANN THORAC SURG, V76, P1668, DOI 10.1016/S0003-4975(03)01015-4; Wolter S, 2008, MOL CELL BIOL, V28, P4407, DOI 10.1128/MCB.00535-07; Yamaguchi T, 2009, J BONE MINER RES, V24, P2056, DOI [10.1359/JBMR.090603, 10.1359/jbmr.090603]; Zenz R, 2005, NATURE, V437, P369, DOI 10.1038/nature03963; Zhang Q, 2006, J BIOL CHEM, V281, P10174, DOI 10.1074/jbc.M513008200; Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012	51	20	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	36					3821	3832		10.1038/onc.2011.101	http://dx.doi.org/10.1038/onc.2011.101			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	817PV	21460858				2022-12-17	WOS:000294687200001
J	Sudol, M				Sudol, M.			From Rous sarcoma virus to plasminogen activator, src oncogene and cancer management	ONCOGENE			English	Review						Rous sarcoma virus; The Rockefeller University; Lipmann; Fischer; urokinase; Affymetrix	DEPENDENT DNA POLYMERASE; SRC/ABL KINASE INHIBITOR; BREAST-CANCER; WW DOMAIN; V-SRC; MESSENGER-RNA; TRANSFORMATION FINGERPRINT; HORMONAL-REGULATION; PLATELET PROTEIN; KIDNEY-CELLS	Plasminogen activator (PLAU) is a serine protease that converts plasminogen to plasmin, a general protease, which promotes fibrinolysis and degradation of extracellular matrix. PLAU was reported in 1970s as one of the robustly induced enzymatic activities in Rous sarcoma virus (RSV)-transformed chicken cells. More than three decades later, with the completion of the sequencing of the chicken genome and the subsequent availability of Affymetrix GeneChip genome arrays, several laboratories have surveyed the transcriptional program affected by the RSV transformation. Interestingly, the PLAU gene was shown to be the most highly upregulated transcript. The induction of PLAU was a transformation-dependent process because viruses with deleted Src gene did not induce the transcription of the PLAU gene. Both Src and PLAU genes are associated with and contribute to the complex phenotype of human cancer. Although the activity and structures of these two enzymes are well characterized, the precise molecular function of these gene products in signaling networks is still not fully understood. Yet, the knowledge of their association with cancer is already translated into the clinical setting. Src kinase inhibitors are being tested in clinical trials of cancer therapy, and PLAU gene and its inhibitor have been included as biomarkers with strong prognostic and therapeutic predictive values. This vignette reviews the history of PLAU and Src discovery, and illuminates the complexity of their relationship, but also points to their emerging impact on public health. Oncogene (2011) 30, 3003-3010; doi: 10.1038/onc.2011.38; published online 7 March 2011	[Sudol, M.] Weis Ctr Res, Geisinger Clin, Lab Signal Transduct & Prote Profiling, Danville, PA 17822 USA; [Sudol, M.] Mt Sinai Sch Med, Dept Med, New York, NY USA	Icahn School of Medicine at Mount Sinai	Sudol, M (corresponding author), Weis Ctr Res, Geisinger Clin, Lab Signal Transduct & Prote Profiling, MC 26-08,100 N Acad Ave, Danville, PA 17822 USA.	msudol1@geisinger.edu			PA Breast Cancer Coalition grants; Geisinger Clinic	PA Breast Cancer Coalition grants; Geisinger Clinic	This work was supported by PA Breast Cancer Coalition grants and by Geisinger Clinic.	Annecke K, 2008, ADV CLIN CHEM, V45, P31, DOI 10.1016/S0065-2423(07)00002-9; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BELL SM, 1990, J BIOL CHEM, V265, P1333; BING RJ, 2008, DIALOGUES CARDIOVASC, V13, P127; Blasi F, 2010, FEBS LETT, V584, P1923, DOI 10.1016/j.febslet.2009.12.039; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; Carriero MV, 2009, MOL CANCER THER, V8, P2708, DOI 10.1158/1535-7163.MCT-09-0174; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; D'Alessio S, 2009, FRONT BIOSCI-LANDMRK, V14, P4575, DOI 10.2741/3550; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; DUBOS R, 1979, J EXP MED, V150, P733; Fischer A, 1925, ARCH MIKROSK ANAT EN, V104, P210, DOI 10.1007/BF02108499; FRANKFORT BJ, 1995, BIOCHEM BIOPH RES CO, V206, P916, DOI 10.1006/bbrc.1995.1130; Gamier L, 1996, NATURE, V381, P744, DOI 10.1038/381744a0; Grusche FA, 2010, CURR BIOL, V20, pR574, DOI 10.1016/j.cub.2010.05.023; Harbeck N, 2007, CRIT REV CL LAB SCI, V44, P179, DOI 10.1080/10408360601040970; Harvey K, 2007, NAT REV CANCER, V7, P182, DOI 10.1038/nrc2070; HENDRICKS M, 1981, P NATL ACAD SCI-BIOL, V78, P5633, DOI 10.1073/pnas.78.9.5633; Hennequin LF, 2006, J MED CHEM, V49, P6465, DOI 10.1021/jm060434q; Hildenbrand R, 2010, EXPERT OPIN INV DRUG, V19, P641, DOI 10.1517/13543781003767400; Huang F, 2007, CANCER RES, V67, P2226, DOI 10.1158/0008-5472.CAN-06-3633; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; Hunter T, 2007, J CLIN INVEST, V117, P2036, DOI 10.1172/JCI31691; JAHNER D, 1991, ONCOGENE, V6, P1259; Jallal H, 2007, CANCER RES, V67, P1580, DOI 10.1158/0008-5472.CAN-06-2027; Janicke F, 2001, J NATL CANCER I, V93, P913, DOI 10.1093/jnci/93.12.913; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; LESLIE ND, 1990, J BIOL CHEM, V265, P1339; LIPMANN F, 1971, WANDERINGS BIOCH, P20; Maeda N, 2008, REV MED VIROL, V18, P387, DOI 10.1002/rmv.592; Malek RL, 2002, ONCOGENE, V21, P7256, DOI 10.1038/sj.onc.1205900; Martin GS, 2004, ONCOGENE, V23, P7910, DOI 10.1038/sj.onc.1208077; Masker K, 2007, VIROLOGY, V364, P10, DOI 10.1016/j.virol.2007.03.026; Maslikowski BM, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-41; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Mayer EL, 2010, CLIN CANCER RES, V16, P3526, DOI 10.1158/1078-0432.CCR-09-1834; Mekkawy AH, 2009, FUTURE ONCOL, V5, P1487, DOI [10.2217/fon.09.108, 10.2217/FON.09.108]; NAGAMINE Y, 1983, CELL, V32, P1181, DOI 10.1016/0092-8674(83)90301-X; NAGAMINE Y, 1984, NUCLEIC ACIDS RES, V12, P9525, DOI 10.1093/nar/12.24.9525; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; Patnaik A, 2002, J VIROL, V76, P2789, DOI 10.1128/JVI.76.6.2789-2795.2002; Paz K, 2004, ONCOGENE, V23, P8455, DOI 10.1038/sj.onc.1207803; Pincetic A, 2008, J BIOL CHEM, V283, P29822, DOI 10.1074/jbc.M804157200; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Rous P, 1911, J EXP MED, V13, P397, DOI 10.1084/jem.13.4.397; Rous P, 1910, J EXP MED, V12, P696, DOI 10.1084/jem.12.5.696; Saad F, 2010, CANCER TREAT REV, V36, P177, DOI 10.1016/j.ctrv.2009.11.005; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Schmitt M, 2004, INT J ONCOL, V25, P1397; Schmitt M, 1997, THROMB HAEMOSTASIS, V78, P285; Stefansson S, 2003, CURR PHARM DESIGN, V9, P1545, DOI 10.2174/1381612033454621; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; SUDOL M, 1985, MOL CELL ENDOCRINOL, V40, P245, DOI 10.1016/0303-7207(85)90180-7; SUDOL M, 1994, ONCOGENE, V9, P2145; SUDOL M, 1984, BIOCHEM J, V219, P971, DOI 10.1042/bj2190971; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; SUDOL M, 2006, DANVILLE NEWS   0816; Sudol M, 2010, TRENDS BIOCHEM SCI, V35, P627, DOI 10.1016/j.tibs.2010.05.010; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; Suzuki Y, 2010, J PHARMACOL SCI, V113, P203, DOI 10.1254/jphs.10R01CP; Tapia VE, 2010, J BIOL CHEM, V285, P19391, DOI 10.1074/jbc.M109.084525; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; Thomssen C, 2009, J NATL CANCER I, V101, P1028, DOI 10.1093/jnci/djp145; Ulisse S, 2009, CURR CANCER DRUG TAR, V9, P32, DOI 10.2174/156800909787314002; UNKELESS JC, 1973, J EXP MED, V137, P85, DOI 10.1084/jem.137.1.85; Vogt Peter K, 2010, Genes Cancer, V1, P6, DOI 10.1177/1947601909356102; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	70	20	21	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	27					3003	3010		10.1038/onc.2011.38	http://dx.doi.org/10.1038/onc.2011.38			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	789IW	21383693				2022-12-17	WOS:000292510100001
J	Testoni, B; Schinzari, V; Guerrieri, F; Gerbal-Chaloin, S; Blandino, G; Levrero, M				Testoni, B.; Schinzari, V.; Guerrieri, F.; Gerbal-Chaloin, S.; Blandino, G.; Levrero, M.			p53-paralog DNp73 oncogene is repressed by IFN alpha/STAT2 through the recruitment of the Ezh2 polycomb group transcriptional repressor	ONCOGENE			English	Article						transcription; p53 family; epigenetics; chromatin dynamics; apoptosis	HEPATOCELLULAR-CARCINOMA DEVELOPMENT; INTERFERON-ALPHA; HEPATITIS-C; COMBINATION THERAPY; CURATIVE TREATMENT; GENE-EXPRESSION; PROTEIN EED; APOPTOSIS; P53; METAANALYSIS	The DNp73 proteins act as trans-repressors of p53 and p73-dependent transcription and exert both anti-apoptotic activity and pro-proliferative activity. DNp73s are frequently up-regulated in a variety of human cancers, including human hepatocellular carcinomas (HCCs). Increased levels of DNp73 proteins confer to HCC cells resistance to apoptosis and, irrespective to p53 status, a chemoresistant phenotype. Here, we show that interferon (IFN)alpha down-regulates DNp73 expression in primary human hepatocytes (PHHs) and HCC cell lines. IFN alpha has been used as pro-apoptotic agent in the treatment of malignancies and there is increasing evidence of IFN alpha effectiveness in HCC treatment and prevention of recurrence. The precise mechanisms by which class I IFNs exert their anti-proliferative and anti-tumor activity remain unclear. IFN alpha binding to its receptor activates multiple intracellular signaling cascades regulating the transcription of numerous direct target genes through the recruitment of a complex comprising of STAT1, STAT2 and IFN regulatory factor (IRF) 9 to their promoters. We found that, in response to IFN alpha, the P2p73 promoter undergoes substantial chromatin remodeling. Histone deacetylases (HDACs) replace histone acetyl transferases. STAT2 is recruited onto the endogenous P2p73 promoter together with the polycomb group protein Ezh2, leading to increased H3K27 methylation and transcriptional repression. The reduction of DNp73 levels by IFN alpha is paralleled by an increased susceptibility to IFN alpha-triggered apoptosis of Huh7 hepatoma cells. Our results show, for the first time, that IFN-stimulated gene factor 3 recruitment may serve both in activating and repressing gene expression and identify the down-regulation of DNp73 as an additional mechanism to counteract the chemoresistance of liver cancer cells. Oncogene (2011) 30, 2670-2678; doi:10.1038/onc.2010.635; published online 14 March 2011	[Testoni, B.; Schinzari, V.; Guerrieri, F.; Levrero, M.] Fdn A Cesalpino, Gene Express Lab, Rome, Italy; [Testoni, B.; Levrero, M.] Univ Roma La Sapienza, Dept Internal Med, Rome, Italy; [Testoni, B.; Blandino, G.; Levrero, M.] IRE, Rome Oncogen Ctr, Rome, Italy; [Schinzari, V.; Guerrieri, F.; Levrero, M.] LEA INSERM U785, Villejuif, France; [Gerbal-Chaloin, S.] INSERM U632, Inst Rech Biotherapie, Montpellier, France	Sapienza University Rome; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Testoni, B (corresponding author), Univ Roma La Sapienza, Gene Express Lab, Dipartimento Med Interna, Policlin Umberto I, Viale Policlin 155, I-00161 Rome, Italy.	barbara.testoni@uniroma1.it; massimo.levrero@uniroma1.it	GERBAL-CHALOIN, sabine/M-8783-2017; Guerrieri, Francesca/K-5504-2016; guerrieri, francesca/G-3908-2013; Levrero, Massimo/G-5680-2016; TESTONI, Barbara/F-3767-2017	GERBAL-CHALOIN, sabine/0000-0002-2549-7899; Guerrieri, Francesca/0000-0003-2751-6050; Levrero, Massimo/0000-0002-4978-0875; TESTONI, Barbara/0000-0001-5588-5465; Guerrieri, Francesca/0000-0002-2021-4394	AIRC; European Community [LSHC-CT-2004-503576]; MIUR-Cofin and Progetti di Ateneo; Sapienza University of Rome; Schering-Plough; AICF (American Italian Cancer Foundation); Fondazione Adriano Buzzati-Traverso; Fondazione A Cesalpino; Rome Oncogenomic Center at the Regina Elena Cancer Institute	AIRC(Fondazione AIRC per la ricerca sul cancro); European Community(European Commission); MIUR-Cofin and Progetti di Ateneo; Sapienza University of Rome; Schering-Plough(Merck & CompanySchering Plough Corporation); AICF (American Italian Cancer Foundation); Fondazione Adriano Buzzati-Traverso; Fondazione A Cesalpino; Rome Oncogenomic Center at the Regina Elena Cancer Institute	ML was supported by grants from AIRC, European Community (LSHC-CT-2004-503576), MIUR-Cofin and Progetti di Ateneo, Sapienza University of Rome and Schering-Plough. BT has been supported by fellowships from the AICF (American Italian Cancer Foundation) and from the Fondazione Adriano Buzzati-Traverso. FG has been supported by fellowships from the Fondazione A Cesalpino and Rome Oncogenomic Center at the Regina Elena Cancer Institute.	Belloni L, 2006, ONCOGENE, V25, P3606, DOI 10.1038/sj.onc.1209321; Breitenstein S, 2009, BRIT J SURG, V96, P975, DOI 10.1002/bjs.6731; Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904; Chattopadhyay D, 2007, CURR PHARM DESIGN, V13, P3292, DOI 10.2174/138161207782360717; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Craxi Antonio, 2005, Clin Liver Dis, V9, P329, DOI 10.1016/j.cld.2004.12.008; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Fattovich G, 2004, GASTROENTEROLOGY, V127, pS35, DOI 10.1053/j.gastro.2004.09.014; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; Fujioka N, 2006, BIOMED RES-TOKYO, V27, P219, DOI 10.2220/biomedres.27.219; Herzer K, 2009, CANCER RES, V69, P855, DOI 10.1158/0008-5472.CAN-08-2831; Ji JF, 2009, NEW ENGL J MED, V361, P1437, DOI 10.1056/NEJMoa0901282; Keskinen P, 1999, VIROLOGY, V263, P364, DOI 10.1006/viro.1999.9983; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Levrero M, 2000, J CELL SCI, V113, P1661; Levrero M, 2006, ONCOGENE, V25, P3834, DOI 10.1038/sj.onc.1209562; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lim R, 2006, HEPATOLOGY, V43, P1074, DOI 10.1002/hep.21170; Lok AS, 2009, GASTROENTEROLOGY, V136, P138, DOI 10.1053/j.gastro.2008.09.014; Lunghi P, 2009, CLIN CANCER RES, V15, P6495, DOI 10.1158/1078-0432.CCR-09-1229; Margueron R, 2009, NATURE, V461, P762, DOI 10.1038/nature08398; Melen K, 2000, J HEPATOL, V33, P764, DOI 10.1016/S0168-8278(00)80308-6; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Miyake Y, 2010, J VIRAL HEPATITIS, V17, P287, DOI 10.1111/j.1365-2893.2009.01181.x; Montgomery ND, 2005, CURR BIOL, V15, P942, DOI 10.1016/j.cub.2005.04.051; Moradpour D, 2005, EUR J GASTROEN HEPAT, V17, P477, DOI 10.1097/00042737-200505000-00002; Muller M, 2005, CELL DEATH DIFFER, V12, P1564, DOI 10.1038/sj.cdd.4401774; Nakaji M, 2004, CARCINOGENESIS, V25, P389, DOI 10.1093/carcin/bgh028; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Noguchi R, 2008, INT J ONCOL, V32, P193; Obi S, 2006, CANCER-AM CANCER SOC, V106, P1990, DOI 10.1002/cncr.21832; Pestka S, 2004, IMMUNOL REV, V202, P8, DOI 10.1111/j.0105-2896.2004.00204.x; Pichard-Garcia L, 2002, METHOD ENZYMOL, V357, P311; Radaeva S, 2002, GASTROENTEROLOGY, V122, P1020, DOI 10.1053/gast.2002.32388; Shiratori Y, 2005, ANN INTERN MED, V142, P105, DOI 10.7326/0003-4819-142-2-200501180-00009; Steele JC, 2006, BRIT J CANCER, V95, P1202, DOI 10.1038/sj.bjc.6603369; Stiewe T, 2004, CLIN CANCER RES, V10, P626, DOI 10.1158/1078-0432.CCR-0153-03; Stiewe T, 2007, NAT REV CANCER, V7, P165, DOI 10.1038/nrc2072; Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531; TESTONI B, CHROMATIN DYNA UNPUB; Testoni B, 2006, CELL CYCLE, V5, P2805, DOI 10.4161/cc.5.23.3525; Uddin S, 2004, J BIOCHEM MOL BIOL, V37, P635; Uka K, 2008, ONCOLOGY-BASEL, V75, P8, DOI 10.1159/000151614; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Xu DW, 2000, BLOOD, V96, P4313, DOI 10.1182/blood.V96.13.4313.h8004313_4313_4318; Yonemitsu Y, 2009, HUM PATHOL, V40, P1304, DOI 10.1016/j.humpath.2009.01.017	48	20	22	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	23					2670	2678		10.1038/onc.2010.635	http://dx.doi.org/10.1038/onc.2010.635			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778CV	21399658	Green Published, hybrid			2022-12-17	WOS:000291677800007
J	Arun, SN; Kaddour-Djebbar, I; Shapiro, BA; Bollag, WB				Arun, S. N.; Kaddour-Djebbar, I.; Shapiro, B. A.; Bollag, W. B.			Ultraviolet B irradiation and activation of protein kinase D in primary mouse epidermal keratinocytes	ONCOGENE			English	Article						apoptosis; epidermis; protein kinase C; protein kinase D; skin; Src	NF-KAPPA-B; RADIATION-INDUCED APOPTOSIS; POTENTIATES DNA-SYNTHESIS; D-DEPENDENT ACTIVATION; G(Q)-COUPLED RECEPTORS; LOOP PHOSPHORYLATION; SKIN-CANCER; C-MU; PROLIFERATION; EXPRESSION	Our previous studies demonstrated that protein kinase D (PKD), a serine/threonine kinase implicated in various cell processes, is upregulated in basal cell carcinoma (BCC), supporting a possible tumorigenic role for PKD in skin. As the greatest risk factor for BCC is sun exposure, the ability of ultraviolet B (UVB) irradiation to activate PKD in primary mouse keratinocytes was investigated. Using western analysis with two autophosphorylation-specific antibodies, we show for the first time that UVB activated PKD in a time-and dose-dependent manner. UVB-induced PKD activation was verified using an in vitro kinase assay. Furthermore, activation was reduced by antioxidant pretreatment, suggesting a link with oxidative stress. UVB-induced PKD activation was mediated primarily by Src family tyrosine kinases rather than protein kinase C (PKC), and in fact, UVB did not alter PKC-mediated transphosphorylation. UVB induced apoptosis dose dependently, and this death could be prevented by overexpression of wild-type PKD, but not mutant PKD or the empty adenovirus. Indeed, a mutant that cannot be phosphorylated by Src kinases exacerbated UVB-elicited apoptosis. Thus, our data indicate that UVB irradiation of keratinocytes induces Src-mediated activation of PKD, which protects cells from UVB-stimulated apoptosis, providing a possible explanation for the observed upregulation of PKD in BCC. Oncogene (2011) 30, 1586-1596; doi: 10.1038/onc.2010.540; published online 6 December 2010	[Bollag, W. B.] Med Coll Georgia, Dept Physiol, Augusta, GA 30912 USA; [Arun, S. N.; Shapiro, B. A.; Bollag, W. B.] Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA; [Kaddour-Djebbar, I.; Bollag, W. B.] Charlie Norwood VA Med Ctr, Augusta, GA USA; [Bollag, W. B.] Med Coll Georgia, Dept Med, Augusta, GA 30912 USA; [Bollag, W. B.] Med Coll Georgia, Dept Dermatol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University System of Georgia; Augusta University; University System of Georgia; Augusta University	Bollag, WB (corresponding author), Med Coll Georgia, Dept Physiol, 1120 15th St, Augusta, GA 30912 USA.	wbollag@mcg.edu		Bollag, Wendy/0000-0003-3146-162X	Veterans' Administration; National Institutes of Health/National Institute of Arthritis, Musculoskeletal and Skin Diseases [AR45212, AR57321]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR057321, R01AR045212, R29AR045212] Funding Source: NIH RePORTER	Veterans' Administration(US Department of Veterans Affairs); National Institutes of Health/National Institute of Arthritis, Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This project was supported by a Merit Award from the Veterans' Administration and grants from the National Institutes of Health/National Institute of Arthritis, Musculoskeletal and Skin Diseases #AR45212 and AR57321 (WBB). We thank Dr Alex Toker for generously providing the various PKD constructs as well as for his useful discussions, and Dr Bert Vogelstein for his kind gift of the AdEasy adenovirus system. We appreciate the expert technical assistance of Mr Peter Parker and Ms Mariya Wilson. This work was submitted in partial fulfilment of the requirements for a doctoral degree from the Medical College of Georgia (SNA).	Assefa Z, 2005, BBA-REV CANCER, V1755, P90, DOI 10.1016/j.bbcan.2005.04.001; Assefa Z, 2003, FEBS LETT, V540, P125, DOI 10.1016/S0014-5793(03)00238-2; Bollag WB, 2004, DRUG NEWS PERSPECT, V17, P117, DOI 10.1358/dnp.2004.17.2.829045; Brash DE, 1996, NAT MED, V2, P525, DOI 10.1038/nm0596-525; Chen WX, 2001, ONCOGENE, V20, P3921, DOI 10.1038/sj.onc.1204530; Denning MF, 2002, CELL DEATH DIFFER, V9, P40, DOI 10.1038/sj.cdd.4400929; Dodd ME, 2005, J INVEST DERMATOL, V125, P294, DOI 10.1111/j.0022-202X.2005.23780.x; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Jacamo R, 2008, J BIOL CHEM, V283, P12877, DOI 10.1074/jbc.M800442200; Jadali A, 2010, J BIOL CHEM, V285, P23385, DOI 10.1074/jbc.M110.105619; Jung EM, 1999, CARCINOGENESIS, V20, P569, DOI 10.1093/carcin/20.4.569; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Marathe GK, 2005, J BIOL CHEM, V280, P35448, DOI 10.1074/jbc.M503811200; Matsumura M, 2003, BIOCHEM BIOPH RES CO, V303, P350, DOI 10.1016/S0006-291X(03)00345-0; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; Prigozhina NL, 2004, CURR BIOL, V14, P88, DOI 10.1016/j.cub.2004.01.003; Przybyszewski J, 1998, CARCINOGENESIS, V19, P1467, DOI 10.1093/carcin/19.8.1467; Reelfs O, 2004, J INVEST DERMATOL, V122, P1440, DOI 10.1111/j.0022-202X.2004.22620.x; Rennecke J, 1999, INT J CANCER, V80, P98, DOI 10.1002/(SICI)1097-0215(19990105)80:1<98::AID-IJC19>3.0.CO;2-D; Ristich VL, 2006, BRIT J DERMATOL, V154, P586, DOI 10.1111/j.1365-2133.2005.07073.x; Sinnett-Smith J, 2004, J BIOL CHEM, V279, P16883, DOI 10.1074/jbc.M313225200; Sinnett-Smith J, 2009, J BIOL CHEM, V284, P13434, DOI 10.1074/jbc.M806554200; Sitailo LA, 2002, J BIOL CHEM, V277, P19346, DOI 10.1074/jbc.M200401200; Song J, 2006, AM J PHYSIOL-CELL PH, V290, pC1469, DOI 10.1152/ajpcell.00486.2005; Storz P, 2004, MOL PHARMACOL, V66, P870, DOI 10.1124/mol.104.000687; Storz P, 2004, MOL CELL BIOL, V24, P2614, DOI 10.1128/MCB.24.7.2614-2626.2004; Storz P, 2003, J BIOL CHEM, V278, P17969, DOI 10.1074/jbc.M213224200; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Storz P, 2005, MOL CELL BIOL, V25, P8520, DOI 10.1128/MCB.25.19.8520-8530.2005; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Waldron RT, 2004, J BIOL CHEM, V279, P27482, DOI 10.1074/jbc.M402875200; Waldron RT, 1999, ELECTROPHORESIS, V20, P382, DOI 10.1002/(SICI)1522-2683(19990201)20:2<382::AID-ELPS382>3.0.CO;2-N; Yeaman C, 2004, NAT CELL BIOL, V6, P106, DOI 10.1038/ncb1090; Zhukova E, 2001, J BIOL CHEM, V276, P40298, DOI 10.1074/jbc.M106512200	41	20	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	13					1586	1596		10.1038/onc.2010.540	http://dx.doi.org/10.1038/onc.2010.540			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	743DU	21132013	Green Accepted			2022-12-17	WOS:000288998300009
J	Lees, JG; Bach, CTT; Bradbury, P; Paul, A; Gunning, PW; O'Neill, GM				Lees, J. G.; Bach, C. T. T.; Bradbury, P.; Paul, A.; Gunning, P. W.; O'Neill, G. M.			The actin-associating protein Tm5NM1 blocks mesenchymal motility without transition to amoeboid motility	ONCOGENE			English	Article						tropomyosin; amoeboid; mesenchymal; actin cytoskeleton; metastasis; adhesion	TUMOR-CELL INVASION; TROPOMYOSIN ISOFORM; CYTOSKELETON; MIGRATION; CANCER; SRC; PLASTICITY; ADHESIONS; DYNAMICS; PROMOTES	Cell migration is an integral component of metastatic disease. The ability of cells to transit between mesenchymal and amoeboid modes of migration has complicated the development of successful therapies designed to target cell migration as a means of inhibiting metastasis. Therefore, investigations of the mechanisms that regulate cell migration and render cells stationary are necessary. Tropomyosins are actin-associating proteins that regulate the activity of several effectors of actin filament dynamics. Previously, we have shown that the tropomyosin isoform Tm5NM1 stabilizes actin filaments and inhibits cell migration in a two-dimensional culture system. Here, we show that Tm5NM1 inhibits the mesenchymal migration of multiple cell lines in an isoform-specific manner. Tm5NM1 stimulates the downregulation of Src kinase activity and a rounded or elliptical morphology in three-dimensional collagen gels, and cells have dramatically reduced capacity to form pseudopodia. Importantly, we find that Tm5NM1 inhibits both the mesenchymal to amoeboid and amoeboid to mesenchymal transitions. Collectively, our data suggest that mimicking the action of Tm5NM1 overexpression represents an approach for effectively inhibiting the mesenchymal mode of migration. Oncogene (2011) 30, 1241-1251; doi:10.1038/onc.2010.516; published online 15 November 2010	[Lees, J. G.; Bach, C. T. T.; Bradbury, P.; Paul, A.; O'Neill, G. M.] Childrens Hosp, Childrens Canc Res Unit, Kids Res Inst, Westmead, NSW 2145, Australia; [Bach, C. T. T.; O'Neill, G. M.] Univ Sydney, Discipline Paediat & Child Hlth, Sydney, NSW 2006, Australia; [Gunning, P. W.] Univ New S Wales, Sch Med Sci, Dept Pharmacol, Sydney, NSW, Australia	University of Sydney; University of Sydney; University of New South Wales Sydney	O'Neill, GM (corresponding author), Childrens Hosp, Childrens Canc Res Unit, Kids Res Inst, Locked Bag 4001, Westmead, NSW 2145, Australia.	geraldio@chw.edu.au	Bradbury, Peta/A-4864-2017; Gunning, Peter W/E-9058-2010; O'Neill, Geraldine/F-3112-2014	Bradbury, Peta/0000-0001-6360-9591; Lees, Justin/0000-0002-0874-2856; O'Neill, Geraldine/0000-0001-9997-8794; Gunning, Peter/0000-0003-0833-3128	National Health and Medical Research Council (NHMRC) [512251]; Ramaciotti Establishment grant; NSW Cancer Institute; Oncology Children's Foundation	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Ramaciotti Establishment grant; NSW Cancer Institute; Oncology Children's Foundation	This study was supported by National Health and Medical Research Council (NHMRC) grant 512251 (GO and PG). PG is a Principal Research Fellow of the NHMRC, JL is the recipient of a Ramaciotti Establishment grant, CB is the recipient of an NHMRC post-graduate scholarship and a NSW Cancer Institute Scholar award, and AP holds an Oncology Children's Foundation-C4 fellowship. We thank Rose Boutros for critical review of the paper and also gratefully acknowledge the generous support of Kaise Stephan and Channel Crossing for Life.	Bach CTT, 2009, MOL CELL BIOL, V29, P1506, DOI 10.1128/MCB.00857-08; Bargon SD, 2005, BBA-MOL CELL RES, V1746, P143, DOI 10.1016/j.bbamcr.2005.10.008; Blanchoin L, 2001, CURR BIOL, V11, P1300, DOI 10.1016/S0960-9822(01)00395-5; Bryce NS, 2003, MOL BIOL CELL, V14, P1002, DOI 10.1091/mbc.E02-04-0244; Carragher NO, 2006, ONCOGENE, V25, P5726, DOI 10.1038/sj.onc.1209582; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Creed SJ, 2008, EUR J CELL BIOL, V87, P709, DOI 10.1016/j.ejcb.2008.03.004; DesMarais V, 2002, J CELL SCI, V115, P4649, DOI 10.1242/jcs.00147; Drappatz J, 2009, EXPERT REV NEUROTHER, V9, P519, DOI [10.1586/ern.09.10, 10.1586/ERN.09.10]; Eichinger L, 1999, MICROSC RES TECHNIQ, V47, P124, DOI 10.1002/(SICI)1097-0029(19991015)47:2<124::AID-JEMT5>3.0.CO;2-8; Fath T, 2010, EUR J CELL BIOL, V89, P489, DOI 10.1016/j.ejcb.2009.11.028; Fidler IJ, 2002, SEMIN CANCER BIOL, V12, P89, DOI 10.1006/scbi.2001.0416; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Friedl P, 2004, CURR OPIN CELL BIOL, V16, P14, DOI 10.1016/j.ceb.2003.11.001; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Friedl P, 2010, J CELL BIOL, V188, P11, DOI 10.1083/jcb.200909003; Gunning P, 2008, PHYSIOL REV, V88, P1, DOI 10.1152/physrev.00001.2007; Gunning PW, 2005, TRENDS CELL BIOL, V15, P333, DOI 10.1016/j.tcb.2005.04.007; Gupton SL, 2005, J CELL BIOL, V168, P619, DOI 10.1083/jcb.200406063; Hillberg L, 2006, EUR J CELL BIOL, V85, P399, DOI 10.1016/j.ejcb.2005.12.005; ISHIKAWA R, 1989, J BIOL CHEM, V264, P7490; KITZING TM, 2010, ONCOGENE, V1, P1; Kruger A, 2001, CANCER RES, V61, P1272; O'Neill GM, 2009, CELL ADHES MIGR, V3, P355, DOI 10.4161/cam.3.4.9468; Percival JM, 2004, MOL BIOL CELL, V15, P268, DOI 10.1091/mbc.e03-03-0176; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; Riedl J, 2008, NAT METHODS, V5, P605, DOI 10.1038/nmeth.1220; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sahai E, 2007, NAT REV CANCER, V7, P737, DOI 10.1038/nrc2229; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Schevzov G, 2005, J HISTOCHEM CYTOCHEM, V53, P557, DOI 10.1369/jhc.4A6505.2005; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Wyckoff JB, 2006, CURR BIOL, V16, P1515, DOI 10.1016/j.cub.2006.05.065; Yamazaki D, 2009, ONCOGENE, V28, P1570, DOI 10.1038/onc.2009.2; Zheng Q, 2008, INT J CANCER, V122, P78, DOI 10.1002/ijc.23025	36	20	20	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	10					1241	1251		10.1038/onc.2010.516	http://dx.doi.org/10.1038/onc.2010.516			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732QD	21076470				2022-12-17	WOS:000288202400010
J	Iglesias-Ara, A; Zenarruzabeitia, O; Fernandez-Rueda, J; Sanchez-Tillo, E; Field, SJ; Celada, A; Zubiaga, AM				Iglesias-Ara, A.; Zenarruzabeitia, O.; Fernandez-Rueda, J.; Sanchez-Tillo, E.; Field, S. J.; Celada, A.; Zubiaga, A. M.			Accelerated DNA replication in E2F1-and E2F2-deficient macrophages leads to induction of the DNA damage response and p21(CIP1)-dependent senescence	ONCOGENE			English	Article						E2F; macrophage; DNA damage response; senescence; DNA hyper-replication	ONCOGENE-INDUCED SENESCENCE; T-CELL PROLIFERATION; CYCLIN-E; PROGENITOR CELLS; E2F2; EXPRESSION; TRANSCRIPTION; SUPPRESSION; MATURATION; P53	E2F1-3 proteins appear to have distinct roles in progenitor cells and in differentiating cells undergoing cell cycle exit. However, the function of these proteins in paradigms of terminal differentiation that involve continued cell division has not been examined. Using compound E2F1/E2F2-deficient mice, we have examined the effects of E2F1 and E2F2 loss on the differentiation and simultaneous proliferation of bone-marrow-derived cells toward the macrophage lineage. We show that E2F1/E2F2 deficiency results in accelerated DNA replication and cellular division during the initial cell division cycles of bone-marrow-derived cells, arguing that E2F1/E2F2 are required to restrain proliferation of pro-monocyte progenitors during their differentiation into macrophages, without promoting their cell cycle exit. Accelerated proliferation is accompanied by early expression of DNA replication and cell cycle regulators. Remarkably, rapid proliferation of E2F1/E2F2 compound mutant cultures is temporally followed by induction of a DNA damage response and the implementation of a p21(CIP1)-dependent senescence. We further show that differentiating E2F1/E2F2-knockout macrophages do not trigger a DNA damage response pathway in the absence of DNA replication. These findings underscore the relevance of E2F1 and E2F2 as suppressors of hematopoietic progenitor expansion. Our data indicate that their absence in differentiating macrophages initiates a senescence program that results from enforcement of a DNA damage response triggered by DNA hyper-replication. Oncogene (2010) 29, 5579-5590; doi:10.1038/onc.2010.296; published online 2 August 2010	[Iglesias-Ara, A.; Zenarruzabeitia, O.; Fernandez-Rueda, J.; Zubiaga, A. M.] Univ Basque Country, Dept Genet Phys Anthropol & Anim Physiol, Bilbao 64448080, Spain; [Sanchez-Tillo, E.; Celada, A.] Inst Res Biomed IRB Barcelona, Macrophage Biol Grp, Barcelona, Spain; [Sanchez-Tillo, E.; Celada, A.] Univ Barcelona, Barcelona, Spain; [Field, S. J.] Univ Calif San Diego, Div Endocrinol & Metab, La Jolla, CA 92093 USA	University of Basque Country; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona; University of California System; University of California San Diego	Zubiaga, AM (corresponding author), Univ Basque Country, Dept Genet Phys Anthropol & Anim Physiol, Bilbao 64448080, Spain.	ana.zubiaga@ehu.es	Iglesias, Ainhoa/AAB-8731-2022; Celada, Antonio/I-1714-2016; zubiaga, ana/S-3457-2019; Iglesias, Ainhoa/H-3021-2015; Zenarruzabeitia, Olatz/AAD-6772-2019	Iglesias, Ainhoa/0000-0002-2056-8213; zubiaga, ana/0000-0002-2132-9708; Iglesias, Ainhoa/0000-0002-2056-8213; Zenarruzabeitia, Olatz/0000-0002-0869-9034; Field, Seth/0000-0002-8893-4806; Celada, Antonio/0000-0003-3883-2171	Spanish Ministry of Science and Innovation [SAF2009-12037, CSD2007-00017]; Basque Government Department of Industry [Etortek-IE06-178]	Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Basque Government Department of Industry(Basque Government)	We thank members of the Zubiaga laboratory for helpful discussions, Naiara Zorrilla for technical support and Dimitri Balomenos for p21<SUP>CIP1</SUP> <SUP>/</SUP> mice. AI is a recipient of the University of the Basque Country postdoctoral fellowship. OZ and JF are recipients of Basque Government fellowships for graduate students. This work was supported by grants to AMZ from the Spanish Ministry of Science and Innovation (SAF2009-12037 and Consolider-Ingenio 2010 Programme, CSD2007-00017) and the Basque Government Department of Industry (Etortek-IE06-178).	Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Balomenos D, 2000, NAT MED, V6, P171, DOI 10.1038/72272; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; BRACKMAN D, 1995, J LEUKOCYTE BIOL, V58, P547, DOI 10.1002/jlb.58.5.547; Braun SE, 1998, BLOOD CELL MOL DIS, V24, P138, DOI 10.1006/bcmd.1998.0181; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Celada A, 1996, J EXP MED, V184, P61, DOI 10.1084/jem.184.1.61; Chen DN, 2009, NATURE, V462, P925, DOI 10.1038/nature08544; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chong JL, 2009, NATURE, V462, P930, DOI 10.1038/nature08677; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Davidson IF, 2006, MOL CELL, V24, P433, DOI 10.1016/j.molcel.2006.09.010; Denchi EL, 2005, MOL CELL BIOL, V25, P2660, DOI 10.1128/MCB.25.7.2660-2672.2005; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Dirlam A, 2007, MOL CELL BIOL, V27, P8713, DOI 10.1128/MCB.01118-07; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Herbig U, 2004, MOL CELL, V14, P501, DOI 10.1016/S1097-2765(04)00256-4; Hwang HC, 2005, ONCOGENE, V24, P2776, DOI 10.1038/sj.onc.1208613; Iglesias A, 2004, J CLIN INVEST, V113, P1398, DOI 10.1172/JCI200418879; Infante A, 2008, CELL CYCLE, V7, P3915, DOI 10.4161/cc.7.24.7379; Kinross KM, 2006, BLOOD, V108, P886, DOI 10.1182/blood-2005-09-008656; Li FX, 2003, MOL CELL BIOL, V23, P3607, DOI 10.1128/MCB.23.10.3607-3622.2003; Liu Q, 1999, MOL CELL BIOL, V19, P6229; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Morris EJ, 2008, NATURE, V455, P552, DOI 10.1038/nature07310; Murga M, 2001, IMMUNITY, V15, P959, DOI 10.1016/S1074-7613(01)00254-0; Olsen CL, 2002, ONCOGENE, V21, P6328, DOI 10.1038/sj.onc.1205780; Paulson QX, 2008, ONCOGENE, V27, P4954, DOI 10.1038/onc.2008.138; Pusapati RV, 2010, MOL CARCINOGEN, V49, P152, DOI 10.1002/mc.20584; Scheijen B, 2004, J BIOL CHEM, V279, P10476, DOI 10.1074/jbc.M313682200; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Timmers C, 2007, MOL CELL BIOL, V27, P65, DOI 10.1128/MCB.02147-06; Wang ZM, 1998, P NATL ACAD SCI USA, V95, P15583, DOI 10.1073/pnas.95.26.15583; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Xaus J, 1999, IMMUNITY, V11, P103, DOI 10.1016/S1074-7613(00)80085-0; Young AP, 2003, ONCOGENE, V22, P7209, DOI 10.1038/sj.onc.1206804; Zhu JW, 2001, MOL CELL BIOL, V21, P8547, DOI 10.1128/MCB.21.24.8547-8564.2001	41	20	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	41					5579	5590		10.1038/onc.2010.296	http://dx.doi.org/10.1038/onc.2010.296			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FX	20676136				2022-12-17	WOS:000282946900005
J	Zauner, L; Melroe, GT; Sigrist, JA; Rechsteiner, MP; Dorner, M; Arnold, M; Berger, C; Bernasconi, M; Schaefer, BW; Speck, RF; Nadal, D				Zauner, L.; Melroe, G. T.; Sigrist, J. A.; Rechsteiner, M. P.; Dorner, M.; Arnold, M.; Berger, C.; Bernasconi, M.; Schaefer, B. W.; Speck, R. F.; Nadal, D.			TLR9 triggering in Burkitt's lymphoma cell lines suppresses the EBV BZLF1 transcription via histone modification	ONCOGENE			English	Article						TLR9; Burkitt's lymphoma; Epstein-Barr virus; Plasmodium falciparum; histone modification	EPSTEIN-BARR-VIRUS; TOLL-LIKE RECEPTOR-9; NF-KAPPA-B; IMMUNE ACTIVATION; LYTIC CYCLE; CPG DNA; INDUCTION; INFECTION; LATENT; REPLICATION	Endemic Burkitt's lymphoma (BL) is considered to preferentially develop in equatorial Africa because of chronic co-infection with Epstein-Barr virus (EBV) and the malaria pathogen Plasmodium falciparum. The interaction and contribution of both pathogens in the oncogenic process are poorly understood. Earlier, we showed that immune activation with a synthetic Toll-like receptor 9 (TLR9) ligand suppresses the initiation of EBV lytic replication in primary human B cells. In this study we investigate the mechanism involved in the suppression of EBV lytic gene expression in BL cell lines. We show that this suppression is dependent on functional TLR9 and MyD88 signaling but independent of downstream signaling elements, including phosphatidylinositol-3 kinase, mitogen-activated protein kinases and nuclear factor-kappa B. We identified TLR9 triggering resulting in histone modifications to negatively affect the activation of the promoter of EBV's master regulatory lytic gene BZLF1. Finally, we show that P. falciparum hemozoin, a natural TLR9 ligand, suppresses induction of EBV lytic gene expression in a dose-dependent manner. Thus, we provide evidence for a possible interaction between P. falciparum and EBV at the B-cell level and the mechanism involved in suppressing lytic and thereby reinforcing latent EBV that has unique oncogenic potential. Oncogene (2010) 29, 4588-4598; doi: 10.1038/onc.2010.203; published online 31 May 2010	[Zauner, L.; Melroe, G. T.; Sigrist, J. A.; Rechsteiner, M. P.; Dorner, M.; Arnold, M.; Berger, C.; Bernasconi, M.; Nadal, D.] Univ Zurich, Univ Childrens Hosp Zurich, Div Infect Dis & Hosp Epidemiol, Lab Expt Infect Dis & Canc Res, Zurich, Switzerland; [Schaefer, B. W.] Univ Zurich, Univ Childrens Hosp Zurich, Div Oncol, Zurich, Switzerland; [Speck, R. F.] Univ Zurich, Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland	University Children's Hospital Zurich; University of Zurich; University Children's Hospital Zurich; University of Zurich; University of Zurich; University Zurich Hospital	Nadal, D (corresponding author), Univ Childrens Hosp, Div Infect Dis & Hosp Epidemiol, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	david.nadal@kispi.uzh.ch	Bernasconi, Michele/GOH-1815-2022; Bernasconi, Michele/CAG-2492-2022; Bernasconi, Michele/C-6734-2008; Dorner, Marcus/B-1398-2010; Speck, Roberto F/O-2433-2016	Bernasconi, Michele/0000-0002-5746-8806; Bernasconi, Michele/0000-0002-5746-8806; Bernasconi, Michele/0000-0002-5746-8806; Schafer, Beat/0000-0001-5988-2915; Speck, Roberto/0000-0002-8453-1137; Dorner, Marcus/0000-0003-0321-4226	Cancer League of the Canton Zurich; Swiss National Foundation [310040-114118]; Oncosuisse; Forschungskredit of the University of Zurich [54192002]	Cancer League of the Canton Zurich; Swiss National Foundation(Swiss National Science Foundation (SNSF)); Oncosuisse; Forschungskredit of the University of Zurich	We thank Jurg Tschopp, Hans-Peter Beck and Sebastian Rusch for providing reagents. This work was supported by grants from the Cancer League of the Canton Zurich, the Swiss National Foundation (no. 310040-114118), Oncosuisse, the Forschungskredit of the University of Zurich (no. 54192002) and UBS donation by a client.	Alazard N, 2003, J VIROL, V77, P8166, DOI 10.1128/JVI.77.14.8166-8172.2003; Ashman RF, 2005, INT IMMUNOL, V17, P411, DOI 10.1093/intimm/dxh222; Berger C, 2001, J MED VIROL, V64, P505, DOI 10.1002/jmv.1078; Brown HJ, 2003, J VIROL, V77, P8532, DOI 10.1128/JVI.77.15.8532-8540.2003; Chene A, 2007, PLOS PATHOG, V3, P826, DOI 10.1371/journal.ppat.0030080; Coban C, 2005, J EXP MED, V201, P19, DOI 10.1084/jem.20041836; Coban C, 2010, CELL HOST MICROBE, V7, P50, DOI 10.1016/j.chom.2009.12.003; Cohen JI, 2000, NEW ENGL J MED, V343, P481, DOI 10.1056/NEJM200008173430707; Countryman JK, 2008, J VIROL, V82, P4706, DOI 10.1128/JVI.00116-08; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; DIRENZO L, 1994, INT J CANCER, V57, P914, DOI 10.1002/ijc.2910570623; Duramad O, 2005, J IMMUNOL, V174, P5193, DOI 10.4049/jimmunol.174.9.5193; FLEMINGTON EK, 1991, J VIROL, V65, P7073, DOI 10.1128/JVI.65.12.7073-7077.1991; Foster SL, 2007, NATURE, V447, P972, DOI 10.1038/nature05836; Heeg K, 2008, INT J MED MICROBIOL, V298, P33, DOI 10.1016/j.ijmm.2007.07.007; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Ishii KJ, 2008, CELL HOST MICROBE, V3, P352, DOI 10.1016/j.chom.2008.05.003; Iwakiri D, 2004, J IMMUNOL, V172, P1561, DOI 10.4049/jimmunol.172.3.1561; Jenkins PJ, 2000, J VIROL, V74, P710, DOI 10.1128/JVI.74.2.710-720.2000; Klein E, 2007, ONCOGENE, V26, P1297, DOI 10.1038/sj.onc.1210240; Krishnegowda G, 2005, J BIOL CHEM, V280, P8606, DOI 10.1074/jbc.M413541200; Kumagai Y, 2008, ADV DRUG DELIVER REV, V60, P795, DOI 10.1016/j.addr.2007.12.004; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; Ladell K, 2007, CELL MICROBIOL, V9, P2055, DOI 10.1111/j.1462-5822.2007.00937.x; LUKA J, 1979, VIROLOGY, V94, P228, DOI 10.1016/0042-6822(79)90455-0; NOVAK EJ, 1994, CYTOMETRY, V17, P135, DOI 10.1002/cyto.990170205; Parroche P, 2007, P NATL ACAD SCI USA, V104, P1919, DOI 10.1073/pnas.0608745104; Peng SL, 2005, CURR OPIN IMMUNOL, V17, P230, DOI 10.1016/j.coi.2005.03.003; Rechsteiner MP, 2008, J VIROL, V82, P1739, DOI 10.1128/JVI.01723-07; Rechsteiner MP, 2007, J GEN VIROL, V88, P1454, DOI 10.1099/vir.0.82790-0; Rickinson A, 2007, FIELDS VIROLOGY; Rochford R, 2005, NAT REV MICROBIOL, V3, P182, DOI 10.1038/nrmicro1089; Ryan JL, 2004, DIAGN MOL PATHOL, V13, P61, DOI 10.1097/00019606-200406000-00001; Sanjuan MA, 2006, J CELL BIOL, V172, P1057, DOI 10.1083/jcb.200508058; TAKADA K, 1984, INT J CANCER, V33, P27, DOI 10.1002/ijc.2910330106; Takeshita F, 2004, SEMIN IMMUNOL, V16, P17, DOI 10.1016/j.smim.2003.10.009; TOVEY MG, 1978, NATURE, V276, P270, DOI 10.1038/276270a0; Tsurumi T, 2005, REV MED VIROL, V15, P3, DOI 10.1002/rmv.441; Yi AK, 1999, INT IMMUNOL, V11, P2015, DOI 10.1093/intimm/11.12.2015; Yuan J, 2006, J VIROL, V80, P2548, DOI 10.1128/JVI.80.5.2548-2565.2006; ZURHAUSEN H, 1978, NATURE, V272, P373	41	20	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2010	29	32					4588	4598		10.1038/onc.2010.203	http://dx.doi.org/10.1038/onc.2010.203			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	638AQ	20514021				2022-12-17	WOS:000280862300009
J	Hecker, RM; Amstutz, RA; Wachtel, M; Walter, D; Niggli, FK; Schafer, BW				Hecker, R. M.; Amstutz, R. A.; Wachtel, M.; Walter, D.; Niggli, F. K.; Schaefer, B. W.			p21 Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment	ONCOGENE			English	Article						rhabdomyosarcoma; PAX3/FKHR; p21; combination treatment	HISTONE DEACETYLASE INHIBITOR; RHABDOMYOSARCOMA STUDY-GROUP; HUMAN COLON-CANCER; INTERGROUP RHABDOMYOSARCOMA; P21(WAF1/CIP1) EXPRESSION; TRANSCRIPTION FACTOR; CELL-LINES; GROWTH; ADOLESCENTS; EXPERIENCE	A number of drugs developed against cancer-specific molecular targets have been shown to offer survival benefits alone or in combination with standard treatments, especially for those cases in which tumor pathogenesis is dominated by a single molecular abnormality. One example for such a tumor type is alveolar rhabdomyosarcoma (aRMS), which is characterized by a specific translocation creating the oncogenic PAX3/FKHR transcription factor, believed to be the molecular basis of the disease. Recently, we were able to show that the small molecule inhibitor PKC412 (midostaurin) shows strong antitumor activity against aRMS by reducing the transcriptional activity of PAX3/FKHR. In this study, we screened for combination strategies that are superior to PKC412-only treatment and found that the combination of PKC412 with histone deacetylase inhibitors like valproic acid (VPA) synergistically induced apoptosis resulting in suppressed aRMS tumor growth in vivo. We provide evidence that the antitumor effect on combination treatment is achieved by VPA-induced reactivation of p21, which is downregulated in aRMS cells by destabilization of the transcriptional regulator EGR1 by PAX3/FKHR. Our study highlights a possible mechanism behind the increased efficacy and indicates that different arms of PAX3/FKHR oncogenicity can be exploited therapeutically by the specific combination of drugs to increase their therapeutic potential. Oncogene (2010) 29, 3942-3952; doi:10.1038/onc.2010.145; published online 10 May 2010	[Hecker, R. M.; Amstutz, R. A.; Wachtel, M.; Walter, D.; Niggli, F. K.; Schaefer, B. W.] Univ Childrens Hosp, Dept Oncol, CH-8032 Zurich, Switzerland	University Children's Hospital Zurich	Schaefer, BW (corresponding author), Univ Childrens Hosp, Dept Oncol, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	beat.schaefer@kispi.uzh.ch	Niggli, Felix/L-6547-2017	Niggli, Felix/0000-0002-7553-3712; Wachtel, Marco/0000-0002-6077-3692; Schafer, Beat/0000-0001-5988-2915	Swiss National Science Foundation (SNF) [3100-109837, 3100-122562]	Swiss National Science Foundation (SNF)(Swiss National Science Foundation (SNSF))	We thank professor Soon Young Shin for providing constructs encoding EGR1 and p21 luciferase reporter plasmid, Silvia Behnke for her help with the stainings of tumor sections and Sarah Steinbacher for her graphical support in designing Figure 6. This work was supported by grants (3100-109837 and 3100-122562) from the Swiss National Science Foundation (SNF).	Amstutz R, 2008, CANCER RES, V68, P3767, DOI 10.1158/0008-5472.CAN-07-2447; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Bali P, 2004, CLIN CANCER RES, V10, P4991, DOI 10.1158/1078-0432.CCR-04-0210; Barlow JW, 2006, PEDIATR BLOOD CANCER, V47, P773, DOI 10.1002/pbc.20650; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Breneman JC, 2003, J CLIN ONCOL, V21, P78, DOI 10.1200/JCO.2003.06.129; Cao L, 2008, CANCER RES, V68, P8039, DOI 10.1158/0008-5472.CAN-08-1712; Choi BH, 2008, CANCER RES, V68, P1369, DOI 10.1158/0008-5472.CAN-07-5222; Della Ragione F, 2003, J BIOL CHEM, V278, P23360, DOI 10.1074/jbc.M300771200; Ebauer M, 2007, ONCOGENE, V26, P7267, DOI 10.1038/sj.onc.1210525; Furukawa Y, 2007, LEUKEMIA, V21, P1005, DOI 10.1038/sj.leu.2404593; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Genini M, 1996, INT J CANCER, V66, P571; Kikuchi K, 2008, BIOCHEM BIOPH RES CO, V365, P568, DOI 10.1016/j.bbrc.2007.11.017; Kim DH, 2007, NAT REV GENET, V8, P173, DOI 10.1038/nrg2006; Kim JS, 2001, BIOCHEM BIOPH RES CO, V281, P866, DOI 10.1006/bbrc.2001.4434; Kolb EA, 2008, PEDIATR BLOOD CANCER, V50, P1190, DOI 10.1002/pbc.21450; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Meyer WH, 2004, CANCER TREAT REV, V30, P269, DOI 10.1016/j.ctrv.2003.11.001; Mottet D, 2009, ONCOGENE, V28, P243, DOI 10.1038/onc.2008.371; Pappo AS, 1999, J CLIN ONCOL, V17, P3487, DOI 10.1200/JCO.1999.17.11.3487; Raney RB, 2001, J PEDIAT HEMATOL ONC, V23, P215, DOI 10.1097/00043426-200105000-00008; Roeb W, 2008, CELL CYCLE, V7, P837, DOI 10.4161/cc.7.7.5652; Roeb W, 2007, P NATL ACAD SCI USA, V104, P18085, DOI 10.1073/pnas.0708910104; Smith LM, 2001, J CLIN ONCOL, V19, P4058, DOI 10.1200/JCO.2001.19.20.4058; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200	28	20	21	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2010	29	27					3942	3952		10.1038/onc.2010.145	http://dx.doi.org/10.1038/onc.2010.145			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	621SL	20453878	Green Accepted			2022-12-17	WOS:000279603200007
J	Kuo, WC; Yang, KT; Hsieh, SL; Lai, MZ				Kuo, W-C; Yang, K-T; Hsieh, S-L; Lai, M-Z			Ezrin is a negative regulator of death receptor-induced apoptosis	ONCOGENE			English	Article						Fas; ezrin; apoptosis; moesin; DISC	ERM PROTEINS; IMMUNOLOGICAL SYNAPSE; ACTIN CYTOSKELETON; T-LYMPHOCYTES; CD95; FAS; MOESIN; PHOSPHORYLATION; ACTIVATION; CELLS	Ezrin links cortical actin filaments with the cell membrane, and has a critical role in many membrane-initiated events. Fas is directly associated with ezrin, but conflicting results have been reported for the involvement of ezrin in Fas-induced cell death. In this study we show that ezrin was associated with Fas in T cells before stimulation and was released shortly after Fas ligand (FasL) engagement. The knockdown of ezrin moderately increased Fas-triggered or tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-triggered cell death in normal T lymphocytes and in H9 cells, but had no effect on death receptor-induced apoptosis in type II cells, such as Jurkat and CEM. Expression of a dominant-negative form of ezrin also led to an increased Fas-induced apoptosis in H9 cells. Ezrin deficiency did not affect the internalization of Fas after Fas ligation. Instead, an enhanced formation of death-inducing signaling complex (DISC) was observed in H9 cells with ezrin knockdown, leading to accelerated caspase-8 activation. Together, our results suggest that ezrin has a negative role in the recruitment of Fas into signaling complexes in type I T cells. Loss of ezrin likely removes the constraint imposed by ezrin and facilitates the assembly of death receptor complex in T cells. Oncogene (2010) 29, 1374-1383; doi:10.1038/onc.2009.417; published online 23 November 2009	[Kuo, W-C; Yang, K-T; Lai, M-Z] Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan; [Kuo, W-C; Hsieh, S-L; Lai, M-Z] Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 112, Taiwan; [Hsieh, S-L] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Lai, M-Z] Natl Taiwan Univ, Inst Immunol, Taipei 10764, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; National Taiwan University	Lai, MZ (corresponding author), Acad Sinica, Inst Mol Biol, 128 Acad Rd,Sect 2, Taipei 11529, Taiwan.	mblai@ccvax.sinica.edu.tw	Hsieh, Shie-Liang Edmond/ABA-9184-2021; Lai, Ming-Zong/AAA-4408-2021	Lai, Ming-Zong/0000-0002-3237-4803	National Health Research Institute [NHRI-EX96-9527NI]; National Science Council [NSC 95-2320-B001-023]; Academia Sinica, Taiwan, ROC.	National Health Research Institute(National Health Research Institutes - Taiwan); National Science Council(Ministry of Science and Technology, Taiwan); Academia Sinica, Taiwan, ROC.(Academia Sinica - Taiwan)	This work was supported by Grant NHRI-EX96-9527NI from National Health Research Institute, NSC 95-2320-B001-023 from National Science Council and an Academia Sinica Investigator Award from Academia Sinica, Taiwan, ROC. We thank Drs I-Chen Ho, Gina Costa and Garry Nolan for critical reagents, Yamin Lin and FACS Core of Institute of Molecular Biology, Academia Sinica for cell sorting and Dr Harry Wilson for editing this paper.	Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Allenspach EJ, 2001, IMMUNITY, V15, P739, DOI 10.1016/S1074-7613(01)00224-2; Belkina NV, 2009, P NATL ACAD SCI USA, V106, P4707, DOI 10.1073/pnas.0805963106; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Brown MJ, 2003, BLOOD, V102, P3890, DOI 10.1182/blood-2002-12-3807; Chakrabandhu K, 2008, CELL DEATH DIFFER, V15, P1824, DOI 10.1038/cdd.2008.115; Chakrabandhu K, 2007, EMBO J, V26, P209, DOI 10.1038/sj.emboj.7601456; Delon J, 2001, IMMUNITY, V15, P691, DOI 10.1016/S1074-7613(01)00231-X; Faure S, 2004, NAT IMMUNOL, V5, P272, DOI 10.1038/ni1039; Feig C, 2007, EMBO J, V26, P221, DOI 10.1038/sj.emboj.7601460; Gautreau A, 2002, CURR OPIN CELL BIOL, V14, P104, DOI 10.1016/S0955-0674(01)00300-3; Gupta N, 2006, NAT IMMUNOL, V7, P625, DOI 10.1038/ni1337; Hao JJ, 2009, J CELL BIOL, V184, P451, DOI 10.1083/jcb.200807047; Hebert M, 2008, J IMMUNOL, V181, P5963, DOI 10.4049/jimmunol.181.9.5963; Ilani T, 2007, J CELL BIOL, V179, P733, DOI 10.1083/jcb.200707199; Kondo T, 1997, J CELL BIOL, V139, P749, DOI 10.1083/jcb.139.3.749; Kulms D, 2002, CELL DEATH DIFFER, V9, P598, DOI 10.1038/sj.cdd.4401002; Lee KH, 2006, EMBO J, V25, P1009, DOI 10.1038/sj.emboj.7601016; Li YS, 2007, J IMMUNOL, V178, P1938, DOI 10.4049/jimmunol.178.3.1938; Lozupone F, 2004, J BIOL CHEM, V279, P9199, DOI 10.1074/jbc.M305561200; Mrass P, 2008, IMMUNITY, V29, P971, DOI 10.1016/j.immuni.2008.10.015; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Niggli V, 2008, INT J BIOCHEM CELL B, V40, P344, DOI 10.1016/j.biocel.2007.02.012; Parlato S, 2000, EMBO J, V19, P5123, DOI 10.1093/emboj/19.19.5123; Peter ME, 2007, CELL, V129, P447, DOI 10.1016/j.cell.2007.04.031; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Piazzolla D, 2005, J CELL BIOL, V171, P1013, DOI 10.1083/jcb.200504137; Ramaswamy M, 2007, J IMMUNOL, V179, P6384, DOI 10.4049/jimmunol.179.10.6384; Roumier A, 2001, IMMUNITY, V15, P715, DOI 10.1016/S1074-7613(01)00225-4; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shaffer MH, 2009, J IMMUNOL, V182, P1021, DOI 10.4049/jimmunol.182.2.1021; Shcherbina A, 1999, FEBS LETT, V443, P31, DOI 10.1016/S0014-5793(98)01674-3; Strasser A, 2009, IMMUNITY, V30, P180, DOI 10.1016/j.immuni.2009.01.001	33	20	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2010	29	9					1374	1383		10.1038/onc.2009.417	http://dx.doi.org/10.1038/onc.2009.417			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	19935704				2022-12-17	WOS:000275170600012
J	Bongiorno-Borbone, L; De Cola, A; Barcaroli, D; Knight, RA; Di Ilio, C; Melino, G; De Laurenzi, V				Bongiorno-Borbone, L.; De Cola, A.; Barcaroli, D.; Knight, R. A.; Di Ilio, C.; Melino, G.; De Laurenzi, V.			FLASH degradation in response to UV-C results in histone locus bodies disruption and cell-cycle arrest	ONCOGENE			English	Article						histone locus bodies; Cajal bodies; UV; FLASH	S-PHASE PROGRESSION; DNA-DAMAGE; CAJAL BODIES; GENE-EXPRESSION; E/CDK2 SUBSTRATE; TRANSCRIPTION; P220(NPAT); CHECKPOINT; G(1); BODY	Eucaryotic cell nuclei contain a number of different organelles that are highly dynamic structures and respond to a variety of stimuli. Here we investigated the effect of UV irradiation on a recently identified group of organelles, Histone Locus Bodies. Histone Locus Bodies contain at least two main proteins, FLASH and NPAT, and have been shown to be involved in replication-dependent histone gene transcription. We show that these organelles are disrupted after sublethal irradiation and both FLASH and NPAT are degraded, which in turn results in cell-cycle arrest at the S/G2 transition. The effect on the cell cycle is due to reduced transcription of histone genes and restoring normal histone protein levels by stabilizing histone mRNA allows cells to progress through the cell cycle. This provides a novel mechanism of S-phase arrest in response to DNA damage that potentially allows DNA repair before cells continue into mitosis, and thus prevents transmission of genomic alterations. Oncogene (2010) 29, 802-810; doi:10.1038/onc.2009.388; published online 16 November 2009	[De Laurenzi, V.] Univ G DAnnunzio, Dipartimento Sci Biomed, CeSI, I-66100 Chieti, Italy; [Bongiorno-Borbone, L.; De Cola, A.; Barcaroli, D.; Melino, G.] Univ Roma Tor Vergata, Dept Expt Med, IDI IRCCS Biochem Lab, Rome, Italy; [Barcaroli, D.; Di Ilio, C.; De Laurenzi, V.] Fdn G DAnnunzio, Ctr Studi SullInvecchiamento, Chieti, Italy; [Knight, R. A.; Melino, G.] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England	G d'Annunzio University of Chieti-Pescara; University of Rome Tor Vergata; G d'Annunzio University of Chieti-Pescara; University of Leicester	De Laurenzi, V (corresponding author), Univ G DAnnunzio, Dipartimento Sci Biomed, CeSI, Via Colle Ara 1, I-66100 Chieti, Italy.	delaurenzi@unich.it	De Laurenzi, Vincenzo/K-7471-2016	De Laurenzi, Vincenzo/0000-0002-7506-1743; De Cola, Antonella/0000-0002-3202-5339	AIRC; MIUR; EU-EPISTEM; MinSan; Telethon and Alleanza Contro il Cancro; FIRC scholarship; MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: researchfish	AIRC(Fondazione AIRC per la ricerca sul cancro); MIUR(Ministry of Education, Universities and Research (MIUR)); EU-EPISTEM(European Commission); MinSan; Telethon and Alleanza Contro il Cancro(Fondazione Telethon); FIRC scholarship(Fondazione AIRC per la ricerca sul cancro); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Peter D Adams for the SLBP expression plasmid. The work was supported by grants from AIRC, MIUR to VDL, AIRC, EU-EPISTEM, FIRB, MIUR, MinSan, Telethon and Alleanza Contro il Cancro to GM. DB was supported by an FIRC scholarship.	Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Barcaroli D, 2006, P NATL ACAD SCI USA, V103, P14802, DOI 10.1073/pnas.0604225103; Barcaroli D, 2006, P NATL ACAD SCI USA, V103, P14808, DOI 10.1073/pnas.0604227103; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bongiorno-Borbone L, 2008, CELL CYCLE, V7, P2357, DOI 10.4161/cc.6344; Callegari AJ, 2007, CELL CYCLE, V6, P660, DOI 10.4161/cc.6.6.3984; Cioce M, 2006, J CELL BIOL, V175, P401, DOI 10.1083/jcb.200604099; Dellaire G, 2007, CELL CYCLE, V6, P1864, DOI 10.4161/cc.6.15.4560; Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44; Ghule PN, 2008, P NATL ACAD SCI USA, V105, P16964, DOI 10.1073/pnas.0809273105; Hall C, 2001, MOL CELL BIOL, V21, P1854, DOI 10.1128/MCB.21.5.1854-1865.2001; Liu JL, 2006, J CELL BIOL, V172, P875, DOI 10.1083/jcb.200511038; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; Marti TM, 2006, P NATL ACAD SCI USA, V103, P9891, DOI 10.1073/pnas.0603779103; Matera AG, 2006, J CELL BIOL, V172, P791, DOI 10.1083/jcb.200602002; Munarriz E, 2004, MOL CELL BIOL, V24, P10593, DOI 10.1128/MCB.24.24.10593-10610.2004; Nelson DM, 2002, MOL CELL BIOL, V22, P7459, DOI 10.1128/MCB.22.21.7459-7472.2002; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Su C, 2004, EMBO J, V23, P1133, DOI 10.1038/sj.emboj.7600120; Wang A, 2004, BIOCHEM BIOPH RES CO, V325, P1509, DOI 10.1016/j.bbrc.2004.10.198; Wei Y, 2003, MOL CELL BIOL, V23, P3669, DOI 10.1128/MCB.23.10.3669-3680.2003; Ye X, 2003, MOL CELL BIOL, V23, P8586, DOI 10.1128/MCB.23.23.8586-8600.2003; Ye XF, 2003, CELL CYCLE, V2, P185, DOI 10.4161/cc.2.3.389; Zhao JY, 2000, GENE DEV, V14, P2283, DOI 10.1101/gad.827700; Zhao JY, 2004, CELL CYCLE, V3, P695	26	20	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					802	810		10.1038/onc.2009.388	http://dx.doi.org/10.1038/onc.2009.388			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19915611				2022-12-17	WOS:000274397800003
J	Reed, CA; Mayhew, CN; McClendon, AK; Yang, X; Witkiewicz, A; Knudsen, ES				Reed, C. A.; Mayhew, C. N.; McClendon, A. K.; Yang, X.; Witkiewicz, A.; Knudsen, E. S.			RB has a critical role in mediating the in vivo checkpoint response, mitigating secondary DNA damage and suppressing liver tumorigenesis initiated by aflatoxin B1	ONCOGENE			English	Article						retinoblastoma tumor suppressor; aflatoxin B1; carbon tetrachloride; DNA damage; cell cycle; hepatocellular carcinoma	RETINOBLASTOMA TUMOR-SUPPRESSOR; CELL-CYCLE CONTROL; HEPATITIS-C; HEPATOCELLULAR CARCINOMAS; PROLIFERATION; GENES; PATHOGENESIS; PROTEINS; CANCER; 13Q	Hepatocellular carcinoma (HCC) is a significant worldwide health concern that is associated with discrete etiological events, encompassing viral infection, metabolic stress and genotoxic compounds. In particular, exposure to the genotoxic hepatocarcinogen aflatoxin B1 (AFB1) is a significant factor in the genesis of human liver cancer. Presumably, genetic events associated with HCC could influence the effect of environmental insults, yielding a predilection for tumor development. The retinoblastoma (RB) tumor suppressor pathway is functionally inactivated in HCC through discrete mechanisms; however, the role of RB in suppressing tumorigenesis in this disease is poorly understood. Therefore, we analysed how RB status affects the response to AFB1 in reference to acute exposures and tumor development reflective of chronic exposure. Liver-specific Rb deletion resulted in an aberrant proliferative response to AFB1. This cell-cycle induction was associated with increased levels of secondary genetic damage and failure in appropriate cell-cycle coupling. This effect of RB loss was unique to AFB1 and involved the induction of a non-canonical proliferative pathway, and was not merely reflective of the overall cell-cycle deregulation or aberrant regenerative responses. The acute responses to AFB1 exposure presaged aberrations in hepatocyte nuclear morphology and ploidy with RB loss. Correspondingly, RB-deficient livers showed significantly enhanced susceptibility to liver tumorigenesis initiated by AFB1. Combined, these studies show that RB has a critical role in mediating checkpoint responses in liver tissue to maintain genome integrity and in suppressing tumorigenesis. Oncogene (2009) 28, 4434-4443; doi:10.1038/onc.2009.303; published online 19 October 2009	[Knudsen, E. S.] Thomas Jefferson Univ, Dept Canc Biol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Mayhew, C. N.] Cincinnati Childrens Hosp, Res Fdn, Div Dev Biol, Cincinnati, OH USA; [Witkiewicz, A.] Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Jefferson University	Knudsen, ES (corresponding author), Thomas Jefferson Univ, Dept Canc Biol, Kimmel Canc Ctr, 233 S 10th St, Philadelphia, PA 19107 USA.	eknudsen@kimmelcancercenter.org	Mayhew, Christopher N/AGB-4929-2022		NCI NIH HHS [R01 CA127387-05, R01 CA127387] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA127387] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Azechi H, 2001, ONCOLOGY-BASEL, V60, P346, DOI 10.1159/000058531; Bioulac-Sage P, 2003, HEPATOLOGY, V37, P480, DOI 10.1053/jhep.2003.50058; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; DeGregori J, 2006, CURR MOL MED, V6, P739; Donehower LA, 1997, CANCER SURV, V29, P329; Edamoto Y, 2003, INT J CANCER, V106, P334, DOI 10.1002/ijc.11254; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; FUJIMOTO Y, 1994, CANCER RES, V54, P281; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Knudsen ES, 2006, CURR MOL MED, V6, P749; Knudsen ES, 2006, EXP BIOL MED, V231, P1271; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Laurent-Puig P, 2006, ONCOGENE, V25, P3778, DOI 10.1038/sj.onc.1209547; LAZAREVA MN, 1981, ONCODEV BIOL MED, V2, P89; Markey MP, 2007, ONCOGENE, V26, P6307, DOI 10.1038/sj.onc.1210450; Mayhew CN, 2007, GASTROENTEROLOGY, V133, P976, DOI 10.1053/j.gastro.2007.06.025; Mayhew CN, 2005, CANCER RES, V65, P4568, DOI 10.1158/0008-5472.CAN-04-4221; McGivern DR, 2009, ANNU REV PATHOL-MECH, V4, P399, DOI 10.1146/annurev.pathol.4.110807.092202; Munakata T, 2005, P NATL ACAD SCI USA, V102, P18159, DOI 10.1073/pnas.0505605102; Munakata T, 2007, PLOS PATHOG, V3, P1335, DOI 10.1371/journal.ppat.0030139; Skawran B, 2008, MODERN PATHOL, V21, P1479, DOI 10.1038/modpathol.2008.147; Stevens C, 2003, CELL CYCLE, V2, P435, DOI 10.4161/cc.2.5.462; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Wikenheiser-Brokamp KA, 2006, CELL MOL LIFE SCI, V63, P767, DOI 10.1007/s00018-005-5487-3; Yang XP, 2003, CANCER RES, V63, P7753; Yu MC, 2004, GASTROENTEROLOGY, V127, pS72, DOI 10.1016/j.gastro.2004.09.018; ZHANG X, 1994, CANCER RES, V54, P4177; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350	30	20	23	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	2009	28	50					4434	4443		10.1038/onc.2009.303	http://dx.doi.org/10.1038/onc.2009.303			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DU	19838213	Green Accepted			2022-12-17	WOS:000272876500003
J	Ong, DCT; Ho, YM; Rudduck, C; Chin, K; Kuo, WL; Lie, DKH; Chua, CLM; Tan, PH; Eu, KW; Seow-Choen, F; Wong, CY; Hong, GS; Gray, JW; Lee, ASG				Ong, D. C. T.; Ho, Y. M.; Rudduck, C.; Chin, K.; Kuo, W-L; Lie, D. K. H.; Chua, C. L. M.; Tan, P. H.; Eu, K. W.; Seow-Choen, F.; Wong, C. Y.; Hong, G. S.; Gray, J. W.; Lee, A. S. G.			LARG at chromosome 11q23 has functional characteristics of a tumor suppressor in human breast and colorectal cancer	ONCOGENE			English	Article						LARG; tumor suppressor; breast cancer; colorectal cancer	NUCLEOTIDE-EXCHANGE FACTORS; LEUKEMIA-ASSOCIATED RHOGEF; CELL LUNG-CANCER; PDZ DOMAINS; HETEROZYGOSITY; IDENTIFICATION; CARCINOMA; GENE; PROTEINS; DELETION	Deletion of 11q23-q24 is frequent in a diverse variety of malignancies, including breast and colorectal carcinoma, implicating the presence of a tumor suppressor gene at that chromosomal region. We examined a 6-Mb region on 11q23 by high-resolution deletion mapping, using both loss of heterozygosity analysis and customized microarray comparative genomic hybridization. LARG (leukemia-associated Rho guanine-nucleotide exchange factor) (also called ARHGEF12), identified from the analysed region, is frequently underexpressed in breast and colorectal carcinomas with a reduced expression observed in all breast cancer cell lines (n = 11), in 12 of 38 (32%) primary breast cancers, 5 of 10 (50%) colorectal cell lines and in 20 of 37 (54%) primary colorectal cancers. Underexpression of the LARG transcript was significantly associated with genomic loss (P = 0.00334). Hypermethylation of the LARG promoter was not detected in either breast or colorectal cancer, and treatment of four breast and four colorectal cancer cell lines with 5-aza-2'-deoxycytidine and/or trichostatin A did not result in a reactivation of LARG. Enforced expression of LARG in breast and colorectal cancer cells by stable transfection resulted in reduced cell proliferation and colony formation, as well as in a markedly slower cell migration rate in colorectal cancer cells, providing functional evidence for LARG as a candidate tumor suppressor gene. Oncogene (2009) 28, 4189-4200; doi: 10.1038/onc.2009.266; published online 7 September 2009	[Lee, A. S. G.] Natl Canc Ctr, Div Med Sci, Mol Oncol Lab, Singapore 169610, Singapore; [Rudduck, C.; Tan, P. H.] Singapore Gen Hosp, Dept Pathol, Singapore 0316, Singapore; [Chin, K.; Kuo, W-L; Gray, J. W.] Univ Calif San Francisco, UCSF Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Kuo, W-L; Gray, J. W.] Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; [Eu, K. W.; Seow-Choen, F.] Singapore Gen Hosp, Dept Colorectal Surg, Singapore 0316, Singapore; [Wong, C. Y.; Hong, G. S.] Singapore Gen Hosp, Dept Gen Surg, Singapore 0316, Singapore; [Lee, A. S. G.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol, Singapore 117595, Singapore	National Cancer Centre Singapore (NCCS); Singapore General Hospital; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Singapore General Hospital; Singapore General Hospital; National University of Singapore	Lee, ASG (corresponding author), Natl Canc Ctr, Div Med Sci, Mol Oncol Lab, Singapore 169610, Singapore.	dmslsg@nccs.com.sg	Gray, Joe/AAX-9549-2020		National Medical Research Council (NMRC) of Singapore [NMRC/0076/1995, NMRC/0440/2000, NMRC/0570/2001, NMRC/0843/2004]; SingHealth Foundation [SHF/FG235P/2005]; Singapore Cancer Society; SGH Research Fund; Cancer Research Education Fund; NCC and Department of Clinical Research, SGH; US Department of Energy [DE-AC02-05CH11231, USAMRMC BC 061995]; National Institutes of Health, National Cancer Institute [P50 CA 58207, P50 CA 83639, P30 CA 82103, U54 CA 112970, U24 CA 126477, P01 CA 64602]; National Human Genome Research Institute [U24 CA 126551]; SmithKline Beecham Corporation; NATIONAL CANCER INSTITUTE [U24CA126551, P50CA058207, U54CA112970, P30CA082103, U24CA126477, P01CA064602, P50CA083639] Funding Source: NIH RePORTER	National Medical Research Council (NMRC) of Singapore(National Medical Research Council, Singapore); SingHealth Foundation(SingHealth); Singapore Cancer Society; SGH Research Fund; Cancer Research Education Fund; NCC and Department of Clinical Research, SGH; US Department of Energy(United States Department of Energy (DOE)); National Institutes of Health, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); SmithKline Beecham Corporation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Glenn Koh for assistance with review of case notes; YC Seo, Angela Chang, S Tohari, Irene HK Lim and Gan Yar Chze for excellent technical assistance; and Dr Eric Yap for helpful discussions. This study was supported by Grants from the National Medical Research Council (NMRC) of Singapore (NMRC/0076/1995, NMRC/0440/2000, NMRC/0570/2001, NMRC/0843/2004); SingHealth Foundation (SHF/FG235P/2005); the Singapore Cancer Society, SGH Research Fund, Cancer Research Education Fund, NCC and Department of Clinical Research, SGH, to AL. We gratefully acknowledge the grant support from the US Department of Energy under Contract No. DE-AC02-05CH11231, USAMRMC BC 061995; National Institutes of Health, National Cancer Institute (P50 CA 58207, P50 CA 83639, P30 CA 82103, U54 CA 112970, U24 CA 126477 P01 CA 64602); National Human Genome Research Institute (U24 CA 126551) and SmithKline Beecham Corporation, to JWG.	Baffa R, 1996, CANCER RES, V56, P268; Bourguignon LYW, 2006, J BIOL CHEM, V281, P14026, DOI 10.1074/jbc.M507734200; Brooks CL, 2009, NAT REV CANCER, V9, P123, DOI 10.1038/nrc2562; Dotto GP, 2008, ONCOGENE, V27, P5115, DOI 10.1038/onc.2008.225; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Gabra H, 1996, CANCER RES, V56, P950; Harris BZ, 2001, J CELL SCI, V114, P3219; Hui ABY, 1996, CANCER RES, V56, P3225; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Koreth J, 1997, ONCOGENE, V14, P431, DOI 10.1038/sj.onc.1200847; Koreth J, 1999, ONCOGENE, V18, P1157, DOI 10.1038/sj.onc.1202372; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Lee ASG, 2000, BRIT J CANCER, V83, P750, DOI 10.1054/bjoc.2000.1366; Lee ASG, 2004, CANCER GENET CYTOGEN, V153, P151, DOI 10.1016/j.cancergencyto.2004.01.007; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Martin B., 2003, ELECT J E GOVT, V1, P11; Massion PP, 2002, CANCER RES, V62, P3636; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; NEGRINI M, 1994, CANCER RES, V54, P1331; NEGRINI M, 1995, CANCER RES, V55, P3003; Plass C, 2002, HUM MOL GENET, V11, P2479, DOI 10.1093/hmg/11.20.2479; Pulido HA, 2000, CANCER RES, V60, P6677; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; RASIO D, 1995, CANCER RES, V55, P3988; Rice KL, 2007, ONCOGENE, V26, P6697, DOI 10.1038/sj.onc.1210755; Robertson G, 1996, CANCER RES, V56, P4487; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Siderovski DP, 1999, CRIT REV BIOCHEM MOL, V34, P215, DOI 10.1080/10409239991209273; Smietana K, 2008, ACTA BIOCHIM POL, V55, P269, DOI 10.18388/abp.2008_3074; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Taya S, 2001, J CELL BIOL, V155, P809, DOI 10.1083/jcb.200106139; Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906; TOMLINSON IPM, 1995, J CLIN PATHOL, V48, P424, DOI 10.1136/jcp.48.5.424; Tomlinson IPM, 1996, J PATHOL, V180, P38, DOI 10.1002/(SICI)1096-9896(199609)180:1<38::AID-PATH638>3.0.CO;2-C; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Yamada T, 2005, J BIOL CHEM, V280, P19358, DOI 10.1074/jbc.M414561200; Young Il Lee, 2003, International Journal of Control, Automation, and Systems, V1, P178	42	20	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2009	28	47					4189	4200		10.1038/onc.2009.266	http://dx.doi.org/10.1038/onc.2009.266			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DQ	19734946	Green Accepted			2022-12-17	WOS:000272876100005
J	Balamurugan, K; Luu, VD; Kaufmann, MR; Hofmann, VS; Boysen, G; Barth, S; Bordoli, MR; Stiehl, DP; Moch, H; Schraml, P; Wenger, RH; Camenisch, G				Balamurugan, K.; Luu, V-D; Kaufmann, M. R.; Hofmann, V. S.; Boysen, G.; Barth, S.; Bordoli, M. R.; Stiehl, D. P.; Moch, H.; Schraml, P.; Wenger, R. H.; Camenisch, G.			Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response	ONCOGENE			English	Article						renal cell carcinoma; tumor immunity; paraneoplastic cerebellar degeneration; oxygen sensing	TRANSCRIPTIONAL ACTIVITY; SPONTANEOUS REGRESSION; TUMOR-IMMUNITY; HIF; HIF-1-ALPHA; ACTIVATION; PROTEIN; ALPHA; DOMAIN; HYDROXYLATION	The onconeuronal cerebellar degeneration-related antigen Cdr2 is associated with paraneoplastic syndromes. Neoplastic expression of Cdr2 in ovary and breast tumors triggers an autoimmune response that suppresses tumor growth by developing tumor immunity, but culminates in cerebellar degeneration when Cdr2-specific immune cells recognize neuronal Cdr2. We identified Cdr2 as a novel interactor of the hypoxia-inducible factor (HIF) prolyl-4-hydroxylase PHD1 and provide evidence that Cdr2 might represent a novel important tumor antigen in renal cancer. Strong Cdr2 protein expression was observed in 54.2% of papillary renal cell carcinoma (pRCC) compared with 7.8% of clear-cell RCC and no staining was observed in chromophobe RCC or oncocytoma. High Cdr2 protein levels correlated with attenuated HIF target gene expression in these solid tumors, and Cdr2 overexpression in tumor cell lines reduced HIF-dependent transcriptional regulation. This effect was because of both attenuation of hypoxic protein accumulation and suppression of the transactivation activity of HIF-1 alpha. pRCC is known for its tendency to avascularity, usually associated with a lower pathological stage and higher survival rates. We provide evidence that Cdr2 protein strongly accumulates in pRCC, attenuates the HIF response to tumor hypoxia and may become of diagnostic importance as novel renal tumor marker. Oncogene (2009) 28, 3274-3285; doi:10.1038/onc.2009.186; published online 6 July 2009	[Balamurugan, K.; Kaufmann, M. R.; Hofmann, V. S.; Barth, S.; Bordoli, M. R.; Stiehl, D. P.; Wenger, R. H.; Camenisch, G.] Univ Zurich UZH, Inst Physiol, Zurich, Switzerland; [Balamurugan, K.; Kaufmann, M. R.; Hofmann, V. S.; Barth, S.; Bordoli, M. R.; Stiehl, D. P.; Wenger, R. H.; Camenisch, G.] Univ Zurich UZH, Zurich Ctr Integrat Human Physiol ZIHP, Zurich, Switzerland; [Luu, V-D; Boysen, G.; Moch, H.; Schraml, P.] Univ Zurich Hosp, Dept Pathol, Inst Surg Pathol, CH-8091 Zurich, Switzerland	University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); University of Zurich; University Zurich Hospital	Camenisch, G (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	gieri.camenisch@access.uzh.ch	Stiehl, Daniel/A-3622-2008; Kuppusamy, Balamurugan/AAC-6020-2022; Wenger, Roland H./B-7953-2009	Wenger, Roland H./0000-0001-7592-4839; Bordoli, Mattia/0000-0001-6917-8753; Stiehl, Daniel/0000-0002-0076-4874; Boysen, Gunther/0000-0002-7610-6085	SNF [3100AO-116047/1]; Sassella Stiftung; Krebsliga des Kantons Zurich; UZH University Research Priority; European Commission EUROXY [LSHCCT-2003-502932, SBF03.0647-2]	SNF; Sassella Stiftung; Krebsliga des Kantons Zurich; UZH University Research Priority; European Commission EUROXY	We would like to thank R Fischer and C Ruber (ETH Zurich, Switzerland) for the generation of monoclonal anti-Cdr2 antibodies, DM Katschinski (Georg August University Gottingen, Germany) for providing the custom-made mouse testis cDNA library, J Nesper (University of Konstanz, Germany) and MO Hottiger (University of Zurich, Switzerland) for help with the yeast two-hybrid screenings, DJ Peet (University of Adelaide, Australia) and N Sang (Thomas Jefferson University, PA, USA) for gifts of plasmids, P Carmeliet and M Schneider (Katholieke Universiteit Leuven and Flanders Institute for Biotechnology, Belgium) for Phd1 MEFs, I Flamme and F Oehme (Bayer HealthCare, Germany) for helpful discussions and P Spielmann, M Storz and S Behnke for excellent technical assistance. This work was supported by SNF 3100AO-116047/1 (RHW and GC), Sassella Stiftung (GC, KB and SB), Krebsliga des Kantons Zurich (GC),UZH University Research Priority Program 'Integrative Human Physiology' and the 6th Framework Programme of the European Commission EUROXY LSHCCT-2003-502932/SBF03.0647-2 (RHW).	Albert ML, 2004, NAT REV CANCER, V4, P36, DOI 10.1038/nrc1255; Albert ML, 2000, ANN NEUROL, V47, P9; Barth S, 2007, MOL CELL BIOL, V27, P3758, DOI 10.1128/MCB.01324-06; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Camenisch G, 1999, FASEB J, V13, P81, DOI 10.1096/fasebj.13.1.81; Coleman ML, 2007, J BIOL CHEM, V282, P24027, DOI 10.1074/jbc.M704102200; Corradi JP, 1997, J NEUROSCI, V17, P1406; Cummins EP, 2006, P NATL ACAD SCI USA, V103, P18154, DOI 10.1073/pnas.0602235103; Darnell JC, 2000, CANCER RES, V60, P2136; Darnell RB, 2003, NAT IMMUNOL, V4, P201, DOI 10.1038/ni0303-201; Darnell RB, 2003, NEW ENGL J MED, V349, P1543, DOI 10.1056/NEJMra023009; Eble J, 2004, WHO CLASSIFICATION T; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Erez N, 2003, CANCER RES, V63, P8777; Ferguson JE, 2007, MOL CELL BIOL, V27, P6407, DOI 10.1128/MCB.00511-07; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Koditz J, 2007, BLOOD, V110, P3610, DOI 10.1182/blood-2007-06-094441; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; KOSARY CL, 1993, NIH PUBLICATION; Kovacs G, 1997, J PATHOL, V183, P131, DOI 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Martin F, 2005, BLOOD, V105, P4613, DOI 10.1182/blood-2004-10-3980; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Moch H, 2002, VIRCHOWS ARCH, V441, P320, DOI 10.1007/s00428-002-0685-y; Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207; OLIVER RTD, 1989, BRIT J UROL, V63, P128, DOI 10.1111/j.1464-410X.1989.tb05147.x; Onishi Tetsuro, 2002, Int J Clin Oncol, V7, P159, DOI 10.1007/s101470200023; Ozer A, 2005, P NATL ACAD SCI USA, V102, P7481, DOI 10.1073/pnas.0502716102; PETERSON K, 1992, NEUROLOGY, V42, P1931, DOI 10.1212/wnl.42.10.1931; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Rolfs A, 1997, J BIOL CHEM, V272, P20055, DOI 10.1074/jbc.272.32.20055; Santomasso BD, 2007, P NATL ACAD SCI USA, V104, P19073, DOI 10.1073/pnas.0704336104; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Shin DH, 2008, ONCOGENE, V27, P1939, DOI 10.1038/sj.onc.1210826; Stiehl DP, 2006, J BIOL CHEM, V281, P23482, DOI 10.1074/jbc.M601719200; Struckmann K, 2008, J PATHOL, V214, P464, DOI 10.1002/path.2310; Takeda K, 2006, MOL CELL BIOL, V26, P8336, DOI 10.1128/MCB.00425-06; To KKW, 2005, J BIOL CHEM, V280, P38102, DOI 10.1074/jbc.M504342200; VOGELZANG NJ, 1992, J UROLOGY, V148, P1247, DOI 10.1016/S0022-5347(17)36874-X; Wanner RM, 2000, BLOOD, V96, P1558, DOI 10.1182/blood.V96.4.1558.h8001558_1558_1565; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12	47	20	20	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2009	28	37					3274	3285		10.1038/onc.2009.186	http://dx.doi.org/10.1038/onc.2009.186			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495LS	19581925				2022-12-17	WOS:000269893700002
J	Gammoh, N; Isaacson, E; Tomaic, V; Jackson, DJ; Doorbar, J; Banks, L				Gammoh, N.; Isaacson, E.; Tomaic, V.; Jackson, D. J.; Doorbar, J.; Banks, L.			Inhibition of HPV-16 E7 oncogenic activity by HPV-16 E2	ONCOGENE			English	Article						HPV; E7; centrosomes; pRb	HUMAN-PAPILLOMAVIRUS TYPE-16; TRANSCRIPTIONAL ACTIVATOR; RETINOBLASTOMA PROTEIN; CENTROSOME DUPLICATION; GENOMIC INSTABILITY; HUMAN KERATINOCYTES; CERVICAL-CANCER; IN-VIVO; E6; ONCOPROTEIN	Human papillomavirus (HPV) E7 is essential in inducing S-phase progression in differentiating epithelial cells. We have previously shown that HPV-16 E7 activity can be controlled by a direct interaction with the viral transcriptional activator E2, thereby inhibiting transforming potential of E7. We have extended these analyses to show that E2 induces a generalized re-localization of E7 within the cell nucleus, one potential consequence of which is the inhibition of E7-induced degradation of pRb. Most importantly, we show that E2 can also inhibit the ability of E7 to induce centrosome abnormalities, thus preventing aberrant mitoses. Taken together, these studies highlight the central importance of E2 in controlling the functions of E7, independently of the ability of E2 to regulate transcription. Oncogene (2009) 28, 2299-2304; doi: 10.1038/onc.2009.78; published online 4 May 2009	[Gammoh, N.; Tomaic, V.; Banks, L.] Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; [Isaacson, E.; Jackson, D. J.; Doorbar, J.] MRC Natl Inst Med Res, Div Virol, London, England	International Center for Genetic Engineering & Biotechnology (ICGEB); MRC National Institute for Medical Research	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	doorba@nimr.mrc.ac.uk; banks@icgeb.org			Associazione Italiana per la Ricerca sul Cancro; UK Medical Research Council; Medical Research Council [MC_U117584278] Funding Source: researchfish; MRC [MC_U117584278] Funding Source: UKRI	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Daniela Gardiol, David Pim and Miranda Thomas for comments on the paper. We also thank Karl Munger for providing anti-HPV-16 E7 monoclonal antibody. This work was supported in part by a research grant from the Associazione Italiana per la Ricerca sul Cancro. EI, DJ and JD were supported by the UK Medical Research Council.	Araujo FD, 2005, J VIROL, V79, P11382, DOI 10.1128/JVI.79.17.11382-11391.2005; Boyer SN, 1996, CANCER RES, V56, P4620; Donaldson MM, 2007, J VIROL, V81, P4338, DOI 10.1128/JVI.02353-06; Doorbar J, 2006, CLIN SCI, V110, P525, DOI 10.1042/CS20050369; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2004, ONCOGENE, V23, P8206, DOI 10.1038/sj.onc.1208012; Duensing S, 2003, J VIROL, V77, P12331, DOI 10.1128/JVI.77.22.12331-12335.2003; Duensing S, 2001, J VIROL, V75, P7712, DOI 10.1128/JVI.75.16.7712-7716.2001; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gammoh N, 2006, J VIROL, V80, P1787, DOI 10.1128/JVI.80.4.1787-1797.2006; Grm HS, 2005, ONCOGENE, V24, P5149, DOI 10.1038/sj.onc.1208701; He WX, 2003, J VIROL, V77, P10566, DOI 10.1128/JVI.77.19.10566-10574.2003; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; Kurg R, 2005, J VIROL, V79, P10528, DOI 10.1128/JVI.79.16.10528-10539.2005; Massimi P, 1999, ONCOGENE, V18, P7748, DOI 10.1038/sj.onc.1203208; Patel D, 2004, CANCER RES, V64, P1299, DOI 10.1158/0008-5472.CAN-03-2917; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Yoshinouchi M, 2003, MOL THER, V8, P762, DOI 10.1016/j.ymthe.2003.08.004	18	20	21	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2009	28	23					2299	2304		10.1038/onc.2009.78	http://dx.doi.org/10.1038/onc.2009.78			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456XM	19421149				2022-12-17	WOS:000266886300006
J	Lee, SJ; Yang, JW; Cho, IJ; Kim, WD; Cho, MK; Lee, CH; Kim, SG				Lee, S. J.; Yang, J. W.; Cho, I. J.; Kim, W. D.; Cho, M. K.; Lee, C. H.; Kim, S. G.			The gep oncogenes, G alpha(12) and G alpha(13), upregulate the transforming growth factor-beta 1 gene	ONCOGENE			English	Article						G alpha(12) members; transforming growth factor-beta 1; hepatic stellate cell; activating protein 1	HEPATIC STELLATE CELLS; KAPPA-B-ALPHA; LIVER FIBROSIS; G-PROTEINS; HEPATOCELLULAR-CARCINOMA; TRANSCRIPTION FACTOR; SIGNALING PATHWAYS; PROMOTER REGION; CIRRHOTIC LIVER; CANCER CELLS	Transforming growth factor-beta 1 (TGF beta 1) plays a role in neoplastic transformation and transdifferentiation. G alpha(12) and G alpha(13), referred to as the gep oncogenes, stimulate mitogenic pathways. Nonetheless, no information is available regarding their roles in the regulation of the TGF beta 1 gene and the molecules linking them to gene transcription. Knockdown or knockout experiments using murine embryonic fibroblasts and hepatic stellate cells indicated that a G alpha(12) and G alpha(13) deficiency reduced constitutive, auto-stimulatory or thrombin-inducible TGF beta 1 gene expression. In contrast, transfection of activated mutants of G alpha(12) and G alpha(13) enabled the knockout cells to promote TGF beta 1 induction. A promoter deletion analysis suggested that activating protein 1 (AP-1) plays a role in TGF beta 1 gene transactivation, which was corroborated by the observation that a deficiency of the G-proteins decreased the AP-1 activity, whereas their activation enhanced it. Moreover, mutation of the AP-1-binding site abrogated the ability of G alpha(12) and G alpha(13) to induce the TGF beta 1 gene. Transfection of a dominant-negative mutant of Rho or Rac, but not Cdc42, prevented gene transactivation and decreased AP-1 activity downstream of G alpha 12 and G alpha 13. In summary, G alpha 12 and G alpha 13 regulate the expression of the TGF beta 1 gene through an increase in Rho/Rac-dependent AP-1 activity, implying that the G-protein-coupled receptor (GPCR)-G alpha(12) pathway is involved in the TGF beta 1-mediated transdifferentiation process.	[Kim, S. G.] Seoul Natl Univ, Coll Pharm, Pharmaceut Sci Res Inst, Seoul 151742, South Korea; [Lee, S. J.; Yang, J. W.; Cho, I. J.; Kim, W. D.; Cho, M. K.; Kim, S. G.] Seoul Natl Univ, Coll Pharm, Innovat Drug Res Ctr Metab & Inflammatory Dis, Seoul 151742, South Korea; [Cho, M. K.] Dongguk Univ, Coll Oriental Med, Kyungju, South Korea; [Lee, C. H.] Hanyang Univ, Coll Med, Inst Biomed Sci, Seoul 133791, South Korea; [Lee, C. H.] Hanyang Univ, Coll Med, Dept Pharmacol, Seoul 133791, South Korea	Seoul National University (SNU); Seoul National University (SNU); Dongguk University; Hanyang University; Hanyang University	Kim, SG (corresponding author), Seoul Natl Univ, Coll Pharm, Pharmaceut Sci Res Inst, Seoul 151742, South Korea.	sgk@snu.ac.kr		Kim, Wondong/0000-0001-9030-9164	Korea government (MEST), Korea [R11-2007-10701001-0]	Korea government (MEST), Korea(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government)	We thank Dr SC Brooks III for helpful discussion and English editing. This work was supported by the Korea Science and Engineering Foundation (KOSEF) grant funded by the Korea government ( MEST) ( No. R11-2007-10701001-0), Korea.	Ankoma-Sey V, 2000, HEPATOLOGY, V31, P141, DOI 10.1002/hep.510310122; Bahr MJ, 1999, HEPATOLOGY, V29, P839, DOI 10.1002/hep.510290333; Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Bataller R, 2000, GASTROENTEROLOGY, V118, P1149, DOI 10.1016/S0016-5085(00)70368-4; Brown JH, 2006, CIRC RES, V98, P730, DOI 10.1161/01.RES.0000216039.75913.9e; Byun HJ, 2006, J BIOL CHEM, V281, P34833, DOI 10.1074/jbc.M605483200; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Coulouarn C, 2008, HEPATOLOGY, V47, P2059, DOI 10.1002/hep.22283; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; DOKTER WHA, 1995, LEUKEMIA, V9, P425; Fiorucci S, 2004, HEPATOLOGY, V39, P365, DOI 10.1002/hep.20054; Fransvea E, 2008, HEPATOLOGY, V47, P1557, DOI 10.1002/hep.22201; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; Fujii T, 2005, J BIOL CHEM, V280, P23041, DOI 10.1074/jbc.M409397200; Gaca MDA, 2002, J HEPATOL, V36, P362, DOI 10.1016/S0168-8278(01)00285-9; George J, 2001, TOXICOLOGY, V156, P129, DOI 10.1016/S0300-483X(00)00352-8; George J, 1996, BBA-PROTEIN STRUCT M, V1292, P215, DOI 10.1016/0167-4838(95)00202-2; Giannelli G, 2005, GASTROENTEROLOGY, V129, P1375, DOI 10.1053/j.gastro.2005.09.055; Goldsmith ZG, 2007, ONCOGENE, V26, P3122, DOI 10.1038/sj.onc.1210407; Graupera M, 2003, HEPATOLOGY, V37, P172, DOI 10.1053/jhep.2003.50004; Gu JL, 2002, P NATL ACAD SCI USA, V99, P9352, DOI 10.1073/pnas.102291599; JENKINS SA, 1985, J HEPATOL, V1, P489, DOI 10.1016/S0168-8278(85)80747-9; Kang KW, 2003, J BIOL CHEM, V278, P17368, DOI 10.1074/jbc.M300471200; Kang KW, 2002, FASEB J, V16, P1988, DOI 10.1096/fj.02-0406fje; Kang KW, 2002, CHEM-BIOL INTERACT, V139, P61, DOI 10.1016/S0009-2797(01)00286-1; Kaufmann R, 2007, J CELL PHYSIOL, V211, P699, DOI 10.1002/jcp.21027; Kawanabe Y, 2002, MOL PHARMACOL, V61, P277, DOI 10.1124/mol.61.2.277; Kelly P, 2007, BIOCHEMISTRY-US, V46, P6677, DOI 10.1021/bi700235f; Ki SH, 2007, J BIOL CHEM, V282, P1938, DOI 10.1074/jbc.M606080200; KIM SJ, 1989, J BIOL CHEM, V264, P402; Kumar RN, 2006, ONCOGENE, V25, P899, DOI 10.1038/sj.onc.1209132; Kuner R, 2002, EUR J NEUROSCI, V16, P2333, DOI 10.1046/j.1460-9568.2002.02402.x; Kurose H, 2003, LIFE SCI, V74, P155, DOI 10.1016/j.lfs.2003.09.003; Lee JS, 2007, HEPATOLOGY, V45, P817, DOI 10.1002/hep.21564; Mikula M, 2006, J CELL PHYSIOL, V209, P560, DOI 10.1002/jcp.20772; Molteni Agostino, 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P451, DOI 10.2174/187152006778226521; Oklu R, 2000, BIOCHEM J, V352, P601, DOI 10.1042/0264-6021:3520601; Olaso E, 1997, HEPATOLOGY, V26, P634, DOI 10.1053/jhep.1997.v26.pm0009303493; Pinzani M, 1996, GASTROENTEROLOGY, V110, P534, DOI 10.1053/gast.1996.v110.pm8566602; Qi Z, 1999, P NATL ACAD SCI USA, V96, P2345, DOI 10.1073/pnas.96.5.2345; Radhika V, 2005, ONCOGENE, V24, P4597, DOI 10.1038/sj.onc.1208665; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; SCHOOK LB, 1992, TOXICOL APPL PHARM, V116, P110, DOI 10.1016/0041-008X(92)90151-H; Smart DE, 2006, HEPATOLOGY, V44, P1432, DOI 10.1002/hep.21436; Solis-Herruzo JA, 1998, CELL SIGNAL, V10, P173, DOI 10.1016/S0898-6568(97)00036-3; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; Weigert C, 2000, J AM SOC NEPHROL, V11, P2007, DOI 10.1681/ASN.V11112007; Xu J, 1997, NATURE, V389, P505, DOI 10.1038/39068; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Yamaguchi Y, 2003, J BIOL CHEM, V278, P14936, DOI 10.1074/jbc.M301409200; Yoshiji H, 2007, CURR MED CHEM, V14, P2749, DOI 10.2174/092986707782360169; Yue JB, 2000, J BIOL CHEM, V275, P30765, DOI 10.1074/jbc.M000039200; Zhao SJ, 2008, CANCER RES, V68, P4221, DOI 10.1158/0008-5472.CAN-07-5123	54	20	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2009	28	9					1230	1240		10.1038/onc.2008.488	http://dx.doi.org/10.1038/onc.2008.488			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415AH	19151758				2022-12-17	WOS:000263906200007
J	Scholl, FA; Dumesic, PA; Barragan, DI; Charron, J; Khavari, PA				Scholl, F. A.; Dumesic, P. A.; Barragan, D. I.; Charron, J.; Khavari, P. A.			Mek1/2 gene dosage determines tissue response to oncogenic Ras signaling in the skin	ONCOGENE			English	Article						MAP kinase; Mek; Ras; cancer; apoptosis	EPIDERMAL HYPERPLASIA; TRANSGENIC MICE; MAP KINASE; MOUSE SKIN; ACTIVATION; PATHWAY; MUTATION; GROWTH; CANCER; DIFFERENTIATION	Ras genes are commonly mutated in human cancers of the skin and other tissues. Oncogenic Ras signals through multiple effector pathways, including the Erk1/2 mitogen-activated protein kinase (MAPK), phosphatidylinositol-3 kinase (PI3K) and the Ral guanine nucleotide exchange factor (RalGEF) cascades. In epidermis, the activation of oncogenic Ras induces hyperplasia and inhibits differentiation, features characteristic of squamous cell carcinoma. The downstream effector pathways required for oncogenic Ras effects in epidermis, however, are undefined. In this study, we investigated the direct contribution of Mek1 and Mek2 MAPKKs to oncogenic Ras signaling. The response of murine epidermis to conditionally active oncogenic Ras was unimpaired by deletion of either Mek1 or Mek2 MAPKKs individually. In contrast, Ras effects were entirely abolished by combined deletion of all Mek1/2 alleles, whereas epidermis retaining only one allele of either Mek1 or Mek2 showed intermediate responsiveness. Thus, the effects of oncogenic Ras on proliferation and differentiation in skin show a gene dosage-dependent requirement for the Erk1/2 MAPK cascade at the level of Mek1/2 MAPKKs.	[Scholl, F. A.; Dumesic, P. A.; Barragan, D. I.; Khavari, P. A.] Stanford Univ, Dept Dermatol, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA; [Charron, J.] Univ Laval, Ctr Rech Cancerol, Hotel Dieu Quebec, CHUQ, Quebec City, PQ, Canada; [Khavari, P. A.] Vet Affairs Palo Alto Healthcare Syst, Palo Alto, CA USA	Stanford University; Laval University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Khavari, PA (corresponding author), Stanford Univ, Dept Dermatol, Sch Med, Program Epithelial Biol, CCSR Bldg,Room 2145,269 Campus Dr, Stanford, CA 94305 USA.	khavari@stanford.edu	Charron, Jean/A-9792-2013	Charron, Jean/0000-0002-5133-0056	US VA Office of Research and Development; NIAMS/NIH [AR49737]; Swiss cancer foundation [BIL SKL-01236-02-2002]; CIHR [MOP-67208]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049737] Funding Source: NIH RePORTER	US VA Office of Research and Development; NIAMS/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Swiss cancer foundation; CIHR(Canadian Institutes of Health Research (CIHR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank A Truong and K Jameson for critical reading of the manuscript, E Fuchs for K14-Cre mice, P Chambon for K14-CreER mice, C Enrile for histological work, H Bernstein, P Bernstein and N Griffiths for support. This study was supported by the US VA Office of Research and Development and by AR49737 from NIAMS/NIH to PAK, the Swiss cancer foundation Grant BIL SKL-01236-02-2002 to FAS and MOP-67208 from CIHR to JC.	[Anonymous], 2007, NATURE, V449, P378; Aoki Y, 2008, HUM MUTAT, V29, P992, DOI 10.1002/humu.20748; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; Belanger LF, 2003, MOL CELL BIOL, V23, P4778, DOI 10.1128/MCB.23.14.4778-4787.2003; Bissonauth V, 2006, DEVELOPMENT, V133, P3429, DOI 10.1242/dev.02526; Brown K, 1998, CURR BIOL, V8, P516, DOI 10.1016/S0960-9822(98)70203-9; Castro AF, 2005, METHODS, V37, P190, DOI 10.1016/j.ymeth.2005.05.015; Chambard JC, 2007, BBA-MOL CELL RES, V1773, P1299, DOI 10.1016/j.bbamcr.2006.11.010; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Dajee M, 2002, ONCOGENE, V21, P1527, DOI 10.1038/sj.onc.1205287; Denley A, 2008, ONCOGENE, V27, P2561, DOI 10.1038/sj.onc.1210918; Denley A, 2008, METHOD ENZYMOL, V438, P291, DOI 10.1016/S0076-6879(07)38020-8; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Estep AL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001279; Fuchs E, 2008, GENE DEV, V22, P976, DOI 10.1101/gad.1645908; Giroux S, 1999, CURR BIOL, V9, P369, DOI 10.1016/S0960-9822(99)80164-X; Gonzalez-Garcia A, 2005, CANCER CELL, V7, P219, DOI 10.1016/j.ccr.2005.01.029; GREENHALGH DA, 1993, MOL CARCINOGEN, V7, P99, DOI 10.1002/mc.2940070208; Gupta S, 2007, CELL, V129, P957, DOI 10.1016/j.cell.2007.03.051; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Kratz CP, 2007, J MOL MED-JMM, V85, P223, DOI 10.1007/s00109-006-0135-4; Li M, 2000, NATURE, V407, P633, DOI 10.1038/35036595; Marks JL, 2008, CANCER RES, V68, P5524, DOI 10.1158/0008-5472.CAN-08-0099; McCubrey JA, 2008, CURR OPIN INVEST DR, V9, P614; Murayama K, 2007, ONCOGENE, V26, P4882, DOI 10.1038/sj.onc.1210274; Naiche LA, 2007, GENESIS, V45, P768, DOI 10.1002/dvg.20353; Oh WJ, 2007, CARCINOGENESIS, V28, P2244, DOI 10.1093/carcin/bgm127; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; Schmidt-Supprian M, 2007, NAT IMMUNOL, V8, P665, DOI 10.1038/ni0707-665; Scholl FA, 2004, CANCER RES, V64, P6035, DOI 10.1158/0008-5472.CAN-04-0017; Scholl FA, 2007, DEV CELL, V12, P615, DOI 10.1016/j.devcel.2007.03.009; Shaul YD, 2007, BBA-MOL CELL RES, V1773, P1213, DOI 10.1016/j.bbamcr.2006.10.005; Sturgill TW, 2008, BIOCHEM BIOPH RES CO, V371, P1, DOI 10.1016/j.bbrc.2008.04.002; Sun BC, 2008, CELL CYCLE, V7, P934, DOI 10.4161/cc.7.7.5622; Tarutani M, 2003, CANCER RES, V63, P319; Vasioukhin V, 1999, P NATL ACAD SCI USA, V96, P8551, DOI 10.1073/pnas.96.15.8551; Wallace EM, 2005, CURR TOP MED CHEM, V5, P215, DOI 10.2174/1568026053507723; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218	39	20	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	12					1485	1495		10.1038/onc.2008.459	http://dx.doi.org/10.1038/onc.2008.459			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	424AH	19198628	Green Accepted			2022-12-17	WOS:000264537400001
J	Zuo, X; Morris, JS; Broaddus, R; Shureiqi, I				Zuo, X.; Morris, J. S.; Broaddus, R.; Shureiqi, I.			15-LOX-1 transcription suppression through the NuRD complex in colon cancer cells	ONCOGENE			English	Article						15-lipoxygenase-1; colon cancer; NuRD; MTA1	HUMAN COLORECTAL-CARCINOMA; HISTONE DEACETYLASE INHIBITORS; DRUG-INDUCED APOPTOSIS; 15-LIPOXYGENASE-1 EXPRESSION; INDUCE APOPTOSIS; DOWN-REGULATION; PROTEIN-1 MTA1; BREAST-CANCER; IN-VIVO; DIFFERENTIATION	15-Lipoxygenase-1 (15-LOX-1) is transcriptionally silenced in cancer cells, and its transcription reactivation (for example, through histone deacetylase inhibitors (HDACIs)) restores apoptosis to cancer cells. However, the exact mechanism underlying 15-LOX-1 transcription reactivation in cancer cells is still undefined. Therefore, we evaluated the critical mechanisms required for 15-LOX-1 transcription reactivation in colon cancer cells. Specific HDAC1 and HDAC2 inhibition activated 15-LOX-1 transcription. 15-LOX-1 transcription was repressed through transcription repressor complex recruitment in the region of -120 to -391 of the 15-LOX-1 promoter. The nucleosome remodeling and histone deacetylase (NuRD) repression complex was recruited to this region. Depsipeptide significantly reduced the recruitment of NuRD key components (for example, metastasis-associated protein 1 (MTA1) and HDAC1) to the 15-LOX-1 promoter before 15-LOX-1 transcriptional activation. Knock down of NuRD key components (for example, MTA1 and HDAC1) by small interfering RNA (siRNA) activated 15-LOX-1 transcription, as measured by luciferase reporter assays in stably transfected SW480 cells with the 15-LOX-1 promoter construct of the -391, but not the -120 region. Relative to expression in normal tissue, MTA1 expression in colorectal cancer mucosa from colorectal cancer patients was negatively related to 15-LOX-1 expression. Thus, our results show that NuRD contributes to 15-LOX-1 transcription suppression in colon cancer cells and that HDACIs can inhibit NuRD recruitment to a promoter to activate gene transcription, as in the case of 15-LOX-1.	[Zuo, X.; Shureiqi, I.] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; [Morris, J. S.] Univ Texas MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA; [Broaddus, R.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Shureiqi, I.] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Shureiqi, I (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, 1515 Holcombe Blvd, Houston, TX 77030 USA.	ishureiqi@mdanderson.org	Shureiqi, imad/T-6214-2019	Shureiqi, Imad/0000-0003-2019-938X; Zuo, Xiangsheng/0000-0002-8593-1132	National Cancer Institute, National Institutes of Health, Department of Health and Human Services R01 [R01 CA106577, R01 CA104278]; Caroline Wiess Law Endowment for Cancer Prevention; Jerry and Maury Rubenstein Foundation; National Colorectal Cancer Research Alliance; NATIONAL CANCER INSTITUTE [R01CA106577, R01CA104278] Funding Source: NIH RePORTER	National Cancer Institute, National Institutes of Health, Department of Health and Human Services R01(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Caroline Wiess Law Endowment for Cancer Prevention; Jerry and Maury Rubenstein Foundation; National Colorectal Cancer Research Alliance; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the National Cancer Institute, National Institutes of Health, Department of Health and Human Services R01 grants CA106577 and CA104278; the Caroline Wiess Law Endowment for Cancer Prevention; the Jerry and Maury Rubenstein Foundation and the National Colorectal Cancer Research Alliance. We thank Merck and Company Inc., Gloucester Pharmaceuticals and the National Cancer Institute for providing SAHA and depsipeptide. We also thank Ann M. Sutton, Department of Scientific Publications, the University of Texas M D Anderson Cancer Center, for editing the manuscript.	Ariel A, 2007, TRENDS IMMUNOL, V28, P176, DOI 10.1016/j.it.2007.02.007; BAER AN, 1991, BIOCHEM BIOPH RES CO, V180, P98, DOI 10.1016/S0006-291X(05)81260-4; Balasenthil S, 2006, HUM PATHOL, V37, P656, DOI 10.1016/j.humpath.2006.01.024; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Chen GG, 2003, INT J CANCER, V107, P837, DOI 10.1002/ijc.11447; Conrad DJ, 2000, AM J RESP CELL MOL, V22, P226, DOI 10.1165/ajrcmb.22.2.3786; Deguchi A, 2005, CANCER RES, V65, P8442, DOI 10.1158/0008-5472.CAN-05-1109; Furumai R, 2002, CANCER RES, V62, P4916; Giannini R, 2005, ANTICANCER RES, V25, P4287; Gibbs JB, 2000, SCIENCE, V287, P1969, DOI 10.1126/science.287.5460.1969; GLEASON MM, 1995, AM J PHYSIOL-CELL PH, V268, pC1301; Hennig R, 2007, NEOPLASIA, V9, P917, DOI 10.1593/neo.07565; Heslin MJ, 2005, ANN SURG, V241, P941, DOI 10.1097/01.sla.0000164177.95620.c1; Hsi LC, 2005, MOL CANCER THER, V4, P1740, DOI 10.1158/1535-7163.MCT-05-0218; Hsi LC, 2004, CANCER RES, V64, P8778, DOI 10.1158/0008-5472.CAN-04-1867; Huang BH, 2005, CELL DEATH DIFFER, V12, P395, DOI 10.1038/sj.cdd.4401567; Jiang WG, 2006, PROSTAG LEUKOTR ESS, V74, P235, DOI 10.1016/j.plefa.2006.01.009; Kamitani H, 1998, J BIOL CHEM, V273, P21569, DOI 10.1074/jbc.273.34.21569; Kamitani H, 2001, CARCINOGENESIS, V22, P187, DOI 10.1093/carcin/22.1.187; Kamitani H, 2000, FEBS LETT, V467, P341, DOI 10.1016/S0014-5793(00)01155-8; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Liu C, 2004, EXP CELL RES, V297, P61, DOI 10.1016/j.yexcr.2004.02.014; Manavathi B, 2007, J BIOL CHEM, V282, P1529, DOI 10.1074/jbc.R600029200; Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4; Merchant N, 2005, ANN SURG, V241, P946; Nixon JB, 2004, PROSTAG LEUKOTR ESS, V70, P7, DOI 10.1016/j.plefa.2003.06.001; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Serhan CN, 2003, J IMMUNOL, V171, P6856, DOI 10.4049/jimmunol.171.12.6856; Shankaranarayanan P, 2001, J BIOL CHEM, V276, P42753, DOI 10.1074/jbc.M102626200; Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402; Shureiqi I, 2000, J NATL CANCER I, V92, P1136, DOI 10.1093/jnci/92.14.1136; Shureiqi I, 2000, CANCER RES, V60, P6846; Shureiqi I, 1999, CARCINOGENESIS, V20, P1985, DOI 10.1093/carcin/20.10.1985; Shureiqi I, 2005, CANCER RES, V65, P11486, DOI 10.1158/0008-5472.CAN-05-2180; Shureiqi I, 2003, P NATL ACAD SCI USA, V100, P9968, DOI 10.1073/pnas.1631086100; Shureiqi I, 2002, CANCER RES, V62, P1178; Shureiqi I, 2001, CANCER RES, V61, P4879; Shureiqi I, 2007, FASEB J, V21, P743, DOI 10.1096/fj.06-6830com; Takamitsu S., 2006, VIRCHOWS ARCH, V448, P422; TAKATA S, 1994, J CLIN INVEST, V93, P499, DOI 10.1172/JCI116999; Wu J, 2003, CARCINOGENESIS, V24, P243, DOI 10.1093/carcin/24.2.243; Wu Y, 2008, MOL THER, V16, P886, DOI 10.1038/mt.2008.44; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang CL, 2005, J INVEST DERMATOL, V125, P1045, DOI 10.1111/j.0022-202X.2005.23925.x; Zhang XY, 2005, P NATL ACAD SCI USA, V102, P13968, DOI 10.1073/pnas.0502330102; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X; Zuo X, 2006, ONCOGENE, V25, P1225, DOI 10.1038/sj.onc.1209160; Zuo XS, 2008, FASEB J, V22, P1981, DOI 10.1096/fj.07-098301	50	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	12					1496	1505		10.1038/onc.2008.494	http://dx.doi.org/10.1038/onc.2008.494			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	424AH	19198625	Bronze, Green Accepted			2022-12-17	WOS:000264537400002
J	Zhang, B; Chambers, KJ; Leprince, D; Faller, DV; Wang, S				Zhang, B.; Chambers, K. J.; Leprince, D.; Faller, D. V.; Wang, S.			RETRACTED: Requirement for chromatin-remodeling complex in novel tumor suppressor HIC1-mediated transcriptional repression and growth control (Retracted article. See vol. 30, pg. 4374, 2011)	ONCOGENE			English	Article; Retracted Publication						HIC1; E2F1; Brg1; SWI/SNF; transcription; cell cycle	GENE HIC1; ANDROGEN RECEPTOR; SWI/SNF COMPLEX; PROHIBITIN; RB; E2F; EXPRESSION; CANCER; IDENTIFICATION; ACTIVATION	HIC1 is a newly discovered tumor suppressor and transcriptional repressor that is frequently silenced in human tumors. HIC1 protein expression has been linked to better outcomes in breast cancers. The molecular mechanism underlying HIC1-mediated transcriptional and growth suppression, and the relevant targets of HIC1-mediated transcriptional modulation, is currently unclear. We have identified an HIC1 DNA-binding site in E2F-responsive gene promoters and demonstrate that HIC1 targets E2F-responsive genes for transcriptional regulation and growth suppression. We and others have recently discovered that Brg1, a central component of the SWI/SNF chromatin-remodeling family, is required for the transcriptional regulation of multiple cell cycle control-related genes, including E2F-responsive promoters. We studied HIC1 interactions with, and dependence upon, Brg1 activity, and found that HIC1 can recruit Brg1 to E2F-responsive promoters and that its transcriptional repression of these genes is dependent upon Brg1. These data indicate that HIC1 is a central molecule in a novel mechanism controlling cell growth and that the disruption of this HIC1-mediated pathway may lead to abnormal cell proliferation and, ultimately, cancer.	[Zhang, B.; Chambers, K. J.; Faller, D. V.; Wang, S.] Boston Univ, Sch Med, Canc Res Ctr, Boston, MA 02118 USA; [Leprince, D.] Inst Pasteur, Inst Biol Lille, CNRS, UMR 8161, F-59019 Lille, France	Boston University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Wang, S (corresponding author), Boston Univ, Sch Med, Canc Res Ctr, R-906,715 Albany St, Boston, MA 02118 USA.	sw184@bu.edu		Leprince, Dominique/0000-0002-1999-0775	Susan G Komen Breast Cancer Foundation Research [BCTR0403163]; National Cancer Institute [CA102940, CA101992]; Karin Grunebaum Cancer Research Foundation; DOD/CDMRP 2008 Breast Cancer Concept Award; Carter Family Foundation for Melanoma Research; BUSM Department of Medicine Pilot Project Grant Award; Aid for Cancer Research; NATIONAL CANCER INSTITUTE [R01CA101992, R03CA102940] Funding Source: NIH RePORTER	Susan G Komen Breast Cancer Foundation Research(Susan G. Komen Breast Cancer Foundation); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Karin Grunebaum Cancer Research Foundation; DOD/CDMRP 2008 Breast Cancer Concept Award(United States Department of Defense); Carter Family Foundation for Melanoma Research; BUSM Department of Medicine Pilot Project Grant Award; Aid for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Srikumar P Chellappan for his continuous support. This study was partially supported by grants from Susan G Komen Breast Cancer Foundation Research Award (BCTR0403163)(SW) and the National Cancer Institute ((CA102940)(SW) and (CA101992)(DVF)) and by the Karin Grunebaum Cancer Research Foundation (DVF). SW is the recipient of DOD/CDMRP 2008 Breast Cancer Concept Award, Carter Family Foundation for Melanoma Research grant award, a BUSM Department of Medicine Pilot Project Grant Award and an Aid for Cancer Research grant award.	Aggerholm A, 2006, EUR J HAEMATOL, V76, P23, DOI 10.1111/j.1600-0609.2005.00559.x; Banine F, 2005, CANCER RES, V65, P3542, DOI 10.1158/0008-5472.CAN-04-3554; Bertrand S, 2004, BBA-GENE STRUCT EXPR, V1678, P57, DOI 10.1016/j.bbaexp.2004.01.009; Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706; Britschgi C, 2006, ONCOGENE, V25, P2030, DOI 10.1038/sj.onc.1209240; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077; Chen WY, 2005, CELL CYCLE, V4, P10, DOI 10.4161/cc.4.1.1361; Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030; Chopin V, 2006, M S-MED SCI, V22, P54, DOI 10.1051/medsci/200622154; Dai Y, 2008, CARCINOGENESIS, V29, P1725, DOI 10.1093/carcin/bgn117; Dai Y, 2007, MOL ENDOCRINOL, V21, P1807, DOI 10.1210/me.2006-0467; Dasgupta P, 2004, MOL CELL BIOL, V24, P9527, DOI 10.1128/MCB.24.21.9527-9541.2004; Deltour S, 2002, MOL CELL BIOL, V22, P4890, DOI 10.1128/MCB.22.13.4890-4901.2002; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Fusaro G, 2002, ONCOGENE, V21, P4539, DOI 10.1038/sj.onc.1205551; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; Guerardel C, 1999, FEBS LETT, V451, P253, DOI 10.1016/S0014-5793(99)00583-9; Inayoshi Y, 2006, J BIOCHEM, V139, P177, DOI 10.1093/jb/mvj015; Lefebvre T, 2004, EUR J BIOCHEM, V271, P3843, DOI 10.1111/j.1432-1033.2004.04316.x; Melki JR, 1999, LEUKEMIA, V13, P877, DOI 10.1038/sj.leu.2401401; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nicoll G, 2001, BRIT J CANCER, V85, P1878, DOI 10.1054/bjoc.2001.2163; Pinte S, 2004, J BIOL CHEM, V279, P38313, DOI 10.1074/jbc.M401610200; Pinte S, 2004, ONCOGENE, V23, P4023, DOI 10.1038/sj.onc.1207504; Stankovic-Valentin N, 2006, FEBS J, V273, P2879, DOI 10.1111/j.1742-4658.2006.05301.x; Stevaux O, 2002, EMBO J, V21, P4927, DOI 10.1093/emboj/cdf501; Strobeck MW, 2001, J BIOL CHEM, V276, P9273, DOI 10.1074/jbc.M009747200; Takahashi Y, 2000, GENE DEV, V14, P804; Waha A, 2004, INT J CANCER, V110, P542, DOI 10.1002/ijc.20165; Wang S, 2002, EMBO J, V21, P3019, DOI 10.1093/emboj/cdf302; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684; Wang S, 2004, EMBO J, V23, P2293, DOI 10.1038/sj.emboj.7600231; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; Wang S, 1998, MOL CELL BIOL, V18, P7487, DOI 10.1128/MCB.18.12.7487; Wong S, 2007, BIOCHEM J, V407, P451, DOI 10.1042/BJ20070151; Zhang B, 2007, ONCOGENE, V26, P7153, DOI 10.1038/sj.onc.1210509	38	20	21	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					651	661		10.1038/onc.2008.419	http://dx.doi.org/10.1038/onc.2008.419			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	19015639	Green Accepted			2022-12-17	WOS:000263076400003
J	Kotadia, S; Kao, LR; Comerford, SA; Jones, RT; Hammer, RE; Megraw, TL				Kotadia, S.; Kao, L. R.; Comerford, S. A.; Jones, R. T.; Hammer, R. E.; Megraw, T. L.			PP2A-dependent disruption of centrosome replication and cytoskeleton organization in Drosophila by SV40 small tumor antigen	ONCOGENE			English	Article						SV40 ST; centriole; centrosome; PP2A; aneuploidy; cyclin E	PROTEIN PHOSPHATASE 2A; SMALL-T-ANTIGEN; HUMAN CELL-TRANSFORMATION; CYCLIN-A PROMOTER; VIRUS TYPE-1 TAX; REGULATORY SUBUNIT; CANCER PROGRESSION; E7 ONCOPROTEIN; GAMMA-TUBULIN; SIMIAN-VIRUS-40	Viruses of the DNA tumor virus family share the ability to transform vertebrate cells through the action of virus-encoded tumor antigens that interfere with normal cell physiology. They accomplish this very efficiently by inhibiting endogenous tumor suppressor proteins that control cell proliferation and apoptosis. Simian virus 40 (SV40) encodes two oncoproteins, large tumor antigen, which directly inhibits the tumor suppressors p53 and Rb, and small tumor antigen (ST), which interferes with serine/threonine protein phosphatase 2A (PP2A). We have constructed a Drosophila model for SV40 ST expression and show that ST induces supernumerary centrosomes, an activity we also demonstrate in human cells. In early Drosophila embryos, ST also caused increased microtubule stability, chromosome segregation errors, defective assembly of actin into cleavage furrows, cleavage failure, a rise in cyclin E levels and embryonic lethality. Using ST mutants and genetic interaction experiments between ST and PP2A subunit mutations, we show that all of these phenotypes are dependent on ST's interaction with PP2A. These analyses demonstrate the validity and utility of Drosophila as a model for viral oncoprotein function in vivo.	[Kotadia, S.; Kao, L. R.; Jones, R. T.; Megraw, T. L.] Univ Texas SW Med Ctr Dallas, Cecil H & Ida Green Ctr Reprod Biol Sci, Dept Pharmacol, Dallas, TX 75390 USA; [Comerford, S. A.] Univ Texas SW Med Ctr Dallas, Cecil H & Ida Green Ctr Reprod Biol Sci, Dept Mol Genet, Dallas, TX 75390 USA; [Hammer, R. E.] Univ Texas SW Med Ctr Dallas, Cecil H & Ida Green Ctr Reprod Biol Sci, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Megraw, TL (corresponding author), Univ Texas SW Med Ctr Dallas, Cecil H & Ida Green Ctr Reprod Biol Sci, Dept Pharmacol, 6001 Forest Pk Rd,Room ND11-120, Dallas, TX 75390 USA.	timothy.megraw@utsouthwestern.edu	Megraw, Tim/U-1442-2019; Megraw, Timothy/T-5186-2019	Hammer, Robert E./0000-0001-5487-7551; Megraw, Timothy/0000-0001-7455-7483; Comerford, Sarah Ann/0000-0002-7452-7759	National Institutes of Health [GM068756]; Welch Foundation [I-1610]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068756] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Welch Foundation(The Welch Foundation); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Estelle Sontag, Hui Zou, Helena Richardson, Stefan Heidmann and Kristen Johansen for reagents and Marc Mumby for a critical reading of our paper. This work was supported by grants from the National Institutes of Health (GM068756) and the Welch Foundation (I-1610).	Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; CALLAINI G, 1990, J CELL SCI, V97, P539; Chen F, 2007, CURR BIOL, V17, P293, DOI 10.1016/j.cub.2007.01.068; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen Y, 2007, NAT STRUCT MOL BIOL, V14, P527, DOI 10.1038/nsmb1254; Cho US, 2007, PLOS BIOL, V5, P1810, DOI 10.1371/journal.pbio.0050202; Cho US, 2007, NATURE, V445, P53, DOI 10.1038/nature05351; Comerford SA, 2003, ONCOGENE, V22, P2515, DOI 10.1038/sj.onc.1206259; Crawford JM, 1998, DEV BIOL, V204, P151, DOI 10.1006/dbio.1998.9061; De Luca A, 2003, CANCER RES, V63, P1430; Duensing A, 2007, ONCOGENE, V26, P6280, DOI 10.1038/sj.onc.1210456; Duensing S, 2004, ONCOGENE, V23, P8206, DOI 10.1038/sj.onc.1208012; Duensing S, 2003, J VIROL, V77, P12331, DOI 10.1128/JVI.77.22.12331-12335.2003; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; Fujii R, 2006, CANCER RES, V66, P9099, DOI 10.1158/0008-5472.CAN-06-1886; Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249; Gaillard S, 2001, J VIROL, V75, P9799, DOI 10.1128/JVI.75.20.9799-9807.2001; Goetz F, 2001, ONCOGENE, V20, P2325, DOI 10.1038/sj.onc.1204355; Hannus M, 2002, DEVELOPMENT, V129, P3493; Hong S, 2007, J BIOL CHEM, V282, P12119, DOI 10.1074/jbc.M610392200; Horn V, 2007, MOL BIOL CELL, V18, P1233, DOI 10.1091/mbc.E06-12-1152; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kleylein-Sohn J, 2007, DEV CELL, V13, P190, DOI 10.1016/j.devcel.2007.07.002; Lavia P, 2003, ONCOGENE, V22, P6508, DOI 10.1038/sj.onc.1206861; Liao Y, 2004, CANCER RES, V64, P5938, DOI 10.1158/0008-5472.CAN-04-1533; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Mateer SC, 1998, J BIOL CHEM, V273, P35339, DOI 10.1074/jbc.273.52.35339; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; Mumby M, 2007, CELL, V130, P21, DOI 10.1016/j.cell.2007.06.034; MUNGRE S, 1994, J VIROL, V68, P1675, DOI 10.1128/JVI.68.3.1675-1681.1994; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Nigg EA, 2007, TRENDS CELL BIOL, V17, P215, DOI 10.1016/j.tcb.2007.03.003; Nitta T, 2006, CANCER SCI, V97, P836, DOI 10.1111/j.1349-7006.2006.00254.x; Nunbhakdi-Craig V, 2003, J VIROL, V77, P2807, DOI 10.1128/JVI.77.5.2807-2818.2003; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pihan GA, 2001, CANCER RES, V61, P2212; Pim D, 2005, ONCOGENE, V24, P7830, DOI 10.1038/sj.onc.1208935; Porras A, 1996, J VIROL, V70, P6902; RAFF JW, 1989, CELL, V57, P611, DOI 10.1016/0092-8674(89)90130-X; Reed SI, 1997, CANCER SURV, V29, P7; Rothwell WF, 2000, CURR TOP DEV BIOL, V49, P409; Saenz-Robles MT, 2001, ONCOGENE, V20, P7899, DOI 10.1038/sj.onc.1204936; Schuchner S, 1999, J VIROL, V73, P9266; Schuh M, 2007, CURR BIOL, V17, P237, DOI 10.1016/j.cub.2006.11.051; Skoczylas C, 2005, VIROLOGY, V332, P596, DOI 10.1016/j.virol.2004.12.017; Skoczylas C, 2004, CELL CYCLE, V3, P606; Sluder G, 2004, CURR OPIN CELL BIOL, V16, P49, DOI 10.1016/j.ceb.2003.11.006; Snaith HA, 1996, J CELL SCI, V109, P3001; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; Sontag JM, 2006, CELL MOL LIFE SCI, V63, P2979, DOI 10.1007/s00018-006-6300-7; Sullivan CS, 2000, MOL CELL BIOL, V20, P6233, DOI 10.1128/MCB.20.17.6233-6243.2000; Sullivan CS, 2002, MICROBIOL MOL BIOL R, V66, P179, DOI 10.1128/MMBR.66.2.179-202.2002; Tournebize R, 1997, EMBO J, V16, P5537, DOI 10.1093/emboj/16.18.5537; Tsou MFB, 2006, CURR OPIN CELL BIOL, V18, P74, DOI 10.1016/j.ceb.2005.12.008; Viquez NM, 2006, J NEUROSCI, V26, P9293, DOI 10.1523/JNEUROSCI.1740-06.2006; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Wiese C, 2006, J CELL SCI, V119, P4143, DOI 10.1242/jcs.03226; Xu YH, 2006, CELL, V127, P1239, DOI 10.1016/j.cell.2006.11.033; Yang CS, 2005, MOL CELL BIOL, V25, P1298, DOI 10.1128/MCB.25.4.1298-1308.2005; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; Zhang J, 2007, MOL BIOL CELL, V18, P4037, DOI 10.1091/mbc.E07-05-0474	66	20	20	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2008	27	49					6334	6346		10.1038/onc.2008.254	http://dx.doi.org/10.1038/onc.2008.254			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363JK	18663356	Green Accepted			2022-12-17	WOS:000260263400003
J	Grether-Beck, S; Salahshour-Fard, M; Timmer, A; Brenden, H; Felsner, I; Walli, R; Fullekrug, J; Krutmann, J				Grether-Beck, S.; Salahshour-Fard, M.; Timmer, A.; Brenden, H.; Felsner, I.; Walli, R.; Fuellekrug, J.; Krutmann, J.			Ceramide and raft signaling are linked with each other in UVA radiation-induced gene expression	ONCOGENE			English	Article						signaling; UVA; rafts; ceramide	LEMLI-OPITZ-SYNDROME; CONGENITAL PHOTOSENSITIVITY SYNDROME; LIPID RAFTS; ACID SPHINGOMYELINASE; BIOLOGICAL-SYSTEMS; PLASMA-MEMBRANE; INSULIN-RECEPTOR; CELL-MEMBRANES; DNA-SEQUENCE; CHOLESTEROL	Solar ultraviolet A (UVA) (320-400 nm) radiation-induced gene expression in keratinocytes is initiated at the level of the cell membrane via generation of singlet oxygen and subsequent formation of ceramide from sphingomyelin. We now report that the UVA response also involves raft signaling and that ceramide and raft signaling are linked with each other. Upon UVA irradiation, the lipid composition of rafts decreased 40% in sphingomyelin and 60% in cholesterol (Chol). Also, decrease of Chol increased the susceptibility towards UVA-induced gene expression, whereas increase of Chol completely abolished their capacity to generate signaling ceramides and to mount the subsequent UVA response. This inhibition was not associated with UVA-induced Chol oxidation and was also seen after treatment of cells with plant sterols. The UVA responsiveness depended on the ratio of Chol versus ceramide in rafts. A ratio smaller than 1 permitted initiation and transduction of the signaling response, whereas a ratio greater than 1, for example, upon sterol pretreatment, abolished this response, indicating that UVA radiation-induced ceramide signaling is controlled by the lipid composition of rafts.	[Grether-Beck, S.; Salahshour-Fard, M.; Timmer, A.; Brenden, H.; Felsner, I.; Walli, R.; Krutmann, J.] Heinrich Heine Univ Duesseldorf gGmbH, Inst Umweltmed Forsch, D-40225 Dusseldorf, Germany; [Fuellekrug, J.] Heidelberg Univ, Heidelberg, Germany	Heinrich Heine University Dusseldorf; Ruprecht Karls University Heidelberg	Grether-Beck, S (corresponding author), Heinrich Heine Univ Duesseldorf gGmbH, Inst Umweltmed Forsch, Aufm Hennekamp 50, D-40225 Dusseldorf, Germany.	grether-beck@uni-duesseldorf.de	Füllekrug, Joachim/A-6581-2008					ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anstey AV, 1999, J AM ACAD DERMATOL, V41, P121, DOI 10.1016/S0190-9622(99)70420-2; Anstey AV, 1999, BRIT J DERMATOL, V141, P406; Azurdia RM, 2001, BRIT J DERMATOL, V144, P143, DOI 10.1046/j.1365-2133.2001.03964.x; BACHOWSKI GJ, 1988, LIPIDS, V23, P580, DOI 10.1007/BF02535601; BATTA AK, 1995, J LIPID RES, V36, P705; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Charman CR, 1998, BRIT J DERMATOL, V138, P885; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Fitzky BU, 1998, P NATL ACAD SCI USA, V95, P8181, DOI 10.1073/pnas.95.14.8181; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fukasawa M, 2000, J BIOL CHEM, V275, P34028, DOI 10.1074/jbc.M005151200; Girotti AW, 1998, J LIPID RES, V39, P1529; GIROTTI AW, 1992, J PHOTOCH PHOTOBIO B, V13, P105, DOI 10.1016/1011-1344(92)85050-5; Girotti AW, 2000, METHOD ENZYMOL, V319, P85; Gniadecki R, 2002, J INVEST DERMATOL, V118, P582, DOI 10.1046/j.1523-1747.2002.01716.x; Grether-Beck S, 2005, J INVEST DERMATOL, V125, P545, DOI 10.1111/j.0022-202X.2005.23782.x; Grether-Beck S, 2003, J BIOL CHEM, V278, P47498, DOI 10.1074/jbc.M309511200; Grether-Beck S, 2000, EMBO J, V19, P5793, DOI 10.1093/emboj/19.21.5793; GretherBeck S, 1996, P NATL ACAD SCI USA, V93, P14586, DOI 10.1073/pnas.93.25.14586; Gulbins E, 2006, AM J PHYSIOL-REG I, V290, pR11, DOI 10.1152/ajpregu.00416.2005; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Johnston I, 2006, LANGMUIR, V22, P11284, DOI 10.1021/la061636s; Kashkar H, 2005, J BIOL CHEM, V280, P20804, DOI 10.1074/jbc.M410869200; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; Korytowski W, 1999, PHOTOCHEM PHOTOBIOL, V70, P484; Linnik KM, 1998, J BIOL CHEM, V273, P21368, DOI 10.1074/jbc.273.33.21368; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; MCCALLUM FS, 1985, BIOCHEM J, V232, P725, DOI 10.1042/bj2320725; MEGHA LE, 2004, J BIOL CHEM, V279, P9997; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P2075, DOI 10.1021/bi0156557; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; Reiterer G, 2005, J NUTR, V135, P2114, DOI 10.1093/jn/135.9.2114; Ridgway ND, 1998, J BIOL CHEM, V273, P31621, DOI 10.1074/jbc.273.47.31621; Rotolo JA, 2005, J BIOL CHEM, V280, P26425, DOI 10.1074/jbc.M414569200; Schmuth M, 2004, J INVEST DERMATOL, V123, P41, DOI 10.1111/j.0022-202X.2004.22707.x; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Schwarz T, 2005, EXP DERMATOL, V14, P788, DOI 10.1111/j.1600-0625.2005.0355g.x; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; SMITH DW, 1964, J PEDIATR-US, V64, P210, DOI 10.1016/S0022-3476(64)80264-X; STADE BG, 1990, IMMUNOBIOLOGY, V182, P79, DOI 10.1016/S0171-2985(11)80585-1; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; TINT GS, 1994, NEW ENGL J MED, V330, P107, DOI 10.1056/NEJM199401133300205; Tyrrell RM, 2006, PROG BIOPHYS MOL BIO, V92, P86, DOI 10.1016/j.pbiomolbio.2006.02.002; Tyrrell RM, 2004, ANTIOXID REDOX SIGN, V6, P835, DOI 10.1089/1523086041798033; Vainio S, 2002, EMBO REP, V3, P95, DOI 10.1093/embo-reports/kvf010; Valencia A, 2006, FREE RADICAL BIO MED, V40, P641, DOI 10.1016/j.freeradbiomed.2005.09.036; VANDEKERCKHOVE J, 1978, P NATL ACAD SCI USA, V75, P1106, DOI 10.1073/pnas.75.3.1106; Wolf C, 1996, J LIPID RES, V37, P1325; Xu F, 2005, P NATL ACAD SCI USA, V102, P14551, DOI 10.1073/pnas.0503590102; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; Yang N, 2004, J BIOL CHEM, V279, P20898, DOI 10.1074/jbc.M400625200; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zhang YG, 2001, J BIOL CHEM, V276, P11775, DOI 10.1074/jbc.M006000200	64	20	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2008	27	35					4768	4778		10.1038/onc.2008.116	http://dx.doi.org/10.1038/onc.2008.116			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18438433				2022-12-17	WOS:000258445100002
J	Wang, X; Di, K; Zhang, X; Han, HY; Wong, YC; Leung, SCL; Ling, MT				Wang, X.; Di, K.; Zhang, X.; Han, H. Y.; Wong, Y. C.; Leung, S. C. L.; Ling, M-T			Id-1 promotes chromosomal instability through modification of APC/C activity during mitosis in response to microtubule disruption	ONCOGENE			English	Article						Id-1; mitosis; aneuploidy; Cdc20; Cdh1	LOOP-HELIX PROTEIN; SPINDLE ASSEMBLY CHECKPOINT; PROSTATE-CANCER; P16(INK4A) EXPRESSION; CELLULAR SENESCENCE; SIGNALING PATHWAY; OVEREXPRESSION; ACTIVATION; ID1; DIFFERENTIATION	Id-1 (Inhibitor of DNA binding/differential-1) plays a positive role in tumorigenesis through regulation of multiple signaling pathways. Recently, it is suggested that upregulation of Id-1 in cancer cells promotes chromosomal instability. However, the underlying molecular mechanism is not known. In this study, we report a novel function of Id-1 in regulation of mitosis through physical interaction with Cdc20 (cell division cycle protein 20) and Cdh1 (Cdc20 homolog 1). During early mitosis, Id-1 interacts with Cdc20 and RASSF1A (Ras association domain family 1A), leading to enhanced APC(Cdc20) activity, which in turn promotes cyclin B1/securin degradation and premature mitosis. During late mitosis, Id-1 binds to Cdh1 and disrupts the interaction between Cdh1 and APC, resulting in suppression of APC Cdh1 activity. On the other hand, overexpression of Cdh1 leads to Id-1 protein degradation, suggesting that Id-1 may also act as a substrate of APC(Cdh1). The negative effect of Id-1 on APC(Cdh1) results in suppression of APC(Cdh1)-induced Aurora A and Cdc20 degradation, leading to failure in cytokinesis. As a result, overexpression of Id-1 in human prostate epithelial cells leads to polyploidy in response to microtubule disruption, and this effect is abolished when Id-1 expression is suppressed using antisense technology. These results demonstrate a novel function of Id-1 in promoting chromosomal instability through modi. cation of APC/C activity during mitosis and provide a novel molecular mechanism accounted for the function of Id-1 as an oncogene.	[Wang, X.; Di, K.; Zhang, X.; Han, H. Y.; Wong, Y. C.; Leung, S. C. L.; Ling, M-T] Univ Hong Kong, Fac Med, Dept Anat, Canc Biol Grp, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Wang, X (corresponding author), Univ Hong Kong, Fac Med, Dept Anat, Canc Biol Grp, 1-F Bldg,21 Sassoon Road, Hong Kong, Hong Kong, Peoples R China.	xhwang@hkucc.hku.hk; patling@hkucc.hku.hk						Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; Bright RK, 1997, CANCER RES, V57, P995; Crane R, 2004, J CELL SCI, V117, P5975, DOI 10.1242/jcs.01418; Di K, 2006, BIOL CELL, V98, P523, DOI 10.1042/BC20060026; Fong S, 2003, P NATL ACAD SCI USA, V100, P13543, DOI 10.1073/pnas.2230238100; Forootan SS, 2007, HUM PATHOL, V38, P1321, DOI 10.1016/j.humpath.2007.02.011; HARA E, 1994, J BIOL CHEM, V269, P2139; Hasskarl J, 2004, ONCOGENE, V23, P1930, DOI 10.1038/sj.onc.1207310; Lasorella A, 2006, NATURE, V442, P471, DOI 10.1038/nature04895; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; Lin ML, 2001, STEM CELLS, V19, P205, DOI 10.1634/stemcells.19-3-205; Ling MT, 2006, DIFFERENTIATION, V74, P481, DOI 10.1111/j.1432-0436.2006.00083.x; Ling MT, 2003, ONCOGENE, V22, P4498, DOI 10.1038/sj.onc.1206693; Ling MT, 2002, ONCOGENE, V21, P8498, DOI 10.1038/sj.onc.1206007; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Mondal G, 2007, CARCINOGENESIS, V28, P81, DOI 10.1093/carcin/bgl100; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Nickoloff BJ, 2000, J BIOL CHEM, V275, P27501; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Ouyang XS, 2002, J UROLOGY, V167, P2598, DOI 10.1016/S0022-5347(05)65044-6; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Schindl M, 2003, CLIN CANCER RES, V9, P779; Schoppmann SF, 2003, INT J CANCER, V104, P677, DOI 10.1002/ijc.11009; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Tang J, 2002, LAB INVEST, V82, P1073, DOI 10.1097/01.LAB.0000022223.65962.3A; Tang ZY, 2004, MOL CELL, V16, P387, DOI 10.1016/j.molcel.2004.09.031; To-Ho KW, 2008, ONCOGENE, V27, P347, DOI 10.1038/sj.onc.1210633; Wong YC, 2004, APOPTOSIS, V9, P279, DOI 10.1023/B:APPT.0000025804.25396.79; Yuen HF, 2006, MODERN PATHOL, V19, P931, DOI 10.1038/modpathol.3800602; Zhang XM, 2007, CANCER SCI, V98, P308, DOI 10.1111/j.1349-7006.2007.00400.x; Zhang XM, 2006, INT J CANCER, V118, P2072, DOI 10.1002/ijc.21592; Zheng WJ, 2004, J BIOL CHEM, V279, P31524, DOI 10.1074/jbc.M400365200	37	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2008	27	32					4456	4466		10.1038/onc.2008.87	http://dx.doi.org/10.1038/onc.2008.87			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18372912				2022-12-17	WOS:000257881700008
J	Chen, Z; Li, J; Li, QS; Fan, JQ; Dong, XM; Xu, JP; Wang, XM; Yang, GW; Yan, P; Wen, GZ; Zhang, YT; Niu, RG; Nan, PH; He, J; Zhou, HM				Chen, Z.; Li, J.; Li, Q. S.; Fan, J. Q.; Dong, X. M.; Xu, J. P.; Wang, X. M.; Yang, G. W.; Yan, P.; Wen, G. Z.; Zhang, Y. T.; Niu, R. G.; Nan, P. H.; He, J.; Zhou, H. M.			Suppression of PPN/MG61 attenuates Wnt/beta-catenin signaling pathway and induces apoptosis in human lung cancer	ONCOGENE			English	Article						lung cancer; PPN/MG61; apoptosis; wnt; diagnosis	MONOCLONAL-ANTIBODY; WNT; CELLS; GENE; INHIBITION; WINGLESS	Wingless and int homologue (Wnt) family proteins have been shown to have important roles in the decision of cell fate and behavior at multiple stages during the development and tumorigenesis. One of the Drosophila segment polarity genes, porcupine (porc) gene, encodes an evolutionarily conserved endoplasmic reticulum membrane protein involving in the post-translational processing of the Wnt family proteins. Here, we report that human homologue of Drosophila porc gene, PPN/MG61, was abundantly expressed in human cancer cell lines, but not in normal cells. We also found that PPN/MG61 was overexpressed in primary lung cancer tissue samples, compared to their matched normaltis sue samples. Furthermore, when we used small interfering RNA to knock down PPN/MG61 mRNA in lung cancer cells expressing the gene, we observed apoptosis induction, along with decreased activity of Wnt pathway in those lung cancer cells. These data suggest that PPN/MG61 may be a novel marker for human lung cancer and that post-translational modification of the Wnt signal molecules by PPN/MG61 may be important for the function of Wnt pathway in lung cancer.	[Chen, Z.; Li, J.; Li, Q. S.; Fan, J. Q.; Zhou, H. M.] Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China; [Dong, X. M.; Xu, J. P.] Beijing ACCB Biotech Ltd, Beijing, Peoples R China; [Wang, X. M.; Yang, G. W.] Beijing Hosp Tradit Chinese Med, Beijing, Peoples R China; [Yan, P.] Hengxing Hosp, Internal Curat Dept Oncol, Baoding, Hebei, Peoples R China; [Wen, G. Z.; Zhang, Y. T.] Chengde N Hosp, Chengdu, Hebei, Peoples R China; [Niu, R. G.] Shanxi Tumor Hosp, Taiyuan, Shanxi, Peoples R China; [Nan, P. H.] Taigang Gen Hosp, Taiyuan, Shanxi, Peoples R China; [He, J.] Chinese Acad Med Sci, Canc Hosp, Beijing 100037, Peoples R China; [Zhou, H. M.] Tsinghua Univ, Yangtze Delta Reg Inst, Jiaxing, Zhejiang, Peoples R China	Tsinghua University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Tsinghua University	Zhou, HM (corresponding author), Tsinghua Univ, Dept Biol Sci & Biotechnol, 1 Qinghuayuan, Beijing 100084, Peoples R China.	zhm-dbs@tsinghua.edu.cn						Akiyama T, 2000, CYTOKINE GROWTH F R, V11, P273, DOI 10.1016/S1359-6101(00)00011-3; Caricasole A, 2002, GENE, V288, P147, DOI 10.1016/S0378-1119(02)00467-5; He B, 2004, NEOPLASIA, V6, P7, DOI 10.1016/S1476-5586(04)80048-4; He BA, 2005, ONCOGENE, V24, P3054, DOI 10.1038/sj.onc.1208511; Hofmann K, 2000, TRENDS BIOCHEM SCI, V25, P111, DOI 10.1016/S0968-0004(99)01539-X; Kadowaki T, 1996, GENE DEV, V10, P3116, DOI 10.1101/gad.10.24.3116; Katoh M, 2005, ONCOL REP, V14, P1583; Mazieres J, 2005, INT J CANCER, V117, P326, DOI 10.1002/ijc.21160; Mazieres J, 2005, ONCOGENE, V24, P5396, DOI 10.1038/sj.onc.1208568; Mikami I, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-53; Mikels AJ, 2006, ONCOGENE, V25, P7461, DOI 10.1038/sj.onc.1210053; Millar JBA, 2002, GENOME BIOL, V3; Moon Randall T, 2004, Nat Rev Genet, V5, P691, DOI 10.1038/nrg1427; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Rhee CS, 2002, ONCOGENE, V21, P6598, DOI 10.1038/sj.onc.1205920; Tanaka K, 2002, J BIOL CHEM, V277, P12816, DOI 10.1074/jbc.M200187200; Tanaka K, 2000, EUR J BIOCHEM, V267, P4300, DOI 10.1046/j.1432-1033.2000.01478.x; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Widelitz R, 2005, GROWTH FACTORS, V23, P111, DOI 10.1080/08977190500125746; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Winn RA, 2005, J BIOL CHEM, V280, P19625, DOI 10.1074/jbc.M409392200; You L, 2004, CANCER RES, V64, P5385, DOI 10.1158/0008-5472.CAN-04-1227; You L, 2004, CANCER RES, V64, P3474, DOI 10.1158/0008-5472.CAN-04-0115; Zhai L, 2004, J BIOL CHEM, V279, P33220, DOI 10.1074/jbc.M403407200	26	20	20	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	24					3483	3488		10.1038/sj.onc.1211006	http://dx.doi.org/10.1038/sj.onc.1211006			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193088				2022-12-17	WOS:000256309900013
J	Leister, P; Felten, A; Chasan, AI; Scheidtmann, KH				Leister, P.; Felten, A.; Chasan, A. I.; Scheidtmann, K. H.			ZIP kinase plays a crucial role in androgen receptor-mediated transcription	ONCOGENE			English	Article						androgen receptor; AATF/Che-1; co-activators; ZIP kinase/DAP like kinase	PROSTATE-CANCER; DLK/ZIP KINASE; NUCLEAR RECEPTORS; GENE-REGULATION; APOPTOSIS; PHOSPHORYLATION; INTERACTS; CHE-1; GROWTH; IDENTIFICATION	The androgen receptor (AR) is a ligand-dependent transcription factor that plays a crucial role in the development and homeostasis of the prostate and in prostate cancer. The transcriptional activity of AR is mediated by interaction with multiple co-activators, which serve in chromatin modi. cation or remodeling, or provide a link between specific and general transcription factors. We have identified zipper interacting protein (ZIP) kinase as a novel transcriptional co-activator of the AR. ZIP kinase enhanced expression of AR-responsive promotor/luciferase reporter constructs in a hormone-and kinase-dependent manner. Similar results were obtained for glucocorticoid receptor but not for progesterone receptor and estrogen receptor. Following hormone treatment, AR and ZIP kinase formed physical complexes and associated with the promoter and enhancer of the prostate-specific antigen gene, as revealed by chromatin immunoprecipitation. Strikingly, depletion of ZIP kinase by siRNA led to significant reduction of AR-mediated transactivation. The interaction of ZIP kinase with AR seems to be mediated in part by apoptosis antagonizing transcription factor and in part by direct binding. Interestingly, AR was not phosphorylated by ZIP kinase in vitro, suggesting that it phosphorylates other co-activators or chromatin proteins.	[Leister, P.; Felten, A.; Chasan, A. I.; Scheidtmann, K. H.] Univ Bonn, Genet Inst, D-53117 Bonn, Germany	University of Bonn	Scheidtmann, KH (corresponding author), Univ Bonn, Genet Inst, Romerstr 164,NRW, D-53117 Bonn, Germany.	kh.scheidtmann@uni-bonn.de		Imam Chasan, Achmet/0000-0001-5137-6890				Bruno T, 2002, CANCER CELL, V2, P387, DOI 10.1016/S1535-6108(02)00182-4; Bruno T, 2006, CANCER CELL, V10, P473, DOI 10.1016/j.ccr.2006.10.012; Burgdorf S, 2004, J BIOL CHEM, V279, P17524, DOI 10.1074/jbc.M313703200; Chen SY, 2006, P NATL ACAD SCI USA, V103, P15969, DOI 10.1073/pnas.0604193103; Debes JD, 2002, CANCER LETT, V187, P1, DOI 10.1016/S0304-3835(02)00413-5; Di Padova M, 2003, J BIOL CHEM, V278, P36496, DOI 10.1074/jbc.M306694200; Engemann H, 2002, NUCLEIC ACIDS RES, V30, P1408, DOI 10.1093/nar/30.6.1408; Fanciulli M, 2000, FASEB J, V14, P904, DOI 10.1096/fasebj.14.7.904; Felten A, 2007, BIOL CHEM, V388, P569, DOI 10.1515/BC.2007.073; Gao S, 2006, J MOL ENDOCRINOL, V36, P463, DOI 10.1677/jme.1.01991; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Haystead TAJ, 2005, CELL SIGNAL, V17, P1313, DOI 10.1016/j.cellsig.2005.05.008; Kawai T, 2003, MOL CELL BIOL, V23, P6174, DOI 10.1128/MCB.23.17.6174-6186.2003; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Kim J, 2004, J CELL BIOCHEM, V93, P233, DOI 10.1002/jcb.20228; Kogel D, 2001, BIOESSAYS, V23, P352, DOI 10.1002/bies.1050; Kogel D, 1999, ONCOGENE, V18, P7212, DOI 10.1038/sj.onc.1203169; Leister P., 2003, SIGNAL TRANSDUCTION, V3, P17, DOI [10.1002/sita.200300020, DOI 10.1002/SITA.200300020]; Lohrum M, 1996, ONCOGENE, V13, P2527; Lonard DM, 2006, CELL, V125, P411, DOI 10.1016/j.cell.2006.04.021; McEwan IJ, 2004, ENDOCR-RELAT CANCER, V11, P281, DOI 10.1677/erc.0.0110281; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Nelson JD, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj004; OTTEN AD, 1988, MOL ENDOCRINOL, V2, P143, DOI 10.1210/mend-2-2-143; Page G, 1999, ONCOGENE, V18, P7265, DOI 10.1038/sj.onc.1203170; Page G, 1999, FEBS LETT, V462, P187, DOI 10.1016/S0014-5793(99)01529-X; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Sato N, 2005, INT IMMUNOL, V17, P1543, DOI 10.1093/intimm/dxh331; Scheidtmann KH, 2007, SIGNAL TRANSDUCTION, V7, P248, DOI 10.1002/sita.200600112; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; Thomas T, 2000, DEV BIOL, V227, P324, DOI 10.1006/dbio.2000.9915; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Wu RC, 2005, ENDOCR REV, V26, P393, DOI 10.1210/er.2004-0018	36	20	24	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	23					3292	3300		10.1038/sj.onc.1210995	http://dx.doi.org/10.1038/sj.onc.1210995			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18084323				2022-12-17	WOS:000256111400008
J	Mizuno, T; Yamasaki, N; Miyazaki, K; Tazaki, T; Koller, R; Oda, H; Honda, Z; Ochi, M; Wolff, L; Honda, H				Mizuno, T.; Yamasaki, N.; Miyazaki, K.; Tazaki, T.; Koller, R.; Oda, H.; Honda, Z-i; Ochi, M.; Wolff, L.; Honda, H.			Overexpression/enhanced kinase activity of BCR/ABL and altered expression of Notch1 induced acute leukemia in p210BCR/ABL transgenic mice	ONCOGENE			English	Article						chronic myelogenous leukemia; blast crisis; transgenic mice; p210BCR/ABL; Notch1	CHRONIC MYELOGENOUS LEUKEMIA; RETROVIRAL INSERTIONAL MUTAGENESIS; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; BCR-ABL; MYELOPROLIFERATIVE DISEASE; CELL LEUKEMIA; BLAST CRISIS; GENE; CML	Chronic myelogenous leukemia (CML) is a hematopoietic disorder, which begins as indolent chronic phase but inevitably progresses to fatal blast crisis. p210BCR/ABL, a constitutively active tyrosine kinase, is responsible for disease initiation but molecular mechanism(s) underlying disease evolution remains largely unknown. To explore this process, we employed retroviral insertional mutagenesis to CML-exhibiting p210BCR/ABL transgenic mice (Tg). Virus infection induced acute lymphoblastic leukemia (ALL) in p210BCR/ABL Tg with a higher frequency and in a shorter latency than wild-type littermates, and inverse PCR detected two retrovirus common integration sites (CISs) in p210BCR/ABL Tg tumors. Interestingly, one CIS was the transgene itself, where retrovirus integrations induced upregulation of p210BCR/ABL and production of truncated BCR/ABL with an enhanced kinase activity. Another CIS was Notch1 gene, where retrovirus integrations resulted in overexpression of Notch1 and generation of Notch1 lacking the C-terminal region (Notch1DC) associated with stable expression of its activated product, C-terminal-truncated Notch intracellular domain (NICDDC). In addition, generation of Tg for both p210BCR/ABL and Notch1DC developed ALL in a shortened period with Stat5 activation, demonstrating the cooperative oncogenicity of Notch1DC/NICDDC with p210BCR/ABL involving Stat5-mediated pathway. These results demonstrated that overexpression/enhanced kinase activity of BCR/ABL and altered expression of Notch1 induces acute leukemia in a transgenic model for CML.	[Mizuno, T.; Yamasaki, N.; Miyazaki, K.; Tazaki, T.; Honda, H.] Hiroshima Univ, Dept Dev Biol, Res Inst Radiat Biol & Med, Minami Ku, Hiroshima 7348553, Japan; [Mizuno, T.; Ochi, M.] Hiroshima Univ, Sch Med, Dept Orthoped Surg, Hiroshima, Japan; [Koller, R.; Wolff, L.] NCI, Cellular Oncol Lab, Leukemogenesis Sect, Bethesda, MD 20892 USA; [Oda, H.] Tokyo Womens Med Univ, Dept Pathol, Tokyo, Japan; [Honda, Z-i] Univ Tokyo, Grad Sch Sci, Dept Allergy & Rheumatol, Fac Med, Tokyo 113, Japan	Hiroshima University; Hiroshima University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Tokyo Women's Medical University; University of Tokyo	Honda, H (corresponding author), Hiroshima Univ, Dept Dev Biol, Res Inst Radiat Biol & Med, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	hhonda@hiroshima-u.ac.jp	Tazaki, Tatsuya/AAT-4215-2021	Tazaki, Tatsuya/0000-0001-9327-9749	NATIONAL CANCER INSTITUTE [ZIABC011027, Z01BC011027] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Calabretta B, 2004, BLOOD, V103, P4010, DOI 10.1182/blood-2003-12-4111; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Grabher C, 2006, NAT REV CANCER, V6, P347, DOI 10.1038/nrc1880; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; Honda H, 1997, BIOCHEM BIOPH RES CO, V234, P376, DOI 10.1006/bbrc.1997.6650; Huettner CS, 2003, BLOOD, V102, P3363, DOI 10.1182/blood-2003-03-0768; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Ilagan Maria Xenia G, 2007, Cell, V128, P1246; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Kamakura S, 2004, NAT CELL BIOL, V6, P547, DOI 10.1038/ncb1138; Koschmieder S, 2005, BLOOD, V105, P324, DOI 10.1182/blood-2003-12-4369; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Lin YW, 2006, BLOOD, V107, P2540, DOI 10.1182/blood-2005-07-3013; Mikkers H, 2003, ADV CANCER RES, V88, P53, DOI 10.1016/S0065-230X(03)88304-5; Monsalve E, 2006, J IMMUNOL, V176, P5362, DOI 10.4049/jimmunol.176.9.5362; Nakamura T, 2005, CANCER SCI, V96, P7, DOI 10.1111/j.1349-7006.2005.00011.x; Niki M, 2004, J EXP MED, V200, P1689, DOI 10.1084/jem.20041306; O'Neil J, 2006, BLOOD, V107, P781, DOI 10.1182/blood-2005-06-2553; Pane F, 2002, ONCOGENE, V21, P8652, DOI 10.1038/sj.onc.1206094; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Scherr M, 2006, BLOOD, V107, P3279, DOI 10.1182/blood-2005-08-3087; SHORE SK, 1994, J BIOL CHEM, V269, P5413; Shuai K, 1996, ONCOGENE, V13, P247; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wolff L, 2003, ONCOGENE, V22, P9265, DOI 10.1038/sj.onc.1207092; Wolff L, 2003, J VIROL, V77, P4965, DOI 10.1128/JVI.77.8.4965-4971.2003; Yamashita N, 2005, BRIT J HAEMATOL, V131, P495, DOI 10.1111/j.1365-2141.2005.05793.x; Ye D, 2006, BLOOD, V107, P4917, DOI 10.1182/blood-2005-10-4110; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829	38	20	21	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	24					3465	3474		10.1038/sj.onc.1211007	http://dx.doi.org/10.1038/sj.onc.1211007			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193087	Green Submitted, Bronze			2022-12-17	WOS:000256309900011
J	Tao, WJ; Lin, H; Sun, T; Samanta, AK; Arlinghaus, R				Tao, W. J.; Lin, H.; Sun, T.; Samanta, A. K.; Arlinghaus, R.			BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor	ONCOGENE			English	Article						BCR-ABL; interleukin-3 receptor; leukemia; oncogenic transformation	TYROSINE PHOSPHORYLATION; MYELOID-LEUKEMIA; CELLS; JAK2; P210; ACTIVATION; INHIBITOR; BCR/ABL; GROWTH; MYC	Oncogenic transformation of hematopoietic cells by the Bcr-Abl oncoprotein directly involves the activation Jak2 tyrosine kinase and the Stat5 transcription factor. Both proteins are normally linked to the interleukin (IL)-3/granulocyte- macrophage colony-stimulating factor receptors for growth and survival. Since fibroblastic cells are not targets of BCR-ABL-induced oncogenesis, we determined whether forced expression of the IL-3 receptor would allow oncogenic transformation of NIH 3T3 fibroblasts known to be resistant to transformation by BCR-ABL. NIH 3T3 cells transduced with the human IL-3 receptor alpha and beta chains were highly susceptible to oncogenic transformation by expression of BCR-ABL. Forced expression of both receptor chains but not either one alone allowed efficient foci formation of NIH 3T3 cells expressing BCR-ABL (triple positive cells), and these cells formed colonies in soft agar, whereas BCR-ABL+ NIH 3T3 cells lacking IL-3 receptor expression did not. Signaling studies indicate that the BCR-ABL/IL-3 receptor+ NIH 3T3 cells utilize the Gab2/PI-3 kinase pathway activated by Jak2, and the Stat5 pathway activated separately by Bcr-Abl, whereas BCR-ABL+ NIH 3T3 cells lacking the IL-3 receptor do not utilize the Jak2 pathway, but still maintain activation of Stat5. The Bcr-Abl kinase inhibitor imatinib mesylate (1 mu M) and two Jak2 kinase inhibitors strongly inhibited agar colony formation and the activation of Gab2 caused by Jak2. All of these findings indicate that Bcr-Abl oncoprotein requires the IL-3 receptor/Jak2/Stat5 pathways for oncogenic transformation of NIH 3T3 fibroblasts.	[Tao, W. J.; Lin, H.; Sun, T.; Samanta, A. K.; Arlinghaus, R.] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77054 USA	University of Texas System; UTMD Anderson Cancer Center	Arlinghaus, R (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, 7435 Fannin St,Unit 951, Houston, TX 77054 USA.	rarlingh@mdanderson.org			NATIONAL CANCER INSTITUTE [P01CA049639] Funding Source: NIH RePORTER; NCI NIH HHS [CA49639, P01 CA049639-09A10019, P01 CA049639] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; GROFFEN J, 1993, LEUKEMIA LYMPHOMA, V11, P19, DOI 10.3109/10428199309047857; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Klejman A, 2002, EMBO J, V21, P5766, DOI 10.1093/emboj/cdf562; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; Miyamoto N, 2001, LEUKEMIA, V15, P1758, DOI 10.1038/sj.leu.2402260; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Samanta AK, 2006, CANCER RES, V66, P6468, DOI 10.1158/0008-5472.CAN-06-0025; Sandberg EM, 2005, J MED CHEM, V48, P2526, DOI 10.1021/jm049470k; SIRARD C, 1994, BLOOD, V83, P1575; Watanabe Sumiko, 1997, Leukemia (Basingstoke), V11, P76; WilsonRawls J, 1996, CANCER RES, V56, P3426; Xie SH, 2002, ONCOGENE, V21, P7137, DOI 10.1038/sj.onc.1205942; Xie SH, 2001, ONCOGENE, V20, P6188, DOI 10.1038/sj.onc.1204834; YOKOTA T, 1993, LEUKEMIA, V7, pS102	16	20	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	22					3194	3200		10.1038/sj.onc.1210979	http://dx.doi.org/10.1038/sj.onc.1210979			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18071309	Green Accepted			2022-12-17	WOS:000255897600012
J	Stocklein, H; Smardova, J; Macak, J; Katzenberger, T; Holler, S; Wessendorf, S; Hutter, G; Dreyling, M; Haralambieva, E; Mader, U; Muller-Hermelink, HK; Rosenwald, A; Ott, G; Kalla, J				Stoecklein, H.; Smardova, J.; Macak, J.; Katzenberger, T.; Hoeller, S.; Wessendorf, S.; Hutter, G.; Dreyling, M.; Haralambieva, E.; Maeder, U.; Mueller-Hermelink, H. K.; Rosenwald, A.; Ott, G.; Kalla, J.			Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma	ONCOGENE			English	Article						diffuse large B-cell lymphoma; del(17p); TP53; HIC1	NON-HODGKINS-LYMPHOMA; COMPARATIVE GENOMIC HYBRIDIZATION; FUNCTIONAL ASSAY; BREAST-CANCER; P53 GENE; DNA HYPERMETHYLATION; DELETED REGION; MULTIPLE GENES; OVARIAN-CANCER; EXPRESSION	Deletions in the short arm of chromosome 17 (17p) involving the tumor suppressor TP53 occur in up to 20% of diffuse large B-cell lymphomas (DLBCLs). Although inactivation of both alleles of a tumor suppressor gene is usually required for tumor development, the overlap between TP53 deletions and mutations is poorly understood in DLBCLs, suggesting the possible existence of additional tumor suppressor genes in 17p. Using a bacterial artificial chromosome (BAC) and Phage 1 artificial chromosome (PAC) contig, we here de. ne a minimally deleted region in DLBCLs encompassing approximately 0.8MB telomeric to the TP53 locus. This genomic region harbors the tumor suppressor Hypermethylated in Cancer 1 (HIC1). Methylation-specific PCR demonstrated hypermethylation of HIC1 exon 1a in a substantial subset of DLBCLs, which is accompanied by simultaneous HIC1 deletion of the second allele in 90% of cases. In contrast, HIC1 inactivation by hypermethylation was rarely encountered in DLBCLs without concomitant loss of the second allele. DLBCL patients with complete inactivation of both HIC1 and TP53 may be characterized by an even inferior clinical course than patients with inactivation of TP53 alone, suggesting a functional cooperation between these two proteins. These findings strongly imply HIC1 as a novel tumor suppressor in a subset of DLBCLs.	[Ott, G.] Robert Bosch Krankenhaus, Dept Clin Pathol, D-70376 Stuttgart, Germany; [Stoecklein, H.; Katzenberger, T.; Hoeller, S.; Haralambieva, E.; Mueller-Hermelink, H. K.; Rosenwald, A.; Ott, G.; Kalla, J.] Univ Wurzburg, Inst Pathol, D-97070 Wurzburg, Germany; [Smardova, J.; Macak, J.] Masaryk Univ, Fac Med, Dept Pathol, Brno, Czech Republic; [Smardova, J.; Macak, J.] Fac Hosp Brno, Brno, Czech Republic; [Wessendorf, S.] Univ Ulm, Innere Med Klin 3, Ulm, Germany; [Hutter, G.; Dreyling, M.] Univ Munchen Grosshadern, Med Klin & Poliklin 2, Munich, Germany; [Maeder, U.] Univ Wurzburg, Interdisciplinary Canc Ctr, Wurzburg, Germany	Bosch; Robert Bosch Krankenhaus; University of Wurzburg; Masaryk University Brno; University Hospital Brno; Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; University of Wurzburg	Ott, G (corresponding author), Robert Bosch Krankenhaus, Dept Clin Pathol, Auerbachstr 110, D-70376 Stuttgart, Germany.	german.ott@rbk.de		Holler, Sylvia/0000-0001-9277-7076				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bea S, 2005, BLOOD, V106, P3183, DOI 10.1182/blood-2005-04-1399; Britschgi C, 2006, ONCOGENE, V25, P2030, DOI 10.1038/sj.onc.1209240; Chen CM, 2004, GENE DEV, V18, P320, DOI 10.1101/gad.1162204; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077; Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Deltour S, 2002, MOL CELL BIOL, V22, P4890, DOI 10.1128/MCB.22.13.4890-4901.2002; Dong SM, 2001, CLIN CANCER RES, V7, P1982; Duddy PM, 2000, J MOL DIAGN, V2, P139, DOI 10.1016/S1525-1578(10)60629-0; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Goff LK, 2000, BRIT J HAEMATOL, V111, P618, DOI 10.1046/j.1365-2141.2000.02352.x; Guerardel C, 2001, J BIOL CHEM, V276, P3078, DOI 10.1074/jbc.M008690200; Haralambieva E, 2002, J PATHOL, V198, P163, DOI 10.1002/path.1197; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hida Y, 2007, ARCH DERMATOL RES, V299, P103, DOI 10.1007/s00403-006-0725-6; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Ichikawa A, 1997, NEW ENGL J MED, V337, P529, DOI 10.1056/NEJM199708213370804; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Issa JPJ, 1997, CANCER RES, V57, P1678; Jaffe ES, 2001, WHO CLASSIFICATION T; Kanai Y, 1999, HEPATOLOGY, V29, P703, DOI 10.1002/hep.510290338; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Koduru PRK, 1997, BLOOD, V90, P4078, DOI 10.1182/blood.V90.10.4078; Konishi H, 2003, ONCOGENE, V22, P1892, DOI 10.1038/sj.onc.1206304; LICHTER P, 1995, METHOD ENZYMOL, V254, P334; Lossos IS, 2005, J CLIN ONCOL, V23, P6351, DOI 10.1200/JCO.2005.05.012; Meinhold-Heerlein I, 2001, ONCOLOGY-BASEL, V60, P176, DOI 10.1159/000055316; Melki JR, 1999, CANCER RES, V59, P3730; Nenutil R, 2005, J PATHOL, V207, P251, DOI 10.1002/path.1838; Phillips NJ, 1996, CANCER RES, V56, P606; Pinte S, 2004, J BIOL CHEM, V279, P38313, DOI 10.1074/jbc.M401610200; Pinyol M, 2000, AM J PATHOL, V156, P1987, DOI 10.1016/S0002-9440(10)65071-7; Prowse AH, 2002, INT J CANCER, V99, P185, DOI 10.1002/ijc.10334; Rathi A, 2003, CLIN CANCER RES, V9, P3674; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Rosenwald A, 2003, J EXP MED, V198, P851, DOI 10.1084/jem.20031074; Rosenwald A, 2003, CANCER CELL, V3, P185, DOI 10.1016/S1535-6108(03)00028-X; Rudiger T, 1998, AM J SURG PATHOL, V22, P1184, DOI 10.1097/00000478-199810000-00003; Sankar M, 1998, LEUKEMIA, V12, P510, DOI 10.1038/sj.leu.2400973; Savage KJ, 2003, BLOOD, V102, P3871, DOI 10.1182/blood-2003-06-1841; SAXENA A, 1992, CANCER RES, V52, P6716; Schlegelberger B, 1999, BLOOD, V94, P3114; Schultz DC, 1996, CANCER RES, V56, P1997; Seitz S, 2001, J PATHOL, V194, P318, DOI 10.1002/1096-9896(200107)194:3<318::AID-PATH881>3.0.CO;2-4; Shaffer LG., 2005, INT SYSTEM HUMAN CYT; Smardova J, 2001, TUMOR BIOL, V22, P59; Stokke T, 2001, BRIT J CANCER, V85, P1900, DOI 10.1054/bjoc.2001.2164; Stokke T, 2000, INT J CANCER, V89, P313, DOI 10.1002/1097-0215(20000720)89:4<313::AID-IJC1>3.0.CO;2-D; von Bergh A, 2000, GENE CHROMOSOME CANC, V28, P14, DOI 10.1002/(SICI)1098-2264(200005)28:1<14::AID-GCC2>3.3.CO;2-O; Waha A, 2004, INT J CANCER, V110, P542, DOI 10.1002/ijc.20165; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812; Zettl A, 2000, AM J PATHOL, V157, P257, DOI 10.1016/S0002-9440(10)64536-1; Zhang QH, 2007, P NATL ACAD SCI USA, V104, P829, DOI 10.1073/pnas.0610590104	58	20	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2008	27	18					2613	2625		10.1038/sj.onc.1210901	http://dx.doi.org/10.1038/sj.onc.1210901			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17982487				2022-12-17	WOS:000255057000011
J	Nardi, V; Raz, T; Cao, X; Wu, CJ; Stone, RM; Cortes, J; Deininger, MWN; Church, G; Zhu, J; Daley, GQ				Nardi, V.; Raz, T.; Cao, X.; Wu, C. J.; Stone, R. M.; Cortes, J.; Deininger, M. W. N.; Church, G.; Zhu, J.; Daley, G. Q.			Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors	ONCOGENE			English	Article						mutations detection; solid-phase PCR; drug resistance	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; DASATINIB BMS-354825; DOMAIN MUTATIONS; IMATINIB; RECOMMENDATIONS; MUTAGENESIS	Resistance to molecularly targeted chemotherapy, and the development of novel agents that are active against resistant forms of target proteins create the need for a sensitive and quantitative assay to monitor drug-resistant mutations in patients to guide treatment and assess response. Here, we describe an application of the polymerase colony (polony) method to identify and quantify known point mutations in the BCR-ABL oncogene in patients with chronic myelogenous leukemia who evolve resistance to ABL kinase inhibitors. The assay can detect mutations with a sensitivity of 10(-4), quantify the burden of drug-resistant cells, and simultaneously monitor the dynamics of several coexisting mutations. As a proof of concept, we analysed blood samples from three patients undergoing therapy with ABL kinase inhibitors and found that the patients' response to therapy correlated with our molecular monitoring. We were also able to detect mutations emerging in patients long before clinical relapse. Therefore, the polony assay could be applied to a larger patient sample to assess the utility of early mutation detection in patient-specific treatment decisions. Finally, this methodology could be a valuable research tool to shed light on the natural behavior of mutations pre-existing kinase inhibitors therapy and either disappearing over time or slowly taking over.	[Cao, X.; Zhu, J.] Duke Univ, Inst Genome Sci & Policy, Dept Cell Biol, Durham, NC 27708 USA; [Nardi, V.; Raz, T.; Daley, G. Q.] Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Biol Chem & Mol Pharmacol,Div Hematol Oncol, Boston, MA 02115 USA; [Wu, C. J.; Stone, R. M.] Childrens Hosp, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Deininger, M. W. N.] Oregon Hlth & Sci Univ, Inst Canc, Div Hematol Oncol, Portland, OR 97201 USA; [Cortes, J.] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA; [Church, G.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Duke University; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Oregon Health & Science University; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; Harvard University; Harvard Medical School	Zhu, J (corresponding author), Duke Univ, Inst Genome Sci & Policy, Dept Cell Biol, 2353A CIEMAS,101 Sci Dr, Durham, NC 27708 USA.	jun.zhu@duke.edu; george.daley@childrens.harvard.edu		church, george/0000-0001-6232-9969; Cortes, Jorge/0000-0002-8636-1071	NATIONAL CANCER INSTITUTE [F32CA101505] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL066987] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA86691, F32-CA101505] Funding Source: Medline; NHLBI NIH HHS [T32 HL066987-06] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Baccarani M, 2006, BLOOD, V108, P1809, DOI 10.1182/blood-2006-02-005686; Bradeen HA, 2006, BLOOD, V108, P2332, DOI 10.1182/blood-2006-02-004580; Butz J, 2003, BMC BIOTECHNOL, V3, DOI 10.1186/1472-6750-3-11; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Diehl F, 2006, NAT METHODS, V3, P551, DOI 10.1038/NMETH898; Hughes T, 2006, BLOOD, V108, P28, DOI 10.1182/blood-2006-01-0092; Kang HY, 2006, HAEMATOLOGICA, V91, P659; KANTARJIAN HM, 2006, BLOOD, V18, P18; Li M, 2006, NAT METHODS, V3, P95, DOI 10.1038/NMETH850; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Mitra RD, 2003, P NATL ACAD SCI USA, V100, P5926, DOI 10.1073/pnas.0936399100; Mitra RD, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.24.e34; Quintas-Cardama A, 2007, BLOOD, V109, P497, DOI 10.1182/blood-2006-07-035493; Soverini S, 2004, CLIN CHEM, V50, P1205, DOI 10.1373/clinchem.2004.031112; Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229; Thomas RK, 2006, NAT MED, V12, P852, DOI 10.1038/nm1437; Willis SG, 2005, BLOOD, V106, P2128, DOI 10.1182/blood-2005-03-1036; ZHAM M, 2006, P NATL ACAD SCI USA, V103, P9244; Zhang K, 2006, NAT GENET, V38, P382, DOI 10.1038/ng1741; Zhu J, 2003, SCIENCE, V301, P836, DOI 10.1126/science.1085792	21	20	44	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2008	27	6					775	782		10.1038/sj.onc.1210698	http://dx.doi.org/10.1038/sj.onc.1210698			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17684485				2022-12-17	WOS:000252884500006
J	Ogawa, E; Okuyama, R; Ikawa, S; Nagoshi, H; Egawa, T; Kurihara, A; Yabuki, M; Tagami, H; Obinata, M; Aiba, S				Ogawa, E.; Okuyama, R.; Ikawa, S.; Nagoshi, H.; Egawa, T.; Kurihara, A.; Yabuki, M.; Tagami, H.; Obinata, M.; Aiba, S.			P51/p63 inhibits ultraviolet B-induced apoptosis via Akt activation	ONCOGENE			English	Article						p51/p63; p53; apoptosis; UV; epidermis	SKIN-CANCER; P53 HOMOLOG; TERMINAL DIFFERENTIATION; HUMAN KERATINOCYTES; DOWN-REGULATION; P63; PATHWAY; DELTA-NP63-ALPHA; TRANSCRIPTION; DEGRADATION	The epidermis must be protected against excess apoptotic cell death in response to ultraviolet-B (UV-B) irradiation. p53 is known to be critical for this protection. Although the p53 family member Delta Np51B/Delta Np63a (an N terminal-deleted form of p51/p63) is abundantly expressed in keratinocytes, its contribution to UV-B-dependent apoptosis is largely unknown. We found that, after a transient increase, Delta Np51B is downregulated in UV-B-irradiated keratinocytes undergoing apoptosis, whereas p53 is upregulated with delayed kinetics. Furthermore, the reduction of Delta Np51B by small interfering RNAs augmented UV- B-dependent apoptosis in keratinocytes, indicating that Delta Np51B blocks keratinocyte apoptosis. Although the exogenous expression of Delta Np51B in keratinocytes did not further block the UV-B-dependent apoptosis, to our surprise the expression of TAp51B (an isoform with a full NH2-terminal transactivation domain that is structurally and functionally similar to p53) decreased apoptosis significantly. The blockade of keratinocyte apoptosis by the p51 was dependent on the phosphorylation of Akt, resulting in the activation of a survival pathway. Thus, in addition to its indispensable roles in epithelial development, p51 acts in adult cells to protect the epidermis against UV-B irradiation by preventing excess depletion of keratinocytes.	[Ogawa, E.; Okuyama, R.; Egawa, T.; Tagami, H.; Aiba, S.] Tohoku Univ, Grad Sch Med, Dept Dermatol, Aoba Ku, Sendai, Miyagi 9808574, Japan; [Ikawa, S.; Nagoshi, H.; Kurihara, A.; Yabuki, M.; Obinata, M.] Tohoku Univ, Inst Dev Aging & Canc, Dept Cell Biol, Aoba Ku, Sendai, Miyagi 9808574, Japan; [Ikawa, S.; Nagoshi, H.; Kurihara, A.; Yabuki, M.] Tohoku Univ, Interdisciplinary Res Ctr, Aoba Ku, Sendai, Miyagi 9808574, Japan	Tohoku University; Tohoku University; Tohoku University	Okuyama, R (corresponding author), Tohoku Univ, Grad Sch Med, Dept Dermatol, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	rokuyama@mail.tains.tohoku.ac.jp	井川, 俊太郎/L-5911-2015					Bamberger C, 2002, J INVEST DERMATOL, V118, P133, DOI 10.1046/j.0022-202x.2001.01649.x; Brunner HG, 2002, J MED GENET, V39, P377, DOI 10.1136/jmg.39.6.377; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; CUI R, 2005, BIOCH BIOPHYS RES CO; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Jiang WD, 1999, ONCOGENE, V18, P4247, DOI 10.1038/sj.onc.1202789; Keyes WM, 2005, GENE DEV, V19, P1986, DOI 10.1101/gad.342305; Koster MI, 2006, CANCER RES, V66, P3981, DOI 10.1158/0008-5472.CAN-06-0027; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; Liefer KM, 2000, CANCER RES, V60, P4016; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mills AA, 2006, CURR OPIN GENET DEV, V16, P38, DOI 10.1016/j.gde.2005.12.001; Okuyama R, 2007, ONCOGENE, V26, P4478, DOI 10.1038/sj.onc.1210235; Okuyama R, 2004, DEV CELL, V6, P551, DOI 10.1016/S1534-5807(04)00098-X; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Papoutsaki M, 2005, ONCOGENE, V24, P6970, DOI 10.1038/sj.onc.1208835; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Thrash BR, 2006, J BIOL CHEM, V281, P12155, DOI 10.1074/jbc.M512116200; Waltermann A, 2003, ONCOGENE, V22, P5686, DOI 10.1038/sj.onc.1206859; Wang HQ, 2003, J BIOL CHEM, V278, P45737, DOI 10.1074/jbc.M300574200; Westfall MD, 2005, CELL CYCLE, V4, P710, DOI 10.4161/cc.4.5.1685; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	26	20	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2008	27	6					848	856		10.1038/sj.onc.1210682	http://dx.doi.org/10.1038/sj.onc.1210682			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17653081				2022-12-17	WOS:000252884500014
J	Takeyama, K; Monti, S; Manis, JP; Dal Cin, P; Getz, G; Beroukhim, R; Dutt, S; Aster, JC; Alt, FW; Golub, TR; Shipp, MA				Takeyama, K.; Monti, S.; Manis, J. P.; Dal Cin, P.; Getz, G.; Beroukhim, R.; Dutt, S.; Aster, J. C.; Alt, F. W.; Golub, T. R.; Shipp, M. A.			Integrative analysis reveals 53BP1 copy loss and decreased expression in a subset of human diffuse large B-cell lymphomas	ONCOGENE			English	Article						DNA damage; 53BP1; lymphoma; genetic abnormalities; high-density single nucleotide polymorphism array	CLASS-SWITCH RECOMBINATION; DNA-DAMAGE; HUMAN GENOME; PROTEIN 53BP1; BCL6; P53; SUPPRESS; BREAKS; TRANSLOCATIONS; TRANSCRIPTION	p53-Binding protein 1 (53BP1) encodes a critical checkpoint protein that localizes to sites of DNA double-strand breaks (DSBs) and participates in DSB repair. Mice that are 53bp1 deficient or hemizygous have an increased incidence of lymphoid malignancies. However, 53BP1 abnormalities in primary human tumors have not been described. By combining high-density single nucleotide polymorphism (HD SNP) array data and gene expression profiles, we found 9 of 63 newly diagnosed human diffuse large B-cell lymphomas (DLBCLs) with single copy loss of the chromosome 15q15 region including the 53BP1 locus; these nine tumors also had significantly lower levels of 53BP1 transcripts. 53BP1 single copy loss found with the HD SNP array platform was subsequently confirmed by fluorescence in situ hybridization. These studies highlight the role of 53BP1 copy loss in primary human DLBCLs and the value of integrative analyses in detecting this genetic lesion in human tumors.	[Takeyama, K.; Beroukhim, R.; Shipp, M. A.] Dana Fraber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Monti, S.; Getz, G.; Beroukhim, R.; Golub, T. R.] Broad Inst Massachusetts Inst Technol, Cambridge, MA USA; [Monti, S.; Getz, G.; Beroukhim, R.; Golub, T. R.] Harvard Univ, Cambridge, MA 02138 USA; [Manis, J. P.; Dutt, S.] Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA; [Dal Cin, P.; Aster, J. C.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Alt, F. W.] Childrens Hosp, Howard Hughes Med Inst, CBR Inst Biomed Res, Boston, MA 02115 USA; [Alt, F. W.] Harvard Med Sch, Dept Genet, Boston, MA 02115 USA; [Golub, T. R.] Dana Fraber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Shipp, MA (corresponding author), Dana Fraber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	margaret_shipp@dfci.harvard.edu			NCI NIH HHS [K08 CA122833-01A1, P01 CA92625, P01 CA092625, K08 CA122833] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA122833, P01CA092625] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams MM, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-19; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BEROUKHIM R, UNPUB GENOME WIDE AN; Chaudhuri J, 2004, NAT REV IMMUNOL, V4, P541, DOI 10.1038/nri1395; Conrad DF, 2006, NAT GENET, V38, P75, DOI 10.1038/ng1697; Fodde R, 2002, SCIENCE, V298, P761, DOI 10.1126/science.1077707; Franco S, 2006, MOL CELL, V21, P201, DOI 10.1016/j.molcel.2006.01.005; Franco S, 2006, DNA REPAIR, V5, P1030, DOI 10.1016/j.dnarep.2006.05.024; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hupe P, 2004, BIOINFORMATICS, V20, P3413, DOI 10.1093/bioinformatics/bth418; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069; Manis JP, 2004, NAT IMMUNOL, V5, P481, DOI 10.1038/ni1067; McCarroll SA, 2006, NAT GENET, V38, P86, DOI 10.1038/ng1696; Mochan TA, 2004, DNA REPAIR, V3, P945, DOI 10.1016/j.dnarep.2004.03.017; Monti S, 2005, BLOOD, V105, P1851, DOI 10.1182/blood-2004-07-2947; Morales JC, 2006, P NATL ACAD SCI USA, V103, P3310, DOI 10.1073/pnas.0511259103; Phan RT, 2004, NATURE, V432, P635, DOI 10.1038/nature03147; Phan RT, 2005, NAT IMMUNOL, V6, P1054, DOI 10.1038/ni1245; Polo JM, 2007, P NATL ACAD SCI USA, V104, P3207, DOI 10.1073/pnas.0611399104; Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Takahashi H, 2006, CLIN CANCER RES, V12, P3265, DOI 10.1158/1078-0432.CCR-06-0076; Ward IM, 2003, MOL CELL BIOL, V23, P2556, DOI 10.1128/MCB.23.7.2556-2563.2003; Ward IM, 2005, MOL CELL BIOL, V25, P10079, DOI 10.1128/MCB.25.22.10079-10086.2005; Ward IM, 2003, J BIOL CHEM, V278, P19579, DOI 10.1074/jbc.C300117200; Wu XS, 2005, NAT IMMUNOL, V6, P964, DOI 10.1038/ni1005-964; Zhao XJ, 2004, CANCER RES, V64, P3060, DOI 10.1158/0008-5472.CAN-03-3308	30	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2008	27	3					318	322		10.1038/sj.onc.1210650	http://dx.doi.org/10.1038/sj.onc.1210650			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17637749				2022-12-17	WOS:000252256000007
J	Callen, E; Nussenzweig, MC; Nussenzweig, A				Callen, E.; Nussenzweig, M. C.; Nussenzweig, A.			Breaking down cell cycle checkpoints and DNA repair during antigen receptor gene assembly	ONCOGENE			English	Review						DNA repair; cell cycle checkpoints; class-switching; V(D)J recombination; ATM; lymphoma	CLASS-SWITCH RECOMBINATION; GENOMIC INSTABILITY; V(D)J RECOMBINATION; CHROMOSOME-ABERRATIONS; REGION RECOMBINATION; ATM; ACTIVATION; ADAPTATION; RADIATION; 53BP1	Double-strand breaks (DSBs) are intermediates in several physiological processes including V(D)J and class switch recombination. They are also potent substrates for chromosomal translocations that arise as by-products of antigen receptor gene assembly in lymphocytes. ATM is one among several key proteins involved in the detection, signaling and repair of DNA breaks. Despite redundancies in DSB signaling pathways, it has recently been demonstrated that ATM deficient lymphocytes can survive and proliferate several generations in vitro and in vivo despite harboring terminally deleted chromosomes produced by V(D)J recombination. In this review, we discuss how two complementary genome maintenance functions mediated by ATM prevent lymphocytes from adapting to persistent DNA damage.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; Rockefeller Univ, Lab Mol Immunol, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Rockefeller University; Howard Hughes Medical Institute	Callen, E (corresponding author), NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA.	callene@mail.nih.gov	Nussenzweig, Michel/AAE-7292-2019					AWA A A, 1978, Journal of Radiation Research, V19, P126, DOI 10.1269/jrr.19.126; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Bertoni F, 1999, GENE CHROMOSOME CANC, V26, P176, DOI 10.1002/(SICI)1098-2264(199910)26:2<176::AID-GCC11>3.3.CO;2-V; Bredemeyer AL, 2006, NATURE, V442, P466, DOI 10.1038/nature04866; Callen E, 2007, CELL, V130, P63, DOI 10.1016/j.cell.2007.06.016; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Cuadrado M, 2006, J EXP MED, V203, P297, DOI 10.1084/jem.20051923; Deckbar D, 2007, J CELL BIOL, V176, P749, DOI 10.1083/jcb.200612047; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; Galgoczy DJ, 2001, MOL CELL BIOL, V21, P1710, DOI 10.1128/MCB.21.5.1710-1718.2001; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Huang CY, 2007, J EXP MED, V204, P1371, DOI 10.1084/jem.20061460; Jankovic M, 2007, NAT IMMUNOL, V8, P801, DOI 10.1038/ni1498; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; KANO Y, 1984, CANCER RES, V44, P3706; Kaye JA, 2004, CURR BIOL, V14, P2096, DOI 10.1016/j.cub.2004.10.051; Kracker S, 2005, P NATL ACAD SCI USA, V102, P1584, DOI 10.1073/pnas.0409191102; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Liyanage M, 2000, BLOOD, V96, P1940, DOI 10.1182/blood.V96.5.1940.h8001940_1940_1946; Lumsden JM, 2004, J EXP MED, V200, P1111, DOI 10.1084/jem.20041074; Manis JP, 2004, NAT IMMUNOL, V5, P481, DOI 10.1038/ni1067; Matei IR, 2007, BLOOD, V109, P1887, DOI 10.1182/blood-2006-05-020917; Morales JC, 2006, P NATL ACAD SCI USA, V103, P3310, DOI 10.1073/pnas.0511259103; Myers JS, 2006, J BIOL CHEM, V281, P9346, DOI 10.1074/jbc.M513265200; NORMAN A, 1966, BLOOD-J HEMATOL, V27, P706, DOI 10.1182/blood.V27.5.706.706; Nussenzweig A, 2007, CELL, V131, P223, DOI 10.1016/j.cell.2007.10.005; NUSSENZWEIG MC, 1988, NATURE, V336, P446, DOI 10.1038/336446a0; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; Pellegrini M, 2006, NATURE, V443, P222, DOI 10.1038/nature05112; Perkins EJ, 2002, GENE DEV, V16, P159, DOI 10.1101/gad.956902; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Petiniot LK, 2000, P NATL ACAD SCI USA, V97, P6664, DOI 10.1073/pnas.97.12.6664; Ramiro AR, 2006, CANCER RES, V66, P7837, DOI 10.1158/0008-5472.CAN-06-0863; Ramiro AR, 2004, CELL, V118, P431, DOI 10.1016/j.cell.2004.08.006; Ramiro AR, 2006, NATURE, V440, P105, DOI 10.1038/nature04495; Reina-San-Martin B, 2005, P NATL ACAD SCI USA, V102, P1590, DOI 10.1073/pnas.0406289102; Reina-San-Martin B, 2004, J EXP MED, V200, P1103, DOI 10.1084/jem.20041162; Reina-San-Martin B, 2003, J EXP MED, V197, P1767, DOI 10.1084/jem.20030569; Reina-San-Martin B, 2007, EUR J IMMUNOL, V37, P235, DOI 10.1002/eji.200636789; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SASAKI MS, 1967, NATURE, V214, P502, DOI 10.1038/214502a0; Shreeram S, 2006, J EXP MED, V203, P2793, DOI 10.1084/jem.20061563; Spruill MD, 1996, MUTAT RES-FUND MOL M, V356, P135, DOI 10.1016/0027-5107(95)00218-9; Stiff T, 2006, EMBO J, V25, P5775, DOI 10.1038/sj.emboj.7601446; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Syljuasen RG, 2006, CANCER RES, V66, P10253, DOI 10.1158/0008-5472.CAN-06-2144; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Vacchio MS, 2007, P NATL ACAD SCI USA, V104, P6323, DOI 10.1073/pnas.0611222104; Ward IM, 2005, MOL CELL BIOL, V25, P10079, DOI 10.1128/MCB.25.22.10079-10086.2005; Ward IM, 2004, J CELL BIOL, V165, P459, DOI 10.1083/jcb.200403021; Yan CT, 2007, NATURE, V449, P478, DOI 10.1038/nature06020; Yoo HY, 2007, J BIOL CHEM, V282, P17501, DOI 10.1074/jbc.M701770200; Yoo HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9	57	20	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2007	26	56					7759	7764		10.1038/sj.onc.1210873	http://dx.doi.org/10.1038/sj.onc.1210873			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SL	18066088				2022-12-17	WOS:000251537900006
J	Zhao, LJ; Subramanian, T; Vijayalingam, S; Chinnadurai, G				Zhao, L-J; Subramanian, T.; Vijayalingam, S.; Chinnadurai, G.			PLDLS-dependent interaction of E1A with CtBP: regulation of CtBP nuclear localization and transcriptional functions	ONCOGENE			English	Article						E1A; CtBP; p300; acetylation; E-cadherin; c-fos	COREPRESSOR CTBP; CELLULAR PHOSPHOPROTEIN; NEGATIVE MODULATION; FAMILY PROTEINS; TERMINAL DOMAIN; ACETYLATION; BINDING; TRANSFORMATION; TUMORIGENESIS; ASSOCIATION	C-terminal binding proteins (CtBPs) are cellular corepressors that are targeted by adenovirus E1A. A conserved motif of E1A (PLDLS) interacts with an N-terminal hydrophobic cleft of CtBPs. Many cellular cofactors also interact with CtBPs through PLDLS-like motifs. E1A interaction with CtBP2 changed the composition of the CtBP2 protein complex and enhanced CtBP2 acetylation. We have identified a mutant of CtBP2 (M48A) that fails to interact with cellular cofactors while interacting normally with E1A. Other cleft mutations in CtBP2 affected interaction of both cellular cofactors and E1A. The M48A mutant did not repress the cellular E-cadherin promoter but inhibited transactivation mediated by the E1A N-terminal region through interaction with the E1A PLDLS motif. In vitro, E1A enhanced CtBP2 acetylation by p300 via a mechanism involving dissociation of acetylated CtBP2 from p300. E1A enhanced nuclear localization of CtBP1 as well as a cytoplasmically localized acetylation-deficient mutant of CtBP2 (3KR-CtBP2) through PLDLS-dependent interaction. Chromatin immunoprecipitation assays revealed presence of CtBP2 on E-cadherin and c-fos promoters. While E1A did not significantly alter targeting of CtBP2 to the E-cadherin and c-fos promoters, it dramatically enhanced promoter targeting of 3KR-CtBP2. Our results raise a possibility that E1A may gain access to cellular promoters through PLDLS-dependent interaction with CtBPs.	Jewish Hosp St Louis, Hlth Sci Ctr, Inst Mol Virol, St Louis, MO 63110 USA	Barnes-Jewish Hospital	Chinnadurai, G (corresponding author), Jewish Hosp St Louis, Hlth Sci Ctr, Inst Mol Virol, 3681 Pk Ave, St Louis, MO 63110 USA.	chinnag@slu.edu			NATIONAL CANCER INSTITUTE [R01CA033616, R01CA084941] Funding Source: NIH RePORTER; NCI NIH HHS [CA-33616, R01 CA084941-07, R01 CA033616, R01 CA084941, CA-84941, R01 CA033616-27] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bergman LM, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-35; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Ghosh MK, 2003, MOL CELL, V12, P255, DOI 10.1016/S1097-2765(03)00225-9; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; LUNDBLAD JR, 2006, CTBP FAMILY PROTEINS, P83; Madison DL, 2002, J BIOL CHEM, V277, P38755, DOI 10.1074/jbc.M207512200; Molloy D, 2006, VIROLOGY, V355, P115, DOI 10.1016/j.virol.2006.05.004; Nardini M, 2003, EMBO J, V22, P3122, DOI 10.1093/emboj/cdg283; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Quinlan KGR, 2006, MOL CELL BIOL, V26, P8159, DOI 10.1128/MCB.00680-06; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; Verger A, 2006, MOL CELL BIOL, V26, P4882, DOI 10.1128/MCB.02402-05; Zhang QH, 2000, P NATL ACAD SCI USA, V97, P14323, DOI 10.1073/pnas.011283598; Zhao LJ, 2006, J BIOL CHEM, V281, P36613, DOI 10.1074/jbc.M603550200; Zhao LJ, 2006, J BIOL CHEM, V281, P4183, DOI 10.1074/jbc.M509051200	22	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7544	7551		10.1038/sj.onc.1210569	http://dx.doi.org/10.1038/sj.onc.1210569			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17546044	Green Accepted			2022-12-17	WOS:000251282100006
J	Chen, M; Rahman, L; Voeller, D; Kastanos, E; Yang, SX; Feigenbaum, L; Allegra, C; Kaye, FJ; Steeg, P; Zajac-Kaye, M				Chen, M.; Rahman, L.; Voeller, D.; Kastanos, E.; Yang, S. X.; Feigenbaum, L.; Allegra, C.; Kaye, F. J.; Steeg, P.; Zajac-Kaye, M.			Transgenic expression of human thymidylate synthase accelerates the development of hyperplasia and tumors in the endocrine pancreas	ONCOGENE			English	Article						thymidylate synthase; transgenic model; islet cell adenoma; endocrine pancreas	DEPENDENT KINASE INHIBITORS; GENE-EXPRESSION; BREAST-CANCER; DNA-SYNTHESIS; MOUSE MODEL; C-MYC; K-RAS; P53; MICE; 5-FLUOROURACIL	Thymidylate synthase ( TS) is an essential enzyme for DNA synthesis and repair and elevated levels of TS have been identified as an important prognostic biomarker for colorectal cancer and several other common human malignancies. In addition, TS gene expression has been linked with cell-cycle regulation and cell proliferation through the ability of retinoblastoma protein to repress the transcriptional activation of E2F target genes such as TS. Therefore, overproduction of TS could participate in the progression to a neoplastic phenotype. Consistent with this model, a recent study has suggested that ectopic TS express ion can induce a transformed phenotype in mammalian cells. To investigate the role of deregulated TS activity in tumor development, we generated transgenic mice that express high levels of catalytically active human TS( hTS) exclusively in the pancreas and low levels of hTS in multiple other tissues. Analyses of pancreatic tissue in TS transgenic mice revealed abnormalities within the endocrine pancreas, ranging from pancreatic islet hyperplasia to the detection of islet cell tumors. Overexpression of hTS in murine islets provides a new model to study genetic alterations associated with the progression from normal cells to hyperplasia to islet cell tumors, and suggests that this mouse model may be useful for regulating TS activity in vivo for development of cancer prevention and new therapies.	Ctr Canc Res, Mol Therapeut Program, Bethesda, MD USA; Natl Clin Target Validat Lab, Div Canc Treatment & Diag, Bethesda, MD USA; NCI, Frederick Canc Res, Lab Anim Sci, Frederick, MD 21701 USA; NCI, Genet Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zajac-Kaye, M (corresponding author), NCI, NIH, Bldg 37 RM 1122,37 Convent Dr, Bethesda, MD 20892 USA.	kayem@exchange.nih.gov	kaye, frederic/E-2437-2011		Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01SC007256, ZIASC007256] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROVA N, 1995, MOL CELL BIOL, V15, P5188; Allegra CJ, 2003, J CLIN ONCOL, V21, P241, DOI 10.1200/JCO.2003.05.044; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Angus SP, 2002, J BIOL CHEM, V277, P44376, DOI 10.1074/jbc.M205911200; Banerjee D, 1998, CANCER RES, V58, P4292; Bertino JR, 2003, CLIN CANCER RES, V9, P1235; Casanovas O, 2005, ONCOGENE, V24, P6597, DOI 10.1038/sj.onc.1208823; Chu E, 1996, Cancer Treat Res, V87, P175; Crabtree JS, 2003, MOL CELL BIOL, V23, P6075, DOI 10.1128/MCB.23.17.6075-6085.2003; Crabtree JS, 2001, P NATL ACAD SCI USA, V98, P1118, DOI 10.1073/pnas.98.3.1118; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Edler D, 2000, CLIN CANCER RES, V6, P1378; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hoeflich A, 1999, ENDOCRINOLOGY, V140, P5488, DOI 10.1210/en.140.12.5488; Johnston PG, 1997, JNCI-J NATL CANCER I, V89, P308, DOI 10.1093/jnci/89.4.308; JOHNSTON PG, 1995, CANCER RES, V55, P1407; JOHNSTON PG, 1993, BIOCHEM PHARMACOL, V45, P2483, DOI 10.1016/0006-2952(93)90230-T; Lewis BC, 2003, GENE DEV, V17, P3127, DOI 10.1101/gad.1140403; Martinez A, 2001, J ENDOCRINOL, V170, P503, DOI 10.1677/joe.0.1700503; Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102; NAVALGUND LG, 1980, J BIOL CHEM, V255, P7386; PAVELIC K, 1995, J PATHOL, V177, P395, DOI 10.1002/path.1711770410; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Pestalozzi BC, 1997, J CLIN ONCOL, V15, P1923, DOI 10.1200/JCO.1997.15.5.1923; Rahman L, 2004, CANCER CELL, V5, P341, DOI 10.1016/S1535-6108(04)00080-7; Rane SG, 2002, MOL CELL BIOL, V22, P644, DOI 10.1128/MCB.22.2.644-656.2002; Sato T, 2000, HEPATO-GASTROENTEROL, V47, P875; Shintani Y, 2003, INT J CANCER, V104, P790, DOI 10.1002/ijc.11014; Takimoto Chris H, 2005, Cancer Chemother Biol Response Modif, V22, P1; Voeller DM, 2002, BIOCHEM BIOPH RES CO, V297, P24, DOI 10.1016/S0006-291X(02)02080-6; Wang EH, 1998, CANCER RES, V58, P4417; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Yang SX, 2005, CLIN CANCER RES, V11, P6226, DOI 10.1158/1078-0432.CCR-05-0270; Zhan Y, 2000, DNA CELL BIOL, V19, P639, DOI 10.1089/10445490050199045	35	20	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2007	26	33					4817	4824		10.1038/sj.onc.1210273	http://dx.doi.org/10.1038/sj.onc.1210273			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297449				2022-12-17	WOS:000248170400006
J	Chun, SY; Chen, F; Washburn, JG; MacDonald, JW; Innes, KL; Zhao, R; Cruz-Correa, MR; Dang, LH; Dang, DT				Chun, S. Y.; Chen, F.; Washburn, J. G.; MacDonald, J. W.; Innes, K. L.; Zhao, R.; Cruz-Correa, M. R.; Dang, L. H.; Dang, D. T.			CDX2 promotes anchorage-independent growth bytranscriptional repression of IGFBP-3	ONCOGENE			English	Article						CDX2; IGFBP-3; colorectal cancer; anchorageindependent growth	FACTOR BINDING PROTEIN-3; GENE-EXPRESSION; FACTOR (IGF)-I; MUTANT MICE; CANCER; TRANSCRIPTION; CELLS	CDX2 is a Drosophila caudal-related homeobox transcription factor that is important for the establishment and maintenance of intestinal epithelial cells. We have reported that CDX2 promotes tumorigenicity in a subset of human colorectal cancer cell lines. Here, we present evidence that CDX2 negatively regulates the well-documented growth inhibitor insulin-like growth factor binding protein-3 IGFBP-3). Specifically, CDX2 binds to the IGFBP-3 gene promoter and can repress IGFBP-3 transcription, protein expression and secretion. Furthermore, inhibition of IGFBP-3 partially rescues the decreased anchorage-independent growth phenotype observed in CDX2 knockout cells. These data demonstrate for the first time that (1) CDX2 can function as a transcriptional repressor, and ( 2) one mechanism by which CDX2 promotes anchorage-independent growth is by transcriptional repression of IGFBP-3.	Univ Michigan, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Affymetrix & cDNA Microarray Core Facil, Ann Arbor, MI 48109 USA; Univ Puerto Rico, Ctr Comprehens Canc, Dept Internal Med, Div Gastroenterol, San Juan, PR 00936 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus	Dang, DT (corresponding author), Univ Michigan, Dept Internal Med, Div Gastroenterol, 1150 W Med Ctr Dr,MSRB I,Room 6514, Ann Arbor, MI 48109 USA.	dangd@umich.edu			NATIONAL CANCER INSTITUTE [P30CA046592, K22CA111897] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK059970] Funding Source: NIH RePORTER; NCI NIH HHS [K22CA111897, 5 P30 CA46592] Funding Source: Medline; NIDDK NIH HHS [K08DK59970] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; Baxter RC, 2001, J CLIN PATHOL-MOL PA, V54, P145, DOI 10.1136/mp.54.3.145; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; CUBBAGE ML, 1990, J BIOL CHEM, V265, P12642; Dang LH, 2006, ONCOGENE, V25, P2264, DOI 10.1038/sj.onc.1209247; Escaffit F, 2006, BIOCHEM BIOPH RES CO, V342, P66, DOI 10.1016/j.bbrc.2006.01.128; FRANCIS GL, 1992, J MOL ENDOCRINOL, V8, P213, DOI 10.1677/jme.0.0080213; GERMAN MS, 1994, GENOMICS, V24, P403, DOI 10.1006/geno.1994.1639; Guo RJ, 2004, CANCER BIOL THER, V3, P593, DOI 10.4161/cbt.3.7.913; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; JAMES R, 1994, J BIOL CHEM, V269, P15229; Krasinski SD, 2001, AM J PHYSIOL-GASTR L, V281, pG69, DOI 10.1152/ajpgi.2001.281.1.G69; Lee HY, 2002, CANCER RES, V62, P3530; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; Rawat VPS, 2004, P NATL ACAD SCI USA, V101, P817, DOI 10.1073/pnas.0305555101; Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3; Sims RJ, 2004, CURR OPIN CELL BIOL, V16, P263, DOI 10.1016/j.ceb.2004.04.004; Yamamoto H, 2003, BIOCHEM BIOPH RES CO, V300, P813, DOI 10.1016/S0006-291X(02)02935-2	19	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4725	4729		10.1038/sj.onc.1210258	http://dx.doi.org/10.1038/sj.onc.1210258			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297462				2022-12-17	WOS:000248037900013
J	Hausherr, A; Tavares, R; Schaffer, M; Obermeier, A; Miksch, C; Mitina, O; Ellwart, J; Hallek, M; Krause, G				Hausherr, A.; Tavares, R.; Schaeffer, M.; Obermeier, A.; Miksch, C.; Mitina, O.; Ellwart, J.; Hallek, M.; Krause, G.			Inhibition of IL-6-dependent growth of myeloma cells by an acidic peptide repressing the gp130-mediated activation of Src family kinases	ONCOGENE			English	Article						myeloma; interleukin-6 signalling; gp130; membrane-permeant peptide; Src family kinases	MULTIPLE-MYELOMA; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; BCR-ABL; IN-VIVO; PROTEIN; RECEPTOR; HCK; INTERLEUKIN-6; SURVIVAL	An acidic domain (AD) of gp130 was previously found to interact with the Src family kinase (SFK) Hck. Here, the in. uence of myristoylated peptides derived from this AD was assessed in the mouse myeloma cell line, 7TD1. The IL-6-dependent growth of 7TD1 c ells was reduced by similar to 75%, if 100 mu M of myristoylated 18mer peptide (18AD) was included in the growth medium, but was unaffected by a control peptide with scrambled sequence (18sc). A similar differential inhibition by peptides 18AD and 18sc was observed for the erythropoietin-dependent growth of BaF-EH cells expressing chimeric erythropoietin receptor-gp130 and human Hck and for the human myeloma cell line INA-6. While the peptide 18AD concentration inhibiting 50% was similar to 30 mu M in 7TD1 and BaF-EH cells, peptide 18AD did not signifi. cantly inhibit growth of IL-6-independent MM1. S myeloma and OKT1 hybridoma cells or of BaF-EH cells supplied with IL-3. Treatment with 100 mu M peptide 18AD caused the same degree or 60% of apoptosis induction as IL-6 deprivation in 7TD1 or INA-6 cells, respectively. Co-immunoprecipitation experiments revealed that peptide 18AD interfered with the association of Hck and gp130 in 7TD1 lysates in a concentration-dependent manner. IL-6-treatment of INA-6 cells induced the kinase activities of Fyn, Lyn and Hck, but not Src, and the IL-6-induced SFK activities were inhibited by peptide 18AD. Expression in 7TD1 cells of a kinase-inactive Hck mutant (K269R) elicited a dominant-negative effect on cell number increases providing further evidence that SFKs are required for gp130 signalling in myeloma cells.	Univ Hosp Cologne, Clin Internal Med 1, D-50923 Cologne, Germany; GSF, Natl Res Ctr Environm & Hlth, Clin Cooperat Grp Gene Therapy, Munich, Germany; GRELUX GmbH, Martinsried, Germany; SIREEN AG, Martinsried, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Mol Immunol, Munich, Germany	University of Cologne; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Krause, G (corresponding author), Univ Hosp Cologne, Clin Internal Med 1, Kerpener Str 62, D-50923 Cologne, Germany.	guenter.krause@uk-koeln.de	Hallek, Michael/Y-3191-2019; Krause, Günter/A-1858-2012	Hallek, Michael/0000-0002-7425-4455; Krause, Günter/0000-0003-3905-0921				Adachi T, 1999, J IMMUNOL, V162, P1496; Adachi T, 1999, J IMMUNOL, V163, P939; Ancey C, 2003, J BIOL CHEM, V278, P16968, DOI 10.1074/jbc.C300081200; Boehning D, 2005, P NATL ACAD SCI USA, V102, P1466, DOI 10.1073/pnas.0409650102; Brocke-Heidrich K, 2004, BLOOD, V103, P242, DOI 10.1182/blood-2003-04-1048; Burger R, 2001, Hematol J, V2, P42, DOI 10.1038/sj.thj.6200075; Chatterjee M, 2002, BLOOD, V100, P3311, DOI 10.1182/blood-2002-01-0102; Contri A, 2005, J CLIN INVEST, V115, P369, DOI 10.1172/JC1200522094; Cote S, 2002, CYTOKINE, V20, P113, DOI 10.1006/cyto.2002.1988; Covic L, 2002, P NATL ACAD SCI USA, V99, P643, DOI 10.1073/pnas.022460899; Dasgupta P, 2000, LIFE SCI, V66, P1557, DOI 10.1016/S0024-3205(00)00476-8; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; Ernst M, 2004, TRENDS GENET, V20, P23, DOI 10.1016/j.tig.2003.11.003; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; French JD, 2000, ACTA ONCOL, V39, P777; Georgii-Hemming P, 1999, BLOOD, V93, P1724, DOI 10.1182/blood.V93.5.1724.405k21_1724_1731; Greenstein S, 2003, EXP HEMATOL, V31, P271, DOI 10.1016/S0301-472X(03)00023-7; Hallek M, 1997, EXP HEMATOL, V25, P1367; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Ishihara K, 2002, CYTOKINE GROWTH F R, V13, P357, DOI 10.1016/S1359-6101(02)00027-8; Kardinal C, 2000, FASEB J, V14, P1529, DOI 10.1096/fj.14.11.1529; Kelemen BR, 2002, J BIOL CHEM, V277, P8741, DOI 10.1074/jbc.M108459200; LaFevre-Bernt M, 1998, J BIOL CHEM, V273, P32129, DOI 10.1074/jbc.273.48.32129; Laszlo GS, 2003, J BIOL CHEM, V278, P27750, DOI 10.1074/jbc.M303670200; Manfredini R, 2003, PEPTIDES, V24, P1207, DOI 10.1016/j.peptides.2003.06.005; Neumann C, 1996, EUR J IMMUNOL, V26, P379, DOI 10.1002/eji.1830260217; Niv MY, 2004, J BIOL CHEM, V279, P1242, DOI 10.1074/jbc.M306723200; Ogata A, 1997, J IMMUNOL, V159, P2212; Ohtani T, 2000, IMMUNITY, V12, P95, DOI 10.1016/S1074-7613(00)80162-4; Podar K, 2004, J BIOL CHEM, V279, P21658, DOI 10.1074/jbc.M305783200; Podar K, 2003, J BIOL CHEM, V278, P5794, DOI 10.1074/jbc.M208636200; Posern G, 1998, ONCOGENE, V16, P1903, DOI 10.1038/sj.onc.1201714; Schaeffer M, 2001, MOL CELL BIOL, V21, P8068, DOI 10.1128/MCB.21.23.8068-8081.2001; Schulze WX, 2004, J BIOL CHEM, V279, P10756, DOI 10.1074/jbc.M309909200; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Trikha M, 2003, CLIN CANCER RES, V9, P4653; Warmuth M, 2003, BLOOD, V101, P664, DOI 10.1182/blood-2002-01-0288; Warmuth M, 1997, J BIOL CHEM, V272, P33260, DOI 10.1074/jbc.272.52.33260	44	20	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	34					4987	4998		10.1038/sj.onc.1210306	http://dx.doi.org/10.1038/sj.onc.1210306			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17310994				2022-12-17	WOS:000248322500011
J	Duan, H; Heckman, CA; Boxer, LM				Duan, H.; Heckman, C. A.; Boxer, L. M.			The immunoglobulin heavy-chain gene 3 ' enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells	ONCOGENE			English	Article						follicular lymphoma; bcl-2; promoter usage; IgH enhancer	LOCUS-CONTROL REGION; EXPRESSION; CHEMORESISTANCE; TRANSCRIPTION; APOPTOSIS; PROTEIN	In t(14;18) lymphomas, bcl-2 is juxtaposed to the immunoglobulin heavy-chain gene (IgH), resulting in increased bcl-2 transcription and resistance to apoptosis. Regulatory elements of both the bcl-2 promoter and the IgH enhancers are believed to play a role in the increased expression of bcl-2 in t(14;18) lymphoma cells. In addition, transcription of the translocated bcl-2 allele is deregulated with activation of the normally minor bcl-2 P2 promoter. The mechanisms involved in the promoter shift from P1 to P2 are not known. We found that the murine IgH 30 enhancers increased bcl-2 P2 promoter activity in an episomal model of the translocation, and IgH enhancer region HS12 had the greatest effect. Quantitative chromatin immunoprecipitation (ChIP) assays revealed that localized histone H3 hyperacetylation of the P2 promoter was observed on the translocated allele in t(14;18) DHL-4 cells and also on the stably transfected bcl-2 promoter-IgH enhancer episomal construct. Analysis of the HS12 enhancer region revealed that a previously identified nuclear factor-kappa B (NF-kappa B) site and a previously uncharacterized downstream Cdx site, both of which are conserved in the human and murine IgH enhancers, were important for its enhancer activity and promoter activation. ChIP assays showed that C/EBP beta bound to the HS12 Cdx site in vivo, and mutation of this site abrogated the binding of C/EBP beta. Reduced expression of C/EBP beta by transfection of small interfering RNA or interference with NF-kappa B activity decreased transcription from the bcl-2 promoters. These results demonstrate that the IgH 30 enhancers, particularly HS12, are important for the deregulation of bcl-2 promoter usage in t(14;18) lymphomas.	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Stanford, CA USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Boxer, LM (corresponding author), Stanford Univ, Sch Med, Dept Hematol, CCSR 1155,269 Campus Dr, Stanford, CA 94305 USA.	lboxer@stanford.edu		Heckman, Caroline/0000-0002-4324-8706	NCI NIH HHS [CA56764] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056764, R56CA056764] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Decary S, 2002, MOL CELL BIOL, V22, P7877, DOI 10.1128/MCB.22.22.7877-7888.2002; DESOIZE B, 1994, ANTICANCER RES, V14, P2291; Duan H, 2005, MOL CELL BIOL, V25, P1608, DOI 10.1128/MCB.25.5.1608-1619.2005; Heckman CA, 2003, CANCER RES, V63, P6666; Heckman CA, 2003, ONCOGENE, V22, P7891, DOI 10.1038/sj.onc.1206639; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Ji L, 1996, J BIOL CHEM, V271, P22687, DOI 10.1074/jbc.271.37.22687; Khamlichi AA, 2000, ADV IMMUNOL, V75, P317, DOI 10.1016/S0065-2776(00)75008-5; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; Krumm A, 1998, P NATL ACAD SCI USA, V95, P13501, DOI 10.1073/pnas.95.23.13501; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; Madisen L, 1998, MOL CELL BIOL, V18, P6281, DOI 10.1128/MCB.18.11.6281; REED JC, 1994, ANN ONCOL, V5, pS61, DOI 10.1093/annonc/5.suppl_1.S61; Schmitt CA, 2001, BLOOD CELL MOL DIS, V27, P206, DOI 10.1006/bcmd.2000.0372; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067	19	20	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2007	26	18					2635	2641		10.1038/sj.onc.1210061	http://dx.doi.org/10.1038/sj.onc.1210061			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17043638				2022-12-17	WOS:000245831200010
J	Erkeland, SJ; Aarts, LH; Irandoust, M; Roovers, O; Klomp, A; Valkhof, M; Gits, J; Eyckerman, S; Tavernier, J; Touw, IP				Erkeland, S. J.; Aarts, L. H.; Irandoust, M.; Roovers, O.; Klomp, A.; Valkhof, M.; Gits, J.; Eyckerman, S.; Tavernier, J.; Touw, I. P.			Novel role of WD40 and SOCS box protein-2 in steady-state distribution of granulocyte colony-stimulating factor receptor and G-CSF-controlled proliferation and differentiation signaling	ONCOGENE			English	Article						WD40 and SOCS box protein; G-CSF receptor; steady-state distribution; forward routing; proliferation-differentiation balance	NEUTROPENIA/ACUTE MYELOID-LEUKEMIA; DISTINCT CYTOPLASMIC REGIONS; UBIQUITIN; ACTIVATION; INTERNALIZATION; GROWTH; DOMAIN; SUPPRESSION; INDUCTION; SURVIVAL	Signals induced by granulocyte colony-stimulating factor (G-CSF), the major cytokine involved in neutrophil development, are tightly controlled by ligand-induced receptor internalization. Truncated G-CSF receptors(GCSF-Rs) that fail to internalize show sustained proliferation and defective differentiation signaling. Steady-state forward routing also determines cell surface levels of cytokine receptors, but mechanisms controlling this are poorly understood. Here, we show that WD40 and suppressor of cytokine signaling (SOCS) box protein-2 (Wsb-2), an SOCS box-containing WD40 protein with currently unknown function, bindsto the COOH-terminal region of G-CSF-R. Removal of this region did not affect internalization, yet resulted in increased membrane expression of G-CSF-R and enhanced proliferation signaling at the expense of differentiation induction. Conversely, Wsb-2 binding to the G-CSF-R reduced its cell surface expression and inhibited proliferation signaling. These effects depended on the SOCS box involved in ubiquitylation and on cytosolic lysines of G-CSF-R and imply a major role for ubiquitylation through the G-CSFR C-terminusin forward routing of the receptor. Importantly, the Wsb-2 gene iscommonly disrupted by virus integrations in mouse leukemia. We conclude that control of forward routing of G-CSF-R is essential for a balanced response of myeloid progenitors to G-CSF and suggest that disturbance of this balance may contribute to myeloid leukemia.	Erasmus Univ, Ctr Med, Dept Hematol, NL-3000 DR Rotterdam, Netherlands; Univ Ghent, Flanders Interuniv Inst Biotechnol, Dept Med Prot Res, Ghent, Belgium	Erasmus University Rotterdam; Ghent University	Touw, IP (corresponding author), Erasmus Univ, Ctr Med, Dept Hematol, POB 1738, NL-3000 DR Rotterdam, Netherlands.	i.touw@erasmusmc.nl	Tavernier, Jan/AAG-3636-2019	Erkeland, Stefan/0000-0002-1019-7957				Aarts LHJ, 2004, BLOOD, V103, P571, DOI 10.1182/blood-2003-07-2250; Aguilar RC, 2003, CURR OPIN CELL BIOL, V15, P184, DOI 10.1016/S0955-0674(03)00010-3; Avalos BR, 1996, BLOOD, V88, P761, DOI 10.1182/blood.V88.3.761.bloodjournal883761; de Koning JP, 2000, ONCOGENE, V19, P3290, DOI 10.1038/sj.onc.1203627; DEMETRI GD, 1991, BLOOD, V78, P2791; Dentice M, 2005, NAT CELL BIOL, V7, P698, DOI 10.1038/ncb1272; Dong F, 1998, J IMMUNOL, V161, P6503; Dong F, 2001, J IMMUNOL, V167, P6447, DOI 10.4049/jimmunol.167.11.6447; DONG F, 1993, MOL CELL BIOL, V13, P7774, DOI 10.1128/MCB.13.12.7774; Erkeland SJ, 2004, J VIROL, V78, P1971, DOI 10.1128/JVI.78.4.1971-1980.2004; Erkeland SJ, 2003, BLOOD, V101, P1111, DOI 10.1182/blood-2002-04-1207; Eyckerman S, 2001, NAT CELL BIOL, V3, P1114, DOI 10.1038/ncb1201-1114; Eyckerman Sven, 2002, Sci STKE, V2002, ppl18; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hermans MHA, 2003, BLOOD, V101, P2584, DOI 10.1182/blood-2002-07-2062; Hermans MHA, 1999, J EXP MED, V189, P683, DOI 10.1084/jem.189.4.683; Heuze ML, 2005, J BIOL CHEM, V280, P5468, DOI 10.1074/jbc.M413040200; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hortner M, 2002, J IMMUNOL, V169, P1219, DOI 10.4049/jimmunol.169.3.1219; Hunter MG, 1999, BLOOD, V93, P440, DOI 10.1182/blood.V93.2.440.402k23_440_446; James P, 1996, GENETICS, V144, P1425; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kario E, 2005, J BIOL CHEM, V280, P7038, DOI 10.1074/jbc.M408575200; Kumar KGS, 2004, J BIOL CHEM, V279, P46614, DOI 10.1074/jbc.M407082200; Kumar KGS, 2003, EMBO J, V22, P5480; McLemore ML, 1998, J CLIN INVEST, V102, P483, DOI 10.1172/JCI3216; Neer EJ, 2000, P NATL ACAD SCI USA, V97, P960, DOI 10.1073/pnas.97.3.960; Reynolds A, 2006, RNA, V12, P988, DOI 10.1261/rna.2340906; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Tavernier J, 2002, CLIN EXP ALLERGY, V32, P1397, DOI 10.1046/j.1365-2745.2002.01520.x; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; van de Geijn GJM, 2004, BLOOD, V104, P667, DOI 10.1182/blood-2003-08-2913; van de Geijn GJM, 2004, REV PHYSIOL BIOCH P, V149, P53; van Zon A, 2002, BIOCHEM BIOPH RES CO, V291, P535, DOI 10.1006/bbrc.2002.6472; Ward AC, 1999, BLOOD, V93, P447, DOI 10.1182/blood.V93.2.447; Ward AC, 1999, J BIOL CHEM, V274, P14956, DOI 10.1074/jbc.274.21.14956	41	20	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	14					1985	1994		10.1038/sj.onc.1210004	http://dx.doi.org/10.1038/sj.onc.1210004			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17001306				2022-12-17	WOS:000245313400001
J	Kikuchi, R; Murakami, M; Sobue, S; Iwasaki, T; Hagiwara, K; Takagi, A; Kojima, T; Asano, H; Suzuki, M; Banno, Y; Nozawa, Y; Murate, T				Kikuchi, R.; Murakami, M.; Sobue, S.; Iwasaki, T.; Hagiwara, K.; Takagi, A.; Kojima, T.; Asano, H.; Suzuki, M.; Banno, Y.; Nozawa, Y.; Murate, T.			Ewing's sarcoma fusion protein, EWS/Fli-1 and Fli-1 protein induce PLD2 but not PLD1 gene expression by binding to an ETS domain of 5 ' promoter	ONCOGENE			English	Article						Ewing's sarcoma; EWS/Fli-1; PLD; gene expression; promoter analysis	PHOSPHOLIPASE D2; CELL; SPECIFICITY; INHIBITION; FAMILY	It was reported that short interfering RNA (siRNA) of EWS/Fli-1 downregulated phospholipase D (PLD)2 in Ewing's sarcoma (EWS) cell line, suggesting that PLD2 is the target of aberrant transcription factor, EWS/Fli-1. Here, we further investigated the regulation of PLD2 gene expression by EWS/Fli-1 and Fli-1 in another EWS cell line, and also in EWS/Fli-1- or Fli-1-transfected cell line. EWS/Fli-1- or Fli-1-overexpressed cells showed higher PLD2 but not PLD1 protein expression and enhanced cell proliferation as compared to mock transfectant. The treatment of these cells with 1-butanol or siRNA of PLD2 inhibited cell growth, suggesting the pivotal role of PLD in cell growth promotion. PLD2 but not PLD1 mRNA level was also increased in EWS/Fli-1 or Fli-1-transfectants. After determining the transcription initiation points, we cloned the 50 promoter of both PLD1 and PLD2 and analysed promoter activities. Results showed that EWS/Fli-1 and Fli- 1 increase PLD2 gene expression by binding to an erythroblast transformation-specific domain (-126 to -120 bp from the transcription initiation site) of PLD2 promoter, which is the minimal and most powerful region. Electrophoresis mobility shift assay using truncated proteins showed that both DNA-binding domain and trans-activating domain were necessary for the enhanced gene expression of PLD2.	Nagoya Univ, Sch Hlth Sci, Higashi Ku, Nagoya, Aichi 4618673, Japan	Nagoya University	Murate, T (corresponding author), Nagoya Univ, Sch Hlth Sci, Higashi Ku, Daiko Minami 1-1-20, Nagoya, Aichi 4618673, Japan.	murate@met.nagoya-u.ac.jp	Kojima, Tetsuhito/I-6271-2014; Kikuchi, Ryosuke/AAX-4971-2021; Suzuki, Motoshi/I-7246-2014	Kojima, Tetsuhito/0000-0002-1905-1065; Suzuki, Motoshi/0000-0003-0682-5006				Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; Banno Y, 1999, J BIOL CHEM, V274, P27385, DOI 10.1074/jbc.274.39.27385; CARNERO A, 1994, ONCOGENE, V9, P1387; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; Foster DA, 2003, MOL CANCER RES, V1, P789; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; LISCOVITCH M, 2000, BIOCHEM J, V345, P410; MAO XH, 1994, J BIOL CHEM, V269, P18216; Nakamura S, 2003, REC RES DEV MAGNET M, V1, P1; Nozawa S, 2005, J BIOL CHEM, V280, P27544, DOI 10.1074/jbc.M411626200; Oikawa T, 2004, CANCER SCI, V95, P626, DOI 10.1111/j.1349-7006.2004.tb03320.x; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; RAMUGOUNDER R, 2004, ONCOGENE, V23, P1; Redina OE, 1998, GENE, V222, P53, DOI 10.1016/S0378-1119(98)00465-X; REDINA OE, 1998, BIOCHEM J, V331, P173; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Sobue S, 2005, J NEUROCHEM, V95, P940, DOI 10.1111/j.1471-4159.2005.03399.x; Toretsky JA, 1997, J NEURO-ONCOL, V31, P9, DOI 10.1023/A:1005716926800; Truong AHL, 2000, ONCOGENE, V19, P6482, DOI 10.1038/sj.onc.1204042; Zhao YT, 2000, BIOCHEM BIOPH RES CO, V278, P140, DOI 10.1006/bbrc.2000.3719	22	20	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	12					1802	1810		10.1038/sj.onc.1209973	http://dx.doi.org/10.1038/sj.onc.1209973			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16964281				2022-12-17	WOS:000244955600014
J	Liu, YE; Pu, W; Jiang, Y; Shi, D; Dackour, R; Shi, YE				Liu, Y. E.; Pu, W.; Jiang, Y.; Shi, D.; Dackour, R.; Shi, Y. E.			Chaperoning of estrogen receptor and induction of mammary gland proliferation by neuronal protein synuclein gamma	ONCOGENE			English	Article						synuclein gamma (SNCG); estrogen receptor; chaperone; hyperplasia; breast cancer; transgenic mouse	BREAST-CANCER CELLS; INHIBITOR-RELATED GENE; HEAT-SHOCK-PROTEIN; ABERRANT EXPRESSION; PARKINSONS-DISEASE; ALZHEIMER-DISEASE; GROWTH INHIBITOR; ALPHA-SYNUCLEIN; METASTASIS; PROMOTES	Synucleins are emerging as central players in the formation of pathologically insoluble deposits characteristic of neurodegenerative diseases. However, synuclein c (SNCG), previously identified as a breast cancer specific gene (BCSG1), is also highly associated with breast cancer progression. Using transgenic mouse model, we demonstrated a role of SNCG in induction of highly proliferative pregnancy-like phenotype of mammary epithelial cells and branching morphology. SNCG participated in the heat shock protein-based multiprotein chaperone complex for steroid receptor signaling. Expression of SNCG in mammary epithelium resulted in a significant stimulation of ER alpha transcriptional activity. SNCG-induced mammary gland proliferation can be effectively blocked by antiestrogen and ovariectomy, indicating that the induced proliferation is mediated by ERa signaling and requires estrogen stimulation. These data indicate the chaperone activity of SNCG on stimulation of steroid receptor signaling in mammary gland and, thus induces extensive mammary gland proliferation and contributes to the hormonal impact on mammary tumorigenesis.	Long Isl Jewish Med Ctr, Dept Radiat Oncol, New Hyde Pk, NY 11040 USA; Sichuan Univ, W China Hosp, State Key Lab, Div Mol Oncol, Chengdu 610064, Peoples R China	Northwell Health; Sichuan University	Shi, YE (corresponding author), Long Isl Jewish Med Ctr, Dept Radiat Oncol, New Hyde Pk, NY 11040 USA.	eshi@lij.edu						Bruening W, 2000, CANCER-AM CANCER SOC, V88, P2154, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2154::AID-CNCR23>3.0.CO;2-9; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Duda JE, 2000, J NEUROSCI RES, V61, P121, DOI 10.1002/1097-4547(20000715)61:2<121::AID-JNR1>3.0.CO;2-4; Galvin JE, 1999, P NATL ACAD SCI USA, V96, P13450, DOI 10.1073/pnas.96.23.13450; Geisler H, 2003, J STEROID BIOCHEM, V86, P245, DOI 10.1016/S0960-0760(03)00364-9; Gupta A, 2003, ONCOGENE, V22, P7593, DOI 10.1038/sj.onc.1206880; Gupta A, 2003, CANCER RES, V63, P664; Inaba S, 2005, BREAST CANCER RES TR, V94, P25, DOI 10.1007/s10549-005-6938-0; Ji HJ, 1997, CANCER RES, V57, P759; Jia TL, 1999, CANCER RES, V59, P742; Jiang YF, 2003, CANCER RES, V63, P3899; Jiang YF, 2004, CANCER RES, V64, P4539, DOI 10.1158/0008-5472.CAN-03-3650; Lavedan C, 1998, HUM GENET, V103, P106, DOI 10.1007/s004390050792; Liu HY, 2005, CANCER RES, V65, P7635, DOI 10.1158/0008-5472.CAN-05-1089; Liu JW, 2000, BREAST CANCER RES TR, V62, P99, DOI 10.1023/A:1006418219012; LU A, 2000, J BIOL CHEM, V277, P31364; Lu AP, 2001, ONCOGENE, V20, P5173, DOI 10.1038/sj.onc.1204668; Ninkina NN, 1998, HUM MOL GENET, V7, P1417, DOI 10.1093/hmg/7.9.1417; Pan ZZ, 2002, J BIOL CHEM, V277, P35050, DOI 10.1074/jbc.M201650200; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Shi YE, 1997, CANCER RES, V57, P3084; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Takeda A, 1998, AM J PATHOL, V152, P367; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Wang MS, 2000, CANCER RES, V60, P6482; Wang MS, 2003, J BIOL CHEM, V278, P47319, DOI 10.1074/jbc.M308131200; WU K, 2006, BREAST CANC RES TREA; Wu KJ, 2003, CANCER EPIDEM BIOMAR, V12, P920; Xiao GW, 1999, P NATL ACAD SCI USA, V96, P3700, DOI 10.1073/pnas.96.7.3700; YOSHIMOTO M, 1995, P NATL ACAD SCI USA, V92, P9141, DOI 10.1073/pnas.92.20.9141	31	20	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	14					2115	2125		10.1038/sj.onc.1210000	http://dx.doi.org/10.1038/sj.onc.1210000			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17016445				2022-12-17	WOS:000245313400013
J	Perez-Caro, M; Gutierrez-Cianca, N; Gonzalez-Herrero, I; Lopez-Hernandez, I; Flores, T; Orfao, A; Sanchez-Martin, M; Gutierrez-Adan, A; Pintado, B; Sanchez-Garcia, I				Perez-Caro, M.; Gutierrez-Cianca, N.; Gonzalez-Herrero, I.; Lopez-Hernandez, I.; Flores, T.; Orfao, A.; Sanchez-Martin, M.; Gutierrez-Adan, A.; Pintado, B.; Sanchez-Garcia, I.			Sustained leukaemic phenotype after inactivation of BCR-ABLp190 in mice	ONCOGENE			English	Article						cancer maintenance; dox regulation; fusion genes; cancer stem cell; mouse models	ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; ABL TYROSINE KINASE; COMPLETE CYTOGENETIC REMISSION; IMATINIB MESYLATE TREATMENT; BCR-ABL; PHILADELPHIA-CHROMOSOME; IN-VIVO; HEMATOPOIETIC PROGENITORS; CANCER DEVELOPMENT	Pharmacological inactivation of cancer genes or products is being used as a strategy for therapy in oncology. To investigate the potential role of BCR-ABLp190 cessation in leukaemia development, we generated mice carrying a tetracycline-repressible BCR-ABLp190 transgene. These mice were morphologically normal at birth, and developed leukaemias. Disease was characterized by the presence of B-cell blasts co-expressingmyeloid markers, reminiscent of the human counterpart. BCR-ABLp190 activation can initiate leukaemia in both young and adult mice. Transitory expression of BCR-ABLp190 is enough to develop leukaemia. Suppression of the BCR-ABLp190 transgene in leukaemic CombitTA-p190 mice did not rescue the malignant phenotype, indicating that BCR-ABLp190 is not required to maintain the disease in mice. Similar results were obtained by inactivation of BCR-ABLp190 with STI571 (Gleevec; Novartis, East Hanover, NJ, USA) in leukaemic CombitTA-p190 mice. However, gradual suppression of BCR-ABLp190 in leukaemic CombitTA-p190 mice identified a minimum level of BCR-ABLp190 expression necessary to revert the specific block in B-cell differentiation in the leukaemic cells. Overall, the findings indicate that BCR-ABLp190 appears to cause epigenetic and/or genetic changes in tumour-maintaining cells that render them insensitive to BCR-ABLp190 inactivation.	Univ Salamanca, Inst Biol Mol & Celular Canc, CSIC, Lab 13, E-37007 Salamanca, Spain; Univ Salamanca, Serv Anat Patol, E-37007 Salamanca, Spain; Univ Salamanca, Serv Citometria, E-37007 Salamanca, Spain; Univ Salamanca, Dept Med, E-37007 Salamanca, Spain; Ctr Invest & Tecnol, Area Reprod Anim, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; University of Salamanca; University of Salamanca	Sanchez-Garcia, I (corresponding author), Univ Salamanca, Inst Biol Mol & Celular Canc, CSIC, Lab 13, Campus Unamuno S-N, E-37007 Salamanca, Spain.	isg@usal.es	Sanchez-Martin, Manuel/N-5327-2016; Gutierrez-Adan, Alfonso/A-1485-2014; 2007, Secribsal/A-1556-2012; SANCHEZ-GARCIA, ISIDRO/A-5631-2019; González-Herrero, Inés/G-8546-2015; Orfao, Alberto/B-5801-2017; Pintado, Belen/N-3233-2014	Sanchez-Martin, Manuel/0000-0001-8370-1336; Gutierrez-Adan, Alfonso/0000-0001-9893-9179; González-Herrero, Inés/0000-0003-1142-4362; Pintado, Belen/0000-0002-8485-2520; SANCHEZ-GARCIA, ISIDRO/0000-0001-6989-9905				Bhatia R, 2003, BLOOD, V101, P4701, DOI 10.1182/blood-2002-09-2780; Chabner BA, 2005, NAT REV CANCER, V5, P65, DOI 10.1038/nrc1529; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0; Chu S, 2005, BLOOD, V105, P2093, DOI 10.1182/blood-2004-03-1114; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; Cobaleda C, 2000, BLOOD, V95, P1007, DOI 10.1182/blood.V95.3.1007.003k35_1007_1013; Cobaleda C, 1998, BIOESSAYS, V20, P922, DOI 10.1002/(SICI)1521-1878(199811)20:11<922::AID-BIES7>3.0.CO;2-O; COPELAN EA, 1995, BLOOD, V85, P1151, DOI 10.1182/blood.V85.5.1151.bloodjournal8551151; Cox CV, 2004, BLOOD, V104, P2919, DOI 10.1182/blood-2004-03-0901; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Etzioni R, 2003, NAT REV CANCER, V3, P243, DOI 10.1038/nrc1041; FORD AM, 1983, EMBO J, V2, P997, DOI 10.1002/j.1460-2075.1983.tb01533.x; GarciaHernandez B, 1997, P NATL ACAD SCI USA, V94, P13239, DOI 10.1073/pnas.94.24.13239; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; GRIFFITHS SD, 1992, ONCOGENE, V7, P1391; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; Mauro MJ, 2001, ONCOLOGIST, V6, P233, DOI 10.1634/theoncologist.6-3-233; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; Meuwissen R, 2001, ONCOGENE, V20, P6551, DOI 10.1038/sj.onc.1204837; O'Dwyer ME, 2001, CURR CANCER DRUG TAR, V1, P49, DOI 10.2174/1568009013334250; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PALACIOS R, 1987, EMBO J, V6, P3687, DOI 10.1002/j.1460-2075.1987.tb02702.x; Perez-Caro M, 2005, CURR GENOMICS, V6, P81, DOI 10.2174/1389202053642276; Perez-Mancera PA, 2005, HUM MOL GENET, V14, P3449, DOI 10.1093/hmg/ddi373; Perez-Mancera PA, 2005, ONCOGENE, V24, P3073, DOI 10.1038/sj.onc.1208505; Sanchez-Garcia I, 1997, ANNU REV GENET, V31, P429, DOI 10.1146/annurev.genet.31.1.429; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; Savage DG, 2002, NEW ENGL J MED, V346, P683, DOI 10.1056/NEJMra013339; Schultze N, 1996, NAT BIOTECHNOL, V14, P499, DOI 10.1038/nbt0496-499; SECKERWALKER LM, 1991, GENE CHROMOSOME CANC, V3, P320; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; SKORSKI T, 1994, P NATL ACAD SCI USA, V91, P4504, DOI 10.1073/pnas.91.10.4504; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; Tabernero MD, 2001, LEUKEMIA, V15, P406, DOI 10.1038/sj.leu.2402060; Towatari M, 2004, BLOOD, V104, P3507, DOI 10.1182/blood-2004-04-1389; Van Etten R A, 2001, Curr Oncol Rep, V3, P228; Wendel HG, 2006, P NATL ACAD SCI USA, V103, P7444, DOI 10.1073/pnas.0602402103; Williams RT, 2006, P NATL ACAD SCI USA, V103, P6688, DOI 10.1073/pnas.0602030103; Wolff NC, 2001, BLOOD, V98, P2808, DOI 10.1182/blood.V98.9.2808; Zhao RCH, 1997, BLOOD, V90, P4687, DOI 10.1182/blood.V90.12.4687.4687_4687_4698	48	20	23	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	12					1702	1713		10.1038/sj.onc.1209968	http://dx.doi.org/10.1038/sj.onc.1209968			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16983340				2022-12-17	WOS:000244955600004
J	Martel, V; Filhol, O; Colas, P; Cochet, C				Martel, V.; Filhol, O.; Colas, P.; Cochet, C.			p53-dependent inhibition of mammalian cell survival by a genetically selected peptide aptamer that targets the regulatory subunit of protein kinase CK2	ONCOGENE			English	Article						CK2 beta subunit; peptidic inhibitors; IE2 protein; p53 activation; cell apoptosis	HETEROGENEOUS RIBONUCLEOPROTEIN-K; BETA-SUBUNIT; ALPHA-SUBUNIT; DNA-DAMAGE; INDUCED APOPTOSIS; CRYSTAL-STRUCTURE; CK2-BETA SUBUNIT; P53; EXPRESSION; BINDING	Based on the perturbation of its expression in human cancers and on its involvement in transformation and tumorigenesis, protein kinase CK2 has recently attracted attention as a potential therapeutic target. To assess the value of CK2 as a target for antiproliferative strategies, we have initiated a program aiming to develop inhibitors targeting specifically the regulatory CK2 beta subunit. Here, we use a two-hybrid approach to isolate from combinatorial libraries, peptide aptamers that specifically interact with CK2b. One of these (P1), which has significant sequence homology to the cytomegalovirus IE2 protein, binds with high affinity to the N-terminal domain of CK2b without disrupting the formation of the CK2 holoenzyme. Expression of green fluorescent protein (GFP)-P1 in different mammalian cell lines activates p53 phosphorylation on serine 15, induces an upregulation of p21 and the release of the Cyt-C and apoptosis-inducing factor proapoptotic proteins triggering caspase-dependent and caspase-independent apoptosis. GFP-P1-induced apoptosis is associated with a p53-dependent pathwayas cell death was abrogated in p53 knocked out cells. In summary, our data show that genetically selected peptide aptamers that specifically target CK2b can induce apoptosis in mammalian cells through the recruitment of a p53-dependent apoptosis pathway. They also emphasize the critical role of CK2b for cell survival and might allow the design of novel proapoptotic agents targeting this protein.	CEA, INSERM EMI0104, Dept Reponse & Dynam Cellulaire, F-38054 Grenoble, France; Aptanomics SA, Lyon, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)	Cochet, C (corresponding author), CEA, INSERM EMI0104, Dept Reponse & Dynam Cellulaire, 17 Rue Martyrs, F-38054 Grenoble, France.	ccochet1@cea.fr	Martel-Frachet, Veronique/B-8657-2014; Filhol-Cochet, Odile/I-3962-2016; Frachet, Véronique/B-8418-2018	Frachet, Véronique/0000-0001-6739-7901; Filhol, Odile/0000-0003-1964-7958; Colas, Pierre/0000-0001-7436-3718; Cochet, Claude/0000-0002-1772-4270				Abraham MC, 2004, TRENDS CELL BIOL, V14, P184, DOI 10.1016/j.tcb.2004.03.002; Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; Andreau K, 2004, J BIOL CHEM, V279, P55937, DOI 10.1074/jbc.M406411200; Bibby AC, 2005, INT J BIOL SCI, V1, P67; Bjorling-Poulsen M, 2005, ONCOGENE, V24, P6194, DOI 10.1038/sj.onc.1208762; Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; Buchou T, 2003, MOL CELL BIOL, V23, P908, DOI 10.1128/MCB.23.3.908-915.2003; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Chantalat L, 1999, EMBO J, V18, P2930, DOI 10.1093/emboj/18.11.2930; Chiou SH, 2001, J IMMUNOL, V167, P4098, DOI 10.4049/jimmunol.167.7.4098; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Colman-Lerner A, 2001, CELL, V107, P739, DOI 10.1016/S0092-8674(01)00596-7; Dagher MC, 1997, BIOTECHNIQUES, V22, P916, DOI 10.2144/97225st05; DOBROWOLSKA G, 1992, EUR J BIOCHEM, V204, P299, DOI 10.1111/j.1432-1033.1992.tb16637.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Fabbrizio E, 1999, ONCOGENE, V18, P4357, DOI 10.1038/sj.onc.1202825; Ferri KF, 2000, NAT CELL BIOL, V2, pE63, DOI 10.1038/35008692; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; Filhol O, 2004, EMBO REP, V5, P351, DOI 10.1038/sj.embor.7400115; Filhol O, 2003, MOL CELL BIOL, V23, P975, DOI 10.1128/MCB.23.3.975-987.2003; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Geyer CR, 2000, METHOD ENZYMOL, V328, P171, DOI 10.1016/S0076-6879(00)28398-5; Ghavidel A, 2001, CELL, V106, P575, DOI 10.1016/S0092-8674(01)00473-1; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; Grein S, 1999, MOL CELL BIOCHEM, V191, P105, DOI 10.1023/A:1006814428582; Guerra B, 1999, FEBS LETT, V462, P353, DOI 10.1016/S0014-5793(99)01553-7; Guerra B, 1999, PHARMACOL THERAPEUT, V82, P303, DOI 10.1016/S0163-7258(98)00064-3; Guerra B, 2003, ONCOGENE, V22, P4933, DOI 10.1038/sj.onc.1206721; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; Leroy D, 1999, MOL CELL BIOCHEM, V191, P43, DOI 10.1023/A:1006832312169; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Loizou JI, 2004, CELL, V117, P17, DOI 10.1016/S0092-8674(04)00206-5; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Luo H, 2004, MOL CELL BIOL, V24, P8356, DOI 10.1128/MCB.24.19.8356-8365.2004; Maizel A, 2002, DEVELOPMENT, V129, P3545; Martel V, 2002, ANN NY ACAD SCI, V973, P272, DOI 10.1111/j.1749-6632.2002.tb04648.x; MESSERLE M, 1991, J VIROL, V65, P1638, DOI 10.1128/JVI.65.3.1638-1643.1991; Niefind K, 2001, EMBO J, V20, P5320, DOI 10.1093/emboj/20.19.5320; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Ruzzene M, 2002, BIOCHEM J, V364, P41, DOI 10.1042/bj3640041; Shimada K, 2004, MICROBIOL IMMUNOL, V48, P205, DOI 10.1111/j.1348-0421.2004.tb03507.x; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; STIGARE J, 1993, MOL CELL BIOCHEM, V129, P77, DOI 10.1007/BF00926578; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Theis-Febvre N, 2003, ONCOGENE, V22, P220, DOI 10.1038/sj.onc.1206107; Unger GM, 2004, CURR CANCER DRUG TAR, V4, P77, DOI 10.2174/1568009043481687; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wadd S, 1999, J BIOL CHEM, V274, P28991, DOI 10.1074/jbc.274.41.28991; Wiebusch L, 2001, EMBO J, V20, P1086, DOI 10.1093/emboj/20.5.1086; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zhou MM, 1995, J BIOL CHEM, V270, P31119, DOI 10.1074/jbc.270.52.31119	60	20	21	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	56					7343	7353		10.1038/sj.onc.1209722	http://dx.doi.org/10.1038/sj.onc.1209722			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16751801				2022-12-17	WOS:000242419100003
J	Subbarayan, V; Krieg, P; Hsi, LC; Kim, J; Yang, P; Sabichi, AL; Llansa, N; Mendoza, G; Logothetis, CJ; Newman, RA; Lippman, SM; Menter, DG				Subbarayan, V.; Krieg, P.; Hsi, L. C.; Kim, J.; Yang, P.; Sabichi, A. L.; Llansa, N.; Mendoza, G.; Logothetis, C. J.; Newman, R. A.; Lippman, S. M.; Menter, D. G.			15-lipoxygenase-2 gene regulation by its product 15-(S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activated receptor gamma	ONCOGENE			English	Article						15-lipoxygenase-2; prostate cancer; gene expression; peroxisome proliferator-activated receptor gamma	PROSTATE-CANCER CELLS; NUCLEAR RECEPTOR; PPAR-GAMMA; ROR-ALPHA; BINDING PROTEIN; FATTY-ACIDS; EXPRESSION; ANDROGEN; LIGANDS; GROWTH	An inverse relationship exists between the expression of 15-lipoxygenase-2 (15-LOX-2) and peroxisome proliferator-activated receptor c (PPARc) in normal prostate epithelial cells (PrECs) compared with their expression in prostate carcinoma cells (PC-3). The reason for this difference, however, is unknown. We hypothesized that this inverse expression partly involves the 15-LOX-2 promoter and 15-S-hydroxyeicosatetraenoic acid (15-(S)HETE), a product of 15- LOX-2 that binds to PPARc. We identified an active steroid nuclear receptor half-site present in the 15-LOX-2 promoter fragment F-5 (-618/+177) that can interact with PPARc. After forced expression of wild-type PPARc, 15-(S)-HETE (1 mu M) decreased F-5 reporter activity in PrECs whereas forced expression of 15-LOX-2 resulted in 15-(S)-HETE production which enhanced F-5 activity in PC-3. In contrast, the expression of dominant-negative PPARc reversed the transcriptional activation of F-5 by enhancing it 202-fold in PrEC or suppressing it in PC-3; the effect in PC-3 was positively increased 150-fold in the presence of 15-(S)-HETE (1 mu M). Peroxisome proliferator-activated receptor c interacted with 15-LOX-2 promoter sequences in pulldown experiments using biotinylated 15-LOX-2 (-560/-596 bp) oligonucleotides. In gelshift analyses PPARc and orphan receptor ROR alpha were shown to interact with the F-5 fragment in PC-3 cells. These data suggest that crosstalk mechanisms exist between the 15-LOX-2 gene and PPARc to counterbalance expression and help explain the inverse relationship of these genes in normal versus cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Unit 1360, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; German Canc Res Ctr, Dept Eicosanoids & Tumor Dev, D-6900 Heidelberg, Germany	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Helmholtz Association; German Cancer Research Center (DKFZ)	Menter, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Unit 1360, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dmenter@mdanderson.org			NCI NIH HHS [CA-16672-28, P01 CA-91844, R21 CA-10241, R21 CA-102145] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA091844, R21CA102145] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berhane K, 2001, GENE, V268, P141, DOI 10.1016/S0378-1119(01)00417-6; Bhatia B, 2005, ONCOGENE, V24, P3583, DOI 10.1038/sj.onc.1208406; Bhatia B, 2003, J BIOL CHEM, V278, P25091, DOI 10.1074/jbc.M301920200; Blanquart C, 2003, J STEROID BIOCHEM, V85, P267, DOI 10.1016/S0960-0760(03)00214-0; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Butler R, 2000, CELL GROWTH DIFFER, V11, P49; Cato A.C., 2002, SCI STKE, V2002, pre9, DOI [10.1126/stke.2002.138.re9, DOI 10.1126/STKE.2002.138.RE9]; Elbrecht A, 1996, BIOCHEM BIOPH RES CO, V224, P431, DOI 10.1006/bbrc.1996.1044; Flores AM, 2005, CHEM-BIOL INTERACT, V151, P121, DOI 10.1016/j.cbi.2004.11.001; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; Hsi LC, 2002, J BIOL CHEM, V277, P40549, DOI 10.1074/jbc.M203522200; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Jack GS, 2000, HUM PATHOL, V31, P1146, DOI 10.1053/hupa.2000.16670; Kang LT, 1998, J LIPID RES, V39, P1476; Kilty I, 1999, EUR J BIOCHEM, V266, P83, DOI 10.1046/j.1432-1327.1999.00818.x; Kim J, 2005, CANCER RES, V65, P6189, DOI 10.1158/0008-5472.CAN-04-4439; Koeffler HP, 2003, CLIN CANCER RES, V9, P1; Krieg P, 2001, GENOMICS, V73, P323, DOI 10.1006/geno.2001.6519; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Moretti RM, 2004, INT J CANCER, V112, P87, DOI 10.1002/ijc.20387; Moretti RM, 2002, ONCOL REP, V9, P1139; Moretti RM, 2001, PROSTATE, V46, P327, DOI 10.1002/1097-0045(20010301)46:4<327::AID-PROS1040>3.0.CO;2-6; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Salas TR, 2003, J BIOL CHEM, V278, P41338, DOI 10.1074/jbc.M302972200; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shankaranarayanan P, 2003, J IMMUNOL, V170, P887, DOI 10.4049/jimmunol.170.2.887; Shappell SB, 1999, AM J PATHOL, V155, P235, DOI 10.1016/S0002-9440(10)65117-6; Shappell SB, 2001, CANCER RES, V61, P497; Sharma GD, 2005, J BIOL CHEM, V280, P7917, DOI 10.1074/jbc.M408852200; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; Subbarayan V, 2005, NEOPLASIA, V7, P280, DOI 10.1593/neo.04457; Subbarayan V, 2004, CANCER EPIDEM BIOMAR, V13, P1710; Subbarayan V, 2001, CANCER RES, V61, P2720; Tang SH, 2004, ONCOGENE, V23, P6942, DOI 10.1038/sj.onc.1207913; Tang SH, 2002, J BIOL CHEM, V277, P16189, DOI 10.1074/jbc.M111936200; Warnmark A, 2003, MOL ENDOCRINOL, V17, P1901, DOI 10.1210/me.2002-0384; Wigren J, 2003, J ENDOCRINOL, V177, P207, DOI 10.1677/joe.0.1770207; Xu XC, 2003, NEOPLASIA, V5, P121, DOI 10.1016/S1476-5586(03)80003-9	39	20	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2006	25	44					6015	6025		10.1038/sj.onc.1209617	http://dx.doi.org/10.1038/sj.onc.1209617			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16682954				2022-12-17	WOS:000240826300010
J	Bossolasco, M; Veillette, F; Bertrand, R; Mes-Masson, AM				Bossolasco, M.; Veillette, F.; Bertrand, R.; Mes-Masson, A. -M			Human TDE1, a TDE1/TMS family member, inhibits apoptosis in vitro and stimulates in vivo tumorigenesis	ONCOGENE			English	Article						TDE1; apoptosis; transformation; tumorigenesis	ANTIGEN TRANSGENIC MICE; SUBCELLULAR-LOCALIZATION; PROTEIN FAMILY; CELL-LINES; EXPRESSION; IDENTIFICATION; GENE; CULTURE; CANCER; TISSUE	We have previously described hTDE1, the human homologue of the recently described TDE1/TMS family of proteins whose members have been identified in several species. Although a defined biochemical activity has yet to be assigned to TDE1/TMS family members, previous results point to the overexpression of family members in tumor cell lines or tissues. To define whether hTDE1 may directly impact on neoplastic transformation, we derived and characterized stable Rat-1 transfectants that constitutively express hTDE1 at the plasma membrane. Expression of hTDE1 in Rat-1 transfectants had a significant effect on cell contact inhibition in vitro as judged by a focus formation assay. In addition, by monitoring caspase-3 activity and Hoechst staining, we determined that hTDE1 overexpression partially protects cells from serum starvation- and etoposide-induced apoptosis. Finally, hTDE1 Rat-1-expressing clones accelerated the formation of tumors in a nude mouse assay. Our results suggest that hTDE1 contributes directly to oncogenesis in vivo that may in part be explained by its effect on apoptosis in vitro.	CHUM, Ctr Rech, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal	Mes-Masson, AM (corresponding author), CHUM, ICM, Hop Notre Dame de Bon Secours, 1560 Sherbrooke St E, Montreal, PQ H2L 4M1, Canada.	anne-marie.mes-masson@umontreal.ca		Mes-Masson, Anne-Marie/0000-0002-6498-266X				Aoki S, 2002, J NEUROSCI, V22, P10751; Bazzoni G, 2004, PHYSIOL REV, V84, P869, DOI 10.1152/physrev.00035.2003; Bossolasco M, 1999, MOL CARCINOGEN, V26, P189, DOI 10.1002/(SICI)1098-2744(199911)26:3<189::AID-MC8>3.0.CO;2-T; CHALIFOUR LE, 1990, ONCOGENE, V5, P1719; CHALIFOUR LE, 1992, MOL CARCINOGEN, V5, P178, DOI 10.1002/mc.2940050304; Corn PG, 2002, BIOESSAYS, V24, P83, DOI 10.1002/bies.10036; Faust M, 2000, CELL TISSUE RES, V301, P329, DOI 10.1007/s004410000256; Ferrigno P, 1999, METHOD CELL BIOL, V58, P107; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Grossman TR, 2000, J EXP BIOL, V203, P447; Inuzuka M, 2005, J BIOL CHEM, V280, P35776, DOI 10.1074/jbc.M505712200; Krueger WHH, 1997, J NEUROCHEM, V69, P1343; Kufe DW, 2003, CANC MED; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; LEBEL M, 1994, DNA SEQUENCE, V5, P31, DOI 10.3109/10425179409039702; Nowell PC, 2002, SEMIN CANCER BIOL, V12, P261, DOI 10.1016/S1044-579X(02)00012-3; ORMEROD MG, 1992, J IMMUNOL METHODS, V153, P57, DOI 10.1016/0022-1759(92)90305-D; Pearce DA, 2000, J NEUROSCI RES, V59, P19, DOI 10.1002/(SICI)1097-4547(20000101)59:1<19::AID-JNR3>3.0.CO;2-Y; Player A, 2003, INT J CANCER, V107, P238, DOI 10.1002/ijc.11391; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RENAN MJ, 1993, MOL CARCINOGEN, V7, P139; Ronot X, 2000, CYTOMETRY, V41, P19, DOI 10.1002/1097-0320(20000901)41:1<19::AID-CYTO3>3.0.CO;2-X; Royle SJ, 2003, BIOESSAYS, V25, P39, DOI 10.1002/bies.10200; Shigeta M, 2003, J CELL BIOL, V163, P165, DOI 10.1083/jcb.200301075; Simpson JC, 2000, EMBO REP, V1, P287, DOI 10.1093/embo-reports/kvd058; Stevens FJ, 1999, SEMIN CELL DEV BIOL, V10, P443, DOI 10.1006/scdb.1999.0315; TEMIN HM, 1958, VIROLOGY, V6, P669, DOI 10.1016/0042-6822(58)90114-4; Xu J, 2003, MOL BIOL REP, V30, P47, DOI 10.1023/A:1022250428015	28	20	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2006	25	33					4549	4558		10.1038/sj.onc.1209488	http://dx.doi.org/10.1038/sj.onc.1209488			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16547497				2022-12-17	WOS:000239457500005
J	Yan, B; Wang, H; Wang, H; Zhuo, D; Li, F; Kon, T; Dewhirst, M; Li, CY				Yan, B.; Wang, H.; Wang, H.; Zhuo, D.; Li, F.; Kon, T.; Dewhirst, M.; Li, C-Y			Apoptotic DNA fragmentation factor maintains chromosome stability in a P53-independent manner	ONCOGENE			English	Article						apoptosis; DNA fragmentation; chromosome instability; tumor/cancer	CELL-CYCLE CHECKPOINTS; THYMIDINE KINASE LOCUS; SACCHAROMYCES-CEREVISIAE; NEUROBLASTOMA TUMORS; COLORECTAL CANCERS; MUTATION ASSAY; ENDONUCLEASE-G; DEGRADATION; INSTABILITY; LINE	DNA fragmentation factor (DFF)/caspase-activated DNase (CAD) is responsible for DNA fragmentation, a hallmark event during apoptosis. Although DNA fragmentation is an evolutionarily conserved process across species, its biological function is not clearly understood. In this study, we constructed cell lines expressing a mutant ICAD (inhibitor of CAD) protein that is resistant to caspase cleavage and therefore constantly binds to DFF/CAD and inhibits DNA fragmentation. We found that irradiation of these cells led to increased chromosome aberrations and aneuploidy when compared with their parental controls. The increased chromosome instability is observed irrespective of cellular P53 status, suggesting that the effect of DFF/CAD is independent of P53. Inhibition of apoptotic DNA fragmentation resulted in increased clonogenic survival of irradiated cells and a delay in removal of cells with DNA damages induced by radiation, an effect similar to that in cells with p53 mutations. Consistent with DFF/CAD's effect on clonogenic survival, tumors established from cells deficient in DNA fragmentation showed enhanced growth in nude mice. Therefore, our results suggest that DFF/CAD plays an important and P53-independent role in maintaining chromosome stability and suppressing tumor development.	Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Sichuan Univ, W China Affiliated Hosp 2, Chengdu, Peoples R China	Duke University; Duke University; Sichuan University	Li, CY (corresponding author), Duke Univ, Med Ctr, Dept Radiat Oncol, Box 3455, Durham, NC 27710 USA.	chuanyuan.li@duke.edu	Dewhirst, Mark/Q-1302-2019; Li, Chuan-Yuan/H-4148-2013	Dewhirst, Mark/0000-0003-3459-6546; 				Abel F, 2004, INT J ONCOL, V25, P1297; Abel F, 2002, BRIT J CANCER, V86, P596, DOI 10.1038/sj.bjc.6600111; Caron H, 1996, NEW ENGL J MED, V334, P225, DOI 10.1056/NEJM199601253340404; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; HOYT MA, 1990, MOL CELL BIOL, V10, P223, DOI 10.1128/MCB.10.1.223; Judson H, 2000, HUM GENET, V106, P406, DOI 10.1007/s004390000257; Kawane K, 2003, NAT IMMUNOL, V4, P138, DOI 10.1038/ni881; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Konishi S, 2002, CANCER-AM CANCER SOC, V95, P2473, DOI 10.1002/cncr.10987; Lechardeur D, 2000, J CELL BIOL, V150, P321, DOI 10.1083/jcb.150.2.321; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; LIBER HL, 1982, MUTAT RES, V94, P467, DOI 10.1016/0027-5107(82)90308-6; LITTLE JB, 1995, J BIOL CHEM, V270, P11033, DOI 10.1074/jbc.270.19.11033; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARIS JM, 1995, CANCER RES, V55, P4664; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; SKOPEK TR, 1978, BIOCHEM BIOPH RES CO, V84, P411, DOI 10.1016/0006-291X(78)90185-7; Slane JM, 2000, BRAIN RES, V867, P70, DOI 10.1016/S0006-8993(00)02258-7; SPENCER F, 1990, GENETICS, V124, P237; Van Gele M, 1998, CANCER RES, V58, P1503; Van Gele M, 1998, GENE CHROMOSOME CANC, V23, P67, DOI 10.1002/(SICI)1098-2264(199809)23:1<67::AID-GCC10>3.0.CO;2-B; van Loo G, 2001, CELL DEATH DIFFER, V8, P1136, DOI 10.1038/sj.cdd.4400944; Yan B, 2006, P NATL ACAD SCI USA, V103, P1504, DOI 10.1073/pnas.0507779103; Yan B, 2003, J BIOL CHEM, V278, P45358, DOI 10.1074/jbc.M307933200; YANDELL DW, 1986, CANCER GENET CYTOGEN, V20, P231, DOI 10.1016/0165-4608(86)90078-6	34	20	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	39					5370	5376		10.1038/sj.onc.1209535	http://dx.doi.org/10.1038/sj.onc.1209535			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16619042				2022-12-17	WOS:000240144900002
J	Ueno, T; Sasaki, K; Yoshida, S; Kajitani, N; Satsuka, A; Nakamura, H; Sakai, H				Ueno, T.; Sasaki, K.; Yoshida, S.; Kajitani, N.; Satsuka, A.; Nakamura, H.; Sakai, H.			Molecular mechanisms of hyperplasia induction by human papillomavirus E7	ONCOGENE			English	Article						HPV; E7; hyperplasia; pRb; p130; pocket proteins	RETINOBLASTOMA TUMOR-SUPPRESSOR; TYPE-16 E7; E6 ONCOPROTEIN; EPITHELIAL HYPERPLASIA; HUMAN KERATINOCYTES; CERVICAL-CARCINOMA; PROTEIN FAMILY; CELLULAR DNA; GENE; DIFFERENTIATION	Infections of human papillomavirus (HPV) induce a variety of benign tumors, such as warts and condylomas. During the process of aberrant cell proliferation, genetic mutations are accumulated in the cells, from which malignant tumor cells arise. The viral oncoproteins E6 and E7 are known to help disrupt the cell cycle checkpoint machinery and accelerate chromosomal instability, events which are critical in malignant conversion. However, the mechanisms involved in the hyperplasia caused by HPV infection have remained unknown. We analysed the effects of regulatory genes of HPV18, a typical high-risk-type HPV, on the formation of the epithelial organ by using an organotypic culture system, and found that E7 had potent activity to induce hyperplasia, to which the disruption of the pRb pathway was well correlated. However, analysis with the E7 variants indicated that other pocket proteins are also involved in the activity.	Kyoto Univ, Inst Virus Res, Lab Gene Anal, Dept Viral Oncol,Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Sakai, H (corresponding author), Kyoto Univ, Inst Virus Res, Lab Gene Anal, Dept Viral Oncol,Sakyo Ku, 53 Kawahara Cho, Kyoto 6068507, Japan.	hsakai@virus.kyoto-u.ac.jp						BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; Balsitis SJ, 2003, MOL CELL BIOL, V23, P9094, DOI 10.1128/MCB.23.24.9094-9103.2003; Basile JR, 2001, J BIOL CHEM, V276, P22522, DOI 10.1074/jbc.M010505200; BLANTON RA, 1992, CELL GROWTH DIFFER, V3, P791; Boutwell R K, 1989, Prog Clin Biol Res, V298, P3; Boyer SN, 1996, CANCER RES, V56, P4620; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; Chien WM, 2000, CELL GROWTH DIFFER, V11, P425; CHOO KB, 1987, VIROLOGY, V161, P259, DOI 10.1016/0042-6822(87)90195-4; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; CORMACK B, 1987, CURRENT PROTOCOLS MO; Davy CE, 2002, J VIROL, V76, P9806, DOI 10.1128/JVI.76.19.9806-9818.2002; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; DOLLARD SC, 1992, GENE DEV, V6, P1131, DOI 10.1101/gad.6.7.1131; DOWHANICK JJ, 1995, J VIROL, V69, P7791, DOI 10.1128/JVI.69.12.7791-7799.1995; Duensing S, 2003, J VIROL, V77, P12331, DOI 10.1128/JVI.77.22.12331-12335.2003; Duensing S, 2001, J VIROL, V75, P7712, DOI 10.1128/JVI.75.16.7712-7716.2001; Duensing S, 2001, CANCER RES, V61, P2356; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Frattini MG, 1996, P NATL ACAD SCI USA, V93, P3062, DOI 10.1073/pnas.93.7.3062; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Gulliver GA, 1997, J VIROL, V71, P5905, DOI 10.1128/JVI.71.8.5905-5914.1997; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; Helt AM, 2002, J VIROL, V76, P10559, DOI 10.1128/JVI.76.20.10559-10568.2002; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; Howley P. M., 2001, FIELDS VIROLOGY, V2, P2197; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Majewski S, 2003, EXP DERMATOL, V12, P721, DOI 10.1111/j.0906-6705.2003.00125.x; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MEYERS C, 1992, SCIENCE, V257, P971, DOI 10.1126/science.1323879; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Munger K, 2004, J VIROL, V78, P11451, DOI 10.1128/JVI.78.21.11451-11460.2004; Nakahara T, 2002, J VIROL, V76, P10914, DOI 10.1128/JVI.76.21.10914-10920.2002; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Nishimura A, 2000, J VIROL, V74, P3752, DOI 10.1128/JVI.74.8.3752-3760.2000; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Pfister Herbert, 2003, J Natl Cancer Inst Monogr, P52; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; Sambrook J, 1989, MOL CLONING LAB MANU, V3, P18; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; Steenbergen RDM, 1998, J VIROL, V72, P749, DOI 10.1128/JVI.72.1.749-757.1998; Thompson DA, 2001, ONCOGENE, V20, P3629, DOI 10.1038/sj.onc.1204483; TSUNENAGA M, 1994, JPN J CANCER RES, V85, P238, DOI 10.1111/j.1349-7006.1994.tb02088.x; Williams SMG, 2005, CANCER RES, V65, P6534, DOI 10.1158/0008-5472.CAN-05-0083; Zhang BY, 2006, P NATL ACAD SCI USA, V103, P437, DOI 10.1073/pnas.0510012103; Zhang JY, 2004, GENE DEV, V18, P17, DOI 10.1101/gad.1160904; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	63	20	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	30					4155	4164		10.1038/sj.onc.1209445	http://dx.doi.org/10.1038/sj.onc.1209445			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16501608				2022-12-17	WOS:000239004800003
J	Calvet, L; Geoerger, B; Regairaz, M; Opolon, P; Machet, L; Morizet, J; Joseph, JM; Elie, N; Vassal, G				Calvet, L.; Geoerger, B.; Regairaz, M.; Opolon, P.; Machet, L.; Morizet, J.; Joseph, J-M; Elie, N.; Vassal, G.			Pleiotrophin, a candidate gene for poor tumor vasculature and in vivo neuroblastoma sensitivityto irinotecan	ONCOGENE			English	Article						neuroblastoma; CPT-11; resistance; pleiotrophin; angiogenesis	AFFIN REGULATORY PEPTIDE; DNA-TOPOISOMERASE-I; GROWTH-FACTOR PLEIOTROPHIN; PEDIATRIC-ONCOLOGY-GROUP; PHASE-I; N-MYC; ANTIANGIOGENIC THERAPY; NEURO-BLASTOMA; EXPRESSION; ANGIOGENESIS	In vivo neuroblastoma ( NB) xenograft model, resistant to the DNA-topoisomerase I inhibitor irinotecan (CPT-11), has been established to study resistance mechanisms acquired in a therapeutic setting. Common mechanisms of resistance were not involved in this resistance. Thus, we compared the gene expression profiles of sensitive, resistant, and reverted tumors using cDNA expression arrays. Expression of selected transcripts was confirmed by quantitative real-time PCR. We found that pleiotrophin (PTN), a heparin-binding growth factor, was the only gene significantly affected: PTN gene expression was downregulated in all resistant tumors (8-14-fold) as compared to sensitive tumors, and was increased (2-4-fold) in all reverted tumors as compared to resistant tumors. PTN thus appeared to be a likely candidate gene associated with resistance to CPT-11 in this in vivo model. To investigate the direct implication of PTN in NB, we transfected two NB cell lines with RNA interferences in order to silence PTN. PTN failed to demonstrate implication in resistance to CPT-11 in vitro but could influence sensitivity to CPT-11 exclusively through an in vivo mechanism. Indeed, vasculature was significantly enhanced in resistant NB xenografts compared to sensitive and reverted xenografts, and we suggest that PTN is acting in our resistant in vivo NB model as an angiostatic factor.	Inst Gustave Roussy, UPRES, EA 3535, F-94805 Villejuif, France; Inst Gustave Roussy, UMR 8121, F-94805 Villejuif, France; CHUV, Dept Pediat, Lausanne, Switzerland; Inst Gustave Roussy, LIPA, F-94805 Villejuif, France	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); UNICANCER; Gustave Roussy	Vassal, G (corresponding author), Inst Gustave Roussy, UPRES, EA 3535, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	gvassal@igr.fr	Elie, Nicolas/ABC-4069-2020; Machet, Laurent/A-2976-2010	Elie, Nicolas/0000-0001-5772-8252; Machet, Laurent/0000-0001-5985-878X				Blaney S, 2001, CLIN CANCER RES, V7, P32; BOURHIS J, 1989, J NATL CANCER I, V81, P1401, DOI 10.1093/jnci/81.18.1401; Bowden ET, 2002, J BIOL CHEM, V277, P35862, DOI 10.1074/jbc.M203963200; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Calvet L, 2004, BRIT J CANCER, V91, P1205, DOI 10.1038/sj.bjc.6602079; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; Choudhuri R, 1997, CANCER RES, V57, P1814; Corbley MJ, 1997, J BIOL CHEM, V272, P24696, DOI 10.1074/jbc.272.39.24696; COURTY J, 1991, BIOCHEM BIOPH RES CO, V180, P145, DOI 10.1016/S0006-291X(05)81267-7; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; Deuel TF, 2002, ARCH BIOCHEM BIOPHYS, V397, P162, DOI 10.1006/abbi.2001.2705; Elie N, 2003, CYTOM PART A, V56A, P37, DOI 10.1002/cyto.a.10075; FANG WJ, 1992, J BIOL CHEM, V267, P25889; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; Furman WL, 1999, J CLIN ONCOL, V17, P1815, DOI 10.1200/JCO.1999.17.6.1815; HAYASHI Y, 1989, CANCER, V63, P126, DOI 10.1002/1097-0142(19890101)63:1<126::AID-CNCR2820630120>3.0.CO;2-Z; Herbst RS, 1998, CANCER CHEMOTH PHARM, V41, P497, DOI 10.1007/s002800050773; Heroult M, 2004, ONCOGENE, V23, P1745, DOI 10.1038/sj.onc.1206879; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Kadomatsu KJ, 2004, CANCER LETT, V204, P127, DOI 10.1016/S0304-3835(03)00450-6; Kim YH, 2003, APPL MICROBIOL BIOT, V63, P75, DOI 10.1007/s00253-003-1332-5; KOMURO H, 1994, MED PEDIATR ONCOL, V23, P487, DOI 10.1002/mpo.2950230607; LAAROUBI K, 1994, GROWTH FACTORS, V10, P89, DOI 10.3109/08977199409010982; Li XG, 1996, ANN NY ACAD SCI, V803, P111, DOI 10.1111/j.1749-6632.1996.tb26381.x; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; Liu R, 1999, AM J PATHOL, V155, P1861, DOI 10.1016/S0002-9440(10)65505-8; Lock RB, 1996, CANCER RES, V56, P4006; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; MILNER PG, 1989, BIOCHEM BIOPH RES CO, V165, P1096, DOI 10.1016/0006-291X(89)92715-0; NAKAGAWARA A, 1995, CANCER RES, V55, P1792; Papadimitriou E, 2001, BIOCHEM BIOPH RES CO, V282, P306, DOI 10.1006/bbrc.2001.4574; Polykratis A, 2004, INT J BIOCHEM CELL B, V36, P1954, DOI 10.1016/j.biocel.2004.02.012; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; Ries LAG, 1999, CANC INCIDENCE SURVI, V99-4649.; Rubin EH, 1996, CANC TREAT RES, V87, P243; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; TEICHER BA, 1995, ONCOL RES, V7, P237; TEICHER BA, 1990, SCIENCE, V247, P1457, DOI 10.1126/science.2108497; Thompson J, 1997, ANTI-CANCER DRUG, V8, P313, DOI 10.1097/00001813-199704000-00002; Thompson J, 1997, CLIN CANCER RES, V3, P423; Vassal G, 1996, BRIT J CANCER, V74, P537, DOI 10.1038/bjc.1996.398; Vassal G, 2003, J CLIN ONCOL, V21, P3844, DOI 10.1200/JCO.2003.08.175; Vassal G, 1997, EUR J CANCER, V33, P2011, DOI 10.1016/S0959-8049(97)00296-7; Vassal G, 2002, MED PEDIATR ONCOL, V39, P257; Wildiers H, 2003, BRIT J CANCER, V88, P1979, DOI 10.1038/sj.bjc.6601005	46	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3150	3159		10.1038/sj.onc.1209348	http://dx.doi.org/10.1038/sj.onc.1209348			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16501609				2022-12-17	WOS:000237951000006
J	Shank-Calvo, JA; Draheim, K; Bhasin, M; Kelliher, MA				Shank-Calvo, J. A.; Draheim, K.; Bhasin, M.; Kelliher, M. A.			P16Ink4a or p19Arf loss contributes to Tal1-induced leukemogenesis in mice	ONCOGENE			English	Article						T-cell leukemia; Tal1/scl; p16(Ink4a); p19(Arf)	ACUTE LYMPHOBLASTIC-LEUKEMIA; ONCOGENIC TRANSCRIPTION FACTORS; LOOP-HELIX PROTEINS; T-CELL; C-MYC; TUMOR SUPPRESSION; MTS1 P16(INK4A); TRANSGENIC MICE; INK4A LOCUS; EXPRESSION	Analysis of the INK4A/ARF locus in human T-ALL patients revealed frequent deletions in exon 2, the exon common to both p16(INK4A) and p14(ARF). Other studies have described selective deletion of exon 1 ss of p14ARF or methylation of the p16INK4A promoter. Therefore, it is unclear from these studies whether loss of p16INK4A and/or p14ARF contributes to the development of T-ALL. To elucidate the relative contribution of the ink4a/arf locus to T-cell leukemogenesis, we mated our tal1 transgenic mice to ink4a/arf-/-, p16(ink4a)-/-,and p19(arf)-/- mice and generated tal1/ink4a/arf+/-, tal1/p16(ink4a)+/-, and tal1/p19(arf) +/- mice. Each of these mice developed T-cell leukemia rapidly, indicating that loss of either p16(ink4a) or p19(arf) cooperates with Tal1 to induce leukemia in mice. Preleukemic studies reveal that Tal1 expression stimulates entry into the cell cycle and thymocyte apoptosis in vivo. Interestingly, mice expressing a DNA-binding mutant of Tal1 do not exhibit increases in S phase cells. The S phase induction is accompanied by an increase in thymocyte apoptosis in tal1 transgenic mice. Whereas apoptosis is reduced to wild-type levels in tal1/ink4a/arf-/- mice, S phase induction remains unaffected. Thus, Tal1 stimulates cell cycle entry independent of the ink4a/arf locus, but its ability to induce apoptosis is Ink4a/Arf-dependent.	Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01650 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA USA; Dana Faber Canc Inst, Immunobiol Lab, Boston, MA USA; Dana Faber Canc Inst, Dept Med Oncol, Boston, MA USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Kelliher, MA (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, 364 Plantat St, Worcester, MA 01650 USA.	michelle.kelliher@umassmed.edu		Bhasin, Manoj/0000-0001-5172-420X	NATIONAL CANCER INSTITUTE [R01CA096899] Funding Source: NIH RePORTER; NCI NIH HHS [CA096899] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Batova A, 1997, CANCER RES, V57, P832; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Cayuela JM, 1996, BLOOD, V87, P2180, DOI 10.1182/blood.V87.6.2180.bloodjournal8762180; CAYUELA JM, 1995, BLOOD, V85, P854, DOI 10.1182/blood.V85.3.854a.bloodjournal853854a; Condorelli GL, 1997, MOL CELL BIOL, V17, P2954, DOI 10.1128/MCB.17.5.2954; Condorelli GL, 1996, CANCER RES, V56, P5113; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Ferrando AA, 2004, BLOOD, V103, P1909, DOI 10.1182/blood-2003-07-2577; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Gardie B, 1998, BLOOD, V91, P1016, DOI 10.1182/blood.V91.3.1016.1016_1016_1020; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; Harrison CJ, 2001, BEST PRACT RES CL HA, V14, P593, DOI 10.1053/beha.2001.0156; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; Herblot S, 2000, NAT IMMUNOL, V1, P138, DOI 10.1038/77819; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kees UR, 1997, BLOOD, V89, P4161, DOI 10.1182/blood.V89.11.4161; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; O'Neil J, 2004, CANCER CELL, V5, P587, DOI 10.1016/j.ccr.2004.05.023; O'Neil J, 2001, ONCOGENE, V20, P3897, DOI 10.1038/sj.onc.1204519; O'Neil J, 2005, BLOOD; Pagliuca A, 2000, CANCER RES, V60, P1376; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Staal FJT, 2005, NAT REV IMMUNOL, V5, P21, DOI 10.1038/nri1529; Valtieri M, 1998, CANCER RES, V58, P562; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Zhou MX, 1997, PEDIATR HEMAT ONCOL, V14, P141, DOI 10.3109/08880019709030900; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	39	20	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					3023	3031		10.1038/sj.onc.1209326	http://dx.doi.org/10.1038/sj.onc.1209326			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16407836				2022-12-17	WOS:000237950800006
J	Haller, K; Kibler, KV; Kasai, T; Chi, YH; Peloponese, JM; Yedavalli, VSRK; Jeang, KT				Haller, K; Kibler, KV; Kasai, T; Chi, YH; Peloponese, JM; Yedavalli, VSRK; Jeang, KT			The N-terminus of rodent and human MAD1 confers species-specific stringency to spindle assembly checkpoint	ONCOGENE			English	Article						aneuploidy; spindle assembly checkpoint; cellular transformation; chromosomal instability; mitotic arrest	VIRUS TYPE-I; MITOTIC CHECKPOINT; SACCHAROMYCES-CEREVISIAE; CELLULAR-TRANSFORMATION; GENOMIC INSTABILITY; GENETIC INSTABILITY; RAT FIBROBLASTS; TAX PROTEIN; LEUKEMIA; CANCER	The spindle assembly checkpoint (SAC) guards against chromosomal mis-segregation and the emergence of aneuploidy. SAC in higher eukaryotes includes at least 10 proteins including MAD1-3, BUB1-3, and Msp1. A long-standing observation has been that rodent cells are more tolerant of microtubule toxins than primate cells indicating that SAC function is more relaxed in the former than the latter. Here, we report on an unexpected functional difference between the rodent and human MAD1 component of the respective SAC. Ectopic expression of human MAD1 in mouse and hamster cells corrected a relaxed SAC to a more stringent form. Our findings posit MAD1 as a species-specific determinant which influences the stringency of cellular response to microtubule depolymerization and spindle damage.	NIAID, Mol Virol Sect, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Jeang, KT (corresponding author), NIAID, Mol Virol Sect, Mol Microbiol Lab, NIH, Bldg 4,Room 306,9000 Rockville Pike, Bethesda, MD 20892 USA.	kj7e@nih.gov	Chi, Ya-Hui/ABE-8550-2020; Jeang, Kuan-Teh/A-2424-2008; Chi, Ya-Hui/B-1080-2010	Chi, Ya-Hui/0000-0002-9216-0938; Peloponese, Jean-Marie/0000-0002-9677-9703	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI001023, ZIAAI000547, Z01AI001023] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abrieu A, 2000, CELL, V102, P817, DOI 10.1016/S0092-8674(00)00070-2; Azran Inbal, 2004, Retrovirology, V1, P20; Babu JR, 2003, J CELL BIOL, V160, P341, DOI 10.1083/jcb.200211048; Basto R, 2000, NAT CELL BIOL, V2, P939, DOI 10.1038/35046592; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Chen RH, 1998, J CELL BIOL, V143, P283, DOI 10.1083/jcb.143.2.283; Chung EN, 2002, MOL BIOL CELL, V13, P1501, DOI 10.1091/mbc.02-01-0003; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; De Antoni A, 2005, CURR BIOL, V15, P214, DOI 10.1016/j.cub.2005.01.038; DOWNES CS, 1990, J CELL BIOL, V110, P1855, DOI 10.1083/jcb.110.6.1855; Draviam VM, 2004, CURR OPIN GENET DEV, V14, P120, DOI 10.1016/j.gde.2004.02.007; Duesberg P, 2003, CELL CYCLE, V2, P202, DOI 10.4161/cc.2.3.382; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Gallardo MH, 2003, J EVOLUTION BIOL, V16, P163, DOI 10.1046/j.1420-9101.2003.00507.x; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Haines DC, 2001, TOXICOL PATHOL, V29, P653, DOI 10.1080/019262301753385988; Hardwick KC, 2000, J CELL BIOL, V148, P871, DOI 10.1083/jcb.148.5.871; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Hoyt MA, 1996, ANNU REV GENET, V30, P7, DOI 10.1146/annurev.genet.30.1.7; Iwanaga Y, 2002, J BIOL CHEM, V277, P31005, DOI 10.1074/jbc.M110666200; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; Lee MS, 2004, P NATL ACAD SCI USA, V101, P10655, DOI 10.1073/pnas.0404102101; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 2004, NAT GENET, V36, P1144, DOI 10.1038/ng1104-1144; Li H, 2004, EMBO J, V23, P4824, DOI 10.1038/sj.emboj.7600479; LING V, 1974, J CELL PHYSIOL, V83, P103, DOI 10.1002/jcp.1040830114; Luo XL, 2004, NAT STRUCT MOL BIOL, V11, P338, DOI 10.1038/nsmb748; Luo XL, 2002, MOL CELL, V9, P59, DOI 10.1016/S1097-2765(01)00435-X; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; Matsuoka M, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-27; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; MIDGLEY AR, 1959, SCIENCE, V130, P40, DOI 10.1126/science.130.3366.40; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nasmyth K, 2005, CELL, V120, P739, DOI 10.1016/j.cell.2005.03.006; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Rao CV, 2005, P NATL ACAD SCI USA, V102, P4365, DOI 10.1073/pnas.0407822102; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Rosin O, 1998, J BIOL CHEM, V273, P6698, DOI 10.1074/jbc.273.12.6698; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; SCHIMKE RT, 1991, COLD SH Q B, V56, P417; Shah JV, 2004, CURR BIOL, V14, P942, DOI 10.1016/j.cub.2004.05.046; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Sironi L, 2001, EMBO J, V20, P6371, DOI 10.1093/emboj/20.22.6371; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; Takatsuki K, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-16; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Vogel C, 2005, J BIOL CHEM, V280, P4025, DOI 10.1074/jbc.C400545200; Wassmann K, 2003, EMBO J, V22, P797, DOI 10.1093/emboj/cdg071; Wassmann K, 1998, P NATL ACAD SCI USA, V95, P11193, DOI 10.1073/pnas.95.19.11193; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4; YUNIS JJ, 1982, SCIENCE, V215, P1525, DOI 10.1126/science.7063861	59	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2137	2147		10.1038/sj.onc.1209259	http://dx.doi.org/10.1038/sj.onc.1209259			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16288203	Bronze			2022-12-17	WOS:000236581200001
J	Barnache, S; Le Scolan, E; Kosmider, O; Denis, N; Moreau-Gachelin, F				Barnache, S; Le Scolan, E; Kosmider, O; Denis, N; Moreau-Gachelin, F			Phosphatidylinositol 4-phosphatase type II is an erythropoietin-responsive gene	ONCOGENE			English	Article						phosphatidylinositol phosphatase; erythroleukemia; erythropoietin; transcriptional regulation	INOSITOL POLYPHOSPHATE 4-PHOSPHATASE; TRANSCRIPTION FACTOR PU.1; PHOSPHOINOSITIDE 3-KINASE; PROLIFERATION; INTERLEUKIN-3; SURVIVAL; RECEPTOR; PROTEIN; KINASE; FAMILY	The erythroleukemia developed by spi-1/PU.1 transgenic mice is a multistep process. At disease onset, preleukemic cells are arrested in differentiation at the proerythroblast stage (HS1 stage) and their survival and growth are under the tight control of erythropoietin (Epo). During disease progression, malignant proerythroblasts characterized by Epo autonomous growth and in vivo tumorigenicity can be isolated (HS2 stage). During analysis of transcriptional pro. ling representive of discrete stages of leukemic progression, we found that the phosphatidylinositol 4-phosphatase type II gene was turned off in malignant cells. PI-4-phosphatase II is an enzyme that hydrolyses the 4-phosphate position of phosphatidylinositol-3-4-bisphosphate (PtdIns(3,4) P-2) to form PtdIns (3) P. Using malignant cells engineered to stably express PI-4-phosphatase II, we showed that PI-4-phosphatase II reduced Akt activation level. Moreover, stimulation of malignant cells with Epo-induced PI-4-phosphatase II transcription pointing this gene as an Epo-responsive gene. This study provides first insight for a physiological role of PI-4-phosphatase II in the proerythroblast by controlling Epo responsiveness through a negative regulation of the PI3K/Akt pathway.	INSERM, Inst Curie, U528, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Moreau-Gachelin, F (corresponding author), INSERM, Inst Curie, U528, 26 Rue Ulm, Paris, France.	framoreau@curie.fr		KOSMIDER, olivier/0000-0002-6021-4057				Barnache S, 2001, BLOOD, V98, P2372, DOI 10.1182/blood.V98.8.2372; Celada A, 1996, J EXP MED, V184, P61, DOI 10.1084/jem.184.1.61; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Ivetac I, 2005, MOL BIOL CELL, V16, P2218, DOI 10.1091/mbc.e04-09-0799; KOMATSU N, 1991, CANCER RES, V51, P341; Liang P, 1997, Methods Mol Biol, V85, P3; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; Munday AD, 1999, P NATL ACAD SCI USA, V96, P3640, DOI 10.1073/pnas.96.7.3640; NORRIS FA, 1995, J BIOL CHEM, V270, P16128, DOI 10.1074/jbc.270.27.16128; Norris FA, 1997, J BIOL CHEM, V272, P23859, DOI 10.1074/jbc.272.38.23859; Nystuen A, 2001, NEURON, V32, P203, DOI 10.1016/S0896-6273(01)00468-8; Oikawa T, 1999, CELL DEATH DIFFER, V6, P599, DOI 10.1038/sj.cdd.4400534; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Tilbrook PA, 1999, INT J BIOCHEM CELL B, V31, P1001, DOI 10.1016/S1357-2725(99)00071-0; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vyas P, 2000, P NATL ACAD SCI USA, V97, P13696, DOI 10.1073/pnas.250476397; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	22	20	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1420	1423		10.1038/sj.onc.1209187	http://dx.doi.org/10.1038/sj.onc.1209187			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247441				2022-12-17	WOS:000235708200016
J	Hayes, CS; DeFeo, K; Lan, L; Paul, B; Sell, C; Gilmour, SK				Hayes, CS; DeFeo, K; Lan, L; Paul, B; Sell, C; Gilmour, SK			Elevated levels of ornithine decarboxylase cooperate with Raf/ERK activation to convert normal keratinocytes into invasive malignant cells	ONCOGENE			English	Article						polyamines; ornithine decarboxylase; invasion; Raf/ERK; Akt	MOUSE EPIDERMAL-CELLS; BINDING PROTEIN RHO; EPITHELIAL-CELLS; RAS TRANSFORMATION; TRANSGENIC MICE; ONCOGENIC RAS; ALPHA-DIFLUOROMETHYLORNITHINE; SIGNALING PATHWAYS; TUMOR PROMOTION; HUMAN CANCER	Ornithine decarboxylase (ODC) overexpression coupled with activated Ras is fully sufficient to oncogenically transform primary keratinocytes. To determine the Ras effector pathways that represent the minimal essential contribution to full oncogenic transformation in this context, we evaluated the cooperativity of different Ras effector mutants with overexpressed ODC in an in vivo tracheal xenotransplantation assay for epithelial cell invasiveness. Primary keratinocytes, isolated from either K6/ODC transgenic mouse skin (expressing increased ODC) or from normal littermate skin were infected with retrovirus producing an activated RasV12 or partial loss-of-function effector mutants of RasV12 that selectively induce only the Raf/ERK, RalGDS, or the PI3-kinase signaling pathway. Whereas keratinocytes expressing a fully activated RasV12 are not invasive in tracheal xenotransplants, ODC-overexpressing keratinocytes acquire an invasive phenotype with additional expression of either RasV12 or activation of the Raf/ERK pathway. Independent of a mutated ras, elevated levels of ODC activate the Akt/mTOR signaling pathway as well as the Rho/Rac pathway in primary keratinocytes. Thus, Raf/ERK signaling is sufficient to cooperate with increased ODC activity in the conversion of normal keratinocytes to invasive cells. In order to promote invasiveness in keratinocytes, elevated levels of ODC may cooperate with Raf/ERK via activation of the Akt and Rho/Rac signaling pathway.	Lankenau Inst Med Res, Wynnewood, PA 19096 USA	Lankenau Medical Center; Lankenau Institute for Medical Research	Gilmour, SK (corresponding author), Lankenau Inst Med Res, 100 Lancaster Ave, Wynnewood, PA 19096 USA.	gilmours@mlhs.org			NCI NIH HHS [CA070739] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070739] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad N, 2001, AM J PATHOL, V159, P885, DOI 10.1016/S0002-9440(10)61764-6; Bedogni B, 2004, CANCER RES, V64, P2552, DOI 10.1158/0008-5472.CAN-03-3327; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Benitah SA, 2004, BBA-REV CANCER, V1705, P121, DOI 10.1016/j.bbcan.2004.10.002; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Collette J, 2004, INT J CANCER, V112, P190, DOI 10.1002/ijc.20398; Feith DJ, 2001, CANCER RES, V61, P6073; Feith DJ, 2005, CANCER RES, V65, P572; Gilmour SK, 1999, CELL GROWTH DIFFER, V10, P739; Gilmour SK, 2001, J INVEST DERMATOL, V117, P1674, DOI 10.1046/j.0022-202x.2001.01597.x; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Jaffer ZM, 2004, J BIOL CHEM, V279, P35123, DOI 10.1074/jbc.R400010200; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Lan L, 2000, CANCER RES, V60, P5696; Lan L, 2005, J INVEST DERMATOL, V124, P602, DOI 10.1111/j.0022-202X.2005.23620.x; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Magee T, 1999, CELL, V98, P9, DOI 10.1016/S0092-8674(00)80601-7; McFarlin DR, 2003, CARCINOGENESIS, V24, P99, DOI 10.1093/carcin/24.1.99; MEGOSH L, 1995, CANCER RES, V55, P4205; OBrien TG, 1997, CANCER RES, V57, P2630; OBRIEN TG, 1975, CANCER RES, V35, P1662; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; PEGG AE, 1988, CANCER RES, V48, P759; Ray RM, 2002, GASTROENTEROLOGY, V123, P196, DOI 10.1053/gast.2002.34216; Ray RM, 2003, J BIOL CHEM, V278, P13039, DOI 10.1074/jbc.M208741200; Ray RM, 2005, J BIOL CHEM, V280, P31091, DOI 10.1074/jbc.M503041200; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Scholl FA, 2004, CANCER RES, V64, P6035, DOI 10.1158/0008-5472.CAN-04-0017; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; Shantz LM, 1998, CANCER RES, V58, P2748; Shantz LM, 2004, BIOCHEM J, V377, P257, DOI 10.1042/BJ20030778; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SISTONEN L, 1987, EXP CELL RES, V168, P518, DOI 10.1016/0014-4827(87)90024-3; Smith MK, 1998, CARCINOGENESIS, V19, P1409, DOI 10.1093/carcin/19.8.1409; Smith MK, 1997, CANCER RES, V57, P2104; STRUGILL TW, 1988, NATURE, V334, P715; Sturge J, 2002, J CELL SCI, V115, P699; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TAKIGAWA M, 1983, CANCER RES, V43, P3732; Tang XW, 2004, J CLIN INVEST, V113, P867, DOI 10.1172/JCI200420732; Tarutani M, 2003, CANCER RES, V63, P319; Ulku AS, 2003, MOL CANCER RES, V1, P1077; VAN AL, 1997, GENE DEV, V11, P2295; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; WEEKS CE, 1982, P NATL ACAD SCI-BIOL, V79, P6028, DOI 10.1073/pnas.79.19.6028; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; YUSPA SH, 1974, EXP CELL RES, V86, P95, DOI 10.1016/0014-4827(74)90653-3; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	68	20	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1543	1553		10.1038/sj.onc.1209198	http://dx.doi.org/10.1038/sj.onc.1209198			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16278677				2022-12-17	WOS:000235890400011
J	Humble, MC; Trempus, CS; Spalding, JW; Cannon, RE; Tennant, RW				Humble, MC; Trempus, CS; Spalding, JW; Cannon, RE; Tennant, RW			Biological, cellular, and molecular characteristics of an inducible transgenic skin tumor model: a review	ONCOGENE			English	Review						ras; epidermal; carcinogenesis; Tg.AC; carcinogen assay; transgenic mouse model	V-HA-RAS; TG.AC MOUSE SKIN; CENTER-DOT-AC; VASCULAR-PERMEABILITY FACTOR; LOCUS-CONTROL REGIONS; EPIDERMAL STEM-CELLS; GLOBIN GENE; ORNITHINE-DECARBOXYLASE; PAPILLOMA DEVELOPMENT; CARCINOGENICITY BIOASSAYS	The genetically initiated Tg.AC transgenic mouse carries a transgene consisting of an oncogenic v-Ha-ras coding region flanked 50 by a mouse zeta-globin promoter and 30 by an SV-40 polyadenylation sequence. Located on chromosome 11, the transgene is transcriptionally silent until activated by chemical carcinogens, UV light, or full-thickness wounding. Expression of the transgene is an early event that drives cellular proliferation resulting in clonal expansion and tumor formation, the unique characteristics now associated with the Tg.AC mouse. This ras-dependent phenotype has resulted in the widespread interest and use of the Tg.AC mouse in experimental skin carcinogenesis and as an alternative carcinogenesis assay. This review examines the general biology of the tumorigenic responses observed in Tg.AC mice, the genetic interactions of the ras transgene, and explores the cellular and molecular regulation of zeta-globin promoted transgene expression. As a prototype alternative model to the current long-term rodent bioassays, the Tg.AC has generated a healthy discussion on the future of transgenic bioassays, and opened the doors for subsequent models for toxicity testing. The further exploration and elucidation of the molecular controls of transgene expression will enhance the usefulness of this mouse and enable a better understanding of the Tg.AC's discriminate response to chemical carcinogens.	NIEHS, Natl ctr Toxicogenom, Res Triangle Pk, NC 27709 USA; Univ N Carolina, Curriculum Toxicol, Chapel Hill, NC 27514 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill	Cannon, RE (corresponding author), NIEHS, Natl ctr Toxicogenom, POB 12233,MD FI-05,111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	cannon1@niehs.nih.gov			NIEHS NIH HHS [T32 ES07126] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES021175, T32ES007126, Z01ES021175, Z01ES100610] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARGYRIS TS, 1985, AM J IND MED, V8, P329, DOI 10.1002/ajim.4700080412; Asano S, 1998, TOXICOL PATHOL, V26, P512, DOI 10.1177/019262339802600407; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; Barry G, 1935, PROC R SOC SER B-BIO, V117, P318, DOI 10.1098/rspb.1935.0032; Battalora MS, 2001, CARCINOGENESIS, V22, P651, DOI 10.1093/carcin/22.4.651; Berenblum I, 1941, CANCER RES, V1, P807; Blanchard KT, 1998, TOXICOL PATHOL, V26, P541, DOI 10.1177/019262339802600410; BOS JL, 1989, CANCER RES, V49, P4682; BOUTWELL RK, 1964, PROG EXP TUMOR RES, V4, P207; Cannon RE, 2000, MOL CARCINOGEN, V29, P229, DOI 10.1002/1098-2744(200012)29:4<229::AID-MC1005>3.0.CO;2-9; Cannon RE, 1997, MOL CARCINOGEN, V20, P108, DOI 10.1002/(SICI)1098-2744(199709)20:1<108::AID-MC12>3.0.CO;2-5; Cannon RE, 1998, MOL CARCINOGEN, V21, P244, DOI 10.1002/(SICI)1098-2744(199804)21:4<244::AID-MC3>3.0.CO;2-K; CARDIFF RD, 1993, AM J PATHOL, V142, P1199; Chan EL, 2005, ONCOGENE, V24, P479, DOI 10.1038/sj.onc.1208231; Chignell CF, 2003, PHOTOCHEM PHOTOBIOL, V77, P77, DOI 10.1562/0031-8655(2003)077<0077:PITTAM>2.0.CO;2; Cohen SM, 2001, TOXICOL SCI, V64, P14, DOI 10.1093/toxsci/64.1.14; Collick A, 1996, EMBO J, V15, P1163, DOI 10.1002/j.1460-2075.1996.tb00455.x; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Deelman H T, 1927, Br Med J, V1, P872; Delker DA, 1999, TOXICOL SCI, V50, P90, DOI 10.1093/toxsci/50.1.90; Dodds AP, 2003, ARCH ORAL BIOL, V48, P843, DOI 10.1016/S0003-9969(03)00178-X; El-Abaseri TB, 2005, CANCER RES, V65, P3958, DOI 10.1158/0008-5472.CAN-04-2204; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; Fraser P, 1998, CURR OPIN CELL BIOL, V10, P361, DOI 10.1016/S0955-0674(98)80012-4; FRENCH JE, 1994, MOL CARCINOGEN, V11, P215, DOI 10.1002/mc.2940110407; Germolec DR, 1997, MUTAT RES-REV MUTAT, V386, P209, DOI 10.1016/S1383-5742(97)00006-9; Gilmour SK, 1999, CELL GROWTH DIFFER, V10, P739; Grosveld F, 1999, CURR OPIN GENET DEV, V9, P152, DOI 10.1016/S0959-437X(99)80023-9; Hansen L A, 1995, Prog Clin Biol Res, V391, P223; Hansen LA, 1996, CARCINOGENESIS, V17, P1825, DOI 10.1093/carcin/17.9.1825; HANSEN LA, 1994, MOL CARCINOGEN, V9, P143, DOI 10.1002/mc.2940090306; HANSEN LA, 1994, P NATL ACAD SCI USA, V91, P7822, DOI 10.1073/pnas.91.16.7822; Hansen LA, 1998, CARCINOGENESIS, V19, P1837, DOI 10.1093/carcin/19.10.1837; HENNINGS H, 1970, CANCER RES, V30, P312; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; Humble MC, 1998, TOXICOL PATHOL, V26, P562, DOI 10.1177/019262339802600413; Humble MC, 2000, GENOMICS, V70, P292, DOI 10.1006/geno.2000.6384; HUMBLE MC, UNPUB; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; Kantz DC, 1999, BIOTECHNIQUES, V27, P278, DOI 10.2144/99272bm13; KARLSSON S, 1985, ANNU REV BIOCHEM, V54, P1071; Kaufman CK, 2003, GENE DEV, V17, P2108, DOI 10.1101/gad.1115203; Kouprina N, 1998, P NATL ACAD SCI USA, V95, P4469, DOI 10.1073/pnas.95.8.4469; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; Larcher F, 1996, CANCER RES, V56, P5391; Lavker RM, 2000, P NATL ACAD SCI USA, V97, P13473, DOI 10.1073/pnas.250380097; LEACH DRF, 1994, BIOESSAYS, V16, P893, DOI 10.1002/bies.950161207; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Leder A, 2002, ONCOGENE, V21, P6657, DOI 10.1038/sj.onc.1205795; Lewis S, 1999, ANN NY ACAD SCI, V870, P45, DOI 10.1111/j.1749-6632.1999.tb08864.x; Lozano J, 2003, CANCER RES, V63, P4232; Lyle S, 1998, J CELL SCI, V111, P3179; Mahler JF, 1998, TOXICOL PATHOL, V26, P501, DOI 10.1177/019262339802600406; Mahler JF, 1996, TOXICOL PATHOL, V24, P710, DOI 10.1177/019262339602400606; MARTHINUSS J, 1995, CELL GROWTH DIFFER, V6, P239; MILLS KJ, 1993, CARCINOGENESIS, V14, P2645, DOI 10.1093/carcin/14.12.2645; MOON A, 2001, BIOCHEMISTRY-US, P46; Morris RJ, 2000, J CLIN INVEST, V106, P3, DOI 10.1172/JCI10508; Murphy JE, 2003, J IMMUNOL, V170, P5697, DOI 10.4049/jimmunol.170.11.5697; OBrien TG, 1997, CANCER RES, V57, P2630; Ohara M, 2003, CANCER SCI, V94, P205, DOI 10.1111/j.1349-7006.2003.tb01420.x; ORKIN SH, 1992, BLOOD, V80, P575; OWENS DM, 1995, CANCER RES, V55, P3171; POTTEN CS, 1983, STEM CELLS THEIR IDE, P200; Pritchard JB, 2003, ENVIRON HEALTH PERSP, V111, P444, DOI 10.1289/ehp.5778; PULLINGER BD, 1945, J PATHOL BACTERIOL, V57, P447; Robinson DE, 2001, TOXICOL PATHOL, V29, P13, DOI 10.1080/019262301753178438; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Sistare FD, 2002, INT J TOXICOL, V21, P65, DOI 10.1080/10915810252826028; Smith MK, 1998, CARCINOGENESIS, V19, P1409, DOI 10.1093/carcin/19.8.1409; SPALDING JW, 1993, CARCINOGENESIS, V14, P1335, DOI 10.1093/carcin/14.7.1335; Spalding JW, 1999, TOXICOL SCI, V49, P241, DOI 10.1093/toxsci/49.2.241; Spalding JW, 2000, TOXICOL SCI, V53, P213, DOI 10.1093/toxsci/53.2.213; STENN KS, 1994, J INVEST DERMATOL, V103, P107, DOI 10.1111/1523-1747.ep12391844; Tennant R, 1997, TOXICOL PATHOL, V25, P240, DOI 10.1177/019262339702500219; Tennant RW, 2001, TOXICOL PATHOL, V29, P51, DOI 10.1080/019262301753178474; Tennant RW, 1996, MUTAT RES-REV GENET, V365, P119, DOI 10.1016/S0165-1110(96)90016-0; TENNANT RW, 1995, ENVIRON HEALTH PERSP, V103, P942, DOI 10.2307/3432740; Tennant RW, 1996, ENVIRON HEALTH PERSP, V104, P1095, DOI 10.2307/3433035; Thompson KL, 1998, TOXICOL PATHOL, V26, P548, DOI 10.1177/019262339802600411; Thompson KL, 2001, MOL CARCINOGEN, V32, P176, DOI 10.1002/mc.10009; Tober KL, 1998, BIOCHEM BIOPH RES CO, V247, P644, DOI 10.1006/bbrc.1998.8787; Trempus CS, 2003, J INVEST DERMATOL, V120, P501, DOI 10.1046/j.1523-1747.2003.12088.x; Trempus CS, 1998, J INVEST DERMATOL, V111, P445, DOI 10.1046/j.1523-1747.1998.00237.x; Trempus CS, 1997, MOL CARCINOGEN, V20, P68, DOI 10.1002/(SICI)1098-2744(199709)20:1<68::AID-MC8>3.0.CO;2-E; Trempus CS, 2000, MOL CARCINOGEN, V27, P24, DOI 10.1002/(SICI)1098-2744(200001)27:1<24::AID-MC5>3.0.CO;2-M; Trempus CS, 1998, AM J PATHOL, V153, P247, DOI 10.1016/S0002-9440(10)65565-4; TUAN D, 1984, P NATL ACAD SCI-BIOL, V81, P2718, DOI 10.1073/pnas.81.9.2718; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; Weaver JL, 1998, TOXICOL PATHOL, V26, P532, DOI 10.1177/019262339802600409; Wei SJ, 2003, J BIOL CHEM, V278, P1758, DOI 10.1074/jbc.M206328200; WRIGHT JT, 1995, ARCH ORAL BIOL, V40, P631, DOI 10.1016/0003-9969(95)00017-J; YISRAELI J, 1988, P NATL ACAD SCI USA, V85, P4638, DOI 10.1073/pnas.85.13.4638	94	20	22	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8217	8228		10.1038/sj.onc.1209000	http://dx.doi.org/10.1038/sj.onc.1209000			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16355251				2022-12-17	WOS:000233956500001
J	Mathieu, J; Giraudier, S; Lanotte, M; Besancon, F				Mathieu, J; Giraudier, S; Lanotte, M; Besancon, F			Retinoid-induced activation of NF-kappa B in APL cells is not essential for granulocytic differentiation, but prolongs the life span of mature cells	ONCOGENE			English	Article						apoptosis; NF-kappa B; ROS; JNK; ATRA; APL	ACUTE PROMYELOCYTIC LEUKEMIA; EWING SARCOMA-CELLS; ALPHA-INDUCED APOPTOSIS; TRANSCRIPTION FACTOR; OXIDATIVE STRESS; JNK ACTIVATION; NEUTROPHIL APOPTOSIS; SIGNAL-TRANSDUCTION; MOLECULAR-BIOLOGY; ACID SYNDROME	All-trans retinoic acid (ATRA) significantly improves the survival of patients with acute promyelocytic leukemia (APL) by inducing granulocytic differentiation of leukemia cells. Since an activation of the transcription factor NF-kappa B occurs during ATRA-induced maturation of APL cells, a mechanistic link between these two processes was investigated. Using an in vitro model for APL, we report that ectopic overexpression of a repressor of NF-kappa B activation did not affect granulocytic differentiation. Importantly, NF-kappa B inhibition markedly resulted in a decreased viability of the differentiated cells, which correlated with increased apoptosis. Apoptosis was accompanied by a sustained activation of the c-Jun N-terminal kinase (JNK). Inhibition of JNK by the specific inhibitor SP600125 or by transfection of a dominant-negative mutant of JNK1 reduced the percentage of apoptotic cells, thus showing that JNK activation constitutes a death signal. Furthermore, impairment of NF-kappa B activation resulted in increased levels of reactive oxygen species (ROS) upon ATRA treatment. ROS accumulation was suppressed by the antioxidant butylated hydroxyanisol, which also abolished ATRA-induced JNK activation and apoptosis. Altogether, our results demonstrate an antiapoptotic effect of NF-kappa B activation during ATRA-induced differentiation of NB4 cells and identify repression of ROS-mediated JNK activation as a mechanism for this effect. Our observations also suggest that NF-kappa B signalling may contribute to an accumulation of mature APL cells and participate in the development of ATRA syndrome.	Hop St Louis, INSERM, U685, Ctr Hayem, F-75475 Paris, France; Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	Besancon, F (corresponding author), Hop St Louis, INSERM, U685, Ctr Hayem, 1 Ave Claude Vellefaux, F-75475 Paris, France.	francoise.besancon@stlouis.inserm.fr						Adcock IM, 2001, PULM PHARMACOL THER, V14, P211, DOI 10.1006/pupt.2001.0283; Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Akgul C, 2003, CELL MOL LIFE SCI, V60, P2402, DOI 10.1007/s00018-003-3110-z; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Bell S, 2003, CELL SIGNAL, V15, P1, DOI 10.1016/S0898-6568(02)00080-3; Benoit GR, 2001, MOL ENDOCRINOL, V15, P1154, DOI 10.1210/me.15.7.1154; Bernard D, 2002, ONCOGENE, V21, P4392, DOI 10.1038/sj.onc.1205536; Berry DM, 2002, EXP CELL RES, V272, P176, DOI 10.1006/excr.2001.5410; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Brouard S, 2002, J BIOL CHEM, V277, P17950, DOI 10.1074/jbc.M108317200; Buccellato LJ, 2004, J BIOL CHEM, V279, P6753, DOI 10.1074/jbc.M310145200; Cai ZZ, 1997, J BIOL CHEM, V272, P96; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen F, 2003, CANCER RES, V63, P7689; Chen F, 2001, AM J PATHOL, V159, P387, DOI 10.1016/S0002-9440(10)61708-7; Chomienne C, 1996, FASEB J, V10, P1025, DOI 10.1096/fasebj.10.9.8801163; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Botton S, 1998, BLOOD, V92, P2712, DOI 10.1182/blood.V92.8.2712.420k03_2712_2718; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; de The H, 2001, ONCOGENE, V20, P7136, DOI 10.1038/sj.onc.1204851; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Djavaheri-Mergny M, 2004, FEBS LETT, V578, P111, DOI 10.1016/j.febslet.2004.10.082; Djavaheri-Mergny M, 2003, ONCOGENE, V22, P2558, DOI 10.1038/sj.onc.1206356; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grolleau A, 1999, J IMMUNOL, V162, P3491; Hamasaki A, 1998, J EXP MED, V188, P1985, DOI 10.1084/jem.188.11.1985; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Iwanaga M, 1998, FREE RADICAL BIO MED, V24, P1256, DOI 10.1016/S0891-5849(97)00443-7; Javelaud D, 2000, ONCOGENE, V19, P61, DOI 10.1038/sj.onc.1203246; Javelaud D, 2001, ONCOGENE, V20, P4365, DOI 10.1038/sj.onc.1204570; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Komura E, 2005, CANCER RES, V65, P3281, DOI 10.1158/0008-5472.CAN-04-2339; Kouba DJ, 2001, J BIOL CHEM, V276, P6214, DOI 10.1074/jbc.M004511200; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; LANOTTE M, 1991, BLOOD, V77, P1080; Larson RS, 2003, BEST PRACT RES CL HA, V16, P453, DOI 10.1016/S1521-6926(03)00043-4; Lin AN, 2002, AGING CELL, V1, P112, DOI 10.1046/j.1474-9728.2002.00014.x; Matsuzawa A, 2002, ANTIOXID REDOX SIGN, V4, P415, DOI 10.1089/15230860260196218; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; Nickols JC, 2003, NAT NEUROSCI, V6, P161, DOI 10.1038/nn995; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Papa S, 2004, J CELL SCI, V117, P5197, DOI 10.1242/jcs.01483; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Puccetti E, 2004, LEUKEMIA, V18, P1169, DOI 10.1038/sj.leu.2403367; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Slack JL, 1999, CANC TREAT, V99, P75; Tallman MS, 2000, BLOOD, V95, P90; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Turco MC, 2004, LEUKEMIA, V18, P11, DOI 10.1038/sj.leu.2403171; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; Waris G, 2003, J BIOL CHEM, V278, P40778, DOI 10.1074/jbc.M303248200; Witcher M, 2003, BLOOD, V102, P237, DOI 10.1182/blood-2002-09-2725; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	64	20	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7145	7155		10.1038/sj.onc.1208889	http://dx.doi.org/10.1038/sj.onc.1208889			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16044154				2022-12-17	WOS:000232990100004
J	Dupuy, AG; L'Hoste, S; Cherfils, J; Camonis, J; Gaudriault, G; de Gunzburg, J				Dupuy, AG; L'Hoste, S; Cherfils, J; Camonis, J; Gaudriault, G; de Gunzburg, J			Novel Rap1 dominant-negative mutants interfere selectively with C3G and Epac	ONCOGENE			English	Article						Rap; GEF; dominant negative; C3G; Epac	NUCLEOTIDE EXCHANGE FACTOR; CELL-ADHESION; B-RAF; SACCHAROMYCES-CEREVISIAE; 2-HYBRID SYSTEM; IN-VIVO; ACTIVATION; DROSOPHILA; PROTEINS; GTPASE	Rap1 is a Ras-related GTPase that is principally involved in integrin- and E-cadherin-mediated adhesion. Rap1 is transiently activated in response to many incoming signals via a large family of guanine nucleotide exchange factors ( GEFs). The lack of potent Rap1 dominant-negative mutants has limited our ability to decipher Rap1-dependent pathways; we have therefore developed a procedure to generate such mutants consisting in the oligonucleotide-mediated mutagenesis of residues 14-19, selection of mutants presenting an enhanced interaction with Epac2 by yeast two-hybrid screening and counter-screening for mutants still interacting with Rap effectors. In detail analysis of their interaction capacity with various Rap-GEFs in the yeast two-hybrid system revealed that mutants of residues 15 and 16 interacted with Epacs, C3G and CalDAG-GEFI, whereas mutants of position 17 had selectively lost their ability to bind CalDAG-GEFI as well as, for some, C3G. In cellular models where Rap1 is activated via endogenous GEFs, the Rap1[S17A] mutant inhibits both the cAMP-Epac and EGF-C3G pathways, whereas Rap1[G15D] selectively interferes with the latter. Finally, Rap1[S17A] is able to act as a bona. de dominant-negative mutant in vivo since it phenocopies the eye-reducing and lethal effects of D-Rap1 deficiency in Drosophila, effects that are overcome by the overexpression of D-Epac or D-Rap1.	Inst Curie, INSERM, U528, F-75005 Paris, France; CNRS, UPR 9063, F-91198 Gif Sur Yvette, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	de Gunzburg, J (corresponding author), Inst Curie, INSERM, U528, 26 Rue Ulm, F-75005 Paris, France.	gunzburg@curie.fr						Asha H, 1999, EMBO J, V18, P605, DOI 10.1093/emboj/18.3.605; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; Beranger F, 1997, NUCLEIC ACIDS RES, V25, P2035, DOI 10.1093/nar/25.10.2035; Biou V, 2004, BIOCHEMISTRY-US, V43, P6833, DOI 10.1021/bi049630u; Bivona TG, 2004, J CELL BIOL, V164, P461, DOI 10.1083/jcb.200311093; Boettner B, 2000, P NATL ACAD SCI USA, V97, P9064, DOI 10.1073/pnas.97.16.9064; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; BRAND AH, 1993, DEVELOPMENT, V118, P401; CHEN SY, 1994, ONCOGENE, V9, P2691; Cherfils J, 1997, EMBO J, V16, P5582, DOI 10.1093/emboj/16.18.5582; Clyde-Smith J, 2000, J BIOL CHEM, V275, P32260, DOI 10.1074/jbc.M006087200; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERGUSON KM, 1991, METHOD ENZYMOL, V195, P188; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Gao XL, 2001, J BIOL CHEM, V276, P42219, DOI 10.1074/jbc.M105760200; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; Hay BA, 1997, P NATL ACAD SCI USA, V94, P5195, DOI 10.1073/pnas.94.10.5195; Hogan C, 2004, MOL CELL BIOL, V24, P6690, DOI 10.1128/mcb.24.15.6690-6700.2004; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Ishimaru S, 1999, EMBO J, V18, P145, DOI 10.1093/emboj/18.1.145; JUNG V, 1994, MOL CELL BIOL, V14, P3707, DOI 10.1128/MCB.14.6.3707; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; Karim FD, 1998, DEVELOPMENT, V125, P1; Katagiri K, 2004, NAT IMMUNOL, V5, P1045, DOI 10.1038/ni1111; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Knox AL, 2002, SCIENCE, V295, P1285, DOI 10.1126/science.1067549; Lafuente EM, 2004, DEV CELL, V7, P585, DOI 10.1016/j.devcel.2004.07.021; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; Liao YH, 1999, J BIOL CHEM, V274, P37815, DOI 10.1074/jbc.274.53.37815; Liao YH, 2001, J BIOL CHEM, V276, P28478, DOI 10.1074/jbc.M101737200; Maillet M, 2003, NAT CELL BIOL, V5, P633, DOI 10.1038/ncb1007; Mirey G, 2003, MOL CELL BIOL, V23, P1112, DOI 10.1128/MCB.23.3.1112-1124.2003; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Nancy V, 1999, J BIOL CHEM, V274, P8737, DOI 10.1074/jbc.274.13.8737; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Ohba Y, 2003, EMBO J, V22, P859, DOI 10.1093/emboj/cdg087; Papin C, 1996, ONCOGENE, V12, P2213; PIZON V, 1988, ONCOGENE, V3, P201; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; Price LS, 2004, J BIOL CHEM, V279, P35127, DOI 10.1074/jbc.M404917200; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; RUBIN GM, 1982, CELL, V29, P987, DOI 10.1016/0092-8674(82)90462-7; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; Shi SL, 2004, ONCOGENE, V23, P8711, DOI 10.1038/sj.onc.1208132; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; TRANSY C, 1995, MOL BIOL REP, V21, P119, DOI 10.1007/BF00986502; Traver S, 2000, BIOCHEM J, V350, P19, DOI 10.1042/0264-6021:3500019; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1	59	20	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4509	4520		10.1038/sj.onc.1208647	http://dx.doi.org/10.1038/sj.onc.1208647			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15856025				2022-12-17	WOS:000230157100004
J	Slupianek, A; Gurdek, E; Koptyra, M; Nowicki, MO; Siddiqui, KM; Groden, J; Skorski, T				Slupianek, A; Gurdek, E; Koptyra, M; Nowicki, MO; Siddiqui, KM; Groden, J; Skorski, T			BLM helicase is activated in BCR/ABL leukemia cells to modulate responses to cisplatin	ONCOGENE			English	Article						BCR/ABL; BLM; RAD51; homologous recombination repair; drug resistance	RECQ FAMILY HELICASES; SYNDROME GENE-PRODUCT; BLOOMS-SYNDROME; DNA-DAMAGE; HOMOLOGOUS RECOMBINATION; FUNCTIONAL INTERACTION; ATAXIA-TELANGIECTASIA; GENOTOXIC TREATMENT; STAT5 ACTIVATION; SYNDROME PROTEIN	Bloom protein (BLM) is a 3'-5' helicase, mutated in Bloom syndrome, which plays an important role in response to DNA double-strand breaks and stalled replication forks. Here, we show that BCR/ABL tyrosine kinase, which also modulates DNA repair capacity, is associated with elevated expression of BLM. Downregulation of BLM by antisense cDNA or dominant-negative mutant inhibits homologous recombination repair (HRR) and increases sensitivity to cisplatin in BCR/ABL-positive cells. Bone marrow cells from mice heterozygous for BLM mutation, BLMCin/+, transfected with BCR/ABL display increased sensitivity to cisplatin compared to those obtained from the wild-type littermates. BCR/ABL promotes interactions of BLM with RAD51, while simultaneous overexpression of BLM and RAD51 in normal cells increases drug resistance. These data suggest that BLM collaborates with RAD51 to facilitate HRR and promotes the resistance of BCR/ABL-positive leukemia cells to DNA-damaging agents.	Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Philadelphia, PA 19122 USA; Univ Cincinnati, Coll Med, Howard Hughes Med Inst, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Howard Hughes Medical Institute; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Slupianek, A (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Biolife Sci Bldg,Room 419 TS,1900 N 12th St, Philadelphia, PA 19122 USA.	aslupian@temple.edu; tomasz.skorski@temple.edu		Nowicki, Michal/0000-0002-5807-0007; Koptyra, Mateusz/0000-0002-3857-6633	NATIONAL CANCER INSTITUTE [U01CA084291, R01CA089052] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 89052, U01 CA 84291] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Arlinghaus Ralph, 2004, Cancer Treat Res, V119, P239; BARTRAM CR, 1976, ANN HUM GENET, V40, P79, DOI 10.1111/j.1469-1809.1976.tb00166.x; Beamish H, 2002, J BIOL CHEM, V277, P30515, DOI 10.1074/jbc.M203801200; Bischof O, 2001, J BIOL CHEM, V276, P12068, DOI 10.1074/jbc.M006462200; Cambier N, 1998, ONCOGENE, V16, P335, DOI 10.1038/sj.onc.1201490; CANITROT Y, 2003, BLOOD, V26, P26; Collis SJ, 2001, NUCLEIC ACIDS RES, V29, P1534, DOI 10.1093/nar/29.7.1534; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; Dierov J, 2004, CANCER CELL, V5, P275, DOI 10.1016/S1535-6108(04)00056-X; Dutertre S, 2000, ONCOGENE, V19, P2731, DOI 10.1038/sj.onc.1203595; Dutertre S, 2002, J BIOL CHEM, V277, P6280, DOI 10.1074/jbc.M105735200; EPNER DE, 1990, ANN INTERN MED, V113, P3, DOI 10.7326/0003-4819-113-1-3; Fabre F, 2002, P NATL ACAD SCI USA, V99, P16887, DOI 10.1073/pnas.252652399; Freire R, 2001, NUCLEIC ACIDS RES, V29, P3172, DOI 10.1093/nar/29.15.3172; Gangloff S, 2000, NAT GENET, V25, P192, DOI 10.1038/76055; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Goss KH, 2002, SCIENCE, V297, P2051, DOI 10.1126/science.1074340; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Heath C, 2004, J BIOL CHEM, V279, P6666, DOI 10.1074/jbc.M308743200; Helleday T, 2003, MUTAT RES-FUND MOL M, V532, P103, DOI 10.1016/j.mrfmmm.2003.08.013; Hoser G, 2003, LEUKEMIA RES, V27, P267, DOI 10.1016/S0145-2126(02)00163-7; Imamura O, 2001, ONCOGENE, V20, P1143, DOI 10.1038/sj.onc.1204195; Issaad C, 2000, LEUKEMIA, V14, P662, DOI 10.1038/sj.leu.2401730; Karow JK, 2000, CURR OPIN GENET DEV, V10, P32, DOI 10.1016/S0959-437X(99)00039-8; Kawabe T, 2000, ONCOGENE, V19, P4764, DOI 10.1038/sj.onc.1203841; KAYTOR MD, 1995, GENETICS, V140, P1441; Keeshan K, 2001, LEUKEMIA, V15, P1823, DOI 10.1038/sj.leu.2402309; Klejman A, 2002, EMBO J, V21, P5766, DOI 10.1093/emboj/cdf562; Langland G, 2002, CANCER RES, V62, P2766; Laurent E, 2003, CLIN CANCER RES, V9, P3722; Li WH, 2004, J CELL BIOL, V165, P801, DOI 10.1083/jcb.200402095; Lindner I, 2003, J IMMUNOL, V171, P1780, DOI 10.4049/jimmunol.171.4.1780; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MAXWELL SA, 1987, CANCER RES, V47, P1731; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Nieborowska-Skorska M, 2002, BLOOD, V99, P4531, DOI 10.1182/blood.V99.12.4531; Nowicki MO, 2004, BLOOD, V104, P3746, DOI 10.1182/blood-2004-05-1941; Nowicki MO, 2003, ONCOGENE, V22, P3952, DOI 10.1038/sj.onc.1206620; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Poot M, 2001, FASEB J, V15, P1224, DOI 10.1096/fj.00-0611fje; Poppe B, 2001, CANCER GENET CYTOGEN, V128, P39, DOI 10.1016/S0165-4608(01)00392-2; Raderschall E, 2002, CANCER RES, V62, P219; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rosell Rafael, 2003, Cancer Control, V10, P297; SCHILD D, 1995, GENETICS, V140, P115; SIP M, 1992, BIOCHEMISTRY-US, V31, P2508, DOI 10.1021/bi00124a010; SIRARD C, 1994, BLOOD, V83, P1575; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Skorski T, 2002, ONCOGENE, V21, P8591, DOI 10.1038/sj.onc.1206087; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Slupianek A, 2002, MOL CELL BIOL, V22, P4189, DOI 10.1128/MCB.22.12.4189-4201.2002; Trojanek J, 2003, MOL CELL BIOL, V23, P7510, DOI 10.1128/MCB.23.21.7510-7524.2003; Turley H, 2001, BRIT J CANCER, V85, P261, DOI 10.1054/bjoc.2001.1874; van der Kuip H, 2001, BLOOD, V98, P1532, DOI 10.1182/blood.V98.5.1532; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; von Kobbe C, 2002, J BIOL CHEM, V277, P22035, DOI 10.1074/jbc.M200914200; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Wu A, 2003, J CELL PHYSIOL, V195, P453, DOI 10.1002/jcp.10261; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Yamamoto M, 2004, BIOCHEM BIOPH RES CO, V319, P1272, DOI 10.1016/j.bbrc.2004.05.113; Zdraveski ZZ, 2000, CHEM BIOL, V7, P39, DOI 10.1016/S1074-5521(00)00064-8	64	20	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3914	3922		10.1038/sj.onc.1208545	http://dx.doi.org/10.1038/sj.onc.1208545			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15750625				2022-12-17	WOS:000229435300007
J	Limoli, CL; Giedzinski, E; Cleaver, JE				Limoli, CL; Giedzinski, E; Cleaver, JE			Alternative recombination pathways in UV-irradiated XP variant cells	ONCOGENE			English	Article						ultraviolet light; polymerase eta (Pol H or hRad30A); recombination; Mre11; Rad50; Rad51; XP variant cells	DOUBLE-STRAND BREAKS; DNA-POLYMERASE-ETA; XERODERMA PIGMENTOSUM-CELLS; HOMOLOGOUS RECOMBINATION; EXCISION REPAIR; REPLICATION INHIBITION; CELLULAR-RESPONSE; PYRIMIDINE DIMER; NUCLEAR FOCI; HISTONE H2AX	XP variant (XP-V) cells lack the damage-specific polymerase eta and exhibit prolonged replication arrest after UV irradiation due to impaired bypass of UV photoproducts. To analyse the outcome of the arrested replication forks, homologous recombination (HR, Rad51 events) and fork breakage (Rad50 events) were assayed by immunofluorescent detection of foci-positive cells. Within 1 h of irradiation, XP-V cells showed more Rad51-positive cells than normal cells, while neither cell type showed an increase in Rad50 foci. Beyond 1 h, the frequency of Rad51-positive cells reached similar levels in both cell types, then declined at higher UV doses. At these later times, Rad50-positive cells increased with dose and to a greater extent in XP-V cells. Few cells were simultaneously positive for both sets of foci, suggesting a mutually exclusive recruitment of recombination proteins, or that these pathways operate at different stages during S phase. Analysis of cells containing a vector of tandemly arranged enhanced green fluorescent protein genes also showed that UV-induced HR was higher in XP-V cells. These results suggest that cells make an early commitment to HR, and that at later times a subset of arrested forks degrade into double-strand breaks, two alternative pathways that are greater in XP-V cells.	Univ Calif San Francisco, Dept Radiat Oncol, Radiat Oncol Res Lab, San Francisco, CA 94103 USA; Univ Calif San Francisco, Ctr Canc, Auerback Melanoma Lab, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Limoli, CL (corresponding author), Univ Calif San Francisco, Dept Radiat Oncol, Radiat Oncol Res Lab, 1855 Folsom St,MCB-200, San Francisco, CA 94103 USA.	limoli@itsa.ucsf.edu	Limoli, Charles/AAW-1748-2020	Limoli, Charles/0000-0002-1321-4142	NIEHS NIH HHS [1 R01 ES 8061] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008061] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BOLLAG RJ, 1989, ANNU REV GENET, V23, P199, DOI 10.1146/annurev.ge.23.120189.001215; Broughton BC, 2002, P NATL ACAD SCI USA, V99, P815, DOI 10.1073/pnas.022473899; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; CLEAVER JE, 1988, J INVEST DERMATOL, V90, P467, DOI 10.1111/1523-1747.ep12460917; Cleaver JE, 1999, CANCER RES, V59, P1102; Cleaver JE, 2002, DNA REPAIR, V1, P41, DOI 10.1016/S1568-7864(01)00004-0; Cordeiro-Stone M, 1999, J MOL BIOL, V289, P1207, DOI 10.1006/jmbi.1999.2847; CordeiroStone M, 1997, J BIOL CHEM, V272, P13945, DOI 10.1074/jbc.272.21.13945; GODWIN AR, 1994, P NATL ACAD SCI USA, V91, P12554, DOI 10.1073/pnas.91.26.12554; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Kannouche P, 2001, GENE DEV, V15, P158, DOI 10.1101/gad.187501; Kannouche P, 2003, EMBO J, V22, P1223, DOI 10.1093/emboj/7595006; Laposa RR, 2003, CANCER RES, V63, P3909; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; Li ZQ, 2002, P NATL ACAD SCI USA, V99, P4459, DOI 10.1073/pnas.062047799; Limoli CL, 2002, MUTAT RES-FUND MOL M, V510, P121, DOI 10.1016/S0027-5107(02)00257-9; Limoli CL, 2002, P NATL ACAD SCI USA, V99, P233, DOI 10.1073/pnas.231611798; Limoli CL, 2000, P NATL ACAD SCI USA, V97, P7939, DOI 10.1073/pnas.130182897; Linke SP, 2003, CANCER RES, V63, P2596; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; PAINTER RB, 1980, MUTAT RES, V70, P337, DOI 10.1016/0027-5107(80)90023-8; PARK SD, 1979, NUCLEIC ACIDS RES, V6, P1151, DOI 10.1093/nar/6.3.1151; PARK SD, 1979, P NATL ACAD SCI USA, V76, P3927, DOI 10.1073/pnas.76.8.3927; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Petrini JHJ, 2003, TRENDS CELL BIOL, V13, P458, DOI 10.1016/S0962-8924(03)00170-3; Robison JG, 2004, J BIOL CHEM, V279, P34802, DOI 10.1074/jbc.M404750200; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Scully R, 2000, ONCOGENE, V19, P6176, DOI 10.1038/sj.onc.1203971; Taghian DG, 1997, MOL CELL BIOL, V17, P6386, DOI 10.1128/MCB.17.11.6386; Thakur M, 2001, GENE CHROMOSOME CANC, V32, P222, DOI 10.1002/gcc.1186; TSUJIMURA T, 1990, P NATL ACAD SCI USA, V87, P1566, DOI 10.1073/pnas.87.4.1566; Wang Y, 2000, GENE DEV, V14, P927; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	37	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3708	3714		10.1038/sj.onc.1208515	http://dx.doi.org/10.1038/sj.onc.1208515			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15750628				2022-12-17	WOS:000229346300002
J	Hamard, PJ; Dalbies-Tran, R; Hauss, C; Davidson, I; Kedinger, C; Chatton, B				Hamard, PJ; Dalbies-Tran, R; Hauss, C; Davidson, I; Kedinger, C; Chatton, B			A functional interaction between ATF7 and TAF12 that is modulated by TAF4	ONCOGENE			English	Article						ATF7; ATFa; TAF4; TAF12; TFIID; MAP kinase	TATA-BINDING PROTEIN; THYROID-HORMONE RECEPTORS; NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATION; C-JUN; MAMMALIAN-CELLS; HISTONE FOLD; CYCLIC-AMP; IN-VIVO; TAF(II)-CONTAINING COMPLEXES	The ATF7 proteins, which are members of the cyclic AMP responsive binding protein (CREB)/activating transcription factor (ATF) family of transcription factors, display quite versatile properties: they can interact with the adenovirus E1a oncoprotein, mediating part of its transcriptional activity; they heterodimerize with the Jun, Fos or related transcription factors, likely modulating their DNA-binding specificity; they also recruit to the promoter a stress-induced protein kinase (JNK2). In the present study, we investigate the functional relationships of ATF7 with hsTAF12 (formerly hsTAF(II)20/15), which has originally been identified as a component of the general transcription factor TFIID. We show that overexpression of hsTAF12 potentiates ATF7-induced transcriptional activation through direct interaction with ATF7, suggesting that TAF12 is a functional partner of ATF7. In support of this conclusion, chromatin immunoprecipitation experiments confirm the interaction of ATF7 with TAF12 on an ATF7-responsive promoter, in the absence of any artificial overexpression of both proteins. We also show that the TAF12-dependent transcriptional activation is competitively inhibited by TAF4. Although both TAF12 isoforms (TAF12-1 and -2, formerly TAF(II)20 and TAF(II)15) interact with the ATF7 activation region through their histone-fold domain, only the largest, hsTAF12-1, mediates transcriptional activation through its N-terminal region.	Univ Strasbourg 1, Ecole Super Biotechnol Strasbourg, CNRS, UMR7100, F-67412 Illkirch Graffenstaden, France; ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Chatton, B (corresponding author), Univ Strasbourg 1, Ecole Super Biotechnol Strasbourg, CNRS, UMR7100, Parc Innovat,Bd Sebastien Brant,BP10413, F-67412 Illkirch Graffenstaden, France.	bchatton@esbs.u-strasbg.fr	CHATTON, Bruno/R-3813-2019; Hamard, Pierre-Jacques/B-7740-2015	Hamard, Pierre-Jacques/0000-0002-2484-6161; CHATTON, Bruno/0000-0003-4515-7119; Davidson, Irwin/0000-0001-5533-1171				Acker J, 1997, J BIOL CHEM, V272, P16815, DOI 10.1074/jbc.272.27.16815; Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Bell B, 1999, EXP CELL RES, V246, P11, DOI 10.1006/excr.1998.4294; Bhaumik SR, 2002, MOL CELL BIOL, V22, P7365, DOI 10.1128/MCB.22.21.7365-7371.2002; Bocco JL, 1996, ONCOGENE, V12, P1971; Brand M, 1999, SCIENCE, V286, P2151, DOI 10.1126/science.286.5447.2151; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHATTON B, 1994, ONCOGENE, V9, P375; CHATTON B, 1995, BIOTECHNIQUES, V18, P142; Cline J, 1996, NUCLEIC ACIDS RES, V24, P3546, DOI 10.1093/nar/24.18.3546; De Graeve F, 1999, ONCOGENE, V18, P3491, DOI 10.1038/sj.onc.1202723; DEDON PC, 1991, ANAL BIOCHEM, V197, P83, DOI 10.1016/0003-2697(91)90359-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; Freiman RN, 2001, SCIENCE, V293, P2084, DOI 10.1126/science.1061935; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; Gangloff YG, 2000, MOL CELL BIOL, V20, P340, DOI 10.1128/MCB.20.1.340-351.2000; Gangloff YG, 2001, TRENDS BIOCHEM SCI, V26, P250, DOI 10.1016/S0968-0004(00)01741-2; Goetz J, 1996, J BIOL CHEM, V271, P29589, DOI 10.1074/jbc.271.47.29589; Ho DT, 2003, J BIOL CHEM, V278, P32662, DOI 10.1074/jbc.M304229200; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; Hoffmann A, 1996, J BIOL CHEM, V271, P18194, DOI 10.1074/jbc.271.30.18194; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; Lavigne AC, 1999, MOL CELL BIOL, V19, P5050; Leurent C, 2004, EMBO J, V23, P719, DOI 10.1038/sj.emboj.7600111; Leurent C, 2002, EMBO J, V21, P3424, DOI 10.1093/emboj/cdf342; LIU F, 1990, NATURE, V345, P361; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Martinez E, 2002, PLANT MOL BIOL, V50, P925, DOI 10.1023/A:1021258713850; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Mazzarelli JM, 1997, J VIROL, V71, P7978, DOI 10.1128/JVI.71.10.7978-7983.1997; Mencia M, 2002, MOL CELL, V9, P823, DOI 10.1016/S1097-2765(02)00490-2; Mengus G, 2000, J BIOL CHEM, V275, P10064, DOI 10.1074/jbc.275.14.10064; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; Munz C, 2003, J BIOL CHEM, V278, P21510, DOI 10.1074/jbc.M212764200; Perletti L, 1999, J BIOL CHEM, V274, P15301, DOI 10.1074/jbc.274.22.15301; Pham AD, 1999, MECH DEVELOP, V84, P3, DOI 10.1016/S0925-4773(99)00051-9; Pollard H, 1998, J BIOL CHEM, V273, P7507, DOI 10.1074/jbc.273.13.7507; Purrello M, 1998, ONCOGENE, V16, P1633, DOI 10.1038/sj.onc.1201673; Shen WC, 2003, EMBO J, V22, P3395, DOI 10.1093/emboj/cdg336; Steghens JP, 1998, BIOCHEM J, V336, P109, DOI 10.1042/bj3360109; Timmers HTM, 2005, TRENDS BIOCHEM SCI, V30, P7, DOI 10.1016/j.tibs.2004.11.007; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Walker AK, 2001, EMBO J, V20, P5269, DOI 10.1093/emboj/20.18.5269; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; Werten S, 2002, J BIOL CHEM, V277, P45502, DOI 10.1074/jbc.M206587200; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0	58	20	24	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3472	3483		10.1038/sj.onc.1208565	http://dx.doi.org/10.1038/sj.onc.1208565			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735663				2022-12-17	WOS:000229038800009
J	Toyoshima, M; Shimura, T; Adiga, SK; Taga, M; Shiraishi, K; Inoue, M; Yuan, ZM; Niwa, O				Toyoshima, M; Shimura, T; Adiga, SK; Taga, M; Shiraishi, K; Inoue, M; Yuan, ZM; Niwa, O			Transcription-independent suppression of DNA synthesis by p53 in sperm-irradiated mouse zygotes	ONCOGENE			English	Article						p53; transcription independent; DNA-binding domain; S-phase checkpoint; X-rays; mouse zygotes	REPLICATION PROTEIN-A; BLOOMS-SYNDROME HELICASE; S-PHASE CHECKPOINT; WILD-TYPE P53; HOMOLOGOUS RECOMBINATION; HOLLIDAY JUNCTIONS; MUTANT P53; P53-DEPENDENT APOPTOSIS; XENOPUS-LAEVIS; HUMAN RAD51	Cell cycle arrest in response to DNA damage is important for the maintenance of genomic integrity in higher eukaryotes. We have previously reported the novel p53-dependent S-phase checkpoint operating in mouse zygotes fertilized with irradiated sperm. In the present study, we analysed the detail of the p53 function required for this S-phase checkpoint in mouse zygotes. The results indicate that ATM kinase is likely to be indispensable for the p53-dependent S-phase checkpoint since the suppression was abrogated by inhibitors such as caffeine and wortmannin. However, ATM phosphorylation site mutant proteins were still capable of suppressing DNA synthesis when microinjected into sperm-irradiated zygotes lacking the functional p53, suggesting that the target of the phosphorylation is not p53. In addition, the suppression was not affected by alpha-amanitin, and p53 protein mutated at the transcriptional activation domain was also functional in the suppression of DNA synthesis. However, p53 proteins mutated at the DNA-binding domain were devoid of the suppressing activity. Taken together, the transcription-independent function of p53 associated with the DNA-binding domain is involved in the S-phase checkpoint in collaboration with yet another unidentified target protein(s).	Kyoto Univ, Dept Late Effect Studies, Ctr Radiat Biol, Sakyo Ku, Kyoto 6068501, Japan; Kanazawa Med Univ, Med Res Inst, Kahoku, Ishikawa 9200293, Japan; Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Kyoto University; Kanazawa Medical University; Harvard University; Harvard T.H. Chan School of Public Health	Niwa, O (corresponding author), Kyoto Univ, Dept Late Effect Studies, Ctr Radiat Biol, Sakyo Ku, Kyoto 6068501, Japan.	oniwa@house.rbc.kyoto-u.ac.jp	Adiga, Satish Kumar/AAU-4386-2020	Adiga, Satish Kumar/0000-0002-2897-4697				Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; Achanta G, 2001, CANCER RES, V61, P8723; Aguilera A, 2001, TRENDS GENET, V17, P318, DOI 10.1016/S0168-9525(01)02309-5; Amariglio F, 1997, ONCOGENE, V15, P2191, DOI 10.1038/sj.onc.1201395; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bertrand P, 2004, TRENDS GENET, V20, P235, DOI 10.1016/j.tig.2004.04.003; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Blaydes JP, 2001, J BIOL CHEM, V276, P4699, DOI 10.1074/jbc.M003485200; Braun KA, 1997, BIOCHEMISTRY-US, V36, P8443, DOI 10.1021/bi970473r; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chen SS, 2002, EMBO J, V21, P4491, DOI 10.1093/emboj/cdf409; Clute P, 1997, DEV BIOL, V185, P1, DOI 10.1006/dbio.1997.8540; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cox MM, 2001, P NATL ACAD SCI USA, V98, P8173, DOI 10.1073/pnas.131004998; Davies SL, 2004, MOL CELL BIOL, V24, P1279, DOI 10.1128/MCB.24.3.1279-1291.2004; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Kumari A, 2004, ONCOGENE, V23, P2324, DOI 10.1038/sj.onc.1207379; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Longhese MP, 2003, MUTAT RES-FUND MOL M, V532, P41, DOI 10.1016/j.mrfmmm.2003.08.009; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Merrick CJ, 2004, J BIOL CHEM, V279, P20067, DOI 10.1074/jbc.M400022200; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; Nayak BK, 2002, ONCOGENE, V21, P7226, DOI 10.1038/sj.onc.1205889; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Pichierri P, 2004, EMBO J, V23, P3154, DOI 10.1038/sj.emboj.7600277; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Shimura T, 2002, MOL CELL BIOL, V22, P2220, DOI 10.1128/MCB.22.7.2220-2228.2002; Shimura T, 2002, RADIAT RES, V158, P735, DOI 10.1667/0033-7587(2002)158[0735:TNSMOT]2.0.CO;2; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; TSUKADA T, 1993, ONCOGENE, V8, P3313; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Yakovleva T, 2002, TRENDS BIOCHEM SCI, V27, P612, DOI 10.1016/S0968-0004(02)02209-0; Yang Q, 2002, J BIOL CHEM, V277, P31980, DOI 10.1074/jbc.M204111200; Yarbrough WG, 2002, CANCER RES, V62, P1171; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou XY, 2002, CANCER RES, V62, P1598	52	20	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3229	3235		10.1038/sj.onc.1208514	http://dx.doi.org/10.1038/sj.onc.1208514			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735681	Green Submitted			2022-12-17	WOS:000228881800001
J	Cao, C; Li, YP; Leng, YM; Li, P; Ma, QJ; Kufe, D				Cao, C; Li, YP; Leng, YM; Li, P; Ma, QJ; Kufe, D			Ubiquitination and degradation of the Arg tyrosine kinase is regulated by oxidative stress	ONCOGENE			English	Article						Arg; c-Abl; oxidative stress; phosphorylation; ubiquitination; proteosomal degradation	C-ABL; APOPTOTIC RESPONSE; CELLULAR-RESPONSE; ACTIVATION; DNA; NUCLEAR; AUTOINHIBITION; MITOCHONDRIA; BINDING; DAMAGE	The c-Abl and Arg nonreceptor tyrosine kinases are activated in the response of cells to oxidative stress. The present studies demonstrate that treatment of cells with 0.1mM H2O2 is associated with increased tyrosine phosphorylation of Arg and little effect on Arg levels. By contrast, exposure to 1.0mM H2O2 decreased Arg phosphorylation. Treatment with 1.0mM H2O2 was also associated with ubiquitination and degradation of Arg. The results show that Arg is stabilized in response to 0.1mM H2O2 by autophosphorylation of Y-261, consistent with involvement of the Arg kinase function in regulating Arg levels. The results further demonstrate that c-Abl-mediated phosphorylation of Arg on Y-261 similarly confers Arg stabilization. In concert with these results, phosphorylation of Arg on Y-261 blocked H2O2-induced ubiquitination and thereby Arg degradation and inactivation. These findings demonstrate that Arg phosphorylation and degradation are differentially regulated by the degree of oxidative stress, and that Arg stability is conferred by phosphorylation of Y-261.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Beijing Inst Biotechnol, Beijing 100850, Peoples R China	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu			NCI NIH HHS [CA42802, CA98628] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042802, R01CA098628] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; Cao C, 2003, J BIOL CHEM, V278, P39609, DOI 10.1074/jbc.M305770200; Cao C, 2003, J BIOL CHEM, V278, P29667, DOI 10.1074/jbc.M301292200; Cao C, 2003, J BIOL CHEM, V278, P12961, DOI 10.1074/jbc.M300058200; Cao C, 2001, J BIOL CHEM, V276, P11465, DOI 10.1074/jbc.C100050200; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; Echarri A, 2001, CURR BIOL, V11, P1759, DOI 10.1016/S0960-9822(01)00538-3; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Ito Y, 2001, MOL CELL BIOL, V21, P6233, DOI 10.1128/MCB.21.18.6233-6242.2001; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 2000, MOL CELL BIOL, V20, P4979, DOI 10.1128/MCB.20.14.4979-4989.2000; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; Kumar S, 2001, J BIOL CHEM, V276, P17281, DOI 10.1074/jbc.M101414200; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tanis KQ, 2003, MOL CELL BIOL, V23, P3884, DOI 10.1128/MCB.23.11.3884-3896.2003; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648	31	20	21	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2433	2440		10.1038/sj.onc.1208454	http://dx.doi.org/10.1038/sj.onc.1208454			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735735				2022-12-17	WOS:000228180600001
J	Moshynska, O; Moshynskyy, I; Misra, V; Saxena, A				Moshynska, O; Moshynskyy, I; Misra, V; Saxena, A			G125A single-nucleotide polymorphism in the human BAX promoter affects gene expression	ONCOGENE			English	Article						apoptosis; BAX; single-nucleotide polymorphism; Luciferase activity; gene expression; chronic lymphocytic leukemia	CHRONIC LYMPHOCYTIC-LEUKEMIA; MICROSATELLITE MUTATOR PHENOTYPE; IN-VIVO; FRAMESHIFT MUTATIONS; HEMATOPOIETIC MALIGNANCIES; DISEASE PROGRESSION; INDUCED APOPTOSIS; P53 EXPRESSION; OVARIAN-CANCER; CELL-SURVIVAL	Earlier we had reported a guanine to adenosine substitution at position 125 (G125A) in the BAX promoter, and its association with higher stage of the disease and failure to achieve complete response to treatment in chronic lymphocytic leukemia (CLL) patients. The aim of this study was to test the hypothesis that G125A leads to a reduction in the transcription of the BAX gene and that this is a direct cause of altered BAX mRNA and protein expression. In lymphocytes of CLL patients, BAX mRNA expression was determined by RNase protection assay and Bax protein was detected by immunoblotting. The presence of G125A in the BAX promoter was associated with lower BAX mRNA (P = 0.004) and protein (P = 0.024) levels. In transient expression assays using wild-type and mutant BAX promoter sequences linked to Luciferase as a reporter, the G125A polymorphism reduced expression of the BAX promoter by 2.6-fold. These studies suggest a mechanism for the biological effect of the G125A.	Univ Saskatchewan, Dept Pathol, Royal Univ Hosp, Coll Med, Saskatoon, SK S7N 0W8, Canada; Univ Saskatchewan, Vaccine & Infect Dis Org, Saskatoon, SK S7N 5E3, Canada; Univ Saskatchewan, Dept Microbiol, Western Coll Vet Med, Saskatoon, SK S7N 5B4, Canada	University of Saskatchewan; University of Saskatchewan; University of Saskatchewan	Saxena, A (corresponding author), Univ Saskatchewan, Dept Pathol, Royal Univ Hosp, Coll Med, Room 2870,2nd Floor,G Wing,103 Hosp Dr, Saskatoon, SK S7N 0W8, Canada.	saxena@sask.usask.ca	Moshynska, Oksana/AAC-6994-2019; Misra, Vikram/AAC-4266-2020; Moshynska, Oksana/AAJ-7893-2020	Moshynska, Oksana/0000-0003-4842-7786; Misra, Vikram/0000-0001-6818-7156; 				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; BODRUG SE, 1995, CELL DEATH DIFFER, V2, P173; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; Caligaris-Cappio F, 1999, J CLIN ONCOL, V17, P399, DOI 10.1200/JCO.1999.17.1.399; Catasus L, 2000, CANCER, V88, P2290, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2290::AID-CNCR13>3.0.CO;2-I; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Cordone I, 1998, BLOOD, V91, P4342, DOI 10.1182/blood.V91.11.4342.411k39_4342_4349; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Kay Neil E, 2002, Hematology Am Soc Hematol Educ Program, P193, DOI 10.1182/asheducation-2002.1.193; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Kitada S, 1999, BRIT J HAEMATOL, V106, P995, DOI 10.1046/j.1365-2141.1999.01642.x; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kokawa K, 1999, CANCER, V85, P1799, DOI 10.1002/(SICI)1097-0142(19990415)85:8<1799::AID-CNCR21>3.3.CO;2-D; Kokawa K, 1999, CANCER, V86, P79; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Lee HS, 2002, MODERN PATHOL, V15, P632, DOI 10.1038/modpathol.3880578; Levitsky VG, 2001, BIOINFORMATICS, V17, P998, DOI 10.1093/bioinformatics/17.11.998; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moshynska O, 2004, JNCI-J NATL CANCER I, V96, P673, DOI 10.1093/jnci/djh122; Moshynska O, 2003, J CLIN PATHOL-MOL PA, V56, P205, DOI 10.1136/mp.56.4.205; Ouyang H, 1998, CLIN CANCER RES, V4, P1071; Peng HZ, 1998, J PATHOL, V186, P378, DOI 10.1002/(SICI)1096-9896(199812)186:4<378::AID-PATH203>3.0.CO;2-5; Pepper C, 1999, BRIT J HAEMATOL, V104, P581, DOI 10.1046/j.1365-2141.1999.01210.x; Pepper C, 1996, BRIT J HAEMATOL, V95, P513, DOI 10.1046/j.1365-2141.1996.d01-1927.x; Pepper C, 1997, BRIT J CANCER, V76, P935, DOI 10.1038/bjc.1997.487; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Sakuragi N, 2002, GYNECOL ONCOL, V86, P288, DOI 10.1006/gyno.2002.6742; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SANCHEZ MS, 1986, ANTIMICROB AGENTS CH, V29, P634, DOI 10.1128/AAC.29.4.634; Sanz L, 2004, BIOCHEM BIOPH RES CO, V315, P562, DOI 10.1016/j.bbrc.2004.01.095; Saxena A, 2004, AM J HEMATOL, V75, P22, DOI 10.1002/ajh.10453; Saxena A, 2002, CANCER LETT, V187, P199, DOI 10.1016/S0304-3835(02)00378-6; Tai YT, 1999, CANCER RES, V59, P2121; Tai YT, 1998, J CLIN ONCOL, V16, P2583, DOI 10.1200/JCO.1998.16.8.2583; Thomas A, 1996, ONCOGENE, V12, P1055; Violette S, 2002, INT J CANCER, V98, P498, DOI 10.1002/ijc.10146; Yamamoto H, 1997, CANCER RES, V57, P4420; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	45	20	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					2042	2049		10.1038/sj.onc.1208377	http://dx.doi.org/10.1038/sj.onc.1208377			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688029				2022-12-17	WOS:000227681900008
J	Yang, WC; Bancroft, L; Augenlicht, LH				Yang, WC; Bancroft, L; Augenlicht, LH			Methylation in the p21(WAF1/cip1) promoter of Apc(+/-), p21(+/-) mice and lack of response to sulindac	ONCOGENE			English	Article						Apc; p21(WAF1/cip1); methylation	FAMILIAL ADENOMATOUS POLYPOSIS; HIGH-RISK DIET; DNA METHYLATION; COLORECTAL-CANCER; TUMOR-SUPPRESSOR; TARGETED INACTIVATION; CELL-PROLIFERATION; GENE-EXPRESSION; 5-AZA-2'-DEOXYCYTIDINE; DECITABINE	p21(WAF1/cip1) plays a critical role in regulating intestinal cell proliferation, maturation and tumorigenesis. Our previous work demonstrated that inactivation of a single p21 allele in Apc1638(+/-) mice was sufficient to accelerate Apc-initiated tumor formation, and that inactivation of only one p21 allele was also sufficient to abrogate duodenal tumor inhibition by sulindac, a nonsteroidal anti-inflammatory drug. To dissect the role of p21 in sulindac inhibition of intestinal tumor development in Apc1638(+/-) mice, we quantified p21 expression from Apc(+/-), p21(+/+), (+/-) or (-/-) mice fed sulindac. In Apc(+/-), p21 wild-type mice fed the sulindac supplemental diet, both p21 mRNA and protein were significantly increased in the. at mucosa and tumors of the duodenum. However, p21 was not induced by sulindac in the duodenal. at mucosa and tumors of Apc(+/-) mice in which one or both p21 alleles had been inactivated. Further investigation revealed that the cytosine residues in a CpG cluster in the promoter region of the mouse p21 gene displayed hypermethylation in the Apc(+/-), p21(+/-) mice. This suggested that although the p21(+/-) mice retained a wild-type allele, this allele was functionally modulated by hypermethylation, and that the inability of sulindac to inhibit tumor formation in Apc(+/-), p21(+/-) mice is likely due to the inability to induce expression of the wild-type, but differentially methylated, p21 allele.	Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Yang, WC (corresponding author), Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.	wyang@montefiore.org	Yang, Wancai/G-3750-2010; Yang, Wancai/O-7655-2019	Yang, Wancai/0000-0001-7437-9197	NCI NIH HHS [CA100926, CA96605, CA87559] Funding Source: Medline; PHS HHS [P01 13330] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U54CA100926, R01CA096605, R01CA087559] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Boolbol SK, 1996, CANCER RES, V56, P2556; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Davis CD, 2003, J NUTR, V133, P2907, DOI 10.1093/jn/133.9.2907; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Esteller M, 2002, SCIENCE, V297, P1807; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Goldberg Y, 1996, ONCOGENE, V12, P893; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Kondo Y, 2004, P NATL ACAD SCI USA, V101, P7398, DOI 10.1073/pnas.0306641101; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Lavelle D, 2003, LEUKEMIA RES, V27, P999, DOI 10.1016/S0145-2126(03)00068-7; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; NUGENT KP, 1993, BRIT J SURG, V80, P1618, DOI 10.1002/bjs.1800801244; Pohlmann P, 2002, AM J CLIN ONCOL-CANC, V25, P496, DOI 10.1097/00000421-200210000-00015; Polyak K, 1996, AM J PATHOL, V149, P381; Pretlow TP, 2003, AM J PATHOL, V163, P1757, DOI 10.1016/S0002-9440(10)63535-3; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Shiff SJ, 1997, GASTROENTEROLOGY, V113, P1992, DOI 10.1016/S0016-5085(97)99999-6; Soh JW, 2003, PROG EXP TUMOR RES, V37, P261; Subbaramaiah K, 1997, P SOC EXP BIOL MED, V216, P201; Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; Xian J, 2004, CANCER RES, V64, P6432, DOI 10.1158/0008-5472.CAN-04-2561; Yang WC, 2003, CANCER RES, V63, P4990; Yang WC, 2001, CANCER RES, V61, P6297; Yang WC, 2001, CANCER RES, V61, P565; Zhu WG, 2004, J BIOL CHEM, V279, P15161, DOI 10.1074/jbc.M311703200	37	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 17	2005	24	12					2104	2109		10.1038/sj.onc.1208444	http://dx.doi.org/10.1038/sj.onc.1208444			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688007				2022-12-17	WOS:000227681900015
J	Takahashi, M; Lin, YM; Nakamura, Y; Furukawa, Y				Takahashi, M; Lin, YM; Nakamura, Y; Furukawa, Y			Isolation and characterization of a novel gene CLUAP1 whose expression is frequently upregulated in colon cancer	ONCOGENE			English	Article						CLUAP1; clusterin; colon cancer	COMPARATIVE GENOMIC HYBRIDIZATION; COLORECTAL CARCINOGENESIS; CELL-DEATH; CLUSTERIN; CARCINOMAS; PROTEIN; INVOLVEMENT; ADENOMAS; COMPLEX; GAINS	To disclose mechanisms of colorectal carcinogenesis and identify novel diagnostic markers and drug targets for treatment of these tumors, we previously analysed the expression profiles of 11 colorectal cancers using a genome-wide cDNA microarray containing 23 040 genes. Among the genes commonly transactivated in the cancers, we identified a novel human gene, which we termed CLUAP1 (clusterin-associated protein 1). It encodes a nuclear protein of 413 amino acids containing a coiled-coil domain. To investigate its function, we searched for CLUAP1-interacting proteins using yeast two-hybrid system and identified nuclear Clusterin. Expression of CLUAP1 was gradually increased in the late S to G2/ M phases of cell cycle and it returned to the basal level in the G0/G1 phases. Suppression of this gene by short interfering RNAs resulted in growth retardation in the transfected cells. These data provide better understanding of colorectal carcinogenesis, and inactivation of CLUAP1 may conceivably serve in the future as a novel therapeutic intervention for treatment of colon cancer.	Univ Tokyo, Inst Med Sci, Mol Med Lab, Human Genome Ctr,Minato Ku, Tokyo 1088639, Japan; Shin Kong Wu Ho Su Mem Hosp, Dept Internal Med, Taipei 11160, Taiwan	University of Tokyo; Shin Kong Wu Ho Su Memorial Hospital	Furukawa, Y (corresponding author), Univ Tokyo, Inst Med Sci, Mol Med Lab, Human Genome Ctr,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	furukawa@ims.u-tokyo.ac.jp		Takahashi, Meiko/0000-0002-8344-5472				Chen XD, 2003, P NATL ACAD SCI USA, V100, P9530, DOI 10.1073/pnas.1233633100; De Angelis PM, 1999, BRIT J CANCER, V80, P526; Debure L, 2003, J CELL SCI, V116, P3109, DOI 10.1242/jcs.00619; He QJ, 2003, CANCER GENET CYTOGEN, V144, P112, DOI 10.1016/S0165-4608(02)00959-7; Hough CD, 2001, CANCER RES, V61, P3869; Kitahara O, 2001, CANCER RES, V61, P3544; Korn WM, 1999, GENE CHROMOSOME CANC, V25, P82, DOI 10.1002/(SICI)1098-2264(199906)25:2<82::AID-GCC2>3.0.CO;2-6; Leskov KS, 2003, J BIOL CHEM, V278, P11590, DOI 10.1074/jbc.M209233200; Lin YM, 2002, ONCOGENE, V21, P4120, DOI 10.1038/sj.onc.1205518; MURPHY BF, 1988, J CLIN INVEST, V81, P1858, DOI 10.1172/JCI113531; Nakao K, 1998, SURG TODAY, V28, P567, DOI 10.1007/s005950050185; Okabe H, 2003, CANCER RES, V63, P3043; Ouyang XS, 2001, CARCINOGENESIS, V22, P965, DOI 10.1093/carcin/22.6.965; Reddy KB, 1996, BIOCHEMISTRY-US, V35, P6157, DOI 10.1021/bi952981b; Redondo M, 2000, AM J PATHOL, V157, P393, DOI 10.1016/S0002-9440(10)64552-X; Shimokawa T, 2003, CANCER RES, V63, P6116; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; Wellmann A, 2000, BLOOD, V96, P398; Yang CR, 1999, NUCLEIC ACIDS RES, V27, P2165, DOI 10.1093/nar/27.10.2165; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907	20	20	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9289	9294		10.1038/sj.onc.1208100	http://dx.doi.org/10.1038/sj.onc.1208100			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15480429				2022-12-17	WOS:000225638000014
J	Meertens, L; Pise-Masison, C; Quere, N; Brady, J; Gessain, A; Mahieux, R				Meertens, L; Pise-Masison, C; Quere, N; Brady, J; Gessain, A; Mahieux, R			Utilization of the CBP but not the p300 co-activator by human T-lymphotropic virus type-2 Tax for p53 inhibition	ONCOGENE			English	Article						HTLV; tax; p53; CBP/p300; NF-kappa B	CELL LEUKEMIA-VIRUS; NF-KAPPA-B; CREB BINDING-PROTEIN; WILD-TYPE P53; II HTLV-II; TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATION FUNCTION; FUNCTIONAL IMPAIRMENT; ABERRANT EXPRESSION; DOMAIN	We previously reported, both in transfected cells and in human T-cell leukemia virus type-2 subtype B infected cells, that the viral transactivator Tax-2B protein could inhibit p53 functions. We have now investigated the mechanism through which Tax-2B represses p53 using GFPTax-2B fusion proteins. We present evidence that Tax-2B inhibition of p53 function is not linked to CREB/ ATF activation, but is uniquely correlated with the interaction of CREB binding protein (CBP), but not p300, with the C-terminus of Tax-2B. Wild type, but not a Tax-2B-M47 mutant, inhibits p53 function in adherent cells. We demonstrate that both Tax-2B and Tax-2B-M47 can bind p300, while Tax-2B-M47 is impaired for CBP binding. Importantly, transfection of increasing amounts of CBP but not p300 or p300/CBP-associated factor (P/CAF) could rescue p53 transcriptional activity in the presence of Tax-2B in nonlymphocytic cells. In lymphoid cells, Tax-2B mediated inhibition of p53 is correlated with the NF-kappaB pathway activation and could be prevented by the overexpression of an IkappaBalpha mutant. Given the similarities between the functional domains of CBP and p300, these results are intriguing and suggest that Tax-2B must bind the CR2 domain of CBP, but not that of p300 in order to repress p53.	Inst Pasteur, Unite Edpidemiol & Physiopathol Virus Oncogenes, F-75724 Paris 15, France; NCI, Virus Tumor Biol Sect, NIH, Bethesda, MD 20892 USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Mahieux, R (corresponding author), Inst Pasteur, Unite Edpidemiol & Physiopathol Virus Oncogenes, 28 Rue Dr Roux, F-75724 Paris 15, France.	rmahieux@pasteur.fr	Meertens, Laurent/E-8043-2017	Meertens, Laurent/0000-0003-2811-3675; mahieux, renaud/0000-0002-5129-6804				ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Alefantis T, 2003, J BIOL CHEM, V278, P21814, DOI 10.1074/jbc.M211576200; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Casoli C, 2004, BLOOD, V103, P995, DOI 10.1182/blood-2003-07-2503; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; Eiraku N, 1996, J VIROL, V70, P1481, DOI 10.1128/JVI.70.3.1481-1492.1996; Endo K, 2002, J VIROL, V76, P2648, DOI 10.1128/JVI.76.6.2648-2653.2002; Fouchard N, 1995, LEUKEMIA, V9, P2087; Gartenhaus RB, 1995, LEUKEMIA, V9, P2082; GESSAIN A, 1985, LANCET, V2, P407; GOREN I, 1995, J VIROL, V69, P5806, DOI 10.1128/JVI.69.9.5806-5811.1995; GRASSMANN R, 1994, ADV CANCER RES, V63, P211, DOI 10.1016/S0065-230X(08)60401-7; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Harrod R, 2003, J BIOL CHEM, V278, P12310, DOI 10.1074/jbc.M211167200; Hirata A, 2004, VIROLOGY, V318, P327, DOI 10.1016/j.virol.2003.10.006; IJICHI S, 1992, J EXP MED, V176, P293, DOI 10.1084/jem.176.1.293; Iwanaga Y, 1999, J VIROL, V73, P1271, DOI 10.1128/JVI.73.2.1271-1277.1999; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Johnson JM, 2001, INT J EXP PATHOL, V82, P135, DOI 10.1046/j.1365-2613.2001.00191.x; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Lewis MJ, 2002, VIROLOGY, V295, P182, DOI 10.1006/viro.2002.1357; Livengood JA, 2002, J BIOL CHEM, V277, P9054, DOI 10.1074/jbc.M108870200; Lu HX, 2002, MOL CELL BIOL, V22, P4450, DOI 10.1128/MCB.22.13.4450-4462.2002; Mahieux R, 2000, J VIROL, V74, P6866, DOI 10.1128/JVI.74.15.6866-6874.2000; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Murphy EL, 1997, NEUROLOGY, V48, P315, DOI 10.1212/WNL.48.2.315; NAGAI H, 1991, JPN J CANCER RES, V82, P1421, DOI 10.1111/j.1349-7006.1991.tb01815.x; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Pise-Masison CA, 2001, J BIOL CHEM, V276, P200, DOI 10.1074/jbc.M005601200; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; REID RL, 1993, ONCOGENE, V8, P3029; Ross TM, 1996, J VIROL, V70, P5194, DOI 10.1128/JVI.70.8.5194-5202.1996; Ross TM, 1997, J VIROL, V71, P8912, DOI 10.1128/JVI.71.11.8912-8917.1997; Ross TM, 2000, J VIROL, V74, P2655, DOI 10.1128/JVI.74.6.2655-2662.2000; Scoggin KES, 2001, MOL CELL BIOL, V21, P5520, DOI 10.1128/MCB.21.16.5520-5530.2001; Semmes OJ, 1996, VIROLOGY, V217, P373, DOI 10.1006/viro.1996.0126; SHAH NP, 1986, MOL CELL BIOL, V6, P3626, DOI 10.1128/MCB.6.11.3626; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Sol-Foulon N, 2002, IMMUNITY, V16, P145, DOI 10.1016/S1074-7613(02)00260-1; SUGITO S, 1991, INT J CANCER, V49, P880, DOI 10.1002/ijc.2910490614; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; Takemoto S, 2000, BLOOD, V95, P3939; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Van PL, 2001, J VIROL, V75, P396, DOI 10.1128/JVI.75.1.396-407.2001; Wang TG, 2000, AIDS RES HUM RETROV, V16, P1661, DOI 10.1089/08892220050193119; YAMATO K, 1993, JPN J CANCER RES, V84, P4, DOI 10.1111/j.1349-7006.1993.tb02775.x; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yu Q, 2001, FEBS LETT, V505, P7, DOI 10.1016/S0014-5793(01)02756-9	57	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5447	5458		10.1038/sj.onc.1207719	http://dx.doi.org/10.1038/sj.onc.1207719			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15156194				2022-12-17	WOS:000222588400004
J	Cabart, P; Chew, HK; Murphy, S				Cabart, P; Chew, HK; Murphy, S			BRCA1 cooperates with NUFIP and P-TEFb to activate transcription by RNA polymerase II	ONCOGENE			English	Article						BRCA1; P-TEFb; NUFIP; RNA polymerase II; transcriptional activator	CARBOXYL-TERMINAL DOMAIN; DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; MAJOR LATE PROMOTER; ELONGATION COMPLEXES; TATA-BOX; DEPENDENT TRANSCRIPTION; FUNCTIONAL INTERACTIONS; BINDING PROTEIN; KINASE-ACTIVITY	The tumor suppressor gene product BRCA1 is a component of the RNA polymerase II (pol II) holoenzyme that is involved, through binding to various regulatory proteins, in either activation or repression of transcription. Using a yeast two-hybrid screen, we have identified a human zinc-finger-containing protein NUFIP that interacts with BRCA1. The ubiquitous, stably expressed, nuclear protein NUFIP specifically stimulates activator-independent pol II transcription in vitro and in vivo. Immunodepletion of the endogenous NUFIP causes a marked decrease of pol II transcription, which is then shown to be restored by stable complex of ectopically produced NUFIP and associated factors. NUFIP not only interacts with BRCA1 but also associates with the positive elongation factor P-TEFb through interaction with the regulatory Cyclin T1 subunit. Cyclin T1 is required for BRCA1- and NUFIP-dependent synergistic activation of pol II transcription in 293 cells. Mutation of the zinc-finger domain abolishes the NUFIP-mediated transcriptional activation. We show that NUFIP is associated with preinitiation complexes, open transcription complexes, and elongation complexes. In addition, NUFIP facilitates ATP-dependent dissociation of hyperphosphorylated pol II from open transcription complexes in vitro.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Calif Davis, Ctr Canc, Div Hematol Oncol, Sacramento, CA 95817 USA	University of Oxford; University of California System; University of California Davis	Cabart, P (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Jack & Pearl Resnick Campus,1300 Morris Pk Ave, Bronx, NY 10461 USA.	pcabart@aecom.yu.edu		Cabart, Pavel/0000-0003-0065-367X				Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; ARIAS JA, 1989, J BIOL CHEM, V264, P3223; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Bardoni B, 1999, HUM MOL GENET, V8, P2557, DOI 10.1093/hmg/8.13.2557; Bardoni B, 2003, EXP CELL RES, V289, P95, DOI 10.1016/S0014-4827(03)00222-2; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; Cabart P, 2001, J BIOL CHEM, V276, P43056, DOI 10.1074/jbc.M108515200; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1999, J CELL PHYSIOL, V181, P385, DOI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4; Chen YM, 1996, CANCER RES, V56, P3168; Chiba N, 2002, CANCER RES, V62, P4222; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; DAHMUS ME, 1994, PROG NUCLEIC ACID RE, V48, P143, DOI 10.1016/S0079-6603(08)60855-7; DAHMUS ME, 1981, J BIOL CHEM, V256, P3332; Deng CX, 2000, BIOESSAYS, V22, P728; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; Edwards MC, 1998, MOL CELL BIOL, V18, P4291, DOI 10.1128/MCB.18.7.4291; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; Fujinaga K, 1999, P NATL ACAD SCI USA, V96, P1285, DOI 10.1073/pnas.96.4.1285; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Ivanov D, 2000, MOL CELL BIOL, V20, P2970, DOI 10.1128/MCB.20.9.2970-2983.2000; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Kim JB, 2001, J BIOL CHEM, V276, P12317, DOI 10.1074/jbc.M010908200; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(01)00270-7; Krum SA, 2003, J BIOL CHEM, V278, P52012, DOI 10.1074/jbc.M308418200; Kugel JF, 1998, P NATL ACAD SCI USA, V95, P9232, DOI 10.1073/pnas.95.16.9232; Kugel JF, 2002, MOL CELL BIOL, V22, P762, DOI 10.1128/MCB.22.3.762-773.2002; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Monteiro ANA, 2000, TRENDS BIOCHEM SCI, V25, P469, DOI 10.1016/S0968-0004(00)01632-7; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Murphy S, 1997, NUCLEIC ACIDS RES, V25, P2068, DOI 10.1093/nar/25.11.2068; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; Narita T, 2003, MOL CELL BIOL, V23, P1863, DOI 10.1128/MCB.23.6.1863-1873.2003; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; PARVIN JD, 1994, J BIOL CHEM, V269, P18414; Parvin JD, 2001, P NATL ACAD SCI USA, V98, P5952, DOI 10.1073/pnas.121184998; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Ping YH, 1999, J BIOL CHEM, V274, P7399, DOI 10.1074/jbc.274.11.7399; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; ROHAN RM, 1987, J BIOL CHEM, V262, P8500; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shore SM, 2003, GENE, V307, P175, DOI 10.1016/S0378-1119(03)00466-9; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Spangler L, 2001, P NATL ACAD SCI USA, V98, P5544, DOI 10.1073/pnas.101004498; Starita LM, 2003, CURR OPIN CELL BIOL, V15, P345, DOI 10.1016/S0955-0674(03)00042-5; SZENTIRMAY MN, 1994, NUCLEIC ACIDS RES, V22, P5341, DOI 10.1093/nar/22.24.5341; Taube R, 2002, MOL CELL BIOL, V22, P321, DOI 10.1128/MCB.22.1.321-331.2002; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Venkitaraman AR, 2001, J CELL SCI, V114, P3591; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yamaguchi Y, 1999, J BIOL CHEM, V274, P8085, DOI 10.1074/jbc.274.12.8085; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298; Zhong Q, 2002, J BIOL CHEM, V277, P28641, DOI 10.1074/jbc.M200748200; Zhong Q, 2002, CANCER RES, V62, P3966; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	84	20	20	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	2004	23	31					5316	5329		10.1038/sj.onc.1207684	http://dx.doi.org/10.1038/sj.onc.1207684			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15107825				2022-12-17	WOS:000222491600007
J	Matsuzaki, Y; Takaoka, Y; Hitomi, T; Nishino, H; Sakai, T				Matsuzaki, Y; Takaoka, Y; Hitomi, T; Nishino, H; Sakai, T			Activation of protein kinase C promotes human cancer cell growth through downregulation of p18(INK4c)	ONCOGENE			English	Article						p18(ink4c); TPA; PKC	CDK INHIBITORS; RETINOBLASTOMA PROTEIN; P18 GENES; P16(INK4A); EXPRESSION; P15(INK4B); MICE; PHOSPHORYLATION; PROLIFERATION; TRANSDUCTION	p18(INK4c), a member of INK4 family of cyclin-dependent kinase inhibitors, negatively regulates the cyclin D-cyclin-dependent kinase 4/6 complexes which promote G1/S transition by phosphorylating the retinoblastoma tumor-suppressor gene product. Several recent studies using p18(INK4c)-null mice revealed that the p18(INK4c) plays an important role in cell proliferation and tumor development. We report here that 12-O-tetradecanoylphorbol-13-acetate (TPA), widely used as a protein kinase C (PKC) activator, suppresses the expression of p18(INK4c) through its promoter, accompanied by the induction of human cancer cell growth. Reduction of p18(INK4c) using small interfering RNA (siRNA) also enhanced cell growth, suggesting that p18(INK4c) is a critical target of TPA. Ro 31-8425, a potent and highly specific PKC inhibitor abrogated the suppressive effect of TPA on p18(INK4c) gene expression. However, the expression of dominant-negative c-Jun (TAM-67) did not inhibit the action of TPA on p18(INK4c). These findings suggest that activation of PKC promotes human cancer cell growth through downregulation of p18(INK4c) in an AP-1 activation-independent manner. These results suggest that the accelerated cellular proliferation of some human tumors caused by enhanced PKC activity at least partially involves the suppression of p18(INK4c), which is a ubiquitously expressed cyclin-dependent kinase inhibitor.	Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kamigyo Ku, Kyoto 6028566, Japan; Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Biochem & Mol Biol, Kamigyo Ku, Kyoto 6028566, Japan	Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine	Sakai, T (corresponding author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kamigyo Ku, Kyoto 6028566, Japan.	tsakai@koto.kpu-m.ac.jp						ALVARO V, 1992, INT J CANCER, V50, P724, DOI 10.1002/ijc.2910500510; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bai F, 2003, MOL CELL BIOL, V23, P1269, DOI 10.1128/MCB.23.4.1269-1277.2003; BIT RA, 1993, J MED CHEM, V36, P21, DOI 10.1021/jm00053a003; BROWN PH, 1994, ONCOGENE, V9, P791; da Rocha AB, 2002, ONCOLOGIST, V7, P17, DOI 10.1634/theoncologist.7-1-17; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; Goekjian PG, 2001, EXPERT OPIN INV DRUG, V10, P2117; Gordge PC, 1996, EUR J CANCER, V32A, P2120, DOI 10.1016/S0959-8049(96)00255-9; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hatta Y, 1997, BRIT J HAEMATOL, V99, P665; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Liebmann C, 2001, CELL SIGNAL, V13, P777, DOI 10.1016/S0898-6568(01)00192-9; Miller CW, 1996, CANCER GENET CYTOGEN, V86, P136, DOI 10.1016/0165-4608(95)00216-2; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OBRIAN CA, 1989, CANCER RES, V49, P3215; Otsuki T, 1996, LEUKEMIA, V10, P356; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Rusin MR, 1996, INT J CANCER, V65, P734, DOI 10.1002/(SICI)1097-0215(19960315)65:6<734::AID-IJC4>3.0.CO;2-#; Schenk PW, 1999, BBA-MOL CELL RES, V1449, P1, DOI 10.1016/S0167-4889(98)00178-5; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Swannie Helen C, 2002, Curr Oncol Rep, V4, P37, DOI 10.1007/s11912-002-0046-7; Virchis Andres, 2002, Hematol J, V3, P131, DOI 10.1038/sj.thj.6200165; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Yamamoto H, 1999, CLIN CANCER RES, V5, P1805; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zindy F, 2000, MOL CELL BIOL, V20, P372, DOI 10.1128/MCB.20.1.372-378.2000; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	36	20	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5409	5414		10.1038/sj.onc.1207702	http://dx.doi.org/10.1038/sj.onc.1207702			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15107819				2022-12-17	WOS:000222491600017
J	Frontelo, P; Leader, JE; Yoo, N; Potocki, AC; Crawford, M; Kulik, M; Lechleider, RJ				Frontelo, P; Leader, JE; Yoo, N; Potocki, AC; Crawford, M; Kulik, M; Lechleider, RJ			Suv39h histone methyltransferases interact with Smads and cooperate in BMP-induced repression	ONCOGENE			English	Article						Smad; BMP; histone methyltransferase; transcription; repression	TRANSCRIPTIONAL ACTIVATION; BREAST-CANCER; I RECEPTORS; LYSINE 9; PROTEINS; METHYLATION; H3; HETEROCHROMATIN; SIGNALS; BINDING	Smad proteins transduce signals from transforming growth factor-beta (TGF-beta) superfamily ligands to regulate the expression of target genes. In order to identify novel partners of Smad proteins in transcriptional regulation, we performed a two-hybrid screen using Smad5, a protein that is activated predominantly by bone morphogenetic protein (BMP) signaling. We identified an interaction between Smad5 and suppressor of variegation 3-9 homolog 2 (Suv39h2), a chromatin modifier enzyme. Suv39h proteins are histone methyltransferases that methylate histone H3 on lysine 9, resulting in transcriptional repression or silencing of target genes. Biochemical studies in mammalian cells demonstrated that Smad5 binds to both known mammalian isoforms of Suv39h proteins, and that Smad proteins activated by the TGF-beta signaling pathway, Smad2 and Smad3, do not bind with significant affinity. Functional studies using the muscle creatine kinase (MCK) promoter, which is suppressed by BMP signaling, demonstrate that Suv39h proteins and Smads cooperate to repress promoter activity. These data suggest a model where association of Smad proteins with Suv39h methyltransferases can repress or silence genes involved in developmental processes, and argues that inefficient gene repression may result in the alteration of the differentiated phenotype. Thus, examination of the Smad - Suv interaction may provide insight into the mechanism of phenotypic determination mediated by BMP signaling.	Georgetown Univ, Sch Med, Dept Cell Biol, Washington, DC 20057 USA; Georgetown Univ, Sch Med, Tumor Biol Program, Washington, DC 20057 USA; Uniformed Serv Univ Hlth Sci, Mol & Cell Biol Program, Bethesda, MD 20814 USA	Georgetown University; Georgetown University; Uniformed Services University of the Health Sciences - USA	Lechleider, RJ (corresponding author), Georgetown Univ, Sch Med, Dept Cell Biol, Box 571436, Washington, DC 20057 USA.	rjl24@georgetown.edu	Yoo, Nam Jin/GNM-9060-2022		NATIONAL CANCER INSTITUTE [R21CA102660] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065681] Funding Source: NIH RePORTER; NCI NIH HHS [CA102660] Funding Source: Medline; NHLBI NIH HHS [HL65681] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; Akiyama S, 1997, EXP CELL RES, V235, P362, DOI 10.1006/excr.1997.3680; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Brubaker KD, 2004, J CELL BIOCHEM, V91, P151, DOI 10.1002/jcb.10679; CAESTECKER MD, 2001, RESP RES, V2, P193; Chakraborty S, 2003, ONCOGENE, V22, P5229, DOI 10.1038/sj.onc.1206600; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Davey C, 2003, J MOL BIOL, V325, P873, DOI 10.1016/S0022-2836(02)01340-2; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Firestein R, 2000, MOL CELL BIOL, V20, P4900, DOI 10.1128/MCB.20.13.4900-4909.2000; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Itoh S, 2000, NUCLEIC ACIDS RES, V28, P4291, DOI 10.1093/nar/28.21.4291; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Keeton EK, 2002, J BIOL CHEM, V277, P28247, DOI 10.1074/jbc.M203898200; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Li JW, 2002, MOL CELL BIOL, V22, P5688, DOI 10.1128/MCB.22.16.5688-5697.2002; Liberati NT, 2001, J BIOL CHEM, V276, P22595, DOI 10.1074/jbc.M010778200; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Melcher M, 2000, MOL CELL BIOL, V20, P3728, DOI 10.1128/MCB.20.10.3728-3741.2000; Melhuish TA, 2000, J BIOL CHEM, V275, P39762, DOI 10.1074/jbc.C000416200; Moustakas A, 2001, J CELL SCI, V114, P4359; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Pouliot F, 2002, J ENDOCRINOL, V172, P187, DOI 10.1677/joe.0.1720187; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; REEVES R, 1985, NUCLEIC ACIDS RES, V13, P3599, DOI 10.1093/nar/13.10.3599; Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073; Snowden AW, 2002, CURR BIOL, V12, P2159, DOI 10.1016/S0960-9822(02)01391-X; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Vaute O, 2002, NUCLEIC ACIDS RES, V30, P475, DOI 10.1093/nar/30.2.475; von Bubnoff A, 2001, DEV BIOL, V239, P1, DOI 10.1006/dbio.2001.0388; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445	43	20	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5242	5251		10.1038/sj.onc.1207660	http://dx.doi.org/10.1038/sj.onc.1207660			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15107829				2022-12-17	WOS:000222382500013
J	Vanni, C; Parodi, A; Mancini, P; Visco, V; Ottaviano, C; Torrisi, MR; Eva, A				Vanni, C; Parodi, A; Mancini, P; Visco, V; Ottaviano, C; Torrisi, MR; Eva, A			Phosphorylation-independent membrane relocalization of ezrin following association with Dbl in vivo	ONCOGENE			English	Article						ERM; Dbl oncogene; PH domain	F-ACTIN BINDING; EZRIN/RADIXIN/MOESIN ERM PROTEINS; RHO-KINASE; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; THREONINE 558; PROTO-DBL; DOMAIN; SITE; MOESIN; ACTIVATION	Ezrin, a widespread protein involved in cell migration, morphogenesis and cell adhesion, belongs to a large family of proteins known as ERM ( ezrin, radixin, moesin). These three closely related proteins are thought to function as linkers between plasma membrane and actin cytoskeleton and their function is regulated by the small GTP-binding protein Rho. It has been previously shown that the active form of radixin can bind in vitro to Dbl, a Rho-specific guanine nucleotide exchange factor, although an in vivo interaction has not yet been demonstrated. In this paper, we attempted to investigate whether ezrin can also associate with Dbl. We show here that Dbl protein can effectively bind both in vitro and in vivo to the N-terminal region ( amino acids 1 - 531) of a constitutively active mutant of ezrin and with the full-length molecule. We found that this binding is mediated by the Dbl pleckstrin homology domain, responsible for the proper subcellular localization of the Dbl protein. Moreover, we show that Dbl induces localization to the plasma membrane of both the active deletion mutant and the full-length ezrin proteins. Finally, we show that the relocalization of ezrin is independent of Dbl GEF activity. These results indicate that Dbl could induce translocation of ezrin to the plasma membrane through a mechanism that does not require ezrin C-terminus phosphorylation by Rho-associated kinases.	Ist Giannina Gaslini, Mol Biol Lab, I-16147 Genoa, Italy; Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, I-00161 Rome, Italy	University of Genoa; IRCCS Istituto Giannina Gaslini; Sapienza University Rome	Eva, A (corresponding author), Ist Giannina Gaslini, Mol Biol Lab, Largo G Gaslini 5, I-16147 Genoa, Italy.	alessandraeva@ospedale-gaslini.ge.it	Eva, Alessandra/J-8268-2016	Eva, Alessandra/0000-0003-2949-078X; mancini, patrizia/0000-0003-0556-2056				ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; Barret C, 2000, J CELL BIOL, V151, P1067, DOI 10.1083/jcb.151.5.1067; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; HART MJ, 1994, J BIOL CHEM, V269, P62; Hayashi K, 1999, J CELL SCI, V112, P1149; Heiska L, 1998, J BIOL CHEM, V273, P21893, DOI 10.1074/jbc.273.34.21893; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Huang LQ, 1999, J BIOL CHEM, V274, P12803, DOI 10.1074/jbc.274.18.12803; Katan M, 1999, FEBS LETT, V452, P36, DOI 10.1016/S0014-5793(99)00531-1; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Nakamura F, 1999, MOL BIOL CELL, V10, P2669, DOI 10.1091/mbc.10.8.2669; Nakamura F, 1996, BIOCHEM BIOPH RES CO, V226, P650, DOI 10.1006/bbrc.1996.1410; Niggli V, 2001, TRENDS BIOCHEM SCI, V26, P604, DOI 10.1016/S0968-0004(01)01927-2; NIGGLI V, 1995, FEBS LETT, V376, P172, DOI 10.1016/0014-5793(95)01270-1; Oshiro N, 1998, J BIOL CHEM, V273, P34663, DOI 10.1074/jbc.273.52.34663; Quang CT, 2000, EMBO J, V19, P4565, DOI 10.1093/emboj/19.17.4565; Razzini G, 2000, J BIOL CHEM, V275, P14873, DOI 10.1074/jbc.275.20.14873; RON D, 1991, NEW BIOL, V3, P372; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; Shaw RJ, 1998, MOL BIOL CELL, V9, P403, DOI 10.1091/mbc.9.2.403; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Takahashi K, 1998, ONCOGENE, V16, P3279, DOI 10.1038/sj.onc.1201874; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; VAN AL, 1997, GENE DEV, V11, P2295; Vanni C, 2002, J BIOL CHEM, V277, P19745, DOI 10.1074/jbc.M111025200; Weernink PAO, 2000, J BIOL CHEM, V275, P10168, DOI 10.1074/jbc.275.14.10168; Yonemura S, 2002, J CELL SCI, V115, P2569; ZANGRILLI D, 1995, CELL TRANSFORMATION, P347; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	34	20	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4098	4106		10.1038/sj.onc.1207509	http://dx.doi.org/10.1038/sj.onc.1207509			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064738				2022-12-17	WOS:000221520200008
J	Arrington, AS; Moore, MS; Butel, JS				Arrington, AS; Moore, MS; Butel, JS			SV40-positive brain tumor in scientist with risk of laboratory exposure to the virus	ONCOGENE			English	Article						brain tumor; meningioma; simian virus 40	LARGE T-ANTIGEN; REGULATORY REGION; TRANSGENIC MICE; SV40 GENOMES; SIMIAN-VIRUS-40; ASSOCIATION; MONKEYS; DISEASE; DNA; IDENTIFICATION	Simian virus 40 ( SV40) is a DNA tumor virus known to induce cancers in laboratory animals. There are numerous reports of the detection of SV40 DNA and/ or proteins in human malignancies of the same types as those induced by SV40 in animals, including brain cancers. However, known exposure to the virus has not yet been linked directly to cancer development in a specific individual. Here we describe the detection of SV40 sequences in the meningioma of a laboratory researcher who had a probable direct exposure to SV40 and subsequently developed a tumor positive for viral DNA sequences indistinguishable from those of the laboratory source. This case suggests a link between viral exposure and tumor development.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Butel, JS (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.	jbutel@bcm.tmc.edu		Butel, Janet/0000-0002-6876-3245	NCI NIH HHS [CA09197] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arrington AS, 2000, ANTICANCER RES, V20, P879; ARRINGTON AS, 2001, HUMAN POLYOMAVIRUSES, P461; Bocchetta M, 2000, P NATL ACAD SCI USA, V97, P10214, DOI 10.1073/pnas.170207097; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; Butel JS, 2000, CARCINOGENESIS, V21, P405, DOI 10.1093/carcin/21.3.405; Butel JS, 1999, J INFECT DIS, V180, P884, DOI 10.1086/314915; BUTEL JS, 1994, METH MOL G, V4, P282; David H, 2001, CANCER LETT, V162, P57, DOI 10.1016/S0304-3835(00)00628-5; EDDY BE, 1962, VIROLOGY, V17, P65, DOI 10.1016/0042-6822(62)90082-X; Evans Alfred S., 1990, Annals of Epidemiology, V1, P71; Gazdar AF, 2002, NAT REV CANCER, V2, P957, DOI 10.1038/nrc947; GERBER P, 1962, VIROLOGY, V18, P582, DOI 10.1016/0042-6822(62)90061-2; GISH WR, 1987, J VIROL, V61, P2864, DOI 10.1128/JVI.61.9.2864-2876.1987; Griffiths DJ, 1998, DEV BIOL STAND, V94, P127; Huang KC, 1999, VIROLOGY, V262, P457, DOI 10.1006/viro.1999.9952; HWANG SP, 1980, VIROLOGY, V105, P196, DOI 10.1016/0042-6822(80)90167-1; ILYINSKII PO, 1992, J VIROL, V66, P6353, DOI 10.1128/JVI.66.11.6353-6360.1992; Jasani B, 2001, SEMIN CANCER BIOL, V11, P49, DOI 10.1006/scbi.2000.0346; KRIEG P, 1984, VIROLOGY, V138, P336, DOI 10.1016/0042-6822(84)90357-X; Lednicky JA, 1998, J VIROL, V72, P3980, DOI 10.1128/JVI.72.5.3980-3990.1998; Lednicky JA, 1997, J GEN VIROL, V78, P1697, DOI 10.1099/0022-1317-78-7-1697; Lednicky JA, 1997, INT J CANCER, V72, P791; LEDNICKY JA, 1995, VIROLOGY, V212, P710, DOI 10.1006/viro.1995.1529; Lednicky JA, 2001, SEMIN CANCER BIOL, V11, P39, DOI 10.1006/scbi.2000.0345; Li RM, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000028249.06596.CF; Ling PD, 2003, J INFECT DIS, V187, P1571, DOI 10.1086/374739; Martini F, 2002, CANCER-AM CANCER SOC, V94, P1037, DOI 10.1002/cncr.10272; Newman JS, 1998, J NEUROVIROL, V4, P394, DOI 10.3109/13550289809114538; ONEILL FJ, 1992, VIRUS RES, V25, P169, DOI 10.1016/0168-1702(92)90132-S; ONEILL FJ, 1981, VIROLOGY, V112, P800, DOI 10.1016/0042-6822(81)90330-5; PINKERT CA, 1987, VIROLOGY, V160, P169, DOI 10.1016/0042-6822(87)90057-2; SHEIN HM, 1967, J NEUROPATH EXP NEUR, V26, P60, DOI 10.1097/00005072-196701000-00005; Stewart AR, 1998, J NEUROVIROL, V4, P182; TAVIS JE, 1994, VIROLOGY, V199, P384, DOI 10.1006/viro.1994.1136; Vilchez RA, 2002, LANCET, V359, P817, DOI 10.1016/S0140-6736(02)07950-3; Vilchez RA, 2003, AM J MED, V114, P675, DOI 10.1016/S0002-9343(03)00087-1	37	20	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2231	2235		10.1038/sj.onc.1207341	http://dx.doi.org/10.1038/sj.onc.1207341			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14676832				2022-12-17	WOS:000220280900013
J	Chelbi-alix, MK; Bobe, P; Benoit, G; Canova, A; Pine, R				Chelbi-alix, MK; Bobe, P; Benoit, G; Canova, A; Pine, R			Arsenic enhances the activation of Stat1 by interferon gamma leading to synergistic expression of IRF-1	ONCOGENE			English	Article						interferon; IRF-1; Stat1; apoptosis; APL	ACUTE PROMYELOCYTIC LEUKEMIA; SIGNALING CROSS-TALK; I-TRANSFORMED-CELLS; TRANS-RETINOIC ACID; PML-RAR-ALPHA; APL CELLS; REGULATORY FACTOR-1; IFN-GAMMA; NB4 CELLS; KAPPA-B	Arsenic trioxide (As2O3) can induce clinical remission in patients with acute promyelocytic leukemia (APL), including those who have relapsed after treatment with all-trans-retinoic acid (RA). In vitro studies with the APL-derived NB4 cell line showed that As2O3 exerts a dose-dependent dual effect, which induces apoptosis at 1 muM, whereas at a lower concentration of 0.1 muM, a partial differentiation of APL is observed. In non-APL cells, interferon (IFN) alpha and 1 muM As2O3 act synergistically to induce apoptosis. In this report, we show that in NB4 cells and in two RA-resistant NB4-derived cell lines, NB4-R1 and NB4-R2, IFNalpha or IFNgamma combined with 0.1 muM As2O3 lead to an increased maturation effect. Moreover, IFNgamma alone is able to differentiate RA-sensitive and -resistant cells with a higher maturation effect on NB4-R2 cells. In contrast, all these cells underwent apoptosis in the presence of the cytokine and a higher concentration of As2O3. IFNgamma boosted As2O3-induced apoptosis in APL cells as tested by TUNEL, Annexin V staining and activation of caspase 3. As2O3 differently altered IFN-induced gene products; it downregulated PML/RARalpha and PML, did not alter PKR and Stat1, and upregulated interferon regulatory family (IRF)-1. Synergism by IFNgamma and arsenic on IRF-1 expression is mediated by a composite element in the IRF-1 promoter that includes an IFNgamma-activation site (GAS) overlapped by a nonconsensus site for nuclear factor kappa B (NFkappaB). Arsenic has no effect on NFkappaB, whereas it enhances the activation of Stat1 by IFNgamma in NB4 cells leading to an increase in IRF-1 expression.	Inst Lwoff, UPR9045, F-94801 Villejuif, France; Hop St Louis, INSERM, U496, F-75010 Paris, France; Publ Hlth Res Inst, Newark, NJ 07103 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Chelbi-alix, MK (corresponding author), Inst Lwoff, UPR9045, 7 Rue Guy Moquet, F-94801 Villejuif, France.			BENOIT, Gerard/0000-0001-9462-6570; Bobe, Pierre/0000-0002-8835-6786				Bazarbachi A, 1999, BLOOD, V93, P278, DOI 10.1182/blood.V93.1.278.401k22_278_283; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Chen GQ, 1997, BLOOD, V89, P3345; Chen Z, 1997, PHARMACOL THERAPEUT, V76, P141, DOI 10.1016/S0163-7258(97)00090-9; DANIEL MT, 1993, BLOOD, V82, P1858; de The H, 2001, ONCOGENE, V20, P7136, DOI 10.1038/sj.onc.1204851; Duprez E, 2000, LEUKEMIA, V14, P255, DOI 10.1038/sj.leu.2401683; Duprez E, 1996, ONCOGENE, V12, P2451; DUPREZ E, 1992, LEUKEMIA, V6, P1281; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; El-Sabban ME, 2000, BLOOD, V96, P2849; Foss GS, 1999, J BIOL CHEM, V274, P35196, DOI 10.1074/jbc.274.49.35196; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; Gil J, 2000, APOPTOSIS, V5, P107, DOI 10.1023/A:1009664109241; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KROGER A, 2002, J INTERFERON CYTOKIN, V1, P5; LANOTTE M, 1991, BLOOD, V77, P1080; MARUYAMA M, 1989, NUCLEIC ACIDS RES, V17, P3292, DOI 10.1093/nar/17.8.3292; MILLER WH, 1995, BLOOD, V85, P3021, DOI 10.1182/blood.V85.11.3021.bloodjournal85113021; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; Pelicano L, 1999, ONCOGENE, V18, P3944, DOI 10.1038/sj.onc.1202802; Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; Percario ZA, 1999, CELL GROWTH DIFFER, V10, P263; Pine R, 1997, NUCLEIC ACIDS RES, V25, P4346, DOI 10.1093/nar/25.21.4346; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; Stadler M, 1995, ONCOGENE, V11, P2565; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; TANIGUCHI T, 1997, BIOCHIM BIOPHYS ACTA, V1333, P9; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Yoshida H, 1996, CANCER RES, V56, P2945; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978; Zhu Q, 2002, BLOOD, V99, P1014	43	20	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2003	22	57					9121	9130		10.1038/sj.onc.1207090	http://dx.doi.org/10.1038/sj.onc.1207090			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14668793				2022-12-17	WOS:000187149100002
J	Berken, A; Abel, J; Unfried, K				Berken, A; Abel, J; Unfried, K			beta 1-integrin mediates asbestos-induced phosphorylation of AKT and ERK1/2 in a rat pleural mesothelial cell line	ONCOGENE			English	Article						asbestos; integrin; mesothelioma; ERK1/2; AKT; FAK	SIGNAL-REGULATED KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; INDUCED CARCINOGENESIS; CROCIDOLITE ASBESTOS; INTEGRINS; FIBRONECTIN; ACTIVATION; PATHWAYS; ADHESION; FAK	Integrin-mediated signalling has been implicated in asbestos-induced carcinogenesis. In studies here, we examined signal transduction events associated with integrin-directed cell reactions triggered by crocidolite asbestos in the pleural mesothelial cell line 4/4 RM-4. Crocidolite fibres induced a significant time- and dose-dependent activation of the extracellular-signal-regulated kinases ERK1 and ERK2. ERK activation was specifically inhibited by integrin-blocking agents, that are integrin-binding peptides containing the sequence arginine-glycine-aspartic acid (RGD), and monoclonal antibodies against the integrin B1-chain. Integrin-dependent activation of ERK1/2 in response to asbestos appeared to be independent of focal adhesion kinase pp125(FAK) (FAK) since FAK autophosphorylation remained unaffected in crocidolite-exposed mesothelial cells. Instead, we observed striking similarities in the kinetics of asbestos-induced ERK1/2 responses and phosphorylation of protein kinase B (AKT) at serine 473, a possible target residue for integrin-linked kinase. As with ERK activation, asbestos-induced AKT stimulation was significantly blocked by both the RGD-peptide and the B1-integrin antibodies. These studies are the first to establish that in mesothelial cells ERK1/2 and AKT are simultaneously phosphorylated upon asbestos exposure in a B1-integrin-dependent manner.	Univ Dusseldorf, Inst Umweltmed Forsch, Dept Toxicol, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Unfried, K (corresponding author), Univ Dusseldorf, Inst Umweltmed Forsch, Dept Toxicol, Hennekamp 50, D-40225 Dusseldorf, Germany.	Klaus.Unfried@uni-duesseldorf.de						Albrecht C, 2002, TOXICOL APPL PHARM, V184, P37, DOI 10.1006/taap.2002.9500; Aplin AE, 1998, PHARMACOL REV, V50, P197; ARONSON JF, 1981, AM J RESP CELL MOL B, V15, P141; BOYLAN AM, 1995, J CLIN INVEST, V96, P1987, DOI 10.1172/JCI118246; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Coffer PJ, 1998, BIOCHEM J, V335, P1; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Jimenez LA, 1997, AM J PHYSIOL-LUNG C, V273, pL1029, DOI 10.1152/ajplung.1997.273.5.L1029; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; KUWAHARA M, 1994, AM J RESP CELL MOL, V10, P167, DOI 10.1165/ajrcmb.10.2.8110473; Lafrenie RM, 1996, J CELL BIOCHEM, V61, P543, DOI 10.1002/(SICI)1097-4644(19960616)61:4<543::AID-JCB7>3.0.CO;2-O; Levy Y, 2003, J BIOL CHEM, V278, P14533, DOI 10.1074/jbc.M207380200; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Liu WH, 2000, AM J RESP CELL MOL, V23, P371, DOI 10.1165/ajrcmb.23.3.4094; Mossman BT, 1998, AM J RESP CRIT CARE, V157, P1666, DOI 10.1164/ajrccm.157.5.9707141; MOSSMAN BT, 1990, SCIENCE, V247, P294, DOI 10.1126/science.2153315; Mossman BT, 1997, ENVIRON HEALTH PERSP, V105, P1121, DOI 10.2307/3433519; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Roller M, 1996, EXP TOXICOL PATHOL, V48, P3, DOI 10.1016/S0940-2993(96)80084-4; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Sandhu H, 2000, INHAL TOXICOL, V12, P337, DOI 10.1080/08958378.2000.11463243; Sandhu H, 2000, CARCINOGENESIS, V21, P1023, DOI 10.1093/carcin/21.5.1023; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Unfried K, 2000, INHAL TOXICOL, V12, P149, DOI 10.1080/08958378.2000.11463208; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Ye JP, 2001, J BIOL CHEM, V276, P5360, DOI 10.1074/jbc.M008814200; Zanella CL, 1996, CANCER RES, V56, P5334; Zanella CL, 1999, AM J PHYSIOL-LUNG C, V277, pL684, DOI 10.1152/ajplung.1999.277.4.L684	30	20	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2003	22	52					8524	8528		10.1038/sj.onc.1207195	http://dx.doi.org/10.1038/sj.onc.1207195			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627993				2022-12-17	WOS:000186650300016
J	McBride', K; Charron, F; Lefebvre, C; Nemer, M				McBride', K; Charron, F; Lefebvre, C; Nemer, M			Interaction with GATA transcription factors provides a mechanism for cell-specific effects of c-Fos	ONCOGENE			English	Article						c-Fos; GATA factors; AP-1; transcription	GENE-EXPRESSION; COOPERATIVE INTERACTION; CARDIAC TRANSCRIPTION; LEUKEMIA GENE; DOCKING SITES; MICE LACKING; JUN; ACTIVATION; PROTEINS; RECEPTOR	c-Fos is a multifunctional transcription factor that is involved in cellular proliferation, differentiation and apoptosis. c-Fos is rapidly induced by a variety of hormones, growth factors and other extracellular stimuli, resulting in cell-specific responses. One potential mechanism underlying the cell-specific effects of c-Fos may be its ability to regulate gene expression through interaction with tissue-restricted transcription factors. We report here that c-Fos interacts with the cell-specific GATA proteins to potentiate their ability to transactivate target promoters, via GATA-binding sites. c-Fos is recruited to GATA proteins through direct interaction with their N-terminal activation domain. Neither the leucine zipper nor the DNA-binding domain of c-Fos is required for physical interaction with GATA proteins. Instead, a C-terminal domain located between amino acids 235 and 296, which is conserved in FosB but not in the nontransforming Fos family members, FosB/SF or Fra-1, is essential for c-Fos-GATA interaction. These data suggest that c-Fos may act as an inducible cofactor for cell-specific transcription factors and unravel a novel mechanism for transcriptional regulation by c-Fos, independent of the well-studied AP-1 pathway. The results also raise the possibility that dysregulated interaction with cell-specific transcription factors may be an important component in cellular transformation by nuclear oncogenes.	Inst Rech Clin Montreal, Lab Dev & Differenciat Cardiaques, Montreal, PQ H2W 1R7, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University	Nemer, M (corresponding author), Inst Rech Clin Montreal, Lab Dev & Differenciat Cardiaques, 110 Ave Pins Ouest, Montreal, PQ H2W 1R7, Canada.		Charron, Frederic/O-8017-2019	Charron, Frederic/0000-0003-3483-8672				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bhalla SS, 2001, J BIOL CHEM, V276, P11439, DOI 10.1074/jbc.M100208200; Bockamp EO, 1998, J BIOL CHEM, V273, P29032, DOI 10.1074/jbc.273.44.29032; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; Charron F, 1999, MOL CELL BIOL, V19, P4355; Charron F, 2001, GENE DEV, V15, P2702, DOI 10.1101/gad.915701; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Ciapponi L, 2001, GENE DEV, V15, P1540, DOI 10.1101/gad.886301; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; Depre C, 1998, NAT MED, V4, P1269, DOI 10.1038/3253; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Fox AH, 1998, J BIOL CHEM, V273, P33595, DOI 10.1074/jbc.273.50.33595; Gottgens B, 2002, GENOME RES, V12, P749, DOI 10.1101/gr.45502; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; Karin M, 2001, J ENDOCRINOL, V169, P447, DOI 10.1677/joe.0.1690447; Kataoka K, 1996, ONCOGENE, V12, P53; KAWANA M, 1995, MOL CELL BIOL, V15, P4225; Kuo CT, 1999, ANNU REV IMMUNOL, V17, P149, DOI 10.1146/annurev.immunol.17.1.149; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; Liang QR, 2001, J BIOL CHEM, V276, P30245, DOI 10.1074/jbc.M102174200; Lim KC, 2000, NAT GENET, V25, P209, DOI 10.1038/76080; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; Lowry JA, 2000, J MOL EVOL, V50, P103, DOI 10.1007/s002399910012; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; McBride K, 2001, CAN J PHYSIOL PHARM, V79, P673, DOI 10.1139/cjpp-79-8-673; McBride K, 1998, MOL CELL BIOL, V18, P5073, DOI 10.1128/MCB.18.9.5073; Miyamoto T, 2001, BLOOD, V98, P2544, DOI 10.1182/blood.V98.8.2544; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Morin S, 2001, MOL CELL BIOL, V21, P1036, DOI 10.1128/MCB.21.4.1036-1044.2001; Nemer G, 2003, DEV BIOL, V254, P131, DOI 10.1016/S0012-1606(02)00026-X; Nemer G, 1999, MAMM GENOME, V10, P993, DOI 10.1007/s003359901146; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PANDEY KN, 1986, BIOCHEM BIOPH RES CO, V138, P399, DOI 10.1016/0006-291X(86)90295-0; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Wenzel A, 2002, J NEUROCHEM, V80, P1089, DOI 10.1046/j.0022-3042.2002.00807.x; WISDOM R, 1992, GENE DEV, V6, P667, DOI 10.1101/gad.6.4.667; YAMAGATA T, 1995, MOL CELL BIOL, V15, P3830; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	58	20	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8403	8412		10.1038/sj.onc.1206877	http://dx.doi.org/10.1038/sj.onc.1206877			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627981				2022-12-17	WOS:000186650300004
J	Motti, ML; Boccia, A; Belletti, B; Bruni, P; Troncone, G; Cito, L; Monaco, M; Chiappetta, G; Baldassarre, G; Palombini, L; Fusco, A; Viglietto, G				Motti, ML; Boccia, A; Belletti, B; Bruni, P; Troncone, G; Cito, L; Monaco, M; Chiappetta, G; Baldassarre, G; Palombini, L; Fusco, A; Viglietto, G			Critical role of cyclin D3 in TSH-dependent growth of thyrocytes and in hyperproliferative diseases of the thyroid gland	ONCOGENE			English	Article						cyclin D3; thyroid; TSH; p27(kip1)	CELL-CYCLE; FRTL-5 CELLS; IN-VITRO; CULTURED THYROCYTES; RAT; EXPRESSION; THYROTROPIN; PROLIFERATION; RECEPTOR; STIMULATION	We report that cyclin D3 is rate limiting for G1 progression in thyroid follicular cells and that its constitutive upregulation by chronic stimulation of the TSH/cAMP pathway plays a role in human and experimental hyperproliferative diseases of the thyroid gland. These conclusions are supported by in vitro and in vivo studies. In rat thyrocytes (PC Cl 3 cells), cyclin D3 expression is enhanced in response to activation of the TSH/cAMP pathway. Interference with the expression of G1 cyclins (in particular cyclin D3) by the antisense methodology strongly reduced TSH-dependent proliferation of PC Cl 3 cells, indicating that proper progression through G1 requires cyclin D3. Accordingly, PC Cl 3 cells engineered to overexpress cyclin D3 (PC- D3 cells) show enhanced growth rate and elude hormone-dependence and contact inhibition. Using an animal experimental model of thyroid stimulation, we demonstrate that cyclin D3 is a key mediator of TSH-dependent proliferation of thyroid follicular cells also in vivo. Cyclin D3 protein levels were higher in the thyrocytes from glands of propylthiouracil-treated rats compared with control animals. The increase in cyclin D3 expression occurred after the propylthiouracil-induced increase in TSH levels and preceded the burst of cell proliferation. Finally, we found that cyclin D3 protein is expressed in a fraction of human goiters but it is strongly overexpressed in most follicular adenomas.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Ist Nazl Tumori, Serv Oncol Sperimentale E, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Sci Morfol & Funz, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; University of Naples Federico II; University of Naples Federico II	Viglietto, G (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, CNR, Ist Endocrinol & Oncol Sperimentale, Via S Pansini 5, I-80131 Naples, Italy.	viglietto@sun.ceos.na.cnr.it	Belletti, Barbara/J-2028-2018; Baldassarre, Gustavo/K-1350-2016; Viglietto, Giuseppe/AAC-2852-2019	Belletti, Barbara/0000-0003-2249-0285; Baldassarre, Gustavo/0000-0002-9750-8825; Viglietto, Giuseppe/0000-0003-2327-7515; Fusco, Alfredo/0000-0003-3332-5197				Baldassarre G, 1999, J CLIN INVEST, V104, P865, DOI 10.1172/JCI6443; BERLINGIERI MT, 1990, BIOCHEM BIOPH RES CO, V173, P172, DOI 10.1016/S0006-291X(05)81037-X; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Carneiro C, 1998, ONCOGENE, V16, P1455, DOI 10.1038/sj.onc.1201662; Coppee F, 1998, ONCOGENE, V17, P631, DOI 10.1038/sj.onc.1201966; Corvilain B, 2001, CLIN ENDOCRINOL, V55, P143, DOI 10.1046/j.1365-2265.2001.01365.x; Davies T, 2002, J CLIN INVEST, V110, P161, DOI 10.1172/JCI200216234; Depoortere F, 1998, J CELL BIOL, V140, P1427, DOI 10.1083/jcb.140.6.1427; Dremier S, 2002, ANN NY ACAD SCI, V968, P106, DOI 10.1111/j.1749-6632.2002.tb04330.x; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Florio T, 2001, MOL ENDOCRINOL, V15, P1838, DOI 10.1210/me.15.10.1838; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; HEDINGER C, 1993, INT HISTOLOGICAL CLA; Henzinger T, 1998, J BIOL CHEM, V273, P14958, DOI 10.1074/jbc.273.24.14958; Kimura T, 1999, EUR J ENDOCRINOL, V140, P94, DOI 10.1530/eje.0.1400094; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; Medina DL, 2000, EUR J ENDOCRINOL, V143, P161, DOI 10.1530/eje.0.1430161; Medina DL, 1999, ENDOCRINOLOGY, V140, P87, DOI 10.1210/en.140.1.87; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Pedrinola F, 2001, THYROID, V11, P15, DOI 10.1089/10507250150500612; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; ROGNONI JB, 1984, ACTA ENDOCRINOL-COP, V105, P40, DOI 10.1530/acta.0.1050040; Saiz AD, 2002, J PATHOL, V198, P157, DOI 10.1002/path.1185; SATO K, 1995, J CLIN INVEST, V96, P1295, DOI 10.1172/JCI118164; Shaughnessy J, 2001, BLOOD, V98, P217, DOI 10.1182/blood.V98.1.217; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SMEDS S, 1983, LAB INVEST, V48, P285; Sonoki T, 2001, BLOOD, V98, P2837, DOI 10.1182/blood.V98.9.2837; Viglietto G, 1999, EUR J ENDOCRINOL, V140, P597, DOI 10.1530/eje.0.1400597; Viglietto G, 1997, ONCOGENE, V15, P2687, DOI 10.1038/sj.onc.1201456; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILSON JD, 1989, THYROID TXB ENDOCRIN; WOLLMAN SH, 1978, ENDOCRINOLOGY, V103, P2306, DOI 10.1210/endo-103-6-2306; WYNFORDTHOMAS D, 1982, J ENDOCRINOL, V94, P131, DOI 10.1677/joe.0.0940131; Yamamoto K, 1996, ENDOCRINOLOGY, V137, P2036, DOI 10.1210/en.137.5.2036	37	20	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2003	22	48					7576	7586		10.1038/sj.onc.1207055	http://dx.doi.org/10.1038/sj.onc.1207055			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576819				2022-12-17	WOS:000186113000004
J	Xie, YT; Tornkvist, M; Aalto, Y; Nilsson, G; Girnita, L; Nagy, B; Knuutila, S; Larsson, O				Xie, YT; Tornkvist, M; Aalto, Y; Nilsson, G; Girnita, L; Nagy, B; Knuutila, S; Larsson, O			Gene expression profile by blocking the SYT-SSX fusion gene in synovial sarcoma cells. Identification of XRCC4 as a putative SYT-SSX target gene	ONCOGENE			English	Article						microarray; antisense; SYT-SSX; synovial sarcoma	TRANSLOCATION; SYT-SSX1; PROTEINS; REPAIR; CANCER; D1	Increasing evidence suggests that the SYT-SSX fusion gene plays an important role in synovial sarcoma development and progression. However, very little is known about the downstream targets of SYT-SSX. In this study, we used antisense oligonucleotides to block the expression of the SYT-SSX fusion gene in synovial sarcoma cells. By comparing SYT-SSX inhibited cells with noninhibited cells, the gene expression pro. le was analysed using cDNA microarray and established by real-time PCR. Herewith, using a filter containing 1176 cancer-relevant genes, we found that the DNA repair gene XRCC4 and the DNA mismatch repair gene MSH2 were downregulated, whereas the gene encoding for the serine/threonine protein kinase PRK (also known as CNK), and the macrophage inhibitory cytokine MICI ( also known as PLAB) were upregulated after the inhibition of SYT-SSX. In comparison, expression of the XRCC4 gene was undergoing the strongest alteration. Consistently, the protein expression of XRCC4 was found to be decreased after SYT-SSX inhibition, whereas there were no detectable changes for the other gene products. Our study provides some clues to elucidate the signaling pathways of the SYT-SSX fusion gene, as well as it demonstrates a valuable model system for search for other SYT-SSX targets.	Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland; Karolinska Hosp, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden; Peking Univ, Sch Oncol, Beijing Canc Hosp, Dept Surg, Beijing, Peoples R China; Karolinska Hosp, Dept Orthoped, SE-17176 Stockholm, Sweden	University of Helsinki; Helsinki University Central Hospital; Karolinska Institutet; Karolinska University Hospital; Peking University; Karolinska Institutet; Karolinska University Hospital	Larsson, O (corresponding author), Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland.		Nagy, Balint/F-6943-2012; Girnita, Leonard/A-4168-2008	Girnita, Leonard/0000-0003-0280-9500				Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; DELEEUW B, 1995, HUM MOL GENET, V4, P1097; dos Santos NR, 2001, GENE CHROMOSOME CANC, V30, P1, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Inagaki H, 2000, MODERN PATHOL, V13, P482, DOI 10.1038/modpathol.3880083; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Ladanyi M, 2001, ONCOGENE, V20, P5755, DOI 10.1038/sj.onc.1204601; Myers KJ, 2000, TRENDS PHARMACOL SCI, V21, P19, DOI 10.1016/S0165-6147(99)01420-0; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Nilsson G, 1999, CANCER RES, V59, P3180; Roth DB, 2000, NATURE, V404, P823, DOI 10.1038/35009180; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; Xie YT, 2002, ONCOGENE, V21, P5791, DOI 10.1038/sj.onc.1205700; Xie YT, 2002, CANCER RES, V62, P3861	19	20	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 23	2003	22	48					7628	7631		10.1038/sj.onc.1207153	http://dx.doi.org/10.1038/sj.onc.1207153			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576825				2022-12-17	WOS:000186113000010
J	Denizot, Y; Gainant, A; Guglielmi, L; Bouvier, S; Cubertafond, P; Mathonnet, M				Denizot, Y; Gainant, A; Guglielmi, L; Bouvier, S; Cubertafond, P; Mathonnet, M			Tissue concentrations of platelet-activating factor in colorectal carcinoma: inverse relationships with Dukes' stage of patients	ONCOGENE			English	Article						acetylhydrolase activity; colorectal carcinoma; phospholipase A2; platelet-activating factor; receptor	HUMAN BREAST-CANCER; FACTOR ACETYLHYDROLASE; FACTOR RECEPTOR; TUMOR-CELLS; FACTOR PAF; EXPRESSION; PROLIFERATION; ANGIOGENESIS; METABOLISM; PROTEIN	The lipid mediator platelet-activating factor (PAF) plays a role in cancer. We investigated its presence in human colon carcinoma by assessing the levels of tissue phospholipase A(2) (PLA(2), the key enzyme in the generation of the lyso-PAF precursor), lyso-PAF, PAF and acetylhydrolase activity (AHA, the key enzyme in PAF degradation) in colorectal cancer patients and by correlating them with Dukes' classification. The results highlighted that the tumour tissues of Dukes' A and B patients had significantly higher PLA(2), lyso-PAF, PAF and AHA levels as compared with nontumour tissues. Dukes' C patients had higher PLA(2), lyso-PAF and AHA levels but unchanged PAF. Dukes' D patients had higher AHA levels but unchanged PLA(2), lyso-PAF and PAF. A pathophysiological role for PAF is suggested in human colon carcinoma.	Fac Med Limoges, CNRS, UMR 6101, Immunol Lab, F-87025 Limoges, France; Serv Chirurg Digest Endocrinienne & Gen, F-87042 Limoges, France	Centre National de la Recherche Scientifique (CNRS)	Denizot, Y (corresponding author), Fac Med Limoges, CNRS, UMR 6101, Immunol Lab, 2 Rue Dr Marcland, F-87025 Limoges, France.		Mathonnet, Muriel/ABD-3021-2020; Denizot, Yves/H-9769-2016	Mathonnet, Muriel/0000-0002-9127-3068; 				Bussolati B, 2000, AM J PATHOL, V157, P1713, DOI 10.1016/S0002-9440(10)64808-0; CAPASSO F, 1991, DRUG EXP CLIN RES, V17, P351; Chaux P, 1996, LAB INVEST, V74, P975; DENIZOT Y, 1997, HDB EXPT PHARM PLATE, P483; Dueck DA, 1996, MOL CELL BIOCHEM, V162, P97; Dupuis F, 1997, BBA-MOL CELL RES, V1359, P241, DOI 10.1016/S0167-4889(97)00106-7; Ellis L M, 2000, Oncologist, V5 Suppl 1, P11; Fallani A, 2002, PROSTAG OTH LIPID M, V70, P209, DOI 10.1016/S0090-6980(02)00109-0; HENDRICKSE CW, 1995, BRIT J SURG, V82, P475, DOI 10.1002/bjs.1800820415; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; Kald B, 1996, DIGESTION, V57, P472, DOI 10.1159/000201376; Kennedy BP, 1998, CANCER RES, V58, P500; Ko HM, 2002, CANCER RES, V62, P1809; MAGGI M, 1994, CANCER RES, V54, P4777; Mannori G, 2000, CLIN EXP METASTAS, V18, P89, DOI 10.1023/A:1026548700247; Montrucchio G, 1998, AM J PATHOL, V153, P1589, DOI 10.1016/S0002-9440(10)65747-1; Ono T, 2000, AM J GASTROENTEROL, V95, P1062; Shetye J, 1998, CLIN CANCER RES, V4, P1921; Sirois MG, 1997, AM J PHYSIOL-HEART C, V272, pH2746, DOI 10.1152/ajpheart.1997.272.6.H2746; Stafforini DM, 1996, BBA-LIPID LIPID MET, V1301, P161, DOI 10.1016/0005-2760(96)00040-9; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; TRIPATHI YB, 1991, LIFE SCI, V49, P1761, DOI 10.1016/0024-3205(91)90319-7; Wang HM, 2003, ONCOGENE, V22, P2186, DOI 10.1038/sj.onc.1206348; Youlyouz I, 2002, MEDIAT INFLAMM, V11, P329, DOI 10.1080/09629350210000015755	24	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 16	2003	22	46					7222	7224		10.1038/sj.onc.1207032	http://dx.doi.org/10.1038/sj.onc.1207032			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562051				2022-12-17	WOS:000185955000014
J	Schavinsky-Khrapunsky, Y; Huleihel, M; Aboud, M; Torgeman, A				Schavinsky-Khrapunsky, Y; Huleihel, M; Aboud, M; Torgeman, A			Role of protein kinase C and the Sp1-p53 complex in activation of p21(WAF-1) expression by 12-O-tetradecanoylphorbol-13-acetate in human T cells	ONCOGENE			English	Article						p21(WAF-1); TPA; PKC; Sp1-p53 complex	LONG TERMINAL REPEAT; VIRUS TYPE-I; TRANSCRIPTION FACTOR SP1; CYCLIN-DEPENDENT KINASES; GROWTH-FACTOR-BETA; INHIBITOR P21(WAF1/CIP1); CARCINOMA CELLS; DNA-REPLICATION; FAMILY-MEMBERS; CDK INHIBITORS	Previous reports have shown that, in certain cell types, p21(WAF-1), which plays a central role in cell proliferation, can be activated by HTLV-I Tax protein and by TPA. Tax and TPA are also known to stimulate HTLV-I gene expression. Since cell proliferation has a major impact on HTLV-I replication, it was of interest to investigate their effect on p21(WAF-1) in human T cells, which are the main target of HTLV-I in human infection. This study demonstrates that p21(WAF-1) is activated in such cells by both factors, each acting through a different mechanism that does not influence the other. The effect of TPA is shown to require PKC activity. Notably, however, examination of different PKC isoforms revealed that PKC-alpha: and PKC-epsilon stimulated p21(WAF-1) expression, whereas PKC-eta was rather inhibitory and PKC-beta1 and beta2 were ineffective. All these isoforms were found to be activated by TPA in the employed T cells, but this apparent paradox was resolved by the observation that when coexpressed together in these cells, the stimulatory PKCs override the inhibitory isoform. Further experiments demonstrated that the PKC-induced p21(WAF-1) activation was mediated by binding of Sp1-p53 complex to the second most upstream of the six Sp1 recognition sites present in its promoter and that this effect did not require the cooperation of an p53-binding site.	Ben Gurion Univ Negev, Fac Hlth Sci, Dept Microbiol & Immunol, Canc Res Ctr, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Inst Appl Biosci, IL-84105 Beer Sheva, Israel	Ben Gurion University; Ben Gurion University	Aboud, M (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Microbiol & Immunol, Canc Res Ctr, IL-84105 Beer Sheva, Israel.	aboud@bgumail.bgu.ac.il	HULEIHEL, MAHMOUD/F-1837-2012					Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Biggs JR, 1999, J BIOL CHEM, V274, P36987, DOI 10.1074/jbc.274.52.36987; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Billon N, 1996, ONCOGENE, V13, P2047; Blatt NB, 2001, BIOORGAN MED CHEM, V9, P1371, DOI 10.1016/S0968-0896(01)00041-4; Boulaire J, 2000, PATHOL BIOL, V48, P190; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; Decker SJ, 1995, J BIOL CHEM, V270, P30841, DOI 10.1074/jbc.270.52.30841; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; ELDAR H, 1990, J BIOL CHEM, V265, P13290; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; GITLIN SD, 1991, J VIROL, V65, P2612, DOI 10.1128/JVI.65.5.2612-2621.1991; Gorospe M, 1999, GENE EXPRESSION, V7, P377; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; GUALBERTO A, 1995, MOL CELL BIOL, V15, P3450; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hingorani R, 2000, J IMMUNOL, V164, P4032, DOI 10.4049/jimmunol.164.8.4032; Hobeika AC, 1997, ONCOGENE, V14, P1165, DOI 10.1038/sj.onc.1200939; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Isonishi S, 2000, BRIT J CANCER, V82, P34, DOI 10.1054/bjoc.1999.0873; Jin YH, 2000, J BIOL CHEM, V275, P30256, DOI 10.1074/jbc.M001902200; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; Koutsodontis G, 2002, BIOCHEMISTRY-US, V41, P12771, DOI 10.1021/bi026141q; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Livneh E, 1996, ONCOGENE, V12, P1545; Lu S, 2000, MOL ENDOCRINOL, V14, P753, DOI 10.1210/me.14.5.753; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MorVaknin N, 1997, VIROLOGY, V232, P337, DOI 10.1006/viro.1997.8566; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; NAMBA H, 1995, CANCER RES, V55, P2075; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Revazova T, 1995, CELL MOL BIOL RES, V41, P377; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Torgeman A, 2001, VIROLOGY, V281, P10, DOI 10.1006/viro.2000.0779; Torgeman A, 2001, EXP CELL RES, V271, P169, DOI 10.1006/excr.2001.5363; Torgeman A, 1999, VIROLOGY, V254, P279, DOI 10.1006/viro.1998.9556; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; YANG S, 2003, TRENDS GENET, V19, P9; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zezula J, 1997, J BIOL CHEM, V272, P29967, DOI 10.1074/jbc.272.47.29967; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	58	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5315	5324		10.1038/sj.onc.1206782	http://dx.doi.org/10.1038/sj.onc.1206782			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917633	Bronze			2022-12-17	WOS:000184734900011
J	Stroh, C; Held, E; Samraj, AK; Schulze-Osthoff, K				Stroh, C; Held, E; Samraj, AK; Schulze-Osthoff, K			Specific inhibition of transcription factor NF-kappa B through intracellular protein delivery of I kappa B alpha by the Herpes virus protein VP22	ONCOGENE			English	Article						NF-kappa B; I kappa B alpha; VP22; protein transduction	BIOLOGICALLY-ACTIVE PROTEINS; GENE-THERAPY; TRANSDUCTION; ACTIVATION; CELLS; EXPRESSION; VIVO; PEPTIDE; TRAFFICKING; DISTINCT	In many cancers, a high constitutive activation of transcription factor NF-kappaB has been implicated in tumor progression and apoptosis resistance, making NF-kappaB an attractive target for cancer therapy. Here, we describe the specific inhibition of NF-kappaB by the intracellular delivery of IkappaBalpha through VP22-mediated protein transduction. The Herpes virus protein VP22 has attracted great attention in gene therapy, because of its ability to migrate from an original expressing cell into surrounding recipient cells, resulting in high levels of protein transduction. To evaluate the use of VP22 as a vehicle for NF-kappaB inhibition, we expressed several versions of VP22-IkappaBalpha fusion proteins in baculovirus, bacteria, and mammalian cells. While we could not detect transcellular migration of different VP22-IkappaBalpha constructs, interestingly, baculovirally expressed VP22-IkappaBalpha was efficiently delivered into cells after exogenous administration. The purified and imported VP22-IkappaBalpha retained its function and efficiently inhibited both constitutive and inducible NF-kappaB activation. We further show that the 34 C-terminal amino acids of VP22 were sufficient for the import property, suggesting also that the ability of intercellular migration and cellular import are not linked to each other. Together, our results demonstrate that recombinant VP22 acts as an efficient vehicle for the exogenous delivery of IkappaBalpha and, moreover, might find applications to block NF-kappaB activation specifically.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany; Univ Munster, Dept Immunol & Cell Biol, D-4400 Munster, Germany	Heinrich Heine University Dusseldorf; University of Munster	Schulze-Osthoff, K (corresponding author), Univ Dusseldorf, Inst Mol Med, Univ Str 1, D-40225 Dusseldorf, Germany.		Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Held, Jurgen/0000-0003-1130-9727				Aradhya S, 2001, CURR OPIN GENET DEV, V11, P300, DOI 10.1016/S0959-437X(00)00194-5; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218; Ferrari D, 1999, J BIOL CHEM, V274, P13205, DOI 10.1074/jbc.274.19.13205; Ford KG, 2001, GENE THER, V8, P1, DOI 10.1038/sj.gt.3301383; Fujihara SM, 2000, J IMMUNOL, V165, P1004, DOI 10.4049/jimmunol.165.2.1004; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; GOEBELER M, 1995, J IMMUNOL, V155, P2459; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Kabouridis PS, 2002, J IMMUNOL, V169, P2587, DOI 10.4049/jimmunol.169.5.2587; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kueltzo LA, 2000, J BIOL CHEM, V275, P33213, DOI 10.1074/jbc.M002476200; Makarov SS, 2000, MOL MED TODAY, V6, P441, DOI 10.1016/S1357-4310(00)01814-1; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Normand N, 2001, J BIOL CHEM, V276, P15042, DOI 10.1074/jbc.M010294200; Phelan A, 1998, NAT BIOTECHNOL, V16, P440, DOI 10.1038/nbt0598-440; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; Swinney DC, 2002, J BIOL CHEM, V277, P23573, DOI 10.1074/jbc.M200842200; Tomita T, 1999, ARTHRITIS RHEUM, V42, P2532, DOI 10.1002/1529-0131(199912)42:12<2532::AID-ANR5>3.0.CO;2-2; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Wills KN, 2001, J VIROL, V75, P8733, DOI 10.1128/JVI.75.18.8733-8741.2001; Wybranietz WA, 2001, GENE THER, V8, P1654, DOI 10.1038/sj.gt.3301564; Wybranietz WA, 1999, J GENE MED, V1, P265; Zender L, 2002, GASTROENTEROLOGY, V123, P608, DOI 10.1053/gast.2002.34756; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174	32	20	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2003	22	34					5367	5373		10.1038/sj.onc.1206544	http://dx.doi.org/10.1038/sj.onc.1206544			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917639				2022-12-17	WOS:000184734900017
J	Huang, S; Qu, LK; Cuddihy, AR; Ragheb, R; Taya, Y; Koromilas, AE				Huang, S; Qu, LK; Cuddihy, AR; Ragheb, R; Taya, Y; Koromilas, AE			Protein kinase inhibitor 2-aminopurine overrides multiple genotoxic stress-induced cellular pathways to promote cell survival	ONCOGENE			English	Article						2-aminopurine; p53; DNA damage; protein phosphorylation; cell cycle control; apoptosis	DOUBLE-STRANDED-RNA; DAMAGE-INDUCED PHOSPHORYLATION; NECROSIS-FACTOR-ALPHA; DNA-DAMAGE; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL ACTIVATION; ENHANCED PHOSPHORYLATION; P53; CHECKPOINT; ATR	2-Aminopurine (2-AP) is an adenine analog shown to cause cells to bypass chemical- and radiation-induced cell cycle arrest through as-yet unidentified mechanisms. 2-AP has also been shown to act as a kinase inhibitor. Tumor suppressor p53 plays an important role in the control of cell cycle and apoptosis in response to genotoxic stress. We were interested in examining the effect of 2-AP on p53 phosphorylation and its possible consequences on checkpoint control in cells subjected to various forms of DNA damage. Here, we show that 2-AP suppresses p53 phosphorylation in response to gamma radiation, adriamycin, or ultraviolet treatment. This is partly explained by the ability of the kinase inhibitor to inhibit ATM or ATR activities in vitro and impair ATM- or ATR-dependent p53 phosphorylation in vivo. However, 2-AP is also capable of inhibiting p53 phosphorylation in cells deficient in ATM, DNA-PK, or ATR suggesting the existence of multiple pathways by which this kinase inhibitor modulates p53 activation. Biologically, the 2AP-mediated inhibition of p53 stabilization enables wildtype p53-containing cells to bypass adriamycin-induced G(2)/M arrest. In the long term, however, 2-AP facilitates cells to resist DNA damage-induced cell death independently, of p53.	McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2T5, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Oncol & Med, Montreal, PQ H3A 2T5, Canada; Natl Inst Canc Res, Div Radiobiol, Chuo Ku, Tokyo 1040045, Japan; McGill Univ, Dept Cell Biol & Anat, Montreal, PQ H3A 2T5, Canada	McGill University; Lady Davis Institute; McGill University; McGill University; National Cancer Center - Japan; McGill University	Koromilas, AE (corresponding author), McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2T5, Canada.	antonis.koromilas@mcgill.ca		Cuddihy, Andrew/0000-0002-9898-0443				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; ANDREASSEN PR, 1992, P NATL ACAD SCI USA, V89, P2272, DOI 10.1073/pnas.89.6.2272; Araki R, 1999, CANCER RES, V59, P3543; Baltzis D, 2002, J BIOL CHEM, V277, P38364, DOI 10.1074/jbc.M203564200; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Ben-Asouli Y, 2002, CELL, V108, P221, DOI 10.1016/S0092-8674(02)00616-5; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Brown EJ, 2000, GENE DEV, V14, P397; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carrier F, 1998, BIOCHEM PHARMACOL, V55, P853, DOI 10.1016/S0006-2952(97)00592-3; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Chehab NH, 2000, GENE DEV, V14, P278; Cheshire JL, 1999, J BIOL CHEM, V274, P4801, DOI 10.1074/jbc.274.8.4801; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Deng J, 2002, CURR BIOL, V12, P1279, DOI 10.1016/S0960-9822(02)01037-0; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; HU YH, 1993, J INTERFERON RES, V13, P323, DOI 10.1089/jir.1993.13.323; Jarrous N, 1996, MOL CELL BIOL, V16, P2814; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Nghiem P, 2002, J BIOL CHEM, V277, P4428, DOI 10.1074/jbc.M106113200; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Osman F, 1999, GENE DEV, V13, P3280, DOI 10.1101/gad.13.24.3280; PALAYOOR ST, 1995, RADIAT RES, V141, P235, DOI 10.2307/3579000; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WATHELET MG, 1989, EUR J BIOCHEM, V184, P503, DOI 10.1111/j.1432-1033.1989.tb15043.x; Wu SY, 2002, J BIOL CHEM, V277, P18077, DOI 10.1074/jbc.M110164200; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	52	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2003	22	24					3721	3733		10.1038/sj.onc.1206490	http://dx.doi.org/10.1038/sj.onc.1206490			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802279				2022-12-17	WOS:000183551000006
J	Kovar, H; Pospisilova, S; Jug, G; Printz, D; Gadner, H				Kovar, H; Pospisilova, S; Jug, G; Printz, D; Gadner, H			Response of Ewing tumor cells to forced and activated p53 expression	ONCOGENE			English	Article						Ewing's sarcoma; apoptosis; p53; EWS-FLI1; irradiation	P53-DEPENDENT GROWTH ARREST; WILD-TYPE P53; PROGNOSTIC IMPACT; DNA-DAMAGE; P53-MEDIATED APOPTOSIS; ANTICANCER AGENTS; ADENOVIRUS E1A; PROTEIN-KINASE; CYCLE ARREST; C-MYC	The EWS-FLI1 transcription factor is consistently expressed in 85% of Ewing tumors (EFT). In heterologous cells, EWS-FLI1 induces p53-dependent cell cycle arrest or apoptosis. It has been speculated that the p53 tumor suppressor pathway may be generally compromised in EFT despite only rare p53 mutations. In order to test for functional integrity of this pathway, we have investigated a series of EFT cell lines that differ from each other with respect to their endogenous p53 and INK4A gene status for their response to ectopic p53 expression and to stimulation of endogenous p53 activity by X-ray treatment. Significant interindividual and intratumoral variations in the apoptotic propensity of EFT cell lines to transient expression of ectopic p53 were observed, which was independent of the level of p53 expression. In cell lines with a low apoptotic incidence, apoptosis was delayed and the surviving fraction showed a prolonged growth arrest. Complete resistance to p53-induced apoptosis in two cell lines established from the same patient was associated with a high BCL2/BAX ratio and low levels of APAF1. Sensitivity to X-rays showed a trend towards a higher apoptotic rate in wild-type (wt) p53 expressing than in p53 mutant cells. However, one wt p53-expressing EFT cell line was completely refractory to irradiation-stimulated cell death despite high apoptotic responsiveness to ectopic p53. No difference in Ser15 phosphorylation and the transcriptional activation of p53 targets was observed in wt p53 EFT cell lines irrespective of the induction of cell death or growth arrest. All together, our results demonstrate that despite significant variability in the outcome, cell death or cell cycle arrest, the p53 downstream pathway and the DNA damage signaling pathway are functionally intact in EFT.	St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria	Saint Anna Children's Hospital	Kovar, H (corresponding author), St Anna Childrens Hosp, Childrens Canc Res Inst, Kinderspitalgasse 6, A-1090 Vienna, Austria.		Pospisilova, Sarka/D-7200-2012	Pospisilova, Sarka/0000-0001-7136-2680; Kovar, Heinrich/0000-0001-6873-9109				Beltinger CP, 1996, GENOMICS, V35, P94, DOI 10.1006/geno.1996.0327; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; de Alava E, 2000, CANCER-AM CANCER SOC, V89, P783, DOI 10.1002/1097-0142(20000815)89:4<783::AID-CNCR10>3.0.CO;2-Q; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; Deneen B, 2001, ONCOGENE, V20, P6731, DOI 10.1038/sj.onc.1204875; Di Como CJ, 1998, ONCOGENE, V16, P2527; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Gorgoulis VG, 1998, BRIT J CANCER, V77, P374, DOI 10.1038/bjc.1998.60; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Grenet J, 1998, GENOMICS, V49, P385, DOI 10.1006/geno.1998.5300; Guimaraes DP, 2002, BIOCHIMIE, V84, P83, DOI 10.1016/S0300-9084(01)01356-6; Hadano S, 1999, MAMM GENOME, V10, P757; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; HAMELIN R, 1994, INT J CANCER, V57, P336, DOI 10.1002/ijc.2910570308; Hattinger CM, 1999, GENE CHROMOSOME CANC, V24, P243, DOI 10.1002/(SICI)1098-2264(199903)24:3<243::AID-GCC10>3.0.CO;2-A; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, ONCOGENE, V10, P1563; HERMEKING H, 1995, ONCOGENE, V11, P1409; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Kovar H, 1997, ONCOGENE, V15, P2225, DOI 10.1038/sj.onc.1201397; KOVAR H, 1993, ONCOGENE, V8, P2683; Kovar H, 2000, CANCER RES, V60, P1557; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Kovar H, 2000, ONCOGENE, V19, P4096, DOI 10.1038/sj.onc.1203780; Kovar Heinrich, 1998, Current Opinion in Oncology, V10, P334, DOI 10.1097/00001622-199807000-00010; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LADANYI M, 1995, J PATHOL, V175, P211, DOI 10.1002/path.1711750209; Lahti J M, 1995, Prog Cell Cycle Res, V1, P329; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MCKEON C, 1988, CANCER RES, V48, P4307; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; OConnor PM, 1997, CANCER RES, V57, P4285; OUCHIDA M, 1995, ONCOGENE, V11, P1049; PARK DJ, 1994, ONCOGENE, V9, P1899; Pietenpol JA, 1996, P NATL ACAD SCI USA, V93, P8390, DOI 10.1073/pnas.93.16.8390; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RENZING J, 1995, ONCOGENE, V10, P1865; Sanchez-Prieto R, 1999, NAT MED, V5, P1076, DOI 10.1038/12516; Sollazzo MR, 1999, TUMORI, V85, P167, DOI 10.1177/030089169908500304; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Toretsky JA, 1997, J NEURO-ONCOL, V31, P9, DOI 10.1023/A:1005716926800; VECCHIO G, 1989, ONCOGENE, V4, P897; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wei G, 2000, CANCER-AM CANCER SOC, V89, P793, DOI 10.1002/1097-0142(20000815)89:4<793::AID-CNCR11>3.0.CO;2-M; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yonish-Rouach E, 1994, Cell Death Differ, V1, P39; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x; Zucman-Rossi J, 1998, P NATL ACAD SCI USA, V95, P11786, DOI 10.1073/pnas.95.20.11786	57	20	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 22	2003	22	21					3193	3204		10.1038/sj.onc.1206391	http://dx.doi.org/10.1038/sj.onc.1206391			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761489				2022-12-17	WOS:000183040000001
J	Andreozzi, F; Melillo, RM; Carlomagno, F; Oriente, F; Miele, C; Fiory, F; Santopietro, S; Castellone, MD; Beguinot, F; Santoro, M; Formisano, P				Andreozzi, F; Melillo, RM; Carlomagno, F; Oriente, F; Miele, C; Fiory, F; Santopietro, S; Castellone, MD; Beguinot, F; Santoro, M; Formisano, P			Protein kinase C alpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase	ONCOGENE			English	Article						protein kinase C; tyrosine; phorbol; oncogene; thyroid; familial; papillary; signaling; carcinoma	EPIDERMAL-GROWTH-FACTOR; FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; INSULIN; PHOSPHORYLATION; RAS; PROTOONCOGENE; PATHWAYS; MUSCLE; DELTA	We have studied the role of protein kinase C (PKC) in signaling of the RET tyrosine kinase receptor. By using a chimeric receptor (E/R) in which RET kinase can be tightly controlled by the addition of epidermal growth factor (EGF), we have found that RET triggering induces a strong increase of PKCalpha, PKCdelta and PKCzeta activity and that PKCalpha, not PKCdelta and PKCzeta, forms a ligand-dependent protein complex with E/R. We have identified tyrosine 1062 in the RET carboxyl-terminal tail as the docking site for PKCalpha. Block of PKC activity by bisindolytmaleimide or chronic phorbol esters treatment decreased EGF-induced serine/threonine phosphorylation of E/R, while it caused a similarly sized increase of EGF-induced E/R tyrosine kinase activity and mitogenic signaling. Conversely, acute phorbol esters treatment, which promotes PKC activity, increased the levels of E/R serine/threonine phosphorylation and significantly decreased its phosphotyrosine content. A threefold reduction of tyrosine phosphorylation levels of the constitutively active RET/MEN2A oncoprotein was observed upon coexpression with PKCalpha. We conclude that RET binds to and activates PKCalpha. PKCalpha, in turn, causes RET phosphorylation and downregulates RET tyrosine kinase and downstream signaling, thus functioning as a negative feedback loop to modulate RET activity.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, I-80131 Naples, Italy; Univ Naples Federico II, CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II	Formisano, P (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, Via S Pansini 5, I-80131 Naples, Italy.	fpietro@unina.it	Formisano, Pietro/J-4237-2018; melillo, rosa marina/O-5255-2015; Andreozzi, Francesco/J-4073-2018; ORIENTE, Francesco/J-6652-2018	MELILLO, Rosa Marina/0000-0002-9233-5275; Formisano, Pietro/0000-0001-7020-6870; Andreozzi, Francesco/0000-0001-9375-1513; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037; ORIENTE, Francesco/0000-0003-4375-4526	Telethon [E.0896] Funding Source: Medline	Telethon(Fondazione Telethon)		Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Carlomagno F, 1998, ENDOCRINOLOGY, V139, P3613, DOI 10.1210/en.139.8.3613; Caruso M, 2001, J BIOL CHEM, V276, P45088, DOI 10.1074/jbc.M105451200; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; De Vita G, 2000, CANCER RES, V60, P3727; DECKER SJ, 1984, MOL CELL BIOL, V4, P1718, DOI 10.1128/MCB.4.9.1718; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; Fagin JA, 2002, ENDOCRINOLOGY, V143, P2025, DOI 10.1210/en.143.6.2025; FARESE RV, 1988, BIOCHEM J, V256, P175, DOI 10.1042/bj2560175; Formisano P, 2000, MOL CELL BIOL, V20, P6323, DOI 10.1128/MCB.20.17.6323-6333.2000; Formisano P, 1998, J BIOL CHEM, V273, P13197, DOI 10.1074/jbc.273.21.13197; Fukuda T, 2002, J BIOL CHEM, V277, P19114, DOI 10.1074/jbc.M200643200; GANDINO L, 1994, J BIOL CHEM, V269, P1815; Iwashita T, 1996, ONCOGENE, V12, P481; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Melillo RM, 2001, ONCOGENE, V20, P209, DOI 10.1038/sj.onc.1204049; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Oriente F, 2001, J BIOL CHEM, V276, P37109, DOI 10.1074/jbc.M104405200; Ponder BAJ, 1999, CANCER RES, V59, p1736S; PREISS J, 1986, J BIOL CHEM, V261, P8597; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SEEDORF K, 1995, J BIOL CHEM, V270, P18953, DOI 10.1074/jbc.270.32.18953; Seedorf K, 1995, ANN NY ACAD SCI, V766, P459, DOI 10.1111/j.1749-6632.1995.tb26694.x; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737	36	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2003	22	19					2942	2949		10.1038/sj.onc.1206475	http://dx.doi.org/10.1038/sj.onc.1206475			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771945				2022-12-17	WOS:000182824800009
J	Tutt, A; Connor, F; Bertwistle, D; Kerr, P; Peacock, J; Ross, G; Ashworth, A				Tutt, A; Connor, F; Bertwistle, D; Kerr, P; Peacock, J; Ross, G; Ashworth, A			Cell cycle and genetic background dependence of the effect of loss of BRCA2 on ionizing radiation sensitivity	ONCOGENE			English	Article							HOMOLOGY-DIRECTED REPAIR; CENTROSOME AMPLIFICATION; BREAST-CANCER; MUTATION; P53; INSTABILITY; MICE; RECOMBINATION; MAINTENANCE; DEFICIENT	Carriers of mutations in the BRCA2 gene are at a highly elevated risk of breast and other cancers. The BRCA2 gene encodes a very large protein thought to play a role in DNA repair. To examine the effect of mutation of BRCA2 on sensitivity to ionizing radiation, we used a previously described mouse model system (Brca2(Tr)) in which the Brca2 open reading frame is truncated. Mouse embryo fibroblasts carrying this mutation have a proliferative defect, which we show here can be substantially rescued by genetic ablation of p53. Proliferating Brca2(Tr/Tr)/p53(-/-) cells, like Brca2(Tr/Tr) cells, show genomic instability. We used the clonogenic survival assay, which depends on the ability of cells to proliferate, to examine the cell cycle dependence of radiation sensitivity of Brca2(Tr/Tr)/p53(-/-) compared to p53(-/-) and wild-type cells. This showed that the Brca2 mutation had little effect on cells irradiated in quiescence but sensitized proliferating cells to ionizing radiation on a p53(-/-) background. These results suggest that the major role of Brca2 in mediating cell survival after irradiation is in the S and G(2) phases of the cell cycle.	Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Ashworth, A (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, Fulham Rd, London SW3 6JB, England.			Tutt, Andrew/0000-0001-8715-2901				Bertwistle D, 1997, CANCER RES, V57, P5485; Buchholz TA, 2002, INT J CANCER, V97, P557, DOI 10.1002/ijc.10109; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Foray N, 1999, ONCOGENE, V18, P7334, DOI 10.1038/sj.onc.1203165; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gretarsdottir S, 1998, CANCER RES, V58, P859; Griffin CS, 2000, NAT CELL BIOL, V2, P757, DOI 10.1038/35036399; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Kerr P, 2001, CURR BIOL, V11, pR668, DOI 10.1016/S0960-9822(01)00389-X; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Sansom OJ, 2000, MUTAT RES-FUND MOL M, V452, P149, DOI 10.1016/S0027-5107(00)00089-0; Steel G. G., 1997, BASIC CLIN RADIOBIOL, P40; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; Tutt ANJ, 2002, EMBO REP, V3, P255, DOI 10.1093/embo-reports/kvf037; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9	19	20	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2003	22	19					2926	2931		10.1038/sj.onc.1206522	http://dx.doi.org/10.1038/sj.onc.1206522			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771943				2022-12-17	WOS:000182824800007
J	Yu, JS; Tsai, HC; Wu, CC; Weng, LP; Li, HP; Chung, PJ; Chang, YS				Yu, JS; Tsai, HC; Wu, CC; Weng, LP; Li, HP; Chung, PJ; Chang, YS			Induction of inducible nitric oxide synthase by Epstein-Barr virus B95-8-derived LMP1 in Balb/3T3 cells promotes stress-induced cell death and impairs LMP1-mediated transformation	ONCOGENE			English	Article						LMP1; iNOS; nitric oxide; caspase-3; JNK	NF-KAPPA-B; LATENT MEMBRANE-PROTEIN; HUMAN EPITHELIAL-CELLS; TERMINAL KINASE JNK; NASOPHARYNGEAL CARCINOMA; INDUCED APOPTOSIS; TUMOR-GROWTH; A431 CELLS; FUNCTIONAL DIFFERENCES; BNLF-1 GENE	The latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV) causes cellular transformation and activation of several intracellular signaling events. In this report, we show that BLMP1 (encoded by the LMP1 gene derived from the B95-8 strain of EBV) triggers the expression of inducible nitric oxide synthase (iNOS) in Balb/3T3 fibroblasts. Intriguingly, NLMP1, a natural sequence variant of LMP1 identified in EBV-positive nasopharyngeal carcinoma biopsy, does not similarly induce iNOS expression. BLMP1-induced iNOS in Balb/3T3 cells is active to produce nitric oxide (NO), and NO production can be blocked by several iNOS inhibitors. When subjected to environmental stress, Balb/3T3 cells that produce NO lose viability more rapidly than non NO-producing cells. Blockage of NO generation by iNOS inhibitors enhances the viability of NO-producing cells under stress conditions. The activities of caspase-3 and c-Jun N-terminal kinase, two important regulators mediating stress-induced apoptosis, are significantly potentiated following heat shock treatment of BLMPl-expressing/NO-producing cells, compared to parental and NLMP1-expressing cells. Furthermore, treatment with iNOS inhibitor augmented the cloning efficiency (in culture) and tumor growth (in nude mice) of BLMP1-expressing/NO-producing cells. Collectively, the results demonstrate that BLMP1 induces iNOS expression and NO production in Balb/3T3 cells, which leads to the alteration of cell functions, including sensitivity to environmental stress, capability to colonize independent of anchorage and tumorigenicity in nude mice. Our data additionally implicate that the differential iNOS induction potential of the two LMP1 forms may represent the basis of a functional difference between the two LMP1 proteins.	Chang Gung Univ, Coll Med, Inst Basic Med Sci, Dept Cell & Mol Biol, Tao Yuan, Taiwan; Chang Gung Univ, Coll Med, Inst Basic Med Sci, Dept Microbiol & Immunol, Tao Yuan, Taiwan	Chang Gung University; Chang Gung University	Yu, JS (corresponding author), Chang Gung Univ, Coll Med, Inst Basic Med Sci, Dept Cell & Mol Biol, Tao Yuan, Taiwan.	yusong@mail.cgu.edu.tw	Li, Hsin-Pai/C-7305-2014	Chang, Yu-Sun/0000-0002-6457-3890; Wu, Chih-Ching/0000-0002-7264-9672; Yu, Jau-Song/0000-0002-4295-983X				Aaltomaa SH, 2001, ANTICANCER RES, V21, P3101; Ambs S, 1998, NAT MED, V4, P1371, DOI 10.1038/3957; Ambs S, 1998, CANCER RES, V58, P334; ARVANITAKIS L, 1995, J IMMUNOL, V155, P1047; ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BIRKENBACH M, 1989, J VIROL, V63, P4079, DOI 10.1128/JVI.63.9.4079-4084.1989; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; Campbell IL, 1996, J NEUROIMMUNOL, V71, P31, DOI 10.1016/S0165-5728(96)00129-4; Chan WH, 2000, BIOCHEM J, V351, P221, DOI 10.1042/0264-6021:3510221; Chan WH, 1998, J PROTEIN CHEM, V17, P485, DOI 10.1023/A:1022578820147; CHEN ML, 1992, ONCOGENE, V7, P2131; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; COBBS CS, 1995, CANCER RES, V55, P727; Dawson CW, 2000, VIROLOGY, V272, P204, DOI 10.1006/viro.2000.0344; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Dimmeler S, 1997, NITRIC OXIDE-BIOL CH, V1, P275, DOI 10.1006/niox.1997.0133; Eliopoulos AG, 1998, CURR BIOL, V8, pR196, DOI 10.1016/S0960-9822(98)70123-X; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; ESPTEIN MA, 1964, LANCET, V1, P702; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FAIRBAIRN LJ, 1993, J GEN VIROL, V74, P247, DOI 10.1099/0022-1317-74-2-247; Fielding CA, 2001, J VIROL, V75, P9129, DOI 10.1128/JVI.75.19.9129-9141.2001; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Gao XR, 1999, VIROLOGY, V258, P375, DOI 10.1006/viro.1999.9748; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HANTO DW, 1985, TRANSPLANT P, V17, P89; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; HU LF, 1993, ONCOGENE, V8, P1575; Iwasaki Y, 1998, J VIROL, V72, P8321, DOI 10.1128/JVI.72.10.8321-8326.1998; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; Johnson RJ, 1998, J VIROL, V72, P4038, DOI 10.1128/JVI.72.5.4038-4048.1998; Kawanishi M, 1995, INTERVIROLOGY, V38, P206, DOI 10.1159/000150434; KIEFF E, 1990, VIROLOGY, P1889; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P4737, DOI 10.1073/pnas.71.12.4737; Kleinert H, 1996, J BIOL CHEM, V271, P6039, DOI 10.1074/jbc.271.11.6039; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Li SN, 1996, ONCOGENE, V12, P2129; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; Lu JJY, 1996, J GEN VIROL, V77, P1883, DOI 10.1099/0022-1317-77-8-1883; MacFarlane M, 2000, BIOCHEM J, V348, P93, DOI 10.1042/0264-6021:3480093; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; Martins LM, 1997, TRENDS CELL BIOL, V7, P111; Massi D, 2001, J PATHOL, V194, P194, DOI 10.1002/1096-9896(200106)194:2<194::AID-PATH851>3.0.CO;2-S; Miller WE, 1998, ONCOGENE, V16, P1869, DOI 10.1038/sj.onc.1201696; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; MOSIALOS G, 1994, J VIROL, V68, P1697, DOI 10.1128/JVI.68.3.1697-1705.1994; Murono S, 2001, P NATL ACAD SCI USA, V98, P6905, DOI 10.1073/pnas.121016998; Muschel RJ, 1998, ONCOGENE, V17, P3359, DOI 10.1038/sj.onc.1202580; NAKAGOMI H, 1994, INT J CANCER, V57, P240, DOI 10.1002/ijc.2910570218; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nilsson BO, 1999, INFLAMM RES, V48, P509, DOI 10.1007/s000110050495; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; PENG M, 1992, ONCOGENE, V7, P1775; Riches DWH, 1998, J BIOL CHEM, V273, P22800, DOI 10.1074/jbc.273.35.22800; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; SU IJ, 1992, LEUKEMIA LYMPHOMA, V7, P47, DOI 10.3109/10428199209053601; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; Tang TK, 1998, J CELL BIOCHEM, V70, P442, DOI 10.1002/(SICI)1097-4644(19980915)70:4<442::AID-JCB2>3.3.CO;2-N; Thomsen LL, 1997, CANCER RES, V57, P3300; THOMSEN LL, 1994, CANCER RES, V54, P1352; THOMSEN LL, 1995, BRIT J CANCER, V72, P41, DOI 10.1038/bjc.1995.274; TRIVEDI P, 1994, EUR J CANCER, V30A, P84, DOI 10.1016/S0959-8049(05)80024-3; Valentinis B, 1999, ONCOGENE, V18, P1827, DOI 10.1038/sj.onc.1202471; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; Wilson KT, 1998, CANCER RES, V58, P2929; Xie KP, 1998, CANCER METAST REV, V17, P55, DOI 10.1023/A:1005956721457; Yeh TS, 1997, DNA CELL BIOL, V16, P1311, DOI 10.1089/dna.1997.16.1311; YU JS, 1994, J CELL BIOCHEM, V56, P131, DOI 10.1002/jcb.240560117	89	20	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2002	21	52					8047	8061		10.1038/sj.onc.1205990	http://dx.doi.org/10.1038/sj.onc.1205990			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439755				2022-12-17	WOS:000179097200014
J	Yabana, N; Shibuya, M				Yabana, N; Shibuya, M			Adaptor protein APS binds the NH2-terminal autoinhibitory domain of guanine nucleotide exchange factor Vav3 and augments its activity	ONCOGENE			English	Article						Vav; guanine nucleotide; exchange factor; calponin; homology domain	SH2 DOMAINS; PROTOONCOGENE PRODUCT; PLECKSTRIN HOMOLOGY; SIGNALING PATHWAYS; C-CBL; FAMILY; ACTIVATION; RHO; DBL; MEMBER	The N-terminal calponin homology (CH) domain of Vav guanine nucleotide exchange factor is thought to serve a regulatory role in the autoinhibition, however, its precise function is not entirely clear. We found that the adaptor molecule APS could bind the CH domain of Vav3, a member of the vav proto-oncogene family. The binding of Vav3 and APS was apparently stabilized by the tyrosine phosphorylation of Vav3 by Lck, and the association of APS with Vav3 in turn enhanced the Lck-mediated phosphorylation of Vav3. Focus formation assays demonstrated that APS could increase the transforming activity of proto-Vav3. Further analyses revealed that the Vav3 CH domain could bind the pleckstrin homology (PH) domain of APS and that this binding was indispensable to enhance the transforming activity of Vav3. We present here a novel stimulatory mechanism of Vav3 in which APS directly relieves the autoinhibitory CH domain and furthermore enhances its tyrosine phosphorylation by Lck.	Univ Tokyo, Inst Med Sci, Div Genet, Minato Ku, Tokyo, Japan	University of Tokyo	Shibuya, M (corresponding author), Univ Tokyo, Inst Med Sci, Div Genet, Minato Ku, Shirokanedai 4-6-1, Tokyo, Japan.	shibuya@ims.u-tokyo.ac.jp						Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Abe R, 1999, J BIOL CHEM, V274, P30410, DOI 10.1074/jbc.274.43.30410; ADAMS JM, 1992, ONCOGENE, V7, P611; Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200; Bi F, 2001, MOL CELL BIOL, V21, P1463, DOI 10.1128/MCB.21.5.1463-1474.2001; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Doody GM, 2001, NAT IMMUNOL, V2, P542, DOI 10.1038/88748; Gimona M, 1998, CURR BIOL, V8, pR674; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hobert O, 1996, MOL CELL BIOL, V16, P3066; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Inabe K, 2002, J EXP MED, V195, P189, DOI 10.1084/jem.20011571; Iseki M, 2000, BIOCHEM BIOPH RES CO, V272, P45, DOI 10.1006/bbrc.2000.2736; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Moores SL, 2000, MOL CELL BIOL, V20, P6364, DOI 10.1128/MCB.20.17.6364-6373.2000; Movilla N, 1999, MOL CELL BIOL, V19, P7870; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; RON D, 1989, ONCOGENE, V4, P1067; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schuebel KE, 1996, ONCOGENE, V13, P363; Stradal T, 1998, FEBS LETT, V431, P134, DOI 10.1016/S0014-5793(98)00751-0; Takaki S, 2000, IMMUNITY, V13, P599, DOI 10.1016/S1074-7613(00)00060-1; Tedford K, 2001, NAT IMMUNOL, V2, P548, DOI 10.1038/88756; VAN AL, 1997, GENE DEV, V11, P2295; Wakioka T, 1999, LEUKEMIA, V13, P760, DOI 10.1038/sj.leu.2401397; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163; Yokouchi M, 1999, ONCOGENE, V18, P759, DOI 10.1038/sj.onc.1202326; Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212-9224.2000	48	20	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2002	21	50					7720	7729		10.1038/sj.onc.1205927	http://dx.doi.org/10.1038/sj.onc.1205927			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400014				2022-12-17	WOS:000178756200011
J	Fathallah-Shaykh, HM; Rigen, M; Zhao, LJ; Bansal, K; He, B; Engelhard, HH; Cerullo, L; Von Roenn, K; Byrne, R; Munoz, L; Rosseau, GL; Glick, R; Lichtor, T; DiSavino, E				Fathallah-Shaykh, HM; Rigen, M; Zhao, LJ; Bansal, K; He, B; Engelhard, HH; Cerullo, L; Von Roenn, K; Byrne, R; Munoz, L; Rosseau, GL; Glick, R; Lichtor, T; DiSavino, E			Mathematical modeling of noise and discovery of genetic expression classes in gliomas	ONCOGENE			English	Article						glioma; genetics; mathematical modeling; mathematical computing; genetic techniques	CANDIDATE TUMOR-SUPPRESSOR; UBIQUITIN-PROTEIN LIGASE; BOX BINDING-PROTEIN; HUMAN ASTROCYTOMAS; COLORECTAL-CANCER; POLYSIALIC ACID; CHROMOSOME 8P; BREAST-CANCER; HUMAN BRAIN; CELL-LINE	The microarray array experimental system generates noisy data that require validation by other experimental methods for measuring gene expression. Here we present an algebraic modeling of noise that extracts expression measurements true to a high degree of confidence. This work profiles the expression of 19200 cDNAs in 35 human gliomas; the experiments are designed to generate four replicate spots/gene with switching of probes. The validity of the extracted measurements is confirmed by: (1) cluster analysis that generates a molecular classification differentiating glioblastoma from lower-grade tumors and radiation necrosis; (2) By what other investigators have reported in gliomas using paradigms for assaying molecular expression other than gene profiling; and (3) Real-time RT-PCR. The results yield a genetic analysis of gliomas and identify classes of genetic expression that link novel genes to the biology of gliomas.	Rush Presbyterian St Lukes Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Neurosurg, Chicago, IL 60612 USA; Univ Illinois, Dept Neurosurg, Chicago, IL 60612 USA; Cook Cty Hosp, Dept Neurosurg, Chicago, IL 60612 USA	Rush University; Rush University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; John H Stroger Junior Hospital Cook County	Fathallah-Shaykh, HM (corresponding author), Rush Univ, Med Ctr, 2242 W Harrison St,suite 200, Chicago, IL 60612 USA.			Engelhard, Herbert/0000-0003-4993-9265; Fathallah-Shaykh, Hassan/0000-0002-2690-7685; Rosseau, Gail/0000-0002-5392-435X	NATIONAL CANCER INSTITUTE [R29CA078825, R01CA081367] Funding Source: NIH RePORTER; NCI NIH HHS [R29-CA78825, R01-CA81367] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; AOYAMA A, 1993, INT J CANCER, V55, P760, DOI 10.1002/ijc.2910550511; Becker SA, 1996, CANCER RES, V56, P5092; BELLAHCENE A, 1995, AM J PATHOL, V146, P95; BIANCHI AB, 1991, P NATL ACAD SCI USA, V88, P7590, DOI 10.1073/pnas.88.17.7590; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; BOECK R, 2001, J BIOL CHEM, V271, P431; Casson AG, 1997, INT J CANCER, V72, P739, DOI 10.1002/(SICI)1097-0215(19970904)72:5<739::AID-IJC6>3.0.CO;2-T; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; Denhardt DT, 2001, ANNU REV PHARMACOL, V41, P723, DOI 10.1146/annurev.pharmtox.41.1.723; Dunlop J, 1999, BRAIN RES, V839, P235, DOI 10.1016/S0006-8993(99)01714-X; EVERITT BS, 1993, CLUSTER ANAL, P55; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; Fournier MV, 1999, CANCER RES, V59, P3748; Genini M, 1996, INT J CANCER, V66, P571; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; HIGUCHI M, 1993, ACTA NEUROPATHOL, V85, P481; Hildebrandt H, 1998, CANCER RES, V58, P779; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Imbert A, 1996, GENOMICS, V32, P29, DOI 10.1006/geno.1996.0073; Ise T, 1999, CANCER RES, V59, P342; KAGAN J, 1995, ONCOGENE, V11, P2121; Kato A, 1997, FEBS LETT, V412, P183, DOI 10.1016/S0014-5793(97)00775-8; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; KOCHI N, 1983, ACTA NEUROPATHOL, V59, P119, DOI 10.1007/BF00691597; Kohda T, 2001, GENES CELLS, V6, P237, DOI 10.1046/j.1365-2443.2001.00412.x; Landry CF, 1997, CANCER RES, V57, P4098; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; Lee MLT, 2000, P NATL ACAD SCI USA, V97, P9834, DOI 10.1073/pnas.97.18.9834; Lerebours F, 1999, INT J CANCER, V81, P854, DOI 10.1002/(SICI)1097-0215(19990611)81:6<854::AID-IJC3>3.3.CO;2-T; Lerebours F, 1999, GENE CHROMOSOME CANC, V25, P147, DOI 10.1002/(SICI)1098-2264(199906)25:2<147::AID-GCC10>3.0.CO;2-Z; Marr HS, 2000, CELL TISSUE RES, V302, P139, DOI 10.1007/s004410000277; Matsumoto S, 2000, FEMS MICROBIOL LETT, V182, P297, DOI 10.1016/S0378-1097(99)00606-0; Muir D, 1996, J NEURO-ONCOL, V30, P199; Munch C, 2001, J NEUROL NEUROSUR PS, V71, P675, DOI 10.1136/jnnp.71.5.675; NAKAMURA T, 1992, ONCOGENE, V7, P733; Ohta S, 1997, BIOCHEM BIOPH RES CO, V237, P307, DOI 10.1006/bbrc.1997.7113; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; Oyake T, 1996, MOL CELL BIOL, V16, P6083; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; Richardson RM, 2001, BIOCHEMISTRY-US, V40, P3583, DOI 10.1021/bi0019242; Safak M, 1999, J VIROL, V73, P10146, DOI 10.1128/JVI.73.12.10146-10157.1999; Sage EH, 1997, NAT MED, V3, P144; SAITOH Y, 1995, LAB INVEST, V72, P55; Salicioni AM, 2000, GENOMICS, V69, P54, DOI 10.1006/geno.2000.6315; Schevzov G, 1997, MOL CELL NEUROSCI, V8, P439, DOI 10.1006/mcne.1997.0599; Shibao K, 1999, INT J CANCER, V83, P732; STAMM S, 1993, P NATL ACAD SCI USA, V90, P9857, DOI 10.1073/pnas.90.21.9857; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; Tanaka F, 2000, CANCER RES, V60, P3072; Ue T, 1998, INT J CANCER, V79, P127, DOI 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V; Vocke CD, 1996, CANCER RES, V56, P2411; VONDEIMLING A, 1992, CANCER RES, V52, P4277; Yamato T, 1999, CYTOGENET CELL GENET, V87, P291, DOI 10.1159/000015452; YANG HY, 1994, MOL CHEM NEUROPATHOL, V21, P155, DOI 10.1007/BF02815349; Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V; Zoladek T, 1997, GENETICS, V145, P595	60	20	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7164	7174		10.1038/sj.onc.1205654	http://dx.doi.org/10.1038/sj.onc.1205654			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370806				2022-12-17	WOS:000178504600004
J	Tang, Y; Katuri, V; Iqbal, S; Narayan, T; Wang, ZL; Lu, RS; Mishra, L; Mishra, B				Tang, Y; Katuri, V; Iqbal, S; Narayan, T; Wang, ZL; Lu, RS; Mishra, L; Mishra, B			ELF a beta-spectrin is a neuronal precursor cell marker in developing mammalian brain; structure and organization of the elf/beta-G spectrin gene	ONCOGENE			English	Article						spectrin; ankyrin; cytoskeleton; neuronal stem cells; gene structure	CENTRAL-NERVOUS-SYSTEM; MEMBRANE SKELETON; EPITHELIAL-CELLS; MESSENGER-RNA; ERYTHROCYTE SPECTRIN; MOLECULAR-CLONING; LIVER DEVELOPMENT; NEURAL CELLS; IN-VITRO; IDENTIFICATION	Spectrins play a pivotal role in axonal transport, neurite extension, the organization of synaptic vesicles, as well as for protein sorting in the Golgi apparatus and cell membrane. Among spectrins there is great variability in sequence composition, tissue distribution, and function, with two known genes encoding the alpha-chain, and at least five encoding the beta-chain. It remains unclear as to whether novel beta-spectrins such as elf1-4 are distinct genes or alpha-G-spectrin isoforms. The role for ELF in the developing nervous system has not been identified to date. In this study we demonstrate the genomic structure of elf-3, as well as the expression of ELF in the developing mouse brain using a peptide specific antibody against its distinctive amino-terminal end. Full genomic structural analyses reveal that elf-3 is composed of 31 exons spanning similar to67 kb, and confirm that elf and mouse brain beta-G-spectrin share multiple exons, with a complex form of exon/intron usage. In embryonic stages, E9-12, anti-ELF localized to the primary brain vesicular cells that also labeled strongly with anti-nestin but not anti-vimentin. At E12-14, anti-ELF localized to axonal sprouts in the developing neuroblasts of cortex and purkinje cell layer of the cerebellum, as well as in cell bodies in the diencephalon and metencephalon. Double labeling identified significant co-localization of anti-ELF, nestin and dystrophin in sub ventricular zone cells and in stellate-like cells of the developing forebrain. These studies define clearly the expression of ELF, a new isoform of beta-G-spectrin in the developing brain. Based on its expression pattern, ELF may have a role in neural stem cell development and is a marker of axonal sprouting in mid stages of embryonic development.	Temple Univ, Lab Neural GI Dev, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; DVAMC, Lab Dev Mol Biol, Washington, DC 20422 USA; Temple Univ, Sch Med, Philadelphia, PA 19122 USA; Childrens Hosp, Philadelphia, PA 19104 USA; NHGRI, Clin Gene Therapy Branch, NIH, Bethesda, MD 20892 USA; Georgetown Univ, Washington, DC USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Georgetown University	Mishra, L (corresponding author), Temple Univ, Lab Neural GI Dev, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.	lopamishra@yahoo.com		Mishra, Lopa/0000-0002-6850-0808	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK053861, R01DK056111] Funding Source: NIH RePORTER; NIDDK NIH HHS [1R03 DK53861, 1R01 DK 58637, 1R01 DK56111] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1996, METHOD ENZYMOL, V266, P460; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Beck KA, 1998, BBA-MOL CELL RES, V1404, P153, DOI 10.1016/S0167-4889(98)00054-8; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BENNETT V, 1982, NATURE, V299, P126, DOI 10.1038/299126a0; BIRKENMEIER CS, 1988, P NATL ACAD SCI USA, V85, P8121, DOI 10.1073/pnas.85.21.8121; BLACK JD, 1988, J CELL BIOL, V106, P97, DOI 10.1083/jcb.106.1.97; BLAKESLEE D, 1977, J IMMUNOL METHODS, V17, P361, DOI 10.1016/0022-1759(77)90118-1; BLOCH RJ, 1989, J CELL BIOL, V108, P481, DOI 10.1083/jcb.108.2.481; BLOOM ML, 1993, BLOOD, V82, P2906, DOI 10.1182/blood.V82.9.2906.bloodjournal8292906; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; Chen YW, 2001, J MOL NEUROSCI, V17, P59, DOI 10.1385/JMN:17:1:59; CRAIG SW, 1983, CELL MOTIL CYTOSKEL, V3, P449, DOI 10.1002/cm.970030513; DAHLSTRAND J, 1995, DEV BRAIN RES, V84, P109, DOI 10.1016/0165-3806(94)00162-S; DAVIS J, 1983, J BIOL CHEM, V258, P7757; De Matteis MA, 2000, J CELL SCI, V113, P2331; Devarajan P, 1996, CURR TOP MEMBR, V43, P97; Devarajan P, 1997, P NATL ACAD SCI USA, V94, P10711, DOI 10.1073/pnas.94.20.10711; Devarajan P, 1996, J CELL BIOL, V133, P819, DOI 10.1083/jcb.133.4.819; Doetsch F, 1997, J NEUROSCI, V17, P5046; DUBOWITZ V, 1969, BRAIN, V92, P805, DOI 10.1093/brain/92.4.805; Dubreuil RR, 2000, J CELL BIOL, V149, P647, DOI 10.1083/jcb.149.3.647; Emery A, 1988, DUCHENNE MUSCULAR DY; Fath KR, 1997, J CELL BIOL, V139, P1169, DOI 10.1083/jcb.139.5.1169; Gallagher PG, 1997, J BIOL CHEM, V272, P19220, DOI 10.1074/jbc.272.31.19220; Gallagher PG, 1999, J BIOL CHEM, V274, P6062, DOI 10.1074/jbc.274.10.6062; GALLAGHER PG, 1993, SEMIN HEMATOL, V30, P4; GLENNEY JR, 1983, J CELL BIOL, V96, P1491, DOI 10.1083/jcb.96.5.1491; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; Hammarlund M, 2000, J CELL BIOL, V149, P931, DOI 10.1083/jcb.149.4.931; Hayes NVL, 2000, J CELL SCI, V113, P2023; HU RJ, 1992, J BIOL CHEM, V267, P18715; HU RJ, 1995, J CELL BIOL, V128, P1069, DOI 10.1083/jcb.128.6.1069; JOOSTEN EAJ, 1989, NEUROSCIENCE, V31, P439, DOI 10.1016/0306-4522(89)90386-2; JUNG D, 1991, NEUROSCI LETT, V124, P87, DOI 10.1016/0304-3940(91)90828-H; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KORDELI E, 1990, J CELL BIOL, V110, P1341, DOI 10.1083/jcb.110.4.1341; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; Kunimoto M, 1998, J NEUROCHEM, V71, P2585; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEVINE J, 1981, J CELL BIOL, V90, P631, DOI 10.1083/jcb.90.3.631; LIDOV HGW, 1990, NATURE, V348, P725, DOI 10.1038/348725a0; Lux SE, 1995, BLOOD PRINCIPLES PRA, P1701; MA YP, 1993, MOL BRAIN RES, V18, P87, DOI 10.1016/0169-328X(93)90176-P; MALCHIODIALBEDI F, 1993, J CELL SCI, V106, P67; MARINPADILLA M, 1985, J COMP NEUROL, V235, P82, DOI 10.1002/cne.902350107; Mishra L, 1999, ONCOGENE, V18, P353, DOI 10.1038/sj.onc.1202313; Mishra L, 1997, ONCOGENE, V15, P2361, DOI 10.1038/sj.onc.1201405; Mishra L, 1999, MAMM GENOME, V10, P62, DOI 10.1007/s003359900944; Mishra L, 1998, INT J DEV BIOL, V42, P221; MOON RT, 1987, BIOESSAYS, V7, P159, DOI 10.1002/bies.950070405; Moorthy S, 2000, J CELL BIOL, V149, P915, DOI 10.1083/jcb.149.4.915; MORROW JS, 1997, HDB PHYSIOL 14, P485; NELSON WJ, 1987, J CELL BIOL, V104, P1527, DOI 10.1083/jcb.104.6.1527; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; Ohara O, 1998, MOL BRAIN RES, V57, P181, DOI 10.1016/S0169-328X(98)00068-0; Pinder JC, 2000, NATURE, V406, P253, DOI 10.1038/35018679; RIEDERER BM, 1986, J CELL BIOL, V102, P2088, DOI 10.1083/jcb.102.6.2088; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; Sakaguchi G, 1998, BIOCHEM BIOPH RES CO, V248, P846, DOI 10.1006/bbrc.1998.9067; Sambrook J., 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Scotland P, 1998, J CELL BIOL, V143, P1305, DOI 10.1083/jcb.143.5.1305; Sihag RK, 1996, J NEUROSCI RES, V44, P430, DOI 10.1002/(SICI)1097-4547(19960601)44:5<430::AID-JNR3>3.0.CO;2-G; SIKORSKI AF, 1991, J CELL BIOL, V114, P313, DOI 10.1083/jcb.114.2.313; Sikorski AF, 2000, BRAIN RES, V852, P161, DOI 10.1016/S0006-8993(99)02253-2; SIMAN R, 1987, J NEUROSCI, V7, P55; SOBUE K, 1990, NEUROSCI RES, pS80, DOI 10.1016/0921-8696(90)90035-2; SOBUE K, 1989, NEURON, V3, P311, DOI 10.1016/0896-6273(89)90255-9; SRINIVASAN Y, 1992, J BIOL CHEM, V267, P7483; Stabach PR, 2000, J BIOL CHEM, V275, P21385, DOI 10.1074/jbc.C000159200; Stankewich MC, 1998, P NATL ACAD SCI USA, V95, P14158, DOI 10.1073/pnas.95.24.14158; TAKASHIMA S, 1981, BRAIN RES, V225, P1, DOI 10.1016/0006-8993(81)90314-0; Thomas G, 2000, NAT CELL BIOL, V2, pE71, DOI 10.1038/35010581; THOMAS GH, 1994, DEVELOPMENT, V120, P2039; Wechsler A, 1998, EMBO J, V17, P3931, DOI 10.1093/emboj/17.14.3931; WHITTAKER PA, 1986, GENE, V41, P129, DOI 10.1016/0378-1119(86)90276-3; WINKELMANN JC, 1988, BLOOD, V72, P328; ZAGON IS, 1986, J NEUROSCI, V6, P2977; Zarnescu DC, 1999, J CELL BIOL, V146, P1075, DOI 10.1083/jcb.146.5.1075; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295; Ziemnicka-Kotula D, 1998, J BIOL CHEM, V273, P13681, DOI 10.1074/jbc.273.22.13681; ZIMMER WE, 1991, BRAIN RES BULL, V27, P187, DOI 10.1016/0361-9230(91)90066-S	85	20	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2002	21	34					5255	5267		10.1038/sj.onc.1205548	http://dx.doi.org/10.1038/sj.onc.1205548			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149647				2022-12-17	WOS:000177193900007
J	Wunderlich, M; Berberich, SJ				Wunderlich, M; Berberich, SJ			Mdm2 inhibition of p53 induces E2F1 transactivation via p2l	ONCOGENE			English	Article						Mdm2; E2F1; p53; p21	TRANSCRIPTION FACTOR E2F-1; RING-FINGER DOMAIN; P53-INDEPENDENT APOPTOSIS; DNA-DAMAGE; P53-MEDIATED TRANSACTIVATION; RETINOBLASTOMA PROTEIN; CELL-LINE; S-PHASE; EXPRESSION; DIFFERENTIATION	The transcription factor E2F1 functions as a key regulator for both cell-cycle progression and apoptosis. Mdm2, a major cellular regulator of the p53 tumor suppressor protein, is also closely involved in cell cycle and apoptosis. In addition to regulation of p53, Mdm2 has been reported to stimulate E2F1 transactivation by a mechanism that remains unclear. Here we examined how overexpression of Mdm2 alters E2F1/DP1 transactivation. Using a set of cell lines with differing p53 and Rb status we determined that Mdm2 induction of E2F1 transactivation was p53-dependent, resulting from release of repression by p53. While Mdm2 association with p53 was required to increase E2F1 transactivation, Mdm2 mediated degradation of p53 was not. p53 repression of E2F1 transactivation required a functional DNA binding and transactivation domain. Consistent with Mdm2 activation of E2F1 via an inhibition of p53 transactivation we demonstrate a concomitant reduction in p21 protein levels with Mdm2 overexpression. Furthermore, E2F1 repression by an Rb-phosphorylation mutant could not be reversed by Mdm2 overexpression. Mdm2 was also unable to enhance E2F1 transactivation in Mouse embryo fibroblasts lacking p21. Taken together, these results suggest that Mdm2 activation of E2F1 occurs through the repression of p53-dependent transcription of p21, a p53-target gene and cyclin dependent kinase inhibitor.	Wright State Univ, Dept Biochem & Mol Biol, Dayton, OH 45435 USA	University System of Ohio; Wright State University Dayton	Berberich, SJ (corresponding author), Wright State Univ, Dept Biochem & Mol Biol, 3640 Colonel Glenn Hywy, Dayton, OH 45435 USA.	steven.berberich@wright.edu			NATIONAL CANCER INSTITUTE [R01CA064430, R29CA064430] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA064430-09, R01 CA064430, CA64430] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agah R, 1997, J CLIN INVEST, V100, P2722, DOI 10.1172/JCI119817; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CRESS WD, 1994, J VIROL, V68, P4212, DOI 10.1128/JVI.68.7.4213-4219.1994; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; Holmberg C, 1998, ONCOGENE, V17, P143, DOI 10.1038/sj.onc.1201915; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Hunt KK, 1997, CANCER RES, V57, P4722; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Jackson MW, 1999, DNA CELL BIOL, V18, P693, DOI 10.1089/104454999314971; JACKSON MW, 2001, J BIOL CHEM, V10, P10; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lin JY, 2000, CANCER RES, V60, P5895; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nip J, 1997, MOL CELL BIOL, V17, P1049, DOI 10.1128/MCB.17.3.1049; Nip J, 2001, ONCOGENE, V20, P910, DOI 10.1038/sj.onc.1204171; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	41	20	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2002	21	28					4414	4421		10.1038/sj.onc.1205541	http://dx.doi.org/10.1038/sj.onc.1205541			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080472				2022-12-17	WOS:000176317100007
J	Howlett, CJ; Robbins, SM				Howlett, CJ; Robbins, SM			Membrane-anchored Cbl suppresses Hck protein-tyrosine kinase mediated cellular transformation	ONCOGENE			English	Article						Src family kinases; Cbl; ubiquitination; transformation	C-CBL; GENE HCK; NEGATIVE REGULATOR; CSF-1 RECEPTOR; SRC; GROWTH; PHOSPHORYLATION; DEGRADATION; UBIQUITINATION; ASSOCIATION	The mammalian proto-oncogene CbI and its cellular homologues in Caenorhabtlitis elegans (Sli-1) and Drosophila (D-Cbl) are negative regulators of some growth factor receptor signaling pathways. Herein we show that CbI can negatively regulate another signaling molecule, namely the Src-family kinase Hck by targeting it for degradation. Hck-mediated cellular transformation of murine fibroblasts is reverted by ectopic expression of a membrane-anchored allele of CbI as assessed by the cellular morphology, suppression of anchorage independent growth, and an overall reduction in the total tyrosine phosphorylation levels within the cells. The expression of CbI at the plasma membrane targets both Hck and itself for ubiquitination and degradation, requiring an intact RING finger. Pharmacological inhibition of the proteasome prevents the degradation of Hck correlating with an increase in the phosphotyrosine levels within the cells. Activated Hck and membrane-anchored CbI are present in similar subcellular localizations and co-immunoprecipitate, suggesting that their interaction is required for subsequent ubiquitination and degradation. Interestingly, both constitutively active and kinase-inactive Hck interact with and are targeted for degradation by Cbl. This work illustrates alternate means to regulate Src-family kinases, and suggests that CbI may be able to suppress many signaling pathways that are activated in various proliferative syndromes including cancer.	Univ Calgary, Dept Oncol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Robbins, SM (corresponding author), Univ Calgary, Dept Oncol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	srobbins@ucalgary.ca		Robbins, Stephen/0000-0001-7475-1665				Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Feshchenko EA, 1999, ONCOGENE, V18, P3703, DOI 10.1038/sj.onc.1202672; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harris KF, 1999, P NATL ACAD SCI USA, V96, P13738, DOI 10.1073/pnas.96.24.13738; Howlett CJ, 1999, BIOCHEM BIOPH RES CO, V257, P129, DOI 10.1006/bbrc.1999.0427; Joazeiro CAP, 2000, SCIENCE, V289, P2061, DOI 10.1126/science.289.5487.2061; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Johnson TM, 2000, J BIOL CHEM, V275, P33353, DOI 10.1074/jbc.M002022200; LAW DA, 1992, MOL IMMUNOL, V29, P917, DOI 10.1016/0161-5890(92)90130-P; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; LICHTENBERG U, 1992, ONCOGENE, V7, P849; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Oda H, 1999, P NATL ACAD SCI USA, V96, P9557, DOI 10.1073/pnas.96.17.9557; Okamura-Oho Y, 1997, FEBS LETT, V419, P231, DOI 10.1016/S0014-5793(97)01461-0; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Pawson T, 1997, NATURE, V385, P582, DOI 10.1038/385582b0; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; Rivett AJ, 1998, CURR OPIN IMMUNOL, V10, P110, DOI 10.1016/S0952-7915(98)80040-X; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; Scholz G, 2000, J BIOL CHEM, V275, P14615, DOI 10.1074/jbc.275.19.14615; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Wang Y, 1999, J CELL BIOCHEM, V72, P119; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	42	20	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1707	1716		10.1038/sj.onc.1205228	http://dx.doi.org/10.1038/sj.onc.1205228			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896602				2022-12-17	WOS:000174214200009
J	Jinno, S; Yageta, M; Nagata, A; Okayama, H				Jinno, S; Yageta, M; Nagata, A; Okayama, H			Cdc6 requires anchorage for its expression	ONCOGENE			English	Article						Cdc6; anchorage; Cdk6; cyclin D3; NRK	EPIDERMAL-GROWTH-FACTOR; CYCLIN-DEPENDENT KINASES; CELL-CYCLE; RETINOBLASTOMA PROTEIN; MAMMALIAN CDC6; DNA-REPLICATION; G(1) CONTROL; NRK CELLS; S-PHASE; PHOSPHORYLATION	Fibroblasts need anchorage to extracellular matrix to transit from G(1) to S phase, but no longer after oncogenic transformation. Here we report that Cdc6 protein essential for the activation of replication origins requires anchorage or oncogenic stimulation for its execution. Upon anchorage loss, Cdc6 expression is shut off both transcriptionally and post-transcriptionally in a rat fibroblast despite enforced activation of E2F-dependent promoters. However, stimulation of this cell with oncogenic growth factors suppresses this shutoff and concurrently activates Cdk2 and Cdk6/4, thereby overriding the anchorage requirement for the G(1)-S transition and consequently enabling cells to perform anchorage-independent S phase entry. Analysis with enforced expression of Cdc6 indicates that the G(1) cyclin-dependent kinases and Cdc6 constitute major cell cycle targets for the restriction of the G(1)-S transition by anchorage loss.	Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Jinno, S (corresponding author), Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan.	jinno@m.u-tokyo.ac.jp; okayama@m.u-tokyo.ac.jp	Sakurai-Yageta, Mika/U-1842-2019	Sakurai-Yageta, Mika/0000-0001-5606-3324				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P71; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cifone M A, 1982, Cancer Metastasis Rev, V1, P335, DOI 10.1007/BF00124216; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Coverley D, 2000, J CELL SCI, V113, P1929; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Desdouets C, 1995, Prog Cell Cycle Res, V1, P115; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hengstschlager M, 1999, MUTAT RES-REV MUTAT, V436, P1, DOI 10.1016/S1383-5742(98)00022-2; Hosokawa Y, 1995, BIOCHEM MOL BIOL INT, V37, P393; INOUE S, 1991, J BIOL CHEM, V266, P13311; Jinno S, 1999, ONCOGENE, V18, P565, DOI 10.1038/sj.onc.1202347; Jinno S, 1999, P NATL ACAD SCI USA, V96, P13197, DOI 10.1073/pnas.96.23.13197; KATO J, 1993, GENE DEV, V7, P331; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kizaka-Kondoh S, 2000, FEBS LETT, V466, P160, DOI 10.1016/S0014-5793(99)01784-6; KUME K, 1992, NEW BIOL, V4, P504; Lahaye DHTP, 1999, FEBS LETT, V446, P256, DOI 10.1016/S0014-5793(99)00216-1; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; Lin J, 2001, ONCOGENE, V20, P2000, DOI 10.1038/sj.onc.1204375; Liu KY, 2000, J BIOL CHEM, V275, P31093, DOI 10.1074/jbc.M005451200; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Madine MA, 2000, J STRUCT BIOL, V129, P198, DOI 10.1006/jsbi.2000.4218; MASUDA A, 1992, NEW BIOL, V4, P489; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; OTSUKA H, 1976, J CELL PHYSIOL, V87, P213, DOI 10.1002/jcp.1040870209; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Reed SI, 1997, CANCER SURV, V29, P7; Resnitzky D, 1997, MOL CELL BIOL, V17, P5640, DOI 10.1128/MCB.17.9.5640; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; Stoeber K, 1998, EMBO J, V17, P7219, DOI 10.1093/emboj/17.24.7219; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Yoshikawa Y, 2000, JPN J CANCER RES, V91, P459, DOI 10.1111/j.1349-7006.2000.tb00967.x; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	49	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1777	1784		10.1038/sj.onc.1205249	http://dx.doi.org/10.1038/sj.onc.1205249			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896609				2022-12-17	WOS:000174214200016
J	Shin, CY; Mellon, I; Turker, MS				Shin, CY; Mellon, I; Turker, MS			Multiple mutations are common at mouse Aprt in genotoxin-exposed mismatch repair deficient cells	ONCOGENE			English	Article						multiple mutations; genetic instability; DNA mismatch repair; genotoxin exposure	TRANSCRIPTION-COUPLED REPAIR; NUCLEOTIDE-EXCISION-REPAIR; SILENT MUTATIONS; APC MUTATIONS; P53 MUTATIONS; SKIN TUMORS; MICE; HYPERMUTABILITY; UV; SPECIFICITY	Mismatch repair deficiency is known to contribute to elevated rates of mutations, particularly at mono- and dinucleotide repeat sequences. However, such repeats are often missing from the coding regions of endogenous genes. To determine the types of mutations that can occur within an endogenous gene lacking highly susceptible repeat sequences, we examined mutagenic events at the 2.3 kb mouse Aprt gene in kidney cell lines derived from mice deficient for the PMS2 and MLH1 mismatch repair proteins. The Aprt mutation rate was increased 33-fold and 3.6-20-fold for Mlh1 and Pms2 null cell lines. respectively, when compared with a wildtype kidney cell line. For the Pms2 null cells this increase resulted from both intragenic events, which were predominantly base-pairs substitutions, and loss of heterozygosity events. Almost all mutations in the,Mlh1 null cells were due to base-pair substitutions. A:T-->G:C transitions (54% of small events) were predominant in the Pms2 null cells whereas G:C-A:T transitions (36%) were the most common base-pair change in the Mlh1 null cells. Interestingly, 4-9% of the spontaneous mutant alleles in the mismatch repair deficient cells exhibited two well-separated base-pair substitution events. The percentage of mutant alleles with two and occasionally three base-pair substitutions increased when the Pms2 and Mlh1 null cells were treated with ultraviolet radiation (15-21%) and when the Mlh1 null cells were treated with hydrogen peroxide (35%). In most cases the distance separating the multiple base-pair substitutions on a given allele was in excess of 100 base-pairs, suggesting that the two mutational events were not linked directly to a single DNA lesion. The significance of these results is discussed with regards to the roles for the PMS2 and MLH1 proteins in preventing spontaneous and genotoxin-related mutations.	Oregon Hlth & Sci Univ, CROET, Portland, OR 97201 USA; Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA; Univ Kentucky, Dept Pathol & Lab Med, Lexington, KY USA; Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA	Oregon Health & Science University; Oregon State University; University of Kentucky; Oregon Health & Science University	Turker, MS (corresponding author), Oregon Hlth & Sci Univ, CROET, L606,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	turkerm@ohsu.edu			NATIONAL CANCER INSTITUTE [R01CA076528, R01CA056383] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045535, R29GM045535] Funding Source: NIH RePORTER; NCI NIH HHS [CA56383, CA76528] Funding Source: Medline; NIEHS NIH HHS [1P42 ES10338] Funding Source: Medline; NIGMS NIH HHS [GM45535] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrew SE, 2000, CARCINOGENESIS, V21, P1291, DOI 10.1093/carcin/21.7.1291; Andrew SE, 1997, ONCOGENE, V15, P123, DOI 10.1038/sj.onc.1201180; Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; Baross-Francis A, 1998, P NATL ACAD SCI USA, V95, P8739, DOI 10.1073/pnas.95.15.8739; Baross-Francis A, 2001, ONCOGENE, V20, P619, DOI 10.1038/sj.onc.1204138; BHATTACHARYYA NP, 1995, HUM MOL GENET, V4, P2057, DOI 10.1093/hmg/4.11.2057; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Buettner VL, 2000, MUTAT RES-FUND MOL M, V452, P219, DOI 10.1016/S0027-5107(00)00090-7; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; DROBETSKY EA, 1987, P NATL ACAD SCI USA, V84, P9103, DOI 10.1073/pnas.84.24.9103; Glaab WE, 2000, CANCER RES, V60, P4921; Glaab WE, 1998, MUTAT RES-FUND MOL M, V398, P197, DOI 10.1016/S0027-5107(98)00004-9; Hardman RA, 2001, CANCER RES, V61, P1392; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; HARWOOD J, 1991, MOL CELL BIOL, V11, P3163, DOI 10.1128/MCB.11.6.3163; HORN PL, 1984, J CELL PHYSIOL, V121, P309, DOI 10.1002/jcp.1041210207; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KANJILAL S, 1993, CANCER RES, V53, P2961; Kato T, 1998, MUTAT RES-FUND MOL M, V422, P279, DOI 10.1016/S0027-5107(98)00208-5; Khattar NH, 1997, SOMAT CELL MOLEC GEN, V23, P51, DOI 10.1007/BF02679955; KOZAK C, 1975, SOMAT CELL GENET, V1, P371, DOI 10.1007/BF01538668; Kuraguchi M, 2000, ONCOGENE, V19, P5755, DOI 10.1038/sj.onc.1203962; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; Li GM, 1999, ONCOL RES, V11, P393; Liu HB, 2000, GENETICS, V154, P503; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Loeb KR, 2000, CARCINOGENESIS, V21, P379, DOI 10.1093/carcin/21.3.379; LOEB LA, 1991, CANCER RES, V51, P3075; Luria SE, 1943, GENETICS, V28, P491; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; O'Driscoll M, 1999, CARCINOGENESIS, V20, P799, DOI 10.1093/carcin/20.5.799; Ohzeki S, 1997, CARCINOGENESIS, V18, P1127, DOI 10.1093/carcin/18.6.1127; PARSONS R, 1995, CANCER RES, V55, P5548; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Phear G, 1996, MOL CELL BIOL, V16, P6516; Rose JA, 2000, CANCER RES, V60, P3404; Schmutte C, 1998, BIOL CHEM, V379, P377; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Strauss BS, 2000, MUTAT RES-FUND MOL M, V457, P93, DOI 10.1016/S0027-5107(00)00135-4; Strauss BS, 1998, GENETICS, V148, P1619; Strauss BS, 1997, CARCINOGENESIS, V18, P1445, DOI 10.1093/carcin/18.8.1445; Strauss BS, 1998, SEMIN CANCER BIOL, V8, P431, DOI 10.1006/scbi.1998.0092; Takeuchi S, 1998, CANCER RES, V58, P641; Tobi SE, 1999, CARCINOGENESIS, V20, P1293, DOI 10.1093/carcin/20.7.1293; Tomita-Mitchell A, 2000, MUTAT RES-FUND MOL M, V450, P125, DOI 10.1016/S0027-5107(00)00020-8; Tornaletti S, 1996, BIOESSAYS, V18, P221, DOI 10.1002/bies.950180309; TURKER M, 1995, MUTAT RES-FUND MOL M, V329, P97, DOI 10.1016/0027-5107(95)00046-L; Turker MS, 1998, SEMIN CANCER BIOL, V8, P407, DOI 10.1006/scbi.1998.0112; Turker MS, 1999, CANCER RES, V59, P1837; vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8; Wang HX, 1999, J BIOL CHEM, V274, P16894, DOI 10.1074/jbc.274.24.16894; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; Yao X, 1999, P NATL ACAD SCI USA, V96, P6850, DOI 10.1073/pnas.96.12.6850	57	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1768	1776		10.1038/sj.onc.1205241	http://dx.doi.org/10.1038/sj.onc.1205241			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896608				2022-12-17	WOS:000174214200015
J	Zhou, H; Chen, WD; Qin, XS; Lee, K; Liu, LL; Markowitz, SD; Gerson, SL				Zhou, H; Chen, WD; Qin, XS; Lee, K; Liu, LL; Markowitz, SD; Gerson, SL			MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice	ONCOGENE			English	Article						c-neu transgenic mice; mammary tumor; DNA hypomethylation; MNU; MMTV promoter	METHYL-N-NITROSOUREA; DE-NOVO METHYLATION; HUMAN-BREAST-CANCER; DNA METHYLATION; FOREIGN DNA; HUMAN MGMT; RAS ONCOGENE; INDUCTION; TUMORS; ALKYLTRANSFERASE	The erbB family of receptor tyrosine kinases is frequently implicated in neoplasia. Amplification and overexpression of erbB2/neu has been found in 20 to 40% of human breast cancers. Previous studies using MMTV/c-neu transgenic mice have linked rat neu overexpression to mammary tumor development. In this study, we provide evidence that rat neu overexpression in mammary tumors of MMTV/c-neu transgenic mice is always associated with demethylation of the MMTV promoter, whereas the normal mammary glands of these transgenic mice always contain specific methylated regions of the MMTV promoter. In addition, after exposure to N-methyl-N-nitrosourea (MNU), the latency of mammary tumor development is significantly reduced and again is also associated with MMTV promoter demethylation. Thus, the transition from methylation to hypomethylation of the MMTV promoter induces high-level expression of c-neu and appears to be a prerequisite for transformation from normal to malignant mammary epithelium, either spontaneously or after carcinogen exposure. Expression of transgenic c-neu from the demethylated MMTV promoter appears to be an early event that allows outgrowth of mammary epithelium predisposed to malignant transformation.	Case Western Reserve Univ, Univ Hosp, Div Hematol Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Comprehens Canc, Cleveland, OH 44106 USA; Howard Hughes Med Inst, Cleveland, OH 44106 USA	Case Western Reserve University; University Hospitals of Cleveland; Case Western Reserve University; Howard Hughes Medical Institute	Gerson, SL (corresponding author), Case Western Reserve Univ, Univ Hosp, Div Hematol Oncol, BRB-3W,10900 Euclid Ave, Cleveland, OH 44106 USA.	slg5@po.cwru.edu	CHEN, WEI-DONG/F-4521-2014	CHEN, WEI-DONG/0000-0003-2264-5515	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006288] Funding Source: NIH RePORTER; NIEHS NIH HHS [5R01 ES 06288] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allay E, 1997, ONCOGENE, V15, P2127, DOI 10.1038/sj.onc.1201384; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; Asamoto M, 2000, CARCINOGENESIS, V21, P243, DOI 10.1093/carcin/21.2.243; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; Betzl G, 1996, BIOL CHEM, V377, P711, DOI 10.1515/bchm3.1996.377.11.711; BOEHM TLJ, 1983, RECENT RES CANCER, V84, P212; BOEHM TLJ, 1981, CARCINOGENESIS, V2, P39, DOI 10.1093/carcin/2.1.39; BOEHM TLJ, 1983, J NATL CANCER I, V71, P429; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Cervoni N, 1999, J BIOL CHEM, V274, P8363, DOI 10.1074/jbc.274.13.8363; CHALLITA PM, 1994, P NATL ACAD SCI USA, V91, P2567, DOI 10.1073/pnas.91.7.2567; Cohen BD, 1998, BIOCHEM SOC SYMP, P199; Doerfler W, 1997, TRENDS BIOTECHNOL, V15, P297, DOI 10.1016/S0167-7799(97)01061-5; DOERFLER W, 1995, GENE, V157, P241, DOI 10.1016/0378-1119(95)00080-P; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FONG LYY, 1990, CARCINOGENESIS, V11, P411, DOI 10.1093/carcin/11.3.411; FREI JV, 1980, J NATL CANCER I, V64, P845; Garrick D, 1998, NAT GENET, V18, P56, DOI 10.1038/ng0198-56; GERSON SL, 1985, J CLIN INVEST, V76, P2106, DOI 10.1172/JCI112215; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HANADA M, 1993, BLOOD, V82, P1820; Hung MC, 1999, SEMIN ONCOL, V26, P51; Issa JP, 2000, CURR TOP MICROBIOL, V249, P101; Lorincz MC, 2000, MOL CELL BIOL, V20, P842, DOI 10.1128/MCB.20.3.842-850.2000; LU SJ, 1992, MOL CARCINOGEN, V6, P260, DOI 10.1002/mc.2940060407; Menard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; OREND G, 1995, J VIROL, V69, P1226, DOI 10.1128/JVI.69.2.1226-1242.1995; Pikaart MI, 1998, GENE DEV, V12, P2852, DOI 10.1101/gad.12.18.2852; Qin XS, 1999, ONCOGENE, V18, P4394, DOI 10.1038/sj.onc.1202798; Qin XS, 1999, CARCINOGENESIS, V20, P1667, DOI 10.1093/carcin/20.9.1667; RAO PM, 1989, CARCINOGENESIS, V10, P933, DOI 10.1093/carcin/10.5.933; Robertson G, 1996, NUCLEIC ACIDS RES, V24, P1465, DOI 10.1093/nar/24.8.1465; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Young LH, 1996, MOL CARCINOGEN, V15, P251, DOI 10.1002/(SICI)1098-2744(199604)15:4<251::AID-MC2>3.0.CO;2-J; ZAIDI NH, 1995, CARCINOGENESIS, V16, P451, DOI 10.1093/carcin/16.3.451; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	44	20	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2001	20	42					6009	6017		10.1038/sj.onc.1204830	http://dx.doi.org/10.1038/sj.onc.1204830			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593408				2022-12-17	WOS:000171056300008
J	Bryckaert, M; Guillonneau, X; Hecquet, C; Perani, P; Courtois, Y; Mascarelli, F				Bryckaert, M; Guillonneau, X; Hecquet, C; Perani, P; Courtois, Y; Mascarelli, F			Regulation of proliferation-survival decisions is controlled by FGF1 secretion in retinal pigmented epithelial cells	ONCOGENE			English	Article						FGF1; proliferation; apoptosis; ERK2; retinal pigmented epithelial cells	FIBROBLAST-GROWTH-FACTOR; HUMAN BREAST-CANCER; ACTIVATED PROTEIN-KINASE; FACTOR-I; MAP KINASE; EXTRACELLULAR-MATRIX; NUCLEAR-LOCALIZATION; NEUROTROPHIC FACTORS; PROMOTES APOPTOSIS; CARCINOMA-CELLS	Fibroblast growth factor 1 (FGF1) induces proliferation and differentiation in a wide variety of cells of mesodermal and neuroectodermal origin. FGF1 has no 'classical' signal sequence to direct its secretion, and there has been considerable debate concerning FGF1 secretion and its role in the biological activities of FGF1, We investigated the effects of FGF1 secretion and the signalling induced by signal peptide (SP)-containing FGF1 and SP-less FGF1, on the proliferation and the apoptosis in retinal pigmented epithelial (RPE) cells, Primary RPE cell cultures were transfected with FGF1 (FGF1 cells) and SP-FGF1 (SP-FGF1 cells) cDNAs. SP-FGF1 cells secreted large amount of FGF1 and actively proliferated, whereas FGF1 and control cells did not. Secreted FGF1 induced short-term activation of both FGFR1 and ERK2, which were required for cell proliferation, In contrast, SP-FGF1 cells stopped secreting FGF1 and died rapidly, if cultured in the absence of serum. Surprisingly, FGF1 cells, but not control cells, secreted FGF1 and were resistant to apoptosis induced by serum depletion, Secreted FGF1 induced long-term activation of FGFR1 and ERK2, which was necessary to induce a constant and high level of Bcl-x production, and to induce cell survival in FGF1 cells. Downregulation of ERK2 and Bcl-x increased apoptosis, Thus, the proliferation and survival activities of FGF1 depend on the secretion of FGF1 which is determined by the cell culture conditions. Cell proliferation was SP-dependent, whereas cell survival was not. The signal peptide controls the level and duration, 'whispering or shouting', of ERK2 activation cells which determines FGF1 biological function and may have important implications for anti-degenerative and antiproliferative treatments.	Assoc Claude Bernard, CNRS, INSERM U450, F-75016 Paris, France; IFR Circulat, INSERM U348, F-75010 Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Mascarelli, F (corresponding author), Assoc Claude Bernard, CNRS, INSERM U450, 29 Rue Wilhem, F-75016 Paris, France.		Guillonneau, xavier/E-3995-2017; guillonneau, xavier/AAF-9495-2021; Mascarelli, Frederic/L-8916-2018	Guillonneau, xavier/0000-0001-7379-3935; guillonneau, xavier/0000-0001-7379-3935; Bryckaert, Marijke/0000-0003-3398-0976				Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; Ananyeva NM, 1997, ARTERIOSCL THROM VAS, V17, P445, DOI 10.1161/01.ATV.17.3.445; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BAUDOUIN C, 1993, OPHTHALMIC RES, V25, P52, DOI 10.1159/000267221; BLAM SB, 1988, ONCOGENE, V3, P129; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BRADSHAW RA, 1990, PROG BRAIN RES, V86, P157; Bryckaert M, 1999, ONCOGENE, V18, P7584, DOI 10.1038/sj.onc.1203200; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAO YH, 1993, GROWTH FACTORS, V8, P277, DOI 10.3109/08977199308991573; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042; Chesnut JD, 1996, J IMMUNOL METHODS, V193, P17, DOI 10.1016/0022-1759(96)00032-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARENC JP, 1993, J BIOL CHEM, V268, P5600; DENNIS PA, 1990, J CELL PHYSIOL, V144, P84, DOI 10.1002/jcp.1041440112; Desire L, 1998, DEV DYNAM, V212, P63, DOI 10.1002/(SICI)1097-0177(199805)212:1<63::AID-AJA6>3.0.CO;2-0; Enzmann V, 1998, OPHTHALMIC RES, V30, P189, DOI 10.1159/000055473; FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0; Fenig E, 1999, J CANCER RES CLIN, V125, P556, DOI 10.1007/s004320050316; FENNEWALD SM, 1995, J BIOL CHEM, V270, P21718, DOI 10.1074/jbc.270.37.21718; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; Guillonneau X, 1997, EXP CELL RES, V233, P198, DOI 10.1006/excr.1997.3542; Guillonneau X, 1998, J BIOL CHEM, V273, P22367, DOI 10.1074/jbc.273.35.22367; Guillonneau X, 1996, J CELL PHYSIOL, V166, P170, DOI 10.1002/(SICI)1097-4652(199601)166:1<170::AID-JCP19>3.0.CO;2-J; Guillonneau X, 1998, GROWTH FACTORS, V15, P95, DOI 10.3109/08977199809117186; Guillonneau X, 2000, DEV DYNAM, V217, P24, DOI 10.1002/(SICI)1097-0177(200001)217:1<24::AID-DVDY3>3.0.CO;2-C; GUVAKOVA MA, 1995, J BIOL CHEM, V270, P2620, DOI 10.1074/jbc.270.6.2620; Hackett SF, 1997, EXP EYE RES, V64, P865, DOI 10.1006/exer.1996.0256; HER JH, 1991, NUCLEIC ACIDS RES, V19, P37; Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203; Hjelmeland L M, 1988, Birth Defects Orig Artic Ser, V24, P87; IMAMURA T, 1994, EXP CELL RES, V215, P363, DOI 10.1006/excr.1994.1353; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JOUANNEAU J, 1991, P NATL ACAD SCI USA, V88, P2893, DOI 10.1073/pnas.88.7.2893; Jouanneau J, 1997, ONCOGENE, V14, P671, DOI 10.1038/sj.onc.1200883; JOUANNEAU J, 1995, GROWTH FACTORS, V12, P37, DOI 10.3109/08977199509003212; Karsan A, 1997, AM J PATHOL, V151, P1775; Klingenberg O, 1999, J BIOL CHEM, V274, P18081, DOI 10.1074/jbc.274.25.18081; Konig A, 1997, LEUKEMIA, V11, P258, DOI 10.1038/sj.leu.2400556; Levin LA, 1997, INVEST OPHTH VIS SCI, V38, P2545; LEWIS GP, 1992, J NEUROSCI, V12, P3968; LEZOUALCH F, 1995, J BIOL CHEM, V270, P12100, DOI 10.1074/jbc.270.20.12100; Lin YZ, 1996, J BIOL CHEM, V271, P5305, DOI 10.1074/jbc.271.10.5305; MALECAZE F, 1993, J CELL PHYSIOL, V154, P631, DOI 10.1002/jcp.1041540323; Maloof P, 1999, BREAST CANCER RES TR, V56, P153; MASCARELLI F, 1989, EMBO J, V8, P2265, DOI 10.1002/j.1460-2075.1989.tb08351.x; MASON I, 1994, CURR BIOL, V4, P1158, DOI 10.1016/S0960-9822(00)00263-3; Mishima K, 1998, MODERN PATHOL, V11, P886; Navarro P, 1998, EXP CELL RES, V243, P213, DOI 10.1006/excr.1998.4168; Raguenez G, 1999, BIOCHEM BIOPH RES CO, V258, P745, DOI 10.1006/bbrc.1999.0613; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Ren GY, 2000, JPN J OPHTHALMOL, V44, P308, DOI 10.1016/S0021-5155(00)00149-0; Renaud F, 1996, J BIOL CHEM, V271, P2801, DOI 10.1074/jbc.271.5.2801; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SATO Y, 1988, J CELL BIOL, V107, P1129; Shin JT, 1996, BBA-MOL CELL RES, V1312, P27, DOI 10.1016/0167-4889(96)00013-4; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Spear N, 1998, ARCH BIOCHEM BIOPHYS, V356, P41, DOI 10.1006/abbi.1998.0741; VLODAVSKY I, 1982, EXP CELL RES, V140, P149, DOI 10.1016/0014-4827(82)90166-5; Wang Q, 1998, EXP CELL RES, V238, P177, DOI 10.1006/excr.1997.3820; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; Wiedlocha A, 1996, MOL CELL BIOL, V16, P270; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; Yazlovitskaya EM, 1999, MOL CARCINOGEN, V25, P14, DOI 10.1002/(SICI)1098-2744(199905)25:1<14::AID-MC2>3.0.CO;2-V; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N; ZHAN X, 1993, J BIOL CHEM, V268, P9611	72	20	22	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4917	4929		10.1038/sj.onc.1203872	http://dx.doi.org/10.1038/sj.onc.1203872			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039909				2022-12-17	WOS:000089757800014
J	Lane, TF; Lin, CW; Brown, MA; Solomon, E; Leder, P				Lane, TF; Lin, CW; Brown, MA; Solomon, E; Leder, P			Gene replacement with the human BRCA1 locus: tissue specific expression and rescue of embryonic lethality in mice	ONCOGENE			English	Article						transgenic; BRCA1; tumor suppressor; gene transfer	OVARIAN-CANCER; BRCA1-DEFICIENT MICE; BREAST CARCINOMAS; MEIOTIC CELLS; DNA-REPAIR; MUTATIONS; P53; REGION; SUSCEPTIBILITY; METHYLATION	We have generated transgenic mice that harbor a 140 kb genomic fragment of the human BRCA1 locus (TgN.BRCA1(GEN)). We find that the transgene directs appropriate expression of human BRCA1 transcripts in multiple mouse tissues, and that human BRCA1 protein is expressed and stabilized following exposure to DIVA damage, Such mice are completely normal, with no overt signs of BRCA1 toxicity commonly observed when BRCA1 is expressed from heterologous promoters. Most importantly, however, the transgene rescues the otherwise lethal phenotype associated with the targeted hypomorphic allele (Brca1(Delta exIISA)). Brca1(-/-); TgN.BRCA1(GEN) bigenic animals develop normally and can be maintained as a distinct line. These results show that a 140 kb fragment of chromosome 17 contains all elements necessary for the correct expression, localization, and function of the BRCA1 protein, Further, the model provides evidence that function and regulation of the human BRCA1 gene can be studied and manipulated in a genetically tractable mammalian system.	Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Guys Hosp, Div Med & Mol Genet, GKT, Sch Med, London SE1 9RT, England; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Melbourne; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Lane, TF (corresponding author), Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, 10833 Le Conte Ave,27-139 CHS, Los Angeles, CA 90095 USA.		Brown, Melissa A/F-1451-2010	Lane, Timothy F./0000-0002-0210-970X; Brown, Melissa/0000-0002-2830-9259	Medical Research Council [G9600577] Funding Source: Medline; MRC [G9600577] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; *BIC, 1999, BREAST CANC INF COR; BIESECKER BB, 1993, JAMA-J AM MED ASSOC, V269, P1970, DOI 10.1001/jama.269.15.1970; BROWN MA, 1995, P NATL ACAD SCI USA, V92, P4362, DOI 10.1073/pnas.92.10.4362; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; CHEN JJ, 1999, CANCER RES, V59, P1752; Cressman VL, 1999, MOL CELL BIOL, V19, P7061; Cressman VL, 1999, CELL GROWTH DIFFER, V10, P1; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; Maul GG, 1998, CELL GROWTH DIFFER, V9, P743; Phillips KA, 1999, J NATL CANCER I, V91, P469, DOI 10.1093/jnci/91.5.469; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shao NS, 1996, ONCOGENE, V13, P1; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Whittemore AS, 1997, AM J HUM GENET, V60, P496; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; WILSON CA, 1997, ONCOGENE, V9, P1; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zabludoff SD, 1996, ONCOGENE, V13, P649; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	35	20	21	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4085	4090		10.1038/sj.onc.1203760	http://dx.doi.org/10.1038/sj.onc.1203760			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962568				2022-12-17	WOS:000088955100001
J	von Lintig, FC; Pilz, RB; Boss, GR				von Lintig, FC; Pilz, RB; Boss, GR			Quantitative determination of Rap 1 activation in cyclic nucleotide-treated HL-60 leukemic cells: lack of Rap 1 activation in variant cells	ONCOGENE			English	Article						Rap 1; HL-60; cells; cAMP; cGMP	DEPENDENT PROTEIN-KINASE; CGMP-INDUCED DIFFERENTIATION; HUMAN NEUTROPHILS; BINDING PROTEINS; GENE-EXPRESSION; GROWTH-FACTOR; PHASE-SEPARATION; EXCHANGE PROTEIN; HUMAN-PLATELETS; TRITON X-114	We have previously isolated variant HL-60 cells that are resistant to cGMP-induced differentiation and showed that they are deficient in proteolytic cleavage and/or carboxyl methylation of Rap 1A (J. Biol. Chem. 269, 32155-32161, 1994 and Oncogene 17, 2211-2233, 1998). We have now developed an enzyme-based method for assessing Rap 1 activation which is quantitative and provides a measurement of the per cent of Rap molecules in the active GTP-bound state. Using this method, we show that cAMP and cGMP analogs activate Rap 1 in parental HL-60 cells but not in the variant cells and that H-89, a cAMP-dependent protein kinase inhibitor, has no effect on cAMP-induced Rap 1 activation in parental cells. Thus, cAMP activation of Rap 1 in HL-60 cells is likely through a cAMP-regulated guanine nucleotide exchange factor (cAMP-GEF) and since cAMP does not activate Rap 1 in the variant cells, the data suggest that full post-translational processing of Rap 1 is necessary for cAMP-GEF activation of Rap 1. Activation of Rap 1 by cGMP analogs has not been previously found and suggests possible cross-talk between the NO/cGMP signal transduction pathway and Rap 1 signaling.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Boss, GR (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.			Boss, Gerry/0000-0002-9758-8714	NCI NIH HHS [R21 CA81115] Funding Source: Medline; NIGMS NIH HHS [R01GM055586] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA081115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055586] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI M, 1992, ONCOGENE, V7, P323; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Asha H, 1999, EMBO J, V18, P605, DOI 10.1093/emboj/18.3.605; BOKOCH GM, 1990, BIOCHEM J, V267, P407, DOI 10.1042/bj2670407; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Bos JL, 1997, FEBS LETT, V410, P59, DOI 10.1016/S0014-5793(97)00324-4; BOSS GR, 1989, P NATL ACAD SCI USA, V86, P7174, DOI 10.1073/pnas.86.18.7174; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; CHAPLINSKI TJ, 1982, J CLIN INVEST, V70, P953, DOI 10.1172/JCI110707; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GANONG BR, 1991, ANAL BIOCHEM, V193, P35, DOI 10.1016/0003-2697(91)90039-V; Gudi T, 1996, J BIOL CHEM, V271, P4597; Guha A, 1996, ONCOGENE, V12, P507; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; HART PA, 1990, ONCOGENE, V5, P1099; HATA Y, 1991, J BIOL CHEM, V266, P6571; HATTORI S, 1987, MOL CELL BIOL, V7, P1999, DOI 10.1128/MCB.7.5.1999; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kurachi H, 1997, J BIOL CHEM, V272, P28081, DOI 10.1074/jbc.272.44.28081; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; Liu ML, 1998, ONCOGENE, V17, P2403, DOI 10.1038/sj.onc.1202456; M'Rabet L, 1998, BLOOD, V92, P2133, DOI 10.1182/blood.V92.6.2133.418k19_2133_2140; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; ORITA S, 1993, J BIOL CHEM, V268, P25542; Pham N, 2000, CURR BIOL, V10, P555, DOI 10.1016/S0960-9822(00)00473-5; Pilz RB, 1997, CELL GROWTH DIFFER, V8, P53; PILZ RB, 1994, J BIOL CHEM, V269, P32155; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SCHEELE JS, 1994, J BIOL CHEM, V269, P18599; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; Scheele JS, 1998, ONCOGENE, V17, P2211, DOI 10.1038/sj.onc.1202137; Scheele JS, 1998, MOL CELL BIOCHEM, V185, P111, DOI 10.1023/A:1006834324419; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; SHIRATAKI H, 1991, J BIOL CHEM, V266, P20672; Suhasini M, 1998, MOL CELL BIOL, V18, P6983, DOI 10.1128/MCB.18.12.6983; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; YAMASHIRO S, 1993, LEUKEMIA RES, V17, P129, DOI 10.1016/0145-2126(93)90057-R; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	54	20	20	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2000	19	35					4029	4034		10.1038/sj.onc.1203741	http://dx.doi.org/10.1038/sj.onc.1203741			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962559				2022-12-17	WOS:000088825300008
J	Go, C; He, W; Zhong, L; Li, P; Huang, J; Brinkley, BR; Wang, XJ				Go, C; He, W; Zhong, L; Li, P; Huang, J; Brinkley, BR; Wang, XJ			Aberrant cell cycle progression contributes to the early-stage accelerated carcinogenesis in transgenic epidermis expressing the dominant negative TGF beta RII	ONCOGENE			English	Article						skin carcinogenesis; transforming growth factor beta receptor; transgenic; cell cycle progression; cdk inhibitors; centrosome	GROWTH-FACTOR-BETA; II RECEPTOR GENE; CHEMICAL CARCINOGENESIS; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; DOWN-REGULATION; CDK INHIBITOR; MUTATION; MICE; ARREST	Mutations in the transforming growth factor beta type II receptor (TGF beta RII) have been found in various malignant tumors, suggesting that loss of TGF beta signaling plays a causal role in late-stage cancer development, To test whether loss of TGF beta RII is involved in early-stage carcinogenesis, ne have generated transgenic mice expressing a dominant negative TGF beta RII (Delta beta RII) in the epidermis, These mice exhibited an increased susceptibility to chemical carcinogenesis protocols at both early and late stages. In the current study, parameters for cell cycle progression and chromosome instability were analysed in Delta beta RII tumors. Delta beta RII papillomas showed an increased S phase in flow cytometry. Bromodeoxyuridine (BrdU) labeling and mitotic indices in Delta beta RII papillomas also showed a threefold increase compared to papillomas developing in non-transgenic mice, When papillomas further progressed to squamous cell carcinomas (SCC), both control and Delta beta RII SCC showed similar BrdU labeling indices and percentages of S phase cells. However, Delta beta RII SCC cells showed a sixfold increase in the G2/M population. Mitotic indices in Delta beta RII SCC also showed a threefold increase compared to non-transgenic SCC, Consistent with a perturbed cell cycle, Delta beta RII papillomas and SCC showed reduced expression of the TGF beta target genes p15 (INK4b), p21 (WAF-1) and p27 (Kip1), inhibitors of cyclin-dependent kinases (cdks). However, most Delta beta RII papilloma cells exhibited normal centrosome numbers, and Delta beta RII SCC exhibited a similar extent of centrosome abnormalities compared to control SCC (35-40% cells). Most of Delta beta RII SCC exhibited diploid chromosome profiles. These data indicate that inactivation of TGF beta RII accelerates skin tumorigenesis at early stages by the acceleration of loss of cell cycle control, but not by increased chromosome instability.	Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA; Baylor Coll Med, Dept Otolaryngol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Wang, XJ (corresponding author), Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA.				NCI NIH HHS [CA64255, CA79998] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA064255, R01CA079998] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDAZ CM, 1987, P NATL ACAD SCI USA, V84, P2029, DOI 10.1073/pnas.84.7.2029; BERTSCH S, 1982, CELL TISSUE KINET, V15, P81, DOI 10.1111/j.1365-2184.1982.tb01026.x; Bottinger EP, 1997, EMBO J, V16, P2621, DOI 10.1093/emboj/16.10.2621; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CONTI CJ, 1986, CARCINOGENESIS, V7, P1845, DOI 10.1093/carcin/7.11.1845; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; Filmus Jorge, 1993, Current Opinion in Oncology, V5, P123; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Glick A, 1999, P NATL ACAD SCI USA, V96, P14949, DOI 10.1073/pnas.96.26.14949; Go C, 1999, CANCER RES, V59, P2861; Gorska AE, 1998, CELL GROWTH DIFFER, V9, P229; GREENHALGH DA, 1989, MOL CARCINOGEN, V2, P199, DOI 10.1002/mc.2940020406; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Iacopetta BJ, 1998, J PATHOL, V184, P390; Iavarone A, 1997, NATURE, V387, P417; Imai Y, 1998, INT J CANCER, V76, P407, DOI 10.1002/(SICI)1097-0215(19980504)76:3<407::AID-IJC19>3.0.CO;2-7; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; LU SL, 1995, BIOCHEM BIOPH RES CO, V216, P452, DOI 10.1006/bbrc.1995.2644; Lu SL, 1998, NAT GENET, V19, P17, DOI 10.1038/ng0598-17; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MURPHY CS, 1991, COLD SPRING HARB SYM, V56, P129; MYEROFF LL, 1995, CANCER RES, V55, P5545; Nagahara H, 1999, P NATL ACAD SCI USA, V96, P14961, DOI 10.1073/pnas.96.26.14961; Nagase H, 1999, P NATL ACAD SCI USA, V96, P15032, DOI 10.1073/pnas.96.26.15032; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SATTERWHITE DJ, 1994, INVAS METAST, V14, P309; Takenoshita S, 1997, ONCOGENE, V14, P1255, DOI 10.1038/sj.onc.1200938; VANDIEST PJ, 1992, HUM PATHOL, V23, P603, DOI 10.1016/0046-8177(92)90313-R; Venkatasubbarao K, 1998, GENE CHROMOSOME CANC, V22, P138, DOI 10.1002/(SICI)1098-2264(199806)22:2<138::AID-GCC8>3.0.CO;2-Y; Wang D, 1997, CARCINOGENESIS, V18, P2285, DOI 10.1093/carcin/18.11.2285; Wang XJ, 1998, MOL CARCINOGEN, V23, P185, DOI 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5; Wang XJ, 1997, P NATL ACAD SCI USA, V94, P2386, DOI 10.1073/pnas.94.6.2386; Wang XJ, 1998, ONCOGENE, V17, P35, DOI 10.1038/sj.onc.1201890; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	43	20	24	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3623	3631		10.1038/sj.onc.1203701	http://dx.doi.org/10.1038/sj.onc.1203701			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951568				2022-12-17	WOS:000088568300008
J	Liu, JS; Prolla, G; Rostagno, A; Chiarle, R; Feiner, H; Inghirami, G				Liu, JS; Prolla, G; Rostagno, A; Chiarle, R; Feiner, H; Inghirami, G			Initiation of translation from a downstream in-frame AUG codon on BRCA1 can generate the novel isoform protein Delta BRCA1(17aa)	ONCOGENE			English	Article						BRCA1; translational regulation	SPORADIC BREAST-CANCER; MAMMARY EPITHELIAL-CELLS; DNA-DAMAGE RESPONSE; OVARIAN-CANCER; TRANSCRIPTIONAL ACTIVATION; NUCLEAR PHOSPHOPROTEIN; PROMOTER REGION; SPLICE VARIANTS; FAMILIAL BREAST; TUMOR-FORMATION	Expression of the breast and ovarian cancer gene BRCA1 is regulated at both the transcriptional and post-transcriptional levels. We found that the expression of the BRCA1 protein may also be regulated at the translational level. In addition to an AUG start codon at position 1, BRCA1 mRNA has a second in-frame AUG (+17) that acts as an alternative start codon to generate a novel BRCA1 protein that lacks the first 17 amino acids (Delta BRCA1(17aa)). We fused cDNAs encoding the second exon of BRCA1 of the wild-type BRCA1 gene (wt-BRCA1) and a mutated BRCA1 gene (mt-BRCA1), in which the first initiation site and its Kozak consensus sequence were abolished, with the nucleophosmin (NPM) reporter gene and used them for in vitro and in vivo translation assays, In both systems, the wt-BRCA1-NPM constructs produced two distinct proteins (18 and 16 kD) begun from the first and second AUGs, The mt-BRCA1-NPM constructs produced only the shorter 16-kD protein lacking the first 17 amino acids of the BRCA1 gene. Next, we analysed the N-terminal protein sequence of purified BRCA1 protein from normal thymocytes and found two different BRCA1 proteins, derived from translation of the first and second in-frame AUGs, Thus, BRCA1 protein expression can be regulated at the translation level in normal cells, Characterization of Delta BRCA1(17aa) may shed light on the function and regulation of BRCA1 in normal cells as well as the pathogenesis of breast and ovarian cancers.	NYU Med Ctr, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU Med Ctr, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	New York University; New York University	Inghirami, G (corresponding author), NYU Med Ctr, Sch Med, Dept Pathol, 550 1st Ave, New York, NY 10016 USA.		PROLLA, GABRIEL/T-3669-2018; Prolla, Gabriel/AAH-6332-2019; Rostagno, Agueda/A-5801-2008	CHIARLE, Roberto/0000-0003-1564-8531; Rostagno, Agueda/0000-0002-6817-2074	NATIONAL CANCER INSTITUTE [T32CA009454, R21CA066229] Funding Source: NIH RePORTER; NCI NIH HHS [R21-CA66229, CA-2T32CA09454] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brown MA, 1996, ONCOGENE, V12, P2507; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; COLIZAN JE, CURR PROTOCOLS PRO S; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Cressman VL, 1999, CELL GROWTH DIFFER, V10, P1; Cui JQ, 1998, ONCOL REP, V5, P591; Dobrovic A, 1997, CANCER RES, V57, P3347; EASTON DF, 1993, AM J HUM GENET, V52, P678; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; INGHIRAMI G, 1994, BLOOD, V83, P3581; Irminger-Finger I, 1999, BIOL CHEM, V380, P117, DOI 10.1515/BC.1999.019; Irminger-Finger I, 1998, J CELL BIOL, V143, P1329, DOI 10.1083/jcb.143.5.1329; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Lee WY, 1999, HISTOPATHOLOGY, V34, P106; Lu ML, 1996, CANCER RES, V56, P4578; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu CF, 1997, HUM MOL GENET, V6, P1057, DOI 10.1093/hmg/6.7.1057; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	53	20	21	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 25	2000	19	23					2767	2773		10.1038/sj.onc.1203599	http://dx.doi.org/10.1038/sj.onc.1203599			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851077				2022-12-17	WOS:000087318500005
J	Lucas, L; del Peso, L; Rodriguez, P; Penalva, V; Lacal, JC				Lucas, L; del Peso, L; Rodriguez, P; Penalva, V; Lacal, JC			Ras protein is involved in the physiological regulation of phospholipase D by platelet derived growth factor	ONCOGENE			English	Article						ras; oncogenes; growth factors; PDGF; phospholipase D	KINASE-C-ALPHA; ADP-RIBOSYLATION FACTOR; GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; XENOPUS-LAEVIS OOCYTES; GTP-BINDING PROTEINS; SMOOTH-MUSCLE CELLS; D ACTIVATION; SIGNAL-TRANSDUCTION; LYSOPHOSPHATIDIC ACID	Lipid-derived metabolites play an important role in the regulation of cell responses to external stimuli, including cell growth control, transformation and apoptosis, Phospholipase D (PLD) is one of the critical elements in the regulation of lipid metabolism and the generation of second messengers, some of them involved in cell growth control. Oncogenic Ras proteins affect the activity of PLD by two alternate mechanisms, involving a positive activation and a feedback negative loop. Here we investigate the involvement of the proto-oncogenic Ras protein in the physiological activation of PLD induced by platelet-derived growth factor (PDGF), Over-expression of the wild type Ras protein or some of its regulatory components, such as Shc or Grb2, induces an amplification of PLD activation by PDGF challenge. Furthermore, blocking the endogenous Ras by expression of the dominant negative mutant, H-Ras-Asn(17) completely eliminated the activation of PLD by PDGF, Thus, PDGF requires a complex system for PLD regulation implying the existence of at least two positive regulatory pathways, a Ras-dependent and a PKC-dependent mechanism. These results imply that PLD is an important element in signaling by Ras proteins that is altered after I as-induced transformation.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Lacal, JC (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.		del Peso, Luis/K-9391-2014; Lacal, Juan Carlos/AAL-2235-2020; Lacal, Juan Carlos/N-9064-2015	del Peso, Luis/0000-0003-4014-5688; Lacal, Juan Carlos/0000-0002-1908-2777				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BENAV P, 1989, FEBS LETT, V259, P64, DOI 10.1016/0014-5793(89)81495-4; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BOURGOIN S, 1995, J BIOL CHEM, V270, P3172, DOI 10.1074/jbc.270.7.3172; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CARNERO A, 1994, J CELL BIOCHEM, V54, P478, DOI 10.1002/jcb.240540415; CARNERO A, 1994, ONCOGENE, V9, P1387; CARNERO A, 1995, MOL CELL BIOL, V15, P1094; CARNERO A, 1993, J CELL BIOCHEM, V52, P440, DOI 10.1002/jcb.240520408; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; delPeso L, 1997, BIOCHEM J, V322, P519; delPeso L, 1996, J CELL BIOCHEM, V61, P599, DOI 10.1002/(SICI)1097-4644(19960616)61:4<599::AID-JCB14>3.0.CO;2-B; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; ELDAR H, 1993, J BIOL CHEM, V268, P12560; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FREEMAN EJ, 1994, BIOCHEM J, V304, P543, DOI 10.1042/bj3040543; Frohman MA, 1996, CURR BIOL, V6, P945, DOI 10.1016/S0960-9822(02)00634-6; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOASTIN AS, 1986, CANCER RES, V46, P1015; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; HONG C, 1990, MOL CELL BIOL, V10, P5314; HUANG CF, 1990, J BIOL CHEM, V265, P14858; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JIANG H, 1995, J BIOL CHEM, V270, P6006, DOI 10.1074/jbc.270.11.6006; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KISS Z, 1992, BIOCHEM J, V285, P229, DOI 10.1042/bj2850229; KISS Z, 1991, BIOCHEM J, V276, P505, DOI 10.1042/bj2760505; KONDO T, 1992, J BIOL CHEM, V267, P23609; LACAL JC, 1994, ONCOL REP, V1, P677; Lacal JC, 1997, FEBS LETT, V410, P73, DOI 10.1016/S0014-5793(97)00444-4; LEE YH, 1994, J BIOL CHEM, V269, P26842; LEWOBITZ PF, 1995, MOL CELL BIOL, V15, P6613; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; LIU B, 1995, BIOCHEM BIOPH RES CO, V214, P418, DOI 10.1006/bbrc.1995.2303; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIAN Z, 1989, J BIOL CHEM, V264, P21720; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; YEO EJ, 1994, J BIOL CHEM, V269, P27823; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; Yuryev A, 1998, Cell Res, V8, P81; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	63	20	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					431	437		10.1038/sj.onc.1203323	http://dx.doi.org/10.1038/sj.onc.1203323			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656691				2022-12-17	WOS:000084873700014
J	Gonin, S; Diaz-Latoud, C; Richard, MJ; Ursini, MV; Imbo, A; Manero, F; Arrigo, AP				Gonin, S; Diaz-Latoud, C; Richard, MJ; Ursini, MV; Imbo, A; Manero, F; Arrigo, AP			p53/T-antigen complex disruption in T-antigen transformed NIH3T3 fibroblasts exposed to oxidative stress: correlation with the appearance of a Fas/APO-1/CD95 dependent, caspase independent, necrotic pathway	ONCOGENE			English	Article						T-antigen; oxidative stress; necrosis; p53; Fas	FAS-MEDIATED APOPTOSIS; LARGE TUMOR-ANTIGEN; APO-1/FAS RECEPTOR/LIGAND SYSTEM; DRUG-INDUCED APOPTOSIS; KAPPA-B ACTIVATION; DNA-DAMAGE; GLUTATHIONE-PEROXIDASE; LIGAND EXPRESSION; 3T3 FIBROBLASTS; HEAT-SHOCK	Simian Virus 40 Large T-antigen expressed in NIH3T3 cells increases p53 level and interacts with this tumor suppressor to form large nuclear complexes, We show here that T-antigen sensitizes NIH3T3 cells to loa doses of the oxidative stress inducer menadione, This oxidant increased p53 accumulation and disrupted p53/T-antigen interaction, but not T-antigen/pRb, T-antigen/Hsc70 and p53/Hsc70 complexes; a phenomenon inhibited by the anti-oxidant N-acetyl-cysteine. Analysis of several p53 downstream gene products revealed that the level of Fas receptor, which was sharply reduced by T-antigen expression, was drastically increased in response to menadione treatment. Menadione also induced a T-antigen dependent cleavage of Fas ligand. Analysis performed with Fas receptor antagonist antibody and metalloproteinases inhibitor revealed that menadione triggers a Fas-dependent death of a fraction of T-antigen expressing cells, This Fas pathway does not activate caspase 8 or 3, probably because of the inhibition induced by T-antigen, and leads to a necrotic cell death which contributes at least in part to the hypersensitivity of T-antigen transformed cells to oxidative stress.	Univ Lyon 1, CNRS UMR 5534, Ctr Genet Mol & Cellulaire, Villeurbanne, France; Ctr Hosp Univ, Biochim Lab C, Grenoble, France; CNR, Int Inst Genet & Biophys, I-80125 Naples, Italy	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)	Arrigo, AP (corresponding author), Univ Lyon 1, CNRS UMR 5534, Ctr Genet Mol & Cellulaire, Villeurbanne, France.							ABELLO PA, 1994, ARCH SURG-CHICAGO, V129, P134; AEBI H, 1984, METHOD ENZYMOL, V105, P121; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; Bauer MKA, 1998, J BIOL CHEM, V273, P8048, DOI 10.1074/jbc.273.14.8048; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; BESSHO R, 1994, BIOCHEM PHARMACOL, V48, P1883, DOI 10.1016/0006-2952(94)90586-X; BRAVARD A, 1993, CARCINOGENESIS, V14, P21, DOI 10.1093/carcin/14.1.21; Butler LM, 1998, BRIT J CANCER, V77, P1454, DOI 10.1038/bjc.1998.239; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Eguchi Y, 1997, CANCER RES, V57, P1835; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FABREJONCA N, 1995, EUR J BIOCHEM, V232, P118, DOI 10.1111/j.1432-1033.1995.tb20789.x; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Fenton RG, 1998, CANCER RES, V58, P3391; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Gonin S, 1997, CELL STRESS CHAPERON, V2, P238, DOI 10.1379/1466-1268(1997)002<0238:TBTAAO>2.3.CO;2; Green DR, 1998, NATURE, V396, P629, DOI 10.1038/25248; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HAINAUT P, 1995, ONCOGENE, V10, P27; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kamada S, 1997, ONCOGENE, V15, P285, DOI 10.1038/sj.onc.1201192; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; KHANDJIAN EW, 1995, ONCOGENE, V10, P359; KLAUSING K, 1994, CUR TOP MICROBIOL IM, V144, P31; Koike M, 1996, CANCER LETT, V108, P185, DOI 10.1016/S0304-3835(96)04408-4; KretzRemy C, 1996, J CELL BIOL, V133, P1083, DOI 10.1083/jcb.133.5.1083; Kristjuhan A, 1998, ONCOGENE, V16, P2413, DOI 10.1038/sj.onc.1201749; Lemaire C, 1998, FEBS LETT, V425, P266, DOI 10.1016/S0014-5793(98)00252-X; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MIYASHITA T, 1995, CELL, V80, P293; Moorwood K, 1996, EXP CELL RES, V223, P308, DOI 10.1006/excr.1996.0086; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Paley EL, 1996, CARCINOGENESIS, V17, P939, DOI 10.1093/carcin/17.5.939; Parat MO, 1997, BIOL TRACE ELEM RES, V60, P187, DOI 10.1007/BF02784439; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; ROUQUET N, 1995, ONCOGENE, V11, P1061; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Sompayrac L, 1997, VIROLOGY, V233, P130, DOI 10.1006/viro.1997.8610; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Verhaegh GW, 1998, MOL CARCINOGEN, V21, P205, DOI 10.1002/(SICI)1098-2744(199803)21:3<205::AID-MC8>3.0.CO;2-K; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; von Reyher U, 1998, CANCER RES, V58, P526; Wendel A, 1981, Methods Enzymol, V77, P325; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991	66	20	20	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 23	1999	18	56					8011	8023		10.1038/sj.onc.1203319	http://dx.doi.org/10.1038/sj.onc.1203319			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637512				2022-12-17	WOS:000084634600010
J	Powell, AJ; Darmon, AJ; Gonos, ES; Lam, EWF; Peden, KWC; Jat, PS				Powell, AJ; Darmon, AJ; Gonos, ES; Lam, EWF; Peden, KWC; Jat, PS			Different functions are required for initiation and maintenance of immortalization of rat embryo fibroblasts by SV40 large T antigen	ONCOGENE			English	Article						SV40 T antigen; immortalization; REFs	VIRUS-40 LARGE-T; SIMIAN-VIRUS-40 LARGE-T; LARGE TUMOR-ANTIGEN; SIMIAN VIRUS-40; ADENOVIRUS E1A; J-DOMAIN; TRANSFORMING FUNCTION; CELLULAR PROTEIN-P53; HYDROPHOBIC REGION; P53 BINDING	We have used two different, but complementary assays to characterize functions of SV40 T antigen that are necessary for its ability to immortalize rat embryo fibroblasts. In accordance with previous work, we found that several functions were required. These include activities that map to the p53 binding domain and the amino terminal 176 amino acids which contain the J domain as well as the CR1 and CR2 domain required for binding and sequestering the RE family of pocket proteins. Moreover, we found that even though activities dependent only upon the amino terminus were sufficient for immortalization they were unable to maintain it. This suggests that immortalization by these amino terminal functions requires either additional events or immortalization of a subset of cells within the heterogeneous rat embryo fibroblast population, We further found that an activity dependent upon amino acids 17-27 which remove a portion of the CR1 domain and the predicted alpha-1 helix of the J domain was not necessary to maintain growth but was required for direct immortalization suggesting that at least one of the functions required initially was not required to maintain the immortal state. This represents the first demonstration that some of the functions required for maintenance of the immortal state differ from those required for initiation of immortalization.	Royal Free & Univ Coll Med Sch, Sch Med, Ludwig Inst Canc Res, London W1P 8BT, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Sect Cell Biol & Virol, London W2 1PG, England; US FDA, Ctr Biol Evaluat & Res, Lab Retrovirus Res, Bethesda, MD 20892 USA; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School; Imperial College London; Ludwig Institute for Cancer Research; Imperial College London; US Food & Drug Administration (FDA); University of London; University College London	Jat, PS (corresponding author), UCL, Dept Biochem & Mol Biol, Gower St, London WC1E 6BT, England.		Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576; Powell, Andrew/0000-0003-1540-537X				Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; CAVENDER JF, 1995, J VIROL, V69, P923, DOI 10.1128/JVI.69.2.923-934.1995; CHRISTENSEN JB, 1995, J VIROL, V69, P3945, DOI 10.1128/JVI.69.6.3945-3948.1995; CLARK R, 1983, MOL CELL BIOL, V3, P220, DOI 10.1128/MCB.3.2.220; Conzen SD, 1995, ONCOGENE, V11, P2295; CONZEN SD, 1994, SEMIN VIROL, V5, P349, DOI 10.1006/smvy.1994.1039; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEPPERT W, 1989, ONCOGENE, V4, P1103; DOBBELSTEIN M, 1992, ONCOGENE, V7, P837; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; Gonos ES, 1996, MOL CELL BIOL, V16, P5127; GRUDA MC, 1993, MOL CELL BIOL, V13, P961, DOI 10.1128/MCB.13.2.961; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; IKRAM Z, 1994, P NATL ACAD SCI USA, V91, P6448, DOI 10.1073/pnas.91.14.6448; JAT PS, 1986, J VIROL, V59, P746, DOI 10.1128/JVI.59.3.746-750.1986; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1992, ONCOGENE, V7, P1885; MICHALOVITZ D, 1987, J VIROL, V61, P2648, DOI 10.1128/JVI.61.8.2648-2654.1987; MONTANO X, 1990, P NATL ACAD SCI USA, V87, P7448, DOI 10.1073/pnas.87.19.7448; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; Peden KWC, 1998, VIRUS GENES, V16, P153, DOI 10.1023/A:1007941622680; PEDEN KWC, 1990, J VIROL, V64, P2912, DOI 10.1128/JVI.64.6.2912-2921.1990; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PETIT CA, 1983, VIROLOGY, V127, P74, DOI 10.1016/0042-6822(83)90372-0; PIPAS JM, 1983, MOL CELL BIOL, V3, P203, DOI 10.1128/MCB.3.2.203; Porras A, 1996, J VIROL, V70, P6902; Powell AJ, 1998, EXP CELL RES, V240, P252, DOI 10.1006/excr.1998.3937; RILEY TEW, 1990, MOL CELL BIOL, V10, P6664, DOI 10.1128/MCB.10.12.6664; Salminen A, 1997, BIOCHEM BIOPH RES CO, V238, P712, DOI 10.1006/bbrc.1997.7371; Sheng Q, 1997, J VIROL, V71, P9410, DOI 10.1128/JVI.71.12.9410-9416.1997; SOMPAYRAC L, 1991, VIROLOGY, V181, P412, DOI 10.1016/0042-6822(91)90516-E; SOULE HR, 1979, J VIROL, V30, P523, DOI 10.1128/JVI.30.2.523-532.1979; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; SYMONDS HS, 1993, MOL CELL BIOL, V13, P3255, DOI 10.1128/MCB.13.6.3255; TACK LC, 1989, J VIROL, V63, P3362, DOI 10.1128/JVI.63.8.3362-3367.1989; Tevethia MJ, 1998, VIROLOGY, V243, P303, DOI 10.1006/viro.1998.9056; TEVETHIA MJ, 1988, VIROLOGY, V162, P79; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TIEMANN F, 1994, J VIROL, V68, P2869, DOI 10.1128/JVI.68.5.2869-2878.1994; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; VOUSDEN KH, 1989, ONCOGENE, V4, P153; VOUSDEN KH, 1993, ONCOGENE, V8, P1697; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	56	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7343	7350		10.1038/sj.onc.1203154	http://dx.doi.org/10.1038/sj.onc.1203154			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602490				2022-12-17	WOS:000084119400020
J	Hans, MA; Muller, M; Meyer-Ficca, M; Burkle, A; Kupper, JH				Hans, MA; Muller, M; Meyer-Ficca, M; Burkle, A; Kupper, JH			Overexpression of dominant negative PARP interferes with tumor formation of HeLa cells in nude mice: Evidence for increased tumor cell apoptosis in vivo	ONCOGENE			English	Article						apoptosis; DNA damage; PARP; transfection; tumorigenesis	HUMAN POLY(ADP-RIBOSE) POLYMERASE; DNA-BINDING DOMAIN; TRANSDOMINANT INHIBITION; GAMMA-IRRADIATION; MAMMALIAN-CELLS; HAMSTER-CELLS; CLEAVAGE; PROTEASE; REPAIR; MUTANT	Poly(ADP-ribose) polymerase (PARP(4)) catalyzes the formation of ADP-ribose polymers covalently attached to proteins by using NAD(+) as substrate. PARP is strongly activated by DNA single- or double-strand breaks and is thought to be involved in cellular responses to DNA damage. We characterized a dominant negative PARP mutant, i.e, the DNA-binding domain of this enzyme, whose overexpression in cells leads to increased genetic instability following DNA damage. In order to study whether PARP activity is also implicated in the process of tumorigenesis, me generated stably transfected HeLa cell clones with constitutive overexpression of dominant negative PARP and investigated tumor formation of these clones in nude mice. We found that inhibition of PARP activity dramatically reduces tumor forming ability of HeLa cells. Moreover, me provide strong evidence that the observed reduction in tumor forming ability is due to increased tumor cell apoptosis in viva. Viewed together, our data and those from other groups show that inhibition of PARP enzyme activity interferes with DNA base excision repair and leads to increased genetic instability and recombination but, on the other hand, can sensitize cells to apoptotic stimuli and by this mechanism may prevent tumor formation.	Univ Tubingen, Dept Mol Pathol, D-72076 Tubingen, Germany; German Canc Res Ctr, Dept Tumorvirol, D-69120 Heidelberg, Germany	Eberhard Karls University of Tubingen; Helmholtz Association; German Cancer Research Center (DKFZ)	Kupper, JH (corresponding author), Univ Tubingen, Dept Mol Pathol, Liebermeisterstr 8, D-72076 Tubingen, Germany.		Meyer-Ficca, Mirella/P-1771-2014	Meyer-Ficca, Mirella/0000-0002-9949-8157				Butler AJ, 1999, MOL CELL BIOL, V19, P296; Jeggo PA, 1998, CURR BIOL, V8, pR49, DOI 10.1016/S0960-9822(98)70032-6; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kawamitsu H, 1983, Princess Takamatsu Symp, V13, P41; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Kupper JH, 1996, CANCER RES, V56, P2715; KUPPER JH, 1990, J BIOL CHEM, V265, P18721; Kupper JH, 1996, CYTOTECHNOLOGY, V21, P225, DOI 10.1007/BF00365345; KUPPER JH, 1995, MOL CELL BIOL, V15, P3154; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Oei SL, 1998, BIOCHEMISTRY-US, V37, P1465, DOI 10.1021/bi9727390; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; SATOH MS, 1993, J BIOL CHEM, V268, P5480; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Teraoka H, 1996, FEBS LETT, V393, P1, DOI 10.1016/0014-5793(96)00842-3; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; VanGool L, 1997, EUR J BIOCHEM, V244, P15; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WHITAKER JR, 1980, ANAL BIOCHEM, V109, P156, DOI 10.1016/0003-2697(80)90024-X	24	20	23	2	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7010	7015		10.1038/sj.onc.1203178	http://dx.doi.org/10.1038/sj.onc.1203178			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597301	Bronze			2022-12-17	WOS:000083901900007
J	Kuzmin, I; Geil, L; Ge, HY; Bengtsson, U; Duh, FM; Stanbridge, EJ; Lerman, MI				Kuzmin, I; Geil, L; Ge, HY; Bengtsson, U; Duh, FM; Stanbridge, EJ; Lerman, MI			Analysis of aberrant methylation of the VHL gene by transgenes, monochromosome transfer, and cell fusion	ONCOGENE			English	Article						VHL; methylation; tumor suppressor genes	TUMOR-SUPPRESSOR GENE; PRADER-WILLI SYNDROMES; DNA METHYLATION; RENAL-CARCINOMA; CPG ISLAND; IMPRINTING DEFECTS; ANGELMAN-SYNDROME; MUTATIONS; IDENTIFICATION; CHROMOSOME	Several tumor suppressor genes were shown to be inactivated by a process involving aberrant de novo methylation of their GC-rich promoters which is usually associated with transcriptional repression, The mechanisms underlying this process are poorly understood. In particular this abnormal methylation may be caused and/or maintained by either deficiency of some tl ails-acting factor(s) or by various malfunctions acting in cis, Here we studied the nature of aberrant methylation of the ron Hippel-Lindau (VHL) disease tumor suppressor gene in a human clear cell renal carcinoma cell line, UOK 121, that contains a silent hypermethylated endogenous VHL allele, First, we transfected unmethylated VHL transgenes, driven by the VHL promoter, into UOK 121 cells. Next, to exclude possible position effects that may influence methylation of the introduced VHL genes, we transferred a single chromosome 3, carrying an apparently normal hypomethylated VHL allele into the UOK 121 cells. Finally, ne created somatic cell hybrids between UOK 121 and UMRC 6 cells containing a mutant VHL-expressing hypomethylated allele, In these three experiments both the methylation of the VHL promoter and the transcriptional status of the introduced and endogenous VHL alleles remained unchanged. Our results demonstrate that the putative tr ans-acting factors present in the UOK 121 and UMRC 6 cells are unable to induce changes in methylation pattern of the VHL alleles in all cell lines and hybrids studied. Taken together, the results indicate that ris-specific local features are pivotal in maintaining and perpetuating aberrant methylation of the VHL CpG island. Contribution of some putative tr ans-acting factors cannot be excluded during a period when the aberrant VHL methylation pattern was first generated.	NCI, Intramural Res Support Program, SAIC Frederick, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; NCI, Immunobiol Lab, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of California System; University of California Irvine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Kuzmin, I (corresponding author), NCI, Intramural Res Support Program, SAIC Frederick, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA.				NATIONAL CANCER INSTITUTE [Z01BC008579, R01CA019401, R37CA019401] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000, CA19401] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ainscough JFX, 1997, DEVELOPMENT, V124, P3621; Baylin SB, 1998, ADV CANCER RES, V72, P141; Buiting K, 1998, AM J HUM GENET, V63, P170, DOI 10.1086/301935; BUITING K, 1995, NAT GENET, V9, P395, DOI 10.1038/ng0495-395; Burger J, 1997, AM J HUM GENET, V61, P88, DOI 10.1086/513900; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; COSTA M, 1995, AM J CLIN NUTR, V61, p666S, DOI 10.1093/ajcn/61.3.666S; GEIL L, 1998, IN PRESS MOL CELL PR; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GRAFF JR, 1995, CANCER RES, V55, P5195; GROSSMAN HB, 1985, J SURG ONCOL, V28, P237; HENNIG G, 1995, ONCOGENE, V11, P475; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Kuerbitz SJ, 1996, CELL GROWTH DIFFER, V7, P847; KUZMIN I, 1995, ONCOGENE, V10, P2185; KUZMIN I, 1994, CANCER RES, V54, P2486; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEE YW, 1995, MOL CELL BIOL, V15, P2547; PAYNE SJ, 1994, HUM MOL GENET, V3, P390, DOI 10.1093/hmg/3.2.390; REIS A, 1994, AM J HUM GENET, V54, P741; RICHARDS FM, 1993, HUM MOL GENET, V2, P1750, DOI 10.1093/hmg/2.10.1750; STINSON SF, 1992, ANTICANCER RES, V12, P1035; Stolle C, 1998, HUM MUTAT, V12, P417, DOI 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52; WILLIAMS RD, 1976, IN VITRO CELL DEV B, V12, P623; Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631	26	20	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	1999	18	41					5672	5679		10.1038/sj.onc.1202959	http://dx.doi.org/10.1038/sj.onc.1202959			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523847				2022-12-17	WOS:000083016500008
J	Tchernitsa, OI; Zuber, J; Sers, C; Brinckmann, R; Britsch, SK; Adams, V; Schafer, R				Tchernitsa, OI; Zuber, J; Sers, C; Brinckmann, R; Britsch, SK; Adams, V; Schafer, R			Gene expression profiling of fibroblasts resistant toward oncogene-mediated transformation reveals preferential transcription of negative growth regulators	ONCOGENE			English	Article						suppression subtractive hybridization; RAS; preneoplastic phenotype; tumour suppressor genes	CARCINOMA-CELLS; RAS ONCOGENES; C-JUN; REPLICATIVE SENESCENCE; EMBRYO FIBROBLASTS; KINASE ACTIVATION; BINDING-PROTEIN; CANCER-CELLS; DIFFERENTIATION; SUPPRESSION	The signal-transducing Res proteins are important driving forces of diverse cellular processes such as proliferation, neoplastic transformation, differentiation and growth inhibition. As a step toward understanding the complex mechanisms underlying cellular responses, gene expression patterns were examined in two phenotypically normal fibroblast lines which differ in their sensitivity toward oncogene-mediated transformation. Suppression subtractive hybridization (SSH) was used to establish a subtracted cDNA library specific for the REF52 cell line which, like normal diploid fibroblasts, is refractory toward neoplastic transformation induced by mutated HRAS oncogenes, In contrast, rat 208F control cells can be efficiently transformed by HRAS. The nucleotide sequence of 549 subtracted cDNA clones ('REF52 minus 208F') was determined. We identified 93 preferentially expressed gene fragments in resistant REF52 cells as compared to 208F cells, Seventeen of the 52 known genes (32.6%) are capable of inhibiting cell proliferation or of adversely affecting oncogenic signal transduction pathways. These results suggest that the anti-oncogenic properties of resistant REF52 cells are determined by multiple negative growth regulators. The preneoplastic state expressed in 208F cells is characterized by impairment of unexpectedly redundant control mechanisms. Our results also demonstrate that SSH is a powerful method for identifying specific transcriptional patterns in closely related cell types.	Humboldt Univ, Charite, Inst Pathol, Lab Mol Tumour Pathol, D-10117 Berlin, Germany; Univ Zurich, Inst Pathol, CH-8091 Zurich, Switzerland; Univ Leipzig, Ctr Cardiol, D-04289 Leipzig, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Zurich; Leipzig University	Schafer, R (corresponding author), Humboldt Univ, Charite, Inst Pathol, Lab Mol Tumour Pathol, Schumannstr 20-21, D-10117 Berlin, Germany.		Sers, Christine/B-5438-2010; Zuber, Johannes/E-7517-2011; Schäfer, Reinhold/AAB-5110-2021	Zuber, Johannes/0000-0001-8810-6835; Schafer, Reinhold/0000-0001-7952-2124				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOS JL, 1989, CANCER RES, V49, P4682; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Castle VP, 1997, LAB INVEST, V77, P51; CELANO P, 1993, CELL GROWTH DIFFER, V4, P341; Chang DD, 1998, ONCOGENE, V16, P1921, DOI 10.1038/sj.onc.1201715; Chapline C, 1996, J BIOL CHEM, V271, P6417, DOI 10.1074/jbc.271.11.6417; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; ESINDUY CB, 1995, CARCINOGENESIS, V16, P915, DOI 10.1093/carcin/16.4.915; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FOWLIS DJ, 1993, EUR J CANCER, V29A, P638, DOI 10.1016/S0959-8049(05)80170-4; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Gonos ES, 1998, EXP CELL RES, V240, P66, DOI 10.1006/excr.1998.3948; GRIEGEL S, 1986, INT J CANCER, V38, P697, DOI 10.1002/ijc.2910380513; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; Kato MV, 1996, ONCOGENE, V12, P1361; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lin XY, 1997, CANCER RES, V57, P2304; LIN XY, 1995, MOL CELL BIOL, V15, P2754; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Masuelli L, 1996, MOL CELL BIOL, V16, P5466; MISSALE C, 1993, P NATL ACAD SCI USA, V90, P7961, DOI 10.1073/pnas.90.17.7961; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OBRIEN W, 1986, P NATL ACAD SCI USA, V83, P8659; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHEIBANI N, 1995, P NATL ACAD SCI USA, V92, P6788, DOI 10.1073/pnas.92.15.6788; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Strachan T, 1997, NAT GENET, V16, P126, DOI 10.1038/ng0697-126; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; THEOBALD J, 1995, BRIT J CANCER, V71, P786, DOI 10.1038/bjc.1995.152; vonStein OD, 1997, NUCLEIC ACIDS RES, V25, P2598, DOI 10.1093/nar/25.13.2598; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; ZHU DG, 1992, P NATL ACAD SCI USA, V89, P10218, DOI 10.1073/pnas.89.21.10218; Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X; ZUTTER MM, 1995, P NATL ACAD SCI USA, V92, P7411, DOI 10.1073/pnas.92.16.7411	55	20	23	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 23	1999	18	39					5448	5454		10.1038/sj.onc.1202987	http://dx.doi.org/10.1038/sj.onc.1202987			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498898				2022-12-17	WOS:000082718600009
J	Jeffers, M; Vande Woude, GF				Jeffers, M; Vande Woude, GF			Activating mutations in the Met receptor overcome the requirement for autophosphorylation of tyrosines crucial for wild type signaling	ONCOGENE			English	Article						mutant Met; signaling; autophosphorylation	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; KINASE RECEPTOR; PROTOONCOGENE PRODUCT; CELL-TRANSFORMATION; EPITHELIAL-CELLS; ONCOPROTEIN; MOTILITY; GRB2; SITE	Mutations in Met have been identified in human cancer, and we have previously shown that these mutations deregulate the enzymatic activity of this tyrosine kinase receptor, thereby unleashing its oncogenic potential. Signal transduction via mild type Met has been shown to require the autophosphorylation of two tyrosine doublets; Y8,9 which functions to enhance enzymatic activity, and Y14,15 which provides docking sites for signaling molecules, and in the present investigation we examine the importance of these residues for signaling via mutationally activated Met. We find that activating mutations introduced into a membrane-spanning Met receptor circumvent the normally stringent requirement for Y8,9 phosphorylation, and do so in a largely ligand-dependent fashion. Similarly, activating mutations introduced into a constitutively dimerized cytoplasmic form of Met (i.e. Tpr-Met) facilitate its autophosphorylation and oncogenic activity in the absence of Y8,9 phosphorylation. We also find that activating mutations allow a membrane-spanning Met receptor to overcome the requirement for the Y14,15 phosphorylation in a manner which is largely ligand-independent, These findings support a model whereby activating mutations stabilize an active conformation of the Met kinase via a mechanism which can function independently of Y8,9 autophosphorylation and suggest that signaling via wild type Met and mutationally activated Met may proceed through distinct pathways.	NCI, Div Basic Sci, Natl Canc Inst, FCRDC, Ft Detrick, MD 21702 USA; NCI, ABL Basic Res Program, FCRDC, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Vande Woude, GF (corresponding author), NCI, Div Basic Sci, Natl Canc Inst, FCRDC, Bldg 469,POB B, Ft Detrick, MD 21702 USA.							BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; Jeffers M, 1998, ONCOGENE, V17, P2691, DOI 10.1038/sj.onc.1202209; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jeffers M, 1996, ONCOGENE, V13, P853; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5	37	20	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5120	5125		10.1038/sj.onc.1202902	http://dx.doi.org/10.1038/sj.onc.1202902			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490849				2022-12-17	WOS:000082497100012
J	Ludgate, M; Gire, V; Crisp, M; Ajjan, R; Weetman, A; Ivan, M; Wynford-Thomas, D				Ludgate, M; Gire, V; Crisp, M; Ajjan, R; Weetman, A; Ivan, M; Wynford-Thomas, D			Contrasting effects of activating mutations of G alpha S and the thyrotropin receptor on proliferation and differentiation of thyroid follicular cells	ONCOGENE			English	Article						TSH receptor; G protein; cyclic AMP; oncogene; thyroid	SOMATIC MUTATIONS; TSH RECEPTOR; HYPERFUNCTIONING ADENOMAS; GERMLINE MUTATIONS; GSP ONCOGENE; IN-VITRO; GENE; GROWTH; DESENSITIZATION; IDENTIFICATION	The cyclic AMP pathway is a major regulator of thyrocyte function and proliferation and, predictably, its inappropriate activation is associated with a sub-set of human thyroid tumours, Activating mutations are, however, more common in the thyrotropin receptor (TSHR) than in its downstream transducer, G alpha s. To investigate whether this reflects an inherent difference in their oncogenic potency, we compared the effects of retro retrovirally-transduced mutant (A623I) TSI-IR or (Q227L) G alpha s (GSP), using the rat thyroid cell line FRTL5 and primary human thyrocytes, In FRTL5, expression of GSP or mutant (m) TSHR induced a 2-3-fold increase in basal levels of cAMP. This was associated with TSH-independent proliferation (assessed by both cell number and DNA synthesis) and function las shown by increased expression of thyroglobulin (Tg) and the sodium/iodide symporter). In primary cultures, expression of mTSHR, but not GSP, consistently induced formation of colonies with epithelial morphology and thyroglobulin expression, capable of 10-15 population doublings (PD) compared to less than three in controls. Thus, while mTSHR and GSP exert similar effects in FRTL5, use of primary cultures reveals a major difference in their ability to induce sustained proliferation in normal human thyrocytes, and provides the first direct evidence that mTSHR is sufficient to initiate thyroid tumorigenesis.	Univ Wales Coll Med, Dept Pathol, Canc Res Campaign Labs, Cardiff CF4 4XN, S Glam, Wales; Univ Sheffield, No Gen Hosp, Ctr Clin Sci, Dept Med, Sheffield S5 7AU, S Yorkshire, England	Cardiff University; Northern General Hospital; University of Sheffield	Wynford-Thomas, D (corresponding author), Univ Wales Coll Med, Dept Pathol, Canc Res Campaign Labs, Cardiff CF4 4XN, S Glam, Wales.		Gire, Véronique/AAC-2218-2020; Ivan, Mircea/A-8109-2012; Gire, Veronique/N-7553-2017	Ludgate, Marian/0000-0002-7436-0821; Gire, Veronique/0000-0002-9009-2185; Ivan, Mircea/0000-0003-3424-6642				Ajjan RA, 1998, J ENDOCRINOL, V158, P351, DOI 10.1677/joe.0.1580351; BOND JA, 1994, ONCOGENE, V9, P281; BURNS JS, 1992, INT J ONCOL, V1, P79; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COSTAGLIOLA S, 1994, ENDOCRINOLOGY, V135, P2150, DOI 10.1210/en.135.5.2150; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; Fournes B, 1998, ONCOGENE, V16, P985, DOI 10.1038/sj.onc.1201626; Fuhrer D, 1997, J CLIN ENDOCR METAB, V82, P3885, DOI 10.1210/jc.82.11.3885; Ivan M, 1997, J CLIN ENDOCR METAB, V82, P2702, DOI 10.1210/jc.82.8.2702; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; LALLI E, 1995, P NATL ACAD SCI USA, V92, P9633, DOI 10.1073/pnas.92.21.9633; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; MUCA C, 1994, ONCOGENE, V9, P3647; NEMOZ G, 1995, MOL ENDOCRINOL, V9, P1279, DOI 10.1210/me.9.10.1279; OSULLIVAN C, 1991, MOL CARCINOGEN, V4, P345, DOI 10.1002/mc.2940040503; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; Parma J, 1997, J CLIN ENDOCR METAB, V82, P2695, DOI 10.1210/jc.82.8.2695; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PASCHKE R, 1994, J CLIN ENDOCR METAB, V79, P1785, DOI 10.1210/jc.79.6.1785; Paschke R, 1997, NEW ENGL J MED, V337, P1675, DOI 10.1056/NEJM199712043372307; Porcellini A, 1997, ONCOGENE, V15, P781, DOI 10.1038/sj.onc.1201240; RAPOPORT B, 1982, FEBS LETT, V146, P23, DOI 10.1016/0014-5793(82)80697-2; Russo D, 1996, J CLIN ENDOCR METAB, V81, P1548, DOI 10.1210/jc.81.4.1548; RUSSO D, 1995, J CLIN ENDOCR METAB, V80, P1347, DOI 10.1210/jc.80.4.1347; RUSSO D, 1995, ONCOGENE, V11, P1907; SAID S, 1994, J ENDOCRINOL INVEST, V17, P371, DOI 10.1007/BF03349004; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VANSANDE J, 1995, J CLIN ENDOCR METAB, V80, P2577, DOI 10.1210/jc.80.9.2577; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; WILLIAMS DW, 1988, BRIT J CANCER, V57, P535, DOI 10.1038/bjc.1988.124; WYNFORDTHOMAS D, 1993, CANCER SURV, V16, P115; WYNFORDTHOMAS D, 1982, ACTA ENDOCRINOL-COP, V101, P562, DOI 10.1530/acta.0.1010562; WynfordThomas D, 1997, HORM RES, V47, P145, DOI 10.1159/000185458; WynfordThomas D, 1997, EUR J CANCER, V33, P716, DOI 10.1016/S0959-8049(97)00064-6	37	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4798	4807		10.1038/sj.onc.1202864	http://dx.doi.org/10.1038/sj.onc.1202864			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490813				2022-12-17	WOS:000082184800004
J	Lassus, P; Bertrand, C; Zugasti, O; Chambon, JP; Soussi, T; Mathieu-Mahul, D; Hibner, U				Lassus, P; Bertrand, C; Zugasti, O; Chambon, JP; Soussi, T; Mathieu-Mahul, D; Hibner, U			Anti-apoptotic activity of p53 maps to the COOH-terminal domain and is retained in a highly oncogenic natural mutant	ONCOGENE			English	Article						apoptosis; oncogenesis; p53	DNA-BINDING FUNCTION; WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; GROWTH ARREST; TRANSCRIPTIONAL ACTIVATION; P53-INDUCED APOPTOSIS; GENE-EXPRESSION; PROTEIN; CELLS; IDENTIFICATION	The tumour suppressor p53 plays a complex role in the regulation of apoptosis, High levels of wild type p53 potentiate the apoptotic response, while physiological range, low levels of the protein have an anti-apoptotic activity in serum starved immortalized fibroblasts. Here we report that primary fibroblast-like cells that show normal growth control are also efficiently protected from apoptosis by the endogenous p53 activity, The capacity to inhibit apoptosis is not restricted to the wild type protein: the R --> H175 p53 mutant fully retains the anti-apoptotic activity of the wild type p53, providing a possible explanation for its high oncogenicity. Using a series of point and deletion mutants of p53 under the control of tetracycline-regulated promoter we show that certain mutants, like the wild type, protect cells at low levels but lead to apoptosis when overexpressed, This latter effect is lost upon deletion of a proline-rich domain in the NH2 part of the protein. The anti-apoptotic activity can be mapped to the extreme carboxy-terminal part of the protein and is therefore independent of other well characterized p53 activities. Our results add a new level of complexity to the network of interactions mediated by p53 in normal physiology and pathology.	Inst Med Genet, CNRS, UMR 5535, F-34293 Montpellier 5, France; Inst Curie, CNRS, UMR 218, F-75248 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Universite Paris Cite	Hibner, U (corresponding author), Inst Med Genet, CNRS, UMR 5535, 1919 Route Mende, F-34293 Montpellier 5, France.		Zugasti, Olivier/P-1352-2017; chambon, jean-philippe/A-5532-2013; BERTRAND-GADAY, Christelle/ABA-8619-2021; Mathieu, Daniele/G-6092-2012	BERTRAND-GADAY, Christelle/0000-0003-0461-2402; Lassus, Patrice/0000-0002-2785-7843; soussi, thierry/0000-0001-8184-3293; Hibner, Urszula/0000-0002-5520-7311; Zugasti, Olivier/0000-0002-5616-734X				Abarzua P, 1996, ONCOGENE, V13, P2477; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Bowman T, 1996, GENE DEV, V10, P826, DOI 10.1101/gad.10.7.826; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN JY, 1993, ONCOGENE, V8, P2159; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Fourie AM, 1997, J BIOL CHEM, V272, P19471, DOI 10.1074/jbc.272.31.19471; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GOH HS, 1995, CANCER RES, V55, P5217; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Hansen S, 1996, J BIOL CHEM, V271, P3917; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Kremenetskaya OS, 1997, ONCOL RES, V9, P155; Lassus P, 1998, NUCLEIC ACIDS RES, V26, P5233, DOI 10.1093/nar/26.22.5233; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; LEROYVIARD K, 1995, EMBO J, V14, P2341, DOI 10.1002/j.1460-2075.1995.tb07229.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; LUNA RMD, 1995, NATURE, V378, P203; MacCallum DE, 1996, ONCOGENE, V13, P2575; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHMID P, 1991, DEVELOPMENT, V113, P857; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SUBLER MA, 1994, ONCOGENE, V9, P1351; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; YONISHROUACH E, 1996, ONCOGENE, V12, P2197	68	20	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	1999	18	33					4699	4709		10.1038/sj.onc.1202841	http://dx.doi.org/10.1038/sj.onc.1202841			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467417				2022-12-17	WOS:000082154400007
J	Hagiyama, H; Adachi, T; Yoshida, T; Nomura, T; Miyasaka, N; Honjo, T; Tsubata, T				Hagiyama, H; Adachi, T; Yoshida, T; Nomura, T; Miyasaka, N; Honjo, T; Tsubata, T			Signaling through the antigen receptor of B lymphocytes activates a p53-independent pathway of c-Myc-induced apoptosis	ONCOGENE			English	Article						apoptosis; B lymphocyte; c-Myc; p53	CELL-CYCLE ARREST; DNA-BINDING SITE; TRANSGENIC MICE; LYMPHOMA-CELLS; MEDIATED APOPTOSIS; GROWTH ARREST; P53; EXPRESSION; INDUCTION; PROTEIN	Deregulated expression of c-Myc has been shown to induce or enhance apoptosis in various different cell types, c-Myc requires p53 for apoptosis in some but not all the cell types, indicating heterogeneous mechanisms for c-Myc-induced apoptosis, In B lymphoma line WEHI-231, stable expression of c-Myc has been demonstrated to protect cells from BCR-mediated apoptosis. However, stable expression of c-Myc carrying pro-apoptotic functions may generate variant cells resistant to apoptosis. By utilizing an inducible system for c-Myc, me demonstrated here that deregulated expression of c-Myc induced apoptosis of WEHI-231 by itself, indicating that c-Myc induces apoptosis in WEHI-231 as is the case for other cell types. When transactivation of p53 was inactivated, WEHI-231 cells overexpressing c-Myc no longer underwent apoptosis in the absence of other stimuli, but showed markedly enhanced apoptosis in the presence of BCR ligation. These results indicate that deregulated c-Myc expression enhances apoptosis by a p53-independent pathway in the presence of BCR signaling but requires p53 for apoptosis in the absece of BCR crosslinking in WEHI-231, BCR ligation may thus activate a p53-independent pathway of Myc-induced apoptosis.	Tokyo Med & Dent Univ, Inst Med Res, Dept Immunol, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Fac Med, Dept Internal Med 1, Bunkyo Ku, Tokyo 1138519, Japan; Kyoto Univ, Grad Sch Med, Dept Med Chem, Kyoto 6068501, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Kyoto University	Tsubata, T (corresponding author), Tokyo Med & Dent Univ, Inst Med Res, Dept Immunol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.		Honjo, Tasuku/N-4470-2016; Yoshida, Tsutomu/H-9046-2013; Tsubata, Takeshi/AAI-7489-2021; Yoshida, Tsutomu/A-7486-2012	Tsubata, Takeshi/0000-0003-0760-1258; 				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ASKEW DS, 1991, ONCOGENE, V6, P1915; BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN CH, 1994, RADIAT RES, V139, P307, DOI 10.2307/3578828; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Dong JA, 1997, ONCOGENE, V15, P639, DOI 10.1038/sj.onc.1201237; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ELIYAHU D, 1988, ONCOGENE, V3, P313; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FISCHER G, 1994, J EXP MED, V179, P221, DOI 10.1084/jem.179.1.221; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Lenahan MK, 1996, ONCOGENE, V12, P1847; MCCORMACK JE, 1984, P NATL ACAD SCI-BIOL, V81, P5546, DOI 10.1073/pnas.81.17.5546; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; Sakamuro D, 1995, ONCOGENE, V11, P2411; Scott DW, 1996, INT IMMUNOL, V8, P1375, DOI 10.1093/intimm/8.9.1375; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Trudel M, 1997, J EXP MED, V186, P1873, DOI 10.1084/jem.186.11.1873; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wang KS, 1996, EXPERT SYST APPL, V10, P1, DOI 10.1016/0957-4174(95)00029-1; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WARNER GL, 1992, CELL GROWTH DIFFER, V3, P175; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0; Wu M, 1996, MOL CELL BIOL, V16, P5015; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yi AK, 1996, J IMMUNOL, V157, P4918	37	20	20	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4091	4098		10.1038/sj.onc.1202772	http://dx.doi.org/10.1038/sj.onc.1202772			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435590				2022-12-17	WOS:000081431000006
J	Magdinier, F; Dalla Venezia, N; Lenoir, GM; Frappart, L; Dante, R				Magdinier, F; Dalla Venezia, N; Lenoir, GM; Frappart, L; Dante, R			BRCA1 expression during prenatal development of the human mammary gland	ONCOGENE			English	Article						BRCA1; mRNA; protein; prenatal development; human mammary gland	SPORADIC BREAST-CANCER; OVARIAN-CANCER; SUBCELLULAR-LOCALIZATION; MEIOTIC CELLS; DNA-DAMAGE; GENE; DIFFERENTIATION; MUTATIONS; PROTEIN; TISSUES	Germ-line alterations of BRCA1 are associated with elevated risk of breast cancer. Evidence for the involvement of Brca1 in cellular differentiation and morphogenesis has been obtained in mouse models during embryogenesis, Although the presence of well-conserved functional domains might suggest a similar function for both human and mouse genes, very few data on BRCA1 expression in human fetal tissues are available. We have, therefore, investigated the expression of BRCA1 in the mammary gland from human female fetuses aged between 15 and 33 weeks, Quantification of BRCA1 transcripts, using a competitive reverse transcriptase PCR method, indicates a progressive decrease in BRCA1 expression with increasing fetal age between the 15th and 30th week of gestation. Subsequently, the amount of BRCA1 transcripts becomes similar to that found in adult mammary gland. Analysis of BRCA1 protein revealed, in fetal samples, a 220 kDa band corresponding to the 220 kDa BRCA1 protein described in human cell lines. These later experiments confirm that the relative level of the 220 kDa BRCA1 protein is highest in the early stages of mammary gland development. The temporal patterns of BRCA1 expression in human fetuses suggest a role for BRCA1 in the morphogenesis and differentiation of the human mammary gland.	UCBL1, CNRS, UMR 5641, Genet Lab, F-69373 Lyon 08, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Dante, R (corresponding author), UCBL1, CNRS, UMR 5641, Genet Lab, 8 Ave Rockefeller, F-69373 Lyon 08, France.		Magdinier, Frederique/I-4735-2016; VENEZIA, Nicole DALLA/C-6542-2017	Magdinier, Frederique/0000-0002-0159-9559; VENEZIA, Nicole DALLA/0000-0002-4553-3535				Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Bertwistle D, 1998, CURR OPIN GENET DEV, V8, P14, DOI 10.1016/S0959-437X(98)80056-7; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Dawson E K, 1934, Edinb Med J, V41, P653; Easton D, 1997, NAT GENET, V16, P210, DOI 10.1038/ng0797-210; Ellisen LW, 1998, ANNU REV MED, V49, P425; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GIROD C, 1970, COURS BIOL REPROD; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Lu ML, 1996, CANCER RES, V56, P4578; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Marks JR, 1997, ONCOGENE, V14, P115, DOI 10.1038/sj.onc.1200808; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Ribieras S, 1997, INT J CANCER, V73, P715, DOI 10.1002/(SICI)1097-0215(19971127)73:5<715::AID-IJC17>3.0.CO;2-4; Russo J., 1987, The mammary gland. Development, regulation, and function., P67; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Sakakura T., 1987, The mammary gland. Development, regulation, and function., P37; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Spillman MA, 1996, ONCOGENE, V13, P1639; Tanner JM, 1962, GROWTH ADOLESCENCE, V2nd, P28; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994	38	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	1999	18	27					4039	4043		10.1038/sj.onc.1202780	http://dx.doi.org/10.1038/sj.onc.1202780			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435628	Green Published			2022-12-17	WOS:000081327800015
J	Atfi, A; Prunier, C; Mazars, A; Defachelles, AS; Cayre, Y; Gespach, C; Bourgeade, MF				Atfi, A; Prunier, C; Mazars, A; Defachelles, AS; Cayre, Y; Gespach, C; Bourgeade, MF			The oncogenic TEL/PDGFR beta fusion protein induces cell death through JNK SAPK pathway	ONCOGENE			English	Article						TEL/PDGFR beta; apoptosis; JNK SAPK; PI-3 kinase	SIGNAL-TRANSDUCTION PATHWAY; GROWTH-FACTOR-BETA; CHRONIC MYELOMONOCYTIC LEUKEMIA; JUN ACTIVATION DOMAIN; C-JUN; RECEPTOR-BETA; MAP KINASE; HEMATOPOIETIC-CELLS; PDGFR-BETA; KAPPA-B	The TEL/PDGFR beta (T/P) fusion protein isolated from patients bearing a t(5;12) translocation is transforming when expressed in haematopoietic cells. To examine the signal transduction events activated by this protein, we measured the effect of T/P on activation of the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) in mouse bone marrow-derived Ba/F3 cells. Significant increase in the activity of JNK/SAPK1 was observed in transient transfection as well as in Ba/F3 cells stably expressing T/P, This activation was abrogated when the T/P-expressing cells were treated with a specific inhibitor of the PDGFR beta tyrosine kinase, indicating that the activity of the PDGFR beta part of the fusion protein was involved in JNK/SAPK activation. Expression of a dominant negative mutant of mitogen-activated protein kinase kinase 4 (MKK4), a direct activator of JNK/SAPK, prevented T/P-induced JNK/SAPK activation. In addition, inhibition of phosphoinositide-3 OH kinase (PI-3 kinase), a promoting survival factor, potentiated the effect of T/P on JNK/SAPK activation. Interestingly, expression of T/P was shown to initiate an apoptotic response that was enhanced by treatment of cells with the PI-3 kinase inhibitor LY294002, suggesting that T/P mediated cell death through activation of JNK/SAPK signalling pathway. Consistent with this hypothesis, expression of the dominant negative mutant of MKK4 decreased T/P-mediated apoptosis, while a dominant-negative mutant of PI-3 kinase enhances cell death. These findings indicate that activation of JNK/SAPK by T/P is related to apoptosis rather than cell proliferation and transformation.	Hop St Antoine, INSERM, U482, F-75571 Paris 12, France; Hop St Antoine, INSERM, U417, F-75571 Paris 12, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Bourgeade, MF (corresponding author), CJF 95-02,32 Rue Carnets, F-92140 Clamart, France.		Frottier, Celine Prunier/G-8259-2017	Frottier, Celine Prunier/0000-0002-7784-0273; DEFACHELLES, Anne-Sophie/0000-0002-4277-9871				Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Bourgeade MF, 1998, BLOOD, V91, P3333, DOI 10.1182/blood.V91.9.3333.3333_3333_3339; BUCHDUNGER E, 1995, P NATL ACAD SCI USA, V92, P2558, DOI 10.1073/pnas.92.7.2558; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; LopezIlasaca M, 1997, BIOCHEM BIOPH RES CO, V232, P273, DOI 10.1006/bbrc.1997.6289; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nagata Y, 1997, BLOOD, V89, P2664, DOI 10.1182/blood.V89.8.2664; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Widmann C, 1997, ONCOGENE, V15, P2439, DOI 10.1038/sj.onc.1201421; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	48	20	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	1999	18	26					3878	3885		10.1038/sj.onc.1202734	http://dx.doi.org/10.1038/sj.onc.1202734			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445851				2022-12-17	WOS:000081171700009
J	Davies, J; Badiani, P; Weston, K				Davies, J; Badiani, P; Weston, K			Cooperation of Myb and Myc proteins in T cell lymphomagenesis	ONCOGENE			English	Article						myb; myc; lymphoma	TRANSGENIC MICE; LEUKEMIA-VIRUS; C-MYC; INFECTION; ONCOGENE; REARRANGEMENT; RETROVIRUSES; SENSITIVITY; EXPRESSION; INVITRO	The v-Myb oncogene causes late onset T cell lymphomas when expressed in the T cell lineage of transgenic mice. In order to define the cellular mutations cooperating with v-Myb to cause lymphomas, we have infected v-Myb transgenic mice with Moloney murine leukemia virus (M-MuLV). Tumor formation is significantly accelerated from a mean age of onset of 60 weeks in uninfected vMyb transgenics to 13 weeks in infected vMyb transgenics. We studied the loci into which the M-MuLV had inserted, and found that in 73% of animals, either the c-myc or the N-myc genes had been disrupted and deregulated. Therefore, v-myb and c-myb can cooperate to induce T cell lymphomas.	Inst Canc Res, CRC, Ctr Cell & Mol Biol, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Weston, K (corresponding author), Inst Canc Res, CRC, Ctr Cell & Mol Biol, 237 Fulham Rd, London SW3 6JB, England.							ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; Badiani PA, 1996, ONCOGENE, V13, P2205; CALABRETTA B, 1991, P NATL ACAD SCI USA, V88, P2351, DOI 10.1073/pnas.88.6.2351; FURUTA Y, 1993, TRANSGENIC RES, V2, P199, DOI 10.1007/BF01977350; GISSELBRECHT S, 1978, INT J CANCER, V21, P626, DOI 10.1002/ijc.2910210513; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; HARTLEY JW, 1983, J EXP MED, V158, P16, DOI 10.1084/jem.158.1.16; JACOBS SM, 1994, CANCER GENET CYTOGEN, V75, P31, DOI 10.1016/0165-4608(94)90212-7; JAENISCH R, 1975, P NATL ACAD SCI USA, V72, P4008, DOI 10.1073/pnas.72.10.4008; JIANG X, 1994, MAMM GENOME, V5, P142, DOI 10.1007/BF00352344; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Kung H J, 1991, Curr Top Microbiol Immunol, V171, P1; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; MUSHINSKI JF, 1983, SCIENCE, V220, P795, DOI 10.1126/science.6687762; PELICCI PG, 1984, SCIENCE, V224, P1117, DOI 10.1126/science.6585957; Sanchez-Garcia I, 1997, ANNU REV GENET, V31, P429, DOI 10.1146/annurev.genet.31.1.429; SHINTO Y, 1995, ONCOGENE, V11, P1729; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VILLENEUVE L, 1993, J VIROL, V67, P5733, DOI 10.1128/JVI.67.10.5733-5739.1993; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; Wolff L, 1996, CRIT REV ONCOGENESIS, V7, P245, DOI 10.1615/CritRevOncog.v7.i3-4.60	28	20	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3643	3647		10.1038/sj.onc.1202956	http://dx.doi.org/10.1038/sj.onc.1202956			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380886				2022-12-17	WOS:000080891700010
J	Peng, HQ; Liu, L; Goss, PE; Bailey, D; Hogg, D				Peng, HQ; Liu, L; Goss, PE; Bailey, D; Hogg, D			Chromosomal deletions occur in restricted regions of 5q in testicular germ cell cancer	ONCOGENE			English	Article						testis; germ cell tumor; chromosomal deletions; LOH; 5q14	TUMOR-SUPPRESSOR GENE; MOUSE CHROMOSOME-18; TESTIS CANCER; HUMAN GENOME; HETEROZYGOSITY; CARCINOMA; MUTATION; LUNG; SUSCEPTIBILITY; DEFICIENCY	Since the biologic behavior and molecular genetic changes observed in testicular germ cell cancer differ from those seen in more common epithelial tumors, it is likely that hitherto uncharacterized genes play a role in the development of germ cell tumors, Our previous work on testicular germ cell cancer suggested that chromosome 5q might contain one or more novel tumor suppressor genes that play a role in this malignancy. In this study, we performed a high resolution loss of heterozygosity (LOH) study of testicular cancer using 37 informative markers on chromosome 5, We detected allelic losses in 20/48 (42%) specimens and identified three common sites of loss on chromosome 5q14, 5q21 and 5q34-qter, defined respectively by minimal regions of deletion of less than or equal to 1 cM, 10 cM and similar to 20 (cM), Using an overlapping series of YACs and radiation hybrid mapping, we have constructed a physical map of the 5q14 deletion that should aid in the isolation and characterization of the putative tumor suppressor gene located therein.	Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada; Toronto Gen Hosp, Dept Med, Toronto, ON M5G 2C4, Canada; Toronto Gen Hosp, Dept Pathol, Toronto, ON M5G 2C4, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Hogg, D (corresponding author), Univ Toronto, Dept Med, 100 Coll St,Med Sci Bldg,Room 7238, Toronto, ON M5S 1A8, Canada.							ALJEHANI RMA, 1995, GENE CHROMOSOME CANC, V13, P249, DOI 10.1002/gcc.2870130404; AOKI T, 1994, GENE CHROMOSOME CANC, V10, P177, DOI 10.1002/gcc.2870100305; ASADA Y, 1994, NAT GENET, V6, P363, DOI 10.1038/ng0494-363; Bosl GJ, 1997, NEW ENGL J MED, V337, P242, DOI 10.1056/NEJM199707243370406; Canzian F, 1996, CANCER RES, V56, P3331; DING SF, 1993, CANCER DETECT PREV, V17, P405; FAIRMAN J, 1995, P NATL ACAD SCI USA, V92, P7406, DOI 10.1073/pnas.92.16.7406; GREENWALD BD, 1992, CANCER RES, V52, P741; HAGEMEIJER A, 1996, LEUKEMIA, P131; HATTA Y, 1995, J UROLOGY, V154, P1954, DOI 10.1016/S0022-5347(01)66833-2; HOSOE S, 1994, CANCER RES, V54, P1787; HUDDART RA, 1995, BRIT J CANCER, V72, P642, DOI 10.1038/bjc.1995.387; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; King BL, 1997, CANCER RES, V57, P209; LEAHY MG, 1995, HUM MOL GENET, V4, P1551, DOI 10.1093/hmg/4.9.1551; LOTHE RA, 1995, LAB INVEST, V73, P606; MIURA I, 1992, CANCER RES, V52, P1322; Murty VVVS, 1996, ONCOGENE, V12, P2719; MURTY VVVS, 1994, ONCOGENE, V9, P2245; NAGARAJAN L, 1995, LEUKEMIA LYMPHOMA, V17, P361, DOI 10.3109/10428199509056846; NICHOLSON DMC, 1995, SURF REV LETT, V2, P71, DOI 10.1142/S0218625X95000078; NOGUCHI T, 1985, JNCI-J NATL CANCER I, V75, P385; OZAI A, 1993, CANCER, V71, P3873; PELTOMAKI P, 1990, CANCER GENET CYTOGEN, V48, P1, DOI 10.1016/0165-4608(90)90209-S; PENG HQ, 1993, CANCER RES, V53, P3574; PENG HQ, 1995, CANCER RES, V55, P2871; Rapley E, 1998, APMIS, V106, P64; RODRIGUEZ E, 1992, CANCER RES, V52, P2285; SAKURAI T, 1994, MAMM GENOME, V5, P333, DOI 10.1007/BF00356550; SCHERER SW, 1997, ADV TECHNIQUES CHROM, P37; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; Tamura G, 1996, CANCER RES, V56, P612; WEBER JL, 1989, AM J HUM GENET, V44, P388; Wieland I, 1996, ONCOGENE, V12, P97	34	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 27	1999	18	21					3277	3283		10.1038/sj.onc.1202662	http://dx.doi.org/10.1038/sj.onc.1202662			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359533				2022-12-17	WOS:000080523800010
J	Ritchie, A; Braun, SE; He, J; Broxmeyer, HE				Ritchie, A; Braun, SE; He, J; Broxmeyer, HE			Thrombopoietin-induced conformational change in p53 lies downstream of the p44/p42 mitogen activated protein kinase cascade in the human growth factor-dependent cell line M07e	ONCOGENE			English	Article						MAPK; p53 conformation; thrombopoietin; apoptosis; M07e	WILD-TYPE P53; FACTOR RECEPTOR SUPERFAMILY; TUMOR-SUPPRESSOR PROTEIN; MPL CYTOPLASMIC DOMAIN; C-KIT LIGAND; TYROSINE-PHOSPHORYLATION; HEMATOPOIETIC-CELLS; MEGAKARYOCYTIC DIFFERENTIATION; SHC PHOSPHORYLATION; SIGNALING MOLECULES	Thrombopoietin is a cytokine with potent megakaryocytopoietic and thrombopoietic activities in who. Wild-type p53 is a conformationally flexible, anti-oncogenic transcription factor that plays a principal role in mediating growth factor withdrawal-induced apoptosis in factor-dependent hematopoietic cells. We recently reported that Tpo induces a conformational change in and functional inactivation of p53, coincident with its anti-apoptotic effects, in the human factor-dependent cell line M07e. In an effort to identify potential signaling cascades through which Tpo illicits these effects on p53, we report here that treating M07e cells with MAPK kinase inhibitor PD98059 dramatically suppressed Tpo-induced conformational change in p53 as well as Tpo-enhanced viability in M07e cells in a p53-dependent manner. Furthermore, the expression of constitutively active Raf1 in M07e cells induced conformational change in p53 independent of Tpo stimulation. Inhibition of the JAK/STAT pathway revealed that JAK/STAT signaling plays an insignificant role in conformational modulation of p53 and apoptosis suppression. Inhibition of phosphatidylinositol-3 kinase did not have a significant effect on p53 conformation but did have a weak but significant effect on Tpo-enhanced viability. Cytokine-induced activation of the MAPK pathway and the subsequent functional neutralization of p53, may be an event by which apoptosis is commonly suppressed in hematopoiesis.	Indiana Univ, Sch Med, Dept Microbiol Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med Hematol Oncol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46208 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute	Broxmeyer, HE (corresponding author), Indiana Univ, Sch Med, Dept Microbiol Immunol, Indianapolis, IN 46202 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054037, R01HL056416] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053674] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 54037, R01 HL 56416] Funding Source: Medline; NIDDK NIH HHS [R01 DK 53674] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P6953; Alexander WS, 1996, EMBO J, V15, P6531, DOI 10.1002/j.1460-2075.1996.tb01044.x; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; BACON CM, 1995, FEBS LETT, V370, P63, DOI 10.1016/0014-5793(95)00796-C; BI S, 1993, LEUKEMIA, V7, P1840; BLANDINO G, 1995, ONCOGENE, V10, P731; Brizzi MF, 1996, ONCOGENE, V13, P2067; BROUDY VC, 1995, BLOOD, V85, P1719, DOI 10.1182/blood.V85.7.1719.bloodjournal8571719; CarverMoore K, 1996, BLOOD, V88, P803; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; CohenSolal K, 1997, THROMB HAEMOSTASIS, V78, P37; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Dorsch M, 1997, J EXP MED, V186, P1947, DOI 10.1084/jem.186.12.1947; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gotoh A, 1997, ANN HEMATOL, V75, P207, DOI 10.1007/s002770050344; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1993, CANCER RES, V53, P4469; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HENDRIE PC, 1991, EXP HEMATOL, V19, P1031; KAUSHANSKY K, 1995, P NATL ACAD SCI USA, V92, P3234, DOI 10.1073/pnas.92.8.3234; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Melemed AS, 1997, BLOOD, V90, P3462, DOI 10.1182/blood.V90.9.3462; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1990, ONCOGENE, V5, P1683; MIYASHITA T, 1995, CELL, V80, P293; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morita H, 1996, FEBS LETT, V395, P228, DOI 10.1016/0014-5793(96)01047-2; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; Nagata Y, 1995, FEBS LETT, V377, P497, DOI 10.1016/0014-5793(95)01386-5; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Parrizas M, 1997, J BIOL CHEM, V272, P154; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PICKSLEY SM, 1992, ONCOGENE, V7, P1649; Porteu F, 1996, MOL CELL BIOL, V16, P2473; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Ramsfjell V, 1997, J IMMUNOL, V158, P5169; Reid S, 1996, J IMMUNOL METHODS, V192, P43, DOI 10.1016/0022-1759(96)00004-X; Ritchie A, 1997, BLOOD, V90, P4394; Ritchie A, 1996, STEM CELLS, V14, P330, DOI 10.1002/stem.140330; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; SASAKI K, 1995, BIOCHEM BIOPH RES CO, V216, P338, DOI 10.1006/bbrc.1995.2629; Sattler M, 1997, J CELL PHYSIOL, V171, P28; Sitnicka E, 1996, BLOOD, V87, P4998, DOI 10.1182/blood.V87.12.4998.bloodjournal87124998; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Takahira H, 1997, BLOOD, V89, P1574, DOI 10.1182/blood.V89.5.1574.1574_1574_1584; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; TORTOLANI PJ, 1995, BLOOD, V85, P3444, DOI 10.1182/blood.V85.12.3444.bloodjournal85123444; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMADA M, 1995, BIOCHEM BIOPH RES CO, V217, P230, DOI 10.1006/bbrc.1995.2768; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zauli G, 1997, BLOOD, V89, P883, DOI 10.1182/blood.V89.3.883; ZERRAHN J, 1992, ONCOGENE, V7, P1371; ZHANG W, 1992, ONCOGENE, V7, P1645; ZHANG W, 1994, LEUKEMIA LYMPHOMA, V14, P251, DOI 10.3109/10428199409049675; ZHU YM, 1994, BRIT J CANCER, V69, P468, DOI 10.1038/bjc.1994.85	70	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	1999	18	7					1465	1477		10.1038/sj.onc.1202439	http://dx.doi.org/10.1038/sj.onc.1202439			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050883				2022-12-17	WOS:000078651600008
J	Dkhissi, F; Raynal, SP; Jullien, P; Lawrence, DA				Dkhissi, F; Raynal, SP; Jullien, P; Lawrence, DA			Growth stimulation of murine fibroblasts by TGF-beta 1 depends on the expression of a functional p53 protein	ONCOGENE			English	Article						TGF-beta 1; P53; pRB; SV40; p21Waf; growth stimulation; growth inhibition	LARGE TUMOR-ANTIGEN; RETINOBLASTOMA GENE-PRODUCT; CELL-CYCLE PROGRESSION; FACTOR-BETA; TGF-BETA; MOUSE FIBROBLASTS; TRANSFORMING GROWTH-FACTOR-BETA-1; DOWN-REGULATION; INDUCTION; INHIBITION	Transforming Growth Factor-beta 1 (TGF-beta 1) inhibits the proliferation of most cells, but stimulates some mesenchymal cell types, including murine NIH3T3 fibroblasts, We show here that TGF-beta 1 growth stimulation of NIH3T3 fibroblasts is reversed when these cells are transformed by SV40 or are transfected with a plasmid encoding the SV40 Large T antigen. Inversion of the TGF-beta 1 growth stimulation of NIH3T3 cells is not observed when these cells are transfected with plasmids expressing either a mutant Large T, unable to bind P53, or the E1A adenovirus oncoprotein which binds the retinoblastoma protein pRB but not P53, But when the TGF-beta 1-growth stimulated cells are transfected with a plasmid expressing a mutant form of Large T capable of binding to P53, but not to pRB, or with one expressing the E1B-55 kD adenovirus oncoprotein, which also binds to P53 but not to pRB, the cells are growth-inhibited by TGF-beta 1. The cdk inhibitor p21Waf is decreased in TGF-beta 1-stimulated NIH3T3 fibroblasts and increased in TGF-beta 1-inhibited SV40-transformed cells. Finally, we show that T12 fibroblasts, from a P53 knockout mouse, are growth inhibited by TGF-beta 1 and that they remain so upon transfection with a P53 which is mutant at restrictive temperature, but become growth-stimulated by this factor at permissive temperature when P53 is functional. These data strongly suggest that growth-stimulation of fibroblasts by TGF-beta 1 depends on the presence of a functional P53 protein and that inversion of this response occurs if P53 is absent or inactivated.	CNRS, UPR 9079, F-94801 Villejuif, France; CNRS, Inst Curie, UMR 146, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Lawrence, DA (corresponding author), CNRS, UPR 9079, BP 8, F-94801 Villejuif, France.							ALEXANDROW MG, 1995, CANCER RES, V55, P1452; BENOIST C, 1981, NATURE, V290, P304, DOI 10.1038/290304a0; Benzakour O, 1992, GROWTH FACTORS, V6, P265, DOI [10.3109/08977199209021539, 10.3109/08977199209026933]; BLAYDES JP, 1995, ONCOGENE, V10, P307; DANIEL TO, 1987, J BIOL CHEM, V262, P11893; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evangelisti R, 1997, CELL BIOCHEM FUNCT, V15, P47; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GREGOIRE M, 1984, EXP CELL RES, V152, P38, DOI 10.1016/0014-4827(84)90228-3; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HILL DJ, 1986, J CELL PHYSIOL, V128, P322, DOI 10.1002/jcp.1041280226; HUANG F, 1994, ONCOGENE, V9, P3701; JOCHEMSEN AG, 1987, EMBO J, V6, P3399, DOI 10.1002/j.1460-2075.1987.tb02663.x; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KIM TA, 1993, CANCER LETT, V71, P125, DOI 10.1016/0304-3835(93)90107-K; KIM TA, 1994, J CELL PHYSIOL, V160, P1, DOI 10.1002/jcp.1041600102; KOIKE M, 1994, BIOCHEM BIOPH RES CO, V201, P673, DOI 10.1006/bbrc.1994.1753; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAWRENCE DA, 1995, KIDNEY INT, V47, P19; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; MACHWATE M, 1995, MOL ENDOCRINOL, V9, P187, DOI 10.1210/me.9.2.187; Malliri A, 1996, CELL GROWTH DIFFER, V7, P1291; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MICHIELI P, 1994, CANCER RES, V54, P3391; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MULLER W, 1975, EUR J BIOCHEM, V54, P385, DOI 10.1111/j.1432-1033.1975.tb04149.x; NAGY J A, 1988, Biochimica et Biophysica Acta, V948, P305; OKADOME T, 1994, J BIOL CHEM, V269, P30753; ONG G, 1991, ONCOGENE, V6, P761; ORMEROD MG, 1992, J IMMUNOL METHODS, V153, P57, DOI 10.1016/0022-1759(92)90305-D; PIPAS JM, 1983, MOL CELL BIOL, V3, P203, DOI 10.1128/MCB.3.2.203; RAVITZ MJ, 1995, CANCER RES, V55, P1413; RAYNAL S, 1994, GROWTH FACTORS, V11, P197, DOI 10.3109/08977199409046917; RAYNAL S, 1995, INT J ONCOL, V7, P337; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROBERTS AB, 1990, HDB EXPT PHARM, V95; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Sgambato A, 1997, CELL GROWTH DIFFER, V8, P393; VENTURA F, 1994, EMBO J, V13, P5581, DOI 10.1002/j.1460-2075.1994.tb06895.x; WATABE K, 1994, J NEUROSCI RES, V39, P525, DOI 10.1002/jnr.490390504; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0	49	20	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					703	711		10.1038/sj.onc.1202341	http://dx.doi.org/10.1038/sj.onc.1202341			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989820				2022-12-17	WOS:000078394400015
J	Magae, J; Illenye, S; Chang, YC; Mitsui, Y; Heintz, NH				Magae, J; Illenye, S; Chang, YC; Mitsui, Y; Heintz, NH			Association with E2F-1 governs intracellular trafficking and polyubiquitination of DP-1	ONCOGENE			English	Article						E2F; ubiquitination; c-jun; CKI	UBIQUITIN-PROTEASOME PATHWAY; S-PHASE ENTRY; RETINOBLASTOMA FAMILY PROTEINS; TRANSCRIPTION FACTOR E2F; CELL-CYCLE; DIHYDROFOLATE-REDUCTASE; IN-VIVO; SUBCELLULAR-LOCALIZATION; NUCLEAR-LOCALIZATION; GENE-EXPRESSION	The cell cycle-regulated transcription factor E2F is a family of heterodimers composed of E2F and DP protein subunits, While DP proteins stabilize DNA binding of E2F proteins, and influence the entry of E2F-4 and E2F-5 into the nucleus, the role of DP proteins in E2F-dependent gene expression is not well understood. Using immunolocalization, immunoprecipitation, and cell fractionation experiments, here we show association with E2F subunits governs intracellular trafficking and ubiquitination of DP-1, In transient transfection experiments, DP-1 polypeptides that stably bound E2F-1 entered the nucleus. DP-1 proteins that failed to associate with E2F subunits accumulated in the cell cytoplasm as polyubiquitinated DP-1, A Chinese hamster cell line that conditionally expresses HA-DP-1 was used to examine the effect of DP-1 on cell cycle progression, In serum response experiments, moderate increases in HA-DP-1 led to a threefold increase in E2F DNA binding activity in vitro, a corresponding increase in dhfr gene expression during transition of G1, and higher rates of S phase entry. However, flow cytometry showed cells expressing very high levels of HA-DP-1 failed to enter the S phase. Inhibition of cell cycle progression by high levels of HA-DP-1 was associated with the accumulation of other ubiquitinated cellular proteins, including c-jun and the cyclin-dependent kinase inhibitor p21, indicating that degradation of ubiquitinated proteins is required for progression from G(0) to S phase even in the presence of activated E2F, Under similar conditions, expression of E2F-1 reduced the levels of ubiquitinated cellular proteins and accelerated cell cycle progression. Our studies indicate association with E2F subunits prevents ubiquitin-dependent degradation of DP-1 in the cytoplasm by promoting nuclear entry of E2F/DP heterodimers.	Univ Vermont, Dept Pathol, Coll Med, Burlington, VT 05405 USA; Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 305, Japan	University of Vermont; National Institute of Advanced Industrial Science & Technology (AIST)	Heintz, NH (corresponding author), Univ Vermont, Dept Pathol, Coll Med, Soule Med Alumni Bldg, Burlington, VT 05405 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054726] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54726] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; Gopalkrishnan RV, 1996, ONCOGENE, V13, P2671; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HARPER JW, 1993, CELL, V75, P805; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; JOOSS K, 1995, ONCOGENE, V10, P1529; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Magae J, 1996, J CELL SCI, V109, P1717; Maki CG, 1996, CANCER RES, V56, P2649; MILBRANDT JD, 1981, P NATL ACAD SCI USA, V78, P6042; Muller H, 1997, MOL CELL BIOL, V17, P5508; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Sanchez I, 1996, CURR OPIN CELL BIOL, V8, P318, DOI 10.1016/S0955-0674(96)80004-4; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Schilling Lynda J., 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P19; SCHOWB E, 1994, CELL, V79, P233; Shan B, 1996, CELL GROWTH DIFFER, V7, P689; SHULL S, 1991, J BIOL CHEM, V266, P24398; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; TELFORD WG, 1994, J IMMUNOL METHODS, V172, P1, DOI 10.1016/0022-1759(94)90373-5; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321; Warburg O., 1942, BIOCHEM Z, V310, P384; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wells J, 1996, MOL CELL BIOL, V16, P634; Wells JM, 1997, J BIOL CHEM, V272, P4483, DOI 10.1074/jbc.272.7.4483; Wu CL, 1996, MOL CELL BIOL, V16, P3698; WU CL, 1995, MOL CELL BIOL, V15, P2536; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	50	20	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					593	605		10.1038/sj.onc.1202345	http://dx.doi.org/10.1038/sj.onc.1202345			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989809				2022-12-17	WOS:000078394400004
J	Dhulipala, PDK; Lee, L; Rao, VN; Reddy, ESP				Dhulipala, PDK; Lee, L; Rao, VN; Reddy, ESP			Fli-1b is generated by usage of differential splicing and alternative promoter	ONCOGENE			English	Article						Fli-1; Fli-1b; alternative splicing; alternative promoter; onco-protein; translocation; transcriptional activator	PUTATIVE ONCOGENE SPI-1; MURINE LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; ETS-RELATED PROTEIN; DNA-BINDING DOMAIN; TRANSCRIPTIONAL ACTIVATION; T-CELL; C-ETS; C-ETS-1 PROTOONCOGENE; EWING SARCOMA	The proto-oncogene Fli-1, a member of Ets family is rearranged or activated through proviral integration in erythroleukemias, induced by Friends' Murine Leukemia Virus. The DNA binding domain (ETS domain) of Fli-1 is fused to the RNA binding domain of EWS by t(11q24:22q12) chromosomal translocation in Ewing's sarcoma and primitive neuroectodermal tumors. Screening of human cDNA libraries has identified two different 5'-termini and alternatively spliced forms of the human Fli-1 gene (Fli-1b), suggesting the possible existence of two independent promoters. The genomic sequence adjacent to the alternate exon of human Fli-1b gene shows functional promoter activity when cloned in promoter-less CAT expression vector and transfected into QT-6 cells. The transcription initiation (CAP) site and minimum promoter region necessary for function were localized. The 5'-flanking regions of human Fli-1b and mouse Fli-1 show 80% homology suggesting conserved promoter regulatory elements. The Fli-1b 5'-flanking sequence lacks canonical TATA or CCAAT boxes but contains a partially conserved TATA-like sequence at position 242. Several transcription factor binding sequences like ATF/CREB, E2A-PBX1, EBP, PEA-3, ETS-2, Sp-1, c-Myc, TBP, GATA-1 and Oct-3 were conserved in the promoter sequence. Functional promoter assays revealed that Fli-1b promoter shows very strong transcriptional activation compared to Fli-1 promoter. We also showed that variant Fli-1b has transcriptional activation properties similar to those of Fli-1. Fli-1b and Fli-1 show differential expression in various hematopoietic cell lines. This differential expression and promoter activities of Fli-1 and Fli-1b suggests that several mechanisms are involved in Fli-1 gene regulation which are mediated by many transcription factors.	Allegheny Univ Hlth Sci, Dept Human Genet, Div Canc Genet, Philadelphia, PA 19102 USA; SAIC, Frederick, MD 21702 USA	Drexel University; Science Applications International Corporation (SAIC); SAIC-Frederick	Reddy, ESP (corresponding author), Allegheny Univ Hlth Sci, Dept Human Genet, Div Canc Genet, Broad & Vine St, Philadelphia, PA 19102 USA.				NATIONAL CANCER INSTITUTE [P01CA051083, R01CA058642, R01CA057322] Funding Source: NIH RePORTER; NCI NIH HHS [CA57322, CA 58642, CA 51083] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Barbeau B, 1996, BBA-GENE STRUCT EXPR, V1307, P220, DOI 10.1016/0167-4781(96)00060-7; BAUD V, 1991, GENOMICS, V11, P223, DOI 10.1016/0888-7543(91)90124-W; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BERGERON D, 1992, VIROLOGY, V191, P661, DOI 10.1016/0042-6822(92)90241-G; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BROWN TA, 1992, GENE DEV, V6, P2500; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1988, ONCOGENE RES, V2, P371; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HALUSKA FG, 1987, ANNU REV GENET, V21, P321, DOI 10.1146/annurev.ge.21.120187.001541; HIPSKIND RA, 1991, NATURE, V354, P53534; HROMAS R, 1993, BIOCHIM BIOPHYS ACTA, V1172, P155, DOI 10.1016/0167-4781(93)90283-J; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JEON IS, 1995, ONCOGENE, V10, P1229; JORCYK CL, 1991, ONCOGENE, V6, P523; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MELTON DA, 1987, METHOD ENZYMOL, V152, P288; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OHNO T, 1993, CANCER RES, V53, P5859; PRASAD DDK, 1994, ONCOGENE, V9, P669; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRIBYL LS, 1988, ONCOGENE, V6, P1175; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1993, ONCOGENE, V8, P2167; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; SAMBROOK J, 1989, MOL CLONING LAB MANU, V3; SELLERI L, 1991, P NATL ACAD SCI USA, V88, P887, DOI 10.1073/pnas.88.3.887; SETH A, 1993, ONCOGENE, V8, P1783; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YE K, 1993, P NATL ACAD SCI USA, V90, P2295, DOI 10.1073/pnas.90.6.2295; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; YUNIS JJ, 1989, GENOMICS, V5, P84, DOI 10.1016/0888-7543(89)90090-6	62	20	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 3	1998	17	9					1149	1157		10.1038/sj.onc.1202030	http://dx.doi.org/10.1038/sj.onc.1202030			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764825				2022-12-17	WOS:000075598400010
J	Schwartz, MA; Meredith, JE; Kiosses, WB				Schwartz, MA; Meredith, JE; Kiosses, WB			An activated Rac mutant functions as a dominant negative for membrane ruffling	ONCOGENE			English	Article						Rho family small GTP binding protein; signal transduction; actin cytoskeleton	CELL-CYCLE PROGRESSION; PROTEIN-KINASE; ACTIN POLYMERIZATION; SMALL GTPASES; CDC42; RHO; CASCADE	Previous studies have shown that point mutations in the effector domain of Rad block specific downstream pathways such as PAK, JNK/SAPK kinases and membrane ruffling, Specifically, the F37A mutation, made in a constitutively activated Q61L background, activates PAK but fails to induce membrane ruffles. We now show that Q61L/F37A Rac not only fails to induce ruffling but potently blocks membrane ruffling induced by serum or PDGF, In the presence of serum, cells do extend filopodia, suggesting that this mutant only blocks a subset of the effecters that induce cytoskeletal reorganization. At later times, this rac mutant induces membrane blebbing, but not apoptosis, These results show that Q61L/F37A Rac, is constitutively activated with respect to PAK activation but functions as a dominant negative for another pathway, membrane ruffling, That an effector domain point mutant can simultaneously function as a dominant negative and dominant positive for different pathways implies that effects of these variants on cell functions must be interpreted with caution.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Schwartz, MA (corresponding author), Scripps Res Inst, Dept Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			schwartz, martin/0000-0002-2071-1243	NIGMS NIH HHS [R01 GM27214] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CUNNINGHAM CC, 1995, J CELL BIOL, V129, P1589, DOI 10.1083/jcb.129.6.1589; Fedier A, 1997, CELL MOTIL CYTOSKEL, V37, P326; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Myat MM, 1997, CURR BIOL, V7, P611, DOI 10.1016/S0960-9822(06)00262-4; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	15	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					625	629		10.1038/sj.onc.1201977	http://dx.doi.org/10.1038/sj.onc.1201977			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704928				2022-12-17	WOS:000075195300010
J	Theis, S; Roemer, K				Theis, S; Roemer, K			c-Abl tyrosine kinase can mediate tumor cell apoptosis independently of the Rb and p53 tumor suppressors	ONCOGENE			English	Article						programmed cell death; tyrosine kinase; c-Abl; p53; retinoblastoma	RNA-POLYMERASE-II; RETINOBLASTOMA PROTEIN FUNCTION; TERMINAL REPEATED DOMAIN; GENE-PRODUCT; DNA-DAMAGE; BINDING; GROWTH; PHOSPHORYLATION; CYCLE; ONCOPROTEIN	Tumor cells frequently lack the p53 tumor suppressor because p53 mediates apoptosis in these cells. We report here that c-Abl, and to a greater extent a c-Abl mutant defective for DNA-binding, can provoke programmed cell death in p53-deficient tumor cells. Tyrosine kinase mutant K290R is less cytotoxic, In contrast, a C-terminal deletion mutant that lacks the RNA polymerase II (PolII)/actin interaction domain, fails to mediate apoptosis unless expressed to very high levels. Cytotoxicity is overcome by coexpression of the apoptosis antagonist E1B 19K protein, and partially overcome by full-length retinoblastoma protein (Rb) or the C pocket fragment of Rb (SE Delta) that associates with c-Abl, c-Abl is also highly toxic to Saos-2 cells that are deficient for both Rb and p53, indicating that cell death is not the result of inhibition through c-Abl of the anti-apoptotic function of Rb. Finally, p53 and c-Abl combined induce apoptosis stronger than either protein alone. Unlike Abl-mediated cell death, apoptosis by p53 is antagonized efficiently only by full-length Rb with intact A/B pocket but not by SE Delta. Mutant p53 inhibits apoptosis by p53 but not c-Abl, Thus, c-Abl with intact kinase and PolIII actin-binding domains can affect tumor cell survival independently of Rb and p53.	Univ Saarland, Sch Med, Dept Virol, D-66421 Homburg, Germany	Saarland University	Roemer, K (corresponding author), Univ Saarland, Sch Med, Dept Virol, Bldg 47, D-66421 Homburg, Germany.							Baskaran R, 1996, MOL CELL BIOL, V16, P3361; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GOGA A, 1995, ONCOGENE, V11, P791; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HAUPT Y, 1995, ONCOGENE, V10, P1563; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; Miao YJ, 1996, J BIOL CHEM, V271, P22823, DOI 10.1074/jbc.271.37.22823; MIYASHITA T, 1995, CELL, V80, P293; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Roemer K, 1996, ONCOGENE, V12, P2069; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; THEIS S, 1997, INT J CANCER, V72, P1; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	40	20	20	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					557	564		10.1038/sj.onc.1201973	http://dx.doi.org/10.1038/sj.onc.1201973			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704921				2022-12-17	WOS:000075195300003
J	Barnache, S; Wendling, F; Lacombe, C; Denis, N; Titeux, M; Vainchenker, W; Moreau-Gachelin, F				Barnache, S; Wendling, F; Lacombe, C; Denis, N; Titeux, M; Vainchenker, W; Moreau-Gachelin, F			Spi-1 transgenic mice develop a clonal erythroleukemia which does not depend on p53 mutation	ONCOGENE			English	Article						Spi-1/PU.1; p53; transgenic; leukemia; Friend	VIRUS-INDUCED ERYTHROLEUKEMIA; FOCUS-FORMING VIRUS; FRIEND-VIRUS; ERYTHROPOIETIN RECEPTOR; TRANSCRIPTION FACTOR; TUMORIGENIC CELLS; PUTATIVE ONCOGENE; LEUKEMIA-VIRUS; GENE; ACTIVATION	Spi-1 transcriptional activation and wild-type p53 extinction are two oncogenic alterations involved in the malignant transformation of erythroblasts during the Friend acute erythroleukemia, To dissect the contribution of these alterations in the deregulation of the differentiation and proliferation of erythroblasts, we generated spi-1 transgenic mice. Analysis of these animals revealed that Spi-1 overexpression was directly involved in the block of proerythroblast differentiation. However, the erythroleukemia that develops in these animals evolved in two steps. During the early step (HS1 step), non tumorigenic proerythroblasts remained strictly dependent upon erythropoietin (Epo) for their survival and proliferation. Later on, Epo-independent and tumorigenic proerythroblasts emerged (HS2 step) suggesting that other oncogenes cooperate with Spi-1 to lead to a fully malignant phenotype, By provirus tagging, we demonstrate that the HS1 step was clonal indicating that a cell selection must occur in vivo. Analysis of the nature of p53 in both the in vivo HS1 and HS2 proerythroblasts and in cultured erythroblastic cell lines showed that-p53 was normal in the HS1 primary tissues but was mutated in the HS1 cultured cell lines-p53 was frequently altered in HS2 primary tissues but was found normal in some mice. These data indicate that (1) the blockage of the erythroblast differentiation by Spi-1 occurs independently of p53 alteration (ii) p53 alteration is not necessary to confer Epo independence and tumorigenicity to spi-1 transgenic proerythroblasts.	Inst Curie, INSERM U248, F-75005 Paris, France; Inst Gustave Roussy, INSERM U362, F-94800 Villejuif, France; Hop Cochin, ICGM, INSERM U363, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier	Moreau-Gachelin, F (corresponding author), Inst Curie, INSERM U248, 26 Rue Ulm, F-75005 Paris, France.			Vainchenker, William/0000-0003-4705-202X				AIZAWA S, 1990, EMBO J, V9, P2107, DOI 10.1002/j.1460-2075.1990.tb07379.x; BASSIN RH, 1971, NATURE, V229, P564, DOI 10.1038/229564b0; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DAVID YB, 1988, ONCOGENE, V3, P179; ELIYAHU D, 1988, ONCOGENE, V3, P313; ELLIOTT JI, 1995, EMBO J, V14, P575, DOI 10.1002/j.1460-2075.1995.tb07033.x; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; HICKS GG, 1988, J VIROL, V62, P4752, DOI 10.1128/JVI.62.12.4752-4755.1988; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAVIGUEUR A, 1991, ONCOGENE, V6, P2197; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Milot E, 1996, CELL, V87, P105, DOI 10.1016/S0092-8674(00)81327-6; MOREAUGACHELIN F, 1986, J VIROL, V57, P349, DOI 10.1128/JVI.57.1.349-352.1986; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1985, J VIROL, V53, P292, DOI 10.1128/JVI.53.1.292-295.1985; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1983, BIOCHIMIE, V65, P259, DOI 10.1016/S0300-9084(83)80277-6; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; MUNROE DG, 1988, ONCOGENE, V2, P621; PAUL R, 1989, J VIROL, V63, P4958, DOI 10.1128/JVI.63.11.4958-4961.1989; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; Quang CT, 1997, EMBO J, V16, P5639, DOI 10.1093/emboj/16.18.5639; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074-7613(00)80287-3; SITBON M, 1986, CELL, V47, P851, DOI 10.1016/0092-8674(86)90800-7; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; WENDLING F, 1981, P NATL ACAD SCI-BIOL, V78, P3614, DOI 10.1073/pnas.78.6.3614; WENDLING F, 1983, TUMOR VIRUSES DIFFER, P357; WOLFF L, 1985, SCIENCE, V228, P1549, DOI 10.1126/science.2990034	46	20	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	1998	16	23					2989	2995		10.1038/sj.onc.1202095	http://dx.doi.org/10.1038/sj.onc.1202095			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662331				2022-12-17	WOS:000074125300005
J	Lee, HY; Chaudhary, J; Walsh, GL; Hong, WK; Kurie, JM				Lee, HY; Chaudhary, J; Walsh, GL; Hong, WK; Kurie, JM			Suppression of c-Fos gene transcription with malignant transformation of human bronchial epithelial cells	ONCOGENE			English	Article						Jun N-terminal kinase; extra-cellular signal-related kinase	SERUM RESPONSE ELEMENT; SIGNAL-TRANSDUCTION PATHWAYS; MONOCLONAL-ANTIBODY; SEQUENCE ELEMENTS; PROTO-ONCOGENE; ACTIVATION; GROWTH; INDUCTION; BINDING; EXPRESSION	The Activator Protein-1 (AP-1) complex is a dimeric transcription factor composed of fos and jun proteins that regulates cellular growth and differentiation. We previously demonstrated a reduction in basal AP-1 transcriptional activity associated with the malignant transformation of human bronchial epithelial (HBE) cells that was, in part, a consequence of decreased c-fos expression. In this study, we investigated the mechanisms underlying the reduction in c-fos expression associated with the malignant transformation of HBE cells. c-Fos gene transcription was lower in tumorigenic HBE cells than in normal HBE cells, and the reduction in transcription involved c-fos gene promoter elements from -327 to +40. DNasel footprinting and band shift analyses of motifs within this c-fos promoter region, including a cyclic AMP response element (CRE), serum response element (SRE), sis-inducible element (SIE), and a YY1 site, revealed that binding to these motifs was greater in tumorigenic HBE cells than in normal HBE cells. Site-directed mutagenesis of the CRE partially relieved the repression of c-fas promoter activity in tumorigenic HBE cells. Further, the activity of the Jun N-terminal Kinase (JNK)-dependent pathway, which was a positive regulator of the c-fos promoter, was greater in normal HBE cells than in tumorigenic HBE cells. These findings demonstrate a transcriptionally-mediated suppression of c-fos gene expression associated with the malignant transformation of HBE cells. The decreased activity of the c-fos promoter in tumorigenic 1170I cells appeared to involve suppression through a CRE site and reduced activation by JNK-dependent pathways.	Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Washington State Univ, Dept Genet & Cell Biol, Pullman, WA 99164 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Washington State University	Kurie, JM (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Lee, Ho-Young/0000-0001-7556-9312	NCI NIH HHS [R29-CA67353, P50-CA70907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907, R29CA067353] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; BUSCHER M, 1988, ONCOGENE, V3, P301; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; CURRAN T, 1985, CANCER SURV, V4, P655; FAN Z, 1993, CANCER RES, V53, P4637; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Janknecht R, 1997, J BIOL CHEM, V272, P4219, DOI 10.1074/jbc.272.7.4219; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KIM YH, 1995, CANCER RES, V55, P5603; KLEINSZANTO AJP, 1992, P NATL ACAD SCI USA, V89, P6693, DOI 10.1073/pnas.89.15.6693; Lee HY, 1997, CELL GROWTH DIFFER, V8, P283; Mansour SJ, 1996, CELL GROWTH DIFFER, V7, P243; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Putnam E A, 1992, Surg Oncol, V1, P49, DOI 10.1016/0960-7404(92)90056-Q; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; REDDEL RR, 1988, CANCER RES, V48, P1904; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; Rusch V, 1997, CLIN CANCER RES, V3, P515; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SOBOL RE, 1987, J NATL CANCER I, V79, P403; TALMAGE DA, 1994, ONCOGENE, V9, P3557; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WHALEY PD, 1995, ENDOCRINOLOGY, V136, P3046, DOI 10.1210/en.136.7.3046; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	45	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					3039	3046		10.1038/sj.onc.1201843	http://dx.doi.org/10.1038/sj.onc.1201843			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662337				2022-12-17	WOS:000074125300011
J	Kubota, S; Pomerantz, RJ				Kubota, S; Pomerantz, RJ			A cis-acting peptide signal in human immunodeficiency virus type I Rev which inhibits nuclear entry of small proteins	ONCOGENE			English	Article						Rev; HIV-1; nucleus; entry; transport	VIRAL MESSENGER-RNA; NUCLEOLAR-TARGETING SIGNAL; NF-KAPPA-B; HIV-1 REV; EXPORT SIGNAL; ACTIVATION DOMAIN; CYTOPLASMIC ACCUMULATION; SEQUENCE REQUIREMENTS; MUTATIONAL ANALYSIS; TRANS-ACTIVATOR	A peptide signal, which may control nucleo-cytoplasmic protein trafficking, was newly identified in human immunodeficiency virus type I (HIV-1) Rev, a lentiviral post-transcriptional transactivator. The sequence, in the amino-terminal portion of HIV-1 Rev, maintains a Rev mutant with a dysfunctional nuclear/nucleolar targeting signal outside of the nucleus, although this Rev molecule itself is small enough to pass through the nuclear pores. Transition of this sequence to the N-terminus of human T-lymphocytic leukemia/lymphoma virus type I (HTLV-I) p21(x), which is usually located evenly distributed throughout the cell, resulted in capture of p21(x) in the cytoplasm. Mutational analysis clarified that a 14 residue peptide sequence was sufficient to display this inhibitory effect against nuclear entry. Furthermore, this HIV-1 Rev sequence was capable of inhibiting nuclear entry of a fragment of a human ribosomal protein, when it was fused to the carboxy terminus. The identified nuclear entry inhibitory signal (NIS) contains a conserved hydrophilicity motif, which forms an amphipathic helix. Significantly, this motif and its helical structure were shown to be important for NIS function and the HIV-1 Rev function itself. Possible roles for NIS as a molecular anchor are proposed herein.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Dorrance H Hamilton Labs, Div Infect Dis,Ctr Human Virol, Philadelphia, PA 19107 USA	Jefferson University	Pomerantz, RJ (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Dorrance H Hamilton Labs, Div Infect Dis,Ctr Human Virol, Philadelphia, PA 19107 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036552, R01AI031836] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31836, AI36552] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARRIGO SJ, 1991, GENE DEV, V5, P808, DOI 10.1101/gad.5.5.808; AUER M, 1994, BIOCHEMISTRY-US, V33, P2988, DOI 10.1021/bi00176a031; BERGER J, 1991, VIROLOGY, V183, P630, DOI 10.1016/0042-6822(91)90992-K; BERNEMAN ZN, 1992, P NATL ACAD SCI USA, V89, P3005, DOI 10.1073/pnas.89.7.3005; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DAGOSTINO DM, 1992, MOL CELL BIOL, V12, P1375, DOI 10.1128/MCB.12.3.1375; DALY TJ, 1995, J MOL BIOL, V253, P243, DOI 10.1006/jmbi.1995.0549; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; FURUKAWA K, 1991, FEBS LETT, V295, P141, DOI 10.1016/0014-5793(91)81404-V; FURUTA RA, 1995, J VIROL, V69, P1591, DOI 10.1128/JVI.69.3.1591-1599.1995; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Goldfarb DS, 1997, SCIENCE, V276, P1814, DOI 10.1126/science.276.5320.1814; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HEAPHY S, 1991, P NATL ACAD SCI USA, V88, P7366, DOI 10.1073/pnas.88.16.7366; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HOPE TJ, 1990, J VIROL, V64, P5360, DOI 10.1128/JVI.64.11.5360-5366.1990; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; KAISER ET, 1987, ANNU REV BIOPHYS BIO, V16, P561; KALLAND KH, 1994, MOL CELL BIOL, V14, P7436, DOI 10.1128/MCB.14.11.7436; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUBOTA S, 1992, J VIROL, V66, P2510, DOI 10.1128/JVI.66.4.2510-2513.1992; Kubota S, 1996, VIROLOGY, V220, P502, DOI 10.1006/viro.1996.0339; KUBOTA S, 1991, J VIROL, V65, P2452, DOI 10.1128/JVI.65.5.2452-2456.1991; KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5; KUBOTA S, 1995, EUR J BIOCHEM, V233, P48, DOI 10.1111/j.1432-1033.1995.048_1.x; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; LI ML, 1991, GENE, V107, P329, DOI 10.1016/0378-1119(91)90335-9; MADORE SJ, 1994, VIROLOGY, V202, P186, DOI 10.1006/viro.1994.1334; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; MICHAEL WM, 1995, CELL, V83, P415; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; NOSAKA T, 1989, P NATL ACAD SCI USA, V86, P9798, DOI 10.1073/pnas.86.24.9798; OLSEN HS, 1990, GENE DEV, V4, P1357, DOI 10.1101/gad.4.8.1357; ORITA S, 1991, FEBS LETT, V295, P127, DOI 10.1016/0014-5793(91)81402-T; Palmeri D, 1996, J VIROL, V70, P6442, DOI 10.1128/JVI.70.9.6442-6445.1996; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; POMERANTZ RJ, 1992, J VIROL, V66, P1809, DOI 10.1128/JVI.66.3.1809-1813.1992; RICHARD N, 1994, VIROLOGY, V204, P123, DOI 10.1006/viro.1994.1516; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309; SCHMIDT C, 1995, MOL BIOL CELL, V6, P1875, DOI 10.1091/mbc.6.12.1875; SCHWARZ E, 1994, BBA-BIOENERGETICS, V1187, P270, DOI 10.1016/0005-2728(94)90125-2; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; SMEEKENS S, 1990, TRENDS BIOCHEM SCI, V15, P73, DOI 10.1016/0968-0004(90)90180-J; SRINIVAS SK, 1992, J BIOL CHEM, V267, P7121; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; Szilvay AM, 1997, VIROLOGY, V235, P73, DOI 10.1006/viro.1997.8671; TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WEN W, 1994, J BIOL CHEM, V269, P32214; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WOLFF B, 1995, EXP CELL RES, V217, P31, DOI 10.1006/excr.1995.1060; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	68	20	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 9	1998	16	14					1851	1861		10.1038/sj.onc.1201738	http://dx.doi.org/10.1038/sj.onc.1201738			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583682				2022-12-17	WOS:000072994600008
J	Hemminki, A; Hoglund, P; Pukkala, E; Salovaara, R; Jarvinen, H; Norio, R; Aaltonen, LA				Hemminki, A; Hoglund, P; Pukkala, E; Salovaara, R; Jarvinen, H; Norio, R; Aaltonen, LA			Intestinal cancer in patients with a germline mutation in the down-regulated in adenoma (DRA) gene	ONCOGENE			English	Article						DRA; CLD; cancer; neoplasia; tumor suppressor	CONGENITAL CHLORIDE DIARRHEA; LINKAGE DISEQUILIBRIUM; CYSTIC-FIBROSIS; MUCOSA; COLON; GROWTH; CARCINOMA; ENCODES	A recent study has revealed that germline mutations of the down-regulated in adenoma (DRA) gene are a likely cause of a recessive intestinal absorption defect, congenital chloride diarrhea, This finding was in accordance with previous works showing that DRA encodes a sodium independent transporter for sulfate and oxalate, Although DRA was originally reported as a candidate tumor suppressor, these studies have questioned the relevance of DRA in cancer. To evaluate whether further studies on the role of DRA in tumorigenesis are still of interest, we examined whether individuals carrying germline DRA mutations have an excess of intestinal cancer, Cancer status of 229 members of 36 Finnish congenital chloride diarrhea families (44 homozygous patients, 70 heterozygous parents, and 115 grandparents at 50% risk of being a DRA mutation carrier) was checked at the Finnish Cancer Registry and the risk of intestinal cancer was found slightly elevated (standardized incidence ratio 3.4, 95% confidence interval 1.4-7.0, P<0.05). While this result does not unambiguously demonstrate an increased intestinal cancer risk in DRA mutation carriers, it should promote further studies to determine the possible role of DRA in cancer.	Univ Helsinki, Dept Med Genet, Helsinki 00014, Finland; Univ Helsinki, Haartman Inst, Dept Pathol, Helsinki 00014, Finland; Finnish Canc Registry, Helsinki 00171, Finland; Univ Helsinki, Cent Hosp, Dept Surg 2, Helsinki 00250, Finland; Family Fed Finland, Dept Med Genet, Helsinki 00101, Finland	University of Helsinki; University of Helsinki; Finnish Cancer Registry; University of Helsinki; Helsinki University Central Hospital; Family Federation of Finland	Aaltonen, LA (corresponding author), Univ Helsinki, Dept Med Genet, Haartmaninkatu 3,POB 21, Helsinki 00014, Finland.		Aaltonen, Lauri/A-5375-2010	Aaltonen, Lauri/0000-0001-6839-4286	NATIONAL CANCER INSTITUTE [U01CA067941, R01CA067941] Funding Source: NIH RePORTER; NCI NIH HHS [CA67941] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham EH, 1996, NAT MED, V2, P593, DOI 10.1038/nm0596-593; FILIPE MI, 1974, CANCER-AM CANCER SOC, V34, P282, DOI 10.1002/1097-0142(197408)34:2<282::AID-CNCR2820340211>3.0.CO;2-W; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HOGLUND P, 1995, AM J HUM GENET, V57, P95; HOGLUND P, 1994, AM J HUM GENET, V55, P747; Hoglund P, 1996, NAT GENET, V14, P316, DOI 10.1038/ng1196-316; KYLLONEN LEJ, 1987, ANN CHIR GYNAECOL FE, V76, P185; LAPIS K, 1990, Tokai Journal of Experimental and Clinical Medicine, V15, P155; Mckusick V.A., 1994, MENDELIAN INHERITANC; NAKAMURA N, 1981, CANCER RES, V41, P278; NEGLIA JP, 1995, NEW ENGL J MED, V332, P494, DOI 10.1056/NEJM199502233320803; NORIO R, 1971, Clinical Genetics, V2, P182; PUKKALA E, 1992, USE RECORD LINKAGE S, P125; PUKKALA E, 1987, CANC SOC FINLAND PUB, V37; ROBINSON J, 1984, J CELL BIOL, V98, P946, DOI 10.1083/jcb.98.3.946; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SCHWEINFEST CW, 1993, P NATL ACAD SCI USA, V90, P4166, DOI 10.1073/pnas.90.9.4166; SHAMSUDDIN AKM, 1981, J NATL CANCER I, V66, P413; SILBERG DG, 1995, J BIOL CHEM, V270, P11897, DOI 10.1074/jbc.270.20.11897; TAGUCHI T, 1994, GENOMICS, V20, P146, DOI 10.1006/geno.1994.1148; TEPPO L, 1994, ACTA ONCOL, V33, P365, DOI 10.3109/02841869409098430; VONDIPPE P, 1982, J BIOL CHEM, V257, P4381; YAMORI T, 1987, CANCER RES, V47, P2741	24	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					681	684		10.1038/sj.onc.1201538	http://dx.doi.org/10.1038/sj.onc.1201538			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482116				2022-12-17	WOS:000071816600015
J	Oda, T; Kujovich, J; Reis, M; Newman, B; Druker, BJ				Oda, T; Kujovich, J; Reis, M; Newman, B; Druker, BJ			Identification and characterization of two novel SH2 domain-containing proteins from a yeast two hybrid screen with the ABL tyrosine kinase	ONCOGENE			English	Article						c-Abl; tyrosine kinase; SH2 domains; yeast two hybrid screen	CHRONIC MYELOGENOUS LEUKEMIA; COLONY-STIMULATING FACTOR; RNA-POLYMERASE-II; MIDDLE-T-ANTIGEN; C-ABL; SIGNAL-TRANSDUCTION; SRC HOMOLOGY-2; BCR-ABL; PHILADELPHIA-CHROMOSOME; BINDING DOMAINS	To further our understanding of the molecular mechanism of Bcr-Abl mediated transformation, a yeast two hybrid screen was used to identify proteins binding to the Abl tyrosine kinase. Two partial cDNAs encoding novel SH2 domain-containing proteins were cloned and designated Shd and She. Both have homology to Shb, a previously reported SH2 domain-containing protein. Northern blot analysis showed that She is expressed in heart, lung, brain, and skeletal muscle, while expression of Shd is restricted to the brain. The deduced amino acid sequence of the full length mouse Shd cDNA contains an amino-terminal proline-rich region, and a carboxy-terminal SH2 domain. A bacterially expressed Shd domain bound multiple tyrosine-phosphorylated proteins with relative molecular weights of 200, 170, 130, 100, 90, 78, 72 and 32 kDa from K562 cell lysates. Shd contains five YXXP motifs, a substrate sequence preferred by Abl tyrosine kinases. Shd was tyrosine phosphorylated in COS-7 cells co-transfected with Shd and c-Abl or Bcr-Abl. These results suggest that Shd may be a physiological substrate of c-Abl and may function as an adapter protein in the central nervous system.	OREGON HLTH SCI UNIV,DIV HEMATOL & MED ONCOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOL BIOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT CELL & DEV BIOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University			Oda, Tsukasa/ABI-1855-2020	Oda, Tsukasa/0000-0002-8941-161X; Druker, Brian/0000-0001-8331-8206	NATIONAL CANCER INSTITUTE [R01CA065823] Funding Source: NIH RePORTER; NCI NIH HHS [CA65823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baskaran R, 1996, MOL CELL BIOL, V16, P3361; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BURNS LA, 1993, J BIOL CHEM, V268, P17659; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DAVIS RL, 1985, MOL CELL BIOL, V5, P204, DOI 10.1128/MCB.5.1.204; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DRUKER BJ, 1991, NUCLEIC ACIDS RES, V19, P6855, DOI 10.1093/nar/19.24.6855; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GOGA A, 1995, ONCOGENE, V11, P791; GREENBERGER JS, 1983, P NATL ACAD SCI USA, V80, P2391; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Harlow E LD, 1988, ANTIBODIES LAB MANUA; Heaney C, 1997, BLOOD, V89, P297, DOI 10.1182/blood.V89.1.297.297_297_306; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KANAKURA Y, 1990, BLOOD, V76, P706; KARLSSON T, 1995, ONCOGENE, V10, P1475; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Nakamura T, 1996, ONCOGENE, V13, P1111; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; ODA T, 1994, J BIOL CHEM, V269, P22925; ODA T, 1995, LEUKEMIA, V9, P295; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1993, CELL, V75, P174; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WELSH M, 1994, ONCOGENE, V9, P19; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	61	20	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1255	1262		10.1038/sj.onc.1201299	http://dx.doi.org/10.1038/sj.onc.1201299			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315092				2022-12-17	WOS:A1997XV84500002
J	Yuan, B; Oechsli, N; Hendler, FJ				Yuan, B; Oechsli, N; Hendler, FJ			A region within murine chromosome 7F4, syntenic to the human 11q13 amplicon, is frequently amplified in 4NQO-induced oral cavity tumors	ONCOGENE			English	Article						head and neck neoplasia; chemical carcinogenesis; gene amplification; cyclin D1; chromosome 7	SQUAMOUS-CELL CARCINOMAS; MOUSE SKIN CARCINOGENESIS; HA-RAS GENE; CYCLIN D1; GENOMIC ORGANIZATION; ONCOGENE ACTIVATION; BREAST-CANCER; INT-2 GENE; HETEROZYGOSITY; AMPLIFICATION	Our previous reports have shown that two thirds of 4-nitroquinoline-1-oxide (4NQO)-induced murine oral squamous cell carcinomas (SCC) have Hras1 mutations, Loss of heterozygosity (LOH) involving the distal portion of chromosome (Chr) 7 occurred in half of the tumors with Hras1 mutations, Here, we demonstrate that five of six tumors with LOH have 4-8-fold amplification involving the distal portion of Chr 7 (7F4). Ccnd1, Fgf4 and Fgf3, within the most telomeric region of Chr 7 (70.5 cM), are co-amplified, The region is syntenic to a previously identified human amplicon at 11q13. Only one out of eight tumors without LOH at Chr 7 had twofold amplification; the other seven had no detectable amplification, Significant amplification is restricted to the chromosome with the Hras1 mutation, Gene amplification occurred without overexpression since only one of five tumors with amplification and one of six tumors without Ccnd1 amplification expressed increased protein, Although amplification of 11q13 occurs rather frequently in human tumors, 4NQO-induced oral, cavity tumors in inbred mice are the first example of a murine tumor with consistent amplification, Our observations are strikingly similar to human head and neck SCC where overexpression of genes within the 11q13 amplicon is inconsistently detected, The amplification of genes localized to human 11q13 and the syntenic region on murine Chr 7 during tumorigenesis suggests that similar structural elements are present which predispose these regions to amplification during malignant transformation.	UNIV LOUISVILLE, JAMES GRAHAM BROWN CANC CTR, DEPT BIOCHEM & MOL BIOL, LOUISVILLE, KY 40292 USA; UNIV LOUISVILLE, JAMES GRAHAM BROWN CANC CTR, DEPT MED, LOUISVILLE, KY 40292 USA; UNIV LOUISVILLE, JAMES GRAHAM BROWN CANC CTR, HENRY VOGT CANC RES INST, LOUISVILLE, KY 40292 USA; UNIV LOUISVILLE, CTR GENET & MOL MED, LOUISVILLE, KY 40292 USA; UNIV LOUISVILLE, CTR ENVIRONM HLTH SCI, LOUISVILLE, KY 40292 USA; LOUISVILLE VA MED CTR, LOUISVILLE, KY USA	University of Louisville; University of Louisville; University of Louisville; University of Louisville; University of Louisville					OAPP OPHS HHS [PG94-3, PG95-5] Funding Source: Medline	OAPP OPHS HHS		AKERVALL JA, 1995, CANCER, V76, P853, DOI 10.1002/1097-0142(19950901)76:5<853::AID-CNCR2820760520>3.0.CO;2-6; ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BIANCHI AB, 1991, P NATL ACAD SCI USA, V88, P7590, DOI 10.1073/pnas.88.17.7590; BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; BIANCHI AB, 1993, MAMM GENOME, V4, P220, DOI 10.1007/BF00417566; BREMNER R, 1994, MOL CARCINOGEN, V11, P90, DOI 10.1002/mc.2940110206; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; Bringuier PP, 1996, ONCOGENE, V12, P1747; BROOKES S, 1989, NUCLEIC ACIDS RES, V17, P4037, DOI 10.1093/nar/17.11.4037; BUCHBERG AM, 1992, MAMM GENOME, V3, pS162, DOI 10.1007/BF00648429; BUCHMANN A, 1991, CANCER RES, V51, P4097; CARTER SL, 1994, CANCER RES, V54, P6270; Cha R S, 1992, PCR Methods Appl, V2, P14; CLARK LJ, 1993, BRIT J CANCER, V68, P617, DOI 10.1038/bjc.1993.396; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FILMUS J, 1994, ONCOGENE, V9, P3627; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; FOULKES WD, 1993, BRIT J CANCER, V67, P268, DOI 10.1038/bjc.1993.51; GAFFEY MJ, 1995, HUM PATHOL, V26, P1221, DOI 10.1016/0046-8177(95)90197-3; GILLETT C, 1994, CANCER RES, V54, P1812; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GUSTAFSON CE, 1994, BRIT J CANCER, V70, P395, DOI 10.1038/bjc.1994.315; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HAWKINS BL, 1994, HEAD NECK-J SCI SPEC, V16, P424, DOI 10.1002/hed.2880160506; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HOWELL RE, 1989, J ORAL PATHOL MED, V18, P79, DOI 10.1111/j.1600-0714.1989.tb00741.x; HU LH, 1995, AACR, V36, P542; Huber JL, 1996, INT CONGR SER, V1114, P89; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KEMP CJ, 1993, MOL CARCINOGEN, V7, P147, DOI 10.1002/mc.2940070304; LAMMIE GA, 1992, ONCOGENE, V7, P2381; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; MICHALIDES R, 1995, CANCER RES, V55, P975; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RINCHIK EM, 1992, MAMM GENOME, V3, pS104, DOI 10.1007/BF00648425; RIOU G, 1988, ONCOGENE, V3, P329; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; RUBIN JS, 1995, J LARYNGOL OTOL, V109, P72, DOI 10.1017/S0022215100129305; RUMSBY G, 1990, BRIT J CANCER, V61, P365, DOI 10.1038/bjc.1990.80; SARANATH D, 1991, BRIT J CANCER, V63, P573, DOI 10.1038/bjc.1991.133; SARANATH D, 1991, J CANCER RES CLIN, V117, P484, DOI 10.1007/BF01612771; SOMERS KD, 1990, ONCOGENE, V5, P915; SRIVATSAN ES, 1991, AM J HUM GENET, V49, P868; TSUDA T, 1989, CANCER RES, V49, P5505; VIEL A, 1991, TUMORI, V77, P16, DOI 10.1177/030089169107700104; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WANI MA, 1994, CANCER RES, V54, P2504; WINQVIST R, 1993, CANCER RES, V53, P4486; Winston JT, 1996, ONCOGENE, V12, P127; Yuan B, 1997, MOL CARCINOGEN, V19, P8, DOI 10.1002/(SICI)1098-2744(199705)19:1<8::AID-MC2>3.0.CO;2-D; YUAN B, 1994, CANCER RES, V54, P5310; Yuan B, 1996, GENOMICS, V38, P58, DOI 10.1006/geno.1996.0592	62	20	20	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	1997	15	10					1161	1170		10.1038/sj.onc.1201269	http://dx.doi.org/10.1038/sj.onc.1201269			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294609				2022-12-17	WOS:A1997XU99100005
J	Dupressoir, A; Heidmann, T				Dupressoir, A; Heidmann, T			Expression of intracisternal A-particle retrotransposons in primary tumors of oncogene-expressing transgenic mice	ONCOGENE			English	Article						oncogenes; IAP; tumors; transgenic mice	LONG TERMINAL REPEAT; CAMP RESPONSE ELEMENT; HEMATOPOIETIC-CELLS; HA-RAS; C-MYC; GENES; METHYLATION; SEQUENCE; ACTIVATION; PROMOTER	Intracisternal A-Particle (IAP) sequences are endogenous retrovirus-like mobile elements, present at 1000 copies in the mouse genome, These elements transpose in a replicative manner via an RNA intermediate and its reverse transcription, and their transposition should therefore be tightly controlled by their transcription level, The in vi,to pattern of expression of these potentially mutagenic elements had previously been analysed in normal mice, and we have now investigated their expression in transgenic mice carrying different oncogenes (e.g. c-myc, v-Ha-ras, SV40 T-antigen) under tissue-specific promoters and disclosing tumors within the brain, the mammary or salivary glands, or the lymphoid organs, Northern blot analysis of IAP expression within the resulting tumors demonstrates a lack of significant and/or systematic effect of v-Ha-ras and SV40 T-antigen expression, but a systematic IAP induction in the myc-induced tumors, In this case, however, analysis of double transgenic mice obtained by crossing the tumor-prone mice with previously described transgenic mice carrying IAP reporter genes did not provide any evidence for induction of the IAP transgenes, therefore strongly suggesting that c-myc expression had an effect on only a limited number of IAP sequences - most probably depending on their position and/or methylation state, These results strengthen the importance of in vivo studies for a correct appraisal of complex biological processes, and moderate previous conclusions derived from in vitro analyses on the general activation of IAPs by oncogenes and on the role of these transposable elements in tumorigenesis.	INST GUSTAVE ROUSSY,UNITE PHYSICOCHIM & PHARMACOL MACROMOL BIOL,CNRS URA147,F-94805 VILLEJUIF,FRANCE	UNICANCER; Gustave Roussy			Dupressoir, Anne/M-5280-2018	Dupressoir, Anne/0000-0002-3464-8513				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ASCH BB, 1990, CANCER RES, V50, P2404; ASCH BB, 1993, INT J CANCER, V54, P813, DOI 10.1002/ijc.2910540516; AUGENLICHT LH, 1984, J BIOL CHEM, V259, P1842; BEGEMANN M, 1988, MOL CARCINOGEN, V1, P196, DOI 10.1002/mc.2940010308; COMPERE SJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P129, DOI 10.1016/0304-419X(88)90008-X; DEOCA FHM, 1984, BIOL CELL, V52, P199; DRAGANI TA, 1987, J CANCER RES CLIN, V113, P223, DOI 10.1007/BF00396377; DRAGANI TA, 1986, CANCER RES, V46, P1915; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; DUHRSEN U, 1990, EMBO J, V9, P1087, DOI 10.1002/j.1460-2075.1990.tb08214.x; Dupressoir A, 1996, MOL CELL BIOL, V16, P4495; Dupressoir A, 1995, BBA-GENE STRUCT EXPR, V1264, P397, DOI 10.1016/0167-4781(95)00181-6; FALZON M, 1991, MOL CELL BIOL, V11, P117, DOI 10.1128/MCB.11.1.117; FEENSTRA A, 1986, NUCLEIC ACIDS RES, V14, P4343, DOI 10.1093/nar/14.10.4343; GALIEN R, 1994, ONCOGENE, V9, P1101; GALIEN R, 1991, ONCOGENE, V6, P849; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HEBERLEIN C, 1990, ONCOGENE, V5, P1799; HEIDMANN O, 1991, CELL, V64, P159, DOI 10.1016/0092-8674(91)90217-M; HSIAO WLW, 1986, J VIROL, V57, P1119, DOI 10.1128/JVI.57.3.1119-1126.1986; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; KUFF EL, 1985, MOL CELL BIOL, V5, P474, DOI 10.1128/MCB.5.3.474; KUFF EL, 1990, CANCER CELL-MON REV, V2, P398; Lamb Bruce T., 1991, Gene Expression, V1, P185; Lueders K K, 1995, Curr Top Microbiol Immunol, V194, P405; LUEDERS KK, 1986, NUCLEIC ACIDS RES, V14, P1495, DOI 10.1093/nar/14.3.1495; LUEDERS KK, 1993, MOL CELL BIOL, V13, P7439, DOI 10.1128/MCB.13.12.7439; LURIA S, 1986, J VIROL, V57, P998, DOI 10.1128/JVI.57.3.998-1003.1986; MICHAUD EJ, 1994, GENE DEV, V8, P1463, DOI 10.1101/gad.8.12.1463; MIETZ JA, 1992, MOL CELL BIOL, V12, P220, DOI 10.1128/MCB.12.1.220; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; MOWAT M, 1990, ONCOGENE, V5, P241; Puech A, 1997, J BIOL CHEM, V272, P5995, DOI 10.1074/jbc.272.9.5995; ROLAND J, 1993, CELL GROWTH DIFFER, V4, P891; RONAI Z, 1992, MOL CARCINOGEN, V5, P81, DOI 10.1002/mc.2940050113; SHENONG GLC, 1984, J VIROL, V49, P171, DOI 10.1128/JVI.49.1.171-177.1984; SHENONG GLC, 1982, J VIROL, V42, P411, DOI 10.1128/JVI.42.2.411-421.1982; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; YMER S, 1986, NUCLEIC ACIDS RES, V14, P5901, DOI 10.1093/nar/14.14.5901	43	20	22	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2951	2958		10.1038/sj.onc.1201148	http://dx.doi.org/10.1038/sj.onc.1201148			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205102				2022-12-17	WOS:A1997XF55500009
J	ONeill, FJ; Hu, Y; Chen, T; Carney, H				ONeill, FJ; Hu, Y; Chen, T; Carney, H			Identification of p53 unbound to T-antigen in human cells transformed by simian virus 40 T-antigen	ONCOGENE			English	Article						p53; T-antigen; human cells; transformation; immortalization	TUMOR-SUPPRESSOR P53; MOUSE EMBRYO FIBROBLASTS; MONOCLONAL-ANTIBODIES; CELLULAR-TRANSFORMATION; IMMUNOCHEMICAL ANALYSIS; SV40-TRANSFORMED CELLS; PROTEIN P53; SV40; MUTATIONS; EXPRESSION	In several clones of SV40-transformed human cells, we investigated the relative amounts of large T-Antigen (T-Ag) and p53 proteins, both unbound and associated within complexes, with the goal of identifying changes associated with transformation and immortalization, Cells were transformed by wild type (wt) T-Ag, a functionally temperature sensitive T-Ag (tsA58) and other T-Ag variants, Western analysis showed that while most of the T-Ag was ultimately bound by p53, most of the p53 remained unbound to T-Ag, Unbound p53 remained in the supernatant after a T-Ag immunoprecipitation and p53 was present in two to fourfold excess of T-Ag, In one transformant there was five to tenfold more p53 than T-Ag, p53 was present in transformants in amounts at least 200-fold greater than in untransformed human cells, In wt and variant T-Ag transformants, including those generated with tsA58 T-Ag, large amounts of unbound p53 were present in both pre-crisis and immortal cells and when the cells were grown at permissive or non-permissive temperatures, We also found that in transformants produced by tsA58, an SV40/JCV chimeric T-Ag and other variants, T-Ag appeared to form a complex with p53 slowly perhaps because one or both proteins matured slowly, The presence in transformed human cells of large amounts of unbound p53 and in excesss of T-Ag suggests that sequestration of p53 by T-Ag, resulting from complex formation, is required neither for morphological transformation nor immortalization of human cells, Rather, these results support the proposal that high levels of p53, the T-Ag/p53 complexes, or other biochemical event(s), lead to transformation and immortalization of human cells by T-Ag.	UNIV UTAH, HUNTSMAN CANC INST, DEPT PATHOL, SALT LAKE CITY, UT 84132 USA; VET AFFAIRS MED CTR, SALT LAKE CITY, UT 84148 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA)	ONeill, FJ (corresponding author), UNIV UTAH, HUNTSMAN CANC INST, DEPT ONCOL SCI, DIV MOL BIOL & GENET, SALT LAKE CITY, UT 84132 USA.							Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BARTEK J, 1990, ONCOGENE, V5, P893; BENCHIMOL S, 1982, EMBO J, V1, P1053; CARROLL RB, 1982, J VIROL, V44, P565, DOI 10.1128/JVI.44.2.565-573.1982; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CRAWFORD L, 1983, INT REV EXP PATHOL, V25, P1; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DEPPERT W, 1989, NATO ASI SERIES; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUKASAWA K, 1991, MOL CELL BIOL, V11, P3472, DOI 10.1128/MCB.11.7.3472; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GEE AP, 1981, ANAL BIOCHEM, V116, P524, DOI 10.1016/0003-2697(81)90397-3; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HAGGERTY S, 1989, J VIROL, V63, P2180, DOI 10.1128/JVI.63.5.2180-2190.1989; Hansen R, 1995, ONCOGENE, V11, P2535; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1991, CANCER RES, V51, P5304; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1980, PROC R SOC SER B-BIO, V210, P451, DOI 10.1098/rspb.1980.0146; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LIN JY, 1990, VIROLOGY, V176, P302, DOI 10.1016/0042-6822(90)90258-S; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MICHAELMICHALOVITZ D, 1991, J VIROL, V65, P4160, DOI 10.1128/JVI.65.8.4160-4168.1991; MICHALOVITZ D, 1986, MOL CELL BIOL, V6, P3531, DOI 10.1128/MCB.6.10.3531; MOORE M, 1992, J VIROL, V66, P641, DOI 10.1128/JVI.66.2.641-649.1992; ONEILL FJ, 1990, INTERVIROLOGY, V31, P175, DOI 10.1159/000150152; ONEILL FJ, 1988, VIRUS RES, V11, P109, DOI 10.1016/0168-1702(88)90037-8; ONEILL FJ, 1993, VIRUS RES, V30, P171, DOI 10.1016/0168-1702(93)90005-8; ONEILL FJ, 1992, VIRUS RES, V25, P169, DOI 10.1016/0168-1702(92)90132-S; ONEILL FJ, 1994, VIRUS RES, V34, P237, DOI 10.1016/0168-1702(94)90126-0; ONEILL FJ, 1982, J VIROL, V43, P18, DOI 10.1128/JVI.43.1.18-25.1982; ONEILL FJ, 1995, ONCOGENE, V90, P1131; PRIVES C, 1991, COLD SPRING HARB SYM, V56, P227; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TEGTMEYER P, 1975, J VIROL, V15, P613, DOI 10.1128/JVI.15.3.613-618.1975; TIEMANN F, 1994, ONCOGENE, V9, P1907; TIEMANN F, 1995, J VIROL, V69, P6115, DOI 10.1128/JVI.69.10.6115-6121.1995; TIEMANN F, 1994, J VIROL, V68, P2869, DOI 10.1128/JVI.68.5.2869-2878.1994; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; VANDENHEUVEL SJL, 1992, J VIROL, V66, P591, DOI 10.1128/JVI.66.1.591-595.1992; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YOLKEN RH, 1981, J IMMUNOL METHODS, V54, P209; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZERRAHN J, 1993, J VIROL, V67, P1555, DOI 10.1128/JVI.67.3.1555-1563.1993; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991	59	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 27	1997	14	8					955	965		10.1038/sj.onc.1200913	http://dx.doi.org/10.1038/sj.onc.1200913			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050995				2022-12-17	WOS:A1997WK34400009
J	Iotsova, V; Crepieux, P; Montpellier, C; Laudet, V; Stehelin, D				Iotsova, V; Crepieux, P; Montpellier, C; Laudet, V; Stehelin, D			TATA-less promoters of some Ets-family genes are efficiently repressed by wild-type p53	ONCOGENE			English	Article						p53; Ets; promoter; repression	TRANSCRIPTIONAL ACTIVATION; BINDING PROTEIN; REGULATORY ELEMENTS; DNA; EXPRESSION; SEQUENCE; GROWTH; INITIATOR; INVITRO; DOMAIN	p53 has been reported to repress a number of TATA-containing promoters in transient transfection assays, TATA-less promoters are generally believed to be refractive to p53 repression. We report here that the TATA-less promoters of Ets-family genes (Ets-1 and Ets-2) are efficiently repressed by wild-type but not mutant p53 in transient co-transfection assays, Moreover, p53 was immunologically detected in protein complexes formed on oligonucleotides from both the TATA-containing and TATA-less promoters, Our data suggest that p53 is involved in the regulation of the expression of both promoter types, most probably by protein-protein interaction, A model for p53 function in promoter repression is proposed.	INST PASTEUR,CNRS URA 1160,UNITE ONCOL MOL,F-59018 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			Crepieux, Pascale/X-3217-2019	MONTPELLIER, Claire/0000-0002-3112-8491				AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BAKER SJ, 1990, SCIENCE, V249, P913; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; CHEN JH, 1993, ONCOGENE, V8, P133; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Crepieux Pascale, 1993, Gene Expression, V3, P215; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAISST S, 1994, VIROLOGY, V202, P466, DOI 10.1006/viro.1994.1363; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HU SL, 1981, P NATL ACAD SCI-BIOL, V78, P820, DOI 10.1073/pnas.78.2.820; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Iotsova V, 1996, CELL GROWTH DIFFER, V7, P629; IOTSOVA V, 1995, EUR J CELL BIOL, V68, P122; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SETH A, 1990, ONCOGENE, V5, P1761; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHANG W, 1994, EMBO J, V13, P2335	49	20	21	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2331	2337						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957074				2022-12-17	WOS:A1996VX10800005
J	Kondo, S; Morimura, T; Barnett, GH; Kondo, Y; Peterson, JW; Kaakaji, R; Takeuchi, J; Toms, SA; Liu, JB; Werbel, B; Barna, BP				Kondo, S; Morimura, T; Barnett, GH; Kondo, Y; Peterson, JW; Kaakaji, R; Takeuchi, J; Toms, SA; Liu, JB; Werbel, B; Barna, BP			The transforming activities of MDM2 in cultured neonatal rat astrocytes	ONCOGENE			English	Article						MDM2; astrocyte; p53; bFGF; PDGF; glioma	FIBROBLAST GROWTH-FACTOR; HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN GLIOBLASTOMA CELLS; HUMAN-MALIGNANT GLIOMAS; TUMOR-SUPPRESSOR GENE; SOFT-TISSUE SARCOMAS; HUMAN-BRAIN-TUMORS; P53 MUTATIONS; MESSENGER-RNA; SV40-TRANSFORMED CELLS	Although the molecular events regulating the pathogenesis of malignant astrocytomas remains unclear, the inactivation of tumor suppressor genes may be a key factor. The inactivation of p53 by mutation or deletion, however, is not the only obligatory step in astrocytoma genesis. The MDM2, protein has been shown to bind to and downmodulate p53 function, and to have oncogenic capacity. The MDM2 gene is also amplified and overexpressed in a subset of malignant astrocytomas without p53 mutation. Here we show that overexpression of MDM2 promoted the DNA synthesis of cultured neonatal rat astrocytes (RNB cells), abrogated the transcriptional activity of wild-type p53, conferred invasive activity, and subsequently induced the transformation from astrocytes to high-grade astrocytomas. Intriguingly, MDM2 enhanced the expression of angiogenic mitogens; basic fibroblast growth factor (bFGF) and platelet-derived growth factor (PDGF) in RNB cells. These results indicate that MDM2 may play an important role in the progression of astrocytomas, by not only conferring invasive activity but also stimulating the expression of angiogenic growth factors.	CLEVELAND CLIN FDN,DEPT NEUROSCI,CLEVELAND,OH 44195; NATL UTANO HOSP,DEPT NEUROSURG,UKYO KU,KYOTO 616,JAPAN	Cleveland Clinic Foundation	Kondo, S (corresponding author), CLEVELAND CLIN FDN,DEPT NEUROSURG S80,BRAIN TUMOR CTR,CTR CANC,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.			Peterson, John/0000-0002-5528-8561				ANTONIADES HN, 1987, ONCOGENES GENES GROW, P1; BOGLER O, 1995, CANCER RES, V55, P2476; COLLINS MKL, 1983, J BIOL CHEM, V258, P1689; CORDONCARDO C, 1994, CANCER RES, V54, P794; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FRANKEL RH, 1992, CANCER RES, V52, P1427; FUJIMOTO M, 1989, GENOMICS, V4, P210, DOI 10.1016/0888-7543(89)90302-9; FULTS D, 1989, CANCER RES, V49, P6572; FULTS D, 1992, CANCER RES, V52, P674; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GUHA A, 1995, J NEUROL NEUROSUR PS, V58, P711, DOI 10.1136/jnnp.58.6.711; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IWASAKI K, 1993, J NEUROSURG, V78, P952, DOI 10.3171/jns.1993.78.6.0952; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KONDO S, 1995, BRIT J CANCER, V71, P282, DOI 10.1038/bjc.1995.57; KONDO S, 1995, ONCOGENE, V10, P2001; KONDO S, 1992, NEUROSURGERY, V30, P506; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEACH FS, 1993, CANCER RES, V53, P2231; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MALKIN D, 1993, PRINCIPLES PRACTICE, V7, P1; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MAXWELL M, 1990, J CLIN INVEST, V86, P131, DOI 10.1172/JCI114675; MAXWELL M, 1991, CANCER RES, V51, P1345; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORRISON RS, 1993, J NEUROSCI RES, V34, P502, DOI 10.1002/jnr.490340503; MURPHY PR, 1990, MOL ENDOCRINOL, V4, P196, DOI 10.1210/mend-4-2-196; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Potapova O, 1996, CANCER RES, V56, P280; REIFENBERGER G, 1993, CANCER RES, V53, P2736; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU JK, 1993, NEUROSURGERY, V33, P824; XIANO ZX, 1995, NATURE, V375, P694	51	20	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1773	1779						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895524				2022-12-17	WOS:A1996VM88700023
J	Chang, HW; Li, J; Vogt, PK				Chang, HW; Li, J; Vogt, PK			Domains of the qin protein required for oncogenic transformation	ONCOGENE			English	Article						winged helix domain; transcriptional repression; DNA binding; Qin	GENE FORK-HEAD; DNA-BINDING; FAMILY; MOUSE; HNF-3-BETA; BELONGS; EMBRYO; MOTIF	The gill oncogene is a cell-derived insert in the genome of avian sarcoma virus 31 (ASV 31) and functions as the oncogenic determinant of that virus. Overexpression of the viral and cellular versions of the Qin protein (v-Qin and c-Qin) induces oncogenic transformation of chicken embryo fibroblasts (CEF); v-Qin also rapidly induces fibrosarcomas in chickens. Qin proteins can bind to specific DNA sequences and act as transcriptional repressors. In this study, mutants of Qin were constructed in order to determine the molecular domains required for transformation of chicken embryo fibroblasts. Our data indicate that three regions required for transforming activity are located (i) between residues 74-141 at the amino terminus, (ii) in the winged helix domain and (iii) between residues 383-395 at the carboxyl terminus. A Qin mutant with 12 amino acids deleted from the carboxyl terminus (383-395) showed transforming activity that was lower than that of wild type Qin for CEF. Compare to wild type Qin transformants, the mutant transformed cells had a reduced ability for multilayered and for anchorage independent growth. Deletion of 48 amino acids from the carboxyl terminus of the Qin protein (347-395) completely abolished transforming activity. In contrast, deletion of 74 amino acids from the amino terminus did not affect transformation of CEF. However, further deletion of 68 amino acids (74-141) reduced but did not abolish transforming activity. Finally, deletion in the winged helix domain (218-295) completely abrogated oncogenic capacity in CEF. These results suggest that DIVA binding and transcriptional repression may be important in Qin-induced oncogenic transformation.	Scripps Res Inst, DEPT MOL & EXPT MED, LA JOLLA, CA 92037 USA	Scripps Research Institute			Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NCI NIH HHS [CA 42564] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; CHANG HW, 1995, P NATL ACAD SCI USA, V92, P447, DOI 10.1073/pnas.92.2.447; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; FEDERSPIEL MJ, 1994, VIROLOGY, V203, P211, DOI 10.1006/viro.1994.1478; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LI J, 1995, CANCER RES, V55, P5540; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; PELEG Y, 1994, MOL CELL BIOL, V14, P7816, DOI 10.1128/MCB.14.12.7816; QIAN XB, 1995, NUCLEIC ACIDS RES, V23, P1184, DOI 10.1093/nar/23.7.1184; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WONG WY, 1992, ONCOGENE, V7, P2077	15	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					441	444						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710385				2022-12-17	WOS:A1996VA25200025
J	Hardin, JD; Boast, S; Mendelsohn, M; delosSantos, K; Goff, SP				Hardin, JD; Boast, S; Mendelsohn, M; delosSantos, K; Goff, SP			Transgenes encoding both type I and type IV c-abl proteins rescue the lethality of c-abl mutant mice	ONCOGENE			English	Article						c-abl, transgene; tyrosine kinase; rescue	TARGETED GENE DISRUPTION; VIRUS TRANSFORMING GENE; TYROSINE KINASE; DIFFERENTIAL EXPRESSION; MESSENGER-RNAS; MOUSE-TISSUES; CELL; DNA; BINDING; RECOMBINATION	Mice carrying homozygous mutations in the c-abl gene (abl(ml) or abl(2)) exhibit severe, though variable phenotypes, including a high rate of postnatal mortality, runting, morphological abnormalities, a susceptibility to infections, and selected immune system defects, To further determine the role of the c-Abl protein in vivo, we have generated three lines of mice expressing c-abl transgenes, These minigenes encode the two major forms of the c-abl gene product (c-Abl types I and IV) and a kinase defective type IV c-Abl. The transgenic lines, in Abl-positive genetic backgrounds, were phenotypically almost indistinguishable from their non-transgene littermates and expressed the c-ab! transgene in a variety of tissues at levels comparable to that of the endogenous c-abl gene. When the transgenes were introduced into a mutant c-abl strain by mating, the mutant c-abl phenotype was almost completely rescued by either of the c-abl type I or type IV transgenes, but not by the kinase-defective transgene, These findings suggest that either of the two alternatively spliced c-abl gene products can provide the in vivo functions of c-Abl, and that these functions are dependent on kinase activity.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University; Columbia University; Howard Hughes Medical Institute			Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547	NCI NIH HHS [P01 CA23767] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELSON HT, 1970, CANCER RES, V30, P2213; Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BERNARDS A, 1988, ONCOGENE, V2, P297; BOULTER CA, 1988, EXP CELL RES, V179, P214, DOI 10.1016/0014-4827(88)90360-6; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARDIN JD, 1995, CELL IMMUNOL, V165, P44, DOI 10.1006/cimm.1995.1185; HARDIN JD, 1995, UNPUB; HARIHARAN IK, 1989, MOL CELL BIOL, V9, P2798, DOI 10.1128/MCB.9.7.2798; Heisterkamp Nora, 1991, Transgenic Research, V1, P45, DOI 10.1007/BF02512996; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; Hogan B., 1986, MANIPULATING MOUSE E; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RAY P, 1991, GENE DEV, V5, P2265, DOI 10.1101/gad.5.12a.2265; RENSHAW MW, 1988, MOL CELL BIOL, V8, P4547, DOI 10.1128/MCB.8.10.4547; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; Sambrook J, 1989, MOL CLONING LAB MANU; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHWARTZBERG PL, 1990, P NATL ACAD SCI USA, V87, P3210, DOI 10.1073/pnas.87.8.3210; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SCHWARTZBERG PL, 1989, SCIENCE, V246, P799, DOI 10.1126/science.2554496; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1993, ONCOGENES TUMOR SUPP; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; WANG JYJ, 1984, CELL, V36, P349; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	40	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2669	2677						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700526				2022-12-17	WOS:A1996UW48700021
J	Petropoulos, CJ; Givol, I; Hughes, SH				Petropoulos, CJ; Givol, I; Hughes, SH			Comparative analysis of the structure and function of the chicken c-myc and v-myc genes: v-myc is a more potent inducer of cell proliferation and apoptosis than c-myc	ONCOGENE			English	Article						c-myc; cell cycle; apoptosis; chicken; transcription initiation; translation initiation	WEIGHT NONMUSCLE TROPOMYOSIN; AVIAN MYELOCYTOMATOSIS VIRUS; NUCLEOTIDE-SEQUENCE; RETROVIRUS VECTORS; TRANSFORMING GENE; INDUCED LYMPHOMAS; BURKITT-LYMPHOMA; BURSAL LYMPHOMAS; GROWTH-FACTOR; 1ST EXON	To gain a more complete understanding of c-myc regulation in chickens, we have completed the structural characterization of the chicken c-myc gene and have begun to investigate c-myc transcription and protein expression. A comparison of c-myc Structure and expression between mammals and birds presents an enigma: there are striking similarities in the pattern of gene expression in the absence of obvious sequence similarities in the controlling elements, We have begun to investigate c-myc and v-myc function using retroviral vectors that differ solely in the Myc proteins that they express. We show that while the overexpression of the smaller c-Myc protein is sufficient to induce morphological transformation in chicken embryo fibroblasts, overexpression of v-Myc provides a stronger signal for cells to enter the cell cycle and is a more potent inducer of apoptosis than c-Myc.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick								ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; ARGAUT C, 1991, GENE, V97, P231, DOI 10.1016/0378-1119(91)90056-H; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BONNIEU A, 1990, ONCOGENE, V5, P1585; BRADAC JA, 1989, MOL CELL BIOL, V9, P185, DOI 10.1128/MCB.9.1.185; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CULLEN BR, 1993, CELL, V73, P417, DOI 10.1016/0092-8674(93)90126-B; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; EICK D, 1987, ONCOGENE, V2, P61; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FEDERSPIEL MJ, 1994, VIROLOGY, V203, P211, DOI 10.1006/viro.1994.1478; FORRYSCHAUDIES S, 1990, CELL GROWTH DIFFER, V1, P473; FRYKBERG L, 1987, ONCOGENE, V1, P415; Fulton R, 1996, J VIROL, V70, P1154, DOI 10.1128/JVI.70.2.1154-1162.1996; Givol I, 1995, ONCOGENE, V11, P2609; GIVOL I, 1994, CELL GROWTH DIFFER, V5, P419; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; HAMLYN PH, 1983, NATURE, V304, P135, DOI 10.1038/304135a0; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HAYASHI K, 1987, NUCLEIC ACIDS RES, V15, P6419, DOI 10.1093/nar/15.16.6419; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; LAIRDOFFRINGA IA, 1989, NUCLEIC ACIDS RES, V17, P6499, DOI 10.1093/nar/17.16.6499; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LINIAL M, 1985, P NATL ACAD SCI USA, V82, P53, DOI 10.1073/pnas.82.1.53; NEPVEU A, 1987, ONCOGENE, V1, P243; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NOTTENBURG C, 1986, MOL CELL BIOL, V6, P2800, DOI 10.1128/MCB.6.8.2800; PAPAS TS, 1984, CANCER CELL, V2, P153; PAYNE GS, 1982, NATURE, V295, P209, DOI 10.1038/295209a0; PERSSON H, 1984, SCIENCE, V225, P687, DOI 10.1126/science.6431612; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; PIECHACZYK M, 1988, GENE, V72, P287, DOI 10.1016/0378-1119(88)90154-0; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; REED JC, 1985, P NATL ACAD SCI USA, V82, P4221, DOI 10.1073/pnas.82.12.4221; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEINESS D, 1979, J VIROL, V31, P514, DOI 10.1128/JVI.31.2.514-521.1979; SHELDON M, 1993, MOL CELL BIOL, V13, P1251, DOI 10.1128/MCB.13.2.1251; SHIH CK, 1984, P NATL ACAD SCI-BIOL, V81, P4697, DOI 10.1073/pnas.81.15.4697; STARTWOUT SG, 1987, MOL CELL BIOL, V7, P2052; STEFFEN DL, 1988, VIROLOGY, V164, P55, DOI 10.1016/0042-6822(88)90619-8; STEWART MA, 1986, VIROLOGY, V154, P121, DOI 10.1016/0042-6822(86)90435-6; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; TRIEZENBERG SJ, 1989, CURRENT PROTOCOLS MO, V1; VANBEVEREN C, 1985, RNA TUMOR VIRUSES MO, V2, P686; VASTRIK I, 1994, CRIT REV ONCOGENESIS, V5, P59, DOI 10.1615/CritRevOncog.v5.i1.30; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P2146, DOI 10.1073/pnas.80.8.2146; WATT R, 1983, P NATL ACAD SCI-BIOL, V80, P6307, DOI 10.1073/pnas.80.20.6307; WEI Y, 1990, GENE, V93, P301, DOI 10.1016/0378-1119(90)90240-R	59	20	20	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2611	2621						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700520				2022-12-17	WOS:A1996UW48700015
J	Powell, SM; Cummings, OW; Mullen, JA; Asghar, A; Fuga, G; Piva, P; Minacci, C; Megha, T; Tosi, P; Jackson, CE				Powell, SM; Cummings, OW; Mullen, JA; Asghar, A; Fuga, G; Piva, P; Minacci, C; Megha, T; Tosi, P; Jackson, CE			Characterization of the APC gene in sporadic gastric adenocarcinomas	ONCOGENE			English	Article						gastric carcinoma; adenomatous polyposis coli (APC); mutations; loss of heterozygosity; molecular genetics	FAMILIAL ADENOMATOUS POLYPOSIS; PANCREATIC-CANCER; SOMATIC MUTATIONS; COLORECTAL-CANCER; FREQUENT LOSS; COLI GENE; HETEROZYGOSITY; CARCINOMA; LOCI; MCC	The prominent role of the APC gene in colorectal tumor development is well established. However, its role in tumorigenesis in other tissues is not clear. Hence, DNA from 30 primary sporadic gastric adenocarcinomas was obtained from patients living in a high risk area of the world (North-Central Italy) in order to further define APC's role in gastric tumorigenesis. We thoroughly examined that region of APC which is commonly mutated in colorectal tumors using proven sensitive methods. The IVS protein assay and DNA sequence analysis of APC codons 686 through 1693 revealed no intragenic mutations. However, allelic loss of loci near APC was detected in 7 (28%) of 25 informative gastric adenocarcinomas using two 5q dinucleotide repeat markers for LOH analysis. These results suggest that genetic alteration of a region of APC commonly mutated in colorectal cancer is not a common event during sporadic gastric tumor development, at least in patients from North-Central Italy. Further analysis of chromosome 5q might identify another gene to be significantly altered in these gastric cancers.	INDIANA UNIV, SCH MED, DEPT PATHOL, INDIANAPOLIS, IN 46202 USA; UNIV SIENA, IST ANAT EISTOL PATOL, I-53100 SIENA, ITALY; HENRY FORD HOSP, DEPT MED, DETROIT, MI 48202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; University of Siena; Henry Ford Health System; Henry Ford Hospital	Powell, SM (corresponding author), INDIANA UNIV, SCH MED, DEPT MED, 975 W WALNUT ST IB 424, INDIANAPOLIS, IN 46202 USA.				NCI NIH HHS [1R29CA67000-01] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM JOINT COMM CAN, 1993, MAN STAG CANC; CHONG JM, 1994, CANCER RES, V54, P4595; CORREA P, 1994, CANCER SURV, V20, P55; DAMICO D, 1992, CANCER RES, V52, P1996; FAWCETT TW, 1991, USB EDITORIAL COMMEN, V17, P19; FUCHS CS, 1995, NEW ENGL J MED, V333, P32, DOI 10.1056/NEJM199507063330107; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAN HJ, 1993, CANCER RES, V53, P5087; HORII A, 1992, CANCER RES, V52, P3231; HORII A, 1992, CANCER RES, V52, P6696; HUANG Y, 1992, CANCER RES, V52, P6525; JACKSON CE, 1980, CANCER, V45, P599, DOI 10.1002/1097-0142(19800201)45:3<599::AID-CNCR2820450328>3.0.CO;2-8; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; JEN J, 1994, CANCER RES, V54, P5523; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; MCKIE AB, 1993, INT J CANCER, V55, P598, DOI 10.1002/ijc.2910550414; MIRONOV NM, 1994, CANCER RES, V54, P41; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; NAKATSURU S, 1993, HUM MOL GENET, V2, P1463, DOI 10.1093/hmg/2.9.1463; NAKATSURU S, 1992, HUM MOL GENET, V1, P559, DOI 10.1093/hmg/1.8.559; OFFERHAUS GJA, 1992, GASTROENTEROLOGY, V102, P1980, DOI 10.1016/0016-5085(92)90322-P; OGASAWARA S, 1994, VIRCHOWS ARCH, V424, P607, DOI 10.1007/BF01069740; PARK JG, 1992, DIS COLON RECTUM, V35, P996, DOI 10.1007/BF02253505; PELTOMAKI P, 1993, CANCER RES, V53, P5853; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; POWELL SM, 1994, GASTROENTEROLOGY, V107, P1759, DOI 10.1016/0016-5085(94)90818-4; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; RHYU MG, 1994, GASTROENTEROLOGY, V106, P1584, DOI 10.1016/0016-5085(94)90414-6; SANO T, 1991, CANCER RES, V51, P2926; SEYMOUR AB, 1994, CANCER RES, V54, P2761; SHIAO YH, 1994, AM J PATHOL, V144, P511; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SPIRIO L, 1991, NUCLEIC ACIDS RES, V19, P6348, DOI 10.1093/nar/19.22.6348; STEMMERMANN G, 1994, HUM PATHOL, V25, P968, DOI 10.1016/0046-8177(94)90056-6; STRICKLER JG, 1994, CANCER RES, V54, P4750; TAHARA E, 1993, J CANCER RES CLIN, V119, P265, DOI 10.1007/BF01212724; TAMURA G, 1993, JPN J CANCER RES, V84, P1015, DOI 10.1111/j.1349-7006.1993.tb02794.x; TAMURA G, 1994, CANCER RES, V54, P1149; UCHINO S, 1993, INT J CANCER, V54, P759, DOI 10.1002/ijc.2910540509; UTSUNOMIYA J, 1990, HEREDITARY COLORECTA, P3; VASEN HFA, 1991, LANCET, V338, P877, DOI 10.1016/0140-6736(91)91520-5; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WHELAN SL, 1993, IARC SCI PUBLICATION, V12; WIJNEN J, 1991, NUCLEIC ACIDS RES, V19, P6965, DOI 10.1093/nar/19.24.6965-a	49	20	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	1996	12	9					1953	1959						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649856				2022-12-17	WOS:A1996UK49800014
J	Guthridge, MA; Seldin, M; Basilico, C				Guthridge, MA; Seldin, M; Basilico, C			Induction of expression of growth-related genes by FGF-4 in mouse fibroblasts	ONCOGENE			English	Article						FGFs; transcription; cell cycle; cell proliferation; subtractive hybridization	NUCLEOTIDE-SEQUENCE; ENDOTHELIAL-CELLS; PROTEIN; RECEPTOR; CDNA; DNA; DIFFERENTIATION; CLONING; PHOSPHORYLATION; ORGANIZATION	Cells monitor and respond to extracellular signals from polypeptide growth factors by the induction of a genetic program. Although poorly understood at the molecular level, the biological activity of growth factors is believed to be mediated by the regulation of specific sets of genes. We have isolated a number of cDNAs, the expression of whose corresponding RNAs is induced by FGF-4 (K-FGF) in murine NIH3T3 fibroblasts. The cDNAs (FIN, for FGF-inducible) were isolated using a strategy of subtractive hybridization designed to yield 'late' genes which compared transformed 3T3 cells that constitutively produce FGF-4 with their normal counterpart. The 21 independent cDNAs isolated were found to correspond to known genes (FIN1-12), or novel genes (FIN13-21). Expression of the FIN genes is induced in response to FGF-4 as well as to serum in NIH3T3 cells with delayed kinetics, with maximum stimulation occurring 12-18 h after growth factor treatment. Induction requires protein synthesis and is mostly transcriptional. FIN1-12 encode a broad range of previously described genes, some of which are proposed to have an important role in cell proliferation. The novel clones include a putative serine-threonine phosphatase (FIN13) and a gene with homology to NTP-binding proteins (FIN16). The distribution of expression of the novel FIN clones in adult mouse tissues was highly restricted, although most were expressed in embryos. While expression of novel FIN cDNAs was strongly regulated in NIH3T3 cells, induction of differentiation in PC-12 cells by FGF-4 (as web as by NGF) did not result in significant induction of expression, suggesting that most of the FIN genes are proliferation-specific. Chromosomal localization of novel FIN clones indicated that each segregated independently to separate mouse chromosomes.	NYU,SCH MED,DEPT MICROBIOL,NEW YORK,NY 10016; NYU,SCH MED,KAPLAN CANC CTR,NEW YORK,NY 10016; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	New York University; New York University; Duke University			guthridge, mark a/I-1889-2014	guthridge, mark a/0000-0002-0536-3471	NCI NIH HHS [CA42568] Funding Source: Medline; PHS HHS [H600734] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BISHOP D T, 1985, Genetic Epidemiology, V2, P349, DOI 10.1002/gepi.1370020404; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; BRUNETTI A, 1990, J BIOL CHEM, V265, P5960; BUCHKOVICH KJ, 1994, MOL BIOL CELL, V5, P1225, DOI 10.1091/mbc.5.11.1225; CARTER TC, 1953, J GENET, V51, P441, DOI 10.1007/BF02982937; CARTER TC, 1951, J GENET, V50, P277, DOI 10.1007/BF02996224; CHANG DT, 1994, DEVELOPMENT, V120, P3339; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHEN JW, 1988, J BIOL CHEM, V263, P8754; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DONOVIEL DB, 1990, J CELL PHYSIOL, V145, P16, DOI 10.1002/jcp.1041450104; FALK G, 1988, BIOCHEM J, V254, P109, DOI 10.1042/bj2540109; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; GOLDRING M B, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P301; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; Green EL, 1981, GENETICS PROBABILITY, P77; GUALANDRIS A, 1995, J CELL PHYSIOL, V162, P400, DOI 10.1002/jcp.1041620312; HERR W, 1984, J VIROL, V49, P471, DOI 10.1128/JVI.49.2.471-478.1984; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HURLEY MM, 1993, J BIOL CHEM, V268, P5588; ISAACS HV, 1994, EMBO J, V13, P4469, DOI 10.1002/j.1460-2075.1994.tb06769.x; ISHIDA S, 1993, P NATL ACAD SCI USA, V90, P11152, DOI 10.1073/pnas.90.23.11152; JOHNSON DR, 1979, J EMBRYOL EXP MORPH, V53, P327; KAGHAD M, 1990, NUCLEIC ACIDS RES, V18, P3638, DOI 10.1093/nar/18.12.3638; KLEIN S, 1993, MOL BIOL CELL, V4, P973, DOI 10.1091/mbc.4.10.973; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LI Y, 1994, MOL CELL BIOL, V14, P7660, DOI 10.1128/MCB.14.11.7660; MANN DJ, 1992, BIOCHIM BIOPHYS ACTA, V1130, P100, DOI 10.1016/0167-4781(92)90471-B; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MIGNATTI P, 1991, J CELL BIOL, V113, P1193, DOI 10.1083/jcb.113.5.1193; MOORE R, 1987, J VIROL, V61, P480, DOI 10.1128/JVI.61.2.480-490.1987; NOTARNICOLA SM, 1991, GENE, V97, P77, DOI 10.1016/0378-1119(91)90012-Z; OAKEY RJ, 1991, GENOMICS, V10, P338, DOI 10.1016/0888-7543(91)90317-8; PATEL A, 1995, GENOMICS, V25, P314, DOI 10.1016/0888-7543(95)80146-D; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POTTS JF, 1993, BIOCHEM BIOPH RES CO, V197, P100, DOI 10.1006/bbrc.1993.2446; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; RYDEL RE, 1987, J NEUROSCI, V7, P3639; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5643; SAUNDERS AM, 1990, GENOMICS, V8, P524; SCHERENS B, 1993, YEAST, V9, P1355, DOI 10.1002/yea.320091210; SCHMITT J, 1993, GENE, V132, P267, DOI 10.1016/0378-1119(93)90206-I; SCHWEIZER A, 1993, J CELL SCI, V104, P685; SELDIN MF, 1988, J EXP MED, V167, P688, DOI 10.1084/jem.167.2.688; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SIVE HL, 1988, NUCLEIC ACIDS RES, V16, P10937, DOI 10.1093/nar/16.22.10937; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; TAIJI M, 1992, MOL CELL BIOL, V12, P2193, DOI 10.1128/MCB.12.5.2193; TAKETO M, 1994, GENOMICS, V21, P251, DOI 10.1006/geno.1994.1252; TALARICO D, 1991, MOL CELL BIOL, V11, P1138, DOI 10.1128/MCB.11.2.1138; TERASAWA T, 1993, ARCH BIOCHEM BIOPHYS, V307, P342, DOI 10.1006/abbi.1993.1598; VONDASSOW G, 1993, GENE DEV, V7, P355, DOI 10.1101/gad.7.3.355; WATSON ML, 1992, MAMM GENOME, V2, P158, DOI 10.1007/BF00302874; WATSON ML, 1994, METH MOL G, V5, P369; WEISS R, 1985, RNA TUMOR VIRUSES, P357; WENK J, 1992, FEBS LETT, V297, P135, DOI 10.1016/0014-5793(92)80344-G; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	68	20	25	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1267	1278						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649829				2022-12-17	WOS:A1996UC06700012
J	Nikitin, AY; Jin, JJ; Papewalis, J; Prokopenko, SN; Pozharisski, KM; Winterhager, E; FleskenNikitin, A; Rajewsky, MF				Nikitin, AY; Jin, JJ; Papewalis, J; Prokopenko, SN; Pozharisski, KM; Winterhager, E; FleskenNikitin, A; Rajewsky, MF			Wild type neu transgene counteracts mutant homologue in malignant transformation of rat Schwann cells	ONCOGENE			English	Article						neu (erbB-2); rat schwannomas; ethylnitrosourea; gene dosage; transgenic rats	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; NERVOUS-SYSTEM; NEOPLASTIC TRANSFORMATION; C-ERBB-2 RECEPTOR; PERIPHERAL MYELIN; PROTO-ONCOGENE; HUMAN-BREAST; GENE; EXPRESSION	Mutational activation of the neu (erbB-2) receptor protein tyrosine kinase gene appears to be the triggering event in the process of oncogenesis induced by N-ethyl-N-nitrosourea (EtNU) in immature Schwann cells of the rat peripheral nervous system. Subsequent loss of the wild-type neu allele may represent a critical secondary step towards malignancy. Developmentally-regulated expression of a wild-type rat neu transgene (neu cDNA under the control of the rat P-o promotor) in the Schwann cells of transgenic BDIX and Sprague-Dawley rats exposed to EtNU on postnatal day 1 results in a lower incidence of early atypical proliferates in the trigeminal nerve. Furthermore, re-introduction of the wild-type neu gene into homozygous neu mutant schwannoma cells counteracts the expression of the tumorigenic phenotype. The suppressive action of the wild-type gene over its mutationally activated oncogenic homologue underlines the critical function of the neu gene in the control of differentiation in the Schwann cell lineage, and provides evidence for the responsiveness of cellular phenotypes towards quantitative shifts in the dosage of wild-type vs mutant signal transducing molecules.	UNIV ESSEN GESAMTHSCH,SCH MED,INST CELL BIOL CANC RES,D-45122 ESSEN,GERMANY; UNIV ESSEN GESAMTHSCH,SCH MED,INST ANAT,D-45122 ESSEN,GERMANY; NN PETROV ONCOL RES INST,PATHOL LAB,ST PETERSBURG 189646,RUSSIA	University of Duisburg Essen; University of Duisburg Essen; N.N. Petrov Research Institute of Oncology				Flesken-Nikitin, Andrea/0000-0003-3017-1399				BACUS SS, 1993, CANCER RES, V53, P5251; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P549; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHAZIN VR, 1992, ONCOGENE, V7, P1859; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; COHEN JA, 1992, J NEUROSCI RES, V31, P622, DOI 10.1002/jnr.490310406; DATI C, 1990, ONCOGENE, V5, P1001; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DOBASHI K, 1989, DNA-J MOLEC CELL BIO, V8, P723, DOI 10.1089/dna.1989.8.723; DOUGALL WC, 1994, ONCOGENE, V9, P2103; DRUCKREY H, 1971, ARZNEI-FORSCHUNG, V21, P1274; EPSTEIN RJ, 1992, P NATL ACAD SCI USA, V89, P10435, DOI 10.1073/pnas.89.21.10435; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; HAYES C, 1992, J NEUROSCI RES, V31, P175, DOI 10.1002/jnr.490310123; Hogan B., 1986, MANIPULATING MOUSE E; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JIN JJ, 1993, CELL GROWTH DIFFER, V4, P227; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; LAERUM OD, 1975, J NATL CANCER I, V55, P1177, DOI 10.1093/jnci/55.5.1177; LEMKE G, 1988, NEURON, V1, P73, DOI 10.1016/0896-6273(88)90211-5; LEMKE G, 1985, CELL, V40, P501, DOI 10.1016/0092-8674(85)90198-9; LOFTS FJ, 1993, ONCOGENE, V8, P2813; LOTTI LV, 1992, EXP CELL RES, V202, P274, DOI 10.1016/0014-4827(92)90075-J; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARTE BM, 1995, ONCOGENE, V10, P167; MESSERLE K, 1994, MOL CELL ENDOCRINOL, V105, P1, DOI 10.1016/0303-7207(94)90029-9; MESSING A, 1992, NEURON, V8, P507, DOI 10.1016/0896-6273(92)90279-M; MORGAN L, 1991, J CELL BIOL, V112, P457, DOI 10.1083/jcb.112.3.457; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; NIKITIN AY, 1993, VIRCHOWS ARCH B, V64, P151, DOI 10.1007/BF02915108; NIKITIN AY, 1991, P NATL ACAD SCI USA, V88, P9939, DOI 10.1073/pnas.88.22.9939; NIKITIN AY, 1991, DIFFERENTIATION, V48, P33, DOI 10.1111/j.1432-0436.1991.tb00240.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PENG WW, 1982, SCIENCE, V215, P1102, DOI 10.1126/science.7063842; PERANTONI AO, 1987, P NATL ACAD SCI USA, V84, P6317, DOI 10.1073/pnas.84.17.6317; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; Sambrook J., 1989, MOL CLONING LAB MANU; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; SUEN TS, 1990, MOL CELL BIOL, V10, P6303; SWENBERG JA, 1975, J NATL CANCER I, V55, P147, DOI 10.1093/jnci/55.1.147; TAVERNA D, 1991, CELL GROWTH DIFFER, V2, P145; WEINBERG R, 1993, NEURON, V11, P191, DOI 10.1016/0896-6273(93)90177-S; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WINTERHAGER E, 1991, EUR J CELL BIOL, V55, P133; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	56	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1309	1317						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649833				2022-12-17	WOS:A1996UC06700016
J	Allemand, I; Grimber, G; Kornprobst, M; Bennoun, M; Molina, T; Briand, P; Joulin, V				Allemand, I; Grimber, G; Kornprobst, M; Bennoun, M; Molina, T; Briand, P; Joulin, V			Compensatory apoptosis in response to SV40 large T antigen expression in the liver	ONCOGENE			English	Article						transgenic mice; SV40 T antigen; hepatocarcinogenesis; apoptosis	TRANSGENIC MICE; CELL-DEATH; RAT-LIVER; P53 GENE; DNA; PROTEIN; GROWTH; TUMORIGENESIS; FRAGMENTATION; DISEASE	Transgenesis allows the in vivo determination of the effects of oncogene expression in normal tissues, In an attempt to understand the mechanism underlying liver transformation, we had previously created transgenic mice carrying the SV40 early gene sequences, which developed hepatocarcinoma in a reproducible way, In the present study, we show that constant expression of the transgene was directly correlated to an abnormally increased hepatocyte proliferation, even at the adult stage, We further demonstrate in this model that the preneoplastic stage of hepatocarcinoma is characterized by marked ploidy alterations as early as 1 month, including the emergence of aneuploid and hyperpolyploid cells, and the persistence of an important diploid cell population, We show that this elevated proliferation is early and transiently counterbalanced by a mechanism of apoptosis, which maintains liver homeostasis. The disappearance of this programmed cell death response effective during preneoplasia might signal the commitment of the liver to neoplasia.	INST COCHIN GENET MOLEC, INSERM U380, F-75014 PARIS, FRANCE; UNIV PARIS 06, FAC MED ST ANTOINE, INSERM U402, F-75571 PARIS 12, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite			Molina, Thierry/ABA-5214-2020	Molina, Thierry/0000-0002-3929-9754; allemand, isabelle/0000-0002-8861-7632; JOULIN, Virginie/0000-0003-1091-7819				BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BURSCH W, 1984, CARCINOGENESIS, V5, P453, DOI 10.1093/carcin/5.4.453; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; BURSCH W, 1992, TRENDS PHARMACOL SCI, V13, P245, DOI 10.1016/0165-6147(92)90077-J; CHEN JD, 1992, ONCOGENE, V7, P1167; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLUMBANO A, 1985, LAB INVEST, V52, P670; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUBOIS N, 1991, J HEPATOL, V13, P227, DOI 10.1016/0168-8278(91)90819-W; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FAUSTO N, 1989, LAB INVEST, V60, P4; Fausto Nelson, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P117; FROMM L, 1994, MOL CELL BIOL, V14, P6743, DOI 10.1128/MCB.14.10.6743; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HIRAMATSU N, 1994, HEPATOLOGY, V19, P1354, DOI 10.1002/hep.1840190606; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; LEDDACOLUMBANO GM, 1991, AM J PATHOL, V139, P1099; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MAGAUD JP, 1989, J HISTOCHEM CYTOCHEM, V37, P1517, DOI 10.1177/37.10.2476478; MITA E, 1994, BIOCHEM BIOPH RES CO, V204, P468, DOI 10.1006/bbrc.1994.2483; MOORE M, 1992, J VIROL, V66, P641, DOI 10.1128/JVI.66.2.641-649.1992; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MOSSIN L, 1994, EXP CELL RES, V214, P551, DOI 10.1006/excr.1994.1293; NEVINS JR, 1992, SCIENCE, V258, P424; OBERHAMMER F, 1993, J CELL SCI, V104, P317; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; ROUQUET N, 1995, ONCOGENE, V11, P1061; SANDGREN EP, 1989, ONCOGENE, V4, P715; SCHULTEHERMANN R, 1990, CANCER RES, V50, P5127; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SYMONDS HS, 1993, MOL CELL BIOL, V13, P3255, DOI 10.1128/MCB.13.6.3255; WEBBER EM, 1994, AM J PATHOL, V145, P398; WESSEL R, 1992, VIROLOGY, V189, P293, DOI 10.1016/0042-6822(92)90705-T; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	50	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2583	2590						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545115				2022-12-17	WOS:A1995TP18800014
J	Lee, GH; Ogawa, K; Nishimori, H; Drinkwater, NR				Lee, GH; Ogawa, K; Nishimori, H; Drinkwater, NR			Most liver epithelial cell lines from C3B6F(1) mice exhibit parentally-biased loss of heterozygosity at the Lci (Liver cell immortalization) locus on chromosome 4	ONCOGENE			English	Article						hepatocyte; immortalization; tumor suppressor	TUMOR PROGRESSION; MOUSE-LIVER; SHORT ARM; HEPATOCELLULAR CARCINOMAS; GENETIC SUSCEPTIBILITY; B6C3F1 MOUSE; CANCER; NEOPLASIA; BREAST; EXPRESSION	Liver epithelial cell lines established from F-1 animals generated from hepatocarcinogen-sensitive C3H/HeJ and -resistant C57BL/6J mice were analysed for loss of heterozygosity at more than 60 simple sequence repeat marker loci distributed over all of the autosomal chromosomes, Nineteen of 20 clonal cell lines showed loss of heterozygosity at a chromosome 4 locus, designated Lci (Liver cell immortalization) and in most of the cases (18 of 19), alleles from the hepatocarcinogen-resistant parental strain, C57BL/6J, were lost, Detailed deletion mapping localized the putative suppressor gene for immortalization to within a 2 cM interval which includes a cluster of genes for gap junctional proteins. We also observed a loss of heterozygosity on chromosomes 7, 14, or 17 in more than 50% of the cell lines.	ASAHIKAWA MED COLL, DEPT PATHOL, ASAHIKAWA, HOKKAIDO 078, JAPAN; UNIV WISCONSIN, SCH MED, MCARDLE LAB CANC RES, MADISON, WI 53076 USA	Asahikawa Medical College; University of Wisconsin System; University of Wisconsin Madison					NATIONAL CANCER INSTITUTE [P30CA007175, P01CA022484] Funding Source: NIH RePORTER; NCI NIH HHS [CA07175, CA22484] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; BEER DG, 1988, CANCER RES, V48, P1610; Bennett L. M., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P144; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; CHO KR, 1992, J CELL BIOCHEM, P137; DAVIS LM, 1994, CARCINOGENESIS, V15, P1637; DEVILEE P, 1994, CANCER RES, V51, P1637; DIETRICH W, 1992, GENETICS, V131, P423; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DOULL J, 1987, ARCH TOXICOL, P3; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; DRAGANI TA, 1987, J CANCER RES CLIN, V113, P223, DOI 10.1007/BF00396377; DRAGANI TA, 1991, CANCER RES, V51, P6299; DRINKWATER NR, 1986, CARCINOGENESIS, V7, P1701, DOI 10.1093/carcin/7.10.1701; DRINKWATER NR, 1991, PROG EXP TUMOR RES, V33, P1; ELICEIRI B, 1991, P NATL ACAD SCI USA, V88, P2179, DOI 10.1073/pnas.88.6.2179; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FUJIMORI M, 1991, CANCER RES, V51, P89; GARIBOLDI M, 1993, CANCER RES, V53, P209; GENUARDI M, 1989, AM J HUM GENET, V45, P73; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GRASSO P, 1975, MOUSE HEPATIC NEOPLA, P111; HANIGAN MH, 1988, CARCINOGENESIS, V9, P885, DOI 10.1093/carcin/9.6.885; HEGI ME, 1994, CANCER RES, V54, P6257; Hillyard A. L., 1993, Mouse Genome, V91, P15; HOLDER JW, 1993, CANCER RES, V53, P3475; JANSSENTIMMEN U, 1986, CARCINOGENESIS, V7, P1475, DOI 10.1093/carcin/7.9.1475; JONES G, 1974, MOUSE HEPATIC NEOPLA, P21; KADOHAMA T, 1994, ONCOGENE, V9, P2845; KRESS S, 1992, MOL CARCINOGEN, V6, P148, DOI 10.1002/mc.2940060210; LEE GH, 1989, CANCER RES, V49, P403; LEE GH, 1990, CARCINOGENESIS, V11, P1145, DOI 10.1093/carcin/11.7.1145; LEE GH, 1995, GENETICS, V139, P387; LEE GH, 1991, INT J CANCER, V47, P60, DOI 10.1002/ijc.2910470112; LEISTER I, 1990, CANCER RES, V50, P7232; MANENTI G, 1994, GENOMICS, V23, P118, DOI 10.1006/geno.1994.1466; MANENTI G, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P119; MITAKA T, 1991, HEPATOLOGY, V13, P21, DOI 10.1016/0270-9139(91)90211-D; MOLEY JF, 1992, CANCER RES, V52, P770; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; NISHIMORI H, 1994, INT J CANCER, V59, P108, DOI 10.1002/ijc.2910590120; NORDENSKJOLD M, 1988, IMPORTANT ADV ONCOLO, V4, P83; OYAMADA M, 1990, MOL CARCINOGEN, V3, P273, DOI 10.1002/mc.2940030507; Poole T. M., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P255; POTTER M, 1994, CANCER RES, V54, P969; REYNOLDS SH, 1987, SCIENCE, V237, P1309, DOI 10.1126/science.3629242; SAPIENZA C, 1991, BIOCHIM BIOPHYS ACTA, V1072, P51, DOI 10.1016/0304-419X(91)90006-7; SATO T, 1990, CANCER RES, V50, P7184; SCRABLE HJ, 1987, NATURE, V329, P645, DOI 10.1038/329645a0; SIMON D, 1991, ONCOGENE, V6, P765; THEILLET C, 1986, CANCER RES, V46, P4776; VANDAMME B, 1992, CANCER RES, V52, P6646; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; WISEMAN RW, 1994, P NATL ACAD SCI USA, V91, P3759, DOI 10.1073/pnas.91.9.3759; WISEMAN RW, 1986, P NATL ACAD SCI USA, V83, P5825, DOI 10.1073/pnas.83.16.5825; YEH SH, 1994, CANCER RES, V54, P4188; YOSHIE M, 1994, TR SOC PATHOL JPN, V88, P157; YOSHIMOTO K, 1989, CANCER RES, V49, P2716	60	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2281	2287						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570178				2022-12-17	WOS:A1995TK70200011
J	GU, J; DUBNER, R; FORNACE, AJ; IADAROLA, MJ				GU, J; DUBNER, R; FORNACE, AJ; IADAROLA, MJ			UREB1, A TYROSINE-PHOSPHORYLATED NUCLEAR-PROTEIN, INHIBITS P53 TRANSACTIVATION	ONCOGENE			English	Note						UREB1; P53; TRANSACTIVATION; SUPPRESSION; TUMOR SUPPRESSOR; TYROSINE PHOSPHORYLATION	WILD-TYPE; E6-AP; E6; UBIQUITINATION; TRANSFORMATION; EXPRESSION; COMPLEX; MUTANT; GROWTH; FORMS	Tumor suppressor p53 is a transcription activator that upregulates target genes containing the p53 binding site, UREB1, a DNA binding protein that is tyrosine phosphorylated in vivo, shares a significant homology with the human papilloma virus E6 associated protein (E6-AP). E6-AP forms a ternary complex with E6 and p53 and participates in the ubiquitination of p53. Based on the homology with E6-AP, but taking into account the nuclear localization of UREB1 and its smaller size, the present study used a transient transfection system to examine whether UREB1 influenced p53-stimulated transcription. Co-transfection of a vector expressing wildtype UREB1 with one expressing p53 into H1299, a p53 negative cell line, resulted in a pronounced suppression of p53 transactivation. The inhibitory effect was significantly attenuated by mutation of a tyrosine residue in the consensus tyrosine phosphorylation sequence of UREB1. These data suggest that optimal suppression of p53 transactivation requires tyrosine phosphorylated UREB1 and that tyrosine phosphorylation and dephosphorylation processes may be involved in the regulation of p53 transactivation.	NCI,MOLEC PHARMACOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	GU, J (corresponding author), NIDR,NEUROBIOL & ANESTHESIOL BRANCH,BLDG 49,RM 1A11,49 CONVENT DR,MSC-4410,BETHESDA,MD 20892, USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X				[Anonymous], 1994, PROGRAM MANUAL WISCO; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; CANTLEY LC, 1991, CELL, V25, P281; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; GU J, 1994, MOL BRAIN RES, V24, P77, DOI 10.1016/0169-328X(94)90120-1; GU J, 1994, BIOTECHNIQUES, V17, P257; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MESSERSMITH DJ, 1994, MOL CELL NEUROSCI, V5, P238, DOI 10.1006/mcne.1994.1028; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1993, P NATL ACAD SCI USA, V91, P8797; SCHREIBER E, 1980, NUCLEIC ACIDS RES, V17, P6419; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YOUNISHROUACH E, 1991, NATURE, V352, P345	27	20	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2175	2178						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478539				2022-12-17	WOS:A1995TF29700030
J	FAVOT, P; YUE, X; HUME, DA				FAVOT, P; YUE, X; HUME, DA			REGULATION OF THE C-FMS PROMOTER IN MURINE TUMOR-CELL LINES	ONCOGENE			English	Article						MACROPHAGE; C-FMS; TRANSCRIPTION; CSF-1; TUMOR PROGRESSION	COLONY-STIMULATING FACTOR; MACROPHAGE GROWTH-FACTOR; CSF RECEPTOR EXPRESSION; FACTOR-I RECEPTOR; PLASMINOGEN-ACTIVATOR; CARCINOMAS INVIVO; PROTO-ONCOGENE; BONE-MARROW; MOUSE; GENE	Macrophage colony-stimulating factor (CSF-1) mRNA was detected in a wide range of murine tumour cell lines. Stable transfection with a CSF-1 receptor (c-fms) expression plasmid increased the number and size of colonies formed in soft agar by tumour cell lines that were already clonogenic, but did not induce transformation in non-clonogenic lines. To identify mechanisms that might lead to ectopic expression of c-fms, the regulation of the exon 2 promoter of the gene, which flanks the transcription start sites in macrophages, was examined. In transient and stable transfections this promoter was as active in non-macrophage tumour cell lines as it was in RAW264 macrophages. Promoter activity in non-macrophage lines was serum-dependent and was activated further in lines stably transfected with c-fms. Cis-acting elements required for serum-dependent activity lay outside the 300 bp proximal promoter that was sufficient for maximal activity in RAW264 macrophages, but the c-fms-responsive elements were retained in the proximal promoter. Exon 2 promoter activity was selectively suppressed in non-macrophage fines inclusion of intron 2, which has been implicated transcription attenuation. Lewis lung carcinoma cells were able to partly bypass this block and expressed c-fms mRNA when grown in limiting serum. The finding that c-fms promoter activity and c-fms mRNA levels are responsive to growth factor signalling pathways provides an insight into mechanisms that may lead to ectopic c-fms expression in tumour cells.	UNIV QUEENSLAND, CTR CELLULAR & MOLEC BIOL, ST LUCIA, QLD 4072, AUSTRALIA	University of Queensland			Hume, David A/C-7695-2013	Hume, David/0000-0002-2615-1478				AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; BAIOCCHI G, 1991, CANCER, V67, P990, DOI 10.1002/1097-0142(19910215)67:4<990::AID-CNCR2820670422>3.0.CO;2-8; BAUKNECHT T, 1994, CANCER DETECT PREV, V18, P231; BELIN D, 1985, EUR J BIOCHEM, V148, P225, DOI 10.1111/j.1432-1033.1985.tb08829.x; BERTRAM JS, 1980, CANCER LETT, V11, P63, DOI 10.1016/0304-3835(80)90130-5; BRUCKNER A, 1992, CANCER RES, V52, P3043; BURTHEM J, 1994, BLOOD, V83, P1381, DOI 10.1182/blood.V83.5.1381.bloodjournal8351381; CASSADY AI, 1991, NUCLEIC ACIDS RES, V19, P6839, DOI 10.1093/nar/19.24.6839; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CROSS M, 1988, P NATL ACAD SCI USA, V85, P6232, DOI 10.1073/pnas.85.17.6232; EVANS R, 1990, BIOTECHNIQUES, V8, P357; FILDERMAN AE, 1992, CANCER RES, V52, P3661; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRANKS LM, 1978, J PATHOL, V124, P35, DOI 10.1002/path.1711240108; GLINIAK BC, 1992, MOL BIOL CELL, V3, P535, DOI 10.1091/mbc.3.5.535; HUME DA, 1983, J CELL PHYSIOL, V117, P189, DOI 10.1002/jcp.1041170209; JIN DI, 1995, MOL CELL BIOL, V15, P693; KACINSKI BM, 1990, INT J RADIAT ONCOL, V19, P619, DOI 10.1016/0360-3016(90)90488-6; KACINSKI BM, 1991, ONCOGENE, V6, P941; KACINSKI BM, 1990, AM J PATHOL, V137, P135; KAUMA SW, 1991, J CLIN ENDOCR METAB, V73, P746, DOI 10.1210/jcem-73-4-746; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; LADNER MB, 1988, P NATL ACAD SCI USA, V85, P6706, DOI 10.1073/pnas.85.18.6706; LANGER SJ, 1988, MOL CELL BIOL, V8, P3872, DOI 10.1128/MCB.8.9.3872; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LEISEROWITZ GS, 1993, GYNECOL ONCOL, V49, P190, DOI 10.1006/gyno.1993.1106; PAIETTA E, 1990, CANCER RES, V50, P2049; PATEK PQ, 1978, NATURE, V276, P510, DOI 10.1038/276510a0; POLLARD JW, 1987, NATURE, V330, P484, DOI 10.1038/330484a0; RAMBALDI A, 1988, J CLIN INVEST, V81, P1030, DOI 10.1172/JCI113413; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; REDDY MA, 1994, J EXP MED, V180, P2309, DOI 10.1084/jem.180.6.2309; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; ROBERTS WM, 1992, BLOOD, V79, P586; ROSS IL, 1994, ONCOGENE, V9, P121; Roth P, 1992, Curr Top Microbiol Immunol, V181, P141; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SANFORD KK, 1948, J NATL CANCER I, V9, P229; SARIBAN E, 1989, BLOOD, V74, P123; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SHERR CJ, 1990, BLOOD, V75, P1; STACEY KJ, 1993, IMMUNOL CELL BIOL, V71, P75, DOI 10.1038/icb.1993.8; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; STORGA D, 1992, INT J EXP PATHOL, V73, P527; TANG RP, 1992, J CELL BIOCHEM, V50, P350, DOI 10.1002/jcb.240500403; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; TILL KJ, 1993, BRIT J HAEMATOL, V83, P223, DOI 10.1111/j.1365-2141.1993.tb08276.x; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336; YUE X, 1993, MOL CELL BIOL, V13, P3191, DOI 10.1128/MCB.13.6.3191; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	54	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	1995	11	7					1371	1381						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478559				2022-12-17	WOS:A1995RY96700019
J	STOREY, A; MASSIMI, P; DAWSON, K; BANKS, L				STOREY, A; MASSIMI, P; DAWSON, K; BANKS, L			CONDITIONAL IMMORTALIZATION OF PRIMARY-CELLS BY HUMAN PAPILLOMAVIRUS TYPE-18 E6 AND EJ-RAS DEFINES AN E6 ACTIVITY IN G(0)/G(1) PHASE WHICH CAN BE SUBSTITUTED FOR MUTATIONS IN P53	ONCOGENE			English	Article						HPV; CELL CYCLE; CHECKPOINT; P53	RETINOBLASTOMA GENE-PRODUCT; CELLULAR TUMOR-ANTIGEN; DNA-BINDING FUNCTION; PRIMARY MOUSE CELLS; TRANSFORMING ACTIVITY; HUMAN KERATINOCYTES; CERVICAL-CARCINOMA; TRANSCRIPTION FACTOR; ADENOVIRUS E1A; E7 FUNCTIONS	The human papillomavirus (HPV) type 18 E6 gene cooperates with activated Ha-ras to immortalize primary mouse cells in culture. Using a plasmid where HPV18 E6 expression is regulated by the glucocorticoid inducible MMTV LTR, we have generated immortalized cell lines in which the continued expression of E6 was necessary for maintenance of the transformed phenotype. In the absence of exogenously added hormone these cells were found to arrest in G(0)/G(1). Furthermore, we demonstrate that the effects of E6 were essentially p53 independent and therefore define a novel function by which E6 is able to modulate cell proliferation. In addition, when the E6 dependent cells were maintained under conditions of prolonged growth arrest by the removal of E6, revertant cells were isolated which were no longer dependent on E6 expression for continued proliferation. These revertant cells were found to have acquired a mutation in the cellular gene p53, suggesting that certain p53 mutations are dominant over an E6 requirement in this assay.	ROYAL LONDON HOSP, DEPT EXPTL DERMATOL, IMPERIAL CANC RES FUND, SKIN TUMOUR LAB, LONDON E1 2BL, ENGLAND	Barts Health NHS Trust; Royal London Hospital; Cancer Research UK	STOREY, A (corresponding author), INT CTR GENET ENGN & BIOTECHNOL, AREA SCI PK, PADRICIANO 99, I-34012 TRIESTE, ITALY.			Storey, Alan/0000-0003-2001-9772				ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; ANSORGE W, 1982, EXP CELL RES, V140, P31, DOI 10.1016/0014-4827(82)90152-5; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANKS L, 1988, VIROLOGY, V165, P326, DOI 10.1016/0042-6822(88)90695-2; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BANKS L, 1990, ONCOGENE, V5, P833; BANKS L, 1990, ONCOGENE, V5, P1383; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARBOSA MS, 1989, ONCOGENE, V4, P1529; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1991, CANCER RES, V51, P6304; KEEN N, 1994, ONCOGENE, V9, P1493; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIYONO T, 1994, J VIROL, V68, P4656, DOI 10.1128/JVI.68.7.4656-4661.1994; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MATLASHEWSKI G, 1987, CANCER CELL, V5, P195; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MOSNER J, 1994, ONCOGENE, V9, P3321; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIM D, 1991, ONCOGENE, V6, P589; PIM D, 1994, ONCOGENE, V9, P1869; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; SOUSSI T, 1990, ONCOGENE, V5, P945; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STOREY A, 1993, ONCOGENE, V8, P919; STOREY A, 1994, KERATINOCYTE HDB, P439; TAYLOR IW, 1980, J HISTOCHEM CYTOCHEM, V28, P1021, DOI 10.1177/28.9.6157714; THOMAS M, 1995, ONCOGENE, V10, P261; TSUNOKAWA Y, 1986, P NATL ACAD SCI USA, V83, P2200, DOI 10.1073/pnas.83.7.2200; VANDENBRULE AJC, 1989, J MED VIROL, V29, P20, DOI 10.1002/jmv.1890290105; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WATANABE S, 1990, J VIROL, V64, P207, DOI 10.1128/JVI.64.1.207-214.1990; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YASUMOTO S, 1986, J VIROL, V57, P572, DOI 10.1128/JVI.57.2.572-577.1986	76	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	1995	11	4					653	661						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651728				2022-12-17	WOS:A1995RQ46900006
J	DANIEL, R; CAI, YL; WONG, PMC; CHUNG, SW				DANIEL, R; CAI, YL; WONG, PMC; CHUNG, SW			DEREGULATION OF C-ABL MEDIATED CELL-GROWTH AFTER RETROVIRAL TRANSFER AND EXPRESSION OF ANTISENSE SEQUENCES	ONCOGENE			English	Article						C-ABL; ANTISENSE; CELL CYCLE	HEMATOPOIETIC STEM-CELLS; TYROSINE KINASE; BINDING; GENE; PROTEIN; CYCLE; ACTIVATION; ONCOGENE	To determine the role of c-abl during cell growth, we constructed a retrovirus vector alpha A, capable of expressing an antisense RNA directed against the abl mRNA, Based on v-abl-mediated 3T3 transformation assay, we showed that the number of transformed foci was reduced 50-94% when alpha A-infected 3T3 cells were superinfected with A-MuLV, Up to a 100% of inhibition could be observed when the time of infection was lengthened. Introduction of the antisense sequence into NM3T3 cells resulted in reduction of growth rate. These cells entered into S phase from G1 phase of the cell cycle earlier in time than untransduced cells, Thus c-abl serves as a checkpoint during G1/S transition in the cell cycle, and its reduction resulted in deregulation of cell growth.	TEMPLE UNIV,FELS INST CANC RES & MOLEC BIOL,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,DEPT LAB MED & PATHOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19140; SUNY DOWNSTATE MED CTR,MORSE INST MOLEC GENET,DEPT IMMUNOL & MICROBIOL,BROOKLYN,NY	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center				Daniel, Rene/0000-0002-3876-6242	NCI NIH HHS [5P30CA12227] Funding Source: Medline; NHLBI NIH HHS [HL46547] Funding Source: Medline; NIDDK NIH HHS [DK41298] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA012227] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046547] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041298] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASKARAN R, 1993, P NATL ACAD SCI USA, V98, P11167; CHEN YY, 1992, P NATL ACAD SCI USA, V89, P6683, DOI 10.1073/pnas.89.15.6683; CHUNG SW, 1988, BLOOD, V71, P973; CHUNG SW, 1991, P NATL ACAD SCI USA, V88, P1585, DOI 10.1073/pnas.88.4.1585; CHUNG SW, 1994, ONCOGENE, V9, P3527; CHUNG SW, 1995, IN PRESS ONCOGENE; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; EMERMAN M, 1984, CELL, V39, P459, DOI 10.1016/0092-8674(84)90453-7; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; HAN XD, 1991, P NATL ACAD SCI USA, V88, P10129, DOI 10.1073/pnas.88.22.10129; HOFFMANN FM, 1991, TRENDS GENET, V7, P351, DOI 10.1016/0168-9525(91)90254-F; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Sambrook J., 1989, MOL CLONING; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; TYBULEWICZ VLJ, 1991, CELL, V65, P1097; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WONG BY, 1994, J VIROL, V68, P5523, DOI 10.1128/JVI.68.9.5523-5531.1994; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798	26	20	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1607	1614						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731715				2022-12-17	WOS:A1995QU68100017
J	SANCHEZGARCIA, I; AXELSON, H; RABBITTS, TH				SANCHEZGARCIA, I; AXELSON, H; RABBITTS, TH			FUNCTIONAL DIVERSITY OF LIM PROTEINS - AMINO-TERMINAL ACTIVATION DOMAINS IN THE ONCOGENIC PROTEINS RBTN1 AND RBTN2	ONCOGENE			English	Article						LIM DOMAIN; LEUKEMIA; TRANSCRIPTION; ACTIVATION DOMAIN	EXPRESSION VECTOR; MAMMALIAN-CELLS; DNA-BINDING; GENE; MOTIF; YEAST; DIFFERENTIATION; HOMEODOMAIN; ENCODES; ELEGANS	The RBTN1 and RBTN2 genes are activated by distinct translocations involving chromosome 11 in some T cell acute leukaemias. The RBTN proteins belong to the LIM family which comprises proteins with one, two or three cysteine-rich LIM domains, sometimes together with homeodomains or protein kinase domains. The RBTN1 and RBTN2 proteins comprise only tandem LIM domains. We report that RBTN1 and RBTN2 proteins are capable of supporting transcriptional transactivation of specific reporter genes in transfection assays. The results, using intact proteins or fusions with the homeodomain of the heterologous protein Isl-1, show that this transcriptional activation ability resides in the NH2-terminal parts of both proteins. The use of yeast assays with RBTN2 shows that RBTN2 forms homodimers and that the NH2-terminal 27 amino acids are sufficient to facilitate transcriptional transactivation. These data expand the functional diversity of the LIM-domain protein family and they augment the previously defined relationship between chromosomal translocations and transcriptional activation.			SANCHEZGARCIA, I (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.		SANCHEZ-GARCIA, ISIDRO/A-5631-2019; Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609; SANCHEZ-GARCIA, ISIDRO/0000-0001-6989-9905				BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MIZUNO K, 1994, ONCOGENE, V9, P1605; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOUTHON MA, 1993, BLOOD, V81, P647; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RABBITTS TH, 1990, NATURE, V346, P418, DOI 10.1038/346418a0; REDDY ESP, 1986, GENE ANAL TECH, V3, P41; ROSE MD, 1990, METHODS YEAST GENETI; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SANCHEZGARCIA I, 1993, SEMIN CANCER BIOL, V4, P349; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WADMAN IA, 1994, ONCOGENE, V9, P3713; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WU RY, 1994, J BIOL CHEM, V269, P25085; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	46	20	21	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1301	1306						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731680				2022-12-17	WOS:A1995QR65100006
J	KRAUT, N; FRAMPTON, J; GRAF, T				KRAUT, N; FRAMPTON, J; GRAF, T			REM-1, A PUTATIVE DIRECT TARGET GENE OF THE MYB-ETS FUSION ONCOPROTEIN IN HEMATOPOIETIC PROGENITORS, IS A MEMBER OF THE RECOVERIN FAMILY	ONCOGENE			English	Article						RETROVIRUS E26; ACUTE AVIAN LEUKEMIA VIRUS; HEMATOPOIETIC STEM CELLS; V-ETS; TARGET GENE	CALCIUM-BINDING PROTEIN; CHICKEN ERYTHROID-CELLS; V-MYB; TRANSCRIPTION FACTORS; MYELOMONOCYTIC CELLS; MOLECULAR-CLONING; NERVOUS-SYSTEM; C-ETS-1 LOCUS; ONCOGENE; DIFFERENTIATION	The Myb-Ets oncoprotein encoded by the E26 avian leukaemia virus represents a fusion of two transcription factors which cooperate in transforming multipotent haematopoietic progenitors (MEPs) in vitro and in vivo, Previous studies with a temperature sensitive mutant in ets (ts1.1 E26) have suggested that the Ets part of the Myb-Ets fusion protein blocks multilineage differentiation of transformed MEPs, by regulating specific target genes, Using this system in a differential screening approach we have now identified a new gene, called rem-1, as a target for the E26 virus, Following shift of ts1.1 mutant transformed cells to the nonpermissive temperature a decreased expression of rem-1 was observed which increased upon downshift, The finding that this reexpression did not require new protein synthesis suggests that the Ets component of the fusion protein directly regulates rem-1 transcription, Rem-1 is related to a family of EF-hand-containing calcium-binding proteins that are predominantly expressed in the brain and in retinal cells, This family includes recoverin and visinin, proteins that have been implicated in regulating photoreception, Rem-1 is likewise expressed in these tissues but in addition in haematopoietic cells and in the gut, Enforced expression of rem-1 in ts1.1-transformed MEP cells, using a retroviral vector, showed that this gene is not sufficient to block their differentiation, but that it may provide them with a growth advantage.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Graf, Thomas/B-4252-2015	Graf, Thomas/0000-0003-2774-4117				BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BEUG H, 1982, J CELL PHYSL S, V1, P195; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRAYKELLER MP, 1993, NEURON, V10, P523, DOI 10.1016/0896-6273(93)90339-S; HURLEY JB, 1993, SCIENCE, V260, P740, DOI 10.1126/science.8097896; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KAJIMOTO Y, 1993, J NEUROCHEM, V61, P1091, DOI 10.1111/j.1471-4159.1993.tb03624.x; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAUT N, 1994, GENE DEV, V8, P33, DOI 10.1101/gad.8.1.33; KUNO T, 1992, BIOCHEM BIOPH RES CO, V184, P1219, DOI 10.1016/S0006-291X(05)80012-9; LAUTENBERGER JA, 1993, J VIROL, V67, P610, DOI 10.1128/JVI.67.1.610-612.1993; LENZ SE, 1992, MOL BRAIN RES, V15, P133, DOI 10.1016/0169-328X(92)90160-D; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P435; NAKANO T, 1992, ONCOGENE, V7, P527; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OKAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P147, DOI 10.1016/S0006-291X(05)80968-4; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; POLANS AS, 1991, J CELL BIOL, V112, P981, DOI 10.1083/jcb.112.5.981; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; QUEVA C, 1993, ONCOGENE, V8, P2511; Sambrook J., 1989, MOL CLONING LAB MANU; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; STOKER AW, 1992, MOL VIROLOGY PRACTIC; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; YAMAGATA K, 1990, NEURON, V2, P469; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	58	20	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1027	1036						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700627				2022-12-17	WOS:A1995QN35300001
J	COMERFORD, SA; MAIKA, SD; LAIMINS, LA; MESSING, A; ELSASSER, HP; HAMMER, RE				COMERFORD, SA; MAIKA, SD; LAIMINS, LA; MESSING, A; ELSASSER, HP; HAMMER, RE			E6 AND E7 EXPRESSION FROM THE HPV-18 LCR - DEVELOPMENT OF GENITAL HYPERPLASIA AND NEOPLASIA IN TRANSGENIC MICE	ONCOGENE			English	Article						HPV-18; CERVICAL NEOPLASIA; SEMINAL VESICLE; PREPUTIAL GLAND; TRANSGENIC MICE	HUMAN PAPILLOMAVIRUS TYPE-16; CARCINOMA CELL-LINES; CERVICAL-CARCINOMA; HUMAN KERATINOCYTES; REGULATORY REGION; UTERINE CERVIX; STROMAL CELLS; GENE-PRODUCTS; T-CELL; PROTEIN	Human papillomavirus type 18 infection is highly associated with malignant tumors of the genital tract. To investigate the tissue specificity of the HPV long control region (LCR) and the transforming ability of the E6-E7 oncoproteins, an HPV-18 transgene containing the viral LCR and E6 and E7 genes was introduced into mice. Three founder males exhibited enlarged seminal vesicles and preputial glands by 50 weeks of age. A line of transgenic mice was established by in vitro fertilization, and subsequent generations of transgenic males and females were monitored for lesions. Approximately 80% of hemizygous transgenic males exhibited enlarged seminal vesicles and preputial glands as early as 12 weeks of age. Histological examination indicated that this enlargement was due to distension by fluid, along with polyploid hyperplasia of the lining secretory epithelium. E6 and E7 transcripts were limited to affected organs and kidney. Approximately 41% of transgenic females developed cervical neoplasms between 1-2 years of age. Histologically, tumors were mesenchymal rather than epithelial in origin. E6 and E7 transcripts were restricted to cervical tumor tissue and kidney. These findings suggest that the HPV-18 LCR has an element(s) which directs expression specifically to the urogenital tract in transgenic mice.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV WISCONSIN, SCH VET MED, DEPT PATHOBIOL SCI, MADISON, WI 53706 USA; UNIV MARBURG, DEPT CELL BIOL, D-35033 MARBURG, GERMANY	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Wisconsin System; University of Wisconsin Madison; Philipps University Marburg				Hammer, Robert E./0000-0001-5487-7551; Comerford, Sarah Ann/0000-0002-7452-7759				APT D, 1993, J VIROL, V67, P4455, DOI 10.1128/JVI.67.8.4455-4463.1993; ARBEIT JM, 1993, AM J PATHOL, V142, P1187; BEDELL MA, 1987, J VIROL, V61, P3635, DOI 10.1128/JVI.61.11.3635-3640.1987; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; BEDELL MA, 1991, J VIROL, V65, P2254, DOI 10.1128/JVI.65.5.2254-2260.1991; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; CHAN WK, 1989, J VIROL, V63, P3261, DOI 10.1128/JVI.63.8.3261-3269.1989; CHEN LP, 1991, P NATL ACAD SCI USA, V88, P110, DOI 10.1073/pnas.88.1.110; CID A, 1993, J VIROL, V67, P6742, DOI 10.1128/JVI.67.11.6742-6752.1993; CINTORINO M, 1991, INT J CANCER, V47, P843, DOI 10.1002/ijc.2910470609; COLE ST, 1987, J MOL BIOL, V193, P599, DOI 10.1016/0022-2836(87)90343-3; COMERFORD SA, 1991, J VIROL, V65, P4681, DOI 10.1128/JVI.65.9.4681-4690.1991; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DIETRICH W, 1992, GENETICS, V131, P423; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DOLLARD SC, 1992, GENE DEV, V6, P1131, DOI 10.1101/gad.6.7.1131; DURST M, 1985, J GEN VIROL, V66, P1515, DOI 10.1099/0022-1317-66-7-1515; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GARCIACARRANCA A, 1988, J VIROL, V62, P4321, DOI 10.1128/JVI.62.11.4321-4330.1988; GIUS D, 1988, J VIROL, V62, P665, DOI 10.1128/JVI.62.3.665-672.1988; GRIEP AE, 1993, J VIROL, V67, P1373, DOI 10.1128/JVI.67.3.1373-1384.1993; HAM J, 1991, TRENDS BIOCHEM SCI, V16, P440, DOI 10.1016/0968-0004(91)90172-R; HAUSEN HZ, 1989, CANCER RES, V49, P4677; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; JOCHMUSKUDIELKA I, 1989, J NATL CANCER I, V81, P1698, DOI 10.1093/jnci/81.22.1698; JONES MH, 1992, ONCOGENE, V7, P1631; KIRCHNER H, 1986, PROG MED VIROL, V33, P1; KONDOH G, 1991, J VIROL, V65, P3335, DOI 10.1128/JVI.65.6.3335-3339.1991; KREIDER JW, 1987, J VIROL, V61, P590, DOI 10.1128/JVI.61.2.590-593.1987; LAMBERT PF, 1993, P NATL ACAD SCI USA, V90, P5583, DOI 10.1073/pnas.90.12.5583; MACK DH, 1991, P NATL ACAD SCI USA, V88, P9102, DOI 10.1073/pnas.88.20.9102; MCBRIDE AA, 1991, J BIOL CHEM, V266, P18411; MCCANCE DJ, 1985, BIOCHIM BIOPHYS ACTA, V823, P195, DOI 10.1016/0304-419X(86)90002-8; MCLEAN CS, 1993, J GEN VIROL, V74, P239, DOI 10.1099/0022-1317-74-2-239; MENEGUZZI G, 1991, VIROLOGY, V181, P62, DOI 10.1016/0042-6822(91)90470-V; MEYERS C, 1992, SCIENCE, V257, P971, DOI 10.1126/science.1323879; MITTAL R, 1993, OBSTET GYNECOL, V81, P5; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; PATER MM, 1988, NATURE, V335, P832, DOI 10.1038/335832a0; ROMANCZUK H, 1992, P NATL ACAD SCI USA, V89, P3159, DOI 10.1073/pnas.89.7.3159; SANG BC, 1992, VIROLOGY, V189, P448, DOI 10.1016/0042-6822(92)90568-A; SAPPINO AP, 1988, INT J CANCER, V41, P707, DOI 10.1002/ijc.2910410512; SAPPINO AP, 1989, VIRCHOWS ARCH A, V415, P551, DOI 10.1007/BF00718649; SASAGAWA T, 1992, CANCER RES, V52, P4420; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHNEIDERMAUNOURY S, 1987, J VIROL, V61, P3295, DOI 10.1128/JVI.61.10.3295-3298.1987; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SELVEY LA, 1990, J IMMUNOL, V145, P3105; SHEPHERD PS, 1992, J GEN VIROL, V73, P1269, DOI 10.1099/0022-1317-73-5-1269; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; SPENCER ES, 1970, BRIT MED J, V3, P251, DOI 10.1136/bmj.3.5717.251; THIERRY F, 1987, EMBO J, V6, P3391, DOI 10.1002/j.1460-2075.1987.tb02662.x; TINDLE RW, 1991, P NATL ACAD SCI USA, V88, P5887, DOI 10.1073/pnas.88.13.5887; TINSLEY JM, 1992, J GEN VIROL, V73, P1251, DOI 10.1099/0022-1317-73-5-1251; VONKNEBEL M, 1992, INT J CANCER, V51, P831, DOI 10.1002/ijc.2910510527; WANK R, 1991, NATURE, V352, P723, DOI 10.1038/352723a0; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; YAGINUMA Y, 1991, CANCER RES, V51, P6506; YASUMOTO S, 1986, J VIROL, V57, P572, DOI 10.1128/JVI.57.2.572-577.1986; YOKOTA J, 1989, CANCER RES, V49, P3598	68	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	1995	10	3					587	597						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845684				2022-12-17	WOS:A1995QF64800020
J	RIETHMACHER, D; LANGHOLZ, O; GODECKE, S; SACHS, M; BIRCHMEIER, C				RIETHMACHER, D; LANGHOLZ, O; GODECKE, S; SACHS, M; BIRCHMEIER, C			BIOCHEMICAL AND FUNCTIONAL-CHARACTERIZATION OF THE MURINE ROS PROTOONCOGENE	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; EPIDERMAL GROWTH-FACTOR; MOUSE MYELOID CELLS; I CSF-1 RECEPTOR; SEVENLESS PROTEIN; HEMATOPOIETIC-CELLS; EGF RECEPTOR; DROSOPHILA-MELANOGASTER; NUCLEOTIDE-SEQUENCE; SIGNAL TRANSDUCTION	The ros gene was originally found because it can, when mutated, induce malignant transformation. The proto-oncogene encodes an orphan receptor tyrosine kinase. We report here the isolation and characterization of the mouse c-ros cDNA and, in addition, the biochemical characterization of the receptor. Both, the endogenous c-ros protein from embryonal tissues and the recombinant protein are glycosylated molecules with an apparent molecular weight of 260 000. Pulse-chase analysis in Sf9 cells demonstrates that the c-ros protein is synthesized as a single chain, uncleaved molecule. Since the specific ligand of c-ros is not known, a hybrid receptor (trk/c-ros) which transmits c-ros-specific signals in response to nerve growth factor (NGF) was used to study the biological activities. In NIH3T3 cells, this trk/c-ros hybrid induces growth, a fusiform cell shape, and loss of contact inhibition of growth. However, the active hybrid receptor cannot replace IL-3 as survival factor in 32D myeloid cells. Compared to other receptors, the active c-ros tyrosine kinase domain displays thus overlapping, but not identical signalling specificities.	MAX PLANCK GESELL,MAX DELBRUCK LAB,D-50829 COLOGNE,GERMANY; MAX DELBRUCK CENTRUM MOLEK MED,D-13122 BERLIN,GERMANY	Max Planck Society; Helmholtz Association; Max Delbruck Center for Molecular Medicine			Riethmacher, Dieter/A-6242-2010; Riethmacher, Dieter/AAP-2227-2021; Riethmacher, Dieter/AAB-8690-2022	Riethmacher, Dieter/0000-0002-4206-5529; 				BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BASLER K, 1988, CELL, V54, P299; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BIRCHMEIER C, 1993, BIOESSAYS, V15, P185, DOI 10.1002/bies.950150307; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; BIRCHMEIER C, 1990, P NATL ACAD SCI USA, V87, P4799, DOI 10.1073/pnas.87.12.4799; BIRCHMEIER C, 1987, P NATL ACAD SCI USA, V84, P9270, DOI 10.1073/pnas.84.24.9270; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; CHEN JM, 1991, ONCOGENE, V6, P257; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; GREENFIELD C, 1988, EMBO J, V7, P139, DOI 10.1002/j.1460-2075.1988.tb02793.x; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; HARLOW E, 1988, ANTIBODIES LABORATOR; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HSIEH P, 1984, J BIOL CHEM, V259, P2375; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KATO JY, 1990, BLOOD, V75, P1780; KATO JY, 1989, MOL CELL BIOL, V9, P4069, DOI 10.1128/MCB.9.9.4069; KATZAV S, 1989, ONCOGENE, V4, P1129; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LANEUVILLE P, 1991, ONCOGENE, V6, P275; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATSUSHIME H, 1990, J VIROL, V64, P2117, DOI 10.1128/JVI.64.5.2117-2125.1990; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NECKAMEYER WS, 1985, J VIROL, V53, P879, DOI 10.1128/JVI.53.3.879-884.1985; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; RIEDEL H, 1989, EMBO J, V8, P2943, DOI 10.1002/j.1460-2075.1989.tb08444.x; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; Sambrook J., 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO M, 1994, MOL CELL BIOL, V13, P663; SCHATT MD, 1990, EMBO J, V9, P481, DOI 10.1002/j.1460-2075.1990.tb08134.x; SHARMA S, 1989, ONCOGENE RES, V5, P91; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONNENBERG E, 1991, EMBO J, V10, P3693, DOI 10.1002/j.1460-2075.1991.tb04937.x; SUMMERS M, 1987, TEX AGR EP STN B, V1555; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WILKS AF, 1993, ADV CANCER RES, V60, P43; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; ZONG CS, 1993, J VIROL, V67, P6453, DOI 10.1128/JVI.67.11.6453-6462.1993	62	20	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3617	3626						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970722				2022-12-17	WOS:A1994PT39200025
J	WU, K; SALAS, PJI; YEE, L; FREGIEN, N; CARRAWAY, KL				WU, K; SALAS, PJI; YEE, L; FREGIEN, N; CARRAWAY, KL			TISSUE AND TUMOR EXPRESSION OF A CELL-SURFACE GLYCOPROTEIN COMPLEX CONTAINING AN INTEGRAL MEMBRANE GLYCOPROTEIN ACTIVATOR OF P185(NEU)	ONCOGENE			English	Article							MAMMARY ADENOCARCINOMA CELLS; GROWTH FACTOR-ALPHA; EGF RECEPTOR; DIFFERENTIATION FACTOR; SIGNAL TRANSDUCTION; SIALOMUCIN COMPLEX; NEU ONCOGENE; TRANSFORMATION; HEREGULIN; PRECURSOR	Ascites 13762 rat mammary adenocarcinoma cells contain an abundant heterodimeric cell surface glycoprotein complex. It is composed of a transmembrane subunit and a sialomucin subunit and is the product of a single gene. The transmembrane subunit has two EGF-like domains and activates the proto-oncogene receptor kinase p185(neu). Southern blot comparisons of the ascites tumor and rat liver demonstrated the presence of the gene encoding the complex in normal tissues and showed an amplification of about fivefold in the ascites tumor. Polymerase chain reaction assays showed the presence of mRNA for the complex in rat brain and lung, but not in liver, pancreas, placenta,intestine, kidney, ovary and uterus. Northern blot analyses showed that the 9 kb transcript for the complex is expressed at an approximately 500-fold higher level in the ascites cells than in rat brain. Immunocytochemical studies using antiserum directed against the transmembrane subunit showed its presence in bronchial epithelium, brain ependymal and neurons of four day old animals and in the endoderm and neuronal cells of embryos. Similar immunocytochemical studies showed the presence of the transmembrane subunit in some human breast tumors. These results suggest that the gene encoding this complex is regulated in a tissue-specific manner, is overexpressed in some tumors and may play a role in tumor progesssion.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL,MIAMI,FL 33101; MT SINAI MED CTR,MIAMI BEACH,FL 33140	University of Miami; University of Miami; Mount Sinai Medical Center			Salas, Pedro J./AAS-9455-2021	Salas, Pedro/0000-0002-7411-1366	NCI NIH HHS [CA 14395, CA 52498] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014395, R01CA052498] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BUCK RL, 1979, ARCH BIOCHEM BIOPHYS, V198, P12, DOI 10.1016/0003-9861(79)90390-4; CARRAWAY CAC, 1993, J BIOL CHEM, V268, P5582; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1992, J CELL SCI, V103, P299; CODINGTON JF, 1983, BIOMEMBRANE, V11, P207; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; CULOUSCOU JM, 1993, J BIOL CHEM, V268, P18407; DOUGALL WC, 1993, J CELL BIOCHEM, V53, P61, DOI 10.1002/jcb.240530108; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Favaloro J, 1980, Methods Enzymol, V65, P718; GOSPODAROWICZ D, 1976, ANNU REV BIOCHEM, V45, P531, DOI 10.1146/annurev.bi.45.070176.002531; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOWARD SC, 1980, BIOCHIM BIOPHYS ACTA, V631, P79, DOI 10.1016/0304-4165(80)90055-0; HUGGINS JW, 1980, CANCER RES, V40, P1873; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8498, DOI 10.1073/pnas.84.23.8498; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; Maniatis T., 1982, MOL CLONING; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MERCOLA M, 1988, DEVELOPMENT, V102, P451; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PETO R, 1975, BRIT J CANCER, V32, P411, DOI 10.1038/bjc.1975.242; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHERBLOM AP, 1980, J BIOL CHEM, V255, P2051; SHERBLOM AP, 1986, CANCER RES, V46, P4543; SHERBLOM AP, 1980, J BIOL CHEM, V255, P783; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STECK PA, 1983, EXP CELL RES, V147, P255, DOI 10.1016/0014-4827(83)90208-2; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; WU K, 1994, J BIOL CHEM, V269, P11950; YU DH, 1991, ONCOGENE, V6, P1991	42	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3139	3147						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936636				2022-12-17	WOS:A1994PM65800005
J	ROLLEY, N; MILNER, J				ROLLEY, N; MILNER, J			SPECIFIC DNA-BINDING BY P53 IS INDEPENDENT OF MUTATION AT SERINE-389, THE CASEIN KINASE-II SITE	ONCOGENE			English	Note							TUMOR SUPPRESSOR PROTEIN; WILD-TYPE; ACTIVATION DOMAIN; MUTANT FORMS; CONFORMATION; TRANSCRIPTION; VARIANTS; OLIGOMERIZATION; TRANSFORMATION; COMPLEXES	The best understood function of p53 is that of cell growth suppression and this is likely to involve sequence-specific DNA binding and modulation of gene expression. Casein kinase II phosphorylates the C-terminal serine of p53 (residue 389 for murine p53) and mutation of this site abolishes p53 growth suppressor function. DNA binding by purified p53 is 'activated' by casein kinase II, suggesting that the carboxyl terminus of p53 represents a critical regulatory domain for sequence-specific DNA binding and hence for growth suppressor function. In the present study we have substituted serine 389 with either aspartic acid (mimics phosphoserine and partially conserves p53 suppressor function) or with alanine, a non-phosphorylable residue which abolishes suppressor function (Milne et al., 1992; Nucleic Acids Research 20, 5565-5570). When expressed in vitro p53(ala389) and p53(asp389) were both indistinguishable from wild type p53 on the basis of size fractionation and immunoreactivity with PAb421, PAb246 and PAb1620. Both mutants also exhibited specific binding for the DNA consensus p53-CON. Since p53(ala389) retains the ability to bind DNA and yet is known to lack growth suppressor function we conclude that phosphorylation by casein kinase II is important for p53 growth suppressor function via a mechanism which is ancilliary to p53 sequence-specific DNA binding.	UNIV YORK,DEPT BIOL,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK								BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BUTCHER S, 1994, BIOCHEM J, V298, P513, DOI 10.1042/bj2980513; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1994, ONCOGENE, V8, P299; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MEDCALF EA, 1993, ONCOGENE, V8, P2001; MEEK DW, 1994, IN PRESS SEMINARS CA; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, ONCOGENE, V5, P1683; MILNER J, 1994, IN PRESS SEMINARS CA, V5; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SRINIVASAN R, 1993, CANCER RES, V53, P5361; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TARUNINA M, 1993, ONCOGENE, V8, P3165; TRUANT R, 1993, J BIOL CHEM, V268, P2284; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VONHIPPEL PH, 1994, SCIENCE, V263, P769, DOI 10.1126/science.8303292; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	41	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3067	3070						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084615				2022-12-17	WOS:A1994PG82200039
J	WILKIE, TM; SCHMIDT, RA; BAETSCHER, M; MESSING, A				WILKIE, TM; SCHMIDT, RA; BAETSCHER, M; MESSING, A			SMOOTH-MUSCLE AND BONE NEOPLASMS IN TRANSGENIC MICE EXPRESSING SV40 T-ANTIGEN	ONCOGENE			English	Article							SOFT-TISSUE SARCOMAS; LARGE TUMOR-ANTIGEN; HEAT-SHOCK PROTEIN; CHOROID-PLEXUS; P53 GENE; SIMIAN VIRUS-40; HYBRID GENE; GERM-LINE; RETINOBLASTOMA; MUTATION	Transgenic mice carrying the SV40 early region fused to the Drosophila hsp70 promoter developed smooth muscle and bone neoplasms. The smooth muscle tumors appeared in aged mice and were preferentially located on the muzzle or eyelids. Multiple neoplasms were often present and each appeared to be an independent proliferation. In contrast, the bone tumors typically developed in the petrous ridge and had all the features of osteogenic sarcomas, displaying distant metastasis and invasion of the brain. Cells in both types of tumors exhibited nuclear expression of SV40 T antigen. Mice homozygous for the transgene had a shorter latency for appearance of smooth muscle tumors and developed osteosarcomas more frequently than hemizygous mice. This model system implicates the cellular T antigen-binding proteins, such as Rb and p53, in the pathogenesis of bone and soft tissue neoplasms in mice.	UNIV WASHINGTON,HOSP PATHOL RC72,SEATTLE,WA 98195; BIOTRANSPLANT INC,BOSTON,MA 02129; UNIV WISCONSIN,SCH VET MED,MADISON,WI 53706	University of Washington; University of Washington Seattle; University of Wisconsin System; University of Wisconsin Madison	WILKIE, TM (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75325, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM011576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022475] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-11576] Funding Source: Medline; NINDS NIH HHS [NS-22475] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ARTAVANISTSAKONAS S, 1979, CELL, V17, P9, DOI 10.1016/0092-8674(79)90290-3; BEHRINGER RR, 1988, P NATL ACAD SCI USA, V85, P2648, DOI 10.1073/pnas.85.8.2648; BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; CHEN JD, 1992, ONCOGENE, V7, P1167; CHOI YW, 1988, MOL CELL BIOL, V8, P3382, DOI 10.1128/MCB.8.8.3382; CICALA C, 1992, VIROLOGY, V190, P475, DOI 10.1016/0042-6822(92)91237-O; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DERKINDEREN DJ, 1988, INT J CANCER, V41, P499, DOI 10.1002/ijc.2910410405; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P646; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HSU SM, 1982, J HISTOCHEM CYTOCHEM, V30, P1079, DOI 10.1177/30.10.6182185; IAVARONE A, 1992, P NATL ACAD SCI USA, V89, P4207, DOI 10.1073/pnas.89.9.4207; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KHANDJIAN EW, 1983, MOL CELL BIOL, V3, P1; KINGSTON RE, 1986, MOL CELL BIOL, V6, P3180, DOI 10.1128/MCB.6.9.3180; KNOWLES BB, 1990, AM J PATHOL, V137, P259; KOTHARY R, 1989, DEVELOPMENT, V105, P707; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEW D, 1993, GENE DEV, V7, P683, DOI 10.1101/gad.7.4.683; LI H, 1991, JPN J CANCER RES, V82, P4, DOI 10.1111/j.1349-7006.1991.tb01736.x; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MESSING A, 1988, ONCOGENE RES, V3, P87; MILLER CW, 1990, CANCER RES, V50, P7950; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OMAR RA, 1984, CANCER RES, V44, P3976; PALMITER RD, 1985, NATURE, V316, P457, DOI 10.1038/316457a0; PORTER PL, 1992, AM J PATHOL, V140, P145; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; Sambrook J., 1989, MOL CLONING LAB MANU; SANDGREN EP, 1989, ONCOGENE, V4, P715; STRATTON MR, 1990, ONCOGENE, V5, P1297; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; STRAUSS PG, 1992, INT J CANCER, V50, P252, DOI 10.1002/ijc.2910500215; SYMONDS H, 1991, J VIROL, V65, P5417, DOI 10.1128/JVI.65.10.5417-5424.1991; TOGUCHIDA J, 1992, CANCER RES, V52, P6194	47	20	21	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2889	2895						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084593				2022-12-17	WOS:A1994PG82200014
J	HAHN, SL; WASYLYK, B				HAHN, SL; WASYLYK, B			THE ONCOPROTEIN V-ETS IS LESS SELECTIVE IN DNA-BINDING THAN C-ETS-1 DUE TO THE C-TERMINAL SEQUENCE CHANGE	ONCOGENE			English	Article							TRANSCRIPTION FACTOR GATA-1; CHICKEN ERYTHROID-CELLS; GENE FAMILY; REDOX REGULATION; LEUKEMIA-VIRUS; ONCOGENIC CONVERSION; PROMOTER SEQUENCES; PUTATIVE ONCOGENE; MYB ONCOPROTEIN; PROTEIN	The oncogene v-ets and the proto-oncogene c-ets-1 code for members of the Ets family of transcription factors that bind to DNA motifs comprising GGA(A/T) through the conserved Ets domain. c-Ets-1 and v-Ets are very similar, differing in sequence only at three positions. In this report we demonstrate that v-Ets has a less stringent target sequence requirement than c-Ets-1. v-Ets binds strongly to a broad spectrum of DNA sequence motifs, and consequently, weaker binding sites have a much greater affinity for v-Ets than c-Ets-1. c-Ets-1 carries two inhibitory domains: the D domain present N-terminal to the DNA binding domain and the C-terminal domain which is mutated in v-Ets. Our results show that the D domain has a stronger inhibitory effect than the C-terminal sequence. The on- and off-rates of c-Ets-1 vary greatly depending on the DNA binding sequences, in contrast to those of v-Ets. The c-Ets-1 on- and off-rates are higher with a strong site than with a weak site. Our data suggest that DNA sequences help c-Ets-1 change from a closed to an open, DNA-binding-competent structure, facilitating its binding to DNA, whereas v-Ets functions without such a process presumably because its different C-terminal sequence generates a constitutively open conformation. The loss of a stringent target sequence selectivity by v-Ets suggests that it might transform cells by altering expression of tightly regulated genes with non-consensus Ets binding sites.	FAC MED STRASBOURG,INST CHIM BIOL,CNRS,LGME,F-67085 STRASBOURG,FRANCE; FAC MED STRASBOURG,INST CHIM BIOL,INSERM,U184,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; AURIGEMMA RE, 1992, J VIROL, V66, P3056, DOI 10.1128/JVI.66.5.3056-3061.1992; AZIZ N, 1993, ONCOGENE, V8, P2259; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; DIEHL JA, 1993, MOL CELL BIOL, V13, P1769, DOI 10.1128/MCB.13.3.1769; FISHER RJ, 1991, ONCOGENE, V6, P2249; FLEISCHMAN LF, 1993, ONCOGENE, V8, P771; Forrest D, 1992, CURR OPIN GENET DEV, V2, P19, DOI 10.1016/S0959-437X(05)80316-8; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HIGGS DR, 1993, CURR BIOL, V3, P548, DOI 10.1016/0960-9822(93)90054-R; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; JAMIN N, 1993, EUR J BIOCHEM, V216, P147, DOI 10.1111/j.1432-1033.1993.tb18126.x; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JORCYK CL, 1991, ONCOGENE, V6, P523; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KOIZUMI S, 1990, ONCOGENE, V5, P675; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAUTENBERGER JA, 1993, J VIROL, V67, P610, DOI 10.1128/JVI.67.1.610-612.1993; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; LEPRINCE D, 1993, VIROLOGY, V194, P855, DOI 10.1006/viro.1993.1330; LEPRINCE D, 1992, ONCOGENE, V7, P9; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; METZ T, 1992, ONCOGENE, V7, P597; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MORGAN IM, 1993, ONCOGENE, V8, P1135; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; MOSIALOS G, 1993, ONCOGENE, V8, P721; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; OKUNO H, 1993, ONCOGENE, V8, P695; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; POGNONEC P, 1990, ONCOGENE, V5, P603; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; RUSCETTI S, 1992, J VIROL, V66, P20, DOI 10.1128/JVI.66.1.20-26.1992; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; SAKAR S, 1993, ONCOGENE, V8, P2245; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; STIEGLER P, 1993, MECH DEVELOP, V41, P163, DOI 10.1016/0925-4773(93)90046-Z; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1993, NUCLEIC ACIDS RES, V21, P523, DOI 10.1093/nar/21.3.523; WASYLYK C, 1992, CELL GROWTH DIFFER, V3, P617; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699	74	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2499	2512						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058313				2022-12-17	WOS:A1994PC05400009
J	CHEN, YY; GILL, GN				CHEN, YY; GILL, GN			POSITIVE AND NEGATIVE REGULATORY ELEMENTS IN THE HUMAN ERBB-2 GENE PROMOTER	ONCOGENE			English	Article							FACTOR RECEPTOR PROMOTER; HUMAN-BREAST-CANCER; RNA POLYMERASE-II; NEU ONCOGENE; C-ERBB-2 PROTOONCOGENE; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; THYROID-HORMONE; PROTO-ONCOGENE; DNA	Analysis of the proximal promoter of the human erbB-2 gene identified a 100 bp region that enhanced activity of the proximal TATA box 200-fold. DNase I footprinting mapped three Sp1 binding sites within this 100 bp region but only one of these sites was of high affinity and strongly correlated to Sp1-dependent activity in who. This Sp1 site overlapped the distal of two similar palindromic sequences. The proximal palindrome did not bind Sp1 but overlaps the CAAT box. When placed in the context of a heterologous promoter, the palindrome functioned as a positive response element. However, removal of the 5' half of the proximal palindrome increased promoter activity indicating that it functions as an inhibitory element within the erbB-2 context. Using electrophoretic mobility shift assays, a nuclear protein was detected that bound to either the 5' or 3' half of the palindrome but not to both. Analysis of the function of mutant sequences revealed maximal activity when both halves of the palindrome were intact with decreased but significant activity persisting when the 3' half of the palindrome was disrupted. Disruption of the 5' half of the palindrome impaired activity to a greater extent. These studies indicate erbB-2 promoter activity is positively regulated by Sp1 and negatively regulated in a position-dependent context by a protein that binds to a palindromic sequence.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NIDDK NIH HHS [DK 13149] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013149, R37DK013149] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERTL AP, 1993, GENE, V136, P361, DOI 10.1016/0378-1119(93)90496-P; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEMOINE NR, 1990, ONCOGENE, V5, P237; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; PRADHY LC, 1982, CELL, V28, P865; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYA H, 1990, MOL CARCINOGEN, V3, P198, DOI 10.1002/mc.2940030406; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; TAL M, 1987, MOL CELL BIOL, V7, P2587; WHITE MRA, 1992, ONCOGENE, V7, P677; XU J, 1993, J BIOL CHEM, V268, P16065; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499	32	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2269	2276						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	7913545				2022-12-17	WOS:A1994NX62900019
J	PHINNEY, DG; KEIPER, CL; FRANCIS, MK; RYDER, K				PHINNEY, DG; KEIPER, CL; FRANCIS, MK; RYDER, K			QUANTITATIVE-ANALYSIS OF THE CONTRIBUTION MADE BY 5'-FLANKING AND 3'-FLANKING SEQUENCES TO THE TRANSCRIPTIONAL REGULATION OF JUNB BY GROWTH-FACTORS	ONCOGENE			English	Article							C-FOS; SIGNAL TRANSDUCTION; MOUSE FIBROBLASTS; GENE; ELEMENTS; ACTIVATION; PROTEINS; COMPLEX; DNA	We have identified four DNAase I-hypersensitive regions (DHRs) at the junB locus, DHR1 is located between sequences - 100 and + 250, DHR2 is centered at - 1000, DHR3 at - 1650, and DHR4 at + 2040 relative to the junB transcriptional start site. Sequence analysis of these DHRs revealed two serum response elements at - 1452 and + 2091, two cyclic AMP response elements at + 2071 and + 2116, and a 12-O-tetradecanoylphorbol-13-acetate (TPA) response element at - 949. To study the contribution made by these cis-elements to junB transcriptional regulation, we stably transfected a recombinant mouse junB gene (JBSV4) containing the intact junB coding sequences, 6.3 kb of 5'-flanking DNA, and 2.0 kb of 3'-flanking DNA into Rat1A cells. The pattern of DHRs identified at the mouse junB locus was re-established at the JBSV4 locus. By directly comparing JBSV4 and rat junB mRNA levels, we found that these genes were induced to equivalent levels by serum, TPA, cyclic AMP, platelet-derived growth factor, epidermal growth factor, and basic fibroblastic growth factor. These results established that JBSV4 resides in a physical environment within chromatin that closely mimics that of the junB locus, and contains the necessary sequence information to recapitulate the transcriptional regulation of junB. By analysing a series of recombinant mouse junB genes containing deletion mutations in 5'-flanking and 3'-flanking sequences, we provide a quantitative assessment of the contribution these sequences make to junB induction by different regulatory agents.	FOX CHASE CANC CTR,PHILADELPHIA,PA 19111	Fox Chase Cancer Center			Phinney, Donald G/D-2155-2014	Phinney, Donald/0000-0002-8688-2619	NATIONAL CANCER INSTITUTE [F32CA009219, P30CA006927, R01CA052752] Funding Source: NIH RePORTER; NCI NIH HHS [CA-52752, F32CA-09219, CA-06927-31] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; BENBROOK DM, 1990, ONCOGENE, V5, P295; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BURCH JBE, 1983, CELL, V33, P65, DOI 10.1016/0092-8674(83)90335-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; KITABAYASHI I, 1993, J BIOL CHEM, V268, P14482; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; PEREZALBUERNE ED, 1993, P NATL ACAD SCI USA, V90, P11960, DOI 10.1073/pnas.90.24.11960; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RENZ M, 1985, EMBO J, V4, P3711, DOI 10.1002/j.1460-2075.1985.tb04139.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SASSONECORSI P, 1990, ONCOGENE, V5, P427; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WU C, 1979, CELL, V16, P807, DOI 10.1016/0092-8674(79)90096-5	20	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2353	2362						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036018				2022-12-17	WOS:A1994NX62900029
J	BRIZZI, MF; BLECHMAN, JM; CAVALLONI, G; GIVOL, D; YARDEN, Y; PEGORARO, L				BRIZZI, MF; BLECHMAN, JM; CAVALLONI, G; GIVOL, D; YARDEN, Y; PEGORARO, L			PROTEIN-KINASE C-DEPENDENT RELEASE OF A FUNCTIONAL WHOLE EXTRACELLULAR DOMAIN OF THE MAST-CELL GROWTH-FACTOR (MGF) RECEPTOR BY MGF-DEPENDENT HUMAN MYELOID CELLS	ONCOGENE			English	Article							TYROSINE KINASE; SIGNAL TRANSDUCTION; KIT PROTOONCOGENE; PHORBOL ESTERS; SI-LOCUS; LIGAND; BINDING; MOUSE; INHIBITION; FORM	The mast cell growth factor (MGF) affects migration, proliferation and differentiation of erythroid and myeloid progenitor cells by binding to a transmembrane receptor tyrosine kinase encoded by the c-Kit proto-oncogene. By using MGF-dependent human myeloid cell lines (M-07e and TF-1), here we show that a Kit-related 100 kDa protein is associated with the cell but it undergoes release into the medium upon treatment with the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA), an activator of protein kinase C. Immunological analysis with a series of antibodies to Kit indicated that the released protein (p100(Kit)) contains the whole glycosylated extracellular portion of the transmembrane Kit protein (p145(Kit)). The secreted protein retained the ability to specifically bind MGF. Moreover, p100(Kit) was able to block the mitogenic effect of MGF on cultured M-07e cells, suggesting that the soluble protein may function as a physiological antagonist of MGF.	UNIV TURIN,DIPARTIMENTO SCI BIOMED & ONCOL UMANA,SEZ CLIN,I-10149 TURIN,ITALY; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	University of Turin; Weizmann Institute of Science			YARDEN, YOSEF/K-1467-2012; Brizzi, Maria Felice/J-7882-2016	Cavalloni, Giuliana/0000-0002-9965-3436				ABKOWITZ JL, 1992, BLOOD, V79, P25, DOI 10.1182/blood.V79.1.25.bloodjournal79125; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; AVANZI GC, 1990, J CELL PHYSIOL, V145, P458, DOI 10.1002/jcp.1041450310; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BLECHMAN JM, 1993, J BIOL CHEM, V268, P4399; BUDEL LM, 1993, LEUKEMIA, V7, P426; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LEE LS, 1979, P NATL ACAD SCI USA, V10, P5178; LEV S, 1992, J BIOL CHEM, V267, P10866; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MCCAFFREY PG, 1984, J BIOL CHEM, V259, P2502; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P1710, DOI 10.1073/pnas.89.5.1710; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; SIBLEY DR, 1988, ENDOCR REV, V9, P38, DOI 10.1210/edrv-9-1-38; THOMOPOULOS P, 1982, EUR J BIOCHEM, V129, P389, DOI 10.1111/j.1432-1033.1982.tb07062.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VU TH, 1989, MOL CELL BIOL, V9, P4563, DOI 10.1128/MCB.9.10.4563; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YEE NS, 1993, J BIOL CHEM, V268, P14189; ZINI MG, 1993, COMMUNICATION; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	37	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1583	1589						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	7514283				2022-12-17	WOS:A1994NL81500008
J	GORUPPI, S; GUSTINCICH, S; BRANCOLINI, C; LEE, WMF; SCHNEIDER, C				GORUPPI, S; GUSTINCICH, S; BRANCOLINI, C; LEE, WMF; SCHNEIDER, C			DISSECTION OF C-MYC DOMAINS INVOLVED IN S-PHASE INDUCTION OF NIH3T3 FIBROBLASTS	ONCOGENE			English	Article							DNA-BINDING; CELL-CYCLE; NUCLEAR-LOCALIZATION; PROTEIN EXPRESSION; MURINE FIBROBLASTS; SURVIVAL FACTORS; MESSENGER-RNA; TRANSFORMATION; GENE; MAX	The product of the c-myc proto-oncogene is an important regulator of cell proliferation and apoptosis in murine fibroblasts. Addition of the tumor promoter, phorbol myristate acetate (PMA), prevents apoptotic cell death induced by low serum concentrations in NIH3T3 cells that constitutively express and are transformed by v-myc. The protective effect of PMA allowed us to analyse the ability of normal c-Myc and Myc deletion mutants to induce serum starved, untransformed NIH3T3 cells to enter S phase. By microinjecting these quiescent cells with wild type and mutant human c-myc plasmids, we showed that full length c-myc is able to induce S phase entry in presence of PMA, but that c-Myc mutants that delete amino acids Delta 7/91, Delta 41/53, Delta 56/103, Delta 106/143, Delta 265/317 and Delta 414/433 are totally inactive. c-Myc did not shorten the period before entry into S phase, since Myc overexpressing cells entered S phase with the same kinetics as control cells when both were stimulated with 20% fetal calf serum (FCS). However, c-Myc overexpression did increase the percentage of cells entering S phase when these cells were stimulated with 2% fetal calf serum. Interestingly, this ability to enhance stimulation by a suboptimal concentration of FCS was retained to a significant degree by Myc mutants that delete amino acids Delta 41/53, Delta 56/103 or Delta 265/317. Finally, Myc mutants that delete Delta 106/143 or Delta 414/433 exerted a dominant negative effect on S phase entry both in quiescent cells stimulated with 2% FCS and in unsynchronized, cycling cells.	LNCIB, I-34012 TRIESTE, ITALY; UNIV PENN, DEPT MED, HEMATOL ONCOL SECT, PHILADELPHIA, PA 19104 USA; UNIV UDINE, DIPARTIMENTO SCI & TECNOL BIOMED, SEZ BIOL, I-33100 UDINE, ITALY	University of Pennsylvania; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine				Gustincich, Stefano/0000-0002-2749-2514; BRANCOLINI, Claudio/0000-0002-6597-5373				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ASKEW DS, 1991, ONCOGENE, V6, P1915; BIGNAMI M, 1988, ONCOGENE, V2, P509; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRANCOLINI C, 1992, J CELL BIOL, V117, P1251, DOI 10.1083/jcb.117.6.1251; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KARN J, 1989, ONCOGENE, V4, P773; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; OHMORI Y, 1993, ONCOGENE, V8, P379; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; Sambrook J., 1989, MOL CLONING LAB MANU; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAMM I, 1991, P NATL ACAD SCI USA, V88, P3372, DOI 10.1073/pnas.88.8.3372; TAMM I, 1990, J CELL PHYSIOL, V143, P494, DOI 10.1002/jcp.1041430314; TAMM I, 1991, J CELL PHYSIOL, V148, P85, DOI 10.1002/jcp.1041480111; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WATERS CM, 1991, ONCOGENE, V6, P797; WATERS CM, 1992, CELL, V69, P119	42	20	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1537	1544						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183547				2022-12-17	WOS:A1994NL81500003
J	LARSEN, J; MEYER, S; STEINLEIN, P; BEUG, H; HAYMAN, MJ				LARSEN, J; MEYER, S; STEINLEIN, P; BEUG, H; HAYMAN, MJ			TRANSFORMATION OF CHICKEN BONE-MARROW CELLS BY THE V-SKI ONCOGENE	ONCOGENE			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; ERYTHROID-DIFFERENTIATION; LEUKEMIA-VIRUS; GROWTH-FACTOR; MIM-1 GENE; PHENOTYPE; MYB; INVITRO; EXPRESSION; MUSCLE	The effect of the v-ski oncogene on the transformation of chicken hematopoietic cells was examined. In initial experiments viruses encoding the v-ski oncoprotein did not transform chicken bone marrow cells. However, whereas viruses encoding the ts-v-sea oncoprotein transform solely erythroid cells, viruses encoding both the v-ski and the ts-v-sea oncogenes were found capable of transforming myeloid cells from the monocytic and/or granulocytic lineages in addition to erythroid cells. Analysis of cell clones transformed by the v-ski/ts-v-sea virus identified one clone that no longer expressed the v-sea protein, indicating that this protein was necessary for the initiation but not the maintenance of transformation. Subsequent experiments testing the effects of various growth factors on transformation of bone marrow cells by the v-ski oncogene product alone identified the avian c-kit ligand (stem cell factor; SCF) as being able to co-operate with the v-ski protein to cause transformation of chicken hematopoietic cells of both myeloid and erythroid lineages.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)					NATIONAL CANCER INSTITUTE [P01CA028146, R01CA042573] Funding Source: NIH RePORTER; NCI NIH HHS [CA42573, CA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1985, MODERN TRENDS HUMA 6, V29, P290; BOYER PL, 1993, ONCOGENE, V8, P457; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; DOMENGET C, 1992, ONCOGENE, V7, P2231; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GRAF T, 1976, VIROLOGY, V71, P423, DOI 10.1016/0042-6822(76)90370-6; HAYMAN MJ, 1987, PATHOL IMMUNOPATH R, V6, P390, DOI 10.1159/000157065; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; KAMPS MP, 1988, ONCOGENE, V2, P305; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KELLIHER MA, 1993, ONCOGENE, V8, P1249; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KORNFELD S, 1983, EXP CELL RES; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LARSEN J, 1992, ONCOGENE, V7, P1903; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; QUEVA C, 1992, DEVELOPMENT, V114, P125; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHROEDER C, 1990, ONCOGENE, V5, P1445; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; SUTRAVE P, 1991, ONCOGENE, V6, P353; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; TIKHONENKO AT, 1992, J VIROL, V66, P946, DOI 10.1128/JVI.66.2.946-955.1992; Varmus H. E., 1982, RNA TUMOR VIRUSES, P369; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	40	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3221	3228						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	7504231				2022-12-17	WOS:A1993MG78200004
J	WOLIN, M; KORNUC, M; HONG, C; SHIN, SK; LEE, F; LAU, R; NIMER, S				WOLIN, M; KORNUC, M; HONG, C; SHIN, SK; LEE, F; LAU, R; NIMER, S			DIFFERENTIAL EFFECT OF HTLV INFECTION AND HTLV TAX ON INTERLEUKIN-3 EXPRESSION	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; T-CELL LEUKEMIA; TRANS-ACTIVATOR PROTEIN; GENE-EXPRESSION; HUMAN-LYMPHOCYTES; MULTI-CSF; RECEPTOR; POLYMERASE; ELEMENT; DNA	To characterize the interactions between human T-cell leukemia virus (HTLV) infection and cellular gene expression, we examined the expression of the lymphokine interleukin 3 (IL-3) in the presence and absence of HTLV infection. IL-3, like granulocyte-macrophage colony-stimulating factor (GM-CSF), is produced by activated but not resting T cells, but although GM-CSF is constitutively expressed in HTLV-infected T cells IL-3 mRNA cannot be detected in either unstimulated or mitogen-stimulated HTLV-infected cells by polymerase chain reaction (PCR) analysis. In contrast, transient co-transfection studies with an IL-3 promoter-CAT reporter gene and an HTLV-II Tax expression construct demonstrate that Tax can transactivate the IL-3 promoter in HTLV-uninfected T cells. To determine whether differences in IL-3 promoter-binding proteins present in HTLV-infected and uninfected T cells account for this discrepancy, DNAase I footprinting of the IL-3 promoter was performed. Although crude nuclear extracts from both cell types protected the IL-3 sequences located between base pairs -168 and -125, the sequences between -125 and -103, which contain the lymphokine consensus sequences CK-1 and CK-2, were protected by extracts from HTLV-infected but not HTLV-uninfected T cells. Deletion of the region containing the CK-1 and CK-2 sequences from an IL-3 promoter CAT construct resulted in a sixfold rise in promoter activity in HTLV-infected but not uninfected T-cell lines, indicating that this region participates in the repression of IL-3 gene expression in HTLV-infected T cells.	UNIV CALIF LOS ANGELES,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	WOLIN, M (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90024, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043025] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43025] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDWIN GC, 1990, P NATL ACAD SCI USA, V87, P3933, DOI 10.1073/pnas.87.10.3933; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; CANN AJ, 1988, ONCOGENE, V3, P123; CHAN JY, 1986, P NATL ACAD SCI USA, V83, P8669, DOI 10.1073/pnas.83.22.8669; CHIRGWIN J, 1979, BIOCHEMISTRY-US, V118, P5294; CROSS SL, 1987, CELL, V49, P4756; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EMERSON SG, 1988, J CLIN INVEST, V82, P1282, DOI 10.1172/JCI113727; FRASER JD, 1992, MOL CELL BIOL, V12, P4357, DOI 10.1128/MCB.12.10.4357; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KAUSHANSKY K, 1989, J IMMUNOL, V143, P2525; LEARY AG, 1987, BLOOD, V70, P1343; MALEFYT RD, 1990, J IMMUNOL, V145, P2297; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NIEMEYER CM, 1989, BLOOD, V73, P945; NIMER SD, 1989, J IMMUNOL, V143, P2374; NIMER SD, 1989, ONCOGENE, V4, P671; NIMER SD, 1988, MOL CELL BIOL, V8, P1979, DOI 10.1128/MCB.8.5.1979; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SALAHUDDIN SZ, 1984, SCIENCE, V223, P703, DOI 10.1126/science.6320367; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHANNON MF, 1990, MOL CELL BIOL, V10, P2950, DOI 10.1128/MCB.10.6.2950; SHOEMAKER SG, 1990, P NATL ACAD SCI USA, V87, P9650, DOI 10.1073/pnas.87.24.9650; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; STANLEY E, 1985, EMBO J, V4, P2569, DOI 10.1002/j.1460-2075.1985.tb03972.x; SUGAMURA K, 1986, Cancer Reviews, V1, P96; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; UCHIYAMA T, 1985, J CLIN INVEST, V76, P446, DOI 10.1172/JCI111992; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0; YOSHIDA MI, 1982, P NATL ACAD SCI USA, V78, P2031	39	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1905	1911						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510934				2022-12-17	WOS:A1993LG68200023
J	HAURY, M; FREITAS, A; HERMITTE, V; COUTINHO, A; HIBNER, U				HAURY, M; FREITAS, A; HERMITTE, V; COUTINHO, A; HIBNER, U			THE PHYSIOLOGY OF BCL-2 EXPRESSION IN MURINE B-LYMPHOCYTES	ONCOGENE			English	Article							MONOCLONAL-ANTIBODY; POPULATION-DYNAMICS; GENE-EXPRESSION; TRANSGENIC MICE; CELL SURVIVAL; MOUSE; RECEPTORS; SELECTION; APOPTOSIS; PROTEIN	Quantitation of bcl-2 gene expression in B-lineage lymphocytes from normal adult mice allows the identification of four cell populations, characterized by successive three- to fivefold increases in average mRNA levels: bone marrow pre-B cells, bone marrow B cells, splenic B cells and long-lived splenic B cells. Thus, in line with previous experiments using overexpression systems, a correlation between longevity and levels of bcl-2 mRNA exists also in the physiology of B-lineage cells. The data are compatible with a quantitative regulation of expression, possibly determined at selective differentiation steps. No difference in bcl-2 expression was detected by comparing splenic IgD+ with IgD- B cells, while distinctly low levels of bcl-2 mRNA were scored in peritoneal CD5+ and CD5- B cells. These observations indicate that the reported persistence of peritoneal B cells may be controlled by mechanisms other than bcl-2 gene expression.	INST PASTEUR,CNRS,URA 359,UNITE IMMUNOBIOL,25 RUE DOCTEUR ROUX,F-75724 PARIS 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite			freitas, antonio/A-2482-2013	freitas, antonio/0000-0001-6392-7178; Hibner, Urszula/0000-0002-5520-7311; Haury, Matthias/0000-0002-1796-1479; Coutinho, Antonio/0000-0002-0857-9227				ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; ANDRADE L, 1989, EUR J IMMUNOL, V19, P1117, DOI 10.1002/eji.1830190623; BRUCE J, 1981, J IMMUNOL, V127, P2496; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; COFFMAN RL, 1981, J EXP MED, V153, P269, DOI 10.1084/jem.153.2.269; Coutinho A, 1992, Int Rev Immunol, V8, P173, DOI 10.3109/08830189209055572; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; Freitas A A, 1989, Int Immunol, V1, P342, DOI 10.1093/intimm/1.4.342; FREITAS AA, 1990, INT IMMUNOL, V2, P15, DOI 10.1093/intimm/2.1.15; FREITAS AA, 1986, IMMUNOL REV, V91, P5, DOI 10.1111/j.1600-065X.1986.tb01482.x; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; GURFINKEL N, 1987, EUR J IMMUNOL, V17, P567, DOI 10.1002/eji.1830170421; HAYAKAWA K, 1985, J EXP MED, V161, P1554, DOI 10.1084/jem.161.6.1554; HERZENBERG LA, 1986, IMMUNOL REV, V93, P81, DOI 10.1111/j.1600-065X.1986.tb01503.x; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; KINCADE PW, 1981, J IMMUNOL METHODS, V42, P17, DOI 10.1016/0022-1759(81)90220-9; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LEVY M, 1987, EUR J IMMUNOL, V17, P295, DOI 10.1002/eji.1830170223; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; MARCOS MAR, 1989, EUR J IMMUNOL, V19, P2031, DOI 10.1002/eji.1830191110; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NATHANSON SD, 1977, J IMMUNOL METHODS, V18, P225, DOI 10.1016/0022-1759(77)90176-4; NERGRINI G, 1987, CELL, V49, P455; NUNEZ G, 1991, NATURE, V353, P71, DOI 10.1038/353071a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OSMOND DG, 1986, IMMUNOL REV, V93, P103, DOI 10.1111/j.1600-065X.1986.tb01504.x; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; ROCHA B, 1983, J IMMUNOL, V131, P2158; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SPRENT J, 1973, CELL IMMUNOL, V7, P40, DOI 10.1016/0008-8749(73)90181-0; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Thomas-Vaslin V, 1989, Int Immunol, V1, P237, DOI 10.1093/intimm/1.3.237; THOMASVASLIN V, 1990, INT IMMUNOL, V2, P74; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; YEH TM, 1991, INT IMMUNOL, V3, P1329, DOI 10.1093/intimm/3.12.1329	40	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1257	1262						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479747				2022-12-17	WOS:A1993KY32800017
J	COOK, JL; WILSON, BA; WOLF, LA; WALKER, TA				COOK, JL; WILSON, BA; WOLF, LA; WALKER, TA			E1A-ONCOGENE EXPRESSION LEVEL IN SARCOMA-CELLS - AN INDEPENDENT DETERMINANT OF CYTOLYTIC SUSCEPTIBILITY AND TUMOR REJECTION	ONCOGENE			English	Article							NATURAL-KILLER CELLS; ADENOVIRUS-TRANSFORMED CELLS; CELLULAR GENE-EXPRESSION; E1A ONCOGENE; ACTIVATED MACROPHAGES; MONOCLONAL-ANTIBODIES; SIMIAN VIRUS-40; NK SENSITIVITY; H-RAS; C-MYC	Ad2/5 E1A oncogene expression induces cytolytic susceptibility of rodent cells to natural killer lymphocytes. To determine whether the requisite thresholds of E1A oncoprotein expression differ for induction of cytolytic susceptibility as compared with other. E1A-related activities, sarcoma cells expressing low or normal levels of E1A oncoproteins were compared for differences in morphological transformation, transactivation of viral genes, cytolytic susceptibility and tumorigenicity. Low-level E1A expression transformed sarcoma cells and transactivated the Ad5 E2A gene but did not induce the increased cytolytic susceptibility observed with normal levels of E1A expression. Furthermore, low-level E1A expressers retained the tumorigenicity of parental cells, whereas normal-level expressers were non-tumorigenic in hosts with intact natural killer (NK)-cell responses. In contrast to E1A, E1B oncogene expression caused no changes in morphological, cytolytic or tumorigenic phenotypes in these sarcoma cells. These data define an expression threshold for E1A-induced cytolytic susceptibility and associated NK-cell-dependent tumor rejection. The results suggest that the cellular mechanisms involved in E1A induction of cytolytic susceptibility differ from those involved in E1A-mediated cellular transformation and viral gene transactivation.	UNIV COLORADO, HLTH SCI CTR, DEPT MED, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT MICROBIOL IMMUNOL, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	COOK, JL (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, DEPT MED, ROBERT W LISLE RES LAB IMMUNOL & TUMOR CELL BIOL, DENVER, CO 80206 USA.				NCI NIH HHS [CA 41387] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA041387, R01CA041387] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SK, 1989, MOL IMMUNOL, V26, P985, DOI 10.1016/0161-5890(89)90117-X; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BRANTON PE, 1984, BIOCHIM BIOPHYS ACTA, V780, P67, DOI 10.1016/0304-419X(84)90007-6; BRUNET LJ, 1988, MOL CELL BIOL, V8, P4799, DOI 10.1128/MCB.8.11.4799; CHAMBERS WH, 1989, J EXP MED, V169, P1373, DOI 10.1084/jem.169.4.1373; COOK JL, 1984, SCIENCE, V224, P612, DOI 10.1126/science.6710160; COOK JL, 1982, INT J CANCER, V30, P795, DOI 10.1002/ijc.2910300619; COOK JL, 1986, P NATL ACAD SCI USA, V83, P6965, DOI 10.1073/pnas.83.18.6965; COOK JL, 1983, P NATL ACAD SCI-BIOL, V80, P5995, DOI 10.1073/pnas.80.19.5995; COOK JL, 1979, CANCER RES, V39, P1455; COOK JL, 1989, J VIROL, V63, P3408, DOI 10.1128/JVI.63.8.3408-3415.1989; COOK JL, 1989, J IMMUNOL, V142, P4527; COOK JL, 1987, J VIROL, V61, P2155, DOI 10.1128/JVI.61.7.2155-2161.1987; COOK JL, 1987, J VIROL, V61, P3510, DOI 10.1128/JVI.61.11.3510-3520.1987; EDDY BE, 1964, PROG EXP TUMOR RES, V4, P1; FRESA KL, 1987, J IMMUNOL, V138, P1215; GOTLIEBSTEMATSK.T, 1964, VIROLOGY, V22, P314, DOI 10.1016/0042-6822(64)90022-4; GREENBERG AH, 1987, CELL IMMUNOL, V109, P444, DOI 10.1016/0008-8749(87)90327-3; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HERBST RS, 1988, J VIROL, V62, P4634, DOI 10.1128/JVI.62.12.4634-4643.1988; HERRMANN CH, 1989, MOL CELL BIOL, V9, P5412, DOI 10.1128/MCB.9.12.5412; HITT MM, 1990, VIROLOGY, V179, P667, DOI 10.1016/0042-6822(90)90134-D; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JOHNSON PW, 1987, J IMMUNOL, V138, P3996; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KARBER G, 1931, ARCH EXP PATHOL PH, V162, P480, DOI DOI 10.1007/BF01863914; KELEKAR A, 1987, MOL CELL BIOL, V7, P3899, DOI 10.1128/MCB.7.11.3899; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; LABOW MA, 1990, MOL CELL BIOL, V10, P3343, DOI 10.1128/MCB.10.7.3343; LANZA LA, 1986, J IMMUNOL, V137, P2716; LEWIS AM, 1985, SCIENCE, V227, P15, DOI 10.1126/science.3843807; LEWIS AM, 1984, CURR TOP MICROBIOL, V110, P1; LEWIS ED, 1985, NATURE, V317, P172, DOI 10.1038/317172a0; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; ORTALDO JR, 1986, PATHOL IMMUNOPATH R, V5, P203, DOI 10.1159/000157014; PHILLIPS B, 1991, J VIROL, V65, P5680, DOI 10.1128/JVI.65.11.5680-5692.1991; PILDER S, 1984, J VIROL, V52, P664, DOI 10.1128/JVI.52.2.664-671.1984; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; POPE JH, 1964, J EXP MED, V120, P121, DOI 10.1084/jem.120.2.121; REICH NC, 1983, VIROLOGY, V128, P480, DOI 10.1016/0042-6822(83)90274-X; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RULEY HE, 1985, CANCER CELLS 3 GROWT, P257; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; SATYABHAMA S, 1988, DNA-J MOLEC CELL BIO, V7, P203, DOI 10.1089/dna.1988.7.203; SHALLOWAY D, 1987, MOL CELL BIOL, V7, P3582, DOI 10.1128/MCB.7.10.3582; SHEIL JM, 1984, J IMMUNOL, V132, P1578; SHENK T, 1991, ADV CANCER RES, V57, P47; STEIN R, 1984, MOL CELL BIOL, V4, P2792, DOI 10.1128/MCB.4.12.2792; TRIMBLE WS, 1986, NATURE, V321, P782, DOI 10.1038/321782a0; VANDENELSEN P, 1983, VIROLOGY, V131, P242, DOI 10.1016/0042-6822(83)90549-4; VANDENELSEN P, 1983, VIROLOGY, V128, P377; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; VERSTEEG R, 1989, J IMMUNOL, V143, P4331; WALKER TA, 1991, P NATL ACAD SCI USA, V88, P6491, DOI 10.1073/pnas.88.15.6491; ZAJCHOWSKI DA, 1988, J VIROL, V62, P1762, DOI 10.1128/JVI.62.5.1762-1767.1988; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	61	20	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1993	8	3					625	635						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437846				2022-12-17	WOS:A1993KN00800013
J	CHEN, JH; JEHA, S; OKA, T				CHEN, JH; JEHA, S; OKA, T			NEGATIVE REGULATORY ELEMENTS IN THE HUMAN ETS1 GENE PROMOTER	ONCOGENE			English	Article							LONG TERMINAL REPEAT; ONCOGENE C-ETS; DNA-BINDING; LOCALIZATION; EXPRESSION; PROTEIN; CELLS; IDENTIFICATION; THYMOCYTES; SEQUENCE	The human ETS1 gene promoter contains binding sites for transcription factors AP1, AP2 and ETS. These factors have been previously shown to be positive regulators for the expression of the ETS1 gene. In our previous report it was inferred that the ETS1 gene promoter also contains negative regulatory elements that might balance and prevent the overexpression of the ETS1 gene product. The studies reported here show that the ETS1 gene promoter also contains binding site motifs for transcription factors PEA3 and OCT. By subjecting deletion constructs of the ETS1 gene promoter to functional analysis, two negative regulatory elements (NREs) were located: NRE1 was mapped to 230 nt at the 5' end of the promoter, and NRE2 was mapped to 350 nt located between the second OCT motif and a 120-base sequence downstream from the SacI site. These NREs can also reduce the activity of a heterogeneous promoter. Gel mobility-shift assays showed that nuclear extracts from B-lymphoid (Daudi), T-lymphoid (HPB) and erthyromyeloid (K562) cells each form one major and several minor complexes with NRE1 and NRE2. The nuclear extract from promyelocytic (HL60) cells does not form complexes with either NRE1 or NRE2. The identification of NREs in the ETS1 gene promoter suggests that these elements play an important role in regulating the ETS1 gene expression in hematopoietic cells.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOLEC GENET,HOUSTON,TX 77030; ASAHIKAWA MED COLL,DEPT PEDIAT,ASAHIKAWA 07811,JAPAN	University of Texas System; UTMD Anderson Cancer Center; Asahikawa Medical College	CHEN, JH (corresponding author), UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT EXPTL PHYS,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.							BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; DETAISNE C, 1984, NATURE, V310, P581, DOI 10.1038/310581a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISHER RJ, 1991, ONCOGENE, V6, P2249; FUJIWARA S, 1988, ONCOGENE, V2, P99; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JORCYK CL, 1991, ONCOGENE, V6, P523; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OKA T, 1991, ONCOGENE, V6, P2077; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; SACCHI N, 1988, LEUKEMIA, V2, P12; STRONG RC, 1985, BLOOD, V65, P21; SVAREN J, 1987, NUCLEIC ACIDS RES, V21, P8739; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOOD WM, 1989, J BIOL CHEM, V264, P14840; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	27	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					133	139						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423991				2022-12-17	WOS:A1993KN00500016
J	REITH, AD; ELLIS, C; MAROC, N; PAWSON, T; BERNSTEIN, A; DUBREUIL, P				REITH, AD; ELLIS, C; MAROC, N; PAWSON, T; BERNSTEIN, A; DUBREUIL, P			W-MUTANT FORMS OF THE FMS RECEPTOR TYROSINE KINASE ACT IN A DOMINANT MANNER TO SUPPRESS CSF-1 DEPENDENT CELLULAR-TRANSFORMATION	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTOR; C-KIT RECEPTOR; POLYMERASE CHAIN-REACTION; PROTO-ONCOGENE; INSULIN-RECEPTOR; SIGNAL TRANSDUCTION; MOUSE DEVELOPMENT; PHOSPHATIDYLINOSITOL KINASE; PHOSPHOTYROSINE ANTIBODY	Point mutations in highly conserved amino acid residues in the catalytic domain of the Kit receptor tyrosine kinase (RTK) are responsible for the coat color, fertility and hematopoietic defects of mice bearing mutant alleles at the dominant white-spotting (W) locus. The dominant nature of structural Kit mutations suggests that expression of other kinase-defective RTKs might also specificity interfere with signal transduction by normal receptors. To test this possibility, we have investigated the functional consequences of introducing analogous mutations into the RTK encoded by the c-fms proto-oncogene. Both Fms37 (glu582-->lys) and Fms42 (asp776-->asn) mutant proteins, corresponding to the strongly dominant-negative W37 and W42 mutant c-kit alleles, had undetectable in vitro kinase activity and were unable to transform Rat-2 fibroblasts in the presence of exogenous CSF-1. Moreover, expression of Fms37 or Fms42 proteins in Rat-2 cells specifically inhibited anchorage-independent growth mediated by the normal Fms receptor in the presence of exogenous CSF-1 and conferred a dominant loss of Fms-associated P13-kinase activity on CSF-1 stimulation. Mutant RTKs, bearing point substitutions identical to those present in mild or severe W mutants, may provide a generally applicable strategy for inducing dominant loss of function defects in RTK-mediated signalling pathways.	UNIV TORONTO, DEPT MED BIOPHYS, TORONTO M5S 1A1, ONTARIO, CANADA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ONTARIO, CANADA; INST CANC RES, CHESTER BEATTY LABS, LONDON SW3 6JB, ENGLAND; INSERM, UNITE 119, F-13009 MARSEILLE, FRANCE	University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Institut National de la Sante et de la Recherche Medicale (Inserm)	REITH, AD (corresponding author), UCL, MIDDLESEX HOSP, LUDWIG INST CANC RES, 91 RIDING HOUSE ST, LONDON W1P 8BT, ENGLAND.		Pawson, Tony J/E-4578-2013; Dubreuil, Patrice/V-4816-2019; dubreuil, patrice/F-5346-2011	Dubreuil, Patrice/0000-0003-1155-1150; dubreuil, patrice/0000-0003-1155-1150; Maroc, Nicolas/0000-0001-7285-509X				ADAMSON ED, 1987, DEVELOPMENT, V99, P449; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ARCECI RJ, 1989, P NATL ACAD SCI USA, V86, P8818, DOI 10.1073/pnas.86.22.8818; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BOULTER CA, 1988, ONCOGENE, V2, P207; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DUBREUIL P, 1991, P NATL ACAD SCI USA, V88, P2341, DOI 10.1073/pnas.88.6.2341; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GEISSLER EN, 1981, GENETICS, V97, P337; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KACSER H, 1981, GENETICS, V97, P639; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLINKHAMER MP, 1989, EMBO J, V8, P2503, DOI 10.1002/j.1460-2075.1989.tb08387.x; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LETWIN K, 1988, ONCOGENE, V3, P621; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MARKS SC, 1976, J HERED, V67, P11, DOI 10.1093/oxfordjournals.jhered.a108657; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MERCOLA M, 1990, DEV BIOL, V138, P114, DOI 10.1016/0012-1606(90)90181-H; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MORAN MF, 1988, ONCOGENE, V3, P665; MOTRO B, 1991, DEVELOPMENT, V113, P1207; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; OHTSUKA M, 1990, MOL CELL BIOL, V10, P1664, DOI 10.1128/MCB.10.4.1664; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; POLLARD JW, 1991, DEV BIOL, V148, P273, DOI 10.1016/0012-1606(91)90336-2; RAY P, 1991, GENE DEV, V5, P2265, DOI 10.1101/gad.5.12a.2265; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REGENSTREIF LJ, 1989, DEV BIOL, V133, P284, DOI 10.1016/0012-1606(89)90319-9; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, GENE DEV, V5, P1115, DOI 10.1101/gad.5.7.1115; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; REITH AD, 1991, GENOME ANAL, V3, P105; ROHRSCHNEIDER LR, 1989, ONCOGENE, V4, P1015; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SHERR CJ, 1990, BLOOD, V75, P1; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; TAIRA M, 1989, SCIENCE, V245, P63, DOI 10.1126/science.2544997; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	87	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1993	8	1					45	53						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380922				2022-12-17	WOS:A1993KN00500006
J	NEGRINI, M; CASTAGNOLI, A; SABBIONI, S; RECANATINI, E; GIOVANNINI, G; POSSATI, L; STANBRIDGE, EJ; NENCI, I; BARBANTIBRODANO, G				NEGRINI, M; CASTAGNOLI, A; SABBIONI, S; RECANATINI, E; GIOVANNINI, G; POSSATI, L; STANBRIDGE, EJ; NENCI, I; BARBANTIBRODANO, G			SUPPRESSION OF TUMORIGENESIS BY THE BREAST-CANCER CELL-LINE MCF-7 FOLLOWING TRANSFER OF A NORMAL HUMAN CHROMOSOME-11	ONCOGENE			English	Article							MESSENGER RIBONUCLEIC-ACID; WILMS TUMOR; RETINOBLASTOMA GENE; RECEPTOR ASSAYS; CARCINOMA-CELLS; PROTO-ONCOGENE; TRANSFER XMMCT; ARM DELETIONS; HUMAN HOMOLOG; ALLELE LOSS	Breast cancer development is associated with several genetic abnormalities. Loss of heterozygosity in the short arm of chromosome 11 has been observed in 30% of tumors. We found homozygosity at five chromosome 11 polymorphic loci in genomic DNA of the MCF-7 breast carcinoma cell line, suggesting a possible loss of one chromosome 11. We have studied the transformed and tumorigenic phenotypes of MCF-7 cells following introduction of a normal human chromosome 11 via microcell fusion. MCF-7/H11 cell hybrids, containing chromosome 11, showed in vitro characteristics similar to the parental cell line. However, tumorigenicity in athymic mice was completely suppressed. Since tumor formation by MCF-7 cells is estrogen dependent, we have analysed the expression of the estrogen receptor and of the estrogen-activated gene pS2. No difference was detected between the parental MCF-7 cells and the derived chromosome 11 cell hybrids, indicating that the mechanism of MCF-7 tumor suppression by chromosome 11-associated functions does not directly involve the estrogen/estrogen receptor molecular pathway.	UNIV ANCONA,INST BIOMED SCI,I-60131 MONTE DAGO,ITALY; UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717; UNIV FERRARA,INST MICROBIOL,I-44100 FERRARA,ITALY; UNIV FERRARA,INST RADIOL,I-44100 FERRARA,ITALY; UNIV FERRARA,INST PATHOL ANAT & HISTOL,I-44100 FERRARA,ITALY	Marche Polytechnic University; University of California System; University of California Irvine; University of Ferrara; University of Ferrara; University of Ferrara	NEGRINI, M (corresponding author), UNIV FERRARA,INTERDEPT CTR CANC RES,VIA LUIGI BORSARI 46,I-44100 FERRARA,ITALY.		Negrini, Massimo/J-2377-2016	Negrini, Massimo/0000-0002-0007-1920	PHS HHS [19104] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BARKER D, 1984, AM J HUM GENET, V36, P1159; BARTEK J, 1990, ONCOGENE, V5, P893; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BERGER SL, 1979, BIOCHEMISTRY-US, V18, P5143, DOI 10.1021/bi00590a018; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DEVILEE P, 1991, ONCOGENE, V6, P1705; DEVILEE P, 1991, ONCOGENE, V6, P311; DICKSON RB, 1987, P NATL ACAD SCI USA, V84, P837, DOI 10.1073/pnas.84.3.837; DICKSON RB, 1986, SCIENCE, V232, P1540, DOI 10.1126/science.3715461; DOWDY SF, 1990, GENE CHROMOSOME CANC, V2, P318, DOI 10.1002/gcc.2870020410; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FOURNIER REK, 1977, P NATL ACAD SCI USA, V74, P319, DOI 10.1073/pnas.74.1.319; GENDLER SJ, 1990, INT J CANCER, V45, P431, DOI 10.1002/ijc.2910450309; GENUARDI M, 1989, AM J HUM GENET, V45, P73; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KOENDERS A, 1983, EUR J CANCER CLIN ON, V19, P1221, DOI 10.1016/0277-5379(83)90199-2; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330a0; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KUGOH HM, 1990, ONCOGENE, V5, P1637; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE JH, 1989, CANCER RES, V49, P1220; LOH WE, 1992, P NATL ACAD SCI USA, V89, P1755, DOI 10.1073/pnas.89.5.1755; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; LUNDBERG C, 1987, P NATL ACAD SCI USA, V84, P2372, DOI 10.1073/pnas.84.8.2372; MACKAY J, 1988, LANCET, V2, P1384; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MCGUIRE WL, 1977, CANCER RES, V37, P637; MISRA BC, 1989, AM J HUM GENET, V45, P565; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OSHIMURA M, 1990, J CELL BIOCHEM, V42, P135, DOI 10.1002/jcb.240420304; PROSSER J, 1990, ONCOGENE, V5, P1573; QUAN F, 1986, NUCLEIC ACIDS RES, V14, P5321, DOI 10.1093/nar/14.13.5321; READ LD, 1989, MOL ENDOCRINOL, V3, P295, DOI 10.1210/mend-3-2-295; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SACEDA M, 1989, MOL ENDOCRINOL, V3, P1782, DOI 10.1210/mend-3-11-1782; Sambrook J., 1989, MOL CLONING LAB MANU; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; Saxon P J, 1987, Methods Enzymol, V151, P313, DOI 10.1016/S0076-6879(87)51026-6; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMIDTKE J, 1984, HUM GENET, V67, P428, DOI 10.1007/BF00291404; SCRABLE HJ, 1987, NATURE, V329, P645, DOI 10.1038/329645a0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOULE HD, 1980, CANCER LETT, V10, P177, DOI 10.1016/0304-3835(80)90042-7; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; THEILLET C, 1990, ONCOGENE, V5, P147; THEILLET C, 1989, ONCOGENE, V4, P915; THEILLET C, 1986, CANCER RES, V46, P4776; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; VARLEY JM, 1988, ONCOGENE, V3, P87; VARLEY JM, 1989, ONCOGENE, V4, P725; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WILLIAMS BP, 1988, ONCOGENE, V3, P345; YEE D, 1988, CANCER RES, V48, P6691; ZHOU DJ, 1988, ONCOGENE, V2, P279	70	20	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2013	2018						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408142				2022-12-17	WOS:A1992JP42400015
J	CHISHOLM, O; STAPLETON, P; SYMONDS, G				CHISHOLM, O; STAPLETON, P; SYMONDS, G			CONSTITUTIVE EXPRESSION OF EXOGENOUS MYC IN MYELOMONOCYTIC CELLS - ACQUISITION OF A MORE TRANSFORMED PHENOTYPE AND INHIBITION OF DIFFERENTIATION INDUCTION	ONCOGENE			English	Article							INDUCED TERMINAL DIFFERENTIATION; HUMAN MONOCYTIC DIFFERENTIATION; PROMYELOCYTIC LEUKEMIA-CELLS; MURINE ERYTHROLEUKEMIA-CELLS; COLONY-STIMULATING FACTORS; ONCOGENE-C-MYC; V-MYC; PROTO-ONCOGENE; MYELOID-LEUKEMIA; MULTISTEP CARCINOGENESIS	The effects of deregulated expression of the human c-myc and MC29 v-myc oncogenes have been examined in a murine myelomonocytic cell line J774 (c-myc) and in a variety of myelomonocytic cell lines of different degrees of maturity generated from primary hematopoietic tissue (v-myc). Introduction of a Moloney murine leukemia virus long terminal repeat (LTR) c-myc construct into J774 cells resulted in constitutive expression of the exogenous myc gene and a concomitant increase in the degree of transformation and tumorigenicity of the cells. In addition, constitutive expression of exogenous inhibited induced differentiation of these cells by a variety of treatments including addition to the medium of lipopolysaccharide (LPS) or the phorbol ester 12-O-tetradecanoyl phorbol 13-acetate (TPA) as well as complete withdrawal of serum from the medium. The degree, of increased transformation, tumorigenicity and inhibition of terminal differentiation was dependent upon the level of exogenous myc expression. For the v-myc-generated myelomonocytic cell lines, introduction of v-myc resulted in a high degree of transformation and, irrespective of the differentiation status of the cells, a block of induced differentiation. These results indicate that the level of constitutive myc expression can affect the transformed phenotype, tumorigenicity and differentiation inducibility of myelomonocytic cells.	CHILDRENS MED RES FDN, LEUKEMIA RES & VIRAL PATHOL UNIT, CAMPERDOWN, NSW 2050, AUSTRALIA; RW JOHNSON PHARMACEUT RES INST SYDNEY, EDGECLIFF, NSW 2027, AUSTRALIA	Children's Medical Research Institute - Australia			Chisholm, Orin/L-4206-2016	Chisholm, Orin/0000-0002-9749-4160				ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BACON TA, 1991, ONCOGENE RES, V6, P21; BAUMBACH WR, 1987, MOL CELL BIOL, V7, P664, DOI 10.1128/MCB.7.2.664; BERLINGIERI MT, 1988, MOL CELL BIOL, V8, P2261, DOI 10.1128/MCB.8.5.2261; BIRCHENALLROBERTS MC, 1989, ONCOGENE, V4, P731; BLOOM BR, 1978, FED PROC, V37, P2765; BONHAM L, 1991, ONCOGENE, V6, P1073; BONHAM L, 1992, IN PRESS ONCOGENE; BRIGHTMAN BK, 1986, J VIROL, V60, P68, DOI 10.1128/JVI.60.1.68-81.1986; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; CHISHOLM O, 1988, NUCLEIC ACIDS RES, V16, P2352, DOI 10.1093/nar/16.5.2352; CHISHOLM O, 1992, INT J CANCER, V51, P149, DOI 10.1002/ijc.2910510126; Clark G., 1981, STAINING PROCEDURES; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COPPOLA JA, 1989, MOL CELL BIOL, V9, P1714, DOI 10.1128/MCB.9.4.1714; CORY S, 1987, ONCOGENE RES, V1, P61; DEXTER TM, 1979, NATURE, V277, P471, DOI 10.1038/277471a0; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; ERBA HP, 1988, MOL CELL BIOL, V8, P1775, DOI 10.1128/MCB.8.4.1775; FALCONE G, 1987, EXP CELL RES, V168, P273, DOI 10.1016/0014-4827(87)90435-6; FILMUS J, 1985, CANCER RES, V45, P822; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GREEN SM, 1989, ONCOGENE, V4, P737; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; ICHIKAWA Y, 1966, P NATL ACAD SCI USA, V56, P488, DOI 10.1073/pnas.56.2.488; JAFFE BD, 1988, ONCOGENE, V2, P167; JUNGI TW, 1986, IMMUNOLOGY, V58, P131; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KOEFFLER HP, 1983, BLOOD, V62, P709; KOREN HS, 1975, J IMMUNOL, V114, P894; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LOTEM J, 1977, J CELL PHYSIOL, V92, P97, DOI 10.1002/jcp.1040920112; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARTIN P, 1986, EMBO J, V5, P1529, DOI 10.1002/j.1460-2075.1986.tb04393.x; MARTINSSON T, 1988, ONCOGENE, V3, P437; MATSUHASHI C, 1981, MEN EKI GAKU JIKKEN; MCCAIRNS E, 1983, MOL CELL BIOCHEM, V56, P165; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; METCALF D, 1986, BLOOD, V67, P257; Metcalf D, 1984, CLONAL CULTURE HEMOP; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; OHNO H, 1988, CANCER RES, V48, P4959; PFEIFER S, 1980, INT J CANCER, V25, P235, DOI 10.1002/ijc.2910250211; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RABBITTS TH, 1985, TRENDS GENET, V1, P327, DOI 10.1016/0168-9525(85)90127-1; RALPH P, 1975, J IMMUNOL, V114, P898; RALPH P, 1977, CANCER RES, V37, P546; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; ROTHBERG PG, 1984, MOL CELL BIOL, V4, P1096, DOI 10.1128/MCB.4.6.1096; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831; SACHS L, 1978, NATURE, V274, P535, DOI 10.1038/274535a0; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SCHNEIDER MD, 1987, MOL CELL BIOL, V7, P1973, DOI 10.1128/MCB.7.5.1973; SEGAL S, 1988, MOL IMMUNOL, V25, P1129, DOI 10.1016/0161-5890(88)90147-2; SHIROKI K, 1986, MOL CELL BIOL, V6, P4379, DOI 10.1128/MCB.6.12.4379; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STAPLETON P, 1991, ONCOGENE, V6, P807; STEWART CC, 1984, MONONUCLEAR PHAGOCYT; SYMONDS G, 1982, EMBO J, V1, P1343, DOI 10.1002/j.1460-2075.1982.tb01320.x; SYMONDS G, 1989, ONCOGENE, V4, P285; SYMONDS G, 1986, MOL CELL BIOL, V6, P1796, DOI 10.1128/MCB.6.5.1796; VENTURA MA, 1987, EXP CELL RES, V170, P290, DOI 10.1016/0014-4827(87)90307-7; WARNER NL, 1969, J NATL CANCER I, V43, P963; WEINBERG RA, 1989, CANCER RES, V49, P3713; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898; ZERLIN M, 1987, ONCOGENE, V1, P19	83	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1992	7	9					1827	1836						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501891				2022-12-17	WOS:A1992JJ37600019
J	TALMAGE, DA; LACKEY, RS				TALMAGE, DA; LACKEY, RS			RETINOIC ACID RECEPTOR-ALPHA SUPPRESSES POLYOMAVIRUS TRANSFORMATION AND C-FOS EXPRESSION IN RAT FIBROBLASTS	ONCOGENE			English	Article							MIDDLE-T-ANTIGEN; ACUTE PROMYELOCYTIC LEUKEMIA; DEPENDENT PROTEIN-KINASE; EMBRYONAL CARCINOMA-CELLS; MESSENGER-RNA; TRANSCRIPTION FACTOR; BINDING PROTEIN; NEGATIVE REGULATION; MOUSE FIBROBLASTS; GROWTH-FACTOR	To explore the molecular mechanisms by which retinoic acid inhibits oncogenic transformation, we have examined the effects of retinoic acid on the polyomavirus-induced transformation of rat fibroblasts. Treatment of rat F111 fibroblasts with high concentrations of retinoic acid (10(-6)M) partially inhibited the ability of polyomavirus to induce dense focus formation (50-70%). This effect was not secondary to a retinoic acid-dependent block of cellular proliferation. To address the role of the retinoic acid receptor (RAR-alpha) in mediating the transformation-inhibitory effect of retinoic acid, we have overexpressed either RAR-alpha or cellular retinoic acid-binding protein I (CRABP) cDNAs in F111 cells. Introduction of a CRABP I expression vector did not alter the responsiveness of F111 cells to retinoic acid in any detectable fashion. In contrast, overexpression of RAR-alpha increased the sensitivity of F111 cells to the transformation-inhibitory action of retinoic acid by 10- to 100-fold. At high concentrations, retinoic acid inhibited transformation of F111-RAR cells by polyomavirus by about 90%. At near physiological concentrations, retinoic acid inhibited transformation by 25-50% in F111-RAR cells but not in control cells. Retinoic acid did not inhibit either the synthesis of polyoma middle T (mT) or pp60c-src, the cellular target for mT action, or the formation of mT:pp60c-src:PI-3 kinase (phosphatidylinositol-3 kinase) complexes. Therefore, RAR-alpha was not acting as a negative regulator of expression of either the polyomavirus middle T oncogene or the cellular proto-oncogene. c-src. It seems likely that RAR-alpha regulates the expression of cellular genes whose products interact in some way with mT-regulated signaling pathways. leading to a ligand-dependent suppression of polyoma transformation. In addition, RAR-alpha overexpression selectively inhibits the serum-stimulated expression of the c-fos gene, but does not affect the expression of a number of other serum- and polyomavirus-inducible genes including c-jun, junB, c-myc and actin.			TALMAGE, DA (corresponding author), COLUMBIA UNIV,INST HUMAN NUTR,630 W 168 ST,NEW YORK,NY 10032, USA.			Talmage, David/0000-0003-4627-3007	NICHD NIH HHS [HD 26854] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD026854] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BENJAMIN TL, 1982, BIOCHIM BIOPHYS ACTA, V695, P69, DOI 10.1016/0304-419X(82)90018-X; BLUMHOFF R, 1990, SCIENCE, V250, P399; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; CHYTIL F, 1987, ANNU REV NUTR, V7, P321, DOI 10.1146/annurev.nu.07.070187.001541; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; FELLI MP, 1991, MOL CELL BIOL, V11, P4771, DOI 10.1128/MCB.11.9.4771; GARCEA RL, 1989, VIROLOGY, V168, P312, DOI 10.1016/0042-6822(89)90271-7; GEBERT JF, 1991, ONCOGENE, V6, P1858; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GIGUERE V, 1989, NATURE, V337, P566, DOI 10.1038/337566a0; GINSBERG D, 1991, ONCOGENE, V6, P669; GLENN GM, 1990, J VIROL, V64, P2193, DOI 10.1128/JVI.64.5.2193-2201.1990; GOODMAN DS, 1984, NEW ENGL J MED, V310, P1023, DOI 10.1056/NEJM198404193101605; GORGA FR, 1990, J VIROL, V64, P105, DOI 10.1128/JVI.64.1.105-112.1990; GROSS L, 1983, ONCOGENIC VIRUSES, P737; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KRAFT AS, 1983, J BIOL CHEM, V258, P9178; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LIPPMAN SM, 1987, CANCER TREAT REP, V71, P391; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MATHEWS JT, 1986, J VIROL, V58, P239; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; PLET A, 1982, J BIOL CHEM, V257, P889; RAJAN N, 1991, J LIPID RES, V32, P1195; RAMEH LE, 1991, ONCOGENE, V6, P1049; RAPTIS L, 1988, BIOCHEM BIOPH RES CO, V154, P306, DOI 10.1016/0006-291X(88)90685-7; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; STRICKLAND S, 1980, DEV BIOL, V78, P76, DOI 10.1016/0012-1606(80)90319-X; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TALMAGE DA, 1988, MOL CELL BIOL, V8, P2309, DOI 10.1128/MCB.8.6.2309; TALMAGE DA, 1991, CELL GROWTH DIFFER, V2, P851; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WANG CY, 1990, MOL CELL BIOL, V10, P6781, DOI 10.1128/MCB.10.12.6781; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; YANG-YEN H-F, 1990, New Biologist, V2, P351; YOO WD, 1991, J VIROL, V65, P5391, DOI 10.1128/JVI.65.10.5391-5400.1991; ZULLO J, 1987, P NATL ACAD SCI USA, V84, P1210, DOI 10.1073/pnas.84.5.1210; [No title captured]	65	20	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1837	1845						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1380150				2022-12-17	WOS:A1992JJ37600020
J	KREIDER, BL; ROVERA, G				KREIDER, BL; ROVERA, G			THE IMMEDIATE EARLY GENE RESPONSE TO A DIFFERENTIATIVE STIMULUS IS DISRUPTED BY THE V-ABL AND V-RAS ONCOGENES	ONCOGENE			English	Article							SERUM GROWTH-FACTORS; PROGENITOR-CELL LINE; C-FOS; PROTO-ONCOGENE; GRANULOCYTIC DIFFERENTIATION; FACTORS ENCODES; 3T3 CELLS; JUN; INDUCTION; TRANSCRIPTION	The immediate early gene activation in response to a differentiative stimulus was investigated in the hematopoietic progenitor cell line 32DC13(G). A transient and coordinated increase in mRNA levels for c-fos, c-jun, jun-B, TIS-7/PC-4, TIS-8/egr-1, and TIS-11 occurred during the first 2 h of treatment with granulocyte colony stimulating factor (G-CSF), which ultimately induces the 32DC13(G) cells to terminally differentiate into neutrophilic granulocytes. This pattern of mRNA induction was disrupted by v-abl and v-ras, two oncogenes known to interfere with G-CSF-induced differentiation of 32DC13(G) cells. Induction of the mRNAs for c-jun and TIS-7/PC-4 was blocked by the presence of v-abl, whereas v-ras caused constitutive expression of c-fos mRNA and blocked the c-jun, jun-B and TIS-7/PC-4 mRNA response. Release of the differentiation block in the ras-transformed 32DC13(G) cells by co-treatment with retinoic acid and G-CSF partially restored the normal c-fos and c-jun mRNA induction pattern, suggesting that the proper activation of these genes may be important for myeloid differentiation.	WISTAR INST,36TH & SPRUCE ST,PHILADELPHIA,PA 19104	The Wistar Institute					NCI NIH HHS [CA 52009, CA 10815, CA 09171] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009171, P30CA010815, P01CA052009] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1988, ONCOGENE HDB; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; KHALILI K, 1984, J MOL BIOL, V180, P1007, DOI 10.1016/0022-2836(84)90268-7; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIM RW, 1989, MOL CELL BIOL, V9, P1790, DOI 10.1128/MCB.9.4.1790; MAVILIO F, 1989, ONCOGENE, V4, P301; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; OHTA M, 1989, PATHOL IMMUNOPATH R, V8, P1, DOI 10.1159/000157134; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; ROVERA G, 1987, ONCOGENE, V1, P29; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TIRONE F, 1989, P NATL ACAD SCI USA, V86, P2088, DOI 10.1073/pnas.86.6.2088; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213	34	20	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					135	140						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1371335				2022-12-17	WOS:A1992HC22700018
J	CHANG, Y; SPICER, DB; SONENSHEIN, GE				CHANG, Y; SPICER, DB; SONENSHEIN, GE			EFFECTS OF IL-3 ON PROMOTER USAGE, ATTENUATION AND ANTISENSE TRANSCRIPTION OF THE C-MYC ONCOGENE IN THE IL-3-DEPENDENT BA F3 EARLY PRE-B CELL-LINE	ONCOGENE			English	Article							INTERLEUKIN-3 DEPENDENCE; GENE; TRANSLOCATION; LYMPHOCYTES; ACTIVATION; ABROGATION; ELEMENT	The c-myc gene uses two major promoters, P1 and P2, for production of mRNA. In most proliferating normal cells, transcripts initiated from P2 predominate over the ones from P1. Furthermore, transcription of normal and translocated c-myc genes is bidirectional and overlapping. In this study, we have measured the effects of interleukin 3 (IL-3) deprivation and restimulation on c-myc promoter usage in the IL-3-dependent pre-B cell line Ba/F3. The rapid drop in c-myc mRNA expression observed in Ba/F3 cells upon IL-3 deprivation is reversible upon restimulation with interleukin. The use of P1 and P2 promoters, as judged by P1/P2 ratio, shifted from 0.2 in cells in exponential growth or in quiescence to 1.3 following IL-3 stimulation. This change was not due to selective instability of one of the two myc transcripts. In vitro nuclear run-on experiments indicated that IL-3 addition resulted in a large release of transcriptional attenuation, as well as a significant increase in transcriptional initiation. These results are consistent with the hypothesis that P1/P2 promoter usage is involved in the control of transcriptional elongation. Furthermore, deprivation of IL-3 resulted in a dramatic increase in antisense transcription, whereas little change was observed in the rate of initiation or elongation of c-myc mRNA precursors. This correlation suggests a negative role for antisense transcription in expression of c-myc mRNA levels in IL-3-deprived Ba/F3 cells.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,80 E CONCORD ST,BOSTON,MA 02118	Boston University					NATIONAL CANCER INSTITUTE [R01CA036355] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007429] Funding Source: NIH RePORTER; NCI NIH HHS [CA 36355] Funding Source: Medline; NHLBI NIH HHS [T32 HL07429] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROOME HE, 1987, MOL CELL BIOL, V7, P2988, DOI 10.1128/MCB.7.8.2988; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; DEAN M, 1983, NATURE, V305, P443, DOI 10.1038/305443a0; DEAN M, 1987, ONCOGENE RES, V1, P279; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALL DJ, 1990, ONCOGENE, V5, P47; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KINDY MS, 1987, MOL CELL BIOL, V7, P2857, DOI 10.1128/MCB.7.8.2857; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; Maniatis T., 1982, MOL CLONING; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; REICIN A, 1986, MOL CELL BIOL, V6, P4088, DOI 10.1128/MCB.6.11.4088; SPENCER C, 1990, IN PRESS ADV CANCER; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STEWART TA, 1984, SCIENCE, V226, P707, DOI 10.1126/science.6494906; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x	22	20	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					1979	1982						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1682864				2022-12-17	WOS:A1991GX11900006
J	NANUS, DM; LYNCH, SA; RAO, PH; ANDERSON, SM; JHANWAR, SC; ALBINO, AP				NANUS, DM; LYNCH, SA; RAO, PH; ANDERSON, SM; JHANWAR, SC; ALBINO, AP			TRANSFORMATION OF HUMAN KIDNEY PROXIMAL TUBULE CELLS BY A SRC-CONTAINING RETROVIRUS	ONCOGENE			English	Article							HUMAN RENAL-CANCER; MOUSE MONOCLONAL-ANTIBODIES; MURINE LEUKEMIA VIRUSES; AVIAN-SARCOMA VIRUSES; SURFACE ANTIGENS; NEOPLASTIC TRANSFORMATION; CARCINOMA; INVITRO; GAP; PROTEINS	Analysis of the cell-surface antigenic phenotypes of normal and malignant renal cells demonstrates that almost-equal-to 90% of cultured normal human kidney cells and virtually all renal cell carcinomas (RCC) derive from the proximal tubule (PT) cell of the nephron. In the present study, the v-src oncogene was introduced into cultured normal human PT cells, and the effects of the v-src-encoded protein (pp60v-src) on the biologic and genetic phenotype of these cells were determined. V-src-containing PT cells underwent a series of phenotypic changes characteristic of renal cells in vivo. These included (i) alterations in morphology, (ii) an increase in proliferative capacity, (iii) loss of contact inhibition, (iv) immortalization and (v) tumorigenicity. Moreover, v-src-infected PT cells developed non-random clonal karyotypic abnormalities which are commonly observed in RCCs, including a deletion of chromosomal region 3p14-21, one of the most frequent deletions observed in human renal tumors. These results indicate that pp60v-src can initiate a complex process leading to the transformation of PT cells. This process includes the induction of genetic instability. Finally, these data provide experimental evidence corroborating cytogenetic and molecular data that a deletion of genes on chromosome 3p is a critical event in the transformation of the human renal cell.	MEM SLOAN KETTERING CANC CTR, MAMMALIAN CELL TRANSFORMAT LAB, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, DEPT MED, DIV SOLID TUMOR ONCOL, GENITOURINARY ONCOL SERV, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, COLL MED, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, SOLID TUMOR IMMUNOL LAB, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, DEPT PATHOL, CYTOGENET SERV, NEW YORK, NY 10021 USA; SUNY STONY BROOK, DEPT PATHOL, STONY BROOK, NY 11794 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NCI NIH HHS [CA09149, R29 CA45241] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA045241] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINO AP, 1986, J EXP MED, V164, P1710, DOI 10.1084/jem.164.5.1710; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ANDERSON SM, 1983, J VIROL, V46, P594, DOI 10.1128/JVI.46.2.594-605.1983; ANGLARD P, 1991, CANCER RES, V51, P1071; BANDER NH, 1987, J UROLOGY, V137, P603, DOI 10.1016/S0022-5347(17)44154-1; BANDER NH, 1985, J UROLOGY, V133, P502, DOI 10.1016/S0022-5347(17)49041-0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERGERHEIM U, 1989, CANCER RES, V49, P1390; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CARDO CC, 1987, AM J PATHOL, V126, P269; CARROLL PR, 1987, CANCER GENET CYTOGEN, V26, P253, DOI 10.1016/0165-4608(87)90059-8; CHATTOPADHYAY SK, 1981, J VIROL, V39, P777, DOI 10.1128/JVI.39.3.777-791.1981; COLLARD JG, 1987, CANCER RES, V47, P6666; EBERT T, 1990, CANCER RES, V50, P5531; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FINSTAD CL, 1985, P NATL ACAD SCI USA, V82, P2955, DOI 10.1073/pnas.82.9.2955; FRADET Y, 1984, P NATL ACAD SCI-BIOL, V81, P224, DOI 10.1073/pnas.81.1.224; GOLDEN A, 1988, ONCOGENE HDB, P149; Harnden DG, 1985, INT SYSTEM HUMAN CYT; HARRIS CC, 1987, CANCER RES, V47, P1; HJELLE B, 1988, P NATL ACAD SCI USA, V85, P4355, DOI 10.1073/pnas.85.12.4355; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; KAWAI S, 1980, J VIROL, V34, P772, DOI 10.1128/JVI.34.3.772-776.1980; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1987, INT J CANCER, V40, P171, DOI 10.1002/ijc.2910400208; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MILES J, 1988, CANCER GENET CYTOGEN, V34, P135, DOI 10.1016/0165-4608(88)90180-X; NANUS DM, 1990, J UROLOGY, V143, P175, DOI 10.1016/S0022-5347(17)39905-6; NANUS DM, 1989, J EXP MED, V169, P953, DOI 10.1084/jem.169.3.953; OGAWA O, 1991, CANCER RES, V51, P949; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PINCUS T, 1975, VIROLOGY, V65, P333, DOI 10.1016/0042-6822(75)90039-2; PRESTI JC, 1991, CANCER RES, V51, P1544; RABOTTI G, 1987, J NATL CANCER I, V78, P817; RHIM JS, 1988, LEUKEMIA, V2, pS151; RHIM JS, 1989, ANTICANCER RES, V9, P1345; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; RHIM JS, 1990, CANCER RES, V50, pS5653; RHIM JS, 1982, P SOC EXP BIOL MED, V170, P350; RITZ J, 1982, LANCET, V2, P60; ROSEN N, 1986, J BIOL CHEM, V261, P3754; Sambrook J., 1989, MOL CLONING LAB MANU; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; UEDA R, 1979, J EXP MED, V150, P564, DOI 10.1084/jem.150.3.564; UEDA R, 1981, P NATL ACAD SCI-BIOL, V78, P5122, DOI 10.1073/pnas.78.8.5122; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALTER TA, 1989, CANCER GENET CYTOGEN, V43, P15, DOI 10.1016/0165-4608(89)90123-4; YOSHIDA MA, 1986, CANCER RES, V46, P2139; Zbar B, 1989, Important Adv Oncol, P41; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	54	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1991	6	11					2105	2111						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1945415				2022-12-17	WOS:A1991GX11900022
J	DHUT, S; CHAPLIN, T; YOUNG, BD				DHUT, S; CHAPLIN, T; YOUNG, BD			NORMAL C-ABL GENE PROTEIN - A NUCLEAR-COMPONENT	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASES; BCR; LOCALIZATION; ONCOGENE; PRODUCT; VIRUS; CELLS; PHOSPHORYLATION; ACTIVATION	The subcellular distribution of the c-abl and bcr-abl gene products from KG1A and K562 cells has been studied by two different techniques. Firstly, physical disruption followed by subcellular fractionation was used to demonstrate that normal c-abl (p145) was recovered from the cytosol and the nuclear fractions of KG1A cells. In contrast, bcr-abl products were recovered exclusively from the cytosol fraction of K562 cells. Secondly, indirect immunofluorescence was used to localize c-abl protein to the cytoplasm, nuclear membrane and infrequently to the nucleus of KG1A cells and bcr-abl protein to only the cytoplasm of K562 cells. Thus both the approaches indicate that there is a component of normal c-abl products which appears to be nuclear and this is not reflected in the distribution of the bcr-abl 210 kDa protein, which remains cytosolic.			DHUT, S (corresponding author), ST BARTHOLOMEWS HOSP, MED ONCOL LAB, IMPERIAL CANC RES FUND, LONDON EC1 7BA, ENGLAND.							BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BERNARDS A, 1987, MOL CELL BIOL, V7, P3231, DOI 10.1128/MCB.7.9.3231; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; DHUT S, 1988, ONCOGENE, V3, P561; DHUT S, 1991, LEUKEMIA, V5, P49; DHUT S, 1990, LEUKEMIA, V4, P745; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FAINSTEIN E, 1989, ONCOGENE, V4, P1477; FOULKES JG, 1985, J BIOL CHEM, V260, P8070; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HUNTER T, 1986, ENZYMES, V17, P191; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KITAZAWA S, 1990, MED ONCOL TUMOR PHAR, V7, P35; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; PAWSON T, 1988, ONCOGENE, V3, P491; Potts W M, 1988, Oncogene Res, V3, P343; REDDY EP, 1988, ONCOGENE HDB, P3; ROHRSCHNEIDER LR, 1979, CELL, V16, P11, DOI 10.1016/0092-8674(79)90183-1; ROHRSCHNEIDER LR, 1984, J VIROL, V51, P547, DOI 10.1128/JVI.51.2.547-552.1984; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WALKER LC, 1987, NATURE, V329, P851, DOI 10.1038/329851a0; WATANABE SM, 1984, J VIROL, V51, P620, DOI 10.1128/JVI.51.3.620-627.1984; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490	31	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1991	6	8					1459	1464						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886716				2022-12-17	WOS:A1991GX27200024
J	KRUEGER, J; ZHAO, YH; MURPHY, D; SUDOL, M				KRUEGER, J; ZHAO, YH; MURPHY, D; SUDOL, M			DIFFERENTIAL EXPRESSION OF P62C-YES IN NORMAL, HYPERPLASTIC AND NEOPLASTIC HUMAN EPIDERMIS	ONCOGENE			English	Article							AVIAN-SARCOMA VIRUS; YES PROTO-ONCOGENE; HUMAN KERATINOCYTES; TRANSFORMING GENE; CELLULAR-YES; C-YES; RECEPTOR; SRC; PRODUCT; KINASE	The protein product of the c-yes proto-oncogene, p62c-yes, is highly expressed in a variety of mammalian cell types, including neurons, spermatozoa, platelets, and epithelial cells. In order to understand the function of p62c-yes in epithelial cells, the expression and localization of p62c-yes was studied in cultured human epidermal keratinocytes and in normal, hyperplastic, and neoplastic human epidermis. Human keratinocytes in culture produce a single 4 kb c-yes mRNA and a 62 kd protein product, p62c-yes, which is active as a protein tyrosine kinase. Using affinity-purified antibodies generated to the aminoterminus of the human c-yes protein, the expression of p62c-yes was localized to keratinocytes in the basal epidermal layer of normal neonatal and adult epidermis. There was a marked reduction in expression of p62c-yes by suprabasal keratinocytes undergoing progressive differentiation. By immunofluorescence microscopy, p62c-yes was localized to the plasma membrane and to a perinuclear cytoplasmic area in cultured keratinocytes. The apparent association of p62c-yes with plasma membranes was particularly evident in suprabasal keratinocytes from hyperplastic epidermis. Neoplastic keratinocytes in basal cell carcinomas showed a marked reduction in p62c-yes expression compared to normal basal keratinocytes in epidermis or to proliferating cultured keratinocytes. Thus the expression of p62c-yes by one epithelial cell type, the keratinocyte, is altered by cellular differentiation and neoplastic transformation. Keratinocytes provide a normal epithelial cell model in which the biochemical function of p62c-yes can be studied.	ROCKEFELLER UNIV,MOLEC ONCOL LAB,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,NEW YORK,NY 10021	Rockefeller University; Cornell University	KRUEGER, J (corresponding author), ROCKEFELLER UNIV,INVESTIGAT DERMATOL LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.				NCRR NIH HHS [M01-RR00102, RR07065-23] Funding Source: Medline; NIAMS NIH HHS [AR07525] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007525] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BASSETSEGUIN EC, 1990, J INVEST DERMATOL, V94, P4182; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DAMM D, 1990, J INVEST DERMATOL, V94, P517; FILVAROFF E, 1990, MOL CELL BIOL, V10, P1164, DOI 10.1128/MCB.10.3.1164; GESSLER M, 1984, BIOSCIENCE REP, V4, P757, DOI 10.1007/BF01128817; GHYSDAEL J, 1981, P NATL ACAD SCI-BIOL, V78, P2611, DOI 10.1073/pnas.78.4.2611; GOTTLIEB AB, 1988, J EXP MED, V167, P670, DOI 10.1084/jem.167.2.670; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KAWAI S, 1980, P NATL ACAD SCI-BIOL, V77, P6199, DOI 10.1073/pnas.77.10.6199; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; KRUEGER JG, 1980, P NATL ACAD SCI-BIOL, V77, P4142, DOI 10.1073/pnas.77.7.4142; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Lever W. F., 1990, HISTOPATHOLOGY SKIN; MAGUIRE HC, 1989, J INVEST DERMATOL, V92, P786, DOI 10.1111/1523-1747.ep12696796; MANSBRIDGE JN, 1987, J INVEST DERMATOL, V89, P253, DOI 10.1111/1523-1747.ep12471216; MURPHY D, 1990, J INVEST DERMATOL, V94, P557; NANNEY LB, 1986, J INVEST DERMATOL, V86, P260, DOI 10.1111/1523-1747.ep12285389; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHIBUYA M, 1982, J VIROL, V42, P143, DOI 10.1128/JVI.42.1.143-152.1982; SHIPLEY GD, 1987, ARCH DERMATOL, V123, P1541; SUDOL M, 1989, J NEUROSCI RES, V24, P1, DOI 10.1002/jnr.490240103; SUDOL M, 1988, ONCOGENE RES, V2, P345; SUDOL M, 1988, NUCLEIC ACIDS RES, V16, P9876, DOI 10.1093/nar/16.20.9876; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; SUN TT, 1985, ANN NY ACAD SCI, V455, P307, DOI 10.1111/j.1749-6632.1985.tb50419.x; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; YOSHIDA MC, 1985, JPN J CANCER RES, V76, P559; ZHANG X, 1989, ONCOGENE, V4, P99; ZHAO YH, 1990, ONCOGENE, V5, P1629	30	20	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					933	940						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	2067846				2022-12-17	WOS:A1991GU62200007
J	GALIEN, R; MERCIER, G; GARCETTE, M; EMANOILRAVIER, R				GALIEN, R; MERCIER, G; GARCETTE, M; EMANOILRAVIER, R			RAS ONCOGENE ACTIVATES THE INTRACISTERNAL A PARTICLE LONG TERMINAL REPEAT PROMOTER THROUGH A CAMP RESPONSE ELEMENT	ONCOGENE			English	Article							LEUCINE ZIPPER PROTEINS; CYCLIC-AMP; ADENYLATE-CYCLASE; DIACYLGLYCEROL PRODUCTION; TRANSCRIPTION FACTOR; POSSIBLE INVOLVEMENT; GENE-TRANSCRIPTION; JUN PROTEINS; DNA ELEMENTS; CROSS-TALK	To understand the mechanism responsible for the high expression of Intracisternal A Particles (IAP) in murine cells transformed by the Kirsten Mouse Sarcoma Virus (Ki-MSV), we have investigated the effect of p21ras on IAP transcription. By transient cotransfections of IAP LTR-CAT plasmids with v-Ki-ras and c-Ki-ras expression vectors, we have found that p21v-Ki-ras, and the p21c-Ki-ras to a lesser extent, stimulate the promoter activity of the 5' IAP LTR. We constructed several plasmids containing the CAT gene under control of IAP LTRs deleted in different regions. CAT assays demonstrate that the ras responsive sequence is a 16 bp oligonucleotide containing an effective c-AMP Response Element (CRE) TGACGTCA, which is located in the U3 region, 20 bp upstream of the CAAT box.	HOP ST LOUIS,RETROVIRUS & RETROTRANSPOSONS VERTEBRES LAB,CNRS,UPR 0043,F-75010 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	EMANOILRAVIER, R (corresponding author), HOP ST LOUIS,RETROVIRUS & RETROTRANSPOSONS VERTEBRES LAB,CNRS,UPR 0043,F-75010 PARIS,FRANCE.							ARENZANASEISDEDOS F, 1989, ONCOGENE, V4, P1359; BAEUERLE PA, 1988, COLD SPRING HARB SYM, V53, P789, DOI 10.1101/SQB.1988.053.01.089; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECKNER SK, 1985, NATURE, V317, P71, DOI 10.1038/317071a0; BENBROOK DM, 1990, ONCOGENE, V5, P295; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLUNDELL MC, 1989, J VIROL, V63, P4814, DOI 10.1128/JVI.63.11.4814-4823.1989; CHAPON D, 1983, NATURE, V302, P33; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DOTTO GP, 1985, NATURE, V318, P472; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FALZON M, 1989, J BIOL CHEM, V264, P21915; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GATTONICELLI S, 1983, NATURE, V306, P795, DOI 10.1038/306795a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARRICH D, 1989, J VIROL, V63, P2585, DOI 10.1128/JVI.63.6.2585-2591.1989; HAWLEY RG, 1982, P NATL ACAD SCI-BIOL, V79, P7425, DOI 10.1073/pnas.79.23.7425; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KEDAR PS, 1990, MOL CELL BIOL, V10, P3852, DOI 10.1128/MCB.10.7.3852; Kuff E. L., 1988, Eukaryotic transposable elements as mutagenic agents.., P79; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; KUFF EL, 1985, MOL CELL BIOL, V5, P474, DOI 10.1128/MCB.5.3.474; LACAL JC, 1987, SCIENCE, V238, P533, DOI 10.1126/science.2821623; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LILLIE JW, 1989, NATURE, V341, P279, DOI 10.1038/341279a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUEDERS KK, 1984, MOL CELL BIOL, V4, P2128, DOI 10.1128/MCB.4.10.2128; LURIA S, 1986, J VIROL, V57, P998, DOI 10.1128/JVI.57.3.998-1003.1986; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MCCOY MS, 1984, MOL CELL BIOL, V4, P1577, DOI 10.1128/MCB.4.8.1577; MERCIER G, 1987, CANCER J, V1, P314; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NICOLAS JF, 1983, TERATOCARCINOMA STEM, P469; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OWEN RD, 1990, MOL CELL BIOL, V10, P1; Pace-Asciak CR, 1983, ENZYMES LIPID ENZYMO, VXVI, P543; RECHAVI G, 1982, NATURE, V300, P607, DOI 10.1038/300607a0; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SATAKE M, 1988, ONCOGENE, V3, P69; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; TREPEL JB, 1987, MOL CELL BIOL, V7, P2644, DOI 10.1128/MCB.7.7.2644; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WIEVEL NA, 1971, INT J CANCER, V7, P165; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0; YOTSUYANAGI Y, 1984, ULTRASTRUCTURE REPRO, P218	54	20	20	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					849	855						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1828874				2022-12-17	WOS:A1991GT82500022
J	RAWSON, C; SHIRAHATA, S; COLLODI, P; NATSUNO, T; BARNES, D				RAWSON, C; SHIRAHATA, S; COLLODI, P; NATSUNO, T; BARNES, D			ONCOGENE TRANSFORMATION FREQUENCY OF NONSENESCENT SFME CELLS IS INCREASED BY C-MYC	ONCOGENE			English	Note							MOUSE EMBRYO CELLS; RAS ONCOGENES; CULTURE; SERUM; GENE; FIBROBLASTS; INHIBITION	Immortalized, postcrisis mouse embryo cell cultures derived in serum-containing medium display genomic abnormalities and an altered, preneoplastic phenotype. These lines can be transformed with single oncogenes, such as Ha-ras, while efficient transformation of precrisis, genomically unaltered rodent embryo cultures require cooperating oncogenes, such as Ha-ras and the mouse c-myc gene constitutively expressed. Serum-free mouse embryo (SFME) cells, cultured under conditions in which serum is replaced by growth factors and other supplements, are 'immortalized' in the genomically unaltered state. SFME cells do not exhibit growth crisis or gross chromosomal aberration, and are dependent on epidermal growth factor for survival, growth inhibited by serum, and are nontumorigenic. Transformation of SFME cells can be achieved with ras alone, but the introduction of c-myc increased the transfection frequency upon subsequent transfection with ras by as much as twenty fold. Similar results were obtained with mutationally activated neu oncogene and with genomic human tumor DNA. Constitutive expression of c-myc alone did not alter the properties of the SFME cells. These results demonstrate that c-myc alters cellular responses to oncogenes in a culture system in which oncogene-induced immortalization is not a factor, indicating that the effects of myc may extend beyond an 'immortalization' function in these cells.	OREGON STATE UNIV,ENVIRONM HLTH SCI CTR,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331	Oregon State University					NCPDCID CDC HHS [NCI-01226] Funding Source: Medline	NCPDCID CDC HHS		AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; CORSARO CM, 1981, SOMAT CELL GENET, V7, P603, DOI 10.1007/BF01549662; GOSPODAROWICZ D, 1984, METHODS MOL CELL BIO, V1, P69; Ham R G, 1979, Methods Enzymol, V58, P44; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LOO D, 1990, J CELL PHYSIOL, V142, P210, DOI 10.1002/jcp.1041420126; LOO D, 1989, J CELL PHYSIOL, V139, P484, DOI 10.1002/jcp.1041390306; LOO DT, 1987, SCIENCE, V236, P200, DOI 10.1126/science.3494308; LOO DT, 1989, CELL GROWTH CELL DIV, P17; Maniatis T., 1982, MOL CLONING; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; RAWSON C, 1990, EXP CELL RES, V186, P177, DOI 10.1016/0014-4827(90)90224-X; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P2112, DOI 10.1073/pnas.80.8.2112; SHIRAHATA S, 1990, J CELL PHYSIOL, V144, P69, DOI 10.1002/jcp.1041440110; SORRENTINO V, 1987, P NATL ACAD SCI USA, V84, P4131, DOI 10.1073/pnas.84.12.4131; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299	22	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					487	489						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	2011405				2022-12-17	WOS:A1991FT34400022
J	KIEM, HP; NOURSE, J; SALTMAN, DL; BLUME, KG; CLEARY, ML				KIEM, HP; NOURSE, J; SALTMAN, DL; BLUME, KG; CLEARY, ML			CONCURRENT ACTIVATION OF C-MYC AND INACTIVATION OF BCL-2 BY CHROMOSOMAL TRANSLOCATION IN A LYMPHOBLASTIC LYMPHOMA CELL-LINE	ONCOGENE			English	Article							BREAKPOINT-CLUSTER REGION; FOLLICULAR LYMPHOMA; BURKITT-LYMPHOMA; T(14-18) TRANSLOCATION; MALIGNANT-LYMPHOMAS; ONCOGENE; LEUKEMIA; DNA; CLONING; GENE	We have characterized a chromosomal translocation in a cell line (SU-DUL5) established from a patient with lymphoblastic lymphoma in which the c-myc gene on chromosome 8 was juxtaposed to a t(14:18). Cytogenetic analysis of this cell line showed 14q+, 18q-, and 8p+ q+ marker chromosomes in the absence of t(14:18). Genomic Southern blot analysis showed juxtaposition of the immunoglobulin heavy chain joining region (JH) with chromosome 18 near the minor breakpoint cluster region (mcr) of the bcl-2 gene. There was also a rearranged c-myc gene detectable with a 5' c-myc probe. Molecular cloning studies showed that the c-myc gene was joined to chromosome 18 DNA. Nucleotide sequence analysis of cloned breakpoint DNA revealed that the crossover between chromosomes 8 and 18 occurred at the 3' end of the bcl-2 gene resulting in replacement of the bcl-2 gene on the 14q+ chromosome with the c-myc gene. As a result of this translocation the SU-DUL5 cell line contains no detectable bcl-2 mRNA or protein but has abundant levels of c-myc mRNA. Our data suggest that bcl-2 inactivation occurred simultaneously with c-myc translocation in a B cell lymphoblastic lymphoma.	STANFORD UNIV, MED CTR, SCH MED, DEPT PATHOL, EXPTL ONCOL LAB, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR,SCH MED,DIV HEMATOL, BONE MARROW TRANSPLANT PROGRAM, STANFORD, CA 94305 USA	Stanford University; Stanford University					NCI NIH HHS [CA42971, CA49605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042971, R37CA042971, P01CA049605] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1986, J EXP MED, V164, P315, DOI 10.1084/jem.164.1.315; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; Croce C M, 1986, Adv Immunol, V38, P245, DOI 10.1016/S0065-2776(08)60008-5; DEJONG D, 1988, NEW ENGL J MED, V318, P1373, DOI 10.1056/NEJM198805263182106; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; EPSTEIN AL, 1978, CANCER, V42, P2379, DOI 10.1002/1097-0142(197811)42:5<2379::AID-CNCR2820420539>3.0.CO;2-4; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAUWERKY CE, 1988, P NATL ACAD SCI USA, V85, P8548, DOI 10.1073/pnas.85.22.8548; GAUWERKY CE, 1988, ONCOGENE, V2, P431; GAUWERKY CE, 1989, P NATL ACAD SCI USA, V86, P8867, DOI 10.1073/pnas.86.22.8867; GUERRASIO A, 1987, J NATL CANCER I, V78, P845; HECHT BK, 1985, CANCER GENET CYTOGEN, V14, P205, DOI 10.1016/0165-4608(85)90186-4; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; LEE JT, 1989, J CLIN INVEST, V84, P1454, DOI 10.1172/JCI114320; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MUFTI GJ, 1983, BLOOD, V62, P1142; NGAN BY, 1989, BLOOD, V73, P1759; PEGORARO L, 1984, P NATL ACAD SCI-BIOL, V81, P7166, DOI 10.1073/pnas.81.22.7166; PETTERSSON U, 1973, J MOL BIOL, V73, P125, DOI 10.1016/0022-2836(73)90164-2; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; ROWLEY JD, 1984, CANCER RES, V44, P3159; SALTMAN D, 1989, J CELL SCI, V94, P743; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310	36	20	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1990	5	12					1815	1819						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET436	2284100				2022-12-17	WOS:A1990ET43600011
J	BARBU, V; DAUTRY, F				BARBU, V; DAUTRY, F			MEVALONATE DEPRIVATION ALTERS THE INDUCTION OF FOS AND MYC BY GROWTH-FACTORS	ONCOGENE			English	Note									INST GUSTAVE ROUSSY,CNRS,ONCOL MOLEC LAB,F-94805 VILLEJUIF,FRANCE; CHU ST ANTOINE,BIOCHIM LAB,F-75571 PARIS 12,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite								BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BECK LA, 1988, J CELL BIOL, V107, P1307, DOI 10.1083/jcb.107.4.1307; BROWN MS, 1980, J LIPID RES, V21, P505; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; DEAN M, 1986, J BIOL CHEM, V261, P9161; FAIRBANKS KP, 1984, J BIOL CHEM, V259, P1546; FAIRBANKS KP, 1986, J CELL PHYSIOL, V127, P216, DOI 10.1002/jcp.1041270205; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HABENICHT AJR, 1980, J BIOL CHEM, V255, P5134; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; MALTESE WA, 1987, J CELL PHYSIOL, V133, P471, DOI 10.1002/jcp.1041330307; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; QUESNEYHUNEEUS V, 1983, J BIOL CHEM, V258, P378; QUESNEYHUNEEUS V, 1979, P NATL ACAD SCI USA, V76, P5056, DOI 10.1073/pnas.76.10.5056; REPKO EM, 1989, J BIOL CHEM, V264, P9945; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SINENSKY M, 1985, P NATL ACAD SCI USA, V82, P3257, DOI 10.1073/pnas.82.10.3257; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; VORBURGER K, 1989, EMBO J, V8, P4007, DOI 10.1002/j.1460-2075.1989.tb08583.x; WITTE LD, 1982, J BIOL CHEM, V257, P5392; WITTE LD, 1985, ANN NY ACAD SCI, P261; WOLDA SL, 1988, J BIOL CHEM, V263, P5997	28	20	20	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1990	5	7					1077	1080						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	2115642				2022-12-17	WOS:A1990DP41500020
J	NISHIKURA, K; KIM, U; MURRAY, JM				NISHIKURA, K; KIM, U; MURRAY, JM			DIFFERENTIATION OF F9 CELLS IS INDEPENDENT OF C-MYC EXPRESSION	ONCOGENE			English	Article									UNIV PENN, SCH MED, DEPT ANAT, PHILADELPHIA, PA 19104 USA	University of Pennsylvania	NISHIKURA, K (corresponding author), WISTAR INST, 36TH & SPRUCE ST, PHILADELPHIA, PA 19104 USA.				NATIONAL CANCER INSTITUTE [R01CA046676] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA46676] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMS HD, 1982, CELL, V29, P427, DOI 10.1016/0092-8674(82)90159-3; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BERK AJ, 1978, P NATL ACAD SCI USA, V75, P1274, DOI 10.1073/pnas.75.3.1274; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOO KH, 1986, DNA-J MOLEC CELL BIO, V5, P529, DOI 10.1089/dna.1.1986.5.529; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CROWLEY TE, 1985, CELL, V43, P633, DOI 10.1016/0092-8674(85)90235-1; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HOGAN BLM, 1981, NATURE, V291, P235, DOI 10.1038/291235a0; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; IZANT JG, 1984, CELL, V36, P1007, DOI 10.1016/0092-8674(84)90050-3; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KURKINEN M, 1983, NUCLEIC ACIDS RES, V11, P6199, DOI 10.1093/nar/11.18.6199; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEVI BZ, 1988, GENE DEV, V2, P554, DOI 10.1101/gad.2.5.554; MANIATIS T, 1975, BIOCHEMISTRY-US, V14, P3787, DOI 10.1021/bi00688a010; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NISHIKURA K, 1988, ONCOGENE, V2, P493; PETERSON MG, 1986, EUR J BIOCHEM, V160, P579, DOI 10.1111/j.1432-1033.1986.tb10077.x; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WAGNER RW, 1988, MOL CELL BIOL, V8, P770, DOI 10.1128/MCB.8.2.770; WAGNER RW, 1989, IN PRESS P NATL ACAD; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363	54	20	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1990	5	7					981	988						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	1695728				2022-12-17	WOS:A1990DP41500005
J	SHARP, NA; LUSCOMBE, MJ; CLEMENS, MJ				SHARP, NA; LUSCOMBE, MJ; CLEMENS, MJ			REGULATION OF C-FGR PROTO-ONCOGENE EXPRESSION IN BURKITTS-LYMPHOMA CELLS - EFFECT OF INTERFERON TREATMENT AND RELATIONSHIP TO EBV STATUS AND C-MYC MESSENGER-RNA LEVELS	ONCOGENE			English	Article									ST GEORGE HOSP,SCH MED,DEPT CELLULAR & MOLEC SCI,DIV BIOCHEM,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND	St Georges University London								ADAMS A, 1975, J GEN VIROL, V28, P207, DOI 10.1099/0022-1317-28-2-207; ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; CHEAH MSC, 1986, NATURE, V319, P238, DOI 10.1038/319238a0; CLEMENS MJ, 1988, J CELL BIOCHEM, V38, P251, DOI 10.1002/jcb.240380404; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EXLEY R, 1987, P NATL ACAD SCI USA, V84, P6467, DOI 10.1073/pnas.84.18.6467; EXLEY R, 1987, INT J CANCER, V40, P53, DOI 10.1002/ijc.2910400110; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HO YS, 1987, CANCER INVEST, V5, P101, DOI 10.3109/07357908709018463; INOUE K, 1987, ONCOGENE, V1, P301; JONAK GJ, 1984, P NATL ACAD SCI-BIOL, V81, P1747, DOI 10.1073/pnas.81.6.1747; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.iy.04.040186.001533; KLEIN C, 1988, INT J CANCER, V42, P29, DOI 10.1002/ijc.2910420107; KNIGHT E, 1985, P NATL ACAD SCI USA, V82, P1151, DOI 10.1073/pnas.82.4.1151; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; Maniatis T., 1982, MOL CLONING; MCMAHON M, 1986, J VIROL, V57, P362, DOI 10.1128/JVI.57.1.362-366.1986; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; NISHIZAWA M, 1986, MOL CELL BIOL, V6, P511, DOI 10.1128/MCB.6.2.511; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; SILVERMAN RH, 1982, EUR J BIOCHEM, V126, P333; TRONICK SR, 1985, P NATL ACAD SCI USA, V82, P6595, DOI 10.1073/pnas.82.19.6595; WILLMAN CL, 1987, P NATL ACAD SCI USA, V84, P4480, DOI 10.1073/pnas.84.13.4480	27	20	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1989	4	8					1043	1046						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AJ297	2548145				2022-12-17	WOS:A1989AJ29700015
J	VECCHIO, G; CAVAZZANA, AO; TRICHE, TJ; RON, D; REYNOLDS, CP; EVA, A				VECCHIO, G; CAVAZZANA, AO; TRICHE, TJ; RON, D; REYNOLDS, CP; EVA, A			EXPRESSION OF THE DBL PROTO-ONCOGENE IN EWINGS SARCOMAS	ONCOGENE			English	Article									NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,ROOM 1E24,BETHESDA,MD 20892; NCI,PATHOL LAB,BETHESDA,MD 20892; CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,I-80131 NAPLES,ITALY; UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90024	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Consiglio Nazionale delle Ricerche (CNR); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Eva, Alessandra/J-8268-2016	Eva, Alessandra/0000-0003-2949-078X; Reynolds, C. Patrick/0000-0002-2827-8536				ASKIN FB, 1979, CANCER, V43, P2438, DOI 10.1002/1097-0142(197906)43:6<2438::AID-CNCR2820430640>3.0.CO;2-9; AURIAS A, 1984, CANCER GENET CYTOGEN, V12, P21, DOI 10.1016/0165-4608(84)90003-7; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; CAILLAUD JM, 1984, CANCER RES, V44, P4432; CAVAZZANA AO, 1987, AM J PATHOL, V127, P507; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; COOPER GM, 1982, SCIENCE, V217, P801, DOI 10.1126/science.6285471; DONNER L, 1985, ADV NEUROBLASTOMA RE, P347; EMANUEL BS, 1986, CANCER GENET CYTOGEN, V19, P81, DOI 10.1016/0165-4608(86)90375-4; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1987, ONCOGENE, V1, P355; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; Ewing, 1921, P NEW YORK PATHOL S, V21, P17; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; HARTMAN KR, IN PRESS CANCER; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MISER JS, 1988, J CLIN ONCOL, V6, P484, DOI 10.1200/JCO.1988.6.3.484; PADUA RA, 1984, NATURE, V311, P671, DOI 10.1038/311671a0; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PEREZATAYDE A, 1985, P SIOP, V18, P61; REYNOLDS CP, 1981, CANCER, V48, P2088, DOI 10.1002/1097-0142(19811101)48:9<2088::AID-CNCR2820480929>3.0.CO;2-U; REYNOLDS CP, 1988, ADV NEUROBLASTOMA RE, P291; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P2112, DOI 10.1073/pnas.80.8.2112; SHIMIZU K, 1985, P NATL ACAD SCI USA, V82, P5641, DOI 10.1073/pnas.82.17.5641; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1318; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; TRICHE TJ, 1983, HUM PATHOL, V14, P569; TURCCAREL C, 1984, CANCER GENET CYTOGEN, V12, P4; WHANGPENG J, 1986, CANCER GENET CYTOGEN, V21, P185, DOI 10.1016/0165-4608(86)90001-4; WHANGPENG J, 1984, NEW ENGL J MED, V311, P584, DOI 10.1056/NEJM198408303110907; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	37	20	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1989	4	7					897	900						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2666909				2022-12-17	WOS:A1989AE58400012
J	WILKISON, WO; SANDGREN, EP; PALMITER, RD; BRINSTER, RL; BELL, RM				WILKISON, WO; SANDGREN, EP; PALMITER, RD; BRINSTER, RL; BELL, RM			ELEVATION OF 1,2-DIACYLGLYCEROL IN RAS-TRANSFORMED NEONATAL LIVER AND PANCREAS OF TRANSGENIC MICE	ONCOGENE			English	Article									UNIV PENN,SCH VET MED,REPROD PHYSIOL LAB,PHILADELPHIA,PA 19104; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	University of Pennsylvania; University of Washington; University of Washington Seattle; Duke University				Brinster, Ralph/0000-0003-1408-7656	NCI NIH HHS [CA 38635] Funding Source: Medline; NICHD NIH HHS [HD 09172] Funding Source: Medline; PHS HHS [DR 20205] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD009172, R37HD009172] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA038635] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMES BN, 1960, J BIOL CHEM, V235, P769; ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BISHOP WR, 1988, ONCOGENE RES, V2, P205; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; GIBBS JB, 1985, TRENDS BIOCHEM SCI, V10, P350, DOI 10.1016/0968-0004(85)90110-0; GRISHAM JW, 1983, SURV SYN PATHOL RES, V1, P49; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; KISHIMOTO A, 1980, J BIOL CHEM, V255, P2273; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LAPETINA EG, 1985, J BIOL CHEM, V260, P1358; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PAI JK, 1988, J BIOL CHEM, V263, P12472; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; PREISS J, 1986, J BIOL CHEM, V261, P8597; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; SANDGREN EP, 1989, IN PRESS ONCOGENE; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; TOOZE J, 1980, MOL BIOL TUMOR VIRUS; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0	27	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1989	4	5					625	628						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U7688	2657577				2022-12-17	WOS:A1989U768800013
J	DHUT, S; DOREY, EL; HORTON, MA; GANESAN, TS; YOUNG, BD				DHUT, S; DOREY, EL; HORTON, MA; GANESAN, TS; YOUNG, BD			IDENTIFICATION OF 2 NORMAL BCR GENE-PRODUCTS IN THE CYTOPLASM	ONCOGENE			English	Article									ST BARTHOLOMEWS HOSP,IMPERIAL CANC RES FUND,LONDON EC1A 7BE,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT MED ONCOL,LONDON EC1A 7BE,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT HAEMATOL,LONDON EC1A 7BE,ENGLAND	Cancer Research UK; University of London; Queen Mary University London; University of London; Queen Mary University London; University of London; Queen Mary University London			GANESAN, Trivadi Sundaram/AAU-1499-2020	GANESAN, Trivadi Sundaram/0000-0002-4671-8099				BARBAS JA, 1988, EMBO J, V7, P625, DOI 10.1002/j.1460-2075.1988.tb02856.x; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; COLLINS S, 1987, MOL CELL BIOL, V7, P2870, DOI 10.1128/MCB.7.8.2870; CROCE CM, 1987, P NATL ACAD SCI USA, V84, P7174, DOI 10.1073/pnas.84.20.7174; DREAZEN O, 1988, HAEMATOLOGY, V25, P35; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LIFSHITZ B, 1988, ONCOGENE, V2, P113; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; WALKER LC, 1987, NATURE, V329, P851, DOI 10.1038/329851a0; WHITE JG, 1987, NATURE, V328, P183, DOI 10.1038/328183a0	16	20	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					561	566						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	3078961				2022-12-17	WOS:A1988R516300012
J	YANG, XM; WALTER, G				YANG, XM; WALTER, G			SPECIFIC KINASE-ACTIVITY AND PHOSPHORYLATION STATE OF PP60C-SRC FROM NEUROBLASTOMAS AND FIBROBLASTS	ONCOGENE			English	Article											YANG, XM (corresponding author), UNIV CALIF SAN DIEGO,DEPT PATHOL,LA JOLLA,CA 92093, USA.							BARNEKOW A, 1984, MOL CELL BIOL, V4, P1179, DOI 10.1128/MCB.4.6.1179; BARNEKOW A, 1986, EMBO J, V5, P701, DOI 10.1002/j.1460-2075.1986.tb04270.x; BARNEKOW A, 1984, BIOCHIM BIOPHYS ACTA, V727, P94; BIEDLER JL, 1973, CANCER RES, V33, P2643; BOLEN JB, 1985, P NATL ACAD SCI USA, V82, P7275, DOI 10.1073/pnas.82.21.7275; BRUGGE J, 1987, GENE DEV, V1, P287, DOI 10.1101/gad.1.3.287; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CARTWRIGHT CA, 1987, MOL CELL BIOL, V7, P1830, DOI 10.1128/MCB.7.5.1830; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLETT MS, 1979, J VIROL, V29, P770, DOI 10.1128/JVI.29.2.770-781.1979; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COUSSENS PM, 1985, MOL CELL BIOL, V5, P2753, DOI 10.1128/MCB.5.10.2753; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; GOULD KL, 1988, IN PRESS MOL CELL BI; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JACOBS C, 1983, CANCER RES, V43, P1696; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH W, 1986, MOL CELL BIOL, V6, P1866, DOI 10.1128/MCB.6.6.1866; LEBEAU JM, 1987, MOL CELL BIOL, V7, P4115, DOI 10.1128/MCB.7.11.4115; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYNCH SA, 1986, SCIENCE, V234, P873, DOI 10.1126/science.3095923; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MATTEN WT, 1987, BIOCHEM J, V248, P691, DOI 10.1042/bj2480691; OPPERMANN H, 1979, P NATL ACAD SCI USA, V76, P1804, DOI 10.1073/pnas.76.4.1804; OSHAUGHNESSY J, 1987, ONCOGENE RES, V2, P1; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PURCHIO AF, 1983, MOL CELL BIOL, V3, P1589, DOI 10.1128/MCB.3.9.1589; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; SCHARTL M, 1982, DIFFERENTIATION, V23, P109, DOI 10.1111/j.1432-0436.1982.tb01273.x; SCHEIDTMANN KH, 1984, J VIROL, V50, P1; SEEGER RC, 1977, CANCER RES, V37, P1364; SEFTON BM, 1980, P NATL ACAD SCI-BIOL, V77, P2059, DOI 10.1073/pnas.77.4.2059; SHILO BZ, 1981, P NATL ACAD SCI-BIOL, V78, P6789, DOI 10.1073/pnas.78.11.6789; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SPECTOR DH, 1978, CELL, V13, P381, DOI 10.1016/0092-8674(78)90206-4; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; WIESTLER OD, 1988, MOL CELL BIOL, V8, P502, DOI 10.1128/MCB.8.1.502	51	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1988	3	3					237	244						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	2462704				2022-12-17	WOS:A1988Q436700001
J	COHEN, N; SALZBERG, A; LEV, Z				COHEN, N; SALZBERG, A; LEV, Z			A BIDIRECTIONAL PROMOTER IS REGULATING THE DROSOPHILA-RAS2 GENE	ONCOGENE			English	Article									TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL	Technion Israel Institute of Technology			Salzberg, Adi/A-9986-2014; Salzberg, Adi/O-1198-2019	Salzberg, Adi/0000-0002-0427-9809; Salzberg, Adi/0000-0002-0427-9809				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BROCK HW, 1987, GENE, V51, P129, DOI 10.1016/0378-1119(87)90301-5; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Elgin S.C.R., 1978, P112; FARNHAM PJ, 1985, P NATL ACAD SCI USA, V82, P3978, DOI 10.1073/pnas.82.12.3978; FURTH ME, 1987, ONCOGENE, V1, P47; GARABEDIAN MJ, 1985, P NATL ACAD SCI USA, V82, P1396, DOI 10.1073/pnas.82.5.1396; GARFINKEL MD, 1983, J MOL BIOL, V168, P765, DOI 10.1016/S0022-2836(83)80074-6; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HOFFMAN EK, 1987, MOL CELL BIOL, V7, P2592, DOI 10.1128/MCB.7.7.2592; HONKAWA H, 1987, MOL CELL BIOL, V7, P2933, DOI 10.1128/MCB.7.8.2933; HU MCT, 1986, GENE, V42, P21; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; IATROU K, 1983, EMBO J, V2, P1431, DOI 10.1002/j.1460-2075.1983.tb01604.x; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; LEV Z, 1985, MOL CELL BIOL, V5, P1540, DOI 10.1128/MCB.5.6.1540; LEV Z, 1987, ANAL BIOCHEM, V160, P332, DOI 10.1016/0003-2697(87)90055-8; LEV Z, 1986, BIOCHIM BIOPHYS ACTA, V867, P144, DOI 10.1016/0167-4781(86)90074-6; LEVANON D, 1985, EMBO J, V4, P77, DOI 10.1002/j.1460-2075.1985.tb02320.x; LEVINSON AD, 1986, TRENDS GENET, V2, P81, DOI 10.1016/0168-9525(86)90184-8; LIN HC, 1985, ANAL BIOCHEM, V147, P114, DOI 10.1016/0003-2697(85)90016-8; MANIATIS T, 1982, LABORATORY MANUAL; MASTERS JN, 1985, MOL CELL BIOL, V5, P493, DOI 10.1128/MCB.5.3.493; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MCGROGAN M, 1985, J BIOL CHEM, V260, P2307; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOZER B, 1985, MOL CELL BIOL, V5, P885, DOI 10.1128/MCB.5.4.885; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; NEUMANSILBERBERG FS, 1984, CELL, V37, P1027; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; NOTHIGER R, 1980, DROS INFOR SERVICE, V55, P162; OSBORNE TF, 1985, CELL, V42, P203, DOI 10.1016/S0092-8674(85)80116-1; PAPAGEORGE AG, 1984, MOL CELL BIOL, V4, P23, DOI 10.1128/MCB.4.1.23; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEJTER ED, 1985, EMBO J, V4, P407, DOI 10.1002/j.1460-2075.1985.tb03643.x; SEGAL D, 1986, MOL CELL BIOL, V6, P2241, DOI 10.1128/MCB.6.6.2241; SEGEV O, 1988, IN PRESS ONCOGENE; SPANDIDOS DA, 1986, FEBS LETT, V203, P169, DOI 10.1016/0014-5793(86)80736-0; STELLER H, 1984, EMBO J, V3, P165, DOI 10.1002/j.1460-2075.1984.tb01778.x; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; SWAROOP A, 1986, MOL CELL BIOL, V6, P833, DOI 10.1128/MCB.6.3.833; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WILLIAMS TJ, 1986, MOL CELL BIOL, V6, P4558, DOI 10.1128/MCB.6.12.4558	55	20	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					137	142						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	3412773				2022-12-17	WOS:A1988Q053400002
J	ARRUSHDI, A; NEGRINI, M; KURZROCK, R; HUEBNER, K; CROCE, CM				ARRUSHDI, A; NEGRINI, M; KURZROCK, R; HUEBNER, K; CROCE, CM			FUSION OF THE BCR AND THE C-ABL GENES IN PH'-POSITIVE ACUTE LYMPHOCYTIC-LEUKEMIA WITH NO REARRANGEMENT IN THE BREAKPOINT CLUSTER REGION	ONCOGENE			English	Article									WISTAR INST ANAT & BIOL,3601 SPRUCE ST,PHILADELPHIA,PA 19104	The Wistar Institute			Negrini, Massimo/J-2377-2016; Young, Richard A/F-6495-2012	Negrini, Massimo/0000-0002-0007-1920; Young, Richard A/0000-0001-8855-8647	NCI NIH HHS [CA 39860] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039860] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARRUSHDI A, 1982, SOMAT CELL GENET, V8, P151, DOI 10.1007/BF01538674; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BERNARDS A, 1987, MOL CELL BIOL, V7, P3231, DOI 10.1128/MCB.7.9.3231; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; DEKLEIN A, 1986, BLOOD, V68, P1369; ERIKSON J, 1986, P NATL ACAD SCI USA, V83, P1807, DOI 10.1073/pnas.83.6.1807; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; GRUBER LN, 1983, AM J CLIN HYPN, V25, P263; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1987, BRIT J HAEMATOL, V67, P55, DOI 10.1111/j.1365-2141.1987.tb02296.x; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; LANGE B, 1987, BLOOD, V70, P192; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; NOWELL PC, 1960, SCIENCE, V132, P1497; RODENHUIS S, 1985, NEW ENGL J MED, V313, P51; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; ROWLEY JD, 1980, CLIN HAEMATOL, V9, P55; SANDBERG AA, 1980, CANCER GENET CYTOGEN, V2, P145, DOI 10.1016/0165-4608(80)90058-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201	30	20	20	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1988	2	4					353	357						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	3283653				2022-12-17	WOS:A1988M947200007
J	KANNER, SB; PARSONS, SJ; PARSONS, JT; GILMER, TM				KANNER, SB; PARSONS, SJ; PARSONS, JT; GILMER, TM			ACTIVATION OF PP60C-SRC TYROSINE KINASE SPECIFIC ACTIVITY IN TUMOR-DERIVED SYRIAN-HAMSTER EMBRYO CELLS	ONCOGENE			English	Article									UNIV VIRGINIA,SCH MED,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,CTR CANC,CHARLOTTESVILLE,VA 22908; NIEHS,PULM PATHOBIOL LAB,RES TRIANGLE PK,NC 27709	University of Virginia; University of Virginia; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)					NCI NIH HHS [CA40042, CA29243, CA08316] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA008316, P01CA040042, R01CA029243, R37CA029243] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNEKOW A, 1986, EMBO J, V5, P701, DOI 10.1002/j.1460-2075.1986.tb04270.x; BARRETT JC, 1978, P NATL ACAD SCI USA, V75, P3761, DOI 10.1073/pnas.75.8.3761; BARRETT JC, 1979, CANCER RES, V39, P1504; BARRETT JC, 1987, MECHANISMS ENV CARCI, V2, P73; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOLEN JB, 1987, ONCOGENE RES, V1, P149; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BOLEN JB, 1987, J VIROL, V61, P3299, DOI 10.1128/JVI.61.10.3299-3305.1987; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1985, MOL CELL BIOL, V5, P2647, DOI 10.1128/MCB.5.10.2647; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CARTWRIGHT CA, 1987, MOL CELL BIOL, V7, P1830, DOI 10.1128/MCB.7.5.1830; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1987, IN PRESS PEPTIDES PR; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DAVIS RL, 1985, MOL CELL BIOL, V5, P204, DOI 10.1128/MCB.5.1.204; GENTRY LE, 1986, MOL CELL BIOL, V6, P735, DOI 10.1128/MCB.6.2.735; GENTRY LE, 1983, J BIOL CHEM, V258, P1219; GILMER TM, 1982, P NATL ACAD SCI-BIOL, V79, P2152, DOI 10.1073/pnas.79.7.2152; GILMER TM, 1987, CANCER RES, V47, P4663; GILMER TM, 1985, MOL CELL BIOL, V5, P1707, DOI 10.1128/MCB.5.7.1707; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HESTERBERG TW, 1984, CANCER RES, V44, P2170; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KANNER SB, 1986, J IMMUNOL, V137, P674; KANNER SB, 1987, J INFECT DIS, V155, P617, DOI 10.1093/infdis/155.4.617; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDBETTER JA, 1987, MOL CELL BIOL, V7, P650, DOI 10.1128/MCB.7.2.650; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUTTRELL DK, 1988, IN PRESS MOL CELL BI; LYNCH SA, 1986, SCIENCE, V234, P873, DOI 10.1126/science.3095923; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MATTEN WT, 1987, BIOCHEM J, V248, P691, DOI 10.1042/bj2480691; MCCARLEY DJ, 1987, P NATL ACAD SCI USA, V84, P5793, DOI 10.1073/pnas.84.16.5793; MCLACHLAN JA, 1982, CANCER RES, V42, P3040; OSHIMURA M, 1986, CANCER GENET CYTOGEN, V22, P225, DOI 10.1016/0165-4608(86)90159-7; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PARSONS SJ, 1986, BIOCHEM BIOPH RES CO, V134, P736, DOI 10.1016/S0006-291X(86)80482-X; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; SEFTON BM, 1986, CURR TOP MICROBIOL, V123, P39; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; THOMASSEN DG, 1985, CANCER RES, V45, P726; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WONG TW, 1983, J BIOL CHEM, V258, P1022; YONEMOTO W, 1985, P NATL ACAD SCI USA, V82, P4568, DOI 10.1073/pnas.82.14.4568	57	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1988	2	4					327	335						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	2452399				2022-12-17	WOS:A1988M947200004
J	AKROYD, J; FINCHAM, VJ; GREEN, AR; LEVANTIS, P; SEARLE, S; WYKE, JA				AKROYD, J; FINCHAM, VJ; GREEN, AR; LEVANTIS, P; SEARLE, S; WYKE, JA			TRANSCRIPTION OF ROUS-SARCOMA PROVIRUSES IN RAT-CELLS IS DETERMINED BY CHROMOSOMAL POSITION EFFECTS THAT FLUCTUATE AND CAN OPERATE OVER LONG DISTANCES	ONCOGENE			English	Article											AKROYD, J (corresponding author), ST BARTHOLOMEWS HOSP,IMPERIAL CANC RES FUND LABS,DOMIN HOUSE,LONDON EC1A 7BE,ENGLAND.			Green, Anthony/0000-0002-9795-0218				ANDERSON SM, 1983, J VIROL, V46, P594, DOI 10.1128/JVI.46.2.594-605.1983; BARKLIS E, 1986, CELL, V47, P391, DOI 10.1016/0092-8674(86)90596-9; CATALA F, 1986, NUCLEIC ACIDS RES, V14, P2481, DOI 10.1093/nar/14.6.2481; CATALA F, 1979, J VIROL, V29, P833, DOI 10.1128/JVI.29.3.833-839.1979; CHISWELL DJ, 1982, NUCLEIC ACIDS RES, V10, P3967, DOI 10.1093/nar/10.13.3967; CHISWELL DJ, 1982, VIROLOGY, V116, P428, DOI 10.1016/0042-6822(82)90137-4; COOK PR, 1982, EMBO J, V1, P447, DOI 10.1002/j.1460-2075.1982.tb01189.x; COOPER GM, 1978, CELL, V15, P573, DOI 10.1016/0092-8674(78)90025-9; DYSON PJ, 1985, EMBO J, V4, P413, DOI 10.1002/j.1460-2075.1985.tb03644.x; DYSON PJ, 1985, EMBO J, V4, P2885, DOI 10.1002/j.1460-2075.1985.tb04018.x; DYSON PJ, 1982, CELL, V30, P491, DOI 10.1016/0092-8674(82)90246-X; FEINSTEIN SC, 1982, J MOL BIOL, V156, P549, DOI 10.1016/0022-2836(82)90266-2; GILLESPIE DAF, 1985, CELL, V41, P279, DOI 10.1016/0092-8674(85)90081-9; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GORMAN CM, 1985, CELL, V42, P519, DOI 10.1016/0092-8674(85)90109-6; GRAF T, 1973, VIROLOGY, V56, P369, DOI 10.1016/0042-6822(73)90314-0; GREEN AR, 1986, EMBO J, V5, P707, DOI 10.1002/j.1460-2075.1986.tb04271.x; HAUSEN HZ, 1986, LANCET, V2, P489; JAENISCH R, 1981, CELL, V24, P519, DOI 10.1016/0092-8674(81)90343-3; LAIMINS LA, 1984, NUCLEIC ACIDS RES, V12, P6427, DOI 10.1093/nar/12.16.6427; LEVANTIS P, 1986, J VIROL, V57, P907, DOI 10.1128/JVI.57.3.907-916.1986; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LUCIW PA, 1983, CELL, V33, P705, DOI 10.1016/0092-8674(83)90013-2; MANIATIS T, 1982, MOL CLONING LABORATO; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; OVERBEEK PA, 1986, SCIENCE, V231, P1574, DOI 10.1126/science.3006249; RALEIGH EA, 1986, P NATL ACAD SCI USA, V83, P9070, DOI 10.1073/pnas.83.23.9070; ROHDEWOHLD H, 1987, J VIROL, V61, P336, DOI 10.1128/JVI.61.2.336-343.1987; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS E, 1982, NATURE, V298, P342; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SEARLE S, 1984, NUCLEIC ACIDS RES, V12, P5193, DOI 10.1093/nar/12.13.5193; SORGE J, 1984, P NATL ACAD SCI-BIOL, V81, P6627, DOI 10.1073/pnas.81.21.6627; SORIANO P, 1986, SCIENCE, V234, P1409, DOI 10.1126/science.3024318; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SVOBODA J, 1986, INTERVIROLOGY, V26, P1, DOI 10.1159/000149682; VARMUS HE, 1981, VIROLOGY, V108, P28, DOI 10.1016/0042-6822(81)90525-0; VIJAYA S, 1986, J VIROL, V60, P683, DOI 10.1128/JVI.60.2.683-692.1986; WEISS R, 1985, RNA TUMOR VIRUSES MO; WYKE JA, 1980, VIROLOGY, V106, P217, DOI 10.1016/0042-6822(80)90246-9; YAMAMOTO T, 1980, CELL, V22, P787, DOI 10.1016/0092-8674(80)90555-3; YOSHIMURA FK, 1987, MOL CELL BIOL, V7, P1296, DOI 10.1128/MCB.7.3.1296	44	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	1	4					347	354						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	K7483	2838783				2022-12-17	WOS:A1987K748300002
J	VARLEY, JM; WAINWRIGHT, AM; BRAMMAR, WJ				VARLEY, JM; WAINWRIGHT, AM; BRAMMAR, WJ			AN UNUSUAL ALTERATION IN C-MYC IN TISSUE FROM A PRIMARY BREAST-CARCINOMA	ONCOGENE			English	Article											VARLEY, JM (corresponding author), UNIV LEICESTER,ICI UNIV JOINT LAB,LEICESTER LE1 7RH,ENGLAND.							ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ANDERSON S, 1981, NUCLEIC ACIDS RES, V9, P3015, DOI 10.1093/nar/9.13.3015; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CROCE CM, 1979, P NATL ACAD SCI USA, V76, P3416, DOI 10.1073/pnas.76.7.3416; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DEININGER PL, 1981, J MOL BIOL, V151, P17, DOI 10.1016/0022-2836(81)90219-9; DENNY CT, 1985, MOL CELL BIOL, V5, P3199, DOI 10.1128/MCB.5.11.3199; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; ERIKSON J, 1981, NATURE, V294, P173, DOI 10.1038/294173a0; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HANIFORD DB, 1983, NATURE, V302, P632, DOI 10.1038/302632a0; HARTL P, 1987, MOL CELL BIOL, V7, P2037, DOI 10.1128/MCB.7.6.2037; HOBART MJ, 1981, ANN HUM GENET, V45, P331, DOI 10.1111/j.1469-1809.1981.tb00346.x; JAGADEESWARAN P, 1982, NATURE, V296, P469, DOI 10.1038/296469a0; KIRSCH IR, 1982, SCIENCE, V216, P301, DOI 10.1126/science.6801764; KMIEC EB, 1986, CELL, V44, P545, DOI 10.1016/0092-8674(86)90264-3; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LEHRMAN MA, 1986, P NATL ACAD SCI USA, V83, P3679, DOI 10.1073/pnas.83.11.3679; LEHRMAN MA, 1985, SCIENCE, V227, P140, DOI 10.1126/science.3155573; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; MALCOLM S, 1982, P NATL ACAD SCI-BIOL, V79, P4957, DOI 10.1073/pnas.79.16.4957; MANIATIS T, 1982, MOL CLONING LABORATO; MARSHALL C, 1985, RNA TUMOR VIRUSES, V2; MCBRIDE OW, 1982, J EXP MED, V155, P1480, DOI 10.1084/jem.155.5.1480; MOULDING D, 1985, NUCLEIC ACIDS RES, V13, P2141; MURPHY W, 1986, P NATL ACAD SCI USA, V83, P2939, DOI 10.1073/pnas.83.9.2939; MURRAY NE, 1977, MOL GEN GENET, V150, P53, DOI 10.1007/BF02425325; NEEL BG, 1982, P NATL ACAD SCI-BIOL, V79, P7842, DOI 10.1073/pnas.79.24.7842; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NICHOLLS RD, 1987, CELL, V49, P369, DOI 10.1016/0092-8674(87)90289-3; NORDHEIM A, 1983, P NATL ACAD SCI-BIOL, V80, P1821, DOI 10.1073/pnas.80.7.1821; OTTOLENGHI S, 1982, NATURE, V300, P700; PARDUE ML, 1987, EMBO J, V6, P1781, DOI 10.1002/j.1460-2075.1987.tb02431.x; PERRY RP, 1983, CELL, V33, P647, DOI 10.1016/0092-8674(83)90006-5; PICCOLI SP, 1984, NATURE, V310, P327, DOI 10.1038/310327a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; ROGERS J, 1983, NATURE, V305, P101, DOI 10.1038/305101a0; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID CW, 1982, SCIENCE, V216, P1065, DOI 10.1126/science.6281889; SHOWE L C, 1986, Cancer Reviews, V2, P18; SHOWE LC, 1987, P NATL ACAD SCI USA, V84, P2824, DOI 10.1073/pnas.84.9.2824; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SUN LK, 1986, NUCLEIC ACIDS RES, V14, P4037, DOI 10.1093/nar/14.10.4037; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TRECO D, 1986, MOL CELL BIOL, V6, P3934, DOI 10.1128/MCB.6.11.3934; VANIN EF, 1983, CELL, V35, P701, DOI 10.1016/0092-8674(83)90103-4; VARLEY JM, 1987, ONCOGENE, V1, P423; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WATT R, 1983, P NATL ACAD SCI-BIOL, V80, P6307, DOI 10.1073/pnas.80.20.6307; WHITTAKER JL, 1986, INT J CANCER, V38, P651, DOI 10.1002/ijc.2910380506; WOLMAN SR, 1983, CANCER METAST REV, V2, P257, DOI 10.1007/BF00048481; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	66	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	1	4					431	438						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	K7483	2838785				2022-12-17	WOS:A1987K748300013
J	Wu, YH; Huang, YF; Chang, TH; Chen, CC; Wu, PY; Huang, SC; Chou, CY				Wu, Yi-Hui; Huang, Yu-Fang; Chang, Tzu-Hao; Chen, Chien-Chin; Wu, Pei-Ying; Huang, Soon-Cen; Chou, Cheng-Yang			COL11A1 activates cancer-associated fibroblasts by modulating TGF-beta 3 through the NF-kappa B/IGFBP2 axis in ovarian cancer cells	ONCOGENE			English	Article							NF-KAPPA-B; TGF-BETA; BREAST-CANCER; CARCINOMA; GROWTH; EXPRESSION; IL-6; CHEMORESISTANCE; SIGNATURE; SURVIVAL	Ovarian cancer has a unique tumor microenvironment (TME) that enables cancer-associated fibroblasts (CAFs) to interact with cellular and matrix constituents and influence tumor development and migration into the peritoneal cavity. Collagen type XI alpha 1 (COL11A1) is overexpressed in CAFs; therefore this study examines its role during CAF activation in epithelial ovarian cancer (EOC). Coculturing human ovarian fibroblasts (HOFs) with high COL11A1-expressing EOC cells or exposure to the conditioned medium of these cells prompted the expression of COL11A1 and CAF phenotypes. Conversely, coculturing HOFs with low COL11A1-expressing EOC cells or COL11A1-knockdown abrogated COL11A1 overexpression and secretion, in addition to CAF activation. Increased p-SP1 expression attributed to COL11A1-mediated extracellular signal-regulated kinase activation (ERK) induced p65 translocation into the nucleus and augmented its binding to the insulin-like growth factor binding protein 2 (IGFBP2) promoter, ultimately inducing TGF-beta 3 activation. The CAF-cancer cell crosstalk triggered interleukin-6 release, which in turn promoted EOC cell proliferation and invasiveness. These in vitro results were confirmed by in vivo findings in a mouse model, showing that COL11A1 overexpression in EOC cells promoted tumor formation and CAF activation, which was inhibited by TGF-beta 3 antibody. Human tumors with high TGF-beta 3 levels showed elevated expression of COL11A1 and IGFBP2, which was associated with poor survival. Our findings suggest the possibility that anti-TGF-beta 3 treatment strategy may be effective in targeting CAFs in COL11A1-positive ovarian tumors.	[Wu, Yi-Hui] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan; [Huang, Yu-Fang; Wu, Pei-Ying; Chou, Cheng-Yang] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Obstet & Gynecol, Tainan, Taiwan; [Chang, Tzu-Hao] Taipei Med Univ, Grad Inst Biomed Informat, Taipei, Taiwan; [Chen, Chien-Chin] Chia Yi Christian Hosp, Dept Pathol, Ditmanson Med Fdn, Chiayi, Taiwan; [Chen, Chien-Chin] Chia Nan Univ Pharm & Sci, Dept Cosmet Sci, Tainan, Taiwan; [Huang, Soon-Cen] Chi Mei Med Ctr, Dept Obstet & Gynecol, Tainan, Taiwan	Chi Mei Hospital; National Cheng Kung University; National Cheng Kung University Hospital; Taipei Medical University; Chia Nan University of Pharmacy & Science; Chi Mei Hospital	Chou, CY (corresponding author), Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Obstet & Gynecol, Tainan, Taiwan.; Huang, SC (corresponding author), Chi Mei Med Ctr, Dept Obstet & Gynecol, Tainan, Taiwan.	hsc.gyn@gmail.com; chougyn@mail.ncku.edu.tw	Chen, Chien-Chin/A-9977-2016; Wu, Pei Ying/AGR-9702-2022	Chen, Chien-Chin/0000-0001-9599-0884; Wu, Yi-Hui/0000-0002-8657-6371; Huang, Soon-Cen/0000-0001-8085-576X	National Science Council (MOST) [108-2314-B-384-011-MY3, 108-2314-B-006-061-MY2]; Chi Mei Medical Center, Liouying Campus [CLFHR10822, CLFHR10911, CMLMOST10901, CLFHR10921]	National Science Council (MOST); Chi Mei Medical Center, Liouying Campus	This work was supported by grants from the National Science Council (MOST: No. 108-2314-B-384-011-MY3 and 108-2314-B-006-061-MY2). The study was also supported by grants from the Chi Mei Medical Center, Liouying Campus (CLFHR10822, CLFHR10911, CMLMOST10901, and CLFHR10921).	Ahmed N, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00256; Barcellos-Hoff MH, 2005, BREAST CANCER RES, V7, P33, DOI 10.1186/bcr972; Bartlett JM, 1997, EUR J CANCER, V33, P2397, DOI 10.1016/S0959-8049(97)00304-3; Bierie B, 2008, CANCER RES, V68, P1809, DOI 10.1158/0008-5472.CAN-07-5597; Biffi G, 2019, CANCER DISCOV, V9, P282, DOI 10.1158/2159-8290.CD-18-0710; Bran G, 2011, IN VIVO, V25, P579; Browning L, 2018, CANCER MANAG RES, V10, P6685, DOI 10.2147/CMAR.S179189; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Cazals V, 1999, BBA-MOL CELL RES, V1448, P349, DOI 10.1016/S0167-4889(98)00095-0; Chen MF, 2012, CLIN SCI, V122, P459, DOI 10.1042/CS20110434; Cheon DJ, 2014, CLIN CANCER RES, V20, P711, DOI 10.1158/1078-0432.CCR-13-1256; Cirri P, 2011, AM J CANCER RES, V1, P482; Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011; D'Arcangelo E, 2020, BRIT J CANCER, V122, P931, DOI 10.1038/s41416-019-0705-1; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Erkan M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-88; Fischer H, 2001, CARCINOGENESIS, V22, P875, DOI 10.1093/carcin/22.6.875; Garcia-Pravia C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078327; Hawsawi NM, 2008, CANCER RES, V68, P2717, DOI 10.1158/0008-5472.CAN-08-0192; Hong SH, 2000, FASEB J, V14, P1499, DOI 10.1096/fj.99-0802com; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lee J, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317695534; Mienaltowski MJ, 2014, ADV EXP MED BIOL, V802, P5, DOI 10.1007/978-94-007-7893-1_2; Nallanthighal S, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2442-z; Navab R, 2011, P NATL ACAD SCI USA, V108, P7160, DOI 10.1073/pnas.1014506108; Papageorgis P, 2015, J ONCOL, V2015, DOI 10.1155/2015/587193; Pickup M, 2013, NAT REV CANCER, V13, P788, DOI 10.1038/nrc3603; Rada M, 2018, ONCOGENE, V37, P4809, DOI 10.1038/s41388-018-0297-x; Ren B, 2006, BBA-REV CANCER, V1765, P178, DOI 10.1016/j.bbcan.2005.11.002; RONNOVJESSEN L, 1995, J CLIN INVEST, V95, P859, DOI 10.1172/JCI117736; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Stover DG, 2007, J CELL BIOCHEM, V101, P851, DOI 10.1002/jcb.21149; Tao LL, 2017, ONCOL LETT, V14, P2611, DOI 10.3892/ol.2017.6497; Verona EV, 2007, CANCER RES, V67, P5737, DOI 10.1158/0008-5472.CAN-07-0444; von Strandmann EP, 2017, TRENDS CANCER, V3, P137, DOI 10.1016/j.trecan.2016.12.005; Worzfeld T, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00024; Wu YH, 2014, ONCOGENE, V33, P3432, DOI 10.1038/onc.2013.307; Wu YH, 2017, INT J CANCER, V141, P2305, DOI 10.1002/ijc.30932; Wu YH, 2015, ONCOTARGET, V6, P23748, DOI 10.18632/oncotarget.4250; Xing F, 2010, FRONT BIOSCI-LANDMRK, V15, P166, DOI 10.2741/3613; Yeung TL, 2013, CANCER RES, V73, P5016, DOI 10.1158/0008-5472.CAN-13-0023; Yu Y, 2014, BRIT J CANCER, V110, P724, DOI 10.1038/bjc.2013.768; Zigrino P, 2005, BIOCHIMIE, V87, P321, DOI 10.1016/j.biochi.2004.10.025	43	19	19	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2021	40	26					4503	4519		10.1038/s41388-021-01865-8	http://dx.doi.org/10.1038/s41388-021-01865-8		JUN 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC8LA	34117361				2022-12-17	WOS:000660409400001
J	Wanior, M; Kramer, A; Knapp, S; Joerger, AC				Wanior, Marek; Kraemer, Andreas; Knapp, Stefan; Joerger, Andreas C.			Exploiting vulnerabilities of SWI/SNF chromatin remodelling complexes for cancer therapy	ONCOGENE			English	Review							BAF COMPLEX; ARID1A EXPRESSION; DNA-BINDING; HISTONE H3; INACTIVATING MUTATIONS; SYNTHETIC LETHALITY; TUMOR PROGRESSION; BROMODOMAIN; INHIBITORS; TARGET	Multi-subunit ATPase-dependent chromatin remodelling complexes SWI/SNF (switch/sucrose non-fermentable) are fundamental epigenetic regulators of gene transcription. Functional genomic studies revealed a remarkable mutation prevalence of SWI/SNF-encoding genes in 20-25% of all human cancers, frequently driving oncogenic programmes. Some SWI/SNF-mutant cancers are hypersensitive to perturbations in other SWI/SNF subunits, regulatory proteins and distinct biological pathways, often resulting in sustained anticancer effects and synthetic lethal interactions. Exploiting these vulnerabilities is a promising therapeutic strategy. Here, we review the importance of SWI/SNF chromatin remodellers in gene regulation as well as mechanisms leading to assembly defects and their role in cancer development. We will focus in particular on emerging strategies for the targeted therapy of SWI/SNF-deficient cancers using chemical probes, including proteolysis targeting chimeras, to induce synthetic lethality.	[Wanior, Marek; Kraemer, Andreas; Knapp, Stefan; Joerger, Andreas C.] Goethe Univ Frankfurt, Inst Pharmaceut Chem, Frankfurt, Germany; [Wanior, Marek; Kraemer, Andreas; Knapp, Stefan; Joerger, Andreas C.] Buchmann Inst Mol Life Sci BMLS, Struct Genom Consortium SGC, Frankfurt, Germany; [Kraemer, Andreas; Knapp, Stefan] Frankfurt Canc Inst FCI, Frankfurt, Germany; [Knapp, Stefan; Joerger, Andreas C.] German Translat Canc Network DKTK, Site Frankfurt Mainz, Frankfurt, Germany	Goethe University Frankfurt	Knapp, S; Joerger, AC (corresponding author), Goethe Univ Frankfurt, Inst Pharmaceut Chem, Frankfurt, Germany.; Knapp, S; Joerger, AC (corresponding author), Buchmann Inst Mol Life Sci BMLS, Struct Genom Consortium SGC, Frankfurt, Germany.; Knapp, S; Joerger, AC (corresponding author), German Translat Canc Network DKTK, Site Frankfurt Mainz, Frankfurt, Germany.	knapp@pharmchem.uni-frankfurt.de; joerger@pharmchem.uni-frankfurt.de	Knapp, Stefan/AAG-2347-2019	Knapp, Stefan/0000-0001-5995-6494; Kramer, Andreas/0000-0003-3294-2660; Joerger, Andreas/0000-0002-1232-0138	SGC; AbbVie [1097737]; Bayer AG; Boehringer Ingelheim; Canada Foundation for Innovation; Eshelman Institute for Innovation; Genentech; Genome Canada through Ontario Genomics Institute [OGI-196]; EU/EFPIA/OICR/McGill/KTH/Diamond, Innovative Medicines Initiative 2 Joint Undertaking [EUbOPEN grant] [875510]; Janssen; Merck KGaA (aka EMD in Canada); Merck KGaA (aka EMD in US); Merck Co (aka MSD); Pfizer; Sao Paulo Research Foundation-FAPESP; Takeda; Wellcome [106169/ZZ14/Z]; Research Training Group Translational Research Innovation-Pharma (TRIP) - Else Kroner-Fresenius Foundation (EKFS); German cancer network DKTK; FCI; German Research Foundation (DFG) [JO 1473/1-3]	SGC; AbbVie(AbbVie); Bayer AG(Bayer AG); Boehringer Ingelheim(Boehringer Ingelheim); Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); Eshelman Institute for Innovation; Genentech(Roche HoldingGenentech); Genome Canada through Ontario Genomics Institute(Genome Canada); EU/EFPIA/OICR/McGill/KTH/Diamond, Innovative Medicines Initiative 2 Joint Undertaking [EUbOPEN grant]; Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Merck KGaA (aka EMD in Canada); Merck KGaA (aka EMD in US); Merck Co (aka MSD); Pfizer(Pfizer); Sao Paulo Research Foundation-FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Takeda(Takeda Pharmaceutical Company Ltd); Wellcome; Research Training Group Translational Research Innovation-Pharma (TRIP) - Else Kroner-Fresenius Foundation (EKFS); German cancer network DKTK; FCI(Fonds der Chemischen Industrie); German Research Foundation (DFG)(German Research Foundation (DFG))	We thank Susanne Muller-Knapp and John Spencer for helpful discussions and for their critical reading of the paper. We are grateful for support by the SGC, a registered charity (no: 1097737) that receives funds from; AbbVie, Bayer AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genentech, Genome Canada through Ontario Genomics Institute [OGI-196], EU/EFPIA/OICR/McGill/KTH/Diamond, Innovative Medicines Initiative 2 Joint Undertaking [EUbOPEN grant 875510], Janssen, Merck KGaA (aka EMD in Canada and US), Merck & Co (aka MSD outside Canada and US), Pfizer, Sao Paulo Research Foundation-FAPESP, Takeda and Wellcome [106169/ZZ14/Z]. MW is also grateful for support by the Research Training Group Translational Research Innovation-Pharma (TRIP), supported by the Else Kroner-Fresenius Foundation (EKFS). SK, ACJ and AK are thankful for support by the German cancer network DKTK and the FCI. ACJ is supported by German Research Foundation (DFG) grant JO 1473/1-3.	Adhikari B, 2020, NAT CHEM BIOL, V16, P1179, DOI 10.1038/s41589-020-00652-y; Agraz-Doblas A, 2020, PREPRINT, DOI [10.1101/2020.01.10.898726., DOI 10.1101/2020.01.10.898726]; Albrecht BK, 2016, U.S. Patent, Patent No. [WO2016138114 A1, 2016138114]; Alexander JM, 2015, DEVELOPMENT, V142, P1418, DOI 10.1242/dev.109496; Alfert A, 2019, EPIGENET CHROMATIN, V12, DOI 10.1186/s13072-019-0264-y; Alimova I, 2019, INT J CANCER, V144, P1983, DOI 10.1002/ijc.31873; Allen MD, 2020, PROTEIN SCI, V29, P1047, DOI 10.1002/pro.3820; Allen MD, 2015, STRUCTURE, V23, P1344, DOI 10.1016/j.str.2015.04.021; Alpsoy A, 2018, J BIOL CHEM, V293, P3892, DOI 10.1074/jbc.RA117.001065; Arbely E, 2011, P NATL ACAD SCI USA, V108, P8251, DOI 10.1073/pnas.1105028108; Arrowsmith CH, 2015, NAT CHEM BIOL, V11, P536, DOI 10.1038/nchembio.1867; Bai J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059772; Banito A, 2018, CANCER CELL, V34, P346, DOI 10.1016/j.ccell.2018.07.006; Bennetzen MV, 2010, MOL CELL PROTEOMICS, V9, P1314, DOI 10.1074/mcp.M900616-MCP200; Bitler BG, 2017, NAT CELL BIOL, V19, P962, DOI 10.1038/ncb3582; Bitler BG, 2015, NAT MED, V21, P231, DOI 10.1038/nm.3799; Bosse T, 2013, MODERN PATHOL, V26, P1525, DOI 10.1038/modpathol.2013.96; Bracken AP, 2019, GENE DEV, V33, P936, DOI 10.1101/gad.326066.119; Brien GL., 2018, ELIFE, V7, P3892; Carugo A, 2019, CANCER CELL, V35, P204, DOI 10.1016/j.ccell.2019.01.006; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan-Penebre E, 2017, MOL CANCER THER, V16, P850, DOI 10.1158/1535-7163.MCT-16-0678; Chandler RL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7118; Chandrasekaran R, 2007, BIOCHEM BIOPH RES CO, V355, P661, DOI 10.1016/j.bbrc.2007.01.193; Charlop-Powers Z, 2010, CELL RES, V20, P529, DOI 10.1038/cr.2010.43; Cheng JX, 2008, MODERN PATHOL, V21, P647, DOI 10.1038/modpathol.2008.44; Cho H, 2013, HUM PATHOL, V44, P1365, DOI 10.1016/j.humpath.2012.11.007; Chory EJ, 2020, ACS CHEM BIOL, V15, P1685, DOI 10.1021/acschembio.0c00312; Clapier CR, 2017, NAT REV MOL CELL BIO, V18, P407, DOI 10.1038/nrm.2017.26; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Clark PGK, 2015, ANGEW CHEM INT EDIT, V54, P6217, DOI 10.1002/anie.201501394; Cochran AG, 2019, NAT REV DRUG DISCOV, V18, P609, DOI 10.1038/s41573-019-0030-7; Crawford TD, 2017, BIOORG MED CHEM LETT, V27, P3534, DOI 10.1016/j.bmcl.2017.05.063; Crew AP, 2019, U.S. Patent, Patent No. [WO20190300521, 20190300521]; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Deribe YL, 2018, NAT MED, V24, P1627, DOI 10.1038/s41591-018-0173-9; Deribe YL, 2018, NAT MED, V24, P1047, DOI 10.1038/s41591-018-0019-5; Drost J, 2010, NAT CELL BIOL, V12, P380, DOI 10.1038/ncb2038; Ehrenhofer-Wolfer K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48152-x; Farnaby W, 2019, NAT CHEM BIOL, V15, P672, DOI 10.1038/s41589-019-0294-6; Fedorov O, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500723; Filippakopoulos P, 2012, CELL, V149, P214, DOI 10.1016/j.cell.2012.02.013; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Frye SV, 2010, NAT CHEM BIOL, V6, P159, DOI 10.1038/nchembio.296; Fukumoto T, 2018, CELL REP, V22, P3393, DOI 10.1016/j.celrep.2018.03.019; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gerstenberger BS, 2016, J MED CHEM, V59, P4800, DOI 10.1021/acs.jmedchem.6b00012; Glaros S, 2007, ONCOGENE, V26, P7058, DOI 10.1038/sj.onc.1210514; Guo CM, 2013, CLIN CHIM ACTA, V417, P39, DOI 10.1016/j.cca.2012.12.012; Hay DA, 2015, MEDCHEMCOMM, V6, P1381, DOI 10.1039/c5md00152h; He S, 2020, SCIENCE, V367, P875, DOI 10.1126/science.aaz9761; Helming KC, 2014, NAT MED, V20, P251, DOI 10.1038/nm.3480; Hodges C, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026930; Hoffman GR, 2014, P NATL ACAD SCI USA, V111, P3128, DOI 10.1073/pnas.1316793111; Hohmann AF, 2016, NAT CHEM BIOL, V12, P672, DOI 10.1038/nchembio.2115; Hong AL., 2019, ELIFE, V8, P818; Howard TP, 2019, CANCER RES, V79, P2404, DOI 10.1158/0008-5472.CAN-18-3066; Hoyer J, 2012, AM J HUM GENET, V90, P565, DOI 10.1016/j.ajhg.2012.02.007; Huang KJ, 2020, CELL CYCLE, V19, P758, DOI 10.1080/15384101.2020.1729450; Januario T, 2017, P NATL ACAD SCI USA, V114, P12249, DOI 10.1073/pnas.1703966114; Joerger AC, 2016, ANNU REV BIOCHEM, V85, P375, DOI 10.1146/annurev-biochem-060815-014710; Jones SE, 2017, CANCER RES, V77, P7014, DOI 10.1158/0008-5472.CAN-17-2056; Kadoch C, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500447; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Kaelin WG, 2009, GENOME MED, V1, DOI 10.1186/gm99; Karim RM, 2020, J MED CHEM, V63, P3227, DOI 10.1021/acs.jmedchem.9b01980; Kelso TWR, 2017, ELIFE, V6, DOI [10.7554/eLife.30506, 10.7554/eLife.30506.001]; Kim KH, 2015, NAT MED, V21, P1491, DOI 10.1038/nm.3968; Knipstein JA, 2012, NEURO-ONCOLOGY, V14, P175, DOI 10.1093/neuonc/nor208; Kohashi K, 2017, CANCER SCI, V108, P547, DOI 10.1111/cas.13173; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Karmer KF, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071537; Langer LF, 2019, ELIFE, V8, DOI 10.7554/eLife.45672; Lee D, 2017, ONCOTARGETS THER, V10, P4153, DOI 10.2147/OTT.S139664; Li M, 2011, NAT GENET, V43, P828, DOI 10.1038/ng.903; Liao LL, 2019, MOL ONCOL, V13, P811, DOI 10.1002/1878-0261.12434; Lu T, 2018, ACTA PHARMACOL SIN, V39, P1544, DOI 10.1038/aps.2017.188; Manceau G, 2013, INT J CANCER, V132, P2217, DOI 10.1002/ijc.27900; Marian CA, 2018, CELL CHEM BIOL, V25, P1443, DOI 10.1016/j.chembiol.2018.08.004; Martin LJ, 2016, J MED CHEM, V59, P4462, DOI 10.1021/acs.jmedchem.5b01865; Mashtalir N, 2020, CELL, V183, P802, DOI 10.1016/j.cell.2020.09.051; Mashtalir N, 2018, CELL, V175, P1272, DOI 10.1016/j.cell.2018.09.032; Mathur R, 2017, NAT GENET, V49, P296, DOI 10.1038/ng.3744; McBride MJ, 2018, CANCER CELL, V33, P1128, DOI 10.1016/j.ccell.2018.05.002; Michel BC, 2018, NAT CELL BIOL, V20, P1410, DOI 10.1038/s41556-018-0221-1; Miller RE, 2016, MOL CANCER THER, V15, P1472, DOI 10.1158/1535-7163.MCT-15-0554; Molina JR, 2018, NAT MED, V24, P1036, DOI 10.1038/s41591-018-0052-4; Muller S, 2018, ELIFE, V7, DOI 10.7554/eLife.34311; Muscat A, 2016, CLIN CANCER RES, V22, P3560, DOI 10.1158/1078-0432.CCR-15-2260; Myrianthopoulos V, 2016, J MED CHEM, V59, P8787, DOI 10.1021/acs.jmedchem.6b00355; Nakayama RT, 2017, NAT GENET, V49, P1613, DOI 10.1038/ng.3958; Nalawansha DA, 2020, CELL CHEM BIOL, V27, P998, DOI 10.1016/j.chembiol.2020.07.020; Nargund AM, 2017, CELL REP, V18, P2893, DOI 10.1016/j.celrep.2017.02.074; Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589; Nijman SMB, 2011, FEBS LETT, V585, P1, DOI 10.1016/j.febslet.2010.11.024; Oba A, 2017, J HEPATOL, V66, P942, DOI 10.1016/j.jhep.2016.12.026; Ochoa D, 2020, NAT BIOTECHNOL, V38, P365, DOI 10.1038/s41587-019-0344-3; Ogiwara H, 2019, CANCER CELL, V35, P177, DOI 10.1016/j.ccell.2018.12.009; Oike T, 2013, CANCER RES, V73, P5508, DOI 10.1158/0008-5472.CAN-12-4593; Papillon JPN, 2018, J MED CHEM, V61, P10155, DOI 10.1021/acs.jmedchem.8b01318; Park Y, 2019, CLIN CANCER RES, V25, P5584, DOI 10.1158/1078-0432.CCR-18-4222; Pavlidou EN., 2020, WORLD ACAD SCI J, V2, P49, DOI [10.3892/wasj.2020.37, DOI 10.3892/WASJ.2020.37]; Peng G, 2009, NAT CELL BIOL, V11, P865, DOI 10.1038/ncb1895; Pettersson Mariell, 2019, Drug Discov Today Technol, V31, P15, DOI 10.1016/j.ddtec.2019.01.002; Porter EG, 2017, J BIOL CHEM, V292, P2601, DOI 10.1074/jbc.M116.746875; Pyo JS, 2018, HUM PATHOL, V73, P66, DOI 10.1016/j.humpath.2017.12.013; Reisman DN, 2003, CANCER RES, V63, P560; Remillard D, 2017, ANGEW CHEM INT EDIT, V56, P5738, DOI 10.1002/anie.201611281; Samartzis EP, 2014, ONCOTARGET, V5, P5295, DOI 10.18632/oncotarget.2092; Santen GWE, 2012, NAT GENET, V44, P379, DOI 10.1038/ng.2217; Schick S, 2019, NAT GENET, V51, P1399, DOI 10.1038/s41588-019-0477-9; Shen JF, 2015, CANCER DISCOV, V5, P752, DOI 10.1158/2159-8290.CD-14-0849; Shorstova T, 2019, CANCER RES, V79, P2761, DOI 10.1158/0008-5472.CAN-18-1545; Sima XX, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222305; Slade D, 2020, GENE DEV, V34, P360, DOI 10.1101/gad.334516.119; Slaughter MJ, 2018, J BIOL CHEM, V293, P13592, DOI 10.1074/jbc.RA118.003381; Smith MJ, 2014, CANCER GENET-NY, V207, P373, DOI 10.1016/j.cancergen.2014.04.001; Stanton BZ, 2017, NAT GENET, V49, P282, DOI 10.1038/ng.3735; Sun HB, 2007, BIOCHEM BIOPH RES CO, V358, P435, DOI 10.1016/j.bbrc.2007.04.139; Sutherell CL, 2016, J MED CHEM, V59, P5095, DOI 10.1021/acs.jmedchem.5b01997; Tagal V, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14098; Theodoulou NH, 2016, J MED CHEM, V59, P1425, DOI 10.1021/acs.jmedchem.5b00256; van der Vaart A, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay3823; Vangamudi B, 2015, CANCER RES, V75, P3865, DOI 10.1158/0008-5472.CAN-14-3798; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vidler LR, 2012, J MED CHEM, V55, P7346, DOI 10.1021/jm300346w; Wang WD, 1998, P NATL ACAD SCI USA, V95, P492, DOI 10.1073/pnas.95.2.492; WANG XF, 2017, NAT GENET, V49, P289, DOI [DOI 10.1038/NG.3746, 10.1038/ng.3746]; Wang XY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08657-5; Wanior M, 2020, J MED CHEM, V63, P14680, DOI 10.1021/acs.jmedchem.0c01242; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Williamson CT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13837; Wilson BG, 2014, MOL CELL BIOL, V34, P1136, DOI 10.1128/MCB.01372-13; Wilson BG, 2010, CANCER CELL, V18, P316, DOI 10.1016/j.ccr.2010.09.006; Wu CJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05694-4; Wu Q, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08234-2; Xia X, 2016, NAT STRUCT MOL BIOL, V23, P722, DOI 10.1038/nsmb.3259; Xue YK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09774-x; Zhang L, 2018, TECHNOL CANCER RES T, V17, DOI 10.1177/1533034618754475; Zoppi V, 2019, J MED CHEM, V62, P699, DOI 10.1021/acs.jmedchem.8b01413	141	19	19	3	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2021	40	21					3637	3654		10.1038/s41388-021-01781-x	http://dx.doi.org/10.1038/s41388-021-01781-x		MAY 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SI8ZW	33941852	Green Published, hybrid			2022-12-17	WOS:000646512200002
J	Ma, YJ; Zha, JY; Yang, XK; Li, QJ; Zhang, QF; Yin, A; Beharry, Z; Huang, HW; Huang, JT; Bartlett, M; Ye, KX; Yin, H; Cai, HJ				Ma, Yongjie; Zha, Junyi; Yang, XiangKun; Li, Qianjin; Zhang, Qingfu; Yin, Amelia; Beharry, Zanna; Huang, Hanwen; Huang, Jiaoti; Bartlett, Michael; Ye, Kaixiong; Yin, Hang; Cai, Houjian			Long-chain fatty acyl-CoA synthetase 1 promotes prostate cancer progression by elevation of lipogenesis and fatty acid beta-oxidation	ONCOGENE			English	Article								Fatty acid metabolism is essential for the biogenesis of cellular components and ATP production to sustain proliferation of cancer cells. Long-chain fatty acyl-CoA synthetases (ACSLs), a group of rate-limiting enzymes in fatty acid metabolism, catalyze the bioconversion of exogenous or de novo synthesized fatty acids to their corresponding fatty acyl-CoAs. In this study, systematical analysis of ACSLs levels and the amount of fatty acyl-CoAs illustrated that ACSL1 were significantly associated with the levels of a broad spectrum of fatty acyl-CoAs, and were elevated in human prostate tumors. ACSL1 increased the biosynthesis of fatty acyl-CoAs including C16:0-, C18:0-, C18:1-, and C18:2-CoA, triglycerides and lipid accumulation in cancer cells. Mechanistically, ACSL1 modulated mitochondrial respiration, beta-oxidation, and ATP production through regulation of CPT1 activity. Knockdown of ACSL1 inhibited the cell cycle, and suppressed the proliferation and migration of prostate cancer cells in vitro, and growth of prostate xenograft tumors in vivo. Our study implicates ACSL1 as playing an important role in prostate tumor progression, and provides a therapeutic strategy of targeting fatty acid metabolism for the treatment of prostate cancer.	[Ma, Yongjie; Zha, Junyi; Yang, XiangKun; Li, Qianjin; Bartlett, Michael; Cai, Houjian] Univ Georgia, Coll Pharm, Dept Pharmaceut & Biomed Sci, Athens, GA 30602 USA; [Zhang, Qingfu; Huang, Jiaoti] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27706 USA; [Yin, Amelia; Yin, Hang] Univ Georgia, Ctr Mol Med, Dept Biochem & Mol Biol, Athens, GA 30602 USA; [Beharry, Zanna] Univ Virgin Isl, Dept Chem & Phys Sci, St Thomas, VI USA; [Huang, Hanwen] Univ Georgia, Dept Epidemiol & Biostat, Athens, GA 30602 USA; [Ye, Kaixiong] Univ Georgia, Dept Genet, Athens, GA 30602 USA; [Ye, Kaixiong] Univ Georgia, Inst Bioinformat, Athens, GA 30602 USA	University System of Georgia; University of Georgia; Duke University; University System of Georgia; University of Georgia; University of the Virgin Islands; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Cai, HJ (corresponding author), Univ Georgia, Coll Pharm, Dept Pharmaceut & Biomed Sci, Athens, GA 30602 USA.	caihj@uga.edu		Bartlett, Michael/0000-0003-0626-3234; Beharry, Zanna/0000-0002-3900-8523; Zha, Junyi/0000-0003-2125-1362; Zhang, Qingfu/0000-0002-9891-1296	NIH [R01CA172495]; DOD [W81XWH-15-1-0507]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense)	This work was supported by NIH (R01CA172495) and DOD (W81XWH-15-1-0507) to HC.	BIEBER LL, 1972, ANAL BIOCHEM, V50, P509, DOI 10.1016/0003-2697(72)90061-9; Butler LM, 2016, ENDOCR-RELAT CANCER, V23, pR219, DOI 10.1530/ERC-15-0556; Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017; Ellis JM, 2011, MOL CELL BIOL, V31, P1252, DOI 10.1128/MCB.01085-10; EPSTEIN JI, 1995, UROLOGY, V45, P81, DOI 10.1016/S0090-4295(95)96904-7; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gazi E, 2007, J LIPID RES, V48, P1846, DOI 10.1194/jlr.M700131-JLR200; Grevengoed TJ, 2015, J LIPID RES, V56, P1572, DOI 10.1194/jlr.M059717; Grevengoed TJ, 2014, ANNU REV NUTR, V34, P1, DOI 10.1146/annurev-nutr-071813-105541; Iijima H, 1996, EUR J BIOCHEM, V242, P186, DOI 10.1111/j.1432-1033.1996.0186r.x; Kim S, 2017, CANCER RES, V77, P6950, DOI 10.1158/0008-5472.CAN-17-0981; Kim S, 2017, J BIOL CHEM, V292, P18422, DOI [10.1074/jbc.M117.798827, 10.1074/jbc.m117.798827]; Koizume S, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091430; Kuemmerle NB, 2011, MOL CANCER THER, V10, P427, DOI 10.1158/1535-7163.MCT-10-0802; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Lee K, 2011, J BIOL CHEM, V286, P25655, DOI 10.1074/jbc.M111.228692; Li LO, 2009, J BIOL CHEM, V284, P27816, DOI 10.1074/jbc.M109.022467; Lloyd MD, 2013, PROG LIPID RES, V52, P220, DOI 10.1016/j.plipres.2013.01.001; Mashima T, 2005, JNCI-J NATL CANCER I, V97, P765, DOI 10.1093/jnci/dji133; Sanchez-Martinez R, 2015, ONCOTARGET, V6, P38719, DOI 10.18632/oncotarget.5340; Schlaepfer IR, 2014, MOL CANCER THER, V13, P2361, DOI 10.1158/1535-7163.MCT-14-0183; Soupene E, 2008, EXP BIOL MED, V233, P507, DOI 10.3181/0710-MR-287; Vargas T, 2015, ONCOTARGET, V6, P7348, DOI 10.18632/oncotarget.3130; Wang YY, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.87489; Wu XY, 2015, ONCOTARGET, V6, P44849, DOI 10.18632/oncotarget.6438; Wu XY, 2014, AM J CLIN EXP UROL, V2, P111; Yan S, 2015, WORLD J GASTROENTERO, V21, P3492, DOI 10.3748/wjg.v21.i12.3492; Yang XK, 2017, ANAL CHEM, V89, P813, DOI 10.1021/acs.analchem.6b03623; Yen CLE, 2008, J LIPID RES, V49, P2283, DOI 10.1194/jlr.R800018-JLR200; Yue SH, 2014, CELL METAB, V19, P393, DOI 10.1016/j.cmet.2014.01.019	30	19	19	3	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2021	40	10					1806	1820		10.1038/s41388-021-01667-y	http://dx.doi.org/10.1038/s41388-021-01667-y		FEB 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU6VJ	33564069	Green Accepted			2022-12-17	WOS:000616489100012
J	Xu, H; Liu, L; Li, WL; Zou, DW; Yu, J; Wang, LF; Wong, CC				Xu, Hui; Liu, Lei; Li, Weilin; Zou, Duowu; Yu, Jun; Wang, Lifu; Wong, Chi Chun			Transcription factors in colorectal cancer: molecular mechanism and therapeutic implications	ONCOGENE			English	Review							NF-KAPPA-B; KRUPPEL-LIKE FACTOR-4; CELL-CYCLE ARREST; TUMOR-SUPPRESSIVE PROPERTIES; ENDOTHELIAL GROWTH-FACTOR; APOPTOSIS IN-VITRO; ACTIVATED T-CELLS; FORKHEAD BOX M1; COLON-CANCER; NUCLEAR-FACTOR	Colorectal cancer (CRC) is a major cause of cancer mortality worldwide, however, the molecular mechanisms underlying the pathogenesis of CRC remain largely unclear. Recent studies have revealed crucial roles of transcription factors in CRC development. Transcription factors essential for the regulation of gene expression by interacting with transcription corepressor/enhancer complexes and they orchestrate downstream signal transduction. Deregulation of transcription factors is a frequent occurrence in CRC, and the accompanying drastic changes in gene expression profiles play fundamental roles in multistep process of tumorigenesis, from cellular transformation, disease progression to metastatic disease. Herein, we summarized current and emerging key transcription factors that participate in CRC tumorigenesis, and highlighted their oncogenic or tumor suppressive functions. Moreover, we presented critical transcription factors of CRC, emphasized the major molecular mechanisms underlying their effect on signal cascades associated with tumorigenesis, and summarized of their potential as molecular biomarkers for CRC prognosis therapeutic response, as well as drug targets for CRC treatment. A better understanding of transcription factors involved in the development of CRC will provide new insights into the pathological mechanisms and reveal novel prognostic biomarkers and therapeutic strategies for CRC.	[Xu, Hui; Liu, Lei; Zou, Duowu; Wang, Lifu] Shanghai Jiao Tong Univ, Sch Med, Dept Gastroenterol, Ruijin Hosp, Shanghai, Peoples R China; [Xu, Hui; Yu, Jun; Wong, Chi Chun] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China; [Xu, Hui; Yu, Jun; Wong, Chi Chun] Chinese Univ Hong Kong, Dept Med & Therapeut, State Key Lab Digest Dis, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China; [Li, Weilin] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Genet, Boston, MA 02115 USA	Shanghai Jiao Tong University; Chinese University of Hong Kong; Chinese University of Hong Kong; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Liu, L; Wang, LF (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Dept Gastroenterol, Ruijin Hosp, Shanghai, Peoples R China.; Wong, CC (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China.; Wong, CC (corresponding author), Chinese Univ Hong Kong, Dept Med & Therapeut, State Key Lab Digest Dis, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China.	ll11860@rjh.com.cn; lifuwang@sjtu.edu.cn; chichun.wong@cuhk.edu.hk	; Jun, Yu/D-8569-2015	Wong, Chi Chun/0000-0003-1362-3541; Jun, Yu/0000-0001-5008-2153	Natural Science Foundation of China [81802331, 81772501]; Research Grants Council-General Research Fund (RGC-GRF), Hong Kong [14101917, 14108718, 14163817, 14110819]; Heath and Medical Research Fund (HMRF) [06170686]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Grants Council-General Research Fund (RGC-GRF), Hong Kong; Heath and Medical Research Fund (HMRF)	This project was supported by the Natural Science Foundation of China (81802331, 81772501), Research Grants Council-General Research Fund (RGC-GRF; 14101917, 14108718, 14163817 and 14110819), Hong Kong; Heath and Medical Research Fund (HMRF) (06170686).	Abdelrahim M, 2005, MOL PHARMACOL, V68, P317, DOI 10.1124/mol.105.011825; Ahmed M, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0406-1; Arques O, 2016, CLIN CANCER RES, V22, P644, DOI 10.1158/1078-0432.CCR-14-3081; Ashida Reiko, 2005, Inflammopharmacology, V13, P113, DOI 10.1163/156856005774423935; Bajpai R, 2017, CRIT REV ONCOL HEMAT, V113, P1, DOI 10.1016/j.critrevonc.2017.02.024; Beishline K, 2015, FEBS J, V282, P224, DOI 10.1111/febs.13148; Bella L, 2014, SEMIN CANCER BIOL, V29, P32, DOI 10.1016/j.semcancer.2014.07.008; Ben-David E, 2014, CANCER RES, V74, P5532, DOI 10.1158/0008-5472.CAN-14-0932; Binion DG, 2008, GUT, V57, P1509, DOI 10.1136/gut.2008.152496; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Buettner R, 2002, CLIN CANCER RES, V8, P945; Bullock MD, 2013, BRIT J CANCER, V109, P387, DOI 10.1038/bjc.2013.355; Cervantes-Madrid DL, 2017, ONCOL LETT, V13, P1411, DOI 10.3892/ol.2017.5571; Chang WC, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-94; Chen FF, 2016, ONCOL REP, V35, P1227, DOI 10.3892/or.2015.4515; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; Chen YJ, 2009, CHEM-BIOL INTERACT, V181, P440, DOI 10.1016/j.cbi.2009.07.004; Chhabra A, 2007, ONCOL REP, V18, P953; Chintharlapalli S, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-371; Conkright MD, 2005, TRENDS CELL BIOL, V15, P457, DOI 10.1016/j.tcb.2005.07.007; Cooks T, 2013, CANCER CELL, V23, P634, DOI 10.1016/j.ccr.2013.03.022; Corvinus FM, 2005, NEOPLASIA, V7, P545, DOI 10.1593/neo.04571; Cruz-Correa M, 2018, GASTROENTEROLOGY, V155, P668, DOI 10.1053/j.gastro.2018.05.031; Dang DT, 2003, ONCOGENE, V22, P3424, DOI 10.1038/sj.onc.1206413; Dang DT, 2000, FEBS LETT, V476, P203, DOI 10.1016/S0014-5793(00)01727-0; Daniel C, 2014, INT J CANCER, V134, P1767, DOI 10.1002/ijc.28329; Dehner M, 2008, J BIOL CHEM, V283, P19201, DOI 10.1074/jbc.M710366200; Demir S, 2020, HAEMATOLOGICA, V105, P170, DOI 10.3324/haematol.2018.199364; Du W, 2012, J CELL PHYSIOL, V227, P2421, DOI 10.1002/jcp.22977; Dunleavy K, 2009, BLOOD, V113, P6069, DOI 10.1182/blood-2009-01-199679; Duque J, 2005, J BIOL CHEM, V280, P8686, DOI 10.1074/jbc.M413076200; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; de Mattos SF, 2008, MOL CANCER THER, V7, P3237, DOI 10.1158/1535-7163.MCT-08-0398; Fitzgerald KA, 2014, EXPERT OPIN THER TAR, V18, P633, DOI 10.1517/14728222.2014.896904; Furqan M, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-90; Gambhir S, 2015, WORLD J GASTROENTERO, V21, P3174, DOI 10.3748/wjg.v21.i11.3174; Gerlach K, 2012, CANCER RES, V72, P4340, DOI 10.1158/0008-5472.CAN-11-4155; Germani A, 2014, CANCER LETT, V344, P110, DOI 10.1016/j.canlet.2013.10.035; Ghaleb AM, 2016, MOL CANCER RES, V14, P385, DOI 10.1158/1541-7786.MCR-15-0410; Goel A, 2004, INT J CANCER, V112, P754, DOI 10.1002/ijc.20472; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Groner B, 2017, MOL CELL ENDOCRINOL, V451, P1, DOI 10.1016/j.mce.2017.05.033; Halasi M, 2013, MOL CANCER THER, V12, P245, DOI 10.1158/1535-7163.MCT-12-0712; Haydon AMM, 2006, GUT, V55, P62, DOI 10.1136/gut.2005.068189; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Hong X, 2012, MOL MED REP, V5, P1215, DOI 10.3892/mmr.2012.801; Hosoi Y, 2004, INT J ONCOL, V25, P461; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Hubbard JM, 2017, DRUGS, V77, P1091, DOI 10.1007/s40265-017-0759-4; Hui KY, 2014, CANCER LETT, V354, P189, DOI 10.1016/j.canlet.2014.08.009; Iacopetta B, 2006, ANN ONCOL, V17, P842, DOI 10.1093/annonc/mdl035; Iacopetta B, 2003, HUM MUTAT, V21, P271, DOI 10.1002/humu.10175; Imamura Y, 2005, ANTICANCER RES, V25, P2627; Ito K, 2008, CANCER CELL, V14, P226, DOI 10.1016/j.ccr.2008.08.004; Itoh N, 2002, CANCER, V94, P3127, DOI 10.1002/cncr.10591; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Jiang WH, 2015, SURG ONCOL, V24, P220, DOI 10.1016/j.suronc.2015.05.004; Jin H, 2015, ONCOL REP, V33, P3171, DOI 10.3892/or.2015.3938; Kane RC, 2003, ONCOLOGIST, V8, P508, DOI 10.1634/theoncologist.8-6-508; Kappelmann M, 2014, EUR J CELL BIOL, V93, P76, DOI 10.1016/j.ejcb.2013.10.003; Khaleghpour K, 2004, CARCINOGENESIS, V25, P241, DOI 10.1093/carcin/bgg195; Kodach LL, 2010, CARCINOGENESIS, V31, P1567, DOI 10.1093/carcin/bgq147; Konstantinopoulos PA, 2011, JAMA-J AM MED ASSOC, V305, P2349, DOI 10.1001/jama.2011.727; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Ku JL, 2004, ONCOGENE, V23, P6736, DOI 10.1038/sj.onc.1207731; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Kunnumakkara AB, 2007, CANCER RES, V67, P3853, DOI 10.1158/0008-5472.CAN-06-4257; Lagadec P, 2008, BRIT J CANCER, V98, P335, DOI 10.1038/sj.bjc.6604082; Lai PS, 2015, EXPERT OPIN THER PAT, V25, P1397, DOI 10.1517/13543776.2015.1086749; Lambert SA, 2018, CELL, V172, P650, DOI 10.1016/j.cell.2018.01.029; Lee CWL, 2010, CANCER RES, V70, P4243, DOI 10.1158/0008-5472.CAN-09-3805; Lee TI, 2013, CELL, V152, P1237, DOI 10.1016/j.cell.2013.02.014; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li DW, 2013, CLIN CANCER RES, V19, P62, DOI 10.1158/1078-0432.CCR-12-1588; Li XL, 2015, WORLD J GASTROENTERO, V21, P84, DOI 10.3748/wjg.v21.i1.84; Liang HS, 2011, CANCER LETT, V313, P91, DOI 10.1016/j.canlet.2011.08.028; Lin L, 2011, CANCER RES, V71, P7226, DOI 10.1158/0008-5472.CAN-10-4660; Liu SH, 2014, GASTROENTEROLOGY, V147, P847, DOI 10.1053/j.gastro.2014.06.006; Liu Y, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0856-3; Lu SY, 2010, INT J CANCER, V126, P416, DOI 10.1002/ijc.24761; Lund IK, 2011, CURR DRUG TARGETS, V12, P1744; Luo H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.3; Madrigal P, 2018, TRENDS CELL BIOL, V28, P509, DOI 10.1016/j.tcb.2018.04.009; Mariani F, 2014, WORLD J GASTROENTERO, V20, P9716, DOI 10.3748/wjg.v20.i29.9716; Marzi L, 2016, BRIT J CANCER, V115, P1223, DOI 10.1038/bjc.2016.313; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mishra L, 2005, ONCOGENE, V24, P5775, DOI 10.1038/sj.onc.1208924; Nagarsheth N, 2016, CANCER RES, V76, P275, DOI 10.1158/0008-5472.CAN-15-1938; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Ogino S, 2007, VIRCHOWS ARCH, V450, P529, DOI 10.1007/s00428-007-0398-3; Okugawa Y, 2015, GASTROENTEROLOGY, V149, P1204, DOI 10.1053/j.gastro.2015.07.011; Page BDG, 2011, EXPERT OPIN THER PAT, V21, P65, DOI 10.1517/13543776.2011.539205; Pandey MK, 2012, INT J CANCER, V130, P213, DOI 10.1002/ijc.25997; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Patel M, 2018, TRANSL RES, V197, P43, DOI 10.1016/j.trsl.2018.02.002; Patel NV, 2010, CANCER EPIDEM BIOMAR, V19, P2631, DOI 10.1158/1055-9965.EPI-10-0677; Poynter JN, 2009, CANCER EPIDEM BIOMAR, V18, P2745, DOI 10.1158/1055-9965.EPI-09-0517; Prasad S, 2010, MOL CELL BIOCHEM, V336, P25, DOI 10.1007/s11010-009-0267-2; Qazi AK, 2015, CANCER LETT, V359, P47, DOI 10.1016/j.canlet.2014.12.034; Qi WT, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-219; Qi WT, 2011, AM J PHYSIOL-GASTR L, V300, pG264, DOI 10.1152/ajpgi.00416.2010; Rajitha B, 2016, CANCER LETT, V373, P227, DOI 10.1016/j.canlet.2016.01.052; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Robbs BK, 2008, MOL CELL BIOL, V28, P7168, DOI 10.1128/MCB.00256-08; Roger L, 2010, J CELL SCI, V123, P1295, DOI 10.1242/jcs.061002; Russo A, 2005, J CLIN ONCOL, V23, P7518, DOI 10.1200/JCO.2005.00.471; Sakai E, 2016, CANCER SCI, V107, P820, DOI 10.1111/cas.12930; Sakamoto KM, 2009, CLIN CANCER RES, V15, P2583, DOI 10.1158/1078-0432.CCR-08-1137; Sakamoto K, 2009, CLIN CANCER RES, V15, P2248, DOI 10.1158/1078-0432.CCR-08-1383; Sampurno S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.119; Sandoval Salemiz, 2009, Adv Hematol, V2009, P634292, DOI 10.1155/2009/634292; Sarkar M, 2015, ONCOGENE, V34, P5843, DOI 10.1038/onc.2015.42; Schaffer M, 2015, CURR OPIN CLIN NUTR, V18, P605, DOI 10.1097/MCO.0000000000000227; Schulz-Heddergott R, 2018, CANCER CELL, V34, P298, DOI 10.1016/j.ccell.2018.07.004; Seo HS, 2008, CANCER RES, V68, P6065, DOI 10.1158/0008-5472.CAN-07-5376; Seymour MT, 2007, LANCET, V370, P143, DOI 10.1016/S0140-6736(07)61087-3; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shen H, 2011, CURR PHARM DESIGN, V17, P560, DOI 10.2174/138161211795222603; Shen LL, 2007, P NATL ACAD SCI USA, V104, P18654, DOI 10.1073/pnas.0704652104; Shi Q, 2001, CANCER RES, V61, P4143; Shoeb M, 2013, FREE RADICAL BIO MED, V63, P280, DOI 10.1016/j.freeradbiomed.2013.05.039; Song IS, 2015, GASTROENTEROLOGY, V149, P1006, DOI 10.1053/j.gastro.2015.06.007; Song KH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.462; Soong R, 2009, BRIT J CANCER, V100, P676, DOI 10.1038/sj.bjc.6604899; Spano JP, 2006, EUR J CANCER, V42, P2668, DOI 10.1016/j.ejca.2006.07.006; Stein Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246197; Steven A, 2015, MOL CANCER RES, V13, P1248, DOI 10.1158/1541-7786.MCR-14-0590; Subramaniam MM, 2009, AM J GASTROENTEROL, V104, P426, DOI 10.1038/ajg.2008.141; Subramaniam MM, 2009, BBA-REV CANCER, V1796, P315, DOI 10.1016/j.bbcan.2009.07.004; Sunami Y, 2011, J CLIN INVEST, V121, P2551, DOI 10.1172/JCI58454; Sung JJY, 2008, GUT, V57, P1166, DOI 10.1136/gut.2007.146316; Takayama T, 2006, J GASTROENTEROL, V41, P185, DOI 10.1007/s00535-006-1801-6; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Tortola S, 1999, J CLIN ONCOL, V17, P1375, DOI 10.1200/JCO.1999.17.5.1375; Tripathi MK, 2014, CANCER RES, V74, P6947, DOI 10.1158/0008-5472.CAN-14-1592; Uddin S, 2011, AM J PATHOL, V178, P537, DOI 10.1016/j.ajpath.2010.10.020; Vaiopoulos AG, 2013, J MOL MED, V91, P1029, DOI 10.1007/s00109-013-1045-x; van Grevenynghe J, 2012, CYTOKINE GROWTH F R, V23, P215, DOI 10.1016/j.cytogfr.2012.05.008; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Waby JS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-275; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Wang D, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00897-z; Wang F, 2013, J PATHOL, V229, P12, DOI 10.1002/path.4078; Wang XW, 2017, ONCOL LETT, V13, P2867, DOI 10.3892/ol.2017.5851; Watson IR, 2013, NAT REV GENET, V14, P703, DOI 10.1038/nrg3539; Weisz L, 2007, CANCER RES, V67, P2396, DOI 10.1158/0008-5472.CAN-06-2425; Wierstra I, 2013, ADV CANCER RES, V119, P191, DOI 10.1016/B978-0-12-407190-2.00016-2; Xia YF, 2014, CANCER IMMUNOL RES, V2, P823, DOI 10.1158/2326-6066.CIR-14-0112; Xie FC, 2015, J MED CHEM, V58, P5075, DOI 10.1021/acs.jmedchem.5b00468; Xiong H, 2008, NEOPLASIA, V10, P287, DOI 10.1593/neo.07971; Xiong H, 2009, LAB INVEST, V89, P717, DOI 10.1038/labinvest.2009.11; Xu J, 2008, J CANCER RES CLIN, V134, P891, DOI 10.1007/s00432-008-0353-y; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yang KK, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0158-1; Yang VW, 2019, MOL CANCER RES, V17, P165, DOI 10.1158/1541-7786.MCR-18-0399; Yeh JE, 2013, CURR OPIN ONCOL, V25, P652, DOI 10.1097/01.cco.0000432528.88101.1a; Yoshida Y, 2007, GASTROENTEROLOGY, V132, P1420, DOI 10.1053/j.gastro.2007.01.036; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Yu LL, 2004, WORLD J GASTROENTERO, V10, P3255, DOI 10.3748/wjg.v10.i22.3255; Yue M, 2018, CELL CYCLE, V17, P240, DOI 10.1080/15384101.2017.1407892; Zhang J, 2017, RECENT PAT ANTI-CANC, V12, P247, DOI [10.2174/1574892812666170508124932, 10.2174/1574892812666170424144352]; Zhang W, 2006, MOL CELL BIOL, V26, P2055, DOI 10.1128/MCB.26.6.2055-2064.2006; Zhang WH, 2005, AM J CLIN PATHOL, V124, P11, DOI 10.1309/T1H2Y2CHWY7PD2BN; Zhang X, 2017, ONCOGENE, V36, P807, DOI 10.1038/onc.2016.249; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067; Zhao YY, 2013, ONCOL REP, V30, P1782, DOI 10.3892/or.2013.2627; Zhou XJ, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0677-x	170	19	19	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1555	1569		10.1038/s41388-020-01587-3	http://dx.doi.org/10.1038/s41388-020-01587-3		DEC 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33323976				2022-12-17	WOS:000599126500009
J	Han, AN; Purwin, TJ; Bechtel, N; Liao, C; Chua, V; Seifert, E; Sato, T; Schug, ZT; Speicher, DW; Harbour, JW; Aplin, AE				Han, Anna; Purwin, Timothy J.; Bechtel, Nelisa; Liao, Connie; Chua, Vivian; Seifert, Erin; Sato, Takami; Schug, Zachary T.; Speicher, David W.; William Harbour, J.; Aplin, Andrew E.			BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors	ONCOGENE			English	Article							TARGETING CANCER METABOLISM; FATTY-ACID OXIDATION; CELL-METABOLISM; GENE; EXPRESSION; PROTEIN; ASSOCIATION; GLYCOLYSIS; REGULATOR; SUBTYPES	Cancer cell metabolism is a targetable vulnerability; however, a precise understanding of metabolic heterogeneity is required. Inactivating mutations in BRCA1-associated protein 1 (BAP1) are associated with metastasis in uveal melanoma (UM), the deadliest adult eye cancer. BAP1 functions in UM remain unclear. UM patient sample analysis divided BAP1 mutant UM tumors into two subgroups based on oxidative phosphorylation (OXPHOS) gene expression suggesting metabolic heterogeneity. Consistent with patient data, transcriptomic analysis of BAP1 mutant UM cell lines also showed OXPHOShigh or OXPHOSlow subgroups. Integrated RNA sequencing, metabolomics, and molecular analyses showed that OXPHOS(high)BAP1 mutant UM cells utilize glycolytic and nucleotide biosynthesis pathways, whereas OXPHOS(low)BAP1 mutant UM cells employ fatty acid oxidation. Furthermore, the two subgroups responded to different classes of metabolic suppressors. Our findings indicate that targeting cancer metabolism is a promising therapeutic option for BAP1 mutant UM; however, tailored approaches may be required due to metabolic heterogeneities.	[Han, Anna; Purwin, Timothy J.; Bechtel, Nelisa; Liao, Connie; Chua, Vivian; Aplin, Andrew E.] Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA 19107 USA; [Seifert, Erin] Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA; [Sato, Takami] Thomas Jefferson Univ, Dept Med Oncol, Philadelphia, PA 19107 USA; [Sato, Takami; Aplin, Andrew E.] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Schug, Zachary T.; Speicher, David W.] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA; [Speicher, David W.] Wistar Inst Anat & Biol, Prote & Metab Facil, 3601 Spruce St, Philadelphia, PA 19104 USA; [William Harbour, J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33101 USA; [William Harbour, J.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33101 USA; [William Harbour, J.] Univ Miami, Miller Sch Med, Interdisciplinary Stem Cell Inst, Miami, FL 33101 USA	Jefferson University; Jefferson University; Jefferson University; Jefferson University; The Wistar Institute; The Wistar Institute; Bascom Palmer Eye Institute; University of Miami; University of Miami; University of Miami	Aplin, AE (corresponding author), Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA 19107 USA.; Aplin, AE (corresponding author), Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA.	Andrew.Aplin@Jefferson.edu		Schug, Zachary/0000-0003-4197-8227; Han, Anna/0000-0001-8180-6214; Purwin, Timothy/0000-0002-7053-8039	Melanoma Research Alliance team science award [559058]; National Institutes of Health (NIH)/National Cancer Institute (NCI) [R01 CA196278, R01 CA253977, P50CA174523]; National Cancer Center; American Association for Cancer Research (AACR)/Ocular Melanoma Foundation; NCI [P01 CA114046];  [P30CA010815];  [S10OD023586]	Melanoma Research Alliance team science award; National Institutes of Health (NIH)/National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Center; American Association for Cancer Research (AACR)/Ocular Melanoma Foundation; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; 	We thank Dr. Sergio Roman-Roman (Uveal Melanoma Translational Group, Department of Translational Research, Institute Curie, PSL Research University, Paris, France) for cell lines. We thank Dr. Michele Carbone (University of Hawaii Cancer Center, Honolulu, HI, USA) for BAP1 cDNA. This work was supported by a Melanoma Research Alliance team science award (#559058) to AEA and JWH. Further support was from National Institutes of Health (NIH)/National Cancer Institute (NCI), R01 CA196278 and R01 CA253977 to AEA, P50CA174523 to DWS and fellowships from the National Cancer Center and American Association for Cancer Research (AACR)/Ocular Melanoma Foundation (OMF) awarded to AH and VC. This work was also supported by grant from NCI P01 CA114046. The Wistar Proteomics and Metabolomics Facility was supported by P30CA010815 and S10OD023586.	Amirouchene-Angelozzi N, 2014, MOL ONCOL, V8, P1508, DOI 10.1016/j.molonc.2014.06.004; Baughman JM, 2016, CELL REP, V16, P583, DOI 10.1016/j.celrep.2016.05.096; Bononi A, 2017, CELL DEATH DIFFER, V24, P1694, DOI 10.1038/cdd.2017.95; Camarda R, 2016, NAT MED, V22, P427, DOI 10.1038/nm.4055; Carracedo A, 2013, NAT REV CANCER, V13, P227, DOI 10.1038/nrc3483; Cheng HY, 2017, MOL CANCER THER, V16, P516, DOI 10.1158/1535-7163.MCT-16-0552; Chua V, 2018, CURR OPIN ONCOL, V30, P134, DOI 10.1097/CCO.0000000000000425; Daemen A, 2015, P NATL ACAD SCI USA, V112, pE4410, DOI 10.1073/pnas.1501605112; Dai FY, 2017, P NATL ACAD SCI USA, V114, P3192, DOI 10.1073/pnas.1619588114; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200; Desler Claus, 2012, J Aging Res, V2012, P192503, DOI 10.1155/2012/192503; Dey A, 2012, SCIENCE, V337, P1541, DOI 10.1126/science.1221711; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Gaude E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13041; Goodwin J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15503; Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472; Hebert L, 2017, ONCOTARGET, V8, P72513, DOI 10.18632/oncotarget.19872; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Izawa T, 2015, CELL REP, V11, P1625, DOI 10.1016/j.celrep.2015.05.019; JAGER MJ, 2020, NAT REV DIS PRIMERS, V6, P1, DOI DOI 10.1038/s41572-019-0135-7; Johansson PA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16276-8; Jones NP, 2012, DRUG DISCOV TODAY, V17, P232, DOI 10.1016/j.drudis.2011.12.017; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Kalirai H, 2014, BRIT J CANCER, V111, P1373, DOI 10.1038/bjc.2014.417; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Karlsson J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15606-0; Klebe S, 2015, BIOMARK RES, V3, DOI 10.1186/s40364-015-0040-5; Kruiswijk F, 2015, NAT REV MOL CELL BIO, V16, P393, DOI 10.1038/nrm4007; Lehuede C, 2016, CANCER RES, V76, P5201, DOI 10.1158/0008-5472.CAN-16-0266; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liem Minh Phan, 2014, Cancer Biology Medicine, V11, P1, DOI 10.7497/j.issn.2095-3941.2014.01.001; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Luke JJ, 2015, PIGM CELL MELANOMA R, V28, P135, DOI 10.1111/pcmr.12304; Luo WJ, 2013, BIOINFORMATICS, V29, P1830, DOI 10.1093/bioinformatics/btt285; Ma JF, 2013, EXPERT REV PROTEOMIC, V10, P365, DOI 10.1586/14789450.2013.820536; Matatall KA, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-371; Misaghi S, 2009, MOL CELL BIOL, V29, P2181, DOI 10.1128/MCB.01517-08; Molina JR, 2018, NAT MED, V24, P1036, DOI 10.1038/s41591-018-0052-4; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Pacella I, 2018, P NATL ACAD SCI USA, V115, pE6546, DOI 10.1073/pnas.1720113115; Peng XX, 2018, CELL REP, V23, P255, DOI 10.1016/j.celrep.2018.03.077; Porporato PE, 2014, CELL REP, V8, P754, DOI 10.1016/j.celrep.2014.06.043; Postow MA, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.9074; Rai K, 2016, CLIN GENET, V89, P285, DOI 10.1111/cge.12630; Robertson AG, 2017, CANCER CELL, V32, P204, DOI 10.1016/j.ccell.2017.07.003; Scheuermann JC, 2010, NATURE, V465, P243, DOI 10.1038/nature08966; Seedor RS, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.9592; SHIELDS JA, 1991, SURV OPHTHALMOL, V36, P161, DOI 10.1016/0039-6257(91)90001-V; Singh Arun D, 2005, Ophthalmol Clin North Am, V18, P75, DOI 10.1016/j.ohc.2004.07.002; Singh AD, 2011, OPHTHALMOLOGY, V118, P1881, DOI 10.1016/j.ophtha.2011.01.040; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; van Essen TH, 2014, BRIT J OPHTHALMOL, V98, P1738, DOI 10.1136/bjophthalmol-2014-305047; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; Vivas-Garcia Y, 2020, MOL CELL, V77, P120, DOI 10.1016/j.molcel.2019.10.014; Wang A, 2016, J CLIN PATHOL, V69, P750, DOI 10.1136/jclinpath-2016-203866; Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170; Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD608, DOI 10.1093/nar/gkx1089; Yu H, 2010, MOL CELL BIOL, V30, P5071, DOI 10.1128/MCB.00396-10; Yu LL, 2017, CANCER RES, V77, P1564, DOI 10.1158/0008-5472.CAN-16-2074	62	19	19	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					618	632		10.1038/s41388-020-01554-y	http://dx.doi.org/10.1038/s41388-020-01554-y		NOV 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33208912	Green Accepted			2022-12-17	WOS:000590925500001
J	Wen, SM; He, YD; Wang, LW; Zhang, J; Quan, CY; Niu, YJ; Huang, HJ				Wen, Simeng; He, Yundong; Wang, Liewei; Zhang, Jun; Quan, Changyi; Niu, Yuanjie; Huang, Haojie			Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer	ONCOGENE			English	Article							INTEGRATIVE CLINICAL GENOMICS; PHOSPHOLIPID-METABOLISM; CELL IDENTITY; SELECTIVE-INHIBITION; ENZALUTAMIDE; TRANSCRIPTION; DEPENDENCIES; BICALUTAMIDE; STIMULATION; MECHANISMS	Next generation antiandrogens such as enzalutamide (Enz) are effective initially for the treatment of castration-resistant prostate cancer (CRPC). However, the disease often relapses and the underlying mechanisms remain elusive. By performing H3-lysine-27 acetylation (H3K27ac) ChIP-seq in Enz-resistant CRPC cells, we identified a group of super enhancers (SEs) that are abnormally activated in Enz-resistant CRPC cells and associated with enhanced transcription of a subset of tumor promoting genes such asCHPT1, which catalyzes phosphatidylcholine (PtdCho) synthesis and regulates choline metabolism. Increased CHPT1 conferred CRPC resistance to Enz in vitro and in mice. While androgen receptor (AR) primarily binds to a putativeCHPT1enhancer and mediates androgen-dependent expression ofCHPT1gene in Enz-sensitive prostate cancer cells, AR binds to a different enhancer within theCHPT1SE locus and facilities androgen-independent expression ofCHPT1in Enz-resistant cells. We further identified a long-non coding RNA transcribed atCHPT1enhancer (also known as enhancer RNA) that binds to the H3K27ac reader BRD4 and participates in regulatingCHPT1SE activity andCHPT1gene expression. Our findings demonstrate that aberrantly activated SE upregulates CHPT1 expression and confers Enz resistance in CRPC, suggesting that SE-mediated expression of downstream effectors such as CHPT1 can be viable targets to overcome Enz resistance in PCa.	[Wen, Simeng; Quan, Changyi; Niu, Yuanjie] Tianjin Med Univ, Tianjin Inst Urol, Hosp 2, Dept Urol, Tianjin, Peoples R China; [Wen, Simeng; He, Yundong; Huang, Haojie] Mayo Clin, Dept Biochem & Mol Biol, Coll Med & Sci, Rochester, MN 55905 USA; [Wang, Liewei] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Coll Med & Sci, Rochester, MN USA; [Zhang, Jun] Mayo Clin, Dept Lab Med & Pathol, Coll Med & Sci, Scottsdale, AZ USA; [Huang, Haojie] Mayo Clin, Dept Urol, Coll Med & Sci, Rochester, MN 55905 USA; [Huang, Haojie] Mayo Clin, Ctr Canc, Coll Med & Sci, Rochester, MN 55905 USA	Tianjin Medical University; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic	Quan, CY; Niu, YJ (corresponding author), Tianjin Med Univ, Tianjin Inst Urol, Hosp 2, Dept Urol, Tianjin, Peoples R China.; Huang, HJ (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, Coll Med & Sci, Rochester, MN 55905 USA.; Huang, HJ (corresponding author), Mayo Clin, Dept Urol, Coll Med & Sci, Rochester, MN 55905 USA.; Huang, HJ (corresponding author), Mayo Clin, Ctr Canc, Coll Med & Sci, Rochester, MN 55905 USA.	quancy98@163.com; niuyuanjie9317@163.com; huang.haojie@mayo.edu			Mayo Clinic Foundation; National Natural Science Foundation of China [81972654]; Tianjin International Student Science and Technology Activities Launched Project [20160014]; Tianjin science and technology commission [18JCZDJC34800]	Mayo Clinic Foundation; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tianjin International Student Science and Technology Activities Launched Project; Tianjin science and technology commission	This work was supported in part by the Mayo Clinic Foundation (to HH) and the National Natural Science Foundation of China (81972654 to SW), Tianjin International Student Science and Technology Activities Launched Project (20160014 to SW), and Tianjin science and technology commission (18JCZDJC34800 to CQ).	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116; Ackerstaff E, 2003, J CELL BIOCHEM, V90, P525, DOI 10.1002/jcb.10659; Anthony ML, 1999, J BIOL CHEM, V274, P19686, DOI 10.1074/jbc.274.28.19686; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Beagrie RA, 2016, BIOESSAYS, V38, P881, DOI 10.1002/bies.201600032; Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chapuy B, 2013, CANCER CELL, V24, P777, DOI 10.1016/j.ccr.2013.11.003; Chatterjee D, 2001, BIOCHEM BIOPH RES CO, V282, P861, DOI 10.1006/bbrc.2001.4662; Cho WK, 2018, SCIENCE, V361, P412, DOI 10.1126/science.aar4199; Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228; Di Micco R, 2014, CELL REP, V9, P234, DOI 10.1016/j.celrep.2014.08.055; Donati B, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0915-9; Doroshow DB, 2017, ANN ONCOL, V28, P1776, DOI 10.1093/annonc/mdx157; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Glunde K, 2004, CANCER RES, V64, P4270, DOI 10.1158/0008-5472.CAN-03-3829; Glunde K, 2011, NAT REV CANCER, V11, P835, DOI 10.1038/nrc3162; Hah N, 2015, P NATL ACAD SCI USA, V112, pE297, DOI 10.1073/pnas.1424028112; Hajmirza A, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6010016; He Y, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00361; Heidenreich A, 2017, EUR UROL, V71, P534, DOI 10.1016/j.eururo.2016.07.027; Hentze MW, 2018, NAT REV MOL CELL BIO, V19, P327, DOI 10.1038/nrm.2017.130; Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053; Jia M, 2016, CANCER RES, V76, P5634, DOI 10.1158/0008-5472.CAN-15-2910; Katz-Brull R, 2001, MAGNET RESON MED, V46, P31, DOI 10.1002/mrm.1157; Khan A, 2018, EPIGENETICS-US, V13, P910, DOI 10.1080/15592294.2018.1514231; Kim TK, 2010, NATURE, V465, P182, DOI 10.1038/nature09033; Ko JY, 2017, MOL CELLS, V40, P169, DOI 10.14348/molcells.2017.0033; Kohli M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145176; Kvaratskhelia M, 2014, NUCLEIC ACIDS RES, V42, P10209, DOI 10.1093/nar/gku769; Larue RC, 2014, NUCLEIC ACIDS RES, V42, P4868, DOI 10.1093/nar/gku135; Lee TI, 2013, CELL, V152, P1237, DOI 10.1016/j.cell.2013.02.014; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Lin D, 2014, CANCER RES, V74, P1272, DOI 10.1158/0008-5472.CAN-13-2921-T; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Lunde BM, 2007, NAT REV MOL CELL BIO, V8, P479, DOI 10.1038/nrm2178; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Miquel K, 1998, J BIOL CHEM, V273, P26179, DOI 10.1074/jbc.273.40.26179; Mousavi K, 2013, MOL CELL, V51, P606, DOI 10.1016/j.molcel.2013.07.022; Niu Y, 2010, ONCOGENE, V29, P3593, DOI 10.1038/onc.2010.121; Ramos B, 2002, MOL PHARMACOL, V62, P1068, DOI 10.1124/mol.62.5.1068; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Robinson DR, 2017, NATURE, V548, P297, DOI 10.1038/nature23306; ROHRSCHNEIDER LR, 1973, CANCER RES, V33, P1945; Sabari BR, 2018, SCIENCE, V361, DOI 10.1126/science.aar3958; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Sen P, 2019, MOL CELL, V73, P684, DOI 10.1016/j.molcel.2019.01.021; Sengupta S, 2017, TRENDS CANCER, V3, P269, DOI 10.1016/j.trecan.2017.03.006; Sharp A, 2019, J CLIN INVEST, V129, P192, DOI 10.1172/JCI122819; Shore ND, 2016, LANCET ONCOL, V17, P153, DOI 10.1016/S1470-2045(15)00518-5; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Stelloo S, 2019, ENDOCR-RELAT CANCER, V26, pR267, DOI 10.1530/ERC-19-0032; Ting YLT, 1996, ANTICANCER RES, V16, P1381; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; WERTZ PW, 1978, CANCER RES, V38, P2900; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; Xie JJ, 2018, GASTROENTEROLOGY, V154, P2137, DOI 10.1053/j.gastro.2018.02.018; Zanconato F, 2018, NAT MED, V24, P1599, DOI 10.1038/s41591-018-0158-8; Zhao Y, 2016, CELL REP, V15, P599, DOI 10.1016/j.celrep.2016.03.038; Zuber V, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3620-y	63	19	20	3	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2020	39	42					6556	6571		10.1038/s41388-020-01456-z	http://dx.doi.org/10.1038/s41388-020-01456-z		SEP 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA9HI	32917955				2022-12-17	WOS:000568475200002
J	Han, H; Wang, S; Meng, J; Lyu, G; Ding, G; Hu, Y; Wang, L; Wu, L; Yang, W; Lv, Y; Jia, S; Zhang, L; Ji, J				Han, H.; Wang, S.; Meng, J.; Lyu, G.; Ding, G.; Hu, Y.; Wang, L.; Wu, L.; Yang, W.; Lv, Y.; Jia, S.; Zhang, L.; Ji, J.			Long noncoding RNA PART1 restrains aggressive gastric cancer through the epigenetic silencing of PDGFBviathe PLZF-mediated recruitment of EZH2	ONCOGENE			English	Article							CELL-PROLIFERATION; PROSTATE-CANCER; RECEPTOR-BETA; METASTASIS; EXPRESSION; PROMOTES; GROWTH; GENE; SUPPRESSION; APOPTOSIS	Current reports refer to the role of long noncoding RNA (lncRNA) prostate androgen-regulated transcript 1 (PART1) as a tumor suppressor in some types of cancer but as an oncogene in other kinds of cancer. In gastric cancer, it had been reported to be downregulated. However, the clinical significance and underlying mechanism of PART1 function in gastric cancer remains undefined. Here, seven differential expression levels of noncoding RNAs (DE-lncRNAs) were screened from gastric cancer through a probe reannotation of a human exon array. PART1 was selected for further study because of its high fold change number. In our cohort, PART1 was identified as a significant downregulated lncRNA in gastric cancer tissues by qPCR and in situ hybridization (ISH), and its low expression was significantly correlated with postoperative metastasis and short overall survival time after surgery. Through the results of gain-of-function experiments, PART1 was confirmed as a tumor suppressor that can decrease not only cell viability, migration, and invasion in vitro but also tumorigenesis and tumor metastasis in vivo. Mechanistically, RNA pull-down and RNA-binding protein immunoprecipitation (RIP) showed that PART1 interacts with androgen receptor (AR), and then, promyelocytic leukemia zinc finger (PLZF) is upregulated in an androgen-independent manner. In a chain reaction, chromatin immunoprecipitation (ChIP) assay additionally illustrated that PLZF upregulation increased the enrichment of EZH2 and H3K27 trimethylation in the platelet-derived growth factor (PDGFB) promotor, thereby inhibition of PDGFB and the subsequent PDGFR beta/PI3K/Akt signaling pathway. Based on these findings, we showed PART1 plays a tumor suppressor rolebypromoting PLZF expression followed by recruitment of EZH2 to mediate epigenetic PDGFB silencing and downstream PI3K/Akt inhibition, suggesting that PART1 has a key role in restraining the aggressive ability of GC cells and providing a novel perspective on lncRNAs in GC progression.	[Han, H.; Ding, G.; Hu, Y.] Peking Univ, Canc Hosp & Inst, Dept Biobank, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing, Peoples R China; [Wang, S.; Meng, J.; Wang, L.; Yang, W.; Lv, Y.] Peking Univ, Dept Clin Lab, Canc Hosp & Inst, Beijing, Peoples R China; [Lyu, G.] Peking Univ, Dept Gastrointestinal Surg, Shenzhen Hosp, Shenzhen, Peoples R China; [Wu, L.] Peking Univ, Dept Cent Lab, Canc Hosp & Inst, Beijing, Peoples R China; [Jia, S.] Peking Univ, Dept Mol Diagnost, Canc Hosp & Inst, Beijing, Peoples R China; [Zhang, L.; Ji, J.] Peking Univ, Dept Gastrointestinal Surg, Canc Hosp & Inst, Beijing, Peoples R China	Peking University; Peking University; Peking University; Peking University; Peking University; Peking University	Jia, S (corresponding author), Peking Univ, Dept Mol Diagnost, Canc Hosp & Inst, Beijing, Peoples R China.; Zhang, L; Ji, J (corresponding author), Peking Univ, Dept Gastrointestinal Surg, Canc Hosp & Inst, Beijing, Peoples R China.	shuqin_jia@hsc.pku.edu.cn; lianhaizhang@bjcancer.org; jijiafu@hsc.pku.edu.cn		Meng, Jialin/0000-0002-4622-833X	National Natural Science Foundation of China [81772632, 81802943]; Science Foundation of Peking University Cancer Hospital [2020-9]; Beijing outstanding talent training program [2018000021469G268]; interdisciplinary medicine Seed Fund of Peking University [BMU2018MX019]; Special funds of the Ministry of Finance for Reform and Development; 'San Ming' Project of Shenzhen city [SZSM 201612051]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science Foundation of Peking University Cancer Hospital; Beijing outstanding talent training program; interdisciplinary medicine Seed Fund of Peking University; Special funds of the Ministry of Finance for Reform and Development; 'San Ming' Project of Shenzhen city	This work was supported by grants from the National Natural Science Foundation of China (81772632, 81802943), Science Foundation of Peking University Cancer Hospital 2020-9, Beijing outstanding talent training program (No. 2018000021469G268), the interdisciplinary medicine Seed Fund of Peking University (No. BMU2018MX019), Special funds of the Ministry of Finance for Reform and Development and 'San Ming' Project of Shenzhen city (no. SZSM 201612051).	Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cao WJ, 2013, WORLD J GASTROENTERO, V19, P3658, DOI 10.3748/wjg.v19.i23.3658; Chen S, 2017, CELL PHYSIOL BIOCHEM, V44, P215, DOI 10.1159/000484648; Chen X, 2018, CLIN CANCER RES, V24, P2002, DOI 10.1158/1078-0432.CCR-17-2376; Cher ML, 1996, CANCER RES, V56, P3091; Dong Y, 2018, EUR REV MED PHARMACO, V22, P1307, DOI 10.26355/eurrev_201803_14472; Fei ZH, 2016, TUMOR BIOL, V37, P1983, DOI 10.1007/s13277-015-3979-9; Feng RM, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0368-6; Gu L, 2018, CANCER MED-US, V7, P1253, DOI 10.1002/cam4.1310; Gu W, 2019, MOL MED REP, V20, P2209, DOI 10.3892/mmr.2019.10478; Guo HF, 2015, J GENET GENOMICS, V42, P343, DOI 10.1016/j.jgg.2015.03.003; Guo Y, 2013, WSPOLCZESNA ONKOL, V17, P150, DOI 10.5114/wo.2013.34618; He XJ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-218; Hsieh CL, 2015, CANCER RES, V75, P1944, DOI 10.1158/0008-5472.CAN-14-3602; Hu L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0322-6; Hu XW, 2018, CURR OPIN GENET DEV, V48, P8, DOI 10.1016/j.gde.2017.10.004; Hu YB, 2017, BIOCHEM BIOPH RES CO, V490, P317, DOI 10.1016/j.bbrc.2017.06.042; Izumi K, 2012, INT J ONCOL, V41, P1587, DOI 10.3892/ijo.2012.1593; Jiang F, 2004, PROSTATE, V59, P426, DOI 10.1002/pros.20000; Jin Y, 2017, ONCOTARGET, V8, P71317, DOI 10.18632/oncotarget.19813; Kodama M, 2010, CANCER SCI, V101, P1984, DOI 10.1111/j.1349-7006.2010.01639.x; Kominea A, 2004, J CANCER RES CLIN, V130, P253, DOI 10.1007/s00432-003-0531-x; Koubi M, 2018, NUCLEIC ACIDS RES, V46, P3339, DOI 10.1093/nar/gky080; Li H, 2014, ONCOTARGET, V5, P2318, DOI 10.18632/oncotarget.1913; Li JJ, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0408-8; Li M, 2017, J CANCER, V8, P1795, DOI 10.7150/jca.18848; Li QL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033379; Li Y, 2017, CANCER LETT, V395, P31, DOI 10.1016/j.canlet.2017.02.035; Lin BY, 2000, CANCER RES, V60, P858; Lin CR, 2018, TRENDS CELL BIOL, V28, P287, DOI 10.1016/j.tcb.2017.11.008; Liu J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0246-6; Liu TM, 2015, STEM CELLS DAYT OHIO, V34, P277; Ma HW, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171193; Ozen M, 1998, CANCER GENET CYTOGEN, V106, P105, DOI 10.1016/S0165-4608(98)00051-X; Peng Y, 2014, BIOSCIENCE REP, V34, P247, DOI 10.1042/BSR20140020; Sugano K, 2015, BEST PRACT RES CL GA, V29, P895, DOI 10.1016/j.bpg.2015.09.013; Sun M, 2018, BIOL CHEM, V399, P387, DOI 10.1515/hsz-2017-0255; Thomassen I, 2014, INT J CANCER, V134, P622, DOI 10.1002/ijc.28373; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Wang GH, 2019, BIOMED PHARMACOTHER, V111, P1334, DOI 10.1016/j.biopha.2019.01.023; Wang JB, 2019, ONCOL REP, V41, P1007, DOI 10.3892/or.2018.6866; Wang Y, 2018, CELL BIOL INT, V42, P1358, DOI 10.1002/cbin.11020; Wen W, 2012, HEPATOLOGY, V55, P1787, DOI 10.1002/hep.25596; Wu Q, 2018, MOL ONCOL, V12, P799, DOI 10.1002/1878-0261.12187; Xia N, 2019, J PATHOL, V248, P304, DOI 10.1002/path.5257; Xu WR, 2018, BIOSCI BIOTECH BIOCH, V82, P456, DOI 10.1080/09168451.2018.1431518; Xue M, 2018, GASTRIC CANCER, V21, P756, DOI 10.1007/s10120-018-0801-6; Yang F, 2012, FEBS J, V279, P3159, DOI 10.1111/j.1742-4658.2012.08694.x; Yu YC, 2017, J CELL MOL MED, V21, P955, DOI 10.1111/jcmm.13035; Zhang XQ, 2013, NEUROBIOL DIS, V58, P123, DOI 10.1016/j.nbd.2013.05.011; Zhang Y, 2018, ASIAN J ANDROL, V20, P511, DOI 10.4103/aja.aja_36_18; Zhang ZZ, 2015, MOL CANCER THER, V14, P1162, DOI 10.1158/1535-7163.MCT-14-0695; Zhao Y, 2014, ONCOL REP, V31, P358, DOI 10.3892/or.2013.2850; Zhou TC, 2020, INT J BIOCHEM CELL B, V118, DOI 10.1016/j.biocel.2019.105637; Zhu DY, 2019, CANCER MED-US, V8, P6064, DOI 10.1002/cam4.2494; Zong L, 2016, LANCET, V388, P2606, DOI 10.1016/S0140-6736(16)32226-7	56	19	19	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2020	39	42					6513	6528		10.1038/s41388-020-01442-5	http://dx.doi.org/10.1038/s41388-020-01442-5		SEP 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA9HI	32901105				2022-12-17	WOS:000567639400001
J	An, PP; Chen, F; Li, ZH; Ling, YY; Peng, YX; Zhang, HS; Li, JX; Chen, ZJ; Wang, HS				An, Panpan; Chen, Feng; Li, Zihan; Ling, Yuyi; Peng, Yanxi; Zhang, Haisheng; Li, Jiexin; Chen, Zhuojia; Wang, Hongsheng			HDAC8 promotes the dissemination of breast cancer cells via AKT/GSK-3 beta/Snail signals	ONCOGENE			English	Article							CARDIAC HYPERTROPHIC RESPONSE; GLYCOGEN-SYNTHASE KINASE-3; HISTONE DEACETYLASE; MESENCHYMAL TRANSITION; PROTEIN; SNAIL; PHOSPHORYLATION; ACETYLATION; INHIBITION; SUPPRESSES	The mechanistic action of histone deacetylase 8 (HDAC8) in cancer motility, including epithelial-mesenchymal transition (EMT), remains largely undefined. We found that the expression of HDAC8 was upregulated in breast cancer (BC) cells and tissues as compared to the controls. Further, BC tissues had the highest values of HDAC8 expression among 31 kinds of cancers. Cellular study indicated that HDAC8 can positively regulate the dissemination and EMT of BC cells. It increased the protein stability of Snail, an important regulator of EMT, by phosphorylation of its motif 2 in serine-rich regions. There are 21 factors that have been reported to regulate the protein stability of Snail. Among them, HDAC8 can decrease the expression of GSK-3 beta through increasing its Ser9-phosphorylation. Mass spectrum analysis indicated that HDAC8 interact with AKT1 to decrease its acetylation while increase its phosphorylation, which further increased Ser9-phosphorylation of GSK-3 beta. The C-terminal of AKT1 was responsible for the interaction between HDAC8 and AKT1. Further, Lys426 was the key residue for HDAC8-regulated deacetylation of AKT1. Moreover, HDAC8/Snail axis acted as adverse prognosis factors for in vivo progression and overall survival (OS) rate of BC patients. Collectively, we found that HDAC8 can trigger the dissemination of BC cells via AKT/GSK-3 beta/Snail signals, which imposed that inhibition of HDAC8 is a potential approach for BC treatment.	[An, Panpan; Chen, Feng; Li, Zihan; Ling, Yuyi; Peng, Yanxi; Zhang, Haisheng; Li, Jiexin; Wang, Hongsheng] Sun Yat Sen Univ, Guangdong Key Lab Chiral Mol & Drug Discovery, Sch Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China; [Chen, Zhuojia] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Peoples R China	Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University	Wang, HS (corresponding author), Sun Yat Sen Univ, Guangdong Key Lab Chiral Mol & Drug Discovery, Sch Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China.; Chen, ZJ (corresponding author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Peoples R China.	chenzhj@sysucc.org.cn; whongsh@mail.sysu.edu.cn		Wang, Hong-Sheng/0000-0001-5729-6074	National Natural Science Foundation of China [81973343, 81673454, 81672608, 31801197]; Fundamental Research Funds for the Central Universities (Sun Yat-sen University) [19ykzd24, 19ykpy130]; Guangdong Provincial Key Laboratory of Construction Foundation [2017B030314030]; Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery [2019B030301005]; Natural Science Foundation of Guangdong Province [2020A1515010291]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities (Sun Yat-sen University); Guangdong Provincial Key Laboratory of Construction Foundation; Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province)	This research was supported by the National Natural Science Foundation of China (Grant Nos. 81973343, 81673454, 81672608, and 31801197), the Fundamental Research Funds for the Central Universities (Sun Yat-sen University) (19ykzd24, 19ykpy130), the Guangdong Provincial Key Laboratory of Construction Foundation (No. 2017B030314030), the Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery (2019B030301005), and the Natural Science Foundation of Guangdong Province (No. 2020A1515010291).	Balasubramanian S, 2008, LEUKEMIA, V22, P1026, DOI 10.1038/leu.2008.9; Beurel E, 2015, PHARMACOL THERAPEUT, V148, P114, DOI 10.1016/j.pharmthera.2014.11.016; Chang R, 2017, THORAC CANCER, V8, P131, DOI 10.1111/1759-7714.12408; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Deardorff MA, 2012, NATURE, V489, P313, DOI 10.1038/nature11316; Domoto T, 2016, CANCER SCI, V107, P1363, DOI 10.1111/cas.13028; Du C, 2010, CANCER RES, V70, P7810, DOI 10.1158/0008-5472.CAN-09-4481; Ecker Jonas, 2013, CNS Oncol, V2, P359, DOI 10.2217/cns.13.24; Gupta M, 2009, BLOOD, V114, P2926, DOI 10.1182/blood-2009-05-220889; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Haberland M, 2009, GENE DEV, V23, P1625, DOI 10.1101/gad.1809209; Higuchi T, 2013, BLOOD, V121, P3640, DOI 10.1182/blood-2012-07-441022; Hojfeldt JW, 2013, NAT REV DRUG DISCOV, V12, P917, DOI 10.1038/nrd4154; Hsu DSS, 2014, CANCER CELL, V26, P534, DOI 10.1016/j.ccell.2014.09.002; Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199; Hua WK, 2017, BLOOD, V130, P2619, DOI 10.1182/blood-2017-03-771386; Iaconelli J, 2017, ACS CHEM BIOL, V12, P2139, DOI 10.1021/acschembio.6b01014; Kvaratskhelia Mamuka, 2008, V488, P213, DOI 10.1007/978-1-60327-475-3_15; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lee H, 2006, MOL CELL BIOL, V26, P5259, DOI 10.1128/MCB.01971-05; Lin XY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09865-9; Liu Q, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0654-3; Long J, 2017, LEUKEMIA, V31, P2761, DOI 10.1038/leu.2017.130; Lopez JE, 2017, J AM CHEM SOC, V139, P16222, DOI 10.1021/jacs.7b07603; Lu LL, 2020, CELL DEATH DIFFER, V27, P255, DOI 10.1038/s41418-019-0353-2; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Narita T, 2019, NAT REV MOL CELL BIO, V20, P156, DOI 10.1038/s41580-018-0081-3; Nieuwenhuis J, 2019, TRENDS CELL BIOL, V29, P80, DOI 10.1016/j.tcb.2018.08.003; Oehme I, 2009, CLIN CANCER RES, V15, P91, DOI 10.1158/1078-0432.CCR-08-0684; Pallet N, 2012, J TRANSPLANT, V2012, DOI 10.1155/2012/348604; Park SY, 2011, ONCOL REP, V25, P1677, DOI 10.3892/or.2011.1236; Qi J, 2015, CELL STEM CELL, V17, P597, DOI 10.1016/j.stem.2015.08.004; Rodriguez MI, 2011, ONCOGENE, V30, P4365, DOI 10.1038/onc.2011.153; Somoza JR, 2004, STRUCTURE, V12, P1325, DOI 10.1016/j.str.2004.04.012; Sundaresan NR, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001465; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Trivedi CM, 2007, NAT MED, V13, P324, DOI 10.1038/nm1552; Vannini A, 2007, EMBO REP, V8, P879, DOI 10.1038/sj.embor.7401047; Vasaikar SV, 2018, NUCLEIC ACIDS RES, V46, pD956, DOI 10.1093/nar/gkx1090; von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004; Yan MW, 2015, CARDIOVASC RES, V105, P340, DOI 10.1093/cvr/cvu254; Yan W, 2013, ONCOGENE, V32, P599, DOI 10.1038/onc.2012.81; Zhang K, 2013, NAT CELL BIOL, V15, P677, DOI 10.1038/ncb2743; Zhang K, 2012, EMBO J, V31, P29, DOI 10.1038/emboj.2011.357; Zheng HQ, 2014, CANCER CELL, V26, P358, DOI 10.1016/j.ccr.2014.07.022; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zhou Y, 2019, CELL DEATH DIFFER, V26, P1442, DOI 10.1038/s41418-018-0222-4	48	19	20	3	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 25	2020	39	26					4956	4969		10.1038/s41388-020-1337-x	http://dx.doi.org/10.1038/s41388-020-1337-x		JUN 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MQ2YO	32499521				2022-12-17	WOS:000537994200001
J	Zhu, ZH; Song, JLE; Guo, YG; Huang, ZY; Chen, XJ; Dang, XN; Huang, YJ; Wang, YH; Ou, WJ; Yang, YL; Yu, W; Liu, CY; Cui, L				Zhu, Zhehui; Song, Jinglue; Guo, Yuegui; Huang, Zhenyu; Chen, Xiaojian; Dang, Xuening; Huang, Yuji; Wang, Yuhan; Ou, Weijun; Yang, Yili; Yu, Wei; Liu, Chen-Ying; Cui, Long			LAMB3 promotes tumour progression through the AKT-FOXO3/4 axis and is transcriptionally regulated by the BRD2/acetylated ELK4 complex in colorectal cancer	ONCOGENE			English	Article							LAMININ GAMMA-2; ACTIVATION; CARCINOMAS; EXPRESSION; BRD4; SUPPRESSES; ADHESION; INVASION; FAMILY; TARGET	Aberrant expression of laminin-332 promotes tumour growth and metastasis in multiple cancers. However, the dysregulated expression and mechanism of action of LAMB3, which encodes the beta 3 subunit of laminin-332, and the mechanism underlying dysregulated LAMB3 expression in CRC remain obscure. Here, we show that LAMB3 is overexpressed in CRC and that this overexpression is correlated with tumour metastasis and poor prognosis. Overexpression of LAMB3 promoted cell proliferation and cell migration in vitro and tumour growth and metastasis in vivo, while knockdown of LAMB3 elicited opposing effects. LAMB3 inhibited the tumour suppressive function of FOXO3/4 by activating AKT in CRC. Both the BET inhibitor JQ1 and the MEK inhibitor U0126 decreased the mRNA level of LAMB3 in multiple CRC cells. Mechanistically, ELK4 cooperated with BRD2 to regulate the transcription of LAMB3 in CRC by directly binding to the ETS binding motifs in the LAMB3 promoter. ELK4 was as acetylated at K125, which enhanced the interaction between ELK4 and BRD2. JQ1 disrupted the interaction between ELK4 and BRD2, resulting in decreased binding of BRD2 to the LAMB3 promoter and downregulation of LAMB3 transcription. Both ELK4 and BRD2 expression was associated with LAMB3 expression in CRC. LAMB3 expression was also negatively correlated with FOXO3/4 in CRC. Our study reveals the pro-tumorigenic role of LAMB3 through the AKT-FOXO3/4 axis and the transcriptional mechanism of LAMB3 in CRC, demonstrating that LAMB3 is a potential therapeutic target that can be targeted by BET inhibitors and MEK inhibitors.	[Zhu, Zhehui; Song, Jinglue; Guo, Yuegui; Wang, Yuhan; Ou, Weijun; Liu, Chen-Ying; Cui, Long] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Colorectal & Anal Surg, Shanghai 200092, Peoples R China; [Zhu, Zhehui; Huang, Zhenyu; Chen, Xiaojian; Dang, Xuening; Huang, Yuji; Liu, Chen-Ying; Cui, Long] Shanghai Colorectal Canc Res Ctr, Shanghai 200092, Peoples R China; [Yang, Yili] Chinese Acad Med Sci, Ctr Syst Med Res, Suzhou Inst Syst Med, Suzhou 215123, Jiangsu, Peoples R China; [Yu, Wei] Fudan Univ, State Key Lab Genet Engn, Shanghai 200438, Peoples R China; [Yu, Wei] Fudan Univ, Collaborat Innovat Ctr Genet & Dev, Sch Life Sci, Shanghai 200438, Peoples R China; [Yu, Wei] Fudan Univ, Zhongshan Hosp, Shanghai 200438, Peoples R China	Shanghai Jiao Tong University; Chinese Academy of Medical Sciences - Peking Union Medical College; Fudan University; Fudan University; Fudan University	Liu, CY; Cui, L (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Colorectal & Anal Surg, Shanghai 200092, Peoples R China.; Liu, CY; Cui, L (corresponding author), Shanghai Colorectal Canc Res Ctr, Shanghai 200092, Peoples R China.; Yu, W (corresponding author), Fudan Univ, State Key Lab Genet Engn, Shanghai 200438, Peoples R China.; Yu, W (corresponding author), Fudan Univ, Collaborat Innovat Ctr Genet & Dev, Sch Life Sci, Shanghai 200438, Peoples R China.; Yu, W (corresponding author), Fudan Univ, Zhongshan Hosp, Shanghai 200438, Peoples R China.	yuw@fudan.edu.cn; liuchenying@xinhuamed.com.cn; cuilong@xinhuamed.com.cn		Zhu, Zhehui/0000-0002-3676-5254; YU, WEI/0000-0001-9898-4607; Liu, Chen-Ying/0000-0002-8930-6182	National Natural Science Foundation of China [81974060, 81874177, 81672517, 31771545, 91749120]; National High Technology Research and Development Program of China (863 Program) [2014AA020801]; National Key R&D Program of China [2019YFC1316002]; Program for Professor of Special Appointment (Young Eastern Scholar) at Shanghai Institutions of Higher Learning; Shanghai Pujiang Program [18PJ1407400]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant [20171918]; Innovative research team of high-level local universities in Shanghai; Innovation Program for Ph.D. students in Shanghai Jiao Tong University School of Medicine [BXJ201827]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High Technology Research and Development Program of China (863 Program)(National High Technology Research and Development Program of China); National Key R&D Program of China; Program for Professor of Special Appointment (Young Eastern Scholar) at Shanghai Institutions of Higher Learning; Shanghai Pujiang Program(Shanghai Pujiang Program); Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant; Innovative research team of high-level local universities in Shanghai; Innovation Program for Ph.D. students in Shanghai Jiao Tong University School of Medicine	This work was supported by the National Natural Science Foundation of China (81974060, 81874177, 81672517, 31771545, and 91749120), the National High Technology Research and Development Program of China (863 Program) (Grant No. 2014AA020801), the National Key R&D Program of China (2019YFC1316002), The Program for Professor of Special Appointment (Young Eastern Scholar) at Shanghai Institutions of Higher Learning (to C-YL), Shanghai Pujiang Program (18PJ1407400), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant (20171918), Innovative research team of high-level local universities in Shanghai and the Innovation Program for Ph.D. students in Shanghai Jiao Tong University School of Medicine (BXJ201827).	Baeza J, 2016, TRENDS BIOCHEM SCI, V41, P231, DOI 10.1016/j.tibs.2015.12.006; Barber MF, 2012, NATURE, V487, P114, DOI 10.1038/nature11043; Blee AM, 2016, ONCOTARGET, V7, P38319, DOI 10.18632/oncotarget.9513; Chen JH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00405-x; Chen XB, 2016, ONCOTARGET, V7, P86695, DOI 10.18632/oncotarget.13435; Choma DP, 2007, J INVEST DERMATOL, V127, P31, DOI 10.1038/sj.jid.5700505; Domogatskaya A, 2012, ANNU REV CELL DEV BI, V28, P523, DOI 10.1146/annurev-cellbio-101011-155750; Feng MB, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0564-9; Fukushima Y, 1998, INT J CANCER, V76, P63, DOI 10.1002/(SICI)1097-0215(19980330)76:1<63::AID-IJC11>3.0.CO;2-H; Gollavilli PN, 2018, CANCER RES, V78, P4760, DOI 10.1158/0008-5472.CAN-18-0484; Hlubek F, 2001, CANCER RES, V61, P8089; Huang ZM, 2018, NAT CHEM BIOL, V14, P1118, DOI 10.1038/s41589-018-0150-0; Irifune H, 2005, CANCER BIOL THER, V4, P449; Jedlicka P, 2008, HISTOL HISTOPATHOL, V23, P1417, DOI 10.14670/HH-23.1417; Jung SN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21216-0; Kai F, 2019, DEV CELL, V49, P332, DOI 10.1016/j.devcel.2019.03.026; Keum N, 2019, NAT REV GASTRO HEPAT, V16, P713, DOI 10.1038/s41575-019-0189-8; Kwon OH, 2011, BIOCHEM BIOPH RES CO, V406, P539, DOI 10.1016/j.bbrc.2011.02.082; Lamonica JM, 2011, P NATL ACAD SCI USA, V108, pE159, DOI 10.1073/pnas.1102140108; Le Rolle AF, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0555-4; Li QJ, 2003, EMBO J, V22, P281, DOI 10.1093/emboj/cdg028; Lohi J, 2000, APMIS, V108, P161, DOI 10.1034/j.1600-0463.2000.d01-40.x; Ma YF, 2017, CLIN CANCER RES, V23, P2027, DOI 10.1158/1078-0432.CCR-16-0453; Manfredi S, 2006, ANN SURG, V244, P254, DOI 10.1097/01.sla.0000217629.94941.cf; Manohar A, 2004, J CELL SCI, V117, P4043, DOI 10.1242/jcs.01277; McCleland ML, 2016, J CLIN INVEST, V126, P639, DOI 10.1172/JCI83265; Moriya Y, 2001, CANCER, V91, P1129, DOI 10.1002/1097-0142(20010315)91:6<1129::AID-CNCR1109>3.0.CO;2-C; Nguyen BP, 2000, J BIOL CHEM, V275, P31896, DOI 10.1074/jbc.M006379200; Olsen J, 2003, BIOCHEM J, V371, P211, DOI 10.1042/BJ20021454; Peng C, 2016, ONCOGENE, V35, P1170, DOI 10.1038/onc.2015.175; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; PYKE C, 1994, AM J PATHOL, V145, P782; Roe JS, 2015, MOL CELL, V58, P1028, DOI 10.1016/j.molcel.2015.04.011; Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028; Sizemore GM, 2017, NAT REV CANCER, V17, P337, DOI 10.1038/nrc.2017.20; Stathis A, 2018, CANCER DISCOV, V8, P24, DOI 10.1158/2159-8290.CD-17-0605; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tani T, 1997, AM J PATHOL, V151, P1289; Tsuruta D, 2008, CURR MED CHEM, V15, P1968, DOI 10.2174/092986708785132834; Wang XL, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0053938, 10.1371/journal.pone.0050627]; Wu TY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0354-y; Young B, 2017, CANCER LETT, V387, P114, DOI 10.1016/j.canlet.2016.01.048; Zhang F, 2018, ONCOGENE, V37, P363, DOI 10.1038/onc.2017.334; Zhang H, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1320-z; Zhou Y, 2016, CANCER RES, V76, P5777, DOI 10.1158/0008-5472.CAN-15-2936; Zou Z, 2014, ONCOGENE, V33, P2395, DOI 10.1038/onc.2013.179	46	19	19	6	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	24					4666	4680		10.1038/s41388-020-1321-5	http://dx.doi.org/10.1038/s41388-020-1321-5		MAY 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LY0HO	32398865				2022-12-17	WOS:000532103100003
J	Zhao, YN; Zhang, JL; Cheng, ASL; Yu, J; To, KF; Kang, W				Zhao, Yanan; Zhang, Jinglin; Cheng, Alfred S. L.; Yu, Jun; To, Ka Fai; Kang, Wei			Gastric cancer: genome damaged by bugs	ONCOGENE			English	Review							EPSTEIN-BARR-VIRUS; HELICOBACTER-PYLORI INFECTION; IN-SITU DETECTION; EPITHELIAL-CELLS; INCREASED RISK; INTERLEUKIN-1 POLYMORPHISMS; CELLULAR MIGRATION; MOLECULAR ANALYSIS; DNA METHYLATION; CARCINOMA CELLS	Gastric cancer (GC) is one of the leading causes of cancer-related death worldwide. The role of the microorganisms in gastric tumorigenesis attracts much attention in recent years. These microorganisms include bacteria, virus, and fungi. Among them, Helicobacter pylori (H. pylori) infection is by far the most important risk factor for GC development, with special reference to the early-onset cases. H. pylori targets multiple cellular components by utilizing various virulence factors to modulate the host proliferation, apoptosis, migration, and inflammatory response. Epstein-Barr virus (EBV) serves as another major risk factor in gastric carcinogenesis. The virus protein, EBER noncoding RNA, and EBV miRNAs contribute to the tumorigenesis by modulating host genome methylation and gene expression. In this review, we summarized the related reports about the colonized microorganism in the stomach and discussed their specific roles in gastric tumorigenesis. Meanwhile, we highlighted the therapeutic significance of eradicating the microorganisms in GC treatment.	[Zhao, Yanan; Zhang, Jinglin; To, Ka Fai; Kang, Wei] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, State Key Lab Translat Oncol, Hong Kong, Peoples R China; [Zhao, Yanan; Zhang, Jinglin; Yu, Jun; To, Ka Fai; Kang, Wei] Chinese Univ Hong Kong, Inst Digest Dis, State Key Lab Digest Dis, Hong Kong, Peoples R China; [Zhao, Yanan; Zhang, Jinglin; To, Ka Fai; Kang, Wei] Chinese Univ Hong Kong, Sir YK Pao Canc Ctr, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China; [Cheng, Alfred S. L.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China; [Yu, Jun] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	To, KF; Kang, W (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, State Key Lab Translat Oncol, Hong Kong, Peoples R China.; To, KF; Kang, W (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, State Key Lab Digest Dis, Hong Kong, Peoples R China.; To, KF; Kang, W (corresponding author), Chinese Univ Hong Kong, Sir YK Pao Canc Ctr, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China.	kfto@cuhk.edu.hk; weikang@cuhk.edu.hk	KANG, Wei/C-5451-2016; Yu, Jun/D-8569-2015	KANG, Wei/0000-0002-4651-677X; Yu, Jun/0000-0001-5008-2153	Research Grants Council of the Hong Kong Special Administrative Region, China [CUHK 14100019, 14118518]; CUHK Direct Grant for Research from The Chinese University of Hong Kong [2018.002]	Research Grants Council of the Hong Kong Special Administrative Region, China(Hong Kong Research Grants Council); CUHK Direct Grant for Research from The Chinese University of Hong Kong	The current manuscript is supported by Research Grants Council of the Hong Kong Special Administrative Region, China [Project nos.: CUHK 14100019, 14118518 (for GRF projects)], and CUHK Direct Grant for Research (2018.002) from The Chinese University of Hong Kong.	Akhiani AA, 2004, J IMMUNOL, V172, P5024, DOI 10.4049/jimmunol.172.8.5024; Akhiani AA, 2002, J IMMUNOL, V169, P6977, DOI 10.4049/jimmunol.169.12.6977; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Alm RA, 2000, INFECT IMMUN, V68, P4155, DOI 10.1128/IAI.68.7.4155-4168.2000; Ando T, 2009, INT J CANCER, V125, P2595, DOI 10.1002/ijc.24666; Axon AT, 2017, GUT, V66, P6, DOI [10.1136/gutjnl-2016-312288, DOI 10.1136/GUTJNL-2016-312288]; Banerjee AS, 2013, VIROLOGY, V443, P294, DOI 10.1016/j.virol.2013.05.020; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Beales ILP, 1997, EUR J GASTROEN HEPAT, V9, P451, DOI 10.1097/00042737-199705000-00008; Bik EM, 2006, P NATL ACAD SCI USA, V103, P732, DOI 10.1073/pnas.0506655103; Bimczok D, 2010, MUCOSAL IMMUNOL, V3, P260, DOI 10.1038/mi.2010.10; Blaser MJ, 2006, EMBO REP, V7, P956, DOI 10.1038/sj.embor.7400812; Bronte-Tinkew DM, 2009, CANCER RES, V69, P632, DOI 10.1158/0008-5472.CAN-08-1191; BURKE AP, 1990, MODERN PATHOL, V3, P377; Camargo MC, 2018, CANCERS, V10, DOI 10.3390/cancers10090284; Camargo MC, 2014, GUT, V63, P236, DOI 10.1136/gutjnl-2013-304531; Cantalupo PG, 2018, VIROLOGY, V513, P208, DOI 10.1016/j.virol.2017.10.017; Cardenas-Mondragon MG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062850; Cheng TC, 2010, INT J ONCOL, V36, P151, DOI 10.3892/ijo_00000486; Chesnokova LS, 2011, J VIROL, V85, P13214, DOI 10.1128/JVI.05580-11; Chesnokova LS, 2009, P NATL ACAD SCI USA, V106, P20464, DOI 10.1073/pnas.0907508106; Cho J, 2016, J GASTRIC CANCER, V16, P1, DOI 10.5230/jgc.2016.16.1.1; Cho SO, 2010, DIGEST DIS SCI, V55, P988, DOI 10.1007/s10620-009-0828-y; Choy EYW, 2008, J EXP MED, V205, P2551, DOI 10.1084/jem.20072581; Coker OO, 2018, GUT, V67, P1024, DOI 10.1136/gutjnl-2017-314281; Colquhoun A, 2015, GUT, V64, P1881, DOI 10.1136/gutjnl-2014-308915; Cristescu R, 2015, NAT MED, V21, P449, DOI 10.1038/nm.3850; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; Delgado S, 2013, MICROB ECOL, V65, P763, DOI 10.1007/s00248-013-0192-5; DElios MM, 1997, J IMMUNOL, V158, P962; Delyria ES, 2009, GASTROENTEROLOGY, V136, P247, DOI 10.1053/j.gastro.2008.09.017; Derks S, 2016, ONCOTARGET, V7, P32925, DOI 10.18632/oncotarget.9076; Dong M, 2016, HUM PATHOL, V53, P25, DOI 10.1016/j.humpath.2016.02.007; Eaton KA, 2001, J IMMUNOL, V166, P7456, DOI 10.4049/jimmunol.166.12.7456; Eaton KA, 2001, INFECT IMMUN, V69, P1025, DOI 10.1128/IAI.69.2.1025-1031.2001; El-Omar EM, 2003, GASTROENTEROLOGY, V124, P1193, DOI 10.1016/S0016-5085(03)00157-4; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; Engstrand L, 2013, BEST PRACT RES CL GA, V27, P39, DOI 10.1016/j.bpg.2013.03.016; Enroth H, 2000, CANCER EPIDEM BIOMAR, V9, P981; Fallone CA, 2016, GASTROENTEROLOGY, V151, P51, DOI 10.1053/j.gastro.2016.04.006; Farrell PJ, 2019, ANNU REV PATHOL-MECH, V14, P29, DOI 10.1146/annurev-pathmechdis-012418-013023; Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027; Ferro A, 2014, EUR J CANCER, V50, P1330, DOI 10.1016/j.ejca.2014.01.029; Franco AT, 2008, CANCER RES, V68, P379, DOI 10.1158/0008-5472.CAN-07-0824; Fukuda M, 2004, J VIROL, V78, P1697, DOI 10.1128/JVI.78.4.1697-1705.2004; Fukuda M, 2007, J VIROL, V81, P9299, DOI 10.1128/JVI.00537-07; Gao JJ, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00202; Geddert H, 2011, CELL ONCOL, V34, P209, DOI 10.1007/s13402-011-0028-6; Gulley ML, 1996, HUM PATHOL, V27, P20, DOI 10.1016/S0046-8177(96)90133-1; Hafsi N, 2004, J IMMUNOL, V173, P1249, DOI 10.4049/jimmunol.173.2.1249; HARN HJ, 1995, HUM PATHOL, V26, P267, DOI 10.1016/0046-8177(95)90056-X; He D, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0525-y; Higashi H, 2004, J BIOL CHEM, V279, P17205, DOI 10.1074/jbc.M309964200; Hino R, 2008, CANCER RES, V68, P1427, DOI 10.1158/0008-5472.CAN-07-3027; Hino R, 2009, CANCER RES, V69, P2766, DOI 10.1158/0008-5472.CAN-08-3070; Hooykaas MJG, 2017, J IMMUNOL, V198, P4062, DOI 10.4049/jimmunol.1501605; Huang JQ, 2003, GASTROENTEROLOGY, V125, P1636, DOI 10.1053/j.gastro.2003.08.033; Hutt-Fletcher LM, 2017, J VIROL, V91, DOI 10.1128/JVI.01677-16; Hwang IR, 2002, GASTROENTEROLOGY, V123, P1793, DOI 10.1053/gast.2002.37043; Ichimura T, 2016, HUM PATHOL, V56, P74, DOI 10.1016/j.humpath.2016.06.002; Imai S, 1998, J VIROL, V72, P4371, DOI 10.1128/JVI.72.5.4371-4378.1998; IMAI S, 1994, P NATL ACAD SCI USA, V91, P9131, DOI 10.1073/pnas.91.19.9131; Iwakiri D, 2003, CANCER RES, V63, P7062; Jackson CB, 2007, J PATHOL, V213, P140, DOI 10.1002/path.2218; Kamboj AK, 2017, MAYO CLIN PROC, V92, P599, DOI 10.1016/j.mayocp.2016.11.017; Kang GH, 2002, AM J PATHOL, V160, P787, DOI 10.1016/S0002-9440(10)64901-2; Kawazoe A, 2019, GASTRIC CANCER, V22, P69, DOI 10.1007/s10120-018-0843-9; Khan G, 2014, INFECT AGENTS CANCER, V9, DOI 10.1186/1750-9378-9-38; Khosravi Y, 2014, SCI WORLD J, DOI 10.1155/2014/610421; Kim H, 2015, CANCER LETT, V356, P733, DOI 10.1016/j.canlet.2014.10.023; Kim JY, 2019, GASTRIC CANCER, V22, P1164, DOI 10.1007/s10120-019-00974-4; Kim MY, 2019, MOL CELLS, V42, P448, DOI 10.14348/molcells.2019.2395; Kim ST, 2018, NAT MED, V24, P1449, DOI 10.1038/s41591-018-0101-z; Kim SM, 2017, BIOCHEM BIOPH RES CO, V494, P550, DOI 10.1016/j.bbrc.2017.10.095; Kim SY, 2015, GASTROENTEROLOGY, V148, P137, DOI 10.1053/j.gastro.2014.09.020; Kim TS, 2019, AM J SURG PATHOL, V43, P851, DOI 10.1097/PAS.0000000000001253; Knorr J, 2019, TRENDS MICROBIOL, V27, P731, DOI 10.1016/j.tim.2019.04.010; Koemans WJ, 2019, CANCER LETT, V442, P279, DOI 10.1016/j.canlet.2018.11.001; Kwok T, 2007, NATURE, V449, P862, DOI 10.1038/nature06187; Lamb A, 2013, J CELL BIOCHEM, V114, P491, DOI 10.1002/jcb.24389; Lamps LW, 2014, ADV ANAT PATHOL, V21, P217, DOI 10.1097/PAP.0000000000000016; LEONCINI L, 1993, INT J CANCER, V53, P898; Leung WK, 2006, CLIN CANCER RES, V12, P3216, DOI 10.1158/1078-0432.CCR-05-2442; Li XX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007985; Liang QY, 2014, GASTROENTEROLOGY, V147, P1350, DOI 10.1053/j.gastro.2014.08.036; Lieberman PM, 2014, SCIENCE, V343, P1323, DOI 10.1126/science.1252786; Lieberman PM, 2013, NAT REV MICROBIOL, V11, P863, DOI 10.1038/nrmicro3135; Liu XS, 2011, GASTROENT RES PRACT, V2011, DOI 10.1155/2011/182832; Louafi F, 2010, J BIOL CHEM, V285, P41328, DOI 10.1074/jbc.M110.146852; Lu SL, 2020, APPL IMMUNOHISTO M M, V28, P360, DOI 10.1097/PAI.0000000000000761; Lundgren A, 2003, INFECT IMMUN, V71, P1755, DOI 10.1128/IAI.71.4.1755-1762.2003; Luo B, 2005, WORLD J GASTROENTERO, V11, P629, DOI 10.3748/wjg.v11.i5.629; Maldonado-Contreras A, 2011, ISME J, V5, P574, DOI 10.1038/ismej.2010.149; Marquitz AR, 2014, J VIROL, V88, P1389, DOI 10.1128/JVI.02662-13; Marquitz AR, 2012, P NATL ACAD SCI USA, V109, P9593, DOI 10.1073/pnas.1202910109; Marquitz AR, 2011, VIROLOGY, V412, P392, DOI 10.1016/j.virol.2011.01.028; Matsusaka K, 2011, CANCER RES, V71, P7187, DOI 10.1158/0008-5472.CAN-11-1349; Menheniott TR, 2015, CELL MICROBIOL, V17, P1570, DOI 10.1111/cmi.12518; Minamitani T, 2015, P NATL ACAD SCI USA, V112, P11612, DOI 10.1073/pnas.1514484112; Mishima S, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0514-3; Murata-Kamiya N, 2007, ONCOGENE, V26, P4617, DOI 10.1038/sj.onc.1210251; Murphy G, 2009, GASTROENTEROLOGY, V137, P824, DOI 10.1053/j.gastro.2009.05.001; Murray PG, 1996, J PATHOL, V178, P44, DOI 10.1002/(SICI)1096-9896(199601)178:1<44::AID-PATH471>3.0.CO;2-0; Nagy TA, 2009, J INFECT DIS, V199, P641, DOI 10.1086/596660; Nakayama M, 2009, J BIOL CHEM, V284, P1612, DOI 10.1074/jbc.M806981200; Namba-Fukuyo H, 2016, ONCOTARGET, V7, P81512, DOI 10.18632/oncotarget.13130; Nanbo A, 2016, J GEN VIROL, V97, P2989, DOI 10.1099/jgv.0.000605; Nardone G, 2015, UNITED EUR GASTROENT, V3, P255, DOI 10.1177/2050640614566846; Niwa T, 2010, CANCER RES, V70, P1430, DOI 10.1158/0008-5472.CAN-09-2755; Ohnishi N, 2008, P NATL ACAD SCI USA, V105, P1003, DOI 10.1073/pnas.0711183105; Okada T, 2013, CANCER SCI, V104, P1309, DOI 10.1111/cas.12228; OTT G, 1994, HISTOPATHOLOGY, V25, P323, DOI 10.1111/j.1365-2559.1994.tb01350.x; Pal AD, 2015, VIROLOGY, V484, P22, DOI 10.1016/j.virol.2015.05.007; Pal AD, 2014, CARCINOGENESIS, V35, P1592, DOI 10.1093/carcin/bgu069; Panda Anshuman, 2018, J Natl Cancer Inst, V110, P316, DOI 10.1093/jnci/djx213; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; Perry S, 2006, EMERG INFECT DIS, V12, P1701, DOI 10.3201/eid1211.060086; Plummer M, 2016, LANCET GLOB HEALTH, V4, pE609, DOI 10.1016/S2214-109X(16)30143-7; Qiu MZ, 2020, INT J CANCER, V146, P272, DOI 10.1002/ijc.32490; Robinson K, 2008, GUT, V57, P1375, DOI 10.1136/gut.2007.137539; ROWLANDS DC, 1993, BRIT J CANCER, V68, P1014, DOI 10.1038/bjc.1993.472; Rudi J, 1997, DIGEST DIS SCI, V42, P1652, DOI 10.1023/A:1018849112533; Saiki Y, 1996, LAB INVEST, V75, P67; Saito R, 2017, MODERN PATHOL, V30, P427, DOI 10.1038/modpathol.2016.202; Saju P, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.26, 10.1038/nmicrobiol.2016.26]; Sasaki S, 2019, GASTRIC CANCER, V22, P486, DOI 10.1007/s10120-018-0880-4; Schulze J, 2009, DTSCH ARZTEBL INT, V106, P837, DOI 10.3238/arztebl.2009.0837; Schuster V, 1996, BLOOD, V87, P1579, DOI 10.1182/blood.V87.4.1579.bloodjournal8741579; SCOTT BB, 1982, GUT, V23, P137, DOI 10.1136/gut.23.2.137; SHIBATA D, 1992, AM J PATHOL, V140, P769; SHIBATA D, 1993, CANCER EPIDEM BIOMAR, V2, P213; Shikata K, 2008, AM J EPIDEMIOL, V168, P1409, DOI 10.1093/aje/kwn276; Shikata K, 2006, INT J CANCER, V119, P196, DOI 10.1002/ijc.21822; Shinozaki A, 2010, CANCER RES, V70, P4719, DOI 10.1158/0008-5472.CAN-09-4620; Shinozaki-Ushiku A, 2015, J VIROL, V89, P5581, DOI 10.1128/JVI.03639-14; Sidagis J, 1997, INT J CANCER, V72, P72, DOI 10.1002/(SICI)1097-0215(19970703)72:1&lt;72::AID-IJC11&gt;3.0.CO;2-C; Sivachandran N, 2012, J VIROL, V86, P60, DOI 10.1128/JVI.05623-11; Sokal EM, 2007, J INFECT DIS, V196, P1749, DOI 10.1086/523813; Song HJ, 2010, GASTROENTEROLOGY, V139, P84, DOI 10.1053/j.gastro.2010.04.002; Stoicov C, 2004, GENE, V341, P1, DOI 10.1016/j.gene.2004.07.023; Stoicov C, 2009, J IMMUNOL, V183, P642, DOI 10.4049/jimmunol.0900511; Strong MJ, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003341; Sugiura M, 1996, BRIT J CANCER, V74, P625, DOI 10.1038/bjc.1996.412; Suzuki M, 2009, CELL HOST MICROBE, V5, P23, DOI 10.1016/j.chom.2008.11.010; Tan MP, 2007, APPL ENVIRON MICROB, V73, P1010, DOI 10.1128/AEM.01675-06; TOKUNAGA M, 1993, AM J PATHOL, V143, P1250; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Tsai CY, 2017, J GASTROEN HEPATOL, V32, P82, DOI 10.1111/jgh.13432; Tsutsumi R, 2006, MOL CELL BIOL, V26, P261, DOI 10.1128/MCB.26.1.261-276.2006; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Ushiku T, 2007, INT J CANCER, V120, P60, DOI 10.1002/ijc.22275; van Beek J, 2006, AM J SURG PATHOL, V30, P59, DOI 10.1097/01.pas.0000176428.06629.1e; Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3; Vinasco K, 2019, BBA-REV CANCER, V1872, DOI 10.1016/j.bbcan.2019.07.004; Virgin HW, 2014, CELL, V157, P142, DOI 10.1016/j.cell.2014.02.032; von Rosenvinge EC, 2013, ISME J, V7, P1354, DOI 10.1038/ismej.2013.33; Wang J, 2019, J BIOL CHEM, V294, P4854, DOI 10.1074/jbc.RA118.006853; Wang JY, 2019, VIROLOGY, V534, P87, DOI 10.1016/j.virol.2019.06.006; Wang ZK, 2014, ALIMENT PHARM THER, V39, P751, DOI 10.1111/apt.12665; WOLFE RR, 1990, AM J CLIN NUTR, V51, P248, DOI 10.1093/ajcn/51.2.248; Wong BCY, 2004, JAMA-J AM MED ASSOC, V291, P187, DOI 10.1001/jama.291.2.187; Wroblewski LE, 2010, CLIN MICROBIOL REV, V23, P713, DOI 10.1128/CMR.00011-10; Xiang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07308-5; Xing XF, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1356144; Xiong D, 2015, P NATL ACAD SCI USA, V112, P11036, DOI 10.1073/pnas.1513359112; Yamaoka Y, 2000, P NATL ACAD SCI USA, V97, P7533, DOI 10.1073/pnas.130079797; Yamaoka Y, 2002, GASTROENTEROLOGY, V123, P414, DOI 10.1053/gast.2002.34781; Yamaoka Y, 1999, J CLIN PATHOL, V52, P215, DOI 10.1136/jcp.52.3.215; Yamaoka Y, 2010, NAT REV GASTRO HEPAT, V7, P629, DOI 10.1038/nrgastro.2010.154; Yamashita S, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0789-8; Yanai H, 1997, GASTROINTEST ENDOSC, V45, P236, DOI 10.1016/S0016-5107(97)70265-7; Ye G, 1997, J CLIN INVEST, V99, P1628, DOI 10.1172/JCI119325; Yu J, 2017, ONCOGENE, V36, P182, DOI 10.1038/onc.2016.187; Yu PC, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011387; YUEN ST, 1994, AM J SURG PATHOL, V18, P1158, DOI 10.1097/00000478-199411000-00010; Zhang H, 2018, NAT MICROBIOL, V3, P164, DOI 10.1038/s41564-017-0080-8; Zhang NN, 2015, SCI REP-UK, V5, DOI 10.1038/srep18057; Zhao J, 2013, BRIT J CANCER, V108, P2557, DOI 10.1038/bjc.2013.263; Zhao JH, 2013, CANCER-AM CANCER SOC, V119, P304, DOI 10.1002/cncr.27724; Zheng X, 2018, J VIROL, V92, DOI 10.1128/JVI.01022-18; Zhuang YA, 2011, IMMUNOBIOLOGY, V216, P200, DOI 10.1016/j.imbio.2010.05.005; Zwolinska-Wcislo M, 2001, MED SCI MONITOR, V7, P266	183	19	20	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	17					3427	3442		10.1038/s41388-020-1241-4	http://dx.doi.org/10.1038/s41388-020-1241-4		MAR 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LH1YK	32123313	Green Published, hybrid			2022-12-17	WOS:000517738400003
J	Li, S; Lavrijsen, M; Bakker, A; Magierowski, M; Magierowska, K; Liu, PY; Wang, WH; Peppelenbosch, MP; Smits, R				Li, Shan; Lavrijsen, Marla; Bakker, Aron; Magierowski, Marcin; Magierowska, Katarzyna; Liu, Pengyu; Wang, Wenhui; Peppelenbosch, Maikel P.; Smits, Ron			Commonly observed RNF43 mutations retain functionality in attenuating Wnt/beta-catenin signaling and unlikely confer Wnt-dependency onto colorectal cancers	ONCOGENE			English	Article							COMPREHENSIVE MOLECULAR CHARACTERIZATION; TUMOR-SUPPRESSOR RNF43; FINGER PROTEIN 43; RECURRENT MUTATIONS; RECEPTOR TURNOVER; GENOMIC LANDSCAPE; CARCINOMA; NEOPLASMS; SUBTYPES; PROMOTES	Cancer-associated RNF43 mutations lead to activation of beta-catenin signaling through aberrantly increasing Wnt-receptor levels at the membrane. Importantly, inactivating RNF43 mutations have been suggested to render cancer cells sensitive to Wnt-based therapeutics. However, the extent to which RNF43 mutations lead to impaired regulation of Wnt/beta-catenin signaling has been poorly investigated. Here, we observed that tumors with a functional mismatch repair system show a predominant 5 '-location of truncating RNF43 mutations, suggesting C-terminal truncations such as the most commonly reported p.G659fs mutation, do not affect beta-catenin signaling. In accordance, expressing C-terminal truncation mutants and wild-type RNF43, showed equal effects on beta-catenin signaling, Wnt-receptor turnover, and DVL-binding. We confirmed these observations at endogenous levels by CRISPR-Cas9-mediated knockout of G659fs RNF43 expression in KM12 cells and generating comparable mutations in HEK293T cells. We could not confirm previous reports linking RNF43 to p53 and E-cadherin breakdown. Our data also suggest that only colorectal cancer cells harboring N-terminal mutations of RNF43 convey Wnt-dependency onto the tumor cells. Results of this study have potentially important clinical implications indicating that Wnt-based therapeutics should be applied cautiously in cancer patients harboring RNF43 mutations.	[Li, Shan; Lavrijsen, Marla; Bakker, Aron; Magierowski, Marcin; Magierowska, Katarzyna; Liu, Pengyu; Wang, Wenhui; Peppelenbosch, Maikel P.; Smits, Ron] Erasmus MC, Univ Med Ctr, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands; [Li, Shan] Army Med Univ, Daping Hosp, Dept Hepatobiliary Surg, Chongqing, Peoples R China; [Magierowski, Marcin; Magierowska, Katarzyna] Jagiellonian Univ, Med Coll, Dept Physiol, Krakow, Poland; [Wang, Wenhui] China Pharmaceut Univ, Dept Pharmacol, State Key Lab Nat Med, Nanjing, Peoples R China	Erasmus University Rotterdam; Erasmus MC; Army Medical University; Jagiellonian University; Collegium Medicum Jagiellonian University; China Pharmaceutical University	Smits, R (corresponding author), Erasmus MC, Univ Med Ctr, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands.	m.j.m.smits@erasmusmc.nl	Li, Shan/GSN-4678-2022	Li, Shan/0000-0003-4446-2218; Magierowski, Marcin/0000-0003-0175-5600; liu, pengyu/0000-0001-6600-6139; Peppelenbosch, Maikel/0000-0001-9112-6028	China Scholarship Council [201408060053, 201408220029]; Erasmus MC Grant; National Science Center Poland [UMO-2015/16/T/NZ4/00176]	China Scholarship Council(China Scholarship Council); Erasmus MC Grant; National Science Center Poland(National Science Centre, Poland)	We wish to thank Dr Louis Vermeulen (AMC, Amsterdam, The Netherlands) for providing us with several of the cell lines used in this study. We are grateful to Dr Erik A.C. Wiemer and Dr Robbert J. Rottier (Erasmus MC, Rotterdam, The Netherlands) for providing us, respectively with H1299 and A549 cell lines. We gratefully acknowledge Dr Aart G. Jochemsen (LUMC, Leiden, The Netherlands) for helpful discussion on p53-related works and providing us the p53-related plasmids. We thank Dr Markus Gerhard (Technische Universitat Munchen, Munich, Germany) for kindly providing HA-tagged RNF43 plasmid. We thank Natascha Nieuwenhuijze (Erasmus MC, Rotterdam, The Netherlands) for help with confocal microscopy. We would like to thank Dr Feng Cong (Novartis Institutes for Biomedical Research, Cambridge, MA, USA) for kindly giving us positive responses and the detailed protocol of surface SNAP-labeling experiments. This work was supported by the China Scholarship Council PhD fellowship (grant numbers 201408060053 to SL and 201408220029 to PL); and an Erasmus MC Grant; MM received financial support from National Science Center Poland (UMO-2015/16/T/NZ4/00176).	Ashkenazy H, 2016, NUCLEIC ACIDS RES, V44, pW344, DOI 10.1093/nar/gkw408; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Behm-Ansmant I, 2007, FEBS LETT, V581, P2845, DOI 10.1016/j.febslet.2007.05.027; Carmon KS, 2014, P NATL ACAD SCI USA, V111, pE1221, DOI 10.1073/pnas.1323106111; Carmon KS, 2011, P NATL ACAD SCI USA, V108, P11452, DOI 10.1073/pnas.1106083108; Eto T, 2018, J PATHOL, V245, P445, DOI 10.1002/path.5098; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Fujii M, 2016, CELL STEM CELL, V18, P827, DOI 10.1016/j.stem.2016.04.003; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Giannakis M, 2016, CELL REP, V15, P857, DOI 10.1016/j.celrep.2016.03.075; Giannakis M, 2014, NAT GENET, V46, P1264, DOI 10.1038/ng.3127; Gibson WJ, 2016, NAT GENET, V48, P848, DOI 10.1038/ng.3602; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; Hao HX, 2016, CANCERS, V8, DOI 10.3390/cancers8060054; Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019; Hashimoto T, 2017, AM J SURG PATHOL, V41, P1188, DOI 10.1097/PAS.0000000000000877; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Jiang XM, 2015, MOL CELL, V58, P522, DOI 10.1016/j.molcel.2015.03.015; Jiang XM, 2013, P NATL ACAD SCI USA, V110, P12649, DOI 10.1073/pnas.1307218110; Jiao YC, 2014, J PATHOL, V232, P428, DOI 10.1002/path.4310; Koo BK, 2015, P NATL ACAD SCI USA, V112, P7548, DOI 10.1073/pnas.1508113112; Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308; Lee HJ, 2015, ELIFE, V4, DOI 10.7554/eLife.08142; Loregger A, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aac6757; Madan B, 2016, ONCOGENE, V35, P2197, DOI 10.1038/onc.2015.280; Mazzoni SM, 2014, CANCER LETT, V355, P1, DOI 10.1016/j.canlet.2014.09.018; Min BH, 2016, J PATHOL, V240, P304, DOI 10.1002/path.4777; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nailwal H, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.131; Neumeyer V, 2019, CARCINOGENESIS, V40, P551, DOI 10.1093/carcin/bgy152; Niu L, 2015, CELL PHYSIOL BIOCHEM, V36, P1835, DOI 10.1159/000430154; Picco G, 2017, EMBO MOL MED, V9, P293, DOI 10.15252/emmm.201606773; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Ryland GL, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0210-y; Ryland GL, 2013, J PATHOL, V229, P469, DOI 10.1002/path.4134; Sakamoto H, 2015, MODERN PATHOL, V28, P261, DOI 10.1038/modpathol.2014.98; Sekine S, 2016, J PATHOL, V239, P133, DOI 10.1002/path.4709; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Shinada K, 2011, BIOCHEM BIOPH RES CO, V404, P143, DOI 10.1016/j.bbrc.2010.11.082; Soumerai TE, 2018, CLIN CANCER RES, V24, P5939, DOI 10.1158/1078-0432.CCR-18-0412; Steinhart Z, 2017, NAT MED, V23, P60, DOI 10.1038/nm.4219; Tsai JH, 2017, HISTOPATHOLOGY, V70, P756, DOI 10.1111/his.13125; Tsukiyama T, 2015, MOL CELL BIOL, V35, P2007, DOI 10.1128/MCB.00159-15; van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053; Vanderwalde A, 2018, CANCER MED-US, V7, P746, DOI 10.1002/cam4.1372; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Wang K, 2011, NAT GENET, V43, P1219, DOI 10.1038/ng.982; Wang WH, 2016, NEOPLASIA, V18, P711, DOI 10.1016/j.neo.2016.10.004; Witkiewicz AK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7744; Wu J, 2011, P NATL ACAD SCI USA, V108, P21188, DOI 10.1073/pnas.1118046108; Xie HY, 2015, INT J CLIN EXP PATHO, V8, P14995; Xie Y, 2013, EMBO REP, V14, P1120, DOI 10.1038/embor.2013.167; Xing CY, 2013, MOL CANCER THER, V12, P94, DOI 10.1158/1535-7163.MCT-12-0672; Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004; Yan HHN, 2017, GUT, V66, P1645, DOI 10.1136/gutjnl-2016-311849; Zebisch M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3787; Zhang YF, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5880-1; Zou Y, 2013, GENE, V531, P112, DOI 10.1016/j.gene.2013.08.054	60	19	20	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	17					3458	3472		10.1038/s41388-020-1232-5	http://dx.doi.org/10.1038/s41388-020-1232-5		FEB 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LH1YK	32103169	Green Submitted			2022-12-17	WOS:000516683200003
J	Wang, T; Jing, B; Xu, DL; Liao, YL; Song, HY; Sun, BB; Guo, WZ; Xu, JH; Li, KM; Hu, M; Liu, SL; Ling, J; Kuang, YB; Zhang, T; Zhang, SW; Yao, F; Zhou, BHP; Deng, J				Wang, Tong; Jing, Bo; Xu, Dongliang; Liao, Yueling; Song, Hongyong; Sun, Beibei; Guo, Wenzheng; Xu, Jianhua; Li, Kaimi; Hu, Min; Liu, Shuli; Ling, Jing; Kuang, Yanbin; Zhang, Tuo; Zhang, Siwei; Yao, Feng; Zhou, Binhua P.; Deng, Jiong			PTGES/PGE(2) signaling links immunosuppression and lung metastasis in Gprc5a-knockout mouse model	ONCOGENE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; CANCER METASTASIS; SUPPRESSOR-CELLS; INDUCED EMT; GM-CSF; GPRC5A; IMMUNOTHERAPY; SYNTHASE-1; EXPRESSION; EPITHELIUM	Chronic inflammation has been linked to promotion of tumorigenesis and metastasis in lung. However, due to lack of a relevant animal model for characterization, the underlying mechanism remains elusive. Lung tumor suppressor gene Gprc5a-knockout (ko) mice are susceptible to lung inflammation, tumorigenesis and metastasis, which resembles the pathological features in human patients. Here, we showed that PTGES/PGE(2) signaling was highly associated with lung tumorigenesis and metastasis in Gprc5a-ko mice. Interestingly, Ptges-knockout in mouse lung tumor cells, although reduced their stemness and EMT-like features, still formed tumors and lung metastasis in immune-deficient nude mice, but not in immune-competent mice. This suggests that the major role of PTGES/PGE(2) signaling in tumorigenicity and lung metastasis is through immunosuppression. Mechanistically, PTGES/PGE(2) signaling intrinsically endows tumor cells resistant to T-cell cytotoxicity, and induces cytokines extrinsically for MDSC recruitment, which is crucial for suppression of T-cell immunity. Importantly, targeting PGE(2) signaling in Gprc5a-ko mice by PTGES inhibitor suppressed MDSC recruitment, restored T cells, and significantly repressed lung metastasis. Thus, PTGES/PGE(2) signaling links immunosuppression and metastasis in an inflammatory lung microenvironment of Gprc5a-ko mouse model.	[Wang, Tong; Jing, Bo; Xu, Dongliang; Liao, Yueling; Song, Hongyong; Guo, Wenzheng; Li, Kaimi; Hu, Min; Zhang, Siwei; Deng, Jiong] Shanghai Jiao Tong Univ, Key Lab Cell Differentiat & Apoptosis, Chinese Minister Educ, Sch Med, Shanghai, Peoples R China; [Wang, Tong; Jing, Bo; Xu, Dongliang; Liao, Yueling; Song, Hongyong; Li, Kaimi; Hu, Min; Zhang, Siwei; Deng, Jiong] Shanghai Jiao Tong Univ, Shanghai Key Lab Tumor Microenvironm & Inflammat, Sch Med, Shanghai, Peoples R China; [Sun, Beibei; Deng, Jiong] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Translat Med Res Ctr, Shanghai, Peoples R China; [Xu, Jianhua] Kunming Med Univ, Dept Pathol, Kunming, Yunnan, Peoples R China; [Liu, Shuli] Shanghai Jiao Tong Univ, Peoples Hosp 9, Dept Oral & Maxillofacial Head & Neck Oncol, Coll Stomatol,Sch Med, Shanghai, Peoples R China; [Ling, Jing] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Oncol, Sch Med, Shanghai, Peoples R China; [Kuang, Yanbin] Dalian Med Univ, Affiliated Hosp 2, Dept Resp Med, Dalian, Peoples R China; [Zhang, Tuo; Yao, Feng] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Thorac Surg, Shanghai, Peoples R China; [Zhou, Binhua P.] Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Markey Canc Ctr, Lexington, KY 40506 USA	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Kunming Medical University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Dalian Medical University; Shanghai Jiao Tong University; University of Kentucky	Deng, J (corresponding author), Shanghai Jiao Tong Univ, Key Lab Cell Differentiat & Apoptosis, Chinese Minister Educ, Sch Med, Shanghai, Peoples R China.; Deng, J (corresponding author), Shanghai Jiao Tong Univ, Shanghai Key Lab Tumor Microenvironm & Inflammat, Sch Med, Shanghai, Peoples R China.; Deng, J (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Translat Med Res Ctr, Shanghai, Peoples R China.; Yao, F (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Thorac Surg, Shanghai, Peoples R China.; Zhou, BHP (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Markey Canc Ctr, Lexington, KY 40506 USA.	yaofeng6796678@126.com; peter.zhou@uky.edu; jiongdeng@shsmu.edu.cn		Yao, Feng/0000-0002-9635-9581; Shuli, Liu/0000-0002-8988-8899; Kuang, Yanbin/0000-0003-3041-7854	National Natural Science Foundation of China [81620108022, 91129303, 91729302, 81572759, 81572693]; Shenzhen Municipal Government of China [KQTD20170810160226082]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenzhen Municipal Government of China	This study was supported by grants from National Natural Science Foundation of China (81620108022, 91129303, 91729302 and 81572759 to JD, 81572693 to FY) and Shenzhen Municipal Government of China (KQTD20170810160226082).	Bottcher JP, 2018, CELL, V172, P1022, DOI 10.1016/j.cell.2018.01.004; Cheng YJ, 1998, J BIOL CHEM, V273, P35008, DOI 10.1074/jbc.273.52.35008; Cortes M, 2017, EMBO J, V36, P3336, DOI 10.15252/embj.201797345; Coulombe F, 2014, IMMUNITY, V40, P554, DOI 10.1016/j.immuni.2014.02.013; Coward JIG, 2012, LUNG CANCER, V75, P133, DOI 10.1016/j.lungcan.2011.11.001; Daley-Bauer LP, 2012, IMMUNITY, V37, P122, DOI 10.1016/j.immuni.2012.04.014; Deng JO, 2010, CANCER PREV RES, V3, P424, DOI 10.1158/1940-6207.CAPR-10-0032; Guo WZ, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108791; Herbst RS, 2018, NATURE, V553, P446, DOI 10.1038/nature25183; Hu M, 2019, AM J CANCER RES, V9, P134; Hutchison S, 2019, VET IMMUNOL IMMUNOP, V216, DOI 10.1016/j.vetimm.2019.109912; Isono M, 2011, LIFE SCI, V88, P693, DOI 10.1016/j.lfs.2011.02.008; Katoh H, 2013, CANCER CELL, V24, P631, DOI 10.1016/j.ccr.2013.10.009; Kawahara K, 2015, BBA-MOL CELL BIOL L, V1851, P414, DOI 10.1016/j.bbalip.2014.07.008; Ke YB, 2017, AM J PHYSIOL-LUNG C, V313, pL710, DOI 10.1152/ajplung.00519.2016; Kim SH, 2016, PIGM CELL MELANOMA R, V29, P297, DOI 10.1111/pcmr.12455; Kudo-Saito C, 2009, CANCER CELL, V15, P195, DOI 10.1016/j.ccr.2009.01.023; Kurtova AV, 2015, NATURE, V517, P209, DOI 10.1038/nature14034; Li KM, 2019, NEOPLASIA, V21, P602, DOI 10.1016/j.neo.2019.03.008; Li W, 2018, CELL METAB, V28, P87, DOI 10.1016/j.cmet.2018.04.022; Liao YL, 2015, CELL CYCLE, V14, P1403, DOI 10.1080/15384101.2015.1006006; Lin Y, 2017, ONCOGENE, V36, P3599, DOI 10.1038/onc.2016.516; Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63; Liu SL, 2015, ONCOTARGET, V6, P6887, DOI 10.18632/oncotarget.3159; Majumder M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041019; Mak MP, 2016, CLIN CANCER RES, V22, P609, DOI 10.1158/1078-0432.CCR-15-0876; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Mondanelli G, 2017, IMMUNITY, V46, P233, DOI 10.1016/j.immuni.2017.01.005; Nandi P, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-3018-2; Ong HS, 2017, HEAD NECK-J SCI SPEC, V39, P2450, DOI 10.1002/hed.24914; Paff M, 2014, HUM VACC IMMUNOTHER, V10, P3322, DOI 10.4161/21645515.2014.983002; Palizgir MT, 2018, IMMUNOPHARM IMMUNOT, V40, P297, DOI 10.1080/08923973.2018.1474921; Prima V, 2017, P NATL ACAD SCI USA, V114, P1117, DOI 10.1073/pnas.1612920114; Quail DF, 2017, NAT CELL BIOL, V19, P974, DOI 10.1038/ncb3578; Roussel M, 2017, J LEUKOCYTE BIOL, V102, P437, DOI 10.1189/jlb.5MA1116-457R; Samuelsson B, 2007, PHARMACOL REV, V59, P207, DOI 10.1124/pr.59.3.1; Schumacher Y, 2016, ONCOGENE, V35, P2602, DOI 10.1038/onc.2015.283; Song HY, 2019, INT J CANCER, V144, P777, DOI 10.1002/ijc.31726; Steele CW, 2016, CANCER CELL, V29, P832, DOI 10.1016/j.ccell.2016.04.014; Tao QG, 2007, JNCI-J NATL CANCER I, V99, P1668, DOI 10.1093/jnci/djm208; Tian XY, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4564-6; Tong DL, 2017, CANCER LETT, V389, P23, DOI 10.1016/j.canlet.2016.12.031; Waghray M, 2016, CANCER DISCOV, V6, P886, DOI 10.1158/2159-8290.CD-15-0947; Wang T, 2019, AM J CANCER RES, V9, P1145; Wang T, 2019, BIOCHEM BIOPH RES CO, V513, P319, DOI [10.1016/ibbrc.2019.03.198, 10.1016/j.bbrc.2019.03.198]; Wu AA, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1016700; Xu JS, 2005, AM J RESP CELL MOL, V32, P381, DOI 10.1165/rcmb.2004-0343OC; Zelenay S, 2015, CELL, V162, P1257, DOI 10.1016/j.cell.2015.08.015; Zhong SS, 2015, CANCER RES, V75, P1801, DOI 10.1158/0008-5472.CAN-14-2005	49	19	20	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	15					3179	3194		10.1038/s41388-020-1207-6	http://dx.doi.org/10.1038/s41388-020-1207-6		FEB 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LB8NS	32060421	hybrid, Green Published			2022-12-17	WOS:000513384600001
J	Wang, JQ; He, CX; Gao, P; Wang, SQ; Lv, RT; Zhou, HH; Zhou, QD; Zhang, K; Sun, J; Fan, CB; Ding, GX; Lan, F				Wang, Jianqing; He, Chenxi; Gao, Peng; Wang, Siqing; Lv, Ruitu; Zhou, Huihui; Zhou, Qidong; Zhang, Ke; Sun, Jian; Fan, Caibin; Ding, Guanxiong; Lan, Fei			HNF1B-mediated repression of SLUG is suppressed by EZH2 in aggressive prostate cancer	ONCOGENE			English	Article							GENOME-WIDE ASSOCIATION; GROUP PROTEIN EZH2; E-CADHERIN; TRANSCRIPTION FACTORS; STEM-CELLS; POLYCOMB; GENE; LOCI; RISK; EXPRESSION	Prostate cancer is the most common malignancy in men in developed countries. Overexpression of enhancer of zeste homolog 2 (EZH2), the major histone H3 lysine 27 methyltransferase, has been connected to prostate cancer malignancy. However, its downstream genes and pathways have not been well established. Here, we show tumor suppressor Hepatocyte Nuclear Factor 1 beta (HNF1B) as a direct downstream target of EZH2. EZH2 binds HNF1B locus and suppresses HNF1B expression in prostate cancer cell lines, which is further supported by the reverse correlation between EZH2 and HNF1B expression in clinical samples. Consistently, restored HNF1B expression significantly suppresses EZH2-mediated overgrowth and EMT processes, including migration and invasion of prostate cancer cell lines. Mechanistically, we find that HNF1B primarily binds the promoters of thousands of target genes, and differentially regulates the expression of 876 genes. We also identify RBBP7/RbAP46 as a HNF1B interacting protein which is required for HNF1B-mediated repression of SLUG expression and EMT process. Importantly, we find that higher HNF1B expression strongly predicts better prognosis of prostate cancer, alone or together with lower EZH2 expression. Taken together, we have established a previously underappreciated axis of EZH2-HNF1B-SLUG in prostate cancer, and also provide evidence supporting HNF1B as a potential prognosis marker for metastatic prostate cancer.	[Wang, Jianqing; Zhang, Ke; Sun, Jian; Fan, Caibin] Nanjing Med Univ, Affiliated Suzhou Hosp, Dept Urol, Suzhou 215002, Jiangsu, Peoples R China; [He, Chenxi; Wang, Siqing; Lv, Ruitu; Lan, Fei] Fudan Univ, Inst Biomed Sci, Key Lab Epigenet & Metab, Minist Sci & Technol, Shanghai 200032, Peoples R China; [He, Chenxi; Wang, Siqing; Lv, Ruitu; Lan, Fei] Fudan Univ, Key Lab Carcinogenesis & Canc Invas, Minist Educ, Liver Canc Inst,Zhongshan Hosp, Shanghai 200032, Peoples R China; [Gao, Peng; Zhou, Qidong; Ding, Guanxiong] Fudan Univ, Huashan Hosp, Dept Urol, Shanghai, Peoples R China; [Zhou, Huihui] Qingdao Univ, Affiliated Yuhuangding Hosp, Dept Pathol, Qingdao 266071, Shandong, Peoples R China	Nanjing Medical University; Fudan University; Fudan University; Fudan University; Qingdao University	Wang, JQ (corresponding author), Nanjing Med Univ, Affiliated Suzhou Hosp, Dept Urol, Suzhou 215002, Jiangsu, Peoples R China.; Lan, F (corresponding author), Fudan Univ, Inst Biomed Sci, Key Lab Epigenet & Metab, Minist Sci & Technol, Shanghai 200032, Peoples R China.; Lan, F (corresponding author), Fudan Univ, Key Lab Carcinogenesis & Canc Invas, Minist Educ, Liver Canc Inst,Zhongshan Hosp, Shanghai 200032, Peoples R China.; Ding, GX (corresponding author), Fudan Univ, Huashan Hosp, Dept Urol, Shanghai, Peoples R China.	jqwang14@fudan.edu.cn; dingguanxiong1981@126.com; fei_lan@fudan.edu.cn	Lyu, Ruitu/ABG-1437-2021; Lyu, Ruitu/ABU-6220-2022; Wang, Siqing/K-6662-2019	Lyu, Ruitu/0000-0003-4597-1604; Lyu, Ruitu/0000-0003-4597-1604; Wang, Siqing/0000-0002-6665-298X	National Natural Science Foundation of China [81802565, 81773014]; Natural Science Foundation of Jiangsu Province [BK20180216]; Key Project of the Scientific Research Project of Nanjing Medical University Affiliated Suzhou Hospital [szslyy2017005]; Shanghai Municipal Science and Technology Major Project [2017SHZDZX01]; National Key Research and Development program of China [2018YFA0108700]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Key Project of the Scientific Research Project of Nanjing Medical University Affiliated Suzhou Hospital; Shanghai Municipal Science and Technology Major Project; National Key Research and Development program of China	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: this study was supported by National Natural Science Foundation of China (81802565 to JW and 81773014 to FL), Natural Science Foundation of Jiangsu Province (BK20180216 to JW), Key Project of the Scientific Research Project of Nanjing Medical University Affiliated Suzhou Hospital (szslyy2017005 to JW), Shanghai Municipal Science and Technology Major Project (2017SHZDZX01 to FL), and National Key Research and Development program of China (2018YFA0108700 to FL).	BERNDTSON WE, 1991, J ANIM SCI, V69, P67; Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118; Bryant RJ, 2007, PROSTATE, V67, P547, DOI 10.1002/pros.20550; Bubancova I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020474; Byles V, 2012, ONCOGENE, V31, P4619, DOI 10.1038/onc.2011.612; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chang CJ, 2012, BRIT J CANCER, V106, P243, DOI 10.1038/bjc.2011.551; Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200; Dardenne E, 2016, CANCER CELL, V30, P563, DOI 10.1016/j.ccell.2016.09.005; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Fu JJ, 2011, CELL RES, V21, P275, DOI 10.1038/cr.2010.118; Gudmundsson J, 2007, NAT GENET, V39, P977, DOI 10.1038/ng2062; Gudmundsson J, 2009, NAT GENET, V41, P1122, DOI 10.1038/ng.448; Guo R, 2014, MOL CELL, V56, P298, DOI 10.1016/j.molcel.2014.08.022; Heliot C, 2013, DEVELOPMENT, V140, P873, DOI 10.1242/dev.086538; Hiesberger T, 2005, J BIOL CHEM, V280, P10578, DOI 10.1074/jbc.M414121200; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kong LC, 2016, NUCLEIC ACIDS RES, V44, P8682, DOI 10.1093/nar/gkw529; Koyanagi M, 2005, J BIOL CHEM, V280, P31470, DOI 10.1074/jbc.M504766200; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Lan F, 2007, NATURE, V448, P718, DOI 10.1038/nature06034; Li HJ, 2016, ONCOGENE, V35, P2266, DOI 10.1038/onc.2015.289; Li M, 2010, J BIOL CHEM, V285, P6285, DOI 10.1074/jbc.M109.057943; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Martin TA, 2005, ANN SURG ONCOL, V12, P488, DOI 10.1245/ASO.2005.04.010; Mei SL, 2017, NUCLEIC ACIDS RES, V45, pD658, DOI 10.1093/nar/gkw983; Michaelis M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019705; Mikami S, 2011, LAB INVEST, V91, P1443, DOI 10.1038/labinvest.2011.111; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Ren G, 2012, CANCER RES, V72, P3091, DOI 10.1158/0008-5472.CAN-11-3546; Rhodes DR, 2003, J NATL CANCER I, V95, P661, DOI 10.1093/jnci/95.9.661; Ross-Adams H, 2016, ONCOTARGET, V7, P74734, DOI 10.18632/oncotarget.12543; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Schumacher FR, 2011, HUM MOL GENET, V20, P3867, DOI 10.1093/hmg/ddr295; Sellers WR, 2002, CANCER CELL, V2, P349, DOI 10.1016/S1535-6108(02)00187-3; Shen L, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-284; Shihara N, 2004, DIABETOLOGIA, V47, P1128, DOI 10.1007/s00125-004-1402-y; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sun J, 2008, NAT GENET, V40, P1153, DOI 10.1038/ng.214; Sun MN, 2017, CANCER RES, V77, P5313, DOI 10.1158/0008-5472.CAN-17-0986; Takata R, 2010, NAT GENET, V42, P751, DOI 10.1038/ng.635; Thomas G, 2008, NAT GENET, V40, P310, DOI 10.1038/ng.91; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wang J, 2017, TUMOR BIOL, V39, p1010428317704821; Xu JF, 2012, NAT GENET, V44, P1231, DOI 10.1038/ng.2424; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498; Yusa K, 2009, NAT METHODS, V6, P363, DOI [10.1038/NMETH.1323, 10.1038/nmeth.1323]	52	19	19	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1335	1346		10.1038/s41388-019-1065-2	http://dx.doi.org/10.1038/s41388-019-1065-2			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31636385	Green Published, hybrid			2022-12-17	WOS:000526714600012
J	Cui, JJ; Quan, M; Xie, DC; Gao, Y; Guha, S; Fallon, MB; Chen, JD; Xie, KP				Cui, Jiujie; Quan, Ming; Xie, Dacheng; Gao, Yong; Guha, Sushovan; Fallon, Michael B.; Chen, Jingde; Xie, Keping			A novel KDM5A/MPC-1 signaling pathway promotes pancreatic cancer progression via redirecting mitochondrial pyruvate metabolism	ONCOGENE			English	Article							DEMETHYLASE KDM5A; H3K4 DEMETHYLASE; TCA CYCLE; PROLIFERATION; REPRESSION; SUBTYPES; CARRIER	Mitochondrial pyruvate carrier 1 (MPC-1) appears to be a tumor suppressor. In this study, we determined the regulation of MPC-1 expression by Lysine demethylase 5A (KDM5A) and critical impact of this novel KDM5A/MPC-1 signaling on PDA progression. TCGA database, paired PDA and adjacent normal pancreatic tissues, PDA tissue array and cell lines were used to determine the levels of MPC-1 and KDM5A expression, and their relationship with the clinicopathologic characteristics and overall survival (OS) of PDA patients. Both in vitro and in vivo models were used to determine biologic impacts of MPC-1 and KDM5A on PDA and mitochondrial pyruvate metabolism, and the mechanism underling reduced MPC-1 expression in PDA. The expression of MPC-1 was decreased in PDA cell lines and tissues, and negatively associated with tumor poorer differentiation, lymph nodes metastasis, higher TNM stages, and patients' overall survival (OS). Functional analysis revealed that restored expression of MPC-1 suppressed the growth, invasion, migration, stemness and tumorigenicity. Re-expression of MPC-1 stimulated the mitochondrial pyruvate metabolism and inhibited glycolysis, while MPC-1-specific inhibitor UK5099 attenuated these effects. Furthermore, KDM5A bound directly to MPC-1 promoter region and transcriptionally suppressed the expression of MPC-1 via demethylation H3K4. Consistently, KDM5A expression was elevated in PDA and promoted PDA cell proliferation in vitro and tumor growth in vivo via suppressing the expression of MPC-1. The expression of KDM5A was inversely correlated with that of MPC-1 in PDA. KDM5A/MPC-1 signaling promoted PDA growth, invasion, migration, and stemness via inhibiting mitochondrial pyruvate metabolism. Targeting KDM5A/MPC-1 signaling may be an effective therapeutic strategy for PDA.	[Cui, Jiujie] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai Canc Inst,Dept Med Oncol, Shanghai, Peoples R China; [Cui, Jiujie] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai Canc Inst,State Key Lab Oncogene & Relat, Shanghai, Peoples R China; [Quan, Ming; Xie, Dacheng; Gao, Yong; Chen, Jingde] Tongji Univ, Shanghai East Hosp, Dept Oncol, Sch Med, Shanghai, Peoples R China; [Quan, Ming; Xie, Dacheng; Gao, Yong; Chen, Jingde] Tongji Univ, Shanghai East Hosp, Tumor Inst, Sch Med, Shanghai, Peoples R China; [Guha, Sushovan; Fallon, Michael B.; Xie, Keping] Univ Arizona, Dept Med, Coll Med Phoenix, Phoenix, AZ 85004 USA; [Xie, Keping] Univ Arizona, Dept Interdisciplinary Oncol, Coll Med Phoenix, Phoenix, AZ 85004 USA	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Tongji University; Tongji University; University of Arizona; University of Arizona	Quan, M; Chen, JD (corresponding author), Tongji Univ, Shanghai East Hosp, Dept Oncol, Sch Med, Shanghai, Peoples R China.; Quan, M; Chen, JD (corresponding author), Tongji Univ, Shanghai East Hosp, Tumor Inst, Sch Med, Shanghai, Peoples R China.; Xie, KP (corresponding author), Univ Arizona, Dept Med, Coll Med Phoenix, Phoenix, AZ 85004 USA.; Xie, KP (corresponding author), Univ Arizona, Dept Interdisciplinary Oncol, Coll Med Phoenix, Phoenix, AZ 85004 USA.	mquan2015@163.com; nade@163.com; kepingxie@gmail.com			National Natural Science Foundation of China [81502018, 81502043, 81602051]; Shanghai "Rising Stars of Medical Talent" Youth Development Program [[2019]72]; Youth Medical Talents-Specialist Program [[2019]72]; Fundamental Research Funds for the Central Universities [22120180029]; Outstanding Clinical Discipline Project of Shanghai Pudong [PWYgy2018-02]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai "Rising Stars of Medical Talent" Youth Development Program; Youth Medical Talents-Specialist Program; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Outstanding Clinical Discipline Project of Shanghai Pudong	This work was supported by grants 81502018 (to JC), 81502043 (to MQ) and 81602051 (to DX) from National Natural Science Foundation of China; grant [2019]72 (to JC) from Shanghai "Rising Stars of Medical Talent" Youth Development Program, Youth Medical Talents-Specialist Program; Fundamental Research Funds for the Central Universities 22120180029 (to MQ); The Outstanding Clinical Discipline Project of Shanghai Pudong (Grant No. PWYgy2018-02).	Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Beshiri ML, 2012, P NATL ACAD SCI USA, V109, P18499, DOI 10.1073/pnas.1216724109; Birsoy K, 2015, CELL, V162, P540, DOI 10.1016/j.cell.2015.07.016; Blair Lauren P, 2011, Cancers (Basel), V3, P1383, DOI 10.3390/cancers3011383; Bricker DK, 2012, SCIENCE, V337, P96, DOI 10.1126/science.1218099; Brivet M, 2003, MOL GENET METAB, V78, P186, DOI 10.1016/S1096-7192(03)00016-7; Collisson EA, 2011, NAT MED, V17, P500, DOI 10.1038/nm.2344; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; FLAVELL RB, 1971, NATURE, V230, P504, DOI 10.1038/230504a0; Gong F, 2017, J CELL BIOL, V216, P1959, DOI 10.1083/jcb.201611135; Herzig S, 2012, SCIENCE, V337, P93, DOI 10.1126/science.1218530; Howe FS, 2017, BIOESSAYS, V39, DOI 10.1002/bies.201600095; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Klose RJ, 2007, CELL, V128, P889, DOI 10.1016/j.cell.2007.02.013; Li XL, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2941-6; Li YQ, 2017, ONCOTARGET, V8, P1058, DOI 10.18632/oncotarget.13717; LOFRUMENTO NE, 1971, B SOC ITAL BIOL SPER, V47, P676; Lopez-Bigas N, 2008, MOL CELL, V31, P520, DOI 10.1016/j.molcel.2008.08.004; Mair B, 2014, TRENDS PHARMACOL SCI, V35, P136, DOI 10.1016/j.tips.2014.01.001; Martinez-Reyes I, 2016, MOL CELL, V61, P199, DOI 10.1016/j.molcel.2015.12.002; Pasini D, 2008, GENE DEV, V22, P1345, DOI 10.1101/gad.470008; Peng JC, 2009, CELL, V139, P1290, DOI 10.1016/j.cell.2009.12.002; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Schell JC, 2017, NAT CELL BIOL, V19, P1027, DOI 10.1038/ncb3593; Schell JC, 2014, MOL CELL, V56, P400, DOI 10.1016/j.molcel.2014.09.026; Shannon CE, 2017, FEBS J, V284, P451, DOI 10.1111/febs.13992; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017; Takaoka Y, 2019, CANCER SCI, V110, P1331, DOI 10.1111/cas.13980; Tu SJ, 2008, NAT STRUCT MOL BIOL, V15, P419, DOI 10.1038/nsmb.1400; Tzatsos A, 2013, J CLIN INVEST, V123, P727, DOI 10.1172/JCI64535; Varaljai R, 2015, GENE DEV, V29, P1817, DOI 10.1101/gad.264036.115; Wang CD, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.238; WARBURG O, 1956, SCIENCE, V124, P269; Yamamoto K, 2014, CARCINOGENESIS, V35, P2404, DOI 10.1093/carcin/bgu136; Yang CD, 2014, MOL CELL, V56, P414, DOI 10.1016/j.molcel.2014.09.025; Zhao DZ, 2016, CELL REP, V15, P288, DOI 10.1016/j.celrep.2016.03.035; Zou HB, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1324-8	39	19	20	0	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					1140	1151		10.1038/s41388-019-1051-8	http://dx.doi.org/10.1038/s41388-019-1051-8			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31641207				2022-12-17	WOS:000511209700014
